PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Tarazi, RA; Mahone, EM; Zabel, TA				Tarazi, Reem A.; Mahone, E. Mark; Zabel, T. Andrew			Self-care independence in children with neurological disorders: An interactional model of adaptive demands and executive dysfunction	REHABILITATION PSYCHOLOGY			English	Article						executive function; adaptive skills; adolescent; transition	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; BEHAVIOR RATING INVENTORY; OF-THE-LITERATURE; HEAD-INJURY; INPATIENT REHABILITATION; NEUROPSYCHOLOGICAL TESTS; ECOLOGICAL VALIDITY; SEVERE HYPOGLYCEMIA; TOURETTE-SYNDROME	Objective: To describe a neuropsychological assessment model that proposes executive functioning as a key moderator in the development of self-care independence. Setting: Inpatient and outpatient rehabilitation facilities. Participants: Transition-age youths with congenital and acquired neurological disorders. Intervention: Transition to the adaptive roles and expectations of adulthood can be challenging for adolescents with neurological disorders and other chronic medical conditions. These individuals frequently encounter functional problems related to additional time requirements, new life skill demands, and increased need for organization and planning. In addition, the neuropsychological consequences of these disorders often include deficits in motor speed and coordination as well as executive control (including planning, organization, and working memory). Consideration of the integrity of executive function skills and the presence of atypical adaptive demands is crucial during planning for transition of individuals into self-care independence and development of an approach to assessment and intervention. Conclusions: Rehabilitation psychologists have the potential to improve the quality of life of adolescents with neurological disorders as they transition into adulthood by considering the "executive burden" posed to the individuals by various combinations of executive dysfunction and atypical adaptive demands.	Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21218 USA	Zabel, TA (corresponding author), Kennedy Krieger Inst, Dept Neuropsychol, 1750 E Fairmt Ave, Baltimore, MD 21231 USA.	zabela@kennedykrieger.org					Anderson CJ, 1998, J VOC REHABIL, V10, P103; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Anderton S, 2005, CHEM WORLD-UK, V2, P19; Arnett JJ, 1998, HUM DEV, V41, P295, DOI 10.1159/000022591; Bedell Gary M, 2002, Pediatr Rehabil, V5, P107, DOI 10.1080/1363849021000013540; Bedell GM, 2004, BRAIN INJURY, V18, P65, DOI 10.1080/0269905031000110517; BORJESON MC, 1990, DEV MED CHILD NEUROL, V32, P698; Boss B J, 1994, SCI Nurs, V11, P3; Brocki KC, 2004, DEV NEUROPSYCHOL, V26, P571, DOI 10.1207/s15326942dn2602_3; Brookshire B, 2004, DEV NEUROPSYCHOL, V25, P61, DOI 10.1207/s15326942dn2501&2_5; BROWN M, 1987, ARCH PHYS MED REHAB, V68, P828; Bruininks R.H., 1996, SCALES INDEPENDENT B; Buran CF, 2004, DEV MED CHILD NEUROL, V46, P244, DOI 10.1017/S0012162204000404; Burmeister R, 2005, CHILD NEUROPSYCHOL, V11, P265, DOI 10.1080/092970490911324; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cummings DD, 2002, CLIN NEUROPHARMACOL, V25, P325, DOI 10.1097/00002826-200211000-00009; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P41; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; Davis M, 2005, J BEHAV HEALTH SER R, V32, P27, DOI 10.1007/BF02287326; Denckla MB, 1996, J DEV BEHAV PEDIATR, V17, P114; Erickson David V, 2004, J Wound Ostomy Continence Nurs, V31, P215; Farias ST, 2003, ARCH CLIN NEUROPSYCH, V18, P655, DOI 10.1016/S0887-6177(02)00159-2; Farmer J E, 1995, Appl Neuropsychol, V2, P107, DOI 10.1207/s15324826an0203&4_2; Fletcher JM, 2005, J NEUROSURG, V102, P268, DOI 10.3171/ped.2005.102.3.0268; Fletcher JM, 1996, DEV NEUROPSYCHOL, V12, P1, DOI 10.1080/87565649609540636; Fry AF, 2000, BIOL PSYCHOL, V54, P1, DOI 10.1016/S0301-0511(00)00051-X; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; GOLDSTEIN LH, 1993, J NEUROL NEUROSUR PS, V56, P274, DOI 10.1136/jnnp.56.3.274; Hannonen R, 2003, DEV MED CHILD NEUROL, V45, P262, DOI 10.1017/S0012162203000501; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Holmbeck GN, 2002, J PEDIATR PSYCHOL, V27, P177, DOI 10.1093/jpepsy/27.2.177; Hommet C, 1999, J CHILD NEUROL, V14, P144, DOI 10.1177/088307389901400302; Hooper CJ, 2004, DEV PSYCHOL, V40, P1148, DOI 10.1037/0012-1649.40.6.1148; Iddon JL, 2004, J NEUROL NEUROSUR PS, V75, P1112, DOI 10.1136/jnnp.2003.029058; Kilkens OJE, 2005, J REHABIL RES DEV, V42, P65, DOI 10.1682/JRRD.2004.08.0093; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Krause JS, 2004, ARCH PHYS MED REHAB, V85, P1257, DOI 10.1016/j.apmr.2003.08.108; Ku JH, 2005, UROL RES, V33, P435, DOI 10.1007/s00240-005-0504-4; Leahy BJ, 1998, BRAIN INJURY, V12, P1025, DOI 10.1080/026990598121936; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Loss N, 1998, CHILD NEUROPSYCHOL, V4, P7, DOI 10.1076/chin.4.1.7.3192; Luciana M, 1998, NEUROPSYCHOLOGIA, V36, P273, DOI 10.1016/S0028-3932(97)00109-7; Mahone EM, 2007, PEDIATRIC NEUROPSYCHOLOGICAL INTERVENTION: A CRITICAL REVIEW OF SCIENCE AND PRACTICE, P287; Mahone EM, 2002, CHILD NEUROPSYCHOL, V8, P258, DOI 10.1076/chin.8.4.258.13510; Mahone EM, 2002, CHILD NEUROPSYCHOL, V8, P52, DOI 10.1076/chin.8.1.52.8719; Mahone EM, 2002, ARCH CLIN NEUROPSYCH, V17, P643, DOI 10.1016/S0887-6177(01)00168-8; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Nigg JT, 2005, J ABNORM PSYCHOL, V114, P706, DOI 10.1037/0021-843X.114.3.706; Nybo T, 2004, J INT NEUROPSYCH SOC, V10, P719, DOI 10.1017/S1355617704105109; Paus T, 2001, BRAIN RES BULL, V54, P255, DOI 10.1016/S0361-9230(00)00434-2; Reynolds C.R., 2004, BEHAV ASSESSMENT SYS; RICHARDS JS, 1991, ARCH PHYS MED REHAB, V72, P275; Romine CB, 2005, APPL NEUROPSYCHOL, V12, P190, DOI 10.1207/s15324826an1204_2; Russell EW, 2001, CLIN NEUROPSYCHOL, V15, P423, DOI 10.1076/clin.15.3.423.10267; Samuelson J J, 1992, Arch Psychiatr Nurs, V6, P287, DOI 10.1016/0883-9417(92)90040-P; Sawin Kathleen J, 2003, SCI Nurs, V20, P72; Schillerstrom JE, 2005, PSYCHOSOMATICS, V46, P508, DOI 10.1176/appi.psy.46.6.508; Schuck SEB, 2005, J LEARN DISABIL-US, V38, P262, DOI 10.1177/00222194050380030701; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Snow JH, 1999, CHILD HEALTH CARE, V28, P241, DOI 10.1207/s15326888chc2803_3; Sommer JL, 2004, BRAIN INJURY, V18, P1297, DOI 10.1080/02699050410001672288; Sparrow S, 2005, VINELAND ADAPTIVE BE; Stineman MG, 1999, SPINAL CORD, V37, P717, DOI 10.1038/sj.sc.3100914; Strudwick SK, 2005, J PEDIATR-US, V147, P680, DOI 10.1016/j.jpeds.2005.06.010; Swaine BR, 2000, AM J PHYS MED REHAB, V79, P412, DOI 10.1097/00002060-200009000-00002; TARAZI R, 2007, J INT NEUROPSYCH SOC, V13, P168; Tate RL, 2004, BRAIN INJURY, V18, P445, DOI 10.1080/02699050310001641183; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; Thompson PM, 2000, NATURE, V404, P190, DOI 10.1038/35004593; Thompson PM, 2005, INT REV NEUROBIOL, V67, P285, DOI 10.1016/S0074-7742(05)67009-2; Tsai PY, 2002, CHILD NERV SYST, V18, P48, DOI 10.1007/s00381-001-0531-6; Watkins LH, 2005, PSYCHOL MED, V35, P571, DOI 10.1017/S0033291704003691; Wechsler D., 1991, WECHSLER INTELLIGENC; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wells T, 2003, SOC FORCES, V82, P803, DOI 10.1353/sof.2004.0029; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; WILMOT CB, 1985, ARCH PHYS MED REHAB, V66, P227, DOI 10.1016/0003-9993(85)90148-0; WOLRAICH M L, 1988, Pediatrician, V15, P21; Woodcock R. W., 1990, WOODCOCK JOHNSON PSY; World Health Organization, 2002, INT CLASS FUNCT DIS; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009; Ylvisaker M, 2000, TOP LANG DISORD, V20, P29, DOI 10.1097/00011363-200020020-00005; ZABEL TA, 2004, CEREBROSPINAL FLUID, V1, pS57	88	28	28	0	11	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2007	52	2					196	205		10.1037/0090-5550.52.2.196			10	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	167EL	WOS:000246433900009					2021-06-18	
J	Cheng, JP; Aslam, HA; Hoffman, AN; Zafonte, RD; Kline, AE				Cheng, Jeffrey P.; Aslam, Haris A.; Hoffman, Ann N.; Zafonte, Ross D.; Kline, Anthony E.			The neurobehavioral benefit conferred by a single systemic administration of 8-OH-DPAT after brain trauma is confined to a narrow therapeutic window	NEUROSCIENCE LETTERS			English	Article						beam-walk; beam-balance; controlled cortical impact; functional recovery; learning and memory; Morris water maze; neurobehavior; serotonin receptor agonists; traumatic brain injury	5-HT1A RECEPTOR AGONIST; CONTROLLED CORTICAL IMPACT; EXCITATORY AMINO-ACIDS; GLUTAMATE RELEASE; COGNITIVE DEFICITS; NMDA RECEPTORS; IN-VITRO; INJURY; 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; RAT	The 5-HT1A receptor agonist 8-OH-DPAT (0.5 mg/kg) enhances behavioral recovery when administered 15 min after experimental traumatic brain injury (TBI). To determine if benefits are still attainable at clinically relevant times, treatment was delayed 1 and 2 It post-TBI and motor/cognitive performance was compared to early (i.e., 15 min) administration. No differences were observed among the vehicle and 8-OH-DPAT groups treated at 1 and 2 h, but all three were significantly impaired versus early 8-OH-DPAT. The data suggest that an early and narrow critical period exists for the behavioral recovery afforded by a single 8-OH-DPAT treatment paradigm. The critical window corresponds to the well documented TBI-induced glutamate increase, suggesting that 8-OH-DPAT may be conferring neuroprotection by attenuating this acute deleterious surge. (c) 2007 Elsevier Ireland Ltd. All rights reserved.	Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA	Kline, AE (corresponding author), Univ Pittsburgh, Ctr Neurosci, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Cheng, Jeffrey/0000-0001-8285-3207	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD043851, R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD046700, HD046700, R03 HD043851, HD043851, R01 HD069620] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS060005] Funding Source: Medline		Alessandri B, 1999, BRAIN RES, V845, P232, DOI 10.1016/S0006-8993(99)01948-4; ANDRADE R, 1992, DRUG DEVELOP RES, V26, P275, DOI 10.1002/ddr.430260307; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Calcagno E, 2006, J NEUROCHEM, V96, P853, DOI 10.1111/j.1471-4159.2005.03600.x; CHOI DW, 1987, J NEUROSCI, V7, P369; De Vry Jean, 1997, Drugs of the Future, V22, P341; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Matsuyama S, 1996, BRAIN RES, V728, P175, DOI 10.1016/0006-8993(96)00395-2; Mauler F, 2001, BRAIN RES, V888, P150, DOI 10.1016/S0006-8993(00)03074-2; Melena J, 2000, EUR J PHARMACOL, V406, P319, DOI 10.1016/S0014-2999(00)00688-9; Mignon LJ, 2005, NEUROREPORT, V16, P699, DOI 10.1097/00001756-200505120-00009; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PREHN JHM, 1991, EUR J PHARMACOL, V203, P213, DOI 10.1016/0014-2999(91)90717-5; RAITERI M, 1991, J PHARMACOL EXP THER, V257, P1184; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Semkova I, 1998, EUR J PHARMACOL, V359, P251, DOI 10.1016/S0014-2999(98)00634-7; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135	25	28	28	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	APR 12	2007	416	2					165	168		10.1016/j.neulet.2007.02.006			4	Neurosciences	Neurosciences & Neurology	161TN	WOS:000246039100012	17321680	Green Accepted			2021-06-18	
J	Folkerts, MM; Parks, EA; Dedman, JR; Kaetzel, MA; Lyeth, BG; Berman, RF				Folkerts, Michael M.; Parks, Elizabeth A.; Dedman, John R.; Kaetzel, Marcia A.; Lyeth, Bruce G.; Berman, Robert F.			Phosphorylation of calcium calmodulin-dependent protein kinase II following lateral fluid percussion brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						calcium; CaMKII; cortex; hippocampus; protein phosphorylation; traumatic brain injury	LONG-TERM POTENTIATION; MAXIMAL CALCINEURIN ACTIVITY; SIGNIFICANT INCREASE; ENTORHINAL CORTEX; CA2+ HOMEOSTASIS; NEURONAL INJURY; SPINAL-CORD; CELL-DEATH; HIPPOCAMPUS; MODEL	Traumatic brain injury (TBI) can dramatically increase levels of intracellular calcium ([Ca2+](i)). One consequence of increased [Ca2+](i) would be altered activity and function of calcium-regulated proteins, including calcium-calmodulin-dependent protein kinase II (CaMKII), which is autophosphorylated on Thr(286) (pCaMKII(286)) in the presence of calcium and calmodulin. Therefore, we hypothesized that TBI would result in increased levels of pCaMKII(286), and that such increases would occur early after injury in brain regions known to be damaged following lateral fluid percussion TBI (i.e., hippocampus and cortex). In order to test this hypothesis, immunostaining of CaMKII was examined in rat hippocampus and cortex after lateral fluid percussion (LFP) injury using an antibody directed against pCaMKII(286). LFP injury produced a marked increase in pCaMKII(286) immunostaining in the hippocampus and overlying cortex 30 min after TBI. The pattern of increased immunostaining was uneven, and unexpectedly absent in some hippocampal CA3 pyramidal neurons. This suggests that phosphatase activity may also increase following TBI, resulting in dephosphorylation of pCaMKII(286) in subpopulations of CA3 pyramidal neurons. Western blotting confirmed a rapid increase in levels of pCaMKII(286) at 10 and 30 min after brain injury, and that it was transient and no longer significantly elevated when examined at 3, 8, and 24 h. These results demonstrate that TBI alters the autophosphorylation state of CaMKII, an important neuronal regulator of critical cell functions, including enzyme activities, cell structure, gene expression, and neuronal plasticity, and provide a molecular mechanism that is likely to contribute to cell injury and impaired plasticity after TBI.	Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA; Pepperdine Univ, Dept Psychol, Malibu, CA 90265 USA; Univ Cincinnati, Coll Med, Genome Res Inst, Cincinnati, OH 45221 USA	Berman, RF (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1 Shields Ave, Davis, CA 95616 USA.	rfberman@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995, R01NS039090] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39090, NS29995] Funding Source: Medline		Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bollag DM, 1991, PROTEIN METHODS; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; CHURN SB, 1990, STROKE, V21, P1715, DOI 10.1161/01.STR.21.12.1715; Colbran RJ, 2004, BIOCHEM J, V378, P1, DOI 10.1042/BJ20031547; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; DASILVA FHL, 1990, PHYSIOL REV, V70, P453; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Glazewski S, 2000, NAT NEUROSCI, V3, P911; GOLDOWITZ D, 1975, EXP NEUROL, V47, P433, DOI 10.1016/0014-4886(75)90075-8; HABERLY LB, 1978, J COMP NEUROL, V181, P781, DOI 10.1002/cne.901810407; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KENNEDY MB, 1990, COLD SPRING HARB SYM, V55, P101; KOSEL KC, 1982, BRAIN RES, V244, P201, DOI 10.1016/0006-8993(82)90079-8; Kurz JE, 2005, BRAIN RES, V1048, P153, DOI 10.1016/j.brainres.2005.04.062; Kurz JE, 2005, J NEUROTRAUM, V22, P476, DOI 10.1089/neu.2005.22.476; Kurz JE, 2001, J NEUROCHEM, V78, P304, DOI 10.1046/j.1471-4159.2001.00426.x; Lie AA, 1998, J NEUROPATH EXP NEUR, V57, P1078, DOI 10.1097/00005072-199811000-00011; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLARD P, 1988, PLANT CELL ENVIRON, V11, P1, DOI 10.1111/j.1365-3040.1988.tb01769.x; MILLER RJ, 1991, PROG NEUROBIOL, V37, P255, DOI 10.1016/0301-0082(91)90028-Y; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Ouyang Y, 1997, J NEUROSCI, V17, P5416; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Racay P, 1996, GEN PHYSIOL BIOPHYS, V15, P193; RAPPAPORT ZH, 1987, STROKE, V18, P760, DOI 10.1161/01.STR.18.4.760; Riedel G, 1999, CELL MOL LIFE SCI, V55, P549, DOI 10.1007/s000180050313; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SCHUSTER J, 1993, ADV COMPOS LETT, V2, P18; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; Strack S, 1997, J NEUROCHEM, V68, P2119; SWANSON LW, 1980, BRAIN RES, V197, P207, DOI 10.1016/0006-8993(80)90446-1; VANGROEN T, 1990, J COMP NEUROL, V302, P515, DOI 10.1002/cne.903020308; WITTER MP, 1986, J COMP NEUROL, V252, P1, DOI 10.1002/cne.902520102; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; WU K, 1990, P NATL ACAD SCI USA, V87, P5298, DOI 10.1073/pnas.87.14.5298; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1; YOUNG W, 1992, J NEUROTRAUM, V9, pS9; Zalewska T, 1996, NEUROCHEM INT, V28, P175, DOI 10.1016/0197-0186(95)00072-0; Zalewska T, 1996, ACTA NEUROBIOL EXP, V56, P41; Zalewska T, 1996, NEUROREPORT, V7, P637, DOI 10.1097/00001756-199601310-00062; ZHOU XR, 1994, NEUROSCI LETT, V171, P45, DOI 10.1016/0304-3940(94)90600-9	65	28	29	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2007	24	4					638	650		10.1089/neu.2006.0188			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	159NE	WOS:000245872000006	17439347				2021-06-18	
J	Hinz, J; Rosmus, M; Popov, A; Moerer, O; Frerichs, I; Quintel, M				Hinz, Jose; Rosmus, Martin; Popov, Aron; Moerer, Onnen; Frerichs, Inez; Quintel, Michael			Effectiveness of an intravascular cooling method compared with a conventional cooling technique in neurologic patients	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						temperature control; intravascular cooling catheter	INTENSIVE-CARE-UNIT; TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; RECTAL TEMPERATURES; BODY-TEMPERATURE; FEVER; HYPERTHERMIA; STROKE; SYSTEM	Fever is common among neurologic patients and is usually treated by antipyretic drugs and external cooling. An alternative method for temperature management may be an intravascular approach. The aim of the study was to compare the effectiveness and the therapeutic costs of this new method with conventional treatment in neurologic patients. Twenty-six patients who suffered from subarachnoid hemorrhage or traumatic brain injury with febrile episodes were included the study and were randomized into 2 different groups. In the "Conventional" group, fever was treated with antipyretic drugs and/or surface cooling techniques to achieve a body core temperature of 36.5 degrees C. In the "CoolGard" group, patients were treated with an intravascular cooling catheter (Coolgard, Alsius, CA). We compared the effectiveness of these 2 approaches by calculating the mean deviation from 36.5 degrees C during a 48-hour period (fever burden). We found a significant difference in the fever burden [CoolGard: -0.49 to 1.22 (median -0.06)degrees C vs. Conventional: 1.05-2.34 (median 1.41)degrees C, P < 0.05]. Costs varied significantly between the CoolGard and the Conventional groups, with markedly higher daily costs in the CoolGard group [CoolGard: 15 to 140 US dollars (USD) (median 39 USD) vs. Conventional: 1 to 9 USD (median 5 USD), P < 0.05]. The effectiveness of the intravascular cooling catheter is excellent compared with conventional cooling therapies.	Univ Gottingen, Dept Anaesthestiol Emergency & Intens Care Med, D-3400 Gottingen, Germany; Univ Gottingen, Dept Cardiovasc Thorac Surg, D-3400 Gottingen, Germany; Univ Hosp Schleswig Holstein, Dept Anaesthesiol & Intens Care Med, Kiel, Germany	Hinz, J (corresponding author), Robert Koch Str 40D, D-37075 Gottingen, Germany.	mail@josehinz.de	Moerer, Onnen/K-6349-2019; Popov, Aron-Frederik/AAA-9933-2020	Popov, Aron-Frederik/0000-0003-4226-3004; Frerichs, Inez/0000-0002-7712-6539			Aiyagari V, 2004, NEUROCRIT CARE, V1, P209, DOI 10.1385/NCC:1:2:209; Al-Senani FM, 2004, RESUSCITATION, V62, P143, DOI 10.1016/j.resuscitation.2004.02.016; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; Broessner G, 2005, CRIT CARE, V9, pR498, DOI 10.1186/cc3771; CASTELLA X, 1995, CRIT CARE MED, V23, P1327, DOI 10.1097/00003246-199508000-00005; Childs C, 2005, ANAESTHESIA, V60, P759, DOI 10.1111/j.1365-2044.2005.04193.x; Correia M, 2000, COCHRANE DB SYST REV; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; JENNETT B, 1976, LANCET, V1, P1031; Jorgensen HS, 1996, LANCET, V348, P193, DOI 10.1016/S0140-6736(05)66135-1; Keenan SP, 2000, JAMA-J AM MED ASSOC, V284, P441, DOI 10.1001/jama.284.4.441; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lenhardt R, 1999, AM J MED, V106, P550, DOI 10.1016/S0002-9343(99)00068-6; MEMEZAWA H, 1995, BRAIN RES, V670, P48, DOI 10.1016/0006-8993(94)01251-C; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Otawara Y, 2003, SURG NEUROL, V60, P159, DOI 10.1016/S0090-3019(03)00083-1; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Schmutzhard E, 2002, CRIT CARE MED, V30, P2481, DOI 10.1097/00003246-200211000-00013; Schwarz S, 2000, NEUROLOGY, V54, P354, DOI 10.1212/WNL.54.2.354; Yu CG, 2001, NEUROSURGERY, V49, P152, DOI 10.1097/00006123-200107000-00023	21	28	32	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	APR	2007	19	2					130	135		10.1097/ANA.0b013e318032a208			6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	153IP	WOS:000245426100008	17414000				2021-06-18	
J	Saltapidas, H; Ponsford, J				Saltapidas, Helen; Ponsford, Jennie			The influence of cultural background on motivation for and participation in rehabilitation and outcome following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						culture; outcome; rehabilitation; traumatic brain injury	BLUNT HEAD-INJURY; IMPACT; ETHNICITY; HANDICAP; FAMILIES; RACE	Aims: To compare motivation for and participation in rehabilitation, outcome, and distress over role changes in persons with traumatic brain injury (TBI) from the dominant English-speaking culture in Australia versus those from minority culturally and linguistically diverse (CALD) backgrounds. Main Measures: Motivation for Traumatic Brain Injury Rehabilitation Questionnaire; Craig Handicap Assessment Reporting Technique. Participants: Two groups of persons with TBI, 38 of English-speaking backgrounds and 32 of CALD backgrounds. Results: Groups had similar education and preinjury employment status, both showed positive attitudes toward rehabilitation and participated equally in rehabilitation. However, CALD participants showed poorer outcomes in several domains, including postinjury employment status, cognitive independence, mobility and social integration, and showed greater distress about changes in ability to perform certain life roles. Conclusions: Differences in outcome and levels of distress over role changes may occur in those from CALD backgrounds following TBI, independent of socioeconomic background and access to rehabilitation. There is a need to further investigate possible reasons for this, including beliefs, coping style, and emotional response to injury.	Epworth Med Fdn, Epworth Rehabil Ctr, Dept Psychol, Richmond, Vic 3121, Australia; Monash Univ, Dept Psychol, Clayton, Vic 3168, Australia	Saltapidas, H (corresponding author), Epworth Med Fdn, Epworth Rehabil Ctr, Dept Psychol, 89 Bridge Rd, Richmond, Vic 3121, Australia.	jennie.ponsford@med.monash.edu.au					Armengol CG, 1999, J HEAD TRAUMA REHAB, V14, P233, DOI 10.1097/00001199-199906000-00004; Banja JD, 1996, DISABIL REHABIL, V18, P279, DOI 10.3109/09638289609165881; BATES MS, 1994, SOC SCI MED, V39, P629, DOI 10.1016/0277-9536(94)90020-5; Blackmer J, 1999, BRAIN INJURY, V13, P627; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CAVALLO MM, 1995, J HEAD TRAUMA REHAB, V10, P66, DOI 10.1097/00001199-199504000-00008; Chervinsky AB, 1998, ARCH CLIN NEUROPSYCH, V13, P433, DOI 10.1016/S0887-6177(97)00016-4; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Daniel A. E., 1983, POWER PRIVILEGE PRES; Finley LY, 1998, PSYCHIATR REHABIL J, V21, P230, DOI 10.1037/h0095308; FITZGERALD MH, 1992, J REHABIL        APR, P38; Gallaher CK, 2001, REHABIL PSYCHOL, V46, P312, DOI 10.1037/0090-5550.46.3.312; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hoofien D, 2001, BRAIN INJURY, V15, P189; Laroche M, 1996, J CROSS CULT PSYCHOL, V27, P114, DOI 10.1177/0022022196271008; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; MILLARD AV, 1992, MED ANTHROPOL Q, V6, P3, DOI 10.1525/maq.1992.6.1.02a00010; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; MOORE AD, 1991, NEUROPSYCHOL REHABIL, V1, P185, DOI DOI 10.1080/09602019108520164; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Nguyen-Long K, 1999, J SOUTHEAST ASIAN ST, V30, P1, DOI 10.1017/S0022463400007992; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Paniagua F. A., 1998, ASSESSING TREATING C; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; Ponsford J., 1995, TRAUMATIC BRAIN INJU; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Possl J, 1996, BRAIN INJURY, V10, P125, DOI 10.1080/026990596124610; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Sastry J, 1998, SOC PSYCHOL QUART, V61, P101, DOI 10.2307/2787064; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Simpson G, 2000, BRAIN INJURY, V14, P125, DOI 10.1080/026990500120790; Stanhope V, 2002, PSYCHIATR REHABIL J, V25, P273, DOI 10.1037/h0095015; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Sue D. W., 1990, COUNSELING CULTURALL; SUINN RM, 1992, EDUC PSYCHOL MEAS, V52, P1041, DOI 10.1177/0013164492052004028; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Uomoto JM, 2000, CRIT ISS NE, P169; Walker N, 2003, AM J PHYS MED REHAB, V82, P936, DOI 10.1097/01.PHM.0000098041.42394.9A; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; Yody BB, 2000, J HEAD TRAUMA REHAB, V15, P1041, DOI 10.1097/00001199-200008000-00006	43	28	28	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2007	22	2					132	139		10.1097/01.HTR.0000265101.75177.8d			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	152NU	WOS:000245369500008	17414315				2021-06-18	
J	Maccotta, L; Buckner, RL; Gilliam, FG; Ojemann, JG				Maccotta, Luigi; Buckner, Randy L.; Gilliam, Frank G.; Ojemann, Jeffrey G.			Changing frontal contributions to memory before and after medial temporal lobectomy	CEREBRAL CORTEX			English	Article						encoding; epilepsy; lateralization; postoperative; prefrontal cortex	POSITRON-EMISSION-TOMOGRAPHY; OBJECT RECOGNITION MEMORY; TRAUMATIC BRAIN-INJURY; FUNCTIONAL MRI; EPISODIC MEMORY; LOBE EPILEPSY; PREFRONTAL CORTEX; RHESUS-MONKEY; ALZHEIMERS-DISEASE; HEMISPHERIC-ASYMMETRY	Frontal recruitment was characterized using functional magnetic resonance imaging (fMRI) during memory encoding in temporal lobe epilepsy (TLE) patients before and after unilateral medial temporal lobectomy. Twenty-four TLE patients and 12 healthy controls underwent a preoperative fMRI session consisting of verbal and nonverbal incidental memory-encoding tasks that typically lead to robust, lateralized frontal activity in controls. A similar postoperative fMRI session was performed in a subset of patients. Preoperatively, the verbal task resulted in significant additional recruitment of right frontal cortex in left TLE patients, compared with controls. Right TLE patients instead showed typically lateralized frontal activation. Bilateral frontal recruitment has been observed in older adults and in young adults in situations of difficult task demands. Typical right-lateralized patterns of frontal recruitment were found in both patient groups during the nonverbal task, indicating that the bilateral frontal recruitment pattern was engaged dynamically depending on the task. After surgery, left TLE patients regained more lateralized frontal activity. These results demonstrated differences in frontal recruitment in left and right TLE patients. Such differences emerged in specific task settings and were influenced by surgery, suggesting a dynamic mechanism of frontal recruitment that can be obtained in TLE patients, possibly as a response to presurgical dysfunction.	Washington Univ, Div Biol & Biomed Sci, Dept Psychol, St Louis, MO USA; Washington Univ, Dept Anat & Neurobiol, St Louis, MO USA; Washington Univ, Dept Radiol, St Louis, MO USA; Washington Univ, Howard Hughes Med Inst, St Louis, MO USA; Washington Univ, Dept Neurol, St Louis, MO USA; Washington Univ, Dept Neurol Surg, St Louis, MO USA	Maccotta, L (corresponding author), Univ Calif San Francisco, Dept Neurol, 505 Parnassus Ave,Box 0114, San Francisco, CA 94143 USA.	luigi.maccotta@ucsf.edu		Maccotta, Luigi/0000-0003-3702-0331; Ojemann, Jeffrey/0000-0001-7580-8934	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K24NS047551] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K24 NS047551] Funding Source: Medline		BACHEVALIER J, 1986, BEHAV BRAIN RES, V20, P249, DOI 10.1016/0166-4328(86)90225-1; BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; BARBAS H, 1993, NEUROSCIENCE, V56, P841, DOI 10.1016/0306-4522(93)90132-Y; BARBAS H, 1988, J COMP NEUROL, V276, P313, DOI 10.1002/cne.902760302; Barbas H, 2000, BRAIN RES BULL, V52, P319, DOI 10.1016/S0361-9230(99)00245-2; BAUER RH, 1976, J COMP PHYSIOL PSYCH, V90, P293, DOI 10.1037/h0087996; Baxendale SA, 1998, NEUROPSY NEUROPSY BE, V11, P12; Becker JT, 1996, NEUROLOGY, V46, P692, DOI 10.1212/WNL.46.3.692; Bellgowan PSF, 1998, NEUROLOGY, V51, P479, DOI 10.1212/WNL.51.2.479; Billingsley RL, 2001, BRAIN, V124, P1218, DOI 10.1093/brain/124.6.1218; Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701; Buckner RL, 1996, P NATL ACAD SCI USA, V93, P1249, DOI 10.1073/pnas.93.3.1249; Buckner RL, 2004, NEURON, V44, P195, DOI 10.1016/j.neuron.2004.09.006; Buckner RL, 2001, NAT REV NEUROSCI, V2, P624, DOI 10.1038/35090048; Buckner RL, 1999, NAT NEUROSCI, V2, P311, DOI 10.1038/7221; Cabeza R, 1997, J NEUROSCI, V17, P391; Cabeza R, 2002, NEUROIMAGE, V17, P1394, DOI 10.1006/nimg.2002.1280; Cabeza R, 2002, PSYCHOL AGING, V17, P85, DOI 10.1037//0882-7974.17.1.85; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; DELLAROCCHETTA AI, 1993, NEUROPSYCHOLOGIA, V31, P503; DEMB JB, 1995, J NEUROSCI, V15, P5870; Detre JA, 1998, NEUROLOGY, V50, P926, DOI 10.1212/WNL.50.4.926; Dolan RJ, 1997, NATURE, V388, P582, DOI 10.1038/41561; Dolcos F, 2002, NEUROSCI BIOBEHAV R, V26, P819, DOI 10.1016/S0149-7634(02)00068-4; Dupont S, 2000, BRAIN, V123, P1722, DOI 10.1093/brain/123.8.1722; Easton A, 2001, BEHAV BRAIN RES, V121, P1, DOI 10.1016/S0166-4328(00)00384-3; Fletcher PC, 2001, BRAIN, V124, P849, DOI 10.1093/brain/124.5.849; Frankland PW, 2005, NAT REV NEUROSCI, V6, P119, DOI 10.1038/nrn1607; FUSTER JM, 1985, BRAIN RES, V330, P299, DOI 10.1016/0006-8993(85)90689-4; Gaffan D, 2002, J NEUROSCI, V22, P7288; Golby AJ, 2002, EPILEPSIA, V43, P855, DOI 10.1046/j.1528-1157.2002.20501.x; GRADY CL, 1994, J NEUROSCI, V14, P1450; Grady CL, 2003, J NEUROSCI, V23, P986, DOI 10.1523/jneurosci.23-03-00986.2003; Grady CL, 2000, CURR OPIN NEUROBIOL, V10, P224, DOI 10.1016/S0959-4388(00)00073-8; JANOWSKY JS, 1989, BEHAV NEUROSCI, V103, P548, DOI 10.1037/0735-7044.103.3.548; Janszky T, 2005, EPILEPSIA, V46, P244, DOI 10.1111/j.0013-9580.2005.10804.x; Jokeit H, 1997, BRAIN, V120, P2283, DOI 10.1093/brain/120.12.2283; Jokeit H, 2001, NEUROLOGY, V57, P1786, DOI 10.1212/WNL.57.10.1786; KAPUR S, 1994, P NATL ACAD SCI USA, V91, P2008, DOI 10.1073/pnas.91.6.2008; Kelley WM, 1998, NEURON, V20, P927, DOI 10.1016/S0896-6273(00)80474-2; Konishi S, 2001, NEUROIMAGE, V13, P364, DOI 10.1006/nimg.2000.0691; Kucera H, 1967, COMPUTATIONAL ANAL P; KUYPERS HGJ, 1965, EXP NEUROL, V11, P245, DOI 10.1016/0014-4886(65)90016-6; Lavenex P, 2002, J COMP NEUROL, V447, P394, DOI 10.1002/cne.10243; Lee TMC, 2002, EPILEPSIA, V43, P283, DOI 10.1046/j.1528-1157.2002.09901.x; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Logan JM, 2002, NEURON, V33, P827, DOI 10.1016/S0896-6273(02)00612-8; Lustig C, 2003, P NATL ACAD SCI USA, V100, P14504, DOI 10.1073/pnas.2235925100; Martin RC, 2001, NEUROLOGY, V57, P597, DOI 10.1212/WNL.57.4.597; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDermott KB, 1999, J COGNITIVE NEUROSCI, V11, P631, DOI 10.1162/089892999563698; Miller BT, 2005, NEURON, V48, P535, DOI 10.1016/j.neuron.2005.11.002; Milner B, 1964, FRONTAL GRANULAR COR, P313; MISHKIN M, 1978, NATURE, V273, P297, DOI 10.1038/273297a0; Ojemann GA, 1997, ANNU REV MED, V48, P317; Ojemann JG, 2002, EPILEPSY BEHAV, V3, P309, DOI 10.1016/S1525-5050(02)00039-2; Parker A, 1998, EUR J NEUROSCI, V10, P3044, DOI 10.1046/j.1460-9568.1998.00306.x; PENFIELD W, 1958, ARCH NEURO PSYCHIATR, V79, P475, DOI 10.1001/archneurpsyc.1958.02340050003001; PERSSON J, 2005, IN PRESS CEREB CORTE; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; Rausch R, 2002, CURR OPIN NEUROL, V15, P185, DOI 10.1097/00019052-200204000-00010; Reuter-Lorenz PA, 2002, TRENDS COGN SCI, V6, P394, DOI 10.1016/S1364-6613(02)01957-5; Reuter-Lorenz PA, 2000, J COGNITIVE NEUROSCI, V12, P174, DOI 10.1162/089892900561814; Rijntjes M, 2002, PROG NEUROBIOL, V66, P109, DOI 10.1016/S0301-0082(01)00027-2; ROSENE DL, 1977, SCIENCE, V198, P315, DOI 10.1126/science.410102; SCHACTER DL, 1987, PSYCHOBIOLOGY, V15, P21; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Simons JS, 2003, NAT REV NEUROSCI, V4, P637, DOI 10.1038/nrn1178; Snyder A. Z., 1996, QUANTIFICATION BRAIN, P131, DOI DOI 10.1016/B978-012389760-2/50028-1; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; Stuss D.T., 1986, FRONTAL LOBES; Talairach J., 1988, COPLANAR STEREOTAXIC; Thompson-Schill SL, 2005, CURR OPIN NEUROBIOL, V15, P219, DOI 10.1016/j.conb.2005.03.006; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; UNGERLEIDER LG, 1989, EXP BRAIN RES, V76, P473, DOI 10.1007/BF00248903; VANHOESEN GW, 1982, TRENDS NEUROSCI, V5, P345, DOI 10.1016/0166-2236(82)90201-6; VOYTKO ML, 1986, BEHAV BRAIN RES, V22, P25, DOI 10.1016/0166-4328(86)90078-1; Wagner AD, 1998, NEUROREPORT, V9, P3711, DOI 10.1097/00001756-199811160-00026; Wagner AD, 1998, SCIENCE, V281, P1188, DOI 10.1126/science.281.5380.1188; Wiebe S, 2003, LANCET, V362, pS48, DOI 10.1016/S0140-6736(03)15075-1	81	28	28	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	FEB	2007	17	2					443	456		10.1093/cercor/bhj161			14	Neurosciences	Neurosciences & Neurology	124JQ	WOS:000243364500019	16547345	Bronze			2021-06-18	
J	Kluger, Y; Riou, B; Rossaint, R; Rizoli, SB; Boffard, KD; Choong, PIT; Warren, B; Tillinger, M				Kluger, Yoram; Riou, Bruno; Rossaint, Rolf; Rizoli, Sandro B.; Boffard, Kenneth David; Choong, Philip Iau Tsau; Warren, Brian; Tillinger, Michael			Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: Post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial	CRITICAL CARE			English	Article							ACTIVATED FACTOR-VII; RECOMBINANT-FACTOR-VIIA; COAGULATION-FACTOR-VII; INTRACRANIAL HEMORRHAGE; HEAD-INJURY; COAGULOPATHY; MANAGEMENT; THERAPY; NOVOSEVEN; EFFICACY	Background Trauma is a leading cause of mortality and morbidity, with traumatic brain injury (TBI) and uncontrolled hemorrhage responsible for the majority of these deaths. Recombinant activated factor VIIa (rFVIIa) is being investigated as an adjunctive hemostatic treatment for bleeding refractory to conventional replacement therapy in trauma patients. TBI is a common component of polytrauma injuries. However, the combination of TBI with polytrauma injuries is associated with specific risk factors and treatment modalities somewhat different from those of polytrauma without TBI. Although rFVIIa treatment may offer added potential benefit for patients with combined TBI and polytrauma, its safety in this population has not yet been assessed. We conducted a post hoc sub analysis of patients with TBI and severe blunt polytrauma enrolled into a prospective, international, double-blind, randomized, placebo-controlled study. Methods A post hoc analysis of study data was performed for 143 patients with severe blunt trauma enrolled in a prospective, randomized, placebo-controlled study, evaluating the safety and efficacy of intravenous rFVIIa (200 + 100 + 100 mu g/kg) or placebo, to identify patients with a computed tomography (CT) diagnosis of TBI. The incidences of ventilator-free days, intensive care unit-free days, and thromboembolic, serious, and adverse events within the 30-day study period were assessed in this cohort. Results Thirty polytrauma patients (placebo, n = 13; rFVIIa, n = 17) were identified as having TBI on CT. No significant differences in rates of mortality (placebo, n = 6, 46%, 90% confidence interval (CI): 22% to 71%; rFVIIa, n = 5, 29%, 90% CI: 12% to 56%; P = 0.19), in median numbers of intensive care unit-free days (placebo = 0, rFVIIa = 3; P = 0.26) or ventilator-free days (placebo = 0, rFVIIa = 10; P = 0.19), or in rates of thromboembolic adverse events (placebo, 15%, 90% CI: 3% to 51%; rFVIIa, 0%, 90% CI: 0% to 53%; P = 0.18) or serious adverse events (placebo, 92%, 90% CI: 68% to 98%; rFVIIa, 82%, 90% CI: 60% to 92%; P = 0.61) were observed between treatment groups. Conclusion The use of a total dose of 400 (200 + 100 + 100) mu g/kg rFVIIa in this group of hemodynamically unstable polytrauma patients with TBI was not associated with an increased risk of mortality or with thromboembolic or adverse events.	Rambam Med Ctr, Dept Surg, IL-31096 Haifa, Israel; Univ Paris 06, Assistance Publ Hop Paris, Hop La Pitie Salpetriere, Dept Emergency Med, Paris, France; Univ Paris 06, Assistance Publ Hop Paris, Hop La Pitie Salpetriere, Dept Surg, Paris, France; Univ Paris 06, Assistance Publ Hop Paris, Hop La Pitie Salpetriere, Dept Anesthesiol & Crit Care, Paris, France; Univ Clin, Inst Anesthesiol, Aachen, Germany; Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; Johannesburg Hosp, Dept Surg, Johannesburg, South Africa; Natl Univ Singapore, Singapore 117548, Singapore; Univ Stellenbosch, Dept Surg, ZA-7505 Tygerberg, South Africa; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark	Kluger, Y (corresponding author), Rambam Med Ctr, Dept Surg, POB 9602, IL-31096 Haifa, Israel.	y_kluger@rambam.health.gov.il	Iau, Philip/B-4641-2011	Boffard, Kenneth/0000-0002-7159-5414; Choong, Peter/0000-0001-7333-7665			Abshire T, 2004, J THROMB HAEMOST, V2, P899, DOI 10.1111/j.1538-7836.2004.00759.x; Ahonen J, 2005, BRIT J ANAESTH, V94, P592, DOI 10.1093/bja/aei094; Amer Soc Anesthesiologists Task Fo, 2006, ANESTHESIOLOGY, V105, P198; Arkin S, 1998, HAEMOSTASIS, V28, P93; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Dereeper E, 1998, RESUSCITATION, V36, P15, DOI 10.1016/S0300-9572(97)00080-4; Deveras RAE, 2002, ANN INTERN MED, V137, P884, DOI 10.7326/0003-4819-137-11-200212030-00009; Dutton RP, 2004, J TRAUMA, V57, P709, DOI 10.1097/01.TA.0000140646.66852.AB; Gerlach R, 2002, J NEUROSURG, V96, P946, DOI 10.3171/jns.2002.96.5.0946; Grounds M, 2003, BLOOD REV, V17, pS11, DOI 10.1016/S0268-960X(03)90002-6; Harrison TD, 2005, J TRAUMA, V59, P150, DOI 10.1097/01.TA.0000171470.39742.8E; Hawryluk GWJ, 2006, J NEUROSURG, V105, P859, DOI 10.3171/jns.2006.105.6.859; Hedner U, 2006, J BIOTECHNOL, V124, P747, DOI 10.1016/j.jbiotec.2006.03.042; Heisel M, 2004, PEDIATR BLOOD CANCER, V43, P703, DOI 10.1002/pbc.20144; Hoffman M, 2001, THROMB HAEMOSTASIS, V85, P958; Hoyt DB, 2004, SEMIN HEMATOL, V41, P40, DOI 10.1053/j.seminhematol.2003.11.009; HOYT DB, 1994, J TRAUMA, V37, P426, DOI 10.1097/00005373-199409000-00016; Karadimov D, 2003, J NEUROSURG ANESTH, V15, P330, DOI 10.1097/00008506-200310000-00008; Kenet G, 1999, LANCET, V354, P1879, DOI 10.1016/S0140-6736(99)05155-7; Koh MBC, 2003, BLOOD REV, V17, P179, DOI 10.1016/S0268-960X(02)00062-0; Levi M, 2005, CRIT CARE MED, V33, P883, DOI 10.1097/01.CCM.0000159087.85970.38; Levi M, 2004, SEMIN HEMATOL, V41, P65, DOI 10.1053/j.seminhematol.2003.11.013; Levi M, 2004, J THROMB HAEMOST, V2, P1695, DOI 10.1111/j.1538-7836.2004.00912.x; Levy JH, 2006, TRANSFUSION, V46, P919, DOI 10.1111/j.1537-2995.2006.00824.x; Lin J, 2003, J NEUROSURG, V98, P737, DOI 10.3171/jns.2003.98.4.0737; Lynn M, 2002, INTENS CARE MED, V28, pS241, DOI 10.1007/s00134-002-1471-7; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Martinowitz U, 2005, J THROMB HAEMOST, V3, P640, DOI 10.1111/j.1538-7836.2005.01203.x; Martinowitz U, 2001, J TRAUMA, V51, P431, DOI 10.1097/00005373-200109000-00002; Martinowitz Uri, 2004, Mil Med, V169, P16; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Midathada MV, 2004, AM J CLIN PATHOL, V121, P124, DOI 10.1309/D0G0C96V05CJ5B4J; Morenski JD, 2003, J NEUROSURG, V98, P611, DOI 10.3171/jns.2003.98.3.0611; O'Connell KA, 2006, JAMA-J AM MED ASSOC, V295, P293, DOI 10.1001/jama.295.3.293; Park P, 2003, NEUROSURGERY, V53, P34, DOI 10.1227/01.NEU.0000068830.54968.A8; Pathak A, 2005, Neurol India, V53, P178; Pickard JD, 2000, BLOOD COAGUL FIBRIN, V11, pS117, DOI 10.1097/00001721-200004001-00022; Rizoli SB, 2006, J TRAUMA, V61, P1419, DOI 10.1097/01.ta.0000243045.56579.74; Roberts HR, 2005, CAN J ANAESTH, V52, P8, DOI 10.1007/BF03018573; Roberts HR, 2004, SEMIN HEMATOL, V41, P101, DOI 10.1053/j.seminhematol.2003.11.019; Romano JG, 2002, NEUROSURGERY, V50, P1026, DOI 10.1097/00006123-200205000-00016; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Segal S, 2004, ACTA OBSTET GYN SCAN, V83, P771, DOI 10.1111/j.0001-6349.2004.00501.x; Siegel LJ, 2004, ANESTHESIOLOGY, V100, P441, DOI 10.1097/00000542-200402000-00037; Soreide E, 2005, INJURY, V36, P1001, DOI 10.1016/j.injury.2005.01.002; Spahn DR, 2007, CRIT CARE, V11, DOI 10.1186/cc5686; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Thomas GOR, 2007, J TRAUMA, V62, P564, DOI 10.1097/TA.0b013e318031afc2; Veshchev Igor, 2002, Med Sci Monit, V8, pCS98; Vincent JL, 2006, CRIT CARE, V10, DOI 10.1186/cc5026; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; Warren O, 2007, ANN THORAC SURG, V83, P707, DOI 10.1016/j.athoracsur.2006.10.033; Welsby IJ, 2005, ANAESTHESIA, V60, P1203, DOI 10.1111/j.1365-2044.2005.04376.x; Wong WY, 2000, HAEMOPHILIA, V6, P50; Zaaroor M, 2004, SEMIN HEMATOL, V41, P175, DOI 10.1053/j.seminhematol.2003.11.033	56	28	28	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2007	11	4							R85	10.1186/cc6092			8	Critical Care Medicine	General & Internal Medicine	224TJ	WOS:000250469000014	17686152	DOAJ Gold, Green Published			2021-06-18	
J	Lux, WE				Lux, Warren E.			A neuropsychiatric perspective on traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						behavior; cognition; depression; diffuse axonal injury; executive function; frontal lobes; mood; neuropsychiatry; rehabilitation; self-awareness; traumatic brain injury	CLOSED-HEAD-INJURY; OBSESSIVE-COMPULSIVE DISORDER; HOMOVANILLIC-ACID; 5-HYDROXYINDOLE-ACETIC ACID; CEREBROSPINAL-FLUID; EARLY INTERVENTION; REHABILITATION; CONSCIOUSNESS; DEPRESSION; LESIONS	Traumatic brain injury (TBI) due to closed mechanisms causes strain injuries to axons that increase in number and severity as injury severity increases. Axons that project up from the brain stem are vulnerable, even in milder concussive injuries, and include axons that participate in key monoaminergic pathways. Although called diffuse axonal injury, the supratentorial injury component typically shows an anterior preponderance in humans. As the injury forces increase, cerebral contusions may be superimposed on the axonal strain injuries, and these contusions show an anterior preponderance as well. The chronic neuropsychiatric manifestations of TBI reflect this injury distribution. In the cognitive sphere, these manifestations almost always include power function disturbances marked by difficulties with cognitive processing speed, multi-tasking, and cognitive endurance. These disturbances may then be followed by disturbances in executive function and self-awareness as injury severity increases. In the behavioral sphere, mood disturbances and disorders of behavioral control and regulation are particularly common.	[Lux, Warren E.] US EPA, Off Sci Advisor, Washington, DC 20460 USA; [Lux, Warren E.] Georgetown Univ, Ctr Clin Bioeth, Washington, DC USA	Lux, WE (corresponding author), US EPA, Off Sci Advisor, 1200 Penn Ave NW,Mail Code 8105R, Washington, DC 20460 USA.	lux.warren@epa.gov					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson J, 2004, PHILOS PSYCHIAT PSYC, V11, P279, DOI DOI 10.1353/PPP; BAKCHINE S, 1989, NEUROLOGY, V39, P777, DOI 10.1212/WNL.39.6.777; BAREGGI SR, 1975, EUR NEUROL, V13, P528, DOI 10.1159/000114709; Berthier ML, 1996, NEUROLOGY, V47, P353, DOI 10.1212/WNL.47.2.353; BLAKE PY, 1995, NEUROLOGY, V45, P1641, DOI 10.1212/WNL.45.9.1641; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Damasio A., 1994, DESCARTESERROR EMOTI; DAMASIO H, 1994, SCIENCE, V265, P1159; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Fujii DEM, 1996, NEUROPSY NEUROPSY BE, V9, P133; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; GUALTIERI CT, 1991, NEUROPSYCHIATRY BEHA, P34; GUALTIERI CT, 1991, NEUROPSYCHIATRY BEHA, P109; GUALTIERI CT, 1991, NEUROPSYCHIATRY BEHA, P37; Hollander E, 1996, NEUROPSY NEUROPSY BE, V9, P230; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; Lee HCB, 2003, INT REV PSYCHIATR, V15, P359, DOI 10.1080/09540260310001606746; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LEWIN J, 1992, BRIT J PSYCHIAT, V161, P261, DOI 10.1192/bjp.161.2.261; Lezak M. D., 1989, ASSESSMENT BEHAV CON, P113; LUX WE, 1996, RECOVERY TRAUMATIC B, P99; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; POPE HG, 1988, COMPR PSYCHIAT, V29, P34, DOI 10.1016/0010-440X(88)90035-1; PORTA M, 1975, EUR NEUROL, V13, P545, DOI 10.1159/000114710; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; Scheutzow MH, 1999, BRAIN INJURY, V13, P705; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; VANWOERKOM TCAM, 1977, LANCET, V1, P812; VECHT CJ, 1975, LIFE SCI, V16, P1179, DOI 10.1016/0024-3205(75)90201-5; VECHT CJ, 1975, ARCH NEUROL-CHICAGO, V32, P792, DOI 10.1001/archneur.1975.00490540036004; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42	45	28	29	0	8	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2007	44	7					951	961		10.1682/JRRD.2007.01.0009			11	Rehabilitation	Rehabilitation	253NL	WOS:000252524800008	18075952	Bronze			2021-06-18	
J	Yasokawa, YT; Shinoda, J; Okumura, A; Nakayama, N; Miwa, K; Iwama, T				Yasokawa, Yu-To; Shinoda, Jun; Okumura, Ayumi; Nakayama, Noriyuki; Miwa, Kazuhiro; Iwama, Toru			Correlation between diffusion-tensor magnetic resonance imaging and motor-evoked potential in chronic severe diffuse axonal injury	JOURNAL OF NEUROTRAUMA			English	Article						diffuse axonal injury; diffusion-tensor imaging; motor dysfunction; motor evoked potential; tractography	TRAUMATIC BRAIN-INJURY; WHITE-MATTER INJURY; HEAD-INJURY; CORPUS-CALLOSUM; MR; TRACTOGRAPHY; EXPERIENCE; RECOVERY; LESIONS; DAMAGE	We conducted a study to evaluate the degree of corticospinal tract (CST) dysfunction associated with diffuse axonal injury (DAI) through analyses of both diffusion-tensor magnetic resonance imaging (DTMRI) and motor-evoked potential (MEP). Using DTMRI and MEP with transcranial magnetic stimulation, we evaluated 138 instances of CST in 52 patients with severe chronic DAI and compared them with the findings in 17 normal volunteers. We determined values of fractional anisotropy (FA) on FA maps obtained with DTMRI of six regions of interest (ROIs) in the CST, consisting of the semioval center, coronal radiation, posterior limb of internal capsule, midbrain, pons and medulla oblongata. The lowest value of %FA for each of the six ROIs in each CST was defined as the minimum %FA, and the lowest magnetic stimulation strength that produced MEP was defined as the minimum threshold for MEP. The mean minimum %FA for CSTs in which MEP could not be obtained even with maximum magnetic stimulation (the MEP-group) was significantly lower than that of CSTs in which MEP could be obtained (the MEP+ group). ROIs with the lowest %FA value were the midbrain in the MEP+ group and the medulla oblongata in the MEP-group. In the MEP+ group, a serial decrease in the minimum %FA value significantly correlated with a serial increase in minimum threshold for MEP. These results show that in patients with chronic DAI, physiological motor dysfunction as revealed by MEP correlates significantly with morphological damage to the CST as detected by DTMRI. This strongly suggests that DTMRI can be a valuable tool for evaluating aberrant motor function and for estimating its severity in DAI.	Kizawa Mem Hosp, Chubu Med Ctr Prolonged Traumat Brain Dysfunct, Minokamo, Gifu 5050034, Japan; Gifu Univ, Grad Sch Med, Dept Neurosurg, Gifu, Japan	Yasokawa, YT (corresponding author), Kizawa Mem Hosp, Chubu Med Ctr Prolonged Traumat Brain Dysfunct, 630 Shimokobi,Kobi Cho, Minokamo, Gifu 5050034, Japan.	yasokawa0512@yahoo.co.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [19790994] Funding Source: KAKEN		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Conforto AB, 2004, CLIN NEUROPHYSIOL, V115, P812, DOI 10.1016/j.clinph.2003.11.010; DILAZZARO V, 2005, J PHYSL, V15, P315; Ellis CM, 1999, NEUROLOGY, V53, P1051, DOI 10.1212/WNL.53.5.1051; Hendler T, 2003, J NEUROSURG, V99, P1018, DOI 10.3171/jns.2003.99.6.1018; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; Kamada K, 2005, J NEUROSURG, V102, P664, DOI 10.3171/jns.2005.102.4.0664; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Khedr EM, 2004, CLIN NEUROPHYSIOL, V115, P1259, DOI 10.1016/j.clinph.2003.08.025; Konishi J, 2005, NEUROLOGY, V64, P108, DOI 10.1212/01.WNL.0000148477.65273.0C; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Masutani Y, 2003, EUR J RADIOL, V46, P53, DOI 10.1016/S0720-048X(02)00328-5; Mori S, 2000, ANN NEUROL, V47, P412, DOI 10.1002/1531-8249(200003)47:3<412::AID-ANA28>3.3.CO;2-8; MOSELEY ME, 1990, RADIOLOGY, V176, P439, DOI 10.1148/radiology.176.2.2367658; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Neuloh G, 2004, ADV TECH STAND NEUR, V29, P171; Okumura Ayumi, 2005, No To Shinkei, V57, P115; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Schluter ND, 1998, BRAIN, V121, P785, DOI 10.1093/brain/121.5.785; Sekimoto K, 2006, J NEUROSURG ANESTH, V18, P106, DOI 10.1097/00008506-200604000-00003; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Werring DJ, 1998, J NEUROL NEUROSUR PS, V65, P863, DOI 10.1136/jnnp.65.6.863; Zeman AZJ, 1997, J NEUROL NEUROSUR PS, V62, P549, DOI 10.1136/jnnp.62.6.549	34	28	34	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					163	173		10.1089/neu.2006.0073			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100016	17263680				2021-06-18	
J	Michelucci, R				Michelucci, Roberto			Optimizing therapy of seizures in neurosurgery	NEUROLOGY			English	Article							QUALITY STANDARDS SUBCOMMITTEE; BRAIN-TUMORS; PRACTICE PARAMETER; TREATING SEIZURES; AMERICAN-ACADEMY; KINDLING MODEL; HEAD-INJURY; PHENYTOIN; ANTICONVULSANT; PROPHYLAXIS	The use of antiepileptic drugs (AEDs) in the neurosurgical setting has a number of implications, including their possible role in the prevention of seizures after acute cerebral insults or brain tumors and the potential for toxicity and interactions when these agents are administered in association with radiotherapy or chemotherapy. This review discusses these controversial issues and draws the following conclusions. 1) AEDs should be prescribed on a short-term basis to prevent seizures occurring within the first week after a cerebral insult (trauma, neurosurgical procedure) but are ineffective to avoid true post-traumatic epilepsy or first seizures in patients with primary or secondary cerebral neoplasms. 2) The use of phenytoin and, to a lesser extent, phenobarbital and carbamazepine during cranial irradiation is associated with an increased risk for severe, potentially fatal, mucocutaneous reactions. In this context, new AEDs with a very low potential for allergic cutaneous reactions should be preferred. 3) Enzyme-inducing AEDs, such as phenytoin, phenobarbital, and carbamazepine, may increase the clearance and reduce the clinical efficacy of corticosteroids and anticancer agents that are also metabolized by the cytochrome P450 system. The newly developed AEDs that are devoid of hepatic metabolism, such as levetiracetam and gabapentin, are now recommended because of good results in preliminary studies and because they do not show interactions with anticancer agents.	Bellaria Hosp, Neurol Unit, Dept Neurosci, I-40139 Bologna, Italy	Michelucci, R (corresponding author), Bellaria Hosp, Neurol Unit, Dept Neurosci, Via Altura 3, I-40139 Bologna, Italy.	roberto.michelucci@ausl.bo.it	Michelucci, Roberto/AAB-9074-2020	Michelucci, Roberto/0000-0002-9655-7940			Ahmed I, 2004, INT J DERMATOL, V43, P67, DOI 10.1111/j.1365-4632.2004.01934.x; Amano K, 1998, EPILEPSY RES, V31, P123, DOI 10.1016/S0920-1211(98)00021-7; Bourg V, 2001, ANN ONCOL, V12, P217, DOI 10.1023/A:1008331708395; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Chang SM, 1998, J CLIN ONCOL, V16, P2188, DOI 10.1200/JCO.1998.16.6.2188; Fetell MR, 1997, J CLIN ONCOL, V15, P3121, DOI 10.1200/JCO.1997.15.9.3121; Gilbar PJ, 2001, ANN PHARMACOTHER, V35, P1367; Glantz MJ, 1996, NEUROLOGY, V46, P985, DOI 10.1212/WNL.46.4.985; Glantz MJ, 2000, NEUROLOGY, V54, P1886, DOI 10.1212/WNL.54.10.1886; GROSSMAN SA, 1989, AM J MED, V87, P505; Jennett B, 1975, EPILEPSY NONMISSILE; Khan RB, 2004, J CHILD NEUROL, V19, P97, DOI 10.1177/08830738040190020301; LACKNER TE, 1991, PHARMACOTHERAPY, V11, P344; Loscher W, 1998, J PHARMACOL EXP THER, V284, P474; MCQUEEN JK, 1983, J NEUROL NEUROSUR PS, V46, P899, DOI 10.1136/jnnp.46.10.899; Micali G, 1999, PHARMACOTHERAPY, V19, P223, DOI 10.1592/phco.19.3.223.30917; NEEF C, 1988, CLIN PHARMACOL THER, V43, P372, DOI 10.1038/clpt.1988.45; Oberndorfer S, 2005, J NEURO-ONCOL, V72, P255, DOI 10.1007/s11060-004-2338-2; Packer RJ, 2003, J CLIN ONCOL, V21, P3255, DOI 10.1200/JCO.2003.01.202; Penovich PE, 2004, EPILEPSIA, V45, P311; Perry JR, 1996, CAN J NEUROL SCI, V23, P128, DOI 10.1017/S0317167100038853; PITKANEN A, 2002, ANTIEPILETIC DRUGS, P169; RABINOWICZ AL, 1995, EPILEPSIA, V36, P513, DOI 10.1111/j.1528-1157.1995.tb00494.x; RAPPORT RL, 1973, J NEUROSURG, V38, P159, DOI 10.3171/jns.1973.38.2.0159; Relling MV, 2000, LANCET, V356, P285, DOI 10.1016/S0140-6736(00)02503-4; RZANY B, 1999, LANCET, V354, P1033; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SERVIT Z, 1981, EPILEPSIA, V22, P315, DOI 10.1111/j.1528-1157.1981.tb04115.x; SILVER JM, 1991, ANN NEUROL, V29, P356, DOI 10.1002/ana.410290404; Striano S, 2002, EPILEPSY RES, V49, P81, DOI 10.1016/S0920-1211(02)00005-0; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; van Breemen Melanie S M, 2005, Curr Neurol Neurosci Rep, V5, P207; Vecht CJ, 2003, SEMIN ONCOL, V30, P49, DOI 10.1053/j.seminoncol.2003.11.030; Vecht CJ, 2003, LANCET NEUROL, V2, P404, DOI 10.1016/S1474-4422(03)00435-6; VITTORIO CC, 1995, ARCH INTERN MED, V155, P2285, DOI 10.1001/archinte.155.21.2285; Wagner GL, 2003, SEIZURE-EUR J EPILEP, V12, P585, DOI 10.1016/S1059-1311(03)00096-7; WOHNS RNW, 1979, J NEUROSURG, V51, P507, DOI 10.3171/jns.1979.51.4.0507; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236	40	28	29	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	DEC 26	2006	67	12		4			S14	S18		10.1212/WNL.67.12_suppl_4.S14			5	Clinical Neurology	Neurosciences & Neurology	122AK	WOS:000243197900004	17190915				2021-06-18	
J	Bayir, A; Kalkan, E; Kocak, S; Ak, A; Cander, B; Bodur, S				Bayir, Aysegul; Kalkan, Erdal; Kocak, Sedat; Ak, Ahmet; Cander, Basar; Bodur, Said			Fibrinolytic markers and neurologic outcome in traumatic brain injury	NEUROLOGY INDIA			English	Article						disseminated intravascular coagulopathy; fibrinogen; Glasgow Coma score; prognosis; traumatic brain injury	DISSEMINATED INTRAVASCULAR COAGULATION; HEAD-INJURY; POSTTRAUMA COAGULATION; COAGULOPATHY; CHILDREN	Aims: To determine the usefulness of fibrinolytic markers as early prognostic indicators in patients with isolated head trauma. Materials and Methods: Sixty-two consecutive patients (26 women and 36 men; mean age 61 years, range 2-76 years) with isolated head trauma seen within the first three hours of the trauma were included in the study. The Glasgow Coma score (GCS), platelet counts (Plt), prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen, fibrin degradation products (FDP) and D-dimer levels were measured. Head computerized tomography (CT) findings were categorized as brain edema, linear fracture, depressed fracture, contusion and bleeding. Plt counts, PT, PTT, fibrinogen, FDP, D-dimer levels and CT findings were compared with both GCS and mortality in the first week. Statistical significance was accepted at P <= 0.05. Results: A marked negative relationship was found between GCS and PT, PTT, FDP and D-climer levels (P < 0.001). Plt levels did not correlate with GCS. Mortality was most strongly related to GCS, PT, FDP and D-dimer levels (P < 0.001, P < 0.001, P < 0.001 and P < 0.001, respectively). We found no relationship between mortality and CT findings, nor was there any significant relationship between Plt, PTT and fibrinogen levels. Conclusion: GCS and fibrinolytic markers measured within the first three hours were useful in determining the prognosis of patients with isolated head trauma.	Selcuk Univ, Meram Fac Med, Emergency Dept, TR-42060 Konya, Turkey; Selcuk Univ, Meram Fac Med, Emergency Med Dept, TR-42060 Konya, Turkey; Selcuk Univ, Meram Fac Med, Neurosurg Dept, TR-42060 Konya, Turkey; Selcuk Univ, Meram Fac Med, Dept Med Stat, TR-42060 Konya, Turkey	Bayir, A (corresponding author), Selcuk Univ, Meram Fac Med, Emergency Dept, TR-42060 Konya, Turkey.	a_bayir@hotmail.com	Kocak, Sedat/AAB-7479-2020	Kocak, Sedat/0000-0001-8265-9615			AUER L, 1978, ACTA NEUROCHIR, V43, P51, DOI 10.1007/BF01809225; Becker S, 1999, EUR J PEDIATR, V158, pS197, DOI 10.1007/PL00014355; BJORKLID E, 1977, THROMB HAEMOSTASIS, V37, P91, DOI 10.1055/s-0038-1649206; BREDBACKA S, 1994, J NEUROSURG ANESTH, V6, P75; CLARK JA, 1980, J NEUROSURG, V52, P266, DOI 10.3171/jns.1980.52.2.0266; DRAYER BP, 1975, JAMA-J AM MED ASSOC, V231, P174, DOI 10.1001/jama.231.2.174; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; GANDO S, 1992, CRIT CARE MED, V20, P594, DOI 10.1097/00003246-199205000-00009; Heesen M, 1997, SURG NEUROL, V47, P32, DOI 10.1016/S0090-3019(96)00373-4; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; Kirsh TD, 2004, EMERGENCY MED COMPRE, P1557; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; Murshid WR, 2002, BRIT J NEUROSURG, V16, P362, DOI 10.1080/0268869021000007597; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Pathak A, 2005, Neurol India, V53, P178; SAWAYA R, 1987, SURG NEUROL, V28, P163, DOI 10.1016/0090-3019(87)90093-0; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; UEDA S, 1985, J NEUROL NEUROSUR PS, V48, P58, DOI 10.1136/jnnp.48.1.58; VALADKA AB, 2000, TRAUMA, P377; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003	22	28	35	0	2	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0028-3886	1998-4022		NEUROL INDIA	Neurol. India	DEC	2006	54	4					363	365		10.4103/0028-3886.28106			3	Neurosciences	Neurosciences & Neurology	110WW	WOS:000242413000013	17114843				2021-06-18	
J	Taylor, AN; Rahman, SU; Tio, DL; Sanders, MJ; Bando, JK; Truong, AH; Prolo, P				Taylor, Anna N.; Rahman, Shayan U.; Tio, Delia L.; Sanders, Matthew J.; Bando, Jennifer K.; Truong, Amy H.; Prolo, Paolo			Lasting neuroendocrine-immune effects of traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						activity; body temperature; corticosterone; lipopolysaccharide; stress	CORTICOTROPIN-RELEASING-FACTOR; PITUITARY-ADRENAL AXIS; CORTICAL IMPACT INJURY; CLOSED-HEAD INJURY; ALCOHOL-CONSUMPTION; TIME-SERIES; ETHANOL; RESPONSES; STRESS; FEVER	Traumatic brain injury (TBI) is a principal cause of long-term physical, cognitive, behavioral, and social deficits in young adults, which frequently coexist with a high incidence of substance abuse disorders. However, few studies have examined the long-term effects of TBI on the neuroendocrine-immune system. TBI was induced in adult male rats under isoflurane anesthesia by cortical contusion injury with a pneumatic piston positioned stereotaxically over the left parietal cortex. Controls underwent sham surgery without injury. At 4 weeks post-injury, the plasma corticosterone response to 30-min restraint stress was significantly blunted in TBI rats compared to the sham controls. One week later, transmitters were implanted for continuous biotelemetric recording of body temperature and spontaneous locomotor activity. At 6 weeks post-injury, the febrile response to i.p. injection of the bacterial endotoxin, lipopolysaccharide (LPS; 50 mu g/kg), was significantly lower in TBI than in sham rats. At 8 weeks, swimming in the forced swim test was significantly less in TBI than sham rats. At 9 weeks, rats were rendered ethanol (EtOH) dependent by feeding an EtOH-containing liquid diet for 14 days. Cosine rhythmometry analysis of circadian body temperature Midline Estimating Statistic of Rhythm (MESOR), amplitudes, and acrophases indicated differential effects of EtOH and withdrawal in the two groups. Light- and dark-phase activity analysis indicated that TBI rats were significantly more active than the sham group, and that EtOH and withdrawal differentially affected their activity. Given the extensive interactions of the neuroendocrine-immune systems, these results demonstrate that TBI produces lasting dysregulation amidst the central substrates for allostasis and circadian rhythmicity.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Inst Brain Res, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; W Los Angeles Healthcare Ctr, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA; Marquette Univ, Dept Psychol, Milwaukee, WI 53233 USA; NIAID, LCMI, NIH, Bethesda, MD 20892 USA; Univ Calif Los Angeles, Sch Dent, Div Oral Biol, Los Angeles, CA 90095 USA	Taylor, AN (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Inst Brain Res, 10833 Le Conte Ave,Box 951763, Los Angeles, CA 90095 USA.	ataylor@mednet.ucla.edu		Bando, Jennifer/0000-0002-1331-7424			Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Blatteis CM, 1998, ANN NY ACAD SCI, V840, P608, DOI 10.1111/j.1749-6632.1998.tb09600.x; Cernak I, 1999, BRAIN INJURY, V13, P1005; CHILDERS MK, 1998, BRAIN INJURY, V12, P547; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; De Kloet ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/er.19.3.269; Fernandez JR, 1998, CHRONOBIOL INT, V15, P191, DOI 10.3109/07420529808998683; Frieboes RM, 1999, J NEUROPSYCH CLIN N, V11, P354, DOI 10.1176/jnp.11.3.354; Goldstein LB, 2003, BRAIN INJURY, V17, P685, DOI 10.1080/0269905031000107179; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Grundy PL, 2001, J NEUROTRAUM, V18, P1373, DOI 10.1089/08977150152725669; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Herman JP, 2003, FRONT NEUROENDOCRIN, V24, P151, DOI 10.1016/j.yfrne.2003.07.001; Hornstein A, 1996, BRAIN INJURY, V10, P145, DOI 10.1080/026990596124647; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KLUGER MJ, 1991, PHYSIOL REV, V71, P93; Kropyvnytskyy I, 2001, BRAIN INJURY, V15, P511, DOI 10.1080/02699050010007515; Lahmame A, 1997, BRAIN RES, V750, P285, DOI 10.1016/S0006-8993(96)01368-6; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; McCullers DL, 2002, BRAIN RES, V947, P41, DOI 10.1016/S0006-8993(02)02904-9; McEwen BS, 2003, HORM BEHAV, V43, P2, DOI 10.1016/S0018-506X(02)00024-7; MOJON A, 1992, CHRONOBIOL INT, V9, P403, DOI 10.3109/07420529209064552; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MORROW LE, 1993, AM J PHYSIOL, V264, pR1010; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; Opp MR, 1997, PHYSIOL BEHAV, V63, P67, DOI 10.1016/S0031-9384(97)00390-9; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Phillips JP, 2003, J HEAD TRAUMA REHAB, V18, P342, DOI 10.1097/00001199-200307000-00005; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; Rasmussen DD, 2000, ALCOHOL CLIN EXP RES, V24, P1836, DOI 10.1097/00000374-200012000-00013; REDEI E, 1986, J PHARMACOL EXP THER, V237, P59; REDEI E, 1988, ENDOCRINOLOGY, V123, P2736, DOI 10.1210/endo-123-6-2736; Rivier C, 1996, BRAIN RES, V726, P1, DOI 10.1016/0006-8993(96)00301-0; Roe SY, 1998, EUR J NEUROSCI, V10, P553, DOI 10.1046/j.1460-9568.1998.00064.x; RUDY TA, 1980, THERMOREGULATORY MEC, P75; Saper CB, 2005, NATURE, V437, P1257, DOI 10.1038/nature04284; SELYE H, 1946, J CLIN ENDOCR METAB, V6, P117, DOI 10.1210/jcem-6-2-117; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; Sholkina Margarita N, 2002, Russ J Immunol, V7, P365; Sternberg EM, 1997, J CLIN INVEST, V100, P2641, DOI 10.1172/JCI119807; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SUTTON RL, 1987, J HEAD TRAUMA REHAB, V2, P50; TABAKOFF B, 1978, J PHARM PHARMACOL, V30, P371, DOI 10.1111/j.2042-7158.1978.tb13259.x; Taylor AN, 1999, J NEUROIMMUNOL, V99, P44, DOI 10.1016/S0165-5728(99)00102-2; Taylor AN, 2005, J NEUROTRAUM, V22, P1253; Taylor AN, 2002, ALCOHOL CLIN EXP RES, V26, P44; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; TAYLOR AN, 2005, SOC NEUR ABST; Weinberg J, 1996, ALCOHOL CLIN EXP RES, V20, P122, DOI 10.1111/j.1530-0277.1996.tb01054.x; Whishaw IQ, 2004, J NEUROTRAUM, V21, P1584, DOI 10.1089/neu.2004.21.1584; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; Woodlee M.T., 2005, BEHAV LAB RAT HDB TE, P129; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	65	28	28	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2006	23	12					1802	1813		10.1089/neu.2006.23.1802			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	120AP	WOS:000243056100008	17184190				2021-06-18	
J	Cuzzocrea, S; Genovese, T; Mazzon, E; Crisafulli, C; Min, W; Di Paola, R; Muia, C; Li, JH; Esposito, E; Bramanti, P; Xu, WZ; Massuda, E; Zhang, J; Wang, ZQ				Cuzzocrea, Salvatore; Genovese, Tiziana; Mazzon, Emanuela; Crisafulli, Concetta; Min, Wookee; Di Paola, Rosanna; Muia, Carmelo; Li, Jia-He; Esposito, Emanuela; Bramanti, Placido; Xu, Weizheng; Massuda, Edmond; Zhang, Jie; Wang, Zhao-Qi			Poly(ADP-ribose) glycohydrolase activity mediates post-traumatic inflammatory reaction after experimental spinal cord trauma	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							NITRIC-OXIDE SYNTHASE; CELL-DEATH; DNA FRAGMENTATION; INJURY; INHIBITION; POLYMERASE; SYNTHETASE; EXPRESSION; APOPTOSIS; ISCHEMIA	The aim of the present study was to examine the role of poly( ADP-ribose) glycohydrolase (PARG) on the modulation of the inflammatory response and tissue injury associated with neurotrauma. Spinal cord trauma was induced in wild-type (WT) mice by the application of vascular clips (force of 24 g) to the dura via a two-level T-6 to T-7 laminectomy. Spinal cord injury in WT mice resulted in severe trauma characterized by edema, neutrophil infiltration, and cytokine production followed by recruitment of other inflammatory cells, production of a range of inflammation mediators, tissue damage, apoptosis, and disease. The genetic disruption of the PARG gene in mice or the pharmacological inhibition of PARG with GPI 16552 [N-bis-(3-phenyl-propyl)9-oxo-fluorene-2,7-diamide] (40 mg/kg i.p. bolus), a novel and potent PARG inhibitor, significantly reduced the degree of spinal cord inflammation and tissue injury (histological score), neutrophil infiltration, cytokine production (tumor necrosis factor-alpha and interleukin-1 beta), and apoptosis. In a separate experiment, we have clearly demonstrated that PARG inhibition significantly ameliorated the recovery of limb function. Taken together, our results indicate that PARG activity modulates the inflammatory response and tissue injury events associated with spinal cord trauma and participate in target organ damage under these conditions.	Univ Messina, Sch Med, Inst Pharmacol, Policlin Univ,Dept Clin & Expt Med & Pharmacol, I-98100 Messina, Italy; Carattere Sci Ctr Neurolesi Bonino Pulejo, Ist Ric & Cura, Messina, Italy; Int Agcy Res Canc, F-69372 Lyon, France; Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy; Guilford Pharmaceut Inc, Baltimore, MD USA; Lilium Pharmaceut, Cockeysville, MD USA	Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Inst Pharmacol, Policlin Univ,Dept Clin & Expt Med & Pharmacol, Torre Biol,Via C Valeria, I-98100 Messina, Italy.	salvator@unime.it	Bramanti, Placido/K-5117-2016; Mazzon, Emanuela/AAL-4334-2020; di paola, rosanna/U-4356-2019	mazzon, emanuela/0000-0002-5073-717X; GENOVESE, Tiziana/0000-0002-3335-7327; di paola, rosanna/0000-0001-6725-8581			Bar-Peled O, 1999, J NEUROSCI RES, V55, P542, DOI 10.1002/(SICI)1097-4547(19990301)55:5<542::AID-JNR2>3.0.CO;2-7; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beattie MS, 2002, PROG BRAIN RES, V137, P37; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Cortes U, 2004, MOL CELL BIOL, V24, P7163, DOI 10.1128/MCB.24.16.7163-7178.2004; Cozzi A, 2006, J CEREBR BLOOD F MET, V26, P684, DOI 10.1038/sj.jcbfm.9600222; Cuzzocrea S, 1998, IMMUNOLOGY, V93, P96; Cuzzocrea S, 2005, FASEB J, V19, P558, DOI 10.1096/fj.04-3117com; Cuzzocrea S, 1998, FREE RADICAL BIO MED, V24, P450, DOI 10.1016/S0891-5849(97)00280-3; Genovese T, 2005, J PHARMACOL EXP THER, V312, P449, DOI 10.1124/jpet.104.076711; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; LI J, 2003, Patent No. 6635756; LI J, 2004, Patent No. 6635786; Liu SF, 1997, J IMMUNOL, V159, P3976; Lu XCM, 2003, BRAIN RES, V978, P99, DOI 10.1016/S0006-8993(03)02774-4; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Nesic-Taylor O, 2005, J NEUROSCI RES, V79, P628, DOI 10.1002/jnr.20400; Patel NSA, 2005, J AM SOC NEPHROL, V16, P712, DOI 10.1681/ASN.2004080677; PIELASMITH TH, 1992, J IMMUNOL, V148, P41; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; Schutte B, 1998, J NEUROSCI METH, V86, P63, DOI 10.1016/S0165-0270(98)00147-2; SLAMA JT, 1995, J MED CHEM, V38, P389, DOI 10.1021/jm00002a021; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Szabo C, 1998, EUR J PHARMACOL, V350, P1, DOI 10.1016/S0014-2999(98)00249-0; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Tyor WR, 2002, J NEUROL SCI, V200, P33, DOI 10.1016/S0022-510X(02)00113-2; West JD, 2005, J BIOL CHEM, V280, P15141, DOI 10.1074/jbc.M413147200; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Ying WH, 2001, P NATL ACAD SCI USA, V98, P12227, DOI 10.1073/pnas.211202598; Ying WH, 2000, NEUROREPORT, V11, P1385, DOI 10.1097/00001756-200005150-00007; Zhang ZY, 1998, EXP NEUROL, V149, P221, DOI 10.1006/exnr.1997.6717	40	28	29	0	2	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	OCT	2006	319	1					127	138		10.1124/jpet.106.108076			12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	087UK	WOS:000240767800013	16825529				2021-06-18	
J	Dinocourt, C; Gallagher, SE; Thompson, SM				Dinocourt, Celine; Gallagher, Sandra E.; Thompson, Scott M.			Injury-induced axonal sprouting in the hippocampus is initiated by activation of trkB receptors	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						brain-derived neurotrophic factor; epilepsy; GAP-43; regeneration; slice culture	TEMPORAL-LOBE EPILEPSY; NEUROTROPHIC FACTOR PROTEIN; FIBER SYNAPTIC REORGANIZATION; EXPERIMENTAL BRAIN TRAUMA; TYROSINE KINASE RECEPTOR; CENTRAL-NERVOUS-SYSTEM; KAINATE-TREATED RATS; CA1 PYRAMIDAL CELLS; MESSENGER-RNA; NEUROPEPTIDE-Y	Penetrating head injuries are often accompanied by the delayed development of post-traumatic epilepsy. Schaffer collateral transection leads to axonal sprouting and hyperexcitability in area CA3 of hippocampal slice cultures. We used this model to test the hypothesis that the injury-induced axonal sprouting results from increased neurotrophin signaling via trkB receptors near the lesion. Using rats and mice, we established that sprouting CA3 pyramidal cell axons are labeled with an antibody to the growth-associated protein GAP-43. We observed two- to threefold increases in the level of brain-derived neurotrophic factor and trkB protein in area CA3 by 24-48 h after Schaffer collateral transection, preceding the onset of axonal sprouting. Finally, we demonstrated that injury-induced axonal sprouting of GAP-43-immunoreactive axons is impaired in hippocampal slice cultures from mice expressing low levels of trkB receptors. We conclude that injury-induced axonal sprouting is initiated by brain-derived neurotrophic factor-trkB signaling and suggest that this process may be critical for the genesis of post-traumatic epilepsy.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Program Med & Res Technol, Baltimore, MD 21201 USA	Thompson, SM (corresponding author), Univ Maryland, Sch Med, Dept Physiol, 655 W Baltimore St, Baltimore, MD 21201 USA.	sthom003@umaryland.edu	Thompson, Scott M/K-8921-2015		NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH65488] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40388] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH065488] Funding Source: NIH RePORTER		Armitage LL, 1998, BRAIN RES, V781, P37, DOI 10.1016/S0006-8993(97)01218-3; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; Bender R, 1998, EXP BRAIN RES, V120, P399, DOI 10.1007/s002210050413; Binder DK, 1999, J NEUROSCI, V19, P4616; Binder DK, 1999, J NEUROSCI, V19, P1424; Cavazos JE, 2004, NEUROSCIENCE, V126, P677, DOI 10.1016/j.neuroscience.2004.04.014; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; Chen X, 2005, NEURON, V46, P13, DOI 10.1016/j.neuron.2005.03.009; Conner JM, 1997, J NEUROSCI, V17, P2295; CORSELLIS JAN, 1984, NEUROPATHOLOGY, P921; Danzer SC, 2004, J NEUROSCI, V24, P11346, DOI 10.1523/JNEUROSCI.3846-04.2004; Elmer E, 1998, NEUROSCIENCE, V83, P351, DOI 10.1016/S0306-4522(97)00387-4; Elmer E, 1996, BRAIN RES, V712, P19, DOI 10.1016/0006-8993(95)01424-1; Emery DL, 2000, J COMP NEUROL, V424, P521; ERNFORS P, 1991, NEURON, V7, P165, DOI 10.1016/0896-6273(91)90084-D; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; Esclapez M, 1999, J COMP NEUROL, V408, P449, DOI 10.1002/(SICI)1096-9861(19990614)408:4<449::AID-CNE1>3.0.CO;2-R; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Fryer RH, 1996, J COMP NEUROL, V374, P21, DOI 10.1002/(SICI)1096-9861(19961007)374:1<21::AID-CNE2>3.0.CO;2-P; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; Gahwiler BH, 1998, CULTURING NERVE CELL, P461; GALL C, 1992, EPILEPSY RES, P171; Gall C M, 1997, Adv Neurol, V72, P9; GALL CM, 1993, EXP NEUROL, V124, P150, DOI 10.1006/exnr.1993.1186; Golarai G, 2001, J NEUROSCI, V21, P8523; He XP, 2004, NEURON, V43, P31, DOI 10.1016/j.neuron.2004.06.019; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; Hu BR, 2004, J CEREBR BLOOD F MET, V24, P934, DOI 10.1097/01.WCB.0000125888.56462.A1; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KLEIN R, 1990, DEVELOPMENT, V109, P845; KOKAIA M, 1995, EXP NEUROL, V133, P215, DOI 10.1006/exnr.1995.1024; Koyama R, 2004, J NEUROSCI, V24, P7215, DOI 10.1523/JNEUROSCI.2045-04.2004; Lamballe F, 1991, Princess Takamatsu Symp, V22, P153; Lehmann TN, 2000, EPILEPSIA, V41, pS190, DOI 10.1111/j.1528-1157.2000.tb01580.x; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; Longo BM, 1997, NEUROSCI LETT, V226, P163, DOI 10.1016/S0304-3940(97)00267-X; MAJOKOWSKI J, 1990, COMPREHENSIVE EPILEP, P281; MATHERN GW, 1995, J NEUROSURG, V82, P211, DOI 10.3171/jns.1995.82.2.0211; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; McKinney RA, 1999, P NATL ACAD SCI USA, V96, P11631, DOI 10.1073/pnas.96.20.11631; MERLIO JP, 1993, NEURON, V10, P151, DOI 10.1016/0896-6273(93)90307-D; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; Mohapel P, 1997, BRAIN RES, V778, P186, DOI 10.1016/S0006-8993(97)01079-2; Murray KD, 2000, J COMP NEUROL, V418, P411, DOI 10.1002/(SICI)1096-9861(20000320)418:4<411::AID-CNE4>3.0.CO;2-F; NADLER JV, 1980, BRAIN RES, V191, P387, DOI 10.1016/0006-8993(80)91289-5; NADLER JV, 1980, BRAIN RES, V182, P1; Perez Y, 1996, EUR J NEUROSCI, V8, P736, DOI 10.1111/j.1460-9568.1996.tb01259.x; Poulsen FR, 2002, BRAIN RES, V950, P103, DOI 10.1016/S0006-8993(02)03009-3; Qiao XX, 2001, J NEUROSCI RES, V64, P268, DOI 10.1002/jnr.1075.abs; REPRESA A, 1989, NEUROSCI LETT, V99, P345, DOI 10.1016/0304-3940(89)90471-0; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Scharfman HE, 2002, EXP NEUROL, V174, P201, DOI 10.1006/exnr.2002.7869; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SCHWARTZ RS, 2002, REV CARDIOVASC ME S5, V3, P4; Siddiqui AH, 2005, BRAIN RES, V1066, P129, DOI 10.1016/j.brainres.2005.10.066; Smith BN, 2002, J NEUROPHYSIOL, V87, P1655, DOI 10.1152/jn.00581.2001; Sommer W., 1880, ARCH PSYCHIAT NERVEN, V10, P631, DOI [DOI 10.1007/BF02224538, 10.1007/BF02224538]; STOPPINI L, 1993, NEUROSCIENCE, V57, P985, DOI 10.1016/0306-4522(93)90043-F; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; Sutula T, 1998, J COMP NEUROL, V390, P578, DOI 10.1002/(SICI)1096-9861(19980126)390:4<578::AID-CNE9>3.0.CO;2-Y; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; Takahashi M, 1999, BRAIN RES, V818, P579, DOI 10.1016/S0006-8993(98)01355-9; Tongiorgi E, 1997, J NEUROSCI, V17, P9492; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Vezzani A, 1999, NEUROSCIENCE, V90, P1445, DOI 10.1016/S0306-4522(98)00553-3; Wyneken U, 2003, EPILEPSIA, V44, P243, DOI 10.1046/j.1528-1157.2003.17602.x; Xu B, 2004, NEUROSCIENCE, V126, P521, DOI 10.1016/j.neuroscience.2004.03.044; Xu BJ, 2000, NEURON, V26, P233, DOI 10.1016/S0896-6273(00)81153-8; Xu BJ, 2000, J NEUROSCI, V20, P6888, DOI 10.1523/JNEUROSCI.20-18-06888.2000; Yan Q, 1997, NEUROSCIENCE, V78, P431, DOI 10.1016/S0306-4522(96)00613-6	74	28	33	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	OCT	2006	24	7					1857	1866		10.1111/j.1460-9568.2006.05067.x			10	Neurosciences	Neurosciences & Neurology	095YL	WOS:000241344100003	17040478				2021-06-18	
J	Phillips, DJ; Nguyen, P; Adamides, AA; Bye, N; Rosenfeld, JV; Kossmann, T; Vallance, S; Murray, L; Morganti-Kossmann, MC				Phillips, David J.; Nguyen, Phuong; Adamides, Alexios A.; Bye, Nicole; Rosenfeld, Jeffrey V.; Kossmann, Thomas; Vallance, Shirley; Murray, Lynnette; Morganti-Kossmann, Maria C.			Activin A release into cerebrospinal fluid in a subset of patients with severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						activin A; inflammation; neuroprotection; traumatic brain injury	INTERSTITIAL GLYCEROL; BARRIER FUNCTION; HEAD-INJURY; SERUM; INTERLEUKIN-6; FOLLISTATIN; EXPRESSION; MODEL; CSF; PATHOPHYSIOLOGY	Activin A is a member of the transforming growth factor-beta superfamily and has been demonstrated to be elevated during inflammation and to have neuroprotective properties following neural insults. In this study, we examined whether traumatic brain injury (TBI) induced a response in activin A or in the concentrations of its binding protein, follistatin. Thirty-nine patients with severe TBI had daily, matched cerebrospinal fluid (CSF) and serum samples collected post-TBI and these were assayed for activin A and follistatin using specific immunoassays. Concentrations of both molecules were assessed relative to a variety of clinical parameters, such as the Glasgow Coma Score, computer tomography classification of TBI, measurement of injury markers, cell metabolism and membrane breakdown products. In about half of the patients, there was a notable increase in CSF activin A concentrations in the first few days post-TBI. There were only minor perturbations in either serum activin or in either CSF or serum follistatin concentrations. The CSF activin A response was not related to any of the common TBI indices, but was strongly correlated with two common markers of brain damage, neuronal specific enolase and S100-beta. Further, activin A levels were also associated with indices of metabolism, such as lactate and pyruvate, excitotoxicity (glutamate) and membrane lipid breakdown products such as glycerol. In one of the two patients who developed a CSF infection, activin A concentrations in CSF became markedly elevated. Thus, some TBI patients have an early release of activin A into the CSF that may result from activation of inflammatory and/or neuroprotective pathways.	Monash Univ, Monash Inst Med Res, Ctr Reprod & Dev, Clayton, Vic 3168, Australia; Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia; Alfred Hosp, Dept Trauma Surg, Melbourne, Vic, Australia; Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic, Australia	Phillips, DJ (corresponding author), Monash Univ, Monash Inst Med Res, Ctr Reprod & Dev, 27-31 Wright St, Clayton, Vic 3168, Australia.	david.phillips@med.monash.edu.au	Rosenfeld, Jeffrey V/B-7249-2011; Phillips, David/A-5007-2009	Morganti-Kossmann, Cristina/0000-0002-0807-2063			Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Florio P, 2004, CLIN CHEM, V50, P2386, DOI 10.1373/clinchem.2004.035774; Foster JA, 2004, J COMP NEUROL, V476, P91, DOI 10.1002/cne.20197; Frykholm P, 2001, J NEUROL NEUROSUR PS, V71, P455, DOI 10.1136/jnnp.71.4.455; Green AJE, 1997, J IMMUNOL METHODS, V205, P35, DOI 10.1016/S0022-1759(97)00050-1; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Hughes PE, 1999, NEUROSCIENCE, V92, P197, DOI 10.1016/S0306-4522(98)00724-6; Jones KL, 2000, ENDOCRINOLOGY, V141, P1905, DOI 10.1210/en.141.5.1905; Jones KL, 2004, J ENDOCRINOL, V182, P69, DOI 10.1677/joe.0.1820069; Knight PG, 1996, J ENDOCRINOL, V148, P267, DOI 10.1677/joe.0.1480267; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kothari RU, 1998, STROKE, V29, P313; Lai M, 1997, NEUROREPORT, V8, P2691, DOI 10.1097/00001756-199708180-00011; Lai M, 1996, NEUROSCIENCE, V70, P1013, DOI 10.1016/0306-4522(95)00413-0; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Maier B, 2005, J NEUROTRAUM, V22, P822, DOI 10.1089/neu.2005.22.822; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Michel U, 2003, J NEUROCHEM, V86, P238, DOI 10.1046/j.1471-4159.2003.01834.x; Michel U, 2003, EUR J ENDOCRINOL, V148, P559, DOI 10.1530/eje.0.1480559; Michel W, 2000, EUR J ENDOCRINOL, V143, P809, DOI 10.1530/eje.0.1430809; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; O'Connor AE, 1999, HUM REPROD, V14, P827, DOI 10.1093/humrep/14.3.827; PARAMORE CG, 1994, ACTA NEUROCHIR, V127, P79, DOI 10.1007/BF01808552; PHILLIPS DJ, 2003, CYTOKINE HDB, V2, P1153; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Schootman M, 2003, BRAIN INJURY, V17, P983, DOI 10.1080/0269905031000110427; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Sulyok S, 2004, MOL CELL ENDOCRINOL, V225, P127, DOI 10.1016/j.mce.2004.07.011; Tong S, 2004, BJOG-INT J OBSTET GY, V111, P326, DOI 10.1111/j.1471-0528.2004.00098.x; Tretter YP, 2000, NAT MED, V6, P812, DOI 10.1038/77548; Tretter YP, 1996, NEUROREPORT, V7, P1819, DOI 10.1097/00001756-199607290-00026; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039	45	28	29	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2006	23	9					1283	1294		10.1089/neu.2006.23.1283			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	085LP	WOS:000240605900001	16958581				2021-06-18	
J	Yildizdas, D; Altunbasak, S; Celik, U; Herguner, O				Yildizdas, D.; Altunbasak, S.; Celik, U.; Herguner, O.			Hypertonic saline treatment in children with cerebral edema	INDIAN PEDIATRICS			English	Article						cerebral edema; hypertonic saline; mannitol	ELEVATED INTRACRANIAL-PRESSURE; MAGNETIC-RESONANCE SPECTROSCOPY; TRAUMATIC BRAIN-INJURY; CHRONIC HYPONATREMIA; HEMORRHAGIC-SHOCK; SODIUM-TRANSPORT; HYPERTENSION; MANNITOL; RESUSCITATION; HYPERNATREMIA		Cukurova Univ, Fac Med, Pediat Intens Care Unit, TR-01330 Adana, Turkey; Cukurova Univ, Fac Med, Dept Pediat Neurol, Adana, Turkey; Cukurova Univ, Fac Med, Dept Pediat Infect Dis, Adana, Turkey	Yildizdas, D (corresponding author), Cukurova Univ, Fac Med, Pediat Intens Care Unit, TR-01330 Adana, Turkey.	rdy90@hotmail.com	Altunbasak, Sakir/K-6271-2018	Altunbasak, Sakir/0000-0002-0779-3272; yildizdas, dincer/0000-0003-0739-5108			BETZ AL, 1983, J NEUROCHEM, V41, P1158, DOI 10.1111/j.1471-4159.1983.tb09066.x; BETZ AL, 1983, J NEUROCHEM, V41, P1150, DOI 10.1111/j.1471-4159.1983.tb09065.x; Bhardwaj Anish, 2004, Curr Opin Crit Care, V10, P126, DOI 10.1097/00075198-200404000-00009; DUCEY JP, 1989, J TRAUMA, V29, P1518; FENSTERMACHER JD, 1966, AM J PHYSIOL, V211, P311; HAUSSINGER D, 1994, GASTROENTEROLOGY, V107, P1475; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; LIEN YHH, 1991, J CLIN INVEST, V88, P303, DOI 10.1172/JCI115292; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; OLSON JE, 1990, J NEUROSCI RES, V27, P241, DOI 10.1002/jnr.490270215; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Pollay M, 1996, NEUROSURGERY, P335; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; Soupart A, 1996, J NEUROPATH EXP NEUR, V55, P106, DOI 10.1097/00005072-199601000-00011; STACK C, 2004, ESSENTIALS PEDIAT IN, P155; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; TODD MM, 1985, J NEUROSURG, V63, P944, DOI 10.3171/jns.1985.63.6.0944; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; VIDEEN JS, 1995, J CLIN INVEST, V95, P788, DOI 10.1172/JCI117728; Weed LH, 1919, AM J PHYSIOL, V48, P531; WEINSTABL C, 1992, ANESTHESIOLOGY, V75, P201; WISE B L, 1961, Surg Forum, V12, P398; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021	29	28	33	0	4	SPRINGER INDIA	NEW DELHI	7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA	0019-6061	0974-7559		INDIAN PEDIATR	Indian Pediatrics	SEP	2006	43	9					771	779					9	Pediatrics	Pediatrics	087QZ	WOS:000240758500002	17033115				2021-06-18	
J	Bruce, BB; Zhang, X; Kedar, S; Newman, NJ; Biousse, V				Bruce, B. B.; Zhang, X.; Kedar, S.; Newman, N. J.; Biousse, V.			Traumatic homonymous hemianopia	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							VISUAL-FIELD DEFECTS; REHABILITATION; PERIMETRY; GOLDMANN; INJURY	Objective: To describe the characteristics of patients with homonymous hemianopia from traumatic brain injury (TBI) seen in our unit between 1989 and 2004. Methods: Only patients with a history of TBI, who had detailed clinical information and results of neuroimaging, were included in our study. Demographic characteristics, clinical features, types of visual field defects, location of lesion and evolution of visual field defects were recorded. Results: Of the 880 patients with homonymous hemianopia seen in our unit, 103 patients (112 with homonymous hemianopia) had TBI (74 men and 29 women, mean age 30.7 (SD 15.3) years). Median time from injury to initial visual field testing was 5 (range 0.5-360) months. In all, 64 (57.1%) patients sustained injuries that were motor vehicle-related; 19 (17%) violence-related; 17 (15.2%) due to falls; and 12 (10.7%) because of other blunt head trauma. Visual field defects included complete homonymous hemianopia in 44 (39.3%) patients and incomplete homonymous hemianopia in 68 (60.7%) patients. The lesion was occipital in 14 (12.5%) patients, associated with optic radiation in 26 (23.2%) and the optic tract in 12 (10.7%), and multiple in 60 (53.6%). Conclusion: Most cases of homonymous hemianopia from TBI were motor vehicle-related. Patients were younger, more often male, and had multiple brain lesions more often than patients with homonymous hemianopia from causes other than TBI. A median delay of 5 months was observed before the documentation of the homonymous hemianopia, which may have a major effect on the success of rehabilitation and driving training in these young patients.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA; Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA	Biousse, V (corresponding author), Emory Eye Ctr, Neuroophthalmol Unit, 1365 B Clifton Rd NE, Atlanta, GA 30322 USA.	vbiouss@emory.edu	Newman, Nancy/AAB-2532-2021; KEDAR, SACHIN/B-2579-2008	Kedar, Sachin/0000-0002-7293-5556; Bruce, Beau/0000-0003-3003-2962	NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30EY006360] Funding Source: NIH RePORTER; NEI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30-EY06360] Funding Source: Medline		Celesia GG, 1997, NEUROLOGY, V49, P88, DOI 10.1212/WNL.49.1.88; FUJINO T, 1986, NEURO-OPHTHALMOLOGY, V6, P17, DOI 10.3109/01658108608997320; GIANUTSOS R, 1988, ARCH PHYS MED REHAB, V69, P573; GRAY CS, 1989, AGE AGEING, V18, P419, DOI 10.1093/ageing/18.6.419; HEINEN M, 2005, NAT TRENDS INJ HOSP; KELTNER JL, 1987, OPHTHALMOLOGY, V94, P1180; Kerkhoff G, 1999, RESTOR NEUROL NEUROS, V15, P255; McKinnon J., 2001, BLACK POPULATION 200; Pambakian A, 2005, J NEURO-OPHTHALMOL, V25, P136; SAVIR H, 1977, SCAND J REHABIL MED, V9, P151; SMITH JL, 1962, AM J OPHTHALMOL, V54, P616, DOI 10.1016/0002-9394(62)92192-X; Szatmary G, 2002, ARCH OPHTHALMOL-CHIC, V120, P1162; TROBE JD, 1973, ARCH OPHTHALMOL-CHIC, V89, P377, DOI 10.1001/archopht.1973.01000040379005; TROBE JD, 2001, NEUROLOGY VISION, P109; UZZELL BP, 1988, ARCH NEUROL-CHICAGO, V45, P420, DOI 10.1001/archneur.1988.00520280066017; Van Stavern GP, 2001, J NEURO-OPHTHALMOL, V21, P112, DOI 10.1097/00041327-200106000-00012; Wall M, 2005, WALSH HOYT CLIN NEUR, P83; Wong AMF, 2000, OPHTHALMOLOGY, V107, P527, DOI 10.1016/S0161-6420(99)00092-5; Zhang X, 2006, NEUROLOGY, V66, P906, DOI 10.1212/01.wnl.0000203913.12088.93; Zhang X, 2006, NEUROLOGY, V66, P901, DOI 10.1212/01.wnl.0000203338.54323.22; ZIHL J, 1995, BRAIN, V118, P891, DOI 10.1093/brain/118.4.891	21	28	28	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2006	77	8					986	988		10.1136/jnnp.2006.088799			3	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	063RP	WOS:000239037600026	16574725	Green Published			2021-06-18	
J	Van Heugten, CM; Hendriksen, J; Rasquin, S; Dijcks, B; Jaeken, D; Vles, JHS				Van Heugten, C. M.; Hendriksen, J.; Rasquin, S.; Dijcks, B.; Jaeken, D.; Vles, J. H. S.			Long-term neuropsychological performance in a cohort of children and adolescents after severe paediatric traumatic brain injury	BRAIN INJURY			English	Article						brain injury; children; cognitive disorders; long-term functioning	REHABILITATION PROGRAM; FOLLOW-UP; RECOVERY; OUTCOMES; PREDICTORS; CHILDHOOD; TBI	Objective: The purpose of the present study was to evaluate progress in neuropsychological performance in children and adolescents with severe paediatric traumatic brain injury (TBI), from admission to the rehabilitation centre up to 3-12 years after the trauma. Methods: Children and adolescents (n = 3 1, mean age at injury 11.8 years, SD = 3.8; at follow-up 18.8 years; SD = 4.5) who all had suffered a TBI participated. A comprehensive neuropsychological test battery was administered at the start of rehabilitation (T 1), around discharge (T2) and in the long-term (at least 3 years after rehabilitation; T3). T I and T2 were clinical assessments; T3 was executed as a follow-up measurement for this study. Results: At T1 and T2, most problems were in the domains of attention, memory and executive functioning. At the start of rehabilitation most deficits were with performal intelligence (61%); at discharge (mean length of stay 411 days) considerably less children had severe deficits on the intelligence domain (23%). At long-term follow-up, most problems were in the domains attention, mental speed and memory. From admission to discharge 42% of the children improved on two or more cognitive tests; from discharge to follow-up this percentage was 13%. Conclusions: In this unique study a clinical cohort of children with severe TBI was followed for many years after injury. Most cognitive deficits were found in the early phase of rehabilitation. Most children did improve on cognitive functioning (40%) during the first year after their injury, whereas at follow-up most children had not changed. At follow-up, more than half of the children (54%) attended a regular school or had a regular job, corresponding to their age and pre-morbid functioning.	Inst Rehabil Res, iRv, NL-6430 AD Hoensbroek, Netherlands; SRL, Rehabil Fdn, Limburgerhof, Germany; Univ Maastricht, Inst Brain & Behav, Maastricht, Netherlands; Univ Hosp Maastricht, Maastricht, Netherlands	Van Heugten, CM (corresponding author), Inst Rehabil Res, iRv, POB 192, NL-6430 AD Hoensbroek, Netherlands.	c.vanheugten@irv.nl					Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V.A, 2001, DEV NEUROPSYCHOLOGY; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Anderson VA, 2000, BRAIN INJURY, V14, P679; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Beaulieu CL, 2002, SURG CLIN N AM, V82, P393, DOI 10.1016/S0039-6109(02)00009-9; Beery K, 1989, VMI DEV TEST VISUAL; BRAND PA, 1985, J GEN PSYCHOL, V12, P201; Brickenkamp R, 2000, TESTKATALOG 2000 200, P60; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fleming J, 1999, BRAIN INJURY, V13, P417; Garth J, 1997, Pediatr Rehabil, V1, P99; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; Hoofien D, 2001, BRAIN INJURY, V15, P189; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Jennett B., 1997, HEAD INJURY, P439; JOHNSON CA, 2001, BRAIN INJURY, V18, P921; Kaufman A. S., 1983, KAUFMAN ASSESSMENT B; Kieslich M, 2001, DISABIL REHABIL, V23, P665; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kline P, 2000, HDB PSYCHOL TESTING, V2; KRAUS MF, 1995, INT J PSYCHIAT MED, V25, P39, DOI 10.2190/BXRM-3M58-WBC5-A7EL; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; RUIJS MBM, 1995, NEUROLOGICAL ASPECTS; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; vanBalen HGG, 1996, DISABIL REHABIL, V18, P181, DOI 10.3109/09638289609166298; VANHAASSEN PP, 1986, WISC R DUTCH VERSION; Vos P.G., 1988, BOURDON VOS TEST; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009	46	28	28	0	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2006	20	9					895	903		10.1080/02699050600832015			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	094ZN	WOS:000241278100002	17062421				2021-06-18	
J	Hotz, GA; Castelblanco, A; Lara, IM; Weiss, AD; Duncan, R; Kuluz, JW				Hotz, Gillian A.; Castelblanco, Andrea; Lara, Isabel M.; Weiss, Alyssa D.; Duncan, Robert; Kuluz, John W.			Snoezelen: A controlled multi-sensory stimulation therapy for children recovering from severe brain injury	BRAIN INJURY			English	Article						behavioural; children; multi-sensory; Snoezelen; therapy	MENTAL-RETARDATION; HEAD TRAUMA; PLASTICITY; DISABILITIES; MANAGEMENT; PEOPLE; SCALE; BEHAVIOR; CARE; AGE	Objective: To investigate the effects of Snoezelen therapy on physiological, cognitive and behavioural changes in children recovering from severe traumatic brain injury (TBI). Methods: An observational study was conducted to assess the physiological, cognitive and behavioural changes of children recovering from severe TBI while receiving Snoezelen therapy. Fifteen subjects completed the pre- and post-Snoezelen treatment measurements computed over 10 consecutive sessions. Physiological, cognitive and behavioural measures were administered. Data was collected prospectively on each session in the Snoezelen room and were analysed by calculating the difference between pre- and post-treatment measurements for each Snoezelen session. Results: Results revealed significant changes on physiological measures. Heart rates decreased for each subject in each treatment session and were found to be significant (p = 0.032). Muscle tone was decreased in all the affected extremities (right upper extremity p=0.009, left upper extremity p=0.020, right lower extremity p=0.036 and left lower extremity p=0.018). Agitation levels decreased over time and the overall cognitive outcome measures showed significant improvement when comparing the beginning of treatment with the end. Conclusion: This study revealed a beneficial use of Snoezelen therapy with children recovering from severe brain injury. However, there continues to be a critical need for evidenced-based research for this patient population and others in this multi-sensory environment.	Ryder Trauma Ctr, DeWitt Daughtry Family Dept Surg, Div Trauma & Surg Crit Care, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33152 USA; Univ Miami, Sch Med, Dept Pediat, Miami, FL 33152 USA	Hotz, GA (corresponding author), Ryder Trauma Ctr, DeWitt Daughtry Family Dept Surg, Div Trauma & Surg Crit Care, 405,1800 NW 10th Ave, Miami, FL 33136 USA.	ghotz@med.miami.edu					ANSELL BJ, 1991, J SPEECH HEAR RES, V34, P1017, DOI 10.1044/jshr.3405.1017; Ayres A.J., 1979, SENSORY INTEGRATION; AYRES AJ, 1980, AM J OCCUP THER, V34, P375, DOI 10.5014/ajot.34.6.375; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Benz B, 1999, RESTOR NEUROL NEUROS, V14, P135; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; CLELAND CC, 1966, AM J MENT DEF, V71, P213; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; Cuvo AJ, 2001, RES DEV DISABIL, V22, P183, DOI 10.1016/S0891-4222(01)00067-1; deBunsen A., 1994, SENSATIONS DISABILIT, P138; Dennis M, 2000, J COMMUN DISORD, V33, P321, DOI 10.1016/S0021-9924(00)00028-9; Fagny M, 2000, REV FRANCOPHONE DEFI, V11, P105; Fields RD, 2005, NEUROSCIENTIST, V11, P528, DOI 10.1177/1073858405282304; FINGER S, 1978, RECOVERY BRAIN DAMAG; FINGER S, 1982, BRAIN DAMAGE RECOVER; *FLOR DEP HIGHW SA, 2002, TRAFF CRASH FACTS 20; Gerber CS, 2005, CRIT CARE NURS Q, V28, P94, DOI 10.1097/00002727-200504000-00002; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; HAGGAR L, 1991, BIMU PUBLICATIONS, V37, P69; Hogg J, 2001, RES DEV DISABIL, V22, P353, DOI 10.1016/S0891-4222(01)00077-4; Houghton S, 1998, J INTELLECT DEV DIS, V23, P267, DOI 10.1080/13668259800033761; HULSEGGE J, 1987, WORLD; Johnston M V, 2001, Adv Pediatr, V48, P1; Johnston MV, 2004, BRAIN DEV-JPN, V26, P73, DOI 10.1016/S0387-7604(03)00102-5; Johnston MV, 2003, PEDIATR RES, V53, P369, DOI 10.1203/01.PDR.0000049517.47493.E9; KAPLAN H, 2005, RES DEV DISABILITY; Kater K M, 1989, West J Nurs Res, V11, P20, DOI 10.1177/019394598901100103; KENYON J, 1998, BRIT J THERAPY REHAB, V5, P619; Kwok H. W. M., 2003, Hong Kong Medical Journal, V9, P122; Lancioni GE, 2005, DISABIL REHABIL, V27, P83, DOI 10.1080/09638280400007406; Lindsay WR, 1997, J INTELL DISABIL RES, V41, P201, DOI 10.1046/j.1365-2788.1997.03535.x; Long A., 1992, BRIT J OCCUPATIONAL, V55, P103; Lotan M, 2005, BRAIN DEV-JPN, V27, pS88, DOI 10.1016/j.braindev.2005.03.021; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MALKMUS D, 1980, REHABILITATION HEAD; Mayr JM, 2003, EUR J PEDIATR, V162, P184, DOI 10.1007/s00431-002-1099-1; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MESSBAUER L, 2004, SNOEZELEN STATE ART; RIVARA FP, 1984, DEV MED CHILD NEUROL, V26, P81; Schofield P, 2000, DISABIL REHABIL, V22, P675, DOI 10.1080/096382800445470; Shapiro M, 1997, BRIT J DEV DISABIL, V43, P140, DOI 10.1179/bjdd.1997.014; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; TEUBER HL, 1967, MED CHILD NEUROLOGY, V4, P3; THOMPSON SBN, 1994, BRIT J OCCUPATIONAL, V57, P341; Tolle Patrizia, 2003, Axone, V25, P20; WEGMAN WE, 1981, PEDIATRICS, V75, P835	50	28	32	0	25	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2006	20	8					879	888		10.1080/02699050600832635			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	081ZO	WOS:000240356300011	17046800				2021-06-18	
J	Svetlov, SI; Xiang, Y; Oli, MW; Foley, DP; Huang, G; Hayes, RL; Ottens, AK; Wang, KKW				Svetlov, S. I.; Xiang, Y.; Oli, M. W.; Foley, D. P.; Huang, G.; Hayes, R. L.; Ottens, A. K.; Wang, K. K. W.			Identification and preliminary validation of novel biomarkers of acute hepatic ischaemia/reperfusion injury using dual-platform proteomic/degradomic approaches	BIOMARKERS			English	Article						biomarkers; rat; liver; ischaemia/ reperfusion; injury; argininosuccinate synthase; estrogen sulfotransferase	MITOCHONDRIAL PERMEABILITY TRANSITION; TRAUMATIC BRAIN-INJURY; ALPHA-II-SPECTRIN; ISCHEMIA-REPERFUSION; LIVER-INJURY; PRESERVATION; ENDOTOXEMIA; MECHANISMS; DISCOVERY; APOPTOSIS	Hepatic ischaemia/reperfusion (I/R), a major cause of liver damage associated with multiple trauma, haemorrhagic and septic shock, and liver transplantation, contributes significantly to multiple organ failure. Development of novel sensitive biomarkers that detect early stages of liver damage is vital for effective management and treatment of ischaemic liver injury. By using high-throughput immunoblotting and cation-anion exchange chromatography/reversed-phase liquid chromatography-tandem mass-spectrometry, we identified several hepatic proteins, including argininosuccinate synthase ( ASS) and estrogen sulfotransferase (EST-1), which were degraded in the liver and rapidly released into circulation during I/R injury. ASS accumulated in serum within 10 min, reached a steady state at 30 min, and persisted up until 3 h after reperfusion following 30 min of total hepatic ischaemia. EST-1 appeared rapidly in blood and attained maximum within 1 hour followed by a decline at 3 h of reperfusion. No ASS or EST-1 protein was detected in serum of control or sham operated rats. ASS and EST-1 exhibited greater sensitivity and specificity toward I/R liver injury as compared with alanine aminotransferase (ALT), an established marker of hepatocellular necrosis. In contrast, serum ASS and EST-1 were undetectable in rats with chronic alcoholic liver disease, while the levels of ALT protein were significantly increased. In addition, ASS, but not EST-1 or ALT-accumulated in blood only 6 h after treatment with hepatotoxic combination of lipopolysaccharide and D-galactosamine. These data demonstrate the utility of ASS and EST-1 as novel sensitive and specific biomarkers of acute liver ischaemic injury for prospective clinical studies.	Univ Florida, Coll Med, Dept Neurosci, Ctr Prot & Biomarkers Res,Lab Mol & Cellular Mch, Gainesville, FL 32610 USA	Svetlov, SI (corresponding author), Univ Florida, Coll Med, Dept Neurosci, Ctr Prot & Biomarkers Res,Lab Mol & Cellular Mch, Gainesville, FL 32610 USA.	svetlov@mbi.ufl.edu	Ottens, Andrew/K-3352-2012	Wang, Kevin/0000-0002-9343-6473; Ottens, Andrew/0000-0002-2118-3796	NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R43 AI094877] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK061649] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS049175-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R43AI094877] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R21DK061649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175] Funding Source: NIH RePORTER		Aldemir D, 2003, TRANSPL P, V35, P2811, DOI 10.1016/j.transproceed.2003.08.048; Dokladny K, 2001, AM J PHYSIOL-REG I, V280, pR338; Haskins WE, 2004, ANAL CHEM, V76, P5523, DOI 10.1021/ac049363y; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Ikemoto M, 2001, CLIN CHEM, V47, P946; Jaeschke H, 1996, SHOCK, V6, P351, DOI 10.1097/00024382-199611000-00009; Jaeschke H, 2003, GASTROENTEROLOGY, V125, P1246, DOI 10.1016/S0016-5085(03)01209-5; Jaeschke H, 2003, AM J PHYSIOL-GASTR L, V284, pG15, DOI 10.1152/ajpgi.00342.2002; Jaeschke H, 1996, J HEPATOL, V25, P774, DOI 10.1016/S0168-8278(96)80253-4; Jaeschke H, 1996, TOXICOL APPL PHARM, V139, P213, DOI 10.1006/taap.1996.0160; Jones JJ, 1999, HEPATOLOGY, V30, P714, DOI 10.1002/hep.510300324; Kim JS, 2003, GASTROENTEROLOGY, V124, P494, DOI 10.1053/gast.2003.50059; Lemasters JJ, 1997, ANNU REV PHARMACOL, V37, P327, DOI 10.1146/annurev.pharmtox.37.1.327; Lemasters JJ, 1997, MOL CELL BIOCHEM, V174, P159, DOI 10.1023/A:1006827601337; LIM SP, 1992, DIGEST DIS SCI, V37, P1275, DOI 10.1007/BF01296572; Malakhov MP, 2003, J BIOL CHEM, V278, P16608, DOI 10.1074/jbc.M208435200; Namisaki T, 2006, J HEPATOL, V44, P568, DOI 10.1016/j.jhep.2005.08.018; Ottens AK, 2005, ANAL CHEM, V77, P4836, DOI 10.1021/ac050478r; Ozaki M, 1995, ENZYME PROTEIN, V48, P213, DOI 10.1159/000474991; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Sakon M, 2002, SURG TODAY, V32, P1, DOI 10.1007/s595-002-8105-8; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Wang KKW, 2004, INT REV NEUROBIOL, V61, P215; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; YANG JC, 2004, DI YI JUN YI DA XUE, V198, P203; Yoo GH, 2002, CLIN CANCER RES, V8, P3910	29	28	29	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1354-750X	1366-5804		BIOMARKERS	Biomarkers	JUL-AUG	2006	11	4					355	369		10.1080/13547500600775110			15	Biotechnology & Applied Microbiology; Toxicology	Biotechnology & Applied Microbiology; Toxicology	083YD	WOS:000240494300006	16908442				2021-06-18	
J	Drake, AI; McDonald, EC; Magnus, NE; Gray, N; Gottshall, K				Drake, Angela I.; McDonald, Eric C.; Magnus, Nathalie E.; Gray, Nicola; Gottshall, Kim			Utility of Glasgow Coma Scale-Extended in symptom prediction following mild traumatic brain injury	BRAIN INJURY			English	Article						Glasgow Coma Scale-Extended; GSC-E; PTA; mild TBI; SAC; concussion	MODERATE HEAD-INJURY; UNITED-STATES; DISCHARGE INSTRUCTIONS; CONCUSSION; SENSITIVITY; AMNESIA	Study objective: To examine the efficacy of the Glasgow Coma Scale-Extended (GCS-E) for the prediction of symptoms commonly associated with mild traumatic brain injury (TBI). Method: Three hundred and sixty-one participants with a mild TBI were evaluated using the GCS-E and the Standardized Assessment of Concussion. A sub-group of 185 participants took part in a more extensive evaluation, which also included measures of depression and vestibular symptoms. All participants had a Glasgow Coma Scale score of 15, but experienced varying lengths of post-traumatic amnesia (PTA) as measured by the GCS-E. Results: Use of the GCS-E for assessment of PTA duration revealed that longer lengths of amnesia following mild TBI were associated with greater incidence of dizziness, depression and cognitive impairments during the first weeks after injury. Conclusion: Results suggest that the GCS-E is a useful tool for the prediction of symptoms associated with mild TBI.	USN, Med Ctr, Spatial Orientat Ctr, Dept Neurosci, San Diego, CA 92152 USA; USN, Med Ctr, Spatial Orientat Ctr, Dept Emergency Med, San Diego, CA 92152 USA; USN, Med Ctr, Spatial Orientat Ctr, Dept Otolaryngol, San Diego, CA 92152 USA	Gray, N (corresponding author), 2464 DEN St, St Augustine, FL 32092 USA.	nparimucha@hotmail.com					Ahmed S, 2000, BRAIN INJURY, V14, P765; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bazarian J, 2000, BRAIN INJURY, V14, P285; BECK AT, 1984, J CLIN PSYCHOL, V40, P1365, DOI 10.1002/1097-4679(198411)40:6<1365::AID-JCLP2270400615>3.0.CO;2-D; BECK AT, 1993, BDI DEPRESSION INVEN; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Fischer J, 2001, Crit Care Nurs Q, V23, P52; FRONSTIN P, 2000, EMPLOYMENT BENEFIT R, V224, P1; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hipskind J E, 1997, Prehosp Disaster Med, V12, P278; Hodgkinson D W, 1994, Eur J Emerg Med, V1, P9, DOI 10.1097/00063110-199403000-00003; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Jennett B, 1989, MILD HEAD INJURY, P23; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Martin K M, 1994, J Neurosci Nurs, V26, P210; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; MOSS NEG, 1994, CLIN REHABIL, V8, P149; Nell V, 2000, ARCH PHYS MED REHAB, V81, P614, DOI 10.1053/mr.2000.3877; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Paterson B, 2001, Rehabil Nurs, V26, P48; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Sanguinetti M, 1987, J Neurosci Nurs, V19, P271; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Taylor DM, 2000, J ACCID EMERG MED, V17, P86; *TBI STAT DEM GRAN, 2000, J HEAD TRAUMA REHAB, V15, P750; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177	42	28	28	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2006	20	5					469	475		10.1080/02699050600676370			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	045GO	WOS:000237730800003	16716993				2021-06-18	
J	Lee, JW; Choi, CG; Chun, MH				Lee, Jung Woo; Choi, Choong Gon; Chun, Min Ho			Usefulness of diffusion tensor imaging for evaluation of motor function in patients with traumatic brain injury - Three case studies	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						diffuse axonal injury; diffusion tensor imaging; fractional anisotropy; motoricity index; traumatic brain injury	CLOSED-HEAD INJURY; AXONAL INJURY; WATER-DIFFUSION; WHITE-MATTER; ABNORMALITIES; MRI	Objectives: To determine whether diffusion tensor imaging (DTI) can detect diffuse axonal injury, and to evaluate the association of DTI findings with motor function in patients with traumatic brain injury Design: Three case studies. Setting: An inpatient rehabilitation unit in Korea. Participants: Three patients with traumatic brain injury in whom conventional neuroiniaging showed normal-appearing white matter. Main Outcome Measures: Patients were studied with DTI. Fractional anisotropy (FA) was measured from 3 different anatomic locations on both sides of the corticospinal tract. Motor function was evaluated using the motoricity index. Results: Fractional anisotropy tended to be reduced in normal-appearing corticospinal tracts that were remote from the involved segment. Diffusion tensor imaging showed reduction of FA in areas consistent with motor dysfunction. Conclusion: Fractional anisotropy of the corticospinal tract may be used in the detection of diffuse axonal injury. The association between decreased motoricity index and decreased FA suggests that DTI may be useful in evaluating patients with traumatic brain injury.	Univ Ulsan, Coll Med, Asan Med Ctr, Dept Rehabil Med, Seoul 138736, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, Seoul 138736, South Korea	Chun, MH (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Rehabil Med, 388-1 Poongnap Dong, Seoul 138736, South Korea.	mhchun@amc.seoul.kr					Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BRODAL A, 1981, NEUROLOGICAL ANATOMY, P185; CHENEVERT TL, 1990, RADIOLOGY, V177, P401, DOI 10.1148/radiology.177.2.2217776; DEMEURISSE G, 1980, EUR NEUROL, V19, P382, DOI 10.1159/000115178; Eriksson SH, 2001, BRAIN, V124, P617, DOI 10.1093/brain/124.3.617; Field AS, 2003, AM J NEURORADIOL, V24, P1461; Filippi M, 2001, NEUROLOGY, V56, P304, DOI 10.1212/WNL.56.3.304; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; LEBIHAN D, 1991, JMRI-J MAGN RESON IM, V1, P7, DOI 10.1002/jmri.1880010103; McKinstry RC, 2002, NEUROLOGY, V59, P824, DOI 10.1212/WNL.59.6.824; MILLER G, 1998, CEREBRAL PALSIES CAU, P112; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; Neil J, 2002, NMR BIOMED, V15, P543, DOI 10.1002/nbm.784; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; Taber KH, 2002, J NEUROPSYCH CLIN N, V14, P1, DOI 10.1176/appi.neuropsych.14.1.1; Werring DJ, 1998, J NEUROL NEUROSUR PS, V65, P863, DOI 10.1136/jnnp.65.6.863; Wieshmann UC, 1999, LANCET, V353, P1242, DOI 10.1016/S0140-6736(99)00248-2; Wieshmann UC, 1999, MAGN RESON IMAGING, V17, P1269, DOI 10.1016/S0730-725X(99)00082-X	27	28	28	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2006	21	3					272	278		10.1097/00001199-200605000-00007			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	044YL	WOS:000237709600007	16717504				2021-06-18	
J	Kelso, ML; Wehner, JM; Collins, AC; Scheff, SW; Pauly, JR				Kelso, ML; Wehner, JM; Collins, AC; Scheff, SW; Pauly, JR			The pathophysiology of traumatic brain injury in alpha 7 nicotinic cholinergic receptor knockout mice	BRAIN RESEARCH			English	Article						nicotinic cholinergic receptor; alpha 7; neuroprotection; neurotrauma; null mutant mouse	PERIPHERAL BENZODIAZEPINE-RECEPTORS; ACETYLCHOLINE-RECEPTORS; ALZHEIMERS-DISEASE; TEMPORAL CORTEX; BINDING-SITES; TIME-COURSE; RAT-BRAIN; EXPRESSION; ACTIVATION; PROTEIN	The alpha 7 nicotinic cholinergic receptor is a ligand-gated ion channel with calcium permeability similar to that of ionotrophic glutamate receptors. Previous studies from our laboratory have implicated changes in expression alpha 7 nicotinic cholinergic receptors in the pathophysiology of traumatic brain injury (TBI). In rats, TBI causes a time-dependent and significant decrease in cortical and hippocampal alpha-[I-125]-bungarotoxin (BTX) binding. We have postulated that deficits in a7 expression may contribute to TBI-induced cognitive impairment and that nicotinic receptor agonists can reverse alpha 7 binding deficits and result in significant cognitive improvement compared to saline-treated controls. Thus, alpha 7 nAChRs could be involved in a form of cholinergically mediated excitotoxicity following brain injury. In the current study, wild-type, heterozygous and null mutant mice were employed to test the hypothesis that genotypic depletion of the a7 receptor would render animals less sensitive to tissue loss and brain inflammation following experimental brain injury. Mice were anesthetized and subjected to a 0.5-mm cortical contusion injury of the somatosensory cortex. Brain inflammation, changes in nicotinic receptor expression and cortical tissue sparing were evaluated in wild-type, heterozygous and homozygous mice 1 week following TBI. in wild-type mice, brain injury caused a significant decrease in BTX binding in several hippocampal regions, consistent with what we have measured in rat brain following TBI. However, there were no genotypic differences in cortical tissue sparing or brain inflammation in this experiment. Although the results of this study were largely negative, it is still plausible that changes in the activity/expression of native alpha 7 receptors contribute to pathophysiology following TBI. However, when null mutant mice develop in the absence of central alpha 7 expression, it is possible that compensatory changes occur that confound the results obtained. (c) 2006 Elsevier B.V. All rights reserved.	Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA; Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, SCOBRIC, Lexington, KY 40536 USA	Pauly, JR (corresponding author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.	jpauly@uky.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828, R01NS042196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P30DA015663] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [5P30DA015663-03] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828, NS42196] Funding Source: Medline		Banerjee C, 2000, NEUROBIOL DIS, V7, P666, DOI 10.1006/nbdi.2000.0317; Burghaus L, 2003, PARKINSONISM RELAT D, V9, P243, DOI 10.1016/S1353-8020(03)00028-2; Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8; CASTRO NG, 1995, BIOPHYS J, V68, P516, DOI 10.1016/S0006-3495(95)80213-4; De Simone R, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-4; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; Dineley KT, 2002, J BIOL CHEM, V277, P22768, DOI 10.1074/jbc.M200164200; Ferchmin PA, 2003, J PHARMACOL EXP THER, V305, P1071, DOI 10.1124/jpet.102.048173; Fucile S, 2004, CELL CALCIUM, V35, P1, DOI 10.1016/j.ceca.2003.08.006; Guan ZZ, 2000, J NEUROCHEM, V74, P237, DOI 10.1046/j.1471-4159.2000.0740237.x; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hazell AS, 1999, NEUROSCI LETT, V271, P5, DOI 10.1016/S0304-3940(99)00489-9; Hellstrom-Lindahl E, 1999, MOL BRAIN RES, V66, P94, DOI 10.1016/S0169-328X(99)00030-3; Herber DL, 2004, J HISTOCHEM CYTOCHEM, V52, P1367, DOI 10.1369/jhc.4A6319.2004; Keller JJ, 2005, BEHAV BRAIN RES, V162, P143, DOI 10.1016/j.bbr.2005.03.004; Kuhlmann AC, 1999, TOXICOL SCI, V48, P107, DOI 10.1093/toxsci/48.1.107; Lacor P, 1999, BRAIN RES, V815, P70, DOI 10.1016/S0006-8993(98)01105-6; Laudenbach V, 2002, FASEB J, V16, P423, DOI 10.1096/fj.01-0532fje; Lee DHS, 2003, J NEUROBIOL, V55, P25, DOI 10.1002/neu.10203; Martin SE, 2004, BRAIN RES, V1022, P254, DOI 10.1016/j.brainres.2004.07.016; Mike A, 2000, BRAIN RES, V882, P155, DOI 10.1016/S0006-8993(00)02863-8; MYERS R, 1991, NEUROSCI LETT, V133, P20, DOI 10.1016/0304-3940(91)90047-W; Oddo S, 2005, P NATL ACAD SCI USA, V102, P3046, DOI 10.1073/pnas.0408500102; OrrUrtreger A, 1997, J NEUROSCI, V17, P9165; PERRY DC, 1995, J PHARMACOL EXP THER, V275, P1030; Quick MW, 2002, J NEUROBIOL, V53, P457, DOI 10.1002/neu.10109; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Rupalla K, 1998, ACTA NEUROPATHOL, V96, P172, DOI 10.1007/s004010050878; Salminen O, 2004, MOL PHARMACOL, V65, P1526, DOI 10.1124/mol.65.6.1526; SEGUELA P, 1993, J NEUROSCI, V13, P596; Shytle RD, 2004, J NEUROCHEM, V89, P337, DOI 10.1046/j.1471-4159.2004.02347.x; Sparks JA, 1999, PSYCHOPHARMACOLOGY, V141, P145, DOI 10.1007/s002130050818; Vela JM, 2002, J NEUROTRAUM, V19, P1503, DOI 10.1089/089771502320914723; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Verbois SL, 2002, J NEUROTRAUM, V19, P1569, DOI 10.1089/089771502762300238; Verbois SL, 2003, NEUROSCIENCE, V119, P1199, DOI 10.1016/S0306-4522(03)00206-9; Verbois SL, 2003, NEUROPHARMACOLOGY, V44, P224, DOI 10.1016/S0028-3908(02)00366-0; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wang W.B., 2000, P SPIE, V3917, P75; Wehner JM, 2004, NEUROSCIENCE, V129, P11, DOI 10.1016/j.neuroscience.2004.07.016	40	28	29	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 14	2006	1083						204	210		10.1016/j.brainres.2006.01.127			7	Neurosciences	Neurosciences & Neurology	040JG	WOS:000237374200022	16545784				2021-06-18	
J	Capilouto, GJ; Wright, HH; Wagovich, SA				Capilouto, Gilson J.; Wright, Heather Harris; Wagovich, Stacy A.			Reliability of main event measurement in the discourse of individuals with aphasia	APHASIOLOGY			English	Article; Proceedings Paper	35th Annual Clinical Aphasiology Conference	MAY 31-JUN 04, 2005	Sanibel Isl, FL				CLOSED-HEAD-INJURY; TRAUMATIC BRAIN-INJURY; NARRATIVE DISCOURSE; CONNECTED SPEECH; ADULTS; COMPREHENSION; STORY	Background: Quantitative measures of discourse skills of adults with aphasia can be valuable in documenting evidenced-based practice. Comprehensive assessment of narrative discourse should include a measure of the ability to relay main events (Nicholas & Brookshire, 1995; Wright, Capilouto, Wagovich, Cranfill, & Davis, 2005). Wright et al. (2005) compared the ability of younger and older healthy adults to relate main events in response to pictured stimuli. Results indicated that the younger group produced a significantly higher proportion of main events as compared to the older group and that the main events measure was stable for individual participants over time. However, performance data and data supporting the stability of the main events measure for individuals with aphasia are needed to extend the clinical usefulness of the main events measure as an assessment tool. Aims: The purpose of this study was (a) to compare the performance of healthy adults and adults with aphasia on their ability to convey main events in pictured stimuli and (b) to establish session-to-session reliability of the authors' main events measure. Methods & Procedures: Eight adults with aphasia (APH) and eight neurologically intact adults (NI) participated in the study. Participants attended two sessions, 7-21 days apart. Each time, participants gave an account of the events from two pictures and two picture sequences (Nicholas & Brookshire, 1993). The resulting language samples were analysed for the proportion of main events conveyed, and test-retest reliability of the measure was assessed. Outcomes & Results: NI adults told a significantly higher proportion of main events than adults with aphasia. The main effect for picture stimulus was also significant; participants told significantly more main events in response to sequential versus single picture stimuli, regardless of group. Test-retest results yielded strong, positive correlations between sessions for both groups. Conclusions: Results indicate that adults with and without aphasia differ in their ability to express the relations and causal links among units of information. Results also indicate that Wright and colleagues' (2005) main events measure demonstrates sufficient stability to provide the foundation for its potential use as a pre- and post-treatment measure. Finally, the finding that the proportion of main events provided in response to stimuli varied according to the nature of the stimuli is consistent with the findings of Wright et al. (2005) and suggests that even for individuals with aphasia, relationships between elements depicted in pictures may be more easily identified and conveyed when sequential pictures are provided as stimuli.	Univ Kentucky, Div Commun Disorders, Lexington, KY 40536 USA; Arizona State Univ, Tempe, AZ USA; Univ Missouri, Columbia, MO USA	Capilouto, GJ (corresponding author), Univ Kentucky, Div Commun Disorders, 900 S Limestone,CTW Bldg, Lexington, KY 40536 USA.	gjcapi2@uky.edu	Wagovich, Stacy/O-8179-2019	Wagovich, Stacy/0000-0001-7800-9310; wright, heather/0000-0001-6922-6364			Armstrong E, 2000, APHASIOLOGY, V14, P875, DOI 10.1080/02687030050127685; BOND S, 1983, CLIN APHASIOLOGY C; BROWNELL HH, 1988, APHASIOLOGY, V2, P247, DOI 10.1080/02687038808248918; Capilouto G, 2005, J COMMUN DISORD, V38, P431, DOI 10.1016/j.jcomdis.2005.03.005; CAPLAN D, 1990, BRAIN LANG, V39, P206, DOI 10.1016/0093-934X(90)90012-6; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); COOPER PV, 1990, J GERONTOL, V45, pP210, DOI 10.1093/geronj/45.5.P210; Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003; Doyle PJ, 1998, APHASIOLOGY, V12, P561, DOI 10.1080/02687039808249558; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Goodglass H., 2000, BOSTON DIAGNOSTIC AP; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; HEATH SB, 1986, TOP LANG DISORD, V7, P84, DOI 10.1097/00011363-198612000-00010; KERTESZ A, 1982, WK APHASIA BATTERY; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; NICHOLAS LE, 1995, J SPEECH HEAR RES, V38, P146, DOI 10.1044/jshr.3801.145; NICHOLAS LE, 1993, J SPEECH HEAR RES, V36, P338, DOI 10.1044/jshr.3602.338; OLNESS G, 2005, CLIN APH C SAN FLOR; Olness G. S., 2002, APHASIOLOGY, V16, P623, DOI [10.1080/02687030244000095, DOI 10.1080/02687030244000095]; Potechin G. G., 1987, APHASIOLOGY, V17, P216; PRINS RS, 1978, BRAIN LANG, V6, P192, DOI 10.1016/0093-934X(78)90058-5; Rosenbek JC., 1989, APHASIA CLIN APPROAC; SKA B, 2004, MIT ENCY COMMUNICAT; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; ULATOWSKA H, 1990, DISCOURSE ABILITY BR, P191; ULATOWSKA HK, 1981, BRAIN LANG, V13, P345, DOI 10.1016/0093-934X(81)90100-0; Ulatowska HK, 2003, APHASIOLOGY, V17, P511, DOI 10.1080/0268703034400102; Ulatowska HK, 2000, BRAIN LANG, V71, P249, DOI 10.1006/brln.1999.2261; WALLACH GP, 1988, LANGUAGE INTERVENTIO; Wright HH, 2005, APHASIOLOGY, V19, P263, DOI 10.1080/02687030444000732; YORKSTON KM, 1980, J SPEECH HEAR DISORD, V45, P27, DOI 10.1044/jshd.4501.27	34	28	28	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology	FEB-APR	2006	20	2-4					205	216		10.1080/02687030500473122			12	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	047PA	WOS:000237890000010					2021-06-18	
J	Cousar, JL; Lai, YC; Marco, CD; Bayir, H; Adelson, PD; Janesko-Feldman, KL; Kochanek, PM; Clark, RSB				Cousar, J'mir L.; Lai, Yichen; Marco, Christina D.; Bayir, Hulya; Adelson, P. David; Janesko-Feldman, Keri L.; Kochanek, Patrick M.; Clark, Robert S. B.			Heme oxygenase 1 in cerebrospinal fluid from infants and children after severe traumatic brain injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						child abuse; head injury; heat shock protein; Hsp32; oxidative stress; stress response	HEAT-SHOCK-PROTEIN; OXIDATIVE STRESS; SPINAL-CORD; RAT-BRAIN; INDUCTION; EXPRESSION; BILIRUBIN; HO-1; GLIA; ANTIOXIDANT	Heme oxygenase 1 (HO-1) is an enzyme important in the catabolism of heme that is induced under conditions of oxidative stress. HO-1 degradation of heme yields biliverdin, bilirubin, carbon monoxide and iron. HO-1 is thought to serve a protective antioxidant function, and upregulation of HO-1 has been demonstrated in experimental models of neurodegeneration, subarachnoid hemorrhage, cerebral ischemia and traumatic brain injury (TBI). We measured HO-1 concentration in cerebral spinal fluid samples from 48 infants and children following TBI and 7 control patients by ELISA. Increased HO-1 was seen in TBI versus control patients mean 2.75 +/- 0.63, peak 4.17 +/- 0.96 ng/ml versus control (< 0.078 ng/ml, not detectable) (p < 0.001). Increased HO-1 concentration was associated with increased injury severity and unfavorable neurological outcome (both p < 0.05). Increased HO-1 concentration was independently associated with younger age; however, statistical analysis could not rule out the possibility that the effect of age was related to inflicted TBI from child abuse. HO-1 increases after TBI and appears to be more prominent in infants compared with older children after injury. Copyright (c) 2006 S. Karger AG, Basel.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	Clark, RSB (corresponding author), Pediat Crit Care Med, 3705 5th Ave, Pittsburgh, PA 15213 USA.	clarkrs@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; Lai, Yi-Chen/0000-0002-9450-5506	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD045968] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R01NS038620] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD40686, R01 HD045968] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS30318, R01 NS38620] Funding Source: Medline		Adelson P David, 2003, Pediatr Crit Care Med, V4, pS65; AMIT Y, 1993, EXP NEUROL, V121, P248, DOI 10.1006/exnr.1993.1092; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Berger RP, 2004, CHILD ABUSE NEGLECT, V28, P739, DOI 10.1016/j.chiabu.2004.01.007; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bergeron M, 1998, DEV BRAIN RES, V105, P181, DOI 10.1016/S0165-3806(97)00169-7; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Chen MZ, 1998, J NEUROTRAUM, V15, P171, DOI 10.1089/neu.1998.15.171; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Hagberg H, 1997, ACTA PAEDIATR, V86, P85; Kaur H, 2003, FEBS LETT, V543, P113, DOI 10.1016/S0014-5793(03)00420-4; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kondo M, 2002, EARLY HUM DEV, V66, P81, DOI 10.1016/S0378-3782(01)00234-1; Kvam E, 2000, FREE RADICAL BIO MED, V28, P1191, DOI 10.1016/S0891-5849(00)00205-7; Lai YC, 2004, J NEUROTRAUM, V21, P229, DOI 10.1089/089771504322972022; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; MAINES MD, 1988, FASEB J, V2, P2557; Matz P, 1996, BRAIN RES, V713, P211, DOI 10.1016/0006-8993(95)01511-6; Mautes AEM, 2000, EXP NEUROL, V166, P254, DOI 10.1006/exnr.2000.7520; Mautes AEM, 1998, BRAIN RES, V795, P17, DOI 10.1016/S0006-8993(98)00230-3; Morse D, 2005, AM J RESP CRIT CARE, V172, P660, DOI 10.1164/rccm.200404-465SO; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Schipper HM, 1998, EXP NEUROL, V150, P60, DOI 10.1006/exnr.1997.6752; Schipper HM, 2000, NEUROLOGY, V54, P1297, DOI 10.1212/WNL.54.6.1297; Seidberg NA, 2003, J NEUROCHEM, V84, P514, DOI 10.1046/j.1471-4159.2003.01547.x; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; Snyder SH, 1998, BRAIN RES REV, V26, P167, DOI 10.1016/S0165-0173(97)00032-5; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; SUN Y, 1990, J BIOL CHEM, V265, P8212; Takeda A, 1996, NEUROSCI LETT, V205, P169, DOI 10.1016/0304-3940(96)12405-8; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x	38	28	28	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					342	347		10.1159/000094160			6	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600011	16943657				2021-06-18	
J	Guskiewicz, KM; Bruce, SL; Cantu, RC; Ferrara, MS; Kelly, JP; McCrea, M; Putukian, M; McLeod, TCV				Guskiewicz, KM; Bruce, SL; Cantu, RC; Ferrara, MS; Kelly, JP; McCrea, M; Putukian, M; McLeod, TCV			Research based recommendations on management of sport related concussion: summary of the National Athletic Trainers' Association position statement	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							NEUROPSYCHOLOGICAL TEST-PERFORMANCE; COMPUTERIZED COGNITIVE ASSESSMENT; COLLEGIATE FOOTBALL PLAYERS; POSTURAL STABILITY; SAFE RETURN; HEAD-INJURY; MILD; RECOVERY; PATHOPHYSIOLOGY; CONSCIOUSNESS		Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; Calif State Univ Penn, California, PA USA; Brigham & Womens Hosp, Neurol Sports Injury Ctr, Boston, MA 02115 USA; Emerson Hosp, Concord, MA USA; Univ Georgia, Athens, GA 30602 USA; Univ Colorado, Sch Med, Denver, CO USA; Waukesha Mem Hosp, Waukesha, WI USA; Princeton Univ, Princeton, NJ 08544 USA; Arizona Sch Hlth Sci, Dept Sport Hlth Care, Mesa, AZ USA	Guskiewicz, KM (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA.	gus@email.unc.edu	Bruce, Scott L./AAQ-1907-2020; McLeod, Tamara/AAU-9435-2020	Bruce, Scott L./0000-0002-3251-073X; Guskiewicz, Kevin/0000-0002-8682-2130			Adams J, 2001, J PEDIATR SURG, V36, P119, DOI 10.1053/jpsu.2001.20026; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailes JE, 2001, J ATHL TRAINING, V36, P236; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; GUSKIEWICZ KM, 2004, AM J MED SPORTS, V6, P13; Halstead PD, 2001, J ATHL TRAINING, V36, P322; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 2001, J ATHL TRAINING, V36, P249; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrory P, 2002, BRIT J SPORT MED, V36, P316, DOI 10.1136/bjsm.36.5.316; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Oliaro S, 2001, J ATHL TRAINING, V36, P257; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Pottinger LS, 1999, ARCH CLIN NEUROPSYCH, V14, P39, DOI 10.1093/arclin/14.1.39a; Riemann BL, 2000, J ATHL TRAINING, V35, P19	41	28	28	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2006	40	1					6	10		10.1136/bjsm.2005.021683			5	Sport Sciences	Sport Sciences	995YG	WOS:000234140600005	16371484	Green Published, Bronze			2021-06-18	
J	Park, SH; Cho, KH; Shin, YS; Kim, SH; Ahn, YH; Cho, KG; Yoon, SH				Park, Se-Hyuck; Cho, Ki Hong; Shin, Yong Sam; Kim, Se Hyuck; Ahn, Young Hwan; Cho, Kyung Gi; Yoon, Soo Han			Penetrating craniofacial injuries in children with wooden and metal chopsticks	PEDIATRIC NEUROSURGERY			English	Article						penetrating craniofacial injury; chopstick; traumatic brain injury	FOREIGN-BODY; ABSCESS; WOUNDS	Penetrating craniofacial injuries with chopsticks in children are peculiar accidents in the Oriental culture. All 10 cases previously reported were caused by wooden chopsticks that required surgical operations. However, there are no reported injuries with metal chopsticks in the past literature which should have been as common as that of wooden chopstick injuries in Asia. We evaluated the difference of injury patterns and clinical observations between wooden and metal chopstick injuries. We reviewed 6 treated children with penetrating craniofacial injuries from chopsticks: one wooden and five metal chopsticks. One child who had penetration through the nasal cavity presented with temporary rhinorrhea, another with mild hemiparesis, and one child with temporary upward gaze limitation of the left eye. Radiological examination revealed 1 patient with epidural hemorrhage, 1 patient with minimal subdural hemorrhage, and 4 with intracerebral hemorrhage that were fortunately too small to receive surgery. We performed surgical procedure only for a child who had a wooden chopstick that had impacted into the temporal cortex. We followed up all 6 children for more than 1 year, and found that all had fully recovered to near-normal neurological status. We observed that penetrating craniofacial injuries with metal chopsticks rarely require surgical intervention and usually results in good outcome because the resultant wound is usually small without broken fragments compared to injuries with wooden chopsticks. Copyright (c) 2006 S. Karger AG, Basel.	Ajou Univ, Sch Med, Dept Neurosurg, Suwon 443721, South Korea; Hallym Univ, Kandong Sacred Heart Hosp, Dept Neurosurg, Seoul, South Korea	Yoon, SH (corresponding author), Ajou Univ, Sch Med, Dept Neurosurg, Suwon 443721, South Korea.	ee80@ajou.ac.kr					Di Roio C, 2000, CHILD NERV SYST, V16, P503, DOI 10.1007/s003810000291; HANSEN JE, 1988, J NEUROSURG, V68, P752, DOI 10.3171/jns.1988.68.5.0752; ILDAN F, 1994, J TRAUMA, V36, P116, DOI 10.1097/00005373-199401000-00020; Ishikawa E, 2000, NEUROL MED-CHIR, V40, P458, DOI 10.2176/nmc.40.458; Kawamura Shingo, 1997, Neurologia Medico-Chirurgica, V37, P332, DOI 10.2176/nmc.37.332; KUROIWA T, 1995, SURG NEUROL, V43, P68, DOI 10.1016/0090-3019(95)80042-F; Leung C. M., 1995, Singapore Medical Journal, V36, P90; Matsumoto S, 1998, AM J NEURORADIOL, V19, P1163; Matsuyama T, 2001, NEUROL MED-CHIR, V41, P345, DOI 10.2176/nmc.41.345; Nishio Y, 2004, ACTA NEUROCHIR, V146, P847, DOI 10.1007/s00701-004-0283-7; Ochiai H, 1999, NEUROL MED-CHIR, V39, P744, DOI 10.2176/nmc.39.744; Shih TY, 2002, PEDIATR NEUROSURG, V37, P35, DOI 10.1159/000065100; Suzuki H, 2002, PAEDIATR ANAESTH, V12, P88, DOI 10.1046/j.1460-9592.2002.0787g.x; Taniura S, 2004, AM J NEURORADIOL, V25, P871; WOOLFSON JM, 1990, OPHTHALMIC PLAST REC, V6, P237, DOI 10.1097/00002341-199012000-00002; YAMAMOTO I, 1985, SURG NEUROL, V23, P396, DOI 10.1016/0090-3019(85)90215-0	16	28	30	0	7	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.		2006	42	3					138	146		10.1159/000091855			9	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	120CC	WOS:000243060200002	16636613				2021-06-18	
J	Thomale, UW; Griebenow, M; Kroppenstedt, SN; Unterberg, AW; Stover, JF				Thomale, UW; Griebenow, M; Kroppenstedt, SN; Unterberg, AW; Stover, JF			The effect of N-acetylcysteine on posttraumatic changes after controlled cortical impact in rats	INTENSIVE CARE MEDICINE			English	Article						brain injury; N-acetylcysteine; controlled cortical impact injury; cerebral perfusion; free radicals; brain edema	TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; HEAD-INJURY; BLOOD-FLOW; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; ACETYL-CYSTEINE; NERVE INJURY; KAPPA-B; ANTIOXIDANT	Objective: The antioxidant potential of N-Acetylcysteine (NAC) and its improvement of posttraumatic mitrochondrial dysfunction have been reported. This study investigated the effect of NAC on posttraumatic changes after controlled cortical Impact (CCI) injury. Design and setting: Prospective randomized controlled animal study. Methods: A moderate left focal cortical contusion was induced using CCI. Either NAC (163 mg/kg bw) or physiological saline was administered intraperitoneally immediately and 2 and 4 h after trauma. Blood gases, temperature, mean arterial blood pressure (MABP), and intracranial pressure (ICP) were monitored. Twenty-four hours after trauma brains were removed and either posttraumatic edema was quantified gravimetrically (n=24], or contusion volume was determined morphometrically using slices staining and computerized image analysis (n=24]. Laser Doppler flowmetry was used to assess pericontusional cortical perfusion before trauma, 30 min and 4 and 24 h after trauma (n=14]. Measurements and results: Physiological parameters remained within normal limits. ICP measurements and water content in traumatized hemispheres did not differ between the groups. Relative contusion volume of the left hemisphere was slightly but nonsignificantly diminished in NAC-treated animals (4.7 +/- 0.4% vs. 5.9 +/- 0.5% in controls). In both groups pericontusional perfusion was significantly reduced at 4 h followed by a state of hyperperfusion at 24 h with no differences between the groups. Conclusions: Despite previously reported neuroprotective abilities of NAC, no positive effect on posttraumatic perfusion, brain edema formation, or contusion volume after focal brain injury was observed in this study.	Humboldt Univ, Virchow Med Ctr, Dept Neurosurg, Charite, D-13353 Berlin, Germany; Univ Heidelberg, Dept Neurosurg, Heidelberg, Germany; Univ Zurich Hosp, Dept Surg, Div Surg Intens Care Med, CH-8091 Zurich, Switzerland	Thomale, UW (corresponding author), Humboldt Univ, Virchow Med Ctr, Dept Neurosurg, Charite, Augustenburger Pl 1, D-13353 Berlin, Germany.	uthomale@charite.de		Misch, Martin/0000-0001-5283-5753			Al Moutaery K, 2003, NEUROSURGERY, V53, P704, DOI 10.1227/01.NEU.0000079487.66013.6F; Aoyama N, 2002, BRAIN RES, V934, P117, DOI 10.1016/S0006-8993(02)02366-1; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Cherian L, 2003, J NEUROTRAUM, V20, P77, DOI 10.1089/08977150360517209; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Cuzzocrea S, 2000, BRIT J PHARMACOL, V130, P1219, DOI 10.1038/sj.bjp.0703421; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; Enblad P, 2004, INTENS CARE MED, V30, P1058, DOI 10.1007/s00134-004-2206-8; Farr SA, 2003, J NEUROCHEM, V84, P1173, DOI 10.1046/j.1471-4159.2003.01580.x; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HARRISON PM, 1991, NEW ENGL J MED, V324, P1852, DOI 10.1056/NEJM199106273242604; Hart AM, 2004, NEUROSCIENCE, V125, P91, DOI 10.1016/j.neuroscience.2003.12.040; Khan M, 2004, J NEUROSCI RES, V76, P519, DOI 10.1002/jnr.20087; KNUCKEY NW, 1995, STROKE, V26, P305, DOI 10.1161/01.STR.26.2.305; Moinard C, 2005, INTENS CARE MED, V31, P281, DOI 10.1007/s00134-004-2489-9; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; Nomoto Y, 2001, NEUROSURGERY, V48, P158, DOI 10.1097/00006123-200101000-00027; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; Schaser KD, 2005, J ORTHOP RES, V23, P231, DOI 10.1016/j.orthres.2004.05.009; Sekhon B, 2003, BRAIN RES, V971, P1, DOI 10.1016/S0006-8993(03)02244-3; Silbergleit R, 1999, RESUSCITATION, V40, P181, DOI 10.1016/S0300-9572(99)00027-1; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Stover JF, 2003, J NEUROTRAUM, V20, P315, DOI 10.1089/089771503765172273; Stover JF, 2000, ACTA NEUROCHIR SUPPL, V76, P171; Stover JF, 2000, J NEUROTRAUM, V17, P1171, DOI 10.1089/neu.2000.17.1171; Stroop R, 1998, ACT NEUR S, V71, P303; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; THOMALE UW, ACTA NEUROCHIR S; Unterberg AW, 1997, ACT NEUR S, V70, P106; Wagner R, 1998, PAIN, V77, P173, DOI 10.1016/S0304-3959(98)00091-8; WENDON JA, 1994, HEPATOLOGY, V19, P1407, DOI 10.1002/hep.1840190614; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Yi JH, 2005, BRAIN RES, V1033, P13, DOI 10.1016/j.brainres.2004.10.055; Yunoki M, 2003, SURG NEUROL, V59, P156, DOI 10.1016/S0090-3019(02)01040-6	39	28	28	0	1	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JAN	2006	32	1					149	155		10.1007/s00134-005-2845-4			7	Critical Care Medicine	General & Internal Medicine	999SN	WOS:000234410900025	16249925				2021-06-18	
J	Thompson, HJ; LeBold, DG; Marklund, N; Morales, DM; Hagner, AP; McIntosh, TK				Thompson, Hilaire J.; LeBold, David G.; Marklund, Niklas; Morales, Diego M.; Hagner, Andrew P.; McIntosh, Tracy K.			Cognitive evaluation of traumatically brain-injured rats using serial testing in the Morris water maze	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article; Proceedings Paper	39th Annual Communicating Nursing Research Conference/20th Annual WIN Assembly	APR 06-08, 2006	Albuquerque, NM			head injury; water maze; shift learning; reversal learning; multiple time points	BEHAVIORAL PLASTICITY; TASK; MOTOR; PERFORMANCE; IMPAIRMENT; STRATEGIES; MAGNESIUM	Purpose: As deficits in memory and cognition are commonly observed in survivors of traumatic brain injury (TBI), causing reduced quality of life for the patient, a major goal in experimental TBI research is to identify and evaluate cognitive dysfunction. The present study assessed the applicability of the serial Morris water maze (MWM) test to determine cognitive function following experimental TBI in the same group of rats which is particularly important for long-term studies and increasingly valuable for the evaluation of novel treatment strategies. Methods: Male Sprague-Dawley rats (n = 27) were anesthetized and subjected to either sham injury (n = 9) or lateral fluid percussion (FP) brain injury of moderate severity (n = 18). At 4 weeks post-injury, animals were trained in a water maze over 3 days (acquisition/learning phase) to find a submerged platform. At 8 weeks post-injury the hidden platform was then moved to the opposite quadrant, and animals were trained to find the new position of the platform over 3 days. Forty-eight hours later, animals were tested for memory retention in a probe trial in which the platform was not present. Results: Brain-injured animals had significant learning impairment (p < 0.0001), shifted-learning impairment (p < 0.001) and memory retention deficits (p < 0.01) in comparison to their sham-injured counterparts over the 8 week testing period. Swim speed and distance were not significantly altered by brain injury at any time point. Conclusion: The validation of this testing paradigm using a clinically relevant experimental brain injury model is an important addition to behavioral outcome testing.	Univ Washington, Seattle, WA 98195 USA; Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Uppsala Hosp, Dept Neurosurg, Uppsala, Sweden	Thompson, HJ (corresponding author), Univ Washington, Box 357266, Seattle, WA 98195 USA.	hilairet@u.washington.edu		Morales, Diego/0000-0001-6672-9046; Marklund, Niklas/0000-0002-9797-5626	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, T32NS043126, P50NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32NR007106] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [L30 DC008284, L30 DC008284-01] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS008803, T32-NS043126, T32 NS043126-01A1, R01 NS040978, T32 NS043126, P50 NS008803-320013, R01-NS40978, P50-NS08803, R01 NS040978-04] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32-NR007106, T32 NR007106, T32 NR007106-07] Funding Source: Medline		Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; Blokland A, 1999, EUR J NEUROSCI, V11, P223, DOI 10.1046/j.1460-9568.1999.00431.x; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Cheney JA, 2001, J CEREBR BLOOD F MET, V21, P396, DOI 10.1097/00004647-200104000-00008; Cirulli F, 2004, HIPPOCAMPUS, V14, P802, DOI 10.1002/hipo.10220; Cirulli F, 2000, NEUROSCI LETT, V287, P207, DOI 10.1016/S0304-3940(00)01173-3; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Day LB, 1996, BEHAV NEUROSCI, V110, P998; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GALLAGHER M, 1993, BEHAV NEUROSCI, V107, P618, DOI 10.1037/0735-7044.107.4.618; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Graziano A, 2003, J NEUROSCI METH, V130, P33, DOI 10.1016/S0165-0270(03)00187-0; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; National Institute of Neurological Disorders and Stroke, TRAUM BRAIN INJ HOP; Pettenuzzo LF, 2003, BRAIN RES PROTOC, V12, P109, DOI 10.1016/j.brainresprot.2003.09.002; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; Prins ML, 2001, J NEUROTRAUM, V18, P31, DOI 10.1089/089771501750055758; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42	24	28	29	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2006	24	2					109	114					6	Neurosciences	Neurosciences & Neurology	058OH	WOS:000238673800005	16720946				2021-06-18	
J	Kulkarni, AR; Aggarwal, SP; Kulkarni, RR; Deshpande, MD; Walimbe, PB; Labhsetwar, AS				Kulkarni, AR; Aggarwal, SP; Kulkarni, RR; Deshpande, MD; Walimbe, PB; Labhsetwar, AS			Ocular manifestations of head injury: a clinical study	EYE			English	Article; Proceedings Paper	Annual Congress of the Royal-College-of-Ophthalmologists	2004	Manchester, ENGLAND	Royal Coll Ophthalmologists		ocular manifestations; head injury; outcome	NEUROOPHTHALMOLOGICAL FINDINGS; TRAUMA	Aim This prospective study aimed to clinically correlate the various ocular findings with the neurological status in cases of closed head injury. Methods A total of 200 consecutive cases of closed head injury admitted to a major teaching hospital underwent a thorough ophthalmic assessment. The Glasgow coma scale (GCS) and the Revised trauma score (RTS) were applied to grade the severity of injury and assess the prognosis. Kendall's tau-b and Fisher's exact test were used in the analysis. Results The main causes of head injury were road traffic accidents 52.5% followed by assaults in 34%. Ocular involvement was found in 167(83.5%) cases. These included corneal and scleral tears in 2%, subconjunctival haemorrhage or ecchymosis in 46%, orbital fractures 12%, pupillary involvement 6.5%, papilloedema 5.5%, intraocular trauma 5.5%, proptosis 3%, lateral rectus palsy 2%, lacrimal gland prolapse 1%, and optic nerve trauma 0.5%. All 21 patients (10.5%) who died had eye involvement. In all, 150 cases (75%) with a RTS of 12 had a good prognosis. Of these 124 (82.6%) had ocular involvement of no neurological significance. Conclusions Although sophisticated imaging techniques are available to localize lesions, early ophthalmic assessment in correlation with the GCS aids in prognosticating outcomes. Pupillary involvement, papilloedema, and ocular motor paresis pointed to a more severe head injury. To our knowledge, this is the only prospective study recording ocular findings in the first few hours and attempting a correlation with the final outcome.	Dudley Guest Hosp, Grp Hosp NHS Trust, Dept Ophthalmol, Dudley DY1 4SE, W Midlands, England; Alexandra Hosp, Dept Orthopaed & Trauma, Redditch, Worcs, England; HV Desai Eye Hosp, Dept Ophthalmol, Pune, Maharashtra, India; Univ Poona, Dept Ophthalmol, BJ Med Coll, Pune 411007, Maharashtra, India; Univ Poona, Sassoon Gen Hosp, Pune 411007, Maharashtra, India	Kulkarni, AR (corresponding author), Dudley Guest Hosp, Grp Hosp NHS Trust, Dept Ophthalmol, Tipton Rd, Dudley DY1 4SE, W Midlands, England.	ruparch2@hotmail.com					*ACS COMM TRAUM, 1993, ADV TRAUM LIF SUPP C; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BAKER RS, 1991, SURV OPHTHALMOL, V35, P245, DOI 10.1016/0039-6257(91)90046-I; Banks Michelle C., 2002, International Ophthalmology Clinics, V42, P1; KEANE JR, 1989, ARCH NEUROL-CHICAGO, V46, P761, DOI 10.1001/archneur.1989.00520430055017; KOWAL L, 1992, AUST NZ J OPHTHALMOL, V20, P35, DOI 10.1111/j.1442-9071.1992.tb00701.x; LEPORE FE, 1995, ARCH NEUROL-CHICAGO, V52, P924, DOI 10.1001/archneur.1995.00540330106022; Mariak Z, 1997, Eur J Ophthalmol, V7, P68; Moster ML, 1999, NEUROLOGY, V52, pA23; *NAT I CLIN EXC LO, 2003, HEAD INJ TRIAG ASS; SABATES NR, 1991, J CLIN NEURO-OPHTHAL, V11, P273; SMITH JL, 1966, CLIN NEUROSURG, V13, P181; Thurman DJ, 1996, WESTERN J MED, V165, P192; Van Stavern GP, 2001, J NEURO-OPHTHALMOL, V21, P112, DOI 10.1097/00041327-200106000-00012	14	28	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-222X	1476-5454		EYE	Eye	DEC	2005	19	12					1257	1263		10.1038/sj.eye.6701753			7	Ophthalmology	Ophthalmology	992AX	WOS:000233857300003	15543173	Bronze			2021-06-18	
J	Hay, E; Moran, C				Hay, E; Moran, C			Discourse formulation in children with closed head injury	AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article						narrative and expository discourse; closed head injury; children	TRAUMATIC BRAIN-INJURY; VERBAL WORKING-MEMORY; LANGUAGE-LEARNING DISABILITIES; SCHOOL-AGE-CHILDREN; SENTENCE COMPREHENSION; INDIVIDUAL-DIFFERENCES; EXPOSITORY DISCOURSE; IMPAIRMENT; CAPACITY; PERFORMANCE	In this study, narrative and expository discourse-retelling abilities were compared in 9 children with closed head injury (CHI) age 9;5-15;3 (years;months) and 9 typically developing age-matched peers. Narrative and expository retellings were analyzed according to language variables (i.e., number of words, number of T-units, and sentential complexity) and information variables (i.e., number of propositions, number of episodic structure elements, and number of global structure elements). A measure of participants' ability to generate a story moral or aim was also taken. The children with CHI differed significantly from their age-matched peers across language and information domains and in their ability to formulate a moral or aim in both the expository and narrative retellings. In addition, differences across genre were found with performance on narrative tasks superior to performance on expository tasks. The exception was that it was easier for participants to generate an aim for the expository passage than a story moral for the narrative passage. The results are discussed relative to a working memory theory of impairment following CHI. Future directions for research are proposed.	Univ Canterbury, Dept Commun Disorders, Christchurch 1, New Zealand	Moran, C (corresponding author), Univ Canterbury, Dept Commun Disorders, Private Bag 4800, Christchurch 1, New Zealand.	catherine.moran@canterbury.ac.nz					Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; Carpenter P.A., 1994, HDB PSYCHOLINGUISTIC, P1075; Chapman S. B., 1997, AM J SPEECH-LANG PAT, V6, P66; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; CHAPMAN SB, 1997, AM J SPEECH-LANG PAT, V6, P50, DOI DOI 10.1044/1058-0360.0602.50; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cowan N, 1996, TOP LANG DISORD, V17, P1, DOI 10.1097/00011363-199611000-00003; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Dollaghan C, 1998, J SPEECH LANG HEAR R, V41, P1136, DOI 10.1044/jslhr.4105.1136; Dunn L. M., 1997, PPVT 3 PEABODY PICTU; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; GAULIN CA, 1994, PERCEPT MOTOR SKILL, V79, P55, DOI 10.2466/pms.1994.79.1.55; Gillam RB, 1997, TOP LANG DISORD, V18, P72, DOI 10.1097/00011363-199711000-00008; Gillam RB, 1999, TOP LANG DISORD, V20, P33, DOI 10.1097/00011363-199911000-00005; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; Hartley L. L., 1995, COGNITIVE COMMUNICAT; Hunt K. W, 1965, GRAMMATICAL STRUCTUR; JORDAN F M, 1990, Brain Injury, V4, P27; JORDAN F M, 1990, Brain Injury, V4, P147, DOI 10.3109/02699059009026159; JORDAN F M, 1992, Brain Injury, V6, P39, DOI 10.3109/02699059209008120; JORDAN FM, 1995, APHASIOLOGY, V9, P23, DOI 10.1080/02687039508248686; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; Jordan FM, 1996, BRAIN INJURY, V10, P729, DOI 10.1080/026990596123990; Jordan FM, 1996, APHASIOLOGY, V10, P755, DOI 10.1080/02687039608248448; Just MA, 1996, PSYCHOL REV, V103, P773, DOI 10.1037/0033-295X.103.4.773; KING J, 1991, J MEM LANG, V30, P580, DOI 10.1016/0749-596X(91)90027-H; LARSON VL, 1995, LANGUAGE DISORDERS O; Montgomery JW, 2002, AM J SPEECH-LANG PAT, V11, P77, DOI 10.1044/1058-0360(2002/009); Montgomery JW, 1996, TOP LANG DISORD, V17, P19, DOI 10.1097/00011363-199611000-00004; Moran C, 2005, BRAIN INJURY, V19, P743, DOI 10.1080/02699050500110199; NELSON N, 1993, CHILDHOOD LANGUAGE; NIPPOLD M, 2003, EXPOSITORY DISCOURS; Nippold MA, 2000, TOP LANG DISORD, V20, P15, DOI 10.1097/00011363-200020020-00004; PAUL R, 1995, LANGUAGE DISORDERS; Scott CM, 2000, J SPEECH LANG HEAR R, V43, P324, DOI 10.1044/jslhr.4302.324; SEMEL W, 1997, CLIN EVALUATION LANG; STEVENS T, 2003, REV PLAYSTATION GAME; Stewart S, 1985, COMMUNICATION SKILLS, P341; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Ulatowska H. K., 1994, DISCOURSE ANAL APPL, P29; WARDLONERGAN JM, 1909, J LEARNING DISABILIT, V32, P213; Weismer SE, 1999, J SPEECH LANG HEAR R, V42, P1249, DOI 10.1044/jslhr.4205.1249; Weismer SE, 1996, TOP LANG DISORD, V17, P33, DOI 10.1097/00011363-199611000-00005; Westerveld M., 2001, NZ J SPEECH LANGUAGE, V56, P5; Windsor J, 2000, J SPEECH LANG HEAR R, V43, P1322, DOI 10.1044/jslhr.4306.1322; YEKOVICH FR, 1990, INFERENCES TEXT COMP, P259	47	28	29	0	7	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1058-0360	1558-9110		AM J SPEECH-LANG PAT	Am. J. Speech-Lang. Pathol.	NOV	2005	14	4					324	336		10.1044/1058-0360(2005/031)			13	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	998JA	WOS:000234313400007	16396615				2021-06-18	
J	Miller, KJ; Schwab, KA; Warden, DL				Miller, KJ; Schwab, KA; Warden, DL			Predictive value of an early Glasgow Outcome Scale score: 15-month score changes	JOURNAL OF NEUROSURGERY			English	Article						head injury; traumatic brain injury; Glasgow Outcome Scale; severity outcome prediction	SEVERE HEAD-INJURY; TRAUMATIC BRAIN-INJURY; DISABILITY; RECOVERY; REHABILITATION; PROGNOSIS; SEVERITY; MODERATE	Object. Does an early Glasgow Outcome Scale (GOS) assessment provide a reliable indicator of later outcome in a patient with traumatic brain injury (TBI)? The authors examined the utility of the GOS during early treatment as a predictor of outcome score 15 months postinjury by analyzing outcome score change in a group of patients with closed head injuries. Methods. Glasgow Outcome Scale scores assessed within 3 months of injury (baseline) were compared with scores obtained at 15 months postinjury in 121 patients, primarily young military personnel. Score changes between baseline and 8 months postinjury were also studied in a subgroup of 72 patients. The impact of initial injury severity (determined by the duration of unconsciousness) on score change was also explored. The GOS scores at three time points within the 15-month period-baseline (within 3 months of injury), 8, and 15 months postinjury-were examined to ascertain when the maximal GOS score had been reached. Conclusions. Baseline GOS score was a reliable predictor of outcome in patients with an initial score of 5 (no disability) or 4 (mild disability), but not in patients with an initial score of 3 (severe disability). Patients who remained unconscious for more than 24 hours did not have significantly lower outcome scores than those who experienced loss of consciousness for less than 24 hours at 15 months postinjury. Interestingly, the duration of unconsciousness did not affect the likelihood of an improved score during the study period in patients with a GOS score of 3 or 4 at baseline. An updated evaluation conducted after the early phases of treatment is needed to provide a realistic prognosis of severe TBI.	Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA; Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA	Schwab, KA (corresponding author), Walter Reed Army Med Brain Injury Ctr, POB 59181, Washington, DC 20012 USA.	Karen.Schwab@na.amedd.army.mil					Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; GROSWASSER, 1997, HDB NEUROLOGICA RATI, P187; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1976, LANCET, V1, P1031; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kaye AH, 2000, LANCET, V356, P1540, DOI 10.1016/S0140-6736(00)03121-4; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Nissen JJ, 1999, J NEUROL NEUROSUR PS, V67, P796, DOI 10.1136/jnnp.67.6.796; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Salazar, 2000, JAMA, V284, P1783; SBORDONE RJ, 1987, REHABILITATION COGNI; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	27	28	30	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2005	103	2					239	245		10.3171/jns.2005.103.2.0239			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	957KI	WOS:000231368300008	16175852				2021-06-18	
J	Day, SM; Strauss, DJ; Shavelle, RM; Reynolds, RJ				Day, SM; Strauss, DJ; Shavelle, RM; Reynolds, RJ			Causes of death in remote symptomatic epilepsy	NEUROLOGY			English	Article							CAUSE-SPECIFIC MORTALITY; RISK-FACTORS; SEIZURES; CHILDREN; SURVIVAL; SUICIDE; PEOPLE	Objective: To determine the causes of death of individuals with developmental disabilities that occur more frequently among those with remote symptomatic epilepsy (i.e., epilepsy occurring in persons with developmental delay or identified brain lesions) than for those without. Methods: The authors compared causes of mortality in persons with (n = 10,030) and without (n = 96,163) history of epilepsy in a California population of persons with mild developmental disabilities, 1988 to 2002. Subjects had traumatic brain injury, cerebral palsy, Down syndrome, autism, or a developmental disability with other or unknown etiology. There were 721,759 person-years of data, with 2,397 deaths. Underlying causes of death were determined from the State of California's official mortality records. Cause-specific death rates and standardized mortality ratios (SMRs) were computed for those with and without epilepsy relative to subjects in the California general population. Comparisons were then made between SMRs of those with and without epilepsy, and CIs on the ratios of SMRs were determined. Results: Death rates for persons with epilepsy were elevated for several causes. The greatest excess was due to seizures (International Classification of Diseases-9 [ICD-9] 345; SMR 53.1, 95% CI 28.0 to 101.0) and convulsions (ICD-9 780.3; SMR 25.2, 95% CI 11.7 to 54.2). Other causes occurring more frequently in those with epilepsy included brain cancer (SMR 5.2, 95% CI 2.2 to 12.1), respiratory diseases (SMR 1.7, 95% CI 1.2 to 2.5), circulatory diseases (SMR 1.3, 95% CI 1.0 to 1.7), and accidents (SMR 2.7, 95% CI 1.9 to 3.7), especially accidental drowning (SMR 12.8, 95% CI 7.0 to 23.2). Conclusions: Remote symptomatic epilepsy is associated with an increased risk of death. Seizures, aspiration pneumonia, and accidental drowning are among the leading contributors.	Life Expectancy Project, San Francisco, CA 94122 USA; Univ Calif San Francisco, Dept Pediat & Neurol, San Francisco, CA 94143 USA	Day, SM (corresponding author), Life Expectancy Project, 1439 17th Ave, San Francisco, CA 94122 USA.	Day@LifeExpectancy.com	Day, Steven/P-1002-2019	Day, Marc/0000-0002-1711-3963; Day, Steven/0000-0001-8305-5813			Antoniuk SA, 2001, ARQ NEURO-PSIQUIAT, V59, P40, DOI 10.1590/S0004-282X2001000100009; BARRACLOUGH BM, 1987, ACTA PSYCHIAT SCAND, V76, P339, DOI 10.1111/j.1600-0447.1987.tb05616.x; Besag FMC, 2001, BRIT MED J, V322, P975, DOI 10.1136/bmj.322.7292.975; Breningstall GN, 2001, PEDIATR NEUROL, V25, P9, DOI 10.1016/S0887-8994(01)00252-1; *CA6 DEP DEV SERV, 1986, CLIENT DEV EV REP; Day SM, 2005, DEV MED CHILD NEUROL, V47, P171, DOI 10.1017/S0012162205000319; Day Steven, 2003, J Insur Med, V35, P155; DIEKEMA DS, 1993, PEDIATRICS, V91, P612; Goldacre MJ, 2004, EUR J PUBLIC HEALTH, V14, P338, DOI 10.1093/eurpub/14.4.338; Gottesman RF, 2003, INT REV PSYCHIATR, V15, P302, DOI 10.1080/09540260310001606683; *IARC, 2004, IARC MON EV CARC RIS, V83, P1; Jones JE, 2003, EPILEPSY BEHAV, V4, pS31, DOI 10.1016/j.yebeh.2003.08.019; Kahn H. A., 1989, STAT METHODS EPIDEMI; KEMP AM, 1993, ARCH DIS CHILD, V68, P684, DOI 10.1136/adc.68.5.684; Langan Y, 2000, SEIZURE-EUR J EPILEP, V9, P179, DOI 10.1053/seiz.2000.0388; Lhatoo S. D., 2002, Hong Kong Medical Journal, V8, P354; Morgan CL, 2002, EPILEPSIA, V43, P1251, DOI 10.1046/j.1528-1157.2002.38701.x; Nashef L, 1997, EPILEPSIA, V38, P1059, DOI 10.1111/j.1528-1157.1997.tb01193.x; Nashef L, 1996, LANCET, V348, P1324, DOI 10.1016/S0140-6736(05)65402-5; Nilsson L, 1997, EPILEPSIA, V38, P1062, DOI 10.1111/j.1528-1157.1997.tb01194.x; Rafnsson V, 2001, NEUROEPIDEMIOLOGY, V20, P232, DOI 10.1159/000054795; ROHATGI V, 1976, INTRO PROBABILITY TH; Shackleton DP, 2002, EPILEPSIA, V43, P445, DOI 10.1046/j.1528-1157.2002.10301.x; Shavelle RM, 2001, J AUTISM DEV DISORD, V31, P569, DOI 10.1023/A:1013247011483; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Sheth SG, 2004, NEUROLOGY, V63, P1002, DOI 10.1212/01.WNL.0000138590.00074.9A; *STAT CA DEP FIN, 2004, DEP FIN RAC ETHN POP; *STAT CA DEP FIN, 1998, RAC ETHN POP AG SEX; *STAT CA DEP HLTH, 1988, ANN MORT TAP 1988 20; *STAT CAL, 2004, DEP FIN RAC ETHN POP; Strauss D, 1999, DEV MED CHILD NEUROL, V41, P580, DOI 10.1017/S001216229900122X; Strauss DJ, 1998, PEDIATR NEUROL, V18, P143, DOI 10.1016/S0887-8994(97)00172-0; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Strauss DJ, 2003, NEUROLOGY, V60, P395, DOI 10.1212/WNL.60.3.395; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x	35	28	29	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JUL 26	2005	65	2					216	222		10.1212/01.wnl.0000169018.44950.68			7	Clinical Neurology	Neurosciences & Neurology	949AD	WOS:000230756300008	16043789				2021-06-18	
J	Fischer, C; Luaute, J				Fischer, C; Luaute, J			Evoked potentials for the prediction of vegetative state in the acute stage of coma	NEUROPSYCHOLOGICAL REHABILITATION			English	Article; Proceedings Paper	Joint Conference of the International-Neuropsychological-Society/German-Society-for-Neuropsychology	JUL 16-19, 2003	Berlin, GERMANY	Int Neuropsychol Soc, German Soc Neuropsychol			EVENT-RELATED POTENTIALS; PROGNOSTIC VALUE; MISMATCH NEGATIVITY; LATENCY; CONSCIOUSNESS	For comatose patients in intensive care units, it is important to anticipate their functional outcome as soon and as reliably as possible. Among clinical variables the Glasgow Coma Score (GCS) and the patient's pupil reactivity are the strongest predictive variables. Evoked potentials help to assess objectively brain function. Over the past 20 years, numerous studies have assessed their prognostic utility in terms of awakening from coma. Fewer studies, however, have focused upon the utility of evoked potentials in predicting progression to the vegetative state. In this area evoked potentials appear to have a highly predictive value. In anoxic coma the abolition of somatosensory evoked potentials (SEPs) is related to a poor outcome, defined as death or survival in a vegetative state, with a 100% specificity. Following traumatic brain injury, the predictive value for unfavourable outcome is 98.5% when there are no focal injuries likely to abolish SEP cortical components. In contrast, the presence of event-related evoked potentials, and particularly mismatched negativity (MMN), is a strong predictor of awakening and precludes comatose patients from moving to a permanent vegetative state (PVS).	Hop Neurol Lyon, F-69677 Bron, France; Hop H Gabrielle, Lyon, France	Fischer, C (corresponding author), Hop Neurol Lyon, 59 Blvd Pinel, F-69677 Bron, France.	catherine.fischer@chu-lyon.fr	Luaute, jacques/H-4618-2017	Luaute, jacques/0000-0002-6387-9572			ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Carter BG, 2001, CRIT CARE MED, V29, P178, DOI 10.1097/00003246-200101000-00036; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; Fischer C, 2004, NEUROLOGY, V63, P669, DOI 10.1212/01.WNL.0000134670.10384.E2; FISCHER C, 1994, NEUROSURGERY, V35, P45, DOI 10.1227/00006123-199407000-00007; GOODWIN SR, 1991, CRIT CARE MED, V19, P518, DOI 10.1097/00003246-199104000-00011; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Guerit J. M., 1993, Neurophysiologie Clinique, V23, P209, DOI 10.1016/S0987-7053(05)80231-X; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; JENNETT B, 1975, LANCET, V1, P480; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; KANEKO S, 2000, KINO ZAIRYO, V3, P5; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI 10.1097/01.PHM.0000043771.90606.81; Logi F, 2003, CLIN NEUROPHYSIOL, V114, P1615, DOI 10.1016/S1388-2457(03)00086-5; Luaute J, 2005, ARCH PHYS MED REHAB, V86, P917, DOI 10.1016/j.apmr.2004.08.011; Madl C, 2000, CRIT CARE MED, V28, P721, DOI 10.1097/00003246-200003000-00020; Mauguiere F, 1999, EEG CL N SU, V50, P31; Naatanen R, 2002, NEUROSCI LETT, V318, P49, DOI 10.1016/S0304-3940(01)02438-7; Naatanen R, 1995, Int J Neurosci, V80, P317, DOI 10.3109/00207459508986107; Nakabayashi M, 2001, INTENS CARE MED, V27, P1210, DOI 10.1007/s001340100984; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; Yvert B, 2001, CEREB CORTEX, V11, P411, DOI 10.1093/cercor/11.5.411; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8; Zingler VC, 2003, EUR NEUROL, V49, P79, DOI 10.1159/000068503	26	28	35	0	8	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL-SEP	2005	15	3-4					372	380		10.1080/09602010443000434			9	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	965PE	WOS:000231961900022	16350978				2021-06-18	
J	Gurr, B; Coetzer, BR				Gurr, B; Coetzer, BR			The effectiveness of cognitive-behavioural therapy for post-traumatic headaches	BRAIN INJURY			English	Article						head injury; post-concussional symptoms; post-traumatic headaches; cognitive-behavioural therapy	POST-CONCUSSION SYNDROME; QUALITY-OF-LIFE; BRAIN-INJURY; PATHOGENESIS; MANAGEMENT; PAIN	Post-traumatic headache is one of the most common symptoms following mild and moderate head injury. Psychological factors are believed to play a role in the cause, maintenance and relief from chronic post-traumatic headache. This research evaluated the effectiveness of a multi-dimensional cognitive-behavioural approach towards rehabilitation of post-traumatic headaches. The sample included 20 participants with post-traumatic headaches from an original sample of 41. Participants acted as their own controls. Outcome measures consisted of self-rating questionnaires to assess headache severity, intensity, duration, functioning and emotional well-being. Emotional and functional headache characteristics were studied using a multi-dimensional investigation which included relatives' perceptions of the sufferers headaches. The intervention proved effective and beneficial for the 20 therapy participants. It is concluded that cognitive-behavioural therapy provides a useful supplement to the treatment of post-traumatic headache.	Poole Community Clin, Brain Injury Serv, Poole BH15 2NT, Dorset, England	Gurr, B (corresponding author), Poole Community Clin, Brain Injury Serv, Shaftesbury Rd, Poole BH15 2NT, Dorset, England.	birgit.gurr@dorsethc-tr.swest.nhs.uk					Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Andrasik F, 2003, NEUROL SCI, V24, pS80; ANDRASIK F, 1990, NEUROL CLIN, V8, P961, DOI 10.1016/S0733-8619(18)30329-3; BENNETT TL, 1988, COGN REHABIL, P34; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; CAVALLINI A, 1995, HEADACHE, V35, P29, DOI 10.1111/j.1526-4610.1995.hed3501030.x; Coetzer B. R, 2004, ILLNESS CRISIS LOSS, V12, P171, DOI DOI 10.1177/1054137303262216; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Cramer JA, 2001, HEADACHE, V41, P402, DOI 10.1046/j.1526-4610.2001.111006402.x; DAWN M, 2003, HEADACHE, V43, P117; EVANS RW, 1992, NEUROL CLIN, V10, P815; FIELDS HF, 1997, HEADACHE, P38; GOLDSTEIN J, 1991, MED CLIN N AM, V75, P641, DOI 10.1016/S0025-7125(16)30439-4; GREENBERGER D, 1995, MIND MOOD CHANGE WAY; Gurr B, 2001, BRAIN INJURY, V15, P387, DOI 10.1080/02699050010005904; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; HAM LP, 1994, CEPHALALGIA, V14, P118, DOI 10.1046/j.1468-2982.1994.1402118.x; HAWTON K, 1998, COGNITIVE BEHAV THER; Holroyd KA, 2000, HEADACHE, V40, P3, DOI 10.1046/j.1526-4610.2000.00001.x; HUNT SM, 1980, MEASURING HLTH STATU; JACOBSON GP, 1995, HEADACHE, V35, P534, DOI 10.1111/j.1526-4610.1995.hed3509534.x; JACOBSON GP, 1994, NEUROLOGY, V44, P837, DOI 10.1212/WNL.44.5.837; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; LIPTON RB, 1995, HEADACHE, V35, P447, DOI 10.1111/j.1526-4610.1995.hed3508447.x; Lipton RB, 1999, HEADACHE, V39, pS9, DOI 10.1111/j.1526-4610.1999.00003.x; Martelli MF, 2004, J HEAD TRAUMA REHAB, V19, P10, DOI 10.1097/00001199-200401000-00003; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; Martin P. R., 1993, PSYCHOL MANAGEMENT C; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McClelland RJ, 1996, J PSYCHOSOM RES, V40, P563, DOI 10.1016/0022-3999(95)00616-8; Melzack R, 1983, CHALLENGE PAIN; Nicholson K, 2004, J HEAD TRAUMA REHAB, V19, P2, DOI 10.1097/00001199-200401000-00002; OST LG, 1987, BEHAV RES THER, V25, P397, DOI 10.1016/0005-7967(87)90017-9; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; PACKARD RC, 1979, HEADACHE, V19, P370, DOI 10.1111/j.1526-4610.1979.hed1907370.x; PACKARD RC, 1994, J NEUROPSYCH CLIN N, V6, P229; PACKARD RC, 1996, BIOFEEDBACK SELF-REG, V21, P93; PADESKY C, 2004, COGNITIVE THERAPY UN; PARKER RS, 1995, J COGNITIVE REHABILI, V13, P14; Passchier J, 1996, HEADACHE, V36, P556, DOI 10.1046/j.1526-4610.1996.3609556.x; Penzien DB, 2002, APPL PSYCHOPHYS BIOF, V27, P163, DOI 10.1023/A:1016247811416; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; Radanov BP, 2001, EUR SPINE J, V10, P403, DOI 10.1007/s005860000227; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Santalucia P, 2000, Med Health R I, V83, P173; Saper JR, 2000, ARCH NEUROL-CHICAGO, V57, P1776, DOI 10.1001/archneur.57.12.1776; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Solomon S, 2001, MED CLIN N AM, V85, P987, DOI 10.1016/S0025-7125(05)70355-2; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Tatrow K, 2003, HEADACHE, V43, P755, DOI 10.1046/j.1526-4610.2003.03133.x; VONKORFF M, 1994, NEUROLOGY, V44, P40; Warner JS, 1996, NEUROLOGY, V46, P915, DOI 10.1212/WNL.46.4.915; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1080/09602010244000444, 10.1016/S0960-9822(02)01374-X]; YAGAMUCHI M, 1992, HEADACHE, V32, P427; YOUNGJOHN J, 1997, AFTERMATH ROAD ACCID, P98; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	57	28	29	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2005	19	7					481	491		10.1080/02699050400005176			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	933IQ	WOS:000229622500002	16134736				2021-06-18	
J	Siddall, ORM				Siddall, ORM			Use of methylphenidate in traumatic brain injury	ANNALS OF PHARMACOTHERAPY			English	Article						methylphenidate; traumatic brain injury	MANAGEMENT	OBJECTIVE: To review literature regarding the effectiveness of methylphenidate in the management of the cognitive and behavioral changes observed following traumatic brain injury (TBI). DATA SOURCES: A literature search was conducted using the following databases: MEDLINE (1966-June 2004); Cochrane Central Register of Controlled Trials, fourth quarter 2004 (1988-June 2004); and International Pharmaceutical Abstracts (1970-June 2004). Methylphenidate and brain injury were the key search terms used. Limits were set to include clinical trial publications, human subjects, and English language. DATA SYNTHESIS: Ten clinical trials evaluating the efficacy and safety of methylphenidate in pediatric and adult patients with TBI are reviewed. Improvements in different aspects of cognition and behavior were evaluated before, during, and after treatment with methylphenidate. The results demonstrated that methylphenidate is likely to improve memory, attention, concentration, and mental processing, but its effects on behavior have not been determined. CONCLUSIONS: Larger, double-blind, placebo-controlled studies are needed to determine optimal doses, during which phase of recovery to begin treatment, length of treatment, and long-term effects for patients with mild, moderate, and severe TBI.	Xavier Univ, Coll Pharm, New Orleans, LA 70125 USA; Tulane Univ Hosp & Clin, Drug Informat Ctr, New Orleans, LA 70112 USA	Siddall, ORM (corresponding author), Xavier Univ, Coll Pharm, New Orleans, LA 70125 USA.	osiddall@tulane.edu					Alban JP, 2004, AM J PHYS MED REHAB, V83, P131, DOI 10.1097/01.phm.0000112308.68586.1d; Arciniegas DB, 2003, INT REV PSYCHIATR, V15, P328, DOI 10.1080/09540260310001606719; Challman TD, 2000, MAYO CLIN PROC, V75, P711; Chesnut Randall M., 1997, Emergency Medicine Clinics of North America, V15, P581, DOI 10.1016/S0733-8627(05)70319-9; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GAULTIERI CT, 1988, BRAIN INJURY, V2, P273; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Kajs-Wyllie Marylyn, 2002, J Neurosci Nurs, V34, P303; Lee HCB, 2003, INT REV PSYCHIATR, V15, P359, DOI 10.1080/09540260310001606746; Leonard BE, 2004, HUM PSYCHOPHARM CLIN, V19, P151, DOI 10.1002/hup.579; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; *NIH, 1998, REH PERS TRAUM BRAIN, V16, P1; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Williams SE, 1998, J HEAD TRAUMA REHAB, V13, P73, DOI 10.1097/00001199-199806000-00007; Zink Brian J., 1996, Emergency Medicine Clinics of North America, V14, P115	25	28	30	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	JUL-AUG	2005	39	7-8					1309	1313		10.1345/aph.1E637			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	941QN	WOS:000230229400023	15914519				2021-06-18	
J	Etherton, J; Bianchini, K; Greve, K; Heinly, M				Etherton, J; Bianchini, K; Greve, K; Heinly, M			Sensitivity and specificity of reliable digit span in malingered pain-related disability	ASSESSMENT			English	Article						malingering; chronic pain; cognition; assessment; attention; back injury	ADULT INTELLIGENCE SCALE; MMPI-2 VALIDITY SCALES; FAKE BAD SCALE; NEUROCOGNITIVE DYSFUNCTION; INJURY; VALIDATION; ATTENTION	The reliable digit span (RDS) performance of chronic pain patients with unambiguous spinal injuries and no evidence of exaggeration or response bias (n = 53) was compared to that of chronic pain patients meeting criteria for definite malingered neurocognitive dysfunction (n = 35), and a group of nonmalingering moderate-severe traumatic brain injury (TBI) patients (n = 69). The results demonstrated that scores of 7 or lower were associated with high specificity (> .90) and sensitivity (up to .60) even when moderate to severe TBI are included. Multiple studies have demonstrated that RDS scores of 7 or lower rarely occur in TBI and pain patients who are not intentionally performing poorly on cognitive testing. This study supports the use of the RDS in detecting response bias in neuropsychological patients complaining of pain as well as in the assessment of pain-related cognitive impairment in patients whose primary complaint is pain.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Loyola Univ, New Orleans, LA 70118 USA	Greve, K (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bianchini K. J., 2004, J FORENSIC NEUROPSYC, V4, P65; Bianchini KJ, 2003, CLIN NEUROPSYCHOL, V17, P574, DOI 10.1076/clin.17.4.574.27946; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, PORTLAND DIGIT RECOG; ECCLESTON C, 1994, BRIT J CLIN PSYCHOL, V33, P535, DOI 10.1111/j.2044-8260.1994.tb01150.x; ECCLESTON C, 1995, BEHAV RES THER, V33, P391, DOI 10.1016/0005-7967(94)00057-Q; Etherton JL, 2005, ASSESSMENT, V12, P101, DOI 10.1177/1073191104270789; ETHERTON JL, IN PRESS ARCHIVES CL; Gervais R.O., 2001, J FORENSIC NEUROPSYC, V2, DOI [DOI 10.1300/J151V02N02_01, https://doi.org/10.1300/J151v02n02_01]; GRACELY RH, 1978, PAIN, V5, P5, DOI 10.1016/0304-3959(78)90020-9; Gracely RH, 1989, TXB PAIN, P257; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; GREVE K, 24 ANN M NAT AC NEUR; Greve KW, 2003, ARCH PHYS MED REHAB, V84, P1233, DOI 10.1016/S0003-9993(03)00145-X; HEINLY M, 2004, 24 ANN M NAT AC NEUR; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Langeluddecke PM, 2003, CLIN NEUROPSYCHOL, V17, P273, DOI 10.1076/clin.17.2.273.16499; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; LARRABEE GJ, 2003, J INT NEUROPSYCH SOC, V9, P282; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Meyers J E, 2000, Appl Neuropsychol, V7, P133, DOI 10.1207/S15324826AN0703_3; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Nicholson K, 2001, NEUROREHABILITATION, V16, P225; OWENS RG, 1995, AM J FORENSIC PSYCH, V13, P61; PECKERMAN A, 1991, PSYCHOPHYSIOLOGY, V28, P485, DOI 10.1111/j.1469-8986.1991.tb01985.x; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; STERN RA, 2003, NEUROPSYCHOLIGICAL A; Strauss E, 2002, ARCH CLIN NEUROPSYCH, V17, P423, DOI 10.1016/S0887-6177(01)00126-3; Thorndike RL., 1986, STANFORD BINET INTEL, V4; Tombaugh TN, 1996, TEST MEMORY MALINGER; Tsushima WT, 2001, ASSESSMENT, V8, P205, DOI 10.1177/107319110100800208; Wechsler D., 1997, WMS 3 WECHSLER MEMOR	40	28	28	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	JUN	2005	12	2					130	136		10.1177/1073191105274859			7	Psychology, Clinical	Psychology	928VG	WOS:000229299200002	15914715				2021-06-18	
J	Ferstl, EC; Walther, K; Guthke, T; von Cramon, DY				Ferstl, EC; Walther, K; Guthke, T; von Cramon, DY			Assessment of story comprehension deficits after brain damage	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							RIGHT-HEMISPHERE; DISCOURSE COMPREHENSION; TEXT COMPREHENSION; MAIN IDEAS; INFERENCES; INJURY; MEMORY; ADULTS; DYSFUNCTION; LISTENERS	A story comprehension task was specifically developed for the clinical diagnosis of text comprehension deficits. The performance of 49 healthy control participants on qualitatively different YeslNo questions confirmed that both salience and explicitness of information had an impact on question difficulty. An unselected group of brain damaged patients (n=96) made more errors, particularly on questions about implicit information. The subgroup of patients with left-hemispheric vascular aetiology (n=18) had particular difficulties with stated details, patients with right-hemispheric vascular aetiology (n=12) with implicit main ideas, and patients with traumatic brain injury (n=34) were most impaired on implicit information. Correlations with neuropsychological test scores also confirmed that the questions successfully tapped different subprocesses of comprehension. Performance on implicit main ideas was correlated with tests of executive functions, whereas the performance on the other three question types was correlated with long-term memory and verbal learning. These results suggest that the story comprehension test is a useful diagnostic tool for neuropsychological assessment.	Max Planck Inst Human Cognit & Brain Sci, D-04103 Leipzig, Germany; Univ Leipzig, Day Clin Cognit Neurol, D-7010 Leipzig, Germany	Ferstl, EC (corresponding author), Max Planck Inst Human Cognit & Brain Sci, Stephanstr 1A, D-04103 Leipzig, Germany.	ferstl@cbs.mpg.de					BEEMAN M, 1993, BRAIN LANG, V44, P80, DOI 10.1006/brln.1993.1006; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BROOKSHIRE RH, 1984, BRAIN LANG, V21, P21, DOI 10.1016/0093-934X(84)90033-6; Brookshire RH, 1993, DISCOURSE COMPREHENS; Brownell H, 1998, RIGHT HEMISPHERE LANGUAGE COMPREHENSION, P309; BROWNELL HH, 1983, BRAIN LANG, V18, P20, DOI 10.1016/0093-934X(83)90002-0; CAPLAN D, 1990, BRAIN LANG, V39, P206, DOI 10.1016/0093-934X(90)90012-6; Caplan D., 1992, LANGUAGE STRUCTURE P; CHAPMAN SB, 1995, HDB NEUROLOGICAL SPE, P387; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Delis DC, 1987, CALIFORNIA VERBAL LE; DERENZI E, 1978, CORTEX, V14, P41, DOI 10.1016/S0010-9452(78)80006-9; Ferstl EC, 1999, CONSTRUCTION OF MENTAL REPRESENTATIONS DURING READING, P247; Ferstl EC, 2002, NEUROPSYCHOLOGY, V16, P292, DOI 10.1037//0894-4105.16.3.292; Ferstl EC, 1999, BRAIN LANG, V70, P385, DOI 10.1006/brln.1999.2151; Ferstl EC, 2001, INT ENCY SOCIAL BEHA, V3; GERMANI MJ, 1992, BRAIN LANG, V42, P308, DOI 10.1016/0093-934X(92)90103-L; GRAESSER AC, 1994, PSYCHOL REV, V101, P371, DOI 10.1037/0033-295X.101.3.371; Guthke T., 2001, APHASIE VERWANDTE GE, V15, P29; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; HAUT M W, 1990, Brain Injury, V4, P281, DOI 10.3109/02699059009026178; Horn W, 1983, LEISTUNGSPRUFSYSTEM; HOUGH MS, 1990, BRAIN LANG, V38, P253, DOI 10.1016/0093-934X(90)90114-V; HUBER W, 1984, ADV NEUROLOGY, V42; Kaczmarek B. L. J., 1987, FRONTAL LOBES REVISI, P225; KACZMAREK BLJ, 1984, BRAIN LANG, V21, P52, DOI 10.1016/0093-934X(84)90035-X; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; Kintsch W., 1998, COMPREHENSION PARADI; Lehman MT, 2000, APHASIOLOGY, V14, P485, DOI 10.1080/026870300401261; Lehrl S, 1991, MEHRFACHWAHL WORTSCH; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MCDONALD S, 1993, APHASIOLOGY, V7, P535, DOI 10.1080/02687039308248629; MCDONALD S, 1986, BRAIN LANG, V29, P68, DOI 10.1016/0093-934X(86)90034-9; Murray LL, 1999, AM J SPEECH-LANG PAT, V8, P137, DOI 10.1044/1058-0360.0802.137; Nicholas L.E., 1995, AM J SPEECH LANGUAGE, V4, P69, DOI [10.1044/1058-0360.0403.69, DOI 10.1044/1058-0360.0403.69]; NICHOLAS LE, 1986, J SPEECH HEAR RES, V29, P462, DOI 10.1044/jshr.2904.462; NOVOA OP, 1987, BRAIN LANG, V30, P206, DOI 10.1016/0093-934X(87)90099-X; PIERCE RS, 1988, APHASIOLOGY, V2, P577, DOI 10.1080/02687038808248968; PRAGATANO GP, 1986, NEUROPSYCHOLOGICAL R; Ronnberg J, 1996, SCAND J PSYCHOL, V37, P46, DOI 10.1111/j.1467-9450.1996.tb00638.x; Singer M., 1994, HDB PSYCHOLINGUISTIC, P479; STEMMER B, 1994, BRAIN LANG, V47, P1, DOI 10.1006/brln.1994.1040; Ulatowska H. K., 1994, DISCOURSE ANAL APPL, P29; Van Dijk T.A., 1983, STRATEGIES DISCOURSE; WEBSTER JS, 1992, J CLIN EXP NEUROPSYC, V14, P222, DOI 10.1080/01688639208402825; Wechsler D., 1987, WECHSLER MEMORY SCAL; WEGNER ML, 1984, BRAIN LANG, V21, P37, DOI 10.1016/0093-934X(84)90034-8; Welland RJ, 2002, J SPEECH LANG HEAR R, V45, P1175, DOI 10.1044/1092-4388(2002/095); Wilson BA, 1996, BEHAV ASSESSMENT DYS; Zimmermann P., 1992, TESTBATTERIE AUFMERK	50	28	29	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR	2005	27	3					367	384		10.1080/13803390490515784			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	913HD	WOS:000228141300007	15969358				2021-06-18	
J	McAdoo, DJ; Hughes, MG; Nie, LH; Shah, B; Clifton, C; Fullwood, S; Hulsebosch, CE				McAdoo, DJ; Hughes, MG; Nie, LH; Shah, B; Clifton, C; Fullwood, S; Hulsebosch, CE			The effect of glutamate receptor blockers on glutamate release following spinal cord injury. Lack of evidence for an ongoing feedback cascade of damage -> glutamate release -> damage -> glutamate release -> etc.	BRAIN RESEARCH			English	Article						glutamate receptor blockers; glutamate release; spinal cord injury; damage cascades; secondary damage	EXCITATORY AMINO-ACID; RAT CEREBRAL-CORTEX; METHYL-D-ASPARTATE; TRAUMATIC BRAIN INJURY; FUNCTIONAL DEFICITS; NMDA ANTAGONISTS; CHANNEL BLOCKER; WHITE-MATTER; SODIUM-CHANNELS; IMPACT INJURY	It is widely hypothesized that excitotoxicity of released glutamate following a CNS insult is propagated by the cyclic cascade: glutamate release -> damage -> glutamate release -> further damage -> etc. We tested this hypothesis by determining the effects of attempting to interrupt the loop by administering glutamate receptor antagonists and Na+-channel blockers on glutamate release following spinal cord injury (SCI). The effects of administering the NMDA receptor blockers MK-801 and memantine, the AMPA/kainate receptor blockers NBQX and GYKI 52466, the AMPA receptor desensitization blocker cyclothiazide and the sodium channel blockers riluzole, mexiletine and QX-314 on post-SCI were determined. Agents were administered into the site of injury by direct injection, by microdialysis or systemically. None of these agents had an appreciable effect on glutamate release following SCI. Thus, it is unlikely that the above cascade produces significant secondary glutamate release and ongoing damage following SCI, although such cascades may worsen other CNS insults. We attribute our results to overwhelming effects of much greater release by direct mechanical damage and reversal of transport following SCI. (c) 2005 Elsevier B.V. All rights reserved.	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA	McAdoo, DJ (corresponding author), Univ Texas, Med Branch, Dept Neurosci & Cell Biol, 301 Univ Blvd, Galveston, TX 77555 USA.	djmcadoo@utmb.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS039161, P01NS011255] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39161, NS11255] Funding Source: Medline		Agrawal SK, 1997, J NEUROTRAUM, V14, P81, DOI 10.1089/neu.1997.14.81; Azbill RD, 2000, BRAIN RES, V871, P175, DOI 10.1016/S0006-8993(00)02430-6; CHEN HSV, 1992, J NEUROSCI, V12, P4427; Danysz W, 2000, AMINO ACIDS, V19, P167, DOI 10.1007/s007260070045; DEMONTIGNY P, 1987, ANAL CHEM, V59, P1098; DOBLE A, 1995, THERAPIE, V50, P319; DOPPENBERG EMR, 1997, ANN NY ACAD SCI, V825, P305; ELLISON G, 1994, NEUROREPORT, V5, P2688, DOI 10.1097/00001756-199412000-00070; ERDO SL, 1991, EUR J PHARMACOL, V198, P215, DOI 10.1016/0014-2999(91)90625-Z; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; GARTHWAITE G, 1992, EUR J NEUROSCI, V4, P353, DOI 10.1111/j.1460-9568.1992.tb00882.x; GOMEZPINILLA F, 1989, EXP NEUROL, V104, P118, DOI 10.1016/S0014-4886(89)80004-4; GOODMAN RM, 1985, NEUROSURGERY, V17, P757, DOI 10.1227/00006123-198511000-00005; GRAHAM SH, 1994, J PHARMACOL EXP THER, V269, P854; GRAHAM SH, 1993, J CEREBR BLOOD F MET, V13, P88, DOI 10.1038/jcbfm.1993.11; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hesselink MB, 1999, PHARMACEUT RES, V16, P637, DOI 10.1023/A:1018856020583; Kanellopoulos GK, 2000, STROKE, V31, P1945, DOI 10.1161/01.STR.31.8.1945; Kwon JY, 1998, ANESTH ANALG, V86, P128, DOI 10.1097/00000539-199801000-00026; Liu D, 1999, NEUROSCIENCE, V93, P1383, DOI 10.1016/S0306-4522(99)00278-X; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; LIU DX, 1993, J NEUROTRAUM, V10, P349, DOI 10.1089/neu.1993.10.349; Liu SL, 1997, BRAIN RES, V756, P160, DOI 10.1016/S0006-8993(97)00137-6; McAdoo DJ, 1999, EXP NEUROL, V159, P538, DOI 10.1006/exnr.1999.7166; McAdoo DJ, 2000, BRAIN RES, V865, P283, DOI 10.1016/S0006-8993(00)02296-4; MELDRUM BS, 1992, BRAIN RES, V593, P1, DOI 10.1016/0006-8993(92)91254-C; Mills CD, 2000, NEUROREPORT, V11, P3067, DOI 10.1097/00001756-200009280-00007; Mills CD, 2001, J NEUROCHEM, V79, P835, DOI 10.1046/j.1471-4159.2001.00630.x; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; Nesic O, 2002, J NEUROSCI RES, V68, P406, DOI 10.1002/jnr.10171; OLNEY JW, 1995, NEUROPSYCHOPHARMACOL, V13, P335, DOI 10.1038/sj.npp.1380292; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; Phillis JW, 2000, BRAIN RES, V868, P105, DOI 10.1016/S0006-8993(00)02303-9; PHILLIS JW, 1994, BRAIN RES BULL, V34, P457, DOI 10.1016/0361-9230(94)90019-1; PHILLIS JW, 1993, NEUROREPORT, V4, P109, DOI 10.1097/00001756-199301000-00029; ROKKAS CK, 1994, ANN THORAC SURG, V58, P312, DOI 10.1016/0003-4975(94)92200-4; Rosenberg LJ, 1999, J NEUROSCI, V19, P6122, DOI 10.1523/JNEUROSCI.19-14-06122.1999; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schwartz G, 2001, J NEUROSURG, V94, P245, DOI 10.3171/spi.2001.94.2.0245; Seki Y, 1999, STROKE, V30, P433, DOI 10.1161/01.STR.30.2.433; SMITH SE, 1993, NEUROREPORT, V4, P1339, DOI 10.1097/00001756-199309150-00013; Strijbos PJLM, 1996, J NEUROSCI, V16, P5004; Stys PK, 1996, NEUROSCIENCE, V71, P27, DOI 10.1016/0306-4522(95)00430-0; Teng YD, 1997, J NEUROSCI, V17, P4359; URENJAK J, 1997, REV CONTEMP PHARMACO, V8, P237; Vera-Portocarrero LP, 2002, BRAIN RES, V927, P104, DOI 10.1016/S0006-8993(01)03329-7; vonEuler M, 1997, J NEUROTRAUM, V14, P53, DOI 10.1089/neu.1997.14.53; WAHL F, 1994, J NEUROCHEM, V63, P1003; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; Wrathall JR, 1997, EXP NEUROL, V145, P565, DOI 10.1006/exnr.1997.6506; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; Xu GY, 2004, EXP NEUROL, V187, P329, DOI 10.1016/j.expneurol.2004.01.029; Xu GY, 1998, NEUROSCIENCE, V86, P1011, DOI 10.1016/S0306-4522(98)00063-3; YAMADA KA, 1993, J NEUROSCI, V13, P3904; YEZIERSKI RP, 1993, J NEUROTRAUM, V10, P445, DOI 10.1089/neu.1993.10.445	58	28	29	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 15	2005	1038	1					92	99		10.1016/j.brainres.2005.01.024			8	Neurosciences	Neurosciences & Neurology	914TP	WOS:000228251000011	15748877				2021-06-18	
J	Melton, AK; Bourgeois, MS				Melton, AK; Bourgeois, MS			Training compensatory memory strategies via the telephone for persons with TBI	APHASIOLOGY			English	Article; Proceedings Paper	34th Annual Clinical Aphasiology Conference	2004	Park City, UT				BRAIN INJURY; DEMENTIA; EFFICACY; ADULTS	Background: Spaced retrieval training has been used to teach individuals with dementia to use compensatory memory strategies. This training has been delivered over the telephone to some persons with dementia. Spaced retrieval applications for individuals with traumatic brain injury have not been reported to date. Aims: The purpose of this study was to investigate the efficacy of spaced retrieval for teaching individuals with traumatic brain injury strategies and facts via the telephone, with an emphasis on generalisation. Methods & Procedures: Seven participants with chronic everyday memory problems due to traumatic brain injury were trained to use memory aids for prospective and episodic memory tasks. Participants demonstrated borderline normal to mild global severity ratings. Functional memory problems were identified and external memory aids were provided if appropriate. Participants were trained using spaced retrieval via the telephone 30 minutes per day; each participant was trained on three memory goals. Participants and some caregivers reported strategy use and generalisation for most trained goals. Outcomes & Results: Results indicated that goal attainment and generalisation were achieved in an average of five 30-minute training sessions, resulting in 94.4% spaced-retrieval goal maintenance at 1 month. Strategy execution at 1 month was reported on 77.7% of goals trained. Conclusions: Spaced retrieval is a viable approach for training individuals with traumatic brain injury to use external memory aids and learn prospective memory tasks. Telephone intervention should be considered as an accessible service delivery alternative to promote generalisation with this population.	Florida State Univ, Reg Rehabil Ctr 302, Tallahassee, FL 32306 USA	Bourgeois, MS (corresponding author), Florida State Univ, Reg Rehabil Ctr 302, Tallahassee, FL 32306 USA.	mbourgeo@garnet.acns.fsu.edu	Bourgeois, Michelle/F-9397-2015	Bourgeois, Michelle/0000-0003-1458-6842			Abrahams Joel P., 1993, Clinical Gerontologist, V12, P57, DOI 10.1300/J018v12n03_06; BADDELEY AD, 1992, NEUROPSYCHOLOGY MEMO, P309; BIRD M, 1995, INT J GERIATR PSYCH, V10, P305, DOI 10.1002/gps.930100407; Bourgeois MS, 2003, J COMMUN DISORD, V36, P361, DOI 10.1016/S0021-9924(03)00051-0; Brush JA, 1998, THERAPY TECHNIQUE IM; BRUSH JA, 1997, ANN CONV OH SPEECH H; Camp C. J., 1996, PROSPECTIVE MEMORY T, P351; Camp CJ, 1996, APPL COGNITIVE PSYCH, V10, P193, DOI 10.1002/(SICI)1099-0720(199606)10:3<193::AID-ACP374>3.0.CO;2-4; CAMP CJ, 1989, EDUC GERONTOL, V15, P641, DOI 10.1080/0380127890150608; CAMP CJ, 1990, CLIN GERONTOLOGIST, V10, P658; Coelho CA, 1996, J SPEECH HEAR RES, V39, pS5, DOI 10.1044/jshr.3905.s5; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOSS JW, 1993, COGNITIVE INTERVENTI; FREEMAN M R, 1992, Brain Injury, V6, P65, DOI 10.3109/02699059209008124; GOLDSTEIN FC, 1991, MEMORY DISORDERS RES; Hayden Claudia M., 1995, Clinical Gerontologist, V16, P80; Helm-Estabrooks N, 1991, BRIEF TEST HEAD INJU; HONSINGER MJ, 1991, COMMUNICATION DISORD, P103; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kowalske K, 2000, J HEAD TRAUMA REHAB, V15, P989, DOI 10.1097/00001199-200008000-00003; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; MCKITRICK LA, 1992, J GERONTOL, V47, P337, DOI DOI 10.1093/GERONJ/47.5.P337; McMahon C. M., 2003, CLIN PSYCHOL, V7, P50, DOI DOI 10.1080/13284200410001707483; Moffat N. J., 1989, EVERYDAY COGNITION A; Raskin SA, 1996, J HEAD TRAUMA REHAB, V11, P32, DOI 10.1097/00001199-199606000-00007; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; SOHLBERG MM, 1985, PROSPECTIVE MEMORY T; Stevens Alan, 1993, Clinical Gerontologist, V13, P106; WEBB DM, 1991, COGNITIVE REHABILITA, P28; WHYTE J, 1988, REHABILITATION MED P, P565	31	28	29	0	10	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology	MAR-MAY	2005	19	3-5					353	364		10.1080/02687030444000804			12	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	931IL	WOS:000229478900013					2021-06-18	
J	Bailes, JE				Bailes, JE			Experience with cervical stenosis and temporary paralysis in athletes	JOURNAL OF NEUROSURGERY-SPINE			English	Article						spinal stenosis; cervical spine; transient spinal cord injury; athlete	SPINAL-CORD CONCUSSION; TRANSIENT QUADRIPLEGIA; FOOTBALL PLAYERS; INJURIES; MYELOPATHY; PARTICIPATION; NEURAPRAXIA; TOMOGRAPHY; MANAGEMENT; HEAD	Object. Transient spinal cord injury (TSCI) in athletes presents one of the most challenging clinical scenarios. Management difficulties in and subsequent return-to-play decisions are especially important in those with cervical canal stenosis. Methods. Ten athletes (nine male and one female patients) were evaluated for TSCI. The diagnostic survey included physical and neurological examinations, plain radiographs with flexion-extension dynamic studies, computerized tomography, and magnetic resonance (MR) imaging. Clinical courses were followed and, in those who returned to contact sports activities, subsequent experience was noted. Symptoms consisted of paralysis, weakness, or numbness in all four extremities, their duration ranging from 15 minutes to 48 hours. Radiography revealed no evidence of fracture/dislocation or ligamentous instability. Spinal stenosis of 8 to 13 mm in length at three or more levels was evident in all cases. Four patients returned to competition without recurrent TSCI (mean follow-up duration 40 months); six individuals retired. The occurrence of TSCI is not uncommon in athletes involved in contact sports. The diagnostic workup focuses on excluding fracture/dislocation, cord contusion, ligamentous infolding or instability, herniated nucleus pulposus, syrinx, or other surgically correctable lesions. There appear to be two groups of athletes who sustain TSCI: those who experience TSCI yet in whom radiographic studies are normal, and those with cervical stenosis, the most difficult management group. Conclusions. It does not appear that a single episode of TSCI in an athlete with spinal stenosis will substantially increase the risk of subsequent catastrophic spinal cord injury in those in whom MR imaging demonstrates preservation of cerebrospinal fluid signal.	W Virginia Univ, Sch Med, Dept Neurosurg, Morgantown, WV 26506 USA	Bailes, JE (corresponding author), POB 9183, Morgantown, WV 26506 USA.						ALLEY RH, 1964, JAMA-J AM MED ASSOC, V188, P418; Bailes JE, 1999, SPORTS-RELATED CONCUSSION, P140; BAILES JE, 1991, NEUROSURGERY, V29, P491, DOI 10.1227/00006123-199110000-00001; BAILES JE, 1990, SURG NEUROL, V34, P155, DOI 10.1016/0090-3019(90)90064-V; BAILES JE, 1996, PRACTICE NEUROSURGER, V2, P1649; Boden BP, 2002, AM J SPORT MED, V30, P791, DOI 10.1177/03635465020300060601; Cantu RC, 2003, NEUROSURGERY, V53, P358, DOI 10.1227/01.NEU.0000073422.01886.88; CANTU RC, 1993, MED SCI SPORT EXER, V25, P316; Cantu RC, 2000, SEMIN NEUROL, V20, P173, DOI 10.1055/s-2000-9825; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; EISMONT FJ, 1984, SPINE, V9, P663, DOI 10.1097/00007632-198410000-00001; EPSTEIN JA, 1979, J NEUROSURG, V51, P362, DOI 10.3171/jns.1979.51.3.0362; FIROOZNIA H, 1985, SURG NEUROL, V23, P165, DOI 10.1016/0090-3019(85)90337-4; FUNK FJ, 1975, CLIN ORTHOP RELAT R, P50, DOI 10.1097/00003086-197506000-00007; GORE DR, 1986, SPINE, V11, P521, DOI 10.1097/00007632-198607000-00003; GROAT RA, 1945, SURG GYNECOL OBSTET, V81, P63; HAMILTON MG, 1992, J NEUROSURG, V77, P700, DOI 10.3171/jns.1992.77.5.0700; HASHIMOTO I, 1977, J NEUROSURG, V47, P912, DOI 10.3171/jns.1977.47.6.0912; HERZOG RJ, 1991, SPINE, V16, pS178, DOI 10.1097/00007632-199106001-00001; HOLMES G, 1915, BMJ-BRIT MED J, V27, P769; Kobrine A I, 1975, Surg Neurol, V3, P261; LADD AL, 1986, J BONE JOINT SURG AM, V68A, P1371, DOI 10.2106/00004623-198668090-00009; Maroon JC, 1996, SPINE, V21, P2294, DOI 10.1097/00007632-199610010-00025; MAROON JC, 1977, JAMA-J AM MED ASSOC, V238, P2049; MATSUURA P, 1989, J BONE JOINT SURG AM, V71A, P183, DOI 10.2106/00004623-198971020-00003; MEYER SA, 1994, AM J SPORT MED, V22, P158, DOI 10.1177/036354659402200202; MURONE I, 1974, J BONE JOINT SURG BR, VB 56, P30; OBERSTEINER H, 1879, WEIN MED JB, V34, P531; PANG D, 1982, J NEUROSURG, V57, P114, DOI 10.3171/jns.1982.57.1.0114; PARKINSON D, 1981, SURG NEUROL, V16, P347, DOI 10.1016/0090-3019(81)90272-X; PAVLOV H, 1987, RADIOLOGY, V164, P771, DOI 10.1148/radiology.164.3.3615879; PENNING L, 1962, NEUROLOGY, V12, P513; SCHER AT, 1981, S AFR MED J, V59, P227; SCHNEIDER R, 1961, JAMA-J AM MED ASSOC, V177, P362, DOI 10.1001/jama.1961.03040320006002; STANLEY JH, 1986, NEURORADIOLOGY, V28, P139, DOI 10.1007/BF00327886; TATOR CH, 1984, CAN J NEUROL SCI, V11, P34, DOI 10.1017/S0317167100045297; TORG JS, 1986, J BONE JOINT SURG AM, V68A, P1354, DOI 10.2106/00004623-198668090-00008; Torg JS, 1996, J BONE JOINT SURG AM, V78A, P1308, DOI 10.2106/00004623-199609000-00003; Torg JS, 1997, J NEUROSURG, V87, P843, DOI 10.3171/jns.1997.87.6.0843; TORG JS, 1993, AM J SPORT MED, V21, P640, DOI 10.1177/036354659302100502; VEIDLINGER OF, 1981, SPINE, V6, P550, DOI 10.1097/00007632-198111000-00004; WATKINS RG, 1996, SPINE SPORTS, P126; ZWIMPFER TJ, 1990, J NEUROSURG, V72, P894, DOI 10.3171/jns.1990.72.6.0894	43	28	29	2	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	JAN	2005	2	1					11	16		10.3171/spi.2005.2.1.0011			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	895OZ	WOS:000226874100004	15658120				2021-06-18	
J	Demorest, RA; Bernhardt, DT; Best, TM; Landry, GL				Demorest, RA; Bernhardt, DT; Best, TM; Landry, GL			Pediatric residency education: Is sports medicine getting its fair share?	PEDIATRICS			English	Article						pediatric residency education; sports medicine; graduate medical education; musculoskeletal; orthopedics	VISITS	Introduction. Sports are the leading injury-related cause for pediatric primary care visits. Pediatric residency education guidelines suggest incorporating sports medicine (SM) education into curricula; however, research is lacking regarding effective teaching methods. Objective. To assess reported US pediatric residency SM curricula, teaching methods, and resident evaluation of SM education. Design/Methods. Chief residents (CRs) and third-year residents (PL3s) from 100 randomly selected US Accreditation Council for Graduate Medical Education-accredited residency programs, stratified by size and geographic location, received surveys regarding programs' SM curriculum and teaching methods and individuals' methods for learning SM. Results. Response rates were 63% and 39% for CRs and PL3s, respectively. According to CRs, 34% of programs had no one in charge of their SM curriculum. Lecture (77%) was the primary method used for teaching SM. Hands-on teaching (37%) was used less frequently. CRs stated that 29% of programs did not include musculoskeletal examination teaching in their curriculums; 24% did not include formal teaching of concussion management, and 29% did not include reasons for medical disqualification. PL3s rated teaching of joint examinations and the preparticipation physical as the most poorly taught components of the physical examination. PL3s rated hands-on teaching and patient experience as the best methods for improving SM education. CRs reported that only 36% of programs have discussed incorporating more SM into their curriculum. Conclusions. SM education is deficient in US pediatric residency programs. Standardized curricula should be developed with a focus on hands-on training as a means for teaching SM to pediatric residents.	Univ Wisconsin, Dept Pediat, Madison, WI USA; Univ Wisconsin, Dept Orthoped & Rehabil & Family Med, Madison, WI USA	Demorest, RA (corresponding author), Childrens Natl Med Ctr, Dept Orthopaed & Sports Med, 111 Michigan Ave NW, Washington, DC 20010 USA.	rdemores@cnmc.org					*ACCR COUNC GRAD M, PROGR REQ RES ED; *AM BOARD PED, 2003 2004 WORKF DAT; *AMB PED ASS, PROP 2004 ED GUID RE; *AMB PED ASS, UPD APA ED GUID REV; BIJUR PE, 1995, ARCH PEDIAT ADOL MED, V149, P1009, DOI 10.1001/archpedi.1995.02170220075010; Burt CW, 2001, ANN EMERG MED, V37, P301, DOI 10.1067/mem.2001.111707; Camp BW, 1998, ARCH PEDIAT ADOL MED, V152, P210; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P736; Cherry Donald K, 2003, Adv Data, P1; ECKLER SJ, 2003, CLIN J SPORT MED, V13, P381; Emans SJ, 1998, PEDIATRICS, V102, P588, DOI 10.1542/peds.102.3.588; Freedman KB, 1998, J BONE JOINT SURG AM, V80A, P1421, DOI 10.2106/00004623-199810000-00003; GORDON MJ, 1991, ACAD MED, V66, P762, DOI 10.1097/00001888-199112000-00012; Hambidge SJ, 2002, PEDIATRICS, V109, P559, DOI 10.1542/peds.109.4.559; HERGENROEDER AC, 2001, PEDIATRICS, V107; Jenkins RR, 2003, PEDIATRICS, V112, P752; *NIH, 1992, NIH PUBL; Perron AD, 2000, AM J EMERG MED, V18, P356, DOI 10.1016/S0735-6757(00)90147-5; Roberts KB, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.4.e2; Stirling J, 1997, Acad Med, V72, P452, DOI 10.1097/00001888-199705000-00092; Stirling JM, 1996, ARCH PEDIAT ADOL MED, V150, P211, DOI 10.1001/archpedi.1996.02170270093014; Sweeney CL, 2003, BRIT J SPORT MED, V37, P219, DOI 10.1136/bjsm.37.3.219; TARAS HL, 1990, AM J DIS CHILD, V144, P1102, DOI 10.1001/archpedi.1990.02150340046021; Young MA, 1996, AM J PHYS MED REHAB, V75, P257, DOI 10.1097/00002060-199607000-00003; Ziv A, 1999, PEDIATRICS, V104, P35, DOI 10.1542/peds.104.1.35; Zonia SC, 2000, ACAD MED, V75, P742, DOI 10.1097/00001888-200007000-00020	26	28	29	1	3	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JAN	2005	115	1					28	33		10.1542/peds.2004-0266			6	Pediatrics	Pediatrics	884KN	WOS:000226083700025	15629978				2021-06-18	
J	Stapert, S; de Kruijk, J; Houx, P; Menheere, P; Twijnstra, A; Jolles, J				Stapert, S; de Kruijk, J; Houx, P; Menheere, P; Twijnstra, A; Jolles, J			S-100B concentration is not related to neurocognitive performance in the first month after mild traumatic brain injury	EUROPEAN NEUROLOGY			English	Article						mild traumatic brain injury; S-100B; neurocognitive performance	NEURON-SPECIFIC ENOLASE; MINOR HEAD-INJURY; COGNITIVE DYSFUNCTION; DAMAGE; SERUM; MANAGEMENT; SYMPTOMS; AGE	The serum concentration of S-100B is reported to reflect the severity of brain damage. The purpose of this study was to determine whether elevated serum S-100B concentrations were related to neuropsychological test performance of patients in the subacute phase of recovery from mild traumatic brain injury (TBI). S-100B concentrations were measured in blood samples taken within 6 h after TBI. Serum S-100B was estimated using an immunoluminometric assay. Cognitive speed and memory were assessed with neuropsychological tests at a median of 13 days ( range 7 - 21 days) after injury. The two groups, formed on a median split of initial serum S-100B concentrations (> or <0.22 mu g/l) did not differ in age or education. The neuropsychological performance of the TBI patients was also compared with that of a healthy control group. Cognitive speed and memory performance of mild TBI patients were inferior compared to those of healthy subjects. There were no significant differences within the TBI group when serum S-100B concentration was taken into consideration. The findings suggest that serum S-100B levels after mild TBI are not predictive of neuropsychological performance in the subacute stage of recovery. Copyright (C) 2005 S. Karger AG, Basel.	Maastricht Univ, Dept Psychol, Inst Brain & Behav, NL-6200 MD Maastricht, Netherlands; Univ Hosp, Dept Neurol, Maastricht, Netherlands	Stapert, S (corresponding author), Maastricht Univ, Dept Psychol, Inst Brain & Behav, POB 616, NL-6200 MD Maastricht, Netherlands.	S.Stapert@psychology.unimaas.nl					Alexander MP, 1998, NEUROLOGY, V51, P336, DOI 10.1212/WNL.51.2.336; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine (ACRM), 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; Bosma H, 2000, LANCET, V356, P912, DOI 10.1016/S0140-6736(00)02685-4; BRAND N, 1985, J GEN PSYCHOL, V112, P201, DOI 10.1080/00221309.1985.9711004; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; HOUX PJ, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P353; Ingebrigtsen T, 1997, ACTA NEUROL SCAND, V95, P51, DOI 10.1111/j.1600-0404.1997.tb00068.x; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2000, ARCH CLIN NEUROPSYCH, V15, P643, DOI 10.1016/S0887-6177(99)00048-7; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Klein M, 1997, J CLIN EXP NEUROPSYC, V19, P77, DOI 10.1080/01688639708403838; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Rasmussen LS, 1999, ACTA ANAESTH SCAND, V43, P495, DOI 10.1034/j.1399-6576.1999.430502.x; van Exel E, 2001, J NEUROL NEUROSUR PS, V71, P29, DOI 10.1136/jnnp.71.1.29; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864	27	28	29	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0014-3022	1421-9913		EUR NEUROL	Eur. Neurol.		2005	53	1					22	26		10.1159/000083678			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	912JL	WOS:000228073900004	15677870	Green Published			2021-06-18	
J	Steele, DL; Rajaratnam, SMW; Redman, JR; Ponsford, JL				Steele, DL; Rajaratnam, SMW; Redman, JR; Ponsford, JL			Effect of traumatic brain injury on the timing of sleep	CHRONOBIOLOGY INTERNATIONAL			English	Article						traumatic brain injury; dim light melatonin onset time; morningness-eveningness; circadian rhythm sleep disorders; sleep disruption	BIOLOGICAL RHYTHM RESEARCH; HUMAN CIRCADIAN-RHYTHMS; LIGHT MELATONIN ONSET; MORNINGNESS-EVENINGNESS; PHASE SYNDROME; INDIVIDUAL-DIFFERENCES; ASSOCIATION; TEMPERATURE; EXPOSURE; DAYTIME	While there have been single case reports of the development of circadian rhythm sleep disorders, most commonly delayed sleep phase syndrome following traumatic brain injury (TBI), to our knowledge there have been no group investigations of changes to sleep timing in this population. The aim of the present study was to investigate sleep timing following TBI using the dim light melatonin onset (DLMO) as a marker of circadian phase and the Morningness-Eveningness Questionnaire (MEQ) as a measure of sleep-wake behavior. A sleep-wake diary was also completed. It was hypothesized that the timing of DLMO would be delayed and that there would be a greater tendency toward eveningness on the MEQ in a post-acute TBI group (n = 10) compared to a gender and age matched control group. Participants were recruited at routine outpatient review appointments (TBI) and from the general population (control) as part of a larger study. They attended the sleep laboratory where questionnaires were completed, some retrospectively, and saliva melatonin samples were collected half-hourly according to a standard protocol. The results show that the TBI and control groups reported similar habitual sleep times and this was reflected on the MEQ. There was, however, significant variability in the TBI group's change from the pre-injury to the current MEQ score. The timing of melatonin onset was not different between the groups. While subtle changes (advances or delays) in this small sample may have cancelled each other out, the present study does not provide conclusive objective evidence of shift in circadian timing of sleep following TBI. Furthermore, although participants did report sleep timing changes, it is concluded that the MEQ may not be suitable for use with this cognitively impaired clinical group.	Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3800, Australia; Epworth Med Fdn, Monash Epworth Res Dept, Melbourne, Vic, Australia	Ponsford, JL (corresponding author), Monash Univ, Sch Psychol Psychiat & Psychol Med, Bldg 17,Clayton Campus, Melbourne, Vic 3800, Australia.	jennie.ponsford@med.monash.edu.au	Rajaratnam, Shantha/D-8144-2012; Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604; Rajaratnam, Shantha/0000-0001-7527-8558			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ASCHOFF J, 1965, SCIENCE, V148, P1427, DOI 10.1126/science.148.3676.1427; Baehr EK, 2000, J SLEEP RES, V9, P117, DOI 10.1046/j.1365-2869.2000.00196.x; BAKER SK, 2000, PRINCIPLES PRACTICE, P606; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Boivin DB, 2003, NEUROLOGY, V60, P1841, DOI 10.1212/01.WNL.0000061482.24750.7C; Cajochen C, 1996, NEUROSCI LETT, V207, P209, DOI 10.1016/0304-3940(96)12517-9; Carson DD, 2002, MOL HUM REPROD, V8, P871, DOI 10.1093/molehr/8.9.871; CZEISLER CA, 1981, SLEEP, V4, P1; Czeisler CA, 2000, PRINCIPLES PRACTICE, P353; Dagan Y, 2002, SLEEP MED REV, V6, P45, DOI 10.1053/smrv.2001.0190; DEACON S, 1994, NEUROSCI LETT, V167, P191, DOI 10.1016/0304-3940(94)91059-6; Dijk DJ, 1997, J BIOL RHYTHM, V12, P627, DOI 10.1177/074873049701200618; DOLLINS AB, 1994, P NATL ACAD SCI USA, V91, P1824, DOI 10.1073/pnas.91.5.1824; Duffy JF, 1996, J PHYSIOL-LONDON, V495, P289, DOI 10.1113/jphysiol.1996.sp021593; Duffy JF, 2001, BEHAV NEUROSCI, V115, P895, DOI 10.1037//0735-7044.115.4.895; Gordijn MCM, 1999, J SLEEP RES, V8, P163, DOI 10.1046/j.1365-2869.1999.00156.x; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HORNE JA, 1976, INT J CHRONOBIOL, V4, P97; Katzenberg D, 1998, SLEEP, V21, P569, DOI 10.1093/sleep/21.6.569; Kayumov L, 2000, Semin Clin Neuropsychiatry, V5, P44; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Lewy AJ, 1999, BIOL SIGNAL RECEPT, V8, P79; Martin G, 2002, IEEE DES TEST COMPUT, V19, P4, DOI 10.1109/MDT.2002.1047738; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Middleton B, 1996, J SLEEP RES, V5, P69, DOI 10.1046/j.1365-2869.1996.d01-67.x; Monk TH, 2003, SLEEP, V26, P208, DOI 10.1093/sleep/26.2.208; Moore RY, 2002, CELL TISSUE RES, V309, P89, DOI 10.1007/s00441-002-0575-2; Nagtegaal JE, 1997, FUNCT NEUROL, V12, P345; Nebel LE, 1996, PSYCHOPHYSIOLOGY, V33, P273, DOI 10.1111/j.1469-8986.1996.tb00424.x; NEUBAUER AC, 1992, PERS INDIV DIFFER, V13, P125, DOI 10.1016/0191-8869(92)90035-N; PATTEN SB, 1992, J AM ACAD CHILD PSY, V31, P100, DOI 10.1097/00004583-199201000-00015; Ponsford J., 1995, TRAUMATIC BRAIN INJU, P1; Quinto C, 2000, NEUROLOGY, V54, P250, DOI 10.1212/WNL.54.1.250; REGESTEIN QR, 1995, AM J PSYCHIAT, V152, P602; SIEGEL S, NONPARAMETIC STAT, P102; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; TEASDALE G, 1974, LANCET, V2, P81; Touitou Y, 2004, CHRONOBIOL INT, V21, P161, DOI 10.1081/CBI-120030045; Tryon WW, 2004, SLEEP, V27, P158, DOI 10.1093/sleep/27.1.158; TUREK FW, 1995, NEUROSCI BIOBEHAV R, V19, P53, DOI 10.1016/0149-7634(94)00030-5; TZISCHINSKY O, 1993, J BIOL RHYTHM, V8, P199, DOI 10.1177/074873049300800303; Voultsios A, 1997, J BIOL RHYTHM, V12, P457, DOI 10.1177/074873049701200507; WIGHT KP, 2001, P NATL ACAD SCI USA, V98, P14027; Yang CM, 2001, SLEEP, V24, P272, DOI 10.1093/sleep/24.3.272; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	47	28	29	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0742-0528	1525-6073		CHRONOBIOL INT	Chronobiol. Int.		2005	22	1					89	105		10.1081/CBI-200042428			17	Biology; Physiology	Life Sciences & Biomedicine - Other Topics; Physiology	922DE	WOS:000228815300008	15865324				2021-06-18	
J	Wolfson, DR; McNally, DS; Clifford, MJ; Vloeberghs, M				Wolfson, DR; McNally, DS; Clifford, MJ; Vloeberghs, M			Rigid-body modelling of shaken baby syndrome	PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART H-JOURNAL OF ENGINEERING IN MEDICINE			English	Article						shaken baby syndrome; rigid-body modelling; head injury; MADYMO; whiplash; neck model	PERMANENT BRAIN-DAMAGE; MENTAL-RETARDATION; IMPACT SYNDROME; HEAD-INJURY; SHAKING; INFANTS; CRITERIA; CHILDREN; MASS	Recent reassessment of the literature on the shaken baby syndrome (SBS) has revealed a lack of scientific evidence and understanding of all aspects of the syndrome. In particular, studies have been unable to clarify the mechanisms of injury, indicating that impact, rather than shaking alone, is necessary to cause the type of brain damage observed. Rigid-body modelling (RBM) was used to investigate the effect of neck stiffness on head motion and head-torso impacts as a possible mechanism of injury. Realistic shaking data obtained from an anthropometric test dummy (ATD) was used to simulate shaking. In each study injury levels for concussion were exceeded, though impact-type characteristics were required to do so in the neck stiffness study. Levels for the type of injury associated with the syndrome were not exceeded. It is unlikely that further gross biornechanical investigation of the syndrome will be able to significantly contribute to the understanding of SBS. Current injury criteria are based on high-energy, single-impact studies. Since this is not the type of loading in SBS it is suggested that their application here is inappropriate and that future studies should focus on injury mechanisms in low-energy cyclic loading.	Univ Nottingham, Inst Biomech, Sch M3, Nottingham NG7 2RD, England	Wolfson, DR (corresponding author), Univ Nottingham, Inst Biomech, Sch M3, Univ Pk, Nottingham NG7 2RD, England.	eaxdrw@nottingham.ac.uk	McNally, Donal S/B-2181-2012; Clifford, Mike/AAC-7945-2019; clifford, mike/D-3736-2013	McNally, Donal S/0000-0002-2436-0831; Clifford, Mike/0000-0001-6379-2672; 			Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; Conway EE, 1998, PEDIATR ANN, V27, P677, DOI 10.3928/0090-4481-19981001-11; Cory CZ, 2003, MED SCI LAW, V43, P317, DOI 10.1258/rsmmsl.43.4.317; Donohoe M, 2003, AM J FOREN MED PATH, V24, P239, DOI 10.1097/01.paf.0000083635.85457.97; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Geddes JF, 2004, BMJ-BRIT MED J, V328, P719, DOI 10.1136/bmj.328.7442.719; GEDEIT RG, 2001, J AGGRESSION MALTREA, V5, P155; Gilliland MGF, 1996, J FORENSIC SCI, V41, P114; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; Harding B, 2004, BMJ-BRIT MED J, V328, P720, DOI 10.1136/bmj.328.7442.720; HENNES H, 2001, J AGGRESS MALTREAT T, V5, P19, DOI DOI 10.1300/J146V05N01_03; JENSEN RK, 1986, J BIOMECH, V19, P359, DOI 10.1016/0021-9290(86)90012-6; King WJ, 2003, CAN MED ASSOC J, V168, P155; Klinich K.D., 1996, TECHNIQUES DEV CHILD; Lantz PE, 2004, BRIT MED J, V328, P754, DOI 10.1136/bmj.328.7442.754; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; Ommaya A.K., 1985, BIOMECHANICS TRAUMA, P245; SCHNEIDER K, 1992, J BIOMECH, V25, P145, DOI 10.1016/0021-9290(92)90271-2; SUN H, 1994, J BIOMECH, V27, P265, DOI 10.1016/0021-9290(94)90003-5; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; THIBAULT LE, 1985, 10 INT C EXP SAF VEH	24	28	28	0	17	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0954-4119	2041-3033		P I MECH ENG H	Proc. Inst. Mech. Eng. Part H-J. Eng. Med.	JAN	2005	219	H1					63	70		10.1243/095441105X9237			8	Engineering, Biomedical	Engineering	910LH	WOS:000227932400007	15777058				2021-06-18	
J	Clausen, T; Scharf, A; Menzel, M; Soukup, J; Holz, C; Rieger, A; Hanisch, F; Brath, E; Nemeth, N; Miko, I; Vajkoczy, P; Radke, J; Henze, D				Clausen, T; Scharf, A; Menzel, M; Soukup, J; Holz, C; Rieger, A; Hanisch, F; Brath, E; Nemeth, N; Miko, I; Vajkoczy, P; Radke, J; Henze, D			Influence of moderate and profound hyperventilation on cerebral blood flow, oxygenation and metabolism	BRAIN RESEARCH			English	Article						hyperventilation; cerebral metabolism; cerebral blood flow; microdialysis; multimodal monitoring	TRAUMATIC BRAIN-INJURY; CARBON-DIOXIDE; HEAD-INJURY; HEMORRHAGIC-SHOCK; NITROUS-OXIDE; TISSUE PO2; INTRACRANIAL-PRESSURE; GLOBAL-ISCHEMIA; AUTO-REGULATION; CO2 REACTIVITY	Objective: The aim of the present study was to examine the impact of moderate and profound hyperventilation on regional cerebral blood flow (rCBF), oxygenation and metabolism. Materials and methods: Twelve anesthetized pigs were subjected to moderate (mHV) and profound (pHV) hyperventilation (target arterial pO(2): 30 and 20 mmHg, respectively) for 30 min each, after baseline normoventilation (BL) for 1 h. Local cerebral extracellular fluid (ECF) concentrations of glucose, lactate, pyruvate and glutamate as well as brain tissue oxygenation (p(ti)O(2)) were monitored using microdialysis and a Licox oxygen sensor, respectively. In nine pigs, regional cerebral blood flow (rCBF) was also continuously measured via a thermal diffusion system. Results: Both moderate and profound hyperventilation resulted in a significant decrease in rCBF (BL: 37.9 +/- 4.3 ml/100 g/min; mHV: 29.4 +/- 3.6 ml/100 g/min; pHV: 23.6 +/- 4.7 ml/100 g/min; p < 0.05) and p(ti)O(2) (BL: 22.7 +/- 4.1 mmHg; mHV: 18.9 +/- 4.9 mmHg; pHV: 13.0 +/- 2.2 mmHg; p < 0.05). A p(ti)O(2) decrease below the critical threshold of 10 mmHg was induced in three animals by moderate hyperventilation and in five animals by profound hyperventilation. Furthermore, significant increases in lactate (BL: 1.06 +/- 0.18 mmol/l; mHV: 1.36 +/- 0.20 mmol/l; pHV: 1.67 +/- 0.17 mmol/l; p < 0.005), pyruvate (BL: 46.4 +/- 7.8 mumol/l; mHV: 58.0 +/- 10.3 mumol/l; pHV: 66.1 +/- 12.7 mumol/l; p < 0.05), and lactate/glucose ratio were observed during hyperventilation. (Data are presented as mean +/- S.E.M.) Conclusions: Both moderate and profound hyperventilation may result in insufficient regional oxygen supply and anaerobic metabolism, even in the uninjured brain. Therefore, the use of hyperventilation cannot be considered as a safe procedure and should either be avoided or used with extreme caution. (C) 2004 Elsevier B.V. All rights reserved.	Univ Halle Wittenberg, Dept Anesthesia & Intens Care Med, D-06120 Halle An Der Saale, Germany; Univ Halle Wittenberg, Dept Neurosurg, Halle An Der Saale, Saale, Germany; Univ Halle Wittenberg, Dept Neurol, Halle An Der Saale, Saale, Germany; Univ Debrecen, Dept Operat Tech & Surg Res, H-4012 Debrecen, Hungary; Hlth Sci Ctr, H-4012 Debrecen, Hungary; Heidelberg Univ, Univ Hosp Mannheim, Dept Neurosurg, D-6800 Mannheim, Germany	Clausen, T (corresponding author), Univ Halle Wittenberg, Dept Anesthesia & Intens Care Med, Ernst Grube Str 40, D-06120 Halle An Der Saale, Germany.	tobias.clausen@medizin.uni-halle.de	Nemeth, Norbert/AAX-8704-2020	Nemeth, Norbert/0000-0002-1162-3778			AKESON J, 1993, ACTA ANAESTH SCAND, V37, P85; ALBERTI E, 1975, BRIT J ANAESTH, V47, P941, DOI 10.1093/bja/47.9.941; Allen CH, 1998, CRIT CARE CLIN, V14, P485, DOI 10.1016/S0749-0704(05)70012-9; ARCHER DP, 1990, ANESTHESIOLOGY, V72, P1031, DOI 10.1097/00000542-199006000-00013; ARCHER DP, 1990, ANESTHESIOLOGY, V73, P798; ARTRU AA, 1989, ANESTHESIOLOGY, V70, P288, DOI 10.1097/00000542-198902000-00018; BAKER AJ, 1991, J NEUROCHEM, V57, P1370, DOI 10.1111/j.1471-4159.1991.tb08303.x; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brian JE, 1998, ANESTHESIOLOGY, V88, P1365, DOI 10.1097/00000542-199805000-00029; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Cormio M, 1999, J NEUROTRAUM, V16, P927, DOI 10.1089/neu.1999.16.927; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; DIETRICH HH, 1994, AM J PHYSIOL, V266, pH1681; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; DRUMMOND JC, 1987, ANESTH ANALG, V66, P1083; DRUMMOND WH, 1981, J PEDIATR-US, V98, P603, DOI 10.1016/S0022-3476(81)80775-5; Edge JA, 1996, BRIT J HOSP MED, V55, P508; FOX J, 1992, ANESTHESIOLOGY, V77, P453, DOI 10.1097/00000542-199209000-00008; Goodman JC, 1996, ACT NEUR S, V67, P37; GROTE J, 1981, PFLUG ARCH EUR J PHY, V391, P195, DOI 10.1007/BF00596170; HARADA J, 1991, J NEUROSURG, V75, P103, DOI 10.3171/jns.1991.75.1.0103; HEFFNER JE, 1983, ARCH INTERN MED, V143, P765, DOI 10.1001/archinte.143.4.765; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Huttunen J, 1999, EXP BRAIN RES, V125, P248, DOI 10.1007/s002210050680; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; JOHNSON JD, 1986, TOXICOL APPL PHARM, V84, P464, DOI 10.1016/0041-008X(86)90251-6; JOHNSON JD, 1987, TOXICOL APPL PHARM, V88, P217, DOI 10.1016/0041-008X(87)90007-X; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; LUNDBERG N, 1959, Acta Psychiatr Scand Suppl, V34, P1; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; Marion DW, 2000, J TRAUMA, V48, P1032; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Oertel M, 2002, ACT NEUR S, V81, P71; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; ROSENBERG AA, 1988, STROKE, V19, P1365, DOI 10.1161/01.STR.19.11.1365; SATO M, 1984, STROKE, V15, P91, DOI 10.1161/01.STR.15.1.91; Schmid-Elsaesser R, 1999, J NEUROL SCI, V162, P14, DOI 10.1016/S0022-510X(98)00300-1; STRINGER WA, 1993, AM J NEURORADIOL, V14, P475; TOMINAGA S, 1976, STROKE, V7, P507, DOI 10.1161/01.STR.7.5.507; Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265; Valtysson J, 1998, ACTA NEUROCHIR, V140, P387, DOI 10.1007/s007010050113; VANICKY I, 1992, NEUROSCI LETT, V135, P167, DOI 10.1016/0304-3940(92)90428-A; YOUNG WL, 1991, BRIT J ANAESTH, V67, P440, DOI 10.1093/bja/67.4.440; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017	49	28	32	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 3	2004	1019	1-2					113	123		10.1016/j.brainres.2004.05.099			11	Neurosciences	Neurosciences & Neurology	851UI	WOS:000223710800014	15306245				2021-06-18	
J	Johnson, EA; Svetlov, SI; Pike, BR; Tolentino, PJ; Shaw, G; Wang, KKW; Hayes, RL; Pineda, JA				Johnson, EA; Svetlov, SI; Pike, BR; Tolentino, PJ; Shaw, G; Wang, KKW; Hayes, RL; Pineda, JA			Cell-specific upregulation of survivin after experimental traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						astrocyte; neuron; PCNA; survivin; traumatic brain injury	MULTIPLE SEQUENCE ALIGNMENT; CONTROLLED CORTICAL IMPACT; ANTI-APOPTOSIS GENE; REACTIVE ASTROCYTES; PROTEIN SURVIVIN; AXONAL INJURY; STEM-CELLS; ADULT-RAT; CYCLIN D1; EXPRESSION	In this study, we examined the expression and cellular localization of survivin and proliferating cell nuclear antigen (PCNA) after controlled cortical impact traumatic brain injury (TBI) in rats. There was a remarkable and sustained induction of survivin mRNA and protein in the ipsilateral cortex and hippocampus of rats after TBI, peaking at five days post injury. In contrast, both survivin mRNA and protein were virtually undetectable in craniotomy control animals. Concomitantly, expression of PCNA was also significantly enhanced in the ipsilateral cortex and hippocampus of these rats with similar temporal and spatial patterns. Immunohistochemistry revealed that survivin and PCNA were co-expressed in the same cells and had a focal distribution within the injured brain. Further analysis revealed a frequent co-localization of survivin and GFAP, an astrocytic marker, in both the ipsilateral cortex and hippocampus, while a much smaller subset of cells showed co-localization of survivin and NeuN, a mature neuronal marker. Neuronal localization of survivin was observed predominantly in the ipsilateral cortex and contralateral hippocampus after TBI. PCNA protein expression was detected in both astrocytes and neurons of the ipsilateral cortex and hippocampus after TBI. Collectively these data demonstrate that the anti-apoptotic protein survivin, previously characterized in cancer cells, is abundantly expressed in brain tissues of adult rats subjected to TBI. We found survivin expression in both astrocytes and a sub-set of neurons. In addition, the expression of survivin was co-incident with PCNA, a cell cycle protein. This suggests that survivin may be involved in regulation of neural cell proliferative responses after traumatic brain injury.	Univ Florida, EF & WL McKnight Brain Inst, Dept Pediat, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosurg, Gainesville, FL 32610 USA; Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA	Pineda, JA (corresponding author), Univ Florida, EF & WL McKnight Brain Inst, Dept Pediat, 100 S Newell Dr,Bldg 59,L1-118, Gainesville, FL 32610 USA.	pinedja@peds.ufl.edu	Pineda, Jose/W-2806-2019; , Gerry/X-2377-2019	Wang, Kevin/0000-0002-9343-6473			Adida C, 1998, AM J PATHOL, V152, P43; Altieri DC, 1999, LAB INVEST, V79, P1327; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; GIULIAN D, 1991, NEUR CONT B, V6, P73; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; Jiang XY, 2001, J CELL BIOCHEM, V83, P342, DOI 10.1002/jcb.1228; Kaya SS, 1999, J NEUROTRAUM, V16, P1187, DOI 10.1089/neu.1999.16.1187; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li FZ, 1999, CANCER RES, V59, P3143; Magavi SS, 2000, NATURE, V405, P951; MIYAKE T, 1992, BRAIN RES, V590, P300, DOI 10.1016/0006-8993(92)91109-R; Muchmore SW, 2000, MOL CELL, V6, P173, DOI 10.1016/S1097-2765(00)00018-6; Norton WT, 1999, NEUROCHEM RES, V24, P213, DOI 10.1023/A:1022505903312; Otaki M, 2000, BBA-GENE STRUCT EXPR, V1493, P188, DOI 10.1016/S0167-4781(00)00142-1; Peterson DA, 2002, CURR OPIN PHARMACOL, V2, P34, DOI 10.1016/S1471-4892(01)00118-7; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Sasaki T, 2002, ACTA NEUROPATHOL, V104, P105, DOI 10.1007/s00401-002-0532-x; Shankar SL, 2001, J NEUROCHEM, V79, P426, DOI 10.1046/j.1471-4159.2001.00596.x; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Smith C, 2001, EUR J NEUROSCI, V13, P443, DOI 10.1046/j.1460-9568.2001.01400.x; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Sykova E, 1999, GLIA, V25, P56, DOI 10.1002/(SICI)1098-1136(19990101)25:1<56::AID-GLIA6>3.0.CO;2-4; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 1998, CANCER RES, V58, P5315; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tolentino PJ, 2002, J NEUROCHEM, V80, P579, DOI 10.1046/j.0022-3042.2001.00726.x; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Wei LH, 2001, INT J GYNECOL CANCER, V11, P81, DOI 10.1046/j.1525-1438.2001.011001081.x; Wu Q, 2000, NEUROBIOL AGING, V21, P797, DOI 10.1016/S0197-4580(00)00219-0; Yagita Y, 2001, STROKE, V32, P1890, DOI 10.1161/01.STR.32.8.1890; Yang Y, 2001, J NEUROSCI, V21, P2661, DOI 10.1523/JNEUROSCI.21-08-02661.2001	53	28	30	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2004	21	9					1183	1195		10.1089/neu.2004.21.1183			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	855HC	WOS:000223962900007	15453988				2021-06-18	
J	Yablon, SA; Rock, WA; Nick, TG; Sherer, M; McGrath, CM; Goodson, KH				Yablon, SA; Rock, WA; Nick, TG; Sherer, M; McGrath, CM; Goodson, KH			Deep vein thrombosis - Prevalence and risk factors in rehabilitation admissions with brain injury	NEUROLOGY			English	Article							POSTOPERATIVE VENOUS THROMBOEMBOLISM; D-DIMER; TRAUMA PATIENTS; PULMONARY-EMBOLISM; PROFILE; TUMORS; HYPERCOAGULABILITY; LIMITATIONS; PROPHYLAXIS; PREVENTION	Objective: To determine the prevalence and risk factors of deep vein thrombosis (DVT) among neurorehabilitation admissions with acquired brain injury (BI). Methods: In this prospective, sequential case series, 709 consecutive initial neurorehabilitation patients with BI < 120 days-including, traumatic brain injury (TBI; n = 360), intracranial hemorrhage (ICH; n = 213), primary brain tumor (n = 66), and hypoxia/other BI (n = 70)-were screened for evidence of DVT with lower extremity venous duplex ultrasonography (VDU). The admission screening protocol combined VDU and a commercial D-dimer (Dimertest(R) [DDLx]) latex agglutination assay. DVT was considered present based upon VDU results only. Results: DVT prevalence was 11.1%, and was higher with brain tumor (21.2%) and ICH (16%) then with TBI (6.7%) (chi(2) test; p = 0.001). DVT risk factors identified by multivariable logistic regression analysis in the overall sample included older age (p = 0.002), type of BI (p = 0.04), DDLx (p = 0.0001), and greater postinjury duration (p = 0.0001), with a trend observed regarding lower Functional Independence Measure (FIM) locomotion (FIM-Loco) subscale score (p = 0.07) However, risk factors also varied with type of BI. Among patients with TBI, only DDLx (p = 0.001) and greater postinjury duration (p 0.001) were associated with DVT. Conclusions: Admission venous duplex ultrasonography revealed occult proximal lower extremity deep vein thrombosis in 11% of neurorehabilitation patients with acquired brain injury. Deep vein thrombosis risk is multifactorial in this heterogenous patient population, with relative factor risk influenced by type of acquired brain injury. Semiquantitative D-dimer latex agglutination assay correlated significantly with presence of deep vein thrombosis.	Univ Mississippi, Med Ctr, Brain Injury Program, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Methodist Rehabil Ctr, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Neurol, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Neurosurg, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Pathol, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Hlth Sci, Jackson, MS 39216 USA; GV Sonny Montgomery Vet Adm Med Ctr, Jackson, MS USA	Yablon, SA (corresponding author), 1350 E Woodrow Wilson, Jackson, MS 39216 USA.	doctory@earthlink.com					BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; BOUNAMEAUX H, 1994, THROMB HAEMOSTASIS, V71, P1; BREDBACKA S, 1994, J NEUROSURG ANESTH, V6, P75; Britt SL, 2003, AM SURGEON, V69, P459; CHERUKU R, 1991, CANCER, V68, P2621, DOI 10.1002/1097-0142(19911215)68:12<2621::AID-CNCR2820681218>3.0.CO;2-7; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P1182, DOI 10.1016/S0003-9993(96)90145-8; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; FLANAGAN SR, 2002, ARCH PHYS MED REHAB, V83, P1649; FUJII Y, 1994, NEUROSURGERY, V35, P26, DOI 10.1227/00006123-199407000-00004; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; HAMILTON MG, 1994, NEUROSURGERY, V34, P280, DOI 10.1227/00006123-199402000-00012; Hammond FM, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199802000-00007; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Harvey RL, 1996, STROKE, V27, P1516, DOI 10.1161/01.STR.27.9.1516; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; JONGBLOETS LMM, 1994, LANCET, V343, P1142, DOI 10.1016/S0140-6736(94)90240-2; Kelly J, 2003, CHEST, V124, P1116, DOI 10.1016/S0012-3692(15)37675-3; Kelly J, 2002, ARCH INTERN MED, V162, P747, DOI 10.1001/archinte.162.7.747; Kroneman H, 1990, Blood Coagul Fibrinolysis, V1, P91, DOI 10.1097/00001721-199003000-00012; Lai JM, 1997, BRAIN INJURY, V11, P331, DOI 10.1080/026990597123485; Meissner MH, 2003, J TRAUMA, V54, P224, DOI 10.1097/01.TA.0000046253.33495.70; Meythaler JM, 2003, ARCH PHYS MED REHAB, V84, P285, DOI 10.1053/apmr.2003.50116; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P1, DOI 10.1016/S0003-9993(96)90210-5; Owings JT, 2001, J TRAUMA, V51, P425, DOI 10.1097/00005373-200109000-00001; Peltonen S, 1997, J NEUROSURG, V87, P207, DOI 10.3171/jns.1997.87.2.0207; Philbrick JT, 2003, CLIN CHEM, V49, P570, DOI 10.1373/49.4.570; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; RUFF RL, 1983, ANN NEUROL, V13, P334, DOI 10.1002/ana.410130320; SAWAYA R, 1992, J NEURO-ONCOL, V14, P113; SAWAYA R, 1992, J NEURO-ONCOL, V14, P119; SAWAYA R, 1992, J NEURO-ONCOL, V14, P127; SCHMIDT U, 1992, J TRAUMA, V33, P312, DOI 10.1097/00005373-199208000-00023; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; Stern JB, 2002, CHEST, V122, P115, DOI 10.1378/chest.122.1.115; Velmahos GC, 1998, J AM COLL SURGEONS, V187, P529, DOI 10.1016/S1072-7515(98)00223-3; Yablon SA, 2000, AM J PHYS MED REHABI, V79, P204; YABLON SA, 1999, ARCH PHYS MED REHAB, V80, P1132	39	28	29	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	AUG 10	2004	63	3					485	491		10.1212/01.WNL.0000133009.24727.9F			7	Clinical Neurology	Neurosciences & Neurology	845GK	WOS:000223229100014	15304579				2021-06-18	
J	Body, R; Perkins, MR				Body, R; Perkins, MR			Validation of linguistic analyses in narrative discourse after traumatic brain injury	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; LANGUAGE DISORDER; STORY STRUCTURE; CHILDREN; COMPREHENSION; ADOLESCENTS; ABILITY; COHESION; ADULTS	Narrative discourse tasks are a common feature of assessment and research after traumatic brain injury (TBI) and other types of brain damage. Although stimulus materials and analysis methods have been developed from a variety of theoretical perspectives, many do not challenge cognitive-linguistic skills sufficiently to highlight individual difficulties in assessment after TBI. This study employed a complex story recall task and it aimed to develop analysis methods that were sensitive to differences in recalled narratives and which could be validated against the perceptions of external raters. Twenty TBI adults and 20 matched control subjects were tested and their narratives analysed in terms of six measures ( T-units , Noun : Pronoun Ratio , Scenes , Errors , Comments and Tentative Statements ). Two groups of raters (one professionally trained, the other not) judged the transcribed narratives on ratings of Content and Clarity. Multiple regression analyses established that two of the linguistic measures in combination predicted ratings of Content, while a further three in combination predicted ratings of Clarity. Cut-off scores were established in order to categorize the TBI and control subjects' performance. The validated measures provide the foundation for analyses of complex narrative as a means of assessment after TBI.	Univ Sheffield, Dept Human Commun Sci, Sheffield S10 2TA, S Yorkshire, England	Body, R (corresponding author), Univ Sheffield, Dept Human Commun Sci, 31 Claremont Crescent, Sheffield S10 2TA, S Yorkshire, England.	r.body@sheffield.ac.uk					Arnott WL, 1997, APHASIOLOGY, V11, P969, DOI 10.1080/02687039708249422; Barnes MA, 2001, BRAIN LANG, V76, P253, DOI 10.1006/brln.2000.2385; Berndt R. S., 2000, QUANTITATIVE PRODUCT; Body R, 1998, BRAIN INJURY, V12, P963, DOI 10.1080/026990598122016; Boudreau DM, 2000, J SPEECH LANG HEAR R, V43, P1146, DOI 10.1044/jslhr.4305.1146; Brown G., 1983, DISCOURSE ANAL; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; CHENERY HJ, 1994, APHASIOLOGY, V8, P159, DOI 10.1080/02687039408248648; Cherney LR, 1997, APHASIOLOGY, V11, P351, DOI 10.1080/02687039708248476; CHERNEY LR, 1990, ANN CONV AM SPEECH L; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; Davis GA, 1997, BRAIN LANG, V56, P183; Docking K, 1999, BRAIN INJURY, V13, P953; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Duchan J, 1994, DISCOURSE ANAL APPL, P1; DUCHAN JF, 1995, DEIXIS NARRATIVE COG, P227; ERNESTBARON CR, 1987, J SPEECH HEAR RES, V30, P44, DOI 10.1044/jshr.3001.44; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Hunt K. W, 1965, GRAMMATICAL STRUCTUR; JOANETTE Y, 1990, DISCOURSE ABILITY BR, P131, DOI DOI 10.1007/978-1-4612-3262-9_6; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; Kintsch W., 1974, REPRESENTATION MEANI; Kuno Susumu., 1987, FUNCTIONAL SYNTAX AN; LI N, 1995, DEIXIS NARRATIVE COG, P287; LILES BZ, 1987, J SPEECH HEAR RES, V30, P185, DOI 10.1044/jshr.3002.185; MANDLER JM, 1977, COGNITIVE PSYCHOL, V9, P111, DOI 10.1016/0010-0285(77)90006-8; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENN L, 1994, APHASIOLOGY, V8, P343, DOI 10.1080/02687039408248664; MERRITT DD, 1987, J SPEECH HEAR RES, V30, P539, DOI 10.1044/jshr.3004.539; NICHOLAS LE, 1995, J SPEECH HEAR RES, V38, P146, DOI 10.1044/jshr.3801.145; Paivio A., 1986, MENTAL REPRESENTATIO; Perkins M. R., 1995, CASE STUDIES CLIN LI, P293; PURCELL SL, 1992, J SPEECH HEAR RES, V35, P354, DOI 10.1044/jshr.3502.354; ROTH FP, 1986, J SPEECH HEAR DISORD, V51, P8, DOI 10.1044/jshd.5101.08; Schiffrin D., 1994, APPROACHES DISCOURSE; SEGAL EM, 1995, DEIXIS NARRATIVE COG, P61; Stein N. L., 1979, NEW DIRECTIONS DISCO, V2, P53; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; Ulatowska H.K., 1990, DISCOURSE ABILITY BR, P180, DOI [10.1007/978-1-4612-3262-9_8, DOI 10.1007/978-1-4612-3262-9_8]; Van Dijk T.A., 1983, STRATEGIES DISCOURSE; Zubin D. A., 1995, DEIXIS NARRATIVE COG, P129	44	28	30	1	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2004	18	7					707	724		10.1080/02699050310001596914			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	821HJ	WOS:000221450700007	15204331				2021-06-18	
J	Goins, MR; Pitovski, DZ				Goins, MR; Pitovski, DZ			Posttonsillectomy taste distortion: A significant complication	LARYNGOSCOPE			English	Article							CHORDA TYMPANI NERVE; GLOSSOPHARYNGEAL; HUMANS; ANESTHESIA; BEHAVIOR; RAT	Objective/Hypothesis. Tonsillectomy is among the most commonly performed procedures. As with any surgery, head and neck surgeons must be aware of possible complications and their potential affects. At our smell and taste center, we have been referred several patients in a 6-month period with the complaint of taste distortion after tonsillectomy. We report in this article a patient that complains of taste distortion after a right tonsillectomy for unilateral tonsillar hypertrophy. Study Design: A prospective study documenting taste distortion after tonsillectomy using clinical, subjective, and objective evaluation. Methods: The clinical course of a patient with taste distortion after a tonsillectomy is described. The gustatory function was investigated by conducting electrogustometry and spatial taste testing. Threshold measurements were determined at three left- and three iright-side tongue regions: 1) the tongue tip region (innervated by the chorda tympani branch of the facial nerve), 2) the lateral margin of the tongue (anterior to the foliate papillae), and 3) the posterior tongue region (innervated by the lingual branch of the glossopharyngeal nerve). Results: After a complete clinical evaluation and taste testing, it was found that the patient suffered an injury to the right lingual branch of the glossopharyngeal nerve. The close anatomic relationship between the palatine tonsil and lingual branch of the glossopharyngeal nerve makes the nerve vulnerable during tonsillectomy. This injury has caused the patient to suffer ageusia to the right posterior one third of the tongue, compensated by a contralateral phantogeusia (phantom taste) with clinical dysgeusia. The phantogeusia was abolished by application of anesthetic to the area where the phantom was perceived. We propose that the phantogeusia is the result of release-of-inhibition in the contralateral glossopharyngeal nerve. Conclusion. Taste distortion (including, phantogeusia and dysgeusia) after tonsillectomy is rarely reported as a complication but has a significant impact on quality of life. This article examines the taste distortion presence as a complication after tonsillectomy to make head and neck surgeons aware of this serious complication and the pathophysiology of taste distortion.	Wake Forest Univ, Bowman Gray Sch Med, Dept Otolaryngol, Ctr Smell & Taste, Winston Salem, NC 27157 USA	Pitovski, DZ (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Otolaryngol, Ctr Smell & Taste, Winston Salem, NC 27157 USA.	dzpito@wfubmc.edu					Bartoshuk L. M., 1994, Chemical Senses, V19, P440; COLCLASURE J B, 1990, Ear Nose and Throat Journal, V69, P155; DERKAY CS, 1993, INT J PEDIATR OTORHI, V25, P1, DOI 10.1016/0165-5876(93)90004-M; Dinkins ME, 1999, J NEUROPHYSIOL, V82, P2565; Duffy VB, 1998, ANN NY ACAD SCI, V855, P805, DOI 10.1111/j.1749-6632.1998.tb10663.x; GIDUCK SA, 1987, J NUTR, V117, P1191; GRILL HJ, 1992, BRAIN RES, V573, P95, DOI 10.1016/0006-8993(92)90117-R; Heald AE, 1998, AIDS, V12, P1667, DOI 10.1097/00002030-199813000-00015; John SJS, 1997, BEHAV NEUROSCI, V111, P188; KROEZE JHA, 1985, PHYSIOL BEHAV, V35, P779, DOI 10.1016/0031-9384(85)90412-3; KVETON JF, 1994, LARYNGOSCOPE, V104, P25; LEHMAN C, 1991, EFFECT ANESTHESIA CH; LEHMAN CD, 1995, PHYSIOL BEHAV, V57, P943, DOI 10.1016/0031-9384(95)91121-R; MACCARTHYLEVENTHAL EM, 1959, LANCET, V2, P1138; Mathey MFAM, 2001, J GERONTOL A-BIOL, V56, pM200, DOI 10.1093/gerona/56.4.M200; Matsuyama H, 1986, Auris Nasus Larynx, V13 Suppl 1, pS43; MCLAUGHLIN S, 1994, AM SCI, V82, P538; Miller I.J., 1991, SMELL TASTE HLTH DIS, P205; Ohtsuka K, 2002, ACTA OTO-LARYNGOL, V122, P99, DOI 10.1080/00016480260046472; OSTROM KM, 1985, CHEM SENSES, V10, P459; SCHIFFMAN SS, 1993, PHYSIOL BEHAV, V53, P395, DOI 10.1016/0031-9384(93)90224-4; Schiffman SS, 1997, JAMA-J AM MED ASSOC, V278, P1357, DOI 10.1001/jama.278.16.1357; STJOHN SJ, 1994, BEHAV NEUROSCI, V108, P131, DOI 10.1037/0735-7044.108.1.131; TONOSAKI K, 1993, PHYSIOL BEHAV, V53, P667, DOI 10.1016/0031-9384(93)90171-B; TRAVERS JB, 1987, BEHAV BRAIN RES, V25, P233, DOI 10.1016/0166-4328(87)90071-4; Vories AA, 1999, OTOLARYNG HEAD NECK, V121, P303; WARWICK ZS, 1993, PHYSIOL BEHAV, V53, P553, DOI 10.1016/0031-9384(93)90153-7; Yanagisawa K, 1998, PHYSIOL BEHAV, V63, P329, DOI 10.1016/S0031-9384(97)00423-X	28	28	30	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0023-852X	1531-4995		LARYNGOSCOPE	Laryngoscope	JUL	2004	114	7					1206	1213		10.1097/00005537-200407000-00015			8	Medicine, Research & Experimental; Otorhinolaryngology	Research & Experimental Medicine; Otorhinolaryngology	837QT	WOS:000222651100015	15235350				2021-06-18	
J	Pelinka, LE; Jafarmadar, M; Redl, H; Bahrami, S				Pelinka, LE; Jafarmadar, M; Redl, H; Bahrami, S			Neuron-specific-enolase is increased in plasma after hemorrhagic shock and after bilateral femur fracture without traumatic brain injury in the rat	SHOCK			English	Article						traumatic brain injury; extracerebral trauma; acidosis; serum markers	SYSTEM-SPECIFIC ENOLASE; CEREBROSPINAL-FLUID; CARDIAC-SURGERY; SERUM-LEVELS; PROTEIN; DAMAGE; BLOOD; S100B; RESUSCITATION; PREDICTOR	Neuron-specific enolase (NSE) is an acknowledged marker of traumatic brain injury. Several markers originally considered reliable in the setting of traumatic brain injury have been challenged after having been studied more extensively. The aim of our experimental study was to determine whether NSE is a reliable marker of traumatic brain injury early after trauma. Hemorrhagic shock was achieved by bleeding anesthetized rats to a mean arterial pressure (MAP) of 30-35 mmHg through a femoral catheter until incipient decompensation. MAP was maintained at 30-35 mmHg until 40% of shed blood had been administered as Ringer's solution and was then increased and maintained at 40-45 mmHg for 40 min by further administration of Ringer's solution, mimicking the phase of inadequate preclinical resuscitation. Blood samples were drawn at the end of the 40-min period of inadequate resuscitation. Femur fracture was achieved in anesthetized rats by bilateral application of forceps. Blood samples were drawn 30 and 60 min after fracture. Hemorrhagic shock caused NSE increase versus laboratory controls at the end of inadequate resuscitation (P < 0.01). Bilateral femur fracture caused NSE increase versus laboratory controls 30 min after fracture, which was significant 60 min after fracture (P < 0.01). During femur fracture, MAP remained at a level that is not associated with shock in rats. Our findings show for the first time that NSE increases after hemorrhagic shock as well as after femur fracture without hemorrhagic shock in rats. From a clinical point of view, these findings indicate that NSE cannot be considered a reliable marker of traumatic brain injury early after trauma in cases associated with hemorrhagic shock and/or femur fracture.	Ludwig Boltzmann Inst Expt & Clin Traumatol, A-1200 Vienna, Austria; AUVA, Res Ctr Workers Compensat Board, A-1200 Vienna, Austria	Pelinka, LE (corresponding author), Ludwig Boltzmann Inst Expt & Clin Traumatol, Donaueschingenstr 13, A-1200 Vienna, Austria.	lindapel@via.at		Bahrami, Soheyl/0000-0002-4563-6251			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; DAY INM, 1984, CLIN CHIM ACTA, V136, P219, DOI 10.1016/0009-8981(84)90295-X; Fogel W, 1997, CRIT CARE MED, V25, P1133, DOI 10.1097/00003246-199707000-00012; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; HULLIN DA, 1980, BIOCHIM BIOPHYS ACTA, V628, P98, DOI 10.1016/0304-4165(80)90355-4; Ishida K, 2003, J CARDIOTHOR VASC AN, V17, P4, DOI 10.1053/jcan.2003.2; ISHIGURO Y, 1982, CLIN CHIM ACTA, V121, P173, DOI 10.1016/0009-8981(82)90056-0; KATO K, 1982, BRAIN RES, V237, P441, DOI 10.1016/0006-8993(82)90455-3; Kleine TO, 2003, BRAIN RES BULL, V61, P265, DOI 10.1016/S0361-9230(03)00090-X; Krumnikl JJ, 2002, ACTA ANAESTH SCAND, V46, P1168, DOI 10.1034/j.1399-6576.2002.460920.x; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; MARANGOS PJ, 1980, J NEUROCHEM, V34, P1254, DOI 10.1111/j.1471-4159.1980.tb09967.x; Meynaar IA, 2003, INTENS CARE MED, V29, P189, DOI 10.1007/s00134-002-1573-2; Missler U, 2002, CLIN CHIM ACTA, V321, P29, DOI 10.1016/S0009-8981(02)00061-X; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Novak L, 1999, J TRAUMA, V47, P834, DOI 10.1097/00005373-199911000-00003; Oh SH, 2003, ARCH NEUROL-CHICAGO, V60, P37, DOI 10.1001/archneur.60.1.37; PELINKA G, 2000, RECONSTR NEUROL NEUR, V16, P282; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Pelinka LE, 2003, SHOCK, V19, P422, DOI 10.1097/01.shk.0000055345.58165.52; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; SCHMECHEL D, 1978, NATURE, V276, P834, DOI 10.1038/276834a0; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; SEMBA R, 1982, J NEUROCHEM, V39, P360, DOI 10.1111/j.1471-4159.1982.tb03956.x; Snyder-Ramos SA, 2003, RESTOR NEUROL NEUROS, V21, P123; Szalay L, 2003, SHOCK, V20, P245, DOI 10.1097/00024382-200309000-00008; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Ytrebo LM, 2001, SCAND J CLIN LAB INV, V61, P217; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	33	28	29	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	JUL	2004	22	1					88	91		10.1097/01.shk.0000130157.34382.3f			4	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	830UU	WOS:000222150100015	15201708				2021-06-18	
J	Abe, T; Takagi, N; Nakano, M; Furuya, M; Takeo, S				Abe, T; Takagi, N; Nakano, M; Furuya, M; Takeo, S			Altered Bad localization and interaction between Bad and Bcl-xL in the hippocampus after transient global ischemia	BRAIN RESEARCH			English	Article						Bad; Bcl-xL; mitochondria; transient global ischemia	SPINAL-CORD-INJURY; CASPASE-3 APOPTOTIC CASCADE; TRAUMATIC BRAIN-INJURY; CYTOCHROME-C RELEASE; CEREBRAL-ISCHEMIA; PROTEIN-KINASE; CELL-DEATH; FOCAL ISCHEMIA; PERMEABILITY TRANSITION; ISOLATED-MITOCHONDRIA	Accumulating evidence indicates that the mitochondrial cell-death pathway, which involves the release of cytochrome c from mitochondria, participates in neuronal cell death after transient cerebral ischemia. However, the upstream events, that induce cytochrome c release after transient global ischemia are not fully understood. Bad is a pro-apoptotic member of the bcl-2 gene family that promotes apoptosis by binding to and inhibiting functions of anti-apoptotic proteins Bcl-2 and Bcl-xL. We investigated the effects of transient (15 min) global ischemia on the intracellular localization of Bad and the interaction of Bad with calcineurin, Akt or Bcl-xL in the vulnerable CA1 and resistant CA3/dentate gyrus of the hippocampus. Immunoblotting analysis revealed that the amount of Bad in mitochondria significantly increased after ischemia. Co-immunoprecipitation studies showed decreased interactions of Bad with Akt and calcineurin in the cytosol and increased binding with Bcl-xL in the mitochondrial fraction of hippocampal CA1, but not in the CA3/dentate gyros region. Further, we examined the effect of recombinant Bad on the cytochrome c release front isolated mitochondria. Treatment with both recombinant Bad and calcium, but not with recombinant Bad alone, induced cytochrome c release. These results suggest that changes in localization and complex formation by Bad are, at least in part, involved in the vulnerability of cells after transient global ischemia. (C) 2004 Elsevier B.V. All rights reserved.	Tokyo Univ Pharm & Life Sci, Dept Pharmacol, Fac Pharmaceut Sci, Hachioji, Tokyo 1910392, Japan	Takagi, N (corresponding author), Tokyo Univ Pharm & Life Sci, Dept Pharmacol, Fac Pharmaceut Sci, 1432-1 Horinouchi, Hachioji, Tokyo 1910392, Japan.	takagino@ps.toyaku.ac.jp					Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao GD, 2001, J CEREBR BLOOD F MET, V21, P321, DOI 10.1097/00004647-200104000-00001; Chen J, 1996, J NEUROCHEM, V67, P64; Clark RSB, 1999, FASEB J, V13, P813; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; Janelidze S, 2001, NEUROBIOL DIS, V8, P147, DOI 10.1006/nbdi.2000.0325; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; LI Y, 1995, AM J PATHOL, V146, P1045; LI Y, 1995, J CEREB BLOOD FLOW M, V15, P89; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/0264-6021:3490547; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; MARTINS E, 1988, J CEREBR BLOOD F MET, V8, P531, DOI 10.1038/jcbfm.1988.93; Namura S, 2000, J CEREBR BLOOD F MET, V20, P1301, DOI 10.1097/00004647-200009000-00004; Namura S, 1998, J NEUROSCI, V18, P3659; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Ouyang YB, 1999, J CEREBR BLOOD F MET, V19, P1126, DOI 10.1097/00004647-199910000-00009; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Polster BM, 2003, J NEUROSCI, V23, P2735; Saito A, 2003, J NEUROSCI, V23, P1710; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Springer JE, 2000, J NEUROSCI, V20, P7246; SUGIO K, 1988, STROKE, V19, P922, DOI 10.1161/str.19.7.922a; Takagi N, 2003, J NEUROCHEM, V84, P67, DOI 10.1046/j.1471-4159.2003.01500.x; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Yoshimoto T, 2001, BRAIN RES, V899, P148, DOI 10.1016/S0006-8993(01)02220-X; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang C, 1999, J NEUROCHEM, V73, P1650, DOI 10.1046/j.1471-4159.1999.0731650.x; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	50	28	30	1	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 29	2004	1009	1-2					159	168		10.1016/j.brainres.2004.03.003			10	Neurosciences	Neurosciences & Neurology	821TQ	WOS:000221486000017	15120593				2021-06-18	
J	Li, J; Goldberg, G; Munin, MC; Wagner, A; Zafonte, R				Li, J; Goldberg, G; Munin, MC; Wagner, A; Zafonte, R			Post-traumatic bilateral facial palsy: a case report and literature review	BRAIN INJURY			English	Article; Proceedings Paper	38th Annual Meeting of the Association-of-Academic-Physiatrists	FEB 28, 2002	LAS VEGAS, NV	Assoc Acad Physiatrists			BELL PALSY; NERVE; PARALYSIS; MANAGEMENT; PREDNISONE; FRACTURES; INJURY	Bilateral facial paralysis due to basilar skull fracture involving the temporal bone is rare and, unlike unilateral facial palsy, it can be difficult to recognize because of a lack of facial asymmetry. Thorough clinical history and physical exam, high-resolution CT scan and electrodiagnostic tests can help to make the diagnosis of bilateral facial nerve palsy and early detection, evaluation and intervention may be important for optimal functional recovery. A 16-year-old male sustained closed head injury after motor vehicle collision. The initial head CT scan showed bilateral temporal bone fractures. On admission to the neurotrauma intensive care unit, his Glasgow Coma Score was 9T. On post-injury day 4, the patient was noted to have incomplete closure of both eyes and 3 days later he had difficulty with bilateral facial muscle movement during a feeding trial. Electrodiagnostic testing confirmed the diagnosis of bilateral facial nerve injury without evidence of significant distal axonal degeneration. A high-resolution CT scan showed bilateral temporal bone fractures without involvement of the fallopian canals. There was no surgical intervention based on the high-resolution CT scan and the delayed onset of facial palsy. A short course of prednisone was administered. By 10 months, the patient showed nearly complete recovery of his bilateral facial nerve function. Early detection, evaluation and intervention are important for optimal functional recovery after facial nerve injury. When the temporal bone is fractured, high suspicion for facial nerve injury, either unilateral or bilateral, is warranted.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA	Zafonte, R (corresponding author), 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	zafonerd@msx.upmc.edu					AUSTIN JR, 1993, LARYNGOSCOPE, V103, P1326; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.251.1.45; Darrouzet V, 2001, OTOLARYNG HEAD NECK, V125, P77, DOI 10.1067/mhn.2001.116182; DIAMOND C, FACIAL NERVE, P162; DUMITRU D, 1988, AM J PHYS MED REHAB, V67, P137, DOI 10.1097/00002060-198808000-00002; FUJITA H, 1983, FACIAL NERVE RES JAP, V3, P124; GEORGE M K, 1991, Ear Nose and Throat Journal, V70, P492; GLASSCOCK ME, 1979, LARYNGOSCOPE, V89, P1389, DOI 10.1002/lary.5540890904; GOIN W, 1980, LARYNGOSCOPE, V90, P1777; GROVE E, 1933, LARYNGOSCOPE ST LOUI, V49, P678; GROVE E, 1933, LARYNGOSCOPE ST LOUI, V49, P833; Harker L A, 1991, OTOLARYNGOLOGIC CLIN, V24, P425; KETTEL K, 1959, P ROY SOC MED, V52, P1069; MAY M, 1976, LARYNGOSCOPE, V86, P1111, DOI 10.1288/00005537-197608000-00003; MCHUGH E, 1963, ARCH OTOLARYNGOL, V78, P433; Miehlke A, 1973, SURG FACIAL NERVE; SHERWEN PJ, 1987, J OTOLARYNGOL, V16, P28; STEENERSON RL, 1986, AM J OTOL, V7, P99; TAVERNER D, 1954, LANCET, V2, P1052; TOS M, 1973, ACTA OTO-LARYNGOL, V75, P353, DOI 10.3109/00016487309139745; WOLF SM, 1978, NEUROLOGY, V28, P158, DOI 10.1212/WNL.28.2.158	21	28	32	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2004	18	3					315	320		10.1080/0269905031000149489			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	763NH	WOS:000188091900007	14726289				2021-06-18	
J	Floyd, CL; Rzigalinski, BA; Sitterding, HA; Willoughby, KA; Ellis, EF				Floyd, CL; Rzigalinski, BA; Sitterding, HA; Willoughby, KA; Ellis, EF			Antagonism of group I metabotropic glutamate receptors and PLC attenuates increases in inositol trisphosphate and reduces reactive gliosis in strain-injured astrocytes	JOURNAL OF NEUROTRAUMA			English	Article						intracellular free calcium; GFAP; IP3; reactive astrocytes; TBI	TRAUMATIC BRAIN-INJURY; STRETCH-INDUCED INJURY; INTRACELLULAR FREE CALCIUM; CULTURED ASTROCYTES; NEURONAL DEATH; UP-REGULATION; CELL-DEATH; NMDA; PROTEIN; MODEL	We have previously found that in vitro traumatic injury uncouples IP3-mediated intracellular free calcium ([Ca2+](i)) signaling in astrocytes (Rzigalinski et al., 1998; Floyd et al., 2001). Since Group I metabotropic glutamate receptors (mGluRs) are coupled to IP3-mediated Ca2+ signaling, we investigated their role in the in vitro strain injury of cultured astrocytes. Astrocytes grown on Silastic membranes were labeled with H-3-myo-inositol and strain (stretch)-injured. Cells injured in the presence of LiCl to prevent inositol phosphate metabolism were acid extracted and inositol phosphates (IPx) isolated using anion exchange columns. Reactive gliosis was assessed as increased glial fibrillary acidic protein immunoreactivity (GFAP-IR). Pre- but not post-injury administration of (RS)-1-aminoindan-15-decarboxylic acid (AIDA) or (S)-4-carboxy-3-hydroxyphenylglycine (S4CH3HPG), both group I mGluR antagonists, attenuated injury-induced increases in IPx. Injury increased GFAP-IR in astrocytes at 24 and 48 h post injury, which was reduced or blocked by AIDA or inhibition of phospholipase C (PLC) with U73122. These findings suggest that strain injury activates Group I mGluRs, causing aberrant IPx production and uncoupling of the PLC signaling pathway. Changes in this signaling pathway may be related to induction of reactive gliosis. Additionally, our results suggest a complex physical coupling between G protein receptor, PLC, and IP3 receptor, in support of the conformational coupling model.	Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA; Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32816 USA; Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA USA	Ellis, EF (corresponding author), Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA.	eellis@mail2.vcu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040490, R01NS027214] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27214, NS-07288, NS-40490] Funding Source: Medline		Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; Anwyl R, 1999, BRAIN RES REV, V29, P83, DOI 10.1016/S0165-0173(98)00050-2; Aronica E, 2000, EUR J NEUROSCI, V12, P2333, DOI 10.1046/j.1460-9568.2000.00131.x; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; CHEN T, 2002, J NEUROTRAUM, V19, P1365; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Davies SJA, 1997, NATURE, V390, P680; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; Fagni L, 2000, TRENDS NEUROSCI, V23, P80, DOI 10.1016/S0166-2236(99)01492-7; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; HAYASHI Y, 1994, J NEUROSCI, V14, P3370; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hoffman SW, 2000, J NEUROTRAUM, V17, P415, DOI 10.1089/neu.2000.17.415; Inglis WL, 1997, BRAIN RES, V755, P17, DOI 10.1016/S0006-8993(97)00101-7; Janssens N, 2001, J NEUROCHEM, V77, P1457, DOI 10.1046/j.1471-4159.2001.00369.x; Lamb RG, 1997, J NEUROCHEM, V68, P1904; Lievens JC, 2000, GLIA, V29, P222, DOI 10.1002/(SICI)1098-1136(20000201)29:3<222::AID-GLIA4>3.0.CO;2-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; MacGregor DG, 1997, EXP NEUROL, V148, P110, DOI 10.1006/exnr.1997.6625; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Moroni F, 1997, J PHARMACOL EXP THER, V281, P721; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; Nebigil CG, 1997, BIOCHEMISTRY-US, V36, P15949, DOI 10.1021/bi971721m; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; OCALLAGHAN JP, 1994, PSYCHOPHARMACOL BULL, V30, P549; Ostrow LW, 2000, J CARDIOVASC PHARM, V36, pS274; Pearson VL, 1999, GLIA, V25, P311, DOI 10.1002/(SICI)1098-1136(19990215)25:4<311::AID-GLIA1>3.0.CO;2-E; Pellegrini-Giampietro DE, 1999, NEUROPHARMACOLOGY, V38, P1607, DOI 10.1016/S0028-3908(99)00097-0; PETITO CK, 1992, PROG BRAIN RES, V94, P381; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; Rostworowski M, 1997, J NEUROSCI, V17, P3664; RUDGE JS, 1990, J NEUROSCI, V10, P3594; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Sattler R, 2000, J MOL MED, V78, P3, DOI 10.1007/s001090000077; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; SCHREIBER D, 1995, P 1995 INT RES C BIO; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; STANIMIROVIC DB, 1995, GLIA, V15, P119, DOI 10.1002/glia.440150204; Strasser U, 1998, EUR J NEUROSCI, V10, P2848, DOI 10.1111/j.1460-9568.1998.00291.x; Stringer JL, 1996, BRAIN RES, V717, P147, DOI 10.1016/0006-8993(96)00059-5; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; Welsh DJ, 1998, AM J RESP CRIT CARE, V158, P1757, DOI 10.1164/ajrccm.158.6.9706054; Westenbroek RE, 1998, J NEUROSCI, V18, P2321; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	69	28	29	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2004	21	2					205	216		10.1089/089771504322778668			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	774WB	WOS:000189008200008	15000761				2021-06-18	
J	Malec, JF; Brown, AW; Moessner, AM				Malec, JF; Brown, AW; Moessner, AM			Personality factors and injury severity in the prediction of early and late traumatic brain injury outcomes	REHABILITATION PSYCHOLOGY			English	Article							HEAD-INJURY; RECOVERY; TRAITS	Objective: To identify personality features predicting early and late outcome after traumatic brain injury (TBI). Design: Multiple regression analyses of data from an inception cohort. Participants: Sixty-nine persons with moderate to severe TBI and significant others (SOs). Outcome Measures: Rasch measure of supervision, independent living, and work (Participation and Independence Measure) at hospital discharge and at 1-year follow-up. Predictor Variables: Duration of posttraumatic amnesia (PTA) and NEO Personality Inventory-Revised completed by participants and SOs to describe participant's preinjury personality. Results: Overall personality variables were within normal limits. Only self-reported Neuroticism, specifically Depression, added significantly to PTA in predicting early outcome. Conclusions: Although self-reported depression negatively affects TBI outcome, other personality features reported by people with TBI and SOs during early recovery are normal and do not affect outcome.	Mayo Clin, Generose ME TBI, Coll Med, Dept Psychiat & Psychol, Rochester, MN 55905 USA; Mayo Clin, Generose ME TBI, Coll Med, Dept Phys Med & Rehabil, Rochester, MN 55905 USA	Malec, JF (corresponding author), Mayo Clin, Generose ME TBI, Coll Med, Dept Psychiat & Psychol, Rochester, MN 55905 USA.	malec.james@mayo.edu		Brown, Allen W./0000-0001-7228-3351			BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; COSTA JPT, 1992, PROFESSIONAL MANUAL; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Hallinan M. T., 1996, SOC PSYCHOL EDUC, V1, P1, DOI DOI 10.1007/BF02333403; JOHNSON O, 1991, POLYCYCL AROMAT COMP, V2, P155; Kurtz JE, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199806000-00002; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Schretlen DJ, 2000, REHABIL PSYCHOL, V45, P260, DOI 10.1037/0090-5550.45.3.260; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wright B.D., 1982, RATING SCALE ANAL	17	28	28	0	5	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	FEB	2004	49	1					55	61		10.1037/0090-5550.49.1.55			7	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	771RQ	WOS:000188800200008					2021-06-18	
J	Gillette, Y; DePompei, R				Gillette, Y; DePompei, R			The potential of electronic organizers as a tool in the cognitive rehabilitation of young people	NEUROREHABILITATION			English	Article						assistive technology; personal data assistants; cell phones; developmental disabilities; mental retardation; traumatic brain injury		Youths who have traumatic brain injury (TBI) or mental retardation and other developmental disabilities often experience cognitive challenges in using memory and organization for learning, managing daily routines, or conducting social interactions. This article presents the results of a survey of 53 youth-parent-teacher triads probing their views regarding the youth's relationship with technology. Since the sample is small, results should be viewed with caution, yet keeping in mind the study presents some of the only data available on the use of generic technologies with youths who have disabilities. Primary findings indicate: 1) youths use a variety of technologies and are more likely to be exposed to computers than cell phones or personal data assistants respectively; 2) youths with finger, reading, and copying skills use more technologies; 3) youths value many varied features of technology, but rated most highly good technical support, simple learning requirements, capacity to store information, and long battery life. The data also indicated that the most common memory and organization strategy the youths used was "someone does it for me".	Univ Akron, Sch Speech Language Pathol & Audiol, Akron, OH 44325 USA	DePompei, R (corresponding author), Univ Akron, Sch Speech Language Pathol & Audiol, Polsky 188K, Akron, OH 44325 USA.	rdepom1@uakron.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A0101607A] Funding Source: Medline		BATSHAW M, 1997, CHILDREN DISABILITIE, P693; Bauer A., 2002, TEACHING EXCEPTIONAL, V35, P18; BEUKELMAN DR, 1998, AUGMENTATIVE ALTERNA, P150; BLOSSER JL, 2003, PEDIAT TRAUMATIC BRA, P5; CAPUTE A, 1996, DEV DISABILITIES INF, P212; CARR EJ, 1994, COMMUNICATIOON BASED, P11; CHESTER CC, 1998, TRAUMATIC BRAIN INJU, P107; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; DEPOMPEI R, 1999, REHABILITATION ADULT, P393; Gillette Y, 2001, J HEAD TRAUMA REHAB, V16, P484, DOI 10.1097/00001199-200110000-00007; GORDON D, 2000, DIGITAL CLASSROOM TE, P143; GRIFFETH M, REHABILITATION ADULT, P393; HUGHES C, 2003, TRANSITION HDB STRAT; KOPPENHAVER D A, 1992, Seminars in Speech and Language, V13, P143, DOI 10.1055/s-2008-1064193; LUECK A, 2001, REVIEW, V33, P21; LYNCH K, 2002, USING AT CHECKLIST F; MacArthur CA, 2000, TOP LANG DISORD, V20, P85, DOI 10.1097/00011363-200020040-00008; MALE M, 2003, TECHNOLOGY INCLUSION, P75; MIKULINCER M, PLENUM SERIES SOCIAL, V11; Mirenda P., 1997, AUGMENT ALTERN COMM, V13, P207, DOI [10.1080/07434619712331278048, DOI 10.1080/07434619712331278048]; Parette P., 2000, Journal of Special Education Technology, V15, P45; PUGLIESE M, 2000, STAGES BOOK; SAINBACK S, 1996, INCLUSION GUIDE ED, P3; Savage R. C., 1994, ED DIMENSIONS ACQUIR, P3; SEMRUDCLIEKMAN, 2001, GUILLIFORD SCH PRACT, P31; SMITH SJ, 1999, J LAW EDUC, V2, P247; Sturm J, 2000, TOP LANG DISORD, V20, P73, DOI 10.1097/00011363-200020020-00007; WEHMEYER ML, 1999, J SPECIAL ED TECHNOL, V14, P48; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P221; Zabala J., 2000, J SPECIAL ED TECHNOL, V15, P25	30	28	28	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2004	19	3					233	243					11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	883HU	WOS:000226003000006	15502256				2021-06-18	
J	Tokutomi, T; Miyagi, T; Morimoto, K; Karukaya, T; Shigemori, M				Tokutomi, T; Miyagi, T; Morimoto, K; Karukaya, T; Shigemori, M			Effect of hypothermia on serum electrolyte, inflammation, coagulation, and nutritional parameters in patients with severe traumatic brain injury	NEUROCRITICAL CARE			English	Article						traumatic brain injury; hypothermia; biochemical parameters; inflammation; coagulopathy; hypokalemia	SEVERE HEAD-INJURY; MILD HYPOTHERMIA; INTRACRANIAL-PRESSURE; POTASSIUM CONCENTRATION; MODERATE HYPOTHERMIA; TEMPERATURE; COAGULOPATHY; RATS; HYPERTENSION; DYSFUNCTION	Introduction: We evaluated the effect of induced hypothermia on biochemical parameters in patients with severe traumatic brain injury. Methods: We obtained hemoglobin, hematocrit, white blood count, lymphocyte count, platelet count, and serum concentrations of sodium, potassium, glucose, albumin, and C-reactive protein, and prothrombin time, hepaplastin test, activated partial thromboplastin time, antithrombin-III, alpha 2PI, and nitrogen excretion on the day of admission, and on days 1, 3,5, 7, 14, and 21 after the injury in 31 patients with severe head injury who were treated with hypothermia of 33 degrees ranging from 48 to 72 hours. We selected 33 normothermic patients as a control group; these patients were selected from patients who had been treated before hypothermia was used as a treatment modality, by the same criteria for hypothermia therapy. We compared the biochemical markers and rectal temperature and intracranial pressure in the hypothermia group with those in the normothermia group. Outcome was assessed using the Glasgow Outcome Scale at 6 months after injury. Results: The demographic characteristics, severity, and outcome were similar in the hypothermia and normothermia group. Intracranial pressure was significantly decreased by hypothermia. Serum potassium concentration decreased significantly during hypothermia. White blood cell counts and C-reactive protein levels were higher after rewarming in the hypothermia group, and these were also higher in the patients with infectious complications, although the incidence of infectious complications did not differ between the hypothermia and normothermia groups. There were no statistically significant prolongations of activated partial thromboplastin time and no decline in prothrombin time with hypothermia. Platelet count, antithrombin-III, and alpha 2PI did not differ significantly between the two groups. Conclusion: Hypothermia of 33 degrees for 48-72 hours does not appear to increase the risk for coagulopathy and infections, although hypothermic patients exhibited significant increments in inflammatory markers such as C-reactive protein and white blood counts after rewarming.	Kurume Univ, Sch Med, Dept Neurosurg, Kurume, Fukuoka 8300011, Japan	Tokutomi, T (corresponding author), Kurume Univ, Sch Med, Dept Neurosurg, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	toku@mail.med.kurume-u.ac.jp					Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; BOELHOUWER RU, 1987, CRIT CARE MED, V15, P310, DOI 10.1097/00003246-198704000-00006; BOLDT J, 1993, ANN THORAC SURG, V55, P652, DOI 10.1016/0003-4975(93)90269-N; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; GADISSEUX P, 1989, TXB HEAD INJURY; GHAJAR JBG, 1993, ADV NEUROS, V21, P173; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GUBLER KD, 1994, J TRAUMA, V36, P847, DOI 10.1097/00005373-199406000-00015; JOHNSTON TD, 1994, J TRAUMA, V37, P413, DOI 10.1097/00005373-199409000-00014; Kawai N, 2001, BRAIN RES, V895, P50, DOI 10.1016/S0006-8993(01)02026-1; Krause KR, 2000, AM SURGEON, V66, P348; Lobo SMA, 2003, CHEST, V123, P2043, DOI 10.1378/chest.123.6.2043; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marion DW, 1996, CRIT CARE MED, V24, pS81; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Miller PR, 1999, J TRAUMA, V47, P1004, DOI 10.1097/00005373-199912000-00003; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Polderman KH, 2001, J NEUROSURG, V94, P697, DOI 10.3171/jns.2001.94.5.0697; REED RL, 1992, J TRAUMA, V33, P465, DOI 10.1097/00005373-199209000-00022; Reny JL, 2002, CRIT CARE MED, V30, P529, DOI 10.1097/00003246-200203000-00006; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; SCHUBERT A, 1995, J NEUROSURG ANESTH, V7, P139, DOI 10.1097/00008506-199504000-00021; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; SPRUNG J, 1992, ACTA ANAESTH SCAND, V36, P825, DOI 10.1111/j.1399-6576.1992.tb03572.x; SPRUNG J, 1991, CRIT CARE MED, V19, P1545, DOI 10.1097/00003246-199112000-00018; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; Tveita T, 1998, J APPL PHYSIOL, V85, P2135; VALERI CR, 1987, ANN SURG, V205, P175, DOI 10.1097/00000658-198702000-00012; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561	34	28	31	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2004	1	2					171	182		10.1385/NCC:1:2:171			12	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	945FN	WOS:000230488500005	16174912				2021-06-18	
J	Zaltzman, R; Alexandrovich, A; Beni, SM; Trembovler, V; Shohami, E; Gozes, I				Zaltzman, R; Alexandrovich, A; Beni, SM; Trembovler, V; Shohami, E; Gozes, I			Brain injury-dependent expression of activity-dependent neuroprotective protein	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						head trauma; gene expression; real-time polymerase chain reaction (PCR); activity-dependent; neuroprotective protein (ADNP)	VASOACTIVE-INTESTINAL-PEPTIDE; CLOSED-HEAD INJURY; RAT-BRAIN; NEUROGENESIS; MICE; NAP; DEFICITS; SYSTEM; MODEL; ADNP	Activity-dependent neuroprotective protein (ADNP), a crucial brain development factor, contains a unique sequence, termed NAPVSIPQ, which protects mice against closed head injury (CHI). The aim of this study was to determine whether CHI affects ADNP mRNA expression in the injured brain hemisphere. Male C57JBL/6J mice were subjected to CHI. Brains were removed 5 h, 24 h, 7 d, and 29 d post-CHI. A comparison was made between ADNP mRNA in the injured versus the noninjured hemisphere using real-time polymerase chain reaction. A nonsignificant change (p > 0.05) was found 5 h, 24 h, and 7 d post-CHI. However, a significant increase (p < 0.05) in ADNP mRNA expression was detected in the injured cerebral hemisphere 29 d post-CHI. The data presented may be associated with ADNP's crucial involvement in brain development and response to injury.	Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel; Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Pharmacol, Jerusalem, Israel	Gozes, I (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel.	igozes@post.tau.ac.il					Bassan M, 1999, J NEUROCHEM, V72, P1283, DOI 10.1046/j.1471-4159.1999.0721283.x; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Benimetskaya L, 1997, NAT MED, V3, P414, DOI 10.1038/nm0497-414; Brenneman DE, 2000, BIOCHEM SOC T, V28, P452, DOI 10.1042/bst0280452; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Delgado M, 2003, FASEB J, V17, P1922, DOI 10.1096/fj.02-1029fje; Delgado M, 2002, J MOL MED, V80, P16, DOI 10.1007/s00109-001-0291-5; Fuhrmann G, 2001, DEV CELL, V1, P377, DOI 10.1016/S1534-5807(01)00038-7; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; Gozes I, 2003, J MOL NEUROSCI, V20, P315, DOI 10.1385/JMN:20:3:315; Gozes I, 2002, J MOL NEUROSCI, V19, P167, DOI 10.1007/s12031-002-0028-0; Gozes I, 2001, TRENDS NEUROSCI, V24, P700, DOI 10.1016/S0166-2236(00)01931-7; Hailer NP, 2001, NEUROSCI LETT, V298, P33, DOI 10.1016/S0304-3940(00)01711-0; Hallbergson AF, 2003, J CLIN INVEST, V112, P1128, DOI 10.1172/JCI200320098; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Hoshino S, 1998, NEUROREPORT, V9, P1879, DOI 10.1097/00001756-199806010-00039; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Pinhasov A, 2003, DEV BRAIN RES, V144, P83, DOI 10.1016/S0165-3806(03)00162-7; Poggi SH, 2003, AM J OBSTET GYNECOL, V189, P790, DOI 10.1067/S0002-9378(03)00834-2; Poggi SH, 2002, AM J OBSTET GYNECOL, V187, P973, DOI 10.1067/mob.2002.127141; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; RALPH P, 1977, J IMMUNOL, V119, P950; Romano J, 2002, J MOL NEUROSCI, V18, P37, DOI 10.1385/JMN:18:1-2:37; Roy NS, 2000, NAT MED, V6, P271; SMITHSWINTOSKY VL, 2000, SOC NEUR 30 ANN M NE; Tan SM, 2000, J IMMUNOL, V165, P2574, DOI 10.4049/jimmunol.165.5.2574; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Zaltzman R, 2003, NEUROREPORT, V14, P481, DOI 10.1097/01.wnr.0000058036.29600.ff; Zamostiano R, 2001, J BIOL CHEM, V276, P708, DOI 10.1074/jbc.M007416200	32	28	29	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.		2004	24	2					181	187		10.1385/JMN:24:2:181			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	864IX	WOS:000224628300004	15456931				2021-06-18	
J	Bridges, EJ; Rouah, F; Johnston, KM				Bridges, EJ; Rouah, F; Johnston, KM			Snowblading injuries in Eastern Canada	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							ALPINE SKIING INJURIES; SNOWBOARDING INJURIES; HEAD-INJURIES; SPINAL-INJURIES; CHILDREN; ADOLESCENTS; RISK; SKIERS; 4-YEAR	Objectives: To evaluate injury patterns of snowbladers and compare them with those of skiers and snowboarders. To determine possible effects of helmet use in these sports on injury to the head and neck. Methods: This prospective case series observational study was conducted by collecting the injury reports from the ski patrol during the 1999-2000 season at Mont Tremblant ski resort, Quebec. All participants in downhill winter sports who presented themselves to the ski patrol with traumatic injury related to their sport were included. A concussion was defined as any loss of consciousness, amnesia, confusion, disorientation, vertigo, or headache that resulted from injury. The ski patroller reported helmet use on the accident report at the time of injury. Results: Snowbladers present with a unique pattern of injury compared with skiers and snowboarders. The incidence of leg, knee, and ankle/foot injuries were 20.5%, 25.6%, and 10.3% respectively. Concussions represented 11% of all injuries. There was no increase in other injury, including neck injury, related to helmet use. Conclusions: Unique injury patterns in snowbladers warrant reconsideration of equipment design. Concussion is a common injury on the ski slope. Although the effects of helmet use on concussion rate are inconclusive based on this study, helmet use did not increase the rate of neck injury, even when adjusted for age.	McGill Sports Med Ctr, Montreal, PQ H2W 1S4, Canada; McGill Univ, Dept Math & Stat, Montreal, PQ H3A 2T5, Canada	Bridges, EJ (corresponding author), McGill Sports Med Ctr, 475 Pine Ave W, Montreal, PQ H2W 1S4, Canada.						ABULABAN RB, 1991, CAN MED ASSOC J, V145, P1097; BLADIN C, 1993, AM J SPORT MED, V21, P701, DOI 10.1177/036354659302100511; BLITZER CM, 1984, AM J SPORT MED, V12, P142, DOI 10.1177/036354658401200210; BOUTER LM, 1989, AM J SPORT MED, V17, P226, DOI 10.1177/036354658901700213; Cadman R, 1996, AM SOC TEST MATER, V1266, P58, DOI 10.1520/STP37914S; CALLE SC, 1995, J PEDIATR SURG, V30, P791, DOI 10.1016/0022-3468(95)90749-1; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; Chissell HR, 1996, SPORTS MED, V22, P141, DOI 10.2165/00007256-199622030-00001; Chow TK, 1996, J TRAUMA, V41, P321, DOI 10.1097/00005373-199608000-00021; Davidson TM, 1996, WESTERN J MED, V164, P231; Davidson TM, 1996, WESTERN J MED, V164, P310; Deibert MC, 1998, J BONE JOINT SURG AM, V80A, P25, DOI 10.2106/00004623-199801000-00006; EKELAND A, 1993, AM SOC TEST MATER, V1182, P43, DOI 10.1520/STP25558S; GANONG RB, 1992, PHYSICIAN SPORTSMED, V20, P114, DOI 10.1080/00913847.1992.11947543; Hagel BE, 1999, CLIN J SPORT MED, V9, P9, DOI 10.1097/00042752-199901000-00003; HAUSER W, 1989, ASTM STP, V1022, P18; Hentschel S, 2001, CAN J NEUROL SCI, V28, P42; Holowenko D, 2000, CLIN J SPORT MED, V10, P67, DOI 10.1097/00042752-200001000-00012; Hosmer D, 1989, APPL LOGISTIC REGRES; JOHNSON RJ, 1997, SKI TRAUMA SAFETY, V11, P37; JOHNSON RJ, 1989, STP AM SOC TESTING M, V1022, P25; Machold W, 2000, J TRAUMA, V48, P1109, DOI 10.1097/00005373-200006000-00018; Macnab A J, 1996, Inj Prev, V2, P286, DOI 10.1136/ip.2.4.286; Meeuwisse WH, 1997, SPORTS MED, V24, P184, DOI 10.2165/00007256-199724030-00008; Nakaguchi H, 1999, J TRAUMA, V46, P1066, DOI 10.1097/00005373-199906000-00017; O'Neill DF, 1999, AM J SPORT MED, V27, P94; PINO EC, 1989, AM J SPORT MED, V17, P778, DOI 10.1177/036354658901700610; PRALL JA, 1995, INJURY, V26, P539, DOI 10.1016/0020-1383(95)00085-N; REQUA RK, 1977, MED SCI SPORT EXER, V9, P185; Sacco DE, 1998, J TRAUMA, V44, P654, DOI 10.1097/00005373-199804000-00016; SAS Institute Inc, 1990, SAS STAT US GUID VER, V2; SAS Institute Inc., 1990, SAS STAT US GUID VER, V1; SHEALY JE, 1993, AM SOC TEST MATER, V1182, P241, DOI 10.1520/STP25575S; Shorter NA, 1999, AM J EMERG MED, V17, P261, DOI 10.1016/S0735-6757(99)90121-3; Shorter NA, 1996, J TRAUMA, V40, P997, DOI 10.1097/00005373-199606000-00024; Sutherland AG, 1996, INJURY, V27, P423, DOI 10.1016/0020-1383(96)00026-5; Tarazi F, 1999, AM J SPORT MED, V27, P177, DOI 10.1177/03635465990270021101; TATOR CH, 1987, CLIN SPORT MED, V6, P101; US Consumer Product Safety Commission, 1999, SKIING HELM EV POT R; WEISS BD, 1994, CLIN SPORT MED, V13, P99; Yamakawa H, 2001, J TRAUMA, V50, P1101, DOI 10.1097/00005373-200106000-00020	41	28	28	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	DEC 1	2003	37	6					511	515		10.1136/bjsm.37.6.511			5	Sport Sciences	Sport Sciences	751YN	WOS:000187118300012	14665590	Green Published, Bronze			2021-06-18	
J	Bianchini, KJ; Greve, KW; Love, JM				Bianchini, KJ; Greve, KW; Love, JM			Definite malingered neurocognitive dysfunction in moderate/severe traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							HEAD-INJURY; PERFORMANCE; MMPI-2; LITIGANTS; DEFICITS; SCALE	There has been disagreement in the literature about whether persons with documented neuropathology can be diagnosed as malingering. To address this question, we present three moderate severe traumatic brain injury patients who were evaluated in the context of litigation who met the Slick, Sherman, and Iverson (1999) criteria for a diagnosis of "Definite Malingered Neurocognitive Dysfunction." Each performed significantly below-chance on at least one forced-choice symptom validity test, thereby demonstrating a deliberate attempt to appear impaired. These cases represent the first definitive evidence of an intentional effort to appear impaired in the context of documented moderate/severe traumatic brain injury.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Jefferson Neurobehav Grp, Metairie, LA USA	Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Arbisi PA, 1995, PSYCHOL ASSESSMENT, V7, P424, DOI 10.1037/1040-3590.7.4.424; Bianchini KJ, 2003, J OCCUP ENVIRON MED, V45, P1087, DOI 10.1097/01.jom.0000085886.18136.7d; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Bigler E, 1997, DIAGNOSTIC CLIN NEUR; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BINDER LM, 2002, J FORENSIC NEUROPSYC, V2, P27; Boone KB, 2003, CLIN NEUROPSYCHOL, V17, P244, DOI 10.1076/clin.17.2.244.16497; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Greene, 2000, MMPI 2 INTERPRETIVE; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREVE K, 2002, 36 ANN M ASS ADV BEH; Greve KW, 2003, ARCH PHYS MED REHAB, V84, P1233, DOI 10.1016/S0003-9993(03)00145-X; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Iverson GL, 1998, BRAIN INJURY, V12, P275, DOI 10.1080/026990598122575; Iverson GL, 2003, HANDBOOK OF FORENSIC NEUROPSYCHOLOGY, P137; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; LARRABEE GJ, 1992, FORENSIC REPORTS, V5, P257; Larrabee GJ, 2000, CLIN GUIDE NEUROPSYC, P301; MAPOU RL, 1988, J CLIN EXP NEUROPSYC, V10, P271, DOI 10.1080/01688638808408241; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; PALMER BW, 1995, CLIN NEUROPSYCHOL, V9, P68, DOI 10.1080/13854049508402060; Reitan RM, 1998, CRIT ISS NE, P163; Reynolds CR, 1998, CRIT ISS NE, P261; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Sweet JJ, 1999, STUD NEUROPSYCHOL DE, P255; Tombaugh T.N., 2003, J FORENSIC NEUROPSYC, V2, P69, DOI [DOI 10.1300/J151V02N03_04, 10.1300/J151v02n03_04]; Tombaugh TN, 1996, TEST MEMORY MALINGER; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	35	28	28	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	NOV	2003	17	4					574	580		10.1076/clin.17.4.574.27946			7	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	776XV	WOS:000189145400013	15168921				2021-06-18	
J	Kennedy, JE; Clement, PF; Curtiss, G				Kennedy, JE; Clement, PF; Curtiss, G			WAIS-III processing speed index scores after TBI: The influence of working memory, psychomotor speed and perceptual processing	CLINICAL NEUROPSYCHOLOGIST			English	Article							TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; INTELLIGENCE; INDICATORS; CHILDREN	This study investigates the extent to which working memory, motor speed and perceptual processing speed influence Wechsler Adult Intelligence Scale-III (WAIS-III) Processing Speed Index (PSI) scores. Sixty-eight adult outpatients with Traumatic Brain Injury (TBI) of varying severity and complete data on all outcome measures were identified. Two cases with outlying values on one outcome measure were omitted from the final sample. Working memory was measured by the Working Memory Index score from the WAIS-III. Motor speed was measured as score on the Halstead-Reitan Finger Oscillation Test (finger tapping) and perceptual processing as score on the Trail Making Test-Part B. In hierarchical multiple regression analyses, working memory accounted for 10% of the variance in PSI scores, whereas motor speed only accounted for 3%. An independent measure of perceptual processing, Trail Making Test-B, accounted for 26% of the variance in WAIS-III PSI scores. The total variance accounted for by the three factors was 56%. Findings confirm that the WAIS-III PSI scores of individuals who have received a TBI reflect perceptual processing speed, with an additional component attributable to working memory. Motor speed made only a small contribution to WAIS-III PSI scores in the present sample.	Wilford Hall USAF Med Ctr, Def & Vet Brain Injury Ctr, San Antonio, TX 78227 USA; Brooke Army Med Ctr, ATTN MCHE CP, Ft Sam Houston, TX 78234 USA; James A Haley Vet Hosp, Def & Vet Brain Injury Ctr, Tampa, FL 33612 USA; Univ S Florida, Dept Psychiat & Behav Med, Tampa, FL USA	Kennedy, JE (corresponding author), Wilford Hall USAF Med Ctr, Def & Vet Brain Injury Ctr, POB 27376, San Antonio, TX 78227 USA.	jan.kennedy@lackland.af.mil	Curtiss, Glenn/ABB-5566-2020				Donders J, 1997, ASSESSMENT, V4, P107, DOI 10.1177/107319119700400114; Fry AF, 2000, BIOL PSYCHOL, V54, P1, DOI 10.1016/S0301-0511(00)00051-X; Halstead WC, 1985, HALSTEAD REITAN NEUR; HANNAY H J, 1982, Journal of Clinical Neuropsychology, V4, P117; Hawkins KA, 1998, CLIN NEUROPSYCHOL, V12, P535, DOI 10.1076/clin.12.4.535.7236; Heaton R.K., 1991, COMPREHENSIVE NORMS; Luciano M, 2001, BEHAV GENET, V31, P581, DOI 10.1023/A:1013397428612; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; *PSYCH CORP, 1997, WECHSL AD INT SCAL; Salthouse TA, 2000, BIOL PSYCHOL, V54, P35, DOI 10.1016/S0301-0511(00)00052-1; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; STERNBERG S, 1969, AM SCI, V57, P421; Sternberg S, 1969, ACTA PSYCHOL, V30, P276, DOI 10.1016/0001-6918(69)90055-9; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; TROMP E, 1991, J CLIN EXP NEUROPSYC, V13, P821, DOI 10.1080/01688639108405100; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Wechsler D, 1997, WAIS 3 ADM SCORING M; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924	19	28	29	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG	2003	17	3					303	307		10.1076/clin.17.3.303.18091			5	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	748DP	WOS:000186847100002	14704894				2021-06-18	
J	Coelho, CA; Youse, KM; Le, KN; Feinn, R				Coelho, CA; Youse, KM; Le, KN; Feinn, R			Narrative and conversational discourse of adults with closed head injuries and non-brain-injured adults: A discriminant analysis	APHASIOLOGY			English	Article; Proceedings Paper	32nd Annual Clinical Aphasiology Conference	JUN, 2002	RIDGEDALE, MO					Background: Although there is general agreement regarding the clinical utility of discourse analyses for detecting the often subtle communicative impairments following closed head injuries (CHI), there is little consensus regarding discourse elicitation or analysis procedures. Consequently it has been difficult to compare findings across studies. Aims: In an effort to facilitate a movement towards the adoption of a more consistent methodology for the assessment of discourse abilities, the current study examined several commonly used measures of discourse performance and the accuracy with which these measures were able to distinguish individuals with CHI from non-brain-injured (NBI) controls. Previous studies have suggested that conversation is less demanding than narrative discourse because such narratives require greater manipulation of extended units of language while conversational discourse can be maintained with minimal responses (Chapman, 1997; Galski, Tompkins, & Johnston, 1998). On the basis of these reports it was hypothesised that the measures of narrative story performance would more accurately discriminate the participant groups than conversational measures. Methods & Procedures: Discourse samples were elicited from 32 adults with CHI and 43 NBI adults. Discourse samples included two story narratives, generation and retelling, and 15 minutes of conversation. A variety of discourse analyses were performed including story narrative measures of grammatical complexity, cohesive adequacy, and story grammar. Measures of conversation included appropriateness and topic initiation. Discriminant function analyses (DFA) were then employed to determine the accuracy of the selected measures in classifying the participants into their respective groups. Outcomes & Results: Results of the DFA with only the story narrative measures indicated that 70% of the cases, 64.5% of the CHI group, and 74.4% of the NBI group were accurately classified. This finding was not significant, suggesting that the story narrative measures did not reliably discriminate the CHI from the NBI participants. The DFA with the conversational measures correctly classified over 77% of the cases, 78.1% of the CHI participants, and 72.1% of the NBI group. This finding was significant, which suggests that the measures of conversational discourse were better able to discriminate the participant groups. A third DFA was performed, with all of the story narrative and conversational discourse measures included, which revealed that the conversational measures, comments and adequate plus responses, and the story narrative measure, T-units within episode structure in the generation task, made the greatest contributions to discriminating between the groups. Overall, group membership was correctly classified by the DFA in 81% of the cases, 84.4% of the CHI group, and 77.5% of the NBI participants. This finding was significant, suggesting that these three discourse measures discriminated the two participant groups with the highest degree of reliability. Conclusions: These findings did not support the hypothesis that the narrative discourse measures would more accurately predict group membership of the CHI and NBI participants than the conversational measures. A variety of factors may account for these findings including the interactive nature of conversation as well as social factors which appear to make this genre more difficult for individuals with CHI and a more sensitive index of their cognitive-communicative impairments.	Univ Connecticut, Dept Commun Sci, Unit 1085, Storrs, CT 06268 USA; Hosp Special Care, New Britain, CT USA; Univ Connecticut, Ctr Hlth, Farmington, CT USA	Coelho, CA (corresponding author), Univ Connecticut, Dept Commun Sci, Unit 1085, Storrs, CT 06268 USA.	coelho@uconn.edu					BLANK M, 1980, APPL PSYCHOLINGUIST, V1, P127, DOI 10.1017/S0142716400000801; Brinton B., 1989, CONVERSATIONAL MANAG; CHAPMAN SB, 1997, AM J SPEECH-LANG PAT, V6, P50, DOI DOI 10.1044/1058-0360.0602.50; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Doyle P.J., 1995, AM J SPEECH-LANG PAT, V4, P130, DOI [10.1044/1058-0360.0404.130, DOI 10.1044/1058-0360.0404.130]; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; HAGAN C, 1980, REHABILITATION HEAD; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HOLLINGSHEAD A, 1972, UNPUB 4 FACTOR INDEX; Kertesz A., 1982, W APHASIA BATTERY; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LILES BZ, 1995, J SPEECH HEAR RES, V38, P415, DOI 10.1044/jshr.3802.415; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; Mackenzie C, 2000, INT J LANG COMM DIS, V35, P269, DOI 10.1080/136828200247188; MANDLER JM, 1977, COGNITIVE PSYCHOL, V9, P111, DOI 10.1016/0010-0285(77)90006-8; Mattis S, 1976, GERIATRIC PSYCHIAT; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; Prince S, 2002, J MED SPEECH-LANG PA, V10, P19; Simmons-Mackie N, 2002, APHASIOLOGY, V16, P837, DOI 10.1080/02687030244000185; Snow P, 1997, APHASIOLOGY, V11, P947, DOI 10.1080/02687039708249421; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Togher L, 2001, J COMMUN DISORD, V34, P131, DOI 10.1016/S0021-9924(00)00045-9; TOGHER L, 1999, BRAIN DAM B, P113; Wilkinson R, 1999, APHASIOLOGY, V13, P327, DOI 10.1080/026870399402127; Winter P., 1976, BEAR FLY; Ylvisaker M., 2001, LANGUAGE INTERVENTIO, P745	31	28	28	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology	MAY	2003	17	5					499	510		10.1080/02687030344000111			12	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	669DB	WOS:000182335700008					2021-06-18	
J	Thatcher, RW; Biver, CJ; North, DM				Thatcher, RW; Biver, CJ; North, DM			Quantitative EEG and the Frye and Daubert standards of admissibility	CLINICAL ELECTROENCEPHALOGRAPHY			English	Article						Daubert; digital EEG; expert testimony; OEEG	TRAUMATIC BRAIN INJURY; TEST-RETEST RELIABILITY; ACADEMY-OF-NEUROLOGY; CLINICAL-NEUROPHYSIOLOGY-SOCIETY; CLOSED-HEAD INJURY; NEUROMETRIC EVALUATION; SPECTRAL PARAMETERS; BIOPHYSICAL LINKAGE; AMPLITUDE; CHILDREN	The 70-year-old Frye standards of "general acceptance" were replaced by the Supreme Court's 1993 Daubert criteria of the scientific method, which established the standards for admissibility of evidence in Federal Court. The four Daubert criteria were: 1- Hypothesis testing, 2- Estimates of error rates, 3- Peer reviewed publication and 4- General acceptance (Daubert v. Merrell Dow Pharmaceuticals, 61 U.S.L.W 4805 (U.S. June 29, 1993)). The present paper starts with the Daubert four factors and then matches them, step by step, to the scientific peer reviewed literature of quantitative EEG (QEEG) in relation to different clinical evaluations. This process shows how the peer reviewed science of the Digital EEG and the Quantitative EEG (QEEG) meet all of the Daubert standards of scientific knowledge. Furthermore, the science and technical aspects of QEEG in measuring the effects of neurological and psychiatric dysfunction also match the recent Supreme Court standards of "technical" and "other specialized" knowledge (General Electric Co v. Joiner, 1997, Kumho Tire Company, Ltd. v. Carmichael, 1999). Finally, it is shown that QEEG scientific knowledge and QEEG "technical" and "other specialized" knowledge meet the trilogy standards of the Supreme Court rulings in support of QEEG's admissibility as a clinically valid method in the evaluation of the nature and extent of neurological and psychiatric disorders.	Bay Pines VA Med Ctr, NeurolImaging Lab, Bay Pines, FL 33744 USA; Univ S Florida, Coll Med, Dept Neurol, Tampa, FL USA	Thatcher, RW (corresponding author), Bay Pines VA Med Ctr, NeurolImaging Lab, Bldg 23,Room 117, Bay Pines, FL 33744 USA.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Arruda JE, 1996, INT J PSYCHOPHYSIOL, V23, P63, DOI 10.1016/0167-8760(96)00032-3; BURGESS A, 1993, ELECTROEN CLIN NEURO, V86, P219, DOI 10.1016/0013-4694(93)90101-Z; Carmines E.G., 1979, RELIABILITY VALIDITY, V17; CHABOT R, 1996, CLIN ELECTROENCEPHAL, V27, P36; CorsiCabrera M, 1997, ELECTROEN CLIN NEURO, V102, P248, DOI 10.1016/S0013-4694(96)95179-6; Cronbach L. J., 1971, ED MEASUREMENT, P443, DOI DOI 10.1037/14353-009; Duffy F. H., 1994, CLIN ELECTROENCEPHAL, V25, P6; ELUL R, 1969, SCIENCE, V164, P328, DOI 10.1126/science.164.3877.328; FOX SS, 1967, SCIENCE, V147, P888; FROST JD, 1966, EXP NEUROL, V14, P506, DOI 10.1016/0014-4886(66)90134-8; GASSER T, 1985, ELECTROEN CLIN NEURO, V60, P312, DOI 10.1016/0013-4694(85)90005-7; Hamilton-Bruce M A, 1991, Clin Exp Neurol, V28, P219; Harmony T, 1993, Int J Neurosci, V68, P263, DOI 10.3109/00207459308994281; HAYES WL, 1973, STAT SOC SCI; Hoffman DA, 1999, J NEUROPSYCH CLIN N, V11, P401, DOI 10.1176/jnp.11.3.401; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; JOHN ER, 1972, SCIENCE, V177, P850, DOI 10.1126/science.177.4052.850; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; JOHN ER, 1980, SCIENCE, V210, P1255, DOI 10.1126/science.7434026; JOHN ER, 1983, PROG NEUROBIOL, V21, P239, DOI 10.1016/0301-0082(83)90014-X; KAISER G, 1999, FRIENDLY GUIDE WAVEL; KAYE H, 1981, INT J NEUROSCI, V13, P15, DOI 10.3109/00207458108991792; LUND TR, 1995, PSYCHOPHYSIOLOGY, V32, P66, DOI 10.1111/j.1469-8986.1995.tb03407.x; MAHLE S, 2001, DAUBERT LAW SCI EXPE; MAS F, 1993, CLIN ELECTROENCEPHAL, V24, P118, DOI 10.1177/155005949302400309; NIEDERMEYER E, 1994, ELCTROENCEPHALOGRAPH; Nunnally J.C., 1978, PSYCHOMETRIC THEORY; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; POLLOCK VE, 1991, ELECTROEN CLIN NEURO, V79, P20, DOI 10.1016/0013-4694(91)90152-T; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; Prichep L., 1987, HDB ELECTROENCEPHALO, P449; ROBINET RW, 1997, QUANTUM MECH; RUIJS MBM, 1994, NEUROPEDIATRICS, V25, P73, DOI 10.1055/s-2008-1071589; SALINSKY MC, 1991, ELECTROEN CLIN NEURO, V79, P382, DOI 10.1016/0013-4694(91)90203-G; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Thatcher R. W., 1989, ELECTROENCEPHALOGR C, V73, DOI [10.1016/0013-4694(89)90188-0, DOI 10.1016/0013-4694(89)90188-0, https://doi.org/10.1016/0013-4694(89)90188-0]; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; THATCHER RW, 1987, SCIENCE, V236, P1110, DOI 10.1126/science.3576224; Thatcher RW, 1998, NEUROIMAGE, V8, P307, DOI 10.1006/nimg.1998.0365; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; Thatcher RW, 2001, CLIN NEUROPHYSIOL, V112, P1729, DOI 10.1016/S1388-2457(01)00609-5; Thatcher RW, 1999, CLIN ELECTROENCEPHAL, V30, P94, DOI 10.1177/155005949903000304; THATCHER RW, 1988, J NEUROTHERAPY, V2, P8; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; von Bierbrauer A., 1993, EEG EMG Z ELEKTROENZ, V23, P151; WIRSEN A, 1992, ELECTROEN CLIN NEURO, V84, P127, DOI 10.1016/0168-5597(92)90017-6	48	28	29	0	6	EEG & CLINICAL NEUROSCIENCE SOC (E C N S)	WHEATON	805 W LIBERTY DR, PO BOX 725, WHEATON, IL 60187 USA	0009-9155			CLIN ELECTROENCEPHAL	Clin. Electroencephalogr.	APR	2003	34	2					39	53		10.1177/155005940303400203			15	Engineering, Biomedical; Clinical Neurology	Engineering; Neurosciences & Neurology	681BD	WOS:000183016000001	12784902				2021-06-18	
J	Magnoni, S; Stocchetti, N; Colombo, G; Carlin, A; Colombo, A; Lipton, JM; Catania, A				Magnoni, S; Stocchetti, N; Colombo, G; Carlin, A; Colombo, A; Lipton, JM; Catania, A			alpha-Melanocyte-stimulating hormone is decreased in plasma of patients with acute brain injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; alpha-melanocyte-stimulating hormone (alpha-MSH); subarachnoid hemorrhage (SAH); traumatic brain injury (TBI); tumor necrosis factor-alpha (TNF-alpha)	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; CEREBROSPINAL-FLUID; HEAD-INJURY; RAT-BRAIN; TNF-ALPHA; CYTOKINES; ACTIVATION; PITUITARY; MSH	The neuropeptide alpha-melanocyte-stimulating hormone (alpha-MSH) is a proopiomelanocortin derivative that has potent anti-inflammatory influences within the brain. The aim of the present research was to determine if there are changes in blood concentrations of this peptide in patients with acute traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH). Concomitantly, we recorded clinical parameters and measured blood concentrations of the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha). Twenty-three patients were enrolled in this study-18 had TBI and five SAH. Blood samples for determination of alpha-MSH and TNF- a were collected daily from day 1 to day 4 after injury. Baseline concentration of plasma alpha-MSH in patients with acute brain injury of either traumatic or vascular origin was significantly lower than in controls. Patients with TBI or SAH had similar a-MSH concentrations and the peptide remained consistently low over four post-injury days. Circulating TNF-alpha on day one was measurable in all patients and there was a negative correlation between plasma TNF-alpha and alpha-MSH. alpha-MSH was measured again after the acute phase in eight patients. The peptide was substantially increased in all subjects except for two who had an unfavorable outcome. From the well-known protective anti-inflammatory influences of alpha-MSH in the host, reduction in this circulating peptide may have detrimental consequences in brain injury. The data raise the possibility that restoration of normal circulating alpha-MSH through administration of the peptide could be beneficial in patients with brain injury.	IRCCS, Osped Maggiore Milano, Dept Anesthesia & Intens Care, I-20122 Milan, Italy; IRCCS, Osped Maggiore Milano, Div Internal Med, I-20122 Milan, Italy; Zengen Inc, Woodland Hills, CA USA	Catania, A (corresponding author), IRCCS, Osped Maggiore Milano, Div Med Interna 1, Pad Granelli,Via F Sforza 35, I-20122 Milan, Italy.	anna.catania@unimi.it	Colombo, Gualtiero I./B-4737-2010; Stocchetti, Nino/O-7444-2017	Colombo, Gualtiero I./0000-0002-7348-1939; Stocchetti, Nino/0000-0003-3250-6834; Catania, Anna/0000-0002-8261-7973			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BERKENBOSCH F, 1984, ENDOCRINOLOGY, V115, P1051, DOI 10.1210/endo-115-3-1051; BERTOLINI A, 1986, EUR J PHARMACOL, V130, P19, DOI 10.1016/0014-2999(86)90179-2; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; CARR JA, 1991, NEUROENDOCRINOLOGY, V54, P616, DOI 10.1159/000125968; Carrol JE, 2000, NEUROREPORT, V11, pR1; Catania A, 2000, CRIT CARE MED, V28, P1403, DOI 10.1097/00003246-200005000-00024; CATANIA A, 1993, ENDOCR REV, V14, P564, DOI 10.1210/er.14.5.564; CHEN CLC, 1983, P NATL ACAD SCI-BIOL, V80, P2211, DOI 10.1073/pnas.80.8.2211; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; DELGADO HR, 1999, NEUROIMMUNOMODULAT, V6, P187; Delgado R, 1998, J LEUKOCYTE BIOL, V63, P740; Dunbar JC, 2000, PEPTIDES, V21, P211, DOI 10.1016/S0196-9781(99)00192-8; EBERLE AN, 1988, MELANOTROPINS; Fassbender K, 2000, STROKE, V31, P2971, DOI 10.1161/01.STR.31.12.2971; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; GOETTING MG, 1990, CRIT CARE MED, V18, P1220, DOI 10.1097/00003246-199011000-00006; GOLDMAN H, 1993, ANN EMERG MED, V22, P1035, DOI 10.1016/S0196-0644(05)82747-7; GOLDMAN H, 1993, J NEUROTRAUM, V10, P385, DOI 10.1089/neu.1993.10.385; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Hirashima Y, 1997, NEUROCHEM RES, V22, P1249, DOI 10.1023/A:1021985030331; Huh SK, 1997, NEUROSURGERY, V40, P132, DOI 10.1097/00006123-199701000-00030; Ichiyama T, 1999, EXP NEUROL, V157, P359, DOI 10.1006/exnr.1999.7064; Ichiyama T, 1999, BRAIN RES, V836, P31, DOI 10.1016/S0006-8993(99)01584-X; JENNETT B, 1975, LANCET, V1, P480; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; KIKUCHI T, 1995, NEUROL RES, V17, P106, DOI 10.1080/01616412.1995.11740296; KNIGGE U, 1991, ACTA ENDOCRINOL-COP, V124, P609, DOI 10.1530/acta.0.1240609; LAMACZ M, 1991, ARCH INT PHYSIOL BIO, V99, P205, DOI 10.3109/13813459109146925; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; Lipton JM, 1997, IMMUNOL TODAY, V18, P140, DOI 10.1016/S0167-5699(97)01009-8; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MABLEY J, 1991, EUR J PHARMACOL, V209, P127, DOI 10.1016/0014-2999(91)90023-J; MANZANARES J, 1990, NEUROENDOCRINOLOGY, V52, P200, DOI 10.1159/000125582; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mathiesen T, 1997, J NEUROSURG, V87, P215, DOI 10.3171/jns.1997.87.2.0215; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Ono S, 1998, HUM GENE THER, V9, P1003, DOI 10.1089/hum.1998.9.7-1003; Rajora N, 1997, J NEUROSCI, V17, P2181; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; SAMSON WK, 1981, PEPTIDES, V2, P419, DOI 10.1016/S0196-9781(81)80098-8; Schneider A, 1999, NAT MED, V5, P554; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TILIGADA E, 1989, EXP BRAIN RES, V74, P645	50	28	32	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2003	20	3					251	260		10.1089/089771503321532833			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	661GU	WOS:000181883500003	12820679				2021-06-18	
J	Cox, WM; Heinemann, AW; Miranti, SV; Schmidt, M; Klinger, E; Blount, J				Cox, WM; Heinemann, AW; Miranti, SV; Schmidt, M; Klinger, E; Blount, J			Outcomes of systematic motivational counseling for substance use following traumatic brain injury	JOURNAL OF ADDICTIVE DISEASES			English	Article						motivational counseling; substance use; traumatic brain injury	GALVESTON ORIENTATION; EMERGENCY ROOM; AMNESIA TEST; PATTERNS	The effects of Systematic Motivational Counseling (SMC) on adults following traumatic brain injury (TBI) were assessed. The sample comprised 40 participants in the SMC Group who received 12 individual SMC sessions and 54 participants in the Comparison Group who received no motivational or substance-abuse treatment. Both groups received rehabilitation for their brain injuries. The SMC additionally focused on participants' personal goals and concerns in various areas of their lives, and helped them to formulate and execute concrete and realistic plans for resolving their concerns. To assess changes across time in the SMC Group, motivational structure, positive and negative affect, and substance use were measured at baseline, immediately after the intervention (mean of 10.2 months from baseline), and at a follow-up (mean of 9.1 months later). Because the comparison group had no SMC intervention, only two assessments were taken: at baseline and at a follow-up (mean of 12.8 months later). Across time, the SMC Group showed significant improvements in motivational structure and a significant reduction in negative affect and the use of substances of abuse. There were no corresponding changes in the Comparison Group. The results indicate that SMC improves motivational indices and may help to moderate substance use; hence they suggest a potential role for SMC in the rehabilitation of patients with TBI. (C) 2003 by The Haworth Press, Inc. All rights reserved.	Univ Coll N Wales, Sch Psychol, Bangor LL57 2AS, Gwynedd, Wales; Northwestern Univ, Sch Med, Dept Phys Med & Rehabil, Chicago, IL USA; Rehabil Inst Chicago, Chicago, IL 60611 USA; Schwab Rehabil Hosp & Care Network, Chicago, IL USA; Lutheran Gen Hosp, Park Ridge, IL 60068 USA; Univ Minnesota, Morris, MN 56267 USA; Stat Comp & Design Consultants, Kansas City, MO USA	Cox, WM (corresponding author), Univ Coll N Wales, Sch Psychol, Bangor LL57 2AS, Gwynedd, Wales.	m.cox@bangor.ac.uk	Heinemann, Allen W./AAI-2790-2021; Heinemann, Allen W/K-6283-2012	Heinemann, Allen W./0000-0003-2782-7326; Heinemann, Allen W/0000-0003-2782-7326			BLOUNT JP, 1996, ALCOHOL DRUG INVENTO; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; Cherpitel CJ, 1998, DRUG ALCOHOL REV, V17, P423, DOI 10.1080/09595239800187261; Cox W.M., 1990, WHY PEOPLE DRINK PAR, P291; Cox WM, 2000, ADDICT RES, V8, P121, DOI 10.3109/16066350009004415; COX WM, 1988, J ABNORM PSYCHOL, V97, P168, DOI 10.1037/0021-843X.97.2.168; COX WM, 1991, MOTIVATIONAL INTERVI, P260; COX WM, IN PRESS J STUDIES A; COX WM, 1996, SYSTEMATIC MNORIVATI; Damasio A. R., 1994, DESCARTESERROR; Howard K. I., 1999, COST EFFECTIVENESS P, P143; Keppel, 1991, DESIGN ANAL RES HDB; Klinger E., 1987, ADV PERSONALITY ASSE, V6, P31; KLINGER E, 1995, ASSESSING ALCOHOL PR, P399; Klinger E, 1995, OXF TEXT CLIN PSY, P267; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Macdonald S, 1999, DRUG ALCOHOL DEPEN, V55, P53, DOI 10.1016/S0376-8716(98)00184-7; MURRAY PK, 1987, REHABIL PSYCHOL, P501; ROSENTHAL M, 1998, REHABILITATION ADULT; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; WEHMAN P, 1990, VOCATIONAL REHABILIT; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	22	28	28	0	5	HAWORTH PRESS INC	BINGHAMTON	10 ALICE ST, BINGHAMTON, NY 13904-1580 USA	1055-0887			J ADDICT DIS	J. Addict. Dis.		2003	22	1					93	110		10.1300/J069v22n01_07			18	Substance Abuse	Substance Abuse	659MN	WOS:000181780600007	12661982				2021-06-18	
J	Diamond, BJ; Shreve, GM; Bonilla, JM; Johnston, MV; Morodan, J; Branneck, R				Diamond, BJ; Shreve, GM; Bonilla, JM; Johnston, MV; Morodan, J; Branneck, R			Telerehabilitation, cognition and user-accessibility	NEUROREHABILITATION			English	Article						telerehabilitation; traumatic brain injury; cognitive impairment; NBCSE	TRAUMATIC BRAIN-INJURY; REHABILITATION	Survivors of traumatic brain injury (TBI) often experience cognitive and physical impairments. The aims of this study were to: 1) build an internet-based, "Virtual Rehabilitation Center" (VRC) that provides rehabilitation, education and support services to individuals with TBI; and 2) to determine the relationships between the nature and severity of the participants' cognitive impairments and their ability to use the VRC. Eight individuals with brain injuries (Age: M = 43, SD = 15.4; Years of Education: M = 13.8, SD = 3.15) participated. The Neurobehavioral Cognitive Status Exam (NBCSE) was used to assess intellectual functioning. The VRC modules consisted of reaction time, functional modules, and communication capabilities. All participants learned how to use the VRC. However, those requiring more "trials to acquisition" showed greater cognitive impairment than those requiring fewer trials in: Construction (p = 0.02), Reasoning-Similarities (p = 0.01) and in calculation and language repetition. (i.e., a non-significant trend). Importantly, all participants learned how to use the system although learning rates varied. Moreover, one case-study demonstrated that learning on the VRC generalized to the community. Overall, impairments on the NBCSE in visual-constructional integration and executive-type functions, as well as language processing appeared to be related to how effectively participants teamed how to use the VRC.	William Paterson Univ, Dept Psychol, Wayne, NJ USA; Kent State Univ, Inst Appl Linguist, Kent, OH 44242 USA; Res & Educ Corp, Kessler Med Rehabil, W Orange, NJ USA; Univ Med & Dent New Jersey, NJ Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA	Diamond, BJ (corresponding author), POB 43592, Montclair, NJ 07043 USA.	diamondb@wpunj.edu	Shreve, Gregory/AAF-4497-2020	Shreve, Gregory/0000-0002-6907-1590			Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; FITZGIBBONS M, 2000, CORRECTIONS TODAY, V62, P104; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; Guerrero JL, 1999, DISABIL REHABIL, V21, P187; GUERRIER T, 2001, INT J COGNITIVE TECH, V6, P3; GUNJAN S, 2000, POPULAR SCI, V257, P58; Judd D. P., 1999, COUNS PSYCHOL, V14, P4; LEWIN ICF, 1992, COST DISORDERS BRAIN; Logan RA, 2000, ARTHRIT CARE RES, V13, P320, DOI 10.1002/1529-0131(200010)13:5<320::AID-ANR12>3.0.CO;2-H; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Nitzkin J L, 1997, Telemed J, V3, P141, DOI 10.1089/tmj.1.1997.3.141; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Popescu VG, 2000, IEEE T INF TECHNOL B, V4, P45, DOI 10.1109/4233.826858; Schopp LH, 2000, J TELEMED TELECARE, V6, P146, DOI 10.1258/1357633001934474; Schultheis MT, 2001, PRESENCE-TELEOP VIRT, V10, P431, DOI 10.1162/1054746011470271; SCHWAMM LH, 1987, ANN INTERN MED, V107, P486, DOI 10.7326/0003-4819-107-4-486; Swett H A, 1995, Conn Med, V59, P593; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Warden DL, 2000, J HEAD TRAUMA REHAB, V15, P1092, DOI 10.1097/00001199-200010000-00003; Webster G, 1999, BRAIN INJURY, V13, P593; 1997, ECONOMIST, V342, P27	22	28	29	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2003	18	2					171	177					7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	743ZU	WOS:000186604100009	12867679				2021-06-18	
J	Hart, T; O'Neil-Pirozzi, T; Morita, C				Hart, T; O'Neil-Pirozzi, T; Morita, C			Clinician expectations for portable electronic devices as cognitive-behavioural orthoses in traumatic brain injury rehabilitation	BRAIN INJURY			English	Article							MEMORY AID; PEOPLE	Objective: To ascertain experiences and expectations of clinicians as to uses of portable electronic devices such as hand-held computers as cognitive-behavioural orthoses in TBI rehabilitation. Design: Survey study. Procedures: A survey developed and piloted with the input of clinician focus groups was completed by 81 TBI clinicians from a variety of disciplines and work settings. Results: About half of the respondents reported prior exposure to clients with TBI who had used portable electronic aids. Of 10 key cognitive/behavioural areas, respondents saw most potential for devices in the areas of learning/memory, planning/organization and initiation; less potential was seen for social/interpersonal or behavioural difficulties. However, many respondents also identified learning and memory abilities as essential client characteristics for successful use of portable electronics. Cost was identified as a significant barrier to use of portable devices in rehabilitation. Respondents expressed low confidence overall in their ability to guide clients in use of devices; those who reported personal use were significantly more confident than those who did not. Conclusion: Clinicians believe that new electronic devices have potential for treatment of some cognitive impairments, but clinical experimentation may be limited by costs of technology and low clinician confidence.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA	Hart, T (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	thart@einstein.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A980034, H133A70033] Funding Source: Medline		Fuhrer MJ, 2001, AM J PHYS MED REHAB, V80, P528, DOI 10.1097/00002060-200107000-00013; GILES GM, 1989, AM J OCCUP THER, V43, P409, DOI 10.5014/ajot.43.6.409; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; KAYE H, 2000, DISABILITY STAT REPO, V13; Kennedy PR, 1998, NEUROREPORT, V9, P1707, DOI 10.1097/00001756-199806010-00007; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; KREUTZER JS, 1992, J HEAD TRAUMA REHAB, V7, P70; Loebl D, 1999, AM J OCCUP THER, V53, P387, DOI 10.5014/ajot.53.4.387; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; SCHERER M, 1996, HUMAN PERSPECTIVE, P99; Scherer MJ, 2002, DISABIL REHABIL, V24, P1, DOI 10.1080/09638280110066262; Vaccaro MJ, 2002, NEUROREHABILITATION, V17, P169; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wright P, 2001, INT J REHABIL RES, V24, P299, DOI 10.1097/00004356-200112000-00006	19	28	28	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2003	17	5					401	411		10.1080/0269905021000038438			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	660MQ	WOS:000181837300004	12745712				2021-06-18	
J	Skaper, SD				Skaper, S. D.			Poly(ADP-Ribosyl)ation Enzyme-1 as a Target for Neuroprotection in Acute Central Nervous System Injury	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Poly(ADP-ribose) polymerase; DNA repair; neurotoxicity; brain ischemia; neurodegeneration; neuroinflammation; neuroprotection; gene transcription		Poly(ADP-ribose) polymerase 1 (PARP-1) protects the genome by functioning in the DNA damage surveillance network. In response to stresses that are toxic to the genome, PARP-1 activity increases substantially, an event that appears crucial for maintaining genomic integrity. Massive PARP-1 activation, however, can deplete the cell of NAD+ and ATP, ultimately leading to energy failure and cell death. The discovery that cell death may be suppressed by PARP inhibitors or by deletion of the parp-1 gene has prompted a great deal of interest in the process of poly(ADP-ribosyl)ation. Suppression of PARP-1 is capable of protecting against cerebral and cardiac ischemia, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism, traumatic spinal cord injury, and streptozotocin-induced diabetes. The secondary damage of initially surviving neurons in brain stroke accounts for most of the volume of the infarcted area and the subsequent loss of brain function. Microglial migration is strongly controlled in living brain tissue by expression of the integrin CD11a, which is regulated in turn by PARP-1, proposing that PARP-1 downregulation may therefore be a promising strategy in protecting neurons from this secondary damage, as well. As PARP-1 is now recognised as playing a role also in the regulation of gene transcription, this further increases the intricacy of poly(ADP-ribosyl)ation in the control of cell homeostasis and challenges the notion that energy collapse is the sole mechanism by which poly(ADP-ribose) formation contributes to cell death. PARP(s) might regulate cell fate as essential modulators of death and survival transcriptional programs with relation to NF-kappa B and p53, proposing that inhibitors of poly(ADP-ribosyl)ation could therefore prevent the deleterious consequences of neuroinflammation by reducing NF-kappa B activity.	[Skaper, S. D.] GlaxoSmithKline Res & Dev Ltd, Neurol & GI Ctr Excellence Drug Discovery, New Frontiers Sci Pk,Third Ave, Harlow CM19 5AW, Essex, England	Skaper, SD (corresponding author), GlaxoSmithKline Res & Dev Ltd, Neurol & GI Ctr Excellence Drug Discovery, New Frontiers Sci Pk,Third Ave, Harlow CM19 5AW, Essex, England.	Stephen_Skaper-1@gsk.com					Abdelkarim GE, 2001, INT J MOL MED, V7, P255; ALKHATIB HM, 1987, P NATL ACAD SCI USA, V84, P1224, DOI 10.1073/pnas.84.5.1224; Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; ALVAREZGONZALEZ R, 1994, MOL CELL BIOCHEM, V138, P33, DOI 10.1007/BF00928440; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; AOKI K, 1993, BIOCHIM BIOPHYS ACTA, V1158, P251, DOI 10.1016/0304-4165(93)90022-Z; Babiychuk E, 1998, PLANT J, V15, P635, DOI 10.1046/j.1365-313x.1998.00240.x; BANASIK M, 1992, J BIOL CHEM, V267, P1569; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; Benchoua A, 2002, J BIOL CHEM, V277, P34217, DOI 10.1074/jbc.M203941200; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Berghammer H, 1999, FEBS LETT, V449, P259, DOI 10.1016/S0014-5793(99)00448-2; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; BURKART V, 1993, CLIN EXP IMMUNOL, V93, P273; CARSON DA, 1986, EXP CELL RES, V164, P273, DOI 10.1016/0014-4827(86)90028-5; CHAMBON P, 1963, BIOCHEM BIOPH RES CO, V11, P39, DOI 10.1016/0006-291X(63)90024-X; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Chung KT, 1998, FOOD CHEM TOXICOL, V36, P1053, DOI 10.1016/S0278-6915(98)00086-6; COSI C, 1994, J NEUROSCI RES, V39, P38, DOI 10.1002/jnr.490390106; Cosi C, 1996, BRAIN RES, V729, P264, DOI 10.1016/S0006-8993(96)00571-9; Cosi C, 1998, BRAIN RES, V809, P58, DOI 10.1016/S0006-8993(98)00829-4; Cuzzocrea S, 1997, BRIT J PHARMACOL, V121, P1065, DOI 10.1038/sj.bjp.0701234; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dawson Ted M., 1997, P319; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dawson VL, 1996, J NEUROSCI, V16, P2479; DEMURCIA G, 1986, J BIOL CHEM, V261, P7011; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Ding YC, 2001, BRAIN RES, V915, P210, DOI 10.1016/S0006-8993(01)02852-9; Drazen DL, 2001, MOL MED, V7, P761, DOI 10.1007/BF03401966; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; Eguchi Y, 1997, CANCER RES, V57, P1835; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Faro R, 2002, ANN THORAC SURG, V73, P575, DOI 10.1016/S0003-4975(01)03329-X; FERRO AM, 1982, J BIOL CHEM, V257, P7808; FRECHETTE A, 1985, CAN J BIOCHEM CELL B, V63, P764, DOI 10.1139/o85-096; GAAL JC, 1987, TRENDS BIOCHEM SCI, V12, P129, DOI 10.1016/0968-0004(87)90061-2; Goldfarb RD, 2002, CRIT CARE MED, V30, P974, DOI 10.1097/00003246-200205000-00004; Goto S, 2002, STROKE, V33, P1101, DOI 10.1161/01.STR.0000014203.65693.1E; Grilli M, 1999, CELL DEATH DIFFER, V6, P22, DOI 10.1038/sj.cdd.4400463; Gross SS, 1996, TRENDS MICROBIOL, V4, P47, DOI 10.1016/0966-842X(96)81507-1; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; HEIKKILA RE, 1984, NATURE, V311, P467, DOI 10.1038/311467a0; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; JOHNSON GS, 1981, BIOCHEM INT, V2, P611; Jones B, 2002, SOC NEUR ABSTR, V28; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kawamura T, 1998, BIOCHEM BIOPH RES CO, V251, P35, DOI 10.1006/bbrc.1998.9403; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kim YH, 2002, EXP NEUROL, V177, P407, DOI 10.1006/exnr.2002.7990; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Koedel U, 2002, J CEREBR BLOOD F MET, V22, P39, DOI 10.1097/00004647-200201000-00005; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Komjati K, 2002, SOC NEUR ABSTR, V28; KOPIN IJ, 1988, ANNU REV NEUROSCI, V11, P81, DOI 10.1146/annurev.neuro.11.1.81; Kroger H, 1996, INFLAMMATION, V20, P203, DOI 10.1007/BF01487406; KRUPITZA G, 1989, BIOCHEMISTRY-US, V28, P4054, DOI 10.1021/bi00435a063; KRUPITZA G, 1989, BIOCHEMISTRY-US, V28, P2034, DOI 10.1021/bi00431a011; KUKREJA RC, 1992, CARDIOVASC RES, V26, P641, DOI 10.1093/cvr/26.7.641; Lam TT, 1997, RES COMMUN MOL PATH, V95, P241; Langston JW, 1996, NEUROLOGY, V47, pS153, DOI 10.1212/WNL.47.6_Suppl_3.153S; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Le Page C, 1998, BIOCHEM BIOPH RES CO, V243, P451; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Liaudet L, 2000, P NATL ACAD SCI USA, V97, P10203, DOI 10.1073/pnas.170226797; Liaudet L, 2000, SHOCK, V14, P134, DOI 10.1097/00024382-200014020-00010; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Love S, 2000, NEUROPATH APPL NEURO, V26, P55, DOI 10.1046/j.1365-2990.2000.00218.x; Love S, 1998, NEUROREPORT, V9, P955, DOI 10.1097/00001756-199804200-00001; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; Lu X., 2001, Society for Neuroscience Abstracts, V27, P2025; Lyons RJ, 2001, J BIOL CHEM, V276, P17172, DOI 10.1074/jbc.M009756200; Mabley JG, 2001, INFLAMM RES, V50, P561, DOI 10.1007/PL00000234; Mabley JG, 2001, BRIT J PHARMACOL, V133, P909, DOI 10.1038/sj.bjp.0704156; Mabuchi T, 2000, STROKE, V31, P1735, DOI 10.1161/01.STR.31.7.1735; Mahajan PB, 1998, PLANT PHYSIOL, V118, P895, DOI 10.1104/pp.118.3.895; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Mandir AS, 2000, J NEUROSCI, V20, P8005; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Mandir AS, 2002, J NEUROCHEM, V83, P186, DOI 10.1046/j.1471-4159.2002.01144.x; Masutani M, 1999, P NATL ACAD SCI USA, V96, P2301, DOI 10.1073/pnas.96.5.2301; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; MILAM KM, 1984, SCIENCE, V223, P589, DOI 10.1126/science.6420886; MIWA M, 1971, J BIOL CHEM, V246, P6362; Moroni F, 2001, CELL DEATH DIFFER, V8, P921, DOI 10.1038/sj.cdd.4400884; Nagayama T, 2000, J NEUROCHEM, V74, P1636, DOI 10.1046/j.1471-4159.2000.0741636.x; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OLEINICK NL, 1985, RADIAT RES, V101, P29, DOI 10.2307/3576301; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Pacher P, 2002, DIABETES, V51, P514, DOI 10.2337/diabetes.51.2.514; Parratt JR, 1997, J PHYSIOL PHARMACOL, V48, P493; Perkins E, 2001, CANCER RES, V61, P4175; Pieper AA, 2000, MOL MED, V6, P271, DOI 10.1007/BF03401936; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pieper AA, 2000, P NATL ACAD SCI USA, V97, P1845, DOI 10.1073/pnas.97.4.1845; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Ruf A, 1996, P NATL ACAD SCI USA, V93, P7481, DOI 10.1073/pnas.93.15.7481; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sallmann FR, 2000, J BIOL CHEM, V275, P15504, DOI 10.1074/jbc.275.20.15504; SATOH MS, 1994, BIOCHEMISTRY-US, V33, P7099, DOI 10.1021/bi00189a012; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Schierle GSK, 1999, NEUROREPORT, V10, P3347, DOI 10.1097/00001756-199911080-00017; Schmidt N, 2001, J NEURAL TRANSM, V108, P1263, DOI 10.1007/s007020100004; SCHULZ JB, 1995, J NEUROCHEM, V64, P936, DOI 10.1046/j.1471-4159.1995.64020936.x; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Scott GS, 2001, J NEUROIMMUNOL, V117, P78, DOI 10.1016/S0165-5728(01)00329-0; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Shall S, 2001, MUTAT RES, V460, P1; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Simbulan-Rosenthal CM, 2000, P NATL ACAD SCI USA, V97, P11274, DOI 10.1073/pnas.200285797; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smulson ME, 2000, ADV ENZYME REGUL, V40, P183, DOI 10.1016/S0065-2571(99)00024-2; Soriano FG, 2002, SHOCK, V17, P286, DOI 10.1097/00024382-200204000-00008; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Szabo G, 2002, CIRC RES, V90, P100, DOI 10.1161/hh0102.102657; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tokime T, 1998, J CEREBR BLOOD F MET, V18, P991; Trimmer PA, 1996, NEURODEGENERATION, V5, P233, DOI 10.1006/neur.1996.0031; TSAI YJ, 1992, J BIOL CHEM, V267, P14436; UCHIDA K, 1987, BIOCHEM BIOPH RES CO, V148, P617, DOI 10.1016/0006-291X(87)90921-1; Ullrich O, 2001, FASEB J, V15, P1460, DOI 10.1096/fj.00-0540fje; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Weise J, 2001, CELL DEATH DIFFER, V8, P801, DOI 10.1038/sj.cdd.4400872; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Williams L., 1999, Society for Neuroscience Abstracts, V25, P1061; Williams L.R, 2002, SOC NEUR ABSTR, V28; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0; Yang ZQ, 2000, SHOCK, V13, P60, DOI 10.1097/00024382-200013010-00011; Ying WH, 2001, P NATL ACAD SCI USA, V98, P12227, DOI 10.1073/pnas.211202598; Ying WH, 2000, NEUROREPORT, V11, P1385, DOI 10.1097/00001756-200005150-00007; Ying WH, 2002, J CEREBR BLOOD F MET, V22, P774, DOI 10.1097/00004647-200207000-00002; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4; Youdim MBH, 1997, SCI AM, V276, P52, DOI 10.1038/scientificamerican0197-52; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; ZHANG J, 1995, J NEUROCHEM, V65, P1411; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zhang J, 2000, BIOCHEM BIOPH RES CO, V278, P590, DOI 10.1006/bbrc.2000.3816; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	180	28	28	0	1	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2003	2	5					279	291		10.2174/1568007033482733			13	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	VI5WW	WOS:000497810300001	14529360				2021-06-18	
J	Kupina, NC; Detloff, MR; Dutta, S; Hall, ED				Kupina, NC; Detloff, MR; Dutta, S; Hall, ED			Neuroimmunophilin ligand V-10,367 is neuroprotective after 24-hour delayed administration in a mouse model of diffuse traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						traumatic brain injury; V-10,367; cytoskeleton; calpain; neurofilament; spectrin	AMYLOID PRECURSOR PROTEIN; IMMUNOSUPPRESSANT FK506; AXONAL INJURY; HEAD-INJURY; CYCLOSPORINE-A; IN-VIVO; IMMUNOPHILIN LIGANDS; DOPAMINERGIC-NEURONS; NEUROTROPHIC ACTIONS; PARKINSONS-DISEASE	The authors present two studies that investigate the biochemical and histologic effects of the nonimmunosuppressive neuroimmunophilin (NIMM) ligand V-10,367 in a mouse model of traumatic brain injury (TBI). In study 1, the authors examined the effect of V-10,367 (50 mg/kg x 2 per day, by mouth) on neurofilament M (NFM) protein levels and on alpha-spectrin breakdown products (SBDPs) when dosed for 2 days, starting 24 hours after TBI and killed on day 3. In study 2, V-10,367 was given for 10 days, starting 24 hours after TBI and the mice killed 6 weeks after TBI, to measure the extent of neurodegeneration (amino CuAg stain). The results in study 1 revealed that V-10,367-treatment significantly increased NFM protein levels in both sham and TBI mice. In addition, V-10,367 attenuated SBDP 150 levels in the cortex, striatum, and hippocampus. The results of study 2 indicated that TBI mice treated with V-10,367 demonstrated significantly less neurodegeneration compared to injured, vehicle-treated mice. In summary, these results suggest that NIMMs may be neuroprotective indirectly through inhibition of calpain-mediated cytoskeletal damage and perhaps via maintenance of neuronal plasticity. In the context of this mouse model of TBI, the therapeutic window for V-10,367's positive effects is at least 24 hours after injury, which, in the case of TBI models, is largely unprecedented for a neuroprotective compound.	Pfizer Global Res & Dev, CNS Pharmacol, Ann Arbor, MI USA	Hall, ED (corresponding author), Univ Kentucky, Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, 232 Hlth Sci Res Bldg, Lexington, KY 40536 USA.		Hall, Edward D/F-8930-2013				Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; ARMISTEAD DM, 1995, ACTA CRYSTALLOGR D, V51, P522, DOI 10.1107/S0907444994014502; Bavetta S, 1999, EXP NEUROL, V158, P382, DOI 10.1006/exnr.1999.7119; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Buki A, 2000, J NEUROSCI, V20, P2825; Butcher SP, 1997, J NEUROSCI, V17, P6939; Campbell G, 1999, NEUROREPORT, V10, P3955, DOI 10.1097/00001756-199912160-00042; Costantini LC, 2000, NEUROSCIENCE, V100, P515, DOI 10.1016/S0306-4522(00)00312-2; Costantini LC, 1998, NEUROBIOL DIS, V5, P97, DOI 10.1006/nbdi.1998.0185; Costantini LC, 2001, EUR J NEUROSCI, V13, P1085, DOI 10.1046/j.0953-816x.2001.01473.x; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DAWSON TM, 1994, NEUROSCIENCE, V62, P569, DOI 10.1016/0306-4522(94)90389-1; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; DICKERSON RN, 1990, J AM COLL NUTR, V9, P86; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gogarten W, 1998, J NEUROSURG ANESTH, V10, P101, DOI 10.1097/00008506-199804000-00006; Gold BG, 1997, EXP NEUROL, V147, P269, DOI 10.1006/exnr.1997.6630; Gold BG, 1999, J PHARMACOL EXP THER, V289, P1202; GOLD BG, 1995, J NEUROSCI, V15, P7509; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAFE MR, 1980, J NEUROPATH EXP NEUR, V39, P555, DOI 10.1097/00005072-198009000-00005; Guo X, 2001, EUR J NEUROSCI, V13, P1683, DOI 10.1046/j.0953-816x.2001.01542.x; Hall E.D., 1995, CENTRAL NERVOUS SYST, P213; HALL ED, 1995, NEUROSURGERY 96 MANU, P505; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Harper S, 1999, NEUROSCIENCE, V88, P257, DOI 10.1016/S0306-4522(98)00221-8; HEIMER L, 1970, CONT RES METHODS NEU, P106; Ikonomidou C, 2000, SCIENCE, V287, P1056, DOI 10.1126/science.287.5455.1056; KITAMURA Y, 1994, J NEUROIMMUNOL, V50, P221; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; KUPINA N, 2002, UNPUB EXP NEUROL; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Langham J., 2000, COCHRANE DATABASE SY, V2; LYONS WE, 1994, P NATL ACAD SCI USA, V91, P3191, DOI 10.1073/pnas.91.8.3191; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McIntosh TK, 1996, LAB INVEST, V74, P315; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; Steiner JP, 1997, P NATL ACAD SCI USA, V94, P2019, DOI 10.1073/pnas.94.5.2019; Steiner JP, 1997, NAT MED, V3, P421, DOI 10.1038/nm0497-421; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Toung TJ, 1999, STROKE, V30, P1279, DOI 10.1161/01.STR.30.6.1279; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; YAMAMOTO T, 1986, BRAIN RES, V374, P419, DOI 10.1016/0006-8993(86)90442-7; Young B, 1991, Neurosurg Clin N Am, V2, P301; Zheng JQ, 2001, J NEUROSCI, V21, P9291, DOI 10.1523/JNEUROSCI.21-23-09291.2001	57	28	28	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2002	22	10					1212	1221					10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	600PF	WOS:000178399200009	12368660				2021-06-18	
J	Berger, S; Schwarz, M; Huth, R				Berger, S; Schwarz, M; Huth, R			Hypertonic saline solution and decompressive craniectomy for treatment of intracranial hypertension in pediatric severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; PRESSURE; RESUSCITATION; CHILDREN; COMPLICATIONS; DEXTRAN; EDEMA		Johannes Gutenberg Univ Mainz, Dept Pediat Surg, D-55101 Mainz, Germany; Johannes Gutenberg Univ Mainz, Dept Neurosurg, D-55101 Mainz, Germany; Johannes Gutenberg Univ Mainz, Dept Pediat, Pediat ICU, D-55101 Mainz, Germany	Berger, S (corresponding author), Johannes Gutenberg Univ Mainz, Dept Pediat Surg, Langenbeckstr 1, D-55101 Mainz, Germany.	berger@kinderchir.klinik.uni-mainz.de					BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; CHAN KH, 1990, CHILD NERV SYST, V6, P27, DOI 10.1007/BF00262262; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Gemma M, 1996, J NEUROSURG ANESTH, V8, P137, DOI 10.1097/00008506-199604000-00007; Hartl R, 1997, ZBL CHIR, V122, P181; Hieu PD, 1996, CHILD NERV SYST, V12, P270; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; KOFKE WA, 1993, J NEUROSURG ANESTH, V5, P1; Kreimeier U, 1997, ANAESTHESIST, V46, P309, DOI 10.1007/s001010050406; MORGALLA MH, 1995, SURG NEUROL, V43, P583, DOI 10.1016/0090-3019(95)00034-8; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; POLIN R, 1999, NEUROSURGERY, V41, P84; Qureshi AI, 1999, J TRAUMA, V47, P659, DOI 10.1097/00005373-199910000-00009; Schatzmann C, 1998, ACT NEUR S, V71, P31; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Taylor G, 1996, J PEDIATR SURG, V31, P65, DOI 10.1016/S0022-3468(96)90321-8; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8; VASSAR MJ, 1990, ARCH SURG-CHICAGO, V125, P1309; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; YOUNES RN, 1985, SURGERY, V98, P900; ZORNOW MH, 1990, ACT NEUR S, V51, P324; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021	29	28	29	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2002	53	3					558	563		10.1097/00005373-200209000-00027			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	599GA	WOS:000178324700036	12352497				2021-06-18	
J	Levin, AV				Levin, AV			Ophthalmology of shaken baby syndrome	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article							PERMANENT BRAIN-DAMAGE; OPTIC-NERVE SHEATH; RETINAL HEMORRHAGES; INFANT SYNDROME; HEAD-INJURIES; CARDIOPULMONARY-RESUSCITATION; CHILD-ABUSE; SHAKING; TRAUMA; RETINOSCHISIS	Retinal hemorrhages are an important indicator of Shaken Baby syndrome, However, a thorough description which includes the number, type, and distribution pattern of hemorrhages can be useful in determining their specificity. In particular, numerous preretinal, iatraretinal, and subretinal hemorrhages extending out to the edges of the retina and/or splitting of the retina (traumatic retinoschisis) seem to be particularly indicative of shaking with a very narrow differential diagnosis. Shaking appears to be a key element in creating hemorrhagic retinopathy.	Hosp Sick Children, Dept Ophthalmol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Univ Toronto, Dept Genet, Toronto, ON, Canada; Univ Toronto, Dept Ophthalmol, Toronto, ON M5S 1A1, Canada	Levin, AV (corresponding author), Hosp Sick Children, Dept Ophthalmol, 555 Univ Ave,M158, Toronto, ON M5G 1X8, Canada.	alex.levin@sickkids.ca					AOKI N, 1984, J NEUROSURG, V61, P273, DOI 10.3171/jns.1984.61.2.0273; Aron J J, 1970, Ann Ocul (Paris), V203, P533; BENNETT HS, 1980, CLIN PEDIATR, V19, P633, DOI 10.1177/000992288001900912; Betz P, 1996, FORENSIC SCI INT, V78, P71, DOI 10.1016/0379-0738(95)01866-2; Botash Ann S., 1998, Current Opinion in Pediatrics, V10, P217, DOI 10.1097/00008480-199804000-00018; Brown SM, 1999, ARCH OPHTHALMOL-CHIC, V117, P838; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1946, AM J ROENTGENOL, V56, P163; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; Carter J E, 1983, Child Abuse Negl, V7, P279, DOI 10.1016/0145-2134(83)90005-4; Case ME, 2001, AM J FOREN MED PATH, V22, P112, DOI 10.1097/00000433-200106000-00002; Christian CW, 1999, J PEDIATR-US, V135, P125, DOI 10.1016/S0022-3476(99)70343-4; CLARK RSB, 1995, CLIN PEDIATR, V34, P281, DOI 10.1177/000992289503400512; DiScala C, 2000, ARCH PEDIAT ADOL MED, V154, P16; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; ELNER SG, 1990, ARCH OPHTHALMOL-CHIC, V108, P1094, DOI 10.1001/archopht.1990.01070100050033; Emerson MV, 2001, OPHTHALMOLOGY, V108, P36, DOI 10.1016/S0161-6420(00)00474-7; FAHMY JA, 1973, ACTA OPHTHALMOL, V51, P289; FISCHER H, 1994, CLIN PEDIATR, V33, P696, DOI 10.1177/000992289403301113; GIANGIACOMO J, 1985, Journal of Pediatric Ophthalmology and Strabismus, V22, P234; GILBERTBARNESS E, 1991, AM J FOREN MED PATH, V12, P27, DOI 10.1097/00000433-199103000-00004; GILLILAND MGF, 1994, FORENSIC SCI INT, V68, P117, DOI 10.1016/0379-0738(94)90309-3; GOETTING MG, 1990, PEDIATRICS, V85, P585; Green MA, 1996, BRIT J OPHTHALMOL, V80, P282, DOI 10.1136/bjo.80.4.282; GREENWALD MJ, 1986, OPHTHALMOLOGY, V93, P618; Hattenbach LO, 1999, J AAPOS, V3, P188, DOI 10.1016/S1091-8531(99)70066-2; HOLLENHORST RW, 1958, ARCH OPHTHALMOL-CHIC, V60, P187; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; JOHNSON DL, 1993, NEUROSURGERY, V33, P231; Kivlin JD, 2001, CURR OPIN OPHTHALMOL, V12, P158, DOI 10.1097/00055735-200106000-00002; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; KRAMER K, 1993, CLIN PEDIATR, V32, P366, DOI 10.1177/000992289303200610; Krugman SD, 2000, PEDIATR EMERG CARE, V16, P432, DOI 10.1097/00006565-200012000-00016; LAMBERT SR, 1986, ARCH OPHTHALMOL-CHIC, V104, P1509; LEVIN A, 1986, PEDIATR EMERG CARE, V2, P269; LEVIN A, 2001, APSAC ADVISOR, V13, P17; LEVIN A V, 1989, Pediatric Emergency Care, V5, P181, DOI 10.1097/00006565-198909000-00011; Levin A V, 1991, Pediatr Emerg Care, V7, P129, DOI 10.1097/00006565-199104000-00028; Levin AV, 2000, RECENT ADV PAEDIAT, P151; MADSEN PH, 1972, OPHTHALMOLOGICA, V165, P453, DOI 10.1159/000308538; MASSICOTTE SJ, 1991, OPHTHALMOLOGY, V98, P1124; MULLER PJ, 1974, J NEUROSURG, V41, P160, DOI 10.3171/jns.1974.41.2.0160; MUNGER CE, 1993, AM J FOREN MED PATH, V14, P193, DOI 10.1097/00000433-199309000-00004; Nakagawa TA, 2001, ARCH PEDIAT ADOL MED, V155, P1149, DOI 10.1001/archpedi.155.10.1149; Odom A, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.6.e3; Papasian NC, 2000, PEDIATR NEUROSURG, V33, P188, DOI 10.1159/000055951; Paviglianiti JC, 1999, J AAPOS, V3, P383, DOI 10.1016/S1091-8531(99)70052-2; PIATT J, 1999, NEUROSURG FOCUS, V7, P1; Plunkett J, 1999, AM J FOREN MED PATH, V20, P17, DOI 10.1097/00000433-199903000-00005; Plunkett J, 2001, AM J FOREN MED PATH, V22, P1, DOI 10.1097/00000433-200103000-00001; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; REIBER GD, 1993, AM J FOREN MED PATH, V14, P201, DOI 10.1097/00000433-199309000-00005; SCHOENFELD A, 1985, ARCH OPHTHALMOL-CHIC, V103, P932; SEZEN F, 1971, BRIT J OPHTHALMOL, V55, P248, DOI 10.1136/bjo.55.4.248; SILVERMAN FN, 1972, RADIOLOGY, V104, P337, DOI 10.1148/104.2.337; Smith R A, 1976, Surg Neurol, V5, P246; Tzioumi D, 1998, CHILD ABUSE NEGLECT, V22, P1105, DOI 10.1016/S0145-2134(98)00093-3; WILKINSON WS, 1989, ARCH OPHTHALMOL-CHIC, V107, P1472, DOI 10.1001/archopht.1989.01070020546037; Young TA, 1997, PEDIATR EMERG CARE, V13, P61, DOI 10.1097/00006565-199702000-00018; Zaman F, 1999, ARCH OPHTHALMOL-CHIC, V117, P694	61	28	28	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	APR	2002	13	2					201	+	PII S1042-3680(02)00004-9	10.1016/S1042-3680(02)00004-9			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	573HM	WOS:000176823500006	12391704				2021-06-18	
J	Csokay, A; Egyud, L; Nagy, L; Pataki, G				Csokay, A; Egyud, L; Nagy, L; Pataki, G			Vascular tunnel creation to improve the efficacy of decompressive craniotomy in post-traumatic cerebral edema and ischemic stroke	SURGICAL NEUROLOGY			English	Article						brain swelling; trauma; infarction; decompressive craniectomy; vascular tunnel	HEAD-INJURY; CRANIECTOMY; BRAIN; BIOMECHANICS; SUPPORT; RAT	BACKGROUND Decompressive craniectomy with durotomy has been well described but remains a controversial treatment for traumatic or ischemic brain swelling. Although the technique can reduce intracranial pressure it frequently results in infarction of the brain tissue which extends through the durotomy because of compression and subsequent complications associated with decompressive craniectomy. METHODS All patients treated with surgical decompression were comatose with Grade 3 or 4 Glasgow Coma Scores. Since 1998 we have changed our technique for decompressive craniectomy by creating vascular channels around the major vessels crossing the durotomy margin. Outcomes in 21 patients treated with this technique are compared to 20 patients treated with a conventional decompression and durotomy between 1997 through 1999. RESULTS Clinical outcome was substantially better in the group treated with a vascular tunnel. CONCLUSIONS Our results suggest that placing vascular tunnels at the margins of a durotomy when performing a decompression may reduce vascular congestion and the subsequent ischemia in brain tissue which herniates through the durotomy, leading to better clinical outcomes. (C) 2002 by EIsevier Science Inc.	Natl Inst Traumatol, Dept Neurosurg, Budapest, Hungary; MAV Hosp, Dept Neurosurg, Budapest, Hungary	Csokay, A (corresponding author), Peton U 9-B, H-1039 Budapest, Hungary.						Alexander E, 1987, Br J Neurosurg, V1, P427, DOI 10.3109/02688698708999632; *AM ASS NEUR SURG, 1995, GUID MAN SEV HEAD IN; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Cooper P R, 1976, Surg Neurol, V5, P25; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; CSOKAY A, 2001, HUNGARIAN MED J, V142, P75; DIERSSEN G, 1983, ACTA NEUROCHIR, V69, P53, DOI 10.1007/BF02055853; Doerfler A, 1996, J NEUROSURG, V85, P853, DOI 10.3171/jns.1996.85.5.0853; FISHER CM, 1994, SURG NEUROL, V41, P65, DOI 10.1016/0090-3019(94)90210-0; GAAB MR, 1990, ACT NEUR S, V51, P326; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HASE U, 1978, ACTA NEUROCHIR, V45, P1, DOI 10.1007/BF01774379; HATASHITA S, 1988, STROKE, V19, P91, DOI 10.1161/01.STR.19.1.91; HATASHITA S, 1987, J NEUROSURG, V67, P573, DOI 10.3171/jns.1987.67.4.0573; ISHII S, 1983, INTRACRANIAL PRESSUR, V5, P549; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MOODY RA, 1968, J NEUROSURG, V29, P586, DOI 10.3171/jns.1968.29.6.0586; MORGALLA MH, 1995, SURG NEUROL, V43, P583, DOI 10.1016/0090-3019(95)00034-8; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; RINALDI A, 1990, ACT NEUR S, V51, P394; Rinker CF, 1998, J TRAUMA, V44, P984, DOI 10.1097/00005373-199806000-00009; Shigemori M, 1979, Acta Neurochir Suppl (Wien), V28, P195; Shimada K, 1999, SPINAL CORD, V37, P410, DOI 10.1038/sj.sc.3100858; WHITFIELD P, 1995, STROKE, V26, P1125; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; YAMAURA A, 1979, Neurologia Medico-Chirurgica, V19, P717, DOI 10.2176/nmc.19.717	29	28	31	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	FEB	2002	57	2					126	129	PII S0090-3019(01)00686-3	10.1016/S0090-3019(01)00686-3			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	534HK	WOS:000174578900016	11904208				2021-06-18	
J	Lambert, G; Naredi, S; Eden, E; Rydenhag, B; Friberg, P				Lambert, G; Naredi, S; Eden, E; Rydenhag, B; Friberg, P			Sympathetic nervous activation following subarachnoid hemorrhage: Influence of intravenous clonidine	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						alpha-adrenoreceptors; human; norepinephrine; spillover	INJURY; NORADRENALINE; PLASMA; EDEMA; CATECHOLAMINES; THERAPY; HUMANS	Background: Subarachnoid hemorrhage is often accompanied by systemic complications and cerebral vasospasm. Elevated levels of circulating catecholamines may be involved in the pathophysiology behind these events. The alpha-2-agonist clonidine inhibits sympathetic outflow by a central mechanism. Unrestricted sympathoexcitation may be detrimental and administration of clonidine may be beneficial in these patients. Methods: Using isotope dilution methodology, norepinephrine kinetic determinations, comprising determination of arterial norepinephrine concentration and rates of norepinephrine spillover to and removal, or clearance, from plasma, were performed on three occasions during the first week after subarachnoid hemorrhage in 25 patients. Eleven of these patients received clonidine (continuous iv. infusion 5.8 +/- 0.7 mug.k(-1).24h(-1)) and the remainder, standard therapy. Initial results were compared with 17 healthy age-matched subjects and eight patients suffering from severe traumatic brain injury without traumatic subarachnoid hemorrhage. Results; Subarachnoid hemorrhage patients exhibited markedly elevated arterial plasma norepinephrine concentrations [3.74+/-0.48, P<0.001 vs. healthy subjects (1.59+/-0.11nmol/L) and P<0.05 vs. head trauma patients (1.94+/-0.29umol/L)]. The rate of clearance of norepinephrine from plasma in the subarachnoid patients was also significantly greater than that observed in the healthy subjects (2.66+/-0.15 vs. 2.14+/-0.15L/ min, P < 0.05) and the head trauma patients (2.00+/-0.12L/min, P<0.05). Compared with both control groups, on admission the rate of spillover of norepinephrine to plasma following subarachnoid hemorrhage was markedly elevated (9.11+/-1.12, P<0.001). Clonidine treatment (continuous ix. infusion 5.8 0.7mug.kg(-1)-24h(-1)) did not reduce the increased rate of spillover of norepinephrine to plasma following subarachnoid hemorrhage. Conclusion: Sympathetic nervous activity is markedly elevated following subarachnoid bleeding. Clonidine had no effect on the rate of norepinephrine spillover to, or clearance from, plasma in these patients. Clearly, further studies are required to elucidate the mechanisms responsible for generating sympathetic nervous activation following subarachnoid hemorrhage.	Sahlgrenska Univ Hosp, Dept Clin Physiol, Gothenburg, Sweden; Sahlgrens Univ Hosp, Inst Neurosci, Dept Neurosurg, Gothenburg, Sweden; Sahlgrens Univ Hosp, Inst Surg Sci, Dept Anesthesia & Intens Care, Gothenburg, Sweden; Univ Umea Hosp, Inst Surg & Perioperat Sci, Dept Anesthesia & Intens Care, Umea, Sweden	Lambert, G (corresponding author), Baker Med Res Inst, POB 6492 St Kilda Rd Central, Melbourne, Vic 8008, Australia.		Lambert, Gavin W/E-7384-2010; Lambert, Gavin/Q-4869-2017	Lambert, Gavin W/0000-0003-0315-645X; Lambert, Gavin/0000-0003-0315-645X; Naredi, Silvana/0000-0002-4409-6089			ANDREOLI A, 1987, STROKE, V18, P558, DOI 10.1161/01.STR.18.3.558; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; CRUICKSHANK JM, 1974, BRIT HEART J, V36, P697; ESLER M, 1979, LIFE SCI, V25, P1461, DOI 10.1016/0024-3205(79)90371-0; ESLER M, 1990, PHYSIOL REV, V70, P963; FAULER J, 1993, EUR J CLIN PHARMACOL, V45, P165, DOI 10.1007/BF00315500; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; FOOTE SL, 1983, PHYSIOL REV, V63, P844; Horowitz MB, 1998, ACTA NEUROCHIR, V140, P87, DOI 10.1007/s007010050063; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; KIRNO K, 1993, ANESTHESIOLOGY, V78, P1021, DOI 10.1097/00000542-199306000-00003; KULKA PJ, 1995, ANESTH ANALG, V80, P263, DOI 10.1097/00000539-199502000-00011; Lambert E, 2000, CARDIOVASC RES, V45, P1046, DOI 10.1016/S0008-6363(99)00416-2; Lambert GW, 1998, ACTA PHYSIOL SCAND, V163, P155; LOBATO RD, 1980, J NEUROSURG, V53, P480, DOI 10.3171/jns.1980.53.4.0480; Mayer SA, 1999, STROKE, V30, P780, DOI 10.1161/01.STR.30.4.780; MAYER SA, 1994, NEUROLOGY, V44, P815, DOI 10.1212/WNL.44.5.815; MEDVEDEV OS, 1990, N-S ARCH PHARMACOL, V341, P192; MEYER JS, 1973, BRAIN, V96, P277, DOI 10.1093/brain/96.2.277; Naredi S, 2000, STROKE, V31, P901, DOI 10.1161/01.STR.31.4.901; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; PAYEN D, 1990, CRIT CARE MED, V18, P392, DOI 10.1097/00003246-199004000-00008; Reid J L, 1995, Ann N Y Acad Sci, V763, P673, DOI 10.1111/j.1749-6632.1995.tb32461.x; REID JL, 1981, BRIT J CLIN PHARMACO, V12, P295, DOI 10.1111/j.1365-2125.1981.tb01217.x	25	28	29	1	1	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	FEB	2002	46	2					160	165		10.1034/j.1399-6576.2002.460206.x			6	Anesthesiology	Anesthesiology	533VA	WOS:000174549900006	11942863				2021-06-18	
J	Ward, H; Shum, D; Wallace, G; Boon, J				Ward, H; Shum, D; Wallace, G; Boon, J			Pediatric traumatic brain injury and procedural memory	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED HEAD-INJURY; EXPLICIT MEMORY; IMPLICIT; AMNESIA; SKILL; DISSOCIATION	This study investigated the effects of pediatric Traumatic brain injury (TBI) on procedural memory. Fifteen children with moderate to severe TBI and 15 matched controls were compared on two procedural-memory tasks: motor-perceptual (rotary pursuit) and cognitive (mirror reading). Explicit-memory tasks were also completed: recall or recognition of rotary-pursuit items and mirror-reading words. On both procedural tasks, the TBI group learned at a similar rate and retained equally well as the controls. On the explicit-memory tasks, however, the TBI group recalled and recognized fewer test items than the controls. These results are consistent with those reported in the adult TBI literature and suggest that procedural memory, a type of implicit memory, is preserved in children with TBI. Implications of these findings for the management and rehabilitation of children with TBI were discussed.	Griffith Univ, Sch Appl Psychol, Brisbane, Qld 4111, Australia; Griffith Univ, Neuropsychol Unit, Brisbane, Qld 4111, Australia; Mater Misericordiae Childrens Hosp, Brisbane, Qld, Australia	Ward, H (corresponding author), Griffith Univ, Sch Appl Psychol, Nathan, Qld 4111, Australia.		Wallace, Geoff/H-1252-2013; Shum, David/A-3914-2008	Wallace, Geoff/0000-0001-9306-3542; Shum, David/0000-0002-4810-9262			Baddeley A., 1997, HUMAN MEMORY THEORY; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; Bruce D. A., 1995, TRAUMATIC HEAD INJUR, P40; *CEDR CORP, 1996, SUP PRO EXP LAB SOFT; CLUTTERBUCK PM, 1990, ART TEACHING SPELLIN; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; CORKIN S, 1968, NEUROPSYCHOLOGIA, V6, P255, DOI 10.1016/0028-3932(68)90024-9; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; Eysenck M. W., 1979, LEVELS PROCESSING HU; Francis W. N., 1982, FREQUENCY ANAL ENGLI; GABRIELI JDE, 1995, PSYCHOL SCI, V6, P76, DOI 10.1111/j.1467-9280.1995.tb00310.x; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; GRAF P, 1984, J EXP PSYCHOL LEARN, V10, P164, DOI 10.1037/0278-7393.10.1.164; GREEN DM, 1966, SIGNAL DETECTION THE; HANNAY HJ, 1998, J CLIN EXPT NEUROPSY, V11, P444; Howell D.C., 1999, FUNDAMENTAL STAT BEH, V4th; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JENNETT WB, 1969, BRIT J PSYCHIAT, V4, P40; *KIN, 1998, 3D STUD MAX; MILNER B, 1985, HUM NEUROBIOL, V4, P137; MOSCOVITCH M, 1992, NEUROPSYCHOLOGY MEMO, P5; Moscovitch M., 1989, VARIETIES MEMORY CON, P133; Naito Mika, 1993, P231; NISSEN MJ, 1992, NEUROPSYCHOLOGY MEMO, P203; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; SAINTCYR JA, 1992, NEUROPSYCHOLOGY MEMO, P188; Schacter DL, 2000, OXFORD HDB MEMORY, P627; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P149, DOI 10.1076/jcen.21.2.149.929; Shum D, 1996, J HEAD TRAUMA REHAB, V11, P43, DOI 10.1097/00001199-199604000-00005; SNOW JH, 1994, PEDIAT TRAUMATIC BRA; SQUIRE LR, 1984, NEUROPSYCHOLOGIA, V22, P145, DOI 10.1016/0028-3932(84)90057-5; Vakil E, 1996, BRAIN COGNITION, V31, P75, DOI 10.1006/brcg.1996.0026; WARRINGTON EK, 1968, NATURE, V217, P972, DOI 10.1038/217972a0; Yamadori A, 1996, COGNITIVE BRAIN RES, V5, P49, DOI 10.1016/S0926-6410(96)00040-7; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	35	28	28	0	6	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2002	24	4					458	470		10.1076/jcen.24.4.458.1032			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	568ZJ	WOS:000176574600005	12187459				2021-06-18	
J	Moritz, CH; Rowley, HA; Haughton, VM; Swartz, KR; Jones, J; Badie, B				Moritz, CH; Rowley, HA; Haughton, VM; Swartz, KR; Jones, J; Badie, B			Functional MR imaging assessment of a non-responsive brain injured patient	MAGNETIC RESONANCE IMAGING			English	Article						electroencephalogram; evoked potential; magnetic resonance imaging; traumatic brain injury; fMRI	DEATH	Functional magnetic resonance imaging (fMRI) was requested to assist in the evaluation of a comatose 38-year-old woman who had sustained multiple cerebral contusions from a motor vehicle accident. Previous electrophysiologic studies suggested absence of thalamocortical processing in response to median nerve stimulation. Whole-brain fMRI was performed utilizing visual, somatosensory, and auditory stimulation paradigms. Results demonstrated intact task-correlated sensory and cognitive blood oxygen level dependent (BOLD) hemodynamic response to stimuli. Electrodiagnostic studies were repeated and evoked potentials indicated supratentorial recovery in the cerebrum. At 3-months post trauma the patient had recovered many cognitive & sensorimotor functions, accurately reflecting the prognostic fMRI evaluation. These results indicate that fMRI examinations may provide a useful evaluation for brain function in non-responsive brain trauma patients. (C) 2001 Elsevier Science Inc. All rights reserved.	Univ Wisconsin, Dept Radiol, Madison, WI 53706 USA; Univ Wisconsin, Dept Neurol Surg, Madison, WI 53706 USA; Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA	Moritz, CH (corresponding author), Univ Wisconsin, Dept Radiol, Madison, WI 53706 USA.		Moritz, Chad/A-9298-2009	Moritz, Chad/0000-0002-9985-1176			BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Ishii K, 1996, AM J NEURORADIOL, V17, P731; JONES KM, 1992, AM J NEURORADIOL, V13, P65; Lovblad KO, 2000, STROKE, V31, P539, DOI 10.1161/01.STR.31.2.539; Lowe MJ, 1999, J COMPUT ASSIST TOMO, V23, P463, DOI 10.1097/00004728-199905000-00025; OGAWA S, 1990, P NATL ACAD SCI USA, V97, P9860; ORRISON WW, 1994, AM J NEURORADIOL, V15, P913; WIJDICKS EFM, 1995, NEUROLOGY, V45, P1003, DOI 10.1212/WNL.45.5.1003	9	28	30	0	2	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	0730-725X			MAGN RESON IMAGING	Magn. Reson. Imaging	OCT	2001	19	8					1129	1132		10.1016/S0730-725X(01)00432-5			4	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	494XW	WOS:000172312000011	11711238				2021-06-18	
J	Petrov, T; Underwood, BD; Braun, B; Alousi, SS; Rafols, JA				Petrov, T; Underwood, BD; Braun, B; Alousi, SS; Rafols, JA			Upregulation of iNOS expression and phosphorylation of eIF-2 alpha are paralleled by suppression of protein synthesis in rat hypothalamus in a closed head trauma model	JOURNAL OF NEUROTRAUMA			English	Article						eIF-2 alpha(P) protein; iNOS mRNA; phosphorylation; PVN; SON	NITRIC-OXIDE SYNTHASE; BRAIN INJURY; MESSENGER-RNA; PARAVENTRICULAR NUCLEUS; TRANSLATIONAL CONTROL; SUPRAOPTIC NUCLEUS; NADPH-DIAPHORASE; SPINAL-CORD; NEURONS; INITIATION	When the inducible form of nitric oxide synthase (iNOS) is expressed after challenge to the nervous system, it results in abnormally high concentrations of nitric oxide (NO). Under such conditions, NO could phosphorylate the eukaryotic translation initiation factor (eIF)-2(alpha), thus suppressing protein synthesis in neurons that play a role in endocrine and autonomic functions. Using the Marmarou model of traumatic brain injury (TBI), we observed a rapid increase (at 4 h after TBI) of iNOS mRNA in magno- and parvocellular supraoptic and paraventricular neurons, declining gradually by similar to 30% at 24 h and by similar to 80% at 48 h. Western analysis indicated a trend towards increased iNOS protein synthesis at 4 h, which peaked at 8 h, and tended to decrease at the later time points. At the same time points, we detected immunocytochemically the phosphorylated form of eIF-2 alpha (eIF-2 alpha [P]) as cytoplasmic and more often as nuclear labeling. The incidence of double-labeled [iNOS and eIF-2 alpha (P)] neuronal profiles, particularly at 24 h and 48 h after TBI, was high. De novo protein synthesis assessed quantitatively after infusion of S-35 methionine/cysteine was reduced by similar to 20% at 4 h, remained depressed at 24 h, and did not return to control levels up to 48 h following the trauma. The results suggest that MOS may trigger phosphorylation of eIF-2 alpha, which in turn interferes with protein synthesis at the translational (ribosomal complex) and transcriptional (chromatin) levels. The depression in protein synthesis may include downregulation of iNOS itself, which could be an autoregulatory inhibitory feedback mechanism for NO synthesis. Excessive amounts of NO may also participate in dysfunction of hypothalamic circuits that underlie endocrine and autonomic alterations following TBI.	Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Dept Emergency Med Neurol Surg, Detroit, MI 48202 USA	Petrov, T (corresponding author), Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48202 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39860] Funding Source: Medline		ASSUREY J, 1992, BRIT J PHARMACOL, V108, P833; Atkins CM, 1999, J NEUROSCI, V19, P7241, DOI 10.1523/JNEUROSCI.19-17-07241.1999; BENARROCH EE, 1993, MAYO CLIN PROC, V68, P988, DOI 10.1016/S0025-6196(12)62272-1; Bethea JR, 1998, J NEUROSCI, V18, P3251; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CAVERNER D, 2000, TRANSLATION CONTROL, P66; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; De Marinis L, 1999, CLIN ENDOCRINOL, V50, P741; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; Della Corte F, 1998, CRIT CARE MED, V26, P1419; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Goldstein EN, 1999, ACTA NEUROPATHOL, V98, P493, DOI 10.1007/s004010051115; Harada S, 1999, BRAIN RES, V821, P322, DOI 10.1016/S0006-8993(99)01124-5; Harding HP, 1999, NATURE, V397, P271; Ikonomov OC, 2000, DEV BRAIN RES, V123, P13, DOI 10.1016/S0165-3806(00)00074-2; Jacobs RA, 1997, MOL BRAIN RES, V49, P238, DOI 10.1016/S0169-328X(97)00150-2; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Jhamandas JH, 1996, NEUROREPORT, V7, P2843, DOI 10.1097/00001756-199611250-00006; JHAMANDAS JH, 1989, J COMP NEUROL, V282, P15, DOI 10.1002/cne.902820103; Kim YM, 1998, MOL MED, V4, P179, DOI 10.1007/BF03401915; Kishimoto J, 1996, BRAIN RES, V720, P159, DOI 10.1016/0006-8993(96)00101-1; LEE SB, 1993, VIROLOGY, V192, P380, DOI 10.1006/viro.1993.1048; Lumme A, 1997, EXP NEUROL, V144, P248, DOI 10.1006/exnr.1996.6369; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCKEOWN TR, 1999, J CEREB BLOOD FLO S1, V19, pS510; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; MOOS F, 1989, J PHYSIOL-LONDON, V408, P1, DOI 10.1113/jphysiol.1989.sp017442; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; Okamoto H, 2000, ANESTH ANALG, V91, P896, DOI 10.1097/00000539-200010000-00023; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PETROV T, 1995, NEUROPHARMACOLOGY, V34, P509, DOI 10.1016/0028-3908(95)00002-N; Petrov T, 1995, J NEUROSCI RES, V42, P835, DOI 10.1002/jnr.490420612; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; Rivier C, 1998, NEUROIMMUNOMODULAT, V5, P203, DOI 10.1159/000026338; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SANCHEZ F, 1994, CELL TISSUE RES, V276, P31, DOI 10.1007/BF00354781; SANDI C, 1995, EUR J PHARMACOL, V274, P17, DOI 10.1016/0014-2999(94)00700-H; Satta MA, 1998, NEUROENDOCRINOLOGY, V67, P109, DOI 10.1159/000054305; SAWCHENKO PE, 1982, J COMP NEUROL, V205, P260, DOI 10.1002/cne.902050306; Schoning B, 1999, BRAIN RES PROTOC, V4, P217, DOI 10.1016/S1385-299X(99)00022-7; Silverman RH, 1999, NATURE, V397, P208, DOI 10.1038/16586; Sood R, 2000, GENETICS, V154, P787; Sporbert A, 1999, MOL BRAIN RES, V67, P258, DOI 10.1016/S0169-328X(99)00067-4; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; SWANSON LW, 1983, NEUROENDOCRINOLOGY, V36, P165, DOI 10.1159/000123454; THEODOSIS DT, 1985, NATURE, V313, P682, DOI 10.1038/313682a0; Tschaikowsky K, 2000, ANESTHESIOLOGY, V92, P1093, DOI 10.1097/00000542-200004000-00028; Vanhatalo S, 1998, EXP NEUROL, V150, P107, DOI 10.1006/exnr.1997.6733; Vernet D, 1998, ENDOCRINOLOGY, V139, P3254, DOI 10.1210/en.139.7.3254; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WILLIAMS LM, 1994, AM J PHYSIOL-ENDOC M, V267, pE915; Yuan XQ, 1991, J NEUROTRAUM, V8, P219, DOI 10.1089/neu.1991.8.219	63	28	29	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2001	18	8					799	812		10.1089/089771501316919166			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	464AG	WOS:000170509600006	11526986				2021-06-18	
J	Yu, CG; Jagid, J; Ruenes, G; Dietrich, WD; Marcillo, AE; Yezierski, RP				Yu, CG; Jagid, J; Ruenes, G; Dietrich, WD; Marcillo, AE; Yezierski, RP			Detrimental effects of systemic hyperthermia on locomotor function and histopathological outcome after traumatic spinal cord injury in the rat	NEUROSURGERY			English	Article						hyperthermia; locomotor function; neuroprotection; secondary injury	CEREBRAL-ARTERY OCCLUSION; PERCUSSION BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; FREE-RADICAL ACTIVITY; ACUTE STROKE; PROGNOSTIC-SIGNIFICANCE; ISCHEMIA-REPERFUSION; MODERATE HYPOTHERMIA; MILD HYPERTHERMIA; GLUTAMATE RELEASE	OBJECTIVE: Posttraumatic hyperthermia has been demonstrated to worsen neurological outcome in models of brain injury. The purpose of this study was to examine the effects of systemic hyperthermia on locomotor and morphological outcome measures after traumatic spinal cord injury (SCI) in the rat. METHODS: After a T10 laminectomy, spinal cord contusions were produced from a height of 12.5 mm onto exposed cords (NYU Impactor; New York University Neurosurgery Laboratory, New York, NY) in adult rats that were divided into three groups. Group 1 (n = 9) underwent whole body hyperthermia (rectal temperature, 39.5 degreesC) 30 minutes postinjury for 4 hours, Group 2 (n = 8) underwent normothermia (rectal temperature, 37 degreesC) 30 minutes postinjury for 4 hours, and Group 3 (n = 10) underwent traumatic SCI with no postinjury thermal treatment. Twice-weekly assessments of locomotor function were made during a 6-week survival period using the Basso-Beattie-Breshnahan locomotor rating scale. Forty-four days after injury, animals were perfused, and their spinal cords serially sectioned. Sections were stained with hematoxylin, eosin, and Luxol fast blue for histopathological analysis. The percentage of tissue damage was quantitatively determined by using computer-aided image analysis. RESULTS: The results showed that 4 hours of postinjury hyperthermia significantly worsened locomotor outcome (final Basso-Beattie-Breshnahan scores were 9.7 +/- 0.3 [Group 1] versus 10.8 +/- 0.4 [Group 2] versus 11.3 +/- 0.3 [Group 3]) and led to an increase in the percentage of tissue damage (32.9 +/- 3.2% [Group 1] versus 22.3 +/- 2.8% [Croup 3]). CONCLUSION: These data suggest that complications of SCI (e.g., fever, infection) leading to an elevation of systemic temperature may add to the severity of secondary injury associated with traumatic SCI and significantly affect neurological outcome.	Univ Miami, Sch Med, Miami Project, Miami, FL USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL USA; Univ Miami, Sch Med, Dept Anat & Cell Biol, Miami, FL USA	Yezierski, RP (corresponding author), Univ Florida, Coll Dent, Dept Orthodont, POB 100444,1600 SW Archer Rd,Room D10-19, Gainesville, FL 32610 USA.	ryezierski@dental.ufl.edu	Yu, Chen Guang/C-6176-2011				Agrawal SK, 1997, J NEUROSCI, V17, P1055; Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Alm P, 1998, AMINO ACIDS, V14, P95, DOI 10.1007/BF01345249; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BERALDO PSS, 1993, PARAPLEGIA, V31, P186, DOI 10.1038/sc.1993.35; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Castillo J, 1999, CEREBROVASC DIS, V9, P22, DOI 10.1159/000015891; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHEN H, 1991, NEUROLOGY, V41, P1133, DOI 10.1212/WNL.41.7.1133; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DIETRICH WD, 1999, CURRENT REV CEREBROV, P43; DIETRICH WD, 1997, PRIMER CEREBROVASCUL, P163; Gaviria M, 2000, J NEUROTRAUM, V17, P19, DOI 10.1089/neu.2000.17.19; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; GLOBUS MYT, 1994, STROKE, V25, P254; Grau AJ, 1999, J NEUROL SCI, V171, P115, DOI 10.1016/S0022-510X(99)00261-0; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; HAMMER B, 1993, NEUROREPORT, V5, P72, DOI 10.1097/00001756-199310000-00018; HINDFELT B, 1976, ACTA NEUROL SCAND, V53, P72, DOI 10.1111/j.1600-0404.1976.tb04326.x; Kil HY, 1996, J CEREBR BLOOD F MET, V16, P100, DOI 10.1097/00004647-199601000-00012; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Lancelot E, 1998, NEUROSCI LETT, V242, P131, DOI 10.1016/S0304-3940(98)00095-0; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARSALA M, 1994, STROKE, V25, P2038, DOI 10.1161/01.STR.25.10.2038; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; McAdoo DJ, 1997, J NEUROTRAUM, V14, P507, DOI 10.1089/neu.1997.14.507; MCDONALD JW, 1991, NEUROSCI LETT, V126, P83, DOI 10.1016/0304-3940(91)90377-6; Metz GAS, 2000, J NEUROTRAUM, V17, P1, DOI 10.1089/neu.2000.17.1; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; Montgomerie JZ, 1997, CLIN INFECT DIS, V25, P1285, DOI 10.1086/516144; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; PRZELOMSKI MM, 1986, NEUROLOGY, V36, P427, DOI 10.1212/WNL.36.3.427; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; ROKKAS CK, 1995, J THORAC CARDIOV SUR, V110, P27, DOI 10.1016/S0022-5223(05)80006-6; ROUSSEAUX P, 1980, SURG NEUROL, V14, P459; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; Schwarz S, 2000, NEUROLOGY, V54, P354, DOI 10.1212/WNL.54.2.354; STERNAU IL, 1992, ROLE NEUROTRANSMITTE, P33; Suehiro E, 1999, J NEUROTRAUM, V16, P285, DOI 10.1089/neu.1999.16.285; SUGARMAN B, 1982, JAMA-J AM MED ASSOC, V248, P66, DOI 10.1001/jama.248.1.66; TAKAGI K, 1994, AM J PHYSIOL-HEART C, V267, pH1770; Tatagiba M, 1997, NEUROSURGERY, V40, P541, DOI 10.1097/00006123-199703000-00023; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; Tuzgen S, 1998, SPINAL CORD, V36, P654, DOI 10.1038/sj.sc.3100660; Wakamatsu H, 1999, ANESTH ANALG, V88, P56, DOI 10.1097/00000539-199901000-00011; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Yamamoto K, 1998, NEUROREPORT, V9, P1655, DOI 10.1097/00001756-199805110-00072; Yu CG, 2000, J NEUROSURG, V93, P85, DOI 10.3171/spi.2000.93.1.0085	60	28	29	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2001	49	1					152	158		10.1097/00006123-200107000-00023			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	443MV	WOS:000169345700089	11440437				2021-06-18	
J	Kennedy, MRT				Kennedy, MRT			Retrospective confidence judgements made by adults with traumatic brain injury: relative and absolute accuracy	BRAIN INJURY			English	Article							SELF-AWARENESS; LEARNING JOLS; MEMORY; METAMEMORY; SCALE; UNAWARENESS; DIFFICULTY; DEFICITS	Eighteen adult survivors of moderate or severe traumatic brain injury (TBI) and 18 controls studied and were tested on two lists of noun-pairs, and made item-by-item retrospective confidence judgements (RCJs) of their answers using a Likert scale. For both groups, correlations between RCJ ratings and recall were extremely high, indicating that survivors of TBI were as accurate as non-injured controls when comparing their confidence in one answer to another. However, as groups, survivors of TBI were over-confident and control participants were under-confident, but only when uncertain as to the accuracy of their answer. Recall errors of 'interference' were analysed post-hoc. Survivors of TBI displayed higher confidence in interference errors than in non-interference errors, while control participants did not. These results are discussed within the context of self-monitoring by clinical and non-clinical populations. The importance of both relative and absolute measures of metamemory accuracy is highlighted.	Univ Minnesota, Dept Commun Disorders, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Cognit Sci, Minneapolis, MN 55455 USA	Kennedy, MRT (corresponding author), Univ Minnesota, Dept Commun Disorders, 115 Shevlin Hall,164 Pillsbury Dr SE, Minneapolis, MN 55455 USA.	kenne047@tc.umn.edu					ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; AMMONS RB, 1979, PSYCHOL REP, V45, P943, DOI 10.2466/pr0.1979.45.3.943; AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; BLACHSTEIN H, 1993, NEUROPSYCHOLOGY, V7, P530, DOI DOI 10.1037/0894-4105.7.4.530; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; BROOKS DN, 1975, CORTEX, V2, P329; CICERONE KD, 1991, NEUROPSYCHOLOGY EVER, P271; COSTERMANS J, 1992, J EXP PSYCHOL LEARN, V18, P142, DOI 10.1037/0278-7393.18.1.142; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; CROSSON B, 1993, NEUROPSYCHOLOGY, V7, P193, DOI DOI 10.1037/0894-4105.7.2.193; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; DUNLOSKY J, 1992, MEM COGNITION, V20, P374, DOI 10.3758/BF03210921; DUNLOSKY J, 1994, J MEM LANG, V33, P545, DOI 10.1006/jmla.1994.1026; Dunlosky J, 1998, EDUC PSYCHO, P249; FISCHHOFF B, 1997, J EXPT PSYCHOL HUMAN, V3, P522; FLAVELL JH, 1979, AM PSYCHOL, V34, P906, DOI 10.1037/0003-066X.34.10.906; Fleming JM, 1996, BRAIN INJURY, V10, P1; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; Gonzalez R, 1996, PSYCHOL BULL, V119, P159, DOI 10.1037/0033-2909.119.1.159; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Haut M., 1992, NEUROPSYCHOLOGY, V6, P51; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; JANOWSKY JS, 1989, PSYCHOBIOLOGY, V17, P3; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KENNEDY MR, 1995, AM J SPEECH-LANG PAT, V4, P159; Kennedy MRT, 2000, J SPEECH LANG HEAR R, V43, P1072, DOI 10.1044/jslhr.4305.1072; KENNEDY MRT, 1997, DISS ABSTR INT, V57, P4338; Kertesz A., 1982, W APHASIA BATTERY; KORIAT A, 1980, J EXP PSYCHOL-HUM L, V6, P107, DOI 10.1037/0278-7393.6.2.107; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; LICHTENSTEIN D, 1982, JUDGMENT UNCERTAINTY, P306; Lichtenstein Sarah, 1977, DECISION MAKING CHAN; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; NAWROCKI MD, 2000, THESIS U MINNESOTA M; Nelson T. O., 1990, PSYCHOL LEARN MOTIV, V26, P125, DOI DOI 10.1016/S0079-7421(08)60053-5; NELSON TO, 1991, PSYCHOL SCI, V2, P267, DOI 10.1111/j.1467-9280.1991.tb00147.x; NELSON TO, 1994, PSYCHOL SCI, V5, P207, DOI 10.1111/j.1467-9280.1994.tb00502.x; NELSON TO, 1984, PSYCHOL BULL, V95, P109, DOI 10.1037/0033-2909.95.1.109; Nelson TO, 1998, METACOGNITION AND COGNITIVE NEUROPSYCHOLOGY, P161; Newman AC, 2000, BRAIN INJURY, V14, P333; PAIVIO A, 1968, J EXP PSYCHOL, V76, P1, DOI 10.1037/h0025327; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; REID DB, 1993, J CLIN PSYCHOL, V49, P245, DOI 10.1002/1097-4679(199303)49:2<245::AID-JCLP2270490219>3.0.CO;2-1; REITAN RM, 1985, HALSTADREITAN NEUROP; ROTH DL, 1990, J CLIN EXP NEUROPSYC, V12, P834; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SCHACTER DL, 1991, AWARENESS DEFICIT BR, P127; Schlund MW, 1999, BRAIN INJURY, V13, P375, DOI 10.1080/026990599121566; SCHRAW G, 1994, MEM COGNITION, V22, P63, DOI 10.3758/BF03202762; SHIMAMURA AP, 1986, J EXP PSYCHOL LEARN, V12, P452, DOI 10.1037/0278-7393.12.3.452; THIEDE KW, 1994, J EDUC PSYCHOL, V86, P290, DOI 10.1037/0022-0663.86.2.290; Trosset M W, 1996, J Int Neuropsychol Soc, V2, P315; WEAVER CA, 1995, MEM COGNITION, V23, P12, DOI 10.3758/BF03210553; Wechsler D., 1987, WECHSLER MEMORY SCAL; ZAKAY D, 1992, PSYCHOL REC, V42, P519	61	28	28	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2001	15	6					469	487		10.1080/02699050120517			19	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	439VE	WOS:000169137600001	11394967				2021-06-18	
J	Ginsberg, MD; Zhao, WH; Belayev, L; Alonso, OF; Liu, Y; Loor, JY; Busto, R				Ginsberg, MD; Zhao, WH; Belayev, L; Alonso, OF; Liu, Y; Loor, JY; Busto, R			Diminution of metabolism/blood flow uncoupling following traumatic brain injury in rats in response to high-dose human albumin treatment	JOURNAL OF NEUROSURGERY			English	Article						glucose utilization; cerebral blood flow; deoxyglucose; hyperglycolysis; fluid-percussion injury; image analysis; rat	CEREBRAL BLOOD-FLOW; REDUCES HISTOPATHOLOGICAL DAMAGE; CLOSED-HEAD-INJURY; SERUM-ALBUMIN; GLUCOSE-UTILIZATION; ARTERY OCCLUSION; POSTTRAUMATIC HYPOTHERMIA; INTRALUMINAL SUTURE; DISPARITY ANALYSIS; PLASMA-ALBUMIN	Object. The authors have recently demonstrated that high-dose human albumin is markedly neuroprotective in experimental traumatic brain injury (TBI) and cerebral ischemia. The pathophysiology of TBI involves acute uncoupling of cerebral glucose utilization and blood flow. The intent of this study was to establish whether the use of human albumin therapy in a model of acute TBI would influence this phenomenon. Methods. Anesthetized, physiologically regulated rats received moderate (1.5-2 atm) fluid-percussion injury to the parietal lobe. Fifteen minutes after trauma or sham injury, rats in one group received human albumin (2.5 g/kg) administered intravenously and those in another group received 0.9% saline vehicle. At 60 minutes and 24 hours posttrauma, autoradiographic studies of local cerebral blood flow (LCBF) and local cerebral glucose utilization (LCMRglu) were conducted, and the LCMRglu/LCBF ratio was determined. Sham-injured rats had normal levels of LCBF and LCMRglu, and no differences between vehicle- and albumin-treated rats were evident. Sixty minutes after TBI, LCBF was moderately reduced bilaterally in vehicle-treated rats, whereas in albumin-treated animals, the LCBF contralateral to the side of injury was generally normal. Despite acutely depressed LCBF, LCMRglu in vehicle-treated rats at 60 minutes was paradoxically normal bilaterally, and foci of elevated LCMRglu were noted in the ipsilateral hippocampus and thalamus. By contrast, in albumin-treated rats studied 60 minutes post TBI, reduced LCMRglu values were measured in the ipsilateral caudoputamen and parietal cortex, whereas LCMRglu in other ipsilateral and contralateral sites did not differ from that measured in sham-injured animals. The metabolism/blood flow ratio was normal in sham-injured rats, but became markedly elevated in vehicle-treated rats 60 minutes post-TBI ton average, by threefold ipsilaterally and 2.1-fold contralaterally). By contrast, the mean metabolism/blood flow ratio in albumin-treated animals was elevated by only 1.6-fold ipsilaterally and was normal contralaterally. Twenty-four hours after TBI, LCBF contralateral to the side of injury had generally returned to normal levels in the albumin-treated group. Conclusions. These results demonstrate that human albumin therapy benefits the posttraumatic brain by diminishing the pronounced metabolism > blood flow dissociation that would otherwise occur within the Ist hour after injury. Viewed together with our previous evidence of histological neuroprotection, these findings indicate that human albumin therapy may represent a desirable treatment modality for acute TBI.	Univ Miami, Sch Med, Cerebral Vasc Dis Res Ctr, Dept Neurol D45, Miami, FL 33101 USA; Univ Miami, Sch Med, Neurotrauma Res Ctr, Dept Neurol, Miami, FL 33101 USA	Ginsberg, MD (corresponding author), Univ Miami, Sch Med, Cerebral Vasc Dis Res Ctr, Dept Neurol D45, POB 016960, Miami, FL 33101 USA.	mdginsberg@stroke.med.miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30291, NS 05820] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, P01NS005820, P50NS005820] Funding Source: NIH RePORTER		Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; BACK T, 1995, J CEREBR BLOOD F MET, V15, P566, DOI 10.1038/jcbfm.1995.70; Back T, 1998, NEUROL RES, V20, P643; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Belayev L, 1997, J CEREBR BLOOD F MET, V17, P1266, DOI 10.1097/00004647-199712000-00002; Belayev L, 1998, STROKE, V29, P2587, DOI 10.1161/01.STR.29.12.2587; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Belayev L, 1999, BRAIN RES, V845, P107, DOI 10.1016/S0006-8993(99)01952-6; Belayev L, 1997, J NEUROSURG, V87, P595, DOI 10.3171/jns.1997.87.4.0595; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Chorny I, 1999, J NEUROSURG ANESTH, V11, P273, DOI 10.1097/00008506-199910000-00008; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; DeWitt DS, 1996, CRIT CARE MED, V24, P109, DOI 10.1097/00003246-199601000-00019; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; EMERSON TE, 1989, CRIT CARE MED, V17, P690, DOI 10.1097/00003246-198907000-00020; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; HALLIWELL B, 1990, ARCH BIOCHEM BIOPHYS, V280, P1, DOI 10.1016/0003-9861(90)90510-6; HALLIWELL B, 1988, BIOCHEM PHARMACOL, V37, P569, DOI 10.1016/0006-2952(88)90126-8; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HE P, 1993, AM J PHYSIOL, V265, pH74; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Homayoun P, 1997, J NEUROCHEM, V69, P199; HU ML, 1993, J LAB CLIN MED, V121, P257; Huh PW, 1998, BRAIN RES, V804, P105, DOI 10.1016/S0006-8993(98)00674-X; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KEANEY JF, 1993, J CLIN INVEST, V91, P1582, DOI 10.1172/JCI116364; KOCHWESER J, 1976, NEW ENGL J MED, V294, P311, DOI 10.1056/NEJM197602052940605; KOCHWESER J, 1976, NEW ENGL J MED, V294, P526, DOI 10.1056/NEJM197603042941005; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; LINDSBERG PJ, 1991, ANN NEUROL, V30, P117, DOI 10.1002/ana.410300202; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Mead C O, 1970, Proc Inst Med Chic, V28, P173; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; NADAL A, 1995, P NATL ACAD SCI USA, V92, P1426, DOI 10.1073/pnas.92.5.1426; Nadal A, 1997, GLIA, V19, P343, DOI 10.1002/(SICI)1098-1136(199704)19:4<343::AID-GLIA7>3.0.CO;2-Y; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Peters TJ., 1996, ALL ALBUMIN BIOCH GE; REINHART WH, 1995, EUR J CLIN INVEST, V25, P523, DOI 10.1111/j.1365-2362.1995.tb01739.x; Remmers M, 1999, BRAIN RES, V827, P237, DOI 10.1016/S0006-8993(99)01304-9; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59; SAVAKI HE, 1980, J NEUROCHEM, V35, P495, DOI 10.1111/j.1471-4159.1980.tb06293.x; SCHNITZER JE, 1992, J BIOL CHEM, V267, P24544; SCHNITZER JE, 1992, AM J PHYSIOL, V262, pH246; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SMITH C, 1992, FOOD CHEM TOXICOL, V30, P483, DOI 10.1016/0278-6915(92)90099-7; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Stephenson D, 1999, GLIA, V27, P110, DOI 10.1002/(SICI)1098-1136(199908)27:2<110::AID-GLIA2>3.0.CO;2-C; Tabernero A, 1999, GLIA, V25, P1; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; ZHAO WZ, 1995, J CEREBR BLOOD F MET, V15, P552, DOI 10.1038/jcbfm.1995.69; Zhao WZ, 1999, J NEUROSURG, V90, P510, DOI 10.3171/jns.1999.90.3.0510; Zhao WZ, 1997, J CEREBR BLOOD F MET, V17, P1281, DOI 10.1097/00004647-199712000-00003; ZHAO WZ, 1993, IEEE T MED IMAGING, V12, P782, DOI 10.1109/42.251130; Zhao YW, 1996, BIOCHEMISTRY-US, V35, P7174, DOI 10.1021/bi952242v; Zilles K., 1985, CORTEX RAT STEREOTAX; Zoellner H, 1996, J CELL SCI, V109, P2571	71	28	30	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2001	94	3					499	509		10.3171/jns.2001.94.3.0499			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	405KB	WOS:000167157600019	11235957				2021-06-18	
J	de Kruijk, JR; Twijnstra, A; Meerhoff, S; Leffers, P				de Kruijk, JR; Twijnstra, A; Meerhoff, S; Leffers, P			Management of mild traumatic brain injury: lack of consensus in Europe	BRAIN INJURY			English	Article							MINOR HEAD-INJURIES; CLASSIFICATION; ADMISSION	Mild traumatic brain injury (MTBI) accounts for most traumatic brain injuries and is an important cause of morbidity. Recent studies in various European countries have shown that no consensus exists about management of patients with MTBI. This study describes the management of MTBI patients in various European hospitals. A short questionnaire covering the areas of interest was sent to several EFNS members in European countries. The results of the inquiry show that there is, at present, no consensus about criteria for, or management of MTBI in European hospitals.	Univ Hosp Maastricht, Dept Neurol, NL-6229 HX Maastricht, Netherlands; Maastricht Univ, Fac Med, Maastricht, Netherlands; Maastricht Univ, Dept Epidemiol, Maastricht, Netherlands	de Kruijk, JR (corresponding author), Univ Hosp Maastricht, Dept Neurol, P Debeylaan 25, NL-6229 HX Maastricht, Netherlands.		Leffers, Pieter/B-8642-2009				ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; de Kruijk J R, 1996, Ned Tijdschr Geneeskd, V140, P1763; de Louw A, 1994, Ned Tijdschr Geneeskd, V138, P2197; DEKRUIJK J, 1994, NEDERLANDS TIJDSCHRI, V5, P119; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Ingebrigtsen T, 1997, ACTA NEUROL SCAND, V95, P51, DOI 10.1111/j.1600-0404.1997.tb00068.x; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; KRUGER J, 1991, NERVENARZT, V62, P226; MENDELOW AD, 1982, BRIT MED J, V285, P1530, DOI 10.1136/bmj.285.6354.1530; MILLER JD, 1992, BRIT J SURG, V79, P60, DOI 10.1002/bjs.1800790122; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Murshid WR, 1998, ACTA NEUROCHIR, V140, P56, DOI 10.1007/s007010050058; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; SAUNDERS CE, 1986, ANN EMERG MED, V15, P160, DOI 10.1016/S0196-0644(86)80012-9; SERVADEI F, 1995, J TRAUMA, V39, P696, DOI 10.1097/00005373-199510000-00015; VANTHOOFT F, 1973, COMMOTIO CEREBRI AND; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; VONWILD K, 1998, EUROPEAN J NEUROL S3, V5, pS235; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; WARREN D, 1989, Pediatric Emergency Care, V5, P83, DOI 10.1097/00006565-198906000-00003; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; YOUNG WB, 1994, SEMIN NEUROL, V14, P46, DOI 10.1055/s-2008-1041058	23	28	29	0	0	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2001	15	2					117	123		10.1080/026990501458353			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	398BG	WOS:000166733800004	11260762				2021-06-18	
J	Tyerman, A; Booth, J				Tyerman, A; Booth, J			Family interventions after traumatic brain injury: A service example	NEUROREHABILITATION			English	Article						TBI; family assessment; family education; family interventions	HEAD-INJURY; FOLLOW-UP; RELATIVES; BEHAVIOR; MEMBERS; NEEDS	Traumatic brain injury (TBI) often exerts a major impact upon the family with high levels of stress and distress, particularly amongst primary carers, disruption to family life style and functioning, changes in family roles, and marital and sexual difficulties. In response to the documented impact upon the family a range of family services have been advocated including family education, counselling and support. This paper outlines family services developed within a community head injury service in the UK. The family assessment programme comprises a relatives' screening questionnaire and structured interview schedules and ratings scales, some drawn from the family assessment literature, others developed within the service. Four components of family intervention are described: an annual series of educational workshops; follow-up workshops; individual family support; and specialist marital counselling. Our experience of providing these family services over the last 7 years is discussed along with the need for further evaluation of family assessment and interventions after TBI.	Bedgrove Hlth Ctr, Community Head Injury Serv, Aylesbury HP21 7ET, Bucks, England	Tyerman, A (corresponding author), Bedgrove Hlth Ctr, Community Head Injury Serv, Jansel Sq, Aylesbury HP21 7ET, Bucks, England.						ACORN S, 1995, J ADV NURS, V21, P872, DOI 10.1046/j.1365-2648.1995.21050872.x; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P464; Brown R, 1999, J HEAD TRAUMA REHAB, V14, P257, DOI 10.1097/00001199-199906000-00006; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Florian V, 1989, INT DISABILITY STUDI, V13, P150; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gosling J, 1999, BRAIN INJURY, V13, P785; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; JACOBS HE, 1989, NEUROPSYCHOLOGICAL T; Junque C, 1997, BRAIN INJURY, V11, P251, DOI 10.1080/026990597123557; Kabacoff R.I., 1990, J FAMILY PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Perlesz A, 1998, INT J REHABIL RES, V21, P339, DOI 10.1097/00004356-199812000-00001; PESSAR LF, 1993, BRAIN INJURY, V7, P231, DOI 10.3109/02699059309029675; PETERS L C, 1992, Brain Injury, V6, P461, DOI 10.3109/02699059209008141; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Rosenthal M, 1988, J HEAD TRAUMA REHAB, V3, P42; RUST J, 1988, GOLOMBOK RUST INVENT; SACHS PR, 1991, TREATING FAMILIES BR; SCHAEFER MT, 1981, J MARITAL FAM THER, V7, P47, DOI 10.1111/j.1752-0606.1981.tb01351.x; SOLOMON C R, 1991, Brain Injury, V5, P253, DOI 10.3109/02699059109008096; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Tyerman A, 1987, THESIS U LONDON; TYERMAN A, 1994, 4 C INT ASS STUD TRA; Uysal S, 1998, J HEAD TRAUMA REHAB, V13, P57, DOI 10.1097/00001199-199812000-00007; WHITEHOUSE AM, 1991, COGNITIVE REHABI NOV, P26; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183; YOUNG K, 1994, THESIS BRIT PSYCHOL; ZARSKI J, 1988, J HEAD TRAUMA REHAB, V3, P31	36	28	31	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2001	16	1					59	66					8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	439YA	WOS:000169144100008	11455104				2021-06-18	
J	Verbois, SL; Sullivan, PG; Scheff, SW; Pauly, JR				Verbois, SL; Sullivan, PG; Scheff, SW; Pauly, JR			Traumatic brain injury reduces hippocampal alpha 7 nicotinic cholinergic receptor binding	JOURNAL OF NEUROTRAUMA			English	Article						autoradiography; bungarotoxin; isradipine; MK-801; nicotine; QNB	FLUID-PERCUSSION INJURY; CLOSED-HEAD-INJURY; CONTROLLED CORTICAL IMPACT; RAT-BRAIN; COGNITIVE DEFICITS; ACETYLCHOLINE; MEMORY; CALCIUM; ACETYLTRANSFERASE; DYSFUNCTION	Changes in the expression of central nervous system (CNS) neurotransmitter receptors may contribute to behavioral and physiological deficits that occur following traumatic brain injury (TBI), Studies investigating the neurochemical basis for the protracted cognitive dysfunction that follows TBI have focused in part on cholinergic mechanisms. The present study compared the effects of mild and moderate cortical contusion injury (CCI) on the density of cholinergic receptor subtypes, NMDA-type glutamate receptors, and calcium channel expression. Quantitative autoradiography was used to determine the effects of CCI on receptor expression, 48 h following injury. The most robust and consistent change in receptor binding was in the density of alpha7 nicotinic receptors as determined by alpha-[I-125]-bungarotoxin (BTX) binding. Bilateral deficits in BTX binding were present following both mild and moderate levels of injury. In contrast, changes in the density of alpha3/alpha4 nAChr's, muscarinic AChr's, NMDA-type glutamate receptors, and L-type calcium channel expression were more regionally restricted and lower in magnitude, as compared to changes in BTX binding. The high calcium permeability of the alpha7 nAChr may be related to the extensive decrease in BTX binding that occurs following TBI.	Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	Pauly, JR (corresponding author), Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA.	jpauly@pop.uky.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS3122] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003122] Funding Source: NIH RePORTER		Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; BERTRAND D, 1993, P NATL ACAD SCI USA, V90, P6971, DOI 10.1073/pnas.90.15.6971; CARDENAS DD, 1994, BRAIN INJURY, V8, P579, DOI 10.3109/02699059409151010; Changeux JP, 1998, BRAIN RES REV, V26, P198, DOI 10.1016/S0165-0173(97)00040-4; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; CORTES R, 1984, J NEURAL TRANSM, V60, P169, DOI 10.1007/BF01249092; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; Delbono O, 1997, J PHARMACOL EXP THER, V280, P428; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1996, J NEUROTRAUM, V14, P615; DUNNETT SB, 1993, PROG BRAIN RES, V98, P413; ENTERS EK, 1992, BRAIN RES, V576, P271; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Jenkins LW, 1999, BRAIN RES, V817, P132, DOI 10.1016/S0006-8993(98)01237-2; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; Jones S, 1999, TRENDS NEUROSCI, V22, P555, DOI 10.1016/S0166-2236(99)01471-X; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; Leonard JR, 1997, EXP NEUROL, V143, P177, DOI 10.1006/exnr.1996.6366; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MATTSON MP, 1989, BRAIN RES, V497, P402, DOI 10.1016/0006-8993(89)90289-8; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PAULY JR, 1993, NEUROENDOCRINOLOGY, V57, P262, DOI 10.1159/000126368; PERRY DC, 1995, J PHARMACOL EXP THER, V275, P1030; Pike BR, 1997, EXP NEUROL, V147, P55, DOI 10.1006/exnr.1997.6582; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; PIKE BR, 1997, PHARM BIOCH BEHAV, V57, P1; PORTER RHP, 1994, NEUROSCI LETT, V169, P105, DOI 10.1016/0304-3940(94)90367-0; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; SAHAR A, 1966, J NEUROL NEUROSUR PS, V29, P77, DOI 10.1136/jnnp.29.1.77; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SANDS SB, 1993, BIOPHYS J, V65, P2614, DOI 10.1016/S0006-3495(93)81296-7; Sarter M, 1997, BRAIN RES REV, V23, P28, DOI 10.1016/S0165-0173(96)00009-4; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SEGUELA P, 1993, J NEUROSCI, V13, P596; Shoaib M, 1997, PSYCHOPHARMACOLOGY, V134, P121, DOI 10.1007/s002130050433; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SmithSwintosky VL, 1996, J CEREBR BLOOD F MET, V16, P585, DOI 10.1097/00004647-199607000-00008; Sparks JA, 1999, PSYCHOPHARMACOLOGY, V141, P145, DOI 10.1007/s002130050818; Taverni JP, 1998, BRAIN INJURY, V12, P77; WEAVERS AW, 1999, J ALZHEIMERS DIS, V1, P207; WHITEGBADEBO D, 1993, J NEUROTRAUM, V10, P297, DOI 10.1089/neu.1993.10.297; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x	56	28	28	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2000	17	11					1001	1011		10.1089/neu.2000.17.1001			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	374KY	WOS:000165345400001	11101204				2021-06-18	
J	Robertson, CL; Clark, RSB; Dixon, CE; Alexander, HL; Graham, SH; Wisniewski, SR; Marion, DW; Safar, PJ; Kochanek, PM				Robertson, CL; Clark, RSB; Dixon, CE; Alexander, HL; Graham, SH; Wisniewski, SR; Marion, DW; Safar, PJ; Kochanek, PM			No long-term benefit from hypothermia after severe traumatic brain injury with secondary insult in rats	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; hypothermia; hypoxemia	CONTROLLED CORTICAL IMPACT; SEVERE HEAD-INJURY; ISCHEMIC NEURONAL INJURY; CEREBRAL BLOOD-FLOW; MODERATE HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; MILD HYPOTHERMIA; HIPPOCAMPAL; RELEASE; HYPOXIA	Objectives: To evaluate the effect of application of transient, moderate hypothermia on outcome after experimental traumatic brain injury (TBI) with a secondary hypoxemic insult. Design: Prospective, randomized study. Setting: University-based animal research facility. Subjects: Male Sprague-Dawley rats. Interventions: All rats were subjected to severe TBI followed by 30 mins of moderate hypoxemia, associated with mild hypotension. Rats were randomized to three groups: a) normothermia (37 degrees C +/- 0.5 degrees C); b) immediate hypothermia (32 degrees C +/- 0.5 degrees C initiated after trauma, before hypoxemia); and c) delayed hypothermia (32 degrees C +/- 0.5 degrees C after hypoxemia), The brain temperature was controlled for 4 hrs after TBI and hypoxemia, Measurements and Main Results: Animals were evaluated after TBI for motor and cognitive performance using beam balance (days 1-5 after TBI), beam walking (days 1-5 after TBI), and Morris Water Maze (days 14-18 after TBI) assessments, On day 21 after TBI, rats were perfused with paraformaldehyde and brains were histologically evaluated for lesion volume and hippocampal neuron counts. All three groups showed marked deficits in beam balance, beam walking, and Morris Water Maze performance. However, these deficits did not differ between groups. There was no difference in lesion volume between groups. All animals had significant hippocampal neuronal loss on the side ipsilateral to injury, but this loss was similar between groups. Conclusions:ln this rat model of severe TBI with secondary insult, moderate hypothermia for 4 hrs posttrauma failed to improve motor function, cognitive function, lesion volume or hippocampal neuronal survival. Combination therapies may be necessary in this difficult setting.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Pediat, Safar Ctr Rsuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol Surg, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Publ Hlth, Safar Ctr resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA USA; Pittsburgh Vet Adm Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA	Robertson, CL (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15261 USA.		Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860			Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; KATSURADA K, 1973, SURGERY, V73, P191; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MORIKAWA E, 1991, J CEREB BLOOD FLO S2, V11, pS116; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SINHA RP, 1973, JAMA-J AM MED ASSOC, V224, P1258, DOI 10.1001/jama.224.9.1258; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Zhao WZ, 1999, J NEUROSURG, V90, P510, DOI 10.3171/jns.1999.90.3.0510	38	28	28	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2000	28	9					3218	3223		10.1097/00003246-200009000-00017			6	Critical Care Medicine	General & Internal Medicine	356RW	WOS:000089457500015	11008985				2021-06-18	
J	McColl, MA; Bickenbach, J; Johnston, J; Nishihama, S; Schumaker, M; Smith, K; Smith, M; Yealland, B				McColl, MA; Bickenbach, J; Johnston, J; Nishihama, S; Schumaker, M; Smith, K; Smith, M; Yealland, B			Spiritual issues associated with traumatic-onset disability	DISABILITY AND REHABILITATION			English	Article							HEALTH; ILLNESS; DEFINITION; PEOPLE; SELF	Purpose : The present study used a qualitative approach to discover the concepts used by people with a sudden-onset disability to express issues of spirituality. Using a cross-sectional time frame, the study sought to understand how spiritual issues were experienced at the onset of a disability from the perspective of the disabled person him or herself. The study also compared the perceptions of brain injury respondents to spinal cord injury respondents. Method: The qualitative approach was chosen to capture a detailed understanding of perceptions about spirituality, and the relationship of the disability to the disabled person's spiritual beliefs. The sample consisted of 16 individuals, all of whom had experienced a spinal cord injury or a brain injury. Results : The main findings of the study were as follows: (1) Participants recovering from a disability described spiritual issues relating to five themes which arose directly from the data (awareness, closeness, trust, purpose, vulnerability) and relating to three relationships found throughout the literature on spirituality (intrapersonal, interpersonal and transpersonal). These eight dimensions can be combined to form a matrix, which serves as a framework for considering spiritual issues associated with disability; and (2) There were differences in the spiritual concepts described by the participants with brain injury compared to those with spinal cord injury. In particular, those with brain injuries seemed to place greater emphasis on the importance of their families, and to be more aware of the need for trust in view of their memory deficits. Conclusions : These results represent one of the earliest attempts to take an empirical approach to the development of theory in the area of spirituality and disability. Building on theory developed in other populations (palliative care and ageing), the study offers a theoretical model for clinicians, educators and researchers to better understand spirituality in the context of disability.	Queens Univ, Sch Rehabil Therapy, Kingston, ON, Canada; Queens Univ, Dept Philosophy, Kingston, ON, Canada; Reg Community Brain Injury Serv, Kingston, ON, Canada; Queens Univ, Dept Theol, Kingston, ON, Canada; Queens Univ, Dept Rehabil Med, Kingston, ON, Canada	McColl, MA (corresponding author), Queens Univ, Sch Rehabil Therapy, Kingston, ON, Canada.						*BARB WIR COLL, 1997, NOT ALL VIOL; Bowers C C, 1987, Rehabil Nurs, V12, P90; CARSON V, 1988, J PSYCHOL THEOL, V16, P159; COUSINS N, 1976, NEW ENGL J MED, V295, P1458, DOI 10.1056/NEJM197612232952605; Deegan P., 1988, PSYCHOSOCIAL REHABIL, V11, P11, DOI DOI 10.1037/H0099565; ELKINS DN, 1988, J HUMANIST PSYCHOL, V28, P5, DOI 10.1177/0022167888284002; ELLISON CW, 1983, J PSYCHOL THEOL, V11, P330; Emblen J D, 1992, J Prof Nurs, V8, P41, DOI 10.1016/8755-7223(92)90116-G; FINE SB, 1991, AM J OCCUP THER, V45, P493, DOI 10.5014/ajot.45.6.493; Fitzgerald J, 1997, DISABIL REHABIL, V19, P407, DOI 10.3109/09638289709166565; Frankl VE., 1984, MANS SEARCH MEANING; HAWKS SR, 1995, AM J HEALTH PROMOT, V9, P371, DOI 10.4278/0890-1171-9.5.371; Horsburgh M, 1997, DISABIL REHABIL, V19, P398, DOI 10.3109/09638289709166564; HUNGELMANN J, 1985, J RELIG HEALTH, V24, P147, DOI 10.1007/BF01532258; JONES C, 1982, STUDY SPIRITUALITY; Lindsey E, 1996, J ADV NURS, V24, P465, DOI 10.1046/j.1365-2648.1996.02135.x; LOWREY BJ, 1985, NURS RES, V34, P82; MILLER J, 1983, COPING CHRONIC ILLNE, P287; Miller J F, 1985, J Prof Nurs, V1, P79; Narayanasamy A, 1996, Br J Nurs, V5, P411; Nekolaichuk CL, 1999, SOC SCI MED, V48, P591, DOI 10.1016/S0277-9536(98)00348-7; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; OBRIEN ME, 1982, J RELIG HEALTH, V21, P68, DOI 10.1007/BF02273896; Paloutzian R. F., 1982, LONELINESS SOURCEBOO, P224; *QSR, 1994, NUD IST APPL SOFTW P; REED PG, 1992, RES NURS HEALTH, V15, P349, DOI 10.1002/nur.4770150505; ROSS L, 1995, INT J NURS STUD, V32, P457, DOI 10.1016/0020-7489(95)00007-K; SCHMIDT ND, 1998, QUALITY, V1, P1; Selway D, 1998, DISABIL SOC, V13, P429, DOI 10.1080/09687599826722; SMITH DW, 1995, NURS SCI QUART, V8, P133, DOI 10.1177/089431849500800309; SOEKEN KL, 1987, NURS CLIN N AM, V22, P603; WESTBROOK MT, 1982, SOC SCI MED, V16, P899, DOI 10.1016/0277-9536(82)90209-X; Young E W, 1984, J Am Coll Health, V32, P273	33	28	28	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	AUG	2000	22	12					555	564		10.1080/096382800416805			10	Rehabilitation	Rehabilitation	352QC	WOS:000089228500004	11005745				2021-06-18	
J	DiCarlo, MA; Gfeller, JD; Oliveri, MV				DiCarlo, MA; Gfeller, JD; Oliveri, MV			Effects of coaching on detecting feigned cognitive impairment with the Category Test	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						malingering; coaching strategies; category test	NEUROPSYCHOLOGICAL IMPAIRMENT; BELIEVABLE DEFICITS; HEAD-INJURY; INTELLIGENCE; VALIDITY; BATTERY; FAKING	In a replication and extension of previous research (Tenhula & Sweet, 1996), the current study investigated the utility of the Category Test (CT) for detecting feigned cognitive impairment. Ninety-two undergraduate participants were randomly assigned to one of three groups and administered the CT. A Coached Simulator group was instructed to simulate cognitive impairment and was provided lest-taking strategies to avoid detection. An Uncoached Simulator group was simply insmrcred to feign impairment. A control group was instructed to perform optimally. In addition, the CT results of 30 traumatic brain injury (TBI) patients were analyzed. The results largely supported the utility of five CT malingering indicators identified by TenhrLla and Sweet: (a) number of errors on subtests I and II, (6) number of errors errors on subtest VII, (c) total CT errors, (d) number of errors on 19 "easy" items, and (e) number of criteria exceeded. Correct Classification rates of the five indicators for Uncoached Simulators and optimal performance controls ranged from 87% to 98%. Correct Classification rates for the TBI patients ranged from 70% to 100%. In addition, significantly more Coached Simulators were misclassified as nonsimulators on four of the CT malingering indicators, relative to their Uncoached counterparts. A decision rule of > I error on subtests I and II was consistently the most accurate malingering indicator, regardless of degree of coaching or presence of TBI. This indicator correctly classified 76% of all simulators and 100% of the optimal performance controls and TBI patients. Implications of providing persons with test-taking strategies and the utility of these CT malingering indicators for various populations are discussed. (C) 2000 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	St Louis Univ, St Louis, MO 63103 USA; St Johns Mercy Med Ctr, St Louis, MO 63141 USA	DiCarlo, MA (corresponding author), Roger Williams Med Ctr, Dept Psychiat, 825 Chalkstone Blvd, Providence, RI 02908 USA.						BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Bernard L C, 1991, Arch Clin Neuropsychol, V6, P81, DOI 10.1016/0887-6177(91)90024-4; BOLTER JF, 1985, ANN M NAT AC NEUR PH; Brandt J., 1985, ANN NY ACAD SCI, V44, P502; CULLUM CM, 1984, INT J CLIN NEUROPSYC, V6, P172; DeFilippis NA, 1979, BOOKLET CATEGORY TES; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FRANZEN M D, 1990, Neuropsychology Review, V1, P247, DOI 10.1007/BF01112573; Frederick R. I., 1991, PSYCHOL ASSESSMENT J, V3, P596, DOI DOI 10.1037/1040-3590.3.4.596; Gfeller JD, 1998, J CLIN PSYCHOL, V54, P431, DOI 10.1002/(SICI)1097-4679(199806)54:4<431::AID-JCLP5>3.0.CO;2-Q; GOEBEL RA, 1983, J CLIN PSYCHOL, V39, P731, DOI 10.1002/1097-4679(198309)39:5<731::AID-JCLP2270390515>3.0.CO;2-T; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; IVERSON GL, 1994, SPECIFICITY CATEGORY; Johnstone B, 1997, PSYCHOL ASSESSMENT, V9, P28, DOI 10.1037/1040-3590.9.1.28; Laatsch L., 1991, PSYCHOL ASSESSMENT J, V3, P701; Lamb DG, 1994, PSYCHOL ASSESSMENT, V6, P8; LeesHaley PR, 1997, ASSESSMENT, V4, P321, DOI 10.1177/107319119700400402; LEZAK MD, 1995, NEUROPSYCHOL ASSESSM; MARTIN RC, 1991, ANN M NAT AC NEUR DA; Miller W., 1992, PHYSICAL MED REHABIL, V6, P547; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P271, DOI 10.1016/0887-6177(95)00040-2; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; PERRINE K, 1993, J CLIN EXP NEUROPSYC, V15, P461, DOI 10.1080/01688639308402571; Reitan R.M., 1993, HALSTEADREITAN NEURO; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; ROGERS R, 1983, J PSYCHIAT LAW, V11, P443; Rose FE, 1998, ARCH CLIN NEUROPSYCH, V13, P349, DOI 10.1016/S0887-6177(97)00025-5; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WETTER MW, 1995, PROF PSYCHOL-RES PR, V26, P474, DOI 10.1037/0735-7028.26.5.474; WIGGINS EC, 1988, LAW HUMAN BEHAV, V12, P57, DOI 10.1007/BF01064274	36	28	28	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUL	2000	15	5					399	413		10.1016/S0887-6177(99)00031-1			15	Psychology, Clinical; Psychology	Psychology	336XV	WOS:000088329000006	14590216	Bronze			2021-06-18	
J	O'Connell, MJ				O'Connell, MJ			Prediction of return to work following traumatic brain injury: Intellectual, memory, and demographic variables	REHABILITATION PSYCHOLOGY			English	Article							HEAD-INJURY; REHABILITATION	Objective: To identify predictors of return to work for individuals with traumatic brain injury (TBI). Study Design: Data gathered from a retrospective chart review that included predictor variables (demographic, intellectual, and memory) and an outcome variable (employment status I year postprogram) were entered into a logistical regression analysis. Setting: A Commission for Accreditation of Rehabilitation Facilities-accredited outpatient brain injury program. Participants: Forty-three adults with TBI who completed the brain injury program. Main Outcome Measurer Employment status at I-year follow-up. Results: Individuals with higher scores on measures of Performance IQ and Verbal Memory were more likely to return to work. Conclusions: When the effects of many demographic variables are controlled for intelligence and memory variables can provide valuable information to patients, families, and service providers (e.g., rehabilitation centers) with regard to returning to work after TBI.	Sinai Rehabil Ctr, Baltimore, MD 21215 USA	O'Connell, MJ (corresponding author), Sinai Rehabil Ctr, 2401 W Belvedere Ave, Baltimore, MD 21215 USA.						BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th	9	28	28	0	2	SPRINGER PUBL CO	NEW YORK	536 BROADWAY, NEW YORK, NY 10010-3955 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2000	45	2					212	217		10.1037/0090-5550.45.2.212			6	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	315PT	WOS:000087122700008					2021-06-18	
J	Togher, L				Togher, L			Giving information: The importance of context on communicative opportunity for people with traumatic brain injury	APHASIOLOGY			English	Article							HEAD-INJURY; DISCOURSE; ADULTS; CONVERSATION; POPULATION; LANGUAGE; PARTNERS	This study is one of a series investigating everyday communication skills of people with traumatic brain injury (TBI) using communication partners other than speech pathologists or research assistants. The first of these studies examined telephone conversations where subjects were asked to request specific information during telephone interactions with a range of communication partners. Results indicated that people with TBI were disadvantaged in some of their interactions on the telephone with community agencies and family members during information-seeking interactions, when compared with matched controls. TBI subjects were given less information than matched controls and were also asked for less information. For example, therapists never asked TBI subjects questions to which they didn't already know the answer. This was in contrast to the control interactions, where subjects were asked for novel information. In the current study seven subjects with TBI were compared with seven matched control subjects across two conditions: a community education information-giving session with two schoolboys, and an information-requesting interaction with the researcher. Exchange structure analysis showed that when placed in an information-giving role, TBI subjects gave similar amounts of information as control subjects. TBI subjects used joke telling as an information-giving device, serving a number of communicative functions, which are discussed. There was no significant difference in the amount of information requested or given by TBI and control subjects in the researcher condition; however there were significant qualitative differences in the nature of the requesting. It has been previously emphasized that people with TBI should be evaluated with a number of interlocutors as part of a thorough communication needs assessment (Hartley 1995). Merely varying the interlocutor is not sufficient, however, as the goal of the interaction and the primary speaking roles of participants are also important, and will determine the language choices available to both speakers. Exchange structure analysis is a useful way to delineate these language choices, as it is interpreted in light of the genre of the interaction and the tenor and communicative purpose of the participants.	Univ Sydney, Sch Commun Sci & Disorders, Lidcome, NSW 2141, Australia	Togher, L (corresponding author), Univ Sydney, Sch Commun Sci & Disorders, POB 170, Lidcome, NSW 2141, Australia.		Togher, Leanne/AAC-7083-2019	Togher, Leanne/0000-0002-4518-6748			Adamovich B. B., 1992, SCALES COGNITIVE ABI; ALTZ D., 1982, LANGUAGE SOCIAL IDEN, P196; Bateson G., 1973, STEPS ECOLOGY MIND; Berry M., 1981, STUDIES DISCOURSE AN, P120; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Braun C M, 1989, Brain Inj, V3, P345, DOI 10.3109/02699058909004559; CASHION JL, 1987, J LANGUAGE SOCIAL PS, V5, P303; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; EDELSKY C, 1981, LANG SOC, V10, P383, DOI 10.1017/S004740450000885X; EGGINS S, 1990, THESIS U SYDNEY SYDN; Eggins S., 1997, ANAL CASUAL CONVERSA; Ehrlich J, 1989, Brain Inj, V3, P193, DOI 10.3109/02699058909004552; EHRLICH J, 1985, COGNITIVE REHABILITA, P32; Fairclough N., 1992, DISCOURSE SOCIAL CHA; FISHMAN PM, 1978, LANGUAGE GENDER SOC, P89; Giles G M, 1988, Brain Inj, V2, P75, DOI 10.3109/02699058809150933; GILES H, 1976, HUMOUR LAUGHTER THEO, P75; Glosser G., 1990, BRAIN LANG, V40, P67; Halliday M., 1994, INTRO FUNCTIONAL GRA, V3rd; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Hartley L. L., 1995, COGNITIVE COMMUNICAT; Holmes Janet, 1995, WOMEN MEN POLITENESS; Jefferson Gail, 1987, TALK SOCIAL ORG, P152; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; MALIA K, 1995, BRAIN INJURY, V9, P697, DOI 10.3109/02699059509008226; Martin J. R., 1992, ENGLISH TEXT SYSTEM; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; McTear M., 1991, MISCOMMUNICATION PRO, P195; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; MULKAY M, 1988, HUMOUR; Norrick Neal R, 1993, CONVERSATIONAL JOKIN; PARSONS CL, 1989, AUSTR J HUMAN COMMUN, V17, P37; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/pms.1991.73.3f.1139; Poynton C., 1985, LANGUAGE GENDER MAKI; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SACKS H, 1974, LANGUAGE, V50, P696, DOI 10.2307/412243; SCHLOSS PJ, 1985, APPL RES MENT RETARD, V6, P269, DOI 10.1016/0270-3092(85)90001-3; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1999, APHASIOLOGY, V13, P709, DOI 10.1080/026870399401821; Togher L, 1998, APHASIOLOGY, V12, P755, DOI 10.1080/02687039808249571; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; Togher L, 1996, DISABIL REHABIL, V18, P559, DOI 10.3109/09638289609166317; VENTOLA E, 1987, STRUCTURAL SOCIAL IN; WEST C, 1984, DISCOURSE PROCESS, V7, P107, DOI 10.1080/01638538409544586	48	28	31	0	7	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0268-7038			APHASIOLOGY	Aphasiology	APR	2000	14	4					365	390		10.1080/026870300401414			26	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	315AV	WOS:000087091200003					2021-06-18	
J	Mathew, BP; Dewitt, DS; Bryan, RM; Bukoski, RD; Prough, DS				Mathew, BP; Dewitt, DS; Bryan, RM; Bukoski, RD; Prough, DS			Traumatic brain injury reduces myogenic responses in pressurized rodent middle cerebral arteries	JOURNAL OF NEUROTRAUMA			English	Article						autoregulation; cerebral arteries; myogenic response; traumatic brain injury	FLUID PERCUSSION INJURY; BLOOD-FLOW; AUTO-REGULATION; HEAD-INJURY; ENDOGENOUS OPIOIDS; RAT; AUTOREGULATION; CATS; ENDOTHELIUM; ABNORMALITIES	Traumatic brain injury (TBI) reduces cerebral vascular pressure autoregulation in experimental animals and in patients. In order to understand better the mechanisms of impaired autoregulation, we measured myogenic responses to changes in intraluminal pressure in vitro in pressurized, rodent middle cerebral arteries (MCAs) harvested after TBI. In an approved study, male Sprague-Dawrey rats (275-400 g) were anesthetized, intubated, ventilated with 2.0% isoflurane in O-2/air, and prepared for fluid percussion TBI. The isoflurane concentration was reduced to 1.5%, and rats (n = 6 per group) were randomly assigned to receive sham TBI followed by decapitation 5 or 30 min later or moderate TBI (2.0 atm) followed by decapitation 5 or 30 min later. After decapitation, MCA segments were removed, mounted on an arteriograph, and pressurized. MCA diameters were measured as transmural pressure was sequentially reduced. MCA diameters remained constant or increased in the sham groups as intraluminal pressure was reduced from 100 to 40 mm Hg. In both TBI groups, diameter decreased with each reduction in pressure. In summary, MCAs removed from uninjured, isoflurane-anesthetized rats had normal vasodilatory responses to decreased intraluminal pressure. In contrast, after TBI, myogenic vasodilatory responses were significantly reduced within 5 min of TBI and the impaired myogenic responses persisted for at least 30 min after TBI.	Univ Texas, Med Branch, Dept Anesthesiol, Charles R Allen Res Labs, Galveston, TX 77555 USA; Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Internal Med, Sect Hypertens & Vasc Res, Galveston, TX 77550 USA	Dewitt, DS (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, Charles R Allen Res Labs, 610 Texas Ave, Galveston, TX 77555 USA.		Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019355] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS19355, NS27618] Funding Source: Medline		ARMSTEAD WM, 1994, BRAIN RES, V660, P19, DOI 10.1016/0006-8993(94)90834-6; Bayliss WM, 1902, J PHYSIOL-LONDON, V28, P220; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BRANSTON NM, 1995, CEREBROVAS BRAIN MET, V7, P339; Bryan RM, 1996, ANESTHESIOLOGY, V85, P82, DOI 10.1097/00000542-199607000-00012; Bukoski RD, 1997, AM J PHYSIOL-HEART C, V272, pH1406; BURNSTOCK G, 1994, BRIT J PLAST SURG, V47, P527, DOI 10.1016/0007-1226(94)90136-8; BUSIJA DW, 1993, REGULATION CEREBRAL, P46; DAVIS MJ, 1993, AM J PHYSIOL, V264, pH2168; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS E F, 1989, Journal of Neurotrauma, V6, P31, DOI 10.1089/neu.1989.6.31; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FABIAN RH, 1995, J CEREBR BLOOD F MET, V15, P242, DOI 10.1038/jcbfm.1995.30; Fabian RH, 1998, J NEUROTRAUM, V15, P433, DOI 10.1089/neu.1998.15.433; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fog M, 1937, ARCH NEURO PSYCHIATR, V37, P351, DOI 10.1001/archneurpsyc.1937.02260140137007; Golding EM, 1998, J NEUROTRAUM, V15, P635, DOI 10.1089/neu.1998.15.635; Golding EM, 1998, BRAIN RES, V785, P293, DOI 10.1016/S0006-8993(97)01419-4; HARPER SL, 1984, AM J PHYSIOL, V246, pH17; HONG KW, 1994, AM J PHYSIOL, V266, pH11; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Knot HJ, 1998, J PHYSIOL-LONDON, V508, P199, DOI 10.1111/j.1469-7793.1998.199br.x; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KONTOS HA, 1978, AM J PHYSIOL, V234, P371; LASSEN NA, 1959, PHYSIOL REV, V39, P183; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MCCARRON JG, 1989, BLOOD VESSELS, V26, P315; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MEININGER GA, 1992, AM J PHYSIOL, V263, pH647; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; Nelson MT, 1997, J PHYSIOL-LONDON, V502, P259, DOI 10.1111/j.1469-7793.1997.259bk.x; OSOL G, 1989, J HYPERTENS, V7, pS67; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Roy C S, 1890, J Physiol, V11, P85; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95	44	28	28	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1999	16	12					1177	1186		10.1089/neu.1999.16.1177			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	266WC	WOS:000084322400005	10619196				2021-06-18	
J	Guerit, JM				Guerit, JM			EEG and evoked potentials in the intensive care unit	NEUROPHYSIOLOGIE CLINIQUE-CLINICAL NEUROPHYSIOLOGY			English	Article						brain anoxia; brain death; coma; electroencephalogram; evoked potentials; head trauma; intensive care medicine; neuromonitoring	AUDITORY BRAIN-STEM; LOCKED-IN-SYNDROME; SEVERE HEAD-INJURY; EVENT-RELATED POTENTIALS; POST-TRAUMATIC COMA; EARLY PREDICTION; MIDDLE-LATENCY; SUBARACHNOID HEMORRHAGE; PROGNOSTIC VALUE; CONDUCTION TIME	We review the principal aspects of EEG and evoked potential (EP) neuromonitoring in the intensive care unit. The electrophysiological methods allow functional assessment of comatose patients and can be used (a) as a help to diagnose the origin of coma, (b) as a means to predict outcome, and (c) for monitoring purposes. The combination of the EEG and long-, middle-, and short-latency EPs allows widespread assessment of the cerebral cortex, the brain-stem, and the spinal cord. The EEG and the EP interpretation first requires taking into account non-neurological factors that may interfere with the recorded activities (sensory pathologies, toxic or metabolic problems, body temperature). The sensitivity and the specificity of any neurophysiological technique depend on the etiology of coma. Anoxic comas are associated with a predominantly cortical involvement, while the cortical and brain-stem functions are to be taken into account to interpret the EEG and the EPs in head trauma. The EEG and the EPs can be used to differentiate the comas due to structural lesions from those of metabolic origin, to confirm brain death and help to diagnose psychogenic unresponsiveness or a de-efferented state. While the prognostic value of the EEG is markedly hampered by the widespread use of sedative drugs, it has been possible to design efficient systems based on early- and middle-latency multimodality evoked potentials in anoxic and traumatic comas and, more generally, in all comas associated with an increase of the intracranial pressure. Continuous neuromonitoring techniques are currently under development. They have already been proven useful for the early detection and for the prevention of subclinical seizures, transtentorial herniation, vasospasm, and other causes of brain or spinal-cord ischemia. (C) 1999 Editions scientifiques et medicales Elsevier SAS.	Catholic Univ Louvain, Clin Neurophysiol Unit, B-1200 Brussels, Belgium	Guerit, JM (corresponding author), Catholic Univ Louvain, Clin Neurophysiol Unit, B-1200 Brussels, Belgium.						ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; *AM EL SOC, 1994, J CLIN NEUROPHYSIOL, V11, P10; [Anonymous], 1987, PEDIATRICS, V80, P298; AUSTIN EJ, 1988, NEUROLOGY, V38, P773, DOI 10.1212/WNL.38.5.773; Bassetti C, 1996, J NEUROL NEUROSUR PS, V61, P610, DOI 10.1136/jnnp.61.6.610; BASSETTI C, 1994, J NEUROL NEUROSUR PS, V57, P1403, DOI 10.1136/jnnp.57.11.1403; BECA J, 1995, J PEDIATR-US, V126, P44, DOI 10.1016/S0022-3476(95)70498-1; BINNIE CD, 1970, BMJ-BRIT MED J, V4, P265, DOI 10.1136/bmj.4.5730.265; BLANCAFORT JB, 1995, CHILD NERV SYST, V11, P400, DOI 10.1007/BF00717405; Brierley JB, 1984, GREENFIELDS NEUROPAT, P125; BRUNKO E, 1987, ELECTROEN CLIN NEURO, V66, P15, DOI 10.1016/0013-4694(87)90133-7; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Chatrian GE, 1996, ELECTROEN CLIN NEURO, V99, P103, DOI 10.1016/0013-4694(96)96059-9; Chen R, 1996, CRIT CARE MED, V24, P672, DOI 10.1097/00003246-199604000-00020; CHOKROVERTY S, 1975, NEUROLOGY, V25, P655, DOI 10.1212/WNL.25.7.655; Clinique Bdlsdn, 1989, NEUROPHYSIOL CLIN, V19, P339; COSELLI JS, 1988, ANN THORAC SURG, V45, P638, DOI 10.1016/S0003-4975(10)64766-2; FACCO E, 1985, ELECTROEN CLIN NEURO, V62, P332, DOI 10.1016/0168-5597(85)90041-3; Facco E., 1993, Neurophysiologie Clinique, V23, P237, DOI 10.1016/S0987-7053(05)80233-3; FACCO E, 1989, ELECTROEN CLIN NEURO, V73, P552, DOI 10.1016/0013-4694(89)90265-4; FERBERT A, 1988, ELECTROEN CLIN NEURO, V69, P136, DOI 10.1016/0013-4694(88)90209-X; FIRSCHING R, 1994, NEUROL RES, V16, P18; FISCHER C, 1994, NEUROSURGERY, V35, P45, DOI 10.1227/00006123-199407000-00007; GARCIALARREA L, 1988, NEUROLOGY, V38, P1487, DOI 10.1212/WNL.38.9.1487; GOLDIE WD, 1981, NEUROLOGY, V31, P248, DOI 10.1212/WNL.31.3.248; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; Guerit J. M., 1993, Neurophysiologie Clinique, V23, P209, DOI 10.1016/S0987-7053(05)80231-X; Guerit J M, 1992, Eur J Med, V1, P233; GUERIT JM, 1990, ELECTROEN CLIN NEURO, V77, P163, DOI 10.1016/0168-5597(90)90034-B; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; Guerit JM, 1998, ELECTROEN CLIN NEURO, V106, P1, DOI 10.1016/S0013-4694(97)00077-1; GUERIT JM, 1994, ACTA NEUROL BELG, V94, P174; GUERIT JM, 1998, POTENTIELS EVOQUES; GUTLING E, 1995, NEUROLOGY, V45, P915, DOI 10.1212/WNL.45.5.915; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; *INT FED SOC EL CL, 1983, REC PRACT CLIN NEUR, P66; JORDAN KG, 1995, NEUROL CLIN, V13, P579, DOI 10.1016/S0733-8619(18)30035-5; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; KARNAZE DS, 1985, NEUROLOGY, V35, P1122, DOI 10.1212/WNL.35.8.1122; KULLMANN F, 1995, J HEPATOL, V22, P101, DOI 10.1016/0168-8278(95)80267-3; Landi A, 1994, J Neurosurg Sci, V38, P123; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; Machado C, 1993, J Neurosurg Sci, V37, P125; Madl C, 1996, ARCH NEUROL-CHICAGO, V53, P512, DOI 10.1001/archneur.1996.00550060054017; MADL C, 1993, LANCET, V341, P855, DOI 10.1016/0140-6736(93)93061-5; MARKAND ON, 1984, ELECTROEN CLIN NEURO, V59, P432, DOI 10.1016/0168-5597(84)90002-9; MAUGUIERE F, 1983, BRAIN, V106, P271, DOI 10.1093/brain/106.2.271; Michel C, 1998, NEUROPHYSIOL CLIN, V28, P343, DOI 10.1016/S0987-7053(98)80005-1; Misra UK, 1996, J NEUROL, V243, P96; Mutschler V, 1996, NEUROPHYSIOL CLIN, V26, P158, DOI 10.1016/0987-7053(96)89626-2; NAGAO S, 1979, J NEUROSURG, V51, P846, DOI 10.3171/jns.1979.51.6.0846; NEWLON PG, 1982, J NEUROSURG, V57, P168, DOI 10.3171/jns.1982.57.2.0168; NIEDERMEYER E, 1996, ELECTROENCEPHALOGRAP; Nuwer M R, 1994, Neurosurg Clin N Am, V5, P647; Onofrj M, 1997, J NEUROL NEUROSUR PS, V63, P759, DOI 10.1136/jnnp.63.6.759; Onofrj M, 1996, COGNITIVE BRAIN RES, V4, P95; OTTAVIANI F, 1986, ELECTROEN CLIN NEURO, V65, P196, DOI 10.1016/0168-5597(86)90054-7; PFURTSCHELLER G, 1987, J CLIN NEUROPHYSIOL, V4, P389, DOI 10.1097/00004691-198710000-00004; PohlmannEden B, 1997, INTENS CARE MED, V23, P301, DOI 10.1007/s001340050332; RAEGRANT AD, 1991, ELECTROEN CLIN NEURO, V79, P349, DOI 10.1016/0013-4694(91)90199-E; ROSENBERG C, 1984, ARCH NEUROL-CHICAGO, V41, P835, DOI 10.1001/archneur.1984.04050190041012; ROTHSTEIN TL, 1991, ELECTROEN CLIN NEURO, V79, P101, DOI 10.1016/0013-4694(91)90046-7; RUMPL E, 1979, ELECTROEN CLIN NEURO, V46, P487, DOI 10.1016/0013-4694(79)90002-6; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P583, DOI 10.1016/0013-4694(83)90026-3; SANDRONI C, 1995, EUR J EMERG MED, V2, P3; SOHMER H, 1986, ELECTROEN CLIN NEURO, V64, P334, DOI 10.1016/0013-4694(86)90157-4; SORENSEN K, 1978, J NEUROL NEUROSUR PS, V41, P840, DOI 10.1136/jnnp.41.9.840; STOCKARD JJ, 1978, ANN NEUROL, V3, P368, DOI 10.1002/ana.410030416; STONE JL, 1988, J CLIN NEUROPHYSIOL, V5, P135, DOI 10.1097/00004691-198804000-00002; SYNEK VM, 1988, J CLIN NEUROPHYSIOL, V5, P161, DOI 10.1097/00004691-198804000-00003; TOWLE VL, 1989, ELECTROEN CLIN NEURO, V73, P419, DOI 10.1016/0013-4694(89)90091-6; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; VIGNAENDRA V, 1974, NEUROLOGY, V24, P582, DOI 10.1212/WNL.24.6.582; Wagner W, 1996, BRAIN, V119, P1507, DOI 10.1093/brain/119.5.1507; WALSER H, 1985, ARCH NEUROL-CHICAGO, V42, P32, DOI 10.1001/archneur.1985.04060010038013; WESTMORELAND BF, 1975, ARCH NEUROL-CHICAGO, V32, P713, DOI 10.1001/archneur.1975.00490530035001; YORK DH, 1981, J NEUROSURG, V55, P909, DOI 10.3171/jns.1981.55.6.0909; YOUNG GB, 1994, ELECTROEN CLIN NEURO, V91, P93, DOI 10.1016/0013-4694(94)90030-2; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8	81	28	30	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0987-7053	1769-7131		NEUROPHYSIOL CLIN	Neurophysiol. Clin.-Clin. Neurophysiol.	SEP	1999	29	4					301	317		10.1016/S0987-7053(99)90044-8			17	Clinical Neurology; Neurosciences; Physiology	Neurosciences & Neurology; Physiology	248QD	WOS:000083286100002	10546249				2021-06-18	
J	Blackmer, J; Marshall, SC				Blackmer, J; Marshall, SC			A comparison of traumatic brain injury in the Saskatchewan native North American and non-native North American populations	BRAIN INJURY			English	Article							INDIAN POPULATION; DIABETES-MELLITUS; ALASKA NATIVES; ALCOHOL-ABUSE; PREVALENCE; TRENDS; MORTALITY; QUEBEC	Objective: To compare native North American and non-native North American patients admitted for inpatient rehabilitation following traumatic brain injury in order to identify pertinent differences between the two groups with regards to the initial injury, medical management and allocated resources. Design: A retrospective chart review was performed on all patients admitted to the unit between July 1994 and March 1997 with the diagnosis of traumatic brain injury. Results: Significant differences were found between the two groups in the areas of alcohol and drug involvement with the initial injury (p < 0.0001), geographical location of the injury (p < 0.0001), initial treatment received (p = 0.0102), discharge planning (p < 0.0001), and post-discharge followup (p = 0.0052). Conclusions: The results indicate that native North Americans are more likely to suffer a head injury than non-native North Americans, that alcohol is more likely to be involved, and that native North American patients are less likely to be offered post-discharge resources. Further prospective study to explore these areas is required.	Saskatoon City Hosp, Dept Phys Med & Rehabil, Saskatoon, SK S7K 0M7, Canada; Rehabil Ctr, Ottawa, ON, Canada	Blackmer, J (corresponding author), Saskatoon City Hosp, Dept Phys Med & Rehabil, 701 Queen St, Saskatoon, SK S7K 0M7, Canada.	blackmer@duke.usask.ca					Beauvais F, 1996, AM J PUBLIC HEALTH, V86, P1594, DOI 10.2105/AJPH.86.11.1594; BOYD DL, 1968, ARCH ENVIRON HEALTH, V17, P101, DOI 10.1080/00039896.1968.10665197; BRASSARD P, 1993, CAN MED ASSOC J, V149, P303; CamposOutcalt D, 1997, AM J PUBLIC HEALTH, V87, P282, DOI 10.2105/AJPH.87.2.282; CONWAY GA, 1992, J ACQ IMMUN DEF SYND, V5, P803; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; DELISLE HF, 1993, CAN MED ASSOC J, V148, P41; ERSTAD JL, 1994, IHS PROVIDER, V19, P9; FRASERLEE NJ, 1994, CAN J PUBLIC HEALTH, V85, P197; Gilliland FD, 1995, ALCOHOL CLIN EXP RES, V19, P1572, DOI 10.1111/j.1530-0277.1995.tb01026.x; HISNANICK JJ, 1993, AM J DRUG ALCOHOL AB, V19, P387, DOI 10.3109/00952999309001628; Kraus JF, 1993, HEAD INJURY, P1; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MAY PA, 1988, SURG GEN WORKSH DRUN; Oken E, 1995, AM J PREV MED, V11, P375; RHOADES ER, 1988, PUBLIC HEALTH REP, V103, P621; Sievers ML, 1996, DIABETES CARE, V19, P107, DOI 10.2337/diacare.19.2.107; Soderstrom CA, 1997, JAMA-J AM MED ASSOC, V277, P1769, DOI 10.1001/jama.277.22.1769; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; *SPSS INC, 1989, SPSS WIND REL 6 1; *STAT CAN, 1997, 1991 CENS POP; Sugarman JR, 1996, PUBLIC HEALTH REP, V111, P321; TEASDALE G, 1974, LANCET, V2, P81; TRACKS JGG, 1973, SOC WORK, V18, P30; *UB FDN ARCH INC, 1993, GUID UN DAT SET MED; Walker RD, 1996, AM INDIAN ALASKA NAT, V7, P1; Wall TL, 1996, ALCOHOL CLIN EXP RES, V20, P1159, DOI 10.1111/j.1530-0277.1996.tb01105.x; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P186; Whyte J, 1993, REHABILITATION MED P, P825; WILLS TE, 1969, PINE RIDGE RES B, V8, P49; YOUNG TK, 1991, PREV MED, V20, P474, DOI 10.1016/0091-7435(91)90045-6	31	28	28	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	1999	13	8					627	635					9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	239YW	WOS:000082799200006	10901690				2021-06-18	
J	Lew, HL; Slimp, J; Price, R; Massagli, TL; Robinson, LR				Lew, HL; Slimp, J; Price, R; Massagli, TL; Robinson, LR			Comparison of speech-evoked v tone-evoked P300 response - Implications for predicting outcomes in patients with traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article; Proceedings Paper	Annual Meeting of the Association-of-Academic-Physiatrists	FEB 19-20, 1998	SAN ANTONIO, TEXAS	Assoc Acad Physiatrists		brain injury; auditory event-related potentials; P300; evoked potentials; coma; awakening	EVENT-RELATED POTENTIALS; INITIAL-VALUE; COMA; RECOVERY; LATENCY; LAW	The P300 response is a cognitive event-related potential recorded over the scalp. The tone-evoked P300 response has been used to predict outcomes of patients with brain injury. However, it may lead to false predictions because some normal people have a very small tone-evoked P300 response. It is hypothesized that speech may generate a more robust P300 response than tones. A voice-generator prototype was designed for this study. The rare speech signal was the word "mommy" in a female voice. The common signal was a 1000-Hz tone. Twenty-two normal adults (11 males, 11 females; age range, 18-60 yr) were tested for both speech-evoked and tone-evoked P300 responses. Speech-evoked P300 responses had significantly larger amplitudes (mean, 12.1 mu V) than the tone-evoked responses (mean, 5.9 mu V P < 0.0001). Six subjects with brain injury were also tested using the same protocol: two subjects with severe brain injury showed no response to either stimulus. Both died within 1 wk after the testing. Although two subjects with moderate brain injury could not complete the testing because of agitated behavior, two other subjects with mild traumatic brain injury showed a larger speech-evoked than tone-evoked P300 response. The speech-evoked P300 response may be promising in predicting outcomes of patients with brain injury.	Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA	Lew, HL (corresponding author), Univ Washington, Sch Med, Dept Rehabil Med, Box 356490,1959 NE Pacific St, Seattle, WA 98195 USA.		Robinson, Lawrence/D-8455-2013	Robinson, Lawrence/0000-0002-9590-8745			AHMED I, 1988, CLIN ELECTROENCEPHAL, V19, P78, DOI 10.1177/155005948801900209; DANZE F, 1989, Neurosurgical Review, V12, P477, DOI 10.1007/BF01790694; Fowler B, 1997, BIOL PSYCHOL, V46, P113, DOI 10.1016/S0301-0511(97)05253-8; JENNETT B, 1975, LANCET, V7905, P480; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KUGLER CFA, 1993, GERONTOLOGY, V39, P280; Lew H, 1997, J Am Acad Audiol, V8, P104; NISHIMURA N, 1995, PSYCHIAT CLIN NEUROS, V49, P79, DOI 10.1111/j.1440-1819.1995.tb01863.x; OMAHONY D, 1990, LANCET, V336, P1265, DOI 10.1016/0140-6736(90)92887-N; PAPANICOLAOU AC, 1986, NEUROSURGERY, V18, P173, DOI 10.1227/00006123-198602000-00009; PFURTSCHELLER G, 1985, ELECTROEN CLIN NEURO, V62, P88, DOI 10.1016/0168-5597(85)90020-6; POLICH J, 1989, ELECTROEN CLIN NEURO, V74, P312, DOI 10.1016/0168-5597(89)90061-0; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; TAKESHITA S, 1994, INT J PSYCHOPHYSIOL, V16, P99, DOI 10.1016/0167-8760(94)90046-9; WAYMAN JW, 1992, J ACOUST SOC AM, V91, P3527, DOI 10.1121/1.402841; YINGLING CD, 1990, LANCET, V336, P873, DOI 10.1016/0140-6736(90)92372-O; ZENTNER J, 1992, NEUROSURGERY, V31, P429, DOI 10.1227/00006123-199209000-00007	18	28	33	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL-AUG	1999	78	4					367	371		10.1097/00002060-199907000-00014			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	216AP	WOS:000081418600012	10418844				2021-06-18	
J	Shao, LF; Ciallella, JR; Yan, HQ; Ma, XC; Wolfson, BM; Marion, DW; Dekosky, ST; Dixon, CE				Shao, LF; Ciallella, JR; Yan, HQ; Ma, XC; Wolfson, BM; Marion, DW; Dekosky, ST; Dixon, CE			Differential effects of traumatic brain injury on vesicular acetylcholine transporter and M-2 muscarinic receptor mRNA and protein in rat	JOURNAL OF NEUROTRAUMA			English	Article						cholinergic; cortical impact; M-2; muscarinic; rat; vesicular acetylcholine transporter (VAChT)	CONTROLLED CORTICAL IMPACT; CHOLINE-ACETYLTRANSFERASE ACTIVITY; NEUTROPHIL ACCUMULATION; TEMPORAL CORTEX; HEAD-INJURY; GENE LOCUS; EXPRESSION; HIPPOCAMPAL; DEFICITS; RELEASE	Experimental traumatic brain injury (TBI) produces cholinergic neurotransmission deficits that may contribute to chronic spatial memory deficits. Cholinergic neurotransmission deficits may result from presynaptic alterations in the storage and release of acetylcholine (ACh) or from changes in the receptors for ACh. The vesicular ACh transporter (VAChT) mediates accumulation of ACh into secretory vesicles, and the M-2 muscarinic receptor subtype can modulate cholinergic neurotransmission via a presynaptic inhibitory feedback mechanism. We examined the effects of controlled cortical impact (CCI) injury on hippocampal VAChT and M-2 muscarinic receptor subtype protein and medial septal mRNA levels at 4 weeks following injury. Rats were anesthetized and surgically prepared for CCI injury (4 m/sec, 2.5 to 2.9 mm in depth) and sham surgery. Animals were sacrificed, and coronal sections (35 mu m thick) were cut through the dorsal hippocampus for VAChT and M-2 immunohistochemistry. Semiquantitative measurements of VAChT and M-2 protein in hippocampal homogenates from injured and sham rats were assessed with Western blot analysis. Changes in VAChT and M-2 mRNA levels were evaluated by reverse transcriptase polymerase chain reaction (RT-PCR). At 4 weeks after injury, both immunohistochemical and Western blot methods demonstrated an increase in hippocampal VAChT protein. An increase in VAChT mRNA was also observed. Immunohistochemistry demonstrated a loss of M-2; however, there was no significant change in M-2 mRNA levels in comparison with sham controls. These changes may represent a compensatory response of cholinergic neurons to increase the efficiency of ACh neurotransmission chronically after TBI through differential transcriptional regulation.	Univ Pittsburgh, Med Ctr, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Med Ctr, Dept Psychiat & Neurol, Pittsburgh, PA 15260 USA	Dixon, CE (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurosurg, Brain Trauma Res Ctr, Hill Bldg,Suite 201,3434 5th Ave, Pittsburgh, PA 15260 USA.		Marion, Donald/AAR-5749-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [CDC-R49-CCR310285] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS312296, NIH-NS33150] Funding Source: Medline		Barnes PJ, 1997, LIFE SCI, V60, P1015, DOI 10.1016/S0024-3205(97)00042-8; BERSE B, 1995, J BIOL CHEM, V270, P22101, DOI 10.1074/jbc.270.38.22101; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DASH PK, 1995, J NEUROSCI, V15, P2030; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dixon C. E., 1995, CENTRAL NERVOUS SYST, P255; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dixon CE, 1996, NEUROTRAUMA, P1337; Eiden LE, 1998, J NEUROCHEM, V70, P2227; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Gilmor ML, 1996, J NEUROSCI, V16, P2179; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gupta AK, 1995, J CEREB BLOOD FLOW M, V15, pS33; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hayes R. L., 1992, J HEAD TRAUMA REHAB, V7, P16; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEONARD BE, 1994, MED PSYCHIATRY, V1, P379; LEVEY AI, 1995, J NEUROSCI, V15, P4077; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McIntosh TK, 1996, EUR J ANAESTH, V13, P291, DOI 10.1046/j.1365-2346.1996.00981.x; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; POSMANTUR R, 1996, J NEUROPATHOL EXP NE, V55, P65; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Rouse ST, 1997, LIFE SCI, V60, P1031, DOI 10.1016/S0024-3205(97)00044-1; RUBERG M, 1990, NEUROSCIENCE, V35, P327, DOI 10.1016/0306-4522(90)90086-J; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SINSON G, 1995, J NEUROCHEM, V65, P2209; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; USDIN TB, 1995, TRENDS NEUROSCI, V18, P218, DOI 10.1016/0166-2236(95)93906-E; WEI J, 1994, J NEUROCHEM, V63, P815; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767	50	28	29	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	1999	16	7					555	566		10.1089/neu.1999.16.555			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	220EN	WOS:000081651700001	10447068				2021-06-18	
J	Karlsson, T				Karlsson, T			Multivariate analysis ('forensiometrics') - a new tool in forensic medicine. Differentiation between firearm-related homicides and suicides	FORENSIC SCIENCE INTERNATIONAL			English	Article							FATALITIES	A forensiometric model to discriminate between homicidal and suicidal firearm-fatalities is presented. It is based on a survey of all 45 homicidal and 251 suicidal firearm-fatalities that were examined at the Department of Forensic Medicine in Stockholm, Sweden during the period 1983-92. The model used 15 variables to describe 19.8% of the variation in the data and its goodness of prediction, Q(2), was 0.742. The variables ranked in falling order of covariation with homicide (i.e. correlation with or importance in the prediction of homicide) were: presence of other injuries than firearm-wounds, entrance wound in the front part of the chest except precordium, bullet path through clothes, entrance wound in upper extremity, female victim, entrance wound in abdomen, entrance wound in head except temples, central forehead and mouth, and entrance wound in back. The variables most correlated to suicide were: used firearm found close to victim's body, reported suicidal ideation, victim's age, presence of contact wound(s), male victim, presence of farewell letter and entrance wound in mouth. The model was thereafter validated on a test-set of 18 homicides and 84 suicides during 1993-95. All suicides and 16 homicides were classified by the model in agreement with the previous police and forensic medical examinations. Thus, the model's sensitivity to classify homicides is estimated to be 89% and its specificity 100%. (C) 1999 Elseviar Science Ireland Ltd. All rights reserved.	Natl Board Forens Med, Dept Forens Med, S-17126 Solna, Sweden	Karlsson, T (corresponding author), Natl Board Forens Med, Dept Forens Med, Box 1352, S-17126 Solna, Sweden.						BELL CA, 1991, AM J PUBLIC HEALTH, V81, P729, DOI 10.2105/AJPH.81.6.729; DIMALO VJM, 1985, GUNSHOT WOUNDS PRACT; Druid H, 1997, FORENSIC SCI INT, V88, P147, DOI 10.1016/S0379-0738(97)00104-7; FISCHER J, 1994, FORENSIC SCI INT, V68, P161, DOI 10.1016/0379-0738(94)90355-7; Karger B, 1997, INT J LEGAL MED, V110, P79, DOI 10.1007/s004140050035; KARISSON T, 1993, J FORENSIC SCI, V38, P1409; Karlsson T, 1998, FORENSIC SCI INT, V94, P183, DOI 10.1016/S0379-0738(98)00065-6; Karlsson T, 1998, FORENSIC SCI INT, V93, P21, DOI 10.1016/S0379-0738(98)00025-5; Karlsson T, 1999, FORENSIC SCI INT, V101, P33, DOI 10.1016/S0379-0738(99)00007-9; KRAULAND W, 1984, Archiv fuer Kriminologie, V174, P1; MISSLIWETZ J, 1983, Archiv fuer Kriminologie, V171, P143; OGUNGBEMI K, 1993, FORENSIC SCI INT, V59, P157, DOI 10.1016/0379-0738(93)90154-3; Rogde S, 1996, FORENSIC SCI INT, V80, P211, DOI 10.1016/0379-0738(96)01918-4; SCOTT KWM, 1990, MED SCI LAW, V30, P234, DOI 10.1177/002580249003000312; Sellier K., 1986, FORENSIC SCI PROGR, V1, P91; TARDIFF K, 1994, JAMA-J AM MED ASSOC, V272, P43, DOI 10.1001/jama.272.1.43; THORESEN S, 1984, Z RECHTSMED, V93, P65; UMETRI, 1997, USERS GUIDE SIMCAS V; VONHOFMAN ER, 1927, LEHRBUCH GERICHTLICH; WOLD S, 1978, TECHNOMETRICS, V20, P379	20	28	29	0	4	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	APR 26	1999	101	2					131	140		10.1016/S0379-0738(99)00017-1			10	Medicine, Legal	Legal Medicine	199DE	WOS:000080463700006	10371045				2021-06-18	
J	Dutcher, SA; Underwood, BD; Walker, PD; Diaz, FG; Michael, DB				Dutcher, SA; Underwood, BD; Walker, PD; Diaz, FG; Michael, DB			Patterns of immediate early gene mRNA expression following rodent and human traumatic brain injury	NEUROLOGICAL RESEARCH			English	Article						zif/268; human brain injury; gene expression; cerebral cortex	PROGRAMMED CELL-DEATH; C-FOS; AMINO-ACIDS; PROTEIN; GROWTH; MOUSE; EXCITOTOXICITY; TRANSCRIPTION; HIPPOCAMPUS; INDUCTION	Cell stimulation which leads to degeneration triggers a prolonged wave of immediate early gene (IEG) transcription that correlates with neuronal demise. In order to determine the relevance of the prolonged IEG response to human traumatic brain injury, we analyzed IEG mRNA levels in brain tissue isolated following a controlled penetrating injury and an injection of the excitotoxin Quinolinic acid (QA), as well as from tissue recovered during routine neurosurgery for trauma. Total RNA was extracted from tissue and subjected to Northern analysis of IEG mRNAs (c-fos and zif/268). Both models produced rapid and prolonged waves of IEG transcription that appeared to correlate with the severity of injury. Increases in zif/268 mRNA were observed within 1 h with levels reaching their peak at 6 h following excitotoxic injury and 3 h following a controlled penetration. In general, human traumatic brain injury resulted in variable increases in IEG mRNA levels following traumatic injury with the largest IEC mRNA increases observed in tissue collected 0-10 h after injury. This post-injury time corresponds to the peak of the prolonged IEG response observed in rodents following excitotoxic injury. Comparisons were made in IEG response between rodent frontal cortex and human cortex, because the majority of the human tissue originated from the cerebral cortex. These results further support the hypothesis that prolonged IEG transcription serves as a marker of traumatic brain injury and may play a role in neurodegeneration and/or glial activation. Moreover, observations of similar IEC patterns of expression reinforces the importance of rodent models of brain injury providing useful information directly applicable to human brain injury.	Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI 48201 USA	Dutcher, SA (corresponding author), Univ Detroit, Ctr Hlth, Detroit Med Ctr, Dept Neurosurg, Suite 6E,4201 St Antoine, Detroit, MI 48201 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS030550] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30550] Funding Source: Medline		ALLEN IV, 1983, ACTA NEUROPATHOL, V59, P277, DOI 10.1007/BF00691493; BENEVISTE H, 1984, J NEUROCHEM, V43, P1369; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Cooper PR, 1993, HEAD INJURY, P355; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; CURRAN T, 1995, J NEUROBIOL, V26, P403, DOI 10.1002/neu.480260312; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DRAGUNOW M, 1994, MOL BRAIN RES, V25, P19, DOI 10.1016/0169-328X(94)90274-7; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; Dutcher SA, 1998, J NEUROTRAUM, V15, P421, DOI 10.1089/neu.1998.15.421; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Goodman J. C., 1995, Journal of Neurotrauma, V12, P371; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; HU RM, 1994, J CLIN INVEST, V93, P1820, DOI 10.1172/JCI117167; HUGHES P, 1995, PHARMACOL REV, V47, P133; KASOF GM, 1995, J NEUROSCI, V15, P4238; KONOPKA D, 1995, NEUROSCI LETT, V185, P167, DOI 10.1016/0304-3940(95)11252-R; LEWIS SA, 1984, P NATL ACAD SCI-BIOL, V81, P2743, DOI 10.1073/pnas.81.9.2743; OLNEY JW, 1990, ANNU REV PHARMACOL, V30, P47; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PAXINOS G, 1986, RAT BRAIN STEREOTAXI, P12; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; Sall JM, 1996, EXP NEUROL, V139, P257, DOI 10.1006/exnr.1996.0099; Shan Y, 1997, EXP NEUROL, V144, P406, DOI 10.1006/exnr.1997.6427; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; WALKER PD, 1993, J NEUROSCI RES, V36, P588, DOI 10.1002/jnr.490360511; WALKER PD, 1993, NEUROREPORT, V4, P699, DOI 10.1097/00001756-199306000-00024	31	28	28	0	1	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	APR	1999	21	3					234	242		10.1080/01616412.1999.11740924			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	191LH	WOS:000080023600001	10319329				2021-06-18	
J	Brambrink, AM; Ichord, RN; Martin, LJ; Koehler, RC; Traystman, RJ				Brambrink, AM; Ichord, RN; Martin, LJ; Koehler, RC; Traystman, RJ			Poor outcome after hypoxia-ischemia in newborns is associated with physiological abnormalities during early recovery - Possible relevance to secondary brain injury after head trauma in infants	EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	IIIrd International Congress of Pathophysiology	JUN 28-JUL 03, 1998	LAHTI, FINLAND			brain injury, infants; head trauma; hypoxia, brain injury; ischemia, brain injury; newborns, brain injury	CEREBRAL BLOOD-FLOW; GLASGOW COMA SCALE; RAT-BRAIN; MILD HYPOTHERMIA; IMMATURE RAT; STATUS EPILEPTICUS; INTRACEREBRAL MICRODIALYSIS; INTRACRANIAL HYPERTENSION; INDUCED NEURODEGENERATION; SUBARACHNOID HEMORRHAGE	"Secondary hypoxia/ischemia" (i.e. regional impairment of oxygen and substrate delivery) results in secondary deterioration after traumatic brain injury in adults as well as in children and infants. However, detailed analysis regarding critical physiological abnormalities resulting from hppoxia/ischemia in the immature brain, e.g. acid-base-status, serum glucose levels and brain temperature, and their influence on outcome, are only available from non-traumatic experimental models. In recent studies on hypoxic/asphyxic cardiac arrest in neonatal piglets, we were able to predict short-term outcome using specific physiologic abnormalities immediately after the insult. Severe acidosis, low serum glucose levels and fever after resuscitation were associated with an adverse neurologic recovery one day after the insult. The occurrence of clinically apparent seizure activity during later recovery increased mortality (epileptic state), and survivors had greater neocortical and striatal brain damage. Brain damage after transient hypoxia/ischemia and "secondary brain injury" after head trauma may have some mechanistic overlap, and these findings on physiological predictors of outcome may also apply to pathologic conditions in the post-traumatic immature brain. Evaluation of data from other models of brain injury will be important to develop candidate treatment strategies for head-injured infants and children and may help to initiate specific studies about the possible role of these physiological predictors of brain damage in the traumatically injured immature brain.	Johannes Gutenberg Univ Mainz, Dept Anaesthesiol, D-55131 Mainz, Germany; Johns Hopkins Med Inst, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Anaesthesiol & Crit Care Med, Baltimore, MD 21205 USA	Brambrink, AM (corresponding author), Johannes Gutenberg Univ Mainz, Dept Anaesthesiol, Langenbeckstr 1, D-55131 Mainz, Germany.	brambrin@mail.uni-mainz.de			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS020020] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20020] Funding Source: Medline		*ACS COT, 1993, RES OPT CAR INJ PAT; Almeida A, 1996, PEDIATR RES, V40, P410, DOI 10.1203/00006450-199609000-00008; Alojado ES, 1996, ANESTH ANALG, V83, P1002; AUER RN, 1988, ANN NEUROL, V24, P699, DOI 10.1002/ana.410240602; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; Berg AT, 1997, J CLIN NEUROPHYSIOL, V14, P102, DOI 10.1097/00004691-199703000-00003; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Blumbergs P. C., 1997, HEAD INJURY PATHOPHY, P39; Brambrink A. M., 1996, Society for Neuroscience Abstracts, V22, P1938; BRUDER N, 1994, CRIT CARE MED, V22, P1114, DOI 10.1097/00003246-199407000-00011; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CATALTEPE O, 1995, PEDIATR RES, V38, P251, DOI 10.1203/00006450-199508000-00019; Cherian L, 1997, CRIT CARE MED, V25, P1378, DOI 10.1097/00003246-199708000-00027; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLANCY RR, 1997, FETAL NEONATAL BRAIN, P442; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; COLLINS RC, 1982, SCIENCE, V218, P177, DOI 10.1126/science.7123229; Conti AC, 1998, J NEUROSCI, V18, P5663; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; FLOYD RA, 1997, PRIMER CEREBROVASCUL, P165; Fujisawa H, 1996, J NEUROTRAUM, V13, P245, DOI 10.1089/neu.1996.13.245; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; Goel V, 1996, IEEE T BIO-MED ENG, V43, P1083, DOI 10.1109/10.541250; GORDON E, 1971, ACTA ANAESTH SCAND, V15, P209, DOI 10.1111/j.1399-6576.1971.tb05462.x; HALL ED, 1997, PRIMER CEREBROVASCUL, P200; HATTORI H, 1990, ANN NEUROL, V28, P122, DOI 10.1002/ana.410280203; HAUN SE, 1995, GOLDEN HOUR HDB PEDI, P293; HAUSDORFER J, 1974, MED WELT, V25, P865; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HILLERED L, 1984, J CEREBR BLOOD F MET, V4, P430, DOI 10.1038/jcbfm.1984.62; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HSIANG JK, 1994, CRIT CARE MED, V22, P1471, DOI 10.1097/00003246-199409000-00019; Ikonomidou C, 1996, PEDIATR RES, V39, P1020, DOI 10.1203/00006450-199606000-00015; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; JOHNSTON MV, 1986, PEDIATR NEUROSCI, V12, P87; KATSURA KI, 1997, PRIMER CEREBROVASCUL, P159; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kelly D F, 1995, New Horiz, V3, P453; Kempski O, 1997, J TRAUMA, V42, pS38, DOI 10.1097/00005373-199705001-00007; Kim H, 1996, STROKE, V27, P114, DOI 10.1161/01.STR.27.1.114; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; KUNIEVSKY B, 1994, DEV NEUROSCI-BASEL, V16, P313, DOI 10.1159/000112125; Laptook AR, 1997, PEDIATR RES, V42, P17, DOI 10.1203/00006450-199707000-00004; LAPTOOK AR, 1992, STROKE, V23, P1504, DOI 10.1161/01.STR.23.10.1504; LAPTOOK AR, 1994, BRAIN RES, V638, P78, DOI 10.1016/0006-8993(94)90635-1; LEBLANC MH, 1994, STROKE, V25, P1443, DOI 10.1161/01.STR.25.7.1443; LUDBROOK GL, 1997, HEAD INJURY PATHOPHY, P363; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARMAROU A, 1992, J NEUROTRAUM, V9, pS551; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Martin LJ, 1997, J COMP NEUROL, V377, P262, DOI 10.1002/(SICI)1096-9861(19970113)377:2<262::AID-CNE8>3.0.CO;2-1; Martin LJ, 1997, ANN NEUROL, V42, P335, DOI 10.1002/ana.410420310; MARTIN LJ, 1985, BRAIN RES, V325, P287, DOI 10.1016/0006-8993(85)90324-5; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; MCCALL AL, 1995, BRAIN RES, V670, P29, DOI 10.1016/0006-8993(94)01248-G; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MYERS RE, 1972, AM J OBSTET GYNECOL, V112, P246, DOI 10.1016/0002-9378(72)90124-X; Myers RE, 1977, INTRAUTERINE ASPHYXI, P37; NAWASHIRO H, 1994, ACTA NEUROCHIR, P440; NEVANDER G, 1985, ANN NEUROL, V18, P281, DOI 10.1002/ana.410180303; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; PASCHEN W, 1987, J NEUROCHEM, V48, P154, DOI 10.1111/j.1471-4159.1987.tb13140.x; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; REHNCRONA S, 1979, STROKE, V10, P437, DOI 10.1161/01.STR.10.4.437; REHNCRONA S, 1989, J CEREBR BLOOD F MET, V9, P65, DOI 10.1038/jcbfm.1989.9; REILLY P, 1997, HEAD INJURY, P385; SCHUBERT A, 1992, J NEUROSURG ANESTH, V4, P216, DOI 10.1097/00008506-199207000-00013; SHELDON RA, 1992, PEDIATR RES, V32, P489, DOI 10.1203/00006450-199210000-00022; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; SIESJO BK, 1985, J CEREBR BLOOD F MET, V5, P253, DOI 10.1038/jcbfm.1985.32; SIESJO BK, 1997, PRIMER CEREBROVASCUL, P223; Sirimanne ES, 1996, PEDIATR RES, V39, P591, DOI 10.1203/00006450-199604000-00005; SMITH RF, 1990, J TRAUMA, V30, P1066, DOI 10.1097/00005373-199009000-00002; TASKER RC, 1995, GOLDEN HOUR HDB PEDI, P217; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; THOMPSON CT, 1992, J TRAUMA, V32, P336, DOI 10.1097/00005373-199203000-00011; Thoresen M, 1996, ARCH DIS CHILD-FETAL, V74, pF3, DOI 10.1136/fn.74.1.F3; TREIMAN DM, 1997, J CLIN NEUROPHYSIOL, V14, P159; Trescher WH, 1997, BRAIN DEV-JPN, V19, P326, DOI 10.1016/S0387-7604(97)00027-2; UCHINO H, 1994, STROKE, V25, P1825, DOI 10.1161/01.STR.25.9.1825; Vannucci RC, 1997, PEDIATR RES, V42, P24, DOI 10.1203/00006450-199707000-00005; Vannucci RC, 1996, J CEREBR BLOOD F MET, V16, P1026, DOI 10.1097/00004647-199609000-00028; VANNUCCI RC, 1992, BIOL NEONATE, V62, P215; Vannucci SJ, 1996, J CEREBR BLOOD F MET, V16, P77, DOI 10.1097/00004647-199601000-00009; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; Vink R, 1997, J CEREBR BLOOD F MET, V17, P50, DOI 10.1097/00004647-199701000-00007; VOORHIES TM, 1986, NEUROLOGY, V36, P1115, DOI 10.1212/WNL.36.8.1115; WAGNER KR, 1990, J CEREBR BLOOD F MET, V10, P417, DOI 10.1038/jcbfm.1990.72; *WAN DGAI, 1998, ANASTH INTENSIVMED, V7, P399; WASTERLAIN CG, 1990, NEONATAL SEIZURES, P69; WELCH FA, 1982, J CEREB BLOOD FLOW M, V2, P221; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; Yager JY, 1996, STROKE, V27, P919, DOI 10.1161/01.STR.27.5.919; Yanpeng L, 1996, J PERINAT MED, V24, P581, DOI 10.1515/jpme.1996.24.6.581; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG RSK, 1985, ANN NEUROL, V18, P291, DOI 10.1002/ana.410180304	111	28	28	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0940-2993	1618-1433		EXP TOXICOL PATHOL	Exp. Toxicol. Pathol.	FEB	1999	51	2					151	162		10.1016/S0940-2993(99)80089-X			12	Pathology; Toxicology	Pathology; Toxicology	177NZ	WOS:000079218000007	10192584				2021-06-18	
J	Benz, B; Ritz, A; Kiesow, S				Benz, B; Ritz, A; Kiesow, S			Influence of age-related factors on long-term outcome after traumatic brain injury (TBI) in children: A review of recent literature and some preliminary findings	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						pediatric TBI; age at injury; follow-up; post-traumatic development; long-term outcome	CLOSED HEAD-INJURY; FOLLOW-UP; SEQUELAE; ADOLESCENTS; OLDER	Cerebral plasticity of the immature brain is often inferred to Iced to less serious consequences of early traumatic brain injury (TBI) in the pediatric age group. This notion is seriously challenged by recent research findings. Data from prospective studies point to some children's difficulties in ongoing skill-acquisition and the possibility of late-emerging deficits. Accordingly, preliminary group data of an own ongoing study support the notion of an increased risk for pervasive neuropsychological impairment in subjects with severe TBI and early age at trauma. The pattern of neuropsychological deficits may depend on the developmental level at the time of injury, although effects of hemispheric site of lesion were also found to persist in individual cases. Theoretical considerations and empirical findings stress the importance of a longitudinal developmental perspective for the evaluation of long-term outcome after pediatric TBI.	NRZ Kinder & Jugendliche Friedehorst, D-28717 Bremen, Germany	Benz, B (corresponding author), NRZ Kinder & Jugendliche Friedehorst, Rotdornallee 64, D-28717 Bremen, Germany.	barbara.benz@t-online.de					Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BARTH JT, 1989, MILD HEAD INJURY, P255; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; BENZ B, 1996, FALLBUCH KLIN NEUROP, P241; Benz B, 1993, SPEKTRUM NEUROREHABI, P228; BENZ B, 1993, AKTUELLE NEUROPADIAT, P125; BENZ B, 1997, NEUROLOGISCHE GUTACH, P179; BENZ B, 1996, KINDH ENTWICKL, V5, P221; BOLL TJ, 1983, J CLIN CHILD PSYCHOL, V12, P74, DOI 10.1080/15374418309533114; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CASEY R, 1986, PEDIATRICS, V78, P497; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; DENCKLA M, 1995, TRAUMATIC HEAD INJUR, P3; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; JOHNSON DA, 1989, CHILDRENS HEAD INJUR, P96; Kleinpeter U, 1993, AKTUELLE NEUROPADIAT, P151; KLEINPETER U, 1979, FOLGEZUSTANDE NACH S; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KLUN B, 1993, SPEKTRUM NEUROREHABI, P208; Koelfen W, 1997, MONATSSCHR KINDERH, V145, P489, DOI 10.1007/s001120050147; KRAUS JF, 1987, PEDIATRICS, V79, P501; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LEHMKUHL G, 1986, THESIS HEIDELBERG; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; LordMaes J, 1996, J LEARN DISABIL, V29, P609, DOI 10.1177/002221949602900605; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; MIDDLETON J, 1989, CHILDRENS HEAD INJUR, P96; PIORRECK S, 1993, SPEKTRUM NEUROREHABI, P256; RANTAKALLIO P, 1985, J EPIDEMIOL COMMUN H, V39, P353, DOI 10.1136/jech.39.4.353; RITZ A, 1993, AKTUELLE NEUROPADIAT, P181; RITZ A, 1993, PADIATR PRAX, V45, P237; RITZ A, 1997, HDB POSTTRAUMATISCHE, P108; Ritz A., 1993, SPEKTRUM NEUROREHABI, P208; RUIJS MBM, 1990, CLIN NEUROL NEUROSUR, V92, P323, DOI 10.1016/0303-8467(90)90058-D; SCHNEIDER GE, 1979, NEUROPSYCHOLOGIA, V17, P557, DOI 10.1016/0028-3932(79)90033-2; SHAFFER D, 1995, TRAUMATIC HEAD INJUR, P55; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEUBER HL, 1967, DEV MED CHILD NEUROL, V4, P3	46	28	29	0	1	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		1999	14	2-3					135	141					7	Neurosciences	Neurosciences & Neurology	183XN	WOS:000079579700008	22387509				2021-06-18	
J	Catroppa, C; Anderson, V				Catroppa, C; Anderson, V			Attentional skills in the acute phase following pediatric traumatic brain injury	CHILD NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD INJURY; SUSTAINED ATTENTION; CHILDREN; CHILDHOOD; DEFICITS; SPEED; AGE	Only a limited number of studies have investigated attention following pediatric head-injury. The present study examined sustained attention and processing speed in a group of children who had sustained a mild (n = 27), moderate (n = 33) or severe (n = 16) traumatic brain injury (TBI). No significant differences were evident between the TBI groups on reaction time measures. Results did show that the severe TBI group exhibited greater deficits in the area of sustained attention, in comparison to children with mild and moderate injuries, in the acute stage following traumatic brain injury. This difficulty may impact on the future development of skills dependent on intact attentional capacity.	Royal Childrens Hosp, Melbourne, Vic, Australia; Univ Melbourne, Parkville, Vic 3052, Australia	Catroppa, C (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.						ANDERSON RP, 1973, EXCEPT CHILDREN, P534; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; ANDERSON V, IN PRESS DEV NEUROPS; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; DANIELS A, 1983, POWER PRIVILEGE PRES; Dennis M, 1995, TRAUMATIC HEAD INJUR; Donders J, 1999, DEV NEUROPSYCHOL, V15, P395, DOI 10.1080/87565649909540757; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; FENWICK T, IN PRESS CHILD NEURO; HALE S, 1990, CHILD DEV, V61, P653, DOI 10.2307/1130951; HALPERIN JM, 1991, INT J NEUROSCI, V58, P171, DOI 10.3109/00207459108985433; KAIL R, 1986, CHILD DEV, V57, P969, DOI 10.2307/1130372; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; MILTON SB, 1991, J HEAD TRAUMA REHAB, V6, P35; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; Sparrow S., 1984, VINELAND ADAPTIVE BE; TEASDALE G, 1974, LANCET, V2, P81; Timmermans SR, 1991, COGNITIVE REHABILITA, V9, P26; Wechsler D., 1992, MANUAL WECHSLER INTE; WILLMOTT C, IN PRESS DEV NEUROPS	28	28	28	0	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0929-7049			CHILD NEUROPSYCHOL	Child Neuropsychol.		1999	5	4					251	264		10.1076/0929-7049(199912)05:04;1-R;FT251			14	Clinical Neurology	Neurosciences & Neurology	324XA	WOS:000087645600005	10925709				2021-06-18	
J	Zink, BJ; Sheinberg, MA; Wang, X; Mertz, M; Stern, SA; Betz, AL				Zink, BJ; Sheinberg, MA; Wang, X; Mertz, M; Stern, SA; Betz, AL			Acute ethanol intoxication in a model of traumatic brain injury with hemorrhagic shock: effects on early physiological response	JOURNAL OF NEUROSURGERY			English	Article						ethanol; traumatic brain injury; hemorrhagic shock; cerebral blood flow; ventilation; pig	CEREBRAL BLOOD-FLOW; FREE-RADICAL MECHANISMS; NERVOUS-SYSTEM TRAUMA; SEVERE HEAD-INJURIES; NITRIC-OXIDE; ALCOHOL-INTOXICATION; OXYGEN DELIVERY; INTRACRANIAL-PRESSURE; ARTERIOLES; REDUCTION	Object. Traumatic brain injury (TBI) is exacerbated by hypotension and hypoventilation. Because previous studies have shown a potentiating effect of ethanol (EtOH) on TBI and hemorrhagic shock (HS), the authors investigated the effects of EtOH on the early physiological response to TBI with and without HS. Methods. Anesthetized swine, weighing approximately 20 kg each, underwent fluid-percussion TBI of 3 atm with or without 30 ml/kg hemorrhage for a period of 30 minutes. The mean arterial blood pressure, intracranial pressure, cerebral perfusion pressure (CPP), cardiac output, cerebral venous oxygen saturation, and metabolic parameters were monitored for 3 hours postinjury. Ventilation and the response to hypercapnia were also measured. Regional cerebral blood flow and renal blood flow were measured using dye labeled microspheres. Five groups were studied: control, TBI, TBI/EtOH, TBI/HS, and TBI/HS/EtOH. The EtOH (3.5 g) was given intragastrically 100 minutes preinjury. The TBI/HS/EtOH group demonstrated a 3-hour mortality rate of 56% and postinjury apnea requiring Ventilation in 44% of animals compared with 0% in all other groups. Minute Ventilation and the hypercapnic Ventilatory response were significantly reduced in the postinjury period in the TBI/HS/EtOH group. The animals in this group had significantly lower CPP and cardiac output in the first 60 minutes postinjury, as well as lower renal and cerebral blood flow. Postinjury cerebral venous lactate levels were higher, and cerebral venous pH was lower in the TBI/HS/EtOH group. Conclusions. In this model of TBI, acute EtOH intoxication in the presence of HS potentiates the physiological and metabolic alterations that may contribute to secondary brain injury.	Univ Michigan, Sect Emergency Med, Dept Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Neurosurg Sect, Dept Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA	Zink, BJ (corresponding author), Univ Michigan, Sect Emergency Med, Dept Surg, 1500 E Med Ctr Dr,TC B1 354, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [K08AA000184] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [PHS-G-1-K08AA00184] Funding Source: Medline		ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; BEARD JD, 1973, Q J STUD ALCOHOL, V34, P1303; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CREWS FT, 1993, NIAAA RES MONOGRAPH, V22, P355; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Deitrich R., 1996, PHARM EFFECTS ETHANO; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DILUZIO NR, 1969, EXP MOL PATHOL, V11, P38, DOI 10.1016/0014-4800(69)90069-0; DOBERSTEIN CE, 1993, ANN EMERG MED, V22, P993, DOI 10.1016/S0196-0644(05)82740-4; DURCAN MJ, 1989, PHARMACOL BIOCHEM BE, V32, P667, DOI 10.1016/0091-3057(89)90015-4; EDNA TH, 1982, ACTA CHIR SCAND, V148, P209; ELMER O, 1985, ACTA CHIR SCAND, V151, P305; EVANS L, 1993, J STUD ALCOHOL, V54, P441, DOI 10.15288/jsa.1993.54.441; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FRANCO CD, 1988, J NATL MED ASSOC, V80, P63; GETTLER DT, 1963, ANN SURG, V158, P151, DOI 10.1097/00000658-196308000-00001; GORDON EL, 1995, J CEREBR BLOOD F MET, V15, P532, DOI 10.1038/jcbfm.1995.66; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HARIRI RJ, 1993, J NEUROSURG, V79, P421, DOI 10.3171/jns.1993.79.3.0421; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HORTON JW, 1986, SURGERY, V100, P520; ISRAEL RS, 1988, ANN EMERG MED, V17, P560; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; KIM HJ, 1989, J NEUROSURG, V71, P565, DOI 10.3171/jns.1989.71.4.0565; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; LANCASTER FE, 1992, ALCOHOL CLIN EXP RES, V16, P539, DOI 10.1111/j.1530-0277.1992.tb01413.x; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609010-00010; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARX J, 1990, Emergency Medicine Clinics of North America, V8, P929; Mayhan WG, 1996, ALCOHOL CLIN EXP RES, V20, P538, DOI 10.1111/j.1530-0277.1996.tb01089.x; MAYHAN WG, 1995, STROKE, V26, P2097, DOI 10.1161/01.STR.26.11.2097; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; Mihic S. J., 1996, PHARM TOXIC, P51; Mill John Stuart, 1996, NEUROTRAUMA, P43; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NORDMANN R, 1992, FREE RADICAL BIO MED, V12, P219, DOI 10.1016/0891-5849(92)90030-K; Nordmann R, 1996, PHARM TOXIC, P329; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; PITTS LH, 1990, HDB CLIN NEUROLOGY, V57, P65; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; RAPPAPORT WD, 1990, J TRAUMA, V30, P1518, DOI 10.1097/00005373-199012000-00014; REVES JG, 1972, Q J STUD ALCOHOL, V33, P464; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; SCALEA TM, 1994, CRIT CARE MED, V22, P1610; Schmoker JD, 1996, J NEUROTRAUM, V13, P67, DOI 10.1089/neu.1996.13.67; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; SELIGMAN ML, 1977, LIPIDS, V12, P945, DOI 10.1007/BF02533316; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; Shapira Y, 1997, J NEUROSURG ANESTH, V9, P118, DOI 10.1097/00008506-199704000-00003; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; SIGGINS GR, 1996, PHARM TOXIC, P175; Smith DH, 1996, NEUROTRAUMA, P1445; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YUAN XQ, 1991, CIRC SHOCK, V35, P231; ZHANG A, 1993, EUR J PHARM-ENVIRON, V248, P229, DOI 10.1016/0926-6917(93)90049-V; ZINK BJ, 1988, ANN EMERG MED, V17, P15, DOI 10.1016/S0196-0644(88)80496-7; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; Zink BJ, 1996, ALCOHOL CLIN EXP RES, V20, P1518, DOI 10.1111/j.1530-0277.1996.tb01693.x; ZINK BJ, 1988, CIRC SHOCK, V24, P19; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x	75	28	30	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	DEC	1998	89	6					983	990		10.3171/jns.1998.89.6.0983			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	168TF	WOS:000078708200012	9833825				2021-06-18	
J	Trombly, CA; Radomski, MV; Davis, ES				Trombly, CA; Radomski, MV; Davis, ES			Achievement of self-identified goals by adults with traumatic brain injury: Phase I	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						brain injuries; motivation; planning process, occupational therapy	REHABILITATION; REINTEGRATION; PROGRAM	Objective. This study sought to determine whether persons with traumatic brain injury who received outpatient occupational therapy services achieved self-identified goals related to tasks of daily life. Method. Sixteen participants completed the study Occupational therapists used their usual treatment procedures to restore independence in home and community occupational functioning. The Canadian Occupational Performance Measure identified the five most important problems that interfered with independence in the roles the participant valued as well as the participant's perception of performance ability and satisfaction with performance. Coal Attainment Scaling documented achievement of the five self-identified goals. The independent Living Skills Evaluation (ILSE) and the Reintegration to Normal Living Scale (RNL) measured changes in overall instrumental activities of daily living and community reintegration. Results. The participants significantly achieved (p <.001) their goals from admission to discharge, rated themselves as performing significantly better (p <.001), and were significantly more satisfied (P =.001) with performance after treatment than before. Additionally they improved significantly on the ILSE (p <. 001) and the RNL (p <.001) from admission to discharge. There were no significant changes in perfoemance from discharge to follow-up on any of the scales. Conclusion. Although causality cannot be inferred, it can be concluded that participants attending outpatient occupational therapy significantly improved, and improvements were sustained after discharge, but no further improvement occurred spontaneously.	Boston Univ, Sargent Coll Hlth & Rehabil Sci, Dept Occupat Therapy, Boston, MA 02215 USA; Sister Kenny Inst, Outpatient Brain Injury Program, Minneapolis, MN USA	Trombly, CA (corresponding author), Boston Univ, Sargent Coll Hlth & Rehabil Sci, Dept Occupat Therapy, 635 Commonwealth Ave, Boston, MA 02215 USA.						ASHER IA, 1989, ANNOTATED INDEX OCCU; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; DUNCAN PW, 1990, REHABILITATION ADULT, P264; ELOVIC E, 1996, MED REHABILITATION T, P1; HALLETT JD, 1994, AM J OCCUP THER, V48, P241, DOI 10.5014/ajot.48.3.241; Heinemann AW, 1990, J NEUROL REHABIL, V4, P27; HELLMAN S, 1991, NEW ENGL J MED, V324, P1585, DOI 10.1056/NEJM199105303242208; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; JOHNSON TP, 1980, OCCUPATIONAL THERAPY, V1, P5; JOHNSTON MV, 1994, ARCH PHYSICAL MED RE, V75, P2; JOHNSTON MV, 1996, MED REHABILITATION T, P197; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; Law M., 1994, CANADIAN OCCUPATIONA; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; MAHONEY F I, 1965, Md State Med J, V14, P61; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; MALKMUS D, 1980, REHABILITATION HEAD; Nelson DL, 1996, AM J OCCUP THER, V50, P223, DOI 10.5014/ajot.50.3.223; OTTENBACHER KJ, 1990, AM J OCCUP THER, V44, P519, DOI 10.5014/ajot.44.6.519; PANIKOFF LB, 1983, AM J OCCUP THER, V37, P735, DOI 10.5014/ajot.37.11.735; Rosenthal R., 1991, ESSENTIALS BEHAV RES; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Scott A.D., 1995, OCCUPATIONAL THERAPY, P705; SMIGIELSKI JS, 1992, MAYO CLIN PROC, V67, P767, DOI 10.1016/S0025-6196(12)60802-7; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; WOODDAUPHINEE S, 1987, J CHRON DIS, V40, P491, DOI 10.1016/0021-9681(87)90005-1; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583; ZWEBER B, 1990, Occupational Therapy in Health Care, V7, P45, DOI 10.1080/J003v07n01_05	32	28	28	0	3	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490			AM J OCCUP THER	Am. J. Occup. Ther.	NOV-DEC	1998	52	10					810	818		10.5014/ajot.52.10.810			9	Rehabilitation	Rehabilitation	141JJ	WOS:000077139800006					2021-06-18	
J	Posmantur, RM; Zhao, X; Kampfl, A; Clifton, GL; Hayes, RL				Posmantur, RM; Zhao, X; Kampfl, A; Clifton, GL; Hayes, RL			Immunoblot analyses of the relative contributions of cysteine and aspartic proteases to neurofilament breakdown products following experimental brain injury in rats	NEUROCHEMICAL RESEARCH			English	Article						neurofilaments; calpain; traumatic brain injury; two-dimensional gel electrophoresis; cortex	CALCIUM-ACTIVATED PROTEOLYSIS; AMYOTROPHIC-LATERAL-SCLEROSIS; CONTROLLED CORTICAL IMPACT; PROTEIN-KINASE-II; ALZHEIMERS-DISEASE; CALPAIN INHIBITOR; SPINAL-CORD; NF-H; ICE/CED-3 PROTEASE; HIPPOCAMPAL DAMAGE	Analyses using either one or two-dimensional gel electrophoresis were performed to identify the contribution of several proteases to lower molecular weight (MW) neurofilament 68 (NF68) break down products (BDPs) detected in cortical homogenates following unilateral cortical impact injury in rats. One dimensional immunoblot of BDPs obtained from in vitro cleavage of enriched neurofilaments (NF) by purified mu-calpain, m-calpain, cathepsin, B, cathepsin D, and CPP32 (caspase-3) were compared to in vivo samples from rats following traumatic brain injury (TBI). Comparison of these blots provided information on the relative contribution of different cysteine or aspartic proteases to NF loss following brain injury. As early as 3 hrs post-injury, cortical impact resulted in the presence of several lower MW NF68 immunopositive bands having patterns similar to those previously reported to be produced by calpain mediated proteolysis of neurofilaments. Only mu-calpain and m-calpain in vitro digestion of enriched neurofilaments contributed to the presence of the low MW 57 kD NF68 break down product (BDP) detected in post-TBI samples. Cathepsin B, cathepsin D, and caspase-3 failed to produce either the 53 kD or 57 kD NF BDPs. Further, 1 and 2 dimensional peptide maps containing a 1:1 ratio of in vivo and in vitro tissue samples showed complete comigration of lower MW immunopositive spots produced by TBI or in vitro incubation with m-calpain, thus providing additional evidence for the potential role of calpain activation to the production of NF68 BDPs following TBI. More importantly, 2-dimensional gel electrophoresis detected that immunopositive NF68 spots shifted to the basic pole (+) suggesting that dephosphorylation of the NF68 subunit pool may be associated with NF protein loss following TBI, an observation not previously noted in any model of experimental brain injury.	Univ Texas, Hlth Sci Ctr, Vivian L Smith Ctr Neurol Res, Dept Neurosurg, Houston, TX 77030 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Immunopathol, Dept Neurosci, Ann Arbor, MI 48105 USA; Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria	Hayes, RL (corresponding author), Univ Texas, Hlth Sci Ctr, Vivian L Smith Ctr Neurol Res, Dept Neurosurg, 6431 Fannin,Suite 7-154, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031998, R01NS021458] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS31998, R01 NS21458] Funding Source: Medline		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BANIK NL, 1982, NEUROCHEM RES, V7, P1465, DOI 10.1007/BF00965089; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; CHIN TK, 1983, BIOCHEM J, V215, P239, DOI 10.1042/bj2150239; CRUMRINE RC, 1990, J NEUROCHEM, V55, P2001, DOI 10.1111/j.1471-4159.1990.tb05788.x; DASH PK, 1995, J NEUROSCI, V15, P2030; DAUTIGNY A, 1988, BIOCHEM BIOPH RES CO, V154, P1099, DOI 10.1016/0006-291X(88)90254-9; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GOTO K, 1994, MOL BRAIN RES, V23, P40, DOI 10.1016/0169-328X(94)90209-7; GREENWOOD JA, 1993, J NEUROCHEM, V61, P191, DOI 10.1111/j.1471-4159.1993.tb03555.x; Hall E D, 1985, Cent Nerv Syst Trauma, V2, P75; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HANSON SK, 1994, STROKE, V25, P466, DOI 10.1161/01.STR.25.2.466; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; HARRIS AS, 1988, J BIOL CHEM, V263, P17401; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; Hill IE, 1997, BRAIN RES, V751, P206, DOI 10.1016/S0006-8993(96)01403-5; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; HONG SC, 1994, BRAIN RES, V661, P43, DOI 10.1016/0006-8993(94)91178-9; JULIEN JP, 1982, J BIOL CHEM, V257, P467; KAMAKURA K, 1985, J NEUROSCI RES, V13, P391, DOI 10.1002/jnr.490130306; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWASHIMA S, 1988, BIOCHIM BIOPHYS ACTA, V965, P130, DOI 10.1016/0304-4165(88)90048-7; Kohda Y, 1996, BIOCHEM BIOPH RES CO, V228, P616, DOI 10.1006/bbrc.1996.1706; KUBOTA S, 1986, BIOCHEMISTRY-US, V25, P8396, DOI 10.1021/bi00374a011; LEE VMY, 1987, J NEUROSCI, V7, P3474; Li JH, 1996, J NEUROBIOL, V30, P177, DOI 10.1002/(SICI)1097-4695(199606)30:2<177::AID-NEU1>3.0.CO;2-2; LITERSKY JM, 1995, J NEUROCHEM, V65, P903; LITERSKY JM, 1993, BRAIN RES, V604, P32, DOI 10.1016/0006-8993(93)90349-R; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; MIGHELI A, 1994, NEUROPATH APPL NEURO, V20, P282, DOI 10.1111/j.1365-2990.1994.tb00970.x; MORIOKA M, 1992, J NEUROCHEM, V58, P1798, DOI 10.1111/j.1471-4159.1992.tb10056.x; NAGARAJA TN, 1994, ACTA NEUROPATHOL, V88, P349; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NITATORI T, 1996, J NEUROTRAUM, V6, P369; NIXON RA, 1984, J NEUROCHEM, V43, P507, DOI 10.1111/j.1471-4159.1984.tb00928.x; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; NIXON RA, 1993, BRAIN PATHOL, V3, P29, DOI 10.1111/j.1750-3639.1993.tb00723.x; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Posmantur R, 1997, J NEUROCHEM, V68, P2328; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; SAATMAN KE, 1995, J NEUROPATH EXP NEUR, V55, P852; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SCHLAEPFER W, 1990, CRCS INTRACELLULAR C, P241; SCHLAEPFER WW, 1984, J NEUROCHEM, V43, P857, DOI 10.1111/j.1471-4159.1984.tb12809.x; SCHLAEPFER WW, 1985, J NEUROCHEM, V44, P502, DOI 10.1111/j.1471-4159.1985.tb05442.x; SEUBERT P, 1987, SYNAPSE, V1, P20, DOI 10.1002/syn.890010105; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1989, J NEUROSCI, V9, P1579; SMITH MA, 1995, J NEUROCHEM, V64, P2660; SOUSSAN L, 1994, MOL NEUROBIOL, V9, P83, DOI 10.1007/BF02816107; Stabach PR, 1997, BIOCHEMISTRY-US, V36, P57, DOI 10.1021/bi962034i; SUSUKI H, 1984, NEUROSCI LETT, V89, P240; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; WEILOCH T, 1991, J NEUROCHEM, V56, P1227; YAMASAKI Y, 1992, NEUROSCIENCE, V49, P545, DOI 10.1016/0306-4522(92)90225-Q; YANG KY, 1994, J NEUROTRAUM, V11, P523, DOI 10.1089/neu.1994.11.523; ZHAO X, 1997, IN PRESS J CEREBRAL; ZHAO X, 1997, UNPUB NEUROSCI LETT	86	28	28	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190			NEUROCHEM RES	Neurochem. Res.	OCT	1998	23	10					1265	1276		10.1023/A:1020792132629			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	131BY	WOS:000076556900007	9804282				2021-06-18	
J	Chen, MZ; Clark, RSB; Kochanek, PM; Chen, J; Schiding, JK; Stetler, RA; Simon, RP; Graham, SH				Chen, MZ; Clark, RSB; Kochanek, PM; Chen, J; Schiding, JK; Stetler, RA; Simon, RP; Graham, SH			72-kDa heat shock protein and mRNA expression after controlled cortical impact injury with hypoxemia in rats	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	26th Annual Meeting of the Society-for-Neuroscience	NOV 16-21, 1996	WASHINGTON, D.C.	Soc Neurosci		heat shock protein; hippocampus; hsp72; neuron; stress response; traumatic brain injury	TRAUMATIC BRAIN INJURY; FOCAL CEREBRAL-ISCHEMIA; OXIDE SYNTHASE EXPRESSION; PROGRAMMED CELL-DEATH; HSP70 MESSENGER-RNA; HYPERTHERMIA PROTECTS; TRANSIENT ISCHEMIA; GERBIL HIPPOCAMPUS; CULTURED NEURONS; THERMAL-STRESS	As part of the stress response, the 72 kDa heat shack protein (hsp72) is induced in neurons after ischemic and traumatic brain injury (TBI). To examine the stress response after TBI with secondary insult, we examined the regional and cellular expression of hsp72 mRNA and protein after controlled cortical impact (CCI) injury with secondary hypoxemia and mild hypotension in rats. Rats were killed at 6, 8, 24, 72, or 168 h after trauma. Naive and sham-operated rats were used as controls. Brains were removed, and in situ hybridization (n = 2/group), immunocytochemistry (n = 4/group), and Western blot analysis (n = 3 to 5/group) for hsp72 was performed. Hsp72 mRNA was expressed in neurons in the ipsilateral cortex, CA3 region of the hippocampus, hilus, and dentate gyrus at 6 h. Hsp72 mRNA was expressed primarily in the ipsilateral cortex, at 24 h, and by 72 h hsp72 mRNA expression returned to near basal levels. Hsp72 protein was seen in ipsilateral cortical neurons, hilar neurons, and neurons in the medial aspect of the CA3 region of the hippocampus (CA3-c) at 24 h. At 72 h, hsp72 immunoreactivity was reduced versus 24 h in these same regions, but it was increased versus baseline. Western blot analysis confirmed an increase in hsp72 protein in the ipsilateral cortex. The regional pattern of hsp72 mRNA induction in neurons was similar to the pattern of protein expression after CCI, with the exceptions that hsp72 mRNA, but not protein, was expressed in the dentate gyrus and the lateral aspect of the CA3 region of the hippocampus (CA3-a). The stress response, as detected by hsp72 expression, is induced in some neurons in some regions that are selectively vulnerable to delayed neuronal death in this model of TBI. The failure to translate some proteins including hsp72 may be associated with delayed neuronal death in certain hippocampal regions after TBI.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Neurol, Pittsburgh, PA 15260 USA; Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA	Clark, RSB (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.		Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5P30 HD28836] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2P50 NS 30318-04A1, 1KO8 NS01946-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD028836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001946, P50NS030318] Funding Source: NIH RePORTER		ABE K, 1991, NEUROSCI LETT, V125, P166, DOI 10.1016/0304-3940(91)90018-O; BARBE MF, 1988, SCIENCE, V241, P1817, DOI 10.1126/science.3175623; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; BURDON RH, 1993, MOL ASPECTS MED, V14, P83, DOI 10.1016/0098-2997(93)90020-E; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Chen J, 1996, J CEREBR BLOOD F MET, V16, P566, DOI 10.1097/00004647-199607000-00006; CHOPP M, 1989, NEUROLOGY, V39, P1396, DOI 10.1212/WNL.39.10.1396; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Clark RSB, 1997, J NEUROSCI, V17, P9172; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CURRIE RW, 1981, SCIENCE, V214, P72, DOI 10.1126/science.7280681; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Graham SH, 1996, RESTOR NEUROL NEUROS, V9, P243, DOI 10.3233/RNN-1996-9407; GRAHAM SH, 1996, J NEUROTRAUM, V13, P620; HOSSMANN KA, 1993, PROG BRAIN RES, V96, P161; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KATO H, 1993, BRAIN RES, V615, P240, DOI 10.1016/0006-8993(93)90033-J; KINOUCHI H, 1993, J CEREBR BLOOD F MET, V13, P105, DOI 10.1038/jcbfm.1993.13; KINOUCHI H, 1993, BRAIN RES, V619, P334, DOI 10.1016/0006-8993(93)91630-B; KRAUSE GS, 1993, STROKE, V24, P747, DOI 10.1161/01.STR.24.5.747; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; LI Y, 1992, ACTA NEUROPATHOL, V84, P94, DOI 10.1007/BF00427221; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LINQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; MAILHOS C, 1993, NEUROSCIENCE, V55, P621, DOI 10.1016/0306-4522(93)90428-I; MAILHOS C, 1994, J NEUROCHEM, V63, P1787; Massa SM, 1996, CEREBROVAS BRAIN MET, V8, P95; Matz P, 1996, STROKE, V27, P504, DOI 10.1161/01.STR.27.3.504; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; NOWAK TS, 1985, J NEUROCHEM, V45, P1635, DOI 10.1111/j.1471-4159.1985.tb07236.x; NOWAK TS, 1994, BRAIN PATHOL, V4, P67; NOWAK TS, 1991, J CEREBR BLOOD F MET, V11, P432, DOI 10.1038/jcbfm.1991.84; NOWAK TS, 1994, HEAT SHOCK PROTEINS, P55; Papadopoulos MC, 1996, NEUROREPORT, V7, P429, DOI 10.1097/00001756-199601310-00013; Planas AM, 1997, PROG NEUROBIOL, V51, P607, DOI 10.1016/S0301-0082(97)00004-X; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; RORDORF G, 1991, NEURON, V7, P1043, DOI 10.1016/0896-6273(91)90348-4; SHARP FR, 1991, J CEREBR BLOOD F MET, V11, P621, DOI 10.1038/jcbfm.1991.113; SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800; SIMON RP, 1991, J NEUROSCI, V11, P881; SINZ EH, 1997, J NEUROTRAUM, V14, P769; Soares HD, 1995, J NEUROSCI, V15, P8223; States BA, 1996, J CEREBR BLOOD F MET, V16, P1165, DOI 10.1097/00004647-199611000-00011; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; THILMANN R, 1986, ACTA NEUROPATHOL, V71, P88, DOI 10.1007/BF00687967; TISSIERES A, 1974, J MOL BIOL, V84, P389, DOI 10.1016/0022-2836(74)90447-1; UNEY JB, 1993, FEBS LETT, V334, P313, DOI 10.1016/0014-5793(93)80701-U; VASS K, 1988, ACTA NEUROPATHOL, V77, P128; VASS K, 1989, NEUROSCI LETT, V100, P259, DOI 10.1016/0304-3940(89)90695-2; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wong HR, 1997, BIOCHEM BIOPH RES CO, V231, P257, DOI 10.1006/bbrc.1997.6076; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N	63	28	32	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1998	15	3					171	181		10.1089/neu.1998.15.171			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZA547	WOS:000072375500002	9528917				2021-06-18	
J	Johnson, R				Johnson, R			How do people get back to work after severe head injury? A 10 year follow-up study	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; EMPLOYMENT; RETURN; REHABILITATION; PROGRAM	Sixty four patients, who were previously followed up about 3 years, 6 months post-injury, were investigated again 10 years or more after very severe head injury (post-traumatic amnesia more than 7 days). Of the total, 42% had re-established themselves in employment, a further 20% showed an irregular pattern of work, and the remainder had made little or no attempt to work at all. There were few changes in work status once 18 months to 2 years had elapsed since the injury, and the pattern of employment, once established, tended to remain stable. Settlement of compensation claims did not lead to improvement in work status, and in several cases the converse was true. The first follow-up study showed that support and "in vivo" training at work was essential in helping people back to work, and this could be effective even when there had been a severe brain injury with permanent disability. The longer term follow-up of these patients gave further support to the view that a gradual and supported return to work is essential after severe brain injury if a return to stable employment is to be achieved. A number of guidelines are identified which can help people return to work.	Addenbrookes Hosp, Dept Clin Neuropsychol, Lewin Rehabil Unit, Cambridge CB2 2QQ, England							Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CAIRNS H, 1942, P ROY SOC MED, V35, P299; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; GODFREY HPD, 1993, NEW ZEAL MED J, V106, P301; GREENWOOD RJ, 1993, CLIN REHABIL, V7, P248; HUMPHREY M, 1980, INJURY, V12, P107, DOI 10.1016/0020-1383(80)90133-3; Johnson R, 1987, Int Disabil Stud, V9, P49; JOHNSON R, 1987, INJURY, V18, P7, DOI 10.1016/0020-1383(87)90374-3; JOHNSON R, 1989, INJURY, V20, P5, DOI 10.1016/0020-1383(89)90034-X; Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; JOHNSON RP, 1987, CLIN REHABIL, V1, P319; Kreutzer J S, 1991, Int Disabil Stud, V13, P162; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; McMillan T. M., 1993, CLIN REHABIL, V7, P346; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; MILLER H, 1965, LANCET, V1, P225; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; ODDY M, 1984, CLOSED HEAD INJURY P, P108; OPCS, 1980, CLASS OCC; PARENTE R, 1991, J HEAD TRAUMA REHAB, V6, P35; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; ROBERTS AH, 1976, P ROY SOC MED, V69, P137, DOI 10.1177/003591577606900228; Sale P., 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [DOI 10.1097/00001199-199109000-00004, 10.1097/00001199-199109000-00004.]; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WELLER MPI, 1985, RECENT ADV CLIN PSYC, V5, P245; WEST M, 1991, ARCH PHYS MED REHAB, V72, P127	33	28	28	0	5	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JAN	1998	8	1					61	79		10.1080/713755552			19	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	YW987	WOS:000071994900005					2021-06-18	
J	Phillips, LL; Lyeth, BG; Hamm, RJ; Reeves, TM; Povlishock, JT				Phillips, LL; Lyeth, BG; Hamm, RJ; Reeves, TM; Povlishock, JT			Glutamate antagonism during secondary deafferentation enhances cognition and axo-dendritic integrity after traumatic brain injury	HIPPOCAMPUS			English	Article						neuroexcitation; deafferentation; spatial memory; receptor antagonists	COMBINED FLUID PERCUSSION; LONG-TERM POTENTIATION; ENTORHINAL CORTICAL LESION; RAT DENTATE GYRUS; NEUROTROPHIC FACTOR; MESSENGER-RNA; SYNAPTOPHYSIN IMMUNOREACTIVITY; HIPPOCAMPAL-NEURONS; CORTEX LESIONS; C-FOS	The combination of central fluid percussion traumatic brain injury (TBI) followed 24 h later by a bilateral entorhinal cortical deafferentation (BEG) produces profound cognitive morbidity. We recently showed that MK-801 given prior to TBI in this insult improved spatial memory for up to 15 days. In the present study we examine whether MK-801 treatment of the BEG component in the combined insult model affects cognitive recovery. Two strategies for drug treatment were tested. Fifteen minutes prior to the BEC lesion in the combined insult, rats were given i.p. doses of either 3 mg/kg (acute group) or 1 mg/kg (chronic group) MK-801. The acute group received no further injections, whereas the chronic group received 1 mg/kg MK-801 i.p, twice a day for 2 days post-BEG lesion. Two additional groups of animals received BEC lesion alone and either acute or chronic MK-801 treatment identical with the combined insult cases. Each group was then assessed for spatial memory deficits with the Morris water maze at days 11-15 and 60-64 postinjury. Both acute and chronic MK-801 treatment in the combined insult group significantly reduced spatial memory deficits at 15 days postinjury relative to untreated injured cases (P < .01). This reduction appeared more robust at 15 days and persisted for up to 64 days in the chronically treated group (P <.05). By contrast, neither acute nor chronic MK-801 treatment affected memory performance with the BEC insult alone. Immunocytochemical localization of parvalbumin showed that chronic administration of MK-801 in the combined insult cases attenuated the injury-induced dendritic atrophy of inhibitory neurons in the dentate gyrus and area CA1. Synaptophysin immunobinding revealed that chronic MK-801 treatment of the BEC component of the combined insult normalized the distribution of presynaptic terminals within the dentate gyrus. These results suggest that cognitive deficits produced by head trauma involving both neuroexcitation and deafferentation can be attenuated with chronic application of glutamatergic antagonists during the period of deafferentation injury and that this attenuation is correlated with axo-dendritic integrity. Hippocampus 1998;8:390-407. (C) 1998 Wiley-Liss, Inc.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Psychol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA	Phillips, LL (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980693,MCV Stn, Richmond, VA 23298 USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587, NS 29995, NS 20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995, P50NS012587, R01NS020193, P01NS012587] Funding Source: NIH RePORTER		Alexi T, 1997, NEUROSCIENCE, V78, P73, DOI 10.1016/S0306-4522(97)83046-1; BURGOS I, 1995, BRAIN RES, V692, P154, DOI 10.1016/0006-8993(95)00696-N; CALBAKA LM, 1992, NEUROBIOL AGING, V13, P283; CASTREN E, 1993, EXP NEUROL, V122, P244, DOI 10.1006/exnr.1993.1124; CLUSMANN H, 1994, NEUROSCIENCE, V61, P805, DOI 10.1016/0306-4522(94)90403-0; CONNER JM, 1994, J COMP NEUROL, V345, P409, DOI 10.1002/cne.903450307; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FUKUDA T, 1990, J COMP NEUROL, V302, P100, DOI 10.1002/cne.903020108; GIOVANNINI MG, 1994, J NEUROSCI, V14, P1358; GLOBUS MYT, 1991, NEUROSCI LETT, V127, P39, DOI 10.1016/0304-3940(91)90889-2; Gordon D. E., 1996, Society for Neuroscience Abstracts, V22, P2153; GUTHRIE KM, 1995, J COMP NEUROL, V352, P147, DOI 10.1002/cne.903520111; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1994, J NEUROSURG, V81, P267, DOI 10.3171/jns.1994.81.2.0267; HAUSINGER A, 1995, NEUROREPORT, V6, P637, DOI 10.1097/00001756-199503000-00013; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; HUGHES P, 1993, NEUROREPORT, V4, P183, DOI 10.1097/00001756-199302000-00017; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Keppel, 1991, DESIGN ANAL RES HDB; KESEBERG U, 1995, BEHAV BRAIN RES, V67, P255, DOI 10.1016/0166-4328(94)00156-A; Lee MY, 1997, J NEUROSCI, V17, P1137; LEVINE G, 1991, GUIDE SPSS ANAL VARI; LOESCHE J, 1977, BRAIN RES BULL, V2, P31, DOI 10.1016/0361-9230(77)90022-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MASLIAH E, 1991, EXP NEUROL, V113, P131, DOI 10.1016/0014-4886(91)90169-D; MATTSON MP, 1988, NEURON, V1, P865, DOI 10.1016/0896-6273(88)90134-1; MATTSON MP, 1989, BRAIN RES, V478, P337, DOI 10.1016/0006-8993(89)91514-X; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MIYAZAWA T, 1993, ACTA NEUROPATHOL, V85, P526; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; NITSCH R, 1992, P NATL ACAD SCI USA, V89, P5197, DOI 10.1073/pnas.89.11.5197; NITSCH R, 1993, HIPPOCAMPUS, V3, P247; NORUSIS MJ, SPSS WINDOWS ADV STA; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; PerezNavarro E, 1996, NEUROSCIENCE, V75, P345, DOI 10.1016/0306-4522(96)00336-3; Phillips LL, 1997, J NEUROSCI RES, V49, P197; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; PHILLIPS LL, 1994, NEUROSCIENCE, V58, P503, DOI 10.1016/0306-4522(94)90076-0; PHILLIPS LL, 1995, J NEUROTRAUM, V12, P964; Povlishock John T., 1995, P504; Reeves TM, 1997, NEUROSCIENCE, V77, P431, DOI 10.1016/S0306-4522(96)00486-1; Rossner S, 1996, J NEUROSCI RES, V45, P40; Schultz LM, 1997, NEUROSCIENTIST, V3, P226, DOI 10.1177/107385849700300410; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Shi L. Z., 1995, Yaoxue Xuebao, V30, P789; STROEMER RP, 1992, NEUROSCI LETT, V147, P21, DOI 10.1016/0304-3940(92)90765-Y; Takei N, 1997, J NEUROCHEM, V68, P370; TOMASULO RA, 1991, BRAIN RES, V561, P27, DOI 10.1016/0006-8993(91)90745-H; Wilson DA, 1996, BRAIN RES, V719, P62, DOI 10.1016/0006-8993(96)00083-2; WILSON RC, 1981, J NEUROPHYSIOL, V46, P324; Xing J, 1996, J NEUROPHYSIOL, V75, P184; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037	56	28	30	0	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	1050-9631			HIPPOCAMPUS	Hippocampus		1998	8	4					390	401		10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.0.CO;2-L			12	Neurosciences	Neurosciences & Neurology	116PC	WOS:000075732900007	9744424				2021-06-18	
J	Tate, R; Simpson, G; Flanagan, S; Coffey, M				Tate, R; Simpson, G; Flanagan, S; Coffey, M			Completed suicide after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						disability; neuropsychological impairment; suicide; traumatic brain injury	CLOSED-HEAD-INJURY; FOLLOW-UP; ADJUSTMENT	Suicide ideation and behaviors after traumatic brain injury (TBI) pose a dire, albeit infrequent, clinical emergency. The literature on suicide after TBI is sparse, but that on suicide in the general population may have limited applicability. Persons with TBI frequently experience impairments and disabilities that introduce additional complexities to the management of suicidality in this population. The current study examines in detail the premorbid psychosocial variables, injury details, and posttraumatic sequelae of eight completed suicides after TBI. The eight suicides were among 50 deaths occurring in 896 admissions to a regional brain injury rehabilitation service over a period of 18 years. The most notable feature of the group was the presence of psychiatric and emotional symptomatology in most cases, superimposed on a range of neuropsychological impairments. This combination imposed major limitations on the subjects' psychosocial reintegration, and we propose that it was in this context that they were vulnerable to suicide. The article concludes with recommendations for clinical management of people who exhibit suicide ideation or make suicide attempts after TBI.	LIVERPOOL HOSP,BRAIN INJURY REHABIL UNIT,LIVERPOOL,MERSEYSIDE,ENGLAND; BANKSTOWN LIDCOMBE MENTAL HLTH SERV,SYDNEY,NSW,AUSTRALIA	Tate, R (corresponding author), UNIV SYDNEY,DEPT PSYCHOL A16,SYDNEY,NSW 2006,AUSTRALIA.		Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060			ACHTE KA, 1971, ACTA PSYCHIAT SCAN S, V225, P1; *AUSTR BUR STAT, 1993, CAUS DEATH; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BECK AT, 1979, COGNITIVE THERAPY DE; BONGAR B, 1991, SUICIDAL PATIENT CLI; BROE GA, 1992, BRAIN IMPAIRMENT; EAMES P, 1990, REHABILITATION ADULT; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KLONOFF PS, 1995, J HEAD TRAUMA REHAB, V10, P16, DOI 10.1097/00001199-199512000-00005; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; LISHMAN WA, 1987, ORGANIC PSYCHIATRY; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ROBERTS AH, 1979, SEVERE ACCIDENTAL HE; ROY A, 1982, BRIT J PSYCHIAT, V141, P171, DOI 10.1192/bjp.141.2.171; SCHNEIDMAN ES, 1989, SUICIDE UNDERSTANDIN; SCHOTTE DE, 1987, J CONSULT CLIN PSYCH, V55, P49, DOI 10.1037/0022-006X.55.1.49; STENAGER EN, 1992, J NEUROL NEUROSUR PS, V55, P542, DOI 10.1136/jnnp.55.7.542; STENAGER EN, 1992, ARCH NEUROL-CHICAGO, V49, P1296, DOI 10.1001/archneur.1992.00530360098025; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260	23	28	28	0	3	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1997	12	6					16	28		10.1097/00001199-199712000-00003			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	YK459	WOS:A1997YK45900003					2021-06-18	
J	Baguley, IJ; Felmingham, KL; Lahz, S; Gordon, E; Lazzaro, I; Schotte, DE				Baguley, IJ; Felmingham, KL; Lahz, S; Gordon, E; Lazzaro, I; Schotte, DE			Alcohol abuse and traumatic brain injury: Effect on event-related potentials	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							AUDITORY ODDBALL TASK; CLOSED HEAD-INJURY; REACTION-TIME; P300; PERFORMANCE; VALIDATION; SEQUELAE; STIMULI; AMNESIA; MEMORY	Objective: To examine the individual and combined impact that traumatic brain injury (TBI) and heavy social use of alcohol have on electrophysiologic correlates of working memory and evaluation of task-relevant information. Design: Case-control study. Setting: University hospital brain injury rehabilitation unit. Participants: Forty male volunteers divided into four groups on the basis of their history of TBI and alcohol intake. Subjects with TBI had experienced a severe closed head injury at least 1 year before testing. Main Outcome Measure: Event-related potentials (ERPs) and neuropsychometric tests. Results: Groups showed no significant differences in average age or neuropsychological tests. TBI groups did not differ in time postinjury or on severity measures. Alcohol use measures were significantly greater in the two alcohol groups. N200 latency and P300 amplitude were impaired in heavy social drinkers and in nondrinking subjects with TBI relative to controls, but were significantly impaired in subjects with TBI who were also heavy social drinkers. Conclusion: The results indicate that although alcohol use and TBI independently produce mild alterations in some aspects of late ERP components, the ERP changes an significantly greater when alcohol use and TBI are combined. This study provides evidence that heavy social drinking after TBI has a measurable impact on electrophysiologic correlates of cognition. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	WESTMEAD HOSP,DEPT PSYCHOL MED,COGNIT NEUROSCI UNIT,WESTMEAD,NSW 2145,AUSTRALIA; UNIV SYDNEY,SYDNEY,NSW 2006,AUSTRALIA	Baguley, IJ (corresponding author), WESTMEAD HOSP,BRAIN INJURY REHABIL SERV,WESTMEAD,NSW 2145,AUSTRALIA.		Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; 			Babor TF, 1989, ALCOHOL USE DISORDER; BOHN MJ, 1995, J STUD ALCOHOL, V56, P423, DOI 10.15288/jsa.1995.56.423; CIESIELSKI KT, 1985, ALCOHOL ALCOHOLISM, V20, P403; COHEN HL, 1995, ALCOHOL CLIN EXP RES, V19, P469, DOI 10.1111/j.1530-0277.1995.tb01533.x; CONIGRAVE KM, 1995, ADDICTION, V90, P1349, DOI 10.1111/j.1360-0443.1995.tb03552.x; DEACON D, 1991, ELECTROEN CLIN NEURO, V78, P133, DOI 10.1016/0013-4694(91)90113-I; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; FITZGERALD PG, 1983, BIOL PSYCHOL, V17, P241, DOI 10.1016/0301-0511(83)90003-0; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; HAIG AR, 1995, ELECTROEN CLIN NEURO, V94, P288, DOI 10.1016/0013-4694(95)98480-V; HALGREN E, 1980, SCIENCE, V210, P803, DOI 10.1126/science.7434000; KASEDA Y, 1994, JPN J PSYCHIAT NEUR, V48, P23; KEUTZER JS, 1990, COGNITIVE REHABIL, V8, P14; KRULL KR, 1994, PROG NEURO-PSYCHOPH, V18, P1247, DOI 10.1016/0278-5846(94)90091-4; MEARNS J, 1993, J CLIN PSYCHOL, V49, P714, DOI 10.1002/1097-4679(199309)49:5<714::AID-JCLP2270490515>3.0.CO;2-H; NATAANEN R, 1986, CEREBRAL PSYCHOPHYSI, P169; NATAANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375; Nichols JM, 1996, J STUD ALCOHOL, V57, P125, DOI 10.15288/jsa.1996.57.125; OLBRICH HM, 1986, SURG NEUROL, V26, P112, DOI 10.1016/0090-3019(86)90362-9; ONOFRJ M, 1991, ACTA NEUROL SCAND, V83, P273, DOI 10.1111/j.1600-0404.1991.tb04700.x; OSCARBERMAN M, 1987, ALCOHOL, V4, P289, DOI 10.1016/0741-8329(87)90025-5; PARSONS OA, 1993, NEUROL CLIN, V11, P205; PARSONS OA, 1990, ALCOHOL CLIN EXP RES, V14, P746, DOI 10.1111/j.1530-0277.1990.tb01239.x; POLICH J, 1991, American Journal of EEG Technology, V31, P201; PORJESZ B, 1987, ALCOHOL, V4, P283, DOI 10.1016/0741-8329(87)90024-3; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; REGAN D, 1988, HUMAN BRAIN ELECTROP; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; SEGALOWITZ SJ, 1993, PSYCHOPHYSIOLOGY, V30, P451, DOI 10.1111/j.1469-8986.1993.tb02068.x; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; STEVENS J, 1991, APPL MULTIVARIATE ST; VERLEGER R, 1988, BEHAV BRAIN SCI, V11, P343, DOI 10.1017/S0140525X00058015; WIRSEN A, 1992, ELECTROEN CLIN NEURO, V84, P127, DOI 10.1016/0168-5597(92)90017-6	35	28	29	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	1997	78	11					1248	1253		10.1016/S0003-9993(97)90339-7			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	YE945	WOS:A1997YE94500014	9365356				2021-06-18	
J	LeesHaley, PR; Williams, CW; Zasler, ND; Marguilies, S; English, LT; Stevens, KB				LeesHaley, PR; Williams, CW; Zasler, ND; Marguilies, S; English, LT; Stevens, KB			Response bias in plaintiffs' histories	BRAIN INJURY			English	Article								This study investigated response bias in self-reported history of factors relevant to the assessment of traumatic brain injury, toxic brain injury and related emotional distress. Response bias refers to systematic error in self-report data. A total of 446 subjects (comprising 131 litigating and 315 non-litigating adults from five locations in the United States) completed a symptom questionnaire. Data were obtained from university faculty and students, from patients in clinics specializing in physiatry, neurology, and family medicine, and from plaintiffs undergoing forensic neuropsychological evaluations. Comparisons were made for litigant and non litigant ratings of their past and current cognitive and emotional functioning, including life in general, ability to concentrate, memory, depression, anxiety, alcohol, drugs, ability to work or attend school, irritability, headaches, confusion, self-esteem, and fatigue. Although there is no basis for hypothesizing plaintiffs to be healthier than the general population, plaintiffs rated their pre-injury functioning superior to non-plaintiffs. These findings suggest that response biases need to be taken into account by forensic examiners when relying on litigants' self-reports of pre-injury status.	LEES HALEY PSYCHOL CORP,WOODLAND HILLS,CA; NATL NEUROREHABIL CONSORTIUM INC,RICHMOND,VA; HLTH EDUC SERV,HUNTSVILLE,AL; UNIV KENTUCKY,COLL EDUC,DEPT SPECIAL EDUC & REHABIL COUNSELING,LEXINGTON,KY							Bartlett F.C., 1932, REMEMBERING; BRUNER JS, 1957, PSYCHOL REV, V64, P123, DOI 10.1037/h0043805; EICH E, 1985, PAIN, V23, P375, DOI 10.1016/0304-3959(85)90007-7; FEINSTEIN AR, 1982, NEW ENGL J MED, V307, P1611, DOI 10.1056/NEJM198212233072604; FEINSTEIN AR, 1979, J CHRON DIS, V18, P35; Fiske S.T., 1991, SOC COGNITION; GEHLBACH SH, 1983, INTERPRETING MED LIT; GOETHALS GR, 1973, J EXP PSYCHOL, V9, P491, DOI 10.1016/0022-1031(73)90030-9; KULIK JA, 1986, J PERS SOC PSYCHOL, V50, P587, DOI 10.1037/0022-3514.50.3.587; LEESHALEY PR, PSYCHOL REP, V79, P811; Markus H., 1985, HDB SOCIAL PSYCHOL, V1, P137; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; ROSS M, 1989, PSYCHOL REV, V96, P341, DOI 10.1037/0033-295X.96.2.341; Rothman K. J., 1986, MODERN EPIDEMIOLOGY; SWANN WB, 1981, J EXP SOC PSYCHOL, V17, P351, DOI 10.1016/0022-1031(81)90043-3; SWANN WB, 1981, J PERS SOC PSYCHOL, V41, P1119, DOI 10.1037/0022-3514.41.6.1119; SWANN WB, 1984, PSYCHOL PERSPECTIVES, P33; TAYLOR SE, 1981, SOCIAL COGNITION ONT, P89; Turk DC, 1988, REASONING INFERENCE	19	28	28	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	NOV	1997	11	11					791	799					9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	YA149	WOS:A1997YA14900003	9354256				2021-06-18	
J	AbouHamden, A; Blumbergs, PC; Scott, G; Manavis, J; Wainwright, H; Jones, N; McLean, J				AbouHamden, A; Blumbergs, PC; Scott, G; Manavis, J; Wainwright, H; Jones, N; McLean, J			Axonal injury in falls	JOURNAL OF NEUROTRAUMA			English	Article						falls; human head injury; axonal injury; amyloid precursor protein; axonal injury score; hypoxia-ischemia	AMYLOID PRECURSOR PROTEIN; ACUTE SUBDURAL-HEMATOMA; CLOSED-HEAD-INJURY; HUMAN BRAIN; TRAUMATIC COMA; LEUKO-ARAIOSIS; BETA-APP; LESIONS; DAMAGE; IMMUNOREACTIVITY	Amyloid precursor protein (APP) immunocytochemistry was used as a marker for axonal injury (AI) in a series of 16 cases of head trauma associated with fatal falls. Nine cases were falls from not more than the person's own height (falls from less than or equal to own height) and seven cases were falls from a distance greater than the person's own height (falls from > own height). AI was recorded on a series of line diagrams of standard brain sections divided into 116 sectors. AI around focal lesions (infarcts, hemorrhages, contusions) was distinguished from nonfocal axonal injury that was distant from any focal area of damage. The percentage of sectors showing focal AI provided the Focal Axonal Injury Score (FAIS) and the percentage showing nonfocal AI the Non-Focal Axonal Injury Score (NFAIS). The FAIS is a measure of secondary AI and the NFAIS of diffuse axonal injury (DAI). The percentage of sectors involved with AI (focal and nonfocal) provided the cumulative Axonal Injury Score (AIS). A semiquantitative grading system was also used to assess the severity of axonal injury in each sector and the sum of the grades from all sectors was expressed as a percentage to provide the Axonal Injury Severity Score (AISS). Widespread AI was present in all cases irrespective of the height of the fall. AI was present in the midbrain (94%), pens (94%), corpus callosum (100%), central grey matter (100%), and cerebral hemispheric white matter (94%). AIS ranged from 10 to 94 in falls from less than or equal to own height (mean 73) and from 38 to 92 in falls from > own height (mean 82). AISS ranged from 6 to 95 in falls from less than or equal to own height (mean 65) and 28 to 95 in falls from > own height (mean 72). There was no statistically significant difference in AIS or AISS between the two groups. The extent and severity of AI cannot be predicted from biomechanical data, such as the height of the fall, as the total AI in a given case is a variable mixture of Nonfocal AI (DAI) and Focal AI arising dy secondary mechanisms, and APP immunostaining is unable to distinguish primary from secondary AI. However, the combination of the Hypoxic-Ischemic Score (HIS) defined as the percentage of sectors showing any hypoxic-ischemic damage ranging from neuronal ''red cell change'' to infarction in conjunction with the FAIS and NFAIS provided a measure of the relative contribution of primary and secondary AI in a given brain.	UNIV ADELAIDE,DEPT NEUROSURG,ADELAIDE,SA,AUSTRALIA; UNIV ADELAIDE,ROAD ACCIDENT RES UNIT,NH & MRC,ADELAIDE,SA,AUSTRALIA	AbouHamden, A (corresponding author), INST MED & VET SCI,NEUROPATHOL LAB,POB 14,RUNDLE MALL,ADELAIDE,SA 5000,AUSTRALIA.						ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; ADAMS JH, 1984, LANCET, V2, P1420; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1986, J NEUROL NEUROSUR PS, V49, P1039, DOI 10.1136/jnnp.49.9.1039; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; ADAMS JH, 1992, GREENFIELDS NEUROPAT, P122; ADAMS JH, 1986, ACTA PATHOL LAB MED, V100, P485; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; COCHRAN E, 1991, AM J PATHOL, V139, P485; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; GULTEKIN BH, 1994, ARCH PATHOL LAB MED, V188, P168; HACHINSKI VC, 1987, ARCH NEUROL-CHICAGO, V44, P21, DOI 10.1001/archneur.1987.00520130013009; HEDREEN JC, 1994, J NEUROPATH EXP NEUR, V53, P663, DOI 10.1097/00005072-199411000-00013; HONKANEN R, 1991, INJURY, V22, P225, DOI 10.1016/0020-1383(91)90047-I; IMAJO T, 1992, AM J FOREN MED PATH, V13, P169; JONES NR, 1986, AUST NZ J SURG, V56, P907, DOI 10.1111/j.1445-2197.1986.tb01853.x; KAWAMURA J, 1991, STROKE, V22, P609, DOI 10.1161/01.STR.22.5.609; KOBARI M, 1990, ARCH NEUROL-CHICAGO, V47, P161, DOI 10.1001/archneur.1990.00530020061017; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVI L, 1990, ISRAEL J MED SCI, V26, P555; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MIKLOSSY J, 1991, J NEUROPATH EXP NEUR, V50, P1, DOI 10.1097/00005072-199101000-00001; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; North JB, 1991, P INT RES COUNC BIOK, P77; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; RICHARDS T, 1974, SURGERY, V75, P253; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; SAHUQUILLOBARRIS J, 1988, J NEUROSURG, V68, P894, DOI 10.3171/jns.1988.68.6.0894; SCHWEITZER JB, 1993, ACTA NEUROPATHOL, V85, P503; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHIGEMATSU K, 1992, AM J PATHOL, V140, P787; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; STONE JL, 1983, SURG NEUROL, V19, P216, DOI 10.1016/S0090-3019(83)80005-6; SUENAGA T, 1994, ACTA NEUROPATHOL, V87, P450; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; YAMAKI T, 1992, ACTA NEUROCHIR, V119, P153, DOI 10.1007/BF01541800; YAMASHIMA T, 1984, J NEUROL NEUROSUR PS, V47, P121, DOI 10.1136/jnnp.47.2.121	54	28	28	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1997	14	10					699	713		10.1089/neu.1997.14.699			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	YE057	WOS:A1997YE05700002	9383089				2021-06-18	
J	Wong, AMK; Lee, MY; Kuo, JK; Tang, FT				Wong, AMK; Lee, MY; Kuo, JK; Tang, FT			The development and clinical evaluation of a standing biofeedback trainer	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						biofeedback; postural symmetry; rehabilitation; standing training	HEMIPLEGIC PATIENTS; POSTURAL STABILITY; BALANCE	A new standing biofeedback training device, which includes a height-adjustable work table, weight-bearing sensors, and a real-time visual and auditory feedback system, has been developed for postural training. Sixty persons with hemiplegia after acute stroke or traumatic brain injury were randomly divided into Group A (experimental) and Group B (control). After a training period of 4 weeks, the percentage of postural in Group A and Group B was reduced from 17.2 +/- 10.8% and 17.0 +/- 10.00% to 3.5 +/- 2.2% and 10.1 +/- 16.4 percent, respectively (p=0.003). There was no significant difference between subjects with right or left hemiplegia. The results indicated that this device had a positive training effect on stance symmetry in hemiplegic subjects.	CHANG GUNG UNIV, DEPT ENGN MECH, TAYUAN, TAIWAN	Wong, AMK (corresponding author), CHANG GUNG MEM HOSP, DEPT REHABIL MED, 199 TUNG HWA N RD, TAIPEI 10591, TAIWAN.		Wong, Alice M. K./ABI-1000-2020	Wong, Alice M. K./0000-0003-3586-1292			BOHANNON RW, 1985, PHYS THER, V65, P1323, DOI 10.1093/ptj/65.9.1323; BROOKS VB, 1983, PHYS THER, V63, P664, DOI 10.1093/ptj/63.5.664; DETTMANN MA, 1987, AM J PHYS MED REHAB, V66, P77; DICKSTEIN R, 1984, PHYS THER, V64, P19, DOI 10.1093/ptj/64.1.19; DIFABIO RP, 1990, PHYS THER, V70, P542, DOI 10.1093/ptj/70.9.542; DIFABIO RP, 1991, ARCH PHYS MED REHAB, V72, P292; GOLDIE PA, 1989, ARCH PHYS MED REHAB, V70, P510; HOCHERMAN S, 1984, ARCH PHYS MED REHAB, V65, P588; KEENAN MA, 1984, CLIN ORTHOP RELAT R, P165; KOTTKE FJ, 1978, ARCH PHYS MED REHAB, V59, P567; Mckay M, 1976, J BIOMECH, V9, P453; NASHNER LM, 1979, POSTURE MOVEMENT, P243; SHUMWAYCOOK A, 1988, ARCH PHYS MED REHAB, V69, P395; TWITCHELL TE, 1951, BRAIN, V74, P443, DOI 10.1093/brain/74.4.443; WALL JC, 1986, ARCH PHYS MED REHAB, V67, P550; WINSTEIN CJ, 1989, ARCH PHYS MED REHAB, V70, P755; WU SH, 1990, J OCCUPATIONAL THERA, V8, P1	17	28	28	0	4	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.	JUL	1997	34	3					322	327					6	Rehabilitation	Rehabilitation	XK919	WOS:A1997XK91900010	9239626				2021-06-18	
J	Prough, DS; Lang, J				Prough, DS; Lang, J			Therapy of patients with head injuries: Key parameters for management	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	14th Bodensee Symposium on Microcirculation: Small Volume Resuscitation in Head Injury	JUN 14-16, 1996	BODENSEE, GERMANY				CEREBRAL BLOOD-FLOW; HYPERTONIC FLUID RESUSCITATION; 7.5-PERCENT SODIUM-CHLORIDE; RANDOMIZED CLINICAL-TRIAL; SYSTEMIC OXYGEN DELIVERY; CRITICALLY ILL PATIENTS; TRAUMATIC BRAIN INJURY; HEMORRHAGIC-SHOCK; INTRACRANIAL-PRESSURE; AGGRESSIVE TREATMENT	Background: Secondary brain injury, presumed secondary to ischemia, increases the mortality and morbidity of traumatic brain injury. Although many mechanisms appear to be involved, many potential ischemic insults result from changes in readily observable physiologic variables. Methods: A focused search of scientific articles published in English to determine what data are available to suggest parameters within which key physiologic variables should be maintained. Results: Few data demonstrate that maintenance of variables within specific ranges alters outcome; however, considerable evidence establishes associations with poor outcome and hypotension, intracranial hypertension, and cerebral venous saturation. Key parameters vary somewhat based upon the phase of treatment after injury. Other variables, such as systemic oxygen delivery and brain saturation measured by near-infrared spectroscopy, are less well linked to outcome. Conclusions: Further research is necessary to establish that manipulation of physiologic variables to maintain them within preset ranges improves outcome.		Prough, DS (corresponding author), UNIV TEXAS, MED BRANCH, DEPT ANESTHESIOL, GALVESTON, TX 77555 USA.		Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X			BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BISHOP MH, 1995, J TRAUMA, V38, P780, DOI 10.1097/00005373-199505000-00018; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699; BRAZY JE, 1985, PEDIATRICS, V75, P217; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Chesnut R M, 1995, New Horiz, V3, P366; Chesnut R M, 1995, New Horiz, V3, P581; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; DARBY JM, 1988, NEUROSURGERY, V23, P84, DOI 10.1227/00006123-198807000-00014; Delpy D T, 1989, Adv Exp Med Biol, V248, P41; DELPY DT, 1988, PHYS MED BIOL, V33, P1433, DOI 10.1088/0031-9155/33/12/008; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; GATTINONI L, 1996, YB INTENSIVE CARE EM, P308; Ghajar J, 1995, New Horiz, V3, P395; GOETTING MG, 1990, CRIT CARE MED, V18, P1220, DOI 10.1097/00003246-199011000-00006; GROSS D, 1990, SURG GYNECOL OBSTET, V170, P106; GUNNAR W, 1989, BRAZ J MED BIOL RES, V22, P287; GUNNAR W, 1988, SURGERY, V103, P398; HARTL R, 1995, SHOCK, V3, P274; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; Heyland DK, 1996, CRIT CARE MED, V24, P517, DOI 10.1097/00003246-199603000-00025; JING ZA, 1992, J TRAUMA, V33, P83, DOI 10.1097/00005373-199207000-00016; JOBSISVANDERVLI.FF, 1987, ADV OXYGEN MONITORIN, P209; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Lang E W, 1995, New Horiz, V3, P400; LANIER WL, 1987, ANESTHESIOLOGY, V66, P39, DOI 10.1097/00000542-198701000-00008; LONGSTRETH WT, 1986, NEUROLOGY, V36, P1186, DOI 10.1212/WNL.36.9.1186; Marion D W, 1995, New Horiz, V3, P439; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; METRANGOLO L, 1995, CRIT CARE MED, V23, P1971, DOI 10.1097/00003246-199512000-00005; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Myerson A, 1927, ARCH NEURO PSYCHIATR, V17, P807, DOI 10.1001/archneurpsyc.1927.02200360087006; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1987, CEREBRAL VASCULAR DI, V6, P251; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; Pollard V, 1996, ANESTH ANALG, V82, P278, DOI 10.1097/00000539-199602000-00011; Pollard V, 1996, ANESTH ANALG, V82, P269, DOI 10.1097/00000539-199602000-00010; PROCTOR HJ, 1984, SURGERY, V96, P273; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; PROUGH DS, 1986, J NEUROSURG, V64, P627, DOI 10.3171/jns.1986.64.4.0627; Robertson C S, 1995, New Horiz, V3, P410; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SCALEA TM, 1990, J TRAUMA, V30, P129, DOI 10.1097/00005373-199002000-00001; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; SCHMOKER JD, 1992, J TRAUMA, V33, P476, DOI 10.1097/00005373-199209000-00024; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SMITH DS, 1990, ANESTHESIOLOGY, V73, P12, DOI 10.1097/00000542-199007000-00003; STUART GG, 1983, J NEUROSURG, V59, P601, DOI 10.3171/jns.1983.59.4.0601; SWAN HJC, 1970, NEW ENGL J MED, V283, P447, DOI 10.1056/NEJM197008272830902; TIGHE D, 1995, CRIT CARE MED, V23, P1997, DOI 10.1097/00003246-199512000-00008; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; VRIES JK, 1973, J NEUROSURG, V39, P416, DOI 10.3171/jns.1973.39.3.0416; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; WHITLEY JM, 1991, SURGERY, V110, P514; YU MH, 1995, CRIT CARE MED, V23, P1025, DOI 10.1097/00003246-199506000-00006; Zornow M H, 1995, New Horiz, V3, P488	78	28	28	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	1997	42	5		S			S10	S18		10.1097/00005373-199705001-00003			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	XE879	WOS:A1997XE87900004	9191690				2021-06-18	
J	Cazzadori, A; DiPerri, G; Vento, S; Bonora, S; Fendt, D; Rossi, M; Lanzafame, M; Mirandola, F; Concia, E				Cazzadori, A; DiPerri, G; Vento, S; Bonora, S; Fendt, D; Rossi, M; Lanzafame, M; Mirandola, F; Concia, E			Aetiology of pneumonia following isolated closed head injury	RESPIRATORY MEDICINE			English	Article							MECHANICALLY VENTILATED PATIENTS; PROTECTED SPECIMEN BRUSH; RESPIRATORY-TRACT INFECTIONS; MULTIPLE TRAUMA PATIENTS; CRITICALLY ILL PATIENTS; NOSOCOMIAL PNEUMONIA; BRONCHOALVEOLAR LAVAGE; STAPHYLOCOCCUS-AUREUS; BACTERIAL PNEUMONIA; RISK-FACTORS		UNIV VERONA, BRONCHOSCOPY UNIT, I-37100 VERONA, ITALY; UNIV VERONA, INST IMMUNOL & INFECT DIS, I-37100 VERONA, ITALY; UNIV VERONA, INST NEUROSURG, I-37100 VERONA, ITALY			bonora, stefano/AAC-2993-2019; Vento, Sandro/I-1662-2017; Cazzadori, Angelo/AAH-1058-2019	bonora, stefano/0000-0002-7537-3341; Vento, Sandro/0000-0003-0084-4062; 			AERDTS SJA, 1991, CHEST, V100, P783, DOI 10.1378/chest.100.3.783; BRAUN SR, 1987, CRIT CARE MED, V15, P930; CHASTRE J, 1988, AM J MED, V85, P499; Chesnut Randall M., 1993, P203; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; ESPERSEN F, 1981, SCAND J INFECT DIS, V13, P161, DOI 10.3109/inf.1981.13.issue-3.01; ESPERSEN F, 1981, J INFECT DIS, V144, P19, DOI 10.1093/infdis/144.1.19; FAGON JY, 1988, AM REV RESPIR DIS, V138, P110, DOI 10.1164/ajrccm/138.1.110; FARR BM, 1994, RESP INFECTIONS, P249; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; JIMENEZ P, 1989, CRIT CARE MED, V17, P882, DOI 10.1097/00003246-198909000-00007; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; JOHANSON WG, 1988, AM REV RESPIR DIS, V137, P259, DOI 10.1164/ajrccm/137.2.259; LAFORCE FM, 1981, AM J MED, V70, P664, DOI 10.1016/0002-9343(81)90593-3; LANGER M, 1989, AM REV RESPIR DIS, V140, P302, DOI 10.1164/ajrccm/140.2.302; LANGER M, 1987, INTENS CARE MED, V13, P342; MACRAE W, 1981, BRIT MED J, V283, P1220, DOI 10.1136/bmj.283.6301.1220; MANDELLI M, 1986, LANCET, V2, P1094; MEDURI GU, 1992, CHEST, V102, pS557, DOI 10.1378/chest.102.5_Supplement_1.557S; PINGLETON SK, 1992, CHEST, V102, pS553, DOI 10.1378/chest.102.5_Supplement_1.553S; RELLO J, 1992, CHEST, V102, P525, DOI 10.1378/chest.102.2.525; RELLO J, 1991, CHEST, V100, P439, DOI 10.1378/chest.100.2.439; RELLO J, 1992, EUR RESPIR J, V5, P1249; RELLO J, 1990, AM REV RESPIR DIS, V142, P1320, DOI 10.1164/ajrccm/142.6_Pt_1.1320; STOUTENBEEK CP, 1987, J TRAUMA, V27, P357, DOI 10.1097/00005373-198704000-00003; SWINSCOW T, 1983, STATISTICS SQUARE ON, P28; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523; TORRES A, 1989, AM REV RESPIR DIS, V140, P306, DOI 10.1164/ajrccm/140.2.306; TORRES A, 1993, AM REV RESPIR DIS, V147, P952, DOI 10.1164/ajrccm/147.4.952; WIMBERLEY N, 1979, AM REV RESPIR DIS, V119, P337	30	28	29	0	2	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	0954-6111	1532-3064		RESP MED	Respir. Med.	APR	1997	91	4					193	199		10.1016/S0954-6111(97)90038-X			7	Cardiac & Cardiovascular Systems; Respiratory System	Cardiovascular System & Cardiology; Respiratory System	WV181	WOS:A1997WV18100002	9156141				2021-06-18	
J	Bowen, JM; Clark, E; Bigler, ED; Gardner, M; Nilsson, D; Gooch, J; Pompa, J				Bowen, JM; Clark, E; Bigler, ED; Gardner, M; Nilsson, D; Gooch, J; Pompa, J			Childhood traumatic brain injury: Neuropsychological status at the time of hospital discharge	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							HEAD-INJURY; RECOVERY	The present study examined the status at the time of hospital discharge of 22 children who had sustained moderate to severe closed head injuries. Despite an average length of stay of 46 days, on average the children performed significantly below normal on cognitive, memory, and motor tests. The children who did the worst were those who sustained their injuries riding in a vehicle, as opposed to being hit by a vehicle while walking or riding a bicycle, No reliable associations were found between neuroimaging data and cognitive measures; however, children whose scans showed more diffuse severe injury (e.g. white matter hemorrhages) performed more poorly than those who did not, Of further importance were detailed morphometric analyses of tissue quantity and ventricular volume that showed significantly increased ventricle to brain ratios (VBR) over a 3 to 4 week period following injury.	BRIGHAM YOUNG UNIV,DEPT PSYCHOL,PROVO,UT 84602; BRIGHAM YOUNG UNIV,NEUROL LEARNING & BEHAV CLIN,PROVO,UT 84602; BRIGHAM YOUNG UNIV,PRIMARY CHILDRENS MED CTR,PROVO,UT 84602	Bowen, JM (corresponding author), UNIV UTAH,DEPT EDUC PSYCHOL,327 MILTON BENNION HALL,SALT LAKE CITY,UT 84112, USA.						ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; BIGLER ED, 1992, BRAIN INJURY, V6, P1; BLATTER DD, 1995, AM J NEURORADIOL, V15, P1; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; POLISSAR NL, 1994, BRAIN INJURY, V8, P249, DOI 10.3109/02699059409150977; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333	9	28	29	0	3	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	JAN	1997	39	1					17	25					9	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	WA301	WOS:A1997WA30100005	9003725				2021-06-18	
J	Brzuzy, S; Speziale, BA				Brzuzy, S; Speziale, BA			Persons with traumatic brain injuries and their families: Living arrangements and well-being post injury	SOCIAL WORK IN HEALTH CARE			English	Article							SEVERE HEAD-INJURY; RELATIVES VIEW; RECOVERY	This article discusses an empirical study of 66 single, adult survivors of moderate to severe traumatic brain injury (TBI) who were either living alone or living with their parents. The researchers determined perceived levels of stress, life satisfaction, family satisfaction, and community integration within the two groups. Survivors, who were typically ten years or more pose injury, and selected family members, responded to structured telephone interviews and standardized questionnaires. The findings of the study and their implications point to a need for practice interventions that will reestablish life cycle trajectories and meet developmental needs, as well as reintegrate affected individuals and their families into larger social systems.	OHIO STATE UNIV,COLL SOCIAL WORK,COLUMBUS,OH 43210; ARIZONA STATE UNIV,SCH SOCIAL WORK,TEMPE,AZ 85287							BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Imber-Black E., 1988, FAMILIES LARGER SYST; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; *NAT HEAD INJ FDN, 1988, FACT SHEET; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; *OH REH SERV COMM, 1992, OH HEAD INJ NEEDS AS; OLSON DH, 1985, FAMILY INVENTORIES, P43; PATTERSON JM, 1989, FAMILY SYSTEMS MED, P95; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Rolland J. S., 1994, FAMILIES ILLNESS DIS; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009	27	28	28	0	1	HAWORTH PRESS INC	BINGHAMTON	10 ALICE ST, BINGHAMTON, NY 13904-1580	0098-1389			SOC WORK HEALTH CARE	Soc. Work Health Care		1997	26	1					77	88		10.1300/J010v26n01_05			12	Social Work	Social Work	YJ943	WOS:A1997YJ94300005	9406340				2021-06-18	
J	Geldmacher, DS; Hills, EC				Geldmacher, DS; Hills, EC			Effect of stimulus number, target-to-distractor ratio, and motor speed on visual spatial search quality following traumatic brain injury	BRAIN INJURY			English	Article							NEGLECT; PERFORMANCE; ATTENTION; DISEASE	The object of this study was to investigate stimulus effects and motor limitations on visuospatial performance after traumatic blain injury (TBI). Previous findings have not fully explained the basis of attentional impairments after TBI. There has been little study of the spatial aspects of attention and information processing in this group. We studied 20 patients after severe TBI and 21 healthy controls. Four random-array letter cancellation tasks, varying in number of stimuli (50 and 100) and target-to-distracter ratio (1:4 and 1:9) were employed. Performance was calculated from the number and proportion of cancelled targets, as well as time to completion. TBI subjects were slower on finger tapping and achieved lower cancellation perfomance scores. Both TBI subjects and controls performed better on tasks with target-to-distractor (T/D) ratios of 1:4 than on those with 1:9. There was no effect of stimulus number. We conclude that there are both quantitative (speed) and qualitative contributors to impaired visuospatial ability following TBI. Motor impairments may slow the overall cancellation performance, but the differential effect of T/D ratio in the two populations suggests that TBI impairs quality of research. Accounting for both speed and accuracy suggests increased utility for the cancellation paradigm in clinical and research assessment of visuospatial attention.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT NEUROL, NEW BRUNSWICK, NJ 08903 USA; UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT REHABIL MED, NEW BRUNSWICK, NJ 08903 USA; JOHN F KENNEDY MED CTR, JFK JOHNSON REHABIL INST, CTR HEAD INJURIES, EDISON, NJ USA; JOHN F KENNEDY MED CTR, JFK JOHNSON REHABIL INST, DEPT REHABIL MED, EDISON, NJ USA							ALBERT ML, 1973, NEUROLOGY, V23, P658, DOI 10.1212/WNL.23.6.658; FOLDI NS, 1992, J GERONTOL, V47, pP146, DOI 10.1093/geronj/47.3.P146; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; GELDMACHER DS, 1995, NEUROPSY NEUROPSY BE, V8, P259; GELDMACHER DS, 1994, NEUROPSY NEUROPSY BE, V7, P275; Hagen C., 1972, LEVELS COGNITIVE FUN; HEILMAN KM, 1993, CLIN NEUROPSYCHOLOGY, P279; LEVIN HS, 1988, SCAND J REHABIL MED, P33; LEZAK M, 1983, NEUROPSYCHOLOGICAL A, P554; MCNENY R, 1990, NEUROREHABILITATION, V1, P72; Mesulam M., 1985, PRINCIPLES BEHAV NEU; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1987, NEUROBEHAVIORAL RECO, P390; Shum D. H. K., 1990, CLIN NEUROPSYCHOL, V4, P151, DOI DOI 10.1080/13854049008401508; STONE SP, 1991, J NEUROL NEUROSUR PS, V54, P345, DOI 10.1136/jnnp.54.4.345; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VILLARDITA C, 1983, ARCH NEUROL-CHICAGO, V40, P737, DOI 10.1001/archneur.1983.04050110055008; WEINTRAUB S, 1987, ARCH NEUROL-CHICAGO, V44, P621, DOI 10.1001/archneur.1987.00520180043014	20	28	28	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	1997	11	1					59	66		10.1080/026990597123818			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WB723	WOS:A1997WB72300006	9012552				2021-06-18	
J	Vaz, R; Sarmento, A; Borges, N; Cruz, C; Azevedo, I				Vaz, R; Sarmento, A; Borges, N; Cruz, C; Azevedo, I			Ultrastructural study of brain microvessels in patients with traumatic cerebral contusions	ACTA NEUROCHIRURGICA			English	Article						blood-brain barrier; brain oedema; head trauma; ultrastructure	BLUNT HEAD TRAUMA; WHITE-MATTER EDEMA; ACUTE RESPONSES; INJURY; MODEL; RATS; TOPOGRAPHY; MEMBRANE	Brain tissue from ii patients with traumatic cerebral contusions submitted to surgery was studied. Control biopsy specimens were obtained from 5 patients undergoing ventriculo-peritoneal shunts for ''communicating'' hydrocephalus. After collection, the small fragments were fixed by immersion in glutaraldehyde-osmium and embedded in Epon. Semi-thin sections stained with toluidine blue were observed with the light microscope. Thin sections stained with lead citrate and uranyl acetate were observed using a Jeol electron microscope. In tissues from patients with head trauma a clear space most probably corresponding to fluid accumulation was systematically observed around microvessels. Ultrastructurally endothelial cells from these specimens exhibited signs of marked intracellular oedema, tight junctions being intact. Pinocytotic activity was increased, mainly at the abluminal surface. Swelling of astrocytic perivascular processes and the appearance of macrophagic cells with voluminous lysosomes were also observed. The authors conclude that the oedema of endothelial cells probably represent a central fact in the pathophysiology of traumatic brain oedema and speculate on the putative involvement of stretch-activated receptors in this condition.	HOSP SAO JOAO, FAC MED, DEPT NEUROL & NEUROSURG, OPORTO, PORTUGAL; HOSP SAO JOAO, FAC MED, DEPT THERAPEUT & PHARMACOL, OPORTO, PORTUGAL			Borges, Nuno/K-7051-2013; Sarmento, Antonio/M-5235-2013; Cruz, Celia/K-3977-2013	Sarmento, Antonio/0000-0001-5269-7231; Cruz, Celia/0000-0001-8922-5713; Borges, Nuno/0000-0001-6357-0615; Vaz, Rui/0000-0001-7527-8187			BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; BULLOCK R, 1985, J NEUROSURG, V63, P64, DOI 10.3171/jns.1985.63.1.0064; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EBISU T, 1993, JMRI-J MAGN RESON IM, V3, P863, DOI 10.1002/jmri.1880030612; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; HAGIWARA N, 1992, J PHYSL, V456, P283; Hariri R J, 1994, Neurosurg Clin N Am, V5, P687; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; LONG DM, 1982, CLIN NEUR, V29, P174; MARMAROU A, 1994, ACTA NEUROCHIR, P421; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; NARUSE K, 1993, AM J PHYSIOL, V264, pC1037; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; POPP R, 1992, J PHYSIOL-LONDON, V454, P435, DOI 10.1113/jphysiol.1992.sp019272; RINDER L, 1968, ACTA NEUROPATHOL, V11, P183; SEVICK RJ, 1992, RADIOLOGY, V185, P687, DOI 10.1148/radiology.185.3.1438745; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TORNHEIM PA, 1984, J NEUROSURG, V60, P473, DOI 10.3171/jns.1984.60.3.0473; TORNHEIM PA, 1983, J NEUROSURG, V59, P431, DOI 10.3171/jns.1983.59.3.0431; TORNHEIM PA, 1981, J NEUROSURG, V55, P407, DOI 10.3171/jns.1981.55.3.0407; TORNHEIM PA, 1985, BRAIN RES, V337, P81, DOI 10.1016/0006-8993(85)91611-7; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P	34	28	28	0	2	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		1997	139	3					215	220		10.1007/BF01844754			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	WQ307	WOS:A1997WQ30700019	9143587				2021-06-18	
J	Deshpande, SA; Millis, SR; Reeder, KP; Fuerst, D; Ricker, JH				Deshpande, SA; Millis, SR; Reeder, KP; Fuerst, D; Ricker, JH			Verbal learning subtypes ire traumatic brain injury: A replication	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							HEAD-INJURY; 1-YEAR; COMA	Traumatic brain injury (TBI) has been associated with memory impairments, but the severity and qualitative aspects of such impairment do not appear homogeneous across patients. This study sought to replicate an earlier investigation that found distinct verbal learning subtypes in TBI using the California Verbal Learning Test (CVLT). CVLT data from 88 acute rehabilitation inpatients with mild, moderate, and severe traumatic brain injuries were analyzed with multiple cluster analytic techniques. Cluster analyses yielded five learning subtypes, three of which appeared similar to the subtypes previously identified as Active, Disorganized, and Passive subtypes, and two that appeared similar to the Deficient subgroup. Traumatic brain injury appears to be characterized by heterogeneous, but fairly reliable, verbal learning subtypes that can be detected early postinjury.	REHABIL INST MICHIGAN,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DETROIT,MI 48202; UNIV WINDSOR,WINDSOR,ON N9B 3P4,CANADA				Ricker, Joseph/0000-0003-3415-991X			BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Benton AL, 1983, MULTILINGUAL APHASIA; BLASHFIELD RK, 1980, J CONSULT CLIN PSYCH, V48, P456; CROSSON B, 1989, CLIN NEUROPSYCHOL, V3, P29, DOI DOI 10.1080/13854048908404074; DELIS D, 1987, CALIFORNIA VERBAL LE; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FRIDLUND AJ, 1987, IBM USERS GUIDE CVLT; FUERST DR, 1993, J ABNORM CHILD PSYCH, V21, P597, DOI 10.1007/BF00916445; Haut M., 1992, NEUROPSYCHOLOGY, V6, P51; Heaton R. K, 1981, WISCONSIN CARD SORTI; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; MACQUEEN J, 1967, 5TH P BERK S MATH ST, V1, P281; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; RAND WM, 1971, J AM STAT ASSOC, V66, P846, DOI 10.2307/2284239; Reitan RM., 1985, HALSTEAD REITAN NEUR; SARLE WS, 1985, SAS USERS GUIDE STAT, V5, P255; SOKAL ROBERT R., 1958, UNIV KANSAS SCI BULL, V38, P1409; SOrensen T, 1948, K DANSKE VIDENSK SEL, V5, P1; TEASDALE G, 1974, LANCET, V2, P81; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; Wechsler D., 1987, WECHSLER MEMORY SCAL	23	28	28	0	2	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	1996	18	6					836	842		10.1080/01688639608408306			7	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	WJ027	WOS:A1996WJ02700006	9157108				2021-06-18	
J	Greene, KA; Jacobowitz, R; Marciano, FF; Johnson, BA; Spetzler, RF; Harrington, TR				Greene, KA; Jacobowitz, R; Marciano, FF; Johnson, BA; Spetzler, RF; Harrington, TR			Impact of traumatic subarachnoid hemorrhage on outcome in nonpenetrating head injury .2. Relationship to clinical course and outcome variables during acute hospitalization	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Annual Meeting of the American-College-of-Surgeons Committee-on-Trauma-for-the-Resident	APR, 1994	WASHINGTON, DC	Amer Coll Surgeons, Comm Trauma Resident			CEREBRAL BLOOD-FLOW; ANGIOGRAPHIC FINDINGS; SEVERITY SCORE; ARTERIAL SPASM; BRAIN INJURY; METABOLISM; COMA; CIRCULATION; ULTRASOUND; PRESSURE	Patients with a nonpenetrating head injury and traumatic subarachnoid hemorrhage (tSAH) on admission head computed tomography scan (n = 240) were compared with patients without tSAH matched in terms of admission postresuscitation Glasgow Coma Scale (GCS) values. age, ses, and the presence of orae or more types of intracranial mass lesions, Admission Injury Severity Score was higher only in tSAH patients with admission GCS scores between 13 and 15; GCS values at 6, 24, and 48 hours were lower for tSAH patients. Patients with tSAH underwent fewer craniotomies, but more than twice as many tSAH patients had high intracranial pressure at the time of ventriculostomy placement and 6 hours after admission, tSAH patients underwent more chest procedures and their incidence of hypoxia and hypotension was greater, tSAH patients spent more days in intensive care unit, more total days hospitalized, and had worse Glasgow Outcome Scale scores at acute hospital discharge. Fewer tSAH patients were discharged home, and almost 1.5 times as many tSAH patients died during hospitalization. Given a similar overall degree of injury at admission, patients with tSAH associated with a nonpenetrating head injury had a worse outcome than similar patients without tSAH.	ST JOSEPHS HOSP,BARROW NEUROL INST,DIV NEUROL SURG,PHOENIX,AZ; ST JOSEPHS HOSP,BARROW NEUROL INST,DIV NEURORADIOL,PHOENIX,AZ; ARIZONA STATE UNIV,DEPT MATH,TEMPE,AZ 85287							ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BAIGELMAN W, 1981, NEUROSURGERY, V9, P729, DOI 10.1227/00006123-198112000-00021; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BECKMAN DL, 1985, CENTRAL NERVOUS SYST, P417; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; COLUMELLA F, 1963, ACTA RADIOL DIAGN, V1, P239, DOI 10.1177/028418516300100217; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Enevoldsen E, 1986, Acta Neurochir Suppl (Wien), V36, P133; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FALSETTI HL, 1966, DIS CHEST, V49, P420, DOI 10.1378/chest.49.4.420; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; GREITZ T, 1961, ANGIOGRAPHY, P95; GROLIMUND P, 1988, LANCET, V1, P1173; HUBER P, 1963, Fortschr Geb Rontgenstr Nuklearmed, V98, P292; JENNETT B, 1975, LANCET, V1, P480; LEEDS NE, 1966, ACTA RADIOL DIAGN, V5, P320, DOI 10.1177/02841851660050P135; LEROUX PD, 1992, NEUROSURGERY, V31, P678, DOI 10.1227/00006123-199210000-00010; LEVY ML, 1993, NEUROSURGERY, V32, P532, DOI 10.1227/00006123-199304000-00007; LIN JPT, 1966, ACTA RADIOL DIAGN, V5, P341, DOI 10.1177/02841851660050P138; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; LUERSSEN TG, 1989, INTRACRANIAL PRESSUR, P598; MACPHERS.P, 1973, J NEUROL NEUROSUR PS, V36, P1069, DOI 10.1136/jnnp.36.6.1069; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MILLER JD, 1980, CEREBRAL ARTERIAL SP, P476; MUIZELAAR JP, 1989, TXB HEAD INJURY, P221; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; RUTLEDGE R, 1993, AM J SURG, V166, P244, DOI 10.1016/S0002-9610(05)80966-3; SEILER RW, 1986, J NEUROSURG, V64, P594, DOI 10.3171/jns.1986.64.4.0594; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; TEASDALE G, 1974, LANCET, V2, P81; VILATO RJ, 1962, NEURO-CHIR, V8, P217; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; Wilkins R H, 1990, Neurosurg Clin N Am, V1, P329; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626; WILKINS RH, 1980, CEREBRAL ARTERIAL SP, P472	48	28	29	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1996	41	6					964	971		10.1097/00005373-199612000-00004			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	VY407	WOS:A1996VY40700004	8970547				2021-06-18	
J	Bowman, ML				Bowman, ML			Ecological validity of neuropsychological and other predictors following head injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							TRAUMATIC BRAIN INJURY; PSYCHOSOCIAL CONSEQUENCES; WORK STATUS; RECOVERY; EMPLOYMENT; IMPAIRMENT; SYMPTOMS; TESTS	This study evaluated the predictive value of neuropsychological variables as compared to three other types of variables (demographic, medical, and emotional) in predicting three outcomes (occupational function:OccF; activity impairment:AI; and pension impairment percent) in 483 head-injured ambulatory workers. OccF was equally well-predicted by neuropsychological or demographic variable-families. Al was best predicted by neuropsychological or emotional variable-families, and pension impairment percent was predicted equally well by all but emotional variable-families. Cross-validation showed good stability of the level of prediction. Discriminant analysis correctly classified 72% of subjects as Un/Employed. Neuropsychological test performance is related to important behavior in outpatient brain-injury survivors.		Bowman, ML (corresponding author), SIMON FRASER UNIV, DEPT PSYCHOL, BURNABY, BC V5A 1S6, CANADA.						American Medical Association, 1990, GUID EV PERM IMP; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; *BMDP, 1990, BMDP STAT SOFTW SG I; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; CHUNG F, 1990, ANESTH ANALG, V71, P217; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P489; DIAMOND R, 1988, INT J CLIN NEUROPSYC, V10, P35; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FISHER J, 1959, J CONSULT PSYCHOL, V23, P400, DOI 10.1037/h0044080; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; GODFREY HPD, 1993, NEW ZEAL MED J, V106, P301; GRONWALL D, 1974, LANCET, V2, P605; Hathaway S. R., 1989, MINNESOTA MULTIPHASI; Hathaway SR, 1951, MINNESOTA MULTIPHASI; HEATON RK, 1978, J NERV MENT DIS, V166, P408, DOI 10.1097/00005053-197806000-00004; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; JELLINEK HM, 1982, ARCH PHYS MED REHAB, V63, P160; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; Jennett B., 1986, MED N AM, V36, P5210; KARZMARK P, 1992, Brain Injury, V6, P213, DOI 10.3109/02699059209029662; LANDSMAN IS, 1990, J BEHAV MED, V13, P561, DOI 10.1007/BF00844735; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEVIN HS, 1989, HDB NEUROPSYCHOLOGY, V3, P183; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; MALEC J, 1990, J HEAD TRAUMA REHAB, V5, P60; Malec JF., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; MCSWEENY AJ, 1985, J CLIN EXP NEUROPSYC, V7, P281, DOI 10.1080/01688638508401260; MILLER JD, 1985, J NEUROL NEUROSUR PS, V48, P596; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PUTNAM SH, 1992, CLIN NEUROPSYCHOL, V6, P383; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Russell W Ritchie, 1934, Edinb Med J, V41, P129; SAURELCUBIZOLLES MJ, 1992, BRIT J IND MED, V49, P276; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; Symonds C.P., 1940, INJURIES SKULL BRAIN, P69; TATEMICHI TK, 1994, J NEUROL NEUROSUR PS, V57, P202, DOI 10.1136/jnnp.57.2.202; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223	59	28	28	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	NOV	1996	10	4					382	396		10.1080/13854049608406699			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	VZ755	WOS:A1996VZ75500003					2021-06-18	
J	Maffulli, N; Bundoc, RC; Chan, KM; Cheng, JCY				Maffulli, N; Bundoc, RC; Chan, KM; Cheng, JCY			Paediatric sports injuries in Hong Kong: A seven year survey	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						sports injuries; children; epidemiology	ISOMETRIC STRENGTH; CHILDREN	Objective-To ascertain the epidemiological characteristics of sports injuries in children in Hong Kong. Methods-Retrospective review of all cases seen in the Sports Injury Clinic of the Prince of Wales Hospital, Shatin, Hong Kong, in the period May 1984 to December 1990. The variables studied were age at presentation, gender, side of the body injured, anatomical location of the injury, type and severity of injury, sport played, level (school, recreational, amateur and professional) and frequency of sports participation, length in years of sports practice, and initial management of the injury. Results-Of the 2293 patients seen, 238 were youngsters (54% boys) 16 years old or younger. Ball games accounted for the greatest number of injuries, with 37 children taking part in basketball, 28 in soccer, 12 in volleyball, and 31 children taking part in a variety of other ball games. Of the remaining children, the single largest group was practising track and field, with sprinting and middle distance running accounting for 42 injuries, and 28 children were injured while cycling. Most of the injuries (85%) were classified as non-serious, but 15% of children presented with a total of 21 fractures, two joint dislocations, five concussions, and seven torn knee ligaments. Conclusions-Children sports participation in Hong Kong, although not at high level and not as widespread as in the West, accounts for significant morbidity. These injuries should be carefully monitored to ascertain whether they result in any detrimental long term effects.	CHINESE UNIV HONG KONG, DEPT ORTHOPAED & TRAUMATOL, PRINCE WALES HOSP, SHATIN, NEW TERR, HONG KONG	Maffulli, N (corresponding author), UNIV ABERDEEN, SCH MED, DEPT ORTHOPAED SURG, POLWARTH BLDG, ABERDEEN AB9 2ZD, SCOTLAND.		Maffulli, Nicola/A-1839-2014; Cheng, Jack/J-3878-2018	Maffulli, Nicola/0000-0002-5327-3702; Cheng, Jack/0000-0001-8153-364X			ANDERSEN LB, 1987, EUR J APPL PHYSIOL, V56, P83, DOI 10.1007/BF00696381; BAXTERJONES A, 1993, ARCH DIS CHILD, V68, P130, DOI 10.1136/adc.68.1.130; BEATY J H, 1987, Annals of Sports Medicine, V3, P97; Booth F W, 1975, Exerc Sport Sci Rev, V3, P83; CHAN KM, 1993, BRIT J SPORT MED, V27, P263, DOI 10.1136/bjsm.27.4.263; Gallagher S.S., 1984, AM J PUBLIC HEALTH, V8, P318; KVIST M, 1989, INT J SPORTS MED, V10, P81, DOI 10.1055/s-2007-1024879; LYSENS R, 1984, SPORTS MED, V1, P6, DOI 10.2165/00007256-198401010-00002; LYSENS RJ, 1989, AM J SPORT MED, V17, P612, DOI 10.1177/036354658901700504; MAFFULLI N, 1990, SPORTS MED, V9, P229, DOI 10.2165/00007256-199009040-00004; MAFFULLI N, 1994, BRIT J SPORT MED, V28, P123, DOI 10.1136/bjsm.28.2.123; MAFFULLI N, 1988, ARCH DIS CHILD, V63, P1405, DOI 10.1136/adc.63.11.1405; Maffulli N, 1990, Br J Sports Med, V24, P237; PRAGER BI, 1989, AM J SPORT MED, V17, P681, DOI 10.1177/036354658901700516; Sahlin Y, 1990, Br J Sports Med, V24, P40; SCHMIDTOLSEN S, 1991, AM J SPORT MED, V19, P273, DOI 10.1177/036354659101900311; SOWINSKI J, 1986, NEW STUDIES ATHLETIC, V4, P91; TURSZ A, 1986, AM J SPORT MED, V14, P294, DOI 10.1177/036354658601400409; Yde J, 1990, Br J Sports Med, V24, P51; ZARICZNYJ B, 1980, AM J SPORT MED, V8, P318, DOI 10.1177/036354658000800504	20	28	29	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	SEP	1996	30	3					218	221		10.1136/bjsm.30.3.218			4	Sport Sciences	Sport Sciences	VJ620	WOS:A1996VJ62000011	8889114	Green Published, Bronze			2021-06-18	
J	Gass, CS				Gass, CS			MMPI-2 variables in attention and memory test performance	PSYCHOLOGICAL ASSESSMENT			English	Article								Attention span (Digit Span), verbal list learning, and memory test performance( Wechsler Memory Scale-Revised; WMS-R) were examined in relation to Minnesota Multiphasic Personality Inventory-2 (MMPI-2) measures of depression, anxiety, and psychotic thinking in male patients with closed-head injury (n = 48) and with psychiatric disorder (n = 80). In both samples, MMPI-2 scores were significantly related to Attention Span but independent of List Learning performance. MMPI-2 scores correlated with factor scores derived from the Logical Memory and Visual Reproduction subtests of the WMS-R. The results of a hierarchical regression analysis, which examined the relative effects of neurologic and emotional status, support the view that MMP1-2 scores are relevant to the interpretation of performance on neuropsychological tests of attention and memory.		Gass, CS (corresponding author), VET AFFAIRS MED CTR,PSYCHOL SERV 116B,1201 NW 16TH ST,MIAMI,FL 33125, USA.		Gass, Carlton/AAO-5906-2020				BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; CALSYN DA, 1982, PERCEPT MOTOR SKILL, V55, P1099, DOI 10.2466/pms.1982.55.3f.1099; GASS CS, 1994, J CLIN PSYCHOL, V50, P586, DOI 10.1002/1097-4679(199407)50:4<586::AID-JCLP2270500414>3.0.CO;2-Z; GASS CS, 1991, J CLIN PSYCHOL, V47, P153; HEATON RK, 1978, PSYCHOL BULL, V85, P141, DOI 10.1037/0033-2909.85.1.141; HEATON RK, 1981, HDB CLIN NEUROPSYCHO, V1, P481; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; RABINS PV, 1993, DEMENTIA, P359; RUSSELL EW, 1970, ASSESSMENT BRAIN DAM; STREINER DL, 1994, CAN J PSYCHIAT, V39, P191, DOI 10.1177/070674379403900401; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wolfson D., 1993, HALSTEAD REITAN NEUR	13	28	28	0	3	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242	1040-3590			PSYCHOL ASSESSMENT	Psychol. Assess.	JUN	1996	8	2					135	138		10.1037/1040-3590.8.2.135			4	Psychology, Clinical	Psychology	UT983	WOS:A1996UT98300003					2021-06-18	
J	Olby, NJ; Blakemore, WF				Olby, NJ; Blakemore, WF			A new method of quantifying the extent of tissue loss following spinal cord injury in the rat	EXPERIMENTAL NEUROLOGY			English	Article							COMPRESSION; CONTUSION; NALOXONE; TRAUMA; LESION; CAT; METHYLPREDNISOLONE; REGENERATION; INFARCTION; BRAIN	Many agents are being tested for their ability to limit the development of secondary tissue damage following trauma to the spinal cord by comparing the extent of trauma-induced tissue destruction between groups of animals receiving different treatments. However, the changes that occur following spinal concussion result in initial swelling of the cord and then progressive shrinkage. It is therefore impossible to determine the preinjury cross-sectional area of cord once it has been damaged, making accurate calculation of the extent of tissue destruction difficult. To overcome this problem, a method for predicting the preinjury cross-sectional area of damaged spinal cord was developed in the rat by establishing correction factors that related the cross-sectional area of a reference transverse section to the area of sections at other points along the cord. This method was used to calculate the volume of tissue destruction in groups of rats 48 h, 4 days, and 4 weeks after photochemically induced cord injury. The results were compared with the volume of tissue destruction obtained when calculated from measured rather than predicted cord area. One month following photochemically induced injury, the spinal cord had shrunk significantly. This resulted in significant underestimation of the lesion volume when calculated from the measured area of injured cord. This demonstrates that the preinjury area of the cord must be established in order to calculate the full extent of tissue destruction and that it can be estimated accurately using the method described in this study. (C) 1996 Academic Press, Inc.		Olby, NJ (corresponding author), UNIV CAMBRIDGE, DEPT CLIN VET MED, MADINGLEY RD, CAMBRIDGE CB3 0ES, ENGLAND.			Olby, Natasha/0000-0003-1349-3484	Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		BALENTINE JD, 1978, LAB INVEST, V39, P236; BEHRMANN DL, 1993, EXP NEUROL, V119, P258, DOI 10.1006/exnr.1993.1028; BLIGHT AR, 1994, NEUROSCIENCE, V60, P263, DOI 10.1016/0306-4522(94)90220-8; BRAUGHLER JM, 1987, J NEUROSURG, V67, P102, DOI 10.3171/jns.1987.67.1.0102; BUNGE MB, 1994, EXP NEUROL, V127, P76, DOI 10.1006/exnr.1994.1082; CAMERON T, 1990, EXP NEUROL, V109, P214, DOI 10.1016/0014-4886(90)90076-5; COATES JR, 1995, VET SURG, V24, P128, DOI 10.1111/j.1532-950X.1995.tb01307.x; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; DIETRICH WD, 1984, STROKE, V15, P191; Dohrmann G J, 1976, Surg Neurol, V6, P263; FADEN AI, 1983, NEUROLOGY, V33, P673, DOI 10.1212/WNL.33.6.673; FADEN AI, 1981, ANN NEUROL, V10, P326, DOI 10.1002/ana.410100403; FISH CJ, 1983, NEUROPATH APPL NEURO, V9, P109, DOI 10.1111/j.1365-2990.1983.tb00329.x; GUTH L, 1994, P NATL ACAD SCI USA, V91, P12308, DOI 10.1073/pnas.91.25.12308; HOOVLER DW, 1991, ACTA NEUROPATHOL, V81, P303, DOI 10.1007/BF00305872; MEANS ED, 1981, J NEUROSURG, V55, P200, DOI 10.3171/jns.1981.55.2.0200; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; PAINO CL, 1994, J NEUROCYTOL, V23, P433, DOI 10.1007/BF01207115; PENCALET P, 1993, J NEUROSURG, V78, P603, DOI 10.3171/jns.1993.78.4.0603; PRADO R, 1987, J NEUROSURG, V67, P745, DOI 10.3171/jns.1987.67.5.0745; REIER PJ, 1992, EXP NEUROL, V115, P177, DOI 10.1016/0014-4886(92)90245-L; RICHARDSON PM, 1984, J NEUROCYTOL, V13, P165, DOI 10.1007/BF01148324; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; WAGNER FC, 1981, J NEUROSURG, V54, P802, DOI 10.3171/jns.1981.54.6.0802; WATSON BD, 1986, BRAIN RES, V367, P296, DOI 10.1016/0006-8993(86)91606-9; WATSON BD, 1985, ANN NEUROL, V17, P497, DOI 10.1002/ana.410170513; WRATHALL JR, 1982, ACTA NEUROPATHOL, V57, P59, DOI 10.1007/BF00688878; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209	31	28	30	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	1996	138	1					82	92		10.1006/exnr.1996.0049			11	Neurosciences	Neurosciences & Neurology	UA434	WOS:A1996UA43400009	8593899				2021-06-18	
J	MALIA, K; POWELL, G; TORODE, S				MALIA, K; POWELL, G; TORODE, S			PERSONALITY AND PSYCHOSOCIAL FUNCTION AFTER BRAIN INJURY	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; STRESS RESISTANCE; FOLLOW-UP; REHABILITATION; RECOVERY; HEALTH; TRAUMA	A total of 74 brain-injured patients and 46 non-neurologically matched controls consecutively admitted to a specialist medical rehabilitation unit, were administered the 'Headley Court psychosocial rating scale' and four questionnaires examining personality traits of 'locus of control', use of humour', 'optimism' and 'easy-going disposition'. Both pre- and post-injury personality ratings were obtained. The relatives of all participants were sent the same scales. Personality changes are reported in each of the four areas; however, time post-injury appears to be a significant factor in the type of change reported; in this cross-sectional study, at 6 and 12 months post-injury, changes are noted in all variables except locus of control, whereas at 18 months post-injury only 'easy-going disposition' showed significant change, at 24 months post-injury changes were noted in all variables except optimism, and at 30 months post-injury no changes were noted. In the present study, examining a period of 2.5 years post-injury, the personality changes remain static once they have occurred. Despite widespread reports in the literature on the importance of pre- and post-trauma personality to good psychosocial functioning, the present study found that it was only an 'easy-going disposition' post-trauma that was consistently related to good psychosocial functioning. Reasons for this are discussed.	UNIV SURREY,SURREY,ENGLAND	MALIA, K (corresponding author), RAF,DSMRU,HEADLEY COURT,EPSOM KT18 6JN,SURREY,ENGLAND.						BENYISHAY Y, 1990, C NEW YORK U HEAD TR; BOND MR, 1976, SCAND J REHABIL MED, V8, P127; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1984, PSYCHOL SOCIAL FAMIL, P4; BROOKS N, 1991, Brain Injury, V5, P103, DOI 10.3109/02699059109008082; BROOKS N, 1986, J NEUROL NEUROSUR PS, V47, P764; Cohadon F, 1981, Prog Neurol Surg, V10, P344, DOI 10.1159/000384774; HAGAN C, 1979, REHABILITATION HEAD; HINCKLE LE, 1974, STRESSFUL LIFE EVENT, P9; HOLAHAN CJ, 1987, J PERS SOC PSYCHOL, V52, P946, DOI 10.1037/0022-3514.52.5.946; HOLAHAN CJ, 1985, J PERS SOC PSYCHOL, V49, P739, DOI 10.1037/0022-3514.49.3.739; HOLAHAN CJ, 1986, J PERS SOC PSYCHOL, V51, P389, DOI 10.1037/0022-3514.51.2.389; JACKSON H F, 1992, Brain Injury, V6, P109, DOI 10.3109/02699059209029650; JENNETT B, 1975, LANCET, V1, P480; KINSELLA G, 1988, PSYCHOL MED, V18, P157; Lazarus R. S., 1984, STRESS APPRAISAL COP, P141; Lezak M. D., 1989, ASSESSMENT BEHAV CON, P113; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; Livingston M G, 1985, Int Rehabil Med, V7, P145; MALIA KB, 1993, CLIN REHABILITATION, V7, P35; Martin R. A., 1983, J PERS SOC PSYCHOL, V47, P145; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MILLER L, 1991, COGNITIVE REHABI MAR; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; PRIGATANO GP, 1986, CLIN NEUROPSYCHOLOGY, P136; RANSEEN J, 1990, COGNITIVE REHABI MAR; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M., 1983, REHABILITATION HEAD, P197; Rotter J.B, 1996, Psychological Monographs, V80, P609, DOI DOI 10.1037/H0092976; SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219; SLAGLE DA, 1990, INT J PSYCHIAT MED, V20, P1, DOI 10.2190/BE6W-DCY1-V71N-N7J7; STEPHENS CK, 1991, DISS ABSTR INT B, V51; STERN JM, 1985, ISRAEL J PSYCHIAT, V22, P83; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; 1987, UNPUB FUNCTIONAL ASS	41	28	28	0	4	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1995	9	7					697	712		10.3109/02699059509008226			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RZ814	WOS:A1995RZ81400003	8680397				2021-06-18	
J	CHOU, PI; SADUN, AA; LEE, H				CHOU, PI; SADUN, AA; LEE, H			VASCULATURE AND MORPHOMETRY OF THE OPTIC CANAL AND INTRACANALICULAR OPTIC-NERVE	JOURNAL OF NEURO-OPHTHALMOLOGY			English	Article						OPTIC CANAL; OPHTHALMIC ARTERY; OPTIC NERVE TRAUMA	DECOMPRESSION	Objectives: To study the bony structure of the optic canal and the vasculature of the intracanalicular optic nerve in human cadavers. Materials and Methods: Gross and microscopic examinations were performed in 25 optic canals from 13 cadavers to study the pattern of vascular supply of the intracanalicular optic nerve. Neoprene latex was injected through the most proximal part of the ophthalmic artery in seven optic canals. The intracanalicular branches from the ophthalmic artery were carefully identified and quantified. Quantitative measurements of the canal length, canal thickness, canal transverse area, optic nerve transverse area, and subdural space were done for the other 18 canals by means of semiautomated morphometric analysis system. Each canal was divided into anterior, middle, and posterior parts for better visualization and measurement. Results: The ophthalmic artery gives off three branches that supply the intracanalicular optic nerve: medial collateral branch, lateral collateral branch, and ventral branch. Each branch pierces the dura and then supplies the nerve through the pia mater. The middle medial wall was the thinnest bony part of the canal (0.31 +/- 0.06 mm). The optic canal, optic nerve, and subdural space transverse area varied at different transection levels. The narrowest space was in the middle part of the optic canal. The mean subdural cross-sectional space was only 1.84 mm(2). This, multiplied by the average canal length (11.79 mm), can be considered the potential space for hemorrhage, optic nerve edema, or hematoma. Conclusions: The vasculature within the bony canal is extremely delicate. Due to the limitation of this space, even a tiny amount of blood or swelling of the nerve (21.69 mm(3)) may cause optic nerve compression, It appears that these vessels could easily be disrupted in closed head injury by a shearing or concussive force, leading to ischemic infarction of the optic nerve. Since the narrowest portion of the canal is in the middle portion, it is the middle part of the optic canal that is most critical in doing an optic canal decompression.	UNIV SO CALIF, SCH MED, DOHENY EYE INST, DEPT OPHTHALMOL, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, DOHENY EYE INST, DEPT NEUROSURG, LOS ANGELES, CA 90033 USA	CHOU, PI (corresponding author), TRISERV GEN HOSP, NATL DEF MED CTR,DEPT OPHTHALMOL,42,SEC 3, TING CHOU RD, TAIPEI, TAIWAN.						ANDERSON RL, 1982, OPHTHALMOLOGY, V89, P445; CHOU PI, IN PRESS NEUROOPHTHA; CROMPTON M R, 1970, Brain Behavior and Evolution, V93, P785, DOI 10.1093/brain/93.4.785; FRANCOIS J, 1956, Br J Ophthalmol, V40, P45, DOI 10.1136/bjo.40.1.45; FRANCOIS J, 1954, BRIT J OPHTHALMOL, V38, P472, DOI 10.1136/bjo.38.8.472; FRANCOIS J, 1955, Br J Ophthalmol, V39, P220, DOI 10.1136/bjo.39.4.220; Fukado Y, 1975, Mod Probl Ophthalmol, V14, P474; HABAL MB, 1977, J SURG RES, V22, P527, DOI 10.1016/0022-4804(77)90036-1; Hayreh S S, 1962, Br J Ophthalmol, V46, P165, DOI 10.1136/bjo.46.3.165; Hayreh S S, 1962, Br J Ophthalmol, V46, P212, DOI 10.1136/bjo.46.4.212; Hayreh S S, 1962, Br J Ophthalmol, V46, P65, DOI 10.1136/bjo.46.2.65; HAYREH SS, 1963, ANAL I BARRAQUER, V4, P7; HAYREH SS, 1972, OPTIC NERVE, P59; KENNERDELL JS, 1976, ARCH OPHTHALMOL-CHIC, V94, P1040; LANG J, 1981, CRANIAL NERVES, P77; MANFREDI SJ, 1981, PLAST RECONSTR SURG, V68, P479, DOI 10.1097/00006534-198110000-00001; MANISCALCO JE, 1978, J NEUROSURG, V48, P402, DOI 10.3171/jns.1978.48.3.0402; MATSUZAKI H, 1986, NEURO-OPHTHALMOLOGY, V6, P23, DOI 10.3109/01658108608997321; NIHO S, 1961, AM J OPHTHALMOL, V51, P659, DOI 10.1016/0002-9394(61)91611-7; NIHO S, 1970, CAN J OPHTHALMOLOGY, V5, P22; Pringle JH, 1922, BRIT MED J, V2, P1156; RENN WH, 1975, J NEUROSURG, V43, P288, DOI 10.3171/jns.1975.43.3.0288; Rodger F C, 1943, Br J Ophthalmol, V27, P23, DOI 10.1136/bjo.27.1.23; SAVINO PJ, 1987, OPHTHAL PLAST RECONS, P311; WALSH FRANK B., 1966, INVEST OPHTHALMOL, V5, P433	25	28	44	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1070-8022	1536-5166		J NEURO-OPHTHALMOL	J. Neuro-Ophthal.	SEP	1995	15	3					186	190					5	Clinical Neurology; Ophthalmology	Neurosciences & Neurology; Ophthalmology	RZ792	WOS:A1995RZ79200012	8574366				2021-06-18	
J	BROOKS, CA; LINDSTROM, J; MCCRAY, J; WHITENECK, GG				BROOKS, CA; LINDSTROM, J; MCCRAY, J; WHITENECK, GG			COST OF MEDICAL-CARE FOR A POPULATION-BASED SAMPLE OF PERSONS SURVIVING TRAUMATIC BRAIN INJURY	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							SEVERITY SCORE	To determine the cost of health care services received by persons hospitalized with traumatic brain injuries, a population-based sample of individuals treated at the trauma centers in El Paso County, Colorado, was followed retrospectively for 4 years after injury. Of the random sample of 251 survivors who sustained brain trauma in 1989 and 1990 (stratified by severity), 127 were successfully located and agreed to participate in the research. All medical services provided were identified through both medical record review and extensive patient interviews. Actual charges were obtained directly from the 482 vendors serving these clients. Mean charges for initial hospitalization (including acute care and rehabilitation) ranged from $17,015 for mild injuries to $133,467 for severe injuries. Four-year follow-up charges for rehospitalizations, physician visits, outpatient services, medications, equipment and supplies, attendant care, and miscellaneous services ranged from a mean of $2,323 for mild injuries to $54,701 for severe injuries. At an incidence rate of 69 per 100,000, it is projected that the total costs for new cases of hospitalized traumatic brain injury in any given year in the United States will exceed $8 billion over the course of the first 4 years following injury.	COLORADO DEPT PUBL HLTH & ENVIRONM, DENVER, CO USA	BROOKS, CA (corresponding author), CRAIG HOSP, ENGLEWOOD, CO 80110 USA.						BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BENNETT BR, 1989, J TRAUMA, V29, P556, DOI 10.1097/00005373-198905000-00003; Haase J, 1992, Acta Neurochir Suppl (Wien), V55, P75; HOLMES W, 1991, THESIS U COLORADO DE; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P681, DOI 10.1016/0003-9993(93)90024-5; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; *NAT HEAD INJ F, FACTS TRAUM BRAIN IN; RUSSELL WR, 1988, CURR CONCEPTS REHABI, V4, P19; Sakata R, 1991, Brain Inj, V5, P411, DOI 10.3109/02699059109008114; SCALING JC, 1980, ABBREVIATED INJURY S; *US BUR CENS, 1990, CENS POP GEN POP CHA	13	28	28	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1995	10	4					1	13		10.1097/00001199-199508000-00002			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RN010	WOS:A1995RN01000002					2021-06-18	
J	LEVIN, BE; BROWN, KL; PAWAR, G; DUNNMEYNELL, A				LEVIN, BE; BROWN, KL; PAWAR, G; DUNNMEYNELL, A			WIDESPREAD AND LATERALIZED EFFECTS OF ACUTE TRAUMATIC BRAIN INJURY ON NOREPINEPHRINE TURNOVER IN THE RAT-BRAIN	BRAIN RESEARCH			English	Article						HEAD TRAUMA; CATECHOLAMINE; 3-METHOXY-4-HYDROXYPHENYLGLYCOL; MHPG; CONTUSION; SENSORIMOTOR CORTEX; SOMATOSENSORY CORTEX	SENSORIMOTOR CORTEX INJURY; LOCUS COERULEUS SYSTEM; TRANSIENT ISCHEMIA; NORADRENALINE METABOLISM; BEAM-WALKING; LESION SIZE; RECOVERY; DAMAGE; HIPPOCAMPUS; AMPHETAMINE	Norepinephrine (NE) has been implicated in recovery of function following traumatic brain injury (TBI). While bilateral decreases in brain NE turnover occur at 6-24 h after TBI, it is unknown what effects unilateral TBI might have on brain NE turnover over the first few minutes after injury. Here male Sprague-Dawley rats had unilateral contusions of either the right or left somatosensory cortex produced by an air driven piston. At 30min after TBI, brain NE turnover was assessed by measuring the ratio of 3-methoxy-4-hydroxyphenylglycol (MHPG) to NE levels in various brain regions. Both right and left TBI produced 32-103% increases in NE turnover at the injury site and in the ipsilateral cerebral cortex surrounding, rostral and caudal to the injury as compared to the contralateral, uninjured site or to the homologous sites in uninjured controls. NE turnover was also altered selectively in some brain areas not affected by right TBI. Left TBI decreased NE turnover by 29% in the frontal cortex contralateral to the injury and by 24% bilaterally in the hypothalamus while increasing locus coeruleus NE turnover by 72% compared to uninjured controls. Thus, unilateral cortical TBI produced predominantly ipsilateral increases in cortical NE turnover but variable, bilateral changes in NE turnover in subcortical areas which were dependent upon the side of injury. These subcortical differences may explain some of the lateralized effects of cortical injury on post-injury behavior.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT NEUROSCI,NEWARK,NJ 07103	LEVIN, BE (corresponding author), DEPT VET AFFAIRS MED CTR,NEUROL SERV 127,E ORANGE,NJ 07018, USA.						ARVIN B, 1992, BRAIN RES, V579, P279, DOI 10.1016/0006-8993(92)90061-D; BLOMQVIST P, 1985, NEUROSCI LETT, V58, P353, DOI 10.1016/0304-3940(85)90080-1; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BRODIE BB, 1966, J PHARMACOL EXP THER, V154, P493; BUSTO R, 1985, ANN NEUROL, V18, P329, DOI 10.1002/ana.410180310; CALDERINI G, 1978, BRAIN RES, V157, P303, DOI 10.1016/0006-8993(78)90032-X; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; DUNNMEYNELL AA, 1992, 19TH ANN NEUR S; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; GLOBUS MYT, 1989, J CEREBR BLOOD F MET, V9, P892, DOI 10.1038/jcbfm.1989.123; Goldstein L B, 1990, Restor Neurol Neurosci, V1, P311, DOI 10.3233/RNN-1990-1501; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P320, DOI 10.1037/0735-7044.104.2.320; GUSTAFSON I, 1991, EXP BRAIN RES, V86, P555; GUSTAFSON I, 1989, J CEREBR BLOOD F MET, V9, P171, DOI 10.1038/jcbfm.1989.25; HARIK SI, 1984, ANN NEUROL, V15, P568, DOI 10.1002/ana.410150609; HEILIG M, 1990, J NEURAL TRANSM-GEN, V79, P193, DOI 10.1007/BF01245130; HIAKALA H, 1987, J NEUROCHEM, V49, P1033; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; HUGER F, 1979, J NEUROCHEM, V33, P89, DOI 10.1111/j.1471-4159.1979.tb11710.x; IDA Y, 1982, NEUROBIOL AGING, V3, P233, DOI 10.1016/0197-4580(82)90044-6; KAMISAKI Y, 1992, EUR J PHARMACOL, V217, P57, DOI 10.1016/0014-2999(92)90511-2; KOIDE T, 1986, J CEREBR BLOOD F MET, V6, P559, DOI 10.1038/jcbfm.1986.102; KROBERT KA, 1994, J NEUROCHEM, V62, P2233; LAWTHO D, 1993, EUR J NEUROSCI, V5, P1494, DOI 10.1111/j.1460-9568.1993.tb00217.x; LEVIN BE, 1983, BRAIN RES, V289, P205, DOI 10.1016/0006-8993(83)90021-5; LEVIN BE, 1994, RESTOR NEUROL NEUROS, V7, P5, DOI 10.3233/RNN-1994-7102; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P221, DOI 10.1113/jphysiol.1986.sp016006; MIYAUCHI Y, 1989, J NEUROCHEM, V53, P408, DOI 10.1111/j.1471-4159.1989.tb07349.x; MORAN TH, 1984, LIFE SCI, V35, P1337, DOI 10.1016/0024-3205(84)90389-8; MOURADIAN RD, 1991, BRAIN RES, V546, P83, DOI 10.1016/0006-8993(91)91162-T; NEVANDER G, 1986, EXP BRAIN RES, V63, P439; NISHINO K, 1989, J CEREBR BLOOD F MET, V9, P358, DOI 10.1038/jcbfm.1989.54; NISHINO K, 1991, NEUROSCIENCE, V43, P361, DOI 10.1016/0306-4522(91)90300-D; PACAK K, 1993, HYPERTENSION, V22, P467, DOI 10.1161/01.HYP.22.4.467; PAPPIUS HM, 1991, NEUROCHEM RES, V16, P941, DOI 10.1007/BF00965837; PEARLSON GD, 1981, BRAIN RES, V218, P233, DOI 10.1016/0006-8993(81)91303-2; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; ROBERT B, 1992, AGENTS ACTIONS, V37, P268, DOI 10.1007/BF02028119; SARMENTO A, 1991, N-S ARCH PHARMACOL, V343, P633; SCHANBERG SM, 1968, BIOCHEM PHARMACOL, V17, P247, DOI 10.1016/0006-2952(68)90330-4; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SUTTON RL, 1993, J NEUROTRAUM, V10, pS181; WESTERINK BHC, 1984, J NEUROCHEM, V42, P934, DOI 10.1111/j.1471-4159.1984.tb12694.x; WIELOCH T, 1986, PHARM CEREBRAL ISCHE, P191	49	28	29	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 20	1995	674	2					307	313		10.1016/0006-8993(95)00032-L			7	Neurosciences	Neurosciences & Neurology	QN223	WOS:A1995QN22300017	7796111				2021-06-18	
J	WORLEY, G; HOFFMAN, JM; PAINE, SS; KALMAN, SL; CLAERHOUT, SJ; BOYKO, OB; KANDT, RS; SANTOS, CC; HANSON, MW; OAKES, WJ; COLEMAN, RE				WORLEY, G; HOFFMAN, JM; PAINE, SS; KALMAN, SL; CLAERHOUT, SJ; BOYKO, OB; KANDT, RS; SANTOS, CC; HANSON, MW; OAKES, WJ; COLEMAN, RE			18-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN CHILDREN AND ADOLESCENTS WITH TRAUMATIC BRAIN INJURY	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							GLUCOSE-UTILIZATION; METABOLIC-RATE; HEAD-INJURIES; COMA	Twenty-two previously normal children and adolescents who suffered a severe, non-penetrating traumatic brain injury had PET during rehabilitation at a median of 1.5 months after the injury. Outcome was assessed at a median of 25 months after brain injury. 16 subjects had CT or MRI within 24 days of PET and 11 subjects had a second PET at the point of outcome (median 28 months after first PET). The PET score (obtained by adding the score of 15 brain regions: normal metabolism=1; reduced=0) was significantly associated with the clinical outcome measure. PET earlier than 12 weeks after head trauma correlated with outcome, but later PET did not. PET scores improved significantly between rehabilitation and outcome for the 11 subjects who had two PETs, but improvement was not associated with improvement in clinical condition. PET score did not add to the amount of variance explained in the last regression model for prediction of outcome when the results of contemporaneous CT/MRI and clinical condition were taken into account. The data suggest that routine PET during rehabilitation is no more useful than contemporaneous CT or MRI for prediction of outcome.	EMORY UNIV,SCH MED,ATLANTA,GA; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT NEUROL,WINSTON SALEM,NC 27103; CHILDRENS HOSP ALABAMA,DEPT NEUROSURG,BIRMINGHAM,AL	WORLEY, G (corresponding author), DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710, USA.						ALAVI A, 1989, J NEUROPSYCHIAT, V1, P545; ALAVI A, 1987, J CEREB BLOOD FLO S1, V7, pS646; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BROWN JC, 1975, PSYCHOL MED, V5, P239, DOI 10.1017/S0033291700056592; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; CHUGANI HT, 1986, SCIENCE, V31, P840; Hagen C, 1979, REHABILITATION HEAD, P87; HUANG SC, 1979, J COMPUT ASSIST TOMO, V3, P804; HUANG SC, 1980, AM J PHYSIOL, V238, pE69; JENNETT B, 1975, LANCET, V1, P480; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; PHELPS ME, 1985, SCIENCE, V228, P799, DOI 10.1126/science.2860723; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x	18	28	28	0	4	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	MAR	1995	37	3					213	220					8	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	QM941	WOS:A1995QM94100004	7890126				2021-06-18	
J	KRAUS, MF				KRAUS, MF			NEUROPSYCHIATRIC SEQUELAE OF STROKE AND TRAUMATIC BRAIN INJURY - THE ROLE OF PSYCHOSTIMULANTS	INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE			English	Article; Proceedings Paper	1993 Annual Meeting of American-Psychiatric-Association, Issue Workshop 33	1993	SAN FRANCISCO, CA	Amer Psychiat Assoc		TRAUMATIC BRAIN INJURY; STROKE; METHYLPHENIDATE; DEXTROAMPHETAMINE; PSYCHOSTIMULANTS; NEUROPSYCHIATRIC SEQUELAE; COGNITION; MOOD; CORTICAL RECOVERY	CLOSED-HEAD-INJURY; POSTSTROKE DEPRESSION; ANTIDEPRESSANT THERAPY; LOCOMOTOR FUNCTION; MAJOR DEPRESSION; MEDICAL ILLNESS; CORTEX INJURY; D-AMPHETAMINE; METHYLPHENIDATE; DISORDERS	Objective: The primary purpose of this article is to review certain neuropsychiatric sequelae of stroke and traumatic brain injury (TBI), and the role of the psychostimulants methylphenidate (MPD) and dextroamphetamine (DAMP) in their treatment. Method: A general review of the topic is presented. Controlled and uncontrolled studies involving the use of the psychostimulants are discussed. These consist of 11 studies listed with Medline 2000 that deal specifically with stroke or head injury, with the oldest study reviewed dating back to 1984. Studies concerning the use of psychostimulants in the medically or neurologically ill are reviewed to the extent that they are pertinent. Results: The current literature consists primarily of uncontrolled case studies. However, these are reviewed and found to suggest a role for the use of the psychostimulants, which is discussed. Conclusions: In general, these drugs appear to be a reasonable treatment choice for certain types of mood, behavior, and cognitive symptoms following brain injury. However, it is noted that larger scale controlled studies are needed to adequately assess the clinical usefulness of these drugs.		KRAUS, MF (corresponding author), JOHNS HOPKINS UNIV HOSP,DEPT PSYCHIAT & BEHAV SCI,OSLER 320,BALTIMORE,MD 21287, USA.				NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000149] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32-AG00149] Funding Source: Medline		ALTMAN HJ, 1983, BEHAV BRAIN RES, V7, P51, DOI 10.1016/0166-4328(83)90004-9; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ANGELERI F, 1993, STROKE, V24, P1478, DOI 10.1161/01.STR.24.10.1478; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; ASTROM M, 1993, STROKE, V24, P976, DOI 10.1161/01.STR.24.7.976; Auerbach S., 1989, PHYSICAL MED REHAB S, P1; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; CHIEUH CC, 1975, J PHARM EXPT THERAPE, V193, P559; CLARK ANG, 1979, J AM GERIATR SOC, V27, P174, DOI 10.1111/j.1532-5415.1979.tb06442.x; COLE JO, 1992, J CLIN PSYCHIAT, V53, P333; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; DARVILL FT, 1959, JAMA-J AM MED ASSOC, V169, P1739, DOI 10.1001/jama.1959.03000320041011; DIETRICH WD, 1990, STROKE, V21, P147; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; EVANS RW, 1992, NEUROL CLIN, V10, P815; EVANS RW, 1986, PSYCHOPHARMACOLOGY, V90, P211; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1993, CRIT REV NEURBIOL, V3, P135; FERGUSON JT, 1956, JAMA-J AM MED ASSOC, V160, P259, DOI 10.1001/jama.1956.02960390009003; FERNANDEZ F, 1987, PSYCHOSOMATICS, V28, P455, DOI 10.1016/S0033-3182(87)72476-1; FINKLESTEIN S, 1983, BRAIN RES, V271, P279, DOI 10.1016/0006-8993(83)90290-1; FISCH RZ, 1985, INT J PSYCHIAT MED, V15, P75, DOI 10.2190/FNLD-HTDM-9LP1-X3Y3; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; Gennarelli T. A., 1987, HEAD INJURY, P108; GOLD PE, 1984, BRAIN RES, V305, P103, DOI 10.1016/0006-8993(84)91124-7; GOLDSTEIN LB, 1990, STROKE, V21, P132; GOLDSTEIN LB, 1988, CEREBROVASC DIS, P303; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; GUALTIERI CT, 1985, PSYCHIAT CLIN N AM, V8, P875; HOUSE A, 1987, BMJ-BRIT MED J, V294, P76, DOI 10.1136/bmj.294.6564.76; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; JANE JA, 1982, OUTCOME PATHOLOGY HE, P229; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; KAPLITZ SE, 1975, J AM GERIATR SOC, V23, P271, DOI 10.1111/j.1532-5415.1975.tb00317.x; KATON W, 1980, AM J PSYCHIAT, V137, P963; KAUFMANN MW, 1984, J CLIN PSYCHIAT, V45, P82; KAUFMANN MW, 1984, CAN J PSYCHIAT, V29, P46, DOI 10.1177/070674378402900112; KAUFMANN MW, 1982, PSYCHOSOMATICS, V23, P817; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS MF, 1992, SOUTHERN MED J, V85, P985, DOI 10.1097/00007611-199210000-00012; Kuczenski R, 1983, STIMULANTS NEUROCHEM, P31; LAZARUS LW, 1992, J CLIN PSYCHIAT, V53, P447; LEMBERGER L, 1985, J CLIN PSYCHIAT, V46, P14; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LINGAM VR, 1988, J CLIN PSYCHIAT, V49, P151; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; LIPSEY JR, 1984, LANCET, V1, P297; LITTLE KY, 1993, J CLIN PSYCHIAT, V54, P349; MASAND P, 1991, PSYCHOSOMATICS, V32, P203, DOI 10.1016/S0033-3182(91)72093-8; MORRIS PLP, 1993, AM J PSYCHIAT, V150, P124; MURRAY GB, 1986, J CLIN PSYCHIAT, V47, P258; NATENSHON AL, 1956, DIS NERV SYST, V17, P392; ORLOSKY MJ, 1982, PSYCHOSOMATICS, V23, P609; PARIKH RM, 1987, STROKE, V13, P579; Parmelee D X, 1987, Brain Inj, V1, P41, DOI 10.3109/02699058709034443; PEARLSON GD, 1981, BRAIN RES, V218, P233, DOI 10.1016/0006-8993(81)91303-2; Pickett P, 1990, J Geriatr Psychiatry Neurol, V3, P146, DOI 10.1177/089198879000300304; RANDRUP A, 1970, AMPHETAMINES RELATED, P695; REDING MJ, 1986, ARCH NEUROL-CHICAGO, V43, P763, DOI 10.1001/archneur.1986.00520080011011; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; ROBINSON RG, 1986, BRIT J PSYCHIAT, V148, P541, DOI 10.1192/bjp.148.5.541; ROBINSON RG, 1982, STROKE, V113, P635; SINYOR D, 1986, STROKE, V17, P1102, DOI 10.1161/01.STR.17.6.1102; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; SUTTON RL, 1989, BEHAV NEUROSCI, V103, P837, DOI 10.1037/0735-7044.103.4.837; WADE DT, 1987, BRIT J PSYCHIAT, V151, P200, DOI 10.1192/bjp.151.2.200; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WOODRUFF MI, 1981, LIFE SCI, V29, P2603, DOI 10.1016/0024-3205(81)90633-0; WOODS SW, 1986, J CLIN PSYCHIAT, V47, P12; WROBLEWSKI B, 1990, J CLIN PSYCHOPHARM, V10, P1214; WROBLEWSKI BA, 1992, J CLIN PSYCHIAT, V53, P86	75	28	28	0	8	BAYWOOD PUBL CO INC	AMITYVILLE	26 AUSTIN AVE, AMITYVILLE, NY 11701	0091-2174			INT J PSYCHIAT MED	Int. J. Psychiatr. Med.		1995	25	1					39	51		10.2190/BXRM-3M58-WBC5-A7EL			13	Psychiatry	Psychiatry	RA699	WOS:A1995RA69900003	7649717				2021-06-18	
J	LEE, SC; ZASLER, ND; KREUTZER, JS				LEE, SC; ZASLER, ND; KREUTZER, JS			MALE PITUITARY-GONADAL DYSFUNCTION FOLLOWING SEVERE TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							TRANSIENT HYPOGONADOTROPIC HYPOGONADISM; HEAD TRAUMA; TESTICULAR FUNCTION; COMA; MEN	A prospective study was conducted to evaluate pituitary-gonadal function and correlated parameters in 21 adult males with severe traumatic brain injury during acute inpatient rehabilitation. Serum concentrations of testosterone, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were measured within 1 week after the patient was transferred to the rehabilitation unit. Fourteen of 21 patients (67%) had abnormally low testosterone levels. One of 21 patients had a subnormal FSH level and one had a supranormal level. Three of 21 patients had subnormal LH levels and two had supranormal levels. There was no correlation between the severity of brain injury and the levels of testosterone, FSH or LH. The presence of increased intracranial pressure, hypoxia, skull fracture or abnormal CT findings had no significant influence on the levels of testosterone, FSH or LH. The high incidence of hypotestosteronaemia in survivors of severe traumatic brain injury is seemingly more related to accompanying physiological stressors rather than structural or neurochemical disruption of the hypothalamic-pituitary-gonadal axis. Early identification is important relative to the potential neuromedical and rehabilitative consequences of prolonged hypotestosteronaemia in this patient population.	NATL NEUROREHABIL CONSORTIUM INC,11653 RUTGERS DR,SUITE 100,RICHMOND,VA 23233; MACKAY MEM HOSP,DEPT REHABIL MED,TAIPEI,TAIWAN; VIRGINIA COMMONWEALTH UNIV,VIRGINIA HOSP,COLL MED,DEPT PHYS MED & REHABIL,RICHMOND,VA 23284							CAPPA SF, 1988, BEHAV BRAIN RES, V31, P177, DOI 10.1016/0166-4328(88)90021-6; Ceballos R, 1966, Ala J Med Sci, V3, P185; CLARK JDA, 1988, CLIN ENDOCRINOL, V28, P153; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; DANIEL PM, 1983, MOD TRENDS ENDOCR, P55; EDWARDS OM, 1986, MEDICINE, V65, P281; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; FORBES GB, 1985, METABOLISM, V34, P571, DOI 10.1016/0026-0495(85)90196-9; GORDON HW, 1986, NEUROPSYCHOLOGIA, V24, P563, DOI 10.1016/0028-3932(86)90100-4; HAGEN C, 1971, REHABILITATION HEAD, P10; HARPER CG, 1986, J CLIN PATHOL, V39, P768; HIER DB, 1982, NEW ENGL J MED, V306, P1202, DOI 10.1056/NEJM198205203062003; Kenyon AT, 1938, ENDOCRINOLOGY, V23, P135, DOI 10.1210/endo-23-2-135; KING LR, 1981, NEUROSURGERY, V9, P229, DOI 10.1227/00006123-198109000-00002; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; MEIER DE, 1985, CLIN RES, V33, pA384; MOORADIAN AD, 1987, ENDOCR REV, V8, P1, DOI 10.1210/edrv-8-1-1; MORLEY JE, 1993, J AM GERIATR SOC, V41, P149, DOI 10.1111/j.1532-5415.1993.tb02049.x; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUDMAN D, 1977, J CLIN ENDOCR METAB, V45, P747, DOI 10.1210/jcem-45-4-747; SEMPLE PDA, 1980, CLIN SCI, V58, P105, DOI 10.1042/cs0580105; TENOVER JS, 1992, J CLIN ENDOCR METAB, V75, P1092, DOI 10.1210/jc.75.4.1092; Treip CS, 1970, J CLIN PATHOL, V23, P178, DOI DOI 10.1136/JCP.S3-4.1.178; VOGEL AV, 1985, J CLIN ENDOCR METAB, V60, P658, DOI 10.1210/jcem-60-4-658; WANG C, 1978, CLIN ENDOCRINOL, V9, P249, DOI 10.1111/j.1365-2265.1978.tb02207.x; WANG C, 1978, CLIN ENDOCRINOL, V9, P255, DOI 10.1111/j.1365-2265.1978.tb02208.x; WOLMAN L, 1956, J PATHOL BACTERIOL, V72, P575, DOI 10.1002/path.1700720225; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444; ZASLER ND, 1993, PSYCHIATRIC ASPECTS	30	28	29	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	AUG-SEP	1994	8	6					571	577					7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	PE682	WOS:A1994PE68200009	7987293				2021-06-18	
J	BIGLER, ED; BURR, R; GALE, S; NORMAN, M; KURTH, S; BLATTER, D; ABILDSKOV, T				BIGLER, ED; BURR, R; GALE, S; NORMAN, M; KURTH, S; BLATTER, D; ABILDSKOV, T			DAY OF INJURY CT SCAN AS AN INDEX TO PRE-INJURY BRAIN MORPHOLOGY	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; DEGENERATIVE CHANGES; CORTICAL ATROPHY; COMA	This study compared the ventricle-to-brain ratio (VBR) of the day-of-injury (DOI) computerized tomogram (CT) in traumatic brain-injured (TBI) patients with post-injury (2 months or greater) magnetic resonance (MR) VBRs in the same patients and in medical control subjects. The DOI VBR did not differ significantly from the medical controls, but both (DOI and medical control VBR) differed significantly from post-injury VBR. Additionally, a case study is presented wherein MR imaging studies were obtained prior to TBI so that a direct comparison of preinjury to DOI to post-injury changes could be made. In this case the pre-injury and DOI VBRs were within approximately 9% of each other. In contrast, the post-injury VBR demonstrated over a 100% increase in comparison to either the pre-injury or DOI scan. This case and another case are illustrated using three-dimensional image analysis to represent ventricular change over time. These cases, along with the similarity of the DOI VBR with the medical controls, suggests that the DOI VBR can be utilized as an estimate or index of pre-injury ventricle/brain morphology. This will permit the use of DOI CT data for within-subject designs in TBI research that examines the course of degenerative changes over time.	LDS HOSP, PROVO, UT USA	BIGLER, ED (corresponding author), BRIGHAM YOUNG UNIV, DEPT PSYCHOL, 148B SWKT, PROVO, UT 84602 USA.						Bigler E. D., 1990, TRAUMATIC BRAIN INJU; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; BIGLER ED, 1992, ARCH CLIN NEUROPSYCH, V7, P449, DOI 10.1016/0887-6177(92)90158-J; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; BLATTER D, 1992, JUN AM SOC NEUR M ST; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MACNAMARA SE, 1992, ARCH CLIN NEUROPSYCH, V7, P275, DOI 10.1016/0887-6177(92)90169-N; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; MASSMAN PJ, 1986, INT J NEUROSCI, V30, P87, DOI 10.3109/00207458608985659; Ruff RM, 1989, NEUROPSYCHOLOGICAL F, P161; SALAZAR AM, 1992, CHALLENGES NEUROLOGY, P55; TEASDALE G, 1974, LANCET, V2, P81; VILKKI J, 1992, J CLIN EXP NEUROPSYC, V14, P518, DOI 10.1080/01688639208402841	17	28	28	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	1994	8	3					231	238		10.3109/02699059409150975			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ND714	WOS:A1994ND71400004	8004081				2021-06-18	
J	MORGAN, WE; COKER, NJ; JENKINS, HA				MORGAN, WE; COKER, NJ; JENKINS, HA			HISTOPATHOLOGY OF TEMPORAL BONE-FRACTURES - IMPLICATIONS FOR COCHLEAR IMPLANTATION	LARYNGOSCOPE			English	Article							PROSTHESIS	Temporal bone fractures often cause loss of audiovestibular function. Those patients with bilateral profound sensorineural hearing losses secondary to temporal bone fractures become candidates for cochlear implantation. The authors present the histopathology of five temporal bone fractures in three patients, evaluating specifically the traumatic effects on the neural elements of the inner ear. Transverse fractures of the temporal bone result in severe loss of hair cells, ganglion cells, and other supporting cells in the inner ear. Occasionally labyrinthitis ossificans may occur as a consequence of trauma or infection. While longitudinal fractures do not violate the otic capsule, these same neural elements may be damaged by concussion.	BAYLOR COLL MED,DEPT OTOLARYNGOL & COMMUN SCI,HOUSTON,TX 77030							Benitez J T, 1980, Am J Otol, V1, P163; Clark G M, 1988, Acta Otolaryngol Suppl, V448, P1; CLOPTON BM, 1980, ANN OTO RHINOL LARYN, V89, P5; FREDRICKSON JM, 1963, ARCHIV OTOLARYNGOL, V78, P770; GANTZ BJ, 1988, OTOLARYNG HEAD NECK, V98, P72, DOI 10.1177/019459988809800113; GREEN JD, 1991, OTOLARYNG HEAD NECK, V104, P320, DOI 10.1177/019459989110400306; HOGH JVD, 1968, LARYNGOSCOPE, V78, P899; JENKINS H, 1989, LARYNGOSCOPE, V99, P245; Kerr A, 1968, Acta Otolaryngol, V65, P586, DOI 10.3109/00016486809121002; KHAN AA, 1985, OTOLARYNG HEAD NECK, V93, P177, DOI 10.1177/019459988509300210; Konigsmark BW, 1970, CONT RES METHODS NEU, P315, DOI DOI 10.1007/978-3-642-85986-1_14; LINDSAY JR, 1970, ANN OTO RHINOL LARYN, V79, P699, DOI 10.1177/000348947007900403; LINTHICUM FH, 1991, AM J OTOL, V12, P245; MARSH MA, 1992, ARCH OTOLARYNGOL, V118, P1257; NADOL JB, 1989, ANN OTO RHINOL LARYN, V98, P411, DOI 10.1177/000348948909800602; OTTE J, 1978, LARYNGOSCOPE, V88, P1231; SCHUKNECHT HF, 1951, ANN OTO RHINOL LARYN, V60, P273, DOI 10.1177/000348945106000201; SCHUKNECHT HF, 1950, ANN OTO RHINOL LARYN, V59, P331, DOI 10.1177/000348945005900203; SCHULNECHT H, 1968, Archives of Otolaryngology, V87, P129; STEENERSON RL, 1990, AM J OTOL, V11, P360; WARD PH, 1969, ANN OTO RHINOL LARYN, V78, P227, DOI 10.1177/000348946907800203	21	28	29	0	0	LARYNGOSCOPE CO	ST LOUIS	10 S BROADWAY 14TH FLOOR, ST LOUIS, MO 63102-1741	0023-852X			LARYNGOSCOPE	Laryngoscope	APR	1994	104	4					426	432					7	Medicine, Research & Experimental; Otorhinolaryngology	Research & Experimental Medicine; Otorhinolaryngology	NF733	WOS:A1994NF73300006	8164481				2021-06-18	
J	KARLSSON, T; STJERNSTROM, EL; STJERNSTROM, H; NORLEN, K; WIKLUND, L				KARLSSON, T; STJERNSTROM, EL; STJERNSTROM, H; NORLEN, K; WIKLUND, L			CENTRAL AND REGIONAL BLOOD-FLOW DURING HYPERVENTILATION - AN EXPERIMENTAL-STUDY IN THE PIG	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						BLOOD FLOW; CARDIAC OUTPUT; HEMODYNAMICS; HYPERVENTILATION; HYPOCAPNIA; MICROSPHERES; PIG; SPLANCHNIC CIRCULATION; THERMODILUTION	END-EXPIRATORY PRESSURE; PULMONARY VASOCONSTRICTION; DOG; HEMODYNAMICS; HYPERCAPNIA; HYPOCAPNIA; LAMBS	Mechanical hyperventilation not only reduces brain oedema after neurotrauma but also affects the central and systemic circulation. We have, in pigs, measured blood flow in the pulmonary artery, the portal vein and in the femoral artery, as well as estimated the splanchnic blood flow and studied the relative perfusion using the microsphere technique in normo- and hypocarbia during intermittent positive pressure ventilation. A normoventilated control group did not change in cardiac output, portal vein blood flow, splanchnic blood flow and femoral arterial blood flow. Hyperventilation was performed to a Pco(2) Of 3.0 +/- 0.1 kPa. We found that in pigs ventilated with high tidal volume skeletal muscle blood flow did not change during the first 60 min of hyperventilation but gradually decreased thereafter. Blood flow to the cerebellum decreased soon after the induction of hyperventilation, whereas the cerebral blood flow did not decrease until the second hour of hyperventilation. Cardiac output, splanchnic perfusion and portal vein blood flow all decreased. Myocardial perfusion and arterial blood now to spleen and kidney decreased while pancreatic and liver arterial blood flows were unaffected. It is concluded that mechanical hyperventilation with low frequency and large tidal volumes reduces the flow to most tissues, where the relative decrease according to microsphere measurements is most pronounced in skeletal muscles, heart muscle and cerebellum. However, the changes in cardiac output and splanchnic blood flow were not observed when hyperventilation was induced by increased frequency, keeping the tidal volume constant.	UNIV HOSP UPPSALA,DEPT ANAESTHESIOL & INTENS CARE,UPPSALA,SWEDEN							BRADLEY EL, 1974, SURGERY, V75, P783; BRADLEY SE, 1945, J CLIN INVEST, V24, P890, DOI 10.1172/JCI101676; CAESAR J, 1961, CLIN SCI, V21, P43; CASSIDY SS, 1979, J CLIN INVEST, V64, P620, DOI 10.1172/JCI109502; CULLEN DJ, 1974, ANESTHESIOLOGY, V41, P345, DOI 10.1097/00000542-197410000-00006; FLECKENSTEIN A, 1976, S VASCULAR SMOOTH MU, P117; GARBY L, 1961, SCAND J CLIN LAB INV, V13, P642, DOI 10.3109/00365516109137338; Gordan E, 1969, CEREBRAL BLOOD FLOW, P258; HALDEN E, 1982, ACTA ANAESTH SCAND, V26, P403, DOI 10.1111/j.1399-6576.1982.tb01789.x; HARTMAN J, 1985, PHARMACOLOGIST, V27, P217; JOHNSON EE, 1972, J APPL PHYSIOL, V38, P156; LYRENE RK, 1985, PEDIATR RES, V19, P1268, DOI 10.1203/00006450-198512000-00009; MARRUBINI MLB, 1961, BRIT J ANAESTH, V36, P415; MIYAZAKI M, 1978, ANGIOLOGY, V29, P541, DOI 10.1177/000331977802900705; MORRAY JP, 1988, J PEDIATR-US, V113, P474, DOI 10.1016/S0022-3476(88)80631-0; NEILL WA, 1975, CIRCULATION, V52, P854, DOI 10.1161/01.CIR.52.5.854; PERRY MA, 1981, MEASUREMENT BLOOD FL, P161; PRICE H, 1960, ANESTHESIOLOGY, V6, P652; PRYSROBERTS C, 1968, J APPL PHYSIOL, V25, P80; RUBERTSSON S, 1993, SURG RES COMM, V13, P309; SCHREIBER MD, 1986, PEDIATR RES, V20, P113, DOI 10.1203/00006450-198602000-00003; SEMB BK, 1984, EUR SURG RES, V2, P133; VENUS B, 1988, CRIT CARE MED, V16, P686, DOI 10.1097/00003246-198807000-00008; WEXELS JC, 1986, CAN J PHYSIOL PHARM, V64, P1376, DOI 10.1139/y86-233; WEXELS JC, 1987, CLIN PHYSIOL, V7, P21, DOI 10.1111/j.1475-097X.1987.tb00630.x; YASUE H, 1978, CIRCULATION, V58, P56, DOI 10.1161/01.CIR.58.1.56	26	28	28	0	0	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	FEB	1994	38	2					180	186		10.1111/j.1399-6576.1994.tb03863.x			7	Anesthesiology	Anesthesiology	MY033	WOS:A1994MY03300017	8171955				2021-06-18	
J	WRIGLEY, JM; YOELS, WC; WEBB, CR; FINE, PR				WRIGLEY, JM; YOELS, WC; WEBB, CR; FINE, PR			SOCIAL AND PHYSICAL FACTORS IN THE REFERRAL OF PEOPLE WITH TRAUMATIC BRAIN INJURIES TO REHABILITATION	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SPINAL-CORD INJURY; CARE		UNIV ALABAMA,DEPT SOCIOL,BIRMINGHAM,AL 35394	WRIGLEY, JM (corresponding author), UNIV ALABAMA,INJURY CONTROL RES CTR,933 S 19TH ST,CHSB 19TH,RM 403,UAB STN,BIRMINGHAM,AL 35394, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR403641] Funding Source: Medline		BAMFORD E, 1984, BRIT MED J, V292, P546; Blumer Herbert, 1969, SYMB INTERACT; CAPLAN A, 1987, HASTINGS CTR REP S, P1; CURLEY SP, 1989, MED DECIS MAKING, V9, P116, DOI 10.1177/0272989X8900900206; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P449; FINDLEY TW, 1987, MED CARE, V25, P753, DOI 10.1097/00005650-198708000-00008; HAAS JF, 1988, ARCH PHYS MED REHAB, V69, P329; HEINEMANN AW, 1989, ARCH NEUROL-CHICAGO, V46, P1098, DOI 10.1001/archneur.1989.00520460084017; Kassirer J. P., 1991, LEARNING CLIN REASON; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; KOSKA M, 1988, HOSPITALS, V4, P63; MCSHERRY JA, 1989, AM FAM PHYSICIAN, V40, P186; MELVIN JL, 1988, ARCH PHYS MED REHAB, V69, P163; SCHWARTZ RJ, 1989, J TRAUMA, V29, P1611, DOI 10.1097/00005373-198912000-00002; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V27, P230; Wehman P, 1989, Brain Inj, V3, P397, DOI 10.3109/02699058909004563; YARKONY GM, 1990, AM J PHYS MED REHAB, V69, P23, DOI 10.1097/00002060-199002000-00006; Zola I.K., 1983, SOCIOMEDICAL INQUIRI; 1985, INJURY AM	19	28	28	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1994	75	2					149	155					7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	MW994	WOS:A1994MW99400004	8311670				2021-06-18	
J	CITTAPIETROLUNGO, TJ; ALEXANDER, MA; COOK, SP; PADMAN, R				CITTAPIETROLUNGO, TJ; ALEXANDER, MA; COOK, SP; PADMAN, R			COMPLICATIONS OF TRACHEOSTOMY AND DECANNULATION IN PEDIATRIC AND YOUNG-PATIENTS WITH TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							AIRWAY COMPLICATIONS; TRACHEOTOMY; MANAGEMENT		ALFRED I DUPONT INST,WILMINGTON,DE 19899							BETTS JM, 1989, SINGLE STAGE RECONST; CHEW JY, 1972, ARCHIV OTOLARYNGOL, V96, P538; COTTON RT, 1984, J PEDIATR SURG, V19, P699, DOI 10.1016/S0022-3468(84)80355-3; CRYSDALE WS, 1988, ANN OTO RHINOL LARYN, V97, P439, DOI 10.1177/000348948809700501; DEMPSTER J H, 1986, Journal of the Royal College of Surgeons of Edinburgh, V31, P359; DOWNES JJ, 1985, INT ANESTHESIOL CLIN, V23, P37, DOI 10.1097/00004311-198523040-00005; FISHBURN MJ, 1990, ARCH PHYS MED REHAB, V71, P197; KLINGBEIL GEG, 1988, ARCH PHYS MED REHAB, V69, P493; MALLORY GB, 1991, ARCH PHYS MED REHAB, V72, P43; NOWAK P, 1987, AM J OTOLARYNG, V8, P91, DOI 10.1016/S0196-0709(87)80030-3; OLIVER P, 1962, NEW ENGL J MED, V267, P631, DOI 10.1056/NEJM196209272671301; SABISTON DC, 1986, TXB SURGERY BIOL BAS, P2059; SCOTT JR, 1978, AM J ROENTGENOL, V130, P893; SCOTT JR, 1978, AM J ROENTGENOL, V130, P887; SPLAINGARD ML, 1989, ARCH PHYS MED REHAB, V70, P318; STAUFFER JL, 1981, AM J MED, V70, P65, DOI 10.1016/0002-9343(81)90413-7; TUCKER JA, 1972, ANN OTO RHINOL LARYN, V81, P818, DOI 10.1177/000348947208100611; WETMORE RF, 1982, ANN OTO RHINOL LARYN, V91, P628, DOI 10.1177/000348948209100623; WOO P, 1989, LARYNGOSCOPE, V99, P725	19	28	29	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1993	74	9					905	909					5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	LX551	WOS:A1993LX55100003	8379834				2021-06-18	
J	ZIEGLER, W; HARTMANN, E; HOOLE, P				ZIEGLER, W; HARTMANN, E; HOOLE, P			SYLLABIC TIMING IN DYSARTHRIA	JOURNAL OF SPEECH AND HEARING RESEARCH			English	Article						DYSARTHRIA; SPEECH; TIMING; ACOUSTICS; SYLLABLE	ACQUIRED BRAIN INJURY; SPEECH; COMPATIBILITY; VARIABILITY; UTTERANCES; DURATION; DISEASE; RHYTHM	A new, intensity-based method of measuring syllable duration was used to assess syllabic timing in 75 patients with dysarthria of predominantly traumatic and cerebro-vascular origin and in 30 normal subjects. The applied speech tasks included repetitions of sentences containing chains of plosive-vowel-syllables. The logarithm of the duration of the syllable carrying sentence accent proved to be particularly highly correlated with perceived speech rate. Among the potential sources of temporal variability, segmental influences and the influence of sentence stress were examined. Further, the between-sentence variation of syllable duration was assessed. The resulting measures of variability were correlated with the severity of dysarthric impairment. A strengthening of normal effects was found in the consonant-related variation, whereas intrinsic vowel effects and the influence of sentence stress were largely reduced. These results are discussed from the viewpoint of timing theories in speech and limb motor control. They are considered to provide a valuable background against which the speech impairments of specific neurologic groups can be tested.		ZIEGLER, W (corresponding author), STADT KRANKENHAUS BOGENHAUSEN,NEUROPSYCHOL KLIN,EKN ENTWICKLUNGSGRP,DACHAUER STR 164,W-8000 MUNICH 50,GERMANY.						ACKERMANN H, 1991, J NEUROL NEUROSUR PS, V54, P1093, DOI 10.1136/jnnp.54.12.1093; ADAMS JA, 1987, PSYCHOL BULL, V101, P41, DOI 10.1037/0033-2909.101.1.41; ANTONIADIS Z, 1984, PHONETICA, V41, P72, DOI 10.1159/000261713; CARUSO AJ, 1987, J SPEECH HEAR RES, V30, P80, DOI 10.1044/jshr.3001.80; CAZALETS JR, 1990, BEHAV BRAIN RES, V40, P215, DOI 10.1016/0166-4328(90)90078-S; CHERRY C, 1967, NATURE, V214, P1164, DOI 10.1038/2141164a0; Darley F., 1975, MOTOR SPEECH DISORDE; EDWARDS J, 1988, PHONETICA, V45, P156, DOI 10.1159/000261824; FARMER A, 1980, FOLIA PHONIATR, V32, P267, DOI 10.1159/000264347; Fischer-Jorgensen Eli, 1964, Z PHONETIK SPRACHWIS, V17, P175, DOI 10.1524/stuf.1964.17.16.175; FORREST K, 1989, J ACOUST SOC AM, V85, P2608, DOI 10.1121/1.397755; Fowler C. A., 1981, ATTENTION PERFORMANC, VIX, P521; FOWLER CA, 1978, INFORMATION PROCESSI; FUJIMURA O, 1987, HONOR ILSE LEHISTE; GENTIL M, 1990, BRAIN LANG, V38, P438, DOI 10.1016/0093-934X(90)90126-2; Handel S., 1989, LISTENING INTRO PERC; HUBER W, 1989, J COGNITIVE NEUROSCI, V1, P136; KENT RD, 1979, J SPEECH HEAR RES, V22, P627, DOI 10.1044/jshr.2203.627; KENT RD, 1991, DEV TIMING CONTROL T; KLAPP ST, 1979, MEM COGNITION, V7, P375, DOI 10.3758/BF03196942; KOHLER KJ, 1986, INVARIANCE VARIABILI, P268; LEHISTE I, 1972, J ACOUST SOC AM, V51, P2018, DOI 10.1121/1.1913062; Lindblom B., 1983, PRODUCTION SPEECH, P217, DOI DOI 10.1007/978-1-4613-8202-7_10; MARSDEN CD, 1989, MOVEMENT DISORD, V4, pS26, DOI 10.1002/mds.870040505; MERMELSTEIN P, 1975, J ACOUST SOC AM, V58, P880, DOI 10.1121/1.380738; MORRIS RJ, 1989, J COMMUN DISORD, V22, P23, DOI 10.1016/0021-9924(89)90004-X; NAGASAKI H, 1990, HUM MOVEMENT SCI, V9, P177, DOI 10.1016/0167-9457(90)90026-A; NEWEKLOWSKY G, 1975, PHONETICA, V32, P38, DOI 10.1159/000259685; NOOTEBOOM SG, 1985, TIME MIND BEHAVIOR, P242; OSTRY DJ, 1985, J ACOUST SOC AM, V77, P640, DOI 10.1121/1.391882; PITT MA, 1990, J EXP PSYCHOL HUMAN, V16, P564, DOI 10.1037/0096-1523.16.3.564; ROSEN S, 1992, PHILOS T ROY SOC B, V336, P367, DOI 10.1098/rstb.1992.0070; ROSENBAUM DA, 1987, MEM COGNITION, V15, P217, DOI 10.3758/BF03197719; SAMAR VJ, 1988, J SPEECH HEAR RES, V31, P307, DOI 10.1044/jshr.3103.307; SOROKIN VN, 1980, J ACOUST SOC AM, V68, pS32; TATSUMI IF, 1979, ANN B RILP, V13, P99; TEASDALE N, 1990, J NEUROL NEUROSUR PS, V52, P862; VIVIANI P, 1991, DEV TIMING CONTROL T, P1; VOGEL M, 1983, FOLIA PHONIATR, V35, P294, DOI 10.1159/000265705; WEISMER G, 1985, J ACOUST SOC AM, V78, P49, DOI 10.1121/1.392453; Weismer G., 1984, DYSARTHRIAS PHYSL AC, P101; WING AM, 1973, PERCEPT PSYCHOPHYS, V14, P5, DOI 10.3758/BF03198607; ZIEGLER W, 1986, BRIT J DISORD COMMUN, V21, P173; ZIEGLER W, 1988, BRIT J DISORD COMMUN, V23, P215; ZIEGLER W, 1990, AKUSTISCHE DIMENSION; ZIEGLER W, 1ST P C ICPLA AMST	46	28	28	0	3	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	10801 ROCKVILLE PIKE RD, ROCKVILLE, MD 20852-3279	0022-4685			J SPEECH HEAR RES	J. Speech Hear. Res.	AUG	1993	36	4					683	693		10.1044/jshr.3604.683			11	Language & Linguistics; Rehabilitation	Linguistics; Rehabilitation	LR907	WOS:A1993LR90700004	8377481				2021-06-18	
J	GODFREY, HPD; BISHARA, SN; PARTRIDGE, FM; KNIGHT, RG				GODFREY, HPD; BISHARA, SN; PARTRIDGE, FM; KNIGHT, RG			NEUROPSYCHOLOGICAL IMPAIRMENT AND RETURN TO WORK FOLLOWING SEVERE CLOSED-HEAD INJURY - IMPLICATIONS FOR CLINICAL MANAGEMENT	NEW ZEALAND MEDICAL JOURNAL			English	Article								Aims. To study the rate and timing of return to work following severe closed head injury, and to compare the neuropsychological functioning of patients who successfully return to work with that of patients who fail to return to work. Methods. The vocational status, level of cognitive functioning and personality functioning of a consecutive series of 66 patients who survived severe closed head injury was assessed between six months and three years postinjury. The level of cognitive and personality functioning of patients who returned to work, were compared with that of patients who failed to return to work. Results. Twenty five percent of patients failed to return to work, and a further 17% returned to work under special conditions of employment. Failure to return to work was related to the degree of neuropsychological impairment (cognitive deficit and adverse personality change), injury severity (duration of posttraumatic amnesia), and age. Multiple regression analysis found the total number of neuropsychological symptoms to be the strongest predictor of the patients' return to work. Conclusions. These findings suggest that neuropsychological symptoms are the main mechanism through which severe brain injury affects the ability to return to work. It is recommended that vocational rehabilitation of severe closed head injury patients be based on a comprehensive neuropsychological assessment.	UNIV OTAGO,DEPT SURG NEUROSURG,DUNEDIN,NEW ZEALAND	GODFREY, HPD (corresponding author), UNIV OTAGO,DEPT PSYCHOL,CTR CLIN PSYCHOL RES & TRAINING,POB 56,DUNEDIN,NEW ZEALAND.						BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Brooks D N, 1979, Int Rehabil Med, V1, P160; GODFREY HPD, 1993, IN PRESS J CLIN EXP; GODFREY HPD, 1989, UNPUB MANUAL INPATIE; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; HUMPHREY M, 1980, BRAIN INJURIES, V12, P107; Johnson R, 1987, Int Disabil Stud, V9, P49; KNIGHT RG, 1984, J CONSULT CLIN PSYCH, V52, P769; Nelson H., 1982, NATIONAL ADULT READI; ODONNELL WE, 1984, J CLIN PSYCHOL, V40, P549, DOI 10.1002/1097-4679(198403)40:2<549::AID-JCLP2270400228>3.0.CO;2-1; PARTRIDGE FM, 1991, THESIS U OTAGO; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Raven J.C.C.J., 1977, MANUAL RAVENS PROGR; REY A, 1963, EXAMEN CLIN PSYCHOL; RUSSELL WR, 1961, TRAUMATIC AMNESIAS; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164	16	28	29	0	3	NEW ZEALAND MED ASSN	WELLINGTON	PO BOX 156, WELLINGTON, NEW ZEALAND	0028-8446			NEW ZEAL MED J	N. Z. Med. J.	JUL 28	1993	106	960					301	303					3	Medicine, General & Internal	General & Internal Medicine	LR336	WOS:A1993LR33600002	8341452				2021-06-18	
J	ALFANO, DP; NEILSON, PM; FINK, MP				ALFANO, DP; NEILSON, PM; FINK, MP			LONG-TERM PSYCHOSOCIAL ADJUSTMENT FOLLOWING HEAD OR SPINAL-CORD INJURY	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article						CLOSED HEAD INJURY; SPINAL CORD INJURY; PREINJURY; POSTINJURY; PSYCHOSOCIAL FUNCTIONING	NEUROPSYCHOLOGICAL RECOVERY; SOCIAL-ADJUSTMENT; BRAIN INJURY; REHABILITATION; DEPRESSION; MODERATE; SEQUELAE; DEFICIT; FAMILY; STAFF	The long-term psychosocial sequelae of traumatic injury to the brain or spinal cord were comparatively examined in patients who had sustained either moderate-to-severe closed head injury (CHI) or spinal cord injury (SCI). Both groups experienced significant pre- to postinjury reductions in socioeconomic and employment status. In addition to cognitive dysfunction, the patients with CHI reported significantly greater depressive symptomotology, and a pattern of psychological adjustment characterized by greater chronic tension, social alienation, and moodiness. No differences were found between patients' reports of psychosocial functioning as assessed across a broad range of relevant dimensions that included the vocational, domestic, and social environments. In the group with CHI, memory dysfunction was consistently correlated with a broad range of psychological variables, including degree of depressive symptomotology and anxiety. Memory dysfunction was also the most significant correlate of long-term psychosocial adjustment for the patients with CHI; degree of depressive symptomotology, age at injury, and level of injury to the spinal cord were the most significant correlates for the patients with SCI. The relatives of the patients with CHI reported significantly greater patient dysfunction in the areas of vocational and social-role performance outside the home than did the patients themselves. The results are discussed in terms of the specific and the general long-term sequelae resulting from traumatic injury to the brain or spinal cord and associated implications for rehabilitation.	WASCANA REHABIL CTR, REGINA, SK, CANADA	ALFANO, DP (corresponding author), UNIV REGINA, DEPT PSYCHOL, REGINA S4S 0A2, SASKATCHEWAN, CANADA.						ADAMS RD, 1989, PRINCIPLES NEUROLOGY; Alfano D. P., 1987, CLIN NEUROPSYCHOL, V1, P105; Alfano Dennis P, 1992, Clin Neuropsychol, V6, P134, DOI 10.1080/13854049208401850; ALFANO DP, 1991, J CLIN EXP NEUROPSYC, V13, P23; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; [Anonymous], 1978, INT CLASSIFICATION D; BLISHEN BR, 1976, CAN REV SOC ANTHROP, V13, P71, DOI 10.1111/j.1755-618X.1976.tb00759.x; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Chelune G. J, 1986, NEUROPSYCHOLOGY HDB, P489; Chelune GJ, 1986, ADV CLIN NEUROPSYCHO, P95, DOI DOI 10.1007/978-1-4613-2211-5_; CUSHMAN LA, 1990, ARCH PHYS MED REHAB, V71, P191; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DECKER SD, 1985, AM J OCCUP THER, V39, P740, DOI 10.5014/ajot.39.11.740; Derogatis LR, 1983, PSYCHOSOCIAL ADJUSTM; Devins GM., 1988, PSYCHOL HLTH, V2, P139, DOI [10.1080/08870448808400349, DOI 10.1080/08870448808400349]; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; FINLAYSON MAJ, 1988, CAN PSYCHOL, V29, P250; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; FRANK RG, 1987, CLIN PSYCHOL REV, V7, P611, DOI 10.1016/0272-7358(87)90009-2; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KATKIN ES, 1978, 8TH MENT MEAS YB, V683; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Miller WG, 1986, NEUROPSYCHOLOGY HDB, P347; MILLON T, 1979, PROF PSYCHOL, V10, P529, DOI 10.1037/0735-7028.10.4.529; MILLON T, 1982, BEHAVIORAL HLTH INVE; NEILSON PM, 1991, CAN PSYCHOL, V32, P215; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PANIAK CE, 1991, J CLIN EXP NEUROPSYC, V13, P92; PANIAK CE, 1990, THESIS U WINDSON WIN; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Roueche JR, 1983, COGNITIVE REHABILITA, V1, P4; Spielberger CD., 1989, MANUAL STATE TRAIT A, V2; STAMBROOK M, 1991, J CLIN EXP NEUROPSYC, V13, P521, DOI 10.1080/01688639108401068; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STUSS DT, 1988, J CLIN EXP NEUROPSYC, V10, P42; Tabachnick BG, 1983, USING MULTIVARIATE S; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; TEASDALE G, 1974, LANCET, V2, P81; TRIESCHMANN RB, 1980, SPINAL CORD INJURIES; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	56	28	28	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	APR	1993	6	2					117	125					9	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	KV540	WOS:A1993KV54000007					2021-06-18	
J	GARSKE, GG; THOMAS, KR				GARSKE, GG; THOMAS, KR			SELF-REPORTED SELF-ESTEEM AND DEPRESSION - INDEXES OF PSYCHOSOCIAL ADJUSTMENT FOLLOWING SEVERE TRAUMATIC BRAIN INJURY	REHABILITATION COUNSELING BULLETIN			English	Article								The authors investigated self-reported psychosocial adjustment of young adults who received inpatient treatment for severe closed head injuries and were later discharged into the community.	UNIV WISCONSIN,DEPT REHABIL PSYCHOL & SPECIAL EDUC,MADISON,WI 53706; UNIV WISCONSIN,DEPT THERAPEUT SCI,MADISON,WI 53706	GARSKE, GG (corresponding author), UNIV ILLINOIS,DIV REHABIL EDUC SERV,URBANA,IL 61801, USA.						ABRAMSON LY, 1978, J ABNORM PSYCHOL, V87, P49, DOI 10.1037/0021-843X.87.1.49; Beck A.T., 1987, BECK DEPRESSION INVE; BECK AT, 1979, COGNITIVE THERAPY DE; Beck AT, 1967, DEPRESSION CAUSES TR; BRACY OL, 1986, COGNITIVE REHABILITA, V4, P10; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; BURTON LA, 1988, J NEUROLOGICAL REHAB, V2, P151; COLE JR, 1984, INNOVATIONS HEAD INJ; Crandall R, 1973, MEASURES SOCIAL PSYC, P45; DeJong G., 1990, J HEAD TRAUMA REHAB, V5, P9, DOI [https://doi.org/10.1097/00001199-199003000-00004, DOI 10.1097/00001199-199003000-00004]; FORER SK, 1984, FUNCTIONAL ASSESSMEN, P171; GOLDSTEIN H, 1942, EFFECTS BRAIN INJURI; HEINEMANN AW, 1982, REHABILITATION COUNS, V24, P197; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KRAVETZ S, 1985, REHABIL PSYCHOL, V30, P195, DOI 10.1037//0090-5550.30.4.195; KRAVETZ S, 1973, THESIS U WISCONSIN; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Maslow A., 1954, MOTIVATION PERSONALI; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Meier M. J., 1987, NEUROPSYCHOLOGICAL R; PASINO J, 1979, REHABILITATION HEAD; PRENDERGAST MA, 1975, MEAS EVAL GUID, V8, P92, DOI 10.1080/00256307.1975.12022675; Prigatano G. P., 1987, COMMUNITY REENTRY HE, P1; REAGLES KW, 1976, J REHABIL, V42, P34; REYNOLDS WM, 1988, J PERS ASSESS, V52, P441; Robinson J.P., 1973, MEASURES SOCIAL PSYC; Rogers C.R., 1951, CLIENT CENTERED THER; ROMANO MD, 1984, REHABILITATION PSYCH; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1126/science.148.3671.804; THOMAS KR, 1986, APPL REHABILITATION, P34; TRIESCHMAN R, 1978, PSYCHOL SOCIAL VOCAT; WYLIE RC, 1974, SELF CONCEPT, V1	34	28	28	0	2	AMER COUNSELING ASSOC	ALEXANDRIA	5999 STEVENSON AVE, ALEXANDRIA, VA 22304-3300	0034-3552			REHABIL COUNS BULL	Rehabil. Couns. Bull.	SEP	1992	36	1					44	52					9	Rehabilitation	Rehabilitation	JJ715	WOS:A1992JJ71500004					2021-06-18	
J	DONDERS, J				DONDERS, J			PREMORBID BEHAVIORAL AND PSYCHOSOCIAL ADJUSTMENT OF CHILDREN WITH TRAUMATIC BRAIN INJURY	JOURNAL OF ABNORMAL CHILD PSYCHOLOGY			English	Article							HEAD-INJURIES; SEQUELAE	The premorbid adjustment of 85 six- to sixteen-year-old children with traumatic brain injury was assessed by means of standardized rating forms that were completed by the children's parents and teachers. Parents and teachers were in moderate agreement when rating children's premorbid functioning. Less than 11 % of the children appeared to have premorbid disturbances. Premorbid adjustment did not appear to be clearly related to injury severity or to type of injury. It is concluded that premorbid behavioral and psychosocial factors are not strongly related to the incidence of traumatic brain injury in a sample of children with predominantly relatively severe injuries.		DONDERS, J (corresponding author), MARY FREE BED HOSP & REHABIL CTR,DEPT PSYCHOL,235 WEALTHY SE,GRAND RAPIDS,MI 49503, USA.						ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; ACHENBACH TM, 1987, EMPIRICALLY BASED AS; Achenbach TM, 1986, MANUAL TEACHERS REPO; Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; BIJUR PE, 1986, AM J DIS CHILD, V140, P487, DOI 10.1001/archpedi.1986.02140190097036; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GLASS GV, 1984, STATISTICAL METHODS; JAFFE KM, 1986, J HEAD TRAUMA REHAB, V1, P30; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Lehr E, 1990, PSYCHOL MANAGEMENT T; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; MCGUIRE TL, 1986, J HEAD TRAUMA REHAB, V1, P1; RIVERA FP, 1986, J HEAD TRAUMA REHABI, V1, P7; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; Sparrow S., 1984, VINELAND ADAPTIVE BE; TEASDALE G, 1974, LANCET, V2, P81	19	28	28	0	4	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013	0091-0627			J ABNORM CHILD PSYCH	J. Abnorm. Child Psychol.	JUN	1992	20	3					233	246		10.1007/BF00916690			14	Psychology, Clinical; Psychology, Developmental	Psychology	JA534	WOS:A1992JA53400001	1619132				2021-06-18	
J	DEHAAN, EHF; YOUNG, AW; NEWCOMBE, F				DEHAAN, EHF; YOUNG, AW; NEWCOMBE, F			NEUROPSYCHOLOGICAL IMPAIRMENT OF FACE RECOGNITION UNITS	QUARTERLY JOURNAL OF EXPERIMENTAL PSYCHOLOGY SECTION A-HUMAN EXPERIMENTAL PSYCHOLOGY			English	Article							PROSOPAGNOSIC PATIENT; COVERT RECOGNITION; FACIAL RECOGNITION; UNFAMILIAR FACES; FAMILIAR FACES; EXTERNAL FEATURES; MATCHING FAMILIAR; AWARENESS; IDENTIFICATION; PERCEPTION	Despite the absence of "conscious", overt identification, some patients with face recognition impairments continue covertly to process information regarding face familiarity. The fact that by no means all patients show these covert effects has led to the suggestion that indirect recognition tasks may help in identifying different types of face recognition impairment. The present report describes a number of experiments with the patient NR, who, after a closed head injury, has been severely impaired at recognizing familiar faces. Investigations mostly failed to show overt or covert face recognition, but NR performed at an above-chance level in selecting the familiar face on a task requiring a forced-choice between a familiar and an unfamiliar face. This discrepancy between a degree of rudimentary overt recognition and absence of covert effects on most indirect tests was addressed using a cross-domain identity priming paradigm. This examined separately the possibility of preserved recognition for faces that NR consistently chose correctly in a forced-choice familiarity decision and those on which he performed at chance level. Priming effects were apparent only for the faces that were consistently chosen as "familiar" in forced-choice. We suggest that NR's stored representations of familiar faces are degraded, so that face recognition is possible only via a limited set of relatively preserved representations able to support a rudimentary form of overt recognition and to facilitate performance in matching and priming tasks.	RADCLIFFE INFIRM,OXFORD OX2 6HE,ENGLAND; UNIV DURHAM,DURHAM DH1 3HP,ENGLAND	DEHAAN, EHF (corresponding author), UNIV UTRECHT,DEPT PSYCHONOM,POB 80 140,3508 TC UTRECHT,NETHERLANDS.		Young, Andy/G-2189-2011	Young, Andy/0000-0002-1202-6297; de Haan, Edward/0000-0003-0312-3674			Bauer R. M., 1986, ASPECTS FACE PROCESS, P253, DOI 10.1007/978-94-009-4420-6_27.; BAUER RM, 1984, NEUROPSYCHOLOGIA, V22, P457, DOI 10.1016/0028-3932(84)90040-X; BENTON A L, 1978, Archives of Neurology, V35, P364; BENTON AL, 1973, NEUROSENSORY CTR PUB, V287; BENTON AL, 1977, VISUAL RETENTION TES, V1; BLANCGARIN J, 1984, ANN PSYCHOL, V84, P573; BODAMER J, 1947, Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr, V118, P6, DOI 10.1007/BF00352849; BRUCE V, 1986, BRIT J PSYCHOL, V77, P305, DOI 10.1111/j.2044-8295.1986.tb02199.x; BRUCE V, 1985, BRIT J PSYCHOL, V76, P373, DOI 10.1111/j.2044-8295.1985.tb01960.x; BRUCE V, 1986, Q J EXP PSYCHOL-A, V38, P125, DOI 10.1080/14640748608401588; Bruce V, 1988, RECOGNISING FACES; BRUYER R, 1983, BRAIN COGNITION, V2, P257, DOI 10.1016/0278-2626(83)90014-3; CHAPMAN JC, 1924, CHAPMAN COOK SPEED R; Cheesman J., 1985, READING RES ADV THEO, V5, P311; DAMASIO AR, 1982, NEUROLOGY, V32, P331, DOI 10.1212/WNL.32.4.331; De Haan E.H., 1991, EUR J COGN PSYCHOL, V3, P51, DOI [DOI 10.1080/09541449108406219, 10.1080/09541449108406219]; De Renzi E., 1986, ASPECTS FACE PROCESS, P243, DOI [10.1007/978-94-009-4420-6_26, DOI 10.1007/978-94-009-4420-6_26]; DEHAAN EHF, 1987, COGN NEUROPSYCHOL, V4, P385, DOI 10.1080/02643298708252045; DEHAAN EHF, 1987, CORTEX, V23, P309, DOI 10.1016/S0010-9452(87)80041-2; DEHAAN EHF, 1986, ASPECTS FACE PROCESS, P279; ELLIS AW, 1987, Q J EXP PSYCHOL-A, V39, P193, DOI 10.1080/14640748708401784; ELLIS HD, 1979, PERCEPTION, V8, P431, DOI 10.1068/p080431; Ellis HD, 1986, NEUROPSYCHOLOGY FACE, P1; ENDO M, 1984, Tohoku Psychologica Folia, V43, P23; ETCOFF NL, 1991, J COGNITIVE NEUROSCI, V3, P25, DOI 10.1162/jocn.1991.3.1.25; HAY DC, 1982, NORMALITY PATHOLOGY, P173; Hecaen H., 1981, PERCEIVING REMEMBERI, P39; HUMPHREYS GW, 1981, BRIT J PSYCHOL, V72, P323, DOI 10.1111/j.2044-8295.1981.tb02191.x; HUMPHREYS GW, 1991, NEUROPSYCHOLOGY CONS; JACOBY LL, 1982, CAN J PSYCHOL, V36, P300, DOI 10.1037/h0080638; KUNSTWILSON WR, 1980, SCIENCE, V207, P557, DOI 10.1126/science.7352271; LANDIS T, 1986, CORTEX, V22, P243, DOI 10.1016/S0010-9452(86)80048-X; LANSDELL H, 1968, PHYSIOL BEHAV, V3, P271, DOI 10.1016/0031-9384(68)90097-8; MCNEIL JE, 1991, Q J EXP PSYCHOL-A, V43, P267, DOI 10.1080/14640749108400970; MEADOWS JC, 1974, J NEUROL NEUROSUR PS, V37, P489, DOI 10.1136/jnnp.37.5.489; NEELY JH, 1977, J EXP PSYCHOL GEN, V106, P226, DOI 10.1037/0096-3445.106.3.226; NEWCOMBE F, 1971, J NEUROL NEUROSUR PS, V34, P329, DOI 10.1136/jnnp.34.3.329; NEWCOMBE F, 1989, NEUROPSYCHOLOGIA, V27, P179, DOI 10.1016/0028-3932(89)90170-X; REINGOLD EM, 1988, PERCEPT PSYCHOPHYS, V44, P563, DOI 10.3758/BF03207490; REINGOLD EM, 1990, MIND LANGUAGE, V5, P93; RENAULT B, 1989, NEUROPSYCHOLOGIA, V27, P905, DOI 10.1016/0028-3932(89)90066-3; RIZZO M, 1987, ANN NEUROL, V22, P41, DOI 10.1002/ana.410220111; Schacter D., 1988, THOUGHT LANGUAGE, P242; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; SERGENT J, 1989, BRAIN, V112, P975, DOI 10.1093/brain/112.4.975; SERGENT J, 1990, BRAIN, V113, P989, DOI 10.1093/brain/113.4.989; SHALLICE T, 1988, COGNITIVE NEUROPSYCH, V5, P133, DOI 10.1080/02643298808252929; SHALLICE T, 1986, COGN NEUROPSYCHOL, V3, P429, DOI 10.1080/02643298608252030; THURSTONE LL, 1937, PSYCHOL TEST STUDY M; TRANEL D, 1985, SCIENCE, V228, P1453, DOI 10.1126/science.4012303; TRANEL O, 1987, J CLIN EXP NEUROPSYC, V9, P15; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; Weiskrantz L., 1986, OXFORD PSYCHOL SERIE, V12; YOUNG A W, 1991, European Journal of Cognitive Psychology, V3, P5, DOI 10.1080/09541449108406218; YOUNG AW, 1986, PSYCHOL RES-PSYCH FO, V48, P63, DOI 10.1007/BF00309318; YOUNG AW, 1990, BRAIN COGNITION, V14, P1, DOI 10.1016/0278-2626(90)90056-T; YOUNG AW, 1986, J EXP PSYCHOL HUMAN, V12, P466, DOI 10.1037/0096-1523.12.4.466; YOUNG AW, 1988, Q J EXP PSYCHOL-A, V40, P561, DOI 10.1080/02724988843000087; YOUNG AW, 1988, COGNITIVE NEUROPSYCH, V5, P317, DOI 10.1080/02643298808252938; YOUNG AW, 1985, PERCEPTION, V14, P737, DOI 10.1068/p140737; YOUNG AW, 1989, BRAIN COGNITION, V9, P16, DOI 10.1016/0278-2626(89)90042-0; YOUNG AW, 1988, THOUGHT LANGUAGE, P78; YOUNG AW, UNPUB NATURE SEMANTI; YOUNG AW, 1991, NEUROPSYCHOLOGY CONS; YOUNG AW, 1990, MIND LANG, V5, P29	65	28	28	0	1	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE, EAST SUSSEX, ENGLAND BN3 2FA	0272-4987			Q J EXP PSYCHOL-A	Q. J. Exp. Psychol. Sect A-Hum. Exp. Psychol.	JAN	1992	44	1					141	175		10.1080/14640749208401287			35	Psychology; Psychology, Experimental	Psychology	GY955	WOS:A1992GY95500007	1546182				2021-06-18	
J	OSHIRO, Y; SAKURAI, Y; TANAKA, T; KIKUCHI, T; HIROSE, T; TOTTORI, K				OSHIRO, Y; SAKURAI, Y; TANAKA, T; KIKUCHI, T; HIROSE, T; TOTTORI, K			NOVEL CEREBROPROTECTIVE AGENTS WITH CENTRAL-NERVOUS-SYSTEM STIMULATING ACTIVITY .2. SYNTHESIS AND PHARMACOLOGY OF THE 1-(ACYLAMINO)-7-HYDROXYINDAN DERIVATIVES	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; ASSAY	In a continuous search for a novel cerebroprotective drug with a central nervous system (CNS) stimulating activity, a series of 1-(acylamino)-7-hydroxyindan derivatives has been synthesized and tested for its dual activities. The cerebroprotective activities of the compounds in this series were evaluated in terms of their effect on the survival of mice in hypoxic conditions (210 mmHg), and their CNS stimulating activities were examined by evaluating their promotional effects on the recovery from coma induced by cerebral concussion in mice. Several compounds prolonged the survival of mice in the hypoxic conditions at a dose of 30 mg/kg po. Four compounds in this series showed the CNS-stimulating effect at the same dose. Among them, 7-hydroxy-1-[[4-(3-methoxyphenyl)-1-piperazinyl]acetyl]amino]-2,2,4,6-tetramethylindan (18, OPC-14117), which was active in the two tests with no side effect up to 500 mg/kg po daily for 2 weeks of administration to rats, was selected for preclinical investigations.		OSHIRO, Y (corresponding author), OTSUKA PHARMACEUT CO LTD,INST NEW DRUG RES 3,364-10 KAGASUNO,TOKUSHIMA 77101,JAPAN.						AYER ED, 1990, J MED CHEM, V33, P1145; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; GIANNOTTA SL, 1984, NEUROSURGERY, V15, P497, DOI 10.1227/00006123-198410000-00004; GOLDSTEIN A, 1966, ARCH INT PHARMACOD T, V161, P128; Hashi K, 1988, No To Shinkei, V40, P373; JINNO J, 1990, 12TH ANN M MAGN RES; JOHNSON H, 1986, SIGPLAN NOTICES, V21, P109; MANAKA S, 1977, IGAKU NO AYUMI, V102, P867; MIYAMOTO M, 1981, LIFE SCI, V28, P861, DOI 10.1016/0024-3205(81)90047-3; NAKANISHI M, 1973, LIFE SCI, V13, P467, DOI 10.1016/0024-3205(73)90038-6; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; OSHIRO Y, 1991, J MED CHEM, V34, P2004, DOI 10.1021/jm00111a013; SAFAR P, 1977, BRAIN HEART INFARCT, V2, P251; SMITH AL, 1974, STROKE, V5, P1; STOCKS J, 1974, CLIN SCI MOL MED, V47, P215, DOI 10.1042/cs0470215; SUNO M, 1984, JPN J PHARMACOL, V35, P196, DOI 10.1254/jjp.35.196; TURNBULL MJ, 1976, BRIT J PHARMACOL, V58, P27, DOI 10.1111/j.1476-5381.1976.tb07689.x; YAMAMOTO M, 1983, STROKE, V14, P977, DOI 10.1161/01.STR.14.6.977; YASUDA H, 1978, ARCH INT PHARMACOD T, V233, P136; YASUDA H, 1978, J NEUROCHEM, V37, P934; Yatsu FM, 1972, STROKE, V3, P726, DOI 10.1161/01.STR.3.6.726	21	28	28	0	1	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036	0022-2623			J MED CHEM	J. Med. Chem.	JUL	1991	34	7					2014	2023		10.1021/jm00111a014			10	Chemistry, Medicinal	Pharmacology & Pharmacy	FW170	WOS:A1991FW17000014	1676757				2021-06-18	
J	JORDAN, FM; MURDOCH, BE; BUTTSWORTH, DL				JORDAN, FM; MURDOCH, BE; BUTTSWORTH, DL			CLOSED-HEAD-INJURED CHILDRENS PERFORMANCE ON NARRATIVE TASKS	JOURNAL OF SPEECH AND HEARING RESEARCH			English	Article						CLOSED HEAD INJURY; NARRATIVE; CHILDRENS LANGUAGE	DISCOURSE; COHESION; ADULTS			JORDAN, FM (corresponding author), UNIV QUEENSLAND,DEPT SPEECH & HEARING,ST LUCIA,QLD 4067,AUSTRALIA.		Murdoch, Bruce E/C-1397-2012				Applebee A., 1978, CHILDS CONCEPT STORY; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BLOOM L, 1975, REV CHILD DEV RES, V4; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; Enderby P.M, 1983, BR J DISORD COMMUN, V17, P165; EWINGCOBBS L, 1985, HEAD INJURY REHABILI; EWINGCOBBS L, 1987, J CLIN EXPT NEUROPSY, V5, P575; Fillmore Ch. J, 1968, UNIVERSALS LINGUISTI, P1; GAIDOLFI E, 1980, ITAL J NEUROL SCI, V1, P65; Halliday Michael A. K., 1976, COHESION ENGLISH; HAMMILL D, 1982, TEST LANGUAGE DEV IN; Hammill D. D., 1987, TEST ADOLESCENT LANG; HOLM S, 1979, SCAND J STAT, V6, P65; Johnston J. R., 1982, LANG SPEECH HEAR SER, V13, P144; JORDAN F M, 1990, Brain Injury, V4, P147, DOI 10.3109/02699059009026159; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; Kaplan E., 1983, BOSTON NAMING TEST; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN H, 1983, PEDIATRIC HEAD TRAUM; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; MANDLER JM, 1977, COGNITIVE PSYCHOL, V9, P111, DOI 10.1016/0010-0285(77)90006-8; MCLEOD S, 1989, APR AUSTR ASS SPEECH; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Merritt D. D., 1989, J SPEECH HEAR DISORD, V54, P429; Newcomer P, 1982, TEST LANGUAGE DEV; OLLEY L, 1989, AUSTR J HUMAN COMMUN, V17, P43, DOI DOI 10.3109/asl2.1989.17.issue-1.04; OWENS RE, 1988, LANGUAGE DEV INTRO; PAGE JL, 1985, TOPICS LANGUAGE  MAR, P16; ROTH FP, 1986, J SPEECH HEAR DISORD, V51, P8, DOI 10.1044/jshd.5101.08; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; Spreen O, 1969, NEUROSENSORY CTR COM; Stein NL., 1979, NEW DIRECTIONS DISCO; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1984, CLOSED HEAD INJURY P	37	28	28	0	0	AMER SPEECH-LANG-HEARING ASSN	ROCKVILLE	10801 ROCKVILLE PIKE RD, ROCKVILLE, MD 20852-3279	0022-4685			J SPEECH HEAR RES	J. Speech Hear. Res.	JUN	1991	34	3					572	582		10.1044/jshr.3403.572			11	Language & Linguistics; Rehabilitation	Linguistics; Rehabilitation	FQ361	WOS:A1991FQ36100015	2072682				2021-06-18	
J	GOLDSTEIN, FC; LEVIN, HS; BOAKE, C				GOLDSTEIN, FC; LEVIN, HS; BOAKE, C			CONCEPTUAL ENCODING FOLLOWING SEVERE CLOSED HEAD-INJURY	CORTEX			English	Article									UNIV TEXAS, MED BRANCH, DIV NEUROSURG, D-73, GALVESTON, TX 77550 USA; INST REHAB & RES, HOUSTON, TX USA; EMORY UNIV, DEPT NEUROL, ATLANTA, GA 30322 USA					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BATTIG WF, 1969, J EXP PSYCHOL, V80, P1, DOI 10.1037/h0027577; BENTON AL, 1978, MANUAL MULTILINGUAL; BOND M, 1984, CLOSED HEAD INJURY P; Bousfield WA, 1953, J GEN PSYCHOL, V49, P229, DOI 10.1080/00221309.1953.9710088; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Butters N, 1980, ALCOHOLIC KORSAKOFFS; CERMAK LS, 1974, BRAIN LANG, V1, P141, DOI 10.1016/0093-934X(74)90030-3; CERMAK LS, 1976, BRAIN LANG, V3, P375, DOI 10.1016/0093-934X(76)90033-X; FREEDMAN M, 1986, BRAIN COGNITION, V5, P108, DOI 10.1016/0278-2626(86)90063-1; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Heaton R. K, 1981, WISCONSIN CARD SORTI; HUNT E, 1973, PSYCHOL LEARNING MOT, V7; INCISADELLAROCCHETTA A, 1986, CORTEX, V22, P189, DOI 10.1016/S0010-9452(86)80045-4; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; MOFFAT N, 1984, CLIN MANAGEMENT MEMO; MOSCOVITCH M, 1982, HUMAN MEMORY AMNESIA; OBRIEN RG, 1985, PSYCHOL BULL, V97, P316, DOI 10.1037/0033-2909.97.2.316; OCONNOR M, 1986, NEUROPSYCHOLOGICAL R; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; RICHARDSON JTE, 1984, CORTEX, V20, P413, DOI 10.1016/S0010-9452(84)80009-X; RUBIN DC, 1981, NEUROPSYCHOLOGIA, V19, P137, DOI 10.1016/0028-3932(81)90053-1; SALMON DP, 1986, NEUROPSYCHOLOGICAL R; SCHACTER DL, 1986, CLIN NEUROPSYCHOLOGY; SQUIRE LR, 1982, J EXP PSYCHOL LEARN, V8, P560, DOI 10.1037/0278-7393.8.6.560; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; TEASDALE G, 1974, LANCET, V2, P81; TULVING E, 1984, BEHAV BRAIN SCI, V7, P257, DOI 10.1017/S0140525X00044617; Tulving E, 1983, ELEMENTS EPISODIC ME; TULVING E, 1987, NEUROBEHAVIORAL RECO; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WEINGARTNER H, 1981, J ABNORM PSYCHOL, V90, P187, DOI 10.1037/0021-843X.90.3.187; WEINGARTNER H, 1981, ARCH GEN PSYCHIAT, V38, P42; WICKENS DD, 1970, PSYCHOL REV, V77, P1, DOI 10.1037/h0028569; ZATORRE RJ, 1983, BRAIN COGNITION, V2, P331, DOI 10.1016/0278-2626(83)90017-9; 1985, SAS STAT GUIDE PERSO	41	28	28	0	3	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	DEC	1989	25	4					541	554		10.1016/S0010-9452(89)80016-4			14	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	CH970	WOS:A1989CH97000001	2612174				2021-06-18	
J	SOCKALOSKY, JJ; KRIEL, RL; KRACH, LE; SHEEHAN, M				SOCKALOSKY, JJ; KRIEL, RL; KRACH, LE; SHEEHAN, M			PRECOCIOUS PUBERTY AFTER TRAUMATIC BRAIN INJURY	JOURNAL OF PEDIATRICS			English	Article									GILLETTE CHILDRENS HOSP, PEDIAT HEAD INJURY SERV, ST PAUL, MN 55101 USA	SOCKALOSKY, JJ (corresponding author), ST PAUL RAMSEY MED CTR, DEPT PEDIAT, 640 JACKSON ST, ST PAUL, MN 55101 USA.						ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BACON G, 1982, PRACTICAL APPROACH P, P189; BALAGURA S, 1979, SURG NEUROL, V11, P315; BIERICH JR, 1975, CLIN ENDOCRINOL META, V4, P107, DOI 10.1016/S0300-595X(75)80036-3; BRUCE DA, 1983, PEDIATRIC HEAD TRAUM, P213; COMITE F, 1986, JAMA-J AM MED ASSOC, V255, P2613; CONTE FA, 1980, J CLIN ENDOCR METAB, V50, P163, DOI 10.1210/jcem-50-1-163; Grumbach M.M, 1980, NEUROENDOCRINOLOGY, P249; KAPLAN SL, 1985, CONTROL ONSET PUBERT; LEVIN HS, 1983, PEDIATRIC HEAD TRAUM, P22; MCKIERNAN J, 1978, BMJ-BRIT MED J, V14, P1059; RAYNER PHW, 1976, BRIT MED J, V1, P1385, DOI 10.1136/bmj.1.6022.1385; REITER EO, 1975, PEDIATR RES, V9, P111, DOI 10.1203/00006450-197509020-00011; ROOT AW, 1978, J PEDIATR, V83, P187; ROSS GT, 1981, TXB ENDOCRINOLOGY, P339; ROTH JC, 1972, J CLIN ENDOCR METAB, V35, P926, DOI 10.1210/jcem-35-6-926; SHAUL PW, 1985, AM J DIS CHILD, V139, P467, DOI 10.1001/archpedi.1985.02140070041029; SIGURJONSDOTTIR TJ, 1968, AM J DIS CHILD, V115, P309, DOI 10.1001/archpedi.1968.02100010311003; WILKINS L, 1965, DIAGNOSIS TREATMENT, P225	19	28	28	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	MAR	1987	110	3					373	377		10.1016/S0022-3476(87)80497-3			5	Pediatrics	Pediatrics	G3208	WOS:A1987G320800008	3819938				2021-06-18	
J	KARNAZE, DS; WEINER, JM; MARSHALL, LF				KARNAZE, DS; WEINER, JM; MARSHALL, LF			AUDITORY EVOKED-POTENTIALS IN COMA AFTER CLOSED HEAD-INJURY - A CLINICAL-NEUROPHYSIOLOGIC COMA SCALE FOR PREDICTING OUTCOME	NEUROLOGY			English	Article									UNIV SO CALIF,SCH MED,DEPT MED,LOS ANGELES,CA 90033; UNIV CALIF SAN DIEGO,DIV NEUROSURG,LA JOLLA,CA 92093	KARNAZE, DS (corresponding author), UNIV SO CALIF,SCH MED,DEPT NEUROL,2025 ZONAL AVE,ROOM 5641,LOS ANGELES,CA 90033, USA.						ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; BATES D, 1977, ANN NEUROL, V2, P211, DOI 10.1002/ana.410020306; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GOLDIE WD, 1981, NEUROLOGY, V31, P248, DOI 10.1212/WNL.31.3.248; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; HUME AL, 1979, ANN NEUROL, V5, P379, DOI 10.1002/ana.410050412; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; KARNAZE DS, 1982, NEUROLOGY, V32, P299, DOI 10.1212/WNL.32.3.299; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; LINDSAY KW, 1981, J NEUROL NEUROSUR PS, V44, P796, DOI 10.1136/jnnp.44.9.796; NARAYAN R, 1982, J NEUROSURG, V56, P26; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; PLUM F, 1980, DIAGNOSIS STUPOR COM, P326; SALCMAN M, 1981, NEUROSURGERY, V8, P301; SATYAMURTI S, 1983, ELECTROEN CLIN NEURO, V56, P304, DOI 10.1016/0013-4694(83)90255-9; TAKASHI T, 1980, J NEUROL NEUROSURG P, V43, P1005; TEASDALE G, 1974, LANCET, V2, P81; YORK DH, 1981, J NEUROSURG, V55, P909, DOI 10.3171/jns.1981.55.6.0909	21	28	29	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0028-3878			NEUROLOGY	Neurology		1985	35	8					1122	1126		10.1212/WNL.35.8.1122			5	Clinical Neurology	Neurosciences & Neurology	ANH03	WOS:A1985ANH0300006	4022346				2021-06-18	
J	MEYERS, CA; LEVIN, HS; EISENBERG, HM; GUINTO, FC				MEYERS, CA; LEVIN, HS; EISENBERG, HM; GUINTO, FC			EARLY VERSUS LATE LATERAL VENTRICULAR ENLARGEMENT FOLLOWING CLOSED HEAD-INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article									UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DIV NEURORADIOL,GALVESTON,TX 77550					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 07377-11, NS 9-2314] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS092314] Funding Source: NIH RePORTER		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; DELEON MJ, 1980, NEUROBIOL AGING, V1, P69, DOI 10.1016/0197-4580(80)90027-5; GRONWALL D, 1974, LANCET, V2, P1452; KISHORE PRS, 1978, NEURORADIOLOGY, V16, P261, DOI 10.1007/BF00395266; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; OVERALL JE, 1962, PSYCHOL REP, V10, P799; Plum F., 1980, DIAGNOSIS STUPOR COM, V3; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1969, LATE EFFECTS HEAD IN, P501; SYNEK V, 1976, BRIT J RADIOL, V49, P233, DOI 10.1259/0007-1285-49-579-233; TEASDALE G, 1974, LANCET, V2, P81	15	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry		1983	46	12					1092	1097		10.1136/jnnp.46.12.1092			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	RW430	WOS:A1983RW43000005	6607318	Green Published, Bronze			2021-06-18	
J	Ge, XT; Guo, MT; Hu, TP; Li, WZ; Huang, S; Yin, ZY; Li, Y; Chen, FL; Zhu, LY; Kang, CS; Jiang, RC; Lei, P; Zhang, JN				Ge, Xintong; Guo, Mengtian; Hu, Tianpeng; Li, Wenzhu; Huang, Shan; Yin, Zhenyu; Li, Ying; Chen, Fanglian; Zhu, Luoyun; Kang, Chunsheng; Jiang, Rongcai; Lei, Ping; Zhang, Jianning			Increased Microglial Exosomal miR-124-3p Alleviates Neurodegeneration and Improves Cognitive Outcome after rmTBI	MOLECULAR THERAPY			English	Article							TRAUMATIC BRAIN-INJURY; AMYLOID-BETA; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; APOLIPOPROTEIN-E; EXTRACELLULAR VESICLES; STROMAL CELLS; NEUROGRANIN; MICROVESICLES; EPIDEMIOLOGY	Repetitive mild traumatic brain injury (rmTBI) is considered to be an important risk factor for long-term neurodegenerative disorders such as Alzheimer's disease, which is characterized by beta-amyloid abnormalities and impaired cognitive function. Microglial exosomes have been reported to be involved in the transportation, distribution, and clearance of beta-amyloid in Alzheimer's disease. However, their impacts on the development of neurodegeneration after rmTBI are not yet known. The role of miRNAs in microglial exosomes on regulating post-traumatic neurodegeneration was investigated in the present study. We demonstrated that miR-124-3p level in microglial exosomes from injured brain was significantly altered in the acute, sub-acute, and chronic phases after rmTBI. In in vitro experiments, microglial exosomes with upregulated miR-124-3p (EXO-124) alleviated neurodegeneration in repetitive scratch-injured neurons. The effects were exerted by miR-124-3p targeting Rela, an inhibitory transcription factor of ApoE that promotes the beta-amyloid proteolytic breakdown, thereby inhibiting beta-amyloid abnormalities. In mice with rmTBI, the intravenously injected microglial exosomes were taken up by neurons in injured brain. Besides, miR-124-3p in the exosomes was transferred into hippocampal neurons and alleviated neurodegeneration by targeting the Rela/ApoE signaling pathway. Consequently, EXO-124 treatments improved the cognitive outcome after rmTBI, suggesting a promising therapeutic strategy for future clinical translation.	[Ge, Xintong; Jiang, Rongcai; Zhang, Jianning] Tianjin Med Univ Gen Hosp, Dept Neurosurg, 154 Anshan Rd, Tianjin 300052, Peoples R China; [Ge, Xintong; Li, Ying; Chen, Fanglian; Kang, Chunsheng; Jiang, Rongcai; Zhang, Jianning] Tianjin Neurol Inst, Key Lab Injuries Variat & Regenerat Nervous Syst, Tianjin 300052, Peoples R China; [Ge, Xintong; Li, Ying; Chen, Fanglian; Kang, Chunsheng; Jiang, Rongcai; Zhang, Jianning] Tianjin Neurol Inst, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin 300052, Peoples R China; [Guo, Mengtian; Hu, Tianpeng; Li, Wenzhu; Huang, Shan; Yin, Zhenyu; Lei, Ping] Tianjin Geriatr Inst, Lab Neurotrauma & Neurodegenerat Disorder, Tianjin 300052, Peoples R China; [Guo, Mengtian; Hu, Tianpeng; Li, Wenzhu; Huang, Shan; Yin, Zhenyu; Lei, Ping] Tianjin Med Univ Gen Hosp, Dept Geriatr, 154 Anshan Rd, Tianjin 300052, Peoples R China; [Zhu, Luoyun] Tianjin Med Univ Gen Hosp, Dept Med Examinat, Tianjin 300052, Peoples R China	Jiang, RC; Zhang, JN (corresponding author), Tianjin Med Univ Gen Hosp, Dept Neurosurg, 154 Anshan Rd, Tianjin 300052, Peoples R China.; Lei, P (corresponding author), Tianjin Med Univ Gen Hosp, Dept Geriatr, 154 Anshan Rd, Tianjin 300052, Peoples R China.	jiang116216@163.com; leiping1974@163.com; jnzhang@tmu.edu.cn	Kang, Chunsheng/AAM-5979-2021	Kang, Chunsheng/0000-0002-3255-3369; Ge, Xintong/0000-0001-7153-952X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81501055, 81772060, 81720108015, 81671221]; Tianjin Municipal Science and Technology Commission Natural Fund Project [18JCQNJC81100]	This research was supported by grants from the National Natural Science Foundation of China (grants 81501055, 81772060, 81720108015, and 81671221) and the Tianjin Municipal Science and Technology Commission Natural Fund Project (grant 18JCQNJC81100). The authors appreciate Changzheng Du from Peking University Cancer Hospital and Shu Zhang, Lei Han, Yunfei Wang, Li Liu, Weiyun Cui, and Lei Zhou from the Tianjin Neurological Institute for their technical support.	Agosta F, 2014, ANN NEUROL, V76, P813, DOI 10.1002/ana.24235; Asai H, 2015, NAT NEUROSCI, V18, P1584, DOI 10.1038/nn.4132; Benilova I, 2012, NAT NEUROSCI, V15, P349, DOI 10.1038/nn.3028; Bradley-Whitman MA, 2018, BRAIN INJURY, V32, P363, DOI 10.1080/02699052.2017.1418907; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; Chen S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.135; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Cirrito JR, 2011, P NATL ACAD SCI USA, V108, P14968, DOI 10.1073/pnas.1107411108; Cunha C, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6986175; Dabrowska S, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1571-8; Edwards G, 2017, BIOCHEM BIOPH RES CO, V483, P1137, DOI 10.1016/j.bbrc.2016.07.123; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Ge XT, 2018, J NEUROSCI METH, V308, P162, DOI 10.1016/j.jneumeth.2018.07.021; Ge XT, 2019, J NEUROTRAUM, V36, P1291, DOI 10.1089/neu.2018.5728; Ge XT, 2016, BRAIN RES, V1650, P31, DOI 10.1016/j.brainres.2016.07.015; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Glebov K, 2015, GLIA, V63, P626, DOI 10.1002/glia.22772; Goetzl EJ, 2018, ANN NEUROL, V83, P544, DOI 10.1002/ana.25172; Goetzl EJ, 2016, FASEB J, V30, P4141, DOI 10.1096/fj.201600816R; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gouwens LK, 2018, ACS CHEM NEUROSCI, V9, P1416, DOI 10.1021/acschemneuro.8b00029; Guadagno J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.151; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Han ZL, 2015, DNA CELL BIOL, V34, P703, DOI 10.1089/dna.2015.2800; Hickman SE, 2008, J NEUROSCI, V28, P8354, DOI 10.1523/JNEUROSCI.0616-08.2008; Hooper C, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-144; Huang S, 2018, FASEB J, V32, P512, DOI 10.1096/fj.201700673R; Jamal M, 2018, J MOL NEUROSCI, V65, P84, DOI 10.1007/s12031-018-1074-6; Jiang Q, 2008, NEURON, V58, P681, DOI 10.1016/j.neuron.2008.04.010; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Joshi P, 2014, CELL DEATH DIFFER, V21, P582, DOI 10.1038/cdd.2013.180; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Kvartsberg H, 2015, ALZHEIMERS DEMENT, V11, P1180, DOI 10.1016/j.jalz.2014.10.009; Laskowitz DT, 2017, SCI REP-UK, V7, DOI 10.1038/srep46461; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Leger M, 2013, NAT PROTOC, V8, P2531, DOI 10.1038/nprot.2013.155; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Li L, 2008, BRAIN RES, V1226, P234, DOI 10.1016/j.brainres.2008.06.037; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Namjoshi DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053529; Peacock WF, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00641; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Porro C, 2015, J NEUROIMMUNOL, V288, P70, DOI 10.1016/j.jneuroim.2015.09.006; Qin Z, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00406; Ramos-Cejudo J, 2018, EBIOMEDICINE, V28, P21, DOI 10.1016/j.ebiom.2018.01.021; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Reed-Geaghan EG, 2009, J NEUROSCI, V29, P11982, DOI 10.1523/JNEUROSCI.3158-09.2009; Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035; Song YY, 2019, THERANOSTICS, V9, P2910, DOI 10.7150/thno.30879; Stejskal D, 2011, BIOMED PAP, V155, P263, DOI 10.5507/bp.2011.049; Tarawneh R, 2015, JAMA NEUROL, V72, P656, DOI 10.1001/jamaneurol.2015.0202; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Trotta T, 2018, BIOCHEM PHARMACOL, V148, P184, DOI 10.1016/j.bcp.2017.12.020; Venkat P, 2019, STROKE, V50, P2865, DOI 10.1161/STROKEAHA.119.025371; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Wellington H, 2016, NEUROLOGY, V86, P829, DOI 10.1212/WNL.0000000000002423; Yu AY, 2017, IMMUNOL LETT, V182, P1, DOI 10.1016/j.imlet.2016.12.003; Yuyama K, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00229; Zhang YL, 2017, NATURE, V548, P52, DOI 10.1038/nature23282; Zhang YL, 2017, NEUROCHEM INT, V111, P69, DOI 10.1016/j.neuint.2016.08.003; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhang Y, 2017, MOL NEUROBIOL, V54, P2659, DOI 10.1007/s12035-016-9851-0	67	27	28	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1525-0016	1525-0024		MOL THER	Mol. Ther.	FEB 5	2020	28	2					503	522		10.1016/j.ymthe.2019.11.017			20	Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine	KK6YH	WOS:000512884900018	31843449	Green Published, Other Gold			2021-06-18	
J	Zeiler, FA; Ercole, A; Cabeleira, M; Zoerle, T; Stocchetti, N; Menon, DK; Smielewski, P; Czosnyka, M; Anke, A; Beer, R; Bellander, BM; Buki, A; Chevallard, G; Chieregato, A; Citerio, G; Czeiter, E; Depreitere, B; Eapen, G; Frisvold, S; Helbok, R; Jankowski, S; Kondziella, D; Koskinen, LO; Meyfroidt, G; Moeller, K; Nelson, D; Piippo-Karjalainen, A; Radoi, A; Ragauskas, A; Raj, R; Rhodes, J; Rocka, S; Rossaint, R; Sahuquillo, J; Sakowitz, O; Stevanovic, A; Sundstrom, N; Takala, R; Tamosuitis, T; Tenovuo, O; Vajkoczy, P; Vargiolu, A; Vilcinis, R; Wolf, S; Younsi, A				Zeiler, Frederick A.; Ercole, Ari; Cabeleira, Manuel; Zoerle, Tommaso; Stocchetti, Nino; Menon, David K.; Smielewski, Peter; Czosnyka, Marek; Anke, Audny; Beer, Ronny; Bellander, Bo-Michael; Buki, Andras; Chevallard, Giorgio; Chieregato, Arturo; Citerio, Giuseppe; Czeiter, Endre; Depreitere, Bart; Eapen, George; Frisvold, Shirin; Helbok, Raimund; Jankowski, Stefan; Kondziella, Daniel; Koskinen, Lars-Owe; Meyfroidt, Geert; Moeller, Kirsten; Nelson, David; Piippo-Karjalainen, Anna; Radoi, Andreea; Ragauskas, Arminas; Raj, Rahul; Rhodes, Jonathan; Rocka, Saulius; Rossaint, Rolf; Sahuquillo, Juan; Sakowitz, Oliver; Stevanovic, Ana; Sundstrom, Nina; Takala, Riikka; Tamosuitis, Tomas; Tenovuo, Olli; Vajkoczy, Peter; Vargiolu, Alessia; Vilcinis, Rimantas; Wolf, Stefa; Younsi, Alexander		CENTER-TBI High Resolution	Univariate comparison of performance of different cerebrovascular reactivity indices for outcome association in adult TBI: a CENTER-TBI study	ACTA NEUROCHIRURGICA			English	Article						Autoregulation; Cerebrovascular reactivity; ICP indices; Outcome analysis	TRAUMATIC BRAIN-INJURY; CEREBRAL PERFUSION-PRESSURE; AUTOREGULATION; MANAGEMENT; MODERATE	BackgroundMonitoring cerebrovascular reactivity in adult traumatic brain injury (TBI) has been linked to global patient outcome. Three intra-cranial pressure (ICP)-derived indices have been described. It is unknown which index is superior for outcome association in TBI outside previous single-center evaluations. The goal of this study is to evaluate indices for 6- to 12-month outcome association using uniform data harvested in multiple centers.MethodsUsing the prospectively collected data from the Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI) study, the following indices of cerebrovascular reactivity were derived: PRx (correlation between ICP and mean arterial pressure (MAP)), PAx (correlation between pulse amplitude of ICP (AMP) and MAP), and RAC (correlation between AMP and cerebral perfusion pressure (CPP)). Univariate logistic regression models were created to assess the association between vascular reactivity indices with global dichotomized outcome at 6 to 12months, as assessed by Glasgow Outcome Score-Extended (GOSE). Models were compared via area under the receiver operating curve (AUC) and Delong's test.ResultsTwo separate patient groups from this cohort were assessed: the total population with available data (n=204) and only those without decompressive craniectomy (n=159), with identical results. PRx, PAx, and RAC perform similar in outcome association for both dichotomized outcomes, alive/dead and favorable/unfavorable, with RAC trending towards higher AUC values. There were statistically higher mean values for the index, % time above threshold, and hourly dose above threshold for each of PRx, PAx, and RAC in those patients with poor outcomes.ConclusionsPRx, PAx, and RAC appear similar in their associations with 6- to 12-month outcome in moderate/severe adult TBI, with RAC showing tendency to achieve stronger associations. Further work is required to determine the role for each of these cerebrovascular indices in monitoring of TBI patients.	[Zeiler, Frederick A.; Ercole, Ari; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England; [Zeiler, Frederick A.] Univ Manitoba, Rady Fac Hlth Sci, Dept Surg, Winnipeg, MB R3A 1R9, Canada; [Zeiler, Frederick A.] Univ Manitoba, Rady Fac Hlth Sci, Clinician Investigator Program, Winnipeg, MB, Canada; [Zeiler, Frederick A.; Cabeleira, Manuel; Smielewski, Peter; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Brain Phys Lab,Div Neurosurg, Cambridge, England; [Zoerle, Tommaso; Stocchetti, Nino] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Neuro ICU, Milan, Italy; [Stocchetti, Nino] Milan Univ, Dept Physiopathol & Transplantat, Milan, Italy; [Menon, David K.] Addenbrookes Hosp, Neurosci Crit Care Unit, Cambridge, England; [Menon, David K.] Queens Coll, Cambridge, England; [Menon, David K.] Natl Inst Hlth Res, London, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland; [Anke, Audny] Univ Hosp Northern Norway, Dept Phys Med & Rehabil, Tromso, Norway; [Beer, Ronny; Helbok, Raimund] Med Univ Innsbruck, Dept Neurol, Neurol Intens Care Unit, Innsbruck, Austria; [Bellander, Bo-Michael; Nelson, David] Karolinska Univ Hosp, Dept Neurosurg & Anesthesia & Intens Care Med, Stockholm, Sweden; [Buki, Andras; Czeiter, Endre] Univ Pecs, Dept Neurosurg, Pecs, Hungary; [Buki, Andras; Czeiter, Endre] MTA PTE Clin Neurosci MR Res Grp, Pecs, Hungary; [Buki, Andras; Czeiter, Endre] Univ Pecs, Hungarian Brain Res Program, Janos Szentagothai Res Ctr, Pecs, Hungary; [Chevallard, Giorgio; Chieregato, Arturo] Osped Niguarda Ca Granda, NeuroIntens Care, Milan, Italy; [Citerio, Giuseppe; Vargiolu, Alessia] ASST Monza, Dept Anesthesia & Intens Care, NeuroIntens Care Unit, Monza, Italy; [Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy; [Depreitere, Bart] Univ Hosp Leuven, Dept Neurosurg, Leuven, Belgium; [Frisvold, Shirin] Univ Hosp Northern Norway, Dept Anesthesiol & Intens Care, Tromso, Norway; [Jankowski, Stefan] Sheffield Teaching Hosp NHS Fdn Trust, Neurointens Care, Sheffield, S Yorkshire, England; [Kondziella, Daniel] Reg Hovedstaden Rigshosp, Dept Neurol, Copenhagen, Denmark; [Kondziella, Daniel] Reg Hovedstaden Rigshosp, Dept Clin Neurophysiol, Copenhagen, Denmark; [Kondziella, Daniel] Reg Hovedstaden Rigshosp, Dept Neuroanesthesiol, Copenhagen, Denmark; [Koskinen, Lars-Owe] Umea Univ Hosp, Dept Clin Neurosci, Neurosurg, Umea, Sweden; [Meyfroidt, Geert] Univ Hosp Leuven, Intens Care Med, Leuven, Belgium; [Moeller, Kirsten] Reg Hovedstaden Rigshosp, Dept Neuroanesthesiol, Copenhagen, Denmark; [Piippo-Karjalainen, Anna; Raj, Rahul] Helsinki Univ Cent Hosp, Helsinki, Finland; [Radoi, Andreea; Sahuquillo, Juan] Vall dHebron Univ Hosp, Dept Neurosurg, Barcelona, Spain; [Ragauskas, Arminas; Rocka, Saulius] Kaunas Univ Technol, Dept Neurosurg, Kaunas, Lithuania; [Ragauskas, Arminas; Rocka, Saulius] Vilnius Univ, Vilnius, Lithuania; [Rhodes, Jonathan] NHS Lothian, Dept Anesthesia Crit Care & Pain Med, Edinburgh, Midlothian, Scotland; [Rhodes, Jonathan] Univ Edinburgh, Edinburgh, Midlothian, Scotland; [Rossaint, Rolf; Stevanovic, Ana] Univ Hosp Aachen, Dept Anaesthesiol, Aachen, Germany; [Sakowitz, Oliver] Klinikum Ludwigsburg, Klin Neurochirurg, Ludwigsburg, Germany; [Sakowitz, Oliver; Younsi, Alexander] Univ Hosp Heidelberg, Dept Neurosurg, Heidelberg, Germany; [Sundstrom, Nina] Umea Univ Hosp, Dept Radiat Sci, Biomed Engn, Umea, Sweden; [Takala, Riikka] Turku Univ Cent Hosp, Perioperat Serv Intens Care Med & Pain Management, Turku, Finland; [Takala, Riikka; Tenovuo, Olli] Univ Turku, Turku, Finland; [Tamosuitis, Tomas] Kaunas Univ Hlth Sci, Neurointens Care Unit, Kaunas, Lithuania; [Tenovuo, Olli] Turku Univ Cent Hosp, Rehabil & Brain Trauma, Turku, Finland; [Vajkoczy, Peter] Charite Univ Med Berlin, Neurol Neurochirurg & Psychiat, Berlin, Germany; [Vilcinis, Rimantas] Kaunas Univ Hlth Sci, Dept Neurosurg, Kaunas, Lithuania; [Wolf, Stefa] Charite Univ Med Berlin, Interdisciplinary Neuro Intens Care Unit, Berlin, Germany	Zeiler, FA (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England.; Zeiler, FA (corresponding author), Univ Manitoba, Rady Fac Hlth Sci, Dept Surg, Winnipeg, MB R3A 1R9, Canada.; Zeiler, FA (corresponding author), Univ Manitoba, Rady Fac Hlth Sci, Clinician Investigator Program, Winnipeg, MB, Canada.; Zeiler, FA (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Brain Phys Lab,Div Neurosurg, Cambridge, England.	umzeiler@myumanitoba.ca; ae105@cam.ac.uk; mc916@cam.ac.uk; tommaso.zoerle@policlinico.mi.it; nino.stocchetti@policlinico.mi.it; dkm13@cam.ac.uk; ps10011@cam.ac.uk; mc141@medschl.cam.ac.uk	Citerio, Giuseppe/B-1839-2015; Depreitere, Bart/AAA-9846-2020; Ercole, Ari/B-6288-2009; Younsi, Alexander/AAW-7869-2020; Koskinen, Lars-Owe/AAQ-8957-2020; Raj, Rahul/K-7693-2012; Sahuquillo, Juan/B-3577-2008; Helbok, Raimund/AAA-8361-2021; Moller, Kirsten/A-4751-2009	Citerio, Giuseppe/0000-0002-5374-3161; Depreitere, Bart/0000-0002-7458-0648; Ercole, Ari/0000-0001-8350-8093; Younsi, Alexander/0000-0002-8218-9243; Raj, Rahul/0000-0003-4243-9591; Sahuquillo, Juan/0000-0003-0713-5875; Kondziella, Daniel/0000-0001-5562-9808; Zeiler, Frederick/0000-0003-1737-0510; Radoi, Andreea/0000-0002-0677-3544; Moller, Kirsten/0000-0003-3058-1072; Zoerle, Tommaso/0000-0001-8713-8085	European Union 7th Framework program (EC grant) [602150]; Hannelore Kohl Stiftung (Germany); OneMind (USA); Integra LifeSciences Corporation (USA); National Institute for Health Research (NIHR, UK)National Institute for Health Research (NIHR); Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust; NIHR Clinical Research network	Data used in preparation of this manuscript were obtained in the context of CENTER-TBI, a large collaborative project with the support of the European Union 7th Framework program (EC grant 602150). Additional funding was obtained from the Hannelore Kohl Stiftung (Germany), from OneMind (USA) and from Integra LifeSciences Corporation (USA). DKM was also supported by funding from the National Institute for Health Research (NIHR, UK) through a Senior Investigator award and the Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust. The study also received additional support from the NIHR Clinical Research network. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care, UK.; FAZ has received salary support for dedicated research time, during which this project was completed. Such salary support came from: the Cambridge Commonwealth Trust Scholarship, the University of Manitoba Clinician Investigator Program, and the Royal College of Surgeons of Canada-Harry S. Morton Traveling Fellowship in Surgery.	Aries MJH, 2016, CRIT CARE MED, V44, pE996, DOI 10.1097/CCM.0000000000001816; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Aries MJH, 2012, NEUROCRIT CARE, V17, P67, DOI 10.1007/s12028-012-9687-z; Brady KM, 2008, STROKE, V39, P2531, DOI 10.1161/STROKEAHA.108.514877; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2014, NEUROCRIT CARE, V21, P95, DOI 10.1007/s12028-014-0046-0; Depreitere B, 2016, ACTA NEUROCHIR SUPPL, V122, P245, DOI 10.1007/978-3-319-22533-3_49; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; Doiron D, 2017, INT J EPIDEMIOL, V46, P1372, DOI 10.1093/ije/dyx180; Fraser CD, 2013, J APPL PHYSIOL, V115, P52, DOI 10.1152/japplphysiol.00068.2013; Howells T, 2015, J CLIN MONIT COMPUT, V29, P97, DOI 10.1007/s10877-014-9573-7; Le Roux P, 2014, NEUROCRIT CARE, V21, P282, DOI 10.1007/s12028-014-0077-6; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Needham E, 2017, J NEUROTRAUM, V34, P963, DOI 10.1089/neu.2016.4450; Nourallah B, 2018, ACTA NEUROCHIR, V160, P1315, DOI 10.1007/s00701-018-3555-3; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Zeiler F.A., 2018, J NEUROTRAUMA; Zeiler FA, 2018, J NEUROTRAUM, V35, P2803, DOI 10.1089/neu.2017.5603; Zeiler FA, 2018, J NEUROTRAUM, V35, P963, DOI 10.1089/neu.2017.5241; Zeiler FA, 2018, J NEUROTRAUM, V35, P1107, DOI 10.1089/neu.2017.5472; Zeiler FA, 2017, J NEUROTRAUM, V34, P3224, DOI 10.1089/neu.2017.5086	23	27	27	0	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JUN	2019	161	6					1217	1227		10.1007/s00701-019-03844-1			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HY6FJ	WOS:000468224800025	30877472	Green Published, Other Gold			2021-06-18	
J	Chen, YH; Meng, J; Xu, QH; Long, TL; Bi, FF; Chang, CC; Liu, W				Chen, Yuhua; Meng, Jiao; Xu, Quanhua; Long, Tianli; Bi, Fangfang; Chang, Cuicui; Liu, Wei			Rapamycin improves the neuroprotection effect of inhibition of NLRP3 inflammasome activation after TBI	BRAIN RESEARCH			English	Article						TBI; Rapamycin; NLRP3 inflammasome; Neuroprotection	TRAUMATIC BRAIN-INJURY; NEUROLOGICAL OUTCOMES; MURINE MODEL; MITOPHAGY; SYSTEM; NEUROINFLAMMATION; CONTRIBUTES; DYSFUNCTION; PROTECTS; DEATH	Inflammation is the focus of many studies on traumatic brain injury (TBI) treatment and outcomes improvement. Some studies have demonstrated that the inhibition of NOD-like receptor protein-3 (NLRP3) inflammasome activation is a potential strategy for TBI therapy. Mitophagy is thought to play a crucial role in pathological conditions of TBI. We hypothesize simultaneous mitophagy activation and NLRP3 inflammsome inhibition, plays preferable role in delaying the progression and nerve damage post-TBI. In this study, TBI-mice and oxygen and glucose deprivation (OGD)-induced primary cortical neurons were treated with MCC950 (a NLRP3 selective inhibitor) or Rapamycin (Rap, a mTOR inhibitor, stimulated autophagy and mitophagy). We evaluated the effects of Rap and NLRP3 inhibition on the neurological deficits, neurological damage, and inflammatory response, to determine if Rap further induced the neuroprotection of suppression of NLRP3 inflammasome activation in vivo and in vitro TBI-model. TBI induced NLRP3 inflammasome activation and mitochondrial dys-function, including increased caspase-1 p20 expression, exacerbated the secretion of LDH, IL-beta and IL-18, and disorder of ATP, MMP, ROS and mitophagy (Pink1 and LC3 expression in mitochondria). NLRP3 inhibition and Rap attenuated the neurological damage and mitochondrial dysfunction, while combined treatment showed better neuroprotection compared with single treatment. Collectively, the data demonstrate that mitophagy and NLRP3 inflammasome have the interactivity, and Rap-induced mitophagy further enhances the neuroprotection of inhibition of NLRP3 inflammasome activation post-TBI. Our findings suggest that Rap-activated mitophagy combined with MCC950-induced NLRP3 inflammasome repression may be a potential strategy for TBI therapy.	[Chen, Yuhua; Meng, Jiao; Bi, Fangfang; Chang, Cuicui] Xian Peihua Univ, Dept Cent Lab, Xian 710125, Shaanxi, Peoples R China; [Chen, Yuhua; Xu, Quanhua; Long, Tianli; Liu, Wei] Bijie First Peoples Hosp, Dept Neurosurg, Bijie 551700, Peoples R China	Liu, W (corresponding author), Bijie First Peoples Hosp, Dept Neurosurg, Bijie 551700, Peoples R China.	vincelau@sina.com			Natural Science Foundation of Shaanxi ProvinceNatural Science Foundation of Shaanxi Province [2018JM7141]	The present study was supported by the Natural Science Foundation of Shaanxi Province (No. 2018JM7141).	Alegre F, 2017, SEMIN LIVER DIS, V37, P119, DOI 10.1055/s-0037-1601350; Anthonymuthu TS, 2016, BRAIN RES, V1640, P57, DOI 10.1016/j.brainres.2016.02.006; Butler CR, 2017, ENEURO, V4, DOI 10.1523/ENEURO.0134-17.2017; Butler CR, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00163; Castranio EL, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0569-2; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Cosin-Roger J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00213-3; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Ding K, 2015, J SURG RES, V194, P239, DOI 10.1016/j.jss.2014.09.026; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Gong Z, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1282-6; Hammad A, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1066-z; Harris J, 2018, MITOCHONDRION, V41, P2, DOI 10.1016/j.mito.2017.10.009; Harris J, 2017, MOL IMMUNOL, V86, P10, DOI 10.1016/j.molimm.2017.02.013; Irrera N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00459; Ismael S, 2018, J NEUROTRAUM, V35, P1294, DOI 10.1089/neu.2017.5344; Ismael S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24350-x; Kim MJ, 2016, BMB REP, V49, P529, DOI 10.5483/BMBRep.2016.49.10.115; Kim MJ, 2016, AUTOPHAGY, V12, P1272, DOI 10.1080/15548627.2016.1183081; Lazaridis C, 2018, NEUROPHARMACOLOGY; Lazarou M, 2015, IMMUNOL CELL BIOL, V93, P3, DOI 10.1038/icb.2014.75; Lin C, 2016, J PINEAL RES, V61, P177, DOI 10.1111/jpi.12337; Liu W, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1083-y; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lv JF, 2018, BRAIN RES, V1685, P91, DOI 10.1016/j.brainres.2018.01.032; Ma MW, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6057609; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Mortezaee K, 2018, J CELL PHYSIOL, V233, P5160, DOI 10.1002/jcp.26287; Qian HH, 2017, MOL MED REP, V16, P3922, DOI 10.3892/mmr.2017.7079; Ren HL, 2018, STROKE, V49, P184, DOI 10.1161/STROKEAHA.117.018904; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Shen HH, 2018, AUTOIMMUN REV, V17, P694, DOI 10.1016/j.autrev.2018.01.020; Simon DW, 2017, NAT REV NEUROL, V13, P572, DOI 10.1038/nrneurol.2017.116; Song LM, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00063; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Vaccari JPD, 2016, TRANSL RES, V167, P35, DOI 10.1016/j.trsl.2015.05.003; Wallisch JS, 2017, NEUROCRIT CARE, V27, P44, DOI 10.1007/s12028-017-0378-7; Wu Q, 2018, INT J BIOCHEM CELL B, V94, P44, DOI 10.1016/j.biocel.2017.11.007; Wu Q, 2017, HISTOL HISTOPATHOL, V32, P551, DOI 10.14670/HH-11-841; Xu X, 2018, NEUROBIOL DIS, V117, P15, DOI 10.1016/j.nbd.2018.05.016; Yan YQ, 2015, CELL, V160, P62, DOI 10.1016/j.cell.2014.11.047; Yang SJ, 2014, REDOX BIOL, V3, P63, DOI 10.1016/j.redox.2014.04.001; Yerramothu P, 2018, EYE, V32, P491, DOI 10.1038/eye.2017.241; Yu JJ, 2014, P NATL ACAD SCI USA, V111, P15514, DOI 10.1073/pnas.1414859111; Zhang L, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00190; Zhao Y, 2018, INFLAMMATION; Zhong JJ, 2017, BRAIN BEHAV IMMUN, V65, P183, DOI 10.1016/j.bbi.2017.05.001; Zhou KR, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/9238290; Zou P, 2018, MOL MED REP, V17, P3212, DOI 10.3892/mmr.2017.8241	49	27	27	4	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 1	2019	1710						163	172		10.1016/j.brainres.2019.01.005			10	Neurosciences	Neurosciences & Neurology	HR4PZ	WOS:000463129700017	30615886				2021-06-18	
J	Ritzel, RM; Doran, SJ; Glaser, EP; Meadows, VE; Faden, AI; Stoica, BA; Loane, DJ				Ritzel, Rodney M.; Doran, Sarah J.; Glaser, Ethan P.; Meadows, Victoria E.; Faden, Alan, I; Stoica, Bogdan A.; Loane, David J.			Old age increases microglial senescence, exacerbates secondary neuroinflammation, and worsens neurological outcomes after acute traumatic brain injury in mice	NEUROBIOLOGY OF AGING			English	Article						Aging; Traumatic brain injury; Neuroinflammation; Microglia; Behavior	ALZHEIMERS-DISEASE; OXIDATIVE STRESS; ELDERLY-PATIENTS; YOUNG ADULTHOOD; NEURODEGENERATION; INFLAMMATION; ACTIVATION; DAMAGE; CELLS; DEGRADATION	After traumatic brain injury (TBI), individuals aged over 65 years show increased mortality and worse functional outcomes compared with younger persons. As neuroinflammation is a key pathobiological mechanism of secondary injury after TBI, we examined how aging affects post-traumatic microglial responses and functional outcomes. Young (3-month-old) and aged (18-month-old) male C57BL/6 mice were subjected to moderate-level controlled cortical impact or sham surgery, and neurological function was evaluated. At 72 hours after injury, brain, blood, and spleen leukocyte counts were assessed ex vivo using flow cytometry. Aged mice demonstrated more severe deficits in forelimb grip strength, balance and motor coordination, spontaneous locomotor activity, and anxiety-like behavior. These animals also exhibited more robust microglial proliferation and significantly higher numbers of brain-infiltrating leukocytes. Microglia in aged mice showed impairments in phagocytic activity and higher production of interleukin-1 beta (IL-1 beta). Infiltrating myeloid cells in aged TBI mice also had deficits in phagocytosis but showed diminished proinflammatory cytokine production and greater reactive oxygen species production. Expression of several senescence markers (Bcl-2, p16(ink4a), p21(cip1a), lipofuscin, and H2AX [pS139]) was increased with age and/or TBI in both microglia and injured cortex. Although there was no difference in the number of circulating blood neutrophils as a function of age, young mice exhibited more pronounced TBI-induced splenomegaly and splenic myeloid cell expansion. Thus, worse post-traumatic behavioral outcomes in aged animals are associated with exaggerated microglial responses, increased leukocyte invasion, and upregulation of senescence markers. (C) 2019 Elsevier Inc. All rights reserved.	[Loane, David J.] Univ Maryland, Dept Anesthesiol, Sch Med, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA; Univ Maryland, Ctr Shock Trauma & Anesthesiol Res STAR, Sch Med, Baltimore, MD 21201 USA	Loane, DJ (corresponding author), Univ Maryland, Dept Anesthesiol, Sch Med, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA.	dloane@som.umaryland.edu		Loane, David/0000-0003-0393-3503; Ritzel, Rodney/0000-0002-0160-2930	National Institutes of Health, United StatesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS082308, R01NS037313, F32NS105355, T32AI095190]; National Institute on Aging (NIA) Claude D. Pepper Older Americans Independence Center [P30-AG028747]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [T32AI095190] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS105355, R01NS037313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028747] Funding Source: NIH RePORTER	The authors would like to acknowledge Nicholas Braganca, BSc, and Wesley Shoap, BSc, for their technical assistance. The authors thank Xiaoxuan Fan, PhD, and Karen Underwood, BSc, of the University of Maryland Greenebaum Comprehensive Cancer Center Flow Cytometry Facility for support with flow cytometry studies. This work was supported by the National Institutes of Health, United States grants R01NS082308 (DJL), R01NS037313 (AIF), F32NS105355 (RMR), and T32AI095190 (SJD) and the National Institute on Aging (NIA) Claude D. Pepper Older Americans Independence Center P30-AG028747 (DJL).	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Al-Mashhadi S, 2015, BRAIN PATHOL, V25, P565, DOI 10.1111/bpa.12216; Bhat R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045069; Bisht K, 2016, GLIA, V64, P826, DOI 10.1002/glia.22966; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Chaturvedi M, 2014, MOL NEUROBIOL, V49, P563, DOI 10.1007/s12035-013-8538-z; Cheignon C, 2018, REDOX BIOL, V14, P450, DOI 10.1016/j.redox.2017.10.014; Chen NC, 2018, J GERONTOL A-BIOL, V73, P1187, DOI 10.1093/gerona/gly022; Chiche A, 2017, CELL STEM CELL, V20, P407, DOI 10.1016/j.stem.2016.11.020; Childs BG, 2014, EMBO REP, V15, P1139, DOI 10.15252/embr.201439245; Clausen BH, 2016, SCI REP-UK, V6, DOI 10.1038/srep29291; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Davalli P, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3565127; Doran SJ, 2019, J NEUROTRAUM, V36, P1040, DOI 10.1089/neu.2018.6019; Dutta S, 2016, LIFE SCI, V152, P244, DOI 10.1016/j.lfs.2015.10.025; Elali A, 2016, BRAIN BEHAV IMMUN, V55, P138, DOI 10.1016/j.bbi.2015.07.021; Erturk A, 2016, J NEUROSCI, V36, P9962, DOI 10.1523/JNEUROSCI.1898-15.2016; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Filer William, 2015, N C Med J, V76, P111; Flanagan SR, 2006, CLIN GERIATR MED, V22, P449, DOI 10.1016/j.cger.2005.12.011; Flurkey K, 2007, MOUSE BIOMEDICAL RES, V3, P637; Foster KA, 2008, NEUROBIOL AGING, V29, P598, DOI 10.1016/j.neurobiolaging.2006.11.006; Fulop T, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01960; Gardner RC, 2018, J NEUROTRAUM, V35, P889, DOI 10.1089/neu.2017.5371; Ge X, 2016, PATHOBIOL AGING AGE, V6, DOI 10.3402/pba.v6.32981; Goldberg EL, 2015, IMMUNOL REV, V265, P63, DOI 10.1111/imr.12295; Greenhalgh AD, 2014, J NEUROSCI, V34, P6316, DOI 10.1523/JNEUROSCI.4912-13.2014; Greter M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00249; Hall BM, 2016, AGING-US, V8, P1294, DOI 10.18632/aging.100991; Harvey LA, 2012, INJURY, V43, P1821, DOI 10.1016/j.injury.2012.07.188; Hazeldine J, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00235; He SH, 2017, CELL, V169, P1000, DOI 10.1016/j.cell.2017.05.015; Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001; Herranz N, 2018, J CLIN INVEST, V128, P1238, DOI 10.1172/JCI95148; Hornsby PJ, 2010, CELLULAR SENESCENCE AND TUMOR SUPPRESSION, P85, DOI 10.1007/978-1-4419-1075-2_4; Itoh T, 2013, BRAIN STRUCT FUNCT, V218, P209, DOI 10.1007/s00429-012-0394-5; Jacotte-Simancas A, 2015, J NEUROTRAUM, V32, P739, DOI 10.1089/neu.2014.3502; Jurk D, 2012, AGING CELL, V11, P996, DOI 10.1111/j.1474-9726.2012.00870.x; Karibe H, 2017, NEUROL MED-CHIR, V57, P418, DOI 10.2176/nmc.st.2017-0058; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lopes KO, 2008, GLIA, V56, P1048, DOI 10.1002/glia.20678; Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P676, DOI 10.1016/j.pnpbp.2010.05.004; Majumdar A, 2007, MOL BIOL CELL, V18, P1490, DOI 10.1091/mbc.E06-10-0975; Mak CHK, 2012, CURR GERIATR REP, V1, P171, DOI 10.1007/s13670-012-0017-2; Marin JR, 2017, BRAIN INJURY, V31, P24, DOI 10.1080/02699052.2016.1217351; Marshall JL, 2017, HIST BIOL, P1; Mattson MP, 2018, CELL METAB, V27, P1176, DOI 10.1016/j.cmet.2018.05.011; Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091; Moreno-Garcia A, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00464; Morganti JM, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0547-1; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Musi N., 2018, BIORXIV, V17; Nelson G, 2012, AGING CELL, V11, P345, DOI 10.1111/j.1474-9726.2012.00795.x; Niraula A, 2017, NEUROPSYCHOPHARMACOL, V42, P318, DOI 10.1038/npp.2016.185; Njie EG, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.05.008; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Papa L, 2012, CURR GERIATR REP, V1, P135, DOI 10.1007/s13670-012-0019-0; Patel Anita R, 2013, Int J Physiol Pathophysiol Pharmacol, V5, P73; Prattichizzo F, 2016, AGING-US, V8, P3159, DOI 10.18632/aging.101133; Qin LY, 2013, GLIA, V61, P855, DOI 10.1002/glia.22479; Radak Z, 2011, MOL ASPECTS MED, V32, P305, DOI 10.1016/j.mam.2011.10.010; Ramos-Cejudo J, 2018, EBIOMEDICINE, V28, P21, DOI 10.1016/j.ebiom.2018.01.021; Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253; Ritzel RM, 2018, J NEUROTRAUM, V35, P1419, DOI 10.1089/neu.2017.5399; Ritzel RM, 2018, ACTA NEUROPATHOL, V136, P89, DOI 10.1007/s00401-018-1859-2; Ritzel RM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0329-1; Ritzel RM, 2015, NEUROBIOL AGING, V36, P2153, DOI 10.1016/j.neurobiolaging.2015.02.016; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rosenzweig S, 2013, STROKE, V44, P2579, DOI 10.1161/STROKEAHA.113.001796; Safaiyan S, 2016, NAT NEUROSCI, V19, P995, DOI 10.1038/nn.4325; Salminen A, 2011, EUR J NEUROSCI, V34, P3, DOI 10.1111/j.1460-9568.2011.07738.x; SAMORAJSKI T, 1976, J AM GERIATR SOC, V24, P4, DOI 10.1111/j.1532-5415.1976.tb03246.x; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Sharaf A, 2013, CELL TISSUE RES, V351, P373, DOI 10.1007/s00441-012-1537-y; Shoji H, 2016, MOL BRAIN, V9, DOI 10.1186/s13041-016-0191-9; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Stojiljkovic MR, 2019, NEUROBIOL AGING, V74, P56, DOI 10.1016/j.neurobiolaging.2018.10.007; Streit WJ, 2004, GLIA, V45, P208, DOI 10.1002/glia.10319; Streit WJ, 2014, CURR OPIN IMMUNOL, V29, P93, DOI 10.1016/j.coi.2014.05.005; Streit WJ, 2009, ACTA NEUROPATHOL, V118, P475, DOI 10.1007/s00401-009-0556-6; Sun D, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00095; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Timaru-Kast R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043829; VAUGHAN DW, 1974, J NEUROCYTOL, V3, P405, DOI 10.1007/BF01098730; Venna VR, 2012, ACTA NEUROPATHOL, V124, P425, DOI 10.1007/s00401-012-0990-8; von Bernhardi R, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00124; Wan XY, 2016, WORLD NEUROSURG, V89, P147, DOI 10.1016/j.wneu.2016.01.084; Wang XK, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00012; Wei Z, 2016, CHINESE MED J-PEKING, V129, P1835, DOI 10.4103/0366-6999.186646; Wong WT, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00022; Xu K, 2007, ADV EXP MED BIOL, V599, P199; Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591-018-0092-9; Xu M, 2017, J GERONTOL A-BIOL, V72, P780, DOI 10.1093/gerona/glw154; Zhang S, 2016, NEUROCHEM INT, V96, P46, DOI 10.1016/j.neuint.2016.02.013; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511; Zoller T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030706	99	27	28	3	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	MAY	2019	77						194	206		10.1016/j.neurobiolaging.2019.02.010			13	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	HU5FQ	WOS:000465302200020	30904769	Green Accepted			2021-06-18	
J	Rudolfson, N; Dewan, MC; Park, KB; Shrime, MG; Meara, JG; Alkire, BC				Rudolfson, Niclas; Dewan, Michael C.; Park, Kee B.; Shrime, Mark G.; Meara, John G.; Alkire, Blake C.			The economic consequences of neurosurgical disease in low- and middle-income countries	JOURNAL OF NEUROSURGERY			English	Article						global health; cost of illness; surgical procedures; operative; neurosurgical procedures; economics	STATISTICAL LIFE; GLOBAL BURDEN; AIR-POLLUTION; HEALTH; SURGERY; COSTS; HYDROCEPHALUS; MORTALITY; DEATH	OBJECTIVE The objective of this study was to estimate the economic consequences of neurosurgical disease in low-and middle-income countries (LMICs). METHODS The authors estimated gross domestic product (GDP) losses and the broader welfare losses attributable to 5 neurosurgical disease categories in LMICs using two distinct economic models. The value of lost output (VLO) model projects annual GDP losses due to neurosurgical disease during 2015-2030, and is based on the WHO's "Projecting the Economic Cost of Ill-health" tool. The value of lost economic welfare (VLW) model estimates total welfare losses, which is based on the value of a statistical life and includes nonmarket losses such as the inherent value placed on good health, resulting from neurosurgical disease in 2015 alone. RESULTS The VLO model estimates the selected neurosurgical diseases will result in $4.4 trillion (2013 US dollars, purchasing power parity) in GDP losses during 2015-2030 in the 90 included LMICs. Economic losses are projected to disproportionately affect low-and lower-middle-income countries, risking up to a 0.6% and 0.54% loss of GDP, respectively, in 2030. The VLW model evaluated 127 LMICs, and estimates that these countries experienced $3 trillion (2013 US dollars, purchasing power parity) in economic welfare losses in 2015. Regardless of the model used, the majority of the losses can be attributed to stroke and traumatic brain injury. CONCLUSIONS The economic impact of neurosurgical diseases in LMICs is significant. The magnitude of economic losses due to neurosurgical diseases in LMICs provides further motivation beyond already compelling humanitarian reasons for action.	[Rudolfson, Niclas; Dewan, Michael C.; Park, Kee B.; Shrime, Mark G.; Meara, John G.; Alkire, Blake C.] Harvard Med Sch, Dept Global Hlth & Social Med, Program Global Surg & Social Change, Boston, MA 02115 USA; [Rudolfson, Niclas] Lund Univ, Dept Clin Sci Lund, Surg & Publ Hlth, Lund, Sweden; [Dewan, Michael C.; Shrime, Mark G.] Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN USA; [Alkire, Blake C.] Massachusetts Eye & Ear Infirm, Off Global Surg, Boston, MA 02114 USA; [Shrime, Mark G.; Alkire, Blake C.] Harvard Med Sch, Dept Otol & Laryngol, Boston, MA 02115 USA; [Meara, John G.] Boston Childrens Hosp, Dept Plast & Reconstruct Surg, Boston, MA USA	Rudolfson, N (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	rudolfson@gmail.com	Alkire, Blake/AAY-6463-2020	Rudolfson, Niclas/0000-0002-2393-8494			Abdelgadir J, 2017, WORLD NEUROSURG, V101, P651, DOI 10.1016/j.wneu.2017.02.048; Abegunde DO, 2007, LANCET, V370, P1929, DOI 10.1016/S0140-6736(07)61696-1; Acemoglu D., 2006, 12269 NAT BUR EC RES; Aldy JE, 2008, REV ECON STAT, V90, P573, DOI 10.1162/rest.90.3.573; Alkire B, 2011, WORLD J SURG, V35, P1194, DOI 10.1007/s00268-011-1055-1; Alkire BC, 2015, LANCET GLOB HEALTH, V3, pE316, DOI 10.1016/S2214-109X(15)70115-4; Alkire BC, 2015, LANCET GLOB HEALTH, V3, pS21, DOI 10.1016/S2214-109X(15)70088-4; Alkire BC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034595; Alleyne G, 2002, HLTH EC GROWTH POVER; [Anonymous], 2015, WORLD HLTH ORG; Bhagava A, 2001, J HEALTH ECON, V20, P423, DOI 10.1016/S0167-6296(01)00073-X; Bhalla K, 2007, RISK ANAL, V27, P125, DOI 10.1111/j.1539-6924.2006.00864.x; Black Peter M, 2007, Clin Neurosurg, V54, P185; Bleakley H, 2007, Q J ECON, V122, P73, DOI 10.1162/qjec.121.1.73; Bloom DE, 2000, SCIENCE, V287, P1207, DOI 10.1126/science.287.5456.1207; Bloom DE, 2004, WORLD DEV, V32, P1, DOI 10.1016/j.worlddev.2003.07.002; Bloom DE, 2014, MANSONS TROPICAL DIS; Bloom DE, 2009, DIS DEV REVISITED; Bloom DE., 2011, GLOBAL EC BURDEN NON; Chao TE, 2014, LANCET GLOB HEALTH, V2, pE334, DOI 10.1016/S2214-109X(14)70213-X; Chisholm D, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c924; CUDDINGTON JT, 1993, WORLD BANK ECON REV, V7, P173, DOI 10.1093/wber/7.2.173; Dewan MC, 2019, J NEUROSURG, V130, P1098, DOI 10.3171/2017.10.JNS17347; El-Fiki M, 2010, WORLD NEUROSURG, V73, P254, DOI 10.1016/j.wneu.2010.02.012; Feenstra RC, 2015, AM ECON REV, V105, P3150, DOI 10.1257/aer.20130954; Gallup JL, 2001, AM J TROP MED HYG, V64, P85, DOI 10.4269/ajtmh.2001.64.85; Gawe A., 2015, ESSENTIAL SURG DIS C, V1; Hammitt JK, 2002, RISK ANAL, V22, P985, DOI 10.1111/1539-6924.00265; Jamison DT, 2014, LANCET, V383, P218; Lorentzen P, 2008, J ECON GROWTH, V13, P81, DOI 10.1007/s10887-008-9029-3; Madheswaran S, 2007, SOC INDIC RES, V84, P83, DOI 10.1007/s11205-006-9076-0; Meara JG, 2015, AM J OBSTET GYNECOL, V213, P338, DOI 10.1016/j.ajog.2015.04.010; Murray CJL, 2013, LANCET, V381, P628; Murray CJL, 2012, LANCET, V380, P2063, DOI 10.1016/S0140-6736(12)61899-6; Robinson LA, 2011, J BENEFIT-COST ANAL, V2, DOI [10.2202/2152-2812.1059, 10.2202/2152-2812.1009]; Roman HA, 2012, RISK ANAL, V32, P2133, DOI 10.1111/j.1539-6924.2012.01826.x; Sachs JD, 2001, MACR HLTH INV HLTH E; Shrime MG, 2015, LANCET GLOB HEALTH, V3, pS8, DOI 10.1016/S2214-109X(14)70384-5; Shrime MG, 2015, LANCET GLOB HEALTH, V3, pS38, DOI 10.1016/S2214-109X(15)70085-9; Strauss J, 1998, J ECON LIT, V36, P766; Viscusi WK, 2003, J RISK UNCERTAINTY, V27, P5, DOI 10.1023/A:1025598106257; Vos T, 2016, LANCET, V388, P1545, DOI 10.1016/S0140-6736(16)31678-6; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; Warf BC, 2011, J NEUROSURG-PEDIATR, V8, P509, DOI 10.3171/2011.8.PEDS11163; Warf BC, 2010, WORLD NEUROSURG, V73, P296, DOI 10.1016/j.wneu.2010.02.009; Winkler AS, 2010, WORLD NEUROSURG, V73, P264, DOI 10.1016/j.wneu.2010.03.037; World Health Organization, 2009, WHO GUID ID EC CONS; Yaduma N, 2013, ENVIRON RESOUR ECON, V54, P361, DOI 10.1007/s10640-012-9598-7	48	27	27	0	16	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2019	130	4					1149	1156		10.3171/2017.12.JNS17281			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HR1CV	WOS:000462866700011	29775144	Bronze			2021-06-18	
J	Erdodi, LA				Erdodi, Laszlo A.			Aggregating validity indicators: The salience of domain specificity and the indeterminate range in multivariate models of performance validity assessment	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						Aggregating validity indicators; domain specificity hypothesis; Erdodi Index; indeterminate range; multivariate base rates; performance validity assessment	RECOGNITION MEMORY TEST; TRAUMATIC BRAIN-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; FORCED-CHOICE RECOGNITION; VERBAL-LEARNING TEST; COMPLEX IDEATIONAL MATERIAL; ADULT INTELLIGENCE SCALE; RELIABLE DIGIT SPAN; SYMPTOM VALIDITY; CLASSIFICATION ACCURACY	This study was designed to examine the "domain specificity" hypothesis in performance validity tests (PVTs) and the epistemological status of an "indeterminate range" when evaluating the credibility of a neuropsychological profile using a multivariate model of performance validity assessment. While previous research suggests that aggregating PVTs produces superior classification accuracy compared to individual instruments, the effect of the congruence between the criterion and predictor variable on signal detection and the issue of classifying borderline cases remain understudied. Data from a mixed clinical sample of 234 adults referred for cognitive evaluation (M-Age = 46.6; M-Education = 13.5) were collected. Two validity composites were created: one based on five verbal PVTs (EI-5(VER)) and one based on five nonverbal PVTs (EI-5(NV)) and compared against several other PVTs. Overall, language-based tests of cognitive ability were more sensitive to elevations on the EI-5(VER) compared to visual-perceptual tests; whereas, the opposite was observed with the EI-5(NV). However, the match between predictor and criterion variable had a more complex relationship with classification accuracy, suggesting the confluence of multiple factors (sensory modality, cognitive domain, testing paradigm). An "indeterminate range" of performance validity emerged that was distinctly different from both the Pass and the Fail group. Trichotomized criterion PVTs (Pass-Borderline-Fail) had a negative linear relationship with performance on tests of cognitive ability, providing further support for an "in-between" category separating the unequivocal Pass and unequivocal Fail classification range. The choice of criterion variable can influence classification accuracy in PVT research. Establishing a Borderline range between Pass and Fail more accurately reflected the distribution of scores on multiple PVTs. The traditional binary classification system imposes an artificial dichotomy on PVTs that was not fully supported by the data. Accepting "indeterminate" as a legitimate third outcome of performance validity assessment has the potential to improve the clinical utility of PVTs and defuse debates regarding "near-Passes" and "soft Fails."	[Erdodi, Laszlo A.] Univ Windsor, Dept Psychol, Windsor, ON, Canada	Erdodi, LA (corresponding author), 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com					An KY, 2017, CLIN NEUROPSYCHOL, V31, P193, DOI 10.1080/13854046.2016.1217046; Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Axelrod BN, 2014, CLIN NEUROPSYCHOL, V28, P876, DOI 10.1080/13854046.2014.907583; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Bigler ED, 2014, BRAIN INJURY, V28, P1623, DOI 10.3109/02699052.2014.947627; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2007, ARCH CLIN NEUROPSYCH, V22, P675, DOI 10.1016/j.acn.2007.07.005; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Bush SS, 2014, PSYCHOL INJ LAW, V7, P197, DOI 10.1007/s12207-014-9198-7; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Busse M, 2012, CLIN NEUROPSYCHOL, V26, P675, DOI 10.1080/13854046.2012.679623; Chafetz MD, 2015, CLIN NEUROPSYCHOL, V29, P723, DOI 10.1080/13854046.2015.1099738; Chafetz M, 2011, CLIN NEUROPSYCHOL, V25, P1239, DOI 10.1080/13854046.2011.586785; Cottingham ME, 2014, CLIN NEUROPSYCHOL, V28, P1030, DOI 10.1080/13854046.2014.951397; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; Erdodi L, 2017, APPL NEUROPSYCH-ADUL, V24, P264, DOI 10.1080/23279095.2016.1154856; Erdodi LA, 2018, PSYCHOL ASSESSMENT, V30, P755, DOI 10.1037/pas0000525; Erdodi LA, 2017, BRAIN INJURY, V31, P1362, DOI 10.1080/02699052.2017.1332386; Erdodi LA, 2018, APPL NEUROPSYCH-ADUL, V25, P19, DOI 10.1080/23279095.2016.1232262; Erdodi LA, 2017, PSYCHOL INJ LAW, V10, P96, DOI 10.1007/s12207-017-9282-x; Erdodi LA, 2017, APPL NEUROPSYCH-CHIL, V6, P355, DOI 10.1080/21622965.2016.1198908; Erdodi LA, 2017, J CLIN EXP NEUROPSYC, V39, P369, DOI 10.1080/13803395.2016.1230181; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Fazio RL, 2017, CLIN NEUROPSYCHOL, V31, P251, DOI 10.1080/13854046.2016.1213316; Frederick RI, 2000, ARCH CLIN NEUROPSYCH, V15, P281, DOI 10.1016/S0887-6177(99)00002-5; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2009, ASSESSMENT, V16, P237, DOI 10.1177/1073191108326227; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Hilsabeck RC, 2011, CLIN NEUROPSYCHOL, V25, P1228, DOI 10.1080/13854046.2011.589409; Hopwood CJ, 2007, J PERS ASSESS, V88, P43, DOI 10.1207/s15327752jpa8801_06; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Jasinski LJ, 2011, J CLIN EXP NEUROPSYC, V33, P300, DOI 10.1080/13803395.2010.516743; KANE R L, 1991, Neuropsychology Review, V2, P281, DOI 10.1007/BF01108849; Kanser RJ, 2017, CLIN NEUROPSYCHOL, V31, P644, DOI 10.1080/13854046.2016.1278040; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Larrabee G. J., 2012, FORENSIC NEUROPSYCHO, P117; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Larrabee GJ, 2013, BEHAV SCI LAW, V31, P686, DOI 10.1002/bsl.2087; Leighton A, 2014, J INT NEUROPSYCH SOC, V20, P873, DOI 10.1017/S135561771400085X; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lichtenstein JD, 2017, CHILD NEUROPSYCHOL, V23, P284, DOI 10.1080/09297049.2015.1135422; Lippa SM, 2014, REHABIL PSYCHOL, V59, P306, DOI 10.1037/a0037217; Lu P. H., 2007, ASSESSMENT FEIGNED C, P178; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; O'Bryant SE, 2003, CLIN NEUROPSYCHOL, V17, P69, DOI 10.1076/clin.17.1.69.15624; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Pearson, 2009, ADV CLIN SOL WAIS 4; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Reese CS, 2012, ARCH CLIN NEUROPSYCH, V27, P176, DOI 10.1093/arclin/acr117; ROGERS R, 1990, PROF PSYCHOL-RES PR, V21, P182; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Roth R.M., 2017, PSYCHOL NEUROSCI, V10, DOI [https//doi.org/10.1037/pne0000103, DOI 10.1037/PNE0000103]; Schwartz ES, 2016, J INT NEUROPSYCH SOC, V22, P851, DOI 10.1017/S1355617716000746; Shura RD, 2016, APPL NEUROPSYCH-ADUL, V23, P94, DOI 10.1080/23279095.2015.1014556; Silk-Eglit GM, 2015, APPL NEUROPSYCH-ADUL, V22, P335, DOI 10.1080/23279095.2014.938809; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Sweet JJ, 2000, CLIN NEUROPSYCHOL, V14, P18, DOI 10.1076/1385-4046(200002)14:1;1-8;FT018; Trueblood W., 1994, J CLIN EXPT NEUROPSY, V4, P697, DOI DOI 10.1080/01688639408402671; Vallabhajosula B, 2001, J AM ACAD PSYCHIATRY, V29, P207; Warrington EK., 1984, RECOGNITION MEMORY T; Whiteside DM, 2015, J CLIN EXP NEUROPSYC, V37, P220, DOI 10.1080/13803395.2014.1002758; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791; Young G, 2015, PSYCHOL INJ LAW, V8, P188, DOI 10.1007/s12207-015-9232-4	93	27	27	0	5	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult	MAR 4	2019	26	2					155	172		10.1080/23279095.2017.1384925			18	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	HR3RD	WOS:000463056200006	29111772				2021-06-18	
J	Harmon, KG; Clugston, JR; Dec, K; Hainline, B; Herring, SA; Kane, S; Kontos, AP; Leddy, JJ; McCrea, MA; Poddar, SK; Putukian, M; Wilson, JC; Roberts, WO				Harmon, Kimberly G.; Clugston, James R.; Dec, Katherine; Hainline, Brian; Herring, Stanley A.; Kane, Shawn; Kontos, Anthony P.; Leddy, John J.; McCrea, Michael A.; Poddar, Sourav K.; Putukian, Margot; Wilson, Julie C.; Roberts, William O.			American Medical Society for Sports Medicine Position Statement on Concussion in Sport	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; sport; athlete; youth	KING-DEVICK TEST; HIGH-SCHOOL FOOTBALL; CEREBRAL-BLOOD-FLOW; EXTREMITY MUSCULOSKELETAL INJURY; CHRONIC TRAUMATIC ENCEPHALOPATHY; METABOLIC BRAIN VULNERABILITY; VOLUNTARY EXERCISE; TEMPORAL WINDOW; SCREENING TOOL; NUTRITIONAL SUPPLEMENTS	Sport-related concussion (SRC) is a common injury in recreational and organized sport. Over the past 30 years, there has been significant progress in our scientific understanding of SRC, which in turn has driven the development of clinical guidelines for diagnosis, assessment, and management of SRC. In addition to a growing need for knowledgeable health care professionals to provide evidence-based care for athletes with SRC, media attention and legislation have created awareness and, in some cases, fear about many issues and unknowns surrounding SRC. The American Medical Society for Sports Medicine formed a writing group to review the existing literature on SRC, update its previous position statement, 1 and address current evidence and knowledge gaps regarding SRC. The absence of definitive outcomes-based data is challenging and requires relying on the best available evidence integrated with clinical experience and patient values. This statement reviews the definition, pathophysiology, and epidemiology of SRC, the diagnosis and management of both acute and persistent concussion symptoms, the short-and long-term risks of SRC and repetitive head impact exposure, SRC prevention strategies, and potential future directions for SRC research. The American Medical Society for Sports Medicine is committed to best clinical practices, evidence-based research, and educational initiatives that positively impact the health and safety of athletes.	[Harmon, Kimberly G.] Univ Washington, Dept Family Med, 3800 Montlake Blvd, Seattle, WA 98195 USA; [Harmon, Kimberly G.] Univ Washington, Dept Orthopaed & Sports Med, 3800 Montlake Blvd, Seattle, WA 98195 USA; [Clugston, James R.] Univ Florida, Dept Community Hlth, Gainesville, FL USA; [Clugston, James R.] Univ Florida, Dept Family Med & Neurol, Gainesville, FL USA; [Dec, Katherine] Virginia Commonwealth Univ, Dept Phys Med & Rehabil & Orthopaed Surg, Richmond, VA USA; [Hainline, Brian] Natl Collegiate Athlet Assoc, Indianapolis, IN USA; [Herring, Stanley A.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Kane, Shawn] Univ N Carolina, Dept Family Med, Chapel Hill, NC 27514 USA; [Kontos, Anthony P.] Univ Pittsburgh, Dept Orthoped Surg, Pittsburgh, PA USA; [Clugston, James R.] SUNY Buffalo, UBMD Dept Orthopaed & Sports Med, Buffalo, NY USA; [McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Poddar, Sourav K.] Univ Colorado, Dept Family Med & Orthoped, Denver, CO 80202 USA; [Putukian, Margot] Princeton Univ, Univ Hlth Serv, Internal Medicine Sports Med, Rutgers Robert Wood Johnson Med Sch, Princeton, Princeton, NJ 08544 USA; [Wilson, Julie C.] Univ Colorado, Dept Orthoped, Aurora, CO USA; [Roberts, William O.] Univ Minnesota, Dept Family Med & Community Hlth, Minneapolis, MN USA	Harmon, KG (corresponding author), Univ Washington, Dept Family Med, 3800 Montlake Blvd, Seattle, WA 98195 USA.; Harmon, KG (corresponding author), Univ Washington, Dept Orthopaed & Sports Med, 3800 Montlake Blvd, Seattle, WA 98195 USA.	kharmon@uw.edu		Clugston, James/0000-0002-2103-1039; Roberts, William O/0000-0003-4517-4330			[Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Ashbaugh A, 2016, CURR SPORT MED REP, V15, P16, DOI 10.1249/JSR.0000000000000219; Asken BM, 2018, AM J SPORT MED, V46, P1465, DOI 10.1177/0363546518757984; Asken BM, 2017, JAMA NEUROL, V74, P1255, DOI 10.1001/jamaneurol.2017.2396; Asken BM, 2016, NEUROPSYCHOL REV, V26, P340, DOI 10.1007/s11065-016-9327-z; Asken BM, 2016, J ATHL TRAINING, V51, P329, DOI 10.4085/1062-6050-51.5.02; Barkhoudarian G, 2016, PHYS MED REH CLIN N, V27, P373, DOI 10.1016/j.pmr.2016.01.003; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Bernhardt DT, 2010, PREPARTICIPATION PHY; Besnier F, 2017, ANN PHYS REHABIL MED, V60, P27, DOI 10.1016/j.rehab.2016.07.002; Black AM, 2016, BRIT J SPORT MED, V50, P55, DOI 10.1136/bjsports-2015-095103; Bretzin AC, 2018, AM J SPORT MED, V46, P2263, DOI 10.1177/0363546518778251; Broglio SP, 2018, SPORTS MED, V48, P1255, DOI 10.1007/s40279-017-0813-0; Broglio SP, 2017, J NEUROTRAUM, V34, P2675, DOI 10.1089/neu.2016.4767; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Chin EY, 2016, AM J SPORT MED, V44, P2276, DOI 10.1177/0363546516648141; Clausen M, 2016, J HEAD TRAUMA REHAB, V31, P215, DOI 10.1097/HTR.0000000000000145; Collins MW, 2016, NEUROSURGERY, V79, P912, DOI 10.1227/NEU.0000000000001447; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Davis GA, 2017, BRIT J SPORT MED, V51, P859, DOI 10.1136/bjsports-2017-097492; Davis-Hayes C, 2018, NEUROL-CLIN PRACT, V8, P40, DOI 10.1212/CPJ.0000000000000424; Deshpande SK, 2017, JAMA NEUROL, V74, P909, DOI 10.1001/jamaneurol.2017.1317; Dhawan PS, 2017, NEUROL-CLIN PRACT, V7, P464, DOI 10.1212/CPJ.0000000000000381; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Ebell MH, 2004, AM FAM PHYSICIAN, V69, P548; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P848, DOI 10.1136/bjsports-2017-097506; Echemendia RJ, 2018, BRIT J SPORT MED, V52, P1149, DOI 10.1136/bjsports-2016-097090; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Eckner JT, 2014, BRIT J SPORT MED, V48, P112, DOI 10.1136/bjsports-2012-091579; Eckner JT, 2011, PM&R, V3, P1092, DOI 10.1016/j.pmrj.2011.04.022; Eddy R, 2020, CLIN J SPORT MED, V30, P239, DOI 10.1097/JSM.0000000000000586; Elbin RJ, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0910; Ellis MJ, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00136; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Emery CA, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097452; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Feddermann-Demont N, 2017, BRIT J SPORT MED, V51, P903, DOI 10.1136/bjsports-2016-097403; Fuller GW, 2017, J SCI MED SPORT, V20, P246, DOI 10.1016/j.jsams.2016.07.008; Fuller GW, 2019, BRIT J SPORT MED, V53, P1526, DOI 10.1136/bjsports-2017-098560; Galetta KM, 2015, J NEURO-OPHTHALMOL, V35, P235, DOI 10.1097/WNO.0000000000000226; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Garcia GGP, 2018, SPORTS MED, V48, P1739, DOI 10.1007/s40279-018-0880-x; Griesbach GS, 2014, J NEUROTRAUM, V31, P674, DOI 10.1089/neu.2013.3151; Griesbach GS, 2012, J NEUROTRAUM, V29, P1426, DOI 10.1089/neu.2011.2229; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Grool AM, 2016, JAMA-J AM MED ASSOC, V316, P2504, DOI 10.1001/jama.2016.17396; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hecimoyich M, 2018, J SCI MED SPORT, V21, P1004, DOI 10.1016/j.jsams.2018.03.011; Herman DC, 2017, SPORTS MED, V47, P1003, DOI 10.1007/s40279-016-0607-9; Hoffman N.L., 2017, CLIN J SPORT MED; Houck Z, 2016, AM J SPORT MED, V44, P2269, DOI 10.1177/0363546516645070; Howell DR, 2018, CLIN J SPORT MED; Hugentobler JA, 2015, INT J SPORTS PHYS TH, V10, P676; Iverson GL, 2018, J ALZHEIMERS DIS, V61, P17, DOI 10.3233/JAD-170654; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Janssen PHH, 2017, MAYO CLIN PROC, V92, P66, DOI 10.1016/j.mayocp.2016.09.004; Kamins J, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097464; Kerr ZY, 2017, J ATHL TRAINING, V52, P167, DOI 10.4085/1062-6050-51.6.05; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115594578; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115610545; Kerr Zachary Y, 2014, Inj Epidemiol, V1, P28; King D, 2015, J NEUROL SCI, V351, P58, DOI 10.1016/j.jns.2015.02.035; Krolikowski MP, 2017, AM J SPORT MED, V45, P468, DOI 10.1177/0363546516669701; Lawrence DW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196062; Leddy JJ, 2018, CLIN J SPORTS MED; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2018, CURR SPORT MED REP, V17, P262, DOI 10.1249/JSR.0000000000000505; Leddy JJ, 2018, CLIN J SPORT MED, V28, P13, DOI 10.1097/JSM.0000000000000431; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lehman EJ, 2016, AM J SPORT MED, V44, P2486, DOI 10.1177/0363546516645093; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Leong Danielle F, 2015, J Optom, V8, P131, DOI 10.1016/j.optom.2014.12.005; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lucas JA, 2018, BR J SPORTS MED; Mainwaring L, 2018, INT J PSYCHOPHYSIOL; Makdissi M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097470; Manley G, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097791; Marinides Z, 2015, NEUROL CLIN PRACT, V5, P25, DOI DOI 10.1212/CPJ.000000000; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McAvoy K, 2018, NEUROREHABILITATION, V42, P325, DOI 10.3233/NRE-172381; McCarty CA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0459; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097447; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2017, BRIT J SPORT MED, V51, P877, DOI 10.1136/bjsports-2016-097393; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McLeod TCV, 2015, BRAIN INJURY, V29, P175, DOI 10.3109/02699052.2014.965206; Mead GE, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub3; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Mychasiuk R, 2016, EUR J NEUROSCI, V44, P2407, DOI 10.1111/ejn.13360; National Collegiate Athletic Association (NCAA), 2016, INT CONS DIAGN MAN S; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Norheim N, 2018, BMJ OPEN SPORT EXERC, V4, DOI 10.1136/bmjsem-2018-000412; O'Connor KL, 2017, J ATHL TRAINING, V52, P206, DOI 10.4085/1062-6050.52.2.05; O'Neill JA, 2017, REHABIL PSYCHOL, V62, P300, DOI 10.1037/rep0000155; Oliver JM, 2018, SPORTS MED, V48, pS39, DOI 10.1007/s40279-017-0847-3; Oliver JM, 2016, MED SCI SPORT EXER, V48, P974, DOI 10.1249/MSS.0000000000000875; Patricios J, 2017, BRIT J SPORT MED, V51, P888, DOI 10.1136/bjsports-2016-097441; Putukian M, 2015, CLIN J SPORT MED, V25, P36, DOI 10.1097/JSM.0000000000000102; Randolph C, 2005, J ATHL TRAINING, V40, P139; Resch JE., 2016, BMJ OPEN SPORT EXERC, V2, P000012, DOI [10.1136/bmjsem-2015-000012, DOI 10.1136/BMJSEM-2015-000012]; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; Schmidt JD, 2017, J NEUROTRAUM, V34, P1571, DOI 10.1089/neu.2016.4668; Schneider KJ, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097475; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Seidman DH, 2015, J NEUROL SCI, V356, P97, DOI 10.1016/j.jns.2015.06.021; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stovitz SD, 2017, CURR SPORT MED REP, V16, P50, DOI 10.1249/JSR.0000000000000326; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Trojian TH, 2017, CURR SPORT MED REP, V16, P247, DOI 10.1249/JSR.0000000000000387; Tsushima WT, 2018, ARCH CLIN NEUROPSYCH; Tucker R, 2017, BRIT J SPORT MED, V51, P1147, DOI 10.1136/bjsports-2017-097883; Vagnozzi R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	129	27	27	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2019	29	2					87	100		10.1097/JSM.0000000000000720			14	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	IQ4QE	WOS:000480734500002	30730386	Bronze			2021-06-18	
J	Wu, YG; Liu, W; Zhou, Y; Hilton, T; Zhao, ZL; Liu, W; Wang, M; Yeon, J; Houck, K; Thiagarajan, P; Zhang, FY; Shi, FD; Wu, XP; Li, M; Dong, JF; Zhang, JN				Wu, Yingang; Liu, Wei; Zhou, Yuan; Hilton, Tristan; Zhao, Zilong; Liu, Wei; Wang, Min; Yeon, Jason; Houck, Katie; Thiagarajan, Perumal; Zhang, Fangyi; Shi, Fu-Dong; Wu, Xiaoping; Li, Min; Dong, Jing-fei; Zhang, Jianning			von Willebrand factor enhances microvesicle-induced vascular leakage and coagulopathy in mice with traumatic brain injury	BLOOD			English	Article							THROMBOTIC THROMBOCYTOPENIC PURPURA; WEIBEL-PALADE BODIES; VONWILLEBRAND-FACTOR; FACTOR MULTIMERS; IN-VITRO; COAGULATION; ADAMTS-13; PROTEOLYSIS; PROTEASE; SURFACE	von Willebrand factor (VWF) is an adhesive ligand, and its activity is proteolytically regulated by the metalloprotease ADAMTS-13 (a disintegrin and metalloprotease with thrombospondin type 1 repeat 13). An elevated level of plasma VWF has been widely considered a marker for endothelial cell activation in trauma and inflammation, but its causal role in these pathological conditions remains poorly defined. Using a fluid percussion injury mouse model, we demonstrated that VWF released during acute traumatic brain injury (TBI) was activated and became microvesicle-bound. The VWF-bound microvesicles promoted vascular leakage and systemic coagulation. Recombinant ADAMTS-13 given either before or after TBI reduced the VWF reactivity with minimal influence on VWF secretion. rADAMTS-13 protected the integrity of endothelial cell barriers and prevented TBI-induced coagulopathy by enhancing VWF cleavage without impairing basal hemostasis. Promoting microvesicle clearance by lactadherin had efficacy similar to that of rADAMTS-13. This study uncovers a novel synergistic action between VWF and cellular microvesicles in TBI-induced vascular leakage and coagulopathy and demonstrates protective effects of rADAMTS-13.	[Wu, Yingang; Zhou, Yuan; Zhao, Zilong; Zhang, Jianning] Tianjin Inst Neurol, Dept Neurosurg, Tianjin, Peoples R China; [Wu, Yingang; Zhou, Yuan; Zhao, Zilong; Liu, Wei; Zhang, Jianning] Tianjin Med Univ Gen Hosp, Tianjin, Peoples R China; [Wu, Yingang; Hilton, Tristan; Yeon, Jason; Houck, Katie; Zhang, Jianning] Bloodworks Res Inst, 1551 Eastlake Ave East, Seattle, WA 98102 USA; [Liu, Wei; Wang, Min; Wu, Xiaoping; Dong, Jing-fei] Lanzhou Univ, Sch Med Sci, Inst Pathol, Lanzhou, Gansu, Peoples R China; [Liu, Wei; Wang, Min; Li, Min] Lanzhou Univ, Gansu Prov Key Lab Preclin Study New Drug Dev, Lanzhou, Gansu, Peoples R China; [Liu, Wei; Li, Min] Tianjin Inst Neurol, Dept Neurol, Tianjin, Peoples R China; [Thiagarajan, Perumal] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Thiagarajan, Perumal] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Thiagarajan, Perumal] Michael E DeBakey VA Med Ctr, Ctr Translat Res Inflammatory Dis, Houston, TX USA; [Zhang, Fangyi] Univ Washington, Sch Med, Dept Neurosurg, Seattle, WA USA; [Shi, Fu-Dong] St Josephs Hosp, Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA; [Shi, Fu-Dong; Dong, Jing-fei] Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA	Dong, JF (corresponding author), Bloodworks Res Inst, 1551 Eastlake Ave East, Seattle, WA 98102 USA.; Zhang, JN (corresponding author), Tianjin Med Univ Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China.; Li, M (corresponding author), Lanzhou Univ, Sch Basic Med Sci, Inst Pathol, Lanzhou, Gansu, Peoples R China.	limin@lzu.edu.cn; jfdong@bloodworksnw.org; jianningzhang@hotmail.com	Zhao, Zilong/AAZ-2196-2020		National Institutes of Health, National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS087296]; National Institutes of Health, National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL119391, HL125957]; Natural Science Foundation of China State Key Program [81330029]; Veterans Administration Research ServiceUS Department of Veterans Affairs;  [81271361];  [81271359];  [16PTSTJC00180];  [81672399]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL125957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087296] Funding Source: NIH RePORTER	This study is supported by National Institutes of Health, National Institute of Neurological Disorders and Stroke grant NS087296 (J.-f.D.), National Institutes of Health, National Heart, Lung, and Blood Institute grants HL119391 and HL125957 (J.-f.D.), Natural Science Foundation of China State Key Program Grant 81330029 (J.Z.), and research grants 81271361, 81271359, and 16PTSTJC00180 (J.Z.) and 81672399 (M.L.), and a grant from the Veterans Administration Research Service (P.T.).	Ayme G, 2017, ARTERIOSCL THROM VAS, V37, P1736, DOI 10.1161/ATVBAHA.117.309319; De Oliveira CO, 2007, J NEUROTRAUM, V24, P1331, DOI 10.1089/neu.2006.0159; Denorme F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179258; Dong JF, 2002, BLOOD, V100, P4033, DOI 10.1182/blood-2002-05-1401; Feys HB, 2006, J THROMB HAEMOST, V4, P955, DOI 10.1111/j.1538-7836.2006.01833.x; FOWLER WE, 1985, J CLIN INVEST, V76, P1491, DOI 10.1172/JCI112129; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Gao WW, 2015, BRAIN RES, V1622, P230, DOI 10.1016/j.brainres.2015.04.035; Habe K, 2012, THROMB RES, V129, P598, DOI 10.1016/j.thromres.2011.10.011; Hardaway RM, 2001, SEMIN THROMB HEMOST, V27, P577, DOI 10.1055/s-2001-18863; Huang J, 2009, BLOOD, V113, P1589, DOI 10.1182/blood-2008-05-158584; Hyun J, 2009, THROMB RES, V124, P75, DOI 10.1016/j.thromres.2008.11.020; KAPLAN JE, 1989, AM J PHYSIOL, V257, pH423; Kutcher ME, 2013, J TRAUMA ACUTE CARE, V74, P1223, DOI 10.1097/TA.0b013e31828b7fa1; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/0897715042664885; MAYADAS TN, 1989, J BIOL CHEM, V264, P13497; Moake JL, 1998, J CLIN APHERESIS, V13, P126, DOI 10.1002/(SICI)1098-1101(1998)13:3<126::AID-JCA6>3.0.CO;2-U; Motto DG, 2005, J CLIN INVEST, V115, P2752, DOI 10.1172/JCI26007; Nakano T, 2015, BRAIN RES, V1624, P330, DOI 10.1016/j.brainres.2015.07.027; Nascimbene A, 2017, J HEART LUNG TRANSPL, V36, P477, DOI 10.1016/j.healun.2017.01.010; Padilla A, 2004, BLOOD, V103, P2150, DOI 10.1182/blood-2003-08-2956; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; SPORN LA, 1987, BLOOD, V69, P1531; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; Suidan GL, 2013, ARTERIOSCL THROM VAS, V33, P2112, DOI 10.1161/ATVBAHA.113.301362; Tian Y, 2015, BLOOD, V125, P2151, DOI 10.1182/blood-2014-09-598805; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; VISCHER UM, 1994, BLOOD, V83, P3536; WAGNER DD, 1987, BLOOD, V69, P27; Wu X, 2012, PHARMACOL THERAPEUT, V134, P68, DOI 10.1016/j.pharmthera.2011.12.008; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929; Zhao ZL, 2016, BLOOD, V127, P2763, DOI [10.1182/blood-2015-12688838, 10.1182/blood-2015-12-688838]; Zhou Y, 2018, BLOOD, V131, P563, DOI 10.1182/blood-2017-08-801738	34	27	28	0	13	AMER SOC HEMATOLOGY	WASHINGTON	2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA	0006-4971	1528-0020		BLOOD	Blood	SEP 6	2018	132	10					1075	1084		10.1182/blood-2018-03-841932			10	Hematology	Hematology	GS6WH	WOS:000443840200014	29941674	Bronze, Green Published			2021-06-18	
J	Giacci, MK; Bartlett, CA; Smith, NM; Iyer, KS; Toomey, LM; Jiang, HB; Guagliardo, P; Kilburn, MR; Fitzgerald, M				Giacci, Marcus K.; Bartlett, Carole A.; Smith, Nicole M.; Iyer, K. Swaminathan; Toomey, Lillian M.; Jiang, Haibo; Guagliardo, Paul; Kilburn, Matt R.; Fitzgerald, Melinda			Oligodendroglia Are Particularly Vulnerable to Oxidative Damage after Neurotrauma In Vivo	JOURNAL OF NEUROSCIENCE			English	Article						myelin regulatory factor gene; NanoSIMS; oligodendrocyte precursor cell; oligodendroglia; oxidative stress; proliferation and differentiation	SPINAL-CORD-INJURY; CENTRAL-NERVOUS-SYSTEM; GENE REGULATORY FACTOR; SECONDARY DEGENERATION; OPTIC-NERVE; PROGENITOR CELLS; ADULT CNS; SELECTIVE VULNERABILITY; MULTIPLE-SCLEROSIS; PRECURSOR CELLS	Loss of function following injury to the CNS is worsened by secondary degeneration of neurons and glia surrounding the injury and is initiated by oxidative damage. However, it is not yet known which cellular populations and structures are most vulnerable to oxidative damage in vivo. Using Nanoscale secondary ion mass spectrometry (NanoSIMS), oxidative damage was semiquantified within cellular subpopulations and structures of optic nerve vulnerable to secondary degeneration, following a partial transection of the optic nerve in adult female PVG rats. Simultaneous assessment of cellular subpopulations and structures revealed oligodendroglia as the most vulnerable to DNA oxidation following injury. 5-Ethynyl-2'-deoxyuridine (EdU) was used to label cells that proliferated in the first 3 d after injury. Injury led to increases in DNA, protein, and lipid damage in oligodendrocyte progenitor cells and mature oligodendrocytes at 3 d, regardless of proliferative state, associated with a decline in the numbers of oligodendrocyte progenitor cells at 7 d. O4(+) preoligodendrocytes also exhibited increased lipid peroxidation. Interestingly, EdU(+) mature oligodendrocytes derived after injury demonstrated increased early susceptibility to DNA damage and lipid peroxidation. However, EdU(+) mature oligodendrocytes with high 8-hydroxyguanosine immunoreactivity were more likely to be caspase(3+). By day 28, newly derived mature oligodendrocytes had significantly reduced myelin regulatory factor gene mRNA, indicating that the myelination potential of these cells may be reduced. The proportion of caspase(3+) oligodendrocytes remained higher in EdU(+) cells. Innovative use of NanoSIMS together with traditional immunohistochemistry and in situ hybridization have enabled the first demonstration of subpopulation specific oligodendroglial vulnerability to oxidative damage, due to secondary degeneration in vivo.	[Giacci, Marcus K.; Bartlett, Carole A.; Smith, Nicole M.; Fitzgerald, Melinda] Univ Western Australia, Sch Biol Sci, Expt & Regenerat Neurosci, Perth, WA 6009, Australia; [Smith, Nicole M.; Iyer, K. Swaminathan] Univ Western Australia, Sch Mol Sci, Perth, WA 6009, Australia; [Jiang, Haibo; Guagliardo, Paul; Kilburn, Matt R.] Univ Western Australia, Ctr Microscopy Characterisat & Anal, Perth, WA 6009, Australia; [Bartlett, Carole A.; Toomey, Lillian M.; Fitzgerald, Melinda] Curtin Univ, Curtin Hlth Innovat Res Inst, Perth, WA 6102, Australia; [Toomey, Lillian M.; Fitzgerald, Melinda] Sarich Neurosci Res Inst, Perron Inst Neurol & Translat Sci, Nedlands, WA 6009, Australia	Fitzgerald, M (corresponding author), Curtin Univ, Sarich Neurosci Res Inst, 8 Verdun St, Nedlands, WA 6009, Australia.	lindy.fitzgerald@curtin.edu.au	Smith, Nicole/L-2502-2013; Fitzgerald, Melinda/C-4235-2011; Jiang, Haibo/E-6623-2015; Kilburn, Matthew/C-4515-2011	Smith, Nicole/0000-0002-5519-8152; Fitzgerald, Melinda/0000-0002-4823-8179; Guagliardo, Paul/0000-0003-3488-6754; Jiang, Haibo/0000-0002-2384-4826; Giacci, Marcus/0000-0002-8330-678X; Kilburn, Matthew/0000-0002-1858-8485	National Health and Medical Research Council, AustraliaNational Health and Medical Research Council of Australia [APP1061791, APP1082403]; National Health and Medical Research Council Career Development FellowshipNational Health and Medical Research Council of Australia [APP1087114]	This work was supported by the National Health and Medical Research Council, Australia APP1061791 and APP1082403. M.F. was supported by National Health and Medical Research Council Career Development Fellowship APP1087114. We thank the Australian Microscopy & Microanalysis Research Facility, the Science and Industry Endowment Fund, and the State Government of Western Australian for contributing to the Ion Probe Facility at the University of Western Australia.	Angelo M, 2014, NAT MED, V20, P436, DOI 10.1038/nm.3488; Back SA, 2005, ANN NEUROL, V58, P108, DOI 10.1002/ana.20530; Back SA, 2002, J NEUROSCI, V22, P455, DOI 10.1523/JNEUROSCI.22-02-00455.2002; Back SA, 1998, J NEUROSCI, V18, P6241; Bandura DR, 2009, ANAL CHEM, V81, P6813, DOI 10.1021/ac901049w; Bujalka H, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001625; Busch SA, 2007, CURR OPIN NEUROBIOL, V17, P120, DOI 10.1016/j.conb.2006.09.004; Butts BD, 2008, CELL DEATH DIFFER, V15, P1178, DOI 10.1038/cdd.2008.70; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; Covacci V, 2001, CHEM RES TOXICOL, V14, P1492, DOI 10.1021/tx010021m; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Degterev A, 2008, NAT REV MOL CELL BIO, V9, P378, DOI 10.1038/nrm2393; Doig RLO, 2014, EXP NEUROL, V261, P136, DOI 10.1016/j.expneurol.2014.06.007; Emery B, 2009, CELL, V138, P172, DOI 10.1016/j.cell.2009.04.031; Eminli S, 2008, STEM CELLS, V26, P2467, DOI 10.1634/stemcells.2008-0317; Fancy SPJ, 2004, MOL CELL NEUROSCI, V27, P247, DOI 10.1016/j.mcn.2004.06.015; Fancy SPJ, 2010, EXP NEUROL, V225, P18, DOI 10.1016/j.expneurol.2009.12.020; Fern R, 2000, J NEUROSCI, V20, P34, DOI 10.1523/JNEUROSCI.20-01-00034.2000; Fields RD, 2015, NAT REV NEUROSCI, V16, P756, DOI 10.1038/nrn4023; Fitzgerald M, 2010, J NEUROTRAUM, V27, P439, DOI 10.1089/neu.2009.1112; Fitzgerald M, 2009, INVEST OPHTH VIS SCI, V50, P5456, DOI 10.1167/iovs.09-3717; Fitzgerald M, 2009, EXP NEUROL, V216, P219, DOI 10.1016/j.expneurol.2008.11.026; French HM, 2009, J NEUROSCI RES, V87, P3076, DOI 10.1002/jnr.22139; Funfschilling U, 2012, NATURE, V485, P517, DOI 10.1038/nature11007; Garbern JY, 2007, CELL MOL LIFE SCI, V64, P50, DOI 10.1007/s00018-006-6182-8; Gautier HOB, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9518; Guptarak J, 2014, J NEUROTRAUM, V31, P268, DOI 10.1089/neu.2013.3108; Haider L, 2011, BRAIN, V134, P1914, DOI 10.1093/brain/awr128; Hartman TK, 2007, NEUROBIOL AGING, V28, P921, DOI 10.1016/j.neurobiolaging.2006.05.012; Havrda MC, 2014, CANCER RES, V74, P1822, DOI 10.1158/0008-5472.CAN-13-1839; HERNDON RM, 1977, SCIENCE, V195, P693, DOI 10.1126/science.190678; Hornig J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003907; Juurlink BHJ, 1998, GLIA, V22, P371, DOI 10.1002/(SICI)1098-1136(199804)22:4<371::AID-GLIA6>3.0.CO;2-6; Koenning M, 2012, J NEUROSCI, V32, P12528, DOI 10.1523/JNEUROSCI.1069-12.2012; Liu ZJ, 2007, DEV BIOL, V302, P683, DOI 10.1016/j.ydbio.2006.10.007; Lozic I, 2016, BIOMATERIALS, V74, P200, DOI 10.1016/j.biomaterials.2015.10.001; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; LUDWIN SK, 1979, AM J PATHOL, V95, P683; Mi S, 2009, ANN NEUROL, V65, P304, DOI 10.1002/ana.21581; MORI S, 1970, J COMP NEUROL, V139, P1, DOI 10.1002/cne.901390102; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Nomoto K, 2008, APPL IMMUNOHISTO M M, V16, P71; Ozerdem U, 2002, MICROVASC RES, V63, P129, DOI 10.1006/mvre.2001.2376; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Patel MN, 2002, FREE RADICAL RES, V36, P1139, DOI 10.1080/1071576021000016391; Payne SC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065710; Payne SC, 2012, INVEST OPHTH VIS SCI, V53, P6093, DOI 10.1167/iovs.12-10080; Richardson WD, 2011, NEURON, V70, P661, DOI 10.1016/j.neuron.2011.05.013; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; Rinholm JE, 2016, GLIA, V64, P810, DOI 10.1002/glia.22965; Roth AD, 2016, ADV EXP MED BIOL, V949, P167, DOI 10.1007/978-3-319-40764-7_8; Stolt CC, 2002, GENE DEV, V16, P165, DOI 10.1101/gad.215802; Szymanski CR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066448; Thorburne SK, 1996, J NEUROCHEM, V67, P1014; Tsai JP, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13268; Volpe JJ, 2011, ANN NEUROL, V70, P525, DOI 10.1002/ana.22533; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; Walsh DM, 2016, J THEOR BIOL, V406, P17, DOI 10.1016/j.jtbi.2016.06.028; Wang SL, 2001, NEURON, V29, P603, DOI 10.1016/S0896-6273(01)00237-9; Watanabe M, 2002, J NEUROSCI RES, V69, P826, DOI 10.1002/jnr.10338; Wegner M, 2001, MICROSC RES TECHNIQ, V52, P746, DOI 10.1002/jemt.1059; Xing YL, 2014, J NEUROSCI, V34, P14128, DOI 10.1523/JNEUROSCI.3491-13.2014; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Ye X, 2016, J PATHOL, V239, P139, DOI 10.1002/path.4715; Young KM, 2013, NEURON, V77, P873, DOI 10.1016/j.neuron.2013.01.006; Zai LJ, 2005, GLIA, V50, P247, DOI 10.1002/glia.20176; Zhu XQ, 2008, NEURON GLIA BIOL, V4, P19, DOI 10.1017/S1740925X09000015; Ziabreva I, 2010, GLIA, V58, P1827, DOI 10.1002/glia.21052	68	27	27	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 18	2018	38	29					6491	6504		10.1523/JNEUROSCI.1898-17.2018			14	Neurosciences	Neurosciences & Neurology	GO1GR	WOS:000439698400007	29915135	Green Published, Bronze			2021-06-18	
J	Zu, ZL				Zu, Zhongliang			Towards the complex dependence of MTRasym on T-1w in amide proton transfer (APT) imaging	NMR IN BIOMEDICINE			English	Article						amide proton transfer (APT); chemical exchange saturation transfer (CEST); MRI; T-1w normalization	EXCHANGE SATURATION-TRANSFER; NUCLEAR OVERHAUSER ENHANCEMENT; PH-WEIGHTED MRI; MAGNETIZATION-TRANSFER; TRANSFER CEST; IN-VIVO; PROTEINS; SENSITIVITY; RELAXATION; PEPTIDES	Amide proton transfer (APT) imaging is a variation of chemical exchange saturation transfer MRI that has shown promise in diagnosing tumors, ischemic stroke, multiple sclerosis, traumatic brain injury, etc. Specific quantification of the APT effect is crucial for the interpretation of APT contrast in pathologies. Conventionally, magnetization transfer ratio with asymmetric analysis (MTRasym) has been used to quantify the APT effect. However, some studies indicate that MTRasym is contaminated by water longitudinal relaxation time (T-1w), and thus it is necessary to normalize T-1w in MTRasym to obtain specific quantification of the APT effect. So far, whether to use MTRasym or the T-1w-normalized MTRasym is still under debate in the field. In this paper, the influence of T-1w on the quantification of APT was evaluated through theoretical analysis, numerical simulations, and phantom studies for different experimental conditions. Results indicate that there are two types of T-1w effect (T-1w recovery and T-1w-related saturation), which have inverse influences on the steady-state MTRasym. In situations with no or weak direct water saturation (DS) effect, there is only the T-1w recovery effect, and MTRasym linearly depends on T-1w. In contrast, in situations with significant DS effects, the dependence of MTRasym on T-1w is complex, and is dictated by the competition of these two T-1w effects. Therefore, by choosing appropriate irradiation powers, MTRasym could be roughly insensitive to T-1w. Moreover, in non-steady-state acquisitions with very short irradiation time, MTRasym is also roughly insensitive to T-1w. Therefore, for steady-state APT imaging at high fields or with very low irradiation powers, where there are no significant DS effects, it is necessary to normalize T-1w to improve the specificity of MTRasym. However, in clinical MRI systems (usually low fields or non-steady-state acquisitions), T-1w normalization may not be necessary when appropriate sequence parameters are chosen.	[Zu, Zhongliang] Vanderbilt Univ, Inst Imaging Sci, 221 Kirkland Hall, Nashville, TN 37235 USA; [Zu, Zhongliang] Vanderbilt Univ, Dept Radiol & Radiol Sci, 221 Kirkland Hall, Nashville, TN 37235 USA	Zu, ZL (corresponding author), Vanderbilt Univ, Inst Imaging Sci, Med Ctr North, 1161 21st Ave S,AAA-3112, Nashville, TN 37232 USA.	zhongliang.zu@vanderbilt.edu	Zu, Zhongliang/I-1720-2019; Olagbaju, Oluwatosin/AAY-3686-2020	Zu, Zhongliang/0000-0001-7361-7480; 	National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB017873]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R21EB017873] Funding Source: NIH RePORTER	National Institute of Biomedical Imaging and Bioengineering, Grant/Award Number: EB017873	Cai KJ, 2017, MOL IMAGING BIOL, V19, P225, DOI 10.1007/s11307-016-0995-0; Cai KJ, 2012, NAT MED, V18, P302, DOI 10.1038/nm.2615; Chen LQ, 2014, MAGN RESON MED, V72, P1408, DOI 10.1002/mrm.25053; Dula AN, 2011, MAGN RESON MED, V66, P831, DOI 10.1002/mrm.22862; Goerke S, 2014, NMR BIOMED, V27, P507, DOI 10.1002/nbm.3086; Haris M, 2011, NEUROIMAGE, V54, P2079, DOI 10.1016/j.neuroimage.2010.10.017; Heo HY, 2017, MAGN RESON MED, V78, P871, DOI 10.1002/mrm.26799; Heo HY, 2017, MAGN RESON MED, V77, P1853, DOI 10.1002/mrm.26264; Heo HY, 2017, MAGN RESON MED, V77, P779, DOI 10.1002/mrm.26141; Heo HY, 2016, MAGN RESON MED, V75, P1630, DOI 10.1002/mrm.25795; Jia GA, 2011, J MAGN RESON IMAGING, V33, P647, DOI 10.1002/jmri.22480; Jokivarsi KT, 2007, MAGN RESON MED, V57, P647, DOI 10.1002/mrm.21181; Jones CK, 2006, MAGN RESON MED, V56, P585, DOI 10.1002/mrm.20989; Lee DH, 2017, MAGN RESON MED, V77, P855, DOI 10.1002/mrm.26131; Li H, 2015, NMR BIOMED, V28, P1655, DOI 10.1002/nbm.3428; Li H, 2015, NMR BIOMED, V28, P200, DOI 10.1002/nbm.3243; Liu GS, 2009, MAGN RESON MED, V61, P399, DOI 10.1002/mrm.21863; Ma XY, 2017, SCI REP-UK, V7, DOI 10.1038/srep45696; McMahon MT, 2006, MAGN RESON MED, V55, P836, DOI 10.1002/mrm.20818; Salhotra A, 2008, NMR BIOMED, V21, P489, DOI 10.1002/nbm.1216; Sun PZ, 2008, MAGN RESON MED, V60, P834, DOI 10.1002/mrm.21714; Sun PZ, 2007, J CEREBR BLOOD F MET, V27, P1129, DOI 10.1038/sj.jcbfm.9600424; Sun PZ, 2012, NEUROIMAGE, V60, P1, DOI 10.1016/j.neuroimage.2011.11.091; Sun PZ, 2011, J CEREBR BLOOD F MET, V31, P1743, DOI 10.1038/jcbfm.2011.23; Sun PZ, 2010, STROKE, V41, pS147, DOI 10.1161/STROKEAHA.110.595777; Sun PZ, 2005, J MAGN RESON, V175, P193, DOI 10.1016/j.jmr.2005.04.005; van Zijl PCM, 2003, MAGNET RESON MED, V49, P440, DOI 10.1002/mrm.10398; van Zijl PCM, 2011, MAGN RESON MED, V65, P927, DOI 10.1002/mrm.22761; Walker-Samuel S, 2013, NAT MED, V19, P1067, DOI 10.1038/nm.3252; Wang WZ, 2017, BRAIN BEHAV IMMUN, V64, P344, DOI 10.1016/j.bbi.2017.04.019; Ward KM, 2000, MAGN RESON MED, V44, P799, DOI 10.1002/1522-2594(200011)44:5<799::AID-MRM18>3.0.CO;2-S; Wermter FC, 2015, NMR BIOMED, V28, P1507, DOI 10.1002/nbm.3416; Xu JZ, 2014, NMR BIOMED, V27, P253, DOI 10.1002/nbm.3058; Yuan J, 2014, NMR BIOMED, V27, P1239, DOI 10.1002/nbm.3184; Zaiss M, 2018, MAGN RESON MED, V79, P1708, DOI 10.1002/mrm.26813; Zaiss M, 2015, NMR BIOMED, V28, P217, DOI 10.1002/nbm.3237; Zaiss M, 2014, NMR BIOMED, V27, P240, DOI 10.1002/nbm.3054; Zaiss M, 2013, PHYS MED BIOL, V58, pR221, DOI 10.1088/0031-9155/58/22/R221; Zaiss M, 2013, NMR BIOMED, V26, P1815, DOI 10.1002/nbm.3021; Zaiss M, 2013, NMR BIOMED, V26, P507, DOI 10.1002/nbm.2887; Zhang H, 2017, J CEREBR BLOOD F MET, V37, P3422, DOI 10.1177/0271678X17690165; Zhang XY, 2017, MAGN RESON MED, V78, P588, DOI 10.1002/mrm.26396; Zhao XN, 2011, MAGN RESON MED, V66, P1033, DOI 10.1002/mrm.22891; Zhou JY, 2006, PROG NUCL MAG RES SP, V48, P109, DOI 10.1016/j.pnmrs.2006.01.001; Zhou JY, 2011, NAT MED, V17, P130, DOI 10.1038/nm.2268; Zhou JY, 2003, MAGNET RESON MED, V50, P1120, DOI 10.1002/mrm.10651; Zhou JY, 2003, NAT MED, V9, P1085, DOI 10.1038/nm907	47	27	28	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0952-3480	1099-1492		NMR BIOMED	NMR Biomed.	JUL	2018	31	7							e3934	10.1002/nbm.3934			12	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	GK2HK	WOS:000435948300005	29806717	Green Accepted			2021-06-18	
J	Kuriakose, M; Rao, KVR; Younger, D; Chandra, N				Kuriakose, Matthew; Rao, Kakulavarapu V. Rama; Younger, Daniel; Chandra, Namas			Temporal and Spatial Effects of Blast Overpressure on Blood-Brain Barrier Permeability in Traumatic Brain Injury	SCIENTIFIC REPORTS			English	Article							OXIDATIVE STRESS; MATRIX METALLOPROTEINASES; ALZHEIMERS-DISEASE; REGIONAL-VARIATION; FUNCTIONAL ROLES; VASCULAR VOLUME; CLINICAL-TRIALS; TIGHT JUNCTIONS; RAT MODEL; MILD	Blast-induced traumatic brain injury (bTBI) is a "signature wound" in soldiers during training and in combat and has also become a major cause of morbidity in civilians due to increased insurgency. This work examines the role of blood-brain barrier (BBB) disruption as a result of both primary biomechanical and secondary biochemical injury mechanisms in bTBI. Extravasation of sodium fluorescein (NaF) and Evans blue (EB) tracers were used to demonstrate that compromise of the BBB occurs immediately following shock loading, increases in intensity up to 4 hours and returns back to normal in 24 hours. This BBB compromise occurs in multiple regions of the brain in the anterior-posterior direction of the shock wave, with maximum extravasation seen in the frontal cortex. Compromise of the BBB is confirmed by (a) extravasation of tracers into the brain, (b) quantification of tight-junction proteins (TJPs) in the brain and the blood, and (c) tracking specific blood-borne molecules into the brain and brain-specific proteins into the blood. Taken together, this work demonstrates that the BBB compromise occurs as a part of initial biomechanical loading and is a function of increasing blast overpressures.	[Kuriakose, Matthew; Rao, Kakulavarapu V. Rama; Younger, Daniel; Chandra, Namas] New Jersey Inst Technol, Dept Biomed Engn, Ctr Injury Biomech Mat & Med CIBM3, Newark, NJ 07102 USA	Rao, KVR; Chandra, N (corresponding author), New Jersey Inst Technol, Dept Biomed Engn, Ctr Injury Biomech Mat & Med CIBM3, Newark, NJ 07102 USA.	kakulava@njit.edu; namas.chandra@njit.edu			U.S Army Medical Research and Materiel Command project Primary Blast Injury Criteria for Animal/Human TBI Models using Field Validated Shock Tube [14059001]	This work was supported by U.S Army Medical Research and Materiel Command project Primary Blast Injury Criteria for Animal/Human TBI Models using Field Validated Shock Tube, grant number: 14059001. Authors gratefully acknowledge Prof Raj Gupta, from Department of Defense Blast Injury Research Program Coordinating Office, United States Army Medical Research and Materiel Command, Fort Detrick, MD as well as our laboratory members Stephanie Iring, Madison Taylor, Eren Alay and Dr. Maciej Skotak for their contributions to this work.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772; Abbruscato TJ, 2004, J PHARMACOL EXP THER, V310, P459, DOI 10.1124/jpet.104.066274; Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Allt G, 1997, BRAIN RES REV, V24, P67, DOI 10.1016/S0165-0173(97)00011-8; Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Banks W. A, 2016, NATURE REV DRUG DISC; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Benarroch EE, 2005, MAYO CLIN PROC, V80, P1326, DOI 10.4065/80.10.1326; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; Brown RC, 2004, BRAIN RES, V1014, P221, DOI 10.1016/j.brainres.2004.04.034; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Candelario-Jalil E, 2009, NEUROSCIENCE, V158, P983, DOI 10.1016/j.neuroscience.2008.06.025; Cavaglia M, 2001, BRAIN RES, V910, P81, DOI 10.1016/S0006-8993(01)02637-3; Chandra N, 2012, SHOCK WAVES, V22, P403, DOI 10.1007/s00193-012-0399-2; Chandra N., 2011, U.S. provisional patent application, Patent No. 61542354; Chandra N, 2017, MIL MED, V182, P105, DOI 10.7205/MILMED-D-16-00144; Chen Y, 2011, BRAIN INJURY, V25, P641, DOI 10.3109/02699052.2011.580313; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Correale J, 2007, AUTOIMMUNITY, V40, P148, DOI 10.1080/08916930601183522; Desai BS, 2007, CELL TRANSPLANT, V16, P285, DOI 10.3727/000000007783464731; DEVRIES HE, 2004, BLOOD SPINAL CORD BR, P409; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Fernandez-Lopez D., 2013, BLOOD BRAIN BARRIER, P91; Fiala M, 2002, EUR J CLIN INVEST, V32, P360, DOI 10.1046/j.1365-2362.2002.00994.x; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Haorah J, 2005, ALCOHOL CLIN EXP RES, V29, P999, DOI 10.1097/01.ALC.0000166944.79914.0A; Haorah J, 2007, J NEUROCHEM, V101, P566, DOI 10.1111/j.1471-4159.2006.04393.x; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; HAYES RL, 1994, SEMIN NEUROL, V14, P25, DOI 10.1055/s-2008-1041055; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; HOLASH JA, 1990, J CEREBR BLOOD F MET, V10, P432, DOI 10.1038/jcbfm.1990.75; Huber BR, 2016, NEUROSCIENCE, V319, P206, DOI 10.1016/j.neuroscience.2016.01.022; Hue CD, 2016, J NEUROTRAUM, V33, P1202, DOI 10.1089/neu.2015.4067; Hue CD, 2015, J CEREBR BLOOD F MET, V35, P1191, DOI 10.1038/jcbfm.2015.38; Hue CD, 2013, J NEUROTRAUM, V30, P1652, DOI 10.1089/neu.2012.2773; Hyde DW, 1991, CONWEP CONVENTIONAL; Ilzecka J, 1996, Ann Univ Mariae Curie Sklodowska Med, V51, P123; Jiang Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117982; JOHANSON CE, 1980, BRAIN RES, V190, P3, DOI 10.1016/0006-8993(80)91155-5; Kabu S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127971; Kawoos U, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167510; Kaya M, 2011, METHODS MOL BIOL, V763, P369, DOI 10.1007/978-1-61779-191-8_25; Khatri R, 2012, NEUROLOGY, V79, pS52, DOI 10.1212/WNL.0b013e3182697e70; Kuriakose M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161597; LAMANNA JC, 1986, J CEREBR BLOOD F MET, V6, P717, DOI 10.1038/jcbfm.1986.128; Li W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114173; Ling GSF, 2013, PROC SPIE, V8723, DOI 10.1117/12.2020023; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Louboutin JP, 2011, FASEB J, V25, P737, DOI 10.1096/fj.10-161851; Lucke-Wold BP, 2015, MOL NEUROBIOL, V52, P1119, DOI 10.1007/s12035-014-8902-7; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Mathews ZR, 2015, J EMERG MED, V49, P573, DOI 10.1016/j.jemermed.2015.03.013; Mishra V, 2016, SCI REP-UK, V6, DOI 10.1038/srep26992; More B., 2015, AUSTRALASIAN J PARAM, V4; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Needham CE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00072; Nishioku T, 2009, CELL MOL NEUROBIOL, V29, P309, DOI 10.1007/s10571-008-9322-x; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Oby E, 2006, EPILEPSIA, V47, P1761, DOI 10.1111/j.1528-1167.2006.00817.x; Opdenakker G, 2003, LANCET NEUROL, V2, P747, DOI 10.1016/S1474-4422(03)00587-8; Persidsky Y, 2006, BLOOD, V107, P4770, DOI 10.1182/blood-2005-11-4721; PLUTA R, 1989, J CEREBR BLOOD F MET, V9, P163, DOI 10.1038/jcbfm.1989.24; Polavarapu R, 2007, BLOOD, V109, P3270, DOI 10.1182/blood-2006-08-043125; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Remy S, 2006, BRAIN, V129, P18, DOI 10.1093/brain/awh682; Sandel W. R., 1982, INDOCYANINE GREEN IC; Sandoval KE, 2008, NEUROBIOL DIS, V32, P200, DOI 10.1016/j.nbd.2008.08.005; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shetty A, 2014, FRONTIERS CELLULAR N, V8; Skotak M, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00052; Skotak M, 2013, J NEUROTRAUM, V30, P1147, DOI 10.1089/neu.2012.2652; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Stokum JA, 2017, BEHAV BRAIN RES, V333, P43, DOI 10.1016/j.bbr.2017.06.038; Su EJ, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00385; Szmydynger-Chodobska J, 2010, J NEUROTRAUM, V27, P1449, DOI 10.1089/neu.2010.1331; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; WOLMAN M, 1981, ACTA NEUROPATHOL, V54, P55, DOI 10.1007/BF00691332; Yen LF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068595; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003; Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114	92	27	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 6	2018	8								8681	10.1038/s41598-018-26813-7			14	Multidisciplinary Sciences	Science & Technology - Other Topics	GI3DQ	WOS:000434252000017	29875451	DOAJ Gold, Green Published			2021-06-18	
J	Abeare, CA; Messa, I; Zuccato, BG; Merker, B; Erdodi, L				Abeare, Christopher A.; Messa, Isabelle; Zuccato, Brandon G.; Merker, Bradley; Erdodi, Laszlo			Prevalence of Invalid Performance on Baseline Testing for Sport-Related Concussion by Age and Validity Indicator	JAMA NEUROLOGY			English	Article							IMMEDIATE POST-CONCUSSION; TEST-RETEST RELIABILITY; HIGH-SCHOOL; NEUROPSYCHOLOGICAL ASSESSMENT; NEUROCOGNITIVE TESTS; CLINICAL UTILITY; IMPACT; MANAGEMENT; CHILDREN; PLAYERS	IMPORTANCE Estimated base rates of invalid performance on baseline testing (base rates of failure) for the management of sport-related concussion range from 6.1% to 40.0%, depending on the validity indicator used. The instability of this key measure represents a challenge in the clinical interpretation of test results that could undermine the utility of baseline testing. OBJECTIVES To determine the prevalence of invalid performance on baseline testing and to assess whether the prevalence varies as a function of age and validity indicator. DESIGN, SETTING, AND PARTICIPANTS This retrospective, cross-sectional study included data collected between January 1, 2012, and December 31, 2016, from a clinical referral center in the Midwestern United States. Participants included 7897 consecutively tested, equivalently proportioned male and female athletes aged 10 to 21 years, who completed baseline neurocognitive testing for the purpose of concussion management. INTERVENTIONS Baseline assessment was conducted with the Immediate Postconcussion Assessment and Cognitive Testing (ImPACT), a computerized neurocognitive test designed for assessment of concussion. MAIN OUTCOMES AND MEASURES Base rates of failure on published ImPACT validity indicators were compared within and across age groups. Hypotheses were developed after data collection but prior to analyses. RESULTS Of the 7897 study participants, 4086 (51.7%) were male, mean (SD) age was 14.71 (1.78) years, 7820 (99.0%) were primarily English speaking, and the mean (SD) educational level was 8.79 (1.68) years. The base rate of failure ranged from 6.4% to 47.6% across individual indicators. Most of the sample (55.7%) failed at least 1 of 4 validity indicators. The base rate of failure varied considerably across age groups (117 of 140 [83.6%] for those aged 10 years to 14 of 48 [29.2%] for those aged 21 years), representing a risk ratio of 2.86 (95% CI, 2.60-3.16; P < .001). CONCLUSIONS AND RELEVANCE The results for base rate of failure were surprisingly high overall and varied widely depending on the specific validity indicator and the age of the examinee. The strong age association, with 3 of 4 participants aged 10 to 12 years failing validity indicators, suggests that the clinical interpretation and utility of baseline testing in this age group is questionable. These findings underscore the need for close scrutiny of performance validity indicators on baseline testing across age groups.	[Abeare, Christopher A.; Messa, Isabelle; Zuccato, Brandon G.; Erdodi, Laszlo] Univ Windsor, Dept Psychol, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada; [Merker, Bradley] Henry Ford Hlth Syst, Dept Behav Hlth, Detroit, MI USA	Abeare, CA (corresponding author), Univ Windsor, Dept Psychol, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	cabeare@uwindsor.ca		Abeare, Christopher/0000-0002-7163-7434			An KY, 2017, CLIN NEUROPSYCHOL, V31, P193, DOI 10.1080/13854046.2016.1217046; Barth JT., 1989, MILD HEAD INJURY, P257; Bruce J, 2014, CLIN NEUROPSYCHOL, V28, P14, DOI 10.1080/13854046.2013.866272; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; De Marco AP, 2016, J CHILD NEUROL, V31, P68, DOI 10.1177/0883073814559645; DeRight J, 2015, CHILD NEUROPSYCHOL, V21, P1, DOI 10.1080/09297049.2013.864383; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Gaudet CE, 2017, CLIN NEUROPSYCHOL, V31, P43, DOI 10.1080/13854046.2016.1220622; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Higgins KL, 2017, ARCH CLIN NEUROPSYCH, V32, P259, DOI 10.1093/arclin/acw108; Iverson GL, 2015, BRAIN INJURY, V29, P263, DOI 10.3109/02699052.2014.965214; Kerr ZY, 2015, J ATHL TRAINING, V50, P1174, DOI 10.4085/1062-6050-50.11.11; Lichtenstein JD, 2018, CHILD NEUROPSYCHOL, V24, P247, DOI 10.1080/09297049.2016.1259402; Lichtenstein JD, 2017, CHILD NEUROPSYCHOL, V23, P284, DOI 10.1080/09297049.2015.1135422; Lichtenstein JD, 2014, AM J SPORT MED, V42, P479, DOI 10.1177/0363546513509225; Lovell M.R., 2016, IMPACT PEDIAT ADM IN; Lovell M.R., 2011, CLIN INTERPRETATION; Lovell MR., 2000, IMPACT IMMEDIATE POS; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Marvez A., FOX SPORTS; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Nelson LD, 2015, AM J SPORT MED, V43, P2018, DOI 10.1177/0363546515587714; Rabinowitz AR, 2016, J CLIN EXP NEUROPSYC, V38, P599, DOI 10.1080/13803395.2015.1123224; Randolph C, 2005, J ATHL TRAINING, V40, P139; Reilly R., ESPN; Resch JE, 2013, NEUROPSYCHOL REV, V23, P335, DOI 10.1007/s11065-013-9242-5; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Schatz P, 2012, J CLIN EXP NEUROPSYC, V34, P428, DOI 10.1080/13803395.2012.667789; Szabo AJ, 2013, J ATHL TRAINING, V48, P851, DOI 10.4085/1062-6050-48.6.20; Vaughan CG, 2014, AM J SPORT MED, V42, P1716, DOI 10.1177/0363546514531732; Welsh AJ, 2012, ARCH CLIN NEUROPSYCH, V27, P735, DOI 10.1093/arclin/acs063; West TA, 2014, J NEUROTRAUM, V31, P159, DOI 10.1089/neu.2013.3031	39	27	27	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	JUN	2018	75	6					697	703		10.1001/jamaneurol.2018.0031			7	Clinical Neurology	Neurosciences & Neurology	GI9JJ	WOS:000434840800010	29532050	Green Published, Bronze			2021-06-18	
J	Brennan, PM; Murray, GD; Teasdale, GM				Brennan, Paul M.; Murray, Gordon D.; Teasdale, Graham M.			Simplifying the use of prognostic information in traumatic brain injury. Part 1: The GCS-Pupils score: an extended index of clinical severity	JOURNAL OF NEUROSURGERY			English	Article						Glasgow Coma Scale; head injury; traumatic brain injury; trauma; prognosis; pupil reactivity	GLASGOW COMA SCALE; SEVERE HEAD-INJURY; PREDICTION; VALIDATION; CONSCIOUSNESS; POPULATION; REFLEXES	OBJECTIVE Glasgow Coma Scale (GCS) scores and pupil responses are key indicators of the severity of traumatic brain damage. The aim of this study was to determine what information would be gained by combining these indicators into a single index and to explore the merits of different ways of achieving this. METHODS Information about early GCS scores, pupil responses, late outcomes on the Glasgow Outcome Scale, and mortality were obtained at the individual patient level by reviewing data from the CRASH (Corticosteroid Randomisation After Significant Head Injury; n = 9,045) study and the IMPACT (International Mission for Prognosis and Clinical Trials in TBI; n = 6855) database. These data were combined into a pooled data set for the main analysis. Methods of combining the Glasgow Coma Scale and pupil response data varied in complexity from using a simple arithmetic score (GCS score [range 3-15] minus the number of nonreacting pupils [0, 1, or 2]), which we call the GCS-Pupils score (GCS-P; range 1-15), to treating each factor as a separate categorical variable. The content of information about patient outcome in each of these models was evaluated using Nagelkerke's R-2. RESULTS Separately, the GCS score and pupil response were each related to outcome. Adding information about the pupil response to the GCS score increased the information yield. The performance of the simple GCS-P was similar to the performance of more complex methods of evaluating traumatic brain damage. The relationship between decreases in the GCS-P and deteriorating outcome was seen across the complete range of possible scores. The additional 2 lowest points offered by the GCS-Pupils scale (GCS-P 1 and 2) extended the information about injury severity from a mortality rate of 51% and an unfavorable outcome rate of 70% at GCS score 3 to a mortality rate of 74% and an unfavorable outcome rate of 90% at GCS-P 1. The paradoxical finding that GCS score 4 was associated with a worse outcome than GCS score 3 was not seen when using the GCS-P. CONCLUSIONS A simple arithmetic combination of the GCS score and pupillary response, the GCS-P, extends the information provided about patient outcome to an extent comparable to that obtained using more complex methods. The greater range of injury seventies that are identified and the smoothness of the stepwise pattern of outcomes across the range of scores may be useful in evaluating individual patients and identifying patient subgroups. The GCS-P may be a useful platform onto which information about other key prognostic features can be added in a simple format likely to be useful in clinical practice.	[Brennan, Paul M.] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland; [Murray, Gordon D.] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland; [Teasdale, Graham M.] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland	Brennan, PM (corresponding author), Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland.	paul.brennan@ed.ac.uk		Brennan, Paul/0000-0002-7347-830X			BARLOW P, 1986, NEUROSURGERY, V19, P989, DOI 10.1227/00006123-198612000-00014; BENZER A, 1991, LANCET, V338, P977, DOI 10.1016/0140-6736(91)91840-Q; BORN JD, 1988, ACTA NEUROCHIR, V91, P1, DOI 10.1007/BF01400520; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Brain Trauma Foundation American Association of Neurological Surgeons, 2000, MAN PROGN SEV TRAUM; Eken C, 2009, EUR J EMERG MED, V16, P29, DOI 10.1097/MEJ.0b013e32830346ab; JENNETT B, 1976, LANCET, V1, P1031; Latronico N, 2015, CRIT CARE MED, V43, P505, DOI 10.1097/CCM.0000000000000795; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Moore NA, 2013, BRIT J NEUROSURG, V27, P340, DOI 10.3109/02688697.2012.754402; Moskopp D, 1995, NEUROSURG REV, V18, P253, DOI 10.1007/BF00383876; MOULTON C, 1994, LANCET, V343, P1261, DOI 10.1016/S0140-6736(94)92155-5; Murray GD, 2018, J NEUROSURG, V128, P1621, DOI 10.3171/2017.12.JNS172782; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Nell V, 2000, ARCH PHYS MED REHAB, V81, P614, DOI 10.1053/mr.2000.3877; Osler T, 2016, INJURY, V47, P1879, DOI 10.1016/j.injury.2016.04.016; Peng J, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0508-9; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Reith FCM, 2017, INJURY, V48, P1932, DOI 10.1016/j.injury.2017.05.038; Reith FCM, 2016, INTENS CARE MED, V42, P3, DOI 10.1007/s00134-015-4124-3; Rotheray KR, 2012, RESUSCITATION, V83, P86, DOI 10.1016/j.resuscitation.2011.07.017; Royston P, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b604; Steyerberg EW, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001381; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; TEASDALE G, 1983, LANCET, V2, P678; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611	32	27	29	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2018	128	6					1612	1620		10.3171/2017.12.JNS172780			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GP2IM	WOS:000440653000002	29631516	Bronze			2021-06-18	
J	Oldham, JR; Difabio, MS; Kaminski, TW; Dewolf, RM; Howell, DR; Buckley, TA				Oldham, Jessie R.; Difabio, Melissa S.; Kaminski, Thomas W.; Dewolf, Ryan M.; Howell, David R.; Buckley, Thomas A.			Efficacy of Tandem Gait to Identify Impaired Postural Control after Concussion	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						MILD TRAUMATIC BRAIN INJURY; POSTURAL CONTROL; BALANCE; LOCOMOTION	ERROR SCORING SYSTEM; CONTROL DEFICITS; BALANCE CONTROL; ATHLETIC TRAINERS; BASE-LINE; PERFORMANCE; ADOLESCENTS; RECOVERY; TASK; INSTABILITY	Purpose: The purpose was to evaluate tandem gait (TG), Balance Error Scoring System (BESS), and modified Balance Error Scoring System (mBESS) performance acutely after concussion in collegiate student-athletes. In addition, we sought to evaluate the psychometric properties of TG, including minimal detectable change (MDC), sensitivity, and specificity. Methods: Seventy-six National Collegiate Athletic Association student-athletes performed TG and BESS tests: 38 acutely after concussion and 38 controls. Participants were tested at baseline (time 1) and again acutely after concussion, or the following year for controls (time 2). Ten controls, tested simultaneously by two researchers, established a TG interrater minimal detectable change. A 2 x 2 mixed-design ANOVA compared each outcome variable. An receiver operating characteristic curve analysis was used to evaluate sensitivity, specificity, and area under the curve (AUC). Result: There was a significant interaction (F = 8.757, P = 0.004) for TG whereby the concussion group was slower after concussion (10.59 +/- 1.53 vs 11.80 +/- 2.67 s), whereas there was no difference for controls (10.13 +/- 1.72 vs 9.93 +/- 1.85 s). There was no significant interaction for BESS (F = 0.235, P = 0.630) or mBESS (F = 0.007, P = 0.935). TG had a sensitivity of 0.632, a specificity of 0.605, and an AUC of 0.704. BESS had a sensitivity of 0.447, a specificity of 0.500, and an AUC of 0.508. mBESS had a sensitivity of 0.474, a specificity of 0.632, and an AUC of 0.535. Conclusions: Participants completed TG significantly slower after concussion, whereas no change across time was detected for controls. In contrast, BESS and mBESS performances were similar at both testing times in both groups. Our AUC analysis was acceptable for TG, but a failure for both BESS and mBESS; thus, TG may be a useful alternative for clinicians conducting postconcussion postural control assessments.	[Oldham, Jessie R.; Difabio, Melissa S.; Kaminski, Thomas W.; Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE USA; [Difabio, Melissa S.; Buckley, Thomas A.] Univ Delaware, Biomech & Movement Sci, Newark, DE USA; [Dewolf, Ryan M.] MassGen Hosp Children, Sports Concuss Clin, Boston, MA USA; [Howell, David R.] Univ Colorado, Dept Orthoped, Sch Med, Sports Med Ctr,Colorado Childrens Hosp, Aurora, CO USA	Buckley, TA (corresponding author), Univ Delaware, Human Performance Lab, 541 South Coll Ave, Newark, DE 19716 USA.	Tbuckley@udel.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150; Oldham, Jessie/0000-0003-2801-2110	Grand Alliance Concussion Assessment, Research, and Education Consortium Clinical Study Core; National Collegiate Athletic Association; Department of DefenseUnited States Department of Defense	This study is supported by the Grand Alliance Concussion Assessment, Research, and Education Consortium Clinical Study Core, which is jointly funded by the National Collegiate Athletic Association and the Department of Defense. There are no conflicts of interest associated with the authors of this study. The results of the present study do not constitute endorsement by the American College of Sports Medicine and are presented without fabrication, falsification, or data manipulation.	[Anonymous], 2013, Br J Sports Med, V47, P259; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Buckley TA, 2018, CLIN J SPORT MED, V28, P174, DOI 10.1097/JSM.0000000000000426; Buckley TA, 2017, ARCH PHYS MED REHAB, V98, P1962, DOI 10.1016/j.apmr.2017.05.002; Buckley TA, 2016, J SPORT HEALTH SCI, V5, P61, DOI 10.1016/j.jshs.2016.01.007; Buckley TA, 2015, J ATHL TRAINING, V50, P879, DOI 10.4085/1062-6050-50.7.04; Burk JM, 2013, CLIN J SPORT MED, V23, P312, DOI 10.1097/JSM.0b013e318285633f; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Docherty CL, 2006, CLIN J SPORT MED, V16, P203, DOI 10.1097/00042752-200605000-00003; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P848, DOI 10.1136/bjsports-2017-097506; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; Giorgetti M M, 1998, Physiother Res Int, V3, P274, DOI 10.1002/pri.150; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hanninen T, 2016, J SCI MED SPORT, V19, P636, DOI 10.1016/j.jsams.2015.08.005; Howell D, 2015, J BIOMECH, V48, P3364, DOI 10.1016/j.jbiomech.2015.06.014; Howell DR, 2017, J SCI MED SPORT, V20, P622, DOI 10.1016/j.jsams.2016.11.020; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Kammerlind AS, 2005, EUR J PHYSIOTHER, V7, P96, DOI 10.1080/14038190510010403; Kelly KC, 2014, J ATHL TRAINING, V49, P665, DOI 10.4085/1062-6050-49.3.25; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; Nelson LD, 2017, CLIN J SPORT MED, V27, P381, DOI 10.1097/JSM.0000000000000369; Oldham JR, 2017, SPORTS HEALTH, V9, P305, DOI 10.1177/1941738116680999; Oldham JR, 2016, GAIT POSTURE, V49, P437, DOI 10.1016/j.gaitpost.2016.07.327; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Rahn C, 2015, CLIN J SPORT MED, V25, P248, DOI 10.1097/JSM.0000000000000141; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Schneiders AG, 2008, BRIT J SPORT MED, V42, P1011, DOI 10.1136/bjsm.2007.041665; Schneiders AG, 2010, J SCI MED SPORT, V13, P196, DOI 10.1016/j.jsams.2009.05.004; Shumway-Cook A, 2007, MOTOR CONTROL THEORY, P74; Valovich TC, 2003, J ATHL TRAINING, V38, P51	38	27	27	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JUN	2018	50	6					1162	1168		10.1249/MSS.0000000000001540			7	Sport Sciences	Sport Sciences	GF8ZE	WOS:000432264300005	29315170				2021-06-18	
J	Shen, XM; Shen, SC; Li, J; Hu, Q; Nie, L; Tu, CJ; Wang, X; Poulsen, DJ; Orsburn, BC; Wang, JM; Qu, J				Shen, Xiaomeng; Shen, Shichen; Li, Jun; Hu, Qiang; Nie, Lei; Tu, Chengjian; Wang, Xue; Poulsen, David J.; Orsburn, Benjamin C.; Wang, Jianmin; Qu, Jun			IonStar enables high-precision, low-missing-data proteomics quantification in large biological cohorts	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						quantitative proteomics; label-free quantification; MS1 ion current-based methods; large-cohort analysis; missing data	DATA-INDEPENDENT ACQUISITION; FREE QUANTITATIVE PROTEOMICS; TRAUMATIC BRAIN-INJURY; SPECTROMETRY-BASED PROTEOMICS; RELATIVE PROTEIN ABUNDANCE; TANDEM MASS-SPECTROMETRY; LABEL-FREE; PEPTIDE QUANTIFICATION; BIOMARKER DISCOVERY; SHOTGUN PROTEOMICS	Reproducible quantification of large biological cohorts is critical for clinical/pharmaceutical proteomics yet remains challenging because most prevalent methods suffer from drastically declined commonly quantified proteins and substantially deteriorated quantitative quality as cohort size expands. MS2-based dataindependent acquisition approaches represent tremendous advancements in reproducible protein measurement, but often with limited depth. We developed IonStar, an MS1-based quantitative approach enabling in-depth, high-quality quantification of large cohorts by combining efficient/reproducible experimental procedures with unique data-processing components, such as efficient 3D chromatographic alignment, sensitive and selective direct ion current extraction, and stringent postfeature generation quality control. Compared with several popular label-free methods, IonStar exhibited far lower missing data (0.1%), superior quantitative accuracy/precision [similar to 5% intragroup coefficient of variation (CV)], the widest protein abundance range, and the highest sensitivity/specificity for identifying protein changes (< 5% false altered-protein discovery) in a benchmark sample set (n = 20). We demonstrated the usage of IonStar by a large-scale investigation of traumatic injuries and pharmacological treatments in rat brains (n = 100), quantifying > 7,000 unique protein groups (> 99.8% without missing data across the 100 samples) with a low false discovery rate (FDR), two or more unique peptides per protein, and high quantitative precision. IonStar represents a reliable and robust solution for precise and reproducible protein measurement in large cohorts.	[Shen, Xiaomeng; Shen, Shichen; Li, Jun; Tu, Chengjian; Qu, Jun] Univ Buffalo State Univ New York, Dept Pharmaceut Sci, Buffalo, NY 14214 USA; [Shen, Xiaomeng; Shen, Shichen; Li, Jun; Tu, Chengjian; Wang, Xue; Qu, Jun] Ctr Excellence Bioinformat Life Sci, Buffalo, NY 14203 USA; [Hu, Qiang; Wang, Jianmin] Roswell Pk Comprehens Canc Inst, Dept Biostat & Bioinformat, Buffalo, NY 14263 USA; [Nie, Lei] Shandong Univ, Sch Pharmaceut Sci, Jinan 250012, Shandong, Peoples R China; [Wang, Xue] Roswell Pk Comprehens Canc Inst, Dept Mol & Cellular Biophys, Buffalo, NY 14263 USA; [Poulsen, David J.] Univ Buffalo State Univ New York, Jacobs Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY 14203 USA; [Orsburn, Benjamin C.] Frederick Natl Lab Canc Res, Canc Res Technol Program, Frederick, MD 21701 USA	Qu, J (corresponding author), Univ Buffalo State Univ New York, Dept Pharmaceut Sci, Buffalo, NY 14214 USA.; Qu, J (corresponding author), Ctr Excellence Bioinformat Life Sci, Buffalo, NY 14203 USA.; Wang, JM (corresponding author), Roswell Pk Comprehens Canc Inst, Dept Biostat & Bioinformat, Buffalo, NY 14263 USA.; Orsburn, BC (corresponding author), Frederick Natl Lab Canc Res, Canc Res Technol Program, Frederick, MD 21701 USA.	orsburn@vt.edu; jianmin.wang@roswellpark.org; junqu@buffalo.edu	Nie, Lei/X-6803-2018; wang, xue/AAA-5490-2020	wang, xue/0000-0002-5267-6083; Tu, Chengjian/0000-0001-9589-5609	NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR001412] Funding Source: Medline		Bruderer R, 2015, MOL CELL PROTEOMICS, V14, P1400, DOI 10.1074/mcp.M114.044305; Carrillo B, 2010, BIOINFORMATICS, V26, P98, DOI 10.1093/bioinformatics/btp610; Chawade A, 2015, J PROTEOME RES, V14, P676, DOI 10.1021/pr500665j; Chen LN, 2016, MOL NEUROBIOL, V53, P5079, DOI 10.1007/s12035-015-9440-7; Chen YY, 2013, J PROTEOME RES, V12, P4111, DOI 10.1021/pr400438q; Control CD, 2014, PREV C TRAUM BRAIN I, P1; Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Domon B, 2010, NAT BIOTECHNOL, V28, P710, DOI 10.1038/nbt.1661; Filzmoser P, 2008, COMPUT STAT DATA AN, V52, P1694, DOI 10.1016/j.csda.2007.05.018; Gillet LC, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.O111.016717; Guo TN, 2015, NAT MED, V21, P407, DOI 10.1038/nm.3807; Higgs Richard E., 2008, V428, P209; Karpievitch YV, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S16-S5; Kim S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6277; Lazar C, 2016, J PROTEOME RES, V15, P1116, DOI 10.1021/acs.jproteome.5b00981; Licker V, 2014, PROTEOMICS, V14, P784, DOI 10.1002/pmic.201300342; Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563; Lopez MF, 2011, J PROTEOME RES, V10, P133, DOI 10.1021/pr100153j; Lott K, 2013, J PROTEOMICS, V91, P210, DOI 10.1016/j.jprot.2013.07.010; Ma ZQ, 2009, J PROTEOME RES, V8, P3872, DOI 10.1021/pr900360j; Mann M, 2001, ANNU REV BIOCHEM, V70, P437, DOI 10.1146/annurev.biochem.70.1.437; Margolin AA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007454; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Merl J, 2012, PROTEOMICS, V12, P1902, DOI 10.1002/pmic.201100549; Michalski A, 2011, J PROTEOME RES, V10, P1785, DOI 10.1021/pr101060v; Mischak H, 2007, PROTEOM CLIN APPL, V1, P148, DOI 10.1002/prca.200600771; Mueller LN, 2007, PROTEOMICS, V7, P3470, DOI 10.1002/pmic.200700057; Musunuri S, 2014, J PROTEOME RES, V13, P2056, DOI 10.1021/pr401202d; Nahnsen S, 2013, MOL CELL PROTEOMICS, V12, P549, DOI 10.1074/mcp.R112.025163; Nouri-Nigjeh E, 2014, ANAL CHEM, V86, P8149, DOI 10.1021/ac501380s; Park SK, 2008, NAT METHODS, V5, P319, DOI [10.1038/NMETH.1195, 10.1038/nmeth.1195]; Qian WJ, 2006, MOL CELL PROTEOMICS, V5, P1727, DOI 10.1074/mcp.M600162-MCP200; Rau TF, 2014, INT J MOL SCI, V15, P1402, DOI 10.3390/ijms15011402; Rau TF, 2014, EXP NEUROL, V253, P31, DOI 10.1016/j.expneurol.2013.12.001; Rifai N, 2006, NAT BIOTECHNOL, V24, P971, DOI 10.1038/nbt1235; Rost HL, 2014, NAT BIOTECHNOL, V32, P219, DOI 10.1038/nbt.2841; Sadygov RG, 2006, ANAL CHEM, V78, P8207, DOI 10.1021/ac060923y; Sandin M, 2014, BBA-PROTEINS PROTEOM, V1844, P29, DOI 10.1016/j.bbapap.2013.03.026; Schilling B, 2012, MOL CELL PROTEOMICS, V11, P202, DOI 10.1074/mcp.M112.017707; Searle BC, 2010, PROTEOMICS, V10, P1265, DOI 10.1002/pmic.200900437; Selevsek N, 2015, MOL CELL PROTEOMICS, V14, P739, DOI 10.1074/mcp.M113.035550; Shen SC, 2016, J PROTEOME RES, V15, P1702, DOI 10.1021/acs.jproteome.6b00137; Shen XM, 2017, J PROTEOME RES, V16, P2445, DOI 10.1021/acs.jproteome.7b00061; Shen XM, 2015, J PROTEOME RES, V14, P4147, DOI 10.1021/acs.jproteome.5b00200; Smith RD, 2002, PROTEOMICS, V2, P513, DOI 10.1002/1615-9861(200205)2:5<513::AID-PROT513>3.0.CO;2-W; Sturm M, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-163; Tabb DL, 2010, J PROTEOME RES, V9, P761, DOI 10.1021/pr9006365; Ting YS, 2017, NAT METHODS, V14, P903, DOI [10.1038/NMETH.4390, 10.1038/nmeth.4390]; Tsou CC, 2015, NAT METHODS, V12, P258, DOI [10.1038/NMETH.3255, 10.1038/nmeth.3255]; Tu CJ, 2014, J PROTEOME RES, V13, P5888, DOI 10.1021/pr5008224; Tu CJ, 2014, J PROTEOME RES, V13, P2069, DOI 10.1021/pr401206m; Vizcaino JA, 2016, NUCLEIC ACIDS RES, V44, pD447, DOI 10.1093/nar/gkv1145; Webb-Robertson BJM, 2015, J PROTEOME RES, V14, P1993, DOI 10.1021/pr501138h; Weisser H, 2017, J PROTEOME RES, V16, P2964, DOI 10.1021/acs.jproteome.7b00248; Weisser H, 2013, J PROTEOME RES, V12, P1628, DOI 10.1021/pr300992u; Zhang B, 2016, MOL CELL PROTEOMICS, V15, P1467, DOI 10.1074/mcp.O115.055475; Zybailov B, 2005, ANAL CHEM, V77, P6218, DOI 10.1021/ac050846r	58	27	27	3	9	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	MAY 22	2018	115	21					E4767	E4776		10.1073/pnas.1800541115			10	Multidisciplinary Sciences	Science & Technology - Other Topics	GG4JN	WOS:000432663000008	29743190	Bronze, Green Published			2021-06-18	
J	Walker, WC; Stromberg, KA; Marwitz, JH; Sima, AP; Agyemang, AA; Graham, KM; Harrison-Felix, C; Hoffman, JM; Brown, AW; Kreutzer, JS; Merchant, R				Walker, William C.; Stromberg, Katharine A.; Marwitz, Jennifer H.; Sima, Adam P.; Agyemang, Amma A.; Graham, Kristin M.; Harrison-Felix, Cynthia; Hoffman, Jeanne M.; Brown, Allen W.; Kreutzer, Jeffrey S.; Merchant, Randall			Predicting Long-Term Global Outcome after Traumatic Brain Injury: Development of a Practical Prognostic Tool Using the Traumatic Brain Injury Model Systems National Database	JOURNAL OF NEUROTRAUMA			English	Article						classification tree; functional outcome; Glasgow Outcome Scale; prognosis; traumatic brain injury classification tree	WORKING-AGE INDIVIDUALS; GLASGOW COMA SCALE; REHABILITATION; DISABILITY; TBI; INSTITUTE; TREE; REPRESENTATIVENESS; TRAJECTORIES; RELIABILITY	For patients surviving serious traumatic brain injury (TBI), families and other stakeholders often desire information on longterm functional prognosis, but accurate and easy-to-use clinical tools are lacking. We aimed to build utilitarian decision trees from commonly collected clinical variables to predict Glasgow Outcome Scale (GOS) functional levels at 1, 2, and 5 years after moderate-to-severe closed TBI. Flexible classification tree statistical modeling was used on prospectively collected data from the TBI-Model Systems (TBIMS) inception cohort study. Enrollments occurred at 17 designated, or previously designated, TBIMS inpatient rehabilitation facilities. Analysis included all participants with nonpenetrating TBI injured between January 1997 and January 2017. Sample sizes were 10,125 (year-1), 8,821 (year-2), and 6,165 (year-5) after cross-sectional exclusions (death, vegetative state, insufficient post-injury time, and unavailable outcome). In our final models, post-traumatic amnesia (PTA) duration consistently dominated branching hierarchy and was the lone injury characteristic significantly contributing to GOS predictability. Lower-order variables that added predictability were age, pre-morbid education, productivity, and occupational category. Generally, patient outcomes improved with shorter PTA, younger age, greater pre-morbid productivity, and higher pre-morbid vocational or educational achievement. Across all prognostic groups, the best and worst good recovery rates were 65.7% and 10.9%, respectively, and the best and worst severe disability rates were 3.9% and 64.1%. Predictability in test data sets ranged from C-statistic of 0.691 (year-1; confidence interval [CI], 0.675, 0.711) to 0.731 (year-2; CI,0.724, 0.738). In conclusion, we developed a clinically useful tool to provide prognostic information on long-term functional outcomes for adult survivors of moderate and severe closed TBI. Predictive accuracy for GOS level was demonstrated in an independent test sample. Length of PTA, a clinical marker of injury severity, was by far the most critical outcome determinant.	[Walker, William C.; Marwitz, Jennifer H.; Agyemang, Amma A.; Graham, Kristin M.; Kreutzer, Jeffrey S.; Merchant, Randall] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Box 980677, Richmond, VA 23298 USA; [Stromberg, Katharine A.; Sima, Adam P.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA USA; [Harrison-Felix, Cynthia] Craig Hosp, Traumat Brain Injury Model Syst Natl Data & Stat, Englewood, CO USA; [Hoffman, Jeanne M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Brown, Allen W.] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA	Walker, WC (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Box 980677, Richmond, VA 23298 USA.	william.walker@vcuhealth.org		Sima, Adam/0000-0001-8426-9987	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RHD089097A]; National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR)United States Department of Health & Human Services [90 DP0013]; NIDILRRUnited States Department of Health & Human Services [90AR5025]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD089097] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health (NIH) #RHD089097A.; The data contents for this manuscript were developed under a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR; grant number 90 DP0013). NIDILRR is a Center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS). Post-doctoral fellows were supported by NIDILRR grant number 90AR5025.	Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Bonds B, 2021, J NEUROTRAUM, V38, P1168, DOI 10.1089/neu.2014.3742; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P642; Centers for Disease Control and Prevention, 1988, BEH RISK FACT SURV S; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2015, ARCH PHYS MED REHAB, V96, pS209, DOI 10.1016/j.apmr.2015.03.026; Corrigan JD, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000020; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Cuthbert JP, 2015, ARCH PHYS MED REHAB, V96, P2128, DOI 10.1016/j.apmr.2015.07.020; Cuthbert JP, 2015, J HEAD TRAUMA REHAB, V30, P160, DOI 10.1097/HTR.0000000000000090; Cuthbert JP, 2012, J HEAD TRAUMA REHAB, V27, pE15, DOI 10.1097/HTR.0b013e31826da983; Dams-O'Connor K, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000073; Forslund MV, 2017, BRAIN INJURY, V31, P329, DOI 10.1080/02699052.2016.1255778; Hand DJ, 2001, MACH LEARN, V45, P171, DOI 10.1023/A:1010920819831; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; JENNETT B, 1975, LANCET, V1, P480; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kim H, 2001, J AM STAT ASSOC, V96, P589, DOI 10.1198/016214501753168271; Kothari S., 2006, BRAIN INJURY MED PRI, P529; Kreutzer JS, 2016, ARCH PHYS MED REHAB, V97, P708, DOI 10.1016/j.apmr.2015.12.003; Lefebvre H, 2012, BRAIN INJURY, V26, P1084, DOI 10.3109/02699052.2012.666364; Levi Y, 2013, J INT NEUROPSYCH SOC, V19, P664, DOI 10.1017/S1355617713000192; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Pretz CR, 2013, ARCH PHYS MED REHAB, V94, P2486, DOI 10.1016/j.apmr.2013.06.021; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Walker W.C., 2017, J NEUROL NEUROSUR PS, V81, P87; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Walker WC, 2015, J HEAD TRAUMA REHAB, V30, P231, DOI 10.1097/HTR.0000000000000127; West SL, 2011, NEUROREHABILITATION, V29, P1, DOI 10.3233/NRE-2011-0671; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2001, CURR PHARM DESIGN, V7, P1537, DOI 10.2174/1381612013397276	42	27	27	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2018	35	14					1587	1595		10.1089/neu.2017.5359		MAY 2018	9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GK9FP	WOS:000432412600001	29566600	Green Published, Bronze			2021-06-18	
J	Liu, ZM; Chen, QX; Chen, ZB; Tian, DF; Li, MC; Wang, JM; Wang, L; Liu, BH; Zhang, SQ; Li, F; Ye, H; Zhou, L				Liu, Zai-Ming; Chen, Qian-Xue; Chen, Zhi-Biao; Tian, Dao-Feng; Li, Ming-Chang; Wang, Jun-Min; Wang, Long; Liu, Bao-Hui; Zhang, Shen-Qi; Li, Fei; Ye, Hui; Zhou, Long			RIP3 deficiency protects against traumatic brain injury (TBI) through suppressing oxidative stress, inflammation and apoptosis: Dependent on AMPK pathway	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						Traumatic brain injury; RIP3; Inflammation; Oxidative stress; Apoptosis	CELL-DEATH; TNF-ALPHA; NECROPTOSIS; INHIBITOR; CANCER; AUTOPHAGY; ISCHEMIA; KINASE	Traumatic brain injury (TBI) is a leading cause of disability and mortality in young adults worldwide. The pathophysiology is not fully understood. Programmed necrosis (necroptosis) is a newly identified mechanism of cell death combining features of both apoptosis and necrosis. Receptor-interacting protein 3 (RIP3) plays an important role in programmed necrosis. However, the effect of RIP3-related pathway in TBI is little to be known. We attempted to explore the significance of RIP3 in regulating TBI in vivo. Significantly, TBI induced over-expression of RIP3 in the hippocampus of mice, as well as RIP1 and phosphorylated mixed lineage kinase domain-like protein (MLKL). Mice after TBI exhibited cognitive dysfunction and activation of glia cells, which were significantly attenuated by RIP3-knockout (KO). Moreover, inflammation and oxidative stress in hippocampus were markedly induced by TBI in wild type (WT) mice. Of note, the reduction of pro-inflammatory cytokines and oxidants was observed in RIP3-deficient mice, which was linked to the blockage of NLR pyrin domain containing 3 (NLRP3)/apoptosis-associated speck-like protein containing a CARD (ASC)/Caspase-1 and kelch-like ECH-associated protein 1 (Keap 1) pathways. Further, TBI induced hippocampus apoptosis, evidenced by the increase of cleaved Caspase-8/-3 and poly (ADP)-ribose polymerase (PARP) in WT mice, whereas being decreased by RIP3-knockout. In addition, RIP3 knockout led to phosphorylation of AMP-activated protein kinase a (AMPK alpha) in hippocampus of mice after TBI. And of note, the in vitro findings indicated that RIP3-ablation attenuated oxidative stress, inflammation and apoptosis in astrocytes, which was dependent on AMPK alpha activation. Together, suppressing RIP3 might be served as a therapeutic target against brain injury through inhibiting inflammation, oxidative stress and apoptosis. (C) 2018 Published by Elsevier Inc.	[Liu, Zai-Ming; Chen, Qian-Xue; Chen, Zhi-Biao; Tian, Dao-Feng; Li, Ming-Chang; Wang, Jun-Min; Wang, Long; Liu, Bao-Hui; Zhang, Shen-Qi; Li, Fei; Ye, Hui; Zhou, Long] Wuhan Univ, Renmin Hosp, Dept Neurosurg, Wuhan 430060, Hubei, Peoples R China	Chen, QX (corresponding author), Wuhan Univ, Renmin Hosp, Dept Neurosurg, Wuhan 430060, Hubei, Peoples R China.	chenqx666@sohu.com					Azzam EI, 2012, CANCER LETT, V327, P48, DOI 10.1016/j.canlet.2011.12.012; Hardie DG, 2014, PHYSIOLOGY, V29, P99, DOI 10.1152/physiol.00050.2013; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Ibrahim AS, 2010, MOL VIS, V16, P2033; Jin CC, 2010, J CLIN IMMUNOL, V30, P628, DOI 10.1007/s10875-010-9440-3; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452; Li JX, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.241; Linkermann A, 2013, AM J TRANSPLANT, V13, P2797, DOI 10.1111/ajt.12448; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Liu HC, 2012, BRAIN RES, V1474, P73, DOI 10.1016/j.brainres.2012.07.028; Liu XN, 2014, MOL CANCER THER, V13, P596, DOI 10.1158/1535-7163.MCT-13-0579; Meng LJ, 2015, P NATL ACAD SCI USA, V112, P11007, DOI 10.1073/pnas.1514730112; Metzig MO, 2016, ONCOGENE, V35, P3399, DOI 10.1038/onc.2015.398; Murphy JM, 2014, EMBO REP, V15, P155, DOI 10.1002/embr.201337970; O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862; Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x; Philipp S, 2016, CELL MOL LIFE SCI, V73, P2183, DOI 10.1007/s00018-016-2193-2; Ren JM, 2017, CELL MOL IMMUNOL, V14, P639, DOI 10.1038/cmi.2017.31; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Su ZY, 2015, ONCOTARGET, V6, P8474, DOI 10.18632/oncotarget.3523; Vandenabeele P, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3115re4; Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138; Vince JE, 2012, IMMUNITY, V36, P215, DOI 10.1016/j.immuni.2012.01.012; Vincent EE, 2015, ONCOGENE, V34, P3627, DOI 10.1038/onc.2014.301; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Yabal M, 2014, CELL REP, V7, P1796, DOI 10.1016/j.celrep.2014.05.008; Yu XF, 2015, ONCOTARGET, V6, P1995, DOI 10.18632/oncotarget.3038; Zhang HS, 2012, LIFE SCI, V90, P747, DOI 10.1016/j.lfs.2012.03.013; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	31	27	29	4	20	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	MAY 5	2018	499	2					112	119		10.1016/j.bbrc.2018.02.150			8	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	GD0AF	WOS:000430159400003	29470982				2021-06-18	
J	Krasny-Pacini, A; Evans, J				Krasny-Pacini, Agata; Evans, Jonathan			Single-case experimental designs to assess intervention effectiveness in rehabilitation: A practical guide	ANNALS OF PHYSICAL AND REHABILITATION MEDICINE			English	Article						Methodology; Single-case; Multiple baseline; Alternating treatment; Rehabilitation	COGNITIVE-BEHAVIORAL SUPPORTS; TRAINING VISUAL ANALYSIS; TRAUMATIC BRAIN-INJURY; N-OF-1 TRIALS; SUBJECT DESIGNS; TREATMENT FIDELITY; YOUNG-CHILDREN; SYSTEMATIC EVALUATION; RANDOMIZATION TESTS; CONSORT EXTENSION	Single-case experimental designs (SCED) are experimental designs aiming at testing the effect of an intervention using a small number of patients (typically one to three), using repeated measurements, sequential (+/- randomized) introduction of an intervention and method-specific data analysis, including visual analysis and specific statistics. The aim of this paper is to familiarise professionals working in different fields of rehabilitation with SCEDs and provide practical advice on how to design and implement a SCED in clinical rehabilitation practice. Research questions suitable for SCEDs and the different types of SCEDs (e.g., alternating treatment designs, introduction/withdrawal designs and multiple baseline designs) are reviewed. Practical steps in preparing a SCED design are outlined. Examples from different rehabilitation domains are provided throughout the paper. Challenging issues such as the choice of the repeated measure, assessment of generalisation, randomization, procedural fidelity, replication and generalizability of findings are discussed. Simple rules and resources for data analysis are presented. The utility of SCEDs in physical and rehabilitation medicine (PRM) are discussed. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Krasny-Pacini, Agata] Inst Univ Readaptat Clemenceau Strasbourg, 45 Blvd Clemenceau, F-67082 Strasbourg, France; [Krasny-Pacini, Agata] CHU Strasbourg, Hop Hautepierre, Serv Chirurg Orthoped Infantile, Ave Moliere, F-67098 Strasbourg, France; [Krasny-Pacini, Agata] Hop Univ Pitie Salpetiere, GRC Handicap Cognitif & Readaptat HanCRe, F-75013 Paris, France; [Evans, Jonathan] Univ Glasgow, Acad Ctr, Gartnavel Royal Hosp, Inst Hlth & Wellbeing, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland	Krasny-Pacini, A (corresponding author), Inst Univ Readaptat Clemenceau Strasbourg, 45 Blvd Clemenceau, F-67082 Strasbourg, France.	Agata.krasny@ugecam-alsace.fr					Aarts AA, 2015, SCIENCE, V349, DOI 10.1126/science.aac4716; Arco L, 2008, NEUROPSYCHOL REHABIL, V18, P109, DOI 10.1080/09602010701656706; Baldwin VN, 2015, NEUROPSYCHOL REHABIL, V25, P617, DOI 10.1080/09602011.2014.956764; Blyth KM, 2017, DISABIL REHABIL, V39, P2215, DOI 10.1080/09638288.2016.1219400; Boman IL, 2010, DISABIL REHABIL-ASSI, V5, P339, DOI 10.3109/17483100903131777; Borrelli B, 2005, J CONSULT CLIN PSYCH, V73, P852, DOI 10.1037/0022-006X.73.5.852; Borrelli B, 2011, J PUBLIC HEALTH DENT, V71, pS52, DOI 10.1111/j.1752-7325.2011.00233.x; Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475; Byiers BJ, 2012, AM J SPEECH-LANG PAT, V21, P397, DOI 10.1044/1058-0360(2012/11-0036); Carey LM, 2005, AM J PHYS MED REHAB, V84, P428, DOI 10.1097/01.PHM.0000159971.12096.7F; Chang YJ, 2011, RES DEV DISABIL, V32, P2669, DOI 10.1016/j.ridd.2011.06.006; Cohen LL, 2014, J PEDIATR PSYCHOL, V39, P124, DOI 10.1093/jpepsy/jst065; Cokera P, 2009, NEUROREHABILITATION, V24, P199, DOI 10.3233/NRE-2009-0469; Cosbey J, 2017, J AUTISM DEV DISORD, V47, P564, DOI 10.1007/s10803-016-2977-0; Dallery J, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2227; DIAMOND MF, 1990, PHYS THER, V70, P423, DOI 10.1093/ptj/70.7.423; Ducharme JM, 2002, J EMOT BEHAV DISORD, V10, P241, DOI 10.1177/10634266020100040601; Evans JJ, 2014, NEUROPSYCHOL REHABIL, V24, P305, DOI 10.1080/09602011.2014.903198; Feeney T, 2006, BRAIN INJURY, V20, P629, DOI 10.1080/02699050600744194; Feeney TJ, 2008, J POSIT BEHAV INTERV, V10, P115, DOI 10.1177/1098300707312540; Feeney TJ, 2010, J HEAD TRAUMA REHAB, V25, P416, DOI 10.1097/HTR.0b013e3181fbc0a2; Feeney TJ, 2003, J HEAD TRAUMA REHAB, V18, P33, DOI 10.1097/00001199-200301000-00006; Ferland MB, 2013, BRAIN INJURY, V27, P1461, DOI 10.3109/02699052.2013.823661; Ferreira JJ, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00027; Ferron J, 2003, J EXP EDUC, V71, P267, DOI 10.1080/00220970309602066; Ferron J, 2006, J EXP EDUC, V75, P66, DOI 10.3200/JEXE.75.1.66-81; Fisher WW, 2003, J APPL BEHAV ANAL, V36, P387, DOI 10.1901/jaba.2003.36-387; Gast DL, 2009, SINGLE SUBJECT RES M, P110; Geist K, 2014, J MUSIC THER, V51, P293, DOI 10.1093/jmt/thu032; Gharebaghy S, 2015, PHYS OCCUP THER PEDI, V35, P13, DOI 10.3109/01942638.2014.957428; Goh AE, 2012, REM SPEC EDUC, V33, P271, DOI 10.1177/0741932510383990; Gorczynski P, 2013, J APPL SPORT PSYCHOL, V25, P148, DOI 10.1080/10413200.2012.664606; Graham JE, 2012, ARCH PHYS MED REHAB, V93, pS111, DOI 10.1016/j.apmr.2011.12.017; GUYATT GH, 1990, CONTROL CLIN TRIALS, V11, P88, DOI 10.1016/0197-2456(90)90003-K; Haegele JA, 2015, ADAPT PHYS ACT Q, V32, P285, DOI 10.1123/APAQ.2014-0211; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P824, DOI 10.1080/09602010902995945; Heinicke MR, 2014, BEHAV INTERVENT, V29, P77, DOI 10.1002/bin.1380; Heyvaert M, 2014, NEUROPSYCHOL REHABIL, V24, P507, DOI 10.1080/09602011.2013.818564; Hoogeboom TJ, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001161; Horner RH, 2005, EXCEPT CHILDREN, V71, P165, DOI 10.1177/001440290507100203; Johnston MV, 2010, OTJR-OCCUP PART HEAL, V30, P4, DOI 10.3928/15394492-20091214-02; Kirsch NL, 2004, REHABIL PSYCHOL, V49, P200, DOI 10.1037/0090-5550.49.3.200; Krasny-Pacini A, 2014, J HEAD TRAUMA REHAB, V29, pE49, DOI 10.1097/HTR.0000000000000015; Kratochwill TR, 2013, REM SPEC EDUC, V34, P26, DOI 10.1177/0741932512452794; Kratochwill TR, 2010, PSYCHOL METHODS, V15, P124, DOI 10.1037/a0017736; Lane Justin D, 2017, Am J Occup Ther, V71, p7102300010p1, DOI 10.5014/ajot.2017.022210; Lane JD, 2014, NEUROPSYCHOL REHABIL, V24, P445, DOI 10.1080/09602011.2013.815636; Lane K, 2007, J BEHAV EDUC, V16, P224, DOI 10.1007/s10864-006-9036-4; Lanovaz MJ, 2017, J APPL BEHAV ANAL, V50, P662, DOI 10.1002/jaba.394; Ledford JR, 2014, NEUROPSYCHOL REHABIL, V24, P332, DOI 10.1080/09602011.2013.861352; Levin JR, 2018, DEV NEUROREHABIL, V21, P290, DOI 10.1080/17518423.2016.1197708; Logan KR, 1998, J ASSOC PERS SEVERE, V23, P309, DOI 10.2511/rpsd.23.4.309; Logan LR, 2008, DEV MED CHILD NEUROL, V50, P99, DOI 10.1111/j.1469-8749.2007.02005.x; Lui M, 2012, DISABIL REHABIL-ASSI, V7, P82, DOI 10.3109/17483107.2011.557467; Maggin DM, 2011, J SCHOOL PSYCHOL, V49, P529, DOI 10.1016/j.jsp.2011.05.001; Manolov R, 2017, BEHAV MODIF, V41, P179, DOI 10.1177/0145445516664307; Manolov R, 2017, BEHAV THER, V48, P97, DOI 10.1016/j.beth.2016.04.008; Manolov R, 2014, NEUROPSYCHOL REHABIL, V24, P634, DOI 10.1080/09602011.2014.903199; Mattacola CG, 1997, J ATHL TRAINING, V32, P127; McKerracher G, 2005, NEUROPSYCHOL REHABIL, V15, P115, DOI 10.1080/09602010443000056; Moss A, 2006, STROKE, V37, P3043, DOI 10.1161/01.STR.0000249427.74970.15; NAGANUMA GM, 1988, PHYS THER, V68, P664, DOI 10.1093/ptj/68.5.664; Nikles CJ, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-54; Nikles J, 2017, NEUROREHABILITATION, V40, P11, DOI 10.3233/NRE-161386; Normand MP, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00934; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Onghena P, 2005, CLIN J PAIN, V21, P56, DOI 10.1097/00002508-200501000-00007; Onghena P, 2005, CLIN J PAIN, V21, P69; Parker RI, 2009, BEHAV THER, V40, P357, DOI 10.1016/j.beth.2008.10.006; Perdices M, 2009, NEUROPSYCHOL REHABIL, V19, P904, DOI 10.1080/09602010903040691; PFADT A, 1995, J APPL BEHAV ANAL, V28, P349, DOI 10.1901/jaba.1995.28-349; Raymer AM, 2007, NEUROPSYCHOL REHABIL, V17, P244, DOI 10.1080/09602010600814661; Romeiser-Logan L, 2017, DEV MED CHILD NEUROL, V59, P574, DOI 10.1111/dmcn.13405; Schulz FK, 2010, BMJ-BRIT MED J, DOI [10.1136/bmj.c332340, DOI 10.1136/BMJ.C332340]; Shadish, 2010, SINGLE CASE DESIGNS; Shadish WR, 2011, BEHAV RES METHODS, V43, P971, DOI 10.3758/s13428-011-0111-y; Shamseer L, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1793; Shelton JD, 2014, GLOB HEALTH-SCI PRAC, V2, P253, DOI 10.9745/GHSP-D-14-00066; Smith JD., 2012, PSYCHOL METH, V17; Spillane V, 2007, J ADV NURS, V60, P343, DOI 10.1111/j.1365-2648.2007.04386.x; Sumitani M, 2007, NEUROLOGY, V68, P128, DOI 10.1212/01.wnl.0000250242.99683.57; Sunderland A, 2006, NEUROPSYCHOL REHABIL, V16, P666, DOI 10.1080/09602010500204385; Svoboda E, 2012, NEUROPSYCHOL REHABIL, V22, P408, DOI 10.1080/09602011.2011.652498; Tarlow KR, 2017, BEHAV MODIF, V41, P427, DOI 10.1177/0145445516676750; Tate R. L., 2016, ARCH SCI PSYCHOL, V4, P10, DOI [10.1037/arc0000027, DOI 10.1037/ARC0000027]; Tate RL, 2008, NEUROPSYCHOL REHABIL, V18, P385, DOI 10.1080/09602010802009201; Tate RL, 2017, NEUROPSYCHOL REHABIL, V27, P1, DOI 10.1080/09602011.2016.1190533; Tate RL, 2013, NEUROPSYCHOL REHABIL, V23, P619, DOI 10.1080/09602011.2013.824383; Ten Berge SR, 2012, CLIN REHABIL, V26, P362, DOI 10.1177/0269215511411936; Tunnard C, 2014, NEUROPSYCHOL REHABIL, V24, P382, DOI 10.1080/09602011.2013.872041; Vohra S, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1738; Wehmeyer ML, 2006, J VOCAT REHABIL, V24, P81; Wolfe K, 2015, J APPL BEHAV ANAL, V48, P472, DOI 10.1002/jaba.212; World Health Organization, 2001, INT CLASS FUNCT DIS; Young ND, 2016, J BEHAV EDUC, V25, P95, DOI 10.1007/s10864-015-9234-z	95	27	27	2	11	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	1877-0657	1877-0665		ANN PHYS REHABIL MED	Ann. Phys. Rehabil. Med.	MAY	2018	61	3					164	179		10.1016/j.rehab.2017.12.002			16	Rehabilitation	Rehabilitation	GG1CX	WOS:000432418300008	29253607	Green Accepted, Bronze			2021-06-18	
J	Saw, R; Finch, CF; Samra, D; Baquie, P; Cardoso, T; Hope, D; Orchard, JW				Saw, Richard; Finch, Caroline F.; Samra, David; Baquie, Peter; Cardoso, Tanusha; Hope, Danielle; Orchard, John W.			Injuries in Australian Rules Football: An Overview of Injury Rates, Patterns, and Mechanisms Across All Levels of Play	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						AFL; injury prevention; injury surveillance	CRUCIATE LIGAMENT INJURIES; QUADRICEPS MUSCLE STRAINS; COMMUNITY-LEVEL; PROFESSIONAL FOOTBALL; SURVEILLANCE SYSTEM; HAMSTRING INJURIES; CONCUSSION; EPIDEMIOLOGY; LEAGUE; PREVENTION	Context: The nature of Australian rules football (Australian football) predisposes both unique and common injuries compared with those sustained in other football codes. The game involves a combination of tackling, kicking, high-speed running (more than other football codes), and jumping. Two decades of injury surveillance has identified common injuries at the professional level (Australian Football League [AFL]). Objective: To provide an overview of injuries in Australian rules football, including injury rates, patterns, and mechanisms across all levels of play. Study Design: A narrative review of AFL injuries, football injury epidemiology, and biomechanical and physiological attributes of relevant injuries. Results: The overall injury incidence in the 2015 season was 41.7 injuries per club per season, with a prevalence of 156.2 missed games per club per season. Lower limb injuries are most prevalent, with hamstring strains accounting for 19.1 missed games per club per season. Hamstring strains relate to the volume of high-speed running required in addition to at times having to collect the ball while running in a position of hip flexion and knee extension. Anterior cruciate ligament injuries are also prevalent and can result from contact and noncontact incidents. In the upper limb, shoulder sprains and dislocations account for 11.5 missed games per club per season and largely resulted from tackling and contact. Concussion is less common in AFL than other tackling sports but remains an important injury, which has notably become more prevalent in recent years, theorized to be due to a more conservative approach to management. Although there are less injury surveillance data for non-AFL players (women, community-level, children), many of these injuries appear to also be common across all levels of play. Clinical Relevance: An understanding of injury profiles and mechanisms in Australian football is crucial in identifying methods to reduce injury risk and prepare players for the demands of the game.	[Saw, Richard; Baquie, Peter] Olymp Pk Sports Med Ctr, Olymp Blvd,AAMI Pk, Melbourne, Vic 3004, Australia; [Finch, Caroline F.] Federat Univ Australia, Australian Collaborat Res Injury Sport & Prevent, Ballarat, Vic, Australia; [Samra, David] Stadium Sports Med Clin, Sydney, NSW, Australia; [Cardoso, Tanusha] Alphington Sports Med Clin, Melbourne, Vic, Australia; [Hope, Danielle] Peak Sports Med Clin, Melbourne, Vic, Australia; [Orchard, John W.] Univ Sydney, Sch Publ Hlth, Sydney, NSW, Australia	Saw, R (corresponding author), Olymp Pk Sports Med Ctr, Olymp Blvd,AAMI Pk, Melbourne, Vic 3004, Australia.	richard.saw@gmail.com	Orchard, John W/AAY-7216-2020	Orchard, John W/0000-0003-3530-1711			Australian Football League, 2016, AFL PLAYER MATCH STA; Australian Football League, 2015, AFL INJ SURV 2015; Australian Football League, 2016, LAWS AUSTR FOOTB; Australian Football League, 2015, AUSTR FOOTB LEAG ANN; Bradley T, 2009, BRIT J SPORT MED, V43, P735, DOI 10.1136/bjsm.2008.049858; Braham R, 2004, J SCI MED SPORT, V7, P451, DOI 10.1016/S1440-2440(04)80263-9; Braham R, 2004, J SCI MED SPORT, V7, P96, DOI 10.1016/S1440-2440(04)80048-3; Brukner P, 2016, BRIT J SPORT MED, V50, P205, DOI 10.1136/bjsports-2015-095136; Cochrane JL, 2007, J SCI MED SPORT, V10, P96, DOI 10.1016/j.jsams.2006.05.015; Comin J, 2013, AM J SPORT MED, V41, P111, DOI 10.1177/0363546512463679; Crichton J, 2012, BRIT J SPORT MED, V46, P538, DOI 10.1136/bjsports-2011-090688; Cross TM, 2004, AM J SPORT MED, V32, P710, DOI 10.1177/0363546503261734; Davis G, 2016, J SCI MED SPORT, V19, P898, DOI 10.1016/j.jsams.2016.02.005; Dick R, 2007, J ATHL TRAINING, V42, P221; Donaldson A, 2016, AM J LIFESTYLE MED, V10, P120, DOI 10.1177/1559827614538751; Duhig S, 2016, BRIT J SPORT MED, V50, P1536, DOI 10.1136/bjsports-2015-095679; Ekegren CL, 2015, J SCI MED SPORT, V18, P651, DOI 10.1016/j.jsams.2014.11.390; Ekegren CL, 2015, CLIN J SPORT MED, V25, P162, DOI 10.1097/JSM.0000000000000108; Ekstrand J, 2011, BRIT J SPORT MED, V45, P553, DOI 10.1136/bjsm.2009.060582; Ekstrand J, 2011, AM J SPORT MED, V39, P1226, DOI 10.1177/0363546510395879; EPRISP, 2016, ENGL PROF RUGB INJ S; Finch C, 2006, J SCI MED SPORT, V9, P3, DOI 10.1016/j.jsams.2006.02.009; Finch CF, 2017, AM J SPORT MED, V45, P1921, DOI 10.1177/0363546517691943; Finch CF, 2016, INJURY PREV, V22, P123, DOI 10.1136/injuryprev-2015-041667; Finch CF, 2013, CLIN J SPORT MED, V23, P430, DOI 10.1097/JSM.0b013e31829aa3e8; Finch CF, 2013, MED J AUSTRALIA, V198, P427, DOI 10.5694/mja12.11217; Fortington L. V., 2016, BMJ OPEN SPORT EXERC, V2; Fortington Lauren V, 2015, Inj Epidemiol, V2, P20; Fortington LV, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159008; Gabbe B, 2002, J SCI MED SPORT, V5, P149, DOI 10.1016/S1440-2440(02)80036-6; Gibbs NJ, 2004, J SCI MED SPORT, V7, P248, DOI 10.1016/S1440-2440(04)80016-1; Grimmer K, 2003, J SCI MED SPORT, V6, P328, DOI 10.1016/S1440-2440(03)80026-9; Headey J, 2007, AM J SPORT MED, V35, P1537, DOI 10.1177/0363546507300691; Janssen KW, 2012, SCAND J MED SCI SPOR, V22, P495, DOI 10.1111/j.1600-0838.2010.01253.x; Kemp JL, 2016, J SCI MED SPORT, V19, P305, DOI 10.1016/j.jsams.2015.03.010; Kreisfeld R., 2014, AUSTR SPORTS INJURY; Makdissi M, 2016, J SCI MED SPORT, V19, P859, DOI 10.1016/j.jsams.2016.02.015; Marovic P, 2016, ASPETAR SPORTS MED J, V5, P364; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLaren SJ, 2016, J SCI MED SPORT, V19, P493, DOI 10.1016/j.jsams.2015.05.010; MCMAHON KA, 1993, MED J AUSTRALIA, V159, P301, DOI 10.5694/j.1326-5377.1993.tb137864.x; Mitchell B, 2000, J Sci Med Sport, V3, P30, DOI 10.1016/S1440-2440(00)80045-6; Mohr M, 2003, J SPORT SCI, V21, P519, DOI 10.1080/0264041031000071182; Norton K, 2001, BRIT J SPORT MED, V35, P418, DOI 10.1136/bjsm.35.6.418; Norton K I, 1999, J Sci Med Sport, V2, P389, DOI 10.1016/S1440-2440(99)80011-5; NRL, 2016, NRL TELSTR PREM CLUB; O rchard J, 2000, AUSTR TURFGRASS MANA, V23, P36; Orchard J, 2002, BRIT J SPORT MED, V36, P39, DOI 10.1136/bjsm.36.1.39; Orchard J, 2001, AM J SPORT MED, V29, P196, DOI 10.1177/03635465010290021301; Orchard J, 2014, AFL INJURY SURVEY 20; Orchard J, 2013, AFL INJURY SURVEY 20; Orchard J, 2009, SPORT HLTH, V27, P38; Orchard J., 2008, SPORT HLTH, V26, P17; Orchard JW, 2009, BRIT J SPORT MED, V43, P1026, DOI 10.1136/bjsm.2009.063123; Orchard JW, 2013, OPEN ACCESS J SPORTS, V4, P251, DOI 10.2147/OAJSM.S52417; Orchard JW, 2013, AM J SPORT MED, V41, P734, DOI 10.1177/0363546513476270; Orchard JW, 2005, BRIT J SPORT MED, V39, P704, DOI 10.1136/bjsm.2004.017756; Orchard JW, 2014, MINERVA ORTOP TRAUMA, V65, P355; Romiti M, 2008, BRIT J SPORT MED, V42, P441, DOI 10.1136/bjsm.2007.042721; Shawdon A, 1994, Aust J Sci Med Sport, V26, P59; Tannenbaum EP, 2013, CLIN SPORT MED, V32, P781, DOI 10.1016/j.csm.2013.07.011; Tsikouris G, 2011, BRIT J SPORT MED, V45, pe2; Twomey DM, 2012, J SCI MED SPORT, V15, P305, DOI 10.1016/j.jsams.2011.12.003; Verrall MG, 2014, ASIAN J SPORTS MED, V5; Walden M, 2013, SCAND J MED SCI SPOR, V23, P424, DOI 10.1111/j.1600-0838.2011.01409.x; Waterworth G, 2017, SKELETAL RADIOL, V46, P343, DOI 10.1007/s00256-016-2564-7; White Peta E, 2016, BMJ Open Sport Exerc Med, V2, pe000169, DOI 10.1136/bmjsem-2016-000169; White PE, 2014, BRIT J SPORT MED, V48, P119, DOI 10.1136/bjsports-2013-092785; Wisbey B, 2016, QUANTIFYING CHANGES; Woods C, 2004, BRIT J SPORT MED, V38, P36, DOI 10.1136/bjsm.2002.002352	70	27	27	0	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	MAY-JUN	2018	10	3					208	216		10.1177/1941738117726070			9	Sport Sciences	Sport Sciences	GF7DH	WOS:000432127700003	28825878	Green Published			2021-06-18	
J	Laksari, K; Kurt, M; Babaee, H; Kleiven, S; Camarillo, D				Laksari, Kaveh; Kurt, Mehmet; Babaee, Hessam; Kleiven, Svein; Camarillo, David			Mechanistic Insights into Human Brain Impact Dynamics through Modal Analysis	PHYSICAL REVIEW LETTERS			English	Article							HEAD IMPACT; UNREPORTED CONCUSSION; CEREBRAL CONCUSSION; SHEAR-WAVES; INJURY; DEFORMATION; MODEL; ACCELERATION; DECOMPOSITION; EPIDEMIOLOGY	Although concussion is one of the greatest health challenges today, our physical understanding of the cause of injury is limited. In this Letter, we simulated football head impacts in a finite element model and extracted the most dominant modal behavior of the brain's deformation. We showed that the brain's deformation is most sensitive in low frequency regimes close to 30 Hz, and discovered that for most subconcussive head impacts, the dynamics of brain deformation is dominated by a single global mode. In this Letter, we show the existence of localized modes and multimodal behavior in the brain as a hyperviscoelastic medium. This dynamical phenomenon leads to strain concentration patterns, particularly in deep brain regions, which is consistent with reported concussion pathology.	[Laksari, Kaveh] Univ Arizona, Dept Bioemed Engn, Tucson, AZ USA; [Kurt, Mehmet] Stevens Inst Technol, Dept Mech Engn, Hoboken, NJ 07030 USA; [Babaee, Hessam] Univ Pittsburgh, Dept Mech Engn & Mat Sci, Pittsburgh, PA 15261 USA; [Kleiven, Svein] KTH Royal Inst Technol, Div Neuron Engn, S-11428 Huddinge, Sweden; [Camarillo, David] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA	Kurt, M (corresponding author), Stevens Inst Technol, Dept Mech Engn, Hoboken, NJ 07030 USA.	mkurt@stevens.edu		Kurt, Mehmet/0000-0002-5618-0296	Child Health Research Institute through the Thrasher Early Career Award; Lucile Packard Foundation for Children's Health through the Thrasher Early Career Award; Stanford CTSA through the Thrasher Early Career Award [UL1 TR001085]; Thrasher Research Foundation through the Thrasher Early Career Award; National Institutes of Health (NIH) National Institute of Bio-medical Imaging and Bioengineering (NIBIB)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [3R21EB01761101S1]	This research was supported by Child Health Research Institute, Lucile Packard Foundation for Children's Health, Stanford CTSA (UL1 TR001085) and Thrasher Research Foundation, who funded this work through the Thrasher Early Career Award. This study was also partially supported by the National Institutes of Health (NIH) (Grant No. 3R21EB01761101S1) National Institute of Bio-medical Imaging and Bioengineering (NIBIB) 3R21EB01761101S1. We also thank Dr. Andrew Knutsen and Dr. Philip Bayly for sharing the MRI data.	Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Chen KK, 2012, J NONLINEAR SCI, V22, P887, DOI 10.1007/s00332-012-9130-9; Clayton EH, 2012, J R SOC INTERFACE, V9, P2899, DOI 10.1098/rsif.2012.0325; Coats B, 2012, INT J DEV NEUROSCI, V30, P191, DOI 10.1016/j.ijdevneu.2011.12.009; Costa M, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.198102; Cramer MS, 2003, J ACOUST SOC AM, V114, P1821, DOI 10.1121/1.1610460; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Garrick JG, 2005, CLIN J SPORT MED, V15, P385, DOI 10.1097/01.jsm.0000181438.48892.1b; Giammarinaro B, 2018, PHYS REV APPL, V9, DOI 10.1103/PhysRevApplied.9.014011; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Giordano C., 2014, 2014220002 SAE; Grilli M, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.174501; Grilli M, 2012, J FLUID MECH, V700, P16, DOI 10.1017/jfm.2012.37; GURDJIAN ES, 1968, J NEUROSURG, V29, P70, DOI 10.3171/jns.1968.29.1.0070; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hernandez F, 2015, ANN BIOMED ENG, V43, P1918, DOI 10.1007/s10439-014-1212-4; Holbourn AHS, 1944, J NEUROSURG, V1, P190, DOI 10.3171/jns.1944.1.3.0190; Holbourn AHS, 1943, LANCET, V2, P438; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Jayaprakash KR, 2013, J NONLINEAR SCI, V23, P363, DOI 10.1007/s00332-012-9155-0; Jayaprakash KR, 2011, PHYS REV E, V83, DOI 10.1103/PhysRevE.83.036606; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kerschen G, 2009, MECH SYST SIGNAL PR, V23, P170, DOI 10.1016/j.ymssp.2008.04.002; Kerschen G, 2005, NONLINEAR DYNAM, V41, P147, DOI 10.1007/s11071-005-2803-2; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Knutsen AK, 2014, J BIOMECH, V47, P3475, DOI 10.1016/j.jbiomech.2014.09.010; KORNHAUSER M, 1954, J APPL MECH-T ASME, V21, P371; Kornhauser M., 1961, IMPACT ACCELERATION, P333; Kraitchman DL, 2003, CIRCULATION, V107, P2025, DOI 10.1161/01.CIR.0000062684.47526.47; Kuo C, 2016, J BIOMECH, V49, P1845, DOI 10.1016/j.jbiomech.2016.04.017; Kurt M, 2015, J SOUND VIB, V357, P331, DOI 10.1016/j.jsv.2015.07.012; Kurt M, 2012, ARCH APPL MECH, V82, P1461, DOI 10.1007/s00419-012-0678-5; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Laksari K., 2013, J MECH BEHAVIOR OF B, V32, P132; Laksari K, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0331; Laksari K, 2015, BIOMECH MODEL MECHAN, V14, P459, DOI 10.1007/s10237-014-0616-2; Laksari K, 2012, J BIOMECH, V45, P642, DOI 10.1016/j.jbiomech.2011.12.023; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Massouros PG, 2014, INT J SOLIDS STRUCT, V51, P305, DOI 10.1016/j.ijsolstr.2013.09.022; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PELLMAN EJ, 2003, NEUROSURGERY, V53, P796; Pesheck E, 2001, NONLINEAR DYNAM, V25, P183, DOI 10.1023/A:1012910918498; Rowley CW, 2009, J FLUID MECH, V641, P115, DOI 10.1017/S0022112009992059; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Schmid PJ, 2010, J FLUID MECH, V656, P5, DOI 10.1017/S0022112010001217; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Vakakis A.F., 2008, NONLINEAR TARGETED E, V156; Versace J., 1971, 710881 SAE; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Wu LC, 2016, J BIOMECH, V49, P2918, DOI 10.1016/j.jbiomech.2016.07.004; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019; Yoganandan N, 2009, J BIOMECH, V42, P1177, DOI 10.1016/j.jbiomech.2009.03.029; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhao W, 2016, INTERFACE FOCUS, V6, DOI 10.1098/rsfs.2015.0091; Zou H, 2007, INT J CRASHWORTHINES, V12, P341, DOI 10.1080/13588260701433024	69	27	27	1	10	AMER PHYSICAL SOC	COLLEGE PK	ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA	0031-9007	1079-7114		PHYS REV LETT	Phys. Rev. Lett.	MAR 30	2018	120	13							138101	10.1103/PhysRevLett.120.138101			7	Physics, Multidisciplinary	Physics	GB1AR	WOS:000428783300021	29694192	Green Published, Bronze			2021-06-18	
J	DePalma, RG; Hoffman, SW				DePalma, Ralph G. ae; Hoffman, Stuart W.			Combat blast related traumatic brain injury (TBI): Decade of recognition; promise of progress	BEHAVIOURAL BRAIN RESEARCH			English	Article						Blast injury; mTBI; Brain injury,combat; Neurotrauma		Between April 2007 and December 2015, the Veterans Health Administration (VHA) screened one million combat veterans for traumatic brain injury (TB!), among 2.6 million deployed during operations Enduring Freedom, Iraqi Freedom and New Dawn (OEF/OIF/OND). Since 2007, among those reporting, screened and referred for definitive evaluation, approximately 8.4% of these Veterans received a diagnosis of TBI, the majority characterized as mTBI/Concussion (mTBI) and, in great proportion, related to blast exposures. Mild Traumatic brain injury called "a signature injury" is also known as 'the invisible injury' of these conflicts. Identifying and assessing neuropathological, cellular and resulting cognitive, emotional, behavioral and neurological consequences of mTBI comprise vast clinical and research challenges. We provide a brief overview of current history, injury mechanisms related to blast exposure, coordinated research support, and the need to understand specific cellular and neurological changes occurring with blast injury, particularly mTBI. Published by Elsevier B.V.	[DePalma, Ralph G. ae; Hoffman, Stuart W.] US Dept Vet Affairs, Off Res & Dev, Washington, DC USA; [DePalma, Ralph G. ae] Uniformed Serv Hlth Sci, Norman Rich Dept Surg, Washington, DC USA	DePalma, RG (corresponding author), US Dept Vet Affairs, 810 Vermont Ave NW,10P9, Washington, DC 20420 USA.	ralph.depalma@va.gov	DePalma, Ralph/P-1733-2019		Office of Research and Development of the Veterans Health Administration; DODUnited States Department of Defense; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	The authors acknowledge the support of the Office of Research and Development of the Veterans Health Administration in establishing close working relationships with DOD and NIH which expanded our concepts of brain injury. Timothy J O'Leary MD, PhD energized these relationships and provided a helpful review of the manuscript.	Ahmed F, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00114; [Anonymous], 2015, INT STAT SCI M; [Anonymous], 2016, CHRONIC EFFECTS NEUR; Bidelspach D., 2016, MILD TBI DIAGNOSIS M; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chan H., 2016, BRAIN NEUROTRAUMA MO, P189; DePalma R. G., 2016, EPIDEMIOLOGY MTBI MI, V2011; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; DEPALMA RG, 1967, SURGERY, V62, P505; DEPALMA RGD, 1970, J TRAUM, V10, P122, DOI 10.1097/00005373-197002000-00004; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Gandy S, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-37; Hoffman SW, 2009, CLIN NEUROPSYCHOL, V23, P1400, DOI 10.1080/13854040903369433; Hoge C. W., N ENGL J MED, V358; Kelly JF, 2008, J TRAUMA, V64, pS21, DOI 10.1097/TA.0b013e318160b9fb; Kobeissy F.H., 2015, BRAIN NEUROTRAUMA MO, DOI [10.1201/b18126-53, DOI 10.1201/B18126-53]; Kucherov Y, 2012, J APPL PHYS, V112, DOI 10.1063/1.4765727; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; Modello F., 2016, SCI REP, V20, P28203; Mott D., 2016, B AM PHYS SOC, P2009; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Phillips Y. I., 1991, CONVENTIONAL WARFARE; Rasmussen TE, 2016, J NEUROTRAUM, V33, P511, DOI 10.1089/neu.2016.29007.ter; RHODES RS, 1977, SURG GYNECOL OBSTET, V145, P719; Riedy G, 2016, RADIOLOGY, V279, P207, DOI 10.1148/radiol.2015150438; Ruff RL, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000312; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Shively S. B., 2016, LANCET NEUROL; Stuhmiller J., 2008, BLAST INJURY TRANSLA; TEASDALE G, 1974, LANCET, V2, P81; Vasterling JJ, 2012, PTSD MILD TRAUMATIC; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Young L, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00089	34	27	28	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	MAR 15	2018	340				SI		102	105		10.1016/j.bbr.2016.08.036			4	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	FU9JY	WOS:000424173400012	27555540				2021-06-18	
J	Kataria, H; Alizadeh, A; Shahriary, GM; Rizi, SS; Henrie, R; Santhosh, KT; Thliveris, JA; Karimi-Abdolrezaee, S				Kataria, Hardeep; Alizadeh, Arsalan; Shahriary, Ghazaleh M.; Rizi, Shekoofeh Saboktakin; Henrie, Ryan; Santhosh, Kallivalappil T.; Thliveris, James A.; Karimi-Abdolrezaee, Soheila			Neuregulin-1 promotes remyelination and fosters a pro-regenerative inflammatory response in focal demyelinating lesions of the spinal cord	GLIA			English	Article						IL-10; lysolecithin demyelination; neuregulin-1; neural precursor cells; oligodendrogenesis; remyelination	CHONDROITIN SULFATE PROTEOGLYCANS; CENTRAL-NERVOUS-SYSTEM; NEURAL STEM/PROGENITOR CELLS; SCHWANN-CELL; OLIGODENDROCYTE DIFFERENTIATION; FUNCTIONAL RECOVERY; PRECURSOR CELLS; TERMINAL DIFFERENTIATION; NEUROLOGICAL RECOVERY; NEUROTROPHIC FACTOR	Oligodendroglial cell death and demyelination are hallmarks of neurotrauma and multiple sclerosis that cause axonal damage and functional impairments. Remyelination remains a challenge as the ability of endogenous precursor cells for oligodendrocyte replacement is hindered in the unfavorable milieu of demyelinating conditions. Here, in a rat model of lysolecithin lysophosphatidyl-choline (LPC)-induced focal demyelination, we report that Neuregulin-1 (Nrg-1), an important factor for oligodendrocytes and myelination, is dysregulated in demyelinating lesions and its bio-availability can promote oligodendrogenesis and remyelination. We delivered recombinant human Nrg-11 (rhNrg-11) intraspinally in the vicinity of LPC demyelinating lesion in a sustained manner using poly lactic-co-glycolic acid microcarriers. Availability of Nrg-1 promoted generation and maturation of new oligodendrocytes, and accelerated endogenous remyelination by both oligodendrocyte and Schwann cell populations in demyelinating foci. Importantly, Nrg-1 enhanced myelin thickness in newly remyelinated spinal cord axons. Our complementary in vitro studies also provided direct evidence that Nrg-1 significantly promotes maturation of new oligodendrocytes and facilitates their transition to a myelinating phenotype. Nrg-1 therapy remarkably attenuated the upregulated expression chondroitin sulfate proteoglycans (CSPGs) specific glycosaminoglycans in the extracellular matrix of demyelinating foci and promoted interleukin-10 (IL-10) production by immune cells. CSPGs and IL-10 are known to negatively and positively regulate remyelination, respectively. We found that Nrg-1 effects are mediated through ErbB2 and ErbB4 receptor activation. Our work provides novel evidence that dysregulated levels of Nrg-1 in demyelinating lesions of the spinal cord pose a challenge to endogenous remyelination, and appear to be an underlying cause of myelin thinning in newly remyelinated axons.	[Kataria, Hardeep; Alizadeh, Arsalan; Shahriary, Ghazaleh M.; Rizi, Shekoofeh Saboktakin; Henrie, Ryan; Santhosh, Kallivalappil T.; Karimi-Abdolrezaee, Soheila] Univ Manitoba, Rady Fac Hlth Sci, Spinal Cord Res Ctr, Dept Physiol & Pathophysiol,Regenerat Med Program, Winnipeg, MB, Canada; [Thliveris, James A.] Univ Manitoba, Rady Fac Hlth Sci, Dept Human Anat & Cell Sci, Winnipeg, MB, Canada	Karimi-Abdolrezaee, S (corresponding author), Univ Manitoba, Fac Med, Dept Physiol & Pathophysiol, Regenerat Med Program, 629 Basic Med Sci Bldg,745 Bannatyne Ave, Winnipeg, MB R3E 0J9, Canada.	Soheila.Karimi@umanitoba.ca	Kataria, Hardeep/AAI-8411-2020	Karimi-Abdolrezaee, Soheila/0000-0002-0683-2663	Canadian Institutes of Health Research, CIHRCanadian Institutes of Health Research (CIHR) [MOP 133721]; Multiple Sclerosis Society of Canada, CHRIM [EGID-2936]; Research Manitoba; Rick Hansen Institute; U of M GETS Program, Max Rady College of Medicine, University of Manitoba	Canadian Institutes of Health Research, CIHR, Grant Number: MOP 133721; Multiple Sclerosis Society of Canada (EGID-2936), CHRIM; Research Manitoba; Rick Hansen Institute; U of M GETS Program, Max Rady College of Medicine, University of Manitoba	Alizadeh A, 2017, GLIA, V65, P1152, DOI 10.1002/glia.23150; Alizadeh A, 2016, J PHYSIOL-LONDON, V594, P3539, DOI 10.1113/JP270895; Alizadeh A, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00035; Almad A, 2011, NEUROTHERAPEUTICS, V8, P262, DOI 10.1007/s13311-011-0033-5; BARRES BA, 1993, DEVELOPMENT, V118, P283; Bartus K, 2016, BRAIN, V139, P1394, DOI 10.1093/brain/aww039; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Birchmeier C, 2008, GLIA, V56, P1491, DOI 10.1002/glia.20753; Blakemore WF, 2008, CURR TOP MICROBIOL, V318, P193; BLAKEMORE WF, 1976, NEUROPATH APPL NEURO, V2, P21, DOI 10.1111/j.1365-2990.1976.tb00559.x; BLIGHT AR, 1989, J NEUROL SCI, V91, P15, DOI 10.1016/0022-510X(89)90073-7; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Brinkmann BG, 2008, NEURON, V59, P581, DOI 10.1016/j.neuron.2008.06.028; Bunge R P, 1993, Curr Opin Neurobiol, V3, P805, DOI 10.1016/0959-4388(93)90157-T; Butzkueven H, 2002, NAT MED, V8, P613, DOI 10.1038/nm0602-613; Calver AR, 1998, NEURON, V20, P869, DOI 10.1016/S0896-6273(00)80469-9; Canoll PD, 1996, NEURON, V17, P229, DOI 10.1016/S0896-6273(00)80155-5; Colello RJ, 1997, MOL NEUROBIOL, V15, P83, DOI 10.1007/BF02740617; Crespo D, 2007, EXP NEUROL, V206, P159, DOI 10.1016/j.expneurol.2007.05.001; Denney L, 2012, J IMMUNOL, V189, P551, DOI 10.4049/jimmunol.1103608; Du YZ, 2006, J NEUROSCI RES, V84, P1692, DOI 10.1002/jnr.21080; Duncan ID, 1997, J ANAT, V190, P35, DOI 10.1046/j.1469-7580.1997.19010035.x; Dyck SM, 2015, STEM CELLS, V33, P2550, DOI 10.1002/stem.1979; Elion E. A., 2006, CURRENT PROTOCOLS IN, V35; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Fancy SPJ, 2011, ANNU REV NEUROSCI, V34, P21, DOI 10.1146/annurev-neuro-061010-113629; Fancy SPJ, 2009, GENE DEV, V23, P1571, DOI 10.1101/gad.1806309; FELTS PA, 1992, BRAIN RES, V574, P178, DOI 10.1016/0006-8993(92)90815-Q; Felts PA, 1996, NEUROSCIENCE, V75, P643, DOI 10.1016/0306-4522(96)00282-5; Fernandez PA, 2000, NEURON, V28, P81, DOI 10.1016/S0896-6273(00)00087-8; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Franklin RJM, 2012, NAT REV NEUROL, V8, P624, DOI 10.1038/nrneurol.2012.200; Fricker FR, 2011, FUTUR NEUROL, V6, P809, DOI 10.2217/FNL.11.45; Gauthier MK, 2013, EUR J NEUROSCI, V38, P2693, DOI 10.1111/ejn.12268; Gilson JM, 2002, NEUROREPORT, V13, P1205, DOI 10.1097/00001756-200207020-00027; Guest JD, 2005, EXP NEUROL, V192, P384, DOI 10.1016/j.expneurol.2004.11.033; Hammond TR, 2014, NEURON, V81, P588, DOI 10.1016/j.neuron.2013.11.015; Hartung HP, 2011, LANCET NEUROL, V10, P293, DOI 10.1016/S1474-4422(11)70043-6; Hesp ZC, 2015, J NEUROSCI, V35, P1274, DOI 10.1523/JNEUROSCI.2568-14.2015; Irvine KA, 2008, BRAIN, V131, P1464, DOI 10.1093/brain/awn080; JEFFERY ND, 1995, J NEUROCYTOL, V24, P775, DOI 10.1007/BF01191213; Karimi-Abdolrezaee S, 2006, J NEUROSCI, V26, P3377, DOI 10.1523/JNEUROSCI.4184-05.2006; Karimi-Abdolrezaee S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037589; Karimi-Abdolrezaee S, 2010, J NEUROSCI, V30, P1657, DOI 10.1523/JNEUROSCI.3111-09.2010; Kim JY, 2003, J NEUROSCI, V23, P5561; Kotter MR, 2006, J NEUROSCI, V26, P328, DOI 10.1523/JNEUROSCI.2615-05.2006; Lau LW, 2012, ANN NEUROL, V72, P419, DOI 10.1002/ana.23599; Li Q, 2009, J MOL NEUROSCI, V37, P67, DOI 10.1007/s12031-008-9121-3; Li YG, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0283-y; Lobo-Silva D, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0763-8; Lourenco T, 2016, SCI REP-UK, V6, DOI 10.1038/srep21563; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Mason JL, 2000, J NEUROSCI, V20, P5703; Mason JL, 2004, AM J PATHOL, V164, P1673, DOI 10.1016/S0002-9440(10)63726-1; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; Mei L, 2014, NEURON, V83, P27, DOI 10.1016/j.neuron.2014.06.007; Mencel M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070338; Mi S, 2007, NAT MED, V13, P1228, DOI 10.1038/nm1664; Mikita J, 2011, MULT SCLER J, V17, P2, DOI 10.1177/1352458510379243; Miron VE, 2014, J NEUROCHEM, V130, P165, DOI 10.1111/jnc.12705; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; MODOLELL M, 1995, EUR J IMMUNOL, V25, P1101, DOI 10.1002/eji.1830250436; Mothe AJ, 2008, EXP NEUROL, V213, P176, DOI 10.1016/j.expneurol.2008.05.024; Nait-Oumesmar B, 1999, EUR J NEUROSCI, V11, P4357, DOI 10.1046/j.1460-9568.1999.00873.x; Nashmi R, 2001, NEUROSCIENCE, V104, P235, DOI 10.1016/S0306-4522(01)00009-4; Nave KA, 2014, ANNU REV CELL DEV BI, V30, P503, DOI 10.1146/annurev-cellbio-100913-013101; Ohori Y, 2006, J NEUROSCI, V26, P11948, DOI 10.1523/JNEUROSCI.3127-06.2006; Oluich LJ, 2012, J NEUROSCI, V32, P8317, DOI 10.1523/JNEUROSCI.1053-12.2012; Park SK, 2001, J CELL BIOL, V154, P1245, DOI 10.1083/jcb.200104025; Pedraza CE, 2014, ASN NEURO, V6, DOI 10.1177/1759091414538134; Pendleton JC, 2013, EXP NEUROL, V247, P113, DOI 10.1016/j.expneurol.2013.04.003; Perlin JR, 2011, DEVELOPMENT, V138, P4639, DOI 10.1242/dev.068072; Powers BE, 2013, P NATL ACAD SCI USA, V110, P4075, DOI 10.1073/pnas.1210293110; Roy K, 2007, P NATL ACAD SCI USA, V104, P8131, DOI 10.1073/pnas.0702157104; Ruffini F, 2004, AM J PATHOL, V164, P1519, DOI 10.1016/S0002-9440(10)63709-1; Santhosh KT, 2017, J CONTROL RELEASE, V261, P147, DOI 10.1016/j.jconrel.2017.06.030; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Simmons LJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0703-7; Stolt CC, 2002, GENE DEV, V16, P165, DOI 10.1101/gad.215802; Sussman CR, 2005, J NEUROSCI, V25, P5757, DOI 10.1523/JNEUROSCI.4748-04.2005; Sussman CR, 2000, J NEUROSCI RES, V59, P413, DOI 10.1002/(SICI)1097-4547(20000201)59:3<413::AID-JNR16>3.0.CO;2-G; Syed YA, 2011, J NEUROSCI, V31, P3719, DOI 10.1523/JNEUROSCI.4930-10.2011; Taveggia C, 2008, GLIA, V56, P284, DOI 10.1002/glia.20612; Taveggia C, 2010, NAT REV NEUROL, V6, P276, DOI 10.1038/nrneurol.2010.37; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Van't Veer A, 2009, J NEUROSCI RES, V87, P69, DOI 10.1002/jnr.21841; Vartanian T, 1999, P NATL ACAD SCI USA, V96, P731, DOI 10.1073/pnas.96.2.731; Wang Z, 2007, GLIA, V55, P537, DOI 10.1002/glia.20480; Wolswijk G, 2002, BRAIN, V125, P338, DOI 10.1093/brain/awf031; Xu ZF, 2006, J CEREBR BLOOD F MET, V26, P527, DOI 10.1038/sj.jcbfm.9600212; YANG J, 2009, THE JOURNAL OF CLINI, V119, P3678, DOI DOI 10.1172/JCI37914; Zawadzka M, 2010, CELL STEM CELL, V6, P578, DOI 10.1016/j.stem.2010.04.002; Zhang SX, 2011, HISTOL HISTOPATHOL, V26, P45, DOI 10.14670/HH-26.45; Zhao C, 2015, J NEUROSCI, V35, P11482, DOI 10.1523/JNEUROSCI.3655-14.2015	94	27	29	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	MAR	2018	66	3					538	561		10.1002/glia.23264			24	Neurosciences	Neurosciences & Neurology	FS6MX	WOS:000419912600006	29148104				2021-06-18	
J	Kochanek, PM; Bramlett, HM; Dixon, CE; Dietrich, WD; Mondello, S; Wang, KKW; Hayes, RL; Lafrenaye, A; Povlishock, JT; Tortella, FC; Poloyac, SM; Empey, P; Shear, DA				Kochanek, Patrick M.; Bramlett, Helen M.; Dixon, C. Edward; Dietrich, W. Dalton; Mondello, Stefania; Wang, Kevin K. W.; Hayes, Ronald L.; Lafrenaye, Audrey; Povlishock, John T.; Tortella, Frank C.; Poloyac, Samuel M.; Empey, Philip; Shear, Deborah A.			Operation Brain Trauma Therapy: 2016 Update	MILITARY MEDICINE			English	Article; Proceedings Paper	Military Health System Research Symposium (MHSRS)	2016	FL				CONTROLLED CORTICAL IMPACT; FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE-L1; CLINICAL-TRIALS; DOUBLE-BLIND; HEAD-INJURY; NF-H; ERYTHROPOIETIN; AMANTADINE; LEVETIRACETAM	Operation brain trauma therapy (OBTT) is a multi-center, pre-clinical drug and biomarker screening consortium for traumatic brain injury (TBI). Therapies are screened across three rat models (parasagittal fluid percussion injury, controlled cortical impact [CCI], and penetrating ballistic-like brain injury). Operation brain trauma therapy seeks to define therapies that show efficacy across models that should have the best chance in randomized clinical trials (RCTs) and/or to define model-dependent therapeutic effects, including TBI protein biomarker responses, to guide precision medicine-based clinical trials in targeted pathologies. The results of the first five therapies tested by OBTT (nicotinamide, erythropoietin, cyclosporine [CsA], simvastatin, and levetiracetam) were published in the Journal of Neurotrauma. Operation brain trauma therapy now describes preliminary results on four additional therapies (glibenclamide, kollidon-VA64, AER-271, and amantadine). To date, levetiracetam was beneficial on cognitive outcome, histology, and/or biomarkers in two models. The second most successful drug, glibenclamide, improved motor function and histology in CCI. Other therapies showed model-dependent effects (amantadine and CsA). Critically, glial fibrillary acidic protein levels predicted treatment effects. Operation brain trauma therapy suggests that levetiracetam merits additional pre-clinical and clinical evaluation and that glibenclamide and amantadine merit testing in specific TBI phenotypes. Operation brain trauma therapy has established that rigorous, multi-center consortia could revolutionize TBI therapy and biomarker development.	[Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, Sch Med, 4401 Penn Ave, Pittsburgh, PA 15224 USA; [Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Dept Neurol Surg, Miller Sch Med, 1095 NW 14th Terrace, Miami, FL 33136 USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Safar Ctr Resuscitat Res, 4401 Penn Ave, Pittsburgh, PA 15224 USA; [Mondello, Stefania] Univ Messina, Dept Neurosci, Via Consolare Valeria 1, I-98125 Messina, Italy; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Program Neuroprote & Biomarkers Res, POB 100256, Gainesville, FL 32611 USA; [Wang, Kevin K. W.] Univ Florida, Dept Neurosci, Program Neuroprote & Biomarkers Res, POB 100256, Gainesville, FL 32611 USA; [Wang, Kevin K. W.] Univ Florida, Dept Chem, Program Neuroprote & Biomarkers Res, POB 100256, Gainesville, FL 32611 USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Innovat Res, Ctr Neuroprote & Biomarkers Res, 13400 Progress Blvd, Alachua, FL 32615 USA; [Lafrenaye, Audrey; Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, 1101 East Marshall St, Richmond, VA 23298 USA; [Tortella, Frank C.] Walter Reed Army Inst Res, Dept Army, 503 Robert Grant Ave, Silver Spring, MD 20910 USA; [Poloyac, Samuel M.; Empey, Philip] Univ Pittsburgh, Dept Pharm & Therapeut, Ctr Clin Pharmaceut Sci, 3501 Terrace St, Pittsburgh, PA 15261 USA; [Empey, Philip] Univ Pittsburgh, Clin Translat Sci Inst, 3501 Terrace St, Pittsburgh, PA 15261 USA; [Shear, Deborah A.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Brain Trauma Neuroprotect & Neurorestorat Branch, 503 Robert Grant Ave, Silver Spring, MD 20910 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, Sch Med, 4401 Penn Ave, Pittsburgh, PA 15224 USA.		Empey, Philip/L-9604-2019; Mondello, Stefania/A-1813-2012	Empey, Philip/0000-0001-7474-2339; Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473	Department of DefenseUnited States Department of Defense [W81XWH-10-1-0623, WH81XWH-14-2-0018]	Supported by Department of Defense grants W81XWH-10-1-0623 and WH81XWH-14-2-0018.	Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Begley CG, 2015, CIRC RES, V116, P116, DOI 10.1161/CIRCRESAHA.114.303819; Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a; Bramlett HM, 2016, J NEUROTRAUM, V33, P538, DOI 10.1089/neu.2015.4116; Browning M, 2016, J NEUROTRAUM, V33, P581, DOI 10.1089/neu.2015.4131; Carney N, 2016, NEUROSURGERY, P1, DOI [10.1227/NEU.0000000000001432, DOI 10.1227/NEU.0000000000001432]; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Dixon CE, 2016, J NEUROTRAUM, V33, P553, DOI 10.1089/neu.2015.4122; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Hayakawa K, 2012, SPINAL CORD, V50, P493, DOI 10.1038/sc.2011.184; Hayden E. C., 2011, NATURE NEWS; Jha Ruchira M, 2017, Crit Care Med, V45, pe255, DOI 10.1097/CCM.0000000000002079; Kochanek PM, 2016, J NEUROTRAUM, V33, P606, DOI 10.1089/neu.2015.4133; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Kochanek PM, 2015, CRIT CARE MED, V43, P1544, DOI 10.1097/CCM.0000000000001041; Kochanek PM, 2013, LANCET NEUROL, V12, P1132, DOI 10.1016/S1474-4422(13)70245-X; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kochanek PM, 2011, J TRAUMA, V71, pS15, DOI 10.1097/TA.0b013e31822117fe; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Martinez-Morillo E, 2015, CLIN CHEM LAB MED, V53, P1575, DOI 10.1515/cclm-2014-0908; Mbye LH, 2012, J CEREBR BLOOD F MET, V32, P515, DOI 10.1038/jcbfm.2011.158; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Mountney A, 2016, J NEUROTRAUM, V33, P567, DOI 10.1089/neu.2015.4130; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Neselius S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099870; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Oliver JM, 2016, J NEUROTRAUM, V33, P1784, DOI 10.1089/neu.2015.4295; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Rubenstein R, 2015, J NEUROTRAUM, V32, P342, DOI 10.1089/neu.2014.3548; Shear DA, 2016, J NEUROTRAUM, V33, P523, DOI 10.1089/neu.2015.4115; Shear DA, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00073; Sheth KN, 2016, LANCET NEUROL, V15, P1160, DOI 10.1016/S1474-4422(16)30196-X; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Wallisch J, 2016, J NEUROTRAUM, V33, pA61; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; Wang T, 2014, J NEUROTRAUM, V31, P370, DOI 10.1089/neu.2013.2917; Weisbrod AB, 2012, J TRAUMA ACUTE CARE, V73, P1525, DOI 10.1097/TA.0b013e318270e179; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Zurek J, 2011, BRAIN INJURY, V25, P221, DOI 10.3109/02699052.2010.541895	46	27	28	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	MAR-APR	2018	183			S			303	312		10.1093/milmed/usx184			10	Medicine, General & Internal	General & Internal Medicine	GC0JM	WOS:000429463600043	29635589	Bronze			2021-06-18	
J	Gracies, JM; O'Dell, M; Vecchio, M; Hedera, P; Kocer, S; Rudzinska-Bar, M; Rubin, B; Timerbaeva, SL; Lusakowska, A; Boyer, FC; Grandoulier, AS; Vilain, C; Picaut, P				Gracies, Jean-Michel; O'Dell, Michael; Vecchio, Michele; Hedera, Peter; Kocer, Serdar; Rudzinska-Bar, Monika; Rubin, Bruce; Timerbaeva, Sofiya L.; Lusakowska, Anna; Boyer, Francois Constant; Grandoulier, Anne-Sophie; Vilain, Claire; Picaut, Philippe		Int AbobotulinumtoxinA Adult Upper	EFFECTS OF REPEATED ABOBOTULINUMTOXINA INJECTIONS IN UPPER LIMB SPASTICITY	MUSCLE & NERVE			English	Article						active function; botulinum toxin; open label; stroke; traumatic brain injury; upper limb spasticity	MYASTHENIA-GRAVIS; NERVE-STIMULATION; OUTCOME MEASURE; VALIDATION; MUSCLE; SCALE; RELIABILITY	Introduction: The efficacy of single injections of abobo-tulinumtoxinA (Dysport) is established in adults with upper limb spasticity. In this study we assessed the effects of repeated injections of abobotulinumtoxinA over 1 year. Methods: Patients (n = 258, safety population) received 500 U, 1,000 U, or 1,500 U (1,500-U dose included 500-U shoulder injections) for up to 4 or 5 treatment cycles. Assessments included treatment-emergent adverse events (TEAEs), muscle tone, passive and active range of motion (XV1, XA), angle of catch (XV3), Disability Assessment Scale (DAS) score, Modified Frenchay Scale (MFS) score, and Physician Global Assessment (PGA) score. Results: The incidence of TEAEs decreased across cycles. Muscle tone reduction and XV1 remained stable across cycles, whereas XV3 and XA continued to improve at the finger, wrist, and elbow flexors. DAS and PGA improved across cycles. MFS improved best with 1,500 U. Discussion: A favorable safety profile and continuous improvements in active movements and perceived and active function were associated with repeated abobotulinumtoxinA injections in upper limbmuscles.	[Gracies, Jean-Michel] Univ Paris Est Creteil, Hop Univ Henri Mondor, Serv Reeduc Neurolocomotrice, EA BIOTN 7377, 51 Ave Marechal De Lattre De Tassigny, F-94010 Creteil, France; [O'Dell, Michael] Weill Cornell Med, Dept Rehabil Med, Baker Pavil, New York, NY USA; [Vecchio, Michele] Policlin Vittorio Emanuele Univ Hosp, Dept UO Phys Med & Rehabil, Catania, Italy; [Hedera, Peter] Vanderbilt Univ, Div Movement Disorders, Dept Neurol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Kocer, Serdar] Hop Jura, Ctr Reeduc, Porrentruy, Switzerland; [Rudzinska-Bar, Monika] Med Univ Silesia, Dept Neurol, Fac Med, Katowice, Poland; [Rubin, Bruce] Design Neurosci Ctr, Doral, FL USA; [Timerbaeva, Sofiya L.] Res Ctr Neurol, Moscow, Russia; [Lusakowska, Anna] Med Univ Warsaw, Dept Neurol, Warsaw, Poland; [Boyer, Francois Constant] Hop Univ Sebastopol, Unit Med Phys, EA 3797, Champagne Ardenne, France; [Boyer, Francois Constant] Hop Univ Sebastopol, Unit Readaptat, EA 3797, Champagne Ardenne, France; [Grandoulier, Anne-Sophie; Vilain, Claire; Picaut, Philippe] Ipsen Innovat, Les Ulis, France	Gracies, JM (corresponding author), Univ Paris Est Creteil, Hop Univ Henri Mondor, Serv Reeduc Neurolocomotrice, EA BIOTN 7377, 51 Ave Marechal De Lattre De Tassigny, F-94010 Creteil, France.	jean-michel.gracies@aphp.fr	Kocer, Serdar/AAG-2708-2019; Boyer, Francois Constant/P-4544-2016	Boyer, Francois Constant/0000-0003-1035-9108; Rudzinska - Bar, Monika/0000-0002-1453-6856; Vecchio, Michele/0000-0001-5254-3283	Ipsen Innovation, Les Ulis, France	This study was sponsored by Ipsen Innovation, Les Ulis, France.	Abraham A, 2017, MUSCLE NERVE, V56, P445, DOI 10.1002/mus.25539; Abraham A, 2017, NEUROMUSCULAR DISORD, V27, P646, DOI 10.1016/j.nmd.2017.04.009; Abraham A, 2017, MUSCLE NERVE, V55, P166, DOI 10.1002/mus.25214; Abraham A, 2016, CLIN NEUROPHYSIOL, V127, P3294, DOI 10.1016/j.clinph.2016.08.004; Antozzi C, 2016, MUSCLE NERVE, V53, P32, DOI 10.1002/mus.24911; Barnett C, 2016, NEUROLOGY, V87, P879, DOI 10.1212/WNL.0000000000002971; Barnett Carolina, 2012, J Clin Neuromuscul Dis, V13, P201, DOI 10.1097/CND.0b013e31824619d5; Barohn RJ, 1998, ANN NY ACAD SCI, V841, P769, DOI 10.1111/j.1749-6632.1998.tb11015.x; Burns TM, 2008, MUSCLE NERVE, V38, P957, DOI 10.1002/mus.21053; Burns TM, 2016, MUSCLE NERVE, V54, P1015, DOI 10.1002/mus.25198; Burns TM, 2016, MUSCLE NERVE, V53, P3, DOI 10.1002/mus.24953; Burns TM, 2012, ANN NY ACAD SCI, V1274, P99, DOI 10.1111/j.1749-6632.2012.06812.x; Campbell MJ., 2009, STAT SQUARE ONE, V11th ed.; Farrugia ME, 2014, MUSCLE NERVE, V50, P501, DOI 10.1002/mus.24214; Jaretzki A, 2000, NEUROLOGY, V55, P16, DOI 10.1212/WNL.55.1.16; Katzberg Hans D, 2005, J Clin Neuromuscul Dis, V6, P109, DOI 10.1097/01.cnd.0000155026.66153.f0; Liu GC, 2014, COMPLEMENT THER MED, V22, P877, DOI 10.1016/j.ctim.2014.08.003; Muppidi S, 2011, MUSCLE NERVE, V44, P727, DOI 10.1002/mus.22140; Raggi A, 2016, J NEUROL, V263, P871, DOI 10.1007/s00415-016-8072-9; Russell J, 2015, NEUROMUSCULAR DISORD; Sharshar T, 2000, J NEUROL, V247, P286, DOI 10.1007/s004150050585; TINDALL RSA, 1987, NEW ENGL J MED, V316, P719, DOI 10.1056/NEJM198703193161205; Witoonpanich R, 2011, CLIN NEUROPHYSIOL, V122, P1873, DOI 10.1016/j.clinph.2011.02.026	23	27	29	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0148-639X	1097-4598		MUSCLE NERVE	Muscle Nerve	FEB	2018	57	2					245	254		10.1002/mus.25721			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FS7GA	WOS:000419964700018	28590525	Green Published, Other Gold			2021-06-18	
J	Fang, J; Wang, HD; Zhou, J; Dail, W; Zhu, YH; Zhou, Y; Wang, XL; Zhou, ML				Fang, Jiang; Wang, Handong; Zhou, Jian; Dail, Wei; Zhu, Yihao; Zhou, Yuan; Wang, Xiaoliang; Zhou, Mengliang			Baicalin provides neuroprotection in traumatic brain injury mice model through Akt/Nrf2 pathway	DRUG DESIGN DEVELOPMENT AND THERAPY			English	Article						Baicalin; traumatic brain injury; Akt; nuclear factor erythroid 2-related factor 2; apoptosis; oxidative stress	NRF2-ARE SIGNALING PATHWAY; FOCAL CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; POTENTIAL MECHANISM; SYNAPTIC PROTEINS; RAT MODEL; PI3K/AKT; ACTIVATION; PROTECTS; NEUROTOXICITY	Background: The neuroprotective effects of Baicalin liave been confirmed in several central nervous system (CNS) diseases. However, its possible effect on traumatic brain injury (TBI) model is still not clear. The present study is aimed to investigate the role and the underling mechanisms of 7-D-glucuronic acid-5,6-diliydroxyflavone (Baicalin) on TBI model. Methods: The weight-drop model of TBI in Institute of Cancer Research mice was treated with Baicalin intrapcritoncally at 30 minutes after TBI. LY294002 (LY) (a commonly used PI3K/ Akt pathway inhibitor) was injected into the left ventricle at 30 minutes before TBI. All mice were euthanized at 24 hours after TBI to collect the brain tissue for a series of tests except for neurological function, which was measured at 2 hours and 1 and 3 days post-TBI. Results: Baicalin administration significantly improved neurobehavioral function, alleviated brain edema, and reduced apoptosis-positive cells by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay accompanied with the upregulation of B-cell lymphoma 2 (Bcl-2) and downregulation of Bcl-2-associated X protein (Bax) and cleaved-caspase 3 by Western blot. Besides, TBI-induced oxidant stress status was also restored in the Baicalin group by measuring malondialdehyde (MDA) content, glutathione peroxidase (GPx), and superoxide dismutase (SOD) levels in the injured brain cortex. Furthermore, translocation of Nrf2 to the nucleus was dramatically enhanced by Baicalin verified by immunofluorescence and Western blot analyses. Accordingly, its downstream antioxidative enzymes nicotinamide adenine dinuclcotide phosphate:quinine oxidoreductase 1 (NQO-1) and heme oxygenase 1 (HO-1) were also activated by Baicalin confirmed by quantitative reverse transcription polymerase chain reaction (RT-qPCR) and Western blot. I lowever, cotreutment with Baicalin and LY could partly abolish Baicalin-induced activation of Nrf2 and its neuroprotective effects in TBI. Conclusion: This study demonstrates that Baicalin provides a neuroprotective effect in TBI mice model via activating the Akt/Nrf2 pathway.	[Fang, Jiang; Wang, Handong] Southeast Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China; [Zhou, Jian; Dail, Wei; Zhou, Yuan] Nanjing Med Univ, Jinling Hosp, Jinling Clin Med Coll, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China; [Zhu, Yihao; Wang, Xiaoliang; Zhou, Mengliang] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com		Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81672503, 81571162, 81401026]; Military Medical Youth Training Program [16QNP042]; Project of Hospital Management of Nanjing General Hospital of Nanjing Military Region [2017013]	This study was grant supported by the National Natural Science Foundation of China (nos 81672503, 81571162, and 81401026), Military Medical Youth Training Program (no 16QNP042), and the Project of Hospital Management of Nanjing General Hospital of Nanjing Military Region (no 2017013).	Adibhatla RM, 2010, ANTIOXID REDOX SIGN, V12, P125, DOI [10.1089/ars.2009.2668, 10.1089/ARS.2009.2668]; Ali T, 2018, MOL NEUROBIOL, V55, P6076, DOI 10.1007/s12035-017-0798-6; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brigelius-Flohe R, 2013, BBA-GEN SUBJECTS, V1830, P3289, DOI 10.1016/j.bbagen.2012.11.020; Cao Y, 2010, BRAIN RES, V1357, P115, DOI 10.1016/j.brainres.2010.07.108; Cao YG, 2011, BRAIN RES BULL, V85, P396, DOI 10.1016/j.brainresbull.2011.05.002; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; de Vries HE, 2008, FREE RADICAL BIO MED, V45, P1375, DOI 10.1016/j.freeradbiomed.2008.09.001; Ding HT, 2015, CELL MOL NEUROBIOL, V35, P623, DOI 10.1007/s10571-015-0156-z; Ding H, 2017, NEUROCHEM RES, V42, P337, DOI 10.1007/s11064-016-2077-8; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Du G, 2016, NEUROL RES, V3, P1; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Frebel K, 2006, BIOCHEM SOC T, V34, P1287, DOI 10.1042/BST0341287; Gao YY, 2016, J SURG RES, V206, P67, DOI 10.1016/j.jss.2016.07.014; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; He P, 2017, OXID MED CELL LONGEV, V2017, P1, DOI 10.1155/2017/4820414; Hou ZG, 2012, BRAIN RES BULL, V88, P560, DOI 10.1016/j.brainresbull.2012.06.006; Itoh K, 2004, FREE RADICAL BIO MED, V36, P1208, DOI 10.1016/j.freeradbiomed.2004.02.075; Kang KW, 2002, MOL PHARMACOL, V62, P1001, DOI 10.1124/mol.62.5.1001; Kojima T, 2015, INVEST OPHTH VIS SCI, V56, P8382, DOI 10.1167/iovs.15-18295; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee JS, 2005, CANCER LETT, V224, P171, DOI 10.1016/j.canlet.2004.09.042; Li LR, 2014, CHEM-BIOL INTERACT, V209, P56, DOI 10.1016/j.cbi.2013.12.005; Li WG, 2005, J BIOL CHEM, V280, P28430, DOI 10.1074/jbc.M410601200; Li X, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164237; Liu ZW, 2017, NEUROCHEM RES, V42, P1375, DOI 10.1007/s11064-017-2186-z; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Owuor ED, 2002, BIOCHEM PHARMACOL, V64, P765, DOI 10.1016/S0006-2952(02)01137-1; Shen M, 2017, BIOMED PHARMACOTHER, V95, P885, DOI 10.1016/j.biopha.2017.08.125; Shi XQ, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1401790; Tang GM, 2017, ONCOTARGET, V8, P97977, DOI 10.18632/oncotarget.20105; Tarrago T, 2008, BIOORGAN MED CHEM, V16, P7516, DOI 10.1016/j.bmc.2008.04.067; Tu XK, 2011, NEUROCHEM RES, V36, P2022, DOI 10.1007/s11064-011-0526-y; Tu XK, 2009, NEUROCHEM RES, V34, P1626, DOI 10.1007/s11064-009-9953-4; Wang HC, 2016, WORLD NEUROSURG, V87, P463, DOI 10.1016/j.wneu.2015.10.010; Xi YL, 2016, CHIN J NAT MEDICINES, V14, P48, DOI 10.3724/SP.J.1009.2016.00048; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yang YQ, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00580; Zhang Q, 2016, ONCOTARGET, V7, P80872, DOI 10.18632/oncotarget.12645; Zhang ZJ, 2012, J AGR FOOD CHEM, V60, P8171, DOI 10.1021/jf301511m; Zheng WX, 2014, BRAIN INJURY, V28, P227, DOI 10.3109/02699052.2013.860469; Zhou ZQ, 2017, NEURAL REGEN RES, V12, P1625, DOI 10.4103/1673-5374.217335; Zuo DY, 2016, NEUROTOX RES, V30, P159, DOI 10.1007/s12640-016-9611-y	49	27	28	0	4	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1177-8881			DRUG DES DEV THER	Drug Des. Dev. Ther.		2018	12						2497	2508		10.2147/DDDT.S163951			12	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	GP8QN	WOS:000441177000003	30127597	DOAJ Gold, Green Published			2021-06-18	
J	Heitzer, M; Kaiser, S; Kanagaratnam, M; Zendedel, A; Hartmann, P; Beyer, C; Johann, S				Heitzer, Marius; Kaiser, Sarah; Kanagaratnam, Mithila; Zendedel, Adib; Hartmann, Philipp; Beyer, Cordian; Johann, Sonja			Administration of 17 beta-Estradiol Improves Motoneuron Survival and Down-regulates Inflammasome Activation in Male SOD1(G93A) ALS Mice	MOLECULAR NEUROBIOLOGY			English	Article						Estrogen; Amyotrophic lateral sclerosis; Spinal cord; NLRP3; Interleukin 1 beta; Caspase 1	AMYOTROPHIC-LATERAL-SCLEROSIS; PROTEINASE-INHIBITOR 9; ESTROGEN-RECEPTOR MODULATORS; TRANSGENIC-MOUSE MODEL; TRAUMATIC BRAIN-INJURY; SUPEROXIDE-DISMUTASE 1; SKELETAL-MUSCLE; NLRP3 INFLAMMASOME; SPINAL-CORD; SEX STEROIDS	Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease manifested by the progressive loss of upper and lower motoneurons. The pathomechanism of ALS is complex and not yet fully understood. Neuroinflammation is believed to significantly contribute to disease progression. Inflammasome activation was recently shown in the spinal cord of human sporadic ALS patients and in the SOD1(G93A) mouse model for ALS. In the present study, we investigated the neuroprotective and anti-inflammatory effects of 17 beta-estradiol (E2) treatment in pre-symptomatic and symptomatic male SOD1(G93A) mice. Symptomatic mice with E2 substitution exhibited improved motor performance correlating with an increased survival of motoneurons in the lumbar spinal cord. Expression of NLRP3 inflammasome proteins and levels of activated caspase 1 and mature interleukin 1 beta were significantly reduced in SOD1(G93A) mice supplemented with E2.	[Heitzer, Marius; Kaiser, Sarah; Kanagaratnam, Mithila; Zendedel, Adib; Hartmann, Philipp; Beyer, Cordian; Johann, Sonja] Rhein Westfal TH Aachen, Fac Med, Inst Neuroanat, Wendlingweg 2, D-52074 Aachen, Germany; [Zendedel, Adib] Guilan Univ Med Sci, Fac Med, Dept Anat Sci, Rasht, Iran; [Beyer, Cordian] JARA BRAIN, D-52074 Aachen, Germany	Johann, S (corresponding author), Rhein Westfal TH Aachen, Fac Med, Inst Neuroanat, Wendlingweg 2, D-52074 Aachen, Germany.	sjohann@ukaachen.de			Medical Faculty of the RWTH Aachen University (START)	We would like to thank U. Zahn (Institute of Neuroanatomy) for the technical support. This work was supported by a research grant from the Medical Faculty of the RWTH Aachen University (START, SJ).	Acaz-Fonseca E, 2016, PROG NEUROBIOL, V144, P5, DOI 10.1016/j.pneurobio.2016.06.002; Alves CJ, 2011, BRAIN RES, V1394, P90, DOI 10.1016/j.brainres.2011.02.060; Annand RR, 1999, BIOCHEM J, V342, P655, DOI 10.1042/0264-6021:3420655; Apolloni S, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0658-8; Arevalo MA, 2012, J NEUROENDOCRINOL, V24, P183, DOI 10.1111/j.1365-2826.2011.02156.x; Arevalo MA, 2010, BBA-GEN SUBJECTS, V1800, P1106, DOI 10.1016/j.bbagen.2009.10.002; Ascenzi Paolo, 2006, Molecular Aspects of Medicine, V27, P299, DOI 10.1016/j.mam.2006.07.001; Astiz M, 2014, NEUROTOX RES, V25, P271, DOI 10.1007/s12640-013-9417-0; Ben Haim Lucile, 2015, Front Cell Neurosci, V9, P278, DOI 10.3389/fncel.2015.00278; Blasco H, 2012, AMYOTROPH LATERAL SC, V13, P585, DOI 10.3109/17482968.2012.706303; Boileau C, 2002, ARTHRITIS RHEUM, V46, P2637, DOI 10.1002/art.10518; Boland R, 2008, STEROIDS, V73, P859, DOI 10.1016/j.steroids.2007.12.027; Brites D, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00117; Cario-Toumaniantz C, 1998, J PHYSIOL-LONDON, V508, P659, DOI 10.1111/j.1469-7793.1998.659bp.x; Cervetto C, 2013, TOXICOLOGY, V311, P69, DOI 10.1016/j.tox.2013.04.004; Chakrabarti M, 2014, BRAIN RES BULL, V109, P22, DOI 10.1016/j.brainresbull.2014.09.004; Charlier TD, 2013, J EXP NEUROSCI, V7, P31, DOI 10.4137/JEN.S11268; Chen JY, 2015, MOL MED REP, V12, P1733, DOI 10.3892/mmr.2015.3601; Chen S, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-28; Chiappetta O, 2007, INT REV NEUROBIOL, V82, P357, DOI 10.1016/S0074-7742(07)82019-8; Cho J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061186; Choi CI, 2008, J NEUROL SCI, V268, P40, DOI 10.1016/j.jns.2007.10.024; Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285; Cuzzocrea S, 2008, SHOCK, V29, P362, DOI 10.1097/shk.0b013e31814545dc; Das A, 2011, J ENDOCRINOL, V208, P171, DOI 10.1677/JOE-10-0338; de Jong S, 2013, J NEUROL, V260, P507, DOI 10.1007/s00415-012-6665-5; Dhandapani KM, 2002, BIOL REPROD, V67, P1379, DOI 10.1095/biolreprod.102.003848; Dodel RC, 1999, J NEUROCHEM, V73, P1453, DOI 10.1046/j.1471-4159.1999.0731453.x; Dubyak GR, 2012, CELL MICROBIOL, V14, P1697, DOI 10.1111/cmi.12001; Enns DL, 2010, SPORTS MED, V40, P41, DOI 10.2165/11319760-000000000-00000; Feng L, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0409-2; Fischer LR, 2004, EXP NEUROL, V185, P232, DOI 10.1016/j.expneurol.2003.10.004; Foster HL, 1983, MOUSE BIOMEDICAL RES, P138; Gargiulo-Monachelli GM, 2014, HORM METAB RES, V46, P433, DOI 10.1055/s-0034-1371891; Gravel M, 2016, J NEUROSCI, V36, P1031, DOI 10.1523/JNEUROSCI.0854-15.2016; Groeneveld GJ, 2004, BRAIN RES, V1021, P128, DOI 10.1016/j.brainres.2004.06.024; GURNEY ME, 1994, NEW ENGL J MED, V331, P1721, DOI 10.1056/NEJM199412223312516; Habib P, 2015, J STEROID BIOCHEM, V146, P3, DOI 10.1016/j.jsbmb.2014.02.018; Habib P, 2014, J MOL NEUROSCI, V52, P277, DOI 10.1007/s12031-013-0137-y; Habib P, 2013, J STEROID BIOCHEM, V138, P195, DOI 10.1016/j.jsbmb.2013.06.003; Haisenleder DJ, 2011, ENDOCRINOLOGY, V152, P4443, DOI 10.1210/en.2011-1501; Henkel JS, 2009, J NEUROIMMUNE PHARM, V4, P389, DOI 10.1007/s11481-009-9171-5; Ilieva H, 2009, J CELL BIOL, V187, P761, DOI 10.1083/jcb.200908164; Johann S, 2011, J NEUROENDOCRINOL, V23, P839, DOI 10.1111/j.1365-2826.2011.02192.x; Johann S, 2010, J NEUROENDOCRINOL, V22, P926, DOI 10.1111/j.1365-2826.2010.02006.x; Johann S, 2015, GLIA, V63, P2260, DOI 10.1002/glia.22891; Johann S, 2013, J STEROID BIOCHEM, V137, P71, DOI 10.1016/j.jsbmb.2012.11.006; Kadhim H, 2016, MED HYPOTHESES, V86, P14, DOI 10.1016/j.mehy.2015.11.022; Kanamori H, 2000, J BIOL CHEM, V275, P5867, DOI 10.1074/jbc.275.8.5867; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI 10.1139/y10-103; Kim HJ, 2012, BRAIN, V135, P2865, DOI 10.1093/brain/aws208; Kipp M, 2007, J NEUROENDOCRINOL, V19, P819, DOI 10.1111/j.1365-2826.2007.01588.x; Kipp M, 2016, NEUROSCI BIOBEHAV R, V67, P125, DOI 10.1016/j.neubiorev.2015.11.016; Kitajima Y, 2016, J ENDOCRINOL, V229, P267, DOI 10.1530/JOE-15-0476; Knippenberg S, 2010, BEHAV BRAIN RES, V213, P82, DOI 10.1016/j.bbr.2010.04.042; Krieg AJ, 2004, J BIOL CHEM, V279, P5025, DOI 10.1074/jbc.M307076200; Krieg SA, 2001, MOL ENDOCRINOL, V15, P1971, DOI 10.1210/me.15.11.1971; Lammerding L, 2016, NEUROENDOCRINOLOGY, V103, P460, DOI 10.1159/000439435; Liao B, 2012, EXP NEUROL, V237, P147, DOI 10.1016/j.expneurol.2012.06.011; Logroscino G, 2010, J NEUROL NEUROSUR PS, V81, P385, DOI 10.1136/jnnp.2009.183525; Loram LC, 2012, PSYCHONEUROENDOCRINO, V37, P1688, DOI 10.1016/j.psyneuen.2012.02.018; Lowe DA, 2010, EXERC SPORT SCI REV, V38, P61, DOI 10.1097/JES.0b013e3181d496bc; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; McCombe PA, 2010, GENDER MED, V7, P557, DOI 10.1016/j.genm.2010.11.010; McDowell ML, 2011, NEUROCHEM INT, V59, P175, DOI 10.1016/j.neuint.2011.04.011; Mead RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023244; Meissner F, 2010, P NATL ACAD SCI USA, V107, P13046, DOI 10.1073/pnas.1002396107; Moisse K, 2006, BBA-MOL BASIS DIS, V1762, P1083, DOI 10.1016/j.bbadis.2006.03.001; Mor G, 1999, J NEUROBIOL, V40, P484, DOI 10.1002/(SICI)1097-4695(19990915)40:4<484::AID-NEU6>3.0.CO;2-C; Patel P, 2015, NEUROTHERAPEUTICS, V12, P217, DOI 10.1007/s13311-014-0311-0; Philips T, 2014, EXP NEUROL, V262, P111, DOI 10.1016/j.expneurol.2014.05.015; Philips T, 2011, LANCET NEUROL, V10, P253, DOI 10.1016/S1474-4422(11)70015-1; Platania P, 2005, NEUROBIOL DIS, V20, P461, DOI 10.1016/j.nbd.2005.03.025; Pollanen E, 2010, GROWTH HORM IGF RES, V20, P372, DOI 10.1016/j.ghir.2010.07.003; Popat RA, 2006, NEUROEPIDEMIOLOGY, V27, P117, DOI 10.1159/000095550; Poppe L, 2014, EXP NEUROL, V262, P138, DOI 10.1016/j.expneurol.2014.07.001; Pozzi S, 2006, ANN NY ACAD SCI, V1089, P302, DOI 10.1196/annals.1386.035; Rizzo F, 2014, CELL MOL LIFE SCI, V71, P999, DOI 10.1007/s00018-013-1480-4; Rocha MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073846; Saito T, 2009, CIRC RES, V105, P343, DOI 10.1161/CIRCRESAHA.108.190041; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Scott S, 2008, AMYOTROPH LATERAL SC, V9, P4, DOI 10.1080/17482960701856300; Slowik A, 2015, J STEROID BIOCHEM, V153, P135, DOI 10.1016/j.jsbmb.2015.02.013; Sperlagh B, 2014, TRENDS PHARMACOL SCI, V35, P537, DOI 10.1016/j.tips.2014.08.002; Sunyach C, 2012, NEUROPHARMACOLOGY, V62, P2346, DOI 10.1016/j.neuropharm.2012.02.013; Tanaka K, 2008, EXP NEUROL, V211, P378, DOI 10.1016/j.expneurol.2008.02.004; Thornton P, 2006, J NEUROCHEM, V98, P258, DOI 10.1111/j.1471-4159.2006.03872.x; Thundyil J, 2015, AGEING RES REV, V24, P17, DOI 10.1016/j.arr.2014.11.003; Turner MR, 2013, AMYOTROPH LAT SCL FR, V14, P19, DOI 10.3109/21678421.2013.778554; Vaccari JPD, 2016, J NEUROCHEM, V136, P492, DOI 10.1111/jnc.13404; Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227; Valles SL, 2010, BRAIN RES, V1312, P138, DOI 10.1016/j.brainres.2009.11.044; van der Burgh R, 2016, ONCOTARGET, V7, P19265, DOI 10.18632/oncotarget.8086; Velders M, 2012, FASEB J, V26, P1909, DOI 10.1096/fj.11-194779; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Wei Q, 2015, LAB INVEST, V95, P804, DOI 10.1038/labinvest.2015.63; Xu YJ, 2016, BRAIN BEHAV IMMUN, V56, P175, DOI 10.1016/j.bbi.2016.02.022; Ye L, 2013, J NEUROCHEM, V125, P897, DOI 10.1111/jnc.12263; Young JL, 2000, J EXP MED, V191, P1535, DOI 10.1084/jem.191.9.1535; Zhao JJ, 2013, ARTHRITIS RHEUM-US, V65, P3176, DOI 10.1002/art.38174; Zhao TZ, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.449	102	27	27	2	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	DEC	2017	54	10					8429	8443		10.1007/s12035-016-0322-4			15	Neurosciences	Neurosciences & Neurology	FM8MF	WOS:000415341900071	27957680				2021-06-18	
J	Tal, S; Hadanny, A; Sasson, E; Suzin, G; Efrati, S				Tal, Sigal; Hadanny, Amir; Sasson, Efrat; Suzin, Gil; Efrati, Shai			Hyperbaric Oxygen Therapy Can Induce Angiogenesis and Regeneration of Nerve Fibers in Traumatic Brain Injury Patients	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						hyperbaric oxygen; DTI; tractography; angiogenesis; MRI; perfusion; TBI; post-concussion	POST-CONCUSSION SYNDROME; POSTTRAUMATIC-STRESS-DISORDER; HIGH-RESOLUTION MEASUREMENT; WHITE-MATTER INTEGRITY; TRACER BOLUS PASSAGES; HEAD-INJURIES; CEREBRAL-ISCHEMIA; UNITED-STATES; VISUAL MEMORY; MILD	Background: Recent clinical studies in stroke and traumatic brain injury (TBI) victims suffering chronic neurological injury present evidence that hyperbaric oxygen therapy (HBOT) can induce neuroplasticity. Objective: To assess the neurotherapeutic effect of HBOT on prolonged post-concussion syndrome (PPCS) due to TBI, using brain microstructure imaging. Methods: Fifteen patients afflicted with PPCS were treated with 60 daily HBOT sessions. Imaging evaluation was performed using Dynamic Susceptibility Contrast-Enhanced (DSC) and Diffusion Tensor Imaging (DTI) MR sequences. Cognitive evaluation was performed by an objective computerized battery (NeuroTrax). Results: HBOT was initiated 6 months to 27 years (10.3 +/- 3.2 years) from injury. After HBOT, DTI analysis showed significantly increased fractional anisotropy values and decreased mean diffusivity in both white and gray matter structures. In addition, the cerebral blood flow and volume were increased significantly. Clinically, HBOT induced significant improvement in the memory, executive functions, information processing speed and global cognitive scores. Conclusions: The mechanisms by which HBOT induces brain neuroplasticity can be demonstrated by highly sensitive MRI techniques of DSC and DTI. HBOT can induce cerebral angiogenesis and improve both white and gray microstructures indicating regeneration of nerve fibers. The micro structural changes correlate with the neurocognitive improvements.	[Tal, Sigal; Hadanny, Amir; Efrati, Shai] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel; [Tal, Sigal] Assaf Harofeh Med Ctr, Radiol Dept, Zerifin, Israel; [Hadanny, Amir; Suzin, Gil; Efrati, Shai] Assaf Harofeh Med Ctr, Sagol Ctr Hyperbar Med & Res, Zerifin, Israel; [Hadanny, Amir] Bar Ilan Univ, Fac Med, Ramat Gan, Israel; [Sasson, Efrat] WiseImage, Hod Hasharon, Israel; [Efrati, Shai] Assaf Harofeh Med Ctr, Res & Dev Unit, Zerifin, Israel; [Efrati, Shai] Tel Aviv Univ, Sagol Sch Neurosci, Tel Aviv, Israel	Hadanny, A; Efrati, S (corresponding author), Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.; Hadanny, A; Efrati, S (corresponding author), Assaf Harofeh Med Ctr, Sagol Ctr Hyperbar Med & Res, Zerifin, Israel.; Hadanny, A (corresponding author), Bar Ilan Univ, Fac Med, Ramat Gan, Israel.; Efrati, S (corresponding author), Assaf Harofeh Med Ctr, Res & Dev Unit, Zerifin, Israel.; Efrati, S (corresponding author), Tel Aviv Univ, Sagol Sch Neurosci, Tel Aviv, Israel.	amir.had@gmail.com; efratishai@013.net					Achiron A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071058; Alexander AL, 2011, BRAIN CONNECT, V1, P423, DOI 10.1089/brain.2011.0071; Arenth PM, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e318289ede5; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Barrett KF, 2004, UNDERSEA HYPERBAR M, V31, P395; BAUER RM, 1984, J CLIN NEURO-OPHTHAL, V4, P39; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Boussi-Gross R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079995; Bucur B, 2008, NEUROBIOL AGING, V29, P1070, DOI 10.1016/j.neurobiolaging.2007.02.008; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Charlton RA, 2006, NEUROLOGY, V66, P217, DOI 10.1212/01.wnl.0000194256.15247.83; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen ZQ, 2010, J MAGN RESON IMAGING, V31, P1054, DOI 10.1002/jmri.22142; CHIU WT, 1993, J TRAUMA, V35, P969, DOI 10.1097/00005373-199312000-00034; Doniger GM, 2014, GUIDE NORMATIVE DATA; Duan SS, 2015, INT J NEUROSCI, V125, P625, DOI 10.3109/00207454.2014.956101; Dwolatzky Tzvi, 2003, BMC Geriatr, V3, P4, DOI 10.1186/1471-2318-3-4; Efrati S, 2014, EXPERT REV NEUROTHER, V14, P233, DOI 10.1586/14737175.2014.884928; Efrati S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053716; Golden Z, 2006, DISABIL REHABIL, V28, P1379, DOI 10.1080/09638280600638364; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Haberg AK, 2015, J NEUROSCI RES, V93, P1109, DOI 10.1002/jnr.23534; Hadanny A, 2016, EXPERT REV NEUROTHER, V16, P875, DOI 10.1080/14737175.2016.1205487; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Heilman K M, 1970, Trans Am Neurol Assoc, V95, P259; Hu Q, 2014, STROKE, V45, P1807, DOI 10.1161/STROKEAHA.114.005116; Huang L, 2011, MED GAS RES, V1, DOI 10.1186/2045-9912-1-21; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jiang Q, 2005, NEUROIMAGE, V28, P698, DOI 10.1016/j.neuroimage.2005.06.063; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lee YS, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/512978; Leemans A., 2009, P INT SOC MAG RESON, V17, P3537, DOI DOI 10.1093/occmed/kqr069; Li L, 2016, CHINESE MED J-PEKING, V129, P1091, DOI 10.4103/0366-6999.180518; Lin KC, 2012, J TRAUMA ACUTE CARE, V72, P650, DOI 10.1097/TA.0b013e31823c575f; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lockhart SN, 2014, NEUROPSYCHOL REV, V24, P271, DOI 10.1007/s11065-014-9268-3; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Melton JL, 2005, PSYCHOMETRIC EVALUAT; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Mu J, 2011, MED GAS RES, V1, DOI 10.1186/2045-9912-1-14; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Neubauer RA, 1998, NEUROL RES, V20, pS33; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Ostergaard L, 1996, MAGNET RESON MED, V36, P726, DOI 10.1002/mrm.1910360511; Ostergaard L, 1996, MAGN RESON MED, V36, P715, DOI 10.1002/mrm.1910360510; Ostergaard L, 2014, J CEREBR BLOOD F MET, V34, P1585, DOI 10.1038/jcbfm.2014.131; Peng ZR, 2014, J NEUROL SCI, V342, P114, DOI 10.1016/j.jns.2014.04.037; Perez AM, 2014, J NEUROTRAUM, V31, P1478, DOI 10.1089/neu.2013.3216; Rocha FT, 2005, COGNITIVE BRAIN RES, V22, P359, DOI 10.1016/j.cogbrainres.2004.09.008; Sagi Y, 2012, NEURON, V73, P1195, DOI 10.1016/j.neuron.2012.01.025; Sasson E, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00032; Schweiger A., 2003, ACTA NEUROPSYCHOLOGI, V1, P407, DOI DOI 10.5604/17307503/9168; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Sepehrband F, 2015, HUM BRAIN MAPP, V36, P3687, DOI 10.1002/hbm.22872; Sepulcre J, 2009, NEUROIMAGE, V47, P773, DOI 10.1016/j.neuroimage.2009.04.054; Shi XY, 2006, CHINESE MED J-PEKING, V119, P1978, DOI 10.1097/00029330-200612010-00007; Shi Xiao-yan, 2003, Chin J Traumatol, V6, P346; Shinoura N, 2007, NEUROCASE, V13, P127, DOI 10.1080/13554790701399254; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Sugiyama K, 2009, J NEUROTRAUM, V26, P1879, DOI [10.1089/neu.2008.0839, 10.1089/neu.2008-0839]; Tal S, 2015, RESTOR NEUROL NEUROS, V33, P943, DOI 10.3233/RNN-150585; Thaler A, 2012, NEUROLOGY, V79, P1027, DOI 10.1212/WNL.0b013e3182684646; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Wada T, 2012, AM J NEURORADIOL, V33, P2117, DOI 10.3174/ajnr.A3141; Wright JK, 2009, UNDERSEA HYPERBAR M, V36, P391; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Zhang John H, 2005, Pathophysiology, V12, P63, DOI 10.1016/j.pathophys.2005.01.003; Zur D, 2015, J NEURO-OPHTHALMOL, V35, P26, DOI 10.1097/WNO.0000000000000199	80	27	30	0	14	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	OCT 19	2017	11								508	10.3389/fnhum.2017.00508			12	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	FK1LQ	WOS:000413243300001	29097988	DOAJ Gold, Green Published			2021-06-18	
J	Gao, HB; Han, ZL; Huang, S; Bai, RJ; Ge, XT; Chen, FL; Lei, P				Gao, Huabin; Han, Zhaoli; Huang, Shan; Bai, Ruojing; Ge, Xintong; Chen, Fanglian; Lei, Ping			Intermittent hypoxia caused cognitive dysfunction relate to miRNAs dysregulation in hippocampus	BEHAVIOURAL BRAIN RESEARCH			English	Article						Obstructive sleep apnea; Cognition; microRNA; Intermittent hypoxia; Hippocampus	TRAUMATIC BRAIN-INJURY; OBSTRUCTIVE SLEEP-APNEA; EXPRESSION; MICRORNA; METASTASIS; MIR-21	Intermittent hypoxia (IH) is a characteristic pathophysiological change of obstructive sleep apnea (OSA), a commonly diagnosed chronic sleep disorder. With the process of OSA, patients will suffer from the nervous system damage and appear to multiple cognitive dysfunction. The mechanism that how IH causes cognitive impairment is still unknown. Both control and experimental rats were placed in conditions absence and presence of intermittent hypoxia (IH) for 8 h a day for a week, two weeks and four weeks, and then followed by behavioral assessments with Morris Water Maze (MVVM) test. The results showed that the escape latency of the tested animals to IH significantly increased the escape latency on the last four training days in comparison to the control group. Consistent with this, the expressions of apoptosis/anti-apoptosis proteins were both changed in the hippocampus. Then we utilized the miRNA microarray assay to investigate the level of miRNA expression in rat hippocampus which suffered from intermittent hypoxia. It is noteworthy that the expressions of miR-26b and miR-207 were consistently dysregulated in all the experimental groups post IH. And we utilized qRT-PCR methods to verify the microarray results. Our results showed that microarray based analysis of microRNA expression in rat hippocampus after IH has shown that some microRNAs such as miR-26b and miR-207 could be involved in the OSA-induced cognitive impairments.	[Gao, Huabin; Huang, Shan; Ge, Xintong; Chen, Fanglian] Tianjin Med Univ, Gen Hosp, Tianjin Neurol Inst, Dept Neurosurg, Tianjin 300052, Peoples R China; [Han, Zhaoli; Bai, Ruojing; Lei, Ping] Tianjin Med Univ, Gen Hosp, Tianjin Inst Geriatr, Tianjin 300052, Peoples R China	Lei, P (corresponding author), Tianjin Med Univ, Gen Hosp, Tianjin Geriatr Inst, Dept Geriatr, Tianjin 300052, Peoples R China.	leiping1974@163.com	Ge, Xintong/X-4889-2019	Ge, Xintong/0000-0001-7153-952X	National Clinical Key Subject Construction Project of NHFPC Fund; National Natural Science Funds Fund [81471252]; Tianjin Municipal Science and Technology Commission natural fund project [13JCYBJC23700]; Natural Science Foundation for the YouthNational Natural Science Foundation of China (NSFC) [81501055]	This work was supported by National Clinical Key Subject Construction Project of NHFPC Fund, The National Natural Science Funds Fund (81471252) and Tianjin Municipal Science and Technology Commission natural fund project (13JCYBJC23700)and Natural Science Foundation for the Youth (81501055).	Botling J, 2009, DIAGN MOL PATHOL, V18, P44, DOI 10.1097/PDM.0b013e3181857e92; Chen CYA, 2016, NUCLEIC ACIDS RES, V44, P3772, DOI 10.1093/nar/gkw205; Chen X, 2010, NEUROL RES, V32, P1097, DOI 10.1179/016164110X12681290831162; Dempsey JA, 2010, PHYSIOL REV, V90, P47, DOI 10.1152/physrev.00043.2008; Dewan NA, 2015, CHEST, V147, P266, DOI 10.1378/chest.14-0500; Duan GQ, 2015, TUMOR BIOL, V36, P6201, DOI 10.1007/s13277-015-3305-6; Gao J, 2011, ONCOL LETT, V2, P1019, DOI 10.3892/ol.2011.413; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Goldbart A, 2003, NEUROSCIENCE, V122, P585, DOI 10.1016/j.neuroscience.2003.08.054; Guimbellot JS, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-15; Huang JC, 2007, NAT METHODS, V4, P1045, DOI 10.1038/nmeth1130; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Lam CS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117990; Lavie L, 2015, SLEEP MED REV, V20, P27, DOI 10.1016/j.smrv.2014.07.003; Li DM, 2016, BIOCHEM BIOPH RES CO, V472, P465, DOI 10.1016/j.bbrc.2016.01.163; Li L, 2013, NEUROMOL MED, V15, P593, DOI 10.1007/s12017-013-8244-z; Montalban E, 2014, NEUROMOL MED, V16, P415, DOI 10.1007/s12017-014-8292-z; Nallamshetty S, 2013, FREE RADICAL BIO MED, V64, P20, DOI 10.1016/j.freeradbiomed.2013.05.022; Pickering C, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-97; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Row BW, 2007, ADV EXP MED BIOL, V618, P51; Sabirzhanov B, 2016, CELL DEATH DIFFER, V23, P654, DOI 10.1038/cdd.2015.132; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; Tao J, 2015, NEUROSCIENCE, V305, P1, DOI 10.1016/j.neuroscience.2015.07.064; Tsai MM, 2016, ONCOTARGET, V7, P39511, DOI 10.18632/oncotarget.8629; Wang Y., 2016, TUMOUR BIOL J INT SO; Wang Y, 2016, ONCOTARGET, V7, P24383, DOI 10.18632/oncotarget.8328; Wei N, 2016, MOL NEUROBIOL, V53, P6809, DOI 10.1007/s12035-015-9605-4; Zhao YN, 2016, MOL MED REP, V13, P137, DOI 10.3892/mmr.2015.4505	31	27	28	1	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	SEP 29	2017	335						80	87		10.1016/j.bbr.2017.06.025			8	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	FI5OQ	WOS:000412034100010	28647595				2021-06-18	
J	Giordano, C; Zappala, S; Kleiven, S				Giordano, Chiara; Zappala, Stefano; Kleiven, Svein			Anisotropic finite element models for brain injury prediction: the sensitivity of axonal strain to white matter tract inter-subject variability	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Axonal strain; Brain anisotropy; Traumatic brain injury; Finite element analysis	IN-DIFFUSION MRI; FIBER TRACTS; HEAD; TOLERANCE; TRAUMA; DAMAGE	Computational models incorporating anisotropic features of brain tissue have become a valuable tool for studying the occurrence of traumatic brain injury. The tissue deformation in the direction of white matter tracts (axonal strain) was repeatedly shown to be an appropriate mechanical parameter to predict injury. However, when assessing the reliability of axonal strain to predict injury in a population, it is important to consider the predictor sensitivity to the biological inter-subject variability of the human brain. The present study investigated the axonal strain response of 485 white matter subject-specific anisotropic finite element models of the head subjected to the same loading conditions. It was observed that the biological variability affected the orientation of the preferential directions (coefficient of variation of 39.41% for the elevation angle-coefficient of variation of 29.31% for the azimuth angle) and the determination of the mechanical fiber alignment parameter in the model (gray matter volume 55.55-70.75%). The magnitude of the maximum axonal strain showed coefficients of variation of 11.91%. On the contrary, the localization of the maximum axonal strain was consistent: the peak of strain was typically located in a 2 cm(3) volume of the brain. For a sport concussive event, the predictor was capable of discerning between non-injurious and concussed populations in several areas of the brain. It was concluded that, despite its sensitivity to biological variability, axonal strain is an appropriate mechanical parameter to predict traumatic brain injury.	[Giordano, Chiara; Zappala, Stefano; Kleiven, Svein] Royal Inst Technol KTH, Sch Technol & Hlth, Halsovagen 11C, S-14157 Huddinge, Sweden	Giordano, C (corresponding author), Royal Inst Technol KTH, Sch Technol & Hlth, Halsovagen 11C, S-14157 Huddinge, Sweden.	chiaragi@kth.se		Zappala, Stefano/0000-0002-7057-8575	NIH Institutes and CentersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1U54MH091657]; McDonnell Center for Systems Neuroscience at Washington University; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [U54MH091657] Funding Source: NIH RePORTER	Data were provided [in part] by the Human Connectome Project, WU-Minn Consortium (Principal Investigators: David Van Essen and Kamil Ugurbil; 1U54MH091657) funded by the 16 NIH Institutes and Centers that support the NIH Blueprint for Neuroscience Research; and by the McDonnell Center for Systems Neuroscience at Washington University.	Alexander DC, 2001, IEEE T MED IMAGING, V20, P1131, DOI 10.1109/42.963816; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Burgel U, 2006, NEUROIMAGE, V29, P1092, DOI 10.1016/j.neuroimage.2005.08.040; Burgel U, 1999, NEUROIMAGE, V10, P489, DOI 10.1006/nimg.1999.0497; Caminiti R, 2013, J NEUROSCI, V33, P14501, DOI 10.1523/JNEUROSCI.0761-13.2013; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Colgan NC, 2010, PROG BIOPHYS MOL BIO, V103, P304, DOI 10.1016/j.pbiomolbio.2010.09.008; Corouge I, 2004, 2004 2ND IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING: MACRO TO NANO, VOLS 1 and 2, P344; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; Gennarelli T, 2015, P 2015 IRCOBI C LYON; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Gerig G, 2004, P 26 ANN INT C IEEE; Giordano C, 2014, J BIOMECH, V47, P1052, DOI 10.1016/j.jbiomech.2013.12.036; Giordano Chiara, 2016, Stapp Car Crash J, V60, P363; Giordano Chiara, 2014, Stapp Car Crash J, V58, P29; Glasser MF, 2013, NEUROIMAGE, V80, P105, DOI 10.1016/j.neuroimage.2013.04.127; Grabner G, 2006, LECT NOTES COMPUT SC, V4191, P58; Hardy W, 2007, STAPP CAR CRASH J, P51; Hardy W N, 2001, Stapp Car Crash J, V45, P337; HCP, 2014, WU MINN HCP 500 SUBJ, P101; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Jenkinson M, 2015, TEMPLATES ATLASES IN; Ji SB, 2015, J NEUROTRAUM, V32, P441, DOI 10.1089/neu.2013.3268; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Kang WH, 2015, BIOMECH MODEL MECHAN, V14, P561, DOI 10.1007/s10237-014-0622-4; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Koay CG, 2006, MAGN RESON MED, V55, P930, DOI 10.1002/mrm.20832; Kraft RH, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002619; Kristoffersen A, 2011, MAGN RESON MED, V66, P1639, DOI 10.1002/mrm.22960; Lee CEC, 2009, NEURORADIOLOGY, V51, P3, DOI 10.1007/s00234-008-0441-3; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Newman J A, 2000, Stapp Car Crash J, V44, P215; Oishi K, 2008, NEUROIMAGE, V43, P447, DOI 10.1016/j.neuroimage.2008.07.009; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Sadeghi N, 2015, NEUROIMAGE, V109, P480, DOI 10.1016/j.neuroimage.2014.12.084; Sahoo D, 2015, P IRCOBI C LYON FRAN; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Sotiropoulos SN, 2013, NEUROIMAGE, V80, P125, DOI 10.1016/j.neuroimage.2013.05.057; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Takhounts EG, 2008, STAPP CAR C, V52, P1; Thiebaut de Schotten M, 2011, NEUROIMAGE, V54, P49, DOI 10.1016/j.neuroimage.2010.07.055; Veenith TV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065941; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Yendiki A., 2011, FRONT NEUROINFORM, V5, P1; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	54	27	27	0	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	AUG	2017	16	4					1269	1293		10.1007/s10237-017-0887-5			25	Biophysics; Engineering, Biomedical	Biophysics; Engineering	FA5NH	WOS:000405489600012	28233136	Green Published, Other Gold			2021-06-18	
J	Hawley, C; Sakr, M; Scapinello, S; Salvo, J; Wrenn, P				Hawley, Carol; Sakr, Magdy; Scapinello, Sarah; Salvo, Jesse; Wrenn, Paul			Traumatic brain injuries in older adults-6 years of data for one UK trauma centre: retrospective analysis of prospectively collected data	EMERGENCY MEDICINE JOURNAL			English	Article							SEVERE HEAD-INJURY; GLASGOW COMA SCALE; MORTALITY; SEVERITY; EPIDEMIOLOGY; PREDICTION; VALIDATION; SYSTEM; DEATH; MODEL	Objectives Our aim was to determine the incidence of traumatic brain injury (TBI) in older adults and investigate the relationship between injury characteristics and outcomes. Methods Retrospective analysis of prospectively collected data submitted to Trauma Audit and Research Network (TARN) database for a major trauma centre in the West Midlands, UK, from 2008 to 2014. The Mayo Scale was used to categorise TBI. All patients were aged >= 65 years and were admitted with head or brain injuries meeting TARN inclusion criteria: injury resulting in immediate admission to hospital for 3 days, admitted to a high dependency area or death following trauma. We determined age, gender, mechanism of injury, Injury Severity Score, presenting Glasgow Coma Scale (GCS) and Mayo Score, and the association of outcome (Glasgow Outcome Scale (GOS)) with age and clinical presentation. Results 4413 patients were admitted with trauma meeting TARN criteria: 1389 were >= 65 years and 45% (624) had TBI. For patients >= 65 years with TBI, mean age was 79 (range 65-99); 56% were men. Falls accounted for 85% of all TBIs. Most TBIs were moderate/severe (80%) by the Mayo criteria. Of the 279 patients with subdural haematoma, 28% had neurosurgery. Most patients survived TBI (78%); 57% had a good outcome on GOS at discharge (not requiring care package). Mortality was associated with increased age (17% in ages 65-74 years, 19% in 75-84 years, 30% in >= 85 years, p=0.03). Outcome was significantly associated with injury severity (p=0.0001). Conclusions Patients with TBI represented 45% of all trauma cases meeting TARN inclusion criteria. Falls at home accounted for most TBIs. Most had moderate/severe TBI, yet over half made a good recovery on GOS. Our data indicate that injury prevention initiatives should focus on home safety. Further research is needed to examine rehabilitation and follow-up after hospital discharge.	[Hawley, Carol] Warwick Med Sch, Div Mental Hlth & Wellbeing, Coventry CV4 7AL, W Midlands, England; [Sakr, Magdy] Univ Hosp Coventry & Warwickshire, Dept Emergency Med, Coventry, W Midlands, England; [Scapinello, Sarah] Univ Warwick, Warwick Med Sch, Coventry, W Midlands, England; [Salvo, Jesse; Wrenn, Paul] Univ Hosp Coventry & Warwickshire, Dept Emergency Care, Coventry, W Midlands, England	Hawley, C (corresponding author), Warwick Med Sch, Div Mental Hlth & Wellbeing, Coventry CV4 7AL, W Midlands, England.	c.a.hawley@warwick.ac.uk	Hawley, Carol/AAG-3830-2019; Hawley, Carmel Mary/C-4905-2011	Hawley, Carmel Mary/0000-0002-1392-5649	University of Warwick under University Research Scholarship Scheme	SS received a bursary from the University of Warwick under the University Research Scholarship Scheme. The researchers are independent of the above funding.	Boye NDA, 2013, TRAUMA, V15, P29, DOI 10.1177/1460408612463145; Caterino JM, 2011, ACAD EMERG MED, V18, P1014, DOI 10.1111/j.1553-2712.2011.01164.x; Centers for Disease Control and Prevention (CDC), 2013, INJ PREV CONTR TRAUM; Centres for Disease Control and Prevention, 2013, HOM RECR SAF FALLS O; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gaetani P, 2012, J NEUROSURG SCI, V56, P231; Harvey LA, 2012, INJURY, V43, P1821, DOI 10.1016/j.injury.2012.07.188; Health and Social Care Information Centre, 2012, ACC EM ATT ENGL 2012; Kehoe A, 2015, EMERG MED J, V32, P613, DOI 10.1136/emermed-2013-203488; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Office for National Statistics, 2013, POP EST UK ENGL WAL; Patel HC, 2010, ACTA NEUROCHIR, V152, P1353, DOI 10.1007/s00701-010-0666-x; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel P, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5166; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sterling DA, 2001, J TRAUMA, V50, P116, DOI 10.1097/00005373-200101000-00021; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Swann I, 1999, TRAUMA, V1, P143; TEASDALE G, 1974, LANCET, V2, P81; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Trauma audit and research network, 2014, PROC MAN; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034	28	27	28	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	AUG	2017	34	8					509	+		10.1136/emermed-2016-206506			8	Emergency Medicine	Emergency Medicine	FB0SF	WOS:000405854100005	28052919	Green Published, Bronze			2021-06-18	
J	Seal, KH; Bertenthal, D; Barnes, DE; Byers, AL; Strigo, I; Yaffe, K				Seal, Karen H.; Bertenthal, Daniel.; Barnes, Deborah E.; Byers, Amy L.; Strigo, Irina; Yaffe, Kristine		Chronic Effects Neurotrauma Consor	Association of Traumatic Brain Injury With Chronic Pain in Iraq and Afghanistan Veterans: Effect of Comorbid Mental Health Conditions	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Military Health Scientific Research Symposium	AUG 15-18, 2016	Kissimmee, FL			Chronic pain; Depression; Rehabilitation; Veterans	POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSIVE SYMPTOMS; ENDURING FREEDOM; PERSISTENT PAIN; US VETERANS; POLYTRAUMA; PTSD; WAR; PREVALENCE; REHABILITATION	Objective: To characterize the association between traumatic brain injury (TBI) and chronic pain and pain disability in the context of comorbid conditions, posttraumatic stress disorder (PTSD), and depression to better inform care of combat veterans. Design: Retrospective cohort study. Setting: Medical centers and community clinics. Participants: Combat veterans (N = 116,913) who received Veterans Affairs care between October 1, 2007 and March 31, 2015, completed a Comprehensive Traumatic Brain Injury Evaluation, and received a criterion standard diagnosis of TBI (none, mild, or moderate to severe). Interventions: Not applicable. Main Outcome Measures: Chronic pain defined as >= 2 of the same pain diagnoses >= 90 days apart and pain disability defined as self-reported pain causing moderate to very severe interference with daily functioning. Results: Fifty-seven percent received >= 1 chronic pain diagnosis. Compared to those with no TBI, PTSD, or depression, there was an independent risk for chronic pain in veterans with mild TBI, which was higher in veterans with moderate to severe TBI. The risk of chronic pain was additive and highest when all 3 conditions-TBI, depression, and PTSD-were copresent (adjusted relative risk, 1.53 and 1.62 [95% confidence interval, 1.50-1.66] for mild and moderate or severe TBI, respectively, plus other diagnoses). The relation of pain disability to TBI, PTSD, and depression followed a similar additive pattern. Conclusions: In combat veterans, chronic pain and pain disability are most commonly associated with TBI in conjunction with PTSD, depression, or both. Integrated models of care that simultaneously address pain in conjunction with TBI, PTSD, and depression will likely be the most clinically effective. Published by Elsevier Inc.	[Seal, Karen H.; Bertenthal, Daniel.; Barnes, Deborah E.; Byers, Amy L.; Strigo, Irina; Yaffe, Kristine] San Francisco VA Hlth Care Syst, San Francisco, CA USA; [Seal, Karen H.; Barnes, Deborah E.; Byers, Amy L.; Strigo, Irina; Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA	Seal, KH (corresponding author), Univ Calif San Francisco, San Francisco VA Hlth Care Syst, Dept Med, 4150 Clement St,Box 111A-1, San Francisco, CA 94121 USA.; Seal, KH (corresponding author), Univ Calif San Francisco, San Francisco VA Hlth Care Syst, Dept Psychiat, 4150 Clement St,Box 111A-1, San Francisco, CA 94121 USA.	Karen.Seal@ucsf.edu	strigo, irina A/L-9882-2016	strigo, irina A/0000-0002-8799-716X	Veterans Health Administration Clinical Sciences Research and Development [101 CX001246]; Department of DefenseUnited States Department of Defense [W81XWH-13-2-0095]	Supported by the Veterans Health Administration Clinical Sciences Research and Development (grant no. 101 CX001246) and by the Department of Defense (grant no. W81XWH-13-2-0095). The funders had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.	Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930; Asmundson Gordon J G, 2002, Pain Res Manag, V7, P7; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Bosco MA, 2013, HEADACHE, V53, P1518, DOI 10.1111/head.12172; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Centers for Disease Control and Prevention, 2016, CDC GUID PRESCR OP C; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cifu DX, 2013, J REHABIL RES DEV, V50, P1169, DOI 10.1682/JRRD.2013.01.0006; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Clark ME, 2009, PAIN MED, V10, P456, DOI 10.1111/j.1526-4637.2009.00589.x; Cummings P, 2009, STATA J, V9, P175, DOI 10.1177/1536867X0900900201; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Higgins DM, 2014, PAIN MED, V15, P782, DOI 10.1111/pme.12388; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jaramillo CA, 2016, HEADACHE, V56, P528, DOI 10.1111/head.12726; Krebs EE, 2009, J GEN INTERN MED, V24, P733, DOI 10.1007/s11606-009-0981-1; Lavigne G, 2015, PAIN, V156, pS75, DOI 10.1097/j.pain.0000000000000111; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Maguen S, 2012, J REHABIL RES DEV, V49, P1115, DOI 10.1682/JRRD.2011.02.0015; McLean SA, 2005, PSYCHOSOM MED, V67, P783, DOI 10.1097/01.psy.0000181276.49204.bb; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Otis JD, 2003, J REHABIL RES DEV, V40, P397, DOI 10.1682/JRRD.2003.09.0397; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Scholten JD, 2012, BRAIN INJURY, V26, P1177, DOI 10.3109/02699052.2012.661914; Seal KH, 2016, J REHABIL RES DEV, V53, P185, DOI 10.1682/JRRD.2014.12.0301; Seal KH, 2012, JAMA-J AM MED ASSOC, V307, P940, DOI 10.1001/jama.2012.234; Sherman Kristen Brewer, 2006, Phys Med Rehabil Clin N Am, V17, P473, DOI 10.1016/j.pmr.2005.11.007; Stojanovic MP, 2016, PAIN MED, V17, P2017, DOI 10.1093/pm/pnw042; Stratton KJ, 2014, J REHABIL RES DEV, V51, P1189, DOI 10.1682/JRRD.2014.04.0111; Strigo IA, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2013.116; Sullivan-Singh SJ, 2014, ARCH PHYS MED REHAB, V95, P1100, DOI 10.1016/j.apmr.2014.02.001; Tan G, 2009, PAIN MED, V10, P1237, DOI 10.1111/j.1526-4637.2009.00712.x; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558	38	27	28	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2017	98	8					1636	1645		10.1016/j.apmr.2017.03.026			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	FD1OF	WOS:000407305900017	28455190				2021-06-18	
J	Harrison, EB; Emanuel, K; Lamberty, BG; Morsey, BM; Li, M; Kelso, ML; Yelamanchili, SV; Fox, HS				Harrison, Emily B.; Emanuel, Katy; Lamberty, Benjamin G.; Morsey, Brenda M.; Li, Min; Kelso, Matthew L.; Yelamanchili, Sowmya V.; Fox, Howard S.			Induction of miR-155 after Brain Injury Promotes Type 1 Interferon and has a Neuroprotective Effect	FRONTIERS IN MOLECULAR NEUROSCIENCE			English	Article						gene expression; injury; neurodegeneration; inflammation	TOLL-LIKE RECEPTORS; INFLAMMATORY RESPONSES; MICRORNA EXPRESSION; SIGNALING PATHWAY; DENDRITIC CELLS; CORTICAL IMPACT; I INTERFERON; NEURONS; NEUROINFLAMMATION; MICROGLIA	Traumatic brain injury (TBI) produces profound and lasting neuroinflammation that has both beneficial and detrimental effects. Recent evidence has implicated microRNAs (miRNAs) in the regulation of inflammation both in the periphery and the CNS. We examined the expression of inflammation associated miRNAs in the context of TBI using a mouse controlled cortical impact (CCI) model and found increased levels of miR-21, miR-223 and miR-155 in the hippocampus after CCI. The expression of miR-155 was elevated 9-fold after CCI, an increase confirmed by in situ hybridization (ISH). Interestingly, expression of miR-155 was largely found in neuronal nuclei as evidenced by co-localization with DAPI in MAP2 positive neurons. In miR-155 knock out (KO) mice expression of type I interferons IFN alpha and IFN beta, as well as IFN regulatory factor 1 and IFN-induced chemokine CXCL10 was decreased after TBI relative to wild type (WT) mice. Unexpectedly, miR-155 KO mice had increased levels of microglial marker Iba1 and increased neuronal degeneration as measured by fluoro-jade C (FJC) staining, suggesting a neuroprotective role for miR-155 in the context of TBI. This work demonstrates a role for miR-155 in regulation of the IFN response and neurodegeneration in the aftermath of TBI. While the presence of neuronal nuclear miRNAs has been described previously, their importance in disease states is relatively unknown. Here, we show evidence of dynamic regulation and pathological function of a nuclear miRNA in TBI.	[Harrison, Emily B.; Emanuel, Katy; Lamberty, Benjamin G.; Morsey, Brenda M.; Li, Min; Yelamanchili, Sowmya V.; Fox, Howard S.] Univ Nebraska Med Ctr, Coll Med, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA; [Kelso, Matthew L.] Univ Nebraska Med Ctr, Coll Med, Dept Pharm Practice, Omaha, NE USA; [Harrison, Emily B.] Univ North Carolina Chapel Hill, Chapel Hill, NC USA; [Li, Min] Creighton Univ, Omaha, NE 68178 USA; [Kelso, Matthew L.] Medpace Reference Labs, Cincinnati, OH USA	Fox, HS (corresponding author), Univ Nebraska Med Ctr, Coll Med, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.	hfox@unmc.edu		Harrison, Emily/0000-0002-6934-3875	Nebraska Research Initiative Grant; University of Nebraska Medical Center Graduate Studies Research Fellowship; Herbert L. Davis Fellowship in Pharmacology; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [T32CA196589] Funding Source: NIH RePORTER	This work was supported by a Nebraska Research Initiative Grant, a University of Nebraska Medical Center Graduate Studies Research Fellowship and a Herbert L. Davis Fellowship in Pharmacology.	Bhela S, 2014, J IMMUNOL, V192, P2734, DOI 10.4049/jimmunol.1302326; Buller B, 2010, FEBS J, V277, P4299, DOI 10.1111/j.1742-4658.2010.07818.x; Butovsky O, 2015, INT J DEV NEUROSCI, V47, P5, DOI 10.1016/j.ijdevneu.2015.04.023; Butovsky O, 2015, ANN NEUROL, V77, P75, DOI 10.1002/ana.24304; Cardoso AL, 2016, CURR OPIN PHARMACOL, V26, P1, DOI 10.1016/j.coph.2015.09.001; Cardoso AL, 2012, IMMUNOLOGY, V135, P73, DOI 10.1111/j.1365-2567.2011.03514.x; Ceppi M, 2009, P NATL ACAD SCI USA, V106, P2735, DOI 10.1073/pnas.0811073106; Chaudhuri AD, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00160; Chen RL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050957; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Dagan LN, 2012, BLOOD, V119, P513, DOI 10.1182/blood-2011-08-370536; Dai R, 2011, TRANSL RES, V157, P163, DOI 10.1016/j.trsl.2011.01.007; Delhaye S, 2006, P NATL ACAD SCI USA, V103, P7835, DOI 10.1073/pnas.0602460103; Di Filippo M, 2013, NEUROBIOL DIS, V52, P229, DOI 10.1016/j.nbd.2012.12.009; Eisenhardt SU, 2015, BASIC RES CARDIOL, V110, DOI 10.1007/s00395-015-0490-9; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Fitch MT, 1999, J NEUROSCI, V19, P8182; Gabhann JN, 2010, J IMMUNOL, V184, P2314, DOI 10.4049/jimmunol.0902589; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Gesuete R, 2014, J NEUROPATH EXP NEUR, V73, P378, DOI 10.1097/NEN.0000000000000068; GIULIAN D, 1994, NEUROCHEM INT, V25, P227, DOI 10.1016/0197-0186(94)90066-3; Guedes JR, 2014, HUM MOL GENET, V23, P6286, DOI 10.1093/hmg/ddu348; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Harraz MM, 2012, P NATL ACAD SCI USA, V109, P18962, DOI 10.1073/pnas.1121288109; Harrison EB, 2016, FEBS OPEN BIO, V6, P835, DOI 10.1002/2211-5463.12092; Hauss-Wegrzyniak B, 2002, EXP NEUROL, V176, P336, DOI 10.1006/exnr.2002.7966; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Honda K, 2006, NAT REV IMMUNOL, V6, P644, DOI 10.1038/nri1900; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Karve IP, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0128-15.2016; Khudayberdiev SA, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00043; Kieseier BC, 2011, CNS DRUGS, V25, P491, DOI 10.2165/11591110-000000000-00000; Kosik KS, 2006, NAT REV NEUROSCI, V7, P911, DOI 10.1038/nrn2037; Koval ED, 2013, HUM MOL GENET, V22, P4127, DOI 10.1093/hmg/ddt261; Ksiazek-Winiarek DJ, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/172351; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Lippai D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070945; Liu L., 2014, ADV DIFFER EQU, V217, P9, DOI DOI 10.1371/J0URNAL.P0NE.0103948; Loeb GB, 2012, MOL CELL, V48, P760, DOI 10.1016/j.molcel.2012.10.002; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Maussion G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039301; Meissner L, 2016, J NEUROTRAUM, V33, P713, DOI 10.1089/neu.2015.4077; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; Nudo RJ, 2011, J COMMUN DISORD, V44, P515, DOI 10.1016/j.jcomdis.2011.04.004; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; O'Connell RM, 2012, ANNU REV IMMUNOL, V30, P295, DOI 10.1146/annurev-immunol-020711-075013; O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106; Parisi C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.491; Rasko JEJ, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0375-x; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Roberts TC, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.40; Rosato PC, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005028; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Serafini G, 2014, CELL MOL NEUROBIOL, V34, P17, DOI 10.1007/s10571-013-9997-5; Singh RP, 2013, AUTOIMMUN REV, V12, P1160, DOI 10.1016/j.autrev.2013.07.003; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stanczyk J, 2008, ARTHRITIS RHEUM, V58, P1001, DOI 10.1002/art.23386; Sun TY, 2014, J HUAZHONG U SCI-MED, V34, P548, DOI 10.1007/s11596-014-1313-1; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Thome AD, 2016, J NEUROSCI, V36, P2383, DOI 10.1523/JNEUROSCI.3900-15.2016; Thounaojam MC, 2013, MOL NEUROBIOL, V47, P1034, DOI 10.1007/s12035-013-8400-3; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Wang P, 2010, J IMMUNOL, V185, P6226, DOI 10.4049/jimmunol.1000491; Yelamanchili SV, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.56; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang L, 2012, GLIA, V60, P1888, DOI 10.1002/glia.22404; Zhang XM, 2012, CANCER RES, V72, P4707, DOI 10.1158/0008-5472.CAN-12-0639; Zhou HB, 2010, BLOOD, V116, P5885, DOI 10.1182/blood-2010-04-280156	72	27	27	0	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5099			FRONT MOL NEUROSCI	Front. Molec. Neurosci.	JUL 28	2017	10								228	10.3389/fnmol.2017.00228			12	Neurosciences	Neurosciences & Neurology	FC1MO	WOS:000406601700001	28804446	DOAJ Gold, Green Published			2021-06-18	
J	Wang, RL; Li, JC; Duan, YX; Tao, Z; Zhao, HP; Luo, YM				Wang, Rongliang; Li, Jincheng; Duan, Yunxia; Tao, Zhen; Zhao, Haiping; Luo, Yumin			Effects of Erythropoietin on Gliogenesis during Cerebral Ischemic/Reperfusion Recovery in Adult Mice	AGING AND DISEASE			English	Article						Brain ischemia; Erythropoietin; Microglial polarization; Gliogenesis; White matter injury	TRAUMATIC BRAIN-INJURY; WHITE-MATTER INJURY; MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; SPINAL-CORD-INJURY; NEUROLOGICAL FUNCTION; M2 MICROGLIA; ISCHEMIA; NEUROINFLAMMATION; NEUROGENESIS; ASTROCYTES	Erythropoietin (EPO) promotes oligodendrogenesis and attenuates white matter injury in neonatal rats. However, it is unknown whether this effect extends to adult mice and whether EPO regulate microglia polarization after ischemic stroke. Male adult C57BL/6 mice (25-30g) were subjected to 45 min of middle cerebral artery occlusion (MCAO). EPO (5000 IU/kg) or saline was injected intraperitoneally every other day after reperfusion. Neurological function was evaluated using the rotarod test at 1, 3, 7 and 14 days after MCAO. Brain tissue loss volume was determined by hematoxylin-eosin staining. Immunofluorescence staining and Western blot were also used to assess the severity of white matter injury and phenotypic changes in microglia/macrophages. Bromodeoxyuridine (BrdU) was injected intraperitoneally daily for 1 week to analyze the number of newly proliferating glia cells (oligodendrocytes, microglia, and astrocytes). We found that EPO significantly reduced Brain tissue loss volume, ameliorated white matter injury, and improved neurobehavioral outcomes at 14 days after MCAO (P< 0.05). In addition, EPO also increased the number of newly generated oligodendrocytes and attenuated the rapid hypertrophy and hyperplasia of microglia and astrocytes after ischemic stroke (P< 0.05). Furthermore, EPO reduced M1 microglia and increased M2 microglia (P< 0.05). Taken together, our results suggest that EPO treatment improves white matter integrity after cerebral ischemia, which could be attributed to EPO attenuating gliosis and facilitating the microglial polarization toward the beneficial M2 phenotype to promote oligodendrogenesis.	[Wang, Rongliang; Tao, Zhen; Zhao, Haiping; Luo, Yumin] Capital Med Univ, Xuanwu Hosp, Cerebrovasc Dis Res Inst, Beijing 100053, Peoples R China; [Wang, Rongliang; Tao, Zhen; Zhao, Haiping; Luo, Yumin] Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing 100053, Peoples R China; [Wang, Rongliang; Duan, Yunxia; Tao, Zhen; Zhao, Haiping; Luo, Yumin] Beijing Inst Brain Disorders, Beijing 100053, Peoples R China; [Wang, Rongliang; Duan, Yunxia; Tao, Zhen; Zhao, Haiping; Luo, Yumin] Beijing Key Lab Translat Med Cerebrovasc Dis, Beijing 100053, Peoples R China; [Li, Jincheng] Zibo Cent Hosp, Dept Neurol, Zibo 255036, Peoples R China	Zhao, HP; Luo, YM (corresponding author), Capital Med Univ, Xuanwu Hosp, Cerebrovasc Dis Res Inst, Beijing 100053, Peoples R China.	zhaohaiping1980@163.com; yumin111@ccmu.edu.cn			Natural Science Foundation in ChinaNational Natural Science Foundation of China (NSFC) [81471340, 81641054]	This project was supported by Natural Science Foundation in China (81471340, 81641054).	Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Back SA, 2005, NAT MED, V11, P966, DOI 10.1038/nm1279; Bond WS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00523; Chen YZ, 2013, BRAIN RES, V1495, P11, DOI 10.1016/j.brainres.2012.12.006; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Frisen J, 2016, ANNU REV CELL DEV BI, V32, P127, DOI 10.1146/annurev-cellbio-111315-124953; Goldman SA, 2014, NAT NEUROSCI, V17, P483, DOI 10.1038/nn.3685; Han LJ, 2015, STROKE, V46, P2628, DOI 10.1161/STROKEAHA.115.010091; Hao Z, 2015, TRANSL STROKE RES, V6, P407; Ho PW, 2005, STROKE, V36, P2742, DOI 10.1161/01.STR.0000189748.52500.a7; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Iwai M, 2007, STROKE, V38, P2795, DOI 10.1161/STROKEAHA.107.483008; Iwai M, 2010, STROKE, V41, P1032, DOI 10.1161/STROKEAHA.109.570325; Kuhn HG, 2015, COLD SPRING HARB PER, V7; Lynch AM, 2010, AGING DIS, V1, P262; Ma MM, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-117; Ma QF, 2016, AGING DIS, V7, P705, DOI 10.14336/AD.2016.0320; Matute C, 2013, STROKE, V44, P1204, DOI 10.1161/STROKEAHA.112.658328; McIver SR, 2010, NEUROSCIENCE, V169, P1364, DOI 10.1016/j.neuroscience.2010.04.070; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Shi H, 2015, EXP NEUROL, V272, P17, DOI 10.1016/j.expneurol.2015.03.017; Suenaga J, 2015, EXP NEUROL, V272, P109, DOI 10.1016/j.expneurol.2015.03.021; Susarla BT, 2014, ASN NEURO, V6, P94; Vitellaro-Zuccarello L, 2008, NEUROSCIENCE, V151, P452, DOI 10.1016/j.neuroscience.2007.11.004; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Xu W, 2016, SHOCK VIB, V2016, P1, DOI DOI 10.1016/J.SEPPUR.2016.01.012; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y	31	27	28	0	4	INT SOC AGING & DISEASE	FORT WORTH	EDITORIAL OFF, 3400 CAMP BOWIE BLVD, FORT WORTH, TX 76106 USA	2152-5250			AGING DIS	Aging Dis.	JUL	2017	8	4					410	419		10.14336/AD.2016.1209			10	Geriatrics & Gerontology	Geriatrics & Gerontology	FB6EM	WOS:000406234100005	28840056	DOAJ Gold, Green Published			2021-06-18	
J	Mir, S; Cai, WK; Carlson, SW; Saatman, KE; Andres, DA				Mir, Sajad; Cai, Weikang; Carlson, Shaun W.; Saatman, Kathryn E.; Andres, Douglas A.			IGF-1 mediated Neurogenesis Involves a Novel RIT1/Akt/Sox2 Cascade	SCIENTIFIC REPORTS			English	Article							GROWTH-FACTOR-I; NEURAL STEM-CELLS; ADULT HIPPOCAMPAL NEUROGENESIS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; DENTATE GYRUS; NEURONAL DIFFERENTIATION; TRANSCRIPTION FACTORS; PROGENITOR CELLS; ANALYSIS REVEALS	Insulin-like growth factor 1 (IGF-1) is known to have diverse effects on brain structure and function, including the promotion of stem cell proliferation and neurogenesis in the adult dentate gyrus. However, the intracellular pathways downstream of the IGF-1 receptor that contribute to these diverse physiological actions remain relatively uncharacterized. Here, we demonstrate that the Ras-related GTPase, RIT1, plays a critical role in IGF-1-dependent neurogenesis. Studies in hippocampal neuronal precursor cells (HNPCs) demonstrate that IGF-1 stimulates a RIT1-dependent increase in Sox2 levels, resulting in pro-neural gene expression and increased cellular proliferation. In this novel cascade, RIT1 stimulates Akt-dependent phosphorylation of Sox2 at T118, leading to its stabilization and transcriptional activation. When compared to wild-type HNPCs, RIT1(-/-)HNPCs show deficient IGF-1-dependent Akt signaling and neuronal differentiation, and accordingly, Sox2-dependent hippocampal neurogenesis is significantly blunted following IGF-1 infusion in knockout (RIT1(-/-)) mice. Consistent with a role for RIT1 function in the modulation of activity-dependent plasticity, exercise-mediated potentiation of hippocampal neurogenesis is also diminished in RIT1(-/-)mice. Taken together, these data identify the previously uncharacterized IGF1-RIT1-Akt-Sox2 signaling pathway as a key component of neurogenic niche sensing, contributing to the regulation of neural stem cell homeostasis.	[Mir, Sajad; Cai, Weikang; Andres, Douglas A.] Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; [Cai, Weikang] Harvard Med Sch, Joslin Diabet Ctr, Boston, MA 02215 USA; [Carlson, Shaun W.; Saatman, Kathryn E.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Carlson, Shaun W.; Saatman, Kathryn E.] Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY 40536 USA; [Carlson, Shaun W.] Univ Pittsburgh, Dept Neurosurg, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA	Andres, DA (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.	dandres@uky.edu	Cai, Weikang/K-2394-2019	Cai, Weikang/0000-0001-5638-0805; Carlson, Shaun/0000-0002-1413-5075	National Institutes of Health from the NINDS [R01 NS045103, R01 NS072302]; Kentucky Spinal Cord and Head Injury Research Trust [12-1A, 16-1]; Kentucky Lung Cancer Research Grant; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30GM110787]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM110787] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072302, R01NS045103] Funding Source: NIH RePORTER	This work was supported in part by National Institutes of Health Grant R01 NS045103(DAA) and R01 NS072302 (KES) from the NINDS and the Kentucky Spinal Cord and Head Injury Research Trust (Grants 12-1A and 16-1)(DAA) and a Kentucky Lung Cancer Research Grant(DAA). The funders had no role in study design, data collection and analysis, or preparation of the manuscript. We wish to thank Dr. Michael Mendenhall for assistance in the generation of recombinant viruses. The authors acknowledge the use of facilities in the University of Kentucky Center for Molecular Medicine Genetic Technologies Core. This core is supported in part by NIH Grant Number P30GM110787. We also acknowledge Linda Simmerman in the Spinal Cord and Brain Injury Center and Dr. Carole Moncman in the Department of Molecular and Cellular Biochemistry for help with confocal microscopy.	Aberg MAI, 2000, J NEUROSCI, V20, P2896; Amador-Arjona A, 2015, P NATL ACAD SCI USA, V112, pE1936, DOI 10.1073/pnas.1421480112; Amiri A, 2012, J NEUROSCI, V32, P5880, DOI 10.1523/JNEUROSCI.5462-11.2012; Andersen J, 2014, NEURON, V83, P1085, DOI 10.1016/j.neuron.2014.08.004; Archer TC, 2011, DEV BIOL, V350, P429, DOI 10.1016/j.ydbio.2010.12.013; Arsenijevic Y, 2001, J NEUROSCI, V21, P7194, DOI 10.1523/JNEUROSCI.21-18-07194.2001; Baxter RC, 2014, NAT REV CANCER, V14, P329, DOI 10.1038/nrc3720; BECK KD, 1995, NEURON, V14, P717, DOI 10.1016/0896-6273(95)90216-3; Berger AH, 2014, ONCOGENE, V33, P4418, DOI 10.1038/onc.2013.581; Bonaguidi MA, 2011, CELL, V145, P1142, DOI 10.1016/j.cell.2011.05.024; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Bracko O, 2012, J NEUROSCI, V32, P3376, DOI 10.1523/JNEUROSCI.4248-11.2012; Brazel CY, 2005, AGING CELL, V4, P197, DOI 10.1111/j.1474-9726.2005.00158.x; Brooker GJF, 2000, J NEUROSCI RES, V59, P332, DOI 10.1002/(SICI)1097-4547(20000201)59:3<332::AID-JNR6>3.0.CO;2-2; Bruel-Jungerman E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007901; Cai WK, 2012, NEUROSCI LETT, V531, P125, DOI 10.1016/j.neulet.2012.10.036; Cai WK, 2012, J NEUROSCI, V32, P9887, DOI 10.1523/JNEUROSCI.0375-12.2012; Cai WK, 2011, MOL BIOL CELL, V22, P3231, DOI 10.1091/mbc.E11-05-0400; Carlson SW, 2014, J NEUROPATH EXP NEUR, V73, P734, DOI 10.1097/NEN.0000000000000092; Chaker Z, 2015, AGING CELL, V14, P847, DOI 10.1111/acel.12365; Christian KM, 2014, ANNU REV NEUROSCI, V37, P243, DOI 10.1146/annurev-neuro-071013-014134; Cohen P, 2006, NAT REV MOL CELL BIO, V7, P867, DOI 10.1038/nrm2043; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; D'Addio F, 2015, CELL STEM CELL, V17, P486, DOI 10.1016/j.stem.2015.07.010; Darcy MJ, 2014, HIPPOCAMPUS, V24, P1317, DOI 10.1002/hipo.22313; DRAGO J, 1991, P NATL ACAD SCI USA, V88, P2199, DOI 10.1073/pnas.88.6.2199; Faigle R, 2013, BBA-GEN SUBJECTS, V1830, P2435, DOI 10.1016/j.bbagen.2012.09.002; Fang L, 2014, MOL CELL, V55, P537, DOI 10.1016/j.molcel.2014.06.018; Favaro R, 2009, NAT NEUROSCI, V12, P1248, DOI 10.1038/nn.2397; Fernandez AM, 2012, NAT REV NEUROSCI, V13, P225, DOI 10.1038/nrn3209; Ferretti C, 2014, TISSUE ENG PT A, V20, P2473, DOI [10.1089/ten.tea.2013.0453, 10.1089/ten.TEA.2013.0453]; Fletcher L, 2009, J NEUROSURG, V111, P164, DOI 10.3171/2009.2.JNS081199; Gage FH, 2013, NEURON, V80, P588, DOI 10.1016/j.neuron.2013.10.037; Gao ZL, 2009, NAT NEUROSCI, V12, P1090, DOI 10.1038/nn.2385; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Guo WX, 2012, NAT PROTOC, V7, P2005, DOI 10.1038/nprot.2012.123; Hodge RD, 2011, DEV NEUROBIOL, V71, P680, DOI 10.1002/dneu.20882; Kalluri HSG, 2007, EUR J NEUROSCI, V25, P1041, DOI 10.1111/j.1460-9568.2007.05336.x; Katsimpardi L, 2014, SCIENCE, V344, P630, DOI 10.1126/science.1251141; Kim J, 2011, P NATL ACAD SCI USA, V108, P7838, DOI 10.1073/pnas.1103113108; Kuwabara T, 2009, NAT NEUROSCI, V12, P1097, DOI 10.1038/nn.2360; Lee CHJ, 1996, J NEUROSCI, V16, P6784; Lein PJ, 2007, J NEUROSCI, V27, P4725, DOI 10.1523/JNEUROSCI.5633-06.2007; Liu KC, 2013, CELL SIGNAL, V25, P1264, DOI 10.1016/j.cellsig.2013.02.013; Liu W, 2009, J NEUROSCI RES, V87, P2821, DOI 10.1002/jnr.22129; Madathil SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067204; Mairet-Coello G, 2009, J NEUROSCI, V29, P775, DOI 10.1523/JNEUROSCI.1700-08.2009; Merkle FT, 2015, DEVELOPMENT, V142, P633, DOI 10.1242/dev.117978; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Mir S, 2017, J BIOL CHEM, V292, P2054, DOI 10.1074/jbc.M116.749770; Mir S, 2014, MOL CELL, V56, P786, DOI 10.1016/j.molcel.2014.10.019; Moon HY, 2016, CELL METAB, V24, P332, DOI 10.1016/j.cmet.2016.05.025; Mu YL, 2010, CURR OPIN NEUROBIOL, V20, P416, DOI 10.1016/j.conb.2010.04.010; Nieto-Estevez V, 2016, STEM CELLS, V34, P2194, DOI 10.1002/stem.2397; O'Kusky J, 2012, FRONT NEUROENDOCRIN, V33, P230, DOI 10.1016/j.yfrne.2012.06.002; O'Kusky JR, 2000, J NEUROSCI, V20, P8435, DOI 10.1523/JNEUROSCI.20-22-08435.2000; Oishi K, 2009, P NATL ACAD SCI USA, V106, P13064, DOI 10.1073/pnas.0808400106; Park DH, 2014, CELL REP, V8, P1290, DOI 10.1016/j.celrep.2014.07.060; Peltier J, 2007, DEV NEUROBIOL, V67, P1348, DOI 10.1002/dneu.20506; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Ransome MI, 2013, MOL CELL NEUROSCI, V54, P93, DOI 10.1016/j.mcn.2013.01.005; Ring KL, 2012, CELL STEM CELL, V11, P100, DOI 10.1016/j.stem.2012.05.018; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Russo VC, 2005, ENDOCR REV, V26, P916, DOI 10.1210/er.2004-0024; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Shi GX, 2013, CELL SIGNAL, V25, P2060, DOI 10.1016/j.cellsig.2013.06.002; Siddle K, 2011, J MOL ENDOCRINOL, V47, pR1, DOI 10.1530/JME-11-0022; Siegle JM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5511; Spalding KL, 2013, CELL, V153, P1219, DOI 10.1016/j.cell.2013.05.002; Suh H, 2007, CELL STEM CELL, V1, P515, DOI 10.1016/j.stem.2007.09.002; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thier M, 2012, CELL STEM CELL, V10, P473, DOI 10.1016/j.stem.2012.03.003; Trejo JL, 2001, J NEUROSCI, V21, P1628; van Praag H, 1999, NAT NEUROSCI, V2, P266; Voss MW, 2013, TRENDS COGN SCI, V17, P525, DOI 10.1016/j.tics.2013.08.001; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; Yang L, 2004, CANCER RES, V64, P4394, DOI 10.1158/0008-5472.CAN-04-0343; Ye P, 2006, J NEUROSCI RES, V83, P1, DOI 10.1002/jnr.20688; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Yuan HH, 2015, MOL NEUROBIOL, V51, P512, DOI 10.1007/s12035-014-8717-6; Zhang XC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085241; Zheng HQ, 2014, INT J MOL SCI, V15, P10974, DOI 10.3390/ijms150610974; Zhu W, 2008, STROKE, V39, P1254, DOI 10.1161/STROKEAHA.107.500801; Ziegler AN, 2015, NAT REV ENDOCRINOL, V11, P161, DOI 10.1038/nrendo.2014.208	84	27	30	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 12	2017	7								3283	10.1038/s41598-017-03641-9			14	Multidisciplinary Sciences	Science & Technology - Other Topics	EX2UD	WOS:000403081900074	28607354	DOAJ Gold, Green Published			2021-06-18	
J	Arumugam, TV; Manzanero, S; Furtado, M; Biggins, PJ; Hsieh, YH; Gelderblom, M; MacDonald, KPA; Salimova, E; Li, YI; Korn, O; Dewar, D; Macrae, IM; Ashman, RB; Tang, SC; Rosenthal, NA; Ruitenberg, MJ; Magnus, T; Wells, CA				Arumugam, Thiruma V.; Manzanero, Silvia; Furtado, Milena; Biggins, Patrick J.; Hsieh, Yu-Hsuan; Gelderblom, Mathias; MacDonald, Kelli P. A.; Salimova, Ekaterina; Li, Yu-I; Korn, Othmar; Dewar, Deborah; Macrae, I. Mhairi; Ashman, Robert B.; Tang, Sung-Chun; Rosenthal, Nadia A.; Ruitenberg, Marc J.; Magnus, Tim; Wells, Christine A.			An atypical role for the myeloid receptor Mincle in central nervous system injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						C-type lectin; ischemia; middle cerebral artery occlusion; microglia; sterile inflammation	TOLL-LIKE RECEPTORS; SPINAL-CORD-INJURY; FOCAL CEREBRAL-ISCHEMIA; C-TYPE LECTIN; CANDIDA-ALBICANS; INNATE IMMUNITY; BLOOD-FLOW; STROKE; BRAIN; INFLAMMATION	The C-type lectin Mincle is implicated in innate immune responses to sterile inflammation, but its contribution to associated pathologies is not well understood. Herein, we show that Mincle exacerbates neuronal loss following ischemic but not traumatic spinal cord injury. Loss of Mincle was beneficial in a model of transient middle cerebral artery occlusion but did not alter outcomes following heart or gut ischemia. High functional scores in Mincle KO animals using the focal cerebral ischemia model were accompanied by reduced lesion size, fewer infiltrating leukocytes and less neutrophil-derived cytokine production than isogenic controls. Bone marrow chimera experiments revealed that the presence of Mincle in the central nervous system, rather than recruited immune cells, was the critical regulator of a poor outcome following transient middle cerebral artery occlusion. There was no evidence for a direct role for Mincle in microglia or neural activation, but expression in a subset of macrophages resident in the perivascular niche provided new clues on Mincle's role in ischemic stroke.	[Arumugam, Thiruma V.; Hsieh, Yu-Hsuan] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore; [Arumugam, Thiruma V.; Manzanero, Silvia; Biggins, Patrick J.; Ruitenberg, Marc J.] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia; [Manzanero, Silvia; Korn, Othmar; Wells, Christine A.] Univ Queensland, Australian Inst Bioengn & Nanotechnol, Brisbane, Qld, Australia; [Furtado, Milena; Salimova, Ekaterina; Rosenthal, Nadia A.] Monash Univ, Australian Regenerat Med Inst, Melbourne, Vic, Australia; [Furtado, Milena; Rosenthal, Nadia A.] Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA; [Gelderblom, Mathias; Magnus, Tim] Univ Hosp Hamburg Eppendorf, Dept Neurol, Hamburg, Germany; [MacDonald, Kelli P. A.] Queensland Inst Med Res, Brisbane, Qld, Australia; [Li, Yu-I; Tang, Sung-Chun] Natl Taiwan Univ Hosp, Dept Pathol, Taipei, Taiwan; [Li, Yu-I; Tang, Sung-Chun] Natl Taiwan Univ Hosp, Dept Neurol, Taipei, Taiwan; [Li, Yu-I; Tang, Sung-Chun] Natl Taiwan Univ, Coll Med, Taipei, Taiwan; [Dewar, Deborah; Macrae, I. Mhairi] Univ Glasgow, Inst Neurosci & Psychol, Wellcome Surg Inst, Glasgow, Lanark, Scotland; [Ashman, Robert B.] Univ Queensland, Sch Dent, Brisbane, Qld, Australia; [Tang, Sung-Chun] Natl Taiwan Univ Hosp, Stroke Ctr, Dept Neurol, Taipei, Taiwan; [Ruitenberg, Marc J.] Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia; [Wells, Christine A.] Univ Melbourne, Fac Med, Dept Anat & Neurosci, Melbourne, Vic 3010, Australia	Wells, CA (corresponding author), Univ Melbourne, Fac Med, Dept Anat & Neurosci, Melbourne, Vic 3010, Australia.	wells.c@unimelb.edu.au	MacDonald, Kelli PA/O-2722-2016; Arumugam, Thiruma/AAG-6958-2019; Ashman, Robert B/F-1238-2010; MacDonald, Kelli/AAV-5365-2020; Wells, Christine/A-5071-2010	MacDonald, Kelli PA/0000-0003-3451-4221; Ruitenberg, Marc/0000-0002-6917-0708; Rosenthal, Nadia/0000-0002-7599-7365; , Ekaterina/0000-0002-4362-7108; Wells, Christine/0000-0003-3133-3628; Biggins, Patrick/0000-0002-9388-1411; Manzanero, Silvia/0000-0002-5294-7082; Arumugam, Thiruma/0000-0002-3377-0939	Australian National Health & Medical Research CouncilNational Health and Medical Research Council of Australia [1057846, 1060538]; Spinal Cure Australia (Career Development Fellowship); Singapore National Medical Research Council Collaborative Research GrantNational Medical Research Council, Singapore [NMRC-CBRG-0102/2016]; State Government of Victoria; Australian GovernmentAustralian GovernmentCGIAR; University of QueenslandUniversity of Queensland; Australian Research CouncilAustralian Research Council	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by Australian National Health & Medical Research Council (1057846, 1060538 and Fellowship to NAR), Spinal Cure Australia (Career Development Fellowship to MJR), the Australian Research Council, Singapore National Medical Research Council Collaborative Research Grant (NMRC-CBRG-0102/2016 to TA), the State Government of Victoria, the Australian Government and The University of Queensland.	Andre P, 2011, BLOOD, V118, P5000, DOI 10.1182/blood-2011-06-360743; Bartanusz V, 2011, ANN NEUROL, V70, P194, DOI 10.1002/ana.22421; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Blomster LV, 2013, EXP NEUROL, V247, P226, DOI 10.1016/j.expneurol.2013.05.002; Brea D, 2011, J CEREBR BLOOD F MET, V31, P1424, DOI 10.1038/jcbfm.2010.231; Brennan FH, 2015, J NEUROSCI, V35, P6517, DOI 10.1523/JNEUROSCI.5218-14.2015; Chamorro A, 2012, NAT REV NEUROL, V8, P401, DOI 10.1038/nrneurol.2012.98; de Rivero Vaccari JC, 2014, J NEUROTRAUM, V236, P228; Downes CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057948; Drummond RA, 2011, EUR J IMMUNOL, V41, P276, DOI 10.1002/eji.201041252; Fernandez-Klettl F, 2015, J CEREBR BLOOD F MET, V35, P883, DOI 10.1038/jcbfm.2015.60; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Hall CN, 2014, NATURE, V508, P55, DOI 10.1038/nature13165; Harrison M, 2013, NEUROIMAGE, V68, P22, DOI 10.1016/j.neuroimage.2012.11.048; He Y, 2015, STROKE, V46, P2277, DOI 10.1161/STROKEAHA.115.010088; Heiman A, 2014, BRAIN BEHAV IMMUN, V42, P232, DOI 10.1016/j.bbi.2014.06.203; Holloway PM, 2015, ARTERIOSCL THROM VAS, V35, P1936, DOI 10.1161/ATVBAHA.115.305348; Ishikawa E, 2009, J EXP MED, V206, P2879, DOI 10.1084/jem.20091750; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kim D, 2007, J BIOL CHEM, V282, P14975, DOI 10.1074/jbc.M607277200; Kim WK, 2006, AM J PATHOL, V168, P822, DOI 10.2353/ajpath.2006.050215; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Maestrini I, 2015, NEUROLOGY, V85, P1408, DOI 10.1212/WNL.0000000000002029; Masumoto M, 1999, J IMMUNOL, V163, P5039; MORI E, 1992, STROKE, V23, P712, DOI 10.1161/01.STR.23.5.712; Murray KN, 2013, MOL CELL NEUROSCI, V53, P14, DOI 10.1016/j.mcn.2012.09.004; Neumann J, 2015, ACTA NEUROPATHOL, V129, P259, DOI 10.1007/s00401-014-1355-2; Pamuk ON, 2010, AM J PHYSIOL-GASTR L, V299, pG391, DOI 10.1152/ajpgi.00198.2010; Perdiguero EG, 2013, GLIA, V61, P112, DOI 10.1002/glia.22393; Proebstl D, 2012, J EXP MED, V209, P1219, DOI 10.1084/jem.20111622; Russo MV, 2015, TRENDS IMMUNOL, V36, P637, DOI 10.1016/j.it.2015.08.002; Schoenen H, 2010, J IMMUNOL, V184, P2756, DOI 10.4049/jimmunol.0904013; Shi XR, 2010, CELL TISSUE RES, V342, P21, DOI 10.1007/s00441-010-1040-2; Shichita T, 2012, NAT MED, V18, P911, DOI 10.1038/nm.2749; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Strasser D, 2012, IMMUNITY, V36, P32, DOI 10.1016/j.immuni.2011.11.015; Suzuki Y, 2013, SCI REP-UK, V3, DOI 10.1038/srep03177; Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104; Tarr D, 2013, J CEREBR BLOOD F MET, V33, P1556, DOI 10.1038/jcbfm.2013.107; Vartanian KB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-140; Vijayan D, 2012, IMMUNOL CELL BIOL, V90, P889, DOI 10.1038/icb.2012.24; Wells CA, 2008, J IMMUNOL, V180, P7404, DOI 10.4049/jimmunol.180.11.7404; Wells CA, 2013, STEM CELL RES, V10, P387, DOI 10.1016/j.scr.2012.12.003; Woodruff TM, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-11; Yamasaki S, 2008, NAT IMMUNOL, V9, P1179, DOI 10.1038/ni.1651; Zhang WJ, 2012, P NATL ACAD SCI USA, V109, P10388, DOI 10.1073/pnas.1205210109	47	27	28	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUN	2017	37	6					2098	2111		10.1177/0271678X16661201			14	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	EV8BL	WOS:000402005200016	27492949	Other Gold, Green Published, Green Accepted			2021-06-18	
J	Armistead-Jehle, P; Soble, JR; Cooper, DB; Belanger, HG				Armistead-Jehle, Patrick; Soble, Jason R.; Cooper, Douglas B.; Belanger, Heather G.			6 Unique Aspects of Traumatic Brain Injury in Military and Veteran Populations	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Blast injury; Military; Veteran; Concussion; Posttraumatic stress disorder; Polytrauma; Postconcussive syndrome	POSTTRAUMATIC-STRESS-DISORDER; NEUROBEHAVIORAL SYMPTOM INVENTORY; POLYTRAUMA-CLINICAL-TRIAD; OEF/OIF SERVICE MEMBERS; MENTAL-HEALTH PROBLEMS; VALIDITY TEST; MILD TBI; POSTCONCUSSIVE SYMPTOMS; AFGHANISTAN VETERANS; CULTURAL COMPETENCE	Traumatic brain injury (TBI), in particular mild TBI (mTBI), is a relatively common injury experienced by service members across both deployed and nondeployed environments. Although many of the principles and practices used by civilian health care providers for identifying and treating this injury apply to military settings, there are unique factors that impact mTBI-related care in service members and Veterans. This article reviews several of these factors, including the epidemiology of TBI in the military/Veteran population, the influence of military culture on this condition, and identification and treatment of mTBI in the war zone.	[Armistead-Jehle, Patrick] Concuss Clin, Munson Army Hlth Ctr, 550 Pope Ave, Ft Leavenworth, KS 66027 USA; [Soble, Jason R.] South Texas Vet Healthcare Syst, Psychol Serv, 7400 Merton Minter, San Antonio, TX 78229 USA; [Cooper, Douglas B.] Joint Base San Antonio, Dept Neurol, Def & Vet Brain Injury Ctr, MCHE ZDM N,San Antonio Mil Med Ctr, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA; [Cooper, Douglas B.] Univ Texas San Antonio, Dept Psychiat, Hlth Sci Ctr, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA; [Belanger, Heather G.] James A Haley Vet Hosp, Tampa VA TBI Polytrauma Rehabil Ctr, Ctr Innovat Disabil & Rehabil Res CINDRR, HSR&D, 13000 Bruce B Downs Blvd 116A, Tampa, FL 33612 USA; [Belanger, Heather G.] James A Haley Vet Hosp, Dept Mental Hlth & Behav Sci, 13000 Bruce B Downs Blvd,116B, Tampa, FL 33612 USA; [Belanger, Heather G.] Univ S Florida, Dept Psychiat & Behav Neurosci, 4202 E Fowler Ave, Tampa, FL 33612 USA; [Belanger, Heather G.] Def & Vet Brain Injury Ctr, 13000 Bruce B Downs Blvd,116B, Tampa, FL 33612 USA	Armistead-Jehle, P (corresponding author), Concuss Clin, Munson Army Hlth Ctr, 550 Pope Ave, Ft Leavenworth, KS 66027 USA.	Patrick.j.armistead-jehle.civ@mail.mil	Armistead-Jehle, Patrick/AAU-5741-2020	Armistead-Jehle, Patrick/0000-0002-6784-1432			American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; [Anonymous], 2007, HEALTHC SYST VET INT; Armistead-Jehle P, 2016, APPL NEUROPSYCH-ADUL, V23, P264, DOI 10.1080/23279095.2015.1055564; Armistead-Jehle P, 2013, ARCH CLIN NEUROPSYCH, V28, P297, DOI 10.1093/arclin/act017; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Association of American Medical Colleges, 2013, TAK MIL HLTH HIST 4; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; BELLET PS, 1991, JAMA-J AM MED ASSOC, V266, P1831, DOI 10.1001/jama.266.13.1831; Block C, 2014, J HEAD TRAUMA REHAB, V29, P76, DOI 10.1097/HTR.0b013e3182886d78; Bradford LS, 2015, REHABIL PSYCHOL, V60, P344, DOI 10.1037/rep0000057; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Brown JL, 2012, JAMA-J AM MED ASSOC, V308, P1869, DOI 10.1001/jama.2012.14254; Center for Deployment Psychology, LEARN MIL CULT COURS; Cifu DX, 2013, J REHABIL RES DEV, V50, P1169, DOI 10.1682/JRRD.2013.01.0006; Cole MA, 2015, MIL MED, V180, P956, DOI 10.7205/MILMED-D-14-00581; Cooper DB, 2014, J REHABIL RES DEV, V51, P1023, DOI [10.1682/JRRD.2013.05.0104, 10.1682/JRRD.2013.05.0140]; Cooper DB, 2012, MIL MED, V177, P1157, DOI 10.7205/MILMED-D-12-00098; Cooper DB, 2011, ARCH CLIN NEUROPSYCH, V26, P718, DOI 10.1093/arclin/acr070; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Davis JJ, 2013, REHABIL PSYCHOL, V58, P36, DOI 10.1037/a0031525; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Donnell AJ, 2012, CLIN NEUROPSYCHOL, V26, P1092, DOI 10.1080/13854046.2012.713984; French L., 2008, J SPEC OPER MED, V8, P68; Fulton JJ, 2015, J ANXIETY DISORD, V31, P98, DOI 10.1016/j.janxdis.2015.02.003; Gleeson TD, 2014, ACAD MED, V89, P1201, DOI 10.1097/ACM.0000000000000368; Goldenberg MN, 2012, BASIC TRAINING PRIME; Grills CE, 2016, APPL NEUROPSYCH-ADUL, V23, P295, DOI 10.1080/23279095.2015.1079713; Helmick KM, 2015, BRAIN IMAGING BEHAV, V9, P358, DOI 10.1007/s11682-015-9399-z; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2014, PSYCHIAT SERV, V65, P997, DOI 10.1176/appi.ps.201300307; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; HQDA Executive Order, 16513 HQDA DEP ARM G; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Jak AJ, 2015, CONTEMP CLIN TRIALS, V45, P210, DOI 10.1016/j.cct.2015.10.009; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Krakower J, 2012, ANAL BRIEF, V12; Lange RT, 2015, J CLIN EXP NEUROPSYC, V37, P853, DOI 10.1080/13803395.2015.1064864; Lange RT, 2015, J CLIN EXP NEUROPSYC, V37, P325, DOI 10.1080/13803395.2015.1013021; Lange RT, 2013, J CLIN EXP NEUROPSYC, V35, P192, DOI 10.1080/13803395.2012.761677; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Lypson ML, 2014, DEV SKILLS VETERAN C; Lypson ML, 2012, PATIENT DOCTOR COMMU; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meyer EG, 2016, CURR PSYCHIAT REP, V18, DOI 10.1007/s11920-016-0662-9; Meyer EG, 2015, ACAD PSYCHIATR, V39, P416, DOI 10.1007/s40596-015-0285-1; National Ethics Committee of the Veterans. Health Administration, 2001, ETH AN ETHN DISP HLT; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Pankow SH, 2013, HLTH CARE PROVIDER A, V13; Pietrzak RH, 2009, PSYCHIAT SERV, V60, P1118, DOI 10.1176/ps.2009.60.8.1118; Pugh MJV, 2014, MED CARE, V52, P172, DOI 10.1097/MLR.0000000000000059; Reger MA, 2008, MIL PSYCHOL, V20, P21, DOI 10.1080/08995600701753144; Reslan S, 2017, APPL NEUROPSYCH-ADUL, V24, P132, DOI 10.1080/23279095.2015.1107565; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Ross Paula T, 2015, J Grad Med Educ, V7, P519, DOI 10.4300/JGME-D-14-00568.1; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Soble JR, 2014, CLIN NEUROPSYCHOL, V28, P614, DOI 10.1080/13854046.2014.894576; Spelman JF, 2012, J GEN INTERN MED, V27, P1200, DOI 10.1007/s11606-012-2061-1; Sripada RK, 2013, J TRAUMA STRESS, V26, P369, DOI 10.1002/jts.21813; Sullivan KA, 2016, APPL NEUROPSYCH-ADUL, V23, P353, DOI 10.1080/23279095.2015.1079714; Tanielian T., 2014, READY SERVE COMMUNIT; Taylor BC, 2015, FISCAL YEAR 2014 VA; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; United States Department of Veterans Affairs, NAT CTR VET AN STAT; US Department of Veteran Affairs [homepage on the Internet], VA HLTH CAR UT REC V; Vanderploeg RD, 2014, J HEAD TRAUMA REHAB, V29, P1, DOI 10.1097/HTR.0b013e318281966e; Vaughan CA, 2014, PSYCHIAT SERV, V65, P833, DOI 10.1176/appi.ps.201300111; Wolf GK, 2015, J TRAUMA STRESS, V28, P339, DOI 10.1002/jts.22029; World Health Organization, 1992, ICD 10 CLASS MENT BE	77	27	27	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	MAY	2017	28	2					323	+		10.1016/j.pmr.2016.12.008			16	Rehabilitation	Rehabilitation	EU5AJ	WOS:000401043700010	28390516				2021-06-18	
J	Bosco, FM; Parola, A; Sacco, K; Zettin, M; Angeleri, R				Bosco, Francesca M.; Parola, Alberto; Sacco, Katiuscia; Zettin, Marina; Angeleri, Romina			Communicative-pragmatic disorders in traumatic brain injury: The role of theory of mind and executive functions	BRAIN AND LANGUAGE			English	Article						Communication; Pragmatics; Irony; Deceit; Non-verbal; Theory of mind; Executive functions; Cognitive flexibility; Working memory; Planning	CLOSED-HEAD-INJURY; PREFRONTAL LESIONS; SOCIAL COGNITION; IMPAIRMENTS; LANGUAGE; ADULTS; COMPREHENSION; DEFICITS; ABILITY; CHILDREN	Previous research has shown that communicative-pragmatic ability, as well as executive functions (EF) and Theory of Mind (ToM), may be impaired in individuals with traumatic brain injury (TBI). However, the role of such cognitive deficits in explaining communicative-pragmatic difficulty in TBI has still not been fully investigated. The study examined the relationship between EF (working memory, planning and flexibility) and ToM and communicative-pragmatic impairment in patients with TBI. 30 individuals with TBI and 30 healthy controls were assessed using the Assessment Battery of Communication (ABaCo), and a set of cognitive, EF and ToM, tasks. The results showed that TBI participants performed poorly in comprehension and production tasks in the ABaCo, using both linguistic and extralinguistic means of expression, and that they were impaired in EF and ToM abilities. Cognitive difficulties were able to predict the pragmatic performance of TBI individuals, with both executive functions and ToM contributing to explaining patients' scores on the ABaCo. (C) 2017 Elsevier Inc. All rights reserved.	[Bosco, Francesca M.; Parola, Alberto; Sacco, Katiuscia] Univ Turin, Ctr Cognit Sci, Dept Psychol, Turin, Italy; [Bosco, Francesca M.; Sacco, Katiuscia] Inst Neurosci Turin, Turin, Italy; [Zettin, Marina] Ctr Puzzle, Turin, Italy; [Angeleri, Romina] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA	Parola, A (corresponding author), Dipartimento Psicol, Via Po 14, I-10123 Turin, Italy.	alparola@unito.it	Parola, alberto/AAK-3748-2020; bosco, francesca marina/B-6746-2013	bosco, francesca marina/0000-0001-6101-8587; PAROLA, ALBERTO/0000-0002-6039-0907	University of Turin, Department of Psychology	This research was supported by the University of Turin, Department of Psychology, "Ex-60% fund", Action B.	Altman DG, 1991, PRACTICAL STAT MED R, P403; Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Angeleri R., 2015, BATTERIA ASSESSMENT; Angeleri R, 2016, MINERVA PSICH, V57, P93; Angeleri R, 2012, BEHAV RES METHODS, V44, P845, DOI 10.3758/s13428-011-0174-9; Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Ashman TA, 2006, MT SINAI J MED, V73, P999; Bambini V, 2016, BRAIN LANG, V153, P1, DOI 10.1016/j.bandl.2015.12.002; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Bara BG, 2001, BRAIN LANG, V77, P72, DOI 10.1006/brln.2000.2430; Bara BG., 2010, COGNITIVE PRAGMATICS; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bloom P, 2000, COGNITION, V77, pB25, DOI 10.1016/S0010-0277(00)00096-2; Bosco F. M., 2016, FRONTIERS PSYCHOL, V7; Bosco FM, 2015, INT J LANG COMM DIS, V50, P63, DOI 10.1111/1460-6984.12114; Bosco FM, 2013, J CHILD LANG, V40, P741, DOI 10.1017/S0305000913000081; Bosco FM, 2012, J COMMUN DISORD, V45, P290, DOI 10.1016/j.jcomdis.2012.03.002; Bosco FM, 2012, J COMMUN DISORD, V45, P181, DOI 10.1016/j.jcomdis.2012.01.005; Braun C M, 1989, Brain Inj, V3, P345, DOI 10.3109/02699058909004559; Byom LJ, 2012, INT J LANG COMM DIS, V47, P310, DOI 10.1111/j.1460-6984.2011.00102.x; Capitani E, 1997, J CLIN EXP NEUROPSYC, V19, P795, DOI 10.1080/01688639708403761; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Channon S, 2007, NEUROPSYCHOLOGIA, V45, P1725, DOI 10.1016/j.neuropsychologia.2006.12.021; Channon Shelley, 2003, Cogn Neuropsychiatry, V8, P243, DOI 10.1080/135468000344000002; Colle L, 2013, J COMMUN DISORD, V46, P294, DOI 10.1016/j.jcomdis.2013.01.003; Cummings L, 2009, CLINICAL PRAGMATICS, P1; Cummings L., 2014, PRAGMATIC DISORDERS; Cummings L, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01286; Cummings Louise, 2005, PRAGMATICS MULTIDISC; Dardier V, 2011, J COMMUN DISORD, V44, P359, DOI 10.1016/j.jcomdis.2011.02.001; Della Sala S., 1984, ADV HEPATIC ENCEPHAL, P448; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; Douglas JM, 2010, J SPEECH LANG HEAR R, V53, P365, DOI 10.1044/1092-4388(2009/08-0205); Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; ELITHORN A, 1955, J NEUROL NEUROSUR PS, V18, P287, DOI 10.1136/jnnp.18.4.287; ELITHORN A, 1964, NEUROPSYCHOLOGIA, V2, P327, DOI 10.1016/0028-3932(64)90039-9; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; Gabbatore I, 2015, J HEAD TRAUMA REHAB, V30, pE14, DOI 10.1097/HTR.0000000000000087; Gabbatore L, 2014, MINERVA PSICHIATR, V55, P45; Geraci A, 2010, BRAIN INJURY, V24, P978, DOI 10.3109/02699052.2010.487477; Happe F, 2002, MIND LANG, V17, P24, DOI 10.1111/1468-0017.00187; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Honan CA, 2015, BRAIN LANG, V150, P69, DOI 10.1016/j.bandl.2015.08.007; Huber W., 1983, AACHENER APHASIE TES; Johnco C, 2013, J ANXIETY DISORD, V27, P576, DOI 10.1016/j.janxdis.2012.10.004; Johnson JE, 2012, BRAIN INJURY, V26, P1118, DOI 10.3109/02699052.2012.666370; Kortte Kathleen Bechtold, 2002, Appl Neuropsychol, V9, P106, DOI 10.1207/S15324826AN0902_5; Leslie AM, 2004, TRENDS COGN SCI, V8, P528, DOI 10.1016/j.tics.2004.10.001; Levinson F. C., 1983, PRAGMATICS; Marini A, 2014, NEUROPSYCHOLOGIA, V64, P282, DOI 10.1016/j.neuropsychologia.2014.09.042; Marini A, 2011, NEUROPSYCHOLOGIA, V49, P2904, DOI 10.1016/j.neuropsychologia.2011.06.017; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; Martin I, 2005, APHASIOLOGY, V19, P712, DOI 10.1080/02687030500172203; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, APHASIOLOGY, V7, P535, DOI 10.1080/02687039308248629; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; MCDONALD S, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI DOI 10.1017/S1355617713000428.PUBMED:23351330; McDonald S, 2014, NEUROPSYCHOLOGY, V28, P801, DOI 10.1037/neu0000089; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; Murphy A, 2015, APHASIOLOGY, V29, P151, DOI 10.1080/02687038.2014.959411; NOVELLI G, 1986, Archivio di Psicologia Neurologia e Psichiatria, V47, P278; Parola A, 2016, J NEUROLINGUIST, V39, P10, DOI 10.1016/j.jneuroling.2015.12.003; Pearce S, 1998, BRAIN COGNITION, V38, P150, DOI 10.1006/brcg.1998.1018; Perkins M., 2000, PRAGMATICS CLIN APPL, P7; PERNER J, 1989, CHILD DEV, V60, P689, DOI 10.1111/j.1467-8624.1989.tb02749.x; PERNER J, 1985, J EXP CHILD PSYCHOL, V39, P437, DOI 10.1016/0022-0965(85)90051-7; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rousseaux M, 2010, EUR J NEUROL, V17, P922, DOI 10.1111/j.1468-1331.2009.02945.x; Sacco K, 2008, J COGN SCI, V9, P111; Sacco K., 2016, FRONTIERS BEHAV NEUR, V10; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Spinnler H., 1987, ITAL J NEUROL SCI, V6, P8; Stemmer B., 1999, PRAGMATICS BRAIN LAN, V68; Struchen MA, 2011, J HEAD TRAUMA REHAB, V26, P4, DOI 10.1097/HTR.0b013e3182048e98; Sullivan JR, 2009, APPL NEUROPSYCHOL, V16, P62, DOI 10.1080/09084280802644243; TEASDALE G, 1974, LANCET, V2, P81; Thomas E, 2014, NEUROPSYCHOL REV, V24, P514, DOI 10.1007/s11065-014-9272-7; Tirassa M, 2006, CONSCIOUS COGN, V15, P197, DOI 10.1016/j.concog.2005.06.005; Tirassa M, 2006, COGN SYST RES, V7, P128, DOI 10.1016/j.cogsys.2006.01.002; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; WINNER E, 1977, BRAIN, V100, P717, DOI 10.1093/brain/100.4.717	95	27	28	1	53	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X	1090-2155		BRAIN LANG	Brain Lang.	MAY	2017	168						73	83		10.1016/j.bandl.2017.01.007			11	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	ER4GK	WOS:000398756900007	28161678	Green Published			2021-06-18	
J	Houben, T; Loonen, ICM; Baca, SM; Schenke, M; Meijer, JH; Ferrari, MD; Terwindt, GM; Voskuyl, RA; Charles, A; van den Maagdenberg, AMJM; Tolner, EA				Houben, Thijs; Loonen, Inge C. M.; Baca, Serapio M.; Schenke, Maarten; Meijer, Johanna H.; Ferrari, Michel D.; Terwindt, Gisela M.; Voskuyl, Rob A.; Charles, Andrew; van den Maagdenberg, Arn M. J. M.; Tolner, Else A.			Optogenetic induction of cortical spreading depression in anesthetized and freely behaving mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Behavior; electrophysiology; non-invasive; optogenetics; vascular dynamics	TRAUMATIC BRAIN-INJURY; CEREBRAL-CORTEX; ANOXIC DEPOLARIZATION; TRANSGENIC MICE; MOVING RATS; MIGRAINE; CHANNELRHODOPSIN-2; PROPAGATION; ANESTHESIA; ISCHEMIA	Cortical spreading depression, which plays an important role in multiple neurological disorders, has been studied primarily with experimental models that use highly invasive methods. We developed a relatively non-invasive optogenetic model to induce cortical spreading depression by transcranial stimulation of channelrhodopsin-2 ion channels expressed in cortical layer 5 neurons. Light-evoked cortical spreading depression in anesthetized and freely behaving mice was studied with intracortical DC-potentials, multi-unit activity and/or non-invasive laser Doppler flowmetry, and optical intrinsic signal imaging. In anesthetized mice, cortical spreading depression induction thresholds and propagation rates were similar for invasive (DC-potential) and non-invasive (laser Doppler flowmetry) recording paradigms. Cortical spreading depression-related vascular and parenchymal optical intrinsic signal changes were similar to those evoked with KCl. In freely behaving mice, DC-potential and multi-unit activity recordings combined with laser Doppler flowmetry revealed cortical spreading depression characteristics comparable to those under anesthesia, except for a shorter cortical spreading depression duration. Cortical spreading depression resulted in a short increase followed by prolonged reduction of spontaneous active behavior. Motor function, as assessed by wire grip tests, was transiently and unilaterally suppressed following a cortical spreading depression. Optogenetic cortical spreading depression induction has significant advantages over current models in that multiple cortical spreading depression events can be elicited in a non-invasive and cell type-selective fashion.	[Houben, Thijs; Ferrari, Michel D.; Terwindt, Gisela M.; van den Maagdenberg, Arn M. J. M.; Tolner, Else A.] Leiden Univ, Med Ctr, Dept Neurol, POB 9600, Leiden, Netherlands; [Loonen, Inge C. M.; Schenke, Maarten; Voskuyl, Rob A.; van den Maagdenberg, Arn M. J. M.; Tolner, Else A.] Leiden Univ, Med Ctr, Dept Human Genet, POB 9600, Leiden, Netherlands; [Baca, Serapio M.; Charles, Andrew] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Meijer, Johanna H.] Leiden Univ, Med Ctr, Dept Mol Cell Biol, Lab Neurophysiol, Leiden, Netherlands	van den Maagdenberg, AMJM (corresponding author), Leiden Univ, Med Ctr, Dept Neurol, POB 9600, Leiden, Netherlands.; van den Maagdenberg, AMJM (corresponding author), Leiden Univ, Med Ctr, Dept Human Genet, POB 9600, Leiden, Netherlands.	A.M.J.M.van_den_Maagdenberg@lumc.nl	van den Maagdenberg, Arn M.J.M./AAE-9052-2019	Tolner, Else/0000-0002-6501-9971; Loonen, Inge/0000-0001-9055-8419	European Union's (EU) Seventh Framework programme "EUROHEADPAIN'' [602633]; EU Marie Curie IAPP Program "BRAINPATH'' [612360]; LUMC Fellowship; Migraine Research Foundation [20142781]; Dutch Organization for Scientific Research NWO (Spinoza) [91711319]	The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: This work was supported by the European Union's (EU) Seventh Framework programme "EUROHEADPAIN'' (nr. 602633), EU Marie Curie IAPP Program "BRAINPATH'' (nr 612360), a LUMC Fellowship, the Migraine Research Foundation (nr. 20142781), and the Dutch Organization for Scientific Research NWO (Spinoza 2009, nr. 91711319).	Akcali D, 2010, CEPHALALGIA, V30, P1195, DOI 10.1177/0333102409360828; Aksenov DP, 2015, J CEREBR BLOOD F MET, V35, P1819, DOI 10.1038/jcbfm.2015.130; Arenkiel BR, 2007, NEURON, V54, P205, DOI 10.1016/j.neuron.2007.03.005; ASANUMA H, 1975, BRAIN RES, V96, P103, DOI 10.1016/0006-8993(75)90579-X; Ayata C, 2000, NEUROSCIENCE, V95, P639; Ayata C, 2006, ANN NEUROL, V59, P652, DOI 10.1002/ana.20778; Ayata C, 2004, J CEREBR BLOOD F MET, V24, P1172, DOI 10.1097/01.WCB.0000137057.92786.F3; Ayata C, 2015, PHYSIOL REV, V95, P953, DOI 10.1152/physrev.00027.2014; Ayata C, 2013, CEPHALALGIA, V33, P604, DOI 10.1177/0333102412470216; Becker K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039346; Bolay H, 2002, NAT MED, V8, P136, DOI 10.1038/nm0202-136; Brennan KC, 2007, J NEUROPHYSIOL, V97, P4143, DOI 10.1152/jn.00028.2007; Brodkin J, 2014, J NEUROSCI METH, V224, P48, DOI 10.1016/j.jneumeth.2013.12.010; Chang JC, 2010, BRAIN, V133, P996, DOI 10.1093/brain/awp338; Charles AC, 2013, NAT REV NEUROL, V9, P637, DOI 10.1038/nrneurol.2013.192; Choleris E, 2001, NEUROSCI BIOBEHAV R, V25, P235, DOI 10.1016/S0149-7634(01)00011-2; Deisseroth K, 2015, NAT NEUROSCI, V18, P1213, DOI 10.1038/nn.4091; Dreier JP, 2015, NEURON, V86, P902, DOI 10.1016/j.neuron.2015.04.004; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Faraguna U, 2010, CEREB CORTEX, V20, P2939, DOI 10.1093/cercor/bhq041; Farkas E, 2010, NEUROIMAGE, V51, P734, DOI 10.1016/j.neuroimage.2010.02.055; Fisher SP, 2012, J BIOL RHYTHM, V27, P48, DOI 10.1177/0748730411431550; Godukhin OV, 2001, J NEUROPHYSIOL, V86, P2109; Goold CP, 2010, NEURON, V68, P512, DOI 10.1016/j.neuron.2010.09.020; Hentschke H, 1999, BRAIN RES, V830, P123, DOI 10.1016/S0006-8993(99)01399-2; Hira R, 2009, J NEUROSCI METH, V179, P258, DOI 10.1016/j.jneumeth.2009.02.001; Jasnow AM, 2013, J NEUROSCI, V33, P10396, DOI 10.1523/JNEUROSCI.5539-12.2013; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Masamoto K, 2012, J CEREBR BLOOD F MET, V32, P1233, DOI 10.1038/jcbfm.2012.50; Muramatsu H, 2004, J CEREBR BLOOD F MET, V24, P1167, DOI 10.1097/01.WCB.0000134714.38679.2C; Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100; Osawa S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060928; Pietrobon D, 2014, NAT REV NEUROSCI, V15, P379, DOI 10.1038/nrn3770; Pradhan AA, 2014, BRIT J PHARMACOL, V171, P2375, DOI 10.1111/bph.12591; Seidel JL, 2016, GLIA, V64, P5, DOI 10.1002/glia.22824; Somjen GG, 2001, PHYSIOL REV, V81, P1065; SUGAYA E, 1975, J NEUROPHYSIOL, V38, P822; Sukhotinsky I, 2011, CEPHALALGIA, V31, P1601, DOI 10.1177/0333102411425865; Tepe N, 2015, EUR J NEUROSCI, V41, P120, DOI 10.1111/ejn.12753; TOBIASZ C, 1982, BRAIN RES, V241, P329, DOI 10.1016/0006-8993(82)91071-X; von Bornstadt D, 2015, NEURON, V85, P1117, DOI 10.1016/j.neuron.2015.02.007; Wang H, 2007, P NATL ACAD SCI USA, V104, P8143, DOI 10.1073/pnas.0700384104; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299	44	27	28	0	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2017	37	5					1641	1655		10.1177/0271678X16645113			15	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	ET8CG	WOS:000400525200007	27107026	Green Published, Bronze			2021-06-18	
J	Howell, DR; Stracciolini, A; Geminiani, E; Meehan, WP				Howell, David R.; Stracciolini, Andrea; Geminiani, Ellen; Meehan, William P., III			Dual-task gait differences in female and male adolescents following sport-related concussion	GAIT & POSTURE			English	Article						Brain concussion; Mild traumatic brain injury; Postural balance; Divided attention; Sex difference	BALANCE CONTROL; YOUNG-ADULTS; RECOVERY TRAJECTORIES; GENDER-DIFFERENCES; BASE-LINE; POSTCONCUSSION; MANAGEMENT; STABILITY; WALKING; SINGLE	Concussion may affect females and males differentially. Identification of gender-related differences after concussion, therefore, may help clinicians with individualized evaluations. We examined potential differences in dual-task gait between females and males after concussion. Thirty-five participants diagnosed with a concussion (49% female, mean age = 15.0 +/- 2.1 years, 7.5 +/- 3.0 days post-injury) and 51 controls (51% female, mean age = 14.4 +/- 2.1 years) completed a symptom inventory and single/dual-task gait assessment. The primary outcome variable, the dual-task cost, was calculated as the percent change between single-task and dual-task conditions to account for individual differences in spatio-temporal gait variables. No significant differences in symptom severity measured by the post-concussion symptom scale were observed between females (32.0 +/- 18.0) and males (27.8 +/- 18.2). Compared with males, adolescent females walked with significantly decreased cadence dual-task costs after concussion (-19.7% +/- 10.0% vs. -11.3% +/- 9.2%, p = 0.007) when adjusted for age, height, and prior concussion history. No significant differences were found between female and male control groups on other dual-task cost gait measures. Females and males with concussion also walked with significantly shorter stride lengths than controls during single-task (females: 1.13 +/- 0.11 m vs. 1.26 +/- 0.11 m, p = 0.001; males: 1.14 +/- 0.14 m vs. 1.22 +/- 0.15 m, p = 0.04) and dual-task gait (females: 0.99 +/- 0.10 m vs. 1.10 +/- 0.11 m, p = 0.001; males: 1.00 +/- 0.13 m vs. 1.08 +/- 0.14 m, p = 0.04). Females demonstrated a significantly greater amount of cadence change between single-task and dual-task gait than males after a sport related concussion. Thus, differential alterations may exist during gait among those with a concussion; gender may be one prominent factor affecting dual-task gait.	[Howell, David R.; Stracciolini, Andrea; Geminiani, Ellen; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, 9 Hope Ave,Suite 100, Waltham, MA 02453 USA; [Howell, David R.; Stracciolini, Andrea; Geminiani, Ellen; Meehan, William P., III] Boston Childrens Hosp, Dept Orthopaed, Div Sports Med, Boston, MA USA; [Howell, David R.; Meehan, William P., III] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA; [Stracciolini, Andrea; Geminiani, Ellen; Meehan, William P., III] Harvard Med Sch, Dept Orthopaed Surg, Boston, MA USA; [Meehan, William P., III] Harvard Med Sch, Dept Pediat, Boston, MA USA	Howell, DR (corresponding author), Micheli Ctr Sports Injury Prevent, 9 Hope Ave,Suite 100, Waltham, MA 02453 USA.	David.Howell2@childrens.harvard.edu			National Hockey League Alumni Association through the Corey C. Griffin Pro Am Tournament	This study was funded by philanthropic support from the National Hockey League Alumni Association through the Corey C. Griffin Pro Am Tournament.	Baker JG, 2016, CLIN PEDIATR, V55, P771, DOI 10.1177/0009922815606417; Benedict PA, 2015, J NEUROL SCI, V353, P111, DOI 10.1016/j.jns.2015.04.029; Brown DA, 2015, SPORTS MED, V45, P1027, DOI 10.1007/s40279-015-0335-6; Buckley TA, 2016, J SPORT HEALTH SCI, V5, P417, DOI 10.1016/j.jshs.2015.03.010; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Cossette I., 2016, BRAIN INJURY, P1; Coulthard JT, 2015, GAIT POSTURE, V41, P882, DOI 10.1016/j.gaitpost.2015.03.009; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Dewey DC, 2014, J NEUROL SCI, V345, P131, DOI 10.1016/j.jns.2014.07.026; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Fino PC, 2016, J BIOMECH, V49, P1983, DOI 10.1016/j.jbiomech.2016.05.004; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Horak F, 2015, PHYS THER, V95, P461, DOI 10.2522/ptj.20140253; Howel DR, 2017, J APPL BIOMECH, V33, P24, DOI 10.1123/jab.2015-0323; Howell D. R, 2016, CLIN J SPORT MED; Howell DR, 2016, GAIT POSTURE, V49, P176, DOI 10.1016/j.gaitpost.2016.07.008; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Kerrigan DC, 1998, AM J PHYS MED REHAB, V77, P2, DOI 10.1097/00002060-199801000-00002; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lax ID, 2015, BRAIN INJURY, V29, P1409, DOI 10.3109/02699052.2015.1043344; Mihalik JP, 2013, AM J SPORT MED, V41, P1490, DOI 10.1177/0363546513487982; Miller JH, 2016, J NEUROSURG-PEDIATR, V17, P491, DOI 10.3171/2015.8.PEDS14332; Ono KE, 2016, AM J SPORT MED, V44, P748, DOI 10.1177/0363546515617746; Ponta ML, 2014, OBES SURG, V24, P1915, DOI 10.1007/s11695-014-1254-6; Register-Mihalik JK, 2013, NEUROPSYCHOL REV, V23, P300, DOI 10.1007/s11065-013-9238-1; Sambasivan K, 2015, J PEDIATR REHAB MED, V8, P335, DOI 10.3233/PRM-150351; Schneiders AG, 2010, J SCI MED SPORT, V13, P196, DOI 10.1016/j.jsams.2009.05.004	30	27	27	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362	1879-2219		GAIT POSTURE	Gait Posture	MAY	2017	54						284	289		10.1016/j.gaitpost.2017.03.034			6	Neurosciences; Orthopedics; Sport Sciences	Neurosciences & Neurology; Orthopedics; Sport Sciences	EZ9IT	WOS:000405044400045	28384609				2021-06-18	
J	Register-Mihalik, JK; McLeod, TCV; Linnan, LA; Guskiewicz, KM; Marshall, SW				Register-Mihalik, Johna K.; McLeod, Tamara C. Valovich; Linnan, Laura A.; Guskiewicz, Kevin M.; Marshall, Stephen W.			Relationship Between Concussion History and Concussion Knowledge, Attitudes, and Disclosure Behavior in High School Athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						disclosure; brain injury; education	CANCER; CARE	Objective: Examine the association between self-reported concussion history and measures of concussion knowledge, attitude, and disclosure behavior. Design: Cross-sectional survey. Setting: Classroom. Participants: A convenience sample of high school athletes (n = 167; mean age = 15.7 years) from multiple sports completed a validated survey. Independent Variables: Concussion history (main predictor) was defined as the number of self-recalled concussions during participants' high school career. Main Outcome Measures: The outcomes were recalled concussion disclosure behavior (3 measures) and scales assessing both concussion knowledge and concussion attitude. Results: A greater number of previous concussions was associated with worse attitude to concussion and negative concussion disclosure behavior. For every 3 additional self-recalled concussions, there was a mean decrease of 7.2 points (range of possible scores = 14-98) in concussion attitude score (P = 0.002), a 48% decrease in the self-reported proportion of concussion events disclosed (P = 0.013), and an increased prevalence of self-reported participation in games (67%) and practices (125%) while experiencing signs and symptoms of concussion (P< 0.001). Increased concussion history did not affect concussion knowledge score (P = 0.333). Conclusions: Negative trends in concussion disclosure behavior were identified in youth athletes with a positive history of concussion. Improving disclosure in this subgroup will require targeted efforts addressing negative attitude to concussion.	[Register-Mihalik, Johna K.; Guskiewicz, Kevin M.] Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Register-Mihalik, Johna K.; Guskiewicz, Kevin M.] Univ North Carolina Chapel Hill, Injury Prevent Res Ctr, Chapel Hill, NC USA; [McLeod, Tamara C. Valovich] AT Still Univ, Athlet Training Programs, Mesa, AZ USA; [McLeod, Tamara C. Valovich] AT Still Univ, Sch Osteopath Med, Mesa, AZ USA; [Linnan, Laura A.] Univ North Carolina Chapel Hill, Dept Hlth Behav, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA; [Marshall, Stephen W.] Univ North Carolina Chapel Hill, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA	Register-Mihalik, JK (corresponding author), Matthew Gfeller Sport Related TBI Res Ctr, 2207 Stallings Evans Sports Med Ctr, Chapel Hill, NC 27599 USA.	johnakay@email.unc.edu	McLeod, Tamara/AAU-9435-2020		NFL Charities Medical Research Grant; ICRC award from the National Center for Injury Prevention and Control, Centers for Disease Control and Prevention [R49/CE002479]	Funded in part by a NFL Charities Medical Research Grant. J.R.M. and S.W.M. are partially supported by an ICRC award (R49/CE002479) from the National Center for Injury Prevention and Control, Centers for Disease Control and Prevention.	Bickell NA, 2012, J CLIN ONCOL, V30, P1791, DOI 10.1200/JCO.2011.38.7605; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Corner J, 2006, SOC SCI MED, V62, P1381, DOI 10.1016/j.socscimed.2005.08.012; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Fishbein M., 1975, ATTITUDE INTENTION B; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Spiegelman D, 2005, AM J EPIDEMIOL, V162, P199, DOI 10.1093/aje/kwi188	10	27	27	3	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2017	27	3					321	324		10.1097/JSM.0000000000000349			4	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	ET9NV	WOS:000400635100013	27437911				2021-06-18	
J	Rona, RJ; Burdett, H; Khondoker, M; Chesnokov, M; Green, K; Pernet, D; Jones, N; Greenberg, N; Wessely, S; Fear, NT				Rona, Roberto J.; Burdett, Howard; Khondoker, Mizanur; Chesnokov, Melanie; Green, Kevin; Pernet, David; Jones, Norman; Greenberg, Neil; Wessely, Simon; Fear, Nicola T.			Post-deployment screening for mental disorders and tailored advice about help-seeking in the UK military: a cluster randomised controlled trial	LANCET			English	Article							POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; HEALTH PROBLEMS; ARMED-FORCES; PRIMARY-CARE; IRAQ; PERSONNEL; PTSD; AFGHANISTAN; SYMPTOMS	Background The effectiveness of post-deployment screening for mental disorders has not been assessed in a randomised controlled trial. We aimed to assess whether post-deployment screening for post-traumatic stress disorder (PTSD), depression, anxiety, or alcohol misuse was effective. We defined screening as the presumptive identification of a previously unrecognised disorder using tests to distinguish those who probably had the disorder from those who probably did not so that those people with a probable disorder could be referred appropriately, and assessed effectiveness and consequences for help-seeking by the odds ratio at follow-up between those receiving tailored help-seeking advice and those who received general mental health advice. Methods We did a cluster randomised controlled trial among Royal Marines and Army personnel in the UK military after deployment to Afghanistan. Platoons were randomly assigned (1: 1 initially, then 2: 1) by stratified block randomisation with randomly varying block sizes of two and four to the screening group, which received tailored help-seeking advice, or the control group, which received general mental health advice. Initial assessment took place 6-12 weeks after deployment; follow-up assessments were done 10-24 months later. Follow-up measures were the PTSD Checklist-Civilian Version, Patient Health Questionnaire-9, Generalised Anxiety Disorder-7 scale, Alcohol Use Disorder Identification Test (AUDIT), and self-reported help-seeking from clinical and welfare providers comparing those receiving tailored advice and those receiving only general advice. All participants and all investigators other than the person who analysed the data were masked to allocation. The primary outcomes were PTSD, depression or generalised anxiety disorder, and alcohol misuse at follow-up. A key secondary outcome was assessment of whether post-deployment screening followed by tailored advice would modify help-seeking behaviour. Comparisons were made between screening and control groups, with primary analyses by intention to treat. This trial is registered with the ISRCTN Registry, number ISRCTN19965528. Findings Between Oct 24, 2011, and Oct 31, 2014, 434 platoons comprising 10 190 personnel were included: 274 (6350 personnel) in the screening group and 160 (3840 personnel) in the control group. 5577 (88%) of 6350 personnel received screening and 3996 (63%) completed follow-up, whereas 3149 (82%) of 3840 received the control questionnaire and 2369 (62%) completed follow-up. 1958 (35%) of 5577 personnel in the screening group declined to see the tailored advice, but those with PTSD (83%) or anxiety or depression (84%) were more likely than non-cases (64%) to view the advice (both p<0.0001). At follow-up, there were no significant differences in prevalence between groups for PTSD (adjusted odds ratio 0.92, 95% CI 0.75-1.14), depression or anxiety (0.91, 0.71-1.16), alcohol misuse (0.88, 0.73-1.06), or seeking support for mental disorders (0.92, 0.78-1. 08). Interpretation Post-deployment screening for mental disorders based on tailored advice was not effective at reducing prevalence of mental health disorders nor did it increase help-seeking. Countries that have implemented post-deployment screening programmes for mental disorders should consider monitoring the outcomes of their programmes.	[Rona, Roberto J.; Burdett, Howard; Chesnokov, Melanie; Green, Kevin; Pernet, David; Wessely, Simon] Kings Coll London, Kings Ctr Mil Hlth Res, Dept Psychol Med, London, England; [Jones, Norman; Greenberg, Neil; Fear, Nicola T.] Kings Coll London, Acad Dept Mil Mental Hlth, Dept Psychol Med, London, England; [Khondoker, Mizanur] Univ East Anglia, Norwich Med Sch, Norwich, Norfolk, England; [Green, Kevin] Command Headquarter Operat Stress Management Trau, Portsmouth, Hants, England	Rona, RJ (corresponding author), Kings Coll London, Weston Educ Ctr, Kings Ctr Mil Hlth Res, Dept Psychol Med, London SE5 9RJ, England.	roberto.rona@kcl.ac.uk	Khondoker, Mizanur/O-2656-2019; Wessely, Simon C/A-8713-2008; Khondoker, Mizanur/A-9860-2011	Khondoker, Mizanur/0000-0002-1801-1635; Khondoker, Mizanur/0000-0002-1801-1635; Fear, Nicola/0000-0002-5792-2925; Wessely, Simon Charles/0000-0002-6743-9929; Burdett, Howard/0000-0002-8127-8981; greenberg, neil/0000-0003-4550-2971; Chesnokov, Melanie/0000-0001-6674-422X	US Army Medical Research and Materiel Command-Military Operational Medicine Research Program (USAMRMC-MOMRP)	The US Army Medical Research and Materiel Command-Military Operational Medicine Research Program (USAMRMC-MOMRP).	Adler AB, 2015, BRIT J PSYCHIAT, V207, P346, DOI 10.1192/bjp.bp.114.146506; Babor TF, 2001, GUIDELINES USE PRIMA; Berntsen D, 2012, PSYCHOL SCI, V23, P1557, DOI 10.1177/0956797612457389; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bonanno GA, 2012, BRIT J PSYCHIAT, V200, P317, DOI 10.1192/bjp.bp.111.096552; Burdett H, 2016, INT J METH PSYCH RES, V25, P168, DOI 10.1002/mpr.1501; Casualty Monitor, 2013, MON AN DAT CIV BRIT; Committee on the Assessment of Ongoing Efforts in the Treatment of Posttraumatic Stress Disorder Board on the Health of Select Populations Institute of Medicine, 2014, TREATM POSTTR STRESS; Eekhout I, 2016, LANCET PSYCHIAT, V3, P58, DOI 10.1016/S2215-0366(15)00368-5; Fear NT, 2010, LANCET, V375, P1783, DOI 10.1016/S0140-6736(10)60672-1; Hines LA, 2014, PSYCHIAT SERV, V65, P98, DOI 10.1176/appi.ps.004972012; Hoge CW, 2014, PSYCHIAT SERV, V65, P997, DOI 10.1176/appi.ps.201300307; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Jones M, 2013, PSYCHOL MED, V43, P1703, DOI 10.1017/S0033291712002619; Keeling M, 2012, J MED SCREEN, V19, P206, DOI 10.1258/jms.2012.012054; Kehle-Forbes SM, 2016, PSYCHOL TRAUMA-US, V8, P107, DOI 10.1037/tra0000065; Kroenke K, 2007, ANN INTERN MED, V146, P317, DOI 10.7326/0003-4819-146-5-200703060-00004; Lee DJ, 2016, DEPRESS ANXIETY, V33, P792, DOI 10.1002/da.22511; Lee DJ, 2014, CURR PSYCHIAT REP, V16, DOI 10.1007/s11920-014-0467-7; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Ministry of Defence, 2014, DEF STAT TRI SERV; Ministry of Defence, 2014, OP HERR CAS FAT TABL; Rabe-Hesketh S., 2012, MULTILEVEL LONGITUDI, VI; Rona RJ, 2004, J MED SCREEN, V11, P148, DOI 10.1258/0969141041732193; Rona RJ, 2007, BRIT MED J, V335, P603, DOI 10.1136/bmj.39274.585752.BE; Rona RJ, 2006, BMJ-BRIT MED J, V333, P991, DOI 10.1136/BMJ.38985.610949.55; Rona RJ, 2014, LANCET PSYCHIAT, V1, P531, DOI 10.1016/S2215-0366(14)00062-5; Rona RJ, 2012, J PSYCHIATR RES, V46, P1191, DOI 10.1016/j.jpsychires.2012.05.009; Rona RJ, 2012, J HEAD TRAUMA REHAB, V27, P33, DOI 10.1097/HTR.0b013e318212f814; Seal KH, 2008, AM J PUBLIC HEALTH, V98, P714, DOI 10.2105/AJPH.2007.115519; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Steenkamp MM, 2016, JAMA PSYCHIAT, V73, P431, DOI 10.1001/jamapsychiatry.2015.2879; Steenkamp MM, 2015, JAMA-J AM MED ASSOC, V314, P489, DOI 10.1001/jama.2015.8370; Torgerson DJ, 1998, BRIT MED J, V316, P606, DOI 10.1136/bmj.316.7131.606; Tran US, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0979-2; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Vermetten E, 2014, EUR J PSYCHOTRAUMATO, V5, DOI 10.3402/ejpt.v5.23732; Ware JE., 1993, SF 36 HLTH SURVEY MA; Warner CH, 2011, ARCH GEN PSYCHIAT, V68, P1065, DOI 10.1001/archgenpsychiatry.2011.112; Warner CH, 2011, AM J PSYCHIAT, V168, P378, DOI 10.1176/appi.ajp.2010.10091303; White IR, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d40; Wong E. C., 2015, EVALUATING IMPLEMENT; Zamorski MA, 2014, CAN J PSYCHIAT, V59, P319	46	27	27	0	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 8	2017	389	10077					1410	1423		10.1016/S0140-6736(16)32398-4			14	Medicine, General & Internal	General & Internal Medicine	EQ8OJ	WOS:000398345100033	28215661	Green Accepted			2021-06-18	
J	Loris, ZB; Pieper, AA; Dietrich, WD				Loris, Zachary B.; Pieper, Andrew A.; Dietrich, W. Dalton			The neuroprotective compound P7C3-A20 promotes neurogenesis and improves cognitive function after ischemic stroke	EXPERIMENTAL NEUROLOGY			English	Article						Aminopropyl carbazole; Ischemic stroke; Neuroprotection; Neurogenesis; P7C3-A20; NAD	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; NEURAL STEM-CELLS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; ADULT NEUROGENESIS; HIPPOCAMPAL ATROPHY; SPATIAL MEMORY; RAT; NAMPT; POLY(ADP-RIBOSE)	Ischemic stroke is a devastating condition with few therapeutic interventions available. The neuroprotective compound P7C3-A20 inhibits mature neuronal cell death while also increasing the net magnitude of postnatal neurogenesis in models of neurodegeneration and acute injury. P7C3 compounds enhance flux of nicotinamide adenine dinucleotide (NAD) in mammalian cells, a proposed therapeutic approach to treating cerebral ischemia. The effectiveness of P7C3-A20 treatment on chronic histopathological and behavioral outcomes and neurogenesis after ischemic stroke has not previously been established. Here, a transient middle cerebral artery occlusion in rats was followed by twice daily injection of P7C3-A20 or vehicle for 7 days. P7C3-A20-treated rats performed significantly better than vehicle-treated controls in sensorimotor cylinder and grid-walk tasks, and in a chronic test of spatial learning and memory. These behavioral improvements with P7C3-A20 treatment were correlated with significantly decreased cortical and hippocampal atrophy, and associated with increased neurogenesis in the subventricular zone and hippocampal dentate gyrus subgranular zone. Furthermore, cerebral ischemia significantly reduced NAD in the cortex but P7C3-A20 treatment restored NAD to sham levels. Thus, P7C3-A20 treatment mitigates neurodegeneration and augments repair in the brain after focal ischemia, which translates into chronic behavioral improvement. This suggests a new therapeutic approach of using P7C3 compounds to safely augment NAD and thereby promote two independent processes critical to protecting the brain from ischemic stroke: mature neuron survival and postnatal neurogenesis throughout the post-ischemic brain. Published by Elsevier Inc.	[Loris, Zachary B.; Pieper, Andrew A.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Neurosci Program, Dept Neurol Surg, Miami, FL 33136 USA; [Loris, Zachary B.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Pieper, Andrew A.] Univ Iowa, Carver Coll Med, Dept Psychiat, Iowa City, IA USA; [Pieper, Andrew A.] Univ Iowa, Carver Coll Med, Dept Neurol, Iowa City, IA USA; [Pieper, Andrew A.] Univ Iowa, Carver Coll Med, Dept Free Radical, Iowa City, IA USA; [Pieper, Andrew A.] Univ Iowa, Carver Coll Med, Radiat Biol Program, Oncol Comprehens Canc Ctr,Radiat Dept,Dept Vet Af, Iowa City, IA USA; [Pieper, Andrew A.] Univ Iowa, Pappajohn Biomed Inst, Iowa City, IA USA	Pieper, AA; Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Neurosci Program, Dept Neurol Surg, Miami, FL 33136 USA.	andrew-pieper@uiowa.edu; ddietrich@miami.edu	Pieper, Andrew A/R-5552-2016	Pieper, Andrew/0000-0001-6299-6577	American Heart Association GrantAmerican Heart Association [16PRE27050003]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1NS089443]; University of Iowa; Department of Veterans AffairsUS Department of Veterans Affairs; Titan Neurologic Research fund	The authors would like to thank Dr. Melissa Carballosa-Gautam, Dr. Kristien Van Vlasselaer, Julie Freund, and Enmanuel Perez for their technical contributions to this study. We would also like to acknowledge Ofelia Furones-Alonso for training on the tMCAO model and Dr. Grace Zhai for helping with the NAD assessments. Finally, we would like to thank Dr. Coleen Atkins for her critical review of the manuscript. This work was funded with the support of the American Heart Association Grant # 16PRE27050003 and NINDS RO1NS089443. A.A.P. was supported for this work by funds from an anonymous donor to the Mary Alice Smith Fund for Neuropsychiatry Research, the Titan Neurologic Research fund, and institutional funds from the University of Iowa and the Department of Veterans Affairs.	Amtul Z, 2014, NEUROBIOL AGING, V35, P1605, DOI 10.1016/j.neurobiolaging.2014.01.005; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Bingham D, 2012, J CEREBR BLOOD F MET, V32, P989, DOI 10.1038/jcbfm.2012.16; Blaya MO, 2015, EXP NEUROL, V264, P67, DOI 10.1016/j.expneurol.2014.11.014; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Blokland A, 2004, BEHAV BRAIN RES, V154, P71, DOI 10.1016/j.bbr.2004.01.022; Burkle A, 2005, FEBS J, V272, P4576, DOI 10.1111/j.1742-4658.2005.04864.x; Carmichael S Thomas, 2005, NeuroRx, V2, P396; CHEN CJ, 2016, NEUROLOGY, V86, P2316; De Jesus-Cortes H., 2016, NEUROGENESIS; De Jesus-Cortes H, 2012, P NATL ACAD SCI USA, V109, P17010, DOI 10.1073/pnas.1213956109; De Jesus-Cortest H, 2015, NPJ PARKINSON DIS, V1, DOI 10.1038/npjparkd.2015.10; Dibajnia P, 2013, ACTA PHARMACOL SIN, V34, P78, DOI 10.1038/aps.2012.107; Dirnagl U, 2016, STROKE, V47, P2148, DOI 10.1161/STROKEAHA.116.013244; Dutca LM, 2014, INVEST OPHTH VIS SCI, V55, P8330, DOI 10.1167/iovs.14-15468; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Gil-Bea FJ, 2012, NEUROBIOL DIS, V48, P439, DOI 10.1016/j.nbd.2012.06.020; Gladstone DJ, 2002, STROKE, V33, P2123, DOI 10.1161/01.STR.0000025518.34157.51; Ito H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128445; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Jin KL, 2010, P NATL ACAD SCI USA, V107, P7993, DOI 10.1073/pnas.1000154107; Jing Z, 2014, J CEREBR BLOOD F MET, V34, P1613, DOI 10.1038/jcbfm.2014.119; Kemp SWP, 2015, NEUROSCIENCE, V284, P202, DOI 10.1016/j.neuroscience.2014.10.005; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Krueger H, 2015, STROKE, V46, P2226, DOI 10.1161/STROKEAHA.115.009616; Lee A. S., 2016, ENEURO, P3; Li Y, 2009, CURR TOP DEV BIOL, V87, P149, DOI 10.1016/S0070-2153(09)01205-8; Lichtenwalner RJ, 2006, J CEREBR BLOOD F MET, V26, P1, DOI 10.1038/sj.jcbfm.9600170; Lindau NT, 2014, BRAIN, V137, P739, DOI 10.1093/brain/awt336; Liu YP, 2009, ACTA NEUROPATHOL, V117, P469, DOI 10.1007/s00401-009-0516-1; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MacMillan KS, 2011, J AM CHEM SOC, V133, P1428, DOI 10.1021/ja108211m; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Miller DJ, 2011, NEUROHOSPITALIST, V1, P138, DOI 10.1177/1941875211408731; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Mokin M, 2016, NAT REV NEUROL, V12, P86, DOI 10.1038/nrneurol.2015.240; Morris-Blanco KC, 2014, J CEREBR BLOOD F MET, V34, P1024, DOI 10.1038/jcbfm.2014.51; Naidoo J, 2014, J MED CHEM, V57, P3746, DOI 10.1021/jm401919s; Naidoo J, 2013, TETRAHEDRON LETT, V54, P4429, DOI 10.1016/j.tetlet.2013.06.024; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; O'Collins VE, 2006, ANN NEUROL, V59, P467, DOI 10.1002/ana.20741; Ohab JJ, 2008, NEUROSCIENTIST, V14, P369, DOI 10.1177/1073858407309545; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; Pieper AA, 2014, CHEM SOC REV, V43, P6716, DOI 10.1039/c3cs60448a; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; Pierot L, 2015, STROKE, V46, P1440, DOI 10.1161/STROKEAHA.115.008416; Ramos-Cabrer P, 2011, STROKE, V42, pS7, DOI 10.1161/STROKEAHA.110.596684; Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061; Schaar Krystal L, 2010, Exp Transl Stroke Med, V2, P13, DOI 10.1186/2040-7378-2-13; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Shear DA, 2016, J NEUROTRAUM, V33, P523, DOI 10.1089/neu.2015.4115; Stein LR, 2014, EMBO J, V33, P1321, DOI 10.1002/embj.201386917; Sutherland BA, 2012, INT J STROKE, V7, P407, DOI 10.1111/j.1747-4949.2012.00770.x; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; Tesla R, 2012, P NATL ACAD SCI USA, V109, P17016, DOI 10.1073/pnas.1213960109; Thored P, 2007, STROKE, V38, P3032, DOI 10.1161/STROKEAHA.107.488445; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Walker AK, 2015, MOL PSYCHIATR, V20, P500, DOI 10.1038/mp.2014.34; Wang G, 2014, CELL, V158, P1324, DOI 10.1016/j.cell.2014.07.040; Wang P, 2015, TRENDS PHARMACOL SCI, V36, P891, DOI 10.1016/j.tips.2015.08.012; Wang P, 2011, ANN NEUROL, V69, P360, DOI 10.1002/ana.22236; Wang SN, 2016, CNS NEUROSCI THER, V22, P431, DOI 10.1111/cns.12539; Xing CH, 2012, INT J STROKE, V7, P378, DOI 10.1111/j.1747-4949.2012.00839.x; Yang J, 2015, BRAIN RES, V1629, P231, DOI 10.1016/j.brainres.2015.10.032; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030; Ying WH, 2008, ANTIOXID REDOX SIGN, V10, P179, DOI 10.1089/ars.2007.1672; Yonemori F, 1996, J CEREBR BLOOD F MET, V16, P973, DOI 10.1097/00004647-199609000-00022; Zerna C, 2016, CIRC RES, V118, P1425, DOI 10.1161/CIRCRESAHA.116.307005; Zhao SS, 2013, STROKE, V44, P1698, DOI 10.1161/STROKEAHA.111.000361; Zhao Y, 2015, STROKE, V46, P1966, DOI 10.1161/STROKEAHA.115.009216	76	27	27	1	25	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	2017	290						63	73		10.1016/j.expneurol.2017.01.006			11	Neurosciences	Neurosciences & Neurology	EM5QR	WOS:000395368000006	28077334				2021-06-18	
J	Sufrinko, AM; Marchetti, GF; Cohen, PE; Elbin, RJ; Re, V; Kontos, AP				Sufrinko, Alicia M.; Marchetti, Gregory F.; Cohen, Paul E.; Elbin, R. J.; Re, Valentina; Kontos, Anthony P.			Using Acute Performance on a Comprehensive Neurocognitive, Vestibular, and Ocular Motor Assessment Battery to Predict Recovery Duration After Sport-Related Concussions	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; recovery; neurocognitive; vestibular; ocular motor	HIGH-SCHOOL; ADOLESCENTS; SYMPTOMS; AGE; RELIABILITY; IMPAIRMENT; MIGRAINE; SCALE	Background: A sport-related concussion (SRC) is a heterogeneous injury that requires a multifaceted and comprehensive approach for diagnosis and management, including symptom reports, vestibular/ocular motor assessments, and neurocognitive testing. Purpose: To determine which acute (eg, within 7 days) vestibular, ocular motor, neurocognitive, and symptom impairments predict the duration of recovery after an SRC. Study Design: Cohort study (prognosis); Level of evidence, 2. Methods: Sixty-nine patients with a mean age of 15.3 +/- 1.9 years completed a neurocognitive, vestibular/ocular motor, and symptom assessment within 7 days of a diagnosed concussion. Patients were grouped by recovery time: <= 14 days (n = 27, 39.1%), 15-29 days (n = 25, 36.2%), and 30-90 days (n = 17, 24.6%). Multinomial regression was used to identify the best subset of predictors associated with prolonged recovery relative to <= 14 days. Results: Acute visual motor speed and cognitive-migraine-fatigue symptoms were associated with an increased likelihood of recovery times of 30-90 days and 15-29 days relative to a recovery time of <= 14 days. A model with visual motor speed and cognitive-migraine-fatigue symptoms within the first 7 days of an SRC was 87% accurate at identifying patients with a recovery time of 30-90 days. Conclusion: The current study identified cognitive-migraine-fatigue symptoms and visual motor speed as the most robust predictors of protracted recovery after an SRC according to the Post-concussion Symptom Scale, Immediate Post-concussion Assessment and Cognitive Testing, and Vestibular/Ocular Motor Screening (VOMS). While VOMS components were sensitive in identifying a concussion, they were not robust predictors for recovery. Clinicians may consider particular patterns of performance on clinical measures when providing treatment recommendations and discussing anticipated recovery with patients.	[Sufrinko, Alicia M.; Cohen, Paul E.; Kontos, Anthony P.] Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, 3200 South Water St, Pittsburgh, PA 15203 USA; [Marchetti, Gregory F.] Duquesne Univ, John G Rangos Sr Sch Hlth Sci, Pittsburgh, PA 15219 USA; [Elbin, R. J.] Univ Arkansas, Dept Hlth Human Performance & Recreat, Off Sport Concuss Res, Fayetteville, AR 72701 USA; [Re, Valentina] Univ Milan, Milan, Italy	Sufrinko, AM (corresponding author), Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, 3200 South Water St, Pittsburgh, PA 15203 USA.	sufrinkoam@upmc.edu		Kontos, Anthony/0000-0002-3749-4310			Abu-Arafeh I, 2010, DEV MED CHILD NEUROL, V52, P1088, DOI 10.1111/j.1469-8749.2010.03793.x; Baker JG, 2015, CLIN PEDIATR, V54, P961, DOI 10.1177/0009922815588820; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Covassin T., 2014, ATHLETIC TRAINING SP, V6, DOI [DOI 10.3928/19425864-20140916-01, https://doi.org/10.3928/19425864-20140916-01]; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Iverson GL, 2016, PHYS MED REH CLIN N, V27, P429, DOI 10.1016/j.pmr.2015.12.002; Kontos AP, 2016, CURR PAIN HEADACHE R, V20, DOI 10.1007/s11916-016-0571-y; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Leddy JJ, 2016, PHYS MED REH CLIN N, V27, P437, DOI 10.1016/j.pmr.2015.12.003; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Pastor Patricia N, 2008, Vital Health Stat 10, P1; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e	27	27	27	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	APR	2017	45	5					1187	1194		10.1177/0363546516685061			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	ET4HK	WOS:000400239900026	28192036				2021-06-18	
J	Shively, SB; Edgerton, SL; Iacono, D; Purohit, DP; Qu, BX; Haroutunian, V; Davis, KL; Diaz-Arrastia, R; Perl, DP				Shively, Sharon B.; Edgerton, Sarah L.; Iacono, Diego; Purohit, Dushyant P.; Qu, Bao-Xi; Haroutunian, Vahram; Davis, Kenneth L.; Diaz-Arrastia, Ramon; Perl, Daniel P.			Localized cortical chronic traumatic encephalopathy pathology after single, severe axonal injury in human brain	ACTA NEUROPATHOLOGICA			English	Article						Traumatic brain injury; Chronic traumatic encephalopathy; Axonal injury; Tau; Neurofibrillary tangle; beta-Amyloid plaque	AMYLOID PROTEIN DEPOSITION; APOLIPOPROTEIN-E EPSILON-4; HEAD-INJURY; ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASES; BETA-PROTEIN; WHITE-MATTER; RISK; DEGENERATION; ASSOCIATION	Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with repetitive mild impact traumatic brain injury from contact sports. Recently, a consensus panel defined the pathognomonic lesion for CTE as accumulations of abnormally hyperphosphorylated tau (p-tau) in neurons (neurofibrillary tangles), astrocytes and cell processes distributed around small blood vessels at sulcal depths in irregular patterns within the cortex. The pathophysiological mechanism for this lesion is unknown. Moreover, a subset of CTE cases harbors cortical beta-amyloid plaques. In this study, we analyzed postmortem brain tissues from five institutionalized patients with schizophrenia and history of surgical leucotomy with subsequent survival of at least another 40 years. Because leucotomy involves severing axons bilaterally in prefrontal cortex, this surgical procedure represents a human model of single traumatic brain injury with severe axonal damage and no external impact. We examined cortical tissues at the leucotomy site and at both prefrontal cortex rostral and frontal cortex caudal to the leucotomy site. For comparison, we analyzed brain tissues at equivalent neuroanatomical sites from non-leucotomized patients with schizophrenia, matched in age and gender. All five leucotomy cases revealed severe white matter damage with dense astrogliosis at the axotomy site and also neurofibrillary tangles and p-tau immunoreactive neurites in the overlying gray matter. Four cases displayed p-tau immunoreactivity in neurons, astrocytes and cell processes encompassing blood vessels at cortical sulcal depths in irregular patterns, similar to CTE. The three cases with apolipoprotein E epsilon 4 haplotype showed scattered beta-amyloid plaques in the overlying gray matter, but not the two cases with apolipoprotein E epsilon 3/3 genotype. Brain tissue samples from prefrontal cortex rostral and frontal cortex caudal to the leucotomy site, and all cortical samples from the non-leucotomized patients, showed minimal p-tau and beta-amyloid pathology. These findings suggest that chronic axonal damage contributes to the unique pathology of CTE over time.	[Shively, Sharon B.; Iacono, Diego; Perl, Daniel P.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Shively, Sharon B.; Edgerton, Sarah L.; Iacono, Diego; Qu, Bao-Xi; Diaz-Arrastia, Ramon; Perl, Daniel P.] Ctr Neurosci & Regenerat Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Shively, Sharon B.; Edgerton, Sarah L.; Iacono, Diego] Henry M Jackson Fdn Adv Mil Med, 6720 Rockledge Dr, Bethesda, MD 20817 USA; [Purohit, Dushyant P.] Icahn Sch Med Mt Sinai, Dept Pathol, 1468 Madison Ave, New York, NY 10029 USA; [Qu, Bao-Xi; Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Neurol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Haroutunian, Vahram; Davis, Kenneth L.] Icahn Sch Med Mt Sinai, Dept Psychiat, 1 Gustave L Levy Pl, New York, NY 10029 USA; [Haroutunian, Vahram] Icahn Sch Med Mt Sinai, Dept Neurosci, 1 Gustave L Levy Pl, New York, NY 10029 USA; [Haroutunian, Vahram] James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA; [Davis, Kenneth L.] Icahn Sch Med Mt Sinai, Dept Pharmacol Sci, 1 Gustave L Levy Pl, New York, NY 10029 USA	Perl, DP (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.; Perl, DP (corresponding author), Ctr Neurosci & Regenerat Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	daniel.perl@usuhs.edu	Iacono, Diego/K-8203-2016	Iacono, Diego/0000-0001-5511-0950; Diaz-Arrastia, Ramon/0000-0001-6051-3594	Defense Health Program of the United States Department of Defense; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH45212, MH064673]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH064673] Funding Source: NIH RePORTER	This study was funded by the Defense Health Program of the United States Department of Defense and the National Institutes of Health (grants MH45212, MH064673). This study utilized neuropathology core facilities of Center for Neuroscience and Regenerative Medicine and Uniformed Services University of the Health Sciences within the United States Department of Defense. The authors wish to thank Dr. Peter Davies for the generous gift of CP13 and PHF1 antibodies. We also thank Drs. Charles Rice, Arthur Kellermann, Yvonne Maadox and Regina Armstrong for their continuous encouragement and support, and Patricia Lee for her technical expertise. The cases were obtained from tissue archives of the Pilgrim Psychiatric Center Brain Bank in West Brentwood, NY. The opinions expressed herein are those of the authors and are not necessarily representative of those of the Uniformed Services University of the Health Sciences, the Department of Defense; or, the United States Army, Navy or Air Force.	Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Calero O, 2009, J NEUROSCI METH, V183, P238, DOI 10.1016/j.jneumeth.2009.06.033; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Freeman W, 1950, PSYCHOSURGERY TREATM; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HIRANO A, 1962, ARCH NEUROL-CHICAGO, V6, P114, DOI 10.1001/archneur.1962.00450200028003; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iliff JJ, 2015, LANCET NEUROL, V14, P977, DOI 10.1016/S1474-4422(15)00221-5; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Leclercq PD, 2005, J NEUROL NEUROSUR PS, V76, P229, DOI 10.1136/jnnp.2003.025528; Liu CC, 2013, NAT REV NEUROL, V9, P106, DOI 10.1038/nrneurol.2012.263; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nedergaard M, 2013, SCIENCE, V340, P1529, DOI 10.1126/science.1240514; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Purohit DP, 1998, ARCH GEN PSYCHIAT, V55, P205, DOI 10.1001/archpsyc.55.3.205; Rapp MA, 2010, SCHIZOPHR RES, V116, P90, DOI 10.1016/j.schres.2009.10.013; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Zhao Z, 2015, NAT NEUROSCI, V18, P978, DOI 10.1038/nn.4025; Zlokovic BV, 2010, J NEUROCHEM, V115, P1077, DOI 10.1111/j.1471-4159.2010.07002.x	50	27	27	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAR	2017	133	3					353	366		10.1007/s00401-016-1649-7			14	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	EL9ST	WOS:000394961100002	27885490	Green Published, Other Gold			2021-06-18	
J	Howel, DR; Oldham, JR; DiFabio, M; Vallabhajosula, S; Hall, EE; Ketcham, CJ; Meehan, WP; Buckley, TA				Howel, David R.; Oldham, Jessie R.; DiFabio, Melissa; Vallabhajosula, Srikant; Hall, Eric E.; Ketcham, Caroline J.; Meehan, William P., III; Buckley, Thomas A.			Single-Task and Dual-Task Gait Among Collegiate Athletes of Different Sport Classifications: Implications for Concussion Management	JOURNAL OF APPLIED BIOMECHANICS			English	Article						clinical biomechanics; gait analysis; head injury; sports medicine	ERROR SCORING SYSTEM; BALANCE CONTROL; EXECUTIVE FUNCTION; NORMATIVE DATA; ATTENTION; PERFORMANCE; DEFICITS; ADOLESCENTS; STABILITY; PARADIGM	Gait impairments have been documented following sport-related concussion. Whether preexisting gait pattern differences exist among athletes who participate in different sport classifications, however, remains unclear. Dual-task gait examinations probe the simultaneous performance of everyday tasks (ie, walking and thinking), and can quantify gait performance using inertial sensors. The purpose of this study was to compare the single-task and dual-task gait performance of collision/contact and noncontact athletes. A group of collegiate athletes (n = 265) were tested before their season at 3 institutions (mean age= 19.1 +/- 1.1 years). All participants stood still (single-task standing) and walked while simultaneously completing a cognitive test (dual-task gait), and completed walking trials without the cognitive test (single-task gait). Spatial-temporal gait parameters were compared between collision/contact and noncontact athletes using MANCOVAs; cognitive task performance was compared using ANCOVAs. No significant single-task or dual-task gait differences were found between collision/contact and noncontact athletes. Noncontact athletes demonstrated higher cognitive task accuracy during single-task standing (P = .001) and dual-task gait conditions (P = .02) than collision/contact athletes. These data demonstrate the utility of a dual-task gait assessment outside of a laboratory and suggest that preinjury cognitive task performance during dual-tasks may differ between athletes of different sport classifications.	[Howel, David R.; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA 02453 USA; [Howel, David R.; Meehan, William P., III] Boston Childrens Hosp, Dept Orthopaed, Div Sports Med, Boston, MA 02115 USA; [Howel, David R.; Meehan, William P., III] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA 02115 USA; [DiFabio, Melissa; Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE USA; [DiFabio, Melissa; Buckley, Thomas A.] Univ Delaware, Interdisciplinary Program Biomech & Movement Sci, Newark, DE USA; [Vallabhajosula, Srikant] Elon Univ, Dept Phys Therapy Educ, Elon, NC USA; [Hall, Eric E.; Ketcham, Caroline J.] Elon Univ, Dept Exercise Sci, Elon, NC USA; [Meehan, William P., III] Harvard Med Sch, Dept Pediat, Boston, MA USA; [Meehan, William P., III] Harvard Med Sch, Dept Orthopaed Surg, Boston, MA USA	Howel, DR (corresponding author), Micheli Ctr Sports Injury Prevent, Waltham, MA 02453 USA.; Howel, DR (corresponding author), Boston Childrens Hosp, Dept Orthopaed, Div Sports Med, Boston, MA 02115 USA.; Howel, DR (corresponding author), Boston Childrens Hosp, Brain Injury Ctr, Boston, MA 02115 USA.	David.Howel12@childrens.harvard.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150; Oldham, Jessie/0000-0003-2801-2110; Vallabhajosula, Srikant/0000-0002-7984-1106	National Football League Players Association; National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament; National Collegiate Athletic Association; Department of DefenseUnited States Department of Defense	Dr. Meehan receives royalties from ABC-Clio publishing for the sale of his book, Kids, Sports, and Concussion: A Guide for Coaches and Parents, and royalties from Wolters Kluwer for working as an author for UpToDate. He is under contract with ABC-Clio publishing for a future book titled, Concussions, and with Springer International publishing for a future book titled, Head and Neck Injuries in Young Athletes. His research is funded, in part, by a grant from the National Football League Players Association and by philanthropic support from the National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament. Dr. Buckley's research is funded, in part, by a grant from the National Collegiate Athletic Association and the Department of Defense. Dr. Howell, Ms. Oldham, Ms. DiFabio, Dr. Vallabhajosula, Dr. Hall, and Dr. Ketcham have no conflicts of interest to report.	Baker CS, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12252; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Brown HJ, 2014, MED SCI SPORT EXER, V46, P1610, DOI 10.1249/MSS.0000000000000263; Buckley TA, 2016, J SPORT HEALTH SCI, V5, P417, DOI 10.1016/j.jshs.2015.03.010; Burk JM, 2013, CLIN J SPORT MED, V23, P312, DOI 10.1097/JSM.0b013e318285633f; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Evans KM, 2015, INT J PHYS MED REHAB, V3; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Godde B, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00139; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Howell D, 2015, J BIOMECH, V48, P3364, DOI 10.1016/j.jbiomech.2015.06.014; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Iverson G.L., 2003, IMMEDIATE POSTCONCUS; Iverson GL, 2013, BRAIN INJURY, V27, P596, DOI 10.3109/02699052.2013.772237; Kerrigan DC, 1998, AM J PHYS MED REHAB, V77, P2, DOI 10.1097/00002060-199801000-00002; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Leitner Y, 2007, J NEUROL, V254, P1330, DOI 10.1007/s00415-006-0522-3; Mancini M, 2011, J BIOENG BIONZED S1; Mancini M, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-59; Mancini M, 2012, GAIT POSTURE, V36, P471, DOI 10.1016/j.gaitpost.2012.04.010; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Meagher J, 2015, WORLD J PSYCHIATR, V5, P305, DOI 10.5498/wjp.v5.i3.305; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Parker TM, 2008, MED ENG PHYS, V30, P959, DOI 10.1016/j.medengphy.2007.12.006; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Ponta ML, 2014, OBES SURG, V24, P1915, DOI 10.1007/s11695-014-1254-6; Rahn C, 2015, CLIN J SPORT MED, V25, P248, DOI 10.1097/JSM.0000000000000141; Register-Mihalik JK, 2013, NEUROPSYCHOL REV, V23, P300, DOI 10.1007/s11065-013-9238-1; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Ross LM, 2011, J SPORT REHABIL, V20, P296, DOI 10.1123/jsr.20.3.296; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; SUTHERLAND DH, 1980, J BONE JOINT SURG AM, V62, P336, DOI 10.2106/00004623-198062030-00004; Vallabhajosula S, 2015, J BIOMECH, V48, P921, DOI 10.1016/j.jbiomech.2015.02.024; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wang JJ, 2009, J NEURAL TRANSM, V116, P1087, DOI 10.1007/s00702-009-0269-y; Wright JM, 2014, WILD ENVIRON MED, V25, P319, DOI 10.1016/j.wem.2014.01.004; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720	47	27	27	0	13	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1065-8483	1543-2688		J APPL BIOMECH	J. Appl. Biomech.	FEB	2017	33	1					24	31		10.1123/jab.2015-0323			8	Engineering, Biomedical; Sport Sciences	Engineering; Sport Sciences	EL9EH	WOS:000394921800004	27705076				2021-06-18	
J	Kyyriainen, J; Ndode-Ekane, XE; Pitkanen, A				Kyyriainen, Jenni; Ndode-Ekane, Xavier Ekolle; Pitkanen, Asla			Dynamics of PDGFR beta Expression in Different Cell Types after Brain Injury	GLIA			English	Article						NG2 cell; pericyte; status epilepticus; traumatic brain injury; urokinase-type plasminogen activator receptor	FACTOR RECEPTOR-BETA; PLASMINOGEN-ACTIVATOR RECEPTOR; SMOOTH-MUSCLE-CELLS; MOUSE MODEL; RAT-BRAIN; PERICYTES; DEFICIENT; NG2; INVOLVEMENT; EPILEPTOGENESIS	Platelet-derived growth factor receptor beta (PDGFR beta) is upregulated after brain injury and its depletion results in the blood-brain barrier (BBB) damage. We investigated the time-window and localization of PDGFR beta expression in mice with intrahippocampal kainic acid-induced status epilepticus (SE) and in rats with lateral fluid-percussion-induced traumatic brain injury (TBI). Tissue immunohistochemistry was evaluated at several time-points after SE and TBI. The distribution of PDGFR beta was analyzed, and its cell type-specific expression was verified with double/triple-labeling of astrocytes (GFAP), NG2 cells, and endothelial cells (RECA-1). In normal mouse hippocampus, we found evenly distributed PDGFR beta+ parenchymal cells. In double-labeling, all NG2+ and 40%-60% GFAP+ cells were PDGFR beta+. After SE, PDGFR beta+ cells clustered in the ipsilateral hilus (178% of that in controls at fourth day, 225% at seventh day, P<0.05) and in CA3 (201% at seventh day, P<0.05), but the total number of PDGFR beta+ cells was not altered. As in controls, PDGFR beta-immunoreactivity was detected in parenchymal NG2+ and GFAP+ cells. We also observed PDGFR beta+ structural pericytes, detached reactive pericytes, and endothelial cells. After TBI, PDGFR beta+ cells clustered in the perilesional cortex and thalamus, particularly during the first post-injury week. PDGFR beta immunopositivity was observed in NG2+ and GFAP+ cells, structural pericytes, detached reactive pericytes, and endothelial cells. In some animals, PDGFR beta vascular staining was observed around the cortical glial scar for up to 3 months. Our data revealed an acute accumulation of PDGFR beta+ BBB-related cells in degenerating brain areas, which can be long lasting, suggesting an active role for PDGFR beta-signaling in blood vessel and post-injury tissue recovery.	[Kyyriainen, Jenni; Ndode-Ekane, Xavier Ekolle; Pitkanen, Asla] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, POB 1627, FI-70211 Kuopio, Finland	Pitkanen, A (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, POB 1627, FI-70211 Kuopio, Finland.	asla.pitkanen@uef.fi		Ndode-Ekane, Xavier Ekolle/0000-0001-5682-5632	Academy of FinlandAcademy of FinlandEuropean Commission; COST Action ECMNETEuropean Cooperation in Science and Technology (COST) [BM1001]; ERA-NET Neuron [TBI Epilepsy]; Doctoral Program in Molecular Medicine; Epilepsy Foundation; Finnish Epilepsy Research Foundation	Grant sponsor: The Academy of Finland, COST Action ECMNET [BM1001], ERA-NET Neuron [TBI Epilepsy], Doctoral Program in Molecular Medicine, Epilepsy Foundation and Finnish Epilepsy Research Foundation.	Alonso G, 2005, GLIA, V49, P318, DOI 10.1002/glia.20121; Arimura K, 2012, CURR NEUROVASC RES, V9, P1; Beazely MA, 2009, J BIOL CHEM, V284, P8054, DOI 10.1074/jbc.M805384200; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Dimou L, 2015, GLIA, V63, P1429, DOI 10.1002/glia.22859; Dityatev A, 2014, PROG BRAIN RES, V214, pXIII, DOI 10.1016/B978-0-444-63486-3.09998-9; Dore-Duffy P, 2000, MICROVASC RES, V60, P55, DOI 10.1006/mvre.2000.2244; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; Franklin KB, 2008, MOUSE BRAIN STEREOTA; Fuhrman B, 2009, CARDIOVASC RES, V84, P145, DOI 10.1093/cvr/cvp184; Garbelli R, 2015, NEUROSCIENCE, V306, P18, DOI 10.1016/j.neuroscience.2015.07.090; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; Gril B, 2013, AM J PATHOL, V182, P2368, DOI 10.1016/j.ajpath.2013.02.043; Hamilton TG, 2003, MOL CELL BIOL, V23, P4013, DOI 10.1128/MCB.23.11.4013-4025.2003; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Hill RA, 2014, GLIA, V62, P1195, DOI 10.1002/glia.22664; Huusko N, 2015, BRAIN STRUCT FUNCT, V220, P153, DOI 10.1007/s00429-013-0644-1; Immonen R, 2010, J CEREBR BLOOD F MET, V30, P1318, DOI 10.1038/jcbfm.2010.15; Ishii Y, 2008, MOL CELL NEUROSCI, V37, P507, DOI 10.1016/j.mcn.2007.11.006; Ishii Y, 2006, J NEUROCHEM, V98, P588, DOI 10.1111/j.1471-4159.2006.03922.x; Ishitsuka K, 2012, MICROVASC RES, V83, P352, DOI 10.1016/j.mvr.2012.02.009; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kiyan J, 2005, EMBO J, V24, P1787, DOI 10.1038/sj.emboj.7600669; Lahtinen L, 2009, NEUROSCIENCE, V163, P316, DOI 10.1016/j.neuroscience.2009.06.019; Lehto LJ, 2012, NEUROIMAGE, V61, P761, DOI 10.1016/j.neuroimage.2012.03.002; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LEWIS DA, 1986, J COMP NEUROL, V248, P1, DOI 10.1002/cne.902480102; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Makihara N, 2015, EXP NEUROL, V264, P127, DOI 10.1016/j.expneurol.2014.12.007; Malla R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013731; Meirelles LD, 2016, FRONT BIOSCI-LANDMRK, V21, P130, DOI 10.2741/4380; Milesi S, 2014, NEUROBIOL DIS, V71, P151, DOI 10.1016/j.nbd.2014.07.010; Morita S, 2014, CELL BIOCHEM FUNCT, V32, P51, DOI 10.1002/cbf.2971; Ndode-Ekane XE, 2010, NEUROSCIENCE, V166, P312, DOI 10.1016/j.neuroscience.2009.12.002; Ndode-Ekane XE, 2013, MOL NEUROBIOL, V47, P914, DOI 10.1007/s12035-012-8386-2; NEHLS V, 1992, CELL TISSUE RES, V270, P469, DOI 10.1007/BF00645048; Ong WY, 1999, NEUROSCIENCE, V92, P83, DOI 10.1016/S0306-4522(98)00751-9; Ozen I, 2014, ACTA NEUROPATHOL, V128, P381, DOI 10.1007/s00401-014-1295-x; Ozerdem U, 2002, MICROVASC RES, V63, P129, DOI 10.1006/mvre.2001.2376; Pekny M, 2014, PHYSIOL REV, V94, P1077, DOI 10.1152/physrev.00041.2013; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pitkanen A, 2014, PROG BRAIN RES, V214, P229, DOI 10.1016/B978-0-444-63486-3.00011-6; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Renner O, 2003, MOL BRAIN RES, V113, P44, DOI 10.1016/S0169-328X(03)00085-8; Roder C, 2010, ACTA NEUROCHIR, V152, P2153, DOI 10.1007/s00701-010-0711-9; Rubina KA, 2015, BIOCHEMISTRY-MOSCOW+, V80, P1235, DOI 10.1134/S0006297915100041; Sano H, 2001, CIRCULATION, V103, P2955, DOI 10.1161/01.CIR.103.24.2955; Shen J, 2012, J CEREBR BLOOD F MET, V32, P353, DOI 10.1038/jcbfm.2011.136; Shim AHR, 2010, P NATL ACAD SCI USA, V107, P11307, DOI 10.1073/pnas.1000806107; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Smith HW, 2010, NAT REV MOL CELL BIO, V11, P23, DOI 10.1038/nrm2821; SMITS A, 1991, P NATL ACAD SCI USA, V88, P8159, DOI 10.1073/pnas.88.18.8159; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thomas WE, 1999, BRAIN RES REV, V31, P42, DOI 10.1016/S0165-0173(99)00024-7; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; van Vliet EA, 2007, BRAIN, V130, P521, DOI 10.1093/brain/awl318; van Vliet EA, 2015, SEMIN CELL DEV BIOL, V38, P26, DOI 10.1016/j.semcdb.2014.10.003; van Vliet EA, 2014, NEUROSCIENCE, V277, P455, DOI 10.1016/j.neuroscience.2014.07.030; Vasefi MS, 2013, J NEUROCHEM, V125, P26, DOI 10.1111/jnc.12157; Virgintino D, 2012, ANGIOGENESIS, V15, P761, DOI 10.1007/s10456-012-9292-y; Weissberg I., 2011, EPILEPSY RES TREAT, V2011, DOI DOI 10.1155/2011/143908; Winkler EA, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-32; Zhang LJ, 2013, NEUROL SCI, V34, P639, DOI 10.1007/s10072-012-1090-1; Zhao YJ, 2012, MOL MED REP, V6, P739, DOI 10.3892/mmr.2012.1007	67	27	27	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	FEB	2017	65	2					322	341		10.1002/glia.23094			20	Neurosciences	Neurosciences & Neurology	EK1ER	WOS:000393669100008	27778377				2021-06-18	
J	Mandyam, CD; Schilling, JM; Cui, WH; Egawa, J; Niesman, IR; Kellerhals, SE; Staples, MC; Busija, AR; Risbrough, VB; Posadas, E; Grogman, GC; Chang, JW; Roth, DM; Patel, PM; Patel, HH; Head, BP				Mandyam, Chitra D.; Schilling, Jan M.; Cui, Weihua; Egawa, Junji; Niesman, Ingrid R.; Kellerhals, Sarah E.; Staples, Miranda C.; Busija, Anna R.; Risbrough, Victoria B.; Posadas, Edmund; Grogman, Grace C.; Chang, Jamie W.; Roth, David M.; Patel, Piyush M.; Patel, Hemal H.; Head, Brian P.			Neuron-Targeted Caveolin-1 Improves Molecular Signaling, Plasticity, and Behavior Dependent on the Hippocampus in Adult and Aged Mice	BIOLOGICAL PSYCHIATRY			English	Article						CA1; Caveolin; Dentate gyrus; Membrane/lipid rafts; Neuroplasticity; TrkB	TRAUMATIC BRAIN-INJURY; NERVE GROWTH CONES; SPINAL-CORD-INJURY; LIPID RAFTS; CHEMOTROPIC GUIDANCE; ALZHEIMERS-DISEASE; PLASMA-MEMBRANE; UP-REGULATION; AXON GROWTH; RECEPTORS	BACKGROUND: Studies in vitro demonstrate that neuronal membrane/lipid rafts (MLRs) establish cell polarity by clustering progrowth receptors and tethering cytoskeletal machinery necessary for neuronal sprouting. However, the effect of MLR and MLR-associated proteins on neuronal aging is unknown. METHODS: Here, we assessed the impact of neuron-targeted overexpression of an MLR scaffold protein, caveolin-1 (Cav-1) (via a synapsin promoter, SynCav1), in the hippocampus in vivo in adult (6-month-old) and aged (20-month-old) mice on biochemical, morphologic, and behavioral changes. RESULTS: SynCav1 resulted in increased expression of Cav-1, MLRs, and MLR-localization of Cav-1 and tropomyosin-related kinase B receptor independent of age and time post gene transfer. Cav-1 overexpression in adult mice enhanced dendritic arborization within the apical dendrites of hippocampal cornu ammonis 1 and granule cell neurons, effects that were also observed in aged mice, albeit to a lesser extent, indicating preserved impact of Cav-1 on structural plasticity of hippocampal neurons with age. Cav-1 overexpression enhanced contextual fear memory in adult and aged mice demonstrating improved hippocampal function. CONCLUSIONS: Neuron-targeted overexpression of Cav-1 in the adult and aged hippocampus enhances functional MLRs with corresponding roles in cell signaling and protein trafficking. The resultant structural alterations in hippocampal neurons in vivo are associated with improvements in hippocampal-dependent learning and memory. Our findings suggest Cav-1 as a novel therapeutic strategy in disorders involving impaired hippocampal function.	[Mandyam, Chitra D.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA 92103 USA; [Mandyam, Chitra D.; Staples, Miranda C.] Scripps Res Inst, Comm Neurobiol Addict Disorders, La Jolla, CA 92037 USA; [Schilling, Jan M.; Cui, Weihua; Egawa, Junji; Kellerhals, Sarah E.; Busija, Anna R.; Risbrough, Victoria B.; Posadas, Edmund; Grogman, Grace C.; Chang, Jamie W.; Roth, David M.; Patel, Piyush M.; Patel, Hemal H.; Head, Brian P.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Schilling, Jan M.; Cui, Weihua; Egawa, Junji; Kellerhals, Sarah E.; Busija, Anna R.; Posadas, Edmund; Grogman, Grace C.; Chang, Jamie W.; Roth, David M.; Patel, Piyush M.; Patel, Hemal H.; Head, Brian P.] Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA; [Cui, Weihua] Capital Med Univ, Beijing Tiantan Hosp, Dept Anesthesiol, Beijing, Peoples R China; [Risbrough, Victoria B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Niesman, Ingrid R.] Univ Calif San Diego, Dept Cellular & Mol Med, Sanford Consortium Regenerat Med, La Jolla, CA 92093 USA	Head, BP (corresponding author), Univ Calif San Diego, Dept Anesthesiol, VASDHS 9125,3350 La Jolla Village Dr, San Diego, CA 92161 USA.	bhead@ucsd.edu	Risbrough, Victoria/X-3344-2019; mandyam, chitra/C-9189-2013; Patel, Hemal/C-7325-2019	mandyam, chitra/0000-0002-7354-205X; Patel, Hemal/0000-0001-6722-9625; Cui, Weihua/0000-0003-0893-3991	Veteran Affairs Merit Award from the Department of Veterans Affairs [BX001225, BX000783, BX001963]; National Institutes of Health, Bethesda, MarylandUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS073653, HL091071, HL107200, GM085179, DA034140]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL107200, R01HL091071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007752, R01GM085179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS073653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [T32AA007456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA034140] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX001225, I01BX000783, I01BX001963, I01BX002558] Funding Source: NIH RePORTER	Work in the authors' laboratories is supported by a Veteran Affairs Merit Award from the Department of Veterans Affairs Grant Nos. BX001225 (BPH), BX000783 (DMR), and BX001963 (HHP); and National Institutes of Health, Bethesda, Maryland, Grant Nos. NS073653 (BPH); HL091071 and HL107200 (HHP); GM085179 (PMP), and DA034140 (CDM).	Alto LT, 2009, NAT NEUROSCI, V12, P1106, DOI 10.1038/nn.2365; Anderson P., 2007, HIPPOCAMPUS BOOK; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; Conte V, 2008, RESTOR NEUROL NEUROS, V26, P45; Da Silva JS, 2005, NAT NEUROSCI, V8, P606, DOI 10.1038/nn1442; de Kreu BJ, 2011, J CELL SCI, V124, P2375, DOI 10.1242/jcs.080630; Del Pozo MA, 2007, TRENDS CELL BIOL, V17, P246, DOI 10.1016/j.tcb.2007.03.001; Denny JB, 2006, CURR NEUROPHARMACOL, V4, P293, DOI 10.2174/157015906778520782; Ledesma MD, 2012, PROG LIPID RES, V51, P23, DOI 10.1016/j.plipres.2011.11.004; Fantini J, 2009, BBA-BIOMEMBRANES, V1788, P2345, DOI 10.1016/j.bbamem.2009.08.016; Fjell AM, 2014, PROG NEUROBIOL, V117, P20, DOI 10.1016/j.pneurobio.2014.02.004; Grande-Garcia A, 2008, EUR J CELL BIOL, V87, P641, DOI 10.1016/j.ejcb.2008.02.001; Gresack JE, 2010, BEHAV BRAIN RES, V209, P80, DOI 10.1016/j.bbr.2010.01.018; Guirland C, 2004, NEURON, V42, P51, DOI 10.1016/S0896-6273(04)00157-6; Guirland C, 2007, ADV EXP MED BIOL, V621, P144, DOI 10.1007/978-0-387-76715-4_11; Hattiangady B, 2005, EXP NEUROL, V195, P353, DOI 10.1016/j.expneurol.2005.05.014; Head BP, 2008, FASEB J, V22, P828, DOI 10.1096/fj.07-9299com; Head BP, 2006, J BIOL CHEM, V281, P26391, DOI 10.1074/jbc.M602577200; Head BP, 2014, BBA-BIOMEMBRANES, V1838, P532, DOI 10.1016/j.bbamem.2013.07.018; Head BP, 2011, J BIOL CHEM, V286, P33310, DOI 10.1074/jbc.M111.255976; Head BP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015697; Henley Jeremy M, 2013, Dialogues Clin Neurosci, V15, P11; Higuchi H, 2003, EMBO J, V22, P1790, DOI 10.1093/emboj/cdg177; Huang C, 1999, J BIOL CHEM, V274, P36707, DOI 10.1074/jbc.274.51.36707; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Huber AB, 2003, ANNU REV NEUROSCI, V26, P509, DOI 10.1146/annurev.neuro.26.010302.081139; Jiang L, 2010, NEUROBIOL AGING, V31, P2146, DOI 10.1016/j.neurobiolaging.2008.11.005; Kamiguchi H, 2006, J NEUROCHEM, V98, P330, DOI 10.1111/j.1471-4159.2006.03888.x; Kim A, 2015, BRAIN STRUCT FUNCT, V220, P1705, DOI 10.1007/s00429-014-0755-3; Koch JC, 2013, NEUROBIOL DIS, V51, P168, DOI 10.1016/j.nbd.2012.11.007; Kuruvilla R, 2000, NEURON, V27, P499, DOI 10.1016/S0896-6273(00)00061-1; Leal SL, 2013, AGEING RES REV, V12, P823, DOI 10.1016/j.arr.2013.01.006; Li SL, 2010, NAT NEUROSCI, V13, P1496, DOI 10.1038/nn.2674; Mamounas LA, 2000, J NEUROSCI, V20, P771, DOI 10.1523/JNEUROSCI.20-02-00771.2000; Maren S, 2008, EUR J NEUROSCI, V28, P1661, DOI 10.1111/j.1460-9568.2008.06485.x; Maren S, 2013, NAT REV NEUROSCI, V14, P417, DOI 10.1038/nrn3492; Martin M, 2010, BBA-MOL CELL BIOL L, V1801, P934, DOI 10.1016/j.bbalip.2010.03.011; McKerracher L, 2002, NEURON, V36, P345, DOI 10.1016/S0896-6273(02)01018-8; Mesulam NM, 1999, NEURON, V24, P521, DOI 10.1016/S0896-6273(00)81109-5; Morrison JH, 2014, JAMA PSYCHIAT, V71, P835, DOI 10.1001/jamapsychiatry.2014.380; Nakai Y, 2002, J CELL BIOL, V159, P1097, DOI 10.1083/jcb.200209077; Niesman IR, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-39; Niethammer P, 2002, J CELL BIOL, V157, P521, DOI 10.1083/jcb.200109059; Peiro S, 2000, J BIOL CHEM, V275, P37846, DOI 10.1074/jbc.M000487200; Pereira DB, 2007, J NEUROSCI, V27, P4859, DOI 10.1523/JNEUROSCI.4587-06.2007; Remy F, 2004, NEUROSCI LETT, V358, P25, DOI 10.1016/j.neulet.2003.12.122; Rosenzweig ES, 2003, PROG NEUROBIOL, V69, P143, DOI 10.1016/S0301-0082(02)00126-0; Santiago JM, 2013, J MOL NEUROSCI, V49, P347, DOI 10.1007/s12031-012-9873-7; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Small SA, 2011, NAT REV NEUROSCI, V12, P585, DOI 10.1038/nrn3085; Suzuki S, 2004, J CELL BIOL, V167, P1205, DOI 10.1083/jcb.200404106; Titus DJ, 2013, NEUROSCIENCE, V231, P182, DOI 10.1016/j.neuroscience.2012.12.002; Trovo L, 2011, J CELL SCI, V124, P1308, DOI 10.1242/jcs.078766; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; Willmann R, 2006, EMBO J, V25, P4050, DOI 10.1038/sj.emboj.7601288; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; Yankner BA, 2008, ANNU REV PATHOL-MECH, V3, P41, DOI 10.1146/annurev.pathmechdis.2.010506.092044	60	27	30	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0006-3223	1873-2402		BIOL PSYCHIAT	Biol. Psychiatry	JAN 15	2017	81	2					101	110		10.1016/j.biopsych.2015.09.020			10	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	EO2JY	WOS:000396524000008	26592463	Green Accepted			2021-06-18	
J	Bishop, S; Dech, R; Baker, T; Butz, M; Aravinthan, K; Neary, JP				Bishop, Scott; Dech, Ryan; Baker, Taylor; Butz, Matthew; Aravinthan, Kaishan; Neary, J. Patrick			Parasympathetic baroreflexes and heart rate variability during acute stage of sport concussion recovery	BRAIN INJURY			English	Article						Concussion; heart rate variability; baroreflexes; autonomic nervous system	TRAUMATIC BRAIN-INJURY; CEREBROVASCULAR PRESSURE REACTIVITY; DYNAMIC CEREBRAL AUTOREGULATION; POTASSIUM CHANNELS; CO2 REACTIVITY; BLOOD-PRESSURE; EXERCISE; FLOW; EPIDEMIOLOGY; NEUROPHYSIOLOGY	Primary objective: To assess and compare the parasympathetic state of individuals in healthy vs concussion groups, by measuring cardiovascular metrics under resting and baroreflex conditions using a squat-stand manoeuvre.Research design: This was a retrospective mixed-method study, with participants who sustained a medically diagnosed sport concussion (n = 12), being tested within 72-hours post-injury.Methods and procedures: Participant's heart rate (Electrocardiogram, ECG) and blood pressure (finger plethysmography) data was collected during rest and during 10-second squat-stands (10SS, 0.05 Hz). Blood pressure and heart rate standard deviation data was analysed in the 0-5 seconds and 6-10 seconds periods of squatting and standing. Resting and baroreflex ECG data were analysed via Fourier Transformations for %Low Frequency and %High Frequency (%LF and %HF).Results: The control group alleviated more pressure and had a significantly higher standard deviation of heart rate during the 6-10 seconds of squatting (p < 0.05). Overall heart rate standard deviation in the concussion group was significantly lower than healthy controls when standing (p < 0.05). There were no differences in %LF and % HF between groups or between rest and 10SS.Conclusion: This study provides preliminary evidence that autonomic function is dysregulated following mTBI within the initial 72 hours of injury.	[Bishop, Scott; Dech, Ryan; Baker, Taylor; Aravinthan, Kaishan; Neary, J. Patrick] Univ Regina, Fac Kinesiol & Hlth Studies, 3737 Wascana Pkwy, Regina, SK S4S 0A2, Canada; [Butz, Matthew] Univ Saskatchewan, Coll Med, Saskatoon, SK, Canada	Neary, JP (corresponding author), Univ Regina, Fac Kinesiol & Hlth Studies, 3737 Wascana Pkwy, Regina, SK S4S 0A2, Canada.	patrick.neary@uregina.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Saskatchewan Health Research Foundation	The authors report no conflicts of interest. Funding was provided by the Canadian Institutes of Health Research (JPN) and the Saskatchewan Health Research Foundation (JPN).	Ainslie PN, 2009, AM J PHYSIOL-REG I, V296, pR1473, DOI 10.1152/ajpregu.91008.2008; Arbogast KB, 2013, CLIN PEDIATR, V52, P397, DOI 10.1177/0009922813478160; Bailey DM, 2013, CLIN SCI, V124, P177, DOI 10.1042/CS20120259; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bishop S, 2015, CURRENT RES CONCUSSI, V2, P49; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Blake T, 2015, BRIT J SPORT MED, V48, P569; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; Chang C, 2013, NEUROIMAGE, V68, P93, DOI 10.1016/j.neuroimage.2012.11.038; Critchley HD, 2003, BRAIN, V126, P2139, DOI 10.1093/brain/awg216; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Del Coso J, 2009, EUR J APPL PHYSIOL, V107, P83, DOI 10.1007/s00421-009-1101-y; DeMatteo C, 2015, CLIN PEDIATR, V54, P152, DOI 10.1177/0009922814558256; Edwards MR, 2002, MED SCI SPORT EXER, V34, P1207, DOI 10.1097/00005768-200207000-00024; Erlichman JS, 2009, J NEUROPHYSIOL, V102, P1577, DOI 10.1152/jn.00381.2009; Falvo M, 2012, FASEB J, V26, P1091; Faraci FM, 1996, CLIN EXP PHARMACOL P, V23, P1091, DOI 10.1111/j.1440-1681.1996.tb01175.x; Filosa JA, 2007, EXP PHYSIOL, V92, P641, DOI 10.1113/expphysiol.2006.036368; Folino AF, 2007, PROG CARDIOVASC DIS, V50, P49, DOI 10.1016/j.pcad.2007.01.001; Franke WD, 2006, GERONTOLOGY, V52, P282, DOI 10.1159/000094609; Fuller CW, 2015, BRIT J SPORT MED, V49, P478, DOI 10.1136/bjsports-2013-093381; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gaetz MB, 2009, BRIT J SPORT MED, V43, P508, DOI 10.1136/bjsm.2008.051748; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Grindel Scott H, 2003, Curr Sports Med Rep, V2, P18, DOI 10.1249/00149619-200302000-00005; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; Huckstepp RTR, 2011, J PHYSIOL-LONDON, V589, P5561, DOI 10.1113/jphysiol.2011.214759; Jackson WF, 2005, MICROCIRCULATION, V12, P113, DOI 10.1080/10739680590896072; Jha NK, 2015, CURRENT RES CONCUSSI, V3, P2; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; Koch A, 2005, CLIN AUTON RES, V15, P83, DOI 10.1007/s10286-005-0249-8; La Fountaine MF, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00013; La Fountaine MF, 2009, AUTON NEUROSCI-BASIC, V148, P101, DOI 10.1016/j.autneu.2009.03.001; Leddy J, 2016, PM&R, V8, pS91, DOI 10.1016/j.pmrj.2015.10.017; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Len TK, 2013, BRAIN INJURY, V27, P346, DOI 10.3109/02699052.2012.743185; Marieb E. N., 2007, HUMAN ANATOMY PHYSL; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Mutch WAC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102181; Ogoh S, 2005, AM J PHYSIOL-HEART C, V288, pH1526, DOI 10.1152/ajpheart.00979.2004; Ogoh S, 2005, AM J PHYSIOL-HEART C, V288, pH1461, DOI 10.1152/ajpheart.00948.2004; Ogoh S, 2009, J APPL PHYSIOL, V107, P1370, DOI 10.1152/japplphysiol.00573.2009; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ott MM, 2011, J NEUROPHYSIOL, V105, P2960, DOI 10.1152/jn.00262.2010; Papaioannou V, 2008, J CRIT CARE, V23, P380, DOI 10.1016/j.jcrc.2007.04.006; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; del Paso GAR, 2013, PSYCHOPHYSIOLOGY, V50, P477, DOI 10.1111/psyp.12027; Ryan ML, 2011, J TRAUMA, V70, P1371, DOI 10.1097/TA.0b013e31821858e6; Ryan ML, 2011, ANESTHESIOL RES PRAC, V2011, DOI 10.1155/2011/416590; Schmidt E, 2015, FLUIDS BARRIERS CNS, V12, pO56; Shaffer F, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01040; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Smirl JD, 2015, J APPL PHYSIOL, V119, P487, DOI 10.1152/japplphysiol.00264.2015; Spyer KM, 2009, PHILOS T R SOC B, V364, P2603, DOI 10.1098/rstb.2009.0082; Su CF, 2005, CLIN NEUROPHYSIOL, V116, P1273, DOI 10.1016/j.clinph.2005.01.010; Sviri GE, 2009, J NEUROSURG, V111, P695, DOI 10.3171/2008.10.17686; Taylor AG, 2010, EXPLORE-NY, V6, P29, DOI 10.1016/j.explore.2009.10.004; Thayer JF, 2012, NEUROSCI BIOBEHAV R, V36, P747, DOI 10.1016/j.neubiorev.2011.11.009; Tzeng YC, 2010, J APPL PHYSIOL, V108, P1162, DOI 10.1152/japplphysiol.01390.2009; Wells EM, 2016, J CHILD NEUROL, V31, P86, DOI 10.1177/0883073815570152; Willie CK, 2009, APPL ASPECTS ULTRASO, P1; Zweifel C, 2014, MED ENG PHYS, V36, P638, DOI 10.1016/j.medengphy.2014.03.002; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	67	27	27	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	2					247	259		10.1080/02699052.2016.1226385			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EM2RO	WOS:000395163500013	28045562				2021-06-18	
J	Gardner, AJ; Howell, DR; Levi, CR; Iverson, GL				Gardner, Andrew J.; Howell, David R.; Levi, Christopher R.; Iverson, Grant L.			Evidence of Concussion Signs in National Rugby League Match Play: a Video Review and Validation Study	SPORTS MEDICINE-OPEN			English	Article						Concussion; Video analysis; Injury management; Return to play	SPORT-RELATED CONCUSSION; HIGH-SCHOOL; PROLONGED RECOVERY; PREDICTORS; SEVERITY; FOOTBALL	Background: Many professional sports have introduced sideline video review to help recognise concussions. The reliability and validity of identifying clinical and observable signs of concussion using video analysis has not been extensively explored. This study examined the reliability and validity of clinical signs of concussion using video analysis in the National Rugby League (NRL). Methods: All 201 professional NRL matches from the 2014 season were reviewed to document six signs of possible concussion (unresponsiveness, slow to get up, clutching/shaking head, gait ataxia, vacant stare, and seizure). Results: A total of 127,062 tackles were reviewed. Getting up slowly was the most common observable sign (2240 times in the season, 1.8% of all tackles) but only 223 times where it appeared to be a possible concussion (0.2% of all tackles and 10.0% of the times it occurred). Additionally, clutching/shaking the head occurred 361 times (on 212 occasions this sign appeared to be due to a possible concussion), gait ataxia was observed 102 times, a vacant stare was noted 98 times, unresponsiveness 52 times, and a possible seizure 4 times. On 383 occasions, one or more of the observable signs were identified and deemed associated with a possible concussion. There were 175 incidences in which a player appeared to demonstrate two or more concussion signs, and 54 incidences where a player appeared to demonstrate three or more concussion signs. A total of 60 diagnosed concussions occurred, and the concussion interchange rule was activated 167 times. Intra-rater reliability (kappa = 0.65-1.00) was moderate to perfect for all six video signs; however, the inter-rater reliability was not as strong (kappa = 0.22-0.76). Most of the signs had relatively low sensitivity (0.18-0.75), but high specificity (0.85-1.00). Conclusions: Using video replay, observable signs of concussion appear to be sensitive to concussion diagnoses when reviewing known injuries among professional rugby league players. When reviewing an entire season, however, certain signs occur very commonly and did not identify concussion. Thus, the implementation of video review in the NRL is challenging, but can provide a useful addition to sideline concussion identification and removal from play decisions.	[Gardner, Andrew J.; Levi, Christopher R.] Univ Newcastle, Sch Med & Publ Hlth, Ctr Stroke & Brain Injury, Callaghan, NSW, Australia; [Levi, Christopher R.] John Hunter Hosp, Hunter New England Local Hlth Dist Sports Concuss, Newcastle, NSW, Australia; [Howell, David R.] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Howell, David R.] Boston Childrens Hosp, Div Sports Med, Dept Orthopaed, Boston, MA USA; [Howell, David R.] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA; [Iverson, Grant L.] Harvard Med Sch, Ctr Hlth & Rehabil, Dept Phys Med & Rehabil, 79-96 Thirteenth St, Charlestown, MA USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Charlestown, MA USA; [Iverson, Grant L.] MassGen Hosp Children, Sport Concuss Program, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Home Base, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp Program, Boston, MA USA; [Gardner, Andrew J.] Calvary Mater Hosp, Prior Res Ctr Stroke & Brain Injury, Level 5,McAuley Bldg, Waratah, NSW 2298, Australia	Gardner, AJ (corresponding author), Univ Newcastle, Sch Med & Publ Hlth, Ctr Stroke & Brain Injury, Callaghan, NSW, Australia.; Gardner, AJ (corresponding author), Calvary Mater Hosp, Prior Res Ctr Stroke & Brain Injury, Level 5,McAuley Bldg, Waratah, NSW 2298, Australia.	Andrew.Gardner@neurogard.com.au		Levi, Christopher/0000-0002-9474-796X; Iverson, Grant/0000-0001-7348-9570	Hunter Medical Research Institute (HMRI)	Funding was provided by Hunter Medical Research Institute (HMRI) supported by Anne Greaves.	Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Bock S, 2015, CHILD NERV SYST, V31, P2111, DOI 10.1007/s00381-015-2846-8; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Chermann JF, 2014, ASIAN J SPORTS MED, V5; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Davis G, 2016, J SCI MED SPORT; Echemendia RJ, 2017, BRIT J SPORT MED; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P709, DOI 10.3171/2015.5.PEDS15220; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Gardner A, 2014, BRIT J SPORT MED; Gardner AJ, 2017, SPORTS MED-OPEN, V3, DOI 10.1186/s40798-017-0093-0; Gardner AJ, 2015, BRAIN INJURY, V29, P1182, DOI 10.3109/02699052.2015.1034179; Gardner AW, 2016, INT J VASC MED, V2016, DOI 10.1155/2016/2191350; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hallgren Kevin A, 2012, Tutor Quant Methods Psychol, V8, P23; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; Hutchison MG, 2014, BRIT J SPORT MED, V48, P125, DOI 10.1136/bjsports-2012-092059; IBM Corp, IBM SPSS STAT MAC VE; Kohler R, 2017, BR J SPORTS MED, V51, pA78; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Makdissi M, 2016, J SCI MED SPORT; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2013, BRIT J SPORT MED, V47, P272, DOI 10.1136/bjsports-2013-092145; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McDevitt J, 2015, BRAIN INJURY, V29, P1674, DOI 10.3109/02699052.2015.1075252; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Miller JH, 2016, J NEUROSURG-PEDIATR, V17, P491, DOI 10.3171/2015.8.PEDS14332; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Nelson LD, 2016, CLIN J SPORT MED, V26, P120, DOI 10.1097/JSM.0000000000000207; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Putukian M, 2013, BRIT J SPORT MED, V47, P285, DOI 10.1136/bjsports-2013-092158; Savage J, 2013, J SPORTS MED; Terwilliger VK, 2016, J NEUROTRAUM, V33, P761, DOI 10.1089/neu.2015.4082; Zuckerman SL, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15593	41	27	28	0	1	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	2199-1170	2198-9761		SPORTS MED-OPEN	Sports Med.-Open		2017	3								29	10.1186/s40798-017-0097-9			10	Sport Sciences	Sport Sciences	VI8CR	WOS:000514830000028	28831759	DOAJ Gold, Green Published			2021-06-18	
J	He, ZL; Zhou, YL; Huang, Y; Wang, QQ; Zheng, BB; Zhang, HY; Li, JW; Liu, YL; Wu, FZ; Zhang, X; Tong, SL; Wang, MF; Wang, ZG; He, H; Xu, HZ; Xiao, J				He, Zili; Zhou, Yulong; Huang, Yan; Wang, Qingqing; Zheng, Binbin; Zhang, Hongyu; Li, Jiawei; Liu, Yanlong; Wu, Fenzan; Zhang, Xie; Tong, Songlin; Wang, Maofeng; Wang, Zhouguang; He, Huacheng; Xu, Huazi; Xiao, Jian			Dl-3-n-butylphthalide improves functional recovery in rats with spinal cord injury by inhibiting endoplasmic reticulum stress-induced apoptosis	AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH			English	Article						Dl-3-n-butylphthalide; apoptosis; ER stress; spinal cord injury	FOCAL CEREBRAL-ISCHEMIA; BETA-CELL FUNCTION; ER-STRESS; DIABETIC-RATS; MOUSE MODEL; C-KIT; MICE; SURVIVAL; BARRIER; ONSET	Endoplasmic reticulum (ER) stress-induced apoptosis occurs in the spinal cord following traumatic spinal cord injury (SCI). Dl-3-n-butylphthalide (NBP) exerts an neuroprotective effects against both ischemic brain injury and neurodegenerative diseases; however, the relationship between ER stress-induced apoptosis and the therapeutic effect of NBP in SCI remains unclear. In this study, moderate spinal cord injuries were induced in Sprague-Dawley (SD) rats with a vascular clip. NBP was administered by oral (80 mg/kg/d) gavage 2 h before injury and then once daily for 28 d thereafter. Neurological recovery was assessed using the Basso, Beattie, and Bresnahan (BBB) locomotion rating scale, the inclined plane test, and the footprint analysis. Neuronal cell death was examined by TUNEL staining at 7 days post-injury. ER stress and apoptosis-related proteins were quantified by immunofluorescence staining and western blotting both in vivo and in vitro. Our results showed that NBP significantly decreased spinal cord lesion cavity area and improved locomotor recovery in SD rats after SCI. NBP also decreased neuronal apoptosis and inhibited activation of the caspase 3 cascade. Upregulation of ER stress-related proteins, such as GRP78, ATF-6, ATF-4, PDI, XBP-1, and CHOP, was reversed by NBP treatment in SD rats with SCI. Similarly, NBP effectively ameliorated ER stress and apoptosis-related protein expression induced by incubation with thapsigargin (TG) in PC12 cells. Our findings demonstrate that NBP treatment alleviates secondary SCI by inhibiting ER stress-induced apoptosis, thereby promoting neurological and locomoter functional recovery.	[He, Zili; Zhou, Yulong; Wang, Qingqing; Zheng, Binbin; Li, Jiawei; Xu, Huazi; Xiao, Jian] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed, Wenzhou 325035, Zhejiang, Peoples R China; [He, Zili; Zhou, Yulong; Huang, Yan; Zhang, Hongyu; Liu, Yanlong; Wang, Zhouguang; He, Huacheng; Xiao, Jian] Wenzhou Med Univ, Sch Pharm, Mol Pharmacol Res Ctr, Wenzhou 325035, Zhejiang, Peoples R China; [Zhang, Hongyu; Wang, Maofeng] Wenzhou Med Univ, Dept Biomed Sci Lab, Affiliated Dongyang Hosp, Dongyang 322100, Zhejiang, Peoples R China; [Wu, Fenzan; Tong, Songlin] Wenzhou Med Univ, Affiliated Cixi Peoples Hosp, Dept Neurosurg, Ningbo 315300, Zhejiang, Peoples R China; [Zhang, Xie] Li Hui Li Hosp, Dept Gastroenterol, Ningbo Med Treatment Ctr, Ningbo 315040, Zhejiang, Peoples R China; [Zheng, Binbin] Wenzhou Med Univ, Taizhou Hosp, Dept Orthopaed, Linhai 317000, Zhejiang, Peoples R China	Xiao, J (corresponding author), Wenzhou Med Univ, Sch Pharm, Wenzhou 325035, Zhejiang, Peoples R China.; Xu, HZ (corresponding author), Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed, Wenzhou 325000, Peoples R China.	spinexu@163.com; xfxj2000@126.com	He, Huacheng/F-1941-2018; Zhouguang, Wang/F-7918-2017	He, Huacheng/0000-0001-5177-0636; Zhouguang, Wang/0000-0001-9903-0362	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81572237, 81572227, 81501953, 81601980]; Zhejiang Provincial Natural Science FoundationNatural Science Foundation of Zhejiang Province [Y14H170002, Q16H090023, LY17H090017]; Technologies Science and technology Program of Zhejiang Provincial [2016C33107]; Ningbo City Natural Science Foundation [2015A610213, 2015A610208]	This study was partially supported by a research grant from National Natural Science Foundation of China (81572237, 81572227, 81501953, 81601980), Zhejiang Provincial Natural Science Foundation (Y14H170002, Q16H090023, LY17H090017), Technologies Science and technology Program of Zhejiang Provincial (2016C33107) and Ningbo City Natural Science Foundation (2015A610213, 2015A610208).	Chang Q, 2003, ACTA PHARMACOL SIN, V24, P796; Chong ZZ, 1999, ACTA PHARMACOL SIN, V20, P696; Dai Z, 2008, NEUROPHARMACOLOGY, V55, P1307, DOI 10.1016/j.neuropharm.2008.08.030; Deng W, 1997, Chin Med Sci J, V12, P102; Dong Gao-xiang, 2002, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V24, P93; Feng XH, 2012, NEUROPHARMACOLOGY, V62, P1004, DOI 10.1016/j.neuropharm.2011.10.009; Feng ZC, 2012, DIABETOLOGIA, V55, P2214, DOI 10.1007/s00125-012-2566-5; Feng ZC, 2015, DIABETES, V64, P3852, DOI 10.2337/db15-0054; Feng ZC, 2013, AM J PHYSIOL-ENDOC M, V304, pE557, DOI 10.1152/ajpendo.00453.2012; Feng ZC, 2012, LAB INVEST, V92, P543, DOI 10.1038/labinvest.2011.200; Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200; Hu JY, 2014, CELL BIOCHEM BIOPHYS, V69, P363, DOI 10.1007/s12013-013-9808-0; Huai YP, 2013, NEURAL REGEN RES, V8, P1733, DOI 10.3969/j.issn.1673-5374.2013.19.001; Huang JZ, 2010, NEUROSCI LETT, V475, P89, DOI 10.1016/j.neulet.2010.03.053; Katoh K, 1996, NEUROSCI LETT, V216, P9; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Kuang XH, 2010, NEUROCHEM INT, V57, P738, DOI 10.1016/j.neuint.2010.08.010; Li JM, 2010, BRAIN RES, V1359, P216, DOI 10.1016/j.brainres.2010.08.061; Li JM, 2014, DIABETOLOGIA, V57, P754, DOI 10.1007/s00125-013-3147-y; Li L, 2009, BRAIN RES, V1290, P91, DOI 10.1016/j.brainres.2009.07.020; Lin J. F., 1996, Yaoxue Xuebao, V31, P166; Liu X. G., 1995, Yaoxue Xuebao, V30, P896; Mecha M, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.71; Ohri SS, 2011, GLIA, V59, P1489, DOI 10.1002/glia.21191; Penas C, 2007, J NEUROCHEM, V102, P1242, DOI 10.1111/j.1471-4159.2007.04671.x; Peng Y, 2008, NEUROSCI LETT, V434, P224, DOI 10.1016/j.neulet.2008.01.080; Peng Y, 2009, EUR J PHARMACOL, V621, P38, DOI 10.1016/j.ejphar.2009.08.036; Sakurai M, 2005, J THORAC CARDIOV SUR, V130, P640, DOI 10.1016/j.jtcvs.2005.01.007; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Valenzuela V, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.8; Wang FX, 2016, SCI REP-UK, V6, DOI 10.1038/srep19396; Yamauchi T, 2007, BRAIN RES, V1169, P24, DOI 10.1016/j.brainres.2007.06.093; Zhang HY, 2013, CNS NEUROSCI THER, V19, P20, DOI 10.1111/cns.12013; Zhang HY, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-130; Zhang T, 2010, NEUROL RES, V32, P390, DOI 10.1179/016164110X12670144526264; Zhao C., 2016, IEEE JOURNAL OF BIOM, P1; Zhou KL, 2015, SCI REP-UK, V5, DOI 10.1038/srep17130; Zhou YL, 2016, INT J BIOL SCI, V12, P87, DOI 10.7150/ijbs.13229	38	27	31	1	6	E-CENTURY PUBLISHING CORP	MADISON	40 WHITE OAKS LN, MADISON, WI 53711 USA	1943-8141			AM J TRANSL RES	Am. J. Transl. Res.		2017	9	3					1075	1087					13	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	ER7XK	WOS:000399028800021	28386335				2021-06-18	
J	Moore, L; Evans, D; Hameed, SM; Yanchar, NL; Stelfox, HT; Simons, R; Kortbeek, J; Bourgeois, G; Clement, J; Lauzier, F; Nathens, A; Turgeon, AF				Moore, Lynne; Evans, David; Hameed, Sayed M.; Yanchar, Natalie L.; Stelfox, Henry T.; Simons, Richard; Kortbeek, John; Bourgeois, Gilles; Clement, Julien; Lauzier, Francois; Nathens, Avery; Turgeon, Alexis F.			Mortality in Canadian Trauma Systems A Multicenter Cohort Study	ANNALS OF SURGERY			English	Article						injury; mortality; quality of care; trauma systems	BRAIN-INJURY; QUALITY INDICATOR; CARE; OUTCOMES; VALIDATION; DERIVATION; AUSTRALIA; EVOLUTION; VICTORIA	Objective: To measure the variation in trauma center mortality across Canadian trauma systems, assess the contribution of traumatic brain injury and thoracoabdominal injury to observed variations, and evaluate whether the presence of recommended trauma system components is associated with mortality. Summary Background Data: Injuries represent one of the leading causes of mortality, disability, and health care costs worldwide. Trauma systems have improved injury outcomes, but the impact of trauma system configuration on mortality is unknown. Methods: We conducted a retrospective cohort study of adults admitted for major injury to trauma centers across Canada (2006-2012). Multilevel logistic regression was used to estimate risk-adjusted hospital mortality and assess the impact of 13 recommended trauma system components. Results: Of 78,807 patients, 8382 (10.6%) died in hospital including 6516 (78%) after severe traumatic brain injury and 749 (9%) after severe thoracoabdominal injury. Risk-adjusted mortality varied from 7.0% to 14.2% across provinces (P < 0.0001); 11.1% to 26.0% for severe traumatic brain injury (P < 0.0001), and 4.7% to 5.9% for thoracoabdominal injury (P = 0.2). Mortality decreased with increasing number of recommended trauma system elements; adjusted odds ratio = 0.93 (0.87-0.99). Conclusions: We observed significant variation in trauma center mortality across Canadian provinces, specifically for severe traumatic brain injury. Provinces with more recommended trauma system components had better patient survival. Results suggest that trauma system configuration may be an important determinant of injury mortality. A better understanding of which system processes drive optimal outcomes is required to reduce the burden of injury worldwide.	[Moore, Lynne] Univ Laval, Dept Social & Preventat Med, Quebec City, PQ, Canada; [Moore, Lynne; Lauzier, Francois; Turgeon, Alexis F.] Univ Laval, Axe Sante Populat & Prat Optim Sante,CHU Quebec,H, Populat Hlth & Optimal Hlth Practices Res Unit,Ct, Traumatol Urgence Soins Intensifs Trauma Emergenc, Quebec City, PQ, Canada; [Evans, David; Hameed, Sayed M.; Simons, Richard] Univ British Columbia, Dept Surg, Vancouver, BC, Canada; [Yanchar, Natalie L.] Dalhousie Univ, Dept Surg, Halifax, NS, Canada; [Stelfox, Henry T.] Univ Calgary, Inst Publ Hlth, Dept Crit Care Med Med & Community Hlth Sci HTS, Calgary, AB, Canada; [Kortbeek, John] Univ Calgary, Dept Surg, Div Gen Surg, Calgary, AB, Canada; [Kortbeek, John] Univ Calgary, Div Crit Care, Calgary, AB, Canada; [Bourgeois, Gilles] INESSS, Quebec City, PQ, Canada; [Clement, Julien] Univ Laval, Dept Surg, Quebec City, PQ, Canada; [Lauzier, Francois; Turgeon, Alexis F.] Univ Laval, Dept Anesthesiol & Crit Care Med, Div Crit Care Med, Quebec City, PQ, Canada; [Nathens, Avery] Sunnybrook Hlth Sci Ctr, Div Gen Surg, Toronto, ON, Canada	Moore, L (corresponding author), CHU Quebec, Traumatol Urgence Soins Intensifs Trauma Emergenc, Axe Sante Populat & Prat Optim Sante,Enfant Jesus, Populat Hlth & Optimal Hlth Practices Res Unit,Re, 1401,18e Rue,Local H-012a, Quebec City, PQ G1J 1Z4, Canada.	lynne.moore@fmed.ulaval.ca	Lauzier, Francois/B-9237-2015; Kortbeek, John B/AAO-5298-2020	Lauzier, Francois/0000-0002-6530-5513; Stelfox, Henry/0000-0003-1231-1490	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [110996]; Fonds de la Recherche du Quebec - SanteFonds de la Recherche en Sante du Quebec	Canadian Institutes of Health Research: New Investigator Award (HTS and LM) and research grant (LM; #110996); Fonds de la Recherche du Quebec - Sante: clinician-scientist award (AFT, FL).	Accreditation Guidelines, 2015, ACCR GUID; American College of Surgeons Committee on Trauma, 2014, RESOURCES OPTIMAL CA, V6th; [Anonymous], 2013, CAN TOT POP EST; Asensio J, 2008, CURRENT THERAPY TRAU; Association for the advancement of automotive medicine, 1990, ABBREVIATED INJURY S; Canada P., 2015, COST INJURY CANADA; Cheng CH, 2008, ANN SURG, V247, P335, DOI 10.1097/SLA.0b013e31815ccc2e; Cote N, 2013, NEUROCRIT CARE, V18, P154, DOI 10.1007/s12028-012-9787-9; Donabedian A., 2003, INTRO QUALITY ASSURA; Evans CC, 2013, CJEM, V15, P1; Evans DC, 2007, CAN J SURG, V50, P364; Gabbe BJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020545; Gabbe BJ, 2011, ANN SURG, V253, P138, DOI 10.1097/SLA.0b013e3181f6685b; Hameed SM, 2010, J TRAUMA, V69, P1350, DOI 10.1097/TA.0b013e3181e751f7; Levit K, 2007, HCUP FACTS FIG STAT; Little RJ, 2002, STAT ANAL MISSING DA, V539; MacKenzie EJ, 2007, J TRAUMA, V63, pS54, DOI 10.1097/TA.0b013e31815acb09; Moore L, 2006, J TRAUMA, V60, P802, DOI 10.1097/01.ta.0000200838.55420.ad; Moore L, 2005, J TRAUMA, V59, P698, DOI 10.1097/01.ta.0000177700.54943.ee; Moore L, 2015, WORLD J SURG, V39, P1397, DOI 10.1007/s00268-015-2977-9; Moore L, 2014, ANN SURG, V260, P1121, DOI 10.1097/SLA.0000000000000648; Moore L, 2014, J TRAUMA ACUTE CARE, V76, P1310, DOI 10.1097/TA.0000000000000202; Moore L, 2010, ANN SURG, V251, P952, DOI 10.1097/SLA.0b013e3181d97589; Moore L, 2009, J AM COLL SURGEONS, V209, P572, DOI 10.1016/j.jamcollsurg.2009.07.004; Moore L, 2009, ANN SURG, V249, P1040, DOI 10.1097/SLA.0b013e3181a6cd97; Nathens AB, 2000, J TRAUMA, V48, P25, DOI 10.1097/00005373-200001000-00005; Nathens AB, 2008, REGIONAL TRAUMA SYST; Royston P, 1999, INT J EPIDEMIOL, V28, P964, DOI 10.1093/ije/28.5.964; Shafi S, 2006, J TRAUMA, V61, P1374, DOI 10.1097/01.ta.0000246698.07125.c0; Tisherman SA, 2015, ANN SURG, V261, P586, DOI 10.1097/SLA.0000000000000837; Turgeon AF, 2013, CRIT CARE MED, V41, P1086, DOI 10.1097/CCM.0b013e318275d046; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Utter GH, 2006, J TRAUMA, V60, P529, DOI 10.1097/01.ta.0000204022.36214.9e	33	27	28	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	JAN	2017	265	1					212	217		10.1097/SLA.0000000000001614			6	Surgery	Surgery	EH9QS	WOS:000392106500039	28009748				2021-06-18	
J	Storzbach, D; Twamley, EW; Roost, MS; Golshan, S; Williams, RM; O'Neil, M; Jak, AJ; Turner, AP; Kowalski, HM; Pagulayan, KF; Huckans, M				Storzbach, Daniel; Twamley, Elizabeth W.; Roost, Mai S.; Golshan, Shahrokh; Williams, Rhonda M.; O'Neil, Maya; Jak, Amy J.; Turner, Aaron P.; Kowalski, Halina M.; Pagulayan, Kathleen F.; Huckans, Marilyn			Compensatory Cognitive Training for Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn Veterans With Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive training; mild traumatic brain injury; OEF/OIF/OND Veterans	POSTTRAUMATIC-STRESS-DISORDER; MEMORY QUESTIONNAIRE PRMQ; OF-THE-LITERATURE; NEUROPSYCHOLOGICAL OUTCOMES; RETROSPECTIVE MEMORY; MILITARY PERSONNEL; LATENT STRUCTURE; NORMATIVE DATA; US VETERANS; REHABILITATION	Objective: The purpose of the study was to evaluate the efficacy of group-based compensatory cognitive training (CCT) for Operation Enduring Freedom (OEF)/Operation Iraqi Freedom(OIF)/Operation New Dawn (OND) Veterans with a history of mild traumatic brain injury. Method: One hundred nineteen OEF/OIF/OND Veterans with history of mild traumatic brain injury participated at 3 sites, and 50 of the Veterans were randomized to CCT group, while 69 Veterans were randomized to the usual care control group. The CCT group participated in 10 weeks of CCT. Both CCT and usual care groups were assessed at baseline, 5 weeks (midway through CCT), 10 weeks (immediately following CCT), and 15 weeks (5-week follow-up) on measures of subjective cognitive complaints, use of cognitive strategies, psychological functioning, and objective cognitive performance. Results: Veterans who participated in CCT reported significantly fewer cognitive and memory difficulties and greater use of cognitive strategies. They also demonstrated significant improvements on neurocognitive tests of attention, learning, and executive functioning, which were 3 of the cognitive domains targeted in CCT. Conclusions: Findings indicate that training in compensatory cognitive strategies facilitates behavioral change (ie, use of cognitive strategies) as well as both subjective and objective improvements in targeted cognitive domains.	[Storzbach, Daniel; Roost, Mai S.; O'Neil, Maya; Kowalski, Halina M.; Huckans, Marilyn] VA Portland Healthcare Syst, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA; [Storzbach, Daniel; O'Neil, Maya; Huckans, Marilyn] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA; [Storzbach, Daniel] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; [Twamley, Elizabeth W.; Jak, Amy J.] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Twamley, Elizabeth W.; Golshan, Shahrokh; Jak, Amy J.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Williams, Rhonda M.; Turner, Aaron P.; Pagulayan, Kathleen F.] VA Puget Sound Hlth Care Syst, Seattle, WA USA; [Williams, Rhonda M.; Turner, Aaron P.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; [Pagulayan, Kathleen F.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	Storzbach, D (corresponding author), VA Portland Healthcare Syst, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.	daniel.storzbach@va.gov	Turner, Aaron/A-7902-2009; Pagulayan, Kati/AAR-9225-2020	Turner, Aaron/0000-0001-6897-8003; 	VA Merit Review AwardUS Department of Veterans Affairs [D7217-R]; Veterans Affairs Health Services Research and Development Center of Innovation grant; Center to Improve Veteran Involvement in Care [CIN 13-404]; Agency for Healthcare Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [1 K12 HS019456 01]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K12HS022981] Funding Source: NIH RePORTER	This work was supported by VA Merit Review Award #D7217-R to Daniel Storzbach and Elizabeth Twamley from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development. Author Maya O'Neil is currently receiving funding from a Veterans Affairs Health Services Research and Development Center of Innovation grant, Center to Improve Veteran Involvement in Care, Award #CIN 13-404, and an Agency for Healthcare Research and Quality-funded PCOR K12 award to MEO (#1 K12 HS019456 01). For the remaining authors, none were declared. This material is the result of work supported with resources and the use of facilities at the Veterans Affairs Medical Centers in Portland, Oregon, San Diego, California, and Seattle, Washington.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Beck A., 1996, MANUAL BDI 2; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Benedict RHB, 2003, MULT SCLER J, V9, P95, DOI 10.1191/1352458503ms861oa; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Cappa SF, 2005, EUR J NEUROL, V12, P665; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Crawford JR, 2003, MEMORY, V11, P261, DOI 10.1080/09658210244000027; Crawford JR, 2006, BRIT J CLIN PSYCHOL, V45, P83, DOI 10.1348/014466505X28748; de Frias CM, 2005, PSYCHOL ASSESSMENT, V17, P168, DOI 10.1037/1040-3590.17.2.168; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2004, J INT NEUROPSYCH SOC, V10, P301, DOI 10.1017/S1355617704102191; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dixon RA, 2001, J CLIN EXP NEUROPSYC, V23, P650, DOI 10.1076/jcen.23.5.650.1242; Helmick K, 2010, NEUROREHABILITATION, V26, P239, DOI 10.3233/NRE-2010-0560; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huckans M, 2013, NEUROPSYCHOL REV, V23, P63, DOI 10.1007/s11065-013-9230-9; Huckans M, 2010, J REHABIL RES DEV, V47, P43, DOI 10.1682/JRRD.2009.02.0019; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Mausbach BT, 2007, SCHIZOPHRENIA BULL, V33, P1364, DOI 10.1093/schbul/sbm014; McGurk SR, 2007, AM J PSYCHIAT, V164, P1791, DOI 10.1176/appi.ajp.2007.07060906; Nelson NW, 2012, J INT NEUROPSYCH SOC, V18, P845, DOI 10.1017/S1355617712000616; O'Neil ME, 2014, J INT NEUROPSYCH SOC, V20, P249, DOI [10.1017/S1355617714000204, 10.1017/S135561771300146X]; Robertson GJ., 2006, WRAT 4 WIDE RANGE AC; Scholten JD, 2012, BRAIN INJURY, V26, P1177, DOI 10.3109/02699052.2012.661914; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Shandera-Ochsner AL, 2013, CLIN NEUROPSYCHOL, V27, P881, DOI 10.1080/13854046.2013.802017; Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749; Smith G, 2000, MEMORY, V8, P311, DOI 10.1080/09658210050117735; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Sohlberg McKay Moore, 2005, Seminars in Speech and Language, V26, P268, DOI 10.1055/s-2005-922105; Stroupe KT, 2013, J REHABIL RES DEV, V50, P1047, DOI 10.1682/JRRD.2012.06.0107; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Twamley EW, 2015, J HEAD TRAUMA REHAB, V30, P391, DOI 10.1097/HTR.0000000000000076; Twamley EW, 2014, J REHABIL RES DEV, V51, P59, DOI 10.1682/JRRD.2013.01.0020; Twamley EW, 2012, J CLIN PSYCHIAT, V73, P1212, DOI 10.4088/JCP.12m07686; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Verfaellie M, 2014, NEUROPSYCHOLOGY, V28, P337, DOI 10.1037/neu0000027; WEATHERS FW, 1994, 9 ANN M INT SOC TRAU; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wykes T, 2011, SCHIZOPHRENIA BULL, V37, pS80, DOI 10.1093/schbul/sbr064	49	27	27	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2017	32	1					16	24		10.1097/HTR.0000000000000228			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EI2GH	WOS:000392304400002	27022961				2021-06-18	
J	Villalba, N; Sackheim, AM; Nunez, IA; Hill-Eubanks, DC; Nelson, MT; Wellman, GC; Freeman, K				Villalba, Nuria; Sackheim, Adrian M.; Nunez, Ivette A.; Hill-Eubanks, David C.; Nelson, Mark T.; Wellman, George C.; Freeman, Kalev			Traumatic Brain Injury Causes Endothelial Dysfunction in the Systemic Microcirculation through Arginase-1-Dependent Uncoupling of Endothelial Nitric Oxide Synthase	JOURNAL OF NEUROTRAUMA			English	Article						in vitro studies; oxidative stress; traumatic brain injury; vascular injury; vascular reactivity	L-ARGININE; SMALL-CONDUCTANCE; ARTERIAL TONE; ARGINASE-II; ACTIVATION; OXIDATION; CATECHOLAMINES; INHIBITION; EXPRESSION; HISTONES	Endothelial dysfunction is a hallmark of many chronic diseases, including diabetes and long-term hypertension. We show that acute traumatic brain injury (TBI) leads to endothelial dysfunction in rat mesenteric arteries. Endothelial-dependent dilation was greatly diminished 24 h after TBI because of impaired nitric oxide (NO) production. The activity of arginase, which competes with endothelial NO synthase (eNOS) for the common substrate l-arginine, were also significantly increased in arteries, suggesting that arginase-mediated depletion of l-arginine underlies diminished NO production. Consistent with this, substrate restoration by exogenous application of l-arginine or inhibition of arginase recovered endothelial function. Moreover, evidence for increased reactive oxygen species production, a consequence of l-arginine starvation-dependent eNOS uncoupling, was detected in endothelium and plasma. Collectively, our findings demonstrate endothelial dysfunction in a remote vascular bed after TBI, manifesting as impaired endothelial-dependent vasodilation, with increased arginase activity, decreased generation of NO, and increased O-2-production. We conclude that blood vessels have a "molecular memory'' of neurotrauma, 24 h after injury, because of functional changes in vascular endothelial cells; these effects are pertinent to understanding the systemic inflammatory response that occurs after TBI even in the absence of polytrauma.	[Villalba, Nuria; Hill-Eubanks, David C.; Nelson, Mark T.; Wellman, George C.; Freeman, Kalev] Univ Vermont, Dept Pharmacol, Burlington, VT 05405 USA; [Sackheim, Adrian M.; Nunez, Ivette A.; Wellman, George C.; Freeman, Kalev] Univ Vermont, Dept Surg, Given E301, Burlington, VT 05405 USA; [Nelson, Mark T.] Univ Manchester, Inst Cardiovasc Sci, Manchester, Lancs, England	Freeman, K (corresponding author), Univ Vermont, Dept Surg, Given E301, Burlington, VT 05405 USA.	Kalev.Freeman@uvm.edu		Nelson, Mark/0000-0002-6608-8784; Nunez, Ivette/0000-0003-3213-3628	Totman Medical Research Trust; Fondation LeducqLeducq Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P20-RR-16435, P01-HL-095488, UM1-HL-120877-01, R01-HL-044455, R01-HL-098243, R37-DK-053832, P30-RR-032135-02, P30-GM-103498-02, K08-GM-098795-01, R01-HL-121706-01]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR016435, P30RR032135] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL044455, R01HL098243, P01HL095488, R01HL121706] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R37DK053832] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM103498, K08GM098795] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10OD017969] Funding Source: NIH RePORTER	We thank Sheila Russell for her technical expertise in performing the trauma surgeries. This work was supported by the Totman Medical Research Trust, Fondation Leducq and National Institutes of Health (P20-RR-16435, P01-HL-095488, UM1-HL-120877-01, R01-HL-044455, R01-HL-098243, R37-DK-053832, P30-RR-032135-02, P30-GM-103498-02, K08-GM-098795-01, R01-HL-121706-01).	Abrams ST, 2013, AM J RESP CRIT CARE, V187, P160, DOI 10.1164/rccm.201206-1037OC; Alef MJ, 2011, J CLIN INVEST, V121, P1646, DOI 10.1172/JCI44079; Alkaitis Matthew S, 2012, Curr Heart Fail Rep, V9, P200, DOI 10.1007/s11897-012-0097-5; Allam R, 2014, J MOL MED, V92, P465, DOI 10.1007/s00109-014-1148-z; Anthony DC, 2014, EXP NEUROL, V258, P105, DOI 10.1016/j.expneurol.2014.03.013; Arribas SM, 2007, CLIN HEMORHEOL MICRO, V37, P205; Bode-Boger SM, 2007, PHARMACOL THERAPEUT, V114, P295, DOI 10.1016/j.pharmthera.2007.03.002; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; Bryan RM, 2005, ANESTHESIOLOGY, V102, P1261, DOI 10.1097/00000542-200506000-00028; Bybee KA, 2008, CIRCULATION, V118, P397, DOI 10.1161/CIRCULATIONAHA.106.677625; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; Crane GJ, 2003, J PHYSIOL-LONDON, V553, P183, DOI 10.1113/jphysiol.2003.051896; DHANAKOTI SN, 1990, AM J PHYSIOL, V259, pE437; Dioguardi FS, 2011, J NUTRIGENET NUTRIGE, V4, P90, DOI 10.1159/000327777; Edwards G, 2010, PFLUG ARCH EUR J PHY, V459, P863, DOI 10.1007/s00424-010-0817-1; Endemann DH, 2004, J AM SOC NEPHROL, V15, P1983, DOI 10.1097/01.ASN.0000132474.50966.DA; Feletou M, 2007, ANN MED, V39, P495, DOI 10.1080/07853890701491000; Forstermann U, 2012, EUR HEART J, V33, P829, DOI 10.1093/eurheartj/ehr304; Gaddam Samson Sujit Kumar, 2015, Handb Clin Neurol, V127, P205, DOI 10.1016/B978-0-444-52892-6.00014-3; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GRANGER DL, 1990, J CLIN INVEST, V85, P264, DOI 10.1172/JCI114422; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Hannah RM, 2011, J CEREBR BLOOD F MET, V31, P1175, DOI 10.1038/jcbfm.2010.214; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; Jenkinson CP, 1996, COMP BIOCHEM PHYS B, V114, P107, DOI 10.1016/0305-0491(95)02138-8; Kojima H, 1998, CHEM PHARM BULL, V46, P373; Landmesser U, 2003, J CLIN INVEST, V111, P1201, DOI 10.1172/JCI200314172; Larson BE, 2012, J SURG RES, V173, pE73, DOI 10.1016/j.jss.2011.09.056; Li H, 2001, AM J PHYSIOL-ENDOC M, V280, pE75; Liu H, 2002, J NEUROTRAUM, V19, P327, DOI 10.1089/089771502753594891; Liu YL, 2013, EXP MOL PATHOL, V94, P160, DOI 10.1016/j.yexmp.2012.10.015; Maegele M, 2014, SHOCK, V41, P21, DOI 10.1097/SHK.0000000000000088; Mann KG, 2015, J THROMB HAEMOST, V13, pS63, DOI 10.1111/jth.12981; MONCADA S, 1991, PHARMACOL REV, V43, P109; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Ochoa JB, 2001, ANN SURG, V233, P393, DOI 10.1097/00000658-200103000-00014; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; Okamoto M, 2001, GERONTOLOGY, V47, P131, DOI 10.1159/000052786; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Pribis JP, 2012, JPEN-PARENTER ENTER, V36, P53, DOI 10.1177/0148607111414579; Rael LT, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-57; Rael LT, 2009, J NEUROTRAUM, V26, P1203, DOI [10.1089/neu.2008.0816, 10.1089/neu.2008-0816]; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Rangel-Castilla L, 2010, NEUROL RES, V32, P1033, DOI 10.1179/016164110X12767786356598; RECZKOWSKI RS, 1994, ARCH BIOCHEM BIOPHYS, V312, P31, DOI 10.1006/abbi.1994.1276; Rochette L, 2013, PHARMACOL THERAPEUT, V140, P239, DOI 10.1016/j.pharmthera.2013.07.004; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; Schulman SP, 2006, JAMA-J AM MED ASSOC, V295, P58, DOI 10.1001/jama.295.1.58; Settergren M, 2009, ATHEROSCLEROSIS, V204, P73, DOI 10.1016/j.atherosclerosis.2008.08.034; SHAPIRO HM, 1972, J SURG RES, V13, P138, DOI 10.1016/0022-4804(72)90057-1; Shemyakin A, 2012, CIRCULATION, V126, P2943, DOI 10.1161/CIRCULATIONAHA.112.140335; Sonkusare SK, 2012, SCIENCE, V336, P597, DOI 10.1126/science.1216283; Taylor MS, 2003, CIRC RES, V93, P124, DOI 10.1161/01.RES.0000081980.63146.69; Villalba N, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001474; WALSH MP, 1995, CAN J PHYSIOL PHARM, V73, P565, DOI 10.1139/y95-072; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Yu Y, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/s12933-014-0113-z; Zimmermann C, 2004, CEREBROVASC DIS, V17, P128, DOI 10.1159/000075781	61	27	28	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2017	34	1					192	203		10.1089/neu.2015.4340			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EF6DE	WOS:000390420100021	26757855	Green Published			2021-06-18	
J	Zheng, ZS; Reggente, N; Lutkenhoff, E; Owen, AM; Monti, MM				Zheng, Zhong S.; Reggente, Nicco; Lutkenhoff, Evan; Owen, Adrian M.; Monti, Martin M.			Disentangling disorders of consciousness: Insights from diffusion tensor imaging and machine learning	HUMAN BRAIN MAPPING			English	Article						DTI; MVPA; probabilistic tractography; searchlight; vegetative state; minimally conscious plus; minimally conscious minus; thalamo-cortical; connectivity	PERSISTENT VEGETATIVE STATE; TRAUMATIC BRAIN-INJURY; HUMAN THALAMUS; HEAD-INJURY; CONNECTIVITY; RECOVERY; NEUROPATHOLOGY; REGISTRATION; STIMULATION; NETWORK	Previous studies have suggested that disorders of consciousness (DOC) after severe brain injury may result from disconnections of the thalamo-cortical system. However, thalamo-cortical connectivity differences between vegetative state (VS), minimally conscious state minus (MCS-, i.e., low-level behavior such as visual pursuit), and minimally conscious state plus (MCS+, i.e., high-level behavior such as language processing) remain unclear. Probabilistic tractography in a sample of 25 DOC patients was employed to assess whether structural connectivity in various thalamo-cortical circuits could differentiate between VS, MCS-, and MCS+ patients. First, the thalamus was individually segmented into seven clusters based on patterns of cortical connectivity and tested for univariate differences across groups. Second, reconstructed whole-brain thalamic tracks were used as features in a multivariate searchlight analysis to identify regions along the tracks that were most informative in distinguishing among groups. At the univariate level, it was found that VS patients displayed reduced connectivity in most thalamo-cortical circuits of interest, including frontal, temporal, and sensorimotor connections, as compared with MCS+, but showed more pulvinar-occipital connections when compared with MCS-. Moreover, MCS- exhibited significantly less thalamo-premotor and thalamo-temporal connectivity than MCS+. At the multivariate level, it was found that thalamic tracks reaching frontal, parietal, and sensorimotor regions, could discriminate, up to 100% accuracy, across each pairwise group comparison. Together, these findings highlight the role of thalamo-cortical connections in patients' behavioral profile and level of consciousness. Diffusion tensor imaging combined with machine learning algorithms could thus potentially facilitate diagnostic distinctions in DOC and shed light on the neural correlates of consciousness. Hum Brain Mapp 38:431-443, 2017. (c) 2016 Wiley Periodicals, Inc.	[Zheng, Zhong S.; Reggente, Nicco; Lutkenhoff, Evan; Monti, Martin M.] Univ Calif Los Angeles, Dept Psychol, 8547 Franz Hall, Los Angeles, CA 90095 USA; [Owen, Adrian M.] Univ Western Ontario, Brain & Mind Inst, London, ON, Canada; [Monti, Martin M.] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA USA	Zheng, ZS (corresponding author), Univ Calif Los Angeles, Dept Psychol, 8547 Franz Hall, Los Angeles, CA 90095 USA.	azszheng@ucla.edu		Monti, Martin M/0000-0001-5511-3780	James S. McDonnell Foundation "Scholar Award"; Tiny Blue Dot Foundation; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [U.1055.01.002.00007.01, U.1055.01.002.00001.01]; European Commission ICT Programme [FP7-247919]; Canada Excellence Research Chairs ProgramCanada Research Chairs; National Science Foundation Graduate Research FellowshipNational Science Foundation (NSF) [DGE-1144087]	Contract grant sponsors: This study was supported by the James S. McDonnell Foundation "Scholar Award" (M.M.M), Tiny Blue Dot Foundation (M.M.M), Medical Research Council (U.1055.01.002.00007.01 and U.1055.01.002.00001.01) (A.M.O), European Commission ICT Programme Project FP7-247919 (A.M.O), the Canada Excellence Research Chairs Program (A.M.O), and the National Science Foundation Graduate Research Fellowship DGE-1144087 (Z.S.Z).	Alkire MT, 2000, CONSCIOUS COGN, V9, P370, DOI 10.1006/ccog.1999.0423; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Boly M, 2009, HUM BRAIN MAPP, V30, P2393, DOI 10.1002/hbm.20672; Bruno MA, 2012, J NEUROL, V259, P1087, DOI 10.1007/s00415-011-6303-7; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Childs NL, 1996, BRIT MED J, V313, P944; Correia MM, 2009, MAGN RESON IMAGING, V27, P163, DOI 10.1016/j.mri.2008.06.011; Cortes N, 2012, FRONT COMPUT NEUROSC, V6, P1, DOI 10.3389/fncom.2012.00029; Croall ID, 2014, NEUROLOGY, V83, P494, DOI 10.1212/WNL.0000000000000666; Dehaene S, 2011, NEURON, V70, P200, DOI 10.1016/j.neuron.2011.03.018; Fernandez-Espejo D, 2012, ANN NEUROL, V72, P335, DOI 10.1002/ana.23635; Fernandez-Espejo D, 2011, NEUROIMAGE, V54, P103, DOI 10.1016/j.neuroimage.2010.08.035; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Goodlett C, 2007, LECT NOTES COMPUT SC, V4791, P10; Iglesias JE, 2011, IEEE T MED IMAGING, V30, P1617, DOI 10.1109/TMI.2011.2138152; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Jennett B, 1972, RN, V35; Johansen-Berg H, 2005, CEREB CORTEX, V15, P31, DOI 10.1093/cercor/bhh105; KANNO T, 1987, PACE, V10, P207, DOI 10.1111/j.1540-8159.1987.tb05949.x; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; Kriegeskorte N, 2006, P NATL ACAD SCI USA, V103, P3863, DOI 10.1073/pnas.0600244103; Kriegeskorte N, 2009, NAT NEUROSCI, V12, P535, DOI 10.1038/nn.2303; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2009, NEUROLOGY OF CONSCIOUSNESS: COGNITIVE NEUROSCIENCE AND NEUROPATHOLOGY, P1; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Lutkenhoff ES, 2015, ANN NEUROL, V78, P68, DOI 10.1002/ana.24423; Lutkenhoff ES, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115551; Lutkenhoff ES, 2013, NEUROIMAGE-CLIN, V3, P396, DOI 10.1016/j.nicl.2013.09.010; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Monti MM, 2015, NEUROLOGY, V84, P167, DOI 10.1212/WNL.0000000000001123; Monti MM, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3765; Newcombe VFJ, 2010, J NEUROL NEUROSUR PS, V81, P552, DOI 10.1136/jnnp.2009.196246; Pereira F, 2009, NEUROIMAGE, V45, pS199, DOI 10.1016/j.neuroimage.2008.11.007; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Tononi G, 2012, ARCH ITAL BIOL, V150, P290; Tsubokawa T, 1990, Brain Inj, V4, P315; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Yamamoto T, 2005, NEUROPSYCHOL REHABIL, V15, P406, DOI 10.1080/09602010443000353	51	27	28	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	JAN	2017	38	1					431	443		10.1002/hbm.23370			13	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EF3XY	WOS:000390259700030	27622575	Bronze, Green Published			2021-06-18	
J	Hu, FH; Lamprecht, MR; Wei, L; Morrison, B; Min, W				Hu, Fanghao; Lamprecht, Michael R.; Wei, Lu; Morrison, Barclay; Min, Wei			Bioorthogonal chemical imaging of metabolic activities in live mammalian hippocampal tissues with stimulated Raman scattering	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; NEWLY SYNTHESIZED PROTEINS; LONG-TERM POTENTIATION; IN-VIVO; DENTATE GYRUS; ORGANOTYPIC CULTURES; CLICK CHEMISTRY; LIVING SYSTEMS; SLICE CULTURES; MICROSCOPY	Brain is an immensely complex system displaying dynamic and heterogeneous metabolic activities. Visualizing cellular metabolism of nucleic acids, proteins, and lipids in brain with chemical specificity has been a long-standing challenge. Recent development in metabolic labeling of small biomolecules allows the study of these metabolisms at the global level. However, these techniques generally require nonphysiological sample preparation for either destructive mass spectrometry imaging or secondary labeling with relatively bulky fluorescent labels. In this study, we have demonstrated bioorthogonal chemical imaging of DNA, RNA, protein and lipid metabolism in live rat brain hippocampal tissues by coupling stimulated Raman scattering microscopy with integrated deuterium and alkyne labeling. Heterogeneous metabolic incorporations for different molecular species and neurogenesis with newly-incorporated DNA were observed in the dentate gyrus of hippocampus at the single cell level. We further applied this platform to study metabolic responses to traumatic brain injury in hippocampal slice cultures, and observed marked upregulation of protein and lipid metabolism particularly in the hilus region of the hippocampus within days of mechanical injury. Thus, our method paves the way for the study of complex metabolic profiles in live brain tissue under both physiological and pathological conditions with single-cell resolution and minimal perturbation.	[Hu, Fanghao; Wei, Lu; Min, Wei] Columbia Univ, Dept Chem, New York, NY 10027 USA; [Lamprecht, Michael R.; Morrison, Barclay] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA; [Min, Wei] Columbia Univ, Kavli Inst Brain Sci, New York, NY 10027 USA	Min, W (corresponding author), Columbia Univ, Dept Chem, New York, NY 10027 USA.; Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA.; Min, W (corresponding author), Columbia Univ, Kavli Inst Brain Sci, New York, NY 10027 USA.	bm2119@columbia.edu; wm2256@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Wei, Lu/0000-0001-9170-2283	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1DP2EB016573, EB020892]; US Army Research Office [W911NF-12-1-0594]; Alfred P. Sloan FoundationAlfred P. Sloan Foundation; Camille and Henry Dreyfus Foundation; Army Research LaboratoryUnited States Department of DefenseUS Army Research Laboratory (ARL) [W911NF-10-1-0526]; National Science Foundation Graduate Research FellowshipNational Science Foundation (NSF); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB020892, DP2EB016573] Funding Source: NIH RePORTER	We thank Y. Shen and L. Shi for helpful discussions. W. M. acknowledges support from NIH Director's New Innovator Award (Grant 1DP2EB016573), NIH R01 (Grant EB020892), the US Army Research Office (Grant W911NF-12-1-0594), the Alfred P. Sloan Foundation, and the Camille and Henry Dreyfus Foundation. B.M. acknowledges support from the Army Research Laboratory (Grant W911NF-10-1-0526). M.R.L acknowledges support from a National Science Foundation Graduate Research Fellowship.	Alfonso-Garcia A, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.6.061003; Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Baskin JM, 2007, P NATL ACAD SCI USA, V104, P16793, DOI 10.1073/pnas.0707090104; Beatty KE, 2006, ANGEW CHEM INT EDIT, V45, P7364, DOI 10.1002/anie.200602114; Berenyi A, 2014, J NEUROPHYSIOL, V111, P1132, DOI 10.1152/jn.00785.2013; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Camp CH, 2015, NAT PHOTONICS, V9, P295, DOI 10.1038/NPHOTON.2015.60; Cater HL, 2007, J NEUROCHEM, V101, P434, DOI 10.1111/j.1471-4159.2006.04379.x; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Chen ZX, 2014, J AM CHEM SOC, V136, P8027, DOI 10.1021/ja502706q; Cheng JX, 2015, SCIENCE, V350, DOI 10.1126/science.aaa8870; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Farooqui AA, 2000, CHEM PHYS LIPIDS, V106, P1, DOI 10.1016/S0009-3084(00)00128-6; Freudiger CW, 2008, SCIENCE, V322, P1857, DOI 10.1126/science.1165758; Fu D, 2014, J AM CHEM SOC, V136, P8820, DOI 10.1021/ja504199s; Grammel M, 2013, NAT CHEM BIOL, V9, P475, DOI 10.1038/nchembio.1296; Hang HC, 2011, ACCOUNTS CHEM RES, V44, P699, DOI 10.1021/ar200063v; Hong SL, 2014, ANGEW CHEM INT EDIT, V53, P5827, DOI 10.1002/anie.201400328; Hu FH, 2015, ANGEW CHEM INT EDIT, V54, P9821, DOI 10.1002/anie.201502543; Hu FH, 2014, ANALYST, V139, P2312, DOI 10.1039/c3an02281a; Jao CY, 2008, P NATL ACAD SCI USA, V105, P15779, DOI 10.1073/pnas.0808480105; Jao CY, 2009, P NATL ACAD SCI USA, V106, P15332, DOI 10.1073/pnas.0907864106; Ji MB, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab0195; Krafft C, 2016, CHEM SOC REV, V45, P1819, DOI 10.1039/c5cs00564g; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Lamprecht MR, 2017, J NEUROTRAUM, V34, P97, DOI 10.1089/neu.2015.4306; Lamprecht MR, 2015, J NEUROTRAUM, V32, P1361, DOI 10.1089/neu.2015.3912; Lechene Claude, 2006, J Biol, V5, P20, DOI 10.1186/jbiol42; Lee HJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep07930; Li JJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep06807; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Meaney DF, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026364; Min W, 2011, ANNU REV PHYS CHEM, V62, P507, DOI 10.1146/annurev.physchem.012809.103512; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Ozeki Y, 2012, NAT PHOTONICS, V6, P844, DOI [10.1038/nphoton.2012.263, 10.1038/NPHOTON.2012.263]; Pezacki JP, 2011, NAT CHEM BIOL, V7, P137, DOI 10.1038/NCHEMBIO.525; Prescher JA, 2005, NAT CHEM BIOL, V1, P13, DOI 10.1038/nchembio0605-13; Salic A, 2008, P NATL ACAD SCI USA, V105, P2415, DOI 10.1073/pnas.0712168105; Scharfman HE, 2013, FRONT NEURAL CIRCUIT, V6, DOI 10.3389/fncir.2012.00106; SCHLESSINGER AR, 1975, J COMP NEUROL, V159, P149, DOI 10.1002/cne.901590202; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Suhalim JL, 2012, J BIOPHOTONICS, V5, P387, DOI 10.1002/jbio.201200002; Sundstrom L, 2005, DRUG DISCOV TODAY, V10, P993, DOI 10.1016/S1359-6446(05)03502-6; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Thurman DJ, 2016, J CHILD NEUROL, V31, P20, DOI 10.1177/0883073814544363; Vogel EW, 2016, J NEUROTRAUM, V33, P652, DOI 10.1089/neu.2015.4045; Weeks T, 2009, OPT EXPRESS, V17, P17044, DOI 10.1364/OE.17.017044; Wei L, 2016, ACCOUNTS CHEM RES, V49, P1494, DOI 10.1021/acs.accounts.6b00210; Wei L, 2015, ACS CHEM BIOL, V10, P901, DOI 10.1021/cb500787b; Wei L, 2014, NAT METHODS, V11, P410, DOI [10.1038/NMETH.2878, 10.1038/nmeth.2878]; Wei L, 2013, P NATL ACAD SCI USA, V110, P11226, DOI 10.1073/pnas.1303768110; Yamakoshi H, 2012, J AM CHEM SOC, V134, P20681, DOI 10.1021/ja308529n; Yamakoshi H, 2011, J AM CHEM SOC, V133, P6102, DOI 10.1021/ja108404p; Yuet KP, 2014, ANN BIOMED ENG, V42, P299, DOI 10.1007/s10439-013-0878-3; Yuste R., 2010, IMAGING LAB MANUAL; Zhang DL, 2014, ACCOUNTS CHEM RES, V47, P2282, DOI 10.1021/ar400331q; Zhang D, 2011, J PHYS CHEM LETT, V2, P1248, DOI 10.1021/jz200516n; Zhang DS, 2012, NATURE, V481, P520, DOI 10.1038/nature10745; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	62	27	27	4	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	DEC 21	2016	6								39660	10.1038/srep39660			11	Multidisciplinary Sciences	Science & Technology - Other Topics	EF9IO	WOS:000390644100001	28000773	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	De Simoni, S; Grover, PJ; Jenkins, PO; Honeyfield, L; Quest, RA; Ross, E; Scott, G; Wilson, MH; Majewska, P; Waldman, AD; Patel, MC; Sharp, DJ				De Simoni, Sara; Grover, Patrick J.; Jenkins, Peter O.; Honeyfield, Lesley; Quest, Rebecca A.; Ross, Ewan; Scott, Gregory; Wilson, Mark H.; Majewska, Paulina; Waldman, Adam D.; Patel, Maneesh C.; Sharp, David J.			Disconnection between the default mode network and medial temporal lobes in post-traumatic amnesia	BRAIN			English	Article						post-traumatic amnesia; traumatic brain injury; functional connectivity; default mode network; memory	TRAUMATIC BRAIN-INJURY; MILD COGNITIVE IMPAIRMENT; FUNCTIONAL CONNECTIVITY; ALZHEIMERS-DISEASE; POSTEROMEDIAL CORTEX; POSTERIOR CINGULATE; MEMORY PERFORMANCE; SALIENCE NETWORK; EPISODIC MEMORY; WORKING-MEMORY	Post-traumatic amnesia is very common immediately after traumatic brain injury. It is characterized by a confused, agitated state and a pronounced inability to encode new memories and sustain attention. Clinically, post-traumatic amnesia is an important predictor of functional outcome. However, despite its prevalence and functional importance, the pathophysiology of post-traumatic amnesia is not understood. Memory processing relies on limbic structures such as the hippocampus, parahippocampus and parts of the cingulate cortex. These structures are connected within an intrinsic connectivity network, the default mode network. Interactions within the default mode network can be assessed using resting state functional magnetic resonance imaging, which can be acquired in confused patients unable to perform tasks in the scanner. Here we used this approach to test the hypothesis that the mnemonic symptoms of post-traumatic amnesia are caused by functional disconnection within the default mode network. We assessed whether the hippocampus and parahippocampus showed evidence of transient disconnection from cortical brain regions involved in memory processing. Nineteen patients with traumatic brain injury were classified into post-traumatic amnesia and traumatic brain injury control groups, based on their performance on a paired associates learning task. Cognitive function was also assessed with a detailed neuropsychological test battery. Functional interactions between brain regions were investigated using resting-state functional magnetic resonance imaging. Together with impairments in associative memory, patients in post-traumatic amnesia demonstrated impairments in information processing speed and spatial working memory. Patients in post-traumatic amnesia showed abnormal functional connectivity between the parahippocampal gyrus and posterior cingulate cortex. The strength of this functional connection correlated with both associative memory and information processing speed and normalized when these functions improved. We have previously shown abnormally high posterior cingulate cortex connectivity in the chronic phase after traumatic brain injury, and this abnormality was also observed in patients with post-traumatic amnesia. Patients with post-traumatic amnesia showed evidence of widespread traumatic axonal injury measured using diffusion magnetic resonance imaging. This change was more marked within the cingulum bundle, the tract connecting the parahippocampal gyrus to the posterior cingulate cortex. These findings provide novel insights into the pathophysiology of post-traumatic amnesia and evidence that memory impairment acutely after traumatic brain injury results from altered parahippocampal functional connectivity, perhaps secondary to the effects of axonal injury on white matter tracts connecting limbic structures involved in memory processing.	[De Simoni, Sara; Grover, Patrick J.; Jenkins, Peter O.; Ross, Ewan; Scott, Gregory; Majewska, Paulina; Sharp, David J.] Imperial Coll London, Hammersmith Hosp, Div Brain Sci, Computat Cognit & Clin Neuroimaging Lab, London, England; [Honeyfield, Lesley; Quest, Rebecca A.; Waldman, Adam D.; Patel, Maneesh C.] Charing Cross Hosp, Dept Imaging, London, England; [Wilson, Mark H.] Imperial Coll, St Marys Hosp, Traumat Brain Injury Ctr, London, England	Sharp, DJ (corresponding author), Imperial Coll London, Dept Med, Div Brain Sci, C3NL, Du Cane Rd, London W12 0NN, England.	david.sharp@imperial.ac.uk	Sharp, David J/A-2119-2013; Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Waldman, Adam D/0000-0003-4398-6431; Quest, Rebecca/0000-0002-0457-8665; Scott, Gregory/0000-0001-8063-5871	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIHR-RP-011-048]; Guarantors of Brain Clinical Fellowship; National Institute for Health Research (NIHR) Imperial Biomedical Research Centre; Medical Research Council through Clinician Scientist Fellowship; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish	D.J.S. is funded by a National Institute of Health Research Professorship (NIHR-RP-011-048). P.O.J. is funded by Guarantors of Brain Clinical Fellowship. The research was also supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre and the Medical Research Council through a Clinician Scientist Fellowship awarded to D.J.S.	Ahmed S, 2000, BRAIN INJURY, V14, P765; Andrews-Hanna JR, 2007, NEURON, V56, P924, DOI 10.1016/j.neuron.2007.10.038; Andrews-Hanna JR, 2014, ANN NY ACAD SCI, V1316, P29, DOI 10.1111/nyas.12360; Barnea-Goraly N, 2005, CEREB CORTEX, V15, P1848, DOI 10.1093/cercor/bhi062; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Crespo-Garcia M, 2010, NEUROIMAGE, V50, P1258, DOI 10.1016/j.neuroimage.2010.01.018; Daselaar SM, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.013.2009; Duzel E, 2010, CURR OPIN NEUROBIOL, V20, P143, DOI 10.1016/j.conb.2010.01.004; Dunn CJ, 2014, NEUROIMAGE-CLIN, V4, P473, DOI 10.1016/j.nicl.2014.02.010; Eastvold AD, 2013, J HEAD TRAUMA REHAB, V28, P48, DOI 10.1097/HTR.0b013e31823c9317; Fakhran S, 2013, RADIOLOGY, V269, P249, DOI 10.1148/radiol.13122343; Girardeau G, 2011, CURR OPIN NEUROBIOL, V21, P452, DOI 10.1016/j.conb.2011.02.005; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Ham TE, 2014, BRAIN, V137, P586, DOI 10.1093/brain/awt350; Hampson M, 2006, J NEUROSCI, V26, P13338, DOI 10.1523/JNEUROSCI.3408-06.2006; Hayes SM, 2012, J NEUROSCI, V32, P14622, DOI 10.1523/JNEUROSCI.0700-12.2012; Huijbers W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017463; Jilka SR, 2014, J NEUROSCI, V34, P10798, DOI 10.1523/JNEUROSCI.0518-14.2014; Jones DK, 2013, NEUROPSYCHOLOGIA, V51, P67, DOI 10.1016/j.neuropsychologia.2012.11.018; Kim H, 2010, NEUROIMAGE, V49, P1045, DOI 10.1016/j.neuroimage.2009.07.058; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Konigs M, 2012, J NEUROL NEUROSUR PS, V83, P1048, DOI 10.1136/jnnp-2012-302635; Leech R, 2011, J NEUROSCI, V31, P3217, DOI 10.1523/JNEUROSCI.5626-10.2011; Logothetis NK, 2012, NATURE, V491, P547, DOI 10.1038/nature11618; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Marshman LAG, 2013, J CLIN NEUROSCI, V20, P1475, DOI 10.1016/j.jocn.2012.11.022; Metting Z, 2010, J NEUROTRAUM, V27, P2183, DOI 10.1089/neu.2010.1395; Nyhus E, 2010, NEUROSCI BIOBEHAV R, V34, P1023, DOI 10.1016/j.neubiorev.2009.12.014; Parvizi J, 2006, P NATL ACAD SCI USA, V103, P1563, DOI 10.1073/pnas.0507729103; Poch C, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00036; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ranganath C, 2005, HIPPOCAMPUS, V15, P997, DOI 10.1002/hipo.20141; Schacter DL, 1999, HIPPOCAMPUS, V9, P7, DOI 10.1002/(SICI)1098-1063(1999)9:1<7::AID-HIPO2>3.0.CO;2-K; Schaie K Warner, 2010, ISSBD Bull, V57, P24; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Swainson R, 2001, DEMENT GERIATR COGN, V12, P265, DOI 10.1159/000051269; Tittle A, 2011, BRAIN INJURY, V25, P933, DOI 10.3109/02699052.2011.597042; van Duinkerken E, 2009, DIABETES, V58, P2335, DOI 10.2337/db09-0425; Vincent JL, 2006, J NEUROPHYSIOL, V96, P3517, DOI 10.1152/jn.00048.2006; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Wang L, 2006, NEUROIMAGE, V31, P496, DOI 10.1016/j.neuroimage.2005.12.033; Wang L, 2010, NEUROIMAGE, V51, P910, DOI 10.1016/j.neuroimage.2010.02.046; Ward AM, 2014, HUM BRAIN MAPP, V35, P1061, DOI 10.1002/hbm.22234; Wise RG, 2006, J MAGN RESON IMAGING, V23, P862, DOI 10.1002/jmri.20584; Zhang Y, 2007, NEUROLOGY, V68, P13, DOI 10.1212/01.wnl.0000250326.77323.01; Zhou YX, 2008, ALZHEIMERS DEMENT, V4, P265, DOI 10.1016/j.jalz.2008.04.006	56	27	27	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	DEC	2016	139		12				3137	3150		10.1093/brain/aww241			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EI7US	WOS:000392709800016	27797805	Green Published, Other Gold			2021-06-18	
J	Wang, JS; Su, BS; Zhu, HB; Chen, C; Zhao, G				Wang, Jiansheng; Su, Baishan; Zhu, Hongbin; Chen, Chao; Zhao, Gang			Protective effect of geraniol inhibits inflammatory response, oxidative stress and apoptosis in traumatic injury of the spinal cord through modulation of NF-kappa B and p38 MAPK	EXPERIMENTAL AND THERAPEUTIC MEDICINE			English	Article						geraniol; traumatic injury of the spinal cord; nuclear factor-kappa B; p38 mitogen-activated protein kinase	DNA OXIDATION; BRAIN-INJURY; RECOVERY; RATS; EXPRESSION; PROTEIN; KINASE	Geraniol is a type of monoterpenoid with a rose scent and a slightly sweet flavor. It is found in the volatile oil of various plants, and has anti-inflammatory and anti-oxidant effects. The present study aimed to investigate the protective effect of geraniol in inhibiting the inflammatory response, oxidative stress and apoptosis in traumatic spinal cord injury (SCI), as well as to analyze the mechanism underlying its effect. Adult male Sprague-Dawley rats were induced to traumatic SCI through a surgical procedure and were defined as the SCI model group. SCI or normal rats were then administered 250 mg/kg/day geraniol for 4 weeks. The Basso, Beattie and Bresnahan (BBB) test and the spinal cord water content were used to analyze the effect of geraniol against traumatic SCI in rats. The inflammatory response, oxidative stress, and caspase-9 and-3 activities were measured using commercial ELISA kits. In addition, the associated mechanism was analyzed, using western blot analysis to determine the protein expression levels of nuclear factor (NF)-KB and p38 mitogen-activated protein kinase (MAPK). The results of the present study demonstrated that BBB scores were significantly increased and the spinal cord water content was significantly inhibited in SCI rats after 3 weeks of geraniol treatment. Furthermore, the inflammatory response, oxidative stress, and the caspase-9 and-3 activities were significantly suppressed upon treatment with geraniol. Finally, the mechanism of geraniol against traumatic SCI downregulated the NF-icB and p38 MAPK pathways in SCI rats. Therefore, the protective effect of geraniol is suggested to inhibit the inflammatory response, oxidative stress and apoptosis in traumatic SCI through the modulation of NF-KB and p38 MAPK.	[Wang, Jiansheng; Su, Baishan; Zhu, Hongbin; Chen, Chao; Zhao, Gang] Second Hosp Tangshan, Dept Orthoped, 21 Jianshen North Rd, Tangshan 063000, Hebei, Peoples R China	Zhao, G (corresponding author), Second Hosp Tangshan, Dept Orthoped, 21 Jianshen North Rd, Tangshan 063000, Hebei, Peoples R China.	ts13717517534@163.com					Leite MCA, 2015, MED MYCOL, V53, P275, DOI 10.1093/mmy/myu078; Bao F, 2004, J NEUROCHEM, V90, P1194, DOI 10.1111/j.1471-4159.2004.02580.x; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Chaudhary SC, 2013, J APPL TOXICOL, V33, P828, DOI 10.1002/jat.2739; Emon ST, 2011, TURK NEUROSURG, V21, P197, DOI 10.5137/1019-5149.JTN.3523-10.2; Gong G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105944; Hagvall L, 2007, CHEM RES TOXICOL, V20, P807, DOI 10.1021/tx700017v; Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993-06.2006; Khan AQ, 2013, EXP MOL PATHOL, V94, P419, DOI 10.1016/j.yexmp.2013.01.006; Kim JH, 2012, CELL MOL BIOL, V58, P1780, DOI 10.1170/209; Knechtle B, 2003, EUR J APPL PHYSIOL, V90, P614, DOI 10.1007/s00421-003-0920-5; Kuo CY, 2015, INT J ENV RES PUB HE, V12, P4116, DOI 10.3390/ijerph120404116; Lapczynski A, 2008, FOOD CHEM TOXICOL, V46, pS160, DOI 10.1016/j.fct.2008.06.048; Leski ML, 2001, FREE RADICAL BIO MED, V30, P613, DOI 10.1016/S0891-5849(00)00500-1; Lin B, 2014, EXP THER MED, V7, P66, DOI 10.3892/etm.2013.1371; Marcuzzi A, 2011, IN VIVO, V25, P87; Merlini V, 2011, NAT PROD COMMUN, V6, P465; Prasad SN, 2014, J NEUROSCI RES, V92, P1205, DOI 10.1002/jnr.23393; PRICE S, 1977, NEUROSCI LETT, V4, P49, DOI 10.1016/0304-3940(77)90123-9; Raha S, 2016, LIFE SCI; Reichenfelser W, 2012, J REHABIL MED, V44, P444, DOI 10.2340/16501977-0979; Rodriguez-Barrera R, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/827517; Su YW, 2010, PLANTA MED, V76, P1666, DOI 10.1055/s-0030-1249947; Tan JW, 2014, INT J CLIN EXP PATHO, V7, P1911; Tederko P, 2013, SPINAL CORD, V51, P802, DOI 10.1038/sc.2013.105; Turbes C C, 1997, Biomed Sci Instrum, V34, P351; Vinothkumar V, 2012, MOL CELL BIOCHEM, V369, P17, DOI 10.1007/s11010-012-1364-1; Vuckovic A, 2014, J PAIN, V15, P645, DOI 10.1016/j.jpain.2014.02.005; Weeks DL, 2011, ARCH PHYS MED REHAB, V92, P683, DOI 10.1016/j.apmr.2010.12.026; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Yao AH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/591298; Yarar-Fisher C, 2016, AM J PHYSIOL-ENDOC M, V310, pE754, DOI 10.1152/ajpendo.00240.2015; Zhang XS, 2015, MOL MED REP, V11, P4262, DOI 10.3892/mmr.2015.3330; Zuo DC, 2013, WORLD J GASTROENTERO, V19, P1210, DOI 10.3748/wjg.v19.i8.1210	34	27	29	1	4	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-0981	1792-1015		EXP THER MED	Exp. Ther. Med.	DEC	2016	12	6	A				3607	3613		10.3892/etm.2016.3850			7	Medicine, Research & Experimental	Research & Experimental Medicine	EG5IB	WOS:000391076400021	28105094	Green Published, Bronze			2021-06-18	
J	Adrian, H; Marten, K; Salla, N; Lasse, V				Adrian, Harel; Marten, Kvist; Salla, Nuutinen; Lasse, Valimaa			Biomarkers of Traumatic Brain Injury: Temporal Changes in Body Fluids	ENEURO			English	Article						biomarker; diagnostics; TBI; traumatic brain injury	FIBRILLARY ACIDIC PROTEIN; NEURON-SPECIFIC ENOLASE; C-TERMINAL HYDROLASE-L1; SERUM S100B LEVELS; CEREBROSPINAL-FLUID; INTRACRANIAL LESIONS; COMPUTED-TOMOGRAPHY; CLEAVED-TAU; HEAD-INJURY; SCANDINAVIAN GUIDELINES	Traumatic brain injuries (TBIs) are caused by a hit to the head or a sudden acceleration/ deceleration movement of the head. Mild TBIs (mTBIs) and concussions are difficult to diagnose. Imaging techniques often fail to find alterations in the brain, and computed tomography exposes the patient to radiation. Brain-specific biomolecules that are released upon cellular damage serve as another means of diagnosing TBI and assessing the severity of injury. These biomarkers can be detected from samples of body fluids using laboratory tests. Dozens of TBI biomarkers have been studied, and research related to them is increasing. We reviewed the recent literature and selected 12 biomarkers relevant to rapid and accurate diagnostics of TBI for further evaluation. The objective was especially to get a view of the temporal profiles of the biomarkers' rise and decline after a TBI event. Most biomarkers are rapidly elevated after injury, and they serve as diagnostics tools for some days. Some biomarkers are elevated for months after injury, although the literature on long-term biomarkers is scarce. Clinical utilization of TBI biomarkers is still at a very early phase despite years of active research.	[Adrian, Harel; Marten, Kvist; Salla, Nuutinen; Lasse, Valimaa] Medicortex Finland Oy, Itainen Pitkakatu 4 B, Turku 20520, Finland	Adrian, H (corresponding author), Medicortex Finland Oy, Itainen Pitkakatu 4 B, Turku 20520, Finland.	adrian.harel@medicortex.fi					Stocchero CMA, 2014, APPL PHYSIOL NUTR ME, V39, P340, DOI 10.1139/apnm-2013-0308; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Asadollahi S, 2016, BRAIN INJURY, V30, P172, DOI 10.3109/02699052.2015.1091504; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; BOCK E, 1975, SCAND J IMMUNOL, P31; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Brandner S, 2013, J NEUROTRAUM, V30, P1205, DOI 10.1089/neu.2012.2621; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Buki A, 2000, J NEUROSCI, V20, P2825; Bulut M, 2006, ADV THER, V23, P12, DOI 10.1007/BF02850342; Cheng F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106680; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; De Matteis MA, 2000, J CELL SCI, V113, P2331; Delouche A, 2016, EUR J RADIOL, V85, P25, DOI 10.1016/j.ejrad.2015.11.004; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; DORAN JF, 1983, J NEUROCHEM, V40, P1542, DOI 10.1111/j.1471-4159.1983.tb08124.x; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Ercole A, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0614-3; Erickson JA, 2011, CLIN CHIM ACTA, V412, P2122, DOI 10.1016/j.cca.2011.07.020; FASSBENDER K, 1994, J NEUROL SCI, V122, P135, DOI 10.1016/0022-510X(94)90289-5; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; Gatson JW, 2014, J NEUROSURG, V121, P1232, DOI 10.3171/2014.7.JNS132474; Gebhardt C, 2016, J DTSCH DERMATOL GES, V14, P158, DOI 10.1111/ddg.12727; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Graham MR, 2015, INT J IMMUNOPATH PH, V28, P539, DOI 10.1177/0394632015577045; Hallen M, 2008, CLIN CHEM LAB MED, V46, P1025, DOI 10.1515/CCLM.2008.190; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ho L, 2012, J ALZHEIMERS DIS, V31, P301, DOI 10.3233/JAD-2012-120598; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnson VE, 2016, ACTA NEUROPATHOL, V131, P115, DOI 10.1007/s00401-015-1506-0; KASANTIKUL V, 1989, J SURG ONCOL, V41, P22, DOI 10.1002/jso.2930410109; Kobeissy F.H., 2015, BRAIN NEUROTRAUMA MO; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kulbe JR, 2016, EXP NEUROL, V275, P334, DOI 10.1016/j.expneurol.2015.05.004; Kumar RG, 2015, J HEAD TRAUMA REHAB, V30, P369, DOI 10.1097/HTR.0000000000000067; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; Lee JY, 2015, J KOREAN NEUROSURG S, V58, P93, DOI 10.3340/jkns.2015.58.2.93; Lei J, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1081-8; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Mannix R, 2014, J NEUROTRAUM, V31, P1072, DOI 10.1089/neu.2013.3265; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; MICHETTI F, 1980, J NEUROL SCI, V44, P259, DOI 10.1016/0022-510X(80)90133-1; Missler U, 1999, CLIN CHEM, V45, P138; Mondello S, 2014, SCI REP-UK, V4, DOI 10.1038/srep06446; Mondello S, 2012, BRAIN INJURY, V26, P1629, DOI 10.3109/02699052.2012.700083; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; MOORE IE, 1987, NEUROPATH APPL NEURO, V13, P219, DOI 10.1111/j.1365-2990.1987.tb00185.x; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Olivecrona Z, 2015, BRAIN INJURY, V29, P446, DOI 10.3109/02699052.2014.989403; Oliver J, 2015, J EXP NEUROSCI, V9, P67, DOI 10.4137/JEN.S27921; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Ottens AK, 2014, J NEUROTRAUM, V31, P782, DOI 10.1089/neu.2013.3116; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2016, J NEUROTRAUM, V33, P58, DOI 10.1089/neu.2015.3869; Papa L, 2015, ACAD EMERG MED, V22, P1274, DOI 10.1111/acem.12795; Papa L, 2015, NEUROCRIT CARE, V22, P52, DOI 10.1007/s12028-014-0028-2; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Berger RP, 2006, PEDIATR CRIT CARE ME, V7, P557, DOI 10.1097/01.PCC.0000244426.37793.23; Paus T, 2001, BRAIN RES BULL, V54, P255, DOI 10.1016/S0361-9230(00)00434-2; Pearn ML, 2016, CELL MOL NEUROBIOL A, DOI [10.1007/s10571-016-0400-1, DOI 10.1007/S10571-016-0400-1.]; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; Raad M, 2014, NEUROSCIENCE, V281, P16, DOI 10.1016/j.neuroscience.2014.08.045; Ramont L, 2005, CLIN CHEM LAB MED, V43, P1215, DOI 10.1515/CCLM.2005.210; RIDER CC, 1975, BIOCHEM BIOPH RES CO, V66, P814, DOI 10.1016/0006-291X(75)90582-3; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rodriguez-Rodriguez A, 2012, CLIN CHIM ACTA, V414, P228, DOI 10.1016/j.cca.2012.09.025; Rubenstein R, 2015, J NEUROTRAUM, V32, P342, DOI 10.1089/neu.2014.3548; Santarsieri M, 2015, BRAIN BEHAV IMMUN, V45, P15, DOI 10.1016/j.bbi.2014.09.003; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Shibahashi K, 2016, J NEUROTRAUM, V33, P1826, DOI 10.1089/neu.2015.4237; Siman R, 2015, J NEUROTRAUM, V32, P1294, DOI 10.1089/neu.2014.3698; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Simic G, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6010006; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Sorci G, 1999, CELL CALCIUM, V25, P93, DOI 10.1054/ceca.1998.0012; Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1; Strathmann FG, 2014, CLIN BIOCHEM, V47, P876, DOI 10.1016/j.clinbiochem.2014.01.028; Studer M, 2015, BRAIN INJURY, V29, P1667, DOI 10.3109/02699052.2015.1075250; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Tharp WG, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-290; Thelin EP, 2014, NEUROCRIT CARE, V20, P217, DOI 10.1007/s12028-013-9916-0; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; THOMAS D G T, 1978, Lancet, V1, P113; Tolan NV, 2013, CLIN CHIM ACTA, V424, P216, DOI 10.1016/j.cca.2013.06.009; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; TROJANOWSKI JQ, 1986, J NEUROSCI, V6, P650; Tsitsopoulos PP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00079; Tuttolomondo A, 2014, DRUG DES DEV THER, V8, P2221, DOI 10.2147/DDDT.S67655; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Unden L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0533-y; Vajtr D, 2012, Soud Lek, V57, P7; Vivekanandan S, 2011, BIOCHEM BIOPH RES CO, V411, P312, DOI 10.1016/j.bbrc.2011.06.133; Wang KKW, 2016, J NEUROTRAUM, V33, P1270, DOI 10.1089/neu.2015.3881; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; WITMAN GB, 1976, P NATL ACAD SCI USA, V73, P4070, DOI 10.1073/pnas.73.11.4070; Wolf H, 2016, BRAIN INJURY, V30, P1220, DOI 10.3109/02699052.2016.1170883; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zetterberg H, 2015, MOL CELL NEUROSCI, V66, P99, DOI 10.1016/j.mcn.2015.02.003; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092698; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2	151	27	27	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA		2373-2822		ENEURO	eNeuro	NOV-DEC	2016	3	6							e0294	10.1523/ENEURO.0294-16.2016			13	Neurosciences	Neurosciences & Neurology	EH7CQ	WOS:000391930900026	28032118	DOAJ Gold, Green Published			2021-06-18	
J	Lu, KP; Kondo, A; Albayram, O; Herbert, MK; Liu, HK; Zhou, XZ				Lu, Kun Ping; Kondo, Asami; Albayram, Onder; Herbert, Megan K.; Liu, Hekun; Zhou, Xiao Zhen			Potential of the Antibody Against cis-Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury	JAMA NEUROLOGY			English	Article							PROLYL ISOMERASE PIN1; PROTEIN PHOSPHATASE 2A; AMYLOID-BETA; A-BETA; MOUSE MODEL; NEURODEGENERATIVE DISORDERS; MEDIATED NEURODEGENERATION; NEUROFIBRILLARY TANGLES; UNITED-STATES; HEAD TRAUMA	Alzheimer disease (AD) and chronic traumatic encephalopathy (CTE) share a common neuropathologic signature-neurofibrillary tangles made of phosphorylated tau-but do not have the same pathogenesis or symptoms. Although whether traumatic brain injury (TBI) could cause AD has not been established, CTE is shown to be associated with TBI. Until recently, whether and how TBI leads to tau-mediated neurodegeneration was unknown. The unique prolyl isomerase Pin1 protects against the development of tau-mediated neurodegeneration in AD by converting the phosphorylated Thr231-Pro motif in tau (ptau) from the pathogenic cis conformation to the physiologic trans conformation, thereby restoring ptau function. The recent development of antibodies able to distinguish and eliminate both conformations specifically has led to the discovery of cis-ptau as a precursor of tau-induced pathologic change and an early driver of neurodegeneration that directly links TBI to CTE and possibly to AD. Within hours of TBI in mice or neuronal stress in vitro, neurons prominently produce cis-ptau, which causes and spreads cis-ptau pathologic changes, termed cistauosis. Cistauosis eventually leads to widespread tau-mediated neurodegeneration and brain atrophy. Cistauosis is effectively blocked by the cis-ptau antibody, which targets intracellular cis-ptau for proteasome-mediated degradation and prevents extracellular cis-ptau from spreading to other neurons. Treating TBI mice with cis-ptau antibody not only blocks early cistauosis but also prevents development and spreading of tau-mediated neurodegeneration and brain atrophy and restores brain histopathologic features and functional outcomes. Thus, cistauosis is a common early disease mechanism for AD, TBI, and CTE, and cis-ptau and its antibody may be useful for early diagnosis, treatment, and prevention of these devastating diseases.	[Lu, Kun Ping; Kondo, Asami; Albayram, Onder; Herbert, Megan K.; Liu, Hekun; Zhou, Xiao Zhen] Harvard Med Sch, Div Translat Therapeut, Dept Med, 330 Brookline Ave,Ctr Life Sci Room 0408, Boston, MA 02215 USA; [Lu, Kun Ping; Kondo, Asami; Albayram, Onder; Herbert, Megan K.; Liu, Hekun; Zhou, Xiao Zhen] Harvard Med Sch, Ctr Canc, Beth Israel Deaconess Med Ctr, 330 Brookline Ave,Ctr Life Sci Room 0408, Boston, MA 02215 USA; [Lu, Kun Ping; Liu, Hekun] Fujian Med Univ, Inst Translat Med, Fuzhou, Peoples R China	Lu, KP (corresponding author), Harvard Med Sch, Div Translat Therapeut, Dept Med, 330 Brookline Ave,Ctr Life Sci Room 0408, Boston, MA 02215 USA.; Lu, KP (corresponding author), Harvard Med Sch, Ctr Canc, Beth Israel Deaconess Med Ctr, 330 Brookline Ave,Ctr Life Sci Room 0408, Boston, MA 02215 USA.	klu@bidmc.harvard.edu	LIU, Hekun/AAI-6583-2020; Herbert, Megan/AAN-8333-2021; Herbert, Megan/E-6348-2015	Albayram, Onder/0000-0002-2028-1458; Herbert, Megan/0000-0003-1599-4362	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AG029385, R01AG046319, R01CA167677, R01HL111430]; Alzheimer's AssociationAlzheimer's Association [DVT-14-322623]	This work was supported by grants R01AG029385, R01AG046319, R01CA167677, and R01HL111430 from the National Institutes of Health; grant DVT-14-322623 from the Alzheimer's Association (Dr Lu); and gift donations from the Owens Family Foundation (Drs Lu and Zhou).	Alzheimer's Association, 2016, ALZH DIS FACTS FIG; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Brody DL, 2008, ANNU REV NEUROSCI, V31, P175, DOI 10.1146/annurev.neuro.31.060407.125529; Carter PJ, 2006, NAT REV IMMUNOL, V6, P343, DOI 10.1038/nri1837; Castillo-Carranza DL, 2014, J NEUROSCI, V34, P4260, DOI 10.1523/JNEUROSCI.3192-13.2014; Chen CH, 2015, NEUROBIOL DIS, V76, P13, DOI 10.1016/j.nbd.2014.12.027; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; Clavaguera F, 2015, NEUROPATH APPL NEURO, V41, P47, DOI 10.1111/nan.12197; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; de Calignon A, 2012, NEURON, V73, P685, DOI 10.1016/j.neuron.2011.11.033; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Dolan PJ, 2010, CURR OPIN DRUG DISC, V13, P595; Doody RS, 2014, NEW ENGL J MED, V370, P311, DOI 10.1056/NEJMoa1312889; Eichner T, 2016, J MOL BIOL, V428, P1760, DOI 10.1016/j.jmb.2016.03.009; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frost B, 2010, NAT REV NEUROSCI, V11, P155, DOI 10.1038/nrn2786; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Goedert M, 2000, J NEUROCHEM, V75, P2155, DOI 10.1046/j.1471-4159.2000.0752155.x; Goedert M, 2006, SCIENCE, V314, P777, DOI 10.1126/science.1132814; Gotz J, 2007, BRAIN PATHOL, V17, P91, DOI 10.1111/j.1750-3639.2007.00051.x; Golde TE, 2011, NEURON, V69, P203, DOI 10.1016/j.neuron.2011.01.002; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hamdane M, 2006, MOL CELL NEUROSCI, V32, P155, DOI 10.1016/j.mcn.2006.03.006; Hampel H, 2010, EXP GERONTOL, V45, P30, DOI 10.1016/j.exger.2009.10.010; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kimura T, 2013, J BIOL CHEM, V288, P7968, DOI 10.1074/jbc.M112.433326; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Krishnamurthy Pavan K, 2011, Front Psychiatry, V2, P59, DOI 10.3389/fpsyt.2011.00059; Kutter S, 2016, J MOL BIOL, V428, P1742, DOI 10.1016/j.jmb.2016.03.010; Lee TH, 2011, MOL CELL, V42, P147, DOI 10.1016/j.molcel.2011.03.005; Lee TH, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001906; Lim J, 2008, J CLIN INVEST, V118, P1877, DOI 10.1172/JCI34308; Liou YC, 2003, NATURE, V424, P556, DOI 10.1038/nature01832; Liu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031302; Lu JC, 2009, CARCINOGENESIS, V30, P1717, DOI 10.1093/carcin/bgp171; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2003, BIOESSAYS, V25, P174, DOI 10.1002/bies.10223; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Lu PJ, 1999, NATURE, V399, P784; Luna-Munoz J, 2007, J ALZHEIMERS DIS, V12, P365; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Ma SL, 2012, NEUROBIOL AGING, V33, P804, DOI 10.1016/j.neurobiolaging.2010.05.018; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Masliah E, 2005, NEURON, V46, P857, DOI 10.1016/j.neuron.2005.05.010; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Min SW, 2015, NAT MED, V21, P1154, DOI 10.1038/nm.3951; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nakamura K, 2012, CELL, V149, P232, DOI 10.1016/j.cell.2012.02.016; Nelson PT, 2012, J NEUROPATH EXP NEUR, V71, P362, DOI 10.1097/NEN.0b013e31825018f7; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Nowotny P, 2007, NEUROSCI LETT, V419, P15, DOI 10.1016/j.neulet.2007.03.071; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pastorino L, 2006, NATURE, V440, P528, DOI 10.1038/nature04543; Pawson T, 2005, TRENDS BIOCHEM SCI, V30, P286, DOI 10.1016/j.tibs.2005.04.013; Plassman BL, 2007, NEUROEPIDEMIOLOGY, V29, P125, DOI 10.1159/000109998; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Roberson ED, 2006, SCIENCE, V314, P781, DOI 10.1126/science.1132813; Rosenmann H, 2013, CURR ALZHEIMER RES, V10, P217, DOI 10.2174/1567205011310030001; Salloway S, 2014, NEW ENGL J MED, V370, P322, DOI 10.1056/NEJMoa1304839; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Segat L, 2007, NEUROBIOL AGING, V28, P69, DOI 10.1016/j.neurobiolaging.2005.11.009; Sigurdsson EM, 2014, NEURODEGENER DIS, V13, P103, DOI 10.1159/000354491; Smet C, 2004, BIOCHEMISTRY-US, V43, P2032, DOI 10.1021/bi035479x; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Sultana R, 2006, NEUROBIOL AGING, V27, P918, DOI 10.1016/j.neurobiolaging.2005.05.005; Tampellini D, 2007, J BIOL CHEM, V282, P18895, DOI 10.1074/jbc.M700373200; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Troquier L, 2012, CURR ALZHEIMER RES, V9, P397, DOI 10.2174/156720512800492503; Wang YP, 2016, NAT REV NEUROSCI, V17, P5, DOI 10.1038/nrn.2015.1; Wijsman EM, 2004, AM J HUM GENET, V75, P398, DOI 10.1086/423393; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yanamandra K, 2013, NEURON, V80, P402, DOI 10.1016/j.neuron.2013.07.046; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	92	27	27	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	NOV 1	2016	73	11					1356	1362		10.1001/jamaneurol.2016.2027			7	Clinical Neurology	Neurosciences & Neurology	ED1BL	WOS:000388578600017	27654282	Bronze			2021-06-18	
J	Sparvero, LJ; Amoscato, AA; Fink, AB; Anthonymuthu, T; New, LA; Kochanek, PM; Watkins, S; Kagan, VE; Bayir, H				Sparvero, Louis J.; Amoscato, Andrew A.; Fink, Arthur B.; Anthonymuthu, Tamil; New, Lee Ann; Kochanek, Patrick M.; Watkins, Simon; Kagan, Valerian E.; Bayir, Hulya			Imaging mass spectrometry reveals loss of polyunsaturated cardiolipins in the cortical contusion, hippocampus, and thalamus after traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						cardiolipin; hippocampus; imaging mass spectrometry; lipids; thalamus; traumatic brain injury	SPINAL-CORD-INJURY; IMPROVES MITOCHONDRIAL-FUNCTION; CYTOSOLIC PHOSPHOLIPASE A(2); ARACHIDONIC-ACID METABOLISM; ALPHA-LINOLENIC ACID; DOCOSAHEXAENOIC ACID; RAT-BRAIN; NUTRITIONAL DEPRIVATION; ANTIOXIDANT THERAPIES; OXIDATIVE LIPIDOMICS	Traumatic brain injury (TBI) leads to changes in ion fluxes, alterations in mitochondrial function, and increased generation of reactive oxygen species, resulting in secondary tissue damage. Mitochondria play important signaling rolesincoordination of multiple metabolic platforms in addition to their well-known role in bioenergetics. Mitochondrial signaling strongly depends on cardiolipin (CL), a mitochondria-specific structurally unusual anionic phospholipid containing four fatty acyl chains. While our previous reports indicated that CL is selectively oxidized and presents itself as a target for the redox therapy following TBI, the topography of changes of CL in the injured brain remained to be defined. Here, we present a matrix-assisted laser desorption/ionization imaging study which reports regio-specific changes in CL, in a controlled cortical impact model of TBI in rats. Matrix-assisted laser desorption/ionization imaging revealed that TBI caused early decreases in CL in the contusional cortex, ipsilateral hippocampus, and thalamus with the most highly unsaturated CL species being most susceptible to loss. Phosphatidylinositol was the only other lipid species that exhibited a significant decrease, albeit to a lesser extent than CL. Signals for other lipids remained unchanged. Thisis the first study evaluating the spatial distribution of CL loss after acute brain injury. We propose that the CL loss may constitute an upstream mechanism for CL-driven signaling in different brain regions as an early response mechanism and may also underlie the bioenergetic changes that occur in hippocampal, cortical, and thalamic mitochondria after TBI.	[Sparvero, Louis J.; Amoscato, Andrew A.; Fink, Arthur B.; Kagan, Valerian E.; Bayir, Hulya] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA; [Sparvero, Louis J.; Amoscato, Andrew A.; Fink, Arthur B.; Kagan, Valerian E.; Bayir, Hulya] Univ Pittsburgh, Ctr Free Radical & Antioxidant Hlth, Pittsburgh, PA USA; [Anthonymuthu, Tamil; New, Lee Ann; Kochanek, Patrick M.; Bayir, Hulya] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; [Anthonymuthu, Tamil; New, Lee Ann; Kochanek, Patrick M.; Bayir, Hulya] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Watkins, Simon] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA USA	Bayir, H (corresponding author), Childrens Hosp Pittsburgh, 4401 Penn Ave, Pittsburgh, PA 15224 USA.; Kagan, VE (corresponding author), Bridgeside Point,100 Technol Dr,Room 330, Pittsburgh, PA 15219 USA.	kagan@pitt.edu; bayihx@ccm.upmc.edu	Anthonymuthu, Tamil/I-5534-2019	Kagan, Valerian E./0000-0002-7245-1885; watkins, simon/0000-0003-4092-1552; Amoscato, Andrew/0000-0002-1340-9150	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [ES020693, U19AIO68021, NS076511, NS061817]; NIOSHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [OH008282]; Fulbright Canada; UPCI Cancer Biomarkers Facility [P30CA047904];  [U54 GM103529 08];  [WH81XWH-10-1-0623];  [WH81XWH-14-2-0018]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA047904] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [R01OH008282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES020693] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM103529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061817, R01NS076511] Funding Source: NIH RePORTER	This work was supported by NIH: ES020693, U19AIO68021, NS076511, NS061817; NIOSH OH008282; U54 GM103529 08 (SCW); partial support from Fulbright Canada (VEK); WH81XWH-10-1-0623 and WH81XWH-14-2-0018 (PMK). This project used the UPCI Cancer Biomarkers Facility that is supported in part by award P30CA047904. The authors declare no competing financial interests.	Amoscato AA, 2014, ANAL CHEM, V86, P6587, DOI 10.1021/ac5011876; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Bazan N. G., 1992, ADV NEUROCHEM, V7, P321; Bazan NG, 2005, MOL NEUROBIOL, V32, P89, DOI 10.1385/MN:32:1:089; Bazan NG, 2006, CELL MOL NEUROBIOL, V26, P901, DOI 10.1007/s10571-006-9064-6; Bazan S, 2013, J BIOL CHEM, V288, P401, DOI 10.1074/jbc.M112.425876; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Chambers MC, 2012, NAT BIOTECHNOL, V30, P918, DOI 10.1038/nbt.2377; Chen C, 2005, PROSTAG OTH LIPID M, V77, P65, DOI 10.1016/j.prostaglandins.2005.07.001; Chen H, 2011, ANTIOXID REDOX SIGN, V14, P1505, DOI 10.1089/ars.2010.3576; Chen SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045763; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Chu CT, 2013, NAT CELL BIOL, V15, P1197, DOI 10.1038/ncb2837; Claypool SM, 2012, TRENDS BIOCHEM SCI, V37, P32, DOI 10.1016/j.tibs.2011.09.003; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Contreras MA, 2000, J NEUROCHEM, V75, P2392, DOI 10.1046/j.1471-4159.2000.0752392.x; DeMar JC, 2004, J NEUROCHEM, V91, P1125, DOI 10.1111/j.1471-4159.2004.02789.x; DEMEDIUK P, 1985, P NATL ACAD SCI USA, V82, P7071, DOI 10.1073/pnas.82.20.7071; Ellis CE, 2005, MOL CELL BIOL, V25, P10190, DOI 10.1128/MCB.25.22.10190-10201.2005; Farooqui AA, 2000, NEUROSCIENTIST, V6, P169, DOI 10.1177/107385840000600308; Farooqui AA, 2010, MOL NEUROBIOL, V41, P267, DOI 10.1007/s12035-009-8091-y; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FOLCH J, 1957, J BIOL CHEM, V226, P497; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hankin JA, 2011, J AM SOC MASS SPECTR, V22, P1014, DOI 10.1007/s13361-011-0122-z; HIRASHIMA Y, 1992, J NEUROCHEM, V59, P708, DOI 10.1111/j.1471-4159.1992.tb09426.x; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Iadecola C, 2011, NAT NEUROSCI, V14, P1363, DOI 10.1038/nn.2953; Igarashi M, 2007, J LIPID RES, V48, P152, DOI 10.1194/jlr.M600396-JLR200; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Jin Y, 2004, J NEUROTRAUM, V21, P1396, DOI 10.1089/neu.2004.21.1396; Kagan VE, 2009, FREE RADICAL BIO MED, V46, P1439, DOI 10.1016/j.freeradbiomed.2009.03.004; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kim C, 2008, BMB REP, V41, P555, DOI 10.5483/BMBRep.2008.41.8.555; Kim I, 2011, ANTIOXID REDOX SIGN, V14, P1919, DOI 10.1089/ars.2010.3768; Kuhn H, 2006, PROG LIPID RES, V45, P334, DOI 10.1016/j.plipres.2006.02.003; Lee H, 2004, J NEUROCHEM, V91, P936, DOI 10.1111/j.1471-4159.2004.02786.x; Lee HJ, 2008, J LIPID RES, V49, P162, DOI 10.1194/jlr.M700406-JLR200; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Lukiw WJ, 2008, J NUTR, V138, P2510, DOI 10.3945/jn.108.096016; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; McEwen ML, 2007, J NEUROTRAUM, V24, P613, DOI 10.1089/neu.2006.9969; McEwen ML, 2011, NEUROTHERAPEUTICS, V8, P168, DOI 10.1007/s13311-011-0031-7; Mejia EM, 2016, J BIOENERG BIOMEMBR, V48, P99, DOI 10.1007/s10863-015-9601-4; Mejia EM, 2015, BIOCHEM J, V471, P123, DOI 10.1042/BJ20150648; Mejia Edgard M., 2014, Cardiovascular & Hematological Disorders - Drug Targets, V14, P98; Mejia EM, 2014, CHEM PHYS LIPIDS, V179, P11, DOI 10.1016/j.chemphyslip.2013.10.001; Mitchell RW, 2009, BBA-BIOMEMBRANES, V1788, P2015, DOI 10.1016/j.bbamem.2009.06.002; Mu XJ, 2002, J NEUROTRAUM, V19, P917, DOI 10.1089/089771502320317078; MURPHY EJ, 1994, MOL CHEM NEUROPATHOL, V23, P13, DOI 10.1007/BF02858504; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45, DOI 10.1615/CritRevNeurobiol.v13.i1.30; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Osman C, 2011, J CELL BIOL, V192, P7, DOI 10.1083/jcb.201006159; Patel SP, 2012, NEUROSCIENCE, V210, P296, DOI 10.1016/j.neuroscience.2012.03.006; Patel SP, 2014, EXP NEUROL, V257, P95, DOI 10.1016/j.expneurol.2014.04.026; Patel SP, 2010, J NEUROCHEM, V114, P291, DOI 10.1111/j.1471-4159.2010.06764.x; Patel SP, 2009, J NEUROSCI RES, V87, P130, DOI 10.1002/jnr.21814; PAXINOS G, 1982, RAT BRAIN STEROTAXIC; Phillis JW, 2006, BRAIN RES REV, V52, P201, DOI 10.1016/j.brainresrev.2006.02.002; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Race AM, 2012, J PROTEOMICS, V75, P5111, DOI 10.1016/j.jprot.2012.05.035; Rapoport SI, 1999, NEUROCHEM RES, V24, P1403, DOI 10.1023/A:1022584707352; Rapoport SI, 2001, J MOL NEUROSCI, V16, P243, DOI 10.1385/JMN:16:2-3:243; Rapoport SI, 2001, J LIPID RES, V42, P678; Rapoport SI, 2008, J NUTR, V138, P2515; Robertson CL, 2004, DEV BRAIN RES, V151, P141, DOI 10.1016/j.devbrainres.2004.04.007; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; Robichaud G, 2013, J AM SOC MASS SPECTR, V24, P718, DOI 10.1007/s13361-013-0607-z; Rosca M, 2011, BBA-BIOENERGETICS, V1807, P1373, DOI 10.1016/j.bbabio.2011.02.003; Roux A, 2016, J NEUROSCI METH, V272, P19, DOI 10.1016/j.jneumeth.2016.02.004; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; SCHLAME M, 1993, EUR J BIOCHEM, V212, P727, DOI 10.1111/j.1432-1033.1993.tb17711.x; Schlame M, 2008, J LIPID RES, V49, P1607, DOI 10.1194/jlr.R700018-JLR200; Schlame M, 2013, BBA-MOL CELL BIOL L, V1831, P582, DOI 10.1016/j.bbalip.2012.11.007; Schramm T, 2012, J PROTEOMICS, V75, P5106, DOI 10.1016/j.jprot.2012.07.026; Singh I. N., 2006, J CEREB BLOOD FLOW M, V26, P1; Sparvero LJ, 2012, CHEM PHYS LIPIDS, V165, P545, DOI 10.1016/j.chemphyslip.2012.06.001; Sparvero LJ, 2010, J NEUROCHEM, V115, P1322, DOI 10.1111/j.1471-4159.2010.07055.x; Spector AA, 2009, J LIPID RES, V50, pS52, DOI 10.1194/jlr.R800038-JLR200; Sturm M, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-163; Stys P. K., 1999, J NEUROTRAUM, V16, P984; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Taylor WA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048628; Taylor WA, 2009, J BIOL CHEM, V284, P30360, DOI 10.1074/jbc.M109.048322; Tyurina Y. Y., 2014, NAT CHEM, V26, P1407; Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Winge DR, 2012, MOL CELL BIOL, V32, P2647, DOI 10.1128/MCB.00573-12; Wirtz S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018897; Wolfe L. S., 1994, EICOSANOIDS BASIC NE, P475; Woods AS, 2013, ACS CHEM NEUROSCI, V4, P594, DOI 10.1021/cn300216h; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Xiong YQ, 2009, EXP NEUROL, V216, P105, DOI 10.1016/j.expneurol.2008.11.025; Xu FY, 2010, BBA-BIOMEMBRANES, V1798, P1577, DOI 10.1016/j.bbamem.2010.04.007; Xu Y, 2014, CHEM PHYS LIPIDS, V179, P17, DOI 10.1016/j.chemphyslip.2013.10.005	107	27	27	2	29	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	NOV	2016	139	4					659	675		10.1111/jnc.13840			17	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	EC1DD	WOS:000387842800013	27591733	Green Accepted			2021-06-18	
J	Rigon, A; Turkstra, L; Mutlu, B; Duff, M				Rigon, Arianna; Turkstra, Lyn; Mutlu, Bilge; Duff, Melissa			The female advantage: sex as a possible protective factor against emotion recognition impairment following traumatic brain injury	COGNITIVE AFFECTIVE & BEHAVIORAL NEUROSCIENCE			English	Article						Traumatic brain injury; Emotion recognition; Facial affect recognition; Sex difference	FACIAL AFFECT RECOGNITION; SOCIAL COGNITION; EXPRESSION; PERCEPTION; DEFICITS; CHILDREN; ADULTS; IDENTIFICATION; ADOLESCENTS; FRAMEWORK	Although moderate to severe traumatic brain injury (TBI) leads to facial affect recognition impairments in up to 39% of individuals, protective and risk factors for these deficits are unknown. The aim of the current study was to examine the effect of sex on emotion recognition abilities following TBI. We administered two separate emotion recognition tests (one static and one dynamic) to 53 individuals with moderate to severe TBI (females = 28) and 49 demographically matched comparisons (females = 22). We then investigated the presence of a sex-by-group interaction in emotion recognition accuracy. In the comparison group, there were no sex differences. In the TBI group, however, females significantly outperformed males in the dynamic (but not the static) task. Moreover, males (but not females) with TBI performed significantly worse than comparison participants in the dynamic task. Further analysis revealed that sex differences in emotion recognition abilities within the TBI group could not be explained by lesion location, TBI severity, or other neuropsychological variables. These findings suggest that sex may serve as a protective factor for social impairment following TBI and inform clinicians working with TBI as well as research on the neurophysiological correlates of sex differences in social functioning.	[Rigon, Arianna; Duff, Melissa] Univ Iowa, Interdisciplinary Neurosci Program, 420-1 Seashore Hall,328 Iowa Ave, Iowa City, IA 52242 USA; [Turkstra, Lyn] Univ Wisconsin, Dept Commun Sci & Disorders, 474 Goodnight Hall 1975 Willow Dr, Madison, WI 53706 USA; [Mutlu, Bilge] Univ Wisconsin, Dept Comp Sci, 1210 W Dayton St,Room 6381, Madison, WI 53706 USA; [Duff, Melissa] Univ Iowa, Dept Commun Sci & Disorders, Wendell Johnson Speech & Hearing Clin 121D, 250 Hawkins Dr, Iowa City, IA 52242 USA; [Duff, Melissa] Univ Iowa, Dept Neurol, 2007 Roy Carver Pavil,200 Hawkins Dr, Iowa City, IA 52242 USA	Rigon, A (corresponding author), Univ Iowa, Interdisciplinary Neurosci Program, 420-1 Seashore Hall,328 Iowa Ave, Iowa City, IA 52242 USA.	arianna-rigon@uiowa.edu			NICHD/NCMRRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD071089]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD071089] Funding Source: NIH RePORTER	This work was supported by NICHD/NCMRR grant R01 HD071089.	Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; Baxter D, 2013, ANN NEUROL, V74, P527, DOI 10.1002/ana.23958; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Calvo MG, 2008, BEHAV RES METHODS, V40, P109, DOI 10.3758/BRM.40.1.109; Costa PJ, 2014, J BIOPHARM STAT, V24, P1115, DOI 10.1080/10543406.2014.926366; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; Derogatis L, 1983, BRIEF SYMPTOM INVENT, V13, P595, DOI DOI 10.1017/S0033291700048017; Despins EH, 2016, ARCH PHYS MED REHAB, V97, pS26, DOI 10.1016/j.apmr.2014.06.023; Duff MC, 2012, SEMIN SPEECH LANG, V33, P44, DOI 10.1055/s-0031-1301162; Farace E, 2000, Neurosurg Focus, V8, pe6; Genova HM, 2015, SOC NEUROSCI-UK, V10, P27, DOI 10.1080/17470919.2014.959618; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; GORDON NG, 1972, J CLIN PSYCHOL, V28, P167, DOI 10.1002/1097-4679(197204)28:2<167::AID-JCLP2270280212>3.0.CO;2-X; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Ham TE, 2014, BRAIN, V137, P586, DOI 10.1093/brain/awt350; Holdnack JA, 2011, ASSESSMENT, V18, P178, DOI 10.1177/1073191110393106; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Kessels RPC, 2014, J NEUROPSYCHOL, V8, P75, DOI 10.1111/jnp.12009; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Kret ME, 2012, NEUROPSYCHOLOGIA, V50, P1211, DOI 10.1016/j.neuropsychologia.2011.12.022; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Martins AT, 2012, NEURAL REGEN RES, V7, P101, DOI 10.3969/j.issn.1673-5374.2012.02.004; McClure EB, 2000, PSYCHOL BULL, V126, P424, DOI 10.1037/0033-2909.126.3.424; Merz CJ, 2012, SOC COGN AFFECT NEUR, V7, P819, DOI 10.1093/scan/nsr063; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Montagne B, 2007, PERCEPT MOTOR SKILL, V104, P589, DOI 10.2466/PMS.104.2.589-598; Montagne Barbara, 2005, Cogn Process, V6, P136, DOI 10.1007/s10339-005-0050-6; Moore DW, 2010, NEUROPSYCHOL REHABIL, V20, P340, DOI 10.1080/09602010903250928; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Neumann D, 2016, BRAIN IMAGING BEHAV, V10, P569, DOI 10.1007/s11682-015-9415-3; Olson IR, 2013, SOC COGN AFFECT NEUR, V8, P123, DOI 10.1093/scan/nss119; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/pms.1991.73.3f.1139; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Rigon A., 2015, J NEUROTRAUM, DOI [10.1089/neu.2014.3847, DOI 10.1089/NEU.2014.3847]; Rosenberg H, 2015, NEUROPSYCHOLOGY, V29, P509, DOI 10.1037/neu0000171; Rosenberg H, 2014, J INT NEUROPSYCH SOC, V20, P994, DOI 10.1017/S1355617714000940; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; SHEWAN CM, 1980, J SPEECH HEAR DISORD, V45, P308, DOI 10.1044/jshd.4503.308; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; Veroude K, 2014, SOC COGN AFFECT NEUR, V9, P513, DOI 10.1093/scan/nst015; Wehrle T, 2000, J PERS SOC PSYCHOL, V78, P105, DOI 10.1037/0022-3514.78.1.105; Weisenbach SL, 2014, SOC COGN AFFECT NEUR, V9, P316, DOI 10.1093/scan/nss137; Welborn BL, 2009, SOC COGN AFFECT NEUR, V4, P328, DOI 10.1093/scan/nsp028; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P113, DOI 10.1080/13803390902806543; Willis ML, 2015, SOC COGN AFFECT NEUR, V10, P1677, DOI 10.1093/scan/nsv057; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Wood W, 2000, AM PSYCHOL, V55, P1062, DOI 10.1037/0003-066X.55.9.1062; Yim J, 2013, BRAIN INJURY, V27, P1155, DOI 10.3109/02699052.2013.804203; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104	54	27	28	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1530-7026	1531-135X		COGN AFFECT BEHAV NE	Cogn. Affect. Behav. Neurosci.	OCT	2016	16	5					866	875		10.3758/s13415-016-0437-0			10	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	DV6DV	WOS:000383022300008	27245826	Green Accepted, Bronze			2021-06-18	
J	Jonkergouw, J; van de Vijfeijken, SECM; Nout, E; Theys, T; Van de Casteele, E; Folkersma, H; Depauw, PRAM; Becking, AG				Jonkergouw, J.; van de Vijfeijken, S. E. C. M.; Nout, E.; Theys, T.; Van de Casteele, E.; Folkersma, H.; Depauw, P. R. A. M.; Becking, A. G.			Outcome in patient-specific PEEK cranioplasty: A two-center cohort study of 40 implants	JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY			English	Article						Cranioplasty; Craniectomy; Patient specific implant; PEEK; Computer aided-design and modelling; Cranial vault reconstruction	AFFECTING GRAFT INFECTION; TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; DECOMPRESSIVE CRANIECTOMY; AUTOLOGOUS BONE; POLYETHERETHERKETONE IMPLANTS; CALVARIAL RECONSTRUCTION; CRANIAL DEFECTS; COMPLICATIONS; MANAGEMENT	Objective: The best material choice for cranioplasty following craniectomy remains a subject to discussion. Complication rates after cranioplasty tend to be high. Computer-assisted 3-dimensional modelling of polyetheretherketone (PEEK) was recently introduced for cranial reconstruction. The aim of this study was to evaluate patient- and surgery-related characteristics and risk factors that predispose patients to cranioplasty complications. Material and methods: This retrospective study included a total of 40 cranial PEEK implants in 38 patients, performed at two reference centers in the Netherlands from 2011 to 2014. Complications were registered and patient- and surgery-related data were carefully analysed. Results: The overall complication rate of PEEK cranioplasty was 28%. Complications included infection (13 %), postoperative haematoma (10 %), cerebrospinal fluid leak (2.5 %) and wound-related problems (2.5 %). All postoperative infections required removal of the implant. Nonetheless removed implants could be successfully re-used after re-sterilization. Conclusion: Although overall complication rates after PEEK cranioplasty remain high, outcomes are satisfactory, as our results compare favourably to recent literature reports on cranial vault reconstruction. (C) 2016 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.	[Jonkergouw, J.; Nout, E.] Dept Oral & Maxillofacial Surg Tilburg, Hilvarenbeekseweg 60, NL-5022 GC Tilburg, Netherlands; [Jonkergouw, J.] Univ Hosp Leuven, Dept Oral & Maxillofacial Surg, Herestr 49, B-3000 Leuven, Belgium; [van de Vijfeijken, S. E. C. M.; Becking, A. G.] Acad Med Ctr, Dept Oral & Maxillofacial Surg, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [van de Vijfeijken, S. E. C. M.; Becking, A. G.] Acad Ctr Dent Amsterdam ACTA, Gustav Mahlerlaan 3004, NL-1081 LA Amsterdam, Netherlands; [Theys, T.] Univ Hosp Leuven, Dept Neurosurg, Herestr 49, B-3000 Leuven, Belgium; [Van de Casteele, E.] Univ Antwerp, IMinds Vis Lab, Dept Phys, Antwerp, Belgium; [Folkersma, H.] Acad Med Ctr, Neurosurg Ctr Amsterdam, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [Depauw, P. R. A. M.] Dept Neurosurg Tilburg, Hilvarenbeekseweg 60, NL-5022 GC Tilburg, Netherlands	van de Vijfeijken, SECM (corresponding author), Acad Med Ctr, Dept Oral & Maxillofacial Surg, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	s.e.vandevijfefiken@amc.uva.nl	Theys, Tom/AAG-4536-2019	Theys, Tom/0000-0001-7595-3234; Van de Casteele, Elke/0000-0003-0395-3002			Blum KS, 1997, PEDIATR NEUROSURG, V26, P33, DOI 10.1159/000121158; Bonda DJ, 2015, NEUROSURGERY, V77, P814, DOI 10.1227/NEU.0000000000000899; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cheng Cheng-Hsin, 2014, Clin Neurol Neurosurg, V124, P85, DOI 10.1016/j.clineuro.2014.06.029; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Diedler Jennifer, 2009, J Intensive Care Med, V24, P168, DOI 10.1177/0885066609332808; Ducic J, 2002, J ORAL MAXIL SURG, V60, P272, DOI 10.1053/joms.2002.30575; Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; Dujovny M, 1997, SURG NEUROL, V48, P294, DOI 10.1016/S0090-3019(97)00277-2; Goh RCW, 2010, J PLAST RECONSTR AES, V63, P1479, DOI 10.1016/j.bjps.2009.08.010; Goldstein JA, 2013, CURR OPIN OTOLARYNGO, V21, P400, DOI 10.1097/MOO.0b013e328363003e; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Hanasono MM, 2009, ANN PLAS SURG, V62, P653, DOI 10.1097/SAP.0b013e318184abc7; Hill CS, 2012, BRIT J NEUROSURG, V26, P832, DOI 10.3109/02688697.2012.692839; Honeybul S, 2013, BRAIN INJURY, V27, P979, DOI 10.3109/02699052.2013.794974; Honeybul S, 2012, PLAST RECONSTR SURG, V130, P1110, DOI 10.1097/PRS.0b013e318267d4de; Kakar V, 2009, BRIT J NEUROSURG, V23, P147, DOI 10.1080/02688690902756702; Kim H, 2013, ACTA NEUROCHIR, V155, P2171, DOI 10.1007/s00701-013-1877-8; Klinger DR, 2014, WORLD NEUROSURG, V82, pE525, DOI 10.1016/j.wneu.2013.08.005; Kshettry VR, 2012, NEUROSURGERY, V70, DOI 10.1227/NEU.0b013e31822fef2c; Kuo JR, 2004, J CLIN NEUROSCI, V11, P486, DOI 10.1016/j.jocn.2003.06.005; Kurtz SM, 2007, BIOMATERIALS, V28, P4845, DOI 10.1016/j.biomaterials.2007.07.013; Lee CH, 2012, J TRAUMA ACUTE CARE, V73, P255, DOI 10.1097/TA.0b013e318256a150; Lethaus B, 2014, J CRANIOFAC SURG, V25, P206, DOI 10.1097/SCS.0000000000000396; Lethaus B, 2012, J NEUROTRAUM, V29, P1077, DOI 10.1089/neu.2011.1794; Lethaus B, 2011, J CRANIO MAXILL SURG, V39, P435, DOI 10.1016/j.jcms.2010.10.003; Mak CHK, 2013, VASC HEALTH RISK MAN, V9, P353, DOI 10.2147/VHRM.S34046; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Morley NC, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003435; Perez-Bovet J, 2012, ACTA NEUROCHIR, V154, P1717, DOI 10.1007/s00701-012-1323-3; Piitulainen JM, 2015, WORLD NEUROSURG, V83, P708, DOI 10.1016/j.wneu.2015.01.014; RIFKINSONMANN S, 1988, NEUROSURGERY, V23, P411, DOI 10.1227/00006123-198810000-00001; Rosenthal G, 2014, NEUROSURGERY, V75, P523, DOI 10.1227/NEU.0000000000000477; Sahoo N, 2010, J CRANIOFAC SURG, V21, P79, DOI 10.1097/SCS.0b013e3181c3ba58; Sanan A, 1997, NEUROSURGERY, V40, P588, DOI 10.1097/00006123-199703000-00033; Schirmer CM, 2007, STROKE, V38, P987, DOI 10.1161/01.STR.0000257962.58269.e2; Schoekler B, 2014, CLIN NEUROL NEUROSUR, V120, P64, DOI 10.1016/j.clineuro.2014.02.014; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Shah AM, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13561; STULA D, 1982, J MAXILLOFAC SURG, V10, P142, DOI 10.1016/S0301-0503(82)80030-1; Sundseth J, 2014, ACTA NEUROCHIR, V156, P805, DOI 10.1007/s00701-013-1992-6; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Walcott BP, 2013, J NEUROSURG, V118, P757, DOI 10.3171/2013.1.JNS121626; Whitfield PC, 2001, NEUROSURGERY, V49, P225, DOI 10.1097/00006123-200107000-00042; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Winter CD, 2005, J CLIN NEUROSCI, V12, P619, DOI 10.1016/j.jocn.2005.02.002; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470; Zanaty M, 2015, J NEUROSURG, P1	50	27	27	0	16	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1010-5182	1878-4119		J CRANIO MAXILL SURG	J. Cranio-MaxilloFac. Surg.	SEP	2016	44	9					1266	1272		10.1016/j.jcms.2016.07.005			7	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	DY0GX	WOS:000384776400023	27524384				2021-06-18	
J	Levy, D; Edut, S; Baraz-Goldstein, R; Rubovitch, V; Defrin, R; Bree, D; Gariepy, H; Zhao, J; Pick, CG				Levy, Dan; Edut, Shahaf; Baraz-Goldstein, Renana; Rubovitch, Vardit; Defrin, Ruth; Bree, Dara; Gariepy, Helaine; Zhao, Jun; Pick, Chaim G.			Responses of dural mast cells in concussive and blast models of mild traumatic brain injury in mice: Potential implications for post-traumatic headache	CEPHALALGIA			English	Article						Minimal traumatic brain injury; concussion; blast; mouse; mast cell; dura; posttraumatic headache	COGNITIVE DEFICITS; RECEPTOR AGONISTS; PAIN; MIGRAINE; ACTIVATION; DEGRANULATION; SENSITIZATION; DISRUPTION; MECHANISM; PROTEASES	Background Chronic post-traumatic headache (PTH) is one of the most common symptoms of mild traumatic brain injury (mTBI) but its underlying mechanisms remain unknown. Inflammatory degranulation of dural mast cells (MCs) is thought to promote headache, and may play a role in PTH. Whether mTBI is associated with persistent degranulation of dural MCs is yet to be determined. Methods Histochemistry was used to evaluate time course changes in dural MC density and degranulation level in concussive head trauma and blast mouse models of mTBI. The effects of sumatriptan and the MC stabilizer cromolyn sodium on concussion-evoked dural MC degranulation were also investigated. Results Concussive head injury evoked persistent MC degranulation for at least 30 days. Blast trauma gave rise to a delayed MC degranulation response commencing at seven days that also persisted for at least 30 days. Neither sumatriptan nor cromolyn treatment reduced concussion-evoked persistent MC degranulation. Conclusions mTBI evoked by closed head injury or blast exposure is associated with persistent dural MC degranulation. Such a response in mTBI patients may contribute to PTH. Amelioration of PTH by sumatriptan may not involve inhibition of dural MC degranulation. If persistent dural MC degranulation contributes to PTH, then cromolyn treatment may not be effective.	[Levy, Dan; Bree, Dara; Gariepy, Helaine; Zhao, Jun] Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA; [Levy, Dan; Bree, Dara; Gariepy, Helaine] Harvard Med Sch, Boston, MA USA; [Edut, Shahaf; Baraz-Goldstein, Renana; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Defrin, Ruth] Tel Aviv Univ, Sackler Fac Med, Dept Phys Therapy, IL-69978 Tel Aviv, Israel; [Defrin, Ruth; Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel	Levy, D (corresponding author), Dept Anesthesia Crit Care & Pain Med, 330 Brookline Av DA719, Boston, MA 02215 USA.	dlevy1@bidmc.harvard.edu	Levy, Dan/AAF-1871-2021		NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS077882, NS086830, NS078263]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078263, R21NS077882, R01NS086830] Funding Source: NIH RePORTER	The study was supported by grants from the NIH/NINDS (NS077882, NS086830, NS078263 to DL).	Bankova LG, 2014, J IMMUNOL, V192, P2812, DOI 10.4049/jimmunol.1301794; Benromano T, 2015, EUR J PAIN, V19, P621, DOI 10.1002/ejp.583; BUZZI MG, 1992, BRAIN RES, V583, P137, DOI 10.1016/S0006-8993(10)80017-4; BUZZI MG, 1990, BRIT J PHARMACOL, V99, P202, DOI 10.1111/j.1476-5381.1990.tb14679.x; Defrin R, 2015, J NEUROTRAUM, V32, P28, DOI 10.1089/neu.2014.3359; Defrin R, 2010, EUR J PAIN, V14, P924, DOI 10.1016/j.ejpain.2010.03.004; DiTommaso C, 2014, HEADACHE, V54, P511, DOI 10.1111/head.12254; Ericsson A, 1997, J NEUROSCI, V17, P7166; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Hendrix S, 2013, FASEB J, V27, P920, DOI 10.1096/fj.12-204800; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Karatas H, 2013, SCIENCE, V339, P1092, DOI 10.1126/science.1231897; Keidel M, 2006, HEADACHES, P863; LEDER L-D, 1979, American Journal of Dermatopathology, V1, P39; Levy D, 2004, P NATL ACAD SCI USA, V101, P4274, DOI 10.1073/pnas.0306147101; Levy D, 2007, PAIN, V130, P166, DOI 10.1016/j.pain.2007.03.012; Levy D, 2009, HEADACHE, V49, P953, DOI 10.1111/j.1526-4610.2009.01444.x; Lucas S, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0520-1; Lucas S, 2012, CEPHALALGIA, V32, P600, DOI 10.1177/0333102412445224; Messlinger K, 2009, EXP BRAIN RES, V196, P179, DOI 10.1007/s00221-009-1756-y; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Olesen J, 2009, LANCET NEUROL, V8, P679, DOI 10.1016/S1474-4422(09)70090-0; Pedersen SH, 2015, CEPHALALGIA, V35, P1287, DOI 10.1177/0333102415574846; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Russo AF, 2015, ANNU REV PHARMACOL, V55, P533, DOI 10.1146/annurev-pharmtox-010814-124701; Shimada R, 2012, J CLIN NEUROSCI, V19, P447, DOI 10.1016/j.jocn.2011.06.033; Stokely ME, 2008, J NEUROTRAUM, V25, P52, DOI 10.1089/neu.2007.0397; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Walker WC, 2013, CEPHALALGIA, V33, P998, DOI 10.1177/0333102413482197; Zhang T, 2016, EUR J PHARMACOL, V778, P158, DOI 10.1016/j.ejphar.2015.05.071; Zhang XC, 2007, J PHARMACOL EXP THER, V322, P806, DOI 10.1124/jpet.107.123745; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	35	27	27	0	7	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0333-1024	1468-2982		CEPHALALGIA	Cephalalgia	SEP	2016	36	10					915	923		10.1177/0333102415617412			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DV3XR	WOS:000382859300002	26566937	Green Accepted			2021-06-18	
J	Fino, PC; Nussbaum, MA; Brolinson, PG				Fino, Peter C.; Nussbaum, Maury A.; Brolinson, Per Gunnar			Locomotor deficits in recently concussed athletes and matched controls during single and dual-task turning gait: preliminary results	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article						mTBI; Concussion; Brain injury; Gait; Turning; Dual-task	TRAUMATIC BRAIN-INJURY; STABILITY FOLLOWING CONCUSSION; SPORTS-RELATED CONCUSSION; GOAL-ORIENTED LOCOMOTION; BALANCE CONTROL; HUMAN WALKING; DIVIDED ATTENTION; DYNAMIC STABILITY; CURVED PATHS; HUMANS	Background: There is growing evidence that mild traumatic brain injury (concussion) can affect locomotor characteristics for prolonged periods of time even when physical signs and symptoms are absent. While most locomotor deficits post-concussion have involved straight walking, turning gait has received little attention despite its pervasiveness in everyday locomotion and athletic competition. Methods: This study longitudinally examined kinematic characteristics during preplanned turning in a small sample of recently concussed athletes (n = 4) and healthy matched control athletes (n = 4) to examine potential deficits during single and dual-task turning gait over the initial 6 weeks post-injury, with a one-year follow-up. Turning path kinematics (curvature, obstacle clearance, path length), stride kinematics (stride length, stride width, stride time), and inclination angles were calculated from motion capture of participants walking around an obstacle. Results: Concussed athletes had larger dual-task costs in turning speed and stride time compared to healthy controls. After controlling for speed and turn curvature, recently concussed athletes increased their inclination towards the inside of the turn over time and decreased their stride time compared to controls indicating a prolonged recovery. Kinematic differences between groups were estimated to recover to healthy levels between 100 and 300 days post-injury, suggesting future prospective longitudinal studies should span 6-12 months post-injury. Conclusion: Turning gait should be included in future studies of concussion and may be a clinically useful tool. Future longitudinal studies should consider examining gait changes for up to 6-12 months post-injury.	[Fino, Peter C.] Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,L226, Portland, OR 97239 USA; [Fino, Peter C.; Brolinson, Per Gunnar] Virginia Tech, Dept Mech Engn, Blacksburg, VA 24061 USA; [Nussbaum, Maury A.] Virginia Tech, Dept Ind & Syst Engn, Blacksburg, VA USA; [Brolinson, Per Gunnar] Edward Via Coll Osteopath Med, Blacksburg, VA USA	Fino, PC (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,L226, Portland, OR 97239 USA.; Fino, PC (corresponding author), Virginia Tech, Dept Mech Engn, Blacksburg, VA 24061 USA.	fino@ohsu.edu	Nussbaum, Maury A/A-9655-2008	Nussbaum, Maury A/0000-0002-1887-8431; Fino, Peter/0000-0002-8621-3706	NSF Graduate Research FellowshipNational Science Foundation (NSF) [DGE0822220]; Virginia Tech's Open Access Subvention Fund	PCF was supported by an NSF Graduate Research Fellowship (Grant No. DGE0822220). Opinions and findings do not represent the views of the NSF. Additional support for publication was provided by Virginia Tech's Open Access Subvention Fund.	Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-8; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Chiu SL, 2013, GAIT POSTURE, V38, P717, DOI 10.1016/j.gaitpost.2013.03.010; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Cinelli ME, 2014, PHYSL REP, V2; Cossette I, 2014, ARCH PHYS MED REHAB, V95, P1594, DOI 10.1016/j.apmr.2014.03.019; Courtine G, 2006, EXP BRAIN RES, V170, P320, DOI 10.1007/s00221-005-0215-7; Courtine G, 2003, EUR J NEUROSCI, V18, P191, DOI 10.1046/j.1460-9568.2003.02737.x; Courtine G, 2003, EUR J NEUROSCI, V18, P177, DOI 10.1046/j.1460-9568.2003.02736.x; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; de Leva P, 1996, J BIOMECH, V29, P1223, DOI 10.1016/0021-9290(95)00178-6; Fait P, 2009, BRAIN INJURY, V23, P362, DOI 10.1080/02699050902788485; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Fino P, 2014, J BIOMECH, V47, P1395, DOI 10.1016/j.jbiomech.2014.01.032; Fino PC, 2016, J BIOMECH, V49, P1983, DOI 10.1016/j.jbiomech.2016.05.004; Fino PC, 2015, J BIOMECH, V48, P104, DOI 10.1016/j.jbiomech.2014.10.034; Glaister BC, 2007, J BIOMECH, V40, P3527, DOI 10.1016/j.jbiomech.2007.05.014; Glaister BC, 2007, GAIT POSTURE, V25, P289, DOI 10.1016/j.gaitpost.2006.04.003; Grabiner Mark D, 2005, J Neuroeng Rehabil, V2, P25, DOI 10.1186/1743-0003-2-25; Hewett TE, 2009, BRIT J SPORT MED, V43, P417, DOI 10.1136/bjsm.2009.059162; Hicheur H, 2005, EXP BRAIN RES, V162, P145, DOI 10.1007/s00221-004-2122-8; Hicheur H, 2007, EUR J NEUROSCI, V26, P2376, DOI 10.1111/j.1460-9568.2007.05836.x; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Huxham F, 2006, GAIT POSTURE, V23, P159, DOI 10.1016/j.gaitpost.2005.01.001; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Niechwiej-Szwedo E, 2007, GAIT POSTURE, V25, P70, DOI 10.1016/j.gaitpost.2006.01.002; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Olivier AH, 2007, NEUROSCI LETT, V412, P148, DOI 10.1016/j.neulet.2006.11.005; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pham QC, 2007, EUR J NEUROSCI, V26, P2391, DOI 10.1111/j.1460-9568.2007.05835.x; Powers KC, 2014, GAIT POSTURE, V39, P728, DOI 10.1016/j.gaitpost.2013.10.005; Reed N., 2013, NEUROL NEUROPHYSIOL, V4, P171, DOI DOI 10.4172/2155-9562.1000171; Register-Mihalik JK, 2013, NEUROPSYCHOL REV, V23, P300, DOI 10.1007/s11065-013-9238-1; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Sreenivasa MN, 2008, EXP BRAIN RES, V191, P313, DOI 10.1007/s00221-008-1525-3; Takei Y, 1996, BRAIN RES BULL, V40, P491, DOI 10.1016/0361-9230(96)00147-5; Taylor MJD, 2005, HUM MOVEMENT SCI, V24, P558, DOI 10.1016/j.humov.2005.07.005; Tenenbaum G., 1993, HDB RES SPORT PSYCHO, P171; VIVIANI P, 1985, J EXP PSYCHOL HUMAN, V11, P828, DOI 10.1037/0096-1523.11.6.828; Yamaguchi T, 2013, GAIT POSTURE, V38, P209, DOI 10.1016/j.gaitpost.2012.11.007; Yamaguchi T, 2012, J BIOMECH, V45, P2624, DOI 10.1016/j.jbiomech.2012.08.006; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720	54	27	27	0	17	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1743-0003			J NEUROENG REHABIL	J. NeuroEng. Rehabil.	JUL 25	2016	13								65	10.1186/s12984-016-0177-y			15	Engineering, Biomedical; Neurosciences; Rehabilitation	Engineering; Neurosciences & Neurology; Rehabilitation	DR7QD	WOS:000380093900001	27456969	DOAJ Gold, Green Published			2021-06-18	
J	Aligholi, H; Rezayat, SM; Azari, H; Mehr, SE; Akbari, M; Mousavi, SMM; Attari, F; Alipour, F; Hassanzadeh, G; Gorji, A				Aligholi, Hadi; Rezayat, Seyed Mandi; Azari, Hassan; Mehr, Shahram Ejtemaei; Akbari, Mohammad; Mousavi, Seyed Mostafa Modarres; Attari, Fatemeh; Alipour, Fatemeh; Hassanzadeh, Gholamreza; Gorji, Ali			Preparing neural stem/progenitor cells in PuraMatrix hydrogel for transplantation after brain injury in rats: A comparative methodological study	BRAIN RESEARCH			English	Article						Brain injury; Traumatic brain lesion; Autologous transplantation; Nanoscaffold; Neural tissue engineering	SELF-COMPLEMENTARY OLIGOPEPTIDE; PEPTIDE HYDROGEL; STEM-CELLS; SCAFFOLDS; DIFFERENTIATION; DESIGN; MICROENVIRONMENTS; BIOMATERIALS; PH	Cultivation of neural stem/progenitor cells (NS/PCs) in PuraMatrix (PM) hydrogel is an option for stem cell transplantation. The efficacy of a novel method for placing adult rat NS/PCs in PM (injection method) was compared to encapsulation and surface plating approaches. In addition, the efficacy of injection method for transplantation of autologous NS/PCs was studied in a rat model of brain injury. NS/PCs were obtained from the subventricular zone (SVZ) and cultivated without (control) or with scaffold (three-dimensional cultures; 3D). The effect of different approaches on survival, proliferation, and differentiation of NS/PCs were investigated. In in vivo study, brain injury was induced 45 days after NS/PCs were harvested from the SVZ and phosphate buffered saline, PM, NS/PCs, or PM+NS/PCs were injected into the brain lesion. There was an increase in cell viability and proliferation after injection and surface plating of NS/PCs compared to encapsulation and neural differentiation markers were expressed seven days after culturing the cells. Using injection method, transplantation of NS/PCs cultured in PM resulted in significant reduction of lesion volume, improvement of neurological deficits, and enhancement of surviving cells. In addition, the transplanted cells could differentiate in to neurons, astrocytes, or oligodendrocytes. Our results indicate that the injection and surface plating methods enhanced cell survival and proliferation of NS/PCs and suggest the injection method as a promising approach for transplantation of NS/PCs in brain injury. (C) 2016 Elsevier B.V. All rights reserved.	[Aligholi, Hadi; Mousavi, Seyed Mostafa Modarres; Attari, Fatemeh; Alipour, Fatemeh; Gorji, Ali] Khatam al Anbia Hosp, Shefa Neurosci Res Ctr, Tehran, Iran; [Aligholi, Hadi; Attari, Fatemeh] Univ Tehran Med Sci, Sch Adv Technol Med, Dept Neurosci, Tehran, Iran; [Aligholi, Hadi] Shiraz Univ Med Sci, Sch Adv Med Sci & Technol, Dept Neurosci, Shiraz, Iran; [Rezayat, Seyed Mandi; Mehr, Shahram Ejtemaei] Univ Tehran Med Sci, Sch Med, Dept Pharmacol, Tehran, Iran; [Azari, Hassan] Sch Med, Dept Anat Sci, Neural Stem Cell & Regenerat Neurosci Lab, Shiraz, Iran; [Azari, Hassan] Shiraz Univ Med Sci, Shiraz Stem Cell Inst, Shiraz, Iran; [Akbari, Mohammad; Hassanzadeh, Gholamreza] Univ Tehran Med Sci, Sch Med, Dept Anat, Tehran, Iran; [Gorji, Ali] Mashhad Univ Med Sci, Dept Neurosci, Mashhad, Iran; [Gorji, Ali] Univ Munster, Epilepsy Res Ctr, Dept Neurosurg, D-48149 Munster, Germany; [Gorji, Ali] Univ Munster, Dept Neurol, D-48149 Munster, Germany	Hassanzadeh, G (corresponding author), Univ Tehran Med Sci, Sch Med, Dept Anat, Tehran, Iran.; Gorji, A (corresponding author), Univ Munster, Epilepsy Res Ctr, D-48149 Munster, Germany.	hassanzadeh@tums.ac.ir; gorjial@uni-muenster.de	aligholi, hadi/A-1054-2018; Azari, Hassan/V-6092-2017	aligholi, hadi/0000-0002-2241-5296; Azari, Hassan/0000-0002-8021-3166	Tehran University of Medical Sciences and Health ServicesTehran University of Medical Sciences [11696-87-01-90]; Shefa Neuroscience Research Center [28102]; Iran National Science Foundation (INSF)Iran National Science Foundation (INSF)	We thank Dr. Stjepana Kovac for her critical review of the manuscript. The present study was supported by Tehran University of Medical Sciences and Health Services (Grant no. 11696-87-01-90), Shefa Neuroscience Research Center (Dr. Thesis 28102) and Iran National Science Foundation (INSF).	Aligholi H, 2014, J NEUROSCI METH, V225, P81, DOI 10.1016/j.jneumeth.2013.12.008; Azari Hassan, 2010, J Vis Exp, DOI 10.3791/2393; Azari H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020941; Burdick JA, 2009, TISSUE ENG PT A, V15, P205, DOI 10.1089/ten.tea.2008.0131; Cavalcanti BN, 2013, DENT MATER, V29, P97, DOI 10.1016/j.dental.2012.08.002; Cheng TY, 2013, BIOMATERIALS, V34, P2005, DOI 10.1016/j.biomaterials.2012.11.043; Drury JL, 2003, BIOMATERIALS, V24, P4337, DOI 10.1016/S0142-9612(03)00340-5; FREED LE, 1994, BIO-TECHNOL, V12, P689, DOI 10.1038/nbt0794-689; FROEHLICH JE, 1974, J CELL PHYSIOL, V84, P253, DOI 10.1002/jcp.1040840211; Ghadiri T, 2014, J NEUROSCI METH, V233, P18, DOI 10.1016/j.jneumeth.2014.05.035; Guo JS, 2009, NANOMED-NANOTECHNOL, V5, P345, DOI 10.1016/j.nano.2008.12.001; Hauser CAE, 2010, CHEM SOC REV, V39, P2780, DOI 10.1039/b921448h; Langnaese K, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-53; Liedmann A, 2012, BIORESEARCH OPEN ACC, V1, P16, DOI 10.1089/biores.2012.0209; Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055; Ma, 2005, SCAFFOLDING TISSUE E, P217; Moradi F, 2012, J NEUROSCI RES, V90, P2335, DOI 10.1002/jnr.23120; Nava MM, 2012, BIOMED RES INT, V2012; Ortinau S, 2010, BIOMED ENG ONLINE, V9, DOI 10.1186/1475-925X-9-70; Paxinos G., 2006, RAT BRAIN STEREOTAXI; Peinnequin Andre, 2004, BMC Immunology, V5, P1, DOI 10.1186/1471-2172-5-3; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Shivachar AC, 2008, TOPICS TISSUE ENG, V4; Shrode LD, 1997, J BIOENERG BIOMEMBR, V29, P393, DOI 10.1023/A:1022407116339; Takei J, 2006, AATEX, V11, P170, DOI DOI 10.11232/aatex.11.170; Thonhoff JR, 2008, BRAIN RES, V1187, P42, DOI 10.1016/j.brainres.2007.10.046; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang SF, 2001, TISSUE ENG, V7, P679, DOI 10.1089/107632701753337645; Yang SF, 2002, TISSUE ENG, V8, P1, DOI 10.1089/107632702753503009; Zhang SG, 2005, SEMIN CANCER BIOL, V15, P413, DOI 10.1016/j.semcancer.2005.05.007; ZHANG SG, 1993, P NATL ACAD SCI USA, V90, P3334, DOI 10.1073/pnas.90.8.3334; ZHANG SG, 1995, BIOMATERIALS, V16, P1385, DOI 10.1016/0142-9612(95)96874-Y	32	27	27	0	20	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 1	2016	1642						197	208		10.1016/j.brainres.2016.03.043			12	Neurosciences	Neurosciences & Neurology	DP7EI	WOS:000378661600023	27038753	Bronze			2021-06-18	
J	Sawyer, TW; Wang, YS; Ritzel, DV; Josey, T; Villanueva, M; Shei, YM; Nelson, P; Hennes, G; Weiss, T; Vair, C; Fan, CY; Barnes, J				Sawyer, Thomas W.; Wang, Yushan; Ritzel, David V.; Josey, Tyson; Villanueva, Mercy; Shei, Yimin; Nelson, Peggy; Hennes, Grant; Weiss, Tracy; Vair, Cory; Fan, Changyang; Barnes, Julia			High-Fidelity Simulation of Primary Blast: Direct Effects on the Head	JOURNAL OF NEUROTRAUMA			English	Article						blast; glial fibrillary acidic protein (GFAP); primary blast-induced traumatic brain injury (PbTBI); shockwaves; traumatic brain injury (TBI)	TRAUMATIC BRAIN-INJURY; TIME-DEPENDENT CHANGES; BIOMARKER LEVELS; MOUSE MODEL; EXPOSURE; RAT; OVERPRESSURE; MECHANISM; PATHOLOGY; PROTEIN	The role of primary blast in blast-induced traumatic brain injury (bTBI) is controversial in part due to the technical difficulties of generating free-field blast conditions in the laboratory. The use of traditional shock tubes often results in artifacts, particularly of dynamic pressure, whereas the forces affecting the head are dependent on where the animal is placed relative to the tube, whether the exposure is whole-body or head-only, and on how the head is actually exposed to the insult (restrained or not). An advanced blast simulator (ABS) has been developed that enables high-fidelity simulation of free-field blastwaves, including sharply defined static and dynamic overpressure rise times, underpressures, and secondary shockwaves. Rats were exposed in head-only fashion to single-pulse blastwaves of 15 to 30 psi static overpressure. Head restraints were configured so as to eliminate concussive and minimize whiplash forces exerted on the head, as shown by kinematic analysis. No overt signs of trauma were present in the animals post-exposure. However, significant changes in brain 2',3'-cyclic nucleotide 3'-phosphohydrolase (CNPase) and neurofilament heavy chain levels were evident by 7 days. In contrast to most studies of primary blast-induced TBI (PbTBI), no elevation of glial fibrillary acidic protein (GFAP) levels was noted when head movement was minimized The ABS described in this article enables the generation of shockwaves highly representative of free-field blast. The use of this technology, in concert with head-only exposure, minimized head movement, and the kinematic analysis of the forces exerted on the head provide convincing evidence that primary blast directly causes changes in brain function and that GFAP may not be an appropriate biomarker of PbTBI.	[Sawyer, Thomas W.; Wang, Yushan; Josey, Tyson; Villanueva, Mercy; Shei, Yimin; Nelson, Peggy; Hennes, Grant; Weiss, Tracy; Vair, Cory] Def Res & Dev Canada, Medicine Hat, AB T1A 8K6, Canada; [Ritzel, David V.] Dyn Fx Consulting Ltd, Amherstburg, ON, Canada; [Fan, Changyang; Barnes, Julia] Canada West Biosci, Calgary, AB, Canada	Sawyer, TW (corresponding author), Def Res & Dev Canada, Suffield Res Ctr, Box 4000, Medicine Hat, AB T1A 8K6, Canada.	Thomas.sawyer@drdc-rddc.gc.ca					Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Appelboom G, 2012, ACTA NEUROCHIR, V154, P131, DOI 10.1007/s00701-011-1210-3; Argyros GJ, 1997, TOXICOLOGY, V121, P105, DOI 10.1016/S0300-483X(97)03659-7; Arun P, 2013, NEUROSCI LETT, V552, P87, DOI 10.1016/j.neulet.2013.07.047; Bass R. C., 2006, P PERS ARM SYST S, P233; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Bowen I., 1968, ESTIMATE TOLERANCE D; Cernak I, 2010, MED DATA REV, V2, P297; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Chandra N, 2012, SHOCK WAVES, V22, P403, DOI 10.1007/s00193-012-0399-2; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Chen Y, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00117; CLEMEDSON CJ, 1956, ACTA PHYSIOL SCAND, V37, P202; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Courtney MW, 2011, NEUROIMAGE, V54, pS55, DOI 10.1016/j.neuroimage.2010.05.025; Courtney MW, 2010, REV SCI INSTRUM, V81, DOI 10.1063/1.3518970; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; DREILING CE, 1980, ANAL BIOCHEM, V102, P304, DOI 10.1016/0003-2697(80)90157-8; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guy R J, 2000, J R Nav Med Serv, V86, P27; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Heldt SA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00002; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Mott FW, 1916, LANCET, V1, P331; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Petzold A, 2011, BRAIN, V134, P464, DOI 10.1093/brain/awq360; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Ritzel D. V., 2011, 207 NATO HFM; Romba J., 1961, PROPAGATION AIR SHOC, P17; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Shridharani Jay K, 2012, Front Neurol, V3, P70, DOI 10.3389/fneur.2012.00070; Simard JM, 2014, J NEUROTRAUM, V31, P1292, DOI 10.1089/neu.2013.3016; Skotak M, 2013, J NEUROTRAUM, V30, P1147, DOI 10.1089/neu.2012.2652; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Woods AS, 2013, ACS CHEM NEUROSCI, V4, P594, DOI 10.1021/cn300216h; Yuan AD, 2012, J CELL SCI, V125, P3257, DOI 10.1242/jcs.104729	66	27	27	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2016	33	13					1181	1193		10.1089/neu.2015.3914			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DP2QY	WOS:000378336200384	26582146				2021-06-18	
J	Zakharov, S; Pelclova, D; Urban, P; Navratil, T; Nurieva, O; Kotikova, K; Diblik, P; Kurcova, I; Belacek, J; Komarc, M; Eddleston, M; Hovda, KE				Zakharov, Sergey; Pelclova, Daniela; Urban, Pavel; Navratil, Tomas; Nurieva, Olga; Kotikova, Katerina; Diblik, Pavel; Kurcova, Ivana; Belacek, Jaromir; Komarc, Martin; Eddleston, Michael; Hovda, Knut Erik			Use of Out-of-Hospital Ethanol Administration to Improve Outcome in Mass Methanol Outbreaks	ANNALS OF EMERGENCY MEDICINE			English	Article							ISCHEMIA-REPERFUSION INJURY; TRAUMATIC BRAIN-INJURY; FORMATE CONCENTRATIONS; ADHESIVE INTERACTIONS; CLINICAL-FEATURES; ALCOHOL; MORTALITY; POISONINGS; TOXICITY; DAMAGE	Study objective: Methanol poisoning outbreaks are a global public health issue, with delayed treatment causing poor outcomes. Out-of-hospital ethanol administration may improve outcome, but the difficulty of conducting research in outbreaks has meant that its effects have never been assessed. We study the effect of out-of-hospital ethanol in patients treated during a methanol outbreak in the Czech Republic between 2012 and 2014. Methods: This was an observational case-series study of 100 hospitalized patients with confirmed methanol poisoning. Out-of-hospital ethanol as a "first aid antidote" was administered by paramedic or medical staff before the confirmation of diagnosis to 30 patients; 70 patients did not receive out-of-hospital ethanol from the staff (12 patients self-administered ethanol shortly before presentation). Results: The state of consciousness at first contact with paramedic or medical staff, delay to admission, and serum methanol concentration were similar among groups. The median serum ethanol level on admission in the patients with out-of-hospital administration by paramedic or medical staff was 84.3 mg/dL (interquartile range 32.7 to 129.5 mg/dL). No patients with positive serum ethanol level on admission died compared with 21 with negative serum ethanol level (0% versus 36.2%). Patients receiving out-of-hospital ethanol survived without visual and central nervous system sequelae more often than those not receiving it (90.5% versus 19.0%). A positive association was present between out of-hospital ethanol administration by paramedic or medical staff, serum ethanol concentration on admission, and both total survival and survival without sequelae of poisoning. Conclusion: We found a positive association between out-of-hospital ethanol administration and improved clinical outcome. During mass methanol outbreaks, conscious adults with suspected poisoning should be considered for administration of out-of-hospital ethanol to reduce morbidity and mortality.	[Zakharov, Sergey; Pelclova, Daniela; Urban, Pavel; Navratil, Tomas; Nurieva, Olga; Kotikova, Katerina] Charles Univ Prague, Fac Med 1, Dept Occupat Med, Toxicol Informat Ctr, Prague, Czech Republic; [Kurcova, Ivana] Charles Univ Prague, Fac Med 1, Dept Toxicol & Forens Med, Prague, Czech Republic; [Belacek, Jaromir; Komarc, Martin] Charles Univ Prague, Fac Med 1, Inst Biophys & Informat, Prague, Czech Republic; [Belacek, Jaromir; Komarc, Martin] Gen Univ Hosp, Prague, Czech Republic; [Navratil, Tomas] AS CR, Dept Biomimet Electrochem, J Heyrovsky Inst Phys Chem, Prague, Czech Republic; [Diblik, Pavel] Gen Univ Hosp, Dept Ophthalmol, Prague, Czech Republic; [Eddleston, Michael] Univ Edinburgh, Univ BHF Ctr Cardiovasc Sci, Pharmacol Toxicol & Therapeut, Edinburgh, Midlothian, Scotland; [Hovda, Knut Erik] Oslo Univ Hosp, Dept Acute Med, Norwegian CBRNe Ctr Med, Oslo, Norway	Zakharov, S (corresponding author), Charles Univ Prague, Fac Med 1, Dept Occupat Med, Toxicol Informat Ctr, Prague, Czech Republic.	sergey.zakharov@vfn.cz	Zakharov, Sergey/L-8511-2014; Komarc, Martin/O-2575-2019; Zakharov, Sergey/O-2896-2019; Belacek, Jaromir/AAI-5516-2021; Nurieva, Olga/D-7844-2017; Zacharov, Sergej/C-8946-2017; Pelclova, Daniela/C-8885-2017; Navratil, Tomas/F-4000-2012; Diblik, Pavel/I-2515-2017; Komarc, Martin/A-7308-2017; Belacek, Jaromir/AAM-7404-2021; Urban, Pavel/D-7801-2017; Kotikova, Katerina/D-7852-2017; Zacharov, Sergej/C-8946-2017	Zakharov, Sergey/0000-0001-9864-8304; Komarc, Martin/0000-0003-4106-5217; Zakharov, Sergey/0000-0001-9864-8304; Belacek, Jaromir/0000-0002-5405-9345; Zacharov, Sergej/0000-0003-4480-5460; Pelclova, Daniela/0000-0002-0240-5146; Navratil, Tomas/0000-0003-4633-2601; Diblik, Pavel/0000-0001-9025-8176; Komarc, Martin/0000-0003-4106-5217; Belacek, Jaromir/0000-0002-5405-9345; Urban, Pavel/0000-0002-0898-5524; Kotikova, Katerina/0000-0002-6750-6482; Kotikova, Katerina/0000-0002-6546-3730; Nurieva, Olga/0000-0001-8105-5895; Urban, Pavel/0000-0002-6869-1341; Zacharov, Sergej/0000-0003-0280-9236; Hovda, Knut Erik/0000-0001-6341-8699	Charles University in Prague [P25/1LF/2, P28/1LF/6]; Ministry of Health of the Czech RepublicMinistry of Health, Czech Republic [9/15/NAP]	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist and provided the following details: This study was supported by the Projects of the Charles University in Prague P25/1LF/2 and P28/1LF/6, and the Project of the Ministry of Health of the Czech Republic 9/15/NAP.	Ahmad K, 2000, LANCET, V356, P1911, DOI 10.1016/S0140-6736(05)73469-3; Barceloux DG, 2002, J TOXICOL-CLIN TOXIC, V40, P415; BENNETT IL, 1953, MEDICINE, V32, P431, DOI 10.1097/00005792-195312000-00002; BERGERON R, 1982, NEW ENGL J MED, V307, P1528; Bezdicek O, 2014, CESK SLOV NEUROL N, V77, P320; Blondell RD, 2002, J STUD ALCOHOL, V63, P380, DOI 10.15288/jsa.2002.63.380; Brent J, 2001, NEW ENGL J MED, V344, P424, DOI 10.1056/NEJM200102083440605; Chen CH, 2008, SCIENCE, V321, P1493, DOI 10.1126/science.1158554; Churchill EN, 2009, J MOL CELL CARDIOL, V46, P278, DOI 10.1016/j.yjmcc.2008.09.713; Collins MA, 2009, ALCOHOL CLIN EXP RES, V33, P206, DOI 10.1111/j.1530-0277.2008.00828.x; Eltzschig HK, 2004, BRIT MED BULL, V70, P71, DOI 10.1093/bmb/ldh025; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Friedman LS, 2012, ALCOHOL, V46, P769, DOI 10.1016/j.alcohol.2012.08.006; Hantson P, 2002, Eur J Emerg Med, V9, P278, DOI 10.1097/00063110-200209000-00015; Hovda KE, 2005, J INTERN MED, V258, P181, DOI 10.1111/j.1365-2796.2005.01521.x; Hovda KE, 2004, INTENS CARE MED, V30, P1842, DOI 10.1007/s00134-004-2373-7; JACOBSEN D, 1982, ACTA MED SCAND, V212, P5; JACOBSEN D, 1986, MED TOXICOL ADV DRUG, V1, P309, DOI 10.1007/BF03259846; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Kumar S S, 2003, J Assoc Physicians India, V51, P425; LIESIVUORI J, 1991, PHARMACOL TOXICOL, V69, P157, DOI 10.1111/j.1600-0773.1991.tb01290.x; Louboutin JP, 2012, ALCOHOL, V46, P441, DOI 10.1016/j.alcohol.2012.02.001; Megarbane B, 2005, INTENS CARE MED, V31, P189, DOI 10.1007/s00134-004-2521-0; Megarbane B, 2010, OPEN ACCESS EMERG M, V2, P67, DOI 10.2147/OAEM.S5346; Miyamae M, 1998, AM J PHYSIOL-HEART C, V275, pH50; Miyamae M, 1997, P NATL ACAD SCI USA, V94, P3235, DOI 10.1073/pnas.94.7.3235; Nurieva O, 2016, MONATSH CHEM, V147, P239; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; OSTERLOH JD, 1986, ANN INTERN MED, V104, P200, DOI 10.7326/0003-4819-104-2-200; Paasma R, 2007, CLIN TOXICOL, V45, P152, DOI 10.1080/15563650600956329; Pagel PS, 2002, ANESTH ANALG, V94, P841, DOI 10.1097/00000539-200204000-00012; Roberts DM, 2015, CRIT CARE MED, V43, P461, DOI 10.1097/CCM.0000000000000708; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; SEJERSTED OM, 1983, ACTA MED SCAND, V213, P105; Stehman CR, 2015, J CRIT CARE, V30, P1382, DOI 10.1016/j.jcrc.2015.08.023; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; Wang Q, 2007, FREE RADICAL BIO MED, V43, P1048, DOI 10.1016/j.freeradbiomed.2007.06.018; Wang Q, 2010, MICROCIRCULATION, V17, P427, DOI 10.1111/j.1549-8719.2010.00041.x; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; Yaghoubian A, 2009, AM SURGEON, V75, P950; Yamaguchi T, 2003, FREE RADICAL BIO MED, V34, P365, DOI 10.1016/S0891-5849(02)01292-3; Yamaguchi T, 2002, AM J PHYSIOL-HEART C, V283, pH1019, DOI 10.1152/ajpheart.00173.2002; Yuan Q, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025811; Zakharov S, 2016, MONATSH CHEM, V147, P251, DOI 10.1007/s00706-015-1581-x; Zakharov S, 2015, BIOMED PAP, V159, P666, DOI 10.5507/bp.2015.008; Zakharov S, 2015, CLIN TOXICOL, V53, P884, DOI 10.3109/15563650.2015.1086488; Zakharov S, 2015, CLIN TOXICOL, V53, P797, DOI 10.3109/15563650.2015.1059946; Zakharov S, 2015, MONATSH CHEM, V146, P787, DOI 10.1007/s00706-014-1374-7; Zakharov S, 2015, BASIC CLIN PHARMACOL, V116, P445, DOI 10.1111/bcpt.12338; Zakharov S, 2014, BIOMED PAP, V158, P641, DOI 10.5507/bp.2014.056; Zakharov S, 2014, CLIN TOXICOL, V52, P1013, DOI 10.3109/15563650.2014.974106; Zakharov S, 2014, J APPL BIOMED, V12, P309, DOI 10.1016/j.jab.2014.04.001; Zakharov S, 2014, KIDNEY INT, V86, P199, DOI 10.1038/ki.2014.60; Zhang G, 2012, APPL INCLUDE FOMEPIZ	54	27	27	4	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JUL	2016	68	1					52	61		10.1016/j.annemergmed.2016.01.010			10	Emergency Medicine	Emergency Medicine	DQ1SF	WOS:000378980000012	26875060				2021-06-18	
J	Cacialli, P; Gueguen, MM; Coumailleau, P; D'Angelo, L; Kah, O; Lucini, C; Pellegrini, E				Cacialli, Pietro; Gueguen, Marie-Madeleine; Coumailleau, Pascal; D'Angelo, Livia; Kah, Olivier; Lucini, Carla; Pellegrini, Elisabeth			BDNF Expression in Larval and Adult Zebrafish Brain: Distribution and Cell Identification	PLOS ONE			English	Article							FACTOR MESSENGER-RNA; NEUROTROPHIC FACTOR BDNF; SEX STEROID-HORMONES; RADIAL GLIAL-CELLS; NERVOUS-SYSTEM; TELEOST FISH; NEUROGENESIS; NEURONS; PROTEIN; MODELS	Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family, has emerged as an active mediator in many essential functions in the central nervous system of mammals. BDNF plays significant roles in neurogenesis, neuronal maturation and/or synaptic plasticity and is involved in cognitive functions such as learning and memory. Despite the vast literature present in mammals, studies devoted to BDNF in the brain of other animal models are scarse. Zebrafish is a teleost fish widely known for developmental genetic studies and is emerging as model for translational neuroscience research. In addition, its brain shows many sites of adult neurogenesis allowing higher regenerative properties after traumatic injuries. To add further knowledge on neurotrophic factors in vertebrate brain models, we decided to determine the distribution of bdnf mRNAs in the larval and adult zebrafish brain and to characterize the phenotype of cells expressing bdnf mRNAs by means of double staining studies. Our results showed that bdnf mRNAs were widely expressed in the brain of 7 days old larvae and throughout the whole brain of mature female and male zebrafish. In adults, bdnf mRNAs were mainly observed in the dorsal telencephalon, preoptic area, dorsal thalamus, posterior tuberculum, hypothalamus, synencephalon, optic tectum and medulla oblongata. By combining immunohistochemistry with in situ hybridization, we showed that bdnf mRNAs were never expressed by radial glial cells or proliferating cells. By contrast, bdnf transcripts were expressed in cells with neuronal phenotype in all brain regions investigated. Our results provide the first demonstration that the brain of zebrafish expresses bdnf mRNAs in neurons and open new fields of research on the role of the BDNF factor in brain mechanisms in normal and brain repairs situations.	[Cacialli, Pietro; Gueguen, Marie-Madeleine; Coumailleau, Pascal; Kah, Olivier; Pellegrini, Elisabeth] Univ Rennes 1, Res Inst Hlth Environm & Occupat IRSET, INSERM U1085, Rennes, France; [Cacialli, Pietro; D'Angelo, Livia; Lucini, Carla] Univ Naples Federico II, Dept Vet Med & Anim Prod, Naples, Italy	Pellegrini, E (corresponding author), Univ Rennes 1, Res Inst Hlth Environm & Occupat IRSET, INSERM U1085, Rennes, France.; Lucini, C (corresponding author), Univ Naples Federico II, Dept Vet Med & Anim Prod, Naples, Italy.	elisabeth.pellegrini@univ-rennes1.fr; carla.lucini@unina.it	cacialli, pietro/AAO-1662-2020; Lucini, Carla/E-6828-2013; Pellegrini, Elisabeth/K-1705-2015; kah, olivier/K-7624-2012	cacialli, pietro/0000-0003-1250-0793; Lucini, Carla/0000-0003-2216-6338; Pellegrini, Elisabeth/0000-0003-4821-0966; 	University of Rennes 1, Inserm; European Trans Channel Neuroscience Network Program (TC2N); INSERM (France)Institut National de la Sante et de la Recherche Medicale (Inserm); University of Rennes 1 (France)	This work was supported by the University of Rennes 1, Inserm, and the European Trans Channel Neuroscience Network Program (TC2N).; We greatly appreciate the help of the staff of the zebrafish Biosit facility (Laboratoire de Physiologie et Genetique des Poissons, INRA, Rennes). We thank Colette Vaillant-Capitaine, Prof. Paolo de Girolamo and Prof. Luciana Castaldo for reading the manuscript. We are thankful for INSERM and University of Rennes 1 (France) for funding our research. The European Trans Channel Neuroscience Network Program (TC2N) supported this research.	Adolf B, 2006, DEV BIOL, V295, P278, DOI 10.1016/j.ydbio.2006.03.023; Aid T, 2007, J NEUROSCI RES, V85, P525, DOI 10.1002/jnr.21139; Babin PJ, 2014, PROG NEUROBIOL, V118, P36, DOI 10.1016/j.pneurobio.2014.03.001; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Barbosa JS, 2015, SCIENCE, V348, P789, DOI 10.1126/science.aaa2729; Boyd JG, 2002, EUR J NEUROSCI, V15, P613, DOI 10.1046/j.1460-9568.2002.01891.x; Brenowitz EA, 2013, NEUROSCIENCE, V239, P115, DOI 10.1016/j.neuroscience.2012.09.023; Burbach GJ, 2004, J NEUROSCI, V24, P2421, DOI 10.1523/JNEUROSCI.5599-03.2004; Carbone DL, 2013, NEUROSCIENCE, V239, P295, DOI 10.1016/j.neuroscience.2012.10.073; Carter AR, 2003, MOL CELL NEUROSCI, V22, P1, DOI 10.1016/S1044-7431(02)00015-5; CASTREN E, 1995, NEUROSCIENCE, V64, P71, DOI 10.1016/0306-4522(94)00386-J; Chan JP, 2008, MOL CELL NEUROSCI, V39, P372, DOI 10.1016/j.mcn.2008.07.017; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Chapouton P, 2007, BIOESSAYS, V29, P745, DOI 10.1002/bies.20615; Cohen-Cory S, 2010, DEV NEUROBIOL, V70, P271, DOI 10.1002/dneu.20774; Conner JM, 1997, J NEUROSCI, V17, P2295; CONOVER JC, 1995, NATURE, V375, P235, DOI 10.1038/375235a0; Cosgaya JM, 2002, SCIENCE, V298, P1245, DOI 10.1126/science.1076595; Coumailleau P, 2014, J NEUROENDOCRINOL, V26, P226, DOI 10.1111/jne.12142; Coumailleau P, 2015, GEN COMP ENDOCR, V221, P203, DOI 10.1016/j.ygcen.2015.08.008; D'Angelo L, 2014, J COMP NEUROL, V522, P1004, DOI 10.1002/cne.23457; Dalton VS, 2009, BRAIN BEHAV EVOLUT, V73, P43, DOI 10.1159/000204962; De Felice E, 2014, J ANAT, V224, P564, DOI 10.1111/joa.12168; Diotel N, 2015, MAPPING OF BRAIN LIP, DOI [10.1016/j.gep.2015.11.003, DOI 10.1016/J.GEP.2015.11.003]; Diotel N, 2013, HORM BEHAV, V63, P193, DOI 10.1016/j.yhbeh.2012.04.003; Diotel N, 2010, J COMP NEUROL, V518, P4855, DOI 10.1002/cne.22492; Diotel N, 2010, FRONT NEUROENDOCRIN, V31, P172, DOI 10.1016/j.yfrne.2010.01.003; Duprey-Diaz MV, 2002, J COMP NEUROL, V454, P456, DOI 10.1002/cne.10451; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; Fonseka TM, 2016, J NEUROSCI RES, V94, P3, DOI 10.1002/jnr.23639; Forlano PM, 2001, J NEUROSCI, V21, P8943, DOI 10.1523/JNEUROSCI.21-22-08943.2001; Fumagalli F, 2006, PHARMACOGENOMICS J, V6, P8, DOI 10.1038/sj.tpj.6500337; Galvao RP, 2008, J NEUROSCI, V28, P13368, DOI 10.1523/JNEUROSCI.2918-08.2008; Ganz J, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a019018; Grandel H, 2006, DEV BIOL, V295, P263, DOI 10.1016/j.ydbio.2006.03.040; Heinrich G, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-19; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hill RA, 2012, J NEUROENDOCRINOL, V24, P1553, DOI 10.1111/j.1365-2826.2012.02365.x; Hill RA, 2012, J NEUROENDOCRINOL, V24, P774, DOI 10.1111/j.1365-2826.2012.02277.x; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Ilieva M, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00266; IP NY, 1993, J NEUROSCI, V13, P3394; Janke C, 2010, TRENDS NEUROSCI, V33, P362, DOI 10.1016/j.tins.2010.05.001; KatohSemba R, 1997, J NEUROCHEM, V69, P34; Kidane AH, 2009, ENDOCRINOLOGY, V150, P1361, DOI 10.1210/en.2008-0993; Kim CH, 1996, NEUROSCI LETT, V216, P109, DOI 10.1016/0304-3940(96)13021-4; Kim JY, 2016, STEM CELLS, V34, P888, DOI 10.1002/stem.2276; Kroehne V, 2011, DEVELOPMENT, V138, P4831, DOI 10.1242/dev.072587; Lee J, 2002, J NEUROCHEM, V82, P1367, DOI 10.1046/j.1471-4159.2002.01085.x; Lindholm D, 1996, EUR J NEUROSCI, V8, P1452, DOI 10.1111/j.1460-9568.1996.tb01607.x; Marz M, 2010, GLIA, V58, P870, DOI 10.1002/glia.20971; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; Martin-Jimenez R, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0555-z; Menuet A, 2005, J COMP NEUROL, V485, P304, DOI 10.1002/cne.20497; Miyamoto N, 2015, J NEUROSCI, V35, P14002, DOI 10.1523/JNEUROSCI.1592-15.2015; Mueller T, 2005, AMERICAN JOURNAL OF; Mueller T, 2011, BRAIN RES, V1381, P95, DOI 10.1016/j.brainres.2010.12.089; Murer MG, 1999, NEUROSCIENCE, V88, P1015, DOI 10.1016/S0306-4522(98)00219-X; Newman M, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00189; Nieuwenhuys R, 2009, BRAIN BEHAV EVOLUT, V74, P77, DOI 10.1159/000229014; Northcutt RG, 2011, BRAIN BEHAV EVOLUT, V78, P136, DOI 10.1159/000330830; Pellegrini E, 2007, J COMP NEUROL, V501, P150, DOI 10.1002/cne.21222; Pencea V, 2001, J NEUROSCI, V21, P6706; Peng S, 2009, J NEUROSCI, V29, P9321, DOI 10.1523/JNEUROSCI.4736-08.2009; Preston MA, 2015, GLIA, V63, P177, DOI 10.1002/glia.22755; Quartu M, 2010, BRAIN RES, V1363, P49, DOI 10.1016/j.brainres.2010.09.106; Rattiner LM, 2004, J NEUROSCI, V24, P4796, DOI 10.1523/JNEUROSCI.5654-03.2004; Rostami E, 2014, BRAIN RES, V1542, P195, DOI 10.1016/j.brainres.2013.10.047; Rupp B, 1996, ANAT EMBRYOL, V194, P187; Sambataro F, 2010, MOL PSYCHIATR, V15, P116, DOI 10.1038/mp.2009.64; Scharfman H, 2005, EXP NEUROL, V192, P348, DOI 10.1016/j.expneurol.2004.11.016; SchmidtKastner R, 1996, NEUROSCIENCE, V74, P161, DOI 10.1016/0306-4522(96)00093-0; Skaggs K, 2014, GLIA, V62, P2061, DOI 10.1002/glia.22726; Stewart AM, 2014, TRENDS NEUROSCI, V37, P264, DOI 10.1016/j.tins.2014.02.011; Stewart AM, 2014, PROG NEURO-PSYCHOPH, V50, P27, DOI 10.1016/j.pnpbp.2013.11.014; Tang YP, 2013, NEUROSCIENCE, V250, P578, DOI 10.1016/j.neuroscience.2013.07.062; Tang YP, 2016, J COMP NEUROL, V524, P1081, DOI 10.1002/cne.23893; Tang YP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043687; Tao X, 2002, NEURON, V33, P383, DOI 10.1016/S0896-6273(01)00561-X; Tettamanti G, 2010, GENE, V450, P85, DOI 10.1016/j.gene.2009.07.023; Tokumine J, 2003, J NEUROSCI RES, V74, P552, DOI 10.1002/jnr.10760; Vissio PG, 2008, TISSUE CELL, V40, P261, DOI 10.1016/j.tice.2008.01.001; von Bohlen O, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00036; Wang LC, 2005, ANN NY ACAD SCI, V1040, P512, DOI 10.1196/annals.1327.106; Wang YP, 2014, NEUROREPORT, V25, P954, DOI 10.1097/WNR.0000000000000219; WETMORE C, 1990, EXP NEUROL, V109, P141, DOI 10.1016/0014-4886(90)90068-4; Yamada K, 2002, LIFE SCI, V70, P735, DOI 10.1016/S0024-3205(01)01461-8; Yan Q, 1997, NEUROSCIENCE, V78, P431, DOI 10.1016/S0306-4522(96)00613-6; Zhang F, 2012, J CLIN NEUROSCI, V19, P946, DOI 10.1016/j.jocn.2011.12.022; Zhu BF, 2008, PLOS BIOL, V6, P2476, DOI 10.1371/journal.pbio.0060284; Zigova T, 1998, MOL CELL NEUROSCI, V11, P234, DOI 10.1006/mcne.1998.0684; Zupanc GKH, 2001, BRAIN BEHAV EVOLUT, V58, P250, DOI 10.1159/000057569	93	27	27	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2016	11	6							e0158057	10.1371/journal.pone.0158057			22	Multidisciplinary Sciences	Science & Technology - Other Topics	DP3JL	WOS:000378389200099	27336917	DOAJ Gold, Green Published			2021-06-18	
J	Shetty, VS; Reis, MN; Aulino, JM; Berger, KL; Broder, J; Choudhri, AF; Kendi, AT; Kessler, MM; Kirsch, CF; Luttrull, MD; Mechtler, LL; Prall, JA; Raksin, PB; Roth, CJ; Sharma, A; West, OC; Wintermark, M; Cornelius, RS; Bykowski, J				Shetty, Vilaas S.; Reis, Martin N.; Aulino, Joseph M.; Berger, Kevin L.; Broder, Joshua; Choudhri, Asim F.; Kendi, A. Tuba; Kessler, Marcus M.; Kirsch, Claudia F.; Luttrull, Michael D.; Mechtler, Laszlo L.; Prall, J. Adair; Raksin, Patricia B.; Roth, Christopher J.; Sharma, Aseem; West, O. Clark; Wintermark, Max; Cornelius, Rebecca S.; Bykowski, Julie			ACR Appropriateness Criteria Head Trauma	JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY			English	Article						Appropriateness Criteria; head trauma; traumatic brain injury; vascular; cerebrospinal fluid leak; neuroimaging	COMPUTED TOMOGRAPHIC ANGIOGRAPHY; NEW-ORLEANS CRITERIA; BRAIN-INJURY; TECHNETIUM-99M-HMPAO SPECT; MILD; CT; MANAGEMENT; VALIDATION; GUIDELINES; RULE	Neuroimaging plays an important role in the management of head trauma. Several guidelines have been published for identifying which patients can avoid neuroimaging. Noncontrast head CT is the most appropriate initial examination in patients with minor or mild acute, closed head injury who require neuroimaging as well as patients with moderate to severe acute closed head injury. In short-term follow-up neuroimaging of acute traumatic brain injury, CT and MRI may have complementary roles. In subacute to chronic traumatic brain injury, MRI is the most appropriate initial examination, though CT may have a complementary role in select circumstances. Advanced neuroimaging techniques are areas of active research but are not considered routine clinical practice at this time. In suspected intracranial vascular injury, CT angiography or venography or MR angiography or venography is the most appropriate imaging study. In suspected posttraumatic cerebrospinal fluid leak, high-resolution noncontrast skull base CT is the most appropriate initial imaging study to identify the source, with cisternography reserved for problem solving. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every three years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.	[Shetty, Vilaas S.] St Louis Univ Hosp, 3635 Vista Ave, St Louis, MO 63110 USA; [Reis, Martin N.] St Louis Univ, Sch Med, St Louis, MO USA; [Aulino, Joseph M.] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA; [Berger, Kevin L.] Chesapeake Med Imaging, Annapolis, MD USA; [Broder, Joshua] Duke Univ, Div Emergency Med, Cary, NC USA; [Broder, Joshua] Amer Coll Emergency Phys, Irving, TX USA; [Choudhri, Asim F.] Univ Tennessee, Ctr Hlth Sci, Le Bonheur Childrens Hosp, Memphis, TN 38163 USA; [Kendi, A. Tuba] Emory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA; [Kessler, Marcus M.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA; [Kirsch, Claudia F.; Luttrull, Michael D.] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA; [Mechtler, Laszlo L.] Dent Neurol Inst, Amherst, NY USA; [Mechtler, Laszlo L.] Amer Acad Neurol, Vancouver, BC, Canada; [Prall, J. Adair] Litdeton Adventist Hosp, Littleton, CO USA; [Raksin, Patricia B.] Rush Univ, Chicago, IL 60612 USA; [Roth, Christopher J.] Duke Univ, Med Ctr, Durham, NC USA; [Sharma, Aseem] Washington Univ, Med Ctr, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA; [West, O. Clark] Univ Texas Houston, Houston, TX USA; [Wintermark, Max] Stanford Med Ctr, Stanford, CA USA; [Cornelius, Rebecca S.] Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA; [Bykowski, Julie] Univ Calif San Diego, Ctr Hlth, San Diego, CA 92103 USA	Shetty, VS (corresponding author), St Louis Univ Hosp, 3635 Vista Ave, St Louis, MO 63110 USA.	vshetty@slu.edu	Roth, Christopher/L-3395-2016	Roth, Christopher/0000-0002-9634-7126			Almandoz JED, 2010, RADIOLOGY, V255, P570, DOI 10.1148/radiol.10091565; American College of Radiology, ACR APPR CRIT CLIN C; American College of Radiology, ACRAPPROPRIATENESS C; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Baugnon KL, 2014, NEUROIMAG CLIN N AM, V24, P439, DOI 10.1016/j.nic.2014.03.001; Bell RB, 2004, J ORAL MAXIL SURG, V62, P676, DOI 10.1016/j.joms.2003.08.032; Biffl WL, 2006, J TRAUMA, V60, P745, DOI 10.1097/01.ta.0000204034.94034.c4; Bousser MG, 2007, LANCET NEUROL, V6, P162, DOI 10.1016/S1474-4422(07)70029-7; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Eastman AL, 2006, J TRAUMA, V60, P925, DOI 10.1097/01.ta.0000197479.28714.62; Fiser SM, 1998, AM SURGEON, V64, P1088; Garnett MR, 2001, J NEUROTRAUM, V18, P585, DOI 10.1089/089771501750291828; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Haydel MJ, 2005, JAMA-J AM MED ASSOC, V294, P1551, DOI 10.1001/jama.294.12.1551; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; ICHISE M, 1994, J NUCL MED, V35, P217; JACOBS A, 1994, J NUCL MED, V35, P942; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jantzen KJ, 2010, J HEAD TRAUMA REHAB, V25, P256, DOI 10.1097/HTR.0b013e3181e5477c; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Khandelwal N, 2006, AM J ROENTGENOL, V187, P1637, DOI 10.2214/AJR.05.1249; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; Kinuya K, 2004, NUCL MED COMMUN, V25, P333, DOI 10.1097/00006231-200404000-00004; LANG DA, 1991, ACTA NEUROCHIR, V109, P5, DOI 10.1007/BF01405689; Manolakaki D, 2009, J TRAUMA, V66, P1008, DOI 10.1097/TA.0b013e31819adba2; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Metting Z, 2009, ANN NEUROL, V66, P809, DOI 10.1002/ana.21785; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; National Collaborating Centre for Acute Care (UK), 2007, HEAD INJ TRIAG ASS I; Patterson BO, 2012, BRIT J SURG, V99, P494, DOI 10.1002/bjs.7763; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Reinus WR, 1996, INVEST RADIOL, V31, P101, DOI 10.1097/00004424-199602000-00007; Reljic T, 2014, J NEUROTRAUM, V31, P78, DOI 10.1089/neu.2013.2873; Rice Dale H, 2003, Curr Opin Otolaryngol Head Neck Surg, V11, P19, DOI 10.1097/00020840-200302000-00004; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Shutter L, 2006, J HEAD TRAUMA REHAB, V21, P334, DOI 10.1097/00001199-200607000-00005; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, RADIOLOGY, V245, P831, DOI 10.1148/radiol.2452061509; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stone JA, 1999, AM J NEURORADIOL, V20, P706; Tavender EJ, 2011, ACAD EMERG MED, V18, P880, DOI 10.1111/j.1553-2712.2011.01134.x; TEASDALE G, 1974, LANCET, V2, P81; Wang X, 2014, NEUROL SCI, V35, P1533, DOI 10.1007/s10072-014-1788-3; Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092; Wei SC, 2010, AM J NEURORADIOL, V31, P334, DOI 10.3174/ajnr.A1824; Wintermark M, 2015, AJNR Am J Neuroradiol, V36, pE1, DOI 10.3174/ajnr.A4181; Wintermark Max, 2015, J Am Coll Radiol, V12, pe1, DOI 10.1016/j.jacr.2014.10.014; Yilmazlar S, 2006, NEUROSURG REV, V29, P64, DOI 10.1007/s10143-005-0396-3; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zacharia TT, 2010, EMERG RADIOL, V17, P97, DOI 10.1007/s10140-009-0842-6; Zapalac JS, 2002, OTOLARYNG HEAD NECK, V126, P669, DOI 10.1067/mhn.2002.125755	65	27	27	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1546-1440			J AM COLL RADIOL	J. Am. Coll. Radiol.	JUN	2016	13	6					668	679		10.1016/j.jacr.2016.02.023			12	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	DN4QY	WOS:000377053500016	27262056				2021-06-18	
J	Iorio-Morin, C; Blanchard, J; Richer, M; Mathieu, D				Iorio-Morin, Christian; Blanchard, Jocelyn; Richer, Maxime; Mathieu, David			Tranexamic Acid in Chronic Subdural Hematomas (TRACS): study protocol for a randomized controlled trial	TRIALS			English	Article						Tranexamic acid; Cyklokapron; Conservative management; Medical management; Traumatic; Non-traumatic; Chronic subdural hematoma	TRAUMATIC BRAIN-INJURY; RECURRENCE; MANAGEMENT; RESOLUTION; ETIZOLAM	Background: Chronic subdural hematoma (CSDH) is one of the most frequent reason for cranial neurosurgical consultation. There is no widely accepted medical treatment for this condition. Herein, we present the protocol for the Tranexamic Acid (TXA) in Chronic Subdural Hematomas (TRACS) trial aiming at determining whether TXA can increase the rate of CSDH resolution following conservative management, lower the number of required surgical procedures and decrease the rate of CSDH recurrence following surgical evacuation. Methods: TRACS is a multicenter, double-blind, randomized, parallel-design, placebo-controlled, phase IIB study designed to provide preliminary efficacy data as well as feasibility, safety and incidence data required to plan a larger definitive phase III trial. Consecutive patients presenting with a diagnosis of chronic subdural hematoma will be screened for eligibility. Exclusion criteria include: specific risk factors for thromboembolic disease, anticoagulant use or contraindication to TXA. A total of 130 patients will be randomized to receive either 750 mg of TXA daily or placebo until complete radiological resolution of the CSDH or for a maximum of 20 weeks. CSDH volume will be measured on serial computed tomography (CT) scanning. Cognitive function tests, quality of life questionnaires as well as functional autonomy assessments will be performed at enrollment, at 10 weeks following randomization and at 3 months following treatment cessation. During the treatment period, patients will undergo standard CSDH management with surgery being performed at the discretion of the treating physician. If surgery is performed, the CSDH and its outer membrane will be sampled for in vitro analysis. The primary outcome is the rate of CSDH resolution by 20 weeks without intervening unplanned surgical procedure. Secondary outcomes include: CSDH volume, incidence of surgical evacuation procedures, CSDH recurrence, cognitive functions, functional autonomy, quality of life, incidence of complications and length of hospital stay. Planned subgroup analyses will be performed for conservatively versus surgically managed subjects and highly versus poorly vascularized CSDH. Discussion: CSDH is a frequent morbidity for which an effective medical treatment has yet to be discovered. The TRACS trial will be the first prospective study of TXA for CSDH.	[Iorio-Morin, Christian; Blanchard, Jocelyn; Mathieu, David] Univ Sherbrooke, Ctr Hosp, Dept Surg, Div Neurosurg, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada; [Richer, Maxime] Univ Sherbrooke, Ctr Hosp, Dept Pathol, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada; [Mathieu, David] CHU Sherbrooke, Ctr Rech, Sherbrooke, PQ J1H 5N4, Canada	Iorio-Morin, C (corresponding author), Univ Sherbrooke, Ctr Hosp, Dept Surg, Div Neurosurg, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	christian.iorio-morin@usherbrooke.ca	Iorio-Morin, Christian/I-8696-2019	Iorio-Morin, Christian/0000-0003-2995-7255	Fonds de recherche du Quebec - Sante (FRQS)Fonds de la Recherche en Sante du Quebec	CI-M receives an MD-PhD scholarship from the Fonds de recherche du Quebec - Sante (FRQS). The other authors receive no funding relative to the TRACS trial. Funding for the study is detailed in the Financial support section.	Almenawer SA, 2014, ANN SURG, V259, P449, DOI 10.1097/SLA.0000000000000255; Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583; Devlin NJ, 2013, EUR J HEALTH ECON, V14, pS1, DOI 10.1007/s10198-013-0502-3; Dewan Y, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-87; Henry DA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001886.pub4; Hirashima Y, 2005, NEUROL MED-CHIR, V45, P621, DOI 10.2176/nmc.45.621; Hirashima Y, 2002, NEUROL MED-CHIR, V42, P53, DOI 10.2176/nmc.42.53; HIRASIMA Y, 1994, ACTA NEUROCHIR, V129, P20, DOI 10.1007/BF01400868; Horikoshi T, 1998, NEUROL MED-CHIR, V38, P527, DOI 10.2176/nmc.38.527; Ismail Z, 2013, CAN GERIATR J, V16, P54, DOI 10.5770/cgj.16.81; Kageyama H, 2013, J NEUROSURG, V119, P332, DOI 10.3171/2013.3.JNS122162; Ker K, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3054; KUDO H, 1992, Neurologia Medico-Chirurgica, V32, P207, DOI 10.2176/nmc.32.207; LABADIE EL, 1975, NEUROLOGY, V25, P669, DOI 10.1212/WNL.25.7.669; Levy JH, 2010, ANESTH ANALG, V110, P1271, DOI 10.1213/ANE.0b013e3181d7ac98; Lim Dong-Jun, 1995, Journal of Korean Medical Science, V10, P373; Oh HJ, 2010, J KOREAN NEUROSURG S, V48, P518, DOI 10.3340/jkns.2010.48.6.518; Perel P, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16130; Sambasivan M, 1997, SURG NEUROL, V47, P418, DOI 10.1016/S0090-3019(97)00188-2; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Stanisic M, 2012, ACTA NEUROCHIR, V154, P113, DOI 10.1007/s00701-011-1203-2; Vujkovac B, 2000, NEPHROL DIAL TRANSPL, V15, P107, DOI 10.1093/ndt/15.1.107; Weigel R, 2007, NEUROSURGERY, V61, P788, DOI 10.1227/01.NEU.0000298907.56012.E8; Wellington K, 2003, DRUGS, V63, P1417, DOI 10.2165/00003495-200363130-00008; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Yang M, 2014, J AM MED DIR ASSOC, V15	27	27	28	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1745-6215			TRIALS	Trials	MAY 5	2016	17								235	10.1186/s13063-016-1358-5			11	Medicine, Research & Experimental	Research & Experimental Medicine	DL0SD	WOS:000375342000001	27150916	DOAJ Gold, Green Published			2021-06-18	
J	Gupta, D; Sharma, D; Kannan, N; Prapruettham, S; Mock, C; Wang, J; Qiu, Q; Pandey, RM; Mahapatra, A; Dash, HH; Hecker, JG; Rivara, FP; Rowhani-Rahbar, A; Vavilala, MS				Gupta, Deepak; Sharma, Deepak; Kannan, Nithya; Prapruettham, Suchada; Mock, Charles; Wang, Jin; Qiu, Qian; Pandey, Ravindra M.; Mahapatra, Ashok; Dash, Hari Har; Hecker, James G.; Rivara, Frederick P.; Rowhani-Rahbar, Ali; Vavilala, Monica S.			Guideline Adherence and Outcomes in Severe Adult Traumatic Brain Injury for the CHIRAG (Collaborative Head Injury and Guidelines) Study	WORLD NEUROSURGERY			English	Article						Guidelines; Outcomes; Traumatic brain injury	CARE	We examined the effect of early intensive care unit (ICU) adherence to 2007 Brain Trauma Foundation Guideline indicators after traumatic brain injury (TBI) on inpatient mortality at a level 1 trauma center in India (Jay Prakash Narayan Apex Trauma Center [JPNATC]) and Harborview Medical Center (HMC) in U.S. among adults older than 18 years with severe TBI. At each site, ICU Guideline adherence in first 72 hours for 17 indicators was determined and expressed as a percentage. Outcomes were in-hospital mortality and Glasgow Outcome Scale (GOS) scores at 3, 6, and 12 months after discharge. JPNATC and HMC Guideline adherence rates were 74.9% [11.0] and 71.6%(SD +/- 10.4), and overall in-hospital mortality was 24% and 27%, respectively. At JPNATC, less than 65% ICU Guideline adherence was associated with higher inpatient mortality (adjusted relative risk [aRR], 1.92; 95% confidence interval [CI], 1.11-3.33) and an increase in ICU Guideline adherence rate by 1% was associated with a 3% lower in-hospital mortality (aRR, 0.97; 95% CI, 0.95-0.99). Among patients discharged with a GOS score of 2-4 at JPNATC, 67% improved at 12 months (R-2 = 0.991; P < 0.01; 99% follow-up rate) compared with discharge, but 35%, 25%, and 14% of patients discharged with a GOS score of 3-5 deteriorated at 3, 6, and 12 months to a lower GOS at home. Achieving early ICU adherence to guideline indicators was feasible and associated with significantly lower in-hospital mortality at JPNATC. Although the intracranial pressure (ICP) monitoring rates varied, in-hospitals deaths were similar between the two institutions. Although long-term outcomes generally improved, patients discharged with favorable GOS score often deteriorated at home.	[Gupta, Deepak; Prapruettham, Suchada; Mahapatra, Ashok] All India Inst Med Sci, Jai Prakash Narayan Apex Trauma Ctr, Dept Neurosurg, New Delhi, India; [Pandey, Ravindra M.] All India Inst Med Sci, Dept Biostat, New Delhi, India; [Pandey, Ravindra M.] All India Inst Med Sci, Epidemiol Unit, New Delhi, India; [Sharma, Deepak; Qiu, Qian; Hecker, James G.; Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Sharma, Deepak; Vavilala, Monica S.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Kannan, Nithya; Mock, Charles; Rivara, Frederick P.; Rowhani-Rahbar, Ali] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Mock, Charles] Univ Washington, Dept Surg, Seattle, WA 98195 USA; [Wang, Jin; Rivara, Frederick P.; Vavilala, Monica S.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Dash, Hari Har] Fortis Mem Res Inst, Dept Anesthesiol, Gurgaon, India	Vavilala, MS (corresponding author), Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA.; Vavilala, MS (corresponding author), Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA.; Vavilala, MS (corresponding author), Univ Washington, Dept Pediat, Seattle, WA 98195 USA.	vavilala@u.washington.edu			National Institutes of Health (U.S.) NINDS [5R21NS077444-02]; Department of Biotechnology (India)Department of Biotechnology (DBT) India [DBT N-1349]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS077444] Funding Source: NIH RePORTER	This research was supported by National Institutes of Health (U.S.) NINDS 5R21NS077444-02 and Department of Biotechnology (India) DBT N-1349.	Agrawal Amit, 2014, Int J Crit Illn Inj Sci, V4, P293, DOI 10.4103/2229-5151.147521; Agrawal M, 2014, BRAIN INJURY, V28, P292, DOI 10.3109/02699052.2013.865266; Altman D, 1991, PRACTICAL STAT MED R; [Anonymous], 2008, SURV SAMPL SIZ SOFTW; Biswas R, 2009, J EVAL CLIN PRACT, V15, P873, DOI 10.1111/j.1365-2753.2009.01271.x; Brooks JC, 2015, ARCH PHYS MED REHAB, V96, P1000, DOI 10.1016/j.apmr.2015.02.002; Buck CJ, 2010, INT CLASSIFICATION D; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Centers for Disease Control and Prevention, 2015, TRAUM BRAIN INJ US F; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Cole TB, 2004, JAMA-J AM MED ASSOC, V291, P2531, DOI 10.1001/jama.291.21.2531; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fleiss Joseph L., 2003, STAT METHODS RATES P; Gupta A, 2012, ANN INDIAN ACAD NEUR, V15, P120, DOI 10.4103/0972-2327.94995; Gururaj G, 2002, NEUROL RES, V24, P24, DOI 10.1179/016164102101199503; Hintze J, 2008, PASS 2008; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JENNETT B, 1976, LANCET, V1, P1031; Khan A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132229; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P187, DOI 10.1097/00001199-200505000-00001; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Sahu Madhusmita, 2014, Int J Electron Healthc, V7, P269, DOI 10.1504/IJEH.2014.064327; Sinha S, 2013, NEUROL INDIA, V61, P501, DOI 10.4103/0028-3886.121920; World Health Organization, 2015, VIOL INJ PREV INJ VI; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	27	27	29	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAY	2016	89						169	179		10.1016/j.wneu.2015.12.097			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DM6GM	WOS:000376448700026	26806065	Green Accepted			2021-06-18	
J	Galho, AR; Cordeiro, MF; Ribeiro, SA; Marques, MS; Antunes, MFD; Luz, DC; Hadrich, G; Muccillo-Baisch, AL; Barros, DM; Lima, JV; Dora, CL; Horn, AP				Galho, A. R.; Cordeiro, M. F.; Ribeiro, S. A.; Marques, M. S.; Antunes, M. F. D.; Luz, D. C.; Haedrich, G.; Muccillo-Baisch, A. L.; Barros, D. M.; Lima, J. V.; Dora, C. L.; Horn, A. P.			Protective role of free and quercetin-loaded nanoemulsion against damage induced by intracerebral haemorrhage in rats	NANOTECHNOLOGY			English	Article						quercetin; nanoemulsion; intracerebral haemorrhage; locomotor activity; antioxidant	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; SUBARACHNOID HEMORRHAGE; STROKE; MICE; COLLAGENASE; MODEL; CORTEX; EDEMA	Intracerebral haemorrhage (ICH) is a worldwide public health problem. Experimental studies have shown that oxidative stress plays an important role in the pathogenesis of ICH and could represent a target for its treatment. However, the blood-brain barrier is an obstacle to be overcome, as it hampers the administration of compounds to the central nervous system. In this study, we compared the effects of a quercetin-loaded nanoemulsion (QU-N) with the free form of the drug (QU-SP) in a collagenase-induced ICH rat model. Quercetin (QU) is a polyphenol that has an antioxidant effect in vitro, but due to its high lipophilicity, it has low bioavailability in vivo. In this study, animals submitted or not to ICH were treated with a single intraperitoneal QU dose (free or nanoemulsion) of 30 mg kg(-1). Motor assessment was evaluated by the open field, foot fault and beam walking behavioural tests. 72 h after surgery the haematoma size was evaluated and biochemical measurements were performed. Animals treated with QU-N had a significant improvement in the beam walking and open field tests. Also, QU-N was able to reduce the size of the haematoma, preserving the activity of glutathione S-transferase (GST), increasing GSH content, and the total antioxidant capacity. QU-SP recovered locomotor activity and increased the GSH content and the total antioxidant capacity. Thus, it can be observed that QU presented antioxidant activity in both formulations, but the incorporation into nanoemulsions increased its antioxidant effect, which was reflected in the improvement of the motor skills and in the haematoma size decrement. These results suggest that the nanoemulsion containing QU developed in this study could be promising for future studies on treatments for ICH.	[Galho, A. R.; Cordeiro, M. F.; Marques, M. S.; Antunes, M. F. D.; Luz, D. C.; Barros, D. M.; Lima, J. V.; Horn, A. P.] Univ Fed Rio Grande FURG, Programa Posgrad Ciencias Fisiol Anim Comparada, BR-96210900 Rio Grande, RS, Brazil; [Ribeiro, S. A.] Univ Fed Rio Grande FURG, Inst Ciencias Biol, Histol Lab, BR-96210900 Rio Grande, RS, Brazil; [Haedrich, G.; Muccillo-Baisch, A. L.; Dora, C. L.] Univ Fed Rio Grande FURG, Programa Posgrad Ciencias Saude, BR-96203900 Rio Grande, RS, Brazil; [Muccillo-Baisch, A. L.; Dora, C. L.] Univ Fed Rio Grande FURG, Lab Nanotecnol Aplicada Saude, BR-96203900 Rio Grande, RS, Brazil	Horn, AP (corresponding author), Univ Fed Rio Grande FURG, Programa Posgrad Ciencias Fisiol Anim Comparada, BR-96210900 Rio Grande, RS, Brazil.	anapaulahorn@pq.cnpq.br	Cordeiro, Marcos F/N-4080-2017; Hadrich, Gabriela/AAM-7861-2020; Horn, Ana P/N-3770-2018; Dora, Cristiana Lima/AAF-9520-2021	Cordeiro, Marcos F/0000-0002-2100-1614; 	PROCAD/CNPq [552457/2011-6]; PRONEM/FAPERGS [11/2037-9]	This work was supported by grants from PROCAD/CNPq (grant no. 552457/2011-6) and PRONEM/FAPERGS (grant no. 11/2037-9). Aline Ribeiro Galho was a fellow from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES). The authors would like to thank Andressa Bernardi for critically reviewing the manuscript. The authors declare that they have no conflicts of interest.	Ahmad A, 2011, NEUROCHEM RES, V36, P1360, DOI 10.1007/s11064-011-0458-6; Amado LL, 2009, SCI TOTAL ENVIRON, V407, P2115, DOI 10.1016/j.scitotenv.2008.11.038; Andaluz N, 2002, NEUROSURG CLIN N AM, V13, P385, DOI 10.1016/S1042-3680(02)00006-2; Anderson CS, 2009, CURR OPIN CRIT CARE, V15, P93, DOI 10.1097/MCC.0b013e328325d12c; Artwohl J, 2006, J AM ASSOC LAB ANIM, V45, P98; Beray-Berthat V, 2010, J NEUROSCI METH, V191, P180, DOI 10.1016/j.jneumeth.2010.06.025; Chan ST, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/580626; Cordeiro MF, 2015, WORLD J STEM CELLS, V7, P618, DOI 10.4252/wjsc.v7.i3.618; Dong YS, 2014, INT J MED SCI, V11, P282, DOI 10.7150/ijms.7634; Dora CL, 2012, J BIOMED NANOTECHNOL, V8, P202, DOI 10.1166/jbn.2012.1380; Dora CL, 2011, LAT AM J PHARM, V30, P289; Durrieu V, 2004, J APPL POLYM SCI, V94, P700, DOI 10.1002/app.20933; Fang R, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-19; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Goldstein BL, 2012, J NEUROSCI, V32, P2027, DOI 10.1523/JNEUROSCI.5349-11.2012; Habig W H, 1981, Methods Enzymol, V77, P398; Hadrich G, 2015, PHARM RES, V33, P1; Hadrich G, 2015, DRUG DEV IND PHARM, P1; Haleagrahara N, 2013, J TOXICOL SCI, V38, P25, DOI 10.2131/jts.38.25; Johnston SC, 2009, LANCET NEUROL, V8, P345, DOI 10.1016/S1474-4422(09)70023-7; Jonsson AC, 2008, STROKE, V39, P918, DOI 10.1161/STROKEAHA.107.497602; Jover R, 2006, HEPATOLOGY, V43, P1257, DOI 10.1002/hep.21180; Kilic E, 2008, J PINEAL RES, V45, P142, DOI 10.1111/j.1600-079X.2008.00568.x; Kim M, 2007, BBA-GEN SUBJECTS, V1770, P1627, DOI 10.1016/j.bbagen.2007.08.003; Liao YR, 2015, LIFE SCI, V137, P89, DOI 10.1016/j.lfs.2015.07.015; Liu ZW, 2008, STROKE, V39, P2571, DOI 10.1161/STROKEAHA.107.511659; Lu W, 2016, TRENDS FOOD SCI TECH, V47, P1, DOI 10.1016/j.tifs.2015.10.015; Ma QY, 2011, ACTA NEUROCHIR SUPPL, V111, P3, DOI 10.1007/978-3-7091-0693-8_1; MacLellan CL, 2009, BEHAV BRAIN RES, V198, P321, DOI 10.1016/j.bbr.2008.11.004; Maldonado MA, 2008, NEUROREHAB NEURAL RE, V22, P250, DOI 10.1177/1545968307308551; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Murota Kaeko, 2007, J Med Invest, V54, P370, DOI 10.2152/jmi.54.370; Nakamura T, 2005, BRAIN RES, V1039, P30, DOI 10.1016/j.brainres.2005.01.036; Nishibe M, 2010, J NEUROTRAUM, V27, P2221, DOI 10.1089/neu.2010.1456; Oakes KD, 2003, AQUAT TOXICOL, V63, P447, DOI 10.1016/S0166-445X(02)00204-7; Porritt MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041090; Prakash T, 2011, INDIAN J PHARMACOL, V43, P676, DOI 10.4103/0253-7613.89825; Rivera F, 2004, NEUROTOX RES, V6, P543, DOI 10.1007/BF03033450; Rogerio AP, 2010, PHARMACOL RES, V61, P288, DOI 10.1016/j.phrs.2009.10.005; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; ROSENBERG GA, 1990, STROKE, V21, P801, DOI 10.1161/01.STR.21.5.801; Savard C, 2009, COMPARATIVE MED, V59, P444; Schaar Krystal L, 2010, Exp Transl Stroke Med, V2, P13, DOI 10.1186/2040-7378-2-13; Schwingel TE, 2014, N-S ARCH PHARMACOL, V387, P837, DOI 10.1007/s00210-014-0994-0; Senes M, 2007, ANN CLIN BIOCHEM, V44, P43, DOI 10.1258/000456307779596057; Shang H, 2013, FREE RADICAL RES, V47, P368, DOI 10.3109/10715762.2013.778403; Shelton SB, 2008, J NEUROSCI METH, V168, P431, DOI 10.1016/j.jneumeth.2007.11.003; Shimizu H, 2004, STROKE, V35, P2072, DOI 10.1161/01.STR.0000138022.86509.2d; Tang XAN, 2010, J NEUROSCI METH, V190, P240, DOI 10.1016/j.jneumeth.2010.05.004; Ting YW, 2014, J FUNCT FOODS, V7, P112, DOI 10.1016/j.jff.2013.12.010; Torri C, 1997, MOL CHEM NEUROPATHOL, V30, P15, DOI 10.1007/BF02815147; Turner RJ, 2012, NEUROSCIENCE, V220, P1, DOI 10.1016/j.neuroscience.2012.06.047; Vianna MRM, 2001, BRAZ J MED BIOL RES, V34, P233, DOI 10.1590/S0100-879X2001000200011; Wakade C, 2009, ANTIOXID REDOX SIGN, V11, P35, DOI 10.1089/ars.2008.2056; Wang GH, 2011, J NEUROTRAUM, V28, P2123, DOI 10.1089/neu.2011.1939; White CC, 2003, ANAL BIOCHEM, V318, P175, DOI 10.1016/S0003-2697(03)00143-X; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Yousef MI, 2010, FOOD CHEM TOXICOL, V48, P3246, DOI 10.1016/j.fct.2010.08.034; Yousuf S, 2009, BRAIN RES, V1250, P242, DOI 10.1016/j.brainres.2008.10.068; ZAR Jh, 2009, BIOSTATISTICAL ANAL; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhao LR, 2007, STROKE, V38, P2804, DOI 10.1161/STROKEAHA.107.486217	62	27	27	2	19	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0957-4484	1361-6528		NANOTECHNOLOGY	Nanotechnology	APR 29	2016	27	17							175101	10.1088/0957-4484/27/17/175101			13	Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied	Science & Technology - Other Topics; Materials Science; Physics	DH5AO	WOS:000372797400004	26965041				2021-06-18	
J	Cao, Y; Gao, Y; Xu, SY; Bao, JG; Lin, YY; Luo, XG; Wang, Y; Luo, QZ; Jiang, JY; Neale, JH; Zhong, CL				Cao, Yang; Gao, Yang; Xu, Siyi; Bao, Jingang; Lin, Yingying; Luo, Xingguang; Wang, Yong; Luo, Qizhong; Jiang, Jiyao; Neale, Joseph H.; Zhong, Chunlong			Glutamate carboxypeptidase II gene knockout attenuates oxidative stress and cortical apoptosis after traumatic brain injury	BMC NEUROSCIENCE			English	Article						NAAG; Glutamate carboxypeptidase II; Gene knockout; Traumatic brain injury; Oxidative stress; Apoptosis	NAAG PEPTIDASE INHIBITION; N-ACETYLASPARTYLGLUTAMATE; RECEPTORS; NEUROTOXICITY; ACTIVATION; NEUROTRANSMITTER; EXCITOTOXICITY; ASPARTATE; TOXICITY; RELEASE	Background: Glutamate carboxypeptidase II (GCPII) inactivates the peptide co-transmitter N-acetylaspartylglutamate following synaptic release. Inhibition of GCPII elevates extracellular levels of the peptide, inhibits glutamate release and is neuroprotective in an animal model of traumatic brain injury. GCPII gene knockout mice were used to examine the cellular mechanisms underlying the neuroprotective efficacy of this transmitter system. Results: Following controlled cortical impact injury, GCPII knockout (KO) mice exhibited reduced TUNEL-positive nuclei in the contusion margin of the cerebral cortex relative to wild type mice. Impact injury reduced glutathione levels and superoxide dismutase and glutathione peroxidase activities and increased malondialdehyde. Each of these effects was moderated in KO mice relative to wild type. Similarly, the injury-induced increases in cleaved caspase-3, cytosolic cytochrome c levels and Bcl-2/Bax ratio observed in wild type mice were attenuated in the knockout mice. Conclusions: These data support the hypothesis that the neuroprotective efficacy of GCPII KO in traumatic brain injury is mediated via a reduction in oxidative stress.	[Cao, Yang; Gao, Yang; Xu, Siyi; Bao, Jingang; Lin, Yingying; Wang, Yong; Luo, Qizhong; Jiang, Jiyao; Zhong, Chunlong] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, 160 Pujian Rd, Shanghai 200127, Peoples R China; [Luo, Xingguang] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA; [Neale, Joseph H.] Georgetown Univ, Dept Biol, Washington, DC 20075 USA	Zhong, CL (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, 160 Pujian Rd, Shanghai 200127, Peoples R China.	drchunlongzhong@126.com			Ministry of Science and Technology of ChinaMinistry of Science and Technology, China [2011CB013304]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571184, 81070990, 30670719, 30500525]; Shanghai Science and Technology CommissionShanghai Science & Technology CommitteeScience & Technology Commission of Shanghai Municipality (STCSM) [15140902100, 10QH1401700, 09140901300]; Shanghai Municipal Education CommissionShanghai Municipal Education Commission (SHMEC) [09SG20]	This research was supported in part by a basic research program of project 973 by the Ministry of Science and Technology of China (2011CB013304), and by Grants from the National Natural Science Foundation of China (Nos. 81571184, 81070990, 30670719, 30500525), the Shanghai Science and Technology Commission (Nos. 15140902100, 10QH1401700, 09140901300) and the Shanghai Municipal Education Commission (No. 09SG20). JHN supported by an endowment and generous gifts from Nancy and Daniel Paduano.	Aronica E, 2003, EUR J NEUROSCI, V17, P2106, DOI 10.1046/j.1460-9568.2003.02657.x; Atlante A, 2001, FEBS LETT, V497, P1, DOI 10.1016/S0014-5793(01)02437-1; Ayala A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/360438; Berent-Spillson A, 2007, J NEUROCHEM, V101, P342, DOI 10.1111/j.1471-4159.2006.04373.x; Budd SL, 1996, J NEUROCHEM, V67, P2282; Chen SS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036784; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; D'Onofrio M, 2001, J NEUROCHEM, V78, P435, DOI 10.1046/j.1471-4159.2001.00435.x; Durand D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022235; Gao Y, 2015, J NEUROCHEM, V134, P340, DOI 10.1111/jnc.13123; Gogvadze V, 2006, CHEM-BIOL INTERACT, V163, P4, DOI 10.1016/j.cbi.2006.04.010; He YL, 2012, BRAIN RES, V1433, P127, DOI 10.1016/j.brainres.2011.11.027; Hiebert JB, 2015, AM J MED SCI, V350, P132, DOI 10.1097/MAJ.0000000000000506; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; Ndountse LT, 2009, TOXICOL LETT, V184, P50, DOI 10.1016/j.toxlet.2008.10.013; Neale JH, 2000, J NEUROCHEM, V75, P443, DOI 10.1046/j.1471-4159.2000.0750443.x; Neale JH, 2011, J NEUROCHEM, V119, P891, DOI 10.1111/j.1471-4159.2011.07380.x; Neale JH, 2011, J NEUROCHEM, V118, P490, DOI 10.1111/j.1471-4159.2011.07338.x; Pereira CF, 2000, NEUROSCI RES, V37, P227, DOI 10.1016/S0168-0102(00)00124-3; Sanabria ERG, 2004, J NEUROPHYSIOL, V91, P182, DOI 10.1152/jn.00465.2003; SIMS NR, 1995, INT J BIOCHEM CELL B, V27, P531, DOI 10.1016/1357-2725(95)00026-L; Slomka M, 2008, FOLIA NEUROPATHOL, V46, P69; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Yamada T, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-67; Yao HH, 2005, J NEUROCHEM, V92, P948, DOI 10.1111/j.1471-4159.2004.02937.x; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhong C, 2006, J NEUROCHEM, V97, P1015, DOI 10.1111/j.1471-4159.2006.03786.x; Zhong CL, 2014, INT J NEUROSCI, V124, P867, DOI 10.3109/00207454.2014.890935; Zhong CL, 2005, J NEUROTRAUM, V22, P266, DOI 10.1089/neu.2005.22.266; Zhou F, 2006, J NEUROSCI RES, V84, P268, DOI 10.1002/jnr.20897; Zuo DY, 2012, J BIOL CHEM, V287, P21773, DOI 10.1074/jbc.M112.363226	33	27	27	0	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	APR 18	2016	17								15	10.1186/s12868-016-0251-1			8	Neurosciences	Neurosciences & Neurology	DJ9MN	WOS:000374537700002	27091009	DOAJ Gold, Green Published			2021-06-18	
J	Mitra, J; Shen, KK; Ghose, S; Bourgeat, P; Fripp, J; Salvado, O; Pannek, K; Taylor, DJ; Mathias, JL; Rose, S				Mitra, Jhimli; Shen, Kai-kai; Ghose, Soumya; Bourgeat, Pierrick; Fripp, Jurgen; Salvado, Olivier; Pannek, Kerstin; Taylor, D. Jamie; Mathias, Jane L.; Rose, Stephen			Statistical machine learning to identify traumatic brain injury (TBI) from structural disconnections of white matter networks	NEUROIMAGE			English	Article						Diffusion tractography; Structural network connections; Traumatic brain injury; Network-based statistics; Machine learning	DIFFUSE AXONAL INJURY; NONMISSILE HEAD-INJURY; COGNITIVE DYSFUNCTION; EXECUTIVE FUNCTION; CORPUS-CALLOSUM; MILD; MRI; CLASSIFICATION; MODERATE; MOTION	Identifying diffuse axonal injury (DAI) in patients with traumatic brain injury (TBI) presenting with normal appearing radiological MRI presents a significant challenge. Neuroimaging methods such as diffusion MRI and probabilistic tractography, which probe the connectivity of neural networks, show significant promise. We present a machine learning approach to classify TBI participants primarily with mild traumatic brain injury (mTBI) based on altered structural connectivity patterns derived through the network based statistical analysis of structural connectomes generated from TBI and age-matched control groups. In this approach, higher order diffusion models were used to map white matter connections between 116 cortical and subcortical regions. Tracts between these regions were generated using probabilistic tracking and mean fractional anisotropy (FA) measures along these connections were encoded in the connectivity matrices. Network-based statistical analysis of the connectivity matrices was performed to identify the network differences between a representative subset of the two groups. The affected network connections provided the feature vectors for principal component analysis and subsequent classification by random forest. The validity of the approach was tested using data acquired from a total of 179 TBI patients and 146 controls participants. The analysis revealed altered connectivity within a number of intra-and inter-hemispheric white matter pathways associated with DAI, in consensus with existing literature. A mean classification accuracy of 68.16% +/- 1.81% and mean sensitivity of 80.0% +/- 2.36% were achieved in correctly classifying the TBI patients evaluated on the subset of the participants that was not used for the statistical analysis, in a 10-fold cross-validation framework. These results highlight the potential for statistical machine learning approaches applied to structural connectomes to identify patients with diffusive axonal injury. (C) 2016 Elsevier Inc. All rights reserved.	[Mitra, Jhimli; Shen, Kai-kai; Ghose, Soumya; Bourgeat, Pierrick; Fripp, Jurgen; Salvado, Olivier; Rose, Stephen] CSIRO Hlth & Biosecur, Australian E Hlth & Res Ctr, Herston, Qld, Australia; [Mathias, Jane L.] Univ Adelaide, Sch Psychol, Adelaide, SA, Australia; [Taylor, D. Jamie] Royal Adelaide Hosp, Dept Radiol, Adelaide, SA 5000, Australia; [Pannek, Kerstin] Univ London Imperial Coll Sci Technol & Med, Dept Comp, London, England; [Mitra, Jhimli; Ghose, Soumya] Case Western Reserve Univ, Ctr Computat Imaging & Personalized Diagnost, Cleveland, OH 44106 USA; [Mitra, Jhimli] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA	Mitra, J (corresponding author), CSIRO Hlth & Biosecur, Australian E Hlth & Res Ctr, Herston, Qld, Australia.	jhimli.mitra@case.edu; kaikai.shen@csiro.au; soumya.ghose@case.edu; pierrick.bourgeat@csiro.au; jurgen.fripp@csiro.au; olivier.salvado@csiro.au; kerstin.pannek@gmail.com; jamie.taylor@health.sa.gov.au; jane.mathias@adelaide.edu.au; stephen.rose@csiro.au	Pannek, Kerstin/C-8059-2011; Ghose, Soumya/C-8767-2014; Shen, Kaikai/AAD-9970-2019; Bourgeat, Pierrick T/A-1419-2010; Shen, Kai-kai/B-8724-2011; Fripp, Jurgen/A-8763-2011; Salvado, Olivier/C-8910-2009; Rose, Stephen/C-8044-2009	Pannek, Kerstin/0000-0002-6512-7630; Shen, Kaikai/0000-0002-5956-501X; Bourgeat, Pierrick T/0000-0002-2605-4766; Shen, Kai-kai/0000-0002-5956-501X; Fripp, Jurgen/0000-0001-9705-0079; Salvado, Olivier/0000-0002-2720-8739; Mathias, Jane/0000-0001-8957-8594	National Health and Medical Research Project [519220]	This research was funded by a National Health and Medical Research Project Grant (ID 519220). The authors wish to thank Ms. V. Dennington and Dr. Y. Harman-Smith for their efforts in subject recruitment.	Acosta O, 2009, MED IMAGE ANAL, V13, P730, DOI 10.1016/j.media.2009.07.003; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1986, J NEUROL NEUROSUR PS, V49, P1039, DOI 10.1136/jnnp.49.9.1039; Aljabar P, 2009, NEUROIMAGE, V46, P726, DOI 10.1016/j.neuroimage.2009.02.018; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Archer KJ, 2008, COMPUT STAT DATA AN, V52, P2249, DOI 10.1016/j.csda.2007.08.015; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Aribisala BS, 2010, LECT NOTES COMPUT SC, V6326, P51; Benson RR, 2012, NEUROREHABILITATION, V31, P261, DOI 10.3233/NRE-2012-0795; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Boser B. E., 1992, Proceedings of the Fifth Annual ACM Workshop on Computational Learning Theory, P144, DOI 10.1145/130385.130401; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Breiman L, 2001, STAT SCI, V16, P199, DOI 10.1214/ss/1009213726; BREIMAN L, 2001, MACH LEARN, V45; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00726; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1023/A:1022627411411; Costafreda SG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006353; Dosenbach NUF, 2010, SCIENCE, V329, P1358, DOI 10.1126/science.1194144; Fang P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045972; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Gioia GA, 2010, J HEAD TRAUMA REHAB, V25, P433, DOI 10.1097/HTR.0b013e3181fbc272; Goh SYM, 2014, FRONT NEUROINFORM, V8, DOI 10.3389/fninf.2014.00019; Guyon I, 2002, MACH LEARN, V46, P389, DOI 10.1023/A:1012487302797; Guyon I., 2003, J MACH LEARN RES, V3, P1157, DOI DOI 10.1162/153244303322753616; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Hastie T., 2009, ELEMENTS STAT LEARNI; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Irimia A, 2012, NEUROIMAGE-CLIN, V1, P1, DOI 10.1016/j.nicl.2012.08.002; Irimia Andrei, 2012, Front Neurol, V3, P10, DOI 10.3389/fneur.2012.00010; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Jenkinson M, 2003, MAGNET RESON MED, V49, P193, DOI 10.1002/mrm.10354; Jenkinson M., 2004, 10 ANN M ORG HUM BRA, P1; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jolliffe I, 2002, PRINCIPAL COMPONENT; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Kasahara K, 2012, MAGN RESON IMAGING, V30, P496, DOI 10.1016/j.mri.2011.12.018; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Kurowski B, 2009, J PEDIATR REHAB MED, V2, P273, DOI 10.3233/PRM-2009-0093; Langs G, 2011, NEUROIMAGE, V56, P497, DOI 10.1016/j.neuroimage.2010.07.074; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Liu H, 2008, CH CRC DATA MIN KNOW, P3; Liu MJ, 2012, NEUROREPORT, V23, P265, DOI 10.1097/WNR.0b013e32834f60a5; Lui YW, 2014, NEUROLOGY, V83, P1235, DOI 10.1212/WNL.0000000000000834; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Modat M, 2010, COMPUT METH PROG BIO, V98, P278, DOI 10.1016/j.cmpb.2009.09.002; Morris D, 2011, MAGN RESON MED, V66, P92, DOI 10.1002/mrm.22786; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Olshen RA, 1984, CLASSIFICATION REGRE; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Ourselin S., 2002, Medical Image Computing and Computer-Assisted Intervention - MICCAI 2002. 5th International Conference. Proceedings, Part II (Lecture Notes in Computer Science Vol.2489), P140; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Pannek K, 2012, PEDIATR RADIOL, V42, P1169, DOI 10.1007/s00247-012-2427-x; Pannek K, 2012, NEUROIMAGE, V63, P835, DOI 10.1016/j.neuroimage.2012.07.022; Pannek K, 2010, NEUROIMAGE, V50, P1044, DOI 10.1016/j.neuroimage.2010.01.020; Pearson K, 1901, PHILOS MAG, V2, P559, DOI 10.1080/14786440109462720; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Robinson EC, 2010, NEUROIMAGE, V50, P910, DOI 10.1016/j.neuroimage.2010.01.019; Rohde GK, 2004, MAGN RESON MED, V51, P103, DOI 10.1002/mrm.10677; Rose S, 2012, NEUROIMAGE, V59, P2661, DOI 10.1016/j.neuroimage.2011.08.054; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Sanchez CE, 2012, DEV NEUROPSYCHOL, V37, P379, DOI 10.1080/87565641.2012.688900; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Smith RE, 2015, NEUROIMAGE, V104, P253, DOI 10.1016/j.neuroimage.2014.10.004; Smith RE, 2013, NEUROIMAGE, V67, P298, DOI 10.1016/j.neuroimage.2012.11.049; Smith RE, 2012, NEUROIMAGE, V62, P1924, DOI 10.1016/j.neuroimage.2012.06.005; Sugiyama K., 2013, CASE REPORTS MED, P1; Taber Katherine H, 2013, J Neuropsychiatry Clin Neurosci, V25, P1, DOI 10.1176/appi.neuropsych.12120401; Tang J., 2014, DATA CLASSIFICATION, V37, DOI DOI 10.1201/B17320; Tournier JD, 2007, NEUROIMAGE, V35, P1459, DOI 10.1016/j.neuroimage.2007.02.016; Tournier JD, 2012, INT J IMAG SYST TECH, V22, P53, DOI 10.1002/ima.22005; Tournier JD, 2004, NEUROIMAGE, V23, P1176, DOI 10.1016/j.neuroimage.2004.07.037; van Horn JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037454; Van Leemput K, 1999, IEEE T MED IMAGING, V18, P897, DOI 10.1109/42.811270; Vapnik V., 1963, AUTOM REMOTE CONTROL, V24; Vapnik V, 1964, AUTOM REMOTE CONTROL, P25; Wada T, 2012, AM J NEURORADIOL, V33, P2117, DOI 10.3174/ajnr.A3141; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wang LB, 2012, NEUROIMAGE, V61, P931, DOI 10.1016/j.neuroimage.2012.03.080; Webb W., 1992, NEUROLOGY SPEECH LAN; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yeh P.-H., 2012, OPEN J MED IMAGING, V2, P137, DOI [10.4236/ojmi.2012.24025, DOI 10.4236/OJMI.2012.24025]; Yu B, 2008, 2008 CONFERENCE ON LASERS AND ELECTRO-OPTICS & QUANTUM ELECTRONICS AND LASER SCIENCE CONFERENCE, VOLS 1-9, P947, DOI 10.1109/ISBI.2008.4541154; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041; Ziv E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078824	95	27	27	1	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	APR 1	2016	129						247	259		10.1016/j.neuroimage.2016.01.056			13	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	DH4HD	WOS:000372745300021	26827816				2021-06-18	
J	St Ivany, A; Schminkey, D				St Ivany, Amanda; Schminkey, Donna			Intimate Partner Violence and Traumatic Brain Injury State of the Science and Next Steps	FAMILY & COMMUNITY HEALTH			English	Article						battered woman; IPV; screening; TBI; violence	BATTERED WOMEN; HEAD-INJURY; NEURAL MECHANISMS; HIGH-RISK; RESPONSES; AMYGDALA; OUTCOMES; STRESS; HEALTH; RECOMMENDATIONS	Women who receive traumatic brain injuries (TBI) from intimate partner violence (IPV) are gaining attention; however, research studies are lacking in this area. A review of literature conducted on TBI from IPV found prevalence of 60% to 92% of abused women obtaining a TBI directly correlated with IPV. Adverse overlapping health outcomes are associated with both TBI and IPV. Genetic predisposition and epigenetic changes can occur after TBI and add increased vulnerability to receiving and inflicting a TBI. Health care providers and community health workers need awareness of the link between IPV/TBI to provide appropriate treatment and improve the health of women and families.	[St Ivany, Amanda; Schminkey, Donna] Univ Virginia, Sch Nursing, 202 Jeanette Lancaster Way, Charlottesville, VA 22903 USA	St Ivany, A (corresponding author), Univ Virginia, Sch Nursing, 202 Jeanette Lancaster Way, Charlottesville, VA 22903 USA.	ars2tb@virginia.edu	St Ivany, Amanda/AAC-6228-2019	Schminkey, Donna/0000-0002-4968-8809			Abul-Husn NS, 2014, PHARMACOGEN PERS MED, V7, P227, DOI 10.2147/PGPM.S48887; Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Alexander SA, 2014, AM J CRIT CARE, V23, P49, DOI 10.4037/ajcc2014578; Alston M, 2012, AUST SOC WORK, V65, P39, DOI 10.1080/0312407X.2011.594898; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Anderson JC, 2015, J EMERG NURS, V41, P36, DOI 10.1016/j.jen.2014.01.015; Aupperle RL, 2013, PSYCHIAT RES-NEUROIM, V214, P48, DOI 10.1016/j.pscychresns.2013.05.001; Ballan MS, 2012, VIOLENCE AGAINST WOM, V18, P1083, DOI 10.1177/1077801212461430; Banks ME, 2007, TRAUMA VIOLENCE ABUS, V8, P290, DOI 10.1177/1524838007303503; Becker F, 2011, EUR J HUM GENET, V19, pS6, DOI 10.1038/ejhg.2010.249; BrainLine, 2015, CUM CONC; Breiding MJ, 2014, MMWR SURVEILL SUMM, V63, P1; Breslow JM, 2014, WHAT WEVE LEARNED 2; Burnett C, 2015, VIOLENCE AGAINST WOM, P1; Chan F, 2008, BRAIN INJURY, V22, P471, DOI 10.1080/02699050802084886; Ciocchi S, 2010, NATURE, V468, P277, DOI 10.1038/nature09559; Conley YP, 2014, J NEUROTRAUM, V31, P34, DOI 10.1089/neu.2013.2855; Corrigan JD, 2001, CLIN J WOMENS HLTH, V1, P184; Cousar JL, 2014, J NEUROTRAUM, V31, P34; Davidson J, 2015, NEUROSCIENTIST, V21, P424, DOI 10.1177/1073858414543150; Degeneffe CE, 2008, REHABIL COUNS BULL, V51, P240, DOI 10.1177/0034355207311319; Erdos B, 2015, AM J PHYSIOL-HEART C, V309, pH634, DOI 10.1152/ajpheart.00207.2015; Ford-Gilboe M, 2011, FAMILY VIOLENCE NURS, P115; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Garringer JA, 2013, J NEUROTRAUM, V30, P1415, DOI 10.1089/neu.2012.2565; Higgins D, 2015, J PRIM HEALTH CARE, V7, P102, DOI 10.1071/HC15102; Howell KH, 2015, J INTERPERS VIOLENCE, V30, P232, DOI 10.1177/0886260514533155; Humphreys J, 2011, FAMILY VIOLENCE NURS; Hux K, 2009, BRAIN INJURY, V23, P8, DOI 10.1080/02699050802590353; Jackson H, 2002, PROF PSYCHOL-RES PR, V33, P39, DOI 10.1037//0735-7028.33.1.39; Kieffer-Kristensen R, 2013, NEUROREHABILITATION, V32, P59, DOI 10.3233/NRE-130823; Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030; Kwako LE, 2011, TRAUMA VIOLENCE ABUS, V12, P115, DOI 10.1177/1524838011404251; Lee I, 2013, REV NEUROSCIENCE, V24, P27, DOI 10.1515/revneuro-2012-0073; Lipsky Robert H, 2015, Handb Clin Neurol, V127, P23, DOI 10.1016/B978-0-444-52892-6.00003-9; McKinlay A, 2014, J FAM VIOLENCE, V29, P391, DOI 10.1007/s10896-014-9591-8; Monahan K, 1999, HEALTH SOC WORK, V24, P269, DOI 10.1093/hsw/24.4.269; Niemela M, 2014, GEN HOSP PSYCHIAT, V36, P337, DOI 10.1016/j.genhosppsych.2013.12.012; Nudo RJ, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00887; Orzeck TL, 2010, J LOSS TRAUMA, V15, P167, DOI 10.1080/15325020903375792; Overstreet NM, 2013, BASIC APPL SOC PSYCH, V35, P109, DOI 10.1080/01973533.2012.746599; PBS POV, 2011, SOLD COM; Phelps EA, 2004, CURR OPIN NEUROBIOL, V14, P198, DOI 10.1016/j.conb.2004.03.015; Pinto LA, 2010, AGGRESS VIOLENT BEH, V15, P387, DOI 10.1016/j.avb.2010.07.001; Ponsford J, 2013, NEUROREHABILITATION, V32, P803, DOI 10.3233/NRE-130904; Radtke KM, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.21; Regehr C, 2008, J SOC SERV RES, V34, P5, DOI 10.1080/01488370802085890; Remington A, 2014, SPORTS RELATED CONCU; Retz W, 2004, BEHAV SCI LAW, V22, P415, DOI 10.1002/bsl.589; Rich K, 2014, AFFILIA J WOM SOC WO, V29, P418, DOI 10.1177/0886109914522626; Rodrigo A, 2015, SOC COGN AFFECT NEUR; ROSENBAUM A, 1994, J CONSULT CLIN PSYCH, V62, P1187, DOI 10.1037/0022-006X.62.6.1187; ROSENBAUM A, 1989, AM J PSYCHIAT, V146, P1048; Rubin RD, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00742; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Shirazi SN, 2015, ADV EXP MED BIOL, V872, P235, DOI 10.1007/978-1-4939-2895-8_10; Smith DJ, 2001, J EMERG MED, V21, P323, DOI 10.1016/S0736-4679(01)00402-4; Snell DL, 2011, BRAIN INJURY, V25, P1126, DOI 10.3109/02699052.2011.607786; Stein MB, 2002, BIOL PSYCHIAT, V52, P1079, DOI 10.1016/S0006-3223(02)01414-2; Stuart GL, 2014, VIOLENCE AGAINST WOM, V20, P385, DOI 10.1177/1077801214528587; Tailor K, 2015, J FAM PSYCHOL, V29, P29, DOI 10.1037/a0038584; Valera EM, 2003, J CONSULT CLIN PSYCH, V71, P797, DOI 10.1037/0022-006X.71.4.797; van Vliet-Ruissen C, 2014, NEUROREHABILITATION, V34, P373, DOI 10.3233/NRE-131032; Wang YG, 2011, J NEUROTRAUM, V28, P259, DOI 10.1089/neu.2010.1648; Wang YJ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/293687; Wong JYH, 2014, TRAUMA VIOLENCE ABUS, V15, P22, DOI 10.1177/1524838013496333; Wong J, 2014, CONTEMP NURSE, V46, P170, DOI 10.5172/conu.2014.46.2.170; Wu CT, 2001, SCIENCE, V293, P1103, DOI 10.1126/science.293.5532.1103; Yehuda R, 2015, BIOL PSYCHIAT, V77, P356, DOI 10.1016/j.biopsych.2014.02.006; Yue JK, 2015, NEUROGENETICS, V16, P169, DOI 10.1007/s10048-015-0437-1; Zhang ZY, 2007, NEUROSCI LETT, V429, P1, DOI 10.1016/j.neulet.2007.09.061	72	27	27	1	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0160-6379	1550-5057		FAM COMMUNITY HEALTH	Fam. Community Health	APR-JUN	2016	39	2			SI		129	137		10.1097/FCH.0000000000000094			9	Family Studies; Public, Environmental & Occupational Health	Family Studies; Public, Environmental & Occupational Health	DI5JO	WOS:000373534900008	26882416				2021-06-18	
J	Winkler, EA; Yue, JK; Burke, JF; Chan, AK; Dhall, SS; Berger, MS; Manley, GT; Tarapore, PE				Winkler, Ethan A.; Yue, John K.; Burke, John F.; Chan, Andrew K.; Dhall, Sanjay S.; Berger, Mitchel S.; Manley, Geoffrey T.; Tarapore, Phiroz E.			Adult sports-related traumatic brain injury in United States trauma centers	NEUROSURGICAL FOCUS			English	Article						concussion; mortality; outcome; sports; traumatic brain injury	HIGH-SCHOOL; EXTERNAL VALIDATION; RISK-FACTORS; EPIDEMIOLOGY; CONCUSSIONS; MORBIDITY; SEVERITY; MODERATE; IMPACT; PROGNOSIS	OBJECTIVE Sports-related traumatic brain injury (TBI) is an important public health concern estimated to affect 300,000 to 3.8 million people annually in the United States. Although injuries to professional athletes dominate the media, this group represents only a small proportion of the overall population. Here, the authors characterize the demographics of sports-related TBI in adults from a community-based trauma population and identify predictors of prolonged hospitalization and increased morbidity and mortality rates. METHODS Utilizing the National Sample Program of the National Trauma Data Bank (NTDB), the authors retrospectively analyzed sports-related TBI data from adults (age >= 18 years) across 5 sporting categories-fall or interpersonal contact (FIC), roller sports, skiing/snowboarding, equestrian sports, and aquatic sports. Multivariable regression analysis was used to identify predictors of prolonged hospital length of stay (LOS), medical complications, inpatient mortality rates, and hospital discharge disposition. Statistical significance was assessed at alpha < 0.05, and the Bonferroni correction for multiple comparisons was applied for each outcome analysis. RESULTS From 2003 to 2012, in total, 4788 adult sports-related TBIs were documented in the NTDB, which represented 18,310 incidents nationally. Equestrian sports were the greatest contributors to sports-related TBI (45.2%). Mild TBI represented nearly 86% of injuries overall. Mean (+/- SEM) LOSs in the hospital or intensive care unit (ICU) were 4.25 +/- 0.09 days and 1.60 +/- 0.06 days, respectively. The mortality rate was 3.0% across all patients, but was statistically higher in TBI from roller sports (4.1%) and aquatic sports (7.7%). Age, hypotension on admission to the emergency department (ED), and the severity of head and extracranial injuries were statistically significant predictors of prolonged hospital and ICU LOSs, medical complications, failure to discharge to home, and death. Traumatic brain injury during aquatic sports was similarly associated with prolonged ICU and hospital LOSs, medical complications, and failure to be discharged to home. CONCLUSIONS Age, hypotension on ED admission, severity of head and extracranial injuries, and sports mechanism of injury are important prognostic variables in adult sports-related TBI. Increasing TBI awareness and helmet use-particularly in equestrian and roller sports-are critical elements for decreasing sports-related TBI events in adults.	[Winkler, Ethan A.; Yue, John K.; Burke, John F.; Chan, Andrew K.; Dhall, Sanjay S.; Berger, Mitchel S.; Manley, Geoffrey T.; Tarapore, Phiroz E.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Winkler, Ethan A.; Yue, John K.; Burke, John F.; Chan, Andrew K.; Dhall, Sanjay S.; Manley, Geoffrey T.; Tarapore, Phiroz E.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA	Tarapore, PE (corresponding author), San Francisco Gen Hosp, 1001 Potrero Ave,Bldg 1,Rm 101, San Francisco, CA 94110 USA.	taraporep@neurosurg.ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722			American College of Surgeons, 2013, NAT TRAUM DAT BANK N; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Baschera D, 2015, J NEUROTRAUM, V32, P557, DOI 10.1089/neu.2014.3604; Bekelis K, 2015, ANN SURG, V261, P579, DOI 10.1097/SLA.0000000000000672; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chang SKY, 2006, J TRAUMA, V60, P1041, DOI 10.1097/01.ta.0000218256.39295.8f; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fenerty L, 2013, J TRAUMA ACUTE CARE, V74, P895, DOI 10.1097/TA.0b013e31827e19ca; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Haring RS, 2015, BRAIN INJURY, V29, P989, DOI 10.3109/02699052.2015.1033014; Ibsen LM, 2002, CRIT CARE MED, V30, pS402, DOI 10.1097/00003246-200211001-00004; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kriss TC, 1997, J TRAUMA, V43, P97, DOI 10.1097/00005373-199707000-00022; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Lustenberger T, 2010, J TRAUMA, V69, P924, DOI 10.1097/TA.0b013e3181b9a05a; Majidi S, 2013, AM J EMERG MED, V31, P1215, DOI 10.1016/j.ajem.2013.05.026; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Norwood S, 2000, J TRAUMA, V48, P740, DOI 10.1097/00005373-200004000-00025; Paix BR, 1999, BRIT J SPORT MED, V33, P46, DOI 10.1136/bjsm.33.1.46; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Saigal Rajiv, 2014, Neurosurgery, V75 Suppl 4, pS149, DOI 10.1227/NEU.0000000000000497; Schoenfeld AJ, 2013, SPINE J, V13, P1766, DOI 10.1016/j.spinee.2013.03.024; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Sorli J M, 2000, Inj Prev, V6, P59, DOI 10.1136/ip.6.1.59; SOSIN DM, 1991, BRAIN INJURY, V10, P47, DOI DOI 10.1080/026990596124719; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tominaga GT, 2015, BRAIN INJURY, V29, P1044, DOI 10.3109/02699052.2014.989404; Underwood E, 2013, SCIENCE, V339, P1367, DOI 10.1126/science.339.6126.1367; Wasserman EB, 2016, AM J SPORT MED, V44, P226, DOI 10.1177/0363546515610537; Winkler EA, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15270; Yue JK, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15612; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634; Zuckerman SL, 2015, WORLD NEUROSURG, V83, P1098, DOI 10.1016/j.wneu.2014.12.030	49	27	28	0	14	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	APR	2016	40	4							E4	10.3171/2016.1.FOCUS15613			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DI4NL	WOS:000373476500009	27032921	Bronze			2021-06-18	
J	Jaramillo, CA; Eapen, BC; McGeary, CA; McGeary, DD; Robinson, J; Amuan, M; Pugh, MJ				Jaramillo, Carlos A.; Eapen, Blessen C.; McGeary, Cindy A.; McGeary, Donald D.; Robinson, Jedediah; Amuan, Megan; Pugh, Mary Jo			A cohort study examining headaches among veterans of Iraq and Afghanistan wars: Associations with traumatic brain injury, PTSD, and depression	HEADACHE			English	Article						headache; traumatic brain injury; posttraumatic stress disorder; postconcussive symptoms; persistence; veterans	POSTTRAUMATIC-STRESS-DISORDER; HEAD; MILITARY; SOLDIERS; PREVALENCE; CONCUSSION; SEVERITY; MIGRAINE; BLAST; PAIN	ObjectivesTo describe the prevalence and persistence of headache and associated conditions in an inception cohort of U.S. veterans of Iraq and Afghanistan wars. BackgroundIraq and Afghanistan war veterans (IAV) suffer from persistent and difficult-to-treat headaches that have been found to co-occur with traumatic brain injury (TBI) and other deployment related comorbidities. MethodsThis longitudinal retrospective cohort study used data from the national Veterans Health Administration (VA) data repository for IAV who first received VA care in 2008 (baseline) and also received care each year in 2009, 2010, and 2011. We used ICD-9-CM codes, to identify those treated for headache each year (2008-2011). Individuals with headache diagnosed each year were classified as having persistent headache. We also identified comorbidities that may be associated with baseline headache using algorithms validated for use with ICD-9-CM codes. Comorbidities included TBI, posttraumatic stress disorder (PTSD), depression, and conditions associated with these diagnoses (anxiety, memory/attention/cognition, neck pain, tinnitus/hyperacusis, photosensitivity/photo blurring, insomnia, malaise/fatigue, and vertigo/dizziness). Multivariable logistic regression analysis was used to determine characteristics associated with baseline headache as well as those associated with persistent headache. ResultsAmong all IAV, 38,426 received their first year of VA care in 2008 and had care each year 2009-2011: 13.7% of these were diagnosed with headache in 2008. Veterans diagnosed with headache in 2008 were more likely than those without a headache diagnosis to also have a diagnosis of TBI alone (adjusted odds ratios [AOR] 6.75; 95% CI 5.79-7.86), TBI+depression (AOR 7.09; 95% CI 5.23-9.66), TBI+PTSD (AOR 10.16; 95% CI 8.96-11.53), TBI+PTSD+depression (AOR 9.40; 95% CI 8.12-10.09), and neck pain (AOR 2.44; 95% CI 2.14-2.77). Among those with headache diagnosis in 2008, 24.3% had a headache diagnosis each of the subsequent years of care (persistent headache). While diagnoses of TBI, PTSD, and/or depression at baseline were not associated with headache persistence, persistence was more likely for individuals with baseline tinnitus/hyperacusis (AOR 1.21; 95% CI 1.02-1.45), insomnia (AOR 1.19; 95% CI 1.02-1.39), and vertigo/dizziness (AOR 1.83; 95% CI 1.30-2.57). ConclusionsOur results indicate that TBI alone is a strong predictor of headache in the first year of VA care among IAV and that comorbid psychiatric comorbidities increase the likelihood of headache among individuals with TBI. However, among those with baseline headache, only tinnitus, insomnia, and vertigo were baseline clinical predictors of headache persistence. These results suggest that attention to other symptoms and conditions early in the diagnosis and treatment of headaches may be important for understanding prognosis. These comorbidities offer potential targets for intervention strategies that may help address postdeployment headaches.	[Jaramillo, Carlos A.; Eapen, Blessen C.] South Texas Vet Hlth Care Syst, Polytrauma Rehabil Ctr, San Antonio, TX USA; [Jaramillo, Carlos A.; Eapen, Blessen C.; Robinson, Jedediah] Univ Texas Hlth Sci Ctr San Antonio, Dept Rehabil Med, San Antonio, TX 78229 USA; [McGeary, Cindy A.; McGeary, Donald D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA; [Amuan, Megan] Edith Nourse Rogers Mem Hosp, CHQOER, Bedford, MA USA; [Pugh, Mary Jo] South Texas Vet Hlth Care Syst, San Antonio, TX USA; [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA	Jaramillo, CA (corresponding author), South Texas Vet Healthcare Syst ALMD, Polytrauma Rehabil Ctr, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.	jaramilloc3@uthscsa.edu	Pugh, Mary Jo/K-5336-2019	Pugh, Mary Jo/0000-0003-4196-7763	VA Health Services Research and DevelopmentUS Department of Veterans Affairs [DHI 09-237]	The study was funded by VA Health Services Research and Development (DHI 09-237).	Antonaci F, 2011, J HEADACHE PAIN, V12, P115, DOI 10.1007/s10194-010-0282-4; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Breslau N, 2003, NEUROLOGY, V60, P1308, DOI 10.1212/01.WNL.0000058907.41080.54; Bryan CJ, 2011, HEADACHE, V51, P945, DOI 10.1111/j.1526-4610.2011.01887.x; Burch RC, 2015, HEADACHE, V55, P21, DOI 10.1111/head.12482; Carlson KF, 2013, HEADACHE, V53, P1573, DOI 10.1111/head.12216; CHIBNALL JT, 1994, HEADACHE, V34, P357, DOI 10.1111/j.1526-4610.1994.hed3406357.x; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cifu DX, 2013, J REHABIL RES DEV, V50, P1169, DOI 10.1682/JRRD.2013.01.0006; Cohen SP, 2012, CEPHALALGIA, V32, P94, DOI 10.1177/0333102411422382; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Couch JR, 2007, NEUROLOGY, V69, P1169, DOI 10.1212/01.wnl.0000276985.07981.0a; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Martins HAD, 2009, ARQ NEURO-PSIQUIAT, V67, P43; Defrin R, 2015, J NEUROTRAUM, V32, P28, DOI 10.1089/neu.2014.3359; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; DoD, 2015, WORLDW NUMB TBI DVBI; Dodick DW, 2003, HEADACHE, V43, P282, DOI 10.1046/j.1526-4610.2003.03055.x; ELKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Hebert P L, 1999, Am J Med Qual, V14, P270, DOI 10.1177/106286069901400607; HICKLING EJ, 1992, HEADACHE, V32, P147, DOI 10.1111/j.1526-4610.1992.hed3203147.x; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jaramillo CA, 2015, BRAIN IMAGING BEHAV, V9, P445, DOI 10.1007/s11682-015-9402-8; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; Knol MJ, 2011, EUR J EPIDEMIOL, V26, P253, DOI 10.1007/s10654-011-9563-8; Landy PJB, 1998, INJURY, V29, P199, DOI 10.1016/S0020-1383(97)00178-2; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Norman RS, 2013, BRAIN INJURY, V27, P1623, DOI 10.3109/02699052.2013.834380; Odegard SS, 2011, HEADACHE, V51, P570, DOI 10.1111/j.1526-4610.2011.01859.x; Patil VK, 2011, HEADACHE, V51, P1112, DOI 10.1111/j.1526-4610.2011.01946.x; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Scherer MR, 2009, PHYS THER, V89, P980, DOI 10.2522/ptj.20080353; Seidler GH, 2006, PSYCHOL MED, V36, P1515, DOI 10.1017/S0033291706007963; Selim Alfredo J, 2004, J Ambul Care Manage, V27, P281; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; So CWL, 2009, J VESTIBUL RES-EQUIL, V19, P49, DOI 10.3233/VES-2009-0340; Theeler BJ, 2012, HEADACHE, V52, P732, DOI 10.1111/j.1526-4610.2012.02112.x; Theeler BJ, 2010, HEADACHE, V50, P790, DOI 10.1111/j.1526-4610.2009.01571.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Volcy M, 2005, HEADACHE, V45, P1083, DOI 10.1111/j.1526-4610.2005.05193_2.x; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Walter KH, 2012, REHABIL PSYCHOL, V57, P13, DOI 10.1037/a0026254; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WICKENS T. D., 1989, MULTIWAY CONTINGENCY; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f	54	27	27	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	MAR	2016	56	3					528	539		10.1111/head.12726			12	Clinical Neurology	Neurosciences & Neurology	DH6HG	WOS:000372891000009	26688427				2021-06-18	
J	Lustenberger, T; Kern, M; Relja, B; Wutzler, S; Stormann, P; Marzi, I				Lustenberger, T.; Kern, M.; Relja, B.; Wutzler, S.; Stoermann, P.; Marzi, I.			The effect of brain injury on the inflammatory response following severe trauma	IMMUNOBIOLOGY			English	Article						Brain Injury; TBI; Inflammation; Interleukin 6; CRP; Trauma	HEAD-INJURY; CEREBROSPINAL-FLUID; ORGAN DYSFUNCTION; SERUM IL-6; CHEMOKINES; MORTALITY; CORRELATE; PLASMA; CARE	Introduction: The inflammatory response is an important part of the pathophysiology of severe injury and, in particular, of severe traumatic brain injury (TBI). This study evaluates the inflammatory course following major trauma and focuses on the effect of severe TBI on inflammatory markers. Material and methods: This was a retrospective analysis of prospectively collected data in 123 severely injured (ISS >= 16) trauma patients. The study cohort was divided into patients with isolated TBI (Head AIS >= 3, all other AIS <3), polytraumatized patients with severe TBI (Head AIS >= 3; AIS of other body area >= 3; Polytrauma + TBI) and polytraumatized patients without TBI (Head AIS <3; Polytrauma). Levels of inflammatory markers (Interleukin-6 [IL-6], C-reactive Protein [CRP], leukocytes) measured upon arrival and through hospital days 1-3 were compared between the groups. Results: On admission and through hospital day 3, IL-6 levels were significantly different between the 3 groups (admission: isolated TBI vs. Polytrauma + TBI vs. Polytrauma; 94 +/- 16 vs. 149 +/- 20 vs.. 245 +/- 50 pg/mL; p < 0.05). Interleukin-6 levels peaked on hospital day 1 and declined thereafter. C-reactive protein and leukocyte counts were not significantly different between the cohorts on arrival and peaked on hospital day 2 and 1, respectively. In patients with severe TBI, admission IL-6 levels significantly predicted the development of septic complications (ROC analysis, AUC: 0.88, p = 0.001, 95% CI: 0.79-0.97) and multiple organ dysfunction (ROC analysis, AUC: 0.83, p = 0.001, 95% CI: 0.69-0.96). Conclusion: Severe TBI reduced the inflammatory response following trauma. Significant correlations between admission IL-6 values and the development of MOF, sepsis and the neurological outcome were found in patients with TBI. (C) 2015 Elsevier GmbH. All rights reserved.	[Lustenberger, T.; Kern, M.; Relja, B.; Wutzler, S.; Stoermann, P.; Marzi, I.] Goethe Univ Frankfurt, Dept Trauma Hand & Reconstruct Surg, Frankfurt, Germany	Lustenberger, T (corresponding author), Goethe Univ Frankfurt, Univ Hosp, Dept Trauma Hand & Reconstruct Surg, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	tom.lustenberg@gmail.com	Relja, Borna/B-6642-2016	Relja, Borna/0000-0002-5625-8823			Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Dehne MG, 2002, BURNS, V28, P535, DOI 10.1016/S0305-4179(02)00050-5; Frink M, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-49; Giannoudis PV, 2008, J TRAUMA, V65, P646, DOI 10.1097/TA.0b013e3181820d48; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Lansink KWW, 2013, EUR J TRAUMA EMERG S, V39, P375, DOI 10.1007/s00068-013-0278-2; LaPar DJ, 2012, J AM COLL SURGEONS, V214, P478, DOI 10.1016/j.jamcollsurg.2011.12.015; Leitgeb J, 2013, EUR J TRAUMA EMERG S, V39, P285, DOI 10.1007/s00068-013-0269-3; Maas A. I., 2000, CURR OPIN CRIT CARE, V6, P281; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; OKeefe GE, 1997, ARCH SURG-CHICAGO, V132, P920; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Stensballe J, 2009, ACTA ANAESTH SCAND, V53, P515, DOI 10.1111/j.1399-6576.2008.01801.x; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; van Wessem KJP, 2014, EUR J TRAUMA EMERG S, V40, P127, DOI 10.1007/s00068-014-0392-9; Vanzant EL, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0788-x; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	30	27	31	0	8	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0171-2985			IMMUNOBIOLOGY	Immunobiology	MAR	2016	221	3					427	431		10.1016/j.imbio.2015.11.011			5	Immunology	Immunology	DD7NM	WOS:000370111400004	26688509				2021-06-18	
J	La Fountaine, MF; Toda, M; Testa, AJ; Hill-Lombardi, V				La Fountaine, Michael F.; Toda, Michita; Testa, Anthony J.; Hill-Lombardi, Vicci			Autonomic Nervous System Responses to Concussion: Arterial Pulse Contour Analysis	FRONTIERS IN NEUROLOGY			English	Article						concussion; sympathetic nervous system; arterial stiffness; exercise intolerance	QT INTERVAL VARIABILITY; BLOOD-PRESSURE; STATEMENT; DETERMINANTS; DYSFUNCTION; PREDICTOR; DISEASE; SPORT; REST	The arterial pulse wave (APW) has a distinct morphology whose contours reflect dynamics in cardiac function and peripheral vascular tone as a result of sympathetic nervous system (SNS) control. With a transition from rest to increased metabolic demand, the expected augmentation of SNS outflow will not only affect arterial blood pressure and heart rate but it will also induce changes to the contours of the APW. Following a sports concussion, a transient state cardiovascular autonomic dysfunction is present. How this state affects the APW has yet to be described. A prospective, parallel-group study on cardiovascular autonomic control (i.e., digital electrocardiogram and continuous beat to-beat blood pressure) was performed in the seated upright position in 10 athletes with concussion and 7 non-injured control athletes. Changes in APW were compared at rest and during the first 60 s (F60) of an isometric handgrip test (IHGT) in concussed athletes and non injured controls within 48 h and 1 week of injury. The concussion group was further separated by the length of time until they were permitted to return to play (RTP > 1week; RTP <= 1week). SysSlope, an indirect measurement of stroke volume, was significantly lower in the concussion group at rest and during F60 at 48 h and 1week; a paradoxical decline in SysSlope occurred at each visit during the transition from rest to IHGT F60. The RTP > 1week group had lower SysSlope (405 200; 420 +/- 88; 454 +/- 236 mmHg/s, respectively) at rest 48 h compared to the RTP <= 1week and controls. Similarly at 48 h rest, several measurements of arterial stiffness were abnormal in RTP > 1week compared to RTP <= 1week and controls: peak-to-notch latency (0.12 +/- 0.04; 0.16 +/- 0.02; 0.17 +/- 0.05, respectively), notch relative amplitude (0.70 +/- 0.03; 0.71 +/- 0.04; 0.66 +/- 0.14, respectively), and stiffness index (6.4 +/- 0.2; 5.7 +/- 0.4; 5.8 +/- 0.5, respectively). Use of APW revealed that concussed athletes have a transient increase in peripheral artery stiffness, which may be a compensatory adaptation to a paradoxical decline of stroke volume during the transition from rest to a state of increased metabolic demand within 48 h of concussion. This dysfunction of the SNS appeared to be more pronounced among concussed athletes who were removed from participation for >1 week compared to those who resumed play within 7 days.	[La Fountaine, Michael F.; Hill-Lombardi, Vicci] Seton Hall Univ, Sch Hlth & Med Sci, S Orange, NJ 07079 USA; [La Fountaine, Michael F.; Hill-Lombardi, Vicci] Seton Hall Univ, Inst Adv Study Rehabil & Sports Sci, S Orange, NJ 07079 USA; [Toda, Michita] Univ Wisconsin, Dept Athlet, Madison, WI USA; [Testa, Anthony J.] Seton Hall Univ, Dept Athlet, S Orange, NJ 07079 USA	La Fountaine, MF (corresponding author), Seton Hall Univ, Sch Hlth & Med Sci, S Orange, NJ 07079 USA.; La Fountaine, MF (corresponding author), Seton Hall Univ, Inst Adv Study Rehabil & Sports Sci, S Orange, NJ 07079 USA.	lafounmi@shu.edu	La Fountaine, Michael/Q-6769-2019				Abaji JP, 2016, J NEUROTRAUM, V33, P811, DOI 10.1089/neu.2015.3989; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Benetos A, 1997, HYPERTENSION, V30, P1410, DOI 10.1161/01.HYP.30.6.1410; Berger RD, 1997, CIRCULATION, V96, P1557, DOI 10.1161/01.CIR.96.5.1557; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Conder RL, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00890; DARNE B, 1989, HYPERTENSION, V13, P392, DOI 10.1161/01.HYP.13.4.392; DELIUS W, 1972, ACTA PHYSIOL SCAND, V84, P82, DOI 10.1111/j.1748-1716.1972.tb05158.x; Domanski MJ, 2001, AM J CARDIOL, V87, P675, DOI 10.1016/S0002-9149(00)01482-X; Drew BJ, 2004, CIRCULATION, V110, P2721, DOI 10.1161/01.CIR.0000145144.56673.59; Duprez DA, 2004, AM J HYPERTENS, V17, P647, DOI 10.1016/j.amjhyper.2004.03.671; Fagard RH, 2008, J HUM HYPERTENS, V22, P57, DOI 10.1038/sj.jhh.1002258; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; HARLEY A, 1969, J CLIN INVEST, V48, P895, DOI 10.1172/JCI106048; Herizman AB, 1937, AM J PHYSIOL, V119, P334; Heyer GL, 2016, CLIN J SPORT MED, V26, P40, DOI 10.1097/JSM.0000000000000183; JOANNIDES R, 1995, AM J PHYSIOL-HEART C, V268, pH794; Kozlowski KF, 2013, J ATHL TRAINING, V48, P627, DOI 10.4085/1062-6050-48.5.02; La Fountaine MF, 2014, INT J CARDIOL, V172, pE511, DOI 10.1016/j.ijcard.2014.01.095; La Fountaine MF, 2011, J ATHL TRAINING, V46, P230; La Fountaine MF, 2009, AUTON NEUROSCI-BASIC, V148, P101, DOI 10.1016/j.autneu.2009.03.001; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; LIND AR, 1964, CLIN SCI, V27, P229; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Middleton K, 2010, CLIN J SPORT MED, V20, P491, DOI 10.1097/JSM.0b013e3181fac088; Millasseau SC, 2002, CLIN SCI, V103, P371, DOI 10.1042/cs1030371; Millasseau SC, 2003, AM J HYPERTENS, V16, P467, DOI 10.1016/S0895-7061(03)00569-7; PARATI G, 1989, HYPERTENSION, V13, P647, DOI 10.1161/01.HYP.13.6.647; Sandercock GRH, 2005, INT J CARDIOL, V103, P238, DOI 10.1016/j.ijcard.2004.09.013; Shi P., 2009, Journal of Medical Engineering & Technology, V33, P628, DOI 10.3109/03091900903150980; Vanravenswaaijarts CMA, 1993, ANN INTERN MED, V118, P436, DOI 10.7326/0003-4819-118-6-199303150-00008; Yildiran T, 2010, TEX HEART I J, V37, P284	33	27	27	0	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	FEB 13	2016	7								13	10.3389/fneur.2016.00013			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DE2CF	WOS:000370433100001	26925028	DOAJ Gold, Green Published			2021-06-18	
J	Mohamed, RA; Agha, AM; Abdel-Rahman, AA; Nassar, NN				Mohamed, R. A.; Agha, A. M.; Abdel-Rahman, A. A.; Nassar, N. N.			ROLE OF ADENOSINE A(2A) RECEPTOR IN CEREBRAL ISCHEMIA REPERFUSION INJURY: SIGNALING TO PHOSPHORYLATED EXTRACELLULAR SIGNAL-REGULATED PROTEIN KINASE (pERK1/2)	NEUROSCIENCE			English	Article						A(2A); ischemia reperfusion; pERK1/2; microglia; apoptosis; oxidative stress	TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; C-FOS; FOREBRAIN ISCHEMIA; MICROGLIAL CELLS; FACTOR-ALPHA; ACTIVATION; RATS; EXPRESSION	Following brain ischemia reperfusion (IR), the dramatic increase in adenosine activates A(2A)R to induce further neuronal damage. Noteworthy, A(2A) antagonists have proven efficacious in halting IR injury, however, the detailed downstream signaling remains elusive. To this end, the present study aimed to investigate the possible involvement of phospho-extracellular signal-regulated kinase (pERK1/2) pathway in mediating protection afforded by the central A(2A) blockade. Male Wistar rats (250-270 g) subjected to bilateral carotid occlusion for 45 min followed by a 24-h reperfusion period showed increased infarct size corroborating histopathological damage, memory impairment and motor incoordination as well as increased locomotor activity. Those events were mitigated by the unilateral intrahippocampal administration of the selective A(2A) antagonist SCH58261 via a decrease in pERK1/2 downstream from diacyl glycerol (DAG) signaling. Consequent to pERK1/2 inhibition, reduced hippocampal microglial activation, glial tumor necrosis factor-alpha (TNF-alpha) and brain-derived neurotropic factor (BDNF) expression, glutamate (Glu), inducible nitric oxide synthase (iNOS) and thiobarbituric acid reactive substances (TBARS) were evident in animals receiving SCH58261. Additionally, the anti-inflammatory cytokine interleukin-10 (IL-10) increased following nuclear factor (erythroid-derived 2)-like 2 (Nrf-2). Taken all together, these events suppressed apoptotic pathways via a reduction in cytochrome c (Cyt.c) as well as caspase-3 supporting a crucial role for pERK1/2 inhibition in consequent reduction of inflammatory and excitotoxic cascades as well as correction of the redox imbalance. (C) 2015 IBRO. Published by Elsevier Ltd. All rights reserved.	[Mohamed, R. A.; Agha, A. M.; Nassar, N. N.] Cairo Univ, Fac Pharm, Dept Pharmacol & Toxicol, Cairo 11562, Egypt; [Abdel-Rahman, A. A.] E Carolina Univ, Brody Sch Med, Dept Pharmacol & Toxicol, Greenville, NC 27858 USA	Nassar, NN (corresponding author), Cairo Univ, Fac Pharm, Dept Pharmacol & Toxicol, Kasr El Aini St, Cairo 11562, Egypt.	reham.atef@pharma.cu.edu.eg; azzaagha@yahoo.com; abdelrahmana@ecu.edu; noha.nassar@pharma.cu.edu.eg	Abdel-Rahman, Abdel/AAJ-6753-2020				Abdallah DM, 2011, BRAIN RES, V1385, P257, DOI 10.1016/j.brainres.2011.02.007; Alonso D, 2002, J COMP NEUROL, V443, P183, DOI 10.1002/cne.10111; Alvarez-Diaz A, 2007, NEONATOLOGY, V92, P227, DOI 10.1159/000103741; Baldanzi G, 2010, CELL DEATH DIFFER, V17, P1059, DOI 10.1038/cdd.2009.210; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bender TS, 2009, ALCOHOL CLIN EXP RES, V33, P408, DOI 10.1111/j.1530-0277.2008.00860.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carlezon WA, 2005, TRENDS NEUROSCI, V28, P436, DOI 10.1016/j.tins.2005.06.005; Cheng HC, 2002, J BIOL CHEM, V277, P33930, DOI 10.1074/jbc.M201206200; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; Cunha Rodrigo A, 2005, Purinergic Signal, V1, P111, DOI 10.1007/s11302-005-0649-1; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; D'Cruz BJ, 2002, J CEREBR BLOOD F MET, V22, P843, DOI 10.1097/00004647-200207000-00009; Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010; de Mendonca A, 2000, BRAIN RES REV, V33, P258, DOI 10.1016/S0165-0173(00)00033-3; Edling Y, 2007, GLIA, V55, P328, DOI 10.1002/glia.20464; ELNASR MS, 1992, J PHARMACOL TOXICOL, V27, P23, DOI 10.1016/1056-8719(92)90016-T; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; Fischer AJ, 2009, GLIA, V57, P166, DOI 10.1002/glia.20743; Fredholm BB, 2007, PROG NEUROBIOL, V83, P263, DOI 10.1016/j.pneurobio.2007.07.005; Fujioka S, 2004, MOL CELL BIOL, V24, P7806, DOI 10.1128/MCB.24.17.7806-7819.2004; Galvao RIM, 2005, NEUROCHEM RES, V30, P39, DOI 10.1007/s11064-004-9684-5; Gao C, 2010, HIPPOCAMPUS, V20, P1072, DOI 10.1002/hipo.20705; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Gomes C, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-16; Gui L, 2009, BRAIN RES, V1297, P185, DOI 10.1016/j.brainres.2009.08.050; Gupta S., 2001, Current Molecular Medicine (Hilversum), V1, P317, DOI 10.2174/1566524013363780; Harukuni I, 2006, NEUROL CLIN, V24, P1, DOI 10.1016/j.ncl.2005.10.004; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; Institute for Laboratory Animal Research (ILAR), 1996, GUIDE CARE USE LAB A; Irving EA, 2000, MOL BRAIN RES, V77, P65, DOI 10.1016/S0169-328X(00)00043-7; Janssen YMW, 1997, AM J PHYSIOL-LUNG C, V273, pL789; Jeltsch H, 2001, NEUROBIOL LEARN MEM, V76, P81, DOI 10.1006/nlme.2000.3986; Jones PA, 1998, BRAIN RES, V800, P328, DOI 10.1016/S0006-8993(98)00540-X; Karnam HB, 2009, EPILEPSY RES, V85, P221, DOI 10.1016/j.eplepsyres.2009.03.008; Kim YH, 2010, INT IMMUNOPHARMACOL, V10, P1560, DOI 10.1016/j.intimp.2010.09.007; KURINO M, 1995, J NEUROCHEM, V65, P1282; Latini S, 2001, J NEUROCHEM, V79, P463, DOI 10.1046/j.1471-4159.2001.00607.x; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; Macaya A, 1996, Rev Neurol, V24, P1356; Maddahi A, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-107; Malik ZA, 2011, J ETHNOPHARMACOL, V133, P729, DOI 10.1016/j.jep.2010.10.061; Mao LM, 2007, BRAIN RES BULL, V72, P302, DOI 10.1016/j.brainresbull.2007.01.009; McManus MJ, 2014, MOL CELL NEUROSCI, V63, P13, DOI 10.1016/j.mcn.2014.09.002; Medeiros R, 2007, J NEUROSCI, V27, P5394, DOI 10.1523/JNEUROSCI.5047-06.2007; Melani A, 2009, BRAIN, V132, P1480, DOI 10.1093/brain/awp076; Milot MR, 2009, BEHAV BRAIN RES, V200, P173, DOI 10.1016/j.bbr.2009.01.009; Miyamoto E, 2006, J PHARMACOL SCI, V100, P433, DOI 10.1254/jphs.CPJ06007X; Mohamed RA, 2012, NEUROCHEM RES, V37, P538, DOI 10.1007/s11064-011-0640-x; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Okada S, 2003, INT IMMUNOL, V15, P1275, DOI 10.1093/intimm/dxg126; Olajide OA, 2013, J ETHNOPHARMACOL, V145, P42, DOI 10.1016/j.jep.2012.10.031; OSSENKOPP KP, 1990, PHARMACOL BIOCHEM BE, V36, P875, DOI 10.1016/0091-3057(90)90093-W; Park GH, 2010, NITRIC OXIDE-BIOL CH, V22, P18, DOI 10.1016/j.niox.2009.10.008; Park JS, 2007, J PHARMACOL EXP THER, V320, P1237, DOI 10.1124/jpet.106.114322; Paterniti I, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-31; Pedata F, 2007, PURINERG SIGNAL, V3, P299, DOI 10.1007/s11302-007-9085-8; Pedata F, 2001, ANN NY ACAD SCI, V939, P74; Phillis JW, 1995, BRAIN RES, V705, P79, DOI 10.1016/0006-8993(95)01153-6; Piantadosi CA, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.207738; Quiroz C, 2006, J NEUROSCI, V26, P10808, DOI 10.1523/JNEUROSCI.1661-06.2006; Rebola N, 2011, J NEUROCHEM, V117, P100, DOI 10.1111/j.1471-4159.2011.07178.x; Rehni AK, 2008, FUND CLIN PHARMACOL, V22, P179, DOI 10.1111/j.1472-8206.2008.00567.x; Rehni AK, 2008, PHARMACOL REP, V60, P904; Sairanen TR, 2001, J NEUROL SCI, V186, P87, DOI 10.1016/S0022-510X(01)00508-1; Sandberg M, 2014, NEUROPHARMACOLOGY, V79, P298, DOI 10.1016/j.neuropharm.2013.11.004; Sebastiao AM, 2009, BRIT J PHARMACOL, V158, P15, DOI 10.1111/j.1476-5381.2009.00157.x; Sharifzadeh M, 2005, J NEUROCHEM, V95, P1078, DOI 10.1111/j.1471-4159.2005.03454.x; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tian HP, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-139; Ulrich PT, 1998, STROKE, V29, P2412, DOI 10.1161/01.STR.29.11.2412; Vallee M, 1997, P NATL ACAD SCI USA, V94, P14865, DOI 10.1073/pnas.94.26.14865; Vitkovic L, 2000, MOL PSYCHIATR, V5, P604, DOI 10.1038/sj.mp.4000813; Wang Wei-Bin, 2005, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V21, P278; Wang XK, 2003, J PHARMACOL EXP THER, V304, P172, DOI 10.1124/jpet.102.040246; Yang YL, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-55; Zhang H, 2014, J HUAZHONG U SCI-MED, V34, P354, DOI 10.1007/s11596-014-1282-4; Zhang YS, 2004, MOL CANCER THER, V3, P885; Zhou MA, 2013, BRAIN RES, V1506, P105, DOI 10.1016/j.brainres.2013.02.010; Zhuang SG, 2006, J PHARMACOL EXP THER, V319, P991, DOI 10.1124/jpet.106.107367	83	27	31	0	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	FEB 9	2016	314						145	159		10.1016/j.neuroscience.2015.11.059			15	Neurosciences	Neurosciences & Neurology	CZ9CE	WOS:000367394600013	26642806				2021-06-18	
J	Nichols, JN; Deshane, AS; Niedzielko, TL; Smith, CD; Floyd, CL				Nichols, Jessica N.; Deshane, Alok S.; Niedzielko, Tracy L.; Smith, Cory D.; Floyd, Candace L.			Greater neurobehavioral deficits occur in adult mice after repeated, as compared to single, mild traumatic brain injury (mTBI)	BEHAVIOURAL BRAIN RESEARCH			English	Article						Traumatic brain injury; Mild; Repetitive; Behavior; Learning and memory; Sleep	PROFESSIONAL FOOTBALL PLAYERS; MORRIS WATER MAZE; SLEEP DISTURBANCE; RECURRENT CONCUSSION; MOUSE MODEL; LONG-TERM; UPTAKE INHIBITORS; FLUID PERCUSSION; GENE-EXPRESSION; SPATIAL MEMORY	Mild traumatic brain injury (mTBI) accounts for the majority of all brain injuries and affected individuals typically experience some extent of cognitive and/or neuropsychiatric deficits. Given that repeated mTBIs often result in worsened prognosis, the cumulative effect of repeated mTBIs is an area of clinical concern and on-going pre-clinical research. Animal models are critical in elucidating the underlying mechanisms of single and repeated mTBI-associated deficits, but the neurobehavioral sequelae produced by these models have not been well characterized. Thus, we sought to evaluate the behavioral changes incurred after single and repeated mTBIs in mice utilizing a modified impact-acceleration model. Mice in the mTBI group received 1 impact while the repeated mTBI group received 3 impacts with an inter-injury interval of 24 h. Classic behavior evaluations included the Morris water maze (MWM) to assess learning and memory, elevated plus maze (EPM) for anxiety, and forced swim test (FST) for depression/helplessness. Additionally, species-typical behaviors were evaluated with the marble-burying and nestlet shredding tests to determine motivation and apathy. Non-invasive vibration platforms were used to examine sleep patterns post-mTBI. We found that the repeated mTBI mice demonstrated deficits in MWM testing and poorer performance on species-typical behaviors. While neither single nor repeated mTBI affected behavior in the EPM or FST, sleep disturbances were observed after both single and repeated mTBI. Here, we conclude that behavioral alterations shown after repeated mTBI resemble several of the deficits or disturbances reported by patients, thus demonstrating the relevance of this murine model to study repeated mTBIs. (C) 2015 Elsevier B.V. All rights reserved.	[Nichols, Jessica N.; Deshane, Alok S.; Niedzielko, Tracy L.; Floyd, Candace L.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL 35249 USA; [Smith, Cory D.] Univ Alabama Birmingham, Sch Med, Birmingham, AL 35294 USA	Floyd, CL (corresponding author), Univ Alabama Birmingham, Dept Phys Med & Rehabil, Spain Rehabil Ctr 529C, 1717 6th Ave South, Birmingham, AL 35249 USA.	jnic@uab.edu; adeshane@uab.edu; tracyniedzielko@uabmc.edu; cdsmith2@uab.edu; candacefloyd@uabmc.edu			National Institutes of Health, NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS075162]; NFL Charities Medical Research Grant; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS075162] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health, NINDS grant # R01NS075162 (to CLF) and NFL Charities Medical Research Grant.	Angoa-Perez M, 2013, JOVE-J VIS EXP, DOI 10.3791/50978; Aubert A, 1999, NEUROSCI BIOBEHAV R, V23, P1029, DOI 10.1016/S0149-7634(99)00034-2; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Baumann CR, 2012, NEUROMOL MED, V14, P205, DOI 10.1007/s12017-012-8178-x; Bolton AN, 2014, J NEUROPATH EXP NEUR, V73, P933, DOI 10.1097/NEN.0000000000000115; BROEKKAMP CL, 1986, EUR J PHARMACOL, V126, P223, DOI 10.1016/0014-2999(86)90051-8; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; Centers for Disease Control and Prevention, 2014, REP C TRAUM BRAIN IN; Cheng JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115765; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Committee on Sports-Related Concussions in Youth, 2014, SPORTS REL CONC YOUT; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Deacon RMJ, 2005, BEHAV BRAIN RES, V156, P241, DOI 10.1016/j.bbr.2004.05.027; Deacon R, 2012, JOVE-J VIS EXP, DOI 10.3791/2607; Deacon RMJ, 2006, NAT PROTOC, V1, P122, DOI 10.1038/nprot.2006.20; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feldman LA, 2010, BEHAV BRAIN FUNCT, V6, DOI 10.1186/1744-9081-6-35; Florian C, 2006, LEARN MEMORY, V13, P465, DOI 10.1101/lm.249306; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Imbach LL, 2015, BRAIN, V138, P726, DOI 10.1093/brain/awu391; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/316575; Jirkof P, 2014, J NEUROSCI METH, V234, P139, DOI 10.1016/j.jneumeth.2014.02.001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li X, 2006, LIFE SCI, V78, P1933, DOI 10.1016/j.lfs.2005.08.002; LISTER RG, 1987, PSYCHOPHARMACOLOGY, V92, P180; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Moojen VKM, 2012, BRAIN RES, V1466, P82, DOI 10.1016/j.brainres.2012.05.041; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Nicolas LB, 2006, EUR J PHARMACOL, V547, P106, DOI 10.1016/j.ejphar.2006.07.015; NJUNGE K, 1991, BRIT J PHARMACOL, V104, P105, DOI 10.1111/j.1476-5381.1991.tb12392.x; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Porsolt R.D., 2001, RODENT MODELS OR DEP; Riggio S, 2011, NEUROL CLIN, V29, P35, DOI 10.1016/j.ncl.2010.10.008; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Rowe RK, 2014, BRAIN INJURY, V28, P504, DOI 10.3109/02699052.2014.888768; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schiehser DM, 2011, J CLIN EXP NEUROPSYC, V33, P704, DOI 10.1080/13803395.2011.553587; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Starkstein SE, 2014, PSYCHIAT CLIN N AM, V37, P103, DOI 10.1016/j.psc.2013.10.002; Sullivan KA, 2015, J NEUROTRAUM, V32, P474, DOI 10.1089/neu.2013.3284; Thomas A, 2009, PSYCHOPHARMACOLOGY, V204, P361, DOI 10.1007/s00213-009-1466-y; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Van de Weerd HA, 2001, BEHAV PROCESS, V53, P11, DOI 10.1016/S0376-6357(00)00135-2; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu L, 2014, EXP NEUROL; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	71	27	28	0	33	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	FEB 1	2016	298		B				111	124		10.1016/j.bbr.2015.10.052			14	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	CZ9JM	WOS:000367413900013	26542813				2021-06-18	
J	Saverino, C; Swaine, B; Jaglal, S; Lewko, J; Vernich, L; Voth, J; Calzavara, A; Colantonio, A				Saverino, Cristina; Swaine, Bonnie; Jaglal, Susan; Lewko, John; Vernich, Lee; Voth, Jennifer; Calzavara, Andrew; Colantonio, Angela			Rehospitalization After Traumatic Brain Injury: A Population-Based Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Patient readmission, hospital readmission; Rehabiliation; Risk factors	UNPLANNED HOSPITAL READMISSION; RISK; RATES; CARE; SYSTEM	Objective: To examine, from a Canadian population-based perspective, the incidence and etiology of long-term hospital utilization among persons living with traumatic brain injury (TBI) by age and sex. Design: Retrospective cohort study. Setting: Acute care hospitals. Participants: Index cases of TBI (N=29,269) were identified from the Discharge Abstract Database for fiscal years 2002/2003 through 2009/ 2010 and were followed-up until 36 months after injury. Interventions: Not applicable. Main Outcome Measures: Rehospitalization was defined as admission to an acute care facility that occurred up to 36 months after index injury. Diagnoses associated with subsequent rehospitalization were examined by age and sex. Results: Of the patients with TBI, 35.5% (n=10,390) were subsequently hospitalized during the 3-year follow-up period. Multivariable logistic regression (controlling for index admission hospital) identified men, older age, mechanism of injury being a fall, greater injury severity, rural residence, greater comorbidity, and psychiatric comorbidity to be significant predictors of rehospitalization in a 3-year period postinjury. The most common causes for rehospitalization differed by age and sex. Conclusions: Rehospitalization after TBI is common. Factors associated with rehospitalization can inform long-term postdischarge planning. Findings also support examining causes for rehospitalization by age and sex. (C) 2016 by the American Congress of Rehabilitation Medicine	[Saverino, Cristina] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Saverino, Cristina] Baycrest, Rotman Res Inst, Toronto, ON, Canada; [Saverino, Cristina; Jaglal, Susan; Voth, Jennifer; Colantonio, Angela] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON, Canada; [Swaine, Bonnie] Univ Montreal, Fac Med, Sch Rehabil, Montreal, PQ H3C 3J7, Canada; [Jaglal, Susan] Univ Toronto, Dept Phys Therapy, Toronto, ON, Canada; [Lewko, John] Laurentian Univ, Ctr Res Human Dev, Sudbury, ON P3E 2C6, Canada; [Vernich, Lee] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Calzavara, Andrew; Colantonio, Angela] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Colantonio, Angela] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada	Colantonio, A (corresponding author), 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca		Colantonio, Angela/0000-0003-2094-4765; Jaglal, Susan/0000-0002-2930-1443	Ontario Neurotrauma Foundation [2006-ABI-RTBI-432]; Ontario Neurotrauma Foundation-Reseau provincial de recherche en adaptation-readaptation [ONF-2011-ONF-REPAR2-883]; Toronto Rehabilitation InstituteUniversity of Toronto; Institute for Clinical Evaluative Sciences, Ontario Ministry of Health and Long-Term Care; Canadian Institutes of Health Research Research Chair in Gender, Work and Health from the Institute of Gender and HealthCanadian Institutes of Health Research (CIHR) [CGW-126580]	Supported by the Ontario Neurotrauma Foundation (grant no. 2006-ABI-RTBI-432); Ontario Neurotrauma Foundation-Reseau provincial de recherche en adaptation-readaptation (grant no. ONF-2011-ONF-REPAR2-883); the Toronto Rehabilitation Institute, the Institute for Clinical Evaluative Sciences, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care; and a Canadian Institutes of Health Research Research Chair in Gender, Work and Health (grant no. CGW-126580) from the Institute of Gender and Health.	Association for the Advancement of Automotive Medicine, 2008, ABBR INJ SCAL 2005 U; Boutin A., 2013, CRIT CARE, V17, pP331; Cakir B, 2010, SOUTH MED J, V103, P1079, DOI 10.1097/SMJ.0b013e3181f20a0f; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Canadian Institute for Health Information, 2012, ALL CAUS READM AC CA; Canadian Institute for Health Information, 2004, DAT QUAL DOC DISCH A; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, P85, DOI 10.1016/S0003-9993(99)90312-X; Colantonio A, 2005, ARCH PHYS MED REHAB, V86, pE21; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; CORRIGAN JM, 1992, HEALTH SERV RES, V27, P81; Dai YT, 2002, J FORMOS MED ASSOC, V101, P779; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Jaglal SB, 2009, SPINAL CORD, V47, P604, DOI 10.1038/sc.2009.9; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Johns Hopkins University, 2013, J HOPK ACG SYST; Kim H, 2006, CAN J NEUROL SCI, V33, P48, DOI 10.1017/S0317167100004686; Kim H, 2006, NEUROREHABILITATION, V21, P269; Kralj B, 2000, ONTARIO MED REV, V67, P37; Madi Nawaf, 2007, Healthc Q, V10, P30; Marwitz JH, 2001, J HEAD TRAUMA REHAB, V16, P307, DOI 10.1097/00001199-200108000-00002; McCrone P, 2006, SOC PSYCH PSYCH EPID, V41, P656, DOI 10.1007/s00127-006-0075-x; Moore L, 2014, J TRAUMA ACUTE CARE, V76, P1310, DOI 10.1097/TA.0000000000000202; Moore L, 2014, ANN SURG, V259, P374, DOI 10.1097/SLA.0b013e31828b0fae; Morris DS, 2014, INJURY, V45, P56, DOI 10.1016/j.injury.2013.04.029; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P1884, DOI 10.1016/j.apmr.2012.11.054; Reid RJ, 2001, MED CARE, V39, P86, DOI 10.1097/00005650-200101000-00010; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shipton S, 1996, Home Care Provid, V1, P83, DOI 10.1016/S1084-628X(96)90234-8; STARFIELD B, 1991, HEALTH SERV RES, V26, P53; Swaine BR, 2007, PEDIATRICS, V119, P749, DOI 10.1542/peds.2006-1186; Van Rensbergen G, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-46; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; Weissman JS, 1999, MED CARE, V37, P490, DOI 10.1097/00005650-199905000-00008; Westert GP, 2002, HEALTH POLICY, V61, P269, DOI 10.1016/S0168-8510(01)00236-6; Williams JI, 1996, PATTERNS HLTH CARE O, V2nd; Worrell SS, 2006, J TRAUMA, V60, P379, DOI 10.1097/01.ta.0000203549.15373.7b	37	27	27	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2016	97	2		1			S19	S25		10.1016/j.apmr.2015.04.016			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	DC4RI	WOS:000369207600003	25944501	Bronze			2021-06-18	
J	Namjoshi, DR; Cheng, WH; Carr, M; Martens, KM; Zareyan, S; Wilkinson, A; McInnes, KA; Cripton, PA; Wellington, CL				Namjoshi, Dhananjay R.; Cheng, Wai Hang; Carr, Michael; Martens, Kris M.; Zareyan, Shahab; Wilkinson, Anna; McInnes, Kurt A.; Cripton, Peter A.; Wellington, Cheryl L.			Chronic Exposure to Androgenic-Anabolic Steroids Exacerbates Axonal Injury and Microgliosis in the CHIMERA Mouse Model of Repetitive Concussion	PLOS ONE			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; RECEPTOR MESSENGER-RNA; NATIONAL-FOOTBALL-LEAGUE; BRAIN-INJURY; HEAD-INJURY; POSTCONCUSSION SYNDROME; PROTEIN-TAU; MALE-MICE; SEROTONIN; IMPACT	Concussion is a serious health concern. Concussion in athletes is of particular interest with respect to the relationship of concussion exposure to risk of chronic traumatic encephalopathy (CTE), a neurodegenerative condition associated with altered cognitive and psychiatric functions and profound tauopathy. However, much remains to be learned about factors other than cumulative exposure that could influence concussion pathogenesis. Approximately 20% of CTE cases report a history of substance use including androgenic-anabolic steroids (AAS). How acute, chronic, or historical AAS use may affect the vulnerability of the brain to concussion is unknown. We therefore tested whether antecedent AAS exposure in young, male C57BI/6 mice affects acute behavioral and neuropathological responses to mild traumatic brain injury (TBI) induced with the CHIMERA (Closed Head Impact Model of Engineered Rotational Acceleration) platform. Male C57Bl/6 mice received either vehicle or a cocktail of three AAS (testosterone, nandrolone and 17 alpha-methyltestosterone) from 8-16 weeks of age. At the end of the 7th week of treatment, mice underwent two closed-head TBI or sham procedures spaced 24 h apart using CHIMERA. Post-repetitive TBI (rTBI) behavior was assessed for 7 d followed by tissue collection. AAS treatment induced the expected physiological changes including increased body weight, testicular atrophy, aggression and downregulation of brain 5-HT1B receptor expression. rTBI induced behavioral deficits, widespread axonal injury and white matter microgliosis. While AAS treatment did not worsen post-rTBI behavioral changes, AAS-treated mice exhibited significantly exacerbated axonal injury and microgliosis, indicating that AAS exposure can alter neuronal and innate immune responses to concussive TBI.	[Namjoshi, Dhananjay R.; Cheng, Wai Hang; Carr, Michael; Martens, Kris M.; Zareyan, Shahab; Wilkinson, Anna; Wellington, Cheryl L.] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; [McInnes, Kurt A.; Cripton, Peter A.] Univ British Columbia, Dept Biomech Engn, Vancouver, BC V5Z 1M9, Canada; [Cripton, Peter A.; Wellington, Cheryl L.] Univ British Columbia, Int Collaborat Repair Discoveries, Vancouver, BC V5Z 1M9, Canada	Wellington, CL (corresponding author), Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada.; Wellington, CL (corresponding author), Univ British Columbia, Int Collaborat Repair Discoveries, Vancouver, BC V5Z 1M9, Canada.	wcheryl@mail.ubc.ca	Meijer, Anna/K-5118-2016; Cripton, Peter/AAC-8268-2020	Cripton, Peter/0000-0002-5067-0833; Cheng, Wai Hang/0000-0002-3408-9184; McInnes, Kurt/0000-0001-5931-2963	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP 123461]; Alzheimer Society Research Program Doctoral award; Comissao Technica de Atribuicao de Bolsas para Estudos Pos-Graduados Macao	This work was supported by operating funding from the Canadian Institutes of Health Research (MOP 123461) to CLW (http://www.cihrirsc.gc.ca/e/193.htm). WHC is supported by Alzheimer Society Research Program Doctoral award (http://www.alzheimer.ca/en/Research/Alzheimer-Society-Research-Program) and Comissao Technica de Atribuicao de Bolsas para Estudos Pos-Graduados Macao. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambar G, 2009, GENES BRAIN BEHAV, V8, P161, DOI 10.1111/j.1601-183X.2008.00458.x; ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Bonaventure P, 1998, NEUROSCIENCE, V82, P469; Bressan S, 2016, J PAEDIATR CHILD H, V52, P151, DOI 10.1111/jpc.12967; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cernich AN, 2012, J HEAD TRAUMA REHAB, V27, P253, DOI 10.1097/HTR.0b013e3182585cd5; Clark AS, 2003, NEUROSCI BIOBEHAV R, V27, P413, DOI 10.1016/S0149-7634(03)00064-2; Coccaro EF, 2015, CNS SPECTRUMS, V20, P295, DOI 10.1017/S1092852915000310; Covassin T, 2013, TRANSL STROKE RES, V4, P420, DOI 10.1007/s12975-012-0228-z; Cunningham RL, 2013, HORM BEHAV, V64, P350, DOI 10.1016/j.yhbeh.2012.12.009; de Boer SF, 2005, EUR J PHARMACOL, V526, P125, DOI 10.1016/j.ejphar.2005.09.065; Duke AA, 2013, PSYCHOL BULL, V139, P1148, DOI 10.1037/a0031544; Evans NA, 2004, AM J SPORT MED, V32, P534, DOI 10.1177/0363546503262202; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gerberding JL, 2003, THE REPORT TO CONGRE; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Grimes JM, 2002, PHARMACOL BIOCHEM BE, V73, P713, DOI 10.1016/S0091-3057(02)00880-8; Hartgens F, 2004, SPORTS MED, V34, P513, DOI 10.2165/00007256-200434080-00003; Hoffman JR, 2006, J SPORT SCI MED, V5, P182; Hung Ryan, 2014, Arch Phys Med Rehabil, V95, pS174, DOI 10.1016/j.apmr.2013.08.301; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Johnson VE, 2016, ACTA NEUROPATHOL, V131, P115, DOI 10.1007/s00401-015-1506-0; Kindlundh AMS, 2003, NEUROSCIENCE, V119, P113, DOI 10.1016/S0306-4522(03)00120-9; Kubala KH, 2008, BRAIN RES, V1232, P21, DOI 10.1016/j.brainres.2008.07.065; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Levin B, 2014, NEUROCRIT CARE, V20, P334, DOI 10.1007/s12028-013-9931-1; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; Marshall-Gradisnik S, 2009, CENT EUR J BIOL, V4, P19, DOI 10.2478/s11535-008-0058-x; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McMillan P, 2008, J COMP NEUROL, V511, P788, DOI 10.1002/cne.21867; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mills JD, 2012, NEUROSURGERY, V70, P205, DOI 10.1227/NEU.0b013e3182250918; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Namjoshi DR, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-55; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Namjoshi DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053529; Nelson RJ, 2001, TRENDS NEUROSCI, V24, P713, DOI 10.1016/S0166-2236(00)01996-2; NEVE RL, 1986, MOL BRAIN RES, V1, P271, DOI 10.1016/0169-328X(86)90033-1; Ojo JO, 2016, EXP NEUROL, V275, P389, DOI 10.1016/j.expneurol.2015.06.003; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Penatti CAA, 2009, J NEUROSCI, V29, P12484, DOI 10.1523/JNEUROSCI.3108-09.2009; Popova N K, 2008, Neurosci Behav Physiol, V38, P471, DOI 10.1007/s11055-008-9004-7; Ransohoff RM, 2012, NAT REV IMMUNOL, V12, P623, DOI 10.1038/nri3265; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; Reilly P, 2007, PROG BRAIN RES, V161, P3, DOI 10.1016/S0079-6123(06)61001-7; Robinson S, 2012, HORM BEHAV, V61, P67, DOI 10.1016/j.yhbeh.2011.10.004; Sagoe D, 2014, ANN EPIDEMIOL, V24, P383, DOI 10.1016/j.annepidem.2014.01.009; SANCHEZ C, 1993, PSYCHOPHARMACOLOGY, V110, P53, DOI 10.1007/BF02246950; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Turillazzi E, 2011, MINI-REV MED CHEM, V11, P374, DOI 10.2174/138955711795445925; van Amsterdam J, 2010, REGUL TOXICOL PHARM, V57, P117, DOI 10.1016/j.yrtph.2010.02.001; Varnas K, 2005, SYNAPSE, V56, P21, DOI 10.1002/syn.20128; VIRKKUNEN M, 1995, J PSYCHIATR NEUROSCI, V20, P271	66	27	28	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2016	11	1							e0146540	10.1371/journal.pone.0146540			21	Multidisciplinary Sciences	Science & Technology - Other Topics	DB5BP	WOS:000368528400046	26784694	DOAJ Gold, Green Published			2021-06-18	
J	Iraji, A; Chen, HB; Wiseman, N; Welch, RD; O'Neil, BJ; Haacke, EM; Liu, TM; Kou, ZF				Iraji, Armin; Chen, Hanbo; Wiseman, Natalie; Welch, Robert D.; O'Neil, Brian J.; Haacke, E. Mark; Liu, Tianming; Kou, Zhifeng			Compensation through Functional Hyperconnectivity: A Longitudinal Connectome Assessment of Mild Traumatic Brain Injury	NEURAL PLASTICITY			English	Article							WORKING-MEMORY; NETWORK TOPOLOGY; IMAGING FINDINGS; AXONAL INJURY; CONNECTIVITY; PLASTICITY; ACTIVATION; MRI; PERFORMANCE; DYSFUNCTION	Mild traumatic brain injury (mTBI) is a major public health concern. Functional MRI has reported alterations in several brain networks following mTBI. However, the connectome-scale brain network changes are still unknown. In this study, sixteen mTBI patients were prospectively recruited from an emergency department and followed up at 4-6weeks after injury. Twenty-four healthy controls were also scanned twice with the same time interval. Three hundred fifty-eight brain landmarks that preserve structural and functional correspondence of brain networks across individuals were used to investigate longitudinal brain connectivity. Network-based statistic (NBS) analysis did not find significant difference in the group-by-time interaction and time effects. However, 258 functional pairs show group differences in which mTBI patients have higher functional connectivity. Meta-analysis showed that "Action" and "Cognition" are the most affected functional domains. Categorization of connectomic signatures using multiview group-wise cluster analysis identified two patterns of functional hyperconnectivity among mTBI patients: (I) between the posterior cingulate cortex and the association areas of the brain and (II) between the occipital and the frontal lobes of the brain. Our results demonstrate that brain concussion renders connectome-scale brain network connectivity changes, and the brain tends to be hyperactivated to compensate the pathophysiological disturbances.	[Iraji, Armin; Haacke, E. Mark; Kou, Zhifeng] Wayne State Univ, Dept Biomed Engn, Detroit, MI USA; [Chen, Hanbo; Liu, Tianming] Univ Georgia, Dept Comp Sci, Athens, GA 30602 USA; [Wiseman, Natalie] Wayne State Univ, Dept Psychiat & Behav Neurosci, Detroit, MI 48207 USA; [Welch, Robert D.; O'Neil, Brian J.] Wayne State Univ, Dept Emergency Med, Detroit, MI USA; [Haacke, E. Mark; Kou, Zhifeng] Wayne State Univ, Dept Radiol, Detroit, MI USA	Liu, TM (corresponding author), Univ Georgia, Dept Comp Sci, Athens, GA 30602 USA.	tianming.liu@gmail.com; zhifeng_kou@wayne.edu		Wiseman, Natalie/0000-0003-0884-6425	Department of DefenseUnited States Department of Defense [W81XWH-11-1-0493]; International Society for Magnetic Resonance in Medicine (ISMRM) Seed Grant Award	This study is supported by the Department of Defense (Award no. W81XWH-11-1-0493) and International Society for Magnetic Resonance in Medicine (ISMRM) Seed Grant Award. The first author (Armin Iraji) would also like to sincerely acknowledge Drs. Anthony and Joyce Danielski Kales Endowed Scholars Award which significantly helped to accomplish this work.	Barbey AK, 2015, CURR OPIN BEHAV SCI, V4, P92, DOI 10.1016/j.cobeha.2015.04.002; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bergman K, 2010, J EMERG NURS, V36, P221, DOI 10.1016/j.jen.2009.07.001; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101; Buckner RL, 2007, NEUROIMAGE, V37, P1091, DOI 10.1016/j.neuroimage.2007.01.010; Carter AR, 2012, NEUROIMAGE, V62, P2271, DOI 10.1016/j.neuroimage.2012.02.070; Carter AR, 2010, ANN NEUROL, V67, P365, DOI 10.1002/ana.21905; CDC, 2003, REP C MILD TRAUM BRA; Chen HB, 2013, IEEE T MED IMAGING, V32, P1576, DOI [10.1109/TMI.2013.2259248, 10.1007/978-3-642-33454-2_37]; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Finn ES, 2014, BIOL PSYCHIAT, V76, P397, DOI 10.1016/j.biopsych.2013.08.031; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; Gillebert CR, 2013, NEUROSCIENTIST, V19, P509, DOI 10.1177/1073858412463168; Guerra-Carrillo B, 2014, NEUROSCIENTIST, V20, P522, DOI 10.1177/1073858414524442; Harrington DL, 2015, BRAIN, V138, P2332, DOI 10.1093/brain/awv145; Hebb D.O., 2005, ORG BEHAV NEUROPSYCH; Hillary FG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104021; Hillary FG, 2011, BRAIN, V134, P1555, DOI 10.1093/brain/awr043; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Iraji A, 2015, J NEUROTRAUM, V32, P1031, DOI 10.1089/neu.2014.3610; Iraji A, 2011, IEEE ENG MED BIO, P2796, DOI 10.1109/IEMBS.2011.6090765; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; Kelly C, 2014, NEUROPSYCHOL REV, V24, P63, DOI 10.1007/s11065-014-9252-y; Korgaonkar MS, 2014, BIOL PSYCHIAT, V76, P567, DOI 10.1016/j.biopsych.2014.02.018; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Kou ZF, 2014, NEURAL REGEN RES, V9, P693, DOI 10.4103/1673-5374.131568; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Krienen FM, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0526; Laird Angela R, 2009, Front Neuroinform, V3, P23, DOI 10.3389/neuro.11.023.2009; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Li K., 2010, ADV NEURAL INFORM PR, P1369; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lv JL, 2015, IEEE T BIO-MED ENG, V62, P1120, DOI 10.1109/TBME.2014.2369495; Mackey AP, 2013, J NEUROSCI, V33, P4796, DOI 10.1523/JNEUROSCI.4141-12.2013; Mackey AP, 2012, FRONT NEUROANAT, V6, DOI 10.3389/fnana.2012.00032; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Mayer AR, 2015, J NEUROTRAUM, V32, P1046, DOI 10.1089/neu.2014.3542; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McEwen BS, 2013, NEURON, V79, P16, DOI 10.1016/j.neuron.2013.06.028; Merzenich MM, 2013, PROG BRAIN RES, V207, P1; Messe A, 2015, NEUROIMAGE, V111, P65, DOI 10.1016/j.neuroimage.2015.02.001; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Naunheim RS, 2008, J HEAD TRAUMA REHAB, V23, P116, DOI 10.1097/01.HTR.0000314530.30401.70; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Passingham RE, 2002, NAT REV NEUROSCI, V3, P606, DOI 10.1038/nrn893; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Ricker JH, 2001, J CLIN EXP NEUROPSYC, V23, P196, DOI 10.1076/jcen.23.2.196.1204; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Taubert M, 2011, NEUROIMAGE, V57, P1492, DOI 10.1016/j.neuroimage.2011.05.078; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Voss HU, 2009, PROG BRAIN RES, V175, P483, DOI 10.1016/S0079-6123(09)17532-5; Wan CY, 2010, NEUROSCIENTIST, V16, P566, DOI 10.1177/1073858410377805; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011; Yuan YX, 2013, NEUROINFORMATICS, V11, P47, DOI 10.1007/s12021-012-9165-y; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041; Zhou IY, 2014, NEUROIMAGE, V84, P1, DOI 10.1016/j.neuroimage.2013.08.037; Zhu DJ, 2014, HUM BRAIN MAPP, V35, P2911, DOI 10.1002/hbm.22373; Zhu DJ, 2013, CEREB CORTEX, V23, P786, DOI 10.1093/cercor/bhs072	70	27	27	0	10	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-5904	1687-5443		NEURAL PLAST	Neural. Plast.		2016	2016								4072402	10.1155/2016/4072402			13	Neurosciences	Neurosciences & Neurology	DB3FR	WOS:000368396200001	26819765	DOAJ Gold, Green Published			2021-06-18	
S	Osier, N; Dixon, CE		Kobeissy, F; Dixon, CE; Hayes, RL; Mondello, S		Osier, Nicole; Dixon, C. Edward			The Controlled Cortical Impact Model of Experimental Brain Trauma: Overview, Research Applications, and Protocol	INJURY MODELS OF THE CENTRAL NERVOUS SYSTEM: METHODS AND PROTOCOLS	Methods in Molecular Biology		English	Article; Book Chapter						Traumatic brain injury (TBI); Experimental brain injury; Preclinical; Animal model; Controlled cortical impact (CCI); Common data elements (CDE)	LATERAL FLUID PERCUSSION; ENVIRONMENTAL ENRICHMENT; COGNITIVE DEFICITS; CEREBRAL CONCUSSION; DEPENDENT RESPONSE; HEMORRHAGIC-SHOCK; AXONAL INJURY; MOUSE MODEL; HEAD-INJURY; RAT MODEL	Controlled cortical impact (CCI) is a commonly used and highly regarded model of brain trauma that uses a pneumatically or electromagnetically controlled piston to induce reproducible and well-controlled injury. The CCI model was originally used in ferrets and it has since been scaled for use in many other species. This chapter will describe the historical development of the CCI model, compare and contrast the pneumatic and electromagnetic models, and summarize key short-and long-term consequences of TBI that have been gleaned using this model. In accordance with the recent efforts to promote high-quality evidence through the reporting of common data elements (CDEs), relevant study details-that should be reported in CCI studies-will be noted.	[Osier, Nicole; Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Osier, Nicole] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15260 USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Dixon, C. Edward] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA	Osier, N (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.; Osier, N (corresponding author), Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15260 USA.		Osier, Nicole/Q-7913-2017	Osier, Nicole/0000-0002-2903-6774	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS091062, R01 NS079061, R01 NS084967] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [F31 NR014957, T32 NR009759] Funding Source: Medline; RRD VA [I01 RX001127] Funding Source: Medline; VAUS Department of Veterans Affairs [1I01RX001127-01A1] Funding Source: Federal RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS084967, R01NS079061, R01NS091062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [F31NR014957, T32NR009759] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX001127] Funding Source: NIH RePORTER		Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Cannon WB, 1901, AM J PHYSIOL, V6, P91; Chauhan NB, 2011, RESTOR NEUROL NEUROS, V29, P23, DOI 10.3233/RNN-2011-0573; Chauhan NB, 2010, BRAIN RES, V1360, P177, DOI 10.1016/j.brainres.2010.09.010; Cheng JP, 2012, J NEUROTRAUM, V29, P2684, DOI 10.1089/neu.2012.2560; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Costine BA, 2012, J NEUROTRAUM, V29, P2689, DOI 10.1089/neu.2012.2428; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.0.CO;2-8; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GOVONS SR, 1972, EXP NEUROL, V34, P121, DOI 10.1016/0014-4886(72)90193-8; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HAMM RJ, 1995, EXP NEUROL, V136, P143, DOI 10.1006/exnr.1995.1091; Han RZ, 2009, NEUROSCI BULL, V25, P367, DOI 10.1007/s12264-009-0608-x; Han XD, 2011, J NEUROTRAUM, V28, P995, DOI 10.1089/neu.2010.1563; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hemerka JN, 2012, J NEUROTRAUM, V29, P2192, DOI 10.1089/neu.2011.2303; Hoane Michael R, 2004, Clin Calcium, V14, P65; King C, 2010, J NEUROTRAUM, V27, P1895, DOI 10.1089/neu.2009.1178; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Kline AE, 2001, HEAD TRAUMA, P65; Kramer S P, 1896, Ann Surg, V23, P163, DOI 10.1097/00000658-189601000-00031; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LINDGREN STEN, 1965, BIOPHYSIK, V2, P320; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/0897715042664876; Longhi L, 2011, J CEREBR BLOOD F MET, V31, P1919, DOI 10.1038/jcbfm.2011.42; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; Marklund N, 2009, NEUROSCIENCE, V163, P540, DOI 10.1016/j.neuroscience.2009.06.042; MCDONALD JW, 1989, EXP NEUROL, V106, P289, DOI 10.1016/0014-4886(89)90162-3; McPherson RW, 1994, NEUROBIOLOGY CENTRAL; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Monaco CM, 2013, EXP NEUROL, V247, P410, DOI 10.1016/j.expneurol.2013.01.007; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; OMMAYA A K, 1971, International Journal of Neuroscience, V1, P371, DOI 10.3109/00207457109146986; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Osier ND, 2015, J NEUROTRAUM, V32, P1861, DOI 10.1089/neu.2014.3680; PARKINSON D, 1978, NEUROSURGERY, V3, P176, DOI 10.1227/00006123-197809000-00008; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Rau TF, 2012, J TRAUMA ACUTE CARE, V73, pS165, DOI 10.1097/TA.0b013e318260896a; RINDER L, 1968, ACTA NEUROPATHOL, V11, P183; Sandhir R, 2010, NEUROCHEM INT, V56, P188, DOI 10.1016/j.neuint.2009.10.002; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; Shin SS, 2013, J NEUROTRAUM, V30, P259, DOI 10.1089/neu.2012.2462; Shin SS, 2012, J NEUROTRAUM, V29, P843, DOI 10.1089/neu.2011.1966; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Thompson HJ, 2006, RESTOR NEUROL NEUROS, V24, P109; Tomasevic G, 2012, J NEUROSURG, V116, P1368, DOI 10.3171/2012.2.JNS11888; Xiong Y, 2011, TRANSL STROKE RES, V2, P619, DOI 10.1007/s12975-011-0120-2; Xiong Y, 2012, J NEUROSURG, V116, P1081, DOI 10.3171/2012.1.JNS111729; Xiong Y, 2011, J NEUROSURG, V114, P549, DOI 10.3171/2010.10.JNS10925; Zhang YL, 2012, EXP NEUROL, V235, P336, DOI 10.1016/j.expneurol.2012.02.015	69	27	27	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA	1064-3745		978-1-4939-3816-2; 978-1-4939-3814-8	METHODS MOL BIOL	Methods Mol. Biol.		2016	1462						177	192		10.1007/978-1-4939-3816-2_11	10.1007/978-1-4939-3816-2		16	Biochemical Research Methods; Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	BH1UG	WOS:000398551500013	27604719	Green Accepted			2021-06-18	
J	Dymowski, AR; Owens, JA; Ponsford, JL; Willmott, C				Dymowski, Alicia Rhian; Owens, Jacqueline Anne; Ponsford, Jennie Louise; Willmott, Catherine			Speed of processing and strategic control of attention after traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Information processing speed; Working memory; Strategic control; Attention; Traumatic brain injury	CSF NEUROTRANSMITTER METABOLITES; WORKING-MEMORY LOAD; DIVIDED ATTENTION; AXONAL INJURY; IMPAIRMENTS; DEFICITS	Introduction: Slowed information processing speed has consistently been documented after traumatic brain injury (TBI). Debate continues as to whether deficits in strategic control are proportionate to, or remain after controlling for, reduced speed of processing. The study aim was to investigate the association of speed of processing and strategic control of attention with working memory, selective attention, response inhibition, and mental flexibility task performance after TBI using traditional and novel clinical measures. Method: Twenty-five individuals with complicated mild to severe TBI (post-traumatic amnesia duration, M = 39.52 days, SD = 38.34; worst Glasgow Coma Scale score, M = 7.33, SD = 4.35; time post-injury, M = 392.64 days, SD = 537.19) and 25 matched healthy controls completed assessment of attentional and executive functioning. Measures included the Symbol Digit Modalities Test (SDMT), the computerized Selective Attention Task (SAT), the Ruff 2&7 Selective Attention Test (2&7), the visual n-back, Digit Span, Hayling Test, and Trail Making Test (TMT). Results: t tests revealed that individuals with TBI demonstrated reduced processing speed on the SDMT, n-back, SAT, 2&7, Hayling Test, and TMT-A (p <= .002 for all). Digit Span performance did not differ between groups. Mixed-model ANOVAs revealed that individuals with TBI demonstrated a disproportionate increase in reaction time with complexity, which was accounted for by speed on the SAT but remained on the Hayling Inhibition Test after controlling for speed in ANCOVAs. Mann-Whitney U tests revealed that individuals with TBI also made more errors on the Hayling Test, missed responses on the n-back and were unable to benefit from the automatic condition of the 2&7. Conclusions: While slowed speed of information processing was pervasive across tasks after TBI, residual difficulties in response inhibition remained after controlling for slowness, which suggests impaired strategic control. These findings support targeted intervention for slowed speed of thinking and inhibition following TBI.	[Dymowski, Alicia Rhian; Owens, Jacqueline Anne; Ponsford, Jennie Louise; Willmott, Catherine] Monash Univ, Sch Psychol Sci, Clayton, Vic, Australia; [Dymowski, Alicia Rhian; Owens, Jacqueline Anne; Ponsford, Jennie Louise; Willmott, Catherine] Epworth HealthCare, Monash Epworth Rehabil Res Ctr, Richmond, Vic, Australia; [Ponsford, Jennie Louise] Alfred Hosp, Natl Trauma Res Inst, Ctr Excellence Traumat Brain Injury Rehabil, Prahran, Vic 3181, Australia	Dymowski, AR (corresponding author), Monash Epworth Rehabil Res Ctr, 185-187 Hoddle St, Richmond, Vic 3121, Australia.	Alicia.Dymowski@monash.edu	Willmott, Catherine/AAA-5105-2019	Willmott, Catherine/0000-0001-8517-9035	Epworth Research Institute [80940]	This work was supported by the Epworth Research Institute [Grant 80940].	Asloun S, 2008, J CLIN EXP NEUROPSYC, V30, P481, DOI 10.1080/13803390701550144; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A, 2000, TRENDS COGN SCI, V4, P417, DOI 10.1016/S1364-6613(00)01538-2; Baddeley A. D., 2002, PRINCIPLES FRONTAL L, P246, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0016; Baddeley A. D., 1986, WORKING MEMORY; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Daniel A. E., 1983, POWER PRIVILEGE PRES; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Iverson GL, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/415740; James W., 1890, PRINCIPLES PSYCHOL; Kinsella G., 2008, INFORM PROCESSING SP, P173; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Lewis Frank D, 2013, J Spec Oper Med, V13, P56; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Markianos M, 1996, ACTA NEUROCHIR, V138, P57, DOI 10.1007/BF01411725; MARKIANOS M, 1992, ACTA NEUROL SCAND, V86, P190, DOI 10.1111/j.1600-0404.1992.tb05064.x; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Nelson HE, 1982, NATL ADULT READING T; NORMAN D, 1980, 99 U CAL CTR HUM INF; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Raz Amir, 2004, Anatomical Record Part B:The New Anatomist, V281, P21, DOI 10.1002/ar.b.20035; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; Ruff RM, 1995, RUFF 2 7 SELECTIVE A; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; Shallice, 1997, HAYLING BRIXTON TEST; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T., 2002, PRINCIPLES FRONTAL L, P261, DOI [10.1093/acprof:oso/9780195134971.003.0017, DOI 10.1093/ACPROF:OSO/9780195134971.003.0017]; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith A., 1991, SYMBOL DIGIT MODALIT; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; Spitz G, 2013, BRAIN COGNITION, V83, P34, DOI 10.1016/j.bandc.2013.06.007; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Styles E. A., 2006, PSYCHOL ATTENTION; Tabachnick BG, 2007, USING MULTIVARIATE S; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Turner GR, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00009; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Whyte J, 2010, DELISAS PHYS MED REH, P575; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	55	27	28	0	41	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	NOV 26	2015	37	10					1024	1035		10.1080/13803395.2015.1074663			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	CR5OR	WOS:000361393100002	26325235				2021-06-18	
J	Kerr, ZY; Snook, EM; Lynall, RC; Dompier, TP; Sales, L; Parsons, JT; Hainline, B				Kerr, Zachary Y.; Snook, Erin M.; Lynall, Robert C.; Dompier, Thomas P.; Sales, Latrice; Parsons, John T.; Hainline, Brian			Concussion-Related Protocols and Preparticipation Assessments Used for Incoming Student-Athletes in National Collegiate Athletic Association Member Institutions	JOURNAL OF ATHLETIC TRAINING			English	Article						traumatic brain injuries; return-to-play guidelines; evaluation	STATES HIGH-SCHOOL; FOOTBALL PLAYERS; MANAGEMENT; SENSITIVITY; SPORT; EPIDEMIOLOGY; SPECIFICITY; EDUCATION; SYMPTOMS; SYSTEM	Context: National Collegiate Athletic Association (NCAA) legislation requires that member institutions have policies to guide the recognition and management of sport-related concussions. Identifying the nature of these policies and the mechanisms of their implementation can help identify areas of needed improvement. Objective: To estimate the characteristics and prevalence of concussion-related protocols and preparticipation assessments used for incoming NCAA student-athletes. Design: Cross-sectional study. Setting: Web-based survey. Patients or Other Participants: Head athletic trainers from all 1113 NCAA member institutions were contacted; 327 (29.4%) completed the survey. Intervention(s): Participants received an e-mail link to the Web-based survey. Weekly reminders were sent during the 4-week window. Main Outcome Measure(s): Respondents described concussion-related protocols and preparticipation assessments (eg, concussion history, neurocognitive testing, balance testing, symptom checklists). Descriptive statistics were compared by division and football program status. Results: Most universities provided concussion education to student-athletes (95.4%), had return-to-play policies (96.6%), and obtained the number of previous concussions sustained by incoming student-athletes (97.9%). Fewer had return-to-learn policies (63.3%). Other concussion-history-related information (eg, symptoms, hospitalization) was more often collected by Division I universities. Common preparticipation neurocognitive and balance tests were the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT; 77.1%) and Balance Error Scoring System (46.5%). In total, 43.7% complied with recommendations for preparticipation assessments that included concussion history, neurocognitive testing, balance testing, and symptom checklists. This was due to moderate use of balance testing (56.6%); larger proportions used concussion history (99.7%), neurocognitive testing (83.2%), and symptom checklists (91.7%). More Division I universities (55.2%) complied with baseline assessment recommendations than Division II (38.2%, chi(2) = 5.49, P =.02) and Division III (36.1%, chi(2) = 9.11, P =.002) universities. Conclusions: National Collegiate Athletic Association member institutions implement numerous strategies to monitor student-athletes. Division II and III universities may need additional assistance to collect in-depth concussion histories and conduct balance testing. Universities should continue developing or adapting (or both) return-to-learn policies.	[Kerr, Zachary Y.; Snook, Erin M.; Dompier, Thomas P.] Datalys Ctr Sports Injury Res & Prevent, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA; [Lynall, Robert C.] Univ N Carolina, Human Movement Sci Curriculum, Chapel Hill, NC USA; [Sales, Latrice; Parsons, John T.; Hainline, Brian] Natl Collegiate Athlet Assoc, Indianapolis, IN USA	Kerr, ZY (corresponding author), Datalys Ctr Sports Injury Res & Prevent, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA.	zkerr@datalyscenter.org	Lynall, Robert/M-2888-2014	Lynall, Robert/0000-0002-0785-6640; Kerr, Zachary/0000-0003-1423-1259			Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Baugh CM, 2015, AM J SPORT MED, V43, P47, DOI 10.1177/0363546514553090; Braithwaite D, 2003, FAM PRACT, V20, P545, DOI 10.1093/fampra/cmg509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Dick R, 2007, J ATHL TRAINING, V42, P221; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Kelly KC, 2014, J ATHL TRAINING, V49, P665, DOI 10.4085/1062-6050-49.3.25; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Klossner D, 2013 14 NCAA SPORTS; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Lynall RC, 2013, J ATHL TRAINING, V48, P844, DOI 10.4085/1062-6050-48.6.04; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; O'Donoghue EM., 2009, ATHLETIC TRAINING SP, V1, DOI [DOI 10.3928/19425864-20090427-07, 10.3928/19425864-20090427-07]; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Wilkins JC, 2004, J ATHL TRAINING, V39, P156	31	27	27	0	13	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	NOV	2015	50	11					1174	1181		10.4085/1062-6050-50.11.11			8	Sport Sciences	Sport Sciences	DK2OO	WOS:000374754500008	26540099	Green Published, Bronze			2021-06-18	
J	Labombarda, F; Jure, I; Gonzalez, S; Lima, A; Roig, P; Guennoun, R; Schumacher, M; De Nicola, AF				Labombarda, Florencia; Jure, Ignacio; Gonzalez, Susana; Lima, Analia; Roig, Paulina; Guennoun, Rachida; Schumacher, Michael; De Nicola, Alejandro F.			A functional progesterone receptor is required for immunomodulation, reduction of reactive gliosis and survival of oligodendrocyte precursors in the injured spinal cord	JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY			English	Article						Astrocytes; Knockout mice; Microglia; Neuroinflammation; Progesterone receptor; Spinal cord injury	TRAUMATIC BRAIN-INJURY; TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE; SECONDARY DAMAGE; STEROID-HORMONES; NERVOUS-SYSTEM; WHITE-MATTER; CELL-DEATH; RAT MODEL; EXPRESSION	The anti-inflammatory effects of progesterone have been increasingly recognized in several neuropathological models, including spinal cord inflammation. In the present investigation, we explored the regulation of proinflammatory factors and enzymes by progesterone at several time points after spinal cord injury (SCI) in male rats. We also demonstrated the role of the progesterone receptor (PR) in inhibiting inflammation and reactive gliosis, and in enhancing the survival of oligodendrocyte progenitors cells (OPC) in injured PR knockout (PRKO) mice receiving progesterone. First, after SCI in rats, progesterone greatly attenuated the injury-induced hyperexpression of the mRNAs of interleukin 1 beta (IL1 beta), IL6, tumor necrosis factor alpha (TNF alpha), inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2), all involved in oligodendrocyte damage. Second, the role of the PR was investigated in PRKO mice after SCI, in which progesterone failed to reduce the high expression of IL1 beta, IL6, TNF alpha and I kappa B-alpha mRNAs, the latter being considered an index of reduced NF-kappa B transactivation. These effects occurred in a time framework coincident with a reduction in the astrocyte and microglial responses. In contrast to wild-type mice, progesterone did not increase the density of OPC and did not prevent apoptotic death of these cells in PRKO mice. Our results support a role of PR in: (a) the anti-inflammatory effects of progesterone; (b) the modulation of astrocyte and microglial responses and (c) the prevention of OPC apoptosis, a mechanism that would enhance the commitment of progenitors to the remyelination pathway in the injured spinal cord. (C) 2015 Elsevier Ltd. All rights reserved.	[Labombarda, Florencia; Jure, Ignacio; Lima, Analia; Roig, Paulina; De Nicola, Alejandro F.] Inst Biol & Med Expt, Lab Neuroendocrine Biochem, RA-1428 Buenos Aires, DF, Argentina; [Labombarda, Florencia; Gonzalez, Susana; De Nicola, Alejandro F.] Univ Buenos Aires, Fac Med, Dept Human Biochem, Buenos Aires, DF, Argentina; [Guennoun, Rachida; Schumacher, Michael] INSERM, U1195, F-94276 Le Kremlin Bicetre, France; [Guennoun, Rachida; Schumacher, Michael] Univ Paris Sud, F-94276 Le Kremlin Bicetre, France; [Gonzalez, Susana] Inst Biol & Med Expt, Lab Nocicept & Neuropath Pain, RA-1428 Buenos Aires, DF, Argentina	De Nicola, AF (corresponding author), Inst Biol & Med Expt, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	alejandrodenicola@gmail.com	Guennoun, Rachida/F-2420-2011; Schumacher, Michael/G-3581-2013	Guennoun, Rachida/0000-0002-9219-7300; Schumacher, Michael/0000-0001-6117-5371	Ministry of Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [PICT 2012-0009]; National Research Council of ArgentinaConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) [PIP 112 20120100016]; University of Buenos AiresUniversity of Buenos Aires [Ubacyt 20020100100089]; Roemmers Fundation	This work was supported by grants from the Ministry of Science and Technology (PICT 2012-0009), the National Research Council of Argentina (PIP 112 20120100016), the University of Buenos Aires (Ubacyt 20020100100089) and Roemmers Fundation. These funding sources did not have a role in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. The authors report no conflict of interests.	Arevalo MA, 2013, HORM BEHAV, V63, P216, DOI 10.1016/j.yhbeh.2012.02.021; Arnold S, 2008, J MOL ENDOCRINOL, V41, P289, DOI 10.1677/JME-08-0085; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Boato F, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-6; Bottero Virginie, 2003, Mol Diagn, V7, P187, DOI 10.2165/00066982-200307030-00008; Bracchi-Ricard V, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-92; Bracken MB, 2002, J NEUROSURG, V96, P259, DOI 10.3171/spi.2002.96.3.0259; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Coronel MF, 2014, EUR J PAIN, V18, P348, DOI 10.1002/j.1532-2149.2013.00376.x; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; De Nicola AF, 2013, CNS NEUROL DISORD-DR, V12, P1205; Deng YY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087420; El-Etr M, 2015, GLIA, V63, P104, DOI 10.1002/glia.22736; Erta M, 2012, INT J BIOL SCI, V8, P1254, DOI 10.7150/ijbs.4679; Forstermann U, 1995, Adv Pharmacol, V34, P171; Gago N, 2001, GLIA, V36, P295, DOI 10.1002/glia.1117; Garay LI, 2012, NEUROSCIENCE, V226, P40, DOI 10.1016/j.neuroscience.2012.09.032; Garcia-Ovejero D, 2014, J NEUROTRAUM, V31, P857, DOI 10.1089/neu.2013.3162; Giatti S, 2012, J MOL ENDOCRINOL, V49, pR125, DOI 10.1530/JME-12-0127; Goddard LM, 2013, VASC PHARMACOL, V59, P36, DOI 10.1016/j.vph.2013.06.001; Deniselle MCG, 2012, J NEUROCHEM, V122, P185, DOI 10.1111/j.1471-4159.2012.07753.x; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Hanada M, 2012, ANAL BIOANAL CHEM, V403, P1873, DOI 10.1007/s00216-012-5900-3; Hanada T, 2002, CYTOKINE GROWTH F R, V13, P413, DOI 10.1016/S1359-6101(02)00026-6; Hesp ZC, 2015, J NEUROSCI, V35, P1274, DOI 10.1523/JNEUROSCI.2568-14.2015; Ismail PM, 2002, MOL ENDOCRINOL, V16, P2475, DOI 10.1210/me.2002-0169; Johann S, 2013, J STEROID BIOCHEM, V137, P71, DOI 10.1016/j.jsbmb.2012.11.006; Jurewicz A, 2005, BRAIN, V128, P2675, DOI 10.1093/brain/awh627; Kaplin AI, 2005, J CLIN INVEST, V115, P2731, DOI 10.1172/JCI25141; Kim S, 2011, J NEUROCHEM, V116, P53, DOI 10.1111/j.1471-4159.2010.07084.x; Kroner A, 2014, NEURON, V83, P1098, DOI 10.1016/j.neuron.2014.07.027; Labombarda F, 2006, J NEUROTRAUM, V23, P181, DOI 10.1089/neu.2006.23.181; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2010, NEUROSCIENCE, V166, P94, DOI 10.1016/j.neuroscience.2009.12.012; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2013, NEUROPHARMACOLOGY, V71, P46, DOI 10.1016/j.neuropharm.2013.03.010; Labombarda F, 2011, EXP NEUROL, V231, P135, DOI 10.1016/j.expneurol.2011.06.001; Labombarda F, 2010, NEUROIMMUNOMODULAT, V17, P146, DOI 10.1159/000258709; Labombarda F, 2009, GLIA, V57, P884, DOI 10.1002/glia.20814; Lech M, 2013, BBA-MOL BASIS DIS, V1832, P989, DOI 10.1016/j.bbadis.2012.12.001; Lei BL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103969; Liu DX, 2001, J NEUROCHEM, V77, P1036, DOI 10.1046/j.1471-4159.2001.00306.x; McTigue DM, 2008, J NEUROCHEM, V107, P1, DOI 10.1111/j.1471-4159.2008.05570.x; Meffre D, 2013, NEUROSCIENCE, V231, P111, DOI 10.1016/j.neuroscience.2012.11.039; Menzies FM, 2011, IMMUNOLOGY, V134, P281, DOI 10.1111/j.1365-2567.2011.03488.x; Miller BA, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-28; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Pang YF, 2013, ENDOCRINOLOGY, V154, P283, DOI 10.1210/en.2012-1772; Pascual G, 2006, TRENDS ENDOCRIN MET, V17, P321, DOI 10.1016/j.tem.2006.08.005; Patte-Mensah C, 2006, J MOL NEUROSCI, V28, P17, DOI 10.1385/JMN:28:1:17; Pereira JE, 2009, EXP NEUROL, V220, P71, DOI 10.1016/j.expneurol.2009.07.030; Perrier S, 2006, FEBS LETT, V580, P6289, DOI 10.1016/j.febslet.2006.10.061; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Rabchevsky AG, 2007, GLIA, V55, P831, DOI 10.1002/glia.20508; Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050; Schroeder GD, 2014, SPINE, V39, P971, DOI 10.1097/BRS.0000000000000297; Schumacher M, 2014, PROG NEUROBIOL, V113, P6, DOI 10.1016/j.pneurobio.2013.09.004; Sharma J. N., 2007, Inflammopharmacology, V15, P252, DOI 10.1007/s10787-007-0013-x; Sierra A, 2008, GLIA, V56, P659, DOI 10.1002/glia.20644; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Stein DG, 2011, NEUROSCIENCE, V191, P101, DOI 10.1016/j.neuroscience.2011.04.013; Su ZD, 2011, J NEUROTRAUM, V28, P1089, DOI 10.1089/neu.2010.1597; Subramaniam S, 2004, DEV COMP IMMUNOL, V28, P415, DOI 10.1016/j.dci.2003.09.016; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Watzlawik J, 2010, EXPERT REV NEUROTHER, V10, P441, DOI 10.1586/ERN.10.13; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Ye JN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054590; Zai LJ, 2005, GLIA, V50, P247, DOI 10.1002/glia.20176; Zhou X, 2014, NEURAL REGEN RES, V9, P1787, DOI 10.4103/1673-5374.143423	73	27	27	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-0760			J STEROID BIOCHEM	J. Steroid Biochem. Mol. Biol.	NOV	2015	154						274	284		10.1016/j.jsbmb.2015.09.011			11	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	CV4QI	WOS:000364251200031	26369614				2021-06-18	
J	Ansari, MA				Ansari, Mubeen A.			Temporal profile of M1 and M2 responses in the hippocampus following early 24 h of neurotrauma	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Traumatic brain injury; Neurotrauma; Neuroinflammation; Pro- and anti-inflammatory cytokines; Secondary injury cascades; M1 and M2 responses	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; MICROGLIAL ACTIVATION; INFLAMMATORY RESPONSE; OXIDATIVE STRESS; TIME-COURSE; NEUROINFLAMMATORY PHENOTYPE	Traumatic brain injury (TBI) elicits complex inflammatory assets (M1 and M2 responses) in the brain that include the expression of various cytokines/chemokines and the recruitment of blood cells, contributing secondary injury cascades (SIC), and also recovery processes. The modulation of such inflammatory assets might be a therapeutic option following TBI. The present study assesses a temporal profile of various molecular markers of M1 and M2 response in the hippocampus after TBI. Following a unilateral controlled cortical impact (CCI) on young rats, hippocampal tissues of each brain were harvested at 2, 4, 6, 10, and 24 h post trauma. Including shams (craniotomy only), half of the rats were assessed for gene expression and half for the protein of various markers for M1 [interferon-gamma (IFN gamma), tumor necrosis factor-alpha (TNF alpha), interleukin (1L)-1-beta (IL-1 beta), and IL-6] and M2 [IL-4, IL-10, IL-13, arginase 1 (Arg1), YM1, FIZZ1, and mannose receptor C-1 (MRC1)] responses. Analysis revealed that molecular markers of M1 and M2 responses have heterogeneous injury effects in the hippocampus and that "time-post-injury" is an important factor in determining inflammation status. With the heterogeneous gene expression of pro-inflammatory cytokines, M1 response was significantly elevated at 2 hand declined at 24 h after TBI, however, their levels remained higher than the sham rats. Except IFN gamma, proteins of M1 cytokines were significantly elevated in the first 24 h, and peaked between 2-6 h [TNF alpha (2 h), IL-1 beta (6 h), and IL-6 (4-6 h)]. With the heterogeneous relative gene expression of Arg1, YM1, FIZZ1, and MRC1,levels of M2 cytokines were peaked at 24 h post TBI. IL-10 and IL-13 expression appeared biphasic in the first 24 h. Protein values of IL-4 and IL-13 peaked at 24 h and IL-10 at 6 h post injury. Results suggest that the M1 response rises rapidly after injury and overpowers the initial, comparatively smaller, or transient M2 response. A treatment that can modulate inflammation, reduce SIC, and improve recovery should be initiated early (within 10 h) after TBI. (C) 2015 Published by Elsevier B.V.	[Ansari, Mubeen A.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Ansari, Mubeen A.] Univ Kentucky, Spinal Cord Brain Injury Res Ctr, Lexington, KY 40536 USA	Ansari, MA (corresponding author), Univ Kentucky, Ctr Aging, 229A Sanders Brown, Lexington, KY 40536 USA.	mansa3@email.uky.edu			Kentucky Spinal Cord Head Injury Research Trust [12-16A]	This research was supported by the Kentucky Spinal Cord Head Injury Research Trust #12-16A.	Ajmone-Cat MA, 2013, GLIA, V61, P1698, DOI 10.1002/glia.22550; Amor S, 2010, IMMUNOLOGY, V129, P154, DOI 10.1111/j.1365-2567.2009.03225.x; Ankeny DP, 2009, NEUROSCIENCE, V158, P1112, DOI 10.1016/j.neuroscience.2008.07.001; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Ansari MA, 2014, FREE RADICAL BIO MED, V77, P21, DOI 10.1016/j.freeradbiomed.2014.08.025; Ansari MA, 2013, J NEUROTRAUM, V30, P1542, DOI 10.1089/neu.2013.2910; Anthony DC, 2013, MOL CELL NEUROSCI, V53, P1, DOI 10.1016/j.mcn.2012.11.005; Anthony DC, 2012, BRAIN BEHAV IMMUN, V26, P534, DOI 10.1016/j.bbi.2011.10.011; Babcock AA, 2003, J NEUROSCI, V23, P7922; Baron R, 2008, FASEB J, V22, P2843, DOI 10.1096/fj.08-105866; Bedi SS, 2013, J NEUROSCI METH, V219, P176, DOI 10.1016/j.jneumeth.2013.07.017; Benaroyo L, 1994, Praxis (Bern 1994), V83, P1343; Bialas AR, 2013, NAT NEUROSCI, V16, P1773, DOI 10.1038/nn.3560; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Blond D, 2002, BRAIN RES, V958, P89, DOI 10.1016/S0006-8993(02)03473-X; Boche D, 2013, NEUROPATH APPL NEURO, V39, P3, DOI 10.1111/nan.12011; Bonecchi R, 2000, J IMMUNOL, V164, P3862, DOI 10.4049/jimmunol.164.7.3862; Boulanger LM, 2001, CURR OPIN NEUROBIOL, V11, P568, DOI 10.1016/S0959-4388(00)00251-8; Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Cao L, 2013, NEUROSCI BULL, V29, P189, DOI 10.1007/s12264-013-1324-0; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Filiou MD, 2014, NEUROGENETICS, V15, P201, DOI 10.1007/s10048-014-0409-x; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Franco ECS, 2012, NEUROSCI RES, V73, P122, DOI 10.1016/j.neures.2012.03.006; Fumagalli S, 2013, GLIA, V61, P827, DOI 10.1002/glia.22474; GEHRMANN J, 1993, BRAIN PATHOL, V3, P11, DOI 10.1111/j.1750-3639.1993.tb00720.x; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Girard S, 2013, GLIA, V61, P813, DOI 10.1002/glia.22478; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Hailer NP, 1999, EUR J NEUROSCI, V11, P3359, DOI 10.1046/j.1460-9568.1999.00808.x; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Jang E, 2013, FASEB J, V27, P1176, DOI 10.1096/fj.12-222257; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Johansson S, 2008, STEM CELLS, V26, P2444, DOI 10.1634/stemcells.2008-0116; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kodelja V, 1997, IMMUNOBIOLOGY, V197, P478, DOI 10.1016/S0171-2985(97)80080-0; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mikita J, 2011, MULT SCLER J, V17, P2, DOI 10.1177/1352458510379243; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; O'Callaghan JP, 2008, ANN NY ACAD SCI, V1139, P318, DOI 10.1196/annals.1432.032; Pathipati P, 2013, DEV NEUROSCI-BASEL, V35, P241, DOI 10.1159/000346159; Perego C, 2013, JOVE-J VIS EXP, DOI 10.3791/50605; Phani Sudarshan, 2012, Parkinsonism Relat Disord, V18 Suppl 1, pS207, DOI 10.1016/S1353-8020(11)70064-5; Pineau I, 2010, BRAIN BEHAV IMMUN, V24, P540, DOI 10.1016/j.bbi.2009.11.007; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rao JS, 2012, NEUROCHEM RES, V37, P903, DOI 10.1007/s11064-012-0708-2; Rappert A, 2004, J NEUROSCI, V24, P8500, DOI 10.1523/JNEUROSCI.2451-04.2004; Rocha e Silva M., 1994, AGENTS ACTIONS, V43, P86; Rosas-Ballina M, 2009, J INTERN MED, V265, P663, DOI 10.1111/j.1365-2796.2009.02098.x; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Scheff SW, 2013, EXP NEUROL, V239, P183, DOI 10.1016/j.expneurol.2012.09.019; Scott A, 2004, BRIT J SPORT MED, V38, P248, DOI 10.1136/bjsm.2003.011221; Selenica MLB, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-86; Shechter R, 2013, J PATHOL, V229, P332, DOI 10.1002/path.4106; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; SIESJO BK, 1994, ANN NY ACAD SCI, V747, P140; Sternberg EM, 2006, NAT REV IMMUNOL, V6, P318, DOI 10.1038/nri1810; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Stirling DP, 2014, BRAIN, V137, P707, DOI 10.1093/brain/awt341; Sudduth TL, 2013, J NEUROSCI, V33, P9684, DOI 10.1523/JNEUROSCI.1220-13.2013; Sudduth TL, 2013, NEUROBIOL AGING, V34, P1051, DOI 10.1016/j.neurobiolaging.2012.09.012; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Taylor RA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/746068; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Varnum MM, 2012, ARCH IMMUNOL THER EX, V60, P251, DOI 10.1007/s00005-012-0181-2; Walter J, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-18; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Weekman EM, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-127; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Wilcock DM, 2011, ASN NEURO, V3, DOI 10.1042/AN20110018; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Wirjatijasa F, 2002, J NEUROSCI RES, V68, P579, DOI 10.1002/jnr.10254; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769	94	27	27	0	25	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	OCT 15	2015	357	1-2					41	49		10.1016/j.jns.2015.06.062			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CS5SQ	WOS:000362138800007	26148932				2021-06-18	
J	Ying, CJ; Zhang, F; Zhou, XY; Hu, XT; Chen, J; Wen, XR; Sun, Y; Zheng, KY; Tang, RX; Song, YJ				Ying, Chang-jiang; Zhang, Fang; Zhou, Xiao-yan; Hu, Xiao-tong; Chen, Jing; Wen, Xiang-ru; Sun, Ying; Zheng, Kui-yang; Tang, Ren-xian; Song, Yuan-jian			Anti-inflammatory Effect of Astaxanthin on the Sickness Behavior Induced by Diabetes Mellitus	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Astaxanthin; Diabetes; Inflammation; Cystathionine beta-synthase	CYSTATHIONINE-BETA-SYNTHASE; TRAUMATIC BRAIN-INJURY; HYDROGEN-SULFIDE; FRONTAL-CORTEX; OXIDATIVE STRESS; IN-VIVO; MICE; RATS; ACTIVATION; DEPRESSION	Chronic inflammation appears to play a critical role in sickness behavior caused by diabetes mellitus. Astaxanthin has been used in treating diabetes mellitus and diabetic complications because of its neuroprotective and anti-inflammatory actions. However, whether astaxanthin can improve sickness behavior induced by diabetes and its potential mechanisms are still unknown. The aim of this study was to investigate the effects of astaxanthin on diabetes-elicited abnormal behavior in mice and its corresponding mechanisms. An experimental diabetic model was induced by streptozotocin (150 mg/kg) and astaxanthin (25 mg/kg/day) was provided orally for 10 weeks. Body weight and water consumption were measured, and the sickness behavior was evaluated by the open field test (OFT) and closed field test (CFT). The expression of glial fibrillary acidic protein (GFAP) was measured, and the frontal cortical cleaved caspase-3 positive cells, interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) expression levels were also investigated. Furthermore, cystathionine beta-synthase (CBS) in the frontal cortex was detected to determine whether the protective effect of astaxanthin on sickness behavior in diabetic mice is closely related to CBS. As expected, we observed that astaxanthin improved general symptoms and significantly increase horizontal distance and the number of crossings in the OFT and CFT. Furthermore, data showed that astaxanthin could decrease GFAP-positive cells in the brain and down-regulate the cleaved caspase-3, IL-6, and IL-1 beta, and up-regulate CBS in the frontal cortex. These results suggest that astaxanthin provides neuroprotection against diabetes-induced sickness behavior through inhibiting inflammation, and the protective effects may involve CBS expression in the brain.	[Ying, Chang-jiang] Xuzhou Med Coll, Dept Endocrinol, Affiliated Hosp, Xuzhou 221002, Jiangsu, Peoples R China; [Zhang, Fang; Zhou, Xiao-yan; Hu, Xiao-tong; Chen, Jing; Tang, Ren-xian] Xuzhou Med Coll, Lab Morphol, Xuzhou 221004, Jiangsu, Peoples R China; [Wen, Xiang-ru; Song, Yuan-jian] Xuzhou Med Coll, Jiangsu Key Lab Brain Dis Bioinformat, Xuzhou 221004, Jiangsu, Peoples R China; [Sun, Ying] Xuzhou Med Coll, Dept Neurol, Affiliated Hosp, Xuzhou 221002, Jiangsu, Peoples R China; [Song, Yuan-jian] Xuzhou Med Coll, Dept Genet, Neurobiol Res Ctr, Jiangsu 221004, Jiangsu, Peoples R China; [Zheng, Kui-yang; Tang, Ren-xian] Xuzhou Med Coll, Dept Pathogen Biol & Immunol, Lab Infect & Immun, Xuzhou 221004, Jiangsu, Peoples R China	Tang, RX (corresponding author), Xuzhou Med Coll, Lab Morphol, Xuzhou 221004, Jiangsu, Peoples R China.	tangrenxian-t@163.com; biosongyuanjian@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371300]; Education Departmental Natural Science Research Funds of Jiangsu Provincial Higher School of China [13KJB310021, 13KJD310003]; Project of Xuzhou science and technology plan [KC14SH076]; Foundation of President of Xuzhou Medical College [2012KJZ06]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Qing Lan Project of Jiangsu Province	This work was supported by the National Natural Science Foundation of China (81371300), the Education Departmental Natural Science Research Funds of Jiangsu Provincial Higher School of China (13KJB310021, 13KJD310003), the Project of Xuzhou science and technology plan (KC14SH076), the Foundation of President of Xuzhou Medical College (2012KJZ06), a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and the Qing Lan Project of Jiangsu Province. Thanks to Hongyan Dong, Hongli Yu, Meng Wang, Baole Zhang and Xuebin Qu for their support and help during the experiments.	Aksu I, 2012, NEUROSCI LETT, V531, P176, DOI 10.1016/j.neulet.2012.10.045; Ambati RR, 2014, MAR DRUGS, V12, P128, DOI 10.3390/md12010128; Aminzadeh MA, 2012, NEPHROL DIAL TRANSPL, V27, P498, DOI 10.1093/ndt/gfr560; Bae SK, 2013, J AM CHEM SOC, V135, P9915, DOI 10.1021/ja404004v; Chen C, 2014, DIS MODEL MECH, V7, P723, DOI 10.1242/dmm.016162; Chen ML, 2007, J PSYCHIATR RES, V41, P57, DOI 10.1016/j.jpsychires.2005.03.005; Choi K, 2012, J PSYCHIATR RES, V46, P882, DOI 10.1016/j.jpsychires.2012.03.021; Chourbaji S, 2006, NEUROBIOL DIS, V23, P587, DOI 10.1016/j.nbd.2006.05.001; Damian JP, 2014, EXP ANIM TOKYO, V63, P277, DOI 10.1538/expanim.63.277; Dong LY, 2013, MAR DRUGS, V11, P960, DOI 10.3390/md11030960; El-Akabawy G, 2014, ANN ANAT, V196, P119, DOI 10.1016/j.aanat.2014.01.003; Enhamre-Brolin E, 2013, BEHAV BRAIN RES, V238, P273, DOI 10.1016/j.bbr.2012.10.036; Fu YY, 2014, CELL MOL NEUROBIOL, V34, P651, DOI 10.1007/s10571-014-0039-8; Gibney SM, 2013, BRAIN BEHAV IMMUN, V28, P170, DOI 10.1016/j.bbi.2012.11.010; Giuliani D, 2013, NEUROBIOL LEARN MEM, V104, P82, DOI 10.1016/j.nlm.2013.05.006; Gong QH, 2011, J ALZHEIMERS DIS, V24, P173, DOI 10.3233/JAD-2011-110128; Harden LM, 2011, PSYCHONEUROENDOCRINO, V36, P608, DOI 10.1016/j.psyneuen.2010.09.003; Holmes C, 2011, NEUROLOGY, V77, P212, DOI 10.1212/WNL.0b013e318225ae07; Ishigami M, 2009, ANTIOXID REDOX SIGN, V11, P205, DOI 10.1089/ARS.2008.2132; Ishiki M, 2013, ENDOCRINOLOGY, V154, P2600, DOI 10.1210/en.2012-2198; Jing YH, 2013, NEUROENDOCRINOLOGY, V98, P116, DOI 10.1159/000350435; Katon W, 2010, DEPRESS ANXIETY, V27, P323, DOI 10.1002/da.20683; Katon WJ, 2013, ANN FAM MED, V11, P245, DOI 10.1370/afm.1501; Keleshian VL, 2013, J NEUROCHEM, V125, P63, DOI 10.1111/jnc.12153; Kidd P, 2011, ALTERN MED REV, V16, P355; Kim YJ, 2009, J AGR FOOD CHEM, V57, P8793, DOI 10.1021/jf9019745; Kimura Y, 2006, ANTIOXID REDOX SIGN, V8, P661, DOI 10.1089/ars.2006.8.661; Kleinridders A, 2014, DIABETES, V63, P2232, DOI 10.2337/db14-0568; Lindahl B, 2008, INT J BEHAV MED, V15, P165, DOI 10.1080/10705500802222311; Liu YW, 2014, PHARMACOL BIOCHEM BE, V117, P128, DOI 10.1016/j.pbb.2013.11.027; Liu YW, 2013, PSYCHOPHARMACOLOGY, V228, P585, DOI 10.1007/s00213-013-3061-5; Lu YP, 2010, BRAIN RES, V1360, P40, DOI 10.1016/j.brainres.2010.09.016; Marin DP, 2011, INT IMMUNOPHARMACOL, V11, P103, DOI 10.1016/j.intimp.2010.10.013; Marrero D, 2014, QUAL LIFE RES, V23, P75, DOI 10.1007/s11136-013-0436-3; Meng XF, 2014, MOL NEUROBIOL, V49, P673, DOI 10.1007/s12035-013-8551-2; O'Connor JC, 2005, J IMMUNOL, V174, P4991, DOI 10.4049/jimmunol.174.8.4991; Ola MS, 2014, NEUROL SCI, V35, P1003, DOI 10.1007/s10072-014-1628-5; Patel SS, 2014, METAB BRAIN DIS, V29, P121, DOI 10.1007/s11011-014-9480-0; Petrak F, 2013, DIABETES TECHNOL THE, V15, P702, DOI 10.1089/dia.2012.0257; Qu K, 2008, NEUROCHEM INT, V52, P155, DOI 10.1016/j.neuint.2007.05.016; Rajashree R, 2011, MALAYS J MED SCI, V18, P26; Renner NA, 2013, J CELL PHYSIOL, V228, P1284, DOI 10.1002/jcp.24283; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Saavedra JM, 2012, CELL MOL NEUROBIOL, V32, P667, DOI 10.1007/s10571-011-9754-6; Sajatovic M, 2011, PSYCHIAT SERV, V62, P1001, DOI 10.1176/appi.ps.62.9.1001; Sharma AN, 2010, PHYSIOL BEHAV, V101, P381, DOI 10.1016/j.physbeh.2010.07.002; Shelton RC, 2011, MOL PSYCHIATR, V16, P751, DOI 10.1038/mp.2010.52; Silverman MN, 2013, MOL PSYCHIATR, V18, P1006, DOI 10.1038/mp.2012.131; Sima AAF, 2010, ACTA DIABETOL, V47, P279, DOI 10.1007/s00592-010-0218-0; Sima Anders A F, 2009, Rev Diabet Stud, V6, P37, DOI 10.1900/RDS.2009.6.37; Singh S, 2009, J BIOL CHEM, V284, P22457, DOI 10.1074/jbc.M109.010868; Speranza L, 2012, MAR DRUGS, V10, P890, DOI 10.3390/md10040890; Spulber S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042078; Takao K, 2013, NEUROPSYCHOPHARMACOL, V38, P1409, DOI 10.1038/npp.2013.38; Talaei F, 2014, BMC CELL BIOL, V15, DOI 10.1186/1471-2121-15-1; Tezuka T, 2013, NEUROBIOL DIS, V59, P63, DOI 10.1016/j.nbd.2013.07.003; Tomassoni D, 2013, NEUROSCI LETT, V543, P136, DOI 10.1016/j.neulet.2013.03.025; Tripathi DN, 2008, TOXICOLOGY, V248, P96, DOI 10.1016/j.tox.2008.03.015; Wang HN, 2014, J PSYCHIATR RES, V51, P79, DOI 10.1016/j.jpsychires.2014.01.004; Wilinski B, 2013, PHARMACOL REP, V65, P737, DOI 10.1016/S1734-1140(13)71053-3; Wu TH, 2008, BEHAV BRAIN RES, V193, P183, DOI 10.1016/j.bbr.2008.05.009; Yuan JP, 2011, MOL NUTR FOOD RES, V55, P150, DOI 10.1002/mnfr.201000414; Zhang MY, 2013, J MOL NEUROSCI, V51, P57, DOI 10.1007/s12031-012-9948-5; Zhang MY, 2013, NEUROCHEM RES, V38, P714, DOI 10.1007/s11064-013-0969-4; Zhang Q, 2014, PHARMACOL RES, V84, P32, DOI 10.1016/j.phrs.2014.04.009; Zhang XZ, 2014, ACS CHEM NEUROSCI, V5, P876, DOI 10.1021/cn500185g	66	27	30	4	34	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	OCT	2015	35	7					1027	1037		10.1007/s10571-015-0197-3			11	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	CR6VP	WOS:000361486300012	25971983				2021-06-18	
J	Littleton, AC; Register-Mihalik, JK; Guskiewicz, KM				Littleton, Ashley C.; Register-Mihalik, Johna K.; Guskiewicz, Kevin M.			Test-Retest Reliability of a Computerized Concussion Test: CNS Vital Signs	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						concussion; psychometrics; cognition; computerized neurocognitive testing; Concussion Vital Signs	SPORT-RELATED CONCUSSION; AGE-RELATED DIFFERENCES; HIGH-SCHOOL; ONLINE VERSION; IMPACT; BATTERY; ASSESSMENTS; PERFORMANCE; MANAGEMENT; RECOVERY	Background: Neurocognitive testing is an important concussion evaluation tool, but for neurocognitive tests to be useful, their psychometric properties must be well established. Test-retest reliability of computerized neurocognitive tests can influence their clinical utility. The reliability for a commonly used computerized neurocognitive test, CNS Vital Signs, is not well established. The purpose of this study was to examine test-retest reliability and reliable change indices for CNS Vital Signs in a healthy, physically active college population. Hypothesis: CNS Vital Signs yields acceptable test-retest reliability, with greater reliability between the second and third test administration compared with between the first and second administration. Study Design: Cohort study. Level of Evidence: Level 3. Methods: Forty healthy, active volunteers (16 men, 24 women; mean age, 21.05 +/- 2.17 years) reported to a clinical laboratory for 3 sessions, 1 week apart. At each session, participants were administered CNS Vital Signs. Outcomes included standard scores for the following CNS Vital Signs domains: verbal memory, visual memory, psychomotor speed, cognitive flexibility, complex attention, processing speed, reaction time, executive functioning, and reasoning. Results: Participants performed significantly better on the second session and/or third session than they did on the first testing session on 6 of 9 neurocognitive domains. Pearson r test-retest correlations between sessions ranged from 0.11 to 0.87. Intraclass correlation coefficients ranged from 0.10 to 0.86. Conclusion: Clinicians should consider using reliable change indices to account for practice effects, identify meaningful score changes due to pathology, and inform clinical decisions. Clinical Relevance: This study highlights the importance of clinicians understanding the psychometric properties of computerized neurocognitive tests when using them in the management of sport-related concussion. If CNS Vital Signs is administered twice within a small time frame (such as 1 week), athletes should be expected to improve between the first and second administration.	[Littleton, Ashley C.; Register-Mihalik, Johna K.; Guskiewicz, Kevin M.] Univ N Carolina, Human Movement Sci Curriculum, Chapel Hill, NC 27515 USA; [Littleton, Ashley C.; Register-Mihalik, Johna K.; Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, 209 Fetzer Hall CB 8700, Chapel Hill, NC 27599 USA; [Littleton, Ashley C.; Register-Mihalik, Johna K.; Guskiewicz, Kevin M.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC 27599 USA	Littleton, AC (corresponding author), Univ N Carolina, Human Movement Sci Curriculum, Chapel Hill, NC 27515 USA.; Littleton, AC (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, 209 Fetzer Hall CB 8700, Chapel Hill, NC 27599 USA.	alittlet@live.unc.edu			American Academy of Neurology; NATA; University of Kentucky; Allied Health education	The following author declared potential conflicts of interest: Johna K. Register-Mihalik, PhD, ATC, has received payment for lectures from American Academy of Neurology, NATA, University of Kentucky, and Allied Health education and has received payment for development of educational presentations from Allied Health Education. CNS Vital Signs LLC provided their product free of charge to the researchers.	Broglio SP, 2007, J ATHL TRAINING, V42, P504; CNS Vital Signs LLC, FREQ ASK QUEST; Cole WR, 2013, ARCH CLIN NEUROPSYCH, V28, P732, DOI 10.1093/arclin/act040; Duff K, 2001, ARCH CLIN NEUROPSYCH, V16, P461; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Falleti MG, 2006, J CLIN EXP NEUROPSYC, V28, P1095, DOI 10.1080/13803390500205718; Fleiss J., 1986, DESIGN ANAL CLIN EXP; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Hunt TN, 2009, J ATHL TRAINING, V44, P405, DOI 10.4085/1062-6050-44.4.405; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Leckie RL, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00985; Lovell MR, 2013, J PEDIATR-US, V163, P1192, DOI 10.1016/j.jpeds.2013.05.061; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Register-Mihalik JK, 2012, J ATHL TRAINING, V47, P297, DOI 10.4085/1062-6050-47.3.13; Resch JE, 2013, NEUROPSYCHOL REV, V23, P335, DOI 10.1007/s11065-013-9242-5; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Voss MW, 2011, NEUROSCIENCE, V199, P166, DOI 10.1016/j.neuroscience.2011.10.009	25	27	27	1	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	SEP-OCT	2015	7	5					443	447		10.1177/1941738115586997			5	Sport Sciences	Sport Sciences	V20NT	WOS:000214894000011	26502421	Green Published			2021-06-18	
J	McGlade, E; Rogowska, J; Yurgelun-Todd, D				McGlade, Erin; Rogowska, Jadwiga; Yurgelun-Todd, Deborah			Sex differences in orbitofrontal connectivity in male and female veterans with TBI	BRAIN IMAGING AND BEHAVIOR			English	Article						Traumatic Brain Injury; Orbitofrontal; Functional connectivity; Aggression	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; POSITRON-EMISSION-TOMOGRAPHY; RESTING-STATE; AGGRESSIVE-BEHAVIOR; GENDER-DIFFERENCES; OEF/OIF VETERANS; MENSTRUAL-CYCLE; MILD TBI; PTSD	More female soldiers are now serving in combat theaters than at any other time. However, little is known about possible sex differences underlying the neuropathology and manifestation of one of modern war's signature injuries, traumatic brain injury (TBI). The paucity of information regarding sex differences in TBI is particularly evident when examining changes in executive function and emotion regulation associated with post concussive events. The current study objective was to observe whether patterns of orbitofrontal (OFC) functional connectivity would differ between female veterans with TBI and their male counterparts. The study further sought to determine whether OFC connectivity might be differentially associated with clinical measures of aggression and hostility. Seventeen female veterans and 24 male veterans, age 18 to 25, who met criteria for TBI completed resting state magnetic resonance imaging (MRI) and clinical assessment measures. Imaging data were analyzed using left and right seed regions of the OFC, and regression analyses were conducted to observe the relationship between resting state connectivity and self-reported aggression. Females and males in this study differed in OFC connectivity, with females demonstrating greater connectivity between left and right OFC and parietal and occipital regions and males demonstrating greater connectivity between left and right OFC and frontal and temporal regions. Significant associations between resting state connectivity and clinical measures were found only in male veterans. These findings suggest that TBI may interact with sex-specific patterns of brain connectivity in male and female veterans and exert divergent effects on clinical profiles of aggression post-injury.	[McGlade, Erin; Yurgelun-Todd, Deborah] Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA; [McGlade, Erin; Yurgelun-Todd, Deborah] VISN 19 MIRECC, Salt Lake City, UT USA; [McGlade, Erin; Rogowska, Jadwiga; Yurgelun-Todd, Deborah] Univ Utah, Inst Brain, Salt Lake City, UT USA	McGlade, E (corresponding author), Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA.	erin.mcglade@hsc.utah.edu	McGlade, Erin C/K-1157-2016	McGlade, Erin C/0000-0003-2234-1984	Department of Veterans Affairs Salt Lake City Mental Illness Research, Education & Clinical Center (MIRECC) [1I01CX000253-01]; Military Suicide Research Consortium (MSRC) - Office of the Assistant Secretary of Defense for Health Affairs [W81XWH-10-2-0178]; Veterans AffairsUS Department of Veterans Affairs [I01CX000253] Funding Source: NIH RePORTER	This work was supported by the Department of Veterans Affairs Salt Lake City Mental Illness Research, Education & Clinical Center (MIRECC), Merit Review 1I01CX000253-01 (PI Yurgelun-Todd), and the Military Suicide Research Consortium (MSRC), an effort supported by the Office of the Assistant Secretary of Defense for Health Affairs under Award No. W81XWH-10-2-0178. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Veterans Affairs, MSRC, or Department of Defense.	Afari N, 2015, MIL MED, V180, P296, DOI 10.7205/MILMED-D-14-00255; Angkaw AC, 2013, MIL MED, V178, P1044, DOI 10.7205/MILMED-D-13-00061; Antonucci AS, 2006, PSYCHIAT RES-NEUROIM, V147, P213, DOI 10.1016/j.pscychresns.2005.05.016; Archer J, 2009, BEHAV BRAIN SCI, V32, P249, DOI 10.1017/S0140525X09990951; Arciniegas DB, 2014, PSYCHIAT CLIN N AM, V37, P31, DOI 10.1016/j.psc.2013.12.001; Arenivas A, 2014, BRAIN IMAGING BEHAV, V8, P407, DOI 10.1007/s11682-012-9191-2; Arevalo MA, 2015, NAT REV NEUROSCI, V16, P17, DOI 10.1038/nrn3856; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Berman KF, 1997, P NATL ACAD SCI USA, V94, P8836, DOI 10.1073/pnas.94.16.8836; Beyer F, 2015, CEREB CORTEX, V25, P3057, DOI 10.1093/cercor/bhu101; Bolla KI, 2004, CEREB CORTEX, V14, P1226, DOI 10.1093/cercor/bhh083; Bradley C, 2007, J FAM VIOLENCE, V22, P197, DOI 10.1007/s10896-007-9072-4; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI 10.1037/0022-3514.63.3.452; Campbell S. B., 2015, J TRAUMA DISSOCIATIO, P1, DOI [10.1080/15299732.2014, DOI 10.1080/15299732.2014]; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; Cleverley K, 2012, J AM ACAD CHILD PSY, V51, P1037, DOI 10.1016/j.jaac.2012.07.010; Colantonio A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-102; Congressional Budget Office, 2012, VET HLTH ADM TREATM, DOI [11-2012/reports/02-09-PTSD_0.pdf, DOI 11-2012/REPORTS/02-09-PTSD_0.PDF]; Corcoran K, 2000, MEASURES CLIN PRACTI, V2; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Craske MG, 2012, DEPRESS ANXIETY, V29, P253, DOI 10.1002/da.21930; Cuthbert BN, 2014, PSYCHOPHYSIOLOGY, V51, P1205, DOI 10.1111/psyp.12342; Cuthbert BN, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-126; Damasio A., 1994, DESCARTESERROR EMOTI; Day NL, 2013, J NEUROTRAUM, V30, P1531, DOI 10.1089/neu.2013.2854; Denson TF, 2006, J PERS SOC PSYCHOL, V90, P1032, DOI 10.1037/0022-3514.90.6.1032; Department of Veterans Affairs, 2013, AM WARS; DERMAN RJ, 1995, AM J MED, V98, pS137, DOI 10.1016/S0002-9343(99)80072-2; Elbogen EB, 2013, J NERV MENT DIS, V201, P872, DOI 10.1097/NMD.0b013e3182a6e76b; Fakhran S, 2014, RADIOLOGY, V272, P815, DOI 10.1148/radiol.14132512; Fernandez G, 2003, J NEUROSCI, V23, P3790; Flanagan Julianne C, 2014, Ment Health Subst Use, V7, P315; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; Gallaway MS, 2012, AGGRESSIVE BEHAV, V38, P357, DOI 10.1002/ab.21436; Gansler DA, 2011, PSYCHIAT RES-NEUROIM, V191, P16, DOI 10.1016/j.pscychresns.2010.09.003; Goldstein JM, 2005, NEUROPSYCHOLOGY, V19, P509, DOI 10.1037/0894-4105.19.4.509; Goodkind M, 2015, JAMA PSYCHIAT, V72, P305, DOI 10.1001/jamapsychiatry.2014.2206; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hamilton M, 1969, BR J MED PSYCHOL, V3, P76; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Joffe H, 2006, MENOPAUSE, V13, P411, DOI 10.1097/01.gme.0000189618.48774.7b; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Karairmak O, 2014, PSYCHIAT RES, V219, P536, DOI 10.1016/j.psychres.2014.05.024; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; LaMotte AD, 2014, PSYCHOL ASSESSMENT, V26, P8, DOI 10.1037/a0034579; Love AR, 2015, J INTERPERS VIOLENCE, V30, P2344, DOI 10.1177/0886260514552445; Luxton DD, 2010, DEPRESS ANXIETY, V27, P1027, DOI 10.1002/da.20730; Maccoby EE., 1974, PSYCHOL SEX DIFFEREN; Malkesman O, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00157; Matthews S, 2011, PSYCHIAT RES-NEUROIM, V191, P76, DOI 10.1016/j.pscychresns.2010.09.013; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; Mehta PH, 2010, J COGNITIVE NEUROSCI, V22, P2357, DOI 10.1162/jocn.2009.21389; Miczek KA, 2007, J NEUROSCI, V27, P11803, DOI 10.1523/JNEUROSCI.3500-07.2007; Miles SR, 2016, J INTERPERS VIOLENCE, V31, P1795, DOI 10.1177/0886260515570746; Morissette SB, 2011, REHABIL PSYCHOL, V56, P340, DOI 10.1037/a0025462; New AS, 2007, NEUROPSYCHOPHARMACOL, V32, P1629, DOI 10.1038/sj.npp.1301283; Olff M, 2007, PSYCHOL BULL, V133, P183, DOI 10.1037/0033-2909.133.2.183; Palacios EM, 2013, JAMA NEUROL, V70, P845, DOI 10.1001/jamaneurol.2013.38; Pietrini P, 2000, AM J PSYCHIAT, V157, P1772, DOI 10.1176/appi.ajp.157.11.1772; Protopopescu X, 2005, P NATL ACAD SCI USA, V102, P16060, DOI 10.1073/pnas.0502818102; Rao V, 2009, J NEUROPSYCH CLIN N, V21, P420, DOI 10.1176/appi.neuropsych.21.4.420; Reardon AF, 2014, J ANXIETY DISORD, V28, P488, DOI 10.1016/j.janxdis.2014.05.001; Renner C, 2012, BRAIN INJURY, V26, P1360, DOI 10.3109/02699052.2012.667592; Reynolds WM, 1998, J SCHOOL PSYCHOL, V36, P295, DOI 10.1016/S0022-4405(98)00010-7; Rolls ET, 2004, BRAIN COGNITION, V55, P11, DOI 10.1016/s0278-2626(03)00277-x; Ross DE, 2011, BRAIN INJURY, V25, P1271, DOI 10.3109/02699052.2011.624568; Rudebeck PH, 2008, COGN AFFECT BEHAV NE, V8, P485, DOI 10.3758/CABN.8.4.485; Shandera-Ochsner AL, 2013, CLIN NEUROPSYCHOL, V27, P881, DOI 10.1080/13854046.2013.802017; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Siever LJ, 2008, AM J PSYCHIAT, V165, P429, DOI 10.1176/appi.ajp.2008.07111774; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tanev KS, 2014, BRAIN INJURY, V28, P261, DOI 10.3109/02699052.2013.873821; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Tharp AT, 2016, J INTERPERS VIOLENCE, V31, P1095, DOI 10.1177/0886260514564067; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; United States Department of Veterans Affairs, 2014, TRENDS UT VA PROGR S; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; Weissenbacher A, 2009, NEUROIMAGE, V47, P1408, DOI 10.1016/j.neuroimage.2009.05.005; Whalley HC, 2009, BIPOLAR DISORD, V11, P840, DOI 10.1111/j.1399-5618.2009.00768.x; Wood RLL, 2013, BRAIN INJURY, V27, P253, DOI 10.3109/02699052.2012.743181; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	93	27	27	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	SEP	2015	9	3					535	549		10.1007/s11682-015-9379-3			15	Neuroimaging	Neurosciences & Neurology	CR8LQ	WOS:000361604300014	25864195	Green Published, Other Gold			2021-06-18	
J	Raible, DJ; Frey, LC; Del Angel, YC; Carlsen, J; Hund, D; Russek, SJ; Smith, B; Brooks-Kayal, AR				Raible, Daniel J.; Frey, Lauren C.; Del Angel, Yasmin Cruz; Carlsen, Jessica; Hund, Dana; Russek, Shelley J.; Smith, Bret; Brooks-Kayal, Amy R.			JAK/STAT pathway regulation of GABA(A) receptor expression after differing severities of experimental TBI	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; GABA(A) receptor; JAK/STAT pathway; STAT3	TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA; DENTATE GRANULE CELLS; CLOSED-HEAD INJURY; POSTTRAUMATIC EPILEPSY; STATUS EPILEPTICUS; REDUCED INHIBITION; SUBUNIT EXPRESSION	Synaptic inhibition in the adult brain is primarily mediated by the gamma-aminobutyric acid (GABA) type A receptor (GABA(A)R). The distribution, properties, and dynamics of these receptors are largely determined by their subunit composition. Alteration of subunit composition after a traumatic brain injury (TBI) may result in abnormal increased synaptic firing and possibly contribute to injury-related pathology. Several studies have shown that the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signaling pathway can alter GABA(A)R subunit expression. The present study investigated changes in JAK/STAT pathway activation after two different severities of experimental TBI in the mouse using the controlled cortical impact (CCI) model. It also investigated whether modulating the activation of the JAK/STAT pathway after severe controlled cortical impact (CCI-S) with a JAK/STAT inhibitor (WP1066) alters post-traumatic epilepsy development and/or neurological recovery after injury. Our results demonstrated differential changes in both the activation of STAT3 and the expression of the GABA(A)R alpha 1 and gamma 2 subunit levels that were dependent on the severity of the injury. The change in the GABA(A)R alpha 1 subunit levels appeared to be at least partly transcriptionally mediated. We were able to selectively reverse the decrease in GABA(A)R alpha 1 protein levels with WP1066 treatment after CCI injury. WP1066 treatment also improved the degree of recovery of vestibular motor function after injury. These findings suggest that the magnitude of JAK/STAT pathway activation and GABA(A)R alpha 1 subunit level decrease is dependent on injury severity in this mouse model of TBI. In addition, reducing JAK/STAT pathway activation after severe experimental TBI reverses the decrease in the GABA(A)R alpha 1 protein levels and improves vestibular motor recovery. (C) 2015 Elsevier Inc. All rights reserved.	[Raible, Daniel J.; Brooks-Kayal, Amy R.] Univ Colorado, Neurosci Program, Aurora, CO 80045 USA; [Frey, Lauren C.; Brooks-Kayal, Amy R.] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO USA; [Del Angel, Yasmin Cruz; Carlsen, Jessica; Hund, Dana; Brooks-Kayal, Amy R.] Univ Colorado, Sch Med, Dept Pediat, Div Neurol, Aurora, CO USA; [Russek, Shelley J.] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA; [Smith, Bret] Univ Kentucky, Dept Physiol, Coll Med, Chandler Med Ctr MS508, Lexington, KY 40536 USA; [Brooks-Kayal, Amy R.] Childrens Hosp Colorado, Aurora, CO USA	Brooks-Kayal, AR (corresponding author), Univ Colorado, Neurosci Program, Anschutz Med Campus, Aurora, CO 80045 USA.	draible09@gmail.com; Lauren.Frey@ucdenver.edu; Yasmin.cruzdelangel@ucdenver.edu; Jessica.Carlsen@ucdenver.edu; Dana.hund@ucdenver.edu; srussek@bu.edu; bret.smith@uky.edu; Amy.Brooks-Kayal@childrenscolorado.org		Carlsen, Jessica/0000-0002-1191-9974	Department of DefenseUnited States Department of Defense [W81XWH-11-1-0501]; NIH/NCRR Colorado CTSI Grant [TL1 RR025778]; National Institutes of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051710]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [TL1RR025778] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS083057, R01NS051710, P30NS048154] Funding Source: NIH RePORTER	The funding for this research was provided by the Department of Defense award number W81XWH-11-1-0501 (to ABK, LCF & BNS), NIH/NCRR Colorado CTSI Grant Number TL1 RR025778 (to DJR), and National Institutes of Neurological Disorders and Stroke award number R01NS051710 (to ABK and SJR). Contents are the authors' sole responsibility and do not necessarily represent official DOD or NIH views.	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Faderl S, 2007, LEUKEMIA RES, V31, P91, DOI 10.1016/j.leukres.2006.05.027; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gibson CJ, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-38; Goodkin HP, 2008, J NEUROSCI, V28, P2527, DOI 10.1523/JNEUROSCI.3426-07.2008; Grabenstatter HL, 2014, NEUROBIOL DIS, V62, P73, DOI 10.1016/j.nbd.2013.09.003; Guo DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064078; Hunt RF, 2012, EPILEPSY RES, V99, P167, DOI 10.1016/j.eplepsyres.2011.10.011; Hunt RF, 2010, J NEUROPHYSIOL, V103, P1490, DOI 10.1152/jn.00957.2009; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Hussain SF, 2007, CANCER RES, V67, P9630, DOI 10.1158/0008-5472.CAN-07-1243; Iwamaru A, 2007, ONCOGENE, V26, P2435, DOI 10.1038/sj.onc.1210031; Jia F, 2005, J NEUROPHYSIOL, V94, P4491, DOI 10.1152/jn.00421.2005; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Kharlamov EA, 2011, EPILEPSY RES, V95, P20, DOI 10.1016/j.eplepsyres.2011.02.008; Kobayashi M, 2003, J NEUROSCI, V23, P8471; Kobayashi M, 2003, J NEUROSCI, V23, P2440; Kupferman Michael E, 2009, J Exp Ther Oncol, V8, P117; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Liang J, 2006, J NEUROSCI, V26, P1749, DOI 10.1523/JNEUROSCI.4702-05.2006; Lund IV, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1162396; Mtchedlishvili Z, 2010, NEUROBIOL DIS, V38, P464, DOI 10.1016/j.nbd.2010.03.012; Nusser Z, 1998, J NEUROSCI, V18, P1693; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Peng ZC, 2004, J NEUROSCI, V24, P8629, DOI 10.1523/JNEUROSCI.2877-04.2004; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Raible DJ, 2012, J NEUROTRAUM, V29, P2548, DOI 10.1089/neu.2012.2483; Raol YH, 2006, J NEUROSCI, V26, P11342, DOI 10.1523/JNEUROSCI.3329-06.2006; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sassoe-Pognetto M, 2000, J COMP NEUROL, V420, P481, DOI 10.1002/(SICI)1096-9861(20000515)420:4<481::AID-CNE6>3.0.CO;2-5; Satriotomo I, 2006, J NEUROCHEM, V98, P1353, DOI 10.1111/j.1471-4159.2006.04051.x; Semyanov A, 2004, TRENDS NEUROSCI, V27, P262, DOI 10.1016/j.tins.2004.03.005; Shao LR, 2005, J NEUROPHYSIOL, V94, P952, DOI 10.1152/jn.01342.2004; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Somogyi P, 1996, NEUROPHARMACOLOGY, V35, P1425, DOI 10.1016/S0028-3908(96)00086-X; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Sun CS, 2004, BRAIN RES, V1029, P207, DOI 10.1016/j.brainres.2004.09.056; Sur C, 1999, MOL PHARMACOL, V56, P110; Wei WZ, 2003, J NEUROSCI, V23, P10650; Wen TC, 2001, NEUROSCI LETT, V303, P153, DOI 10.1016/S0304-3940(01)01711-6; Willmore LJ, 2009, NEUROCHEM RES, V34, P688, DOI 10.1007/s11064-008-9841-3; Zhang G, 2004, NEUROSCIENCE, V125, P299, DOI 10.1016/j.neuroscience.2004.01.040; Zhang NH, 2007, J NEUROSCI, V27, P7520, DOI 10.1523/JNEUROSCI.1555-07.2007; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001; Zhao JB, 2011, CYTOKINE, V56, P343, DOI 10.1016/j.cyto.2011.07.018	50	27	27	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2015	271						445	456		10.1016/j.expneurol.2015.07.001			12	Neurosciences	Neurosciences & Neurology	CT2JG	WOS:000362627200045	26172316	Green Accepted, Bronze			2021-06-18	
J	Bellerose, J; Bernier, A; Beaudoin, C; Gravel, J; Beauchamp, MH				Bellerose, Jenny; Bernier, Annie; Beaudoin, Cindy; Gravel, Jocelyn; Beauchamp, Miriam H.			When Injury Clouds Understanding of Others: Theory of Mind after Mild TBI in Preschool Children	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Pediatric; Head injury; Concussion; Social cognition; Perspective taking; Outcome; Social skills	TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; SOCIAL COMPETENCE; HEAD-INJURIES; NEUROPSYCHOLOGICAL FUNCTION; NEUROSURGICAL INTERVENTION; NEUROCOGNITIVE OUTCOMES; INTRACRANIAL LESIONS; BEHAVIORAL OUTCOMES; SHORT-TERM	There is evidence to suggest that social skills, such as the ability to understand the perspective of others (theory of mind), may be affected by childhood traumatic brain injuries; however, studies to date have only considered moderate and severe traumatic brain injury (TBI). This study aimed to assess theory of mind after early, mild TBI (mTBI). Fifty-one children who sustained mTBI between 18 and 60 months were evaluated 6 months post-injury on emotion and desires reasoning and false-belief understanding tasks. Their results were compared to that of 50 typically developing children. The two groups did not differ on baseline characteristics, except for pre- and post-injury externalizing behavior. The mTBI group obtained poorer scores relative to controls on both the emotion and desires task and the false-belief understanding task, even after controlling for pre-injury externalizing behavior. No correlations were found between TBI injury characteristics and theory of mind. This is the first evidence that mTBI in preschool children is associated with theory of mind difficulties. Reduced perspective taking abilities could be linked with the social impairments that have been shown to arise following TBI.	[Bellerose, Jenny; Bernier, Annie; Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Bellerose, Jenny; Beaudoin, Cindy; Gravel, Jocelyn; Beauchamp, Miriam H.] Ste Justine Hosp Res Ctr, Montreal, PQ, Canada	Beauchamp, MH (corresponding author), Univ Montreal, Dept Psychol, CP 6128,Succursale Ctr Ville, Montreal, PQ, Canada.	miriam.beauchamp@umontreal.ca			Fonds de Recherche du Quebec en SanteFonds de la Recherche en Sante du Quebec; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP11036]	This work was supported by the Fonds de Recherche du Quebec en Sante (J.B.) and the Canadian Institutes of Health Research (MOP11036 to M.H.B.). The authors declare no competing financial interests.	Abidin RR., 1995, PARENTING STRESS IND; Achenbach T. M., 2000, MANUAL ASEBA PRESCHO; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson V, 2013, J INT NEUROPSYCH SOC, V19, P539, DOI 10.1017/S1355617712001543; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Anderson V, 2012, J NEUROTRAUM, V29, P143, DOI 10.1089/neu.2011.2012; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Bayley N., 2005, BAYLEY SCALES INFANT, VThird; Beauchamp MH, 2013, HAND CLINIC, V112, P913, DOI 10.1016/B978-0-444-52910-7.00013-1; Beauchamp M, 2011, DEV NEUROPSYCHOL, V36, P578, DOI 10.1080/87565641.2011.555572; Blair C, 2002, AM PSYCHOL, V57, P111, DOI 10.1037//0003-066X.57.2.111; Blishen B. R., 1987, CANADIAN REV SOCIOLO, V24, P365; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Crowe LM, 2012, PEDIATRICS, V129, pE262, DOI 10.1542/peds.2011-0438; Dennis M, 2013, DEV COGN NEUROS-NETH, V5, P25, DOI 10.1016/j.dcn.2012.11.006; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Dennis M, 2009, J CLIN EXP NEUROPSYC, V31, P835, DOI 10.1080/13803390802572419; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feinman S., 1992, SOCIAL REFERENCING S; Garcia D, 2015, J PEDIATR PSYCHOL, V40, P391, DOI 10.1093/jpepsy/jsu093; Harrison L. P., 2003, ADAPTIVE BEHAV ASSES; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; Hughes C, 2011, J EXP CHILD PSYCHOL, V108, P96, DOI 10.1016/j.jecp.2010.07.012; Johnson C., 2000, EARLY CHILD EDUC J, V27, P207, DOI DOI 10.1023/B:ECEJ.0000003356.30481.7A; Kaldoja ML, 2012, BRAIN INJURY, V26, P1005, DOI 10.3109/02699052.2012.660516; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Ladd GW, 1999, ANNU REV PSYCHOL, V50, P333, DOI 10.1146/annurev.psych.50.1.333; Ladd GW, 1996, CHILD DEV, V67, P1103, DOI 10.1111/j.1467-8624.1996.tb01785.x; Ladd GW, 2003, ADV CHILD DEV BEHAV, V31, P43; Ladd GW, 2003, CHILD DEV, V74, P1344, DOI 10.1111/1467-8624.00611; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; Mathias JL, 2013, BRAIN INJURY, V27, P887, DOI 10.3109/02699052.2013.793398; Max JE, 1998, BRAIN INJURY, V12, P41; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Miller ScottA., 2012, THEORY MIND PRESCHOO; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Moore Chris, 1995, JOINT ATTENTION ITS; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; PARKER JG, 1987, PSYCHOL BULL, V102, P357, DOI 10.1037/0033-2909.102.3.357; Pears KC, 2003, SOC DEV, V12, P1, DOI 10.1111/1467-9507.00219; Petersen C, 2008, BRAIN INJURY, V22, P215, DOI 10.1080/02699050801935245; Razza RA, 2009, J APPL DEV PSYCHOL, V30, P332, DOI 10.1016/j.appdev.2008.12.020; Repacholi BM, 1997, DEV PSYCHOL, V33, P12, DOI 10.1037/0012-1649.33.1.12; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Shay N, 2014, J NEUROTRAUM, V31, P1305, DOI 10.1089/neu.2013.3275; Snodgrass C, 2006, BRAIN INJURY, V20, P825, DOI 10.1080/02699050600832585; SPANIER GB, 1976, J MARRIAGE FAM, V38, P15, DOI 10.2307/350547; SREBNIK DS, 1993, AM J ORTHOPSYCHIAT, V63, P526, DOI 10.1037/h0079484; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Walz NC, 2010, J NEUROPSYCHOL, V4, P181, DOI 10.1348/174866410X488788; Walz NC, 2009, DEV NEUROPSYCHOL, V34, P507, DOI 10.1080/87565640902964490; Wechsler, 2002, WECHSLER PRESCHOOL P; Wellman H. M., 1990, CHILDS THEORY MIND; Wellman HM, 2011, CHILD DEV, V82, P780, DOI 10.1111/j.1467-8624.2011.01583.x; WELLMAN HM, 1990, COGNITION, V35, P245, DOI 10.1016/0010-0277(90)90024-E; Wilde Astington J., 2003, INDIVIDUAL DIFFERENC, P13; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	82	27	27	0	21	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	AUG	2015	21	7					483	493		10.1017/S1355617715000569			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	CQ9UW	WOS:000360961700002	26243654				2021-06-18	
J	Cui, CM; Gao, JL; Cui, Y; Sun, LQ; Wang, YC; Wang, KJ; Li, R; Tian, YX; Cui, JZ				Cui, Chang-Meng; Gao, Jun-Ling; Cui, Ying; Sun, Li-Qian; Wang, Yong-Chao; Wang, Kai-Jie; Li, Ran; Tian, Yan-Xia; Cui, Jian-Zhong			Chloroquine exerts neuroprotection following traumatic brain injury via suppression of inflammation and neuronal autophagic death	MOLECULAR MEDICINE REPORTS			English	Article						chloroquine; autophagy; neuroprotection; traumatic brain injury; rats	CLOSED-HEAD INJURY; DOUBLE-EDGED-SWORD; CELL-DEATH; ISCHEMIA; MICE; MECHANISMS; RAPAMYCIN; THERAPY; HEALTH; TARGET	The antimalarial drug, chloroquine (CQ), has been reported as an autophagy inhibitor in a variety of disorders, including Alzheimer's disease and brain ischemia. To the best of our knowledge, no studies to date have examined the potential for CQ to provide neuroprotection in animal models of traumatic brain injury (TBI). The aim of this study was to investigate the neuroprotective actions of CQ in TBI and to determine the mechanisms underlying this effect. Rats were immediately subjected to a diffuse cortical impact injury caused by a modified weight-drop device and divided randomly into three groups: sham-operated, CQ treatment and vehicle. The CQ treatment group was administered CQ (intra-peritoneally, 3 mg/kg body weight) immediately following the induction of injury. The co-localization of neuron-specific nuclear protein (NeuN) and microtubule-associated protein 1 light chain 3 (LC3), was followed by immunofluorescent staining. The expression of LC3 and inflammatory cytokines was identified by western blot analysis. Wet-dry weight method was utilized to evaluate TBI-induced brain edema. Motor function was evaluated using the Neurological Severity Score (NSS) scale and the Morris water maze was employed to assess spatial learning ability. This study demonstrated that the administration of CQ attenuates TBI-induced cerebral edema, and the associated motor and cognitive functional deficits that occur post-injury. Following the induction of cerebral trauma, CQ treatment significantly suppressed neuronal autophagy and reduced expression levels of the inflammatory cytokines, interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha), in the rat hippocampus. Our results have provided in vivo evidence that CQ may exert neuroprotective effects following TBI, in attenuating brain edema and improving neurological functioning, by reducing the damaging consequences of neuronal autophagy and cerebral inflammation.	[Cui, Chang-Meng; Cui, Jian-Zhong] Hebei Med Univ, Dept Surg, Shijiazhuang 050017, Hebei, Peoples R China; [Gao, Jun-Ling; Wang, Yong-Chao; Li, Ran; Tian, Yan-Xia] Hebei United Univ, Sch Basic Med Sci, Tangshan 063000, Hebei, Peoples R China; [Cui, Ying; Sun, Li-Qian; Wang, Kai-Jie; Cui, Jian-Zhong] Tangshan Workers Hosp, Dept Neurosurg, Tangshan 063000, Hebei, Peoples R China	Cui, JZ (corresponding author), Hebei Med Univ, Dept Surg, 361 East Zhongshan Rd, Shijiazhuang 050017, Hebei, Peoples R China.	jzhcuidr2001@163.com			Natural Science Foundation of Hebei, ChinaNatural Science Foundation of Hebei Province [H2012401071, H2014105079]	This study was supported by the grant from the Natural Science Foundation of Hebei, China (grant nos. H2012401071 and H2014105079).	Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; CARO LHP, 1988, EUR J BIOCHEM, V175, P325, DOI 10.1111/j.1432-1033.1988.tb14200.x; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Fullerton HJ, 1998, ANN NEUROL, V44, P357, DOI 10.1002/ana.410440311; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; HOMEWOOD CA, 1972, NATURE, V235, P50, DOI 10.1038/235050a0; Jang CH, 2006, RHEUMATOLOGY, V45, P703, DOI 10.1093/rheumatology/kei282; Janku Filip, 2011, Nat Rev Clin Oncol, V8, P528, DOI 10.1038/nrclinonc.2011.71; Kimura T, 2013, CANCER RES, V73, P3, DOI 10.1158/0008-5472.CAN-12-2464; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Liu CL, 2010, J NEUROCHEM, V115, P68, DOI 10.1111/j.1471-4159.2010.06905.x; Liu HG, 2010, SLEEP MED, V11, P205, DOI 10.1016/j.sleep.2009.05.015; Lopez G, 2011, AUTOPHAGY, V7, P440, DOI 10.4161/auto.7.4.14680; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Puyal J, 2009, ANN NEUROL, V66, P378, DOI 10.1002/ana.21714; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; SEHGAL SN, 1975, J ANTIBIOT, V28, P727, DOI 10.7164/antibiotics.28.727; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J; Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008; Tang JP, 2004, J CEREBR BLOOD F MET, V24, P1133, DOI 10.1097/01.WCB.0000135593.05952.DE; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; vandenBorne BEEM, 1997, J RHEUMATOL, V24, P55; Wang YQ, 2012, NEUROCHEM RES, V37, P1849, DOI 10.1007/s11064-012-0791-4; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhang JY, 2009, J ALZHEIMERS DIS, V16, P39, DOI 10.3233/JAD-2009-0908	33	27	33	2	22	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	AUG	2015	12	2					2323	2328		10.3892/mmr.2015.3611			6	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	CN8GR	WOS:000358678600099	25872478	Bronze			2021-06-18	
J	Seeger, TA; Orr, S; Bodell, L; Lockyer, L; Rajapakse, T; Barlow, KM				Seeger, Trevor A.; Orr, Serena; Bodell, Lisa; Lockyer, Lisette; Rajapakse, Thilinie; Barlow, Karen M.			Occipital Nerve Blocks for Pediatric Posttraumatic Headache: A Case Series	JOURNAL OF CHILD NEUROLOGY			English	Article						postconcussion syndrome; posttraumatic headache; occipital nerve block	TRAUMATIC BRAIN-INJURY; POSTCONCUSSION SYNDROME; CHILDREN; MIGRAINE; INJECTIONS; ADOLESCENTS; RELIABILITY; DISABILITY; MANAGEMENT; SYMPTOMS	Posttraumatic headache is one of the most common and disabling symptoms after traumatic brain injury. However, evidence for treating posttraumatic headache is sparse, especially in the pediatric literature. This retrospective chart review evaluated the use of occipital nerve blocks in adolescents treated for posttraumatic headache following mild traumatic brain injury, presenting to the Complex Concussion and Traumatic Brain Injury clinic. Fifteen patients (mean age 15.47; range: 13-17) received occipital nerve block for posttraumatic headache. Follow-up was obtained in 14 patients at 5.57 (standard deviation = 3.52) months postinjury. The headache burden was high, with all except one having headaches 15 or more days per month (median 30, range 10-30). Sixty-four percent reported long-term response to the occipital nerve blocks, with associated improved quality of life and decreased postconcussion symptom scores (P < .05). One patient reported transient allopecia. Occipital nerve blocks are well tolerated and can be helpful in posttraumatic headache.	[Seeger, Trevor A.; Barlow, Karen M.] Univ Calgary, Calgary, AB, Canada; [Orr, Serena] Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada; [Orr, Serena] Univ Ottawa, Ottawa, ON, Canada; [Bodell, Lisa; Lockyer, Lisette; Rajapakse, Thilinie; Barlow, Karen M.] Alberta Childrens Prov Gen Hosp, Calgary, AB T3B 6A8, Canada	Seeger, TA (corresponding author), Alberta Childrens Prov Gen Hosp, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	tadam.sgr@gmail.com	Barlow, Karen/I-6492-2019; Barlow, Karen/C-1323-2014	Barlow, Karen/0000-0003-2612-8507; Orr, Serena/0000-0002-2879-811X			Ashkenazi A, 2008, J NEUROL NEUROSUR PS, V79, P415, DOI 10.1136/jnnp.2007.124420; Ashkenazi A, 2010, HEADACHE, V50, P943, DOI 10.1111/j.1526-4610.2010.01675.x; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Diener HC, 2010, CURR OPIN INVEST DR, V11, P735; Dubrovsky AS, 2014, HEADACHE, V54, P878, DOI 10.1111/head.12334; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Faul M, 2010, TRAUMATIC BRAIN INJU, P74; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Friedman Mark H, 2002, Heart Dis, V4, P212, DOI 10.1097/00132580-200207000-00003; Gabrhelik T, 2011, Prague Med Rep, V112, P279; GAWEL MJ, 1992, CEPHALALGIA, V12, P9, DOI 10.1046/j.1468-2982.1992.1201009.x; Gelfand AA, 2014, PEDIATR NEUROL, V50, P135, DOI 10.1016/j.pediatrneurol.2013.09.008; Hecht JS, 2004, J HEAD TRAUMA REHAB, V19, P58, DOI 10.1097/00001199-200401000-00006; Herd Anthony, 1994, Journal of Emergency Medicine, V12, P849, DOI 10.1016/0736-4679(94)90496-0; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Jimenez N, 2013, PEDIATRICS, V131, pE1850, DOI 10.1542/peds.2012-3354; Jurgens TP, 2012, J HEADACHE PAIN, V13, P199, DOI 10.1007/s10194-012-0417-x; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Lay CL, 1999, HEADACHE, V39, P275, DOI 10.1046/j.1526-4610.1999.3904275.x; Leibson CL, 2011, EPIDEMIOLOGY, V22, P836, DOI 10.1097/EDE.0b013e318231d535; Leroux E, 2013, CURR PAIN HEADACHE R, V17, DOI 10.1007/s11916-013-0325-z; Lippert-Gruner M, 2012, NEUROL NEUROCHIR POL, V46, P591, DOI 10.5114/ninp.2012.32109; Matharu MS, 2001, NEUROLOGY, V56, P273, DOI 10.1212/WNL.56.2.273; MCBEATH JG, 1994, HEADACHE, V34, P148, DOI 10.1111/j.1526-4610.1994.hed3403148.x; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Packard RC, 2000, HEADACHE, V40, P736, DOI 10.1046/j.1526-4610.2000.00128.x; Rivara FP, 2012, AM J PUBLIC HEALTH, V102, P2074, DOI 10.2105/AJPH.2012.300696; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; SAADAH HA, 1987, HEADACHE, V27, P201, DOI 10.1111/j.1526-4610.1987.hed2704201.x; Shim JH, 2011, KOREAN J ANESTHESIOL, V61, P50, DOI 10.4097/kjae.2011.61.1.50; Tobin J, 2011, HEADACHE, V51, P155, DOI 10.1111/j.1526-4610.2010.01801.x; Tobin JA, 2009, HEADACHE, V49, P1479, DOI 10.1111/j.1526-4610.2009.01549.x; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; van Pelt ED, 2011, EUR J PAEDIATR NEURO, V15, P519, DOI 10.1016/j.ejpn.2011.05.005; Vanderhoek Matthew David, 2013, Anesth Pain Med, V3, P256, DOI 10.5812/aapm.10985; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Weibelt S, 2010, HEADACHE, V50, P1041, DOI 10.1111/j.1526-4610.2010.01687.x; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	40	27	27	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	AUG	2015	30	9					1142	1146		10.1177/0883073814553973			5	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	CN0BN	WOS:000358076900004	25406154				2021-06-18	
J	Yang, LY; Chu, YH; Tweedie, D; Yu, QS; Pick, CG; Hoffer, BJ; Greig, NH; Wang, JY				Yang, L-Y.; Chu, Y-H.; Tweedie, D.; Yu, Q-S.; Pick, C. G.; Hoffer, B. J.; Greig, N. H.; Wang, J-Y			Post-trauma administration of the pifithrin-alpha oxygen analog improves histological and functional outcomes after experimental traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury (TBI); p53; Pifithrin-alpha (PFT-alpha); PFT-alpha oxygen analog; Apoptosis; Controlled cortical impact	HIPPOCAMPAL CA1 NEURONS; FOCAL CEREBRAL-ISCHEMIA; INDUCED APOPTOSIS; CELL-DEATH; PROTEIN EXPRESSION; DOPAMINE NEURONS; P53 INHIBITORS; MESSENGER-RNA; DNA-DAMAGE; CNS INJURY	Traumatic brain injury (TBI) is a major cause of death and disability worldwide. Programmed death of neuronal cells plays a crucial role in acute and chronic neurodegeneration following TBI. The tumor suppressor protein p53, a transcription factor, has been recognized as an important regulator of apoptotic neuronal death. The p53 inactivator pifithrin-alpha (PET-alpha) has been shown to be neuroprotective against stroke. A previous cellular study indicated that PFT-alpha oxygen analog (PFT-alpha (O)) is more stable and active than PET-alpha. We aimed to investigate whether inhibition of p53 using PFT-alpha or PET-alpha (O) would be a potential neuroprotective strategy for TBI. To evaluate whether these drugs protect against excitotoxicity in vitro, primary rat cortical cultures were challenged with glutamate (50 mM) in the presence or absence of various concentrations of the p53 inhibitors PFT-alpha or PET-alpha (O). Cell viability was estimated by LDH assay. In vivo, adult Sprague Dawley rats were subjected to controlled cortical impact (CCI, with 4 m/s velocity, 2 mm deformation). Five hours after injury, PET-alpha or PET-alpha (O) (2 mg/kg, i.v.) was administered to animals. Sensory and motor functions were evaluated by behavioral tests at 24 h after TBI. The p53-positive neurons were identified by double staining with cell-specific markers. Levels of mRNA encoding for p53-regulated genes (BAX, PUMA, Bcl-2 and p21) were measured by reverse transcription followed by real time-PCR from TBI animals without or with PET-alpha/PET-alpha (O) treatment We found that PET-alpha(O) (10 mu M) enhanced neuronal survival against glutamate-induced cytotoxicity in vitro more effectively than PET-alpha (10 mu M). In vivo PET-alpha (O) treatment enhanced functional recovery and decreased contusion volume at 24 h post-injury. Neuroprotection by PET-alpha (O) treatment also reduced p53-positive neurons in the cortical contusion region. In addition, p53-regulated PUMA mRNA levels at 8 h were significantly reduced by PET-alpha (O) administration after TBI. PFT-alpha (O) treatment also decreased phospho-p53 positive neurons in the cortical contusion region. Our data suggest that PET-alpha (O) provided a significant reduction of cortical cell death and protected neurons from glutamate-induced excitotoxicity in vitro, as well as improved neurological functional outcome and reduced brain injury in vivo via anti-apoptotic mechanisms. The inhibition of p53-induced apoptosis by PFT-alpha (O) provides a useful tool to evaluate reversible apoptotic mechanisms and may develop into a novel therapeutic strategy for TBI. (C) 2015 Elsevier Inc. All rights reserved.	[Yang, L-Y.; Chu, Y-H.; Wang, J-Y] Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taipei 110, Taiwan; [Tweedie, D.; Yu, Q-S.; Greig, N. H.] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Pick, C. G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Pick, C. G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel; [Hoffer, B. J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH USA; [Wang, J-Y] Taipei Med Univ, Dept Physiol, Coll Med, Sch Med, Taipei 110, Taiwan	Wang, JY (corresponding author), Taipei Med Univ, Grad Inst Med Sci, Coll Med, 250 Wu Hsing St, Taipei 110, Taiwan.	jywang2010@tmu.edu.tw	Pick, Chaim/D-4789-2009	Wang, Jia-Yi/0000-0002-9106-3351	Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST103-2321-B-038-002]; Intramural Research Program, National Institute on Aging, NIH, USA; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000311, ZIAAG000994] Funding Source: NIH RePORTER	This study was supported in part by a grant from the Ministry of Science and Technology (MOST103-2321-B-038-002 to JY Wang), Taiwan, and by the Intramural Research Program, National Institute on Aging, NIH, USA.	ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; Bae BI, 2005, NEURON, V47, P29, DOI 10.1016/j.neuron.2005.06.005; Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; Biswas SC, 2005, NEUROCHEM RES, V30, P839, DOI 10.1007/s11064-005-6877-5; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Chou J, 2011, CELL TRANSPLANT, V20, P1351, DOI 10.3727/096368910X557173; Covini N, 1999, EUR J NEUROSCI, V11, P781, DOI 10.1046/j.1460-9568.1999.00485.x; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149; Culmsee C, 2003, J NEUROSCI, V23, P8586; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.t01-1-00220.x; Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350; Endo H, 2006, BIOCHEM SOC T, V34, P1283, DOI 10.1042/BST0341283; Engel T, 2011, J CEREBR BLOOD F MET, V31, P1196, DOI 10.1038/jcbfm.2011.26; Eve DJ, 2007, BRAIN RES, V1150, P174, DOI 10.1016/j.brainres.2007.02.088; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Felts PA, 2005, BRAIN, V128, P1649, DOI 10.1093/brain/awh516; Gilman CP, 2003, NEUROMOL MED, V3, P159, DOI 10.1385/NMM:3:3:159; Greig NH, 2004, ANN NY ACAD SCI, V1035, P290, DOI 10.1196/annals.1332.018; Greig NH, 2014, ALZHEIMERS DEMENT, V10, pS62, DOI 10.1016/j.jalz.2013.12.011; Gudkov AV, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001180; Huang YN, 2009, TOXICOL APPL PHARM, V240, P315, DOI 10.1016/j.taap.2009.06.021; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kuroki K, 2009, NEUROSCI LETT, V451, P237, DOI 10.1016/j.neulet.2009.01.019; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Leker RR, 2004, EXP NEUROL, V187, P478, DOI 10.1016/j.expneurol.2004.01.030; LI Y, 1994, STROKE, V25, P849, DOI 10.1161/01.STR.25.4.849; Li Y, 1997, BRAIN RES, V765, P301, DOI 10.1016/S0006-8993(97)00524-6; Liang ZQ, 2007, BRAIN RES, V1145, P190, DOI 10.1016/j.brainres.2007.01.130; Luo Y, 2009, ANN NEUROL, V65, P520, DOI 10.1002/ana.21592; Maas A. I., 2000, CURR OPIN CRIT CARE, V6, P281; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MILLER JD, 1986, NEUROSURG REV, V9, P135, DOI 10.1007/BF01743065; Nair VD, 2006, J BIOL CHEM, V281, P39550, DOI 10.1074/jbc.M603950200; Nakajima Y, 2010, TOHOKU J EXP MED, V221, P229, DOI 10.1620/tjem.221.229; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Niizuma K, 2009, STROKE, V40, P618, DOI 10.1161/STROKEAHA.108.524447; Pietrancosta N, 2006, J MED CHEM, V49, P3645, DOI 10.1021/jm060318n; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj/cdd/4400998; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Reilly P, 2007, PROG BRAIN RES, V161, P3, DOI 10.1016/S0079-6123(06)61001-7; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sohn D, 2009, CELL DEATH DIFFER, V16, P869, DOI 10.1038/cdd.2009.17; Spaethling JM, 2007, PROG BRAIN RES, V161, P27, DOI 10.1016/S0079-6123(06)61003-0; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tobinick E, 2012, CNS DRUGS, V26, P1051, DOI 10.1007/s40263-012-0013-2; Tomasevic G, 1999, MOL BRAIN RES, V70, P304, DOI 10.1016/S0169-328X(99)00146-1; Toth A, 2006, AM J PHYSIOL-HEART C, V291, pH52, DOI 10.1152/ajpheart.01046.2005; Trimmer PA, 1996, NEURODEGENERATION, V5, P233, DOI 10.1006/neur.1996.0031; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; Watanabe H, 1999, BRAIN RES, V837, P38, DOI 10.1016/S0006-8993(99)01652-2; Whiting M. D., 2006, ANIMAL MODELS COGNIT; Yang W, 2008, J TOXICOL ENV HEAL A, V71, P289, DOI 10.1080/15287390701738467; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zhang XD, 2009, AUTOPHAGY, V5, P339, DOI 10.4161/auto.5.3.8174; Zhu XX, 2002, J MED CHEM, V45, P5090, DOI 10.1021/jm020044d	65	27	28	1	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUL	2015	269						56	66		10.1016/j.expneurol.2015.03.015			11	Neurosciences	Neurosciences & Neurology	CJ6YH	WOS:000355640600006	25819102	Green Accepted			2021-06-18	
J	Woods, DL; Wyma, JM; Herron, TJ; Yund, EW				Woods, David L.; Wyma, John M.; Herron, Timothy J.; Yund, E. William			The Effects of Aging, Malingering, and Traumatic Brain Injury on Computerized Trail-Making Test Performance	PLOS ONE			English	Article							REGRESSION-BASED NORMS; D-KEFS TRAIL; NORMATIVE DATA; COGNITIVE IMPAIRMENT; OLDER-ADULTS; TEST-A; TEST-B; AGE; SAMPLE; EDUCATION	The trail making test (TMT) is widely used to assess speed of processing and executive function. However, normative data sets gathered at different sites show significant inconsistencies. Here, we describe a computerized version of the TMT (C-TMT) that increases the precision and replicability of the TMT by permitting a segment-by-segment analysis of performance and separate analyses of dwell-time, move-time, and error time. Experiment 1 examined 165 subjects of various ages and found that completion times on both the C-TMT-A (where subjects connect successively numbered circles) and the C-TMT-B (where subjects connect circles containing alternating letters and numbers) were strongly influenced by age. Experiment 2 examined 50 subjects who underwent three test sessions. The results of the first test session were well fit by the normative data gathered in Experiment 1. Sessions 2 and 3 demonstrated significant learning effects, particularly on the C-TMT-B, and showed good test-retest reliability. Experiment 3 examined performance in subjects instructed to feign symptoms of traumatic brain injury: 44% of subjects produced abnormal completion times on the C-TMT-A, and 18% on the C-TMT-B. Malingering subjects could be distinguished from abnormally slow controls based on (1) disproportionate increases in dwell-time on the C-TMT-A, and (2) greater deficits on the C-TMT-A than on the C-TMT-B. Experiment 4 examined the performance of 28 patients with traumatic brain injury: C-TMT-B completion times were slowed, and TBI patients showed reduced movement velocities on both tests. The C-TMT improves the reliability and sensitivity of the trail making test of processing speed and executive function.	[Woods, David L.; Wyma, John M.; Herron, Timothy J.; Yund, E. William] Vet Affairs Northern Calif Heath Care Syst, Human Cognit Neurophysiol Lab, Martinez, CA 95553 USA; [Woods, David L.] Univ Calif Davis, Dept Neurol, Sacramento, CA 95817 USA; [Woods, David L.] Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA; [Woods, David L.] Univ Calif Davis, Ctr Mind & Brain, Davis, CA 95616 USA	Woods, DL (corresponding author), Vet Affairs Northern Calif Heath Care Syst, Human Cognit Neurophysiol Lab, 150 Muir Rd, Martinez, CA 95553 USA.	dlwoods@ucdavis.edu		Herron, Timothy/0000-0002-4297-014X; Yund, E./0000-0002-6833-0052; Woods, David/0000-0002-8804-3587	VA Research Service Grants [CX000583, CX001000]; Veterans AffairsUS Department of Veterans Affairs [I01CX001000] Funding Source: NIH RePORTER	This research was supported by a VA Research Service Grants CX000583 and CX001000 to DLW. The content is solely the responsibility of the authors and does not necessarily represent the official views of Department of Veterans Affairs or the U.S. Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amodio P, 2002, AGING CLIN EXP RES, V14, P117, DOI 10.1007/BF03324425; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Ashendorf L, 2008, ARCH CLIN NEUROPSYCH, V23, P129, DOI 10.1016/j.acn.2007.11.005; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Bashore TR, 2002, PSYCHOL BULL, V128, P151, DOI 10.1037/0033-2909.128.1.151; Bezdicek O, 2012, ARCH CLIN NEUROPSYCH, V27, P906, DOI 10.1093/arclin/acs084; Bowie CR, 2006, NAT PROTOC, V1, P2277, DOI 10.1038/nprot.2006.390; Buck KK, 2008, J CLIN EXP NEUROPSYC, V30, P312, DOI 10.1080/13803390701390483; Busse M, 2012, CLIN NEUROPSYCHOL, V26, P675, DOI 10.1080/13854046.2012.679623; Cangoz B, 2009, J NEUROL SCI, V283, P73, DOI 10.1016/j.jns.2009.02.313; Cavaco S, 2013, ARCH CLIN NEUROPSYCH, V28, P189, DOI 10.1093/arclin/acs115; de Frias CM, 2007, NEUROPSYCHOLOGIA, V45, P2499, DOI 10.1016/j.neuropsychologia.2007.03.022; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Demery JA, 2010, CLIN NEUROPSYCHOL, V24, P1292, DOI 10.1080/13854046.2010.528452; Donders J, 2015, ASSESSMENT, V22, P17, DOI 10.1177/1073191114530776; Egeland J, 2007, APPL NEUROPSYCHOL, V14, P113, DOI 10.1080/09084280701319953; Era P, 2011, AGING CLIN EXP RES, V23, P135, DOI 10.1007/BF03351077; Fastenau PS, 1998, J CLIN EXP NEUROPSYC, V20, P906, DOI 10.1076/jcen.20.6.906.1104; Fernandez AL, 2008, SCAND J PSYCHOL, V49, P239, DOI 10.1111/j.1467-9450.2008.00637.x; Fine EM, 2011, CLIN NEUROPSYCHOL, V25, P1331, DOI 10.1080/13854046.2011.609838; Garcia-Molina A, 2012, BRAIN INJURY, V26, P864, DOI 10.3109/02699052.2012.655362; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; Haines ME, 2001, CLIN NEUROPSYCHOL, V15, P171, DOI 10.1076/clin.15.2.171.1891; Hart T, 2003, ARCH PHYS MED REHAB, V84, P221, DOI 10.1053/apmr.2003.50023; Heaton RK, 1999, J CLIN EXP NEUROPSYC, V21, P571, DOI 10.1076/jcen.21.4.572.882; Heled E, 2012, J CLIN EXP NEUROPSYC, V34, P151, DOI 10.1080/13803395.2011.625351; Hubel KA, 2013, J CLIN EXP NEUROPSYC, V35, P745, DOI 10.1080/13803395.2013.824070; Ising M, 2014, GENES BRAIN BEHAV, V13, P501, DOI 10.1111/gbb.12132; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; KENNEDY KJ, 1981, PERCEPT MOTOR SKILL, V52, P671, DOI 10.2466/pms.1981.52.2.671; KLUSMAN LE, 1989, PERCEPT MOTOR SKILL, V68, P1199, DOI 10.2466/pms.1989.68.3c.1199; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Levine AJ, 2007, J CLIN EXP NEUROPSYC, V29, P669, DOI 10.1080/13803390600920471; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Li G, 2014, JAMA NEUROL, V71, P742, DOI 10.1001/jamaneurol.2014.445; Lovell MR, 2011, APPL NEUROPSYCHOL, V18, P197, DOI 10.1080/09084282.2011.595446; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Nelson NW, 2012, J INT NEUROPSYCH SOC, V18, P845, DOI 10.1017/S1355617712000616; O'Bryant SE, 2003, CLIN NEUROPSYCHOL, V17, P69, DOI 10.1076/clin.17.1.69.15624; Onoda K, 2013, CLIN INTERV AGING, V8, P353, DOI 10.2147/CIA.S42342; Ozen LJ, 2010, J INT NEUROPSYCH SOC, V16, P556, DOI 10.1017/S1355617710000202; Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH; Perianez JA, 2007, ARCH CLIN NEUROPSYCH, V22, P433, DOI 10.1016/j.acn.2007.01.022; Plotek W, 2014, MED SCI MONITOR, V20, P173, DOI 10.12659/MSM.889776; Poreh A., 2012, ARCH ASSESSMENT PSYC, V2, P57; Powell MR, 2011, CLIN NEUROPSYCHOL, V25, P108, DOI 10.1080/13854046.2010.532912; Rabin LA, 2007, CLIN NEUROPSYCHOL, V21, P727, DOI 10.1080/13854040600888776; Reitan RM., 1985, HALSTEAD REITAN NEUR; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Schneider ALC, 2015, ALZ DIS ASSOC DIS, V29, P32, DOI 10.1097/WAD.0000000000000042; Soukup V M, 1998, Appl Neuropsychol, V5, P65, DOI 10.1207/s15324826an0502_2; Steinberg BA, 2005, CLIN NEUROPSYCHOL, V19, P329, DOI 10.1080/13854040590945210; Then FS, 2014, J OCCUP MED TOXICOL, V9, DOI 10.1186/1745-6673-9-23; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Tombaugh TN, 1996, TEST MEMORY MALINGER; Tsushima WT, 2009, BRAIN INJURY, V23, P809, DOI 10.1080/02699050903200530; Wagner S, 2011, ARCH CLIN NEUROPSYCH, V26, P314, DOI 10.1093/arclin/acr024; Wecker NS, 2000, NEUROPSYCHOLOGY, V14, P409, DOI 10.1037//0894-4105.14.3.409; Woods DL, 2011, J CLIN EXP NEUROPSYC, V33, P101, DOI 10.1080/13803395.2010.493149; Woods DL, 2015, J COGNITIVE EXPT NEU; Woods DL, 2015, ARCH CLIN NEUROPSYCH; Yochim B, 2007, J INT NEUROPSYCH SOC, V13, P704, DOI 10.1017/S1355617707070907; Zalonis I, 2008, CLIN NEUROPSYCHOL, V22, P842, DOI 10.1080/13854040701629301	66	27	27	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2015	10	6							e0124345	10.1371/journal.pone.0124345			30	Multidisciplinary Sciences	Science & Technology - Other Topics	CK1PO	WOS:000355979500006	26060999	DOAJ Gold, Green Published			2021-06-18	
J	Sashindranath, M; Daglas, M; Medcalf, RL				Sashindranath, M.; Daglas, M.; Medcalf, R. L.			Evaluation of gait impairment in mice subjected to craniotomy and traumatic brain injury	BEHAVIOURAL BRAIN RESEARCH			English	Article						Treadmill gait analysis; Traumatic brain injury; Craniotomy; Controlled cortical impact	PLASMINOGEN-ACTIVATOR; DEFICITS; IMPACT	Traumatic brain injury (TBI) represents a significant global health burden and causes long-lasting neuromotor deficits, particularly in individuals who sustain severe TBI. A better understanding of gait impairment after experimental TBI will provide valuable information for the recovery and rehabilitation of TBI survivors. Here we utilised the DigiGait system to perform kinematic gait analysis in mice subjected to brain injury induced by the controlled cortical impact (CCI) TBI model. Naive mice, non-craniotomised and craniotomised mice were included as controls. The temporal and spatial profile of gait was mapped from 3 h to 1-week post-TBI. Remarkably, there was a noticeable alteration in some aspects of gait in craniotomised sham mice from their pre-surgery baseline at various time-points over the testing period. This was not observed in naive mice or non-craniotomised sham controls over the same time period. This finding indicates that the craniotomy procedure alone effects gait. When craniotomised mice were subjected to TBI, additional deleterious effects on gait function were observed, including forelimb stance and swing duration as well as left hindlimb swing and stride duration and frequency. Hence, mice subjected to CCI-induced TBI develop clear alterations in gait but part of this is attributable to the effect of craniotomy alone. This study also highlights the need to include both non-craniotomised and craniotomised sham mice as controls when undertaking the CCI-induced model of TBI, particularly when early time points are being evaluated. (C) 2015 Elsevier B.V. All rights reserved.	[Sashindranath, M.; Daglas, M.; Medcalf, R. L.] Monash Univ, Australian Ctr Blood Dis, Cent Clin Sch, Melbourne, Vic 3004, Australia; [Sashindranath, M.; Daglas, M.; Medcalf, R. L.] Monash Univ, Mol Neurotrauma & Haemostasis, Cent Clin Sch, Melbourne, Vic 3004, Australia	Sashindranath, M (corresponding author), Monash Univ, Australian Ctr Blood Dis, Cent Clin Sch, Level 2,Amrep Bldg, Melbourne, Vic 3004, Australia.	maithili.sashindranath@monash.edu; maria.daglas@monash.edu; robert.medcalf@monash.edu	Medcalf, Robert L/E-9632-2011; Sashindranath, Maithili/AAI-7408-2021	Sashindranath, Maithili/0000-0002-9712-4784	NHMRCNational Health and Medical Research Council of Australia [606660, 1045755]	This study was supported by NHMRC grants 606660 and 1045755 awarded to RLM.	Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Beare JE, 2009, J NEUROTRAUM, V26, P2045, DOI 10.1089/neu.2009.0914; Brooks SP, 2009, NAT REV NEUROSCI, V10, P519, DOI 10.1038/nrn2652; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Cops EJ, 2013, EXP NEUROL, V249, P8, DOI 10.1016/j.expneurol.2013.08.001; Crack PJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-37; Ek CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012021; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Lagraoui Mouna, 2012, Front Neurol, V3, P155, DOI 10.3389/fneur.2012.00155; NAVARI RM, 1978, MICROVASC RES, V16, P304, DOI 10.1016/0026-2862(78)90064-X; Neumann M, 2009, J NEUROSCI METH, V176, P34, DOI 10.1016/j.jneumeth.2008.08.026; Niechwiej-Szwedo E, 2007, GAIT POSTURE, V25, P70, DOI 10.1016/j.gaitpost.2006.01.002; Sashindranath M, 2012, BRAIN, V135, P3251, DOI 10.1093/brain/aws178; Sashindranath M, 2011, LAB INVEST, V91, P1079, DOI 10.1038/labinvest.2011.67; Soblosky JS, 1997, J NEUROSCI METH, V78, P75, DOI 10.1016/S0165-0270(97)00131-3; Williams G, 2010, J HEAD TRAUMA REHAB, V25, P366, DOI 10.1097/HTR.0b013e3181cd3600; Williams G, 2009, ARCH PHYS MED REHAB, V90, P587, DOI 10.1016/j.apmr.2008.10.013	20	27	27	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	JUN 1	2015	286						33	38		10.1016/j.bbr.2015.02.038			6	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	CG8XS	WOS:000353599600006	25721743				2021-06-18	
J	Charolidi, N; Schilling, T; Eder, C				Charolidi, Nicoletta; Schilling, Tom; Eder, Claudia			Microglial Kv1.3 Channels and P2Y12 Receptors Differentially Regulate Cytokine and Chemokine Release from Brain Slices of Young Adult and Aged Mice	PLOS ONE			English	Article							NEURONAL NMDA RECEPTORS; POTASSIUM CHANNELS; INFLAMMATORY RESPONSES; ACTIVATED MICROGLIA; EXPRESSION; ASTROCYTES; CULTURE; MODEL	Brain tissue damage following stroke or traumatic brain injury is accompanied by neuroinflammatory processes, while microglia play a central role in causing and regulating neuroinflammation via production of proinflammatory substances, including cytokines and chemokines. Here, we used brain slices, an established in situ brain injury model, from young adult and aged mice to investigate cytokine and chemokine production with particular focus on the role of microglia. Twenty four hours after slice preparation, higher concentrations of proinflammatory cytokines, i.e. TNF-alpha and IL-6, and chemokines, i.e. CCL2 and CXCL1, were released from brain slices of aged mice than from slices of young adult mice. However, maximal microglial stimulation with LPS for 24 h did not reveal age-dependent differences in the amounts of released cytokines and chemokines. Mechanisms underlying microglial cytokine and chemokine production appear to be similar in young adult and aged mice. Inhibition of microglial Kv1.3 channels with margatoxin reduced release of IL-6, but not release of CCL2 and CXCL1. In contrast, blockade of microglial P2Y12 receptors with PSB0739 inhibited release of CCL2 and CXCL1, whereas release of IL-6 remained unaffected. Cytokine and chemokine production was not reduced by inhibitors of Kir2.1 K+ channels or adenosine receptors. In summary, our data suggest that brain tissue damage-induced production of cytokines and chemokines is age-dependent, and differentially regulated by microglial Kv1.3 channels and P2Y12 receptors.	[Charolidi, Nicoletta; Schilling, Tom; Eder, Claudia] Univ London, Inst Infect & Immun, London SW17 0RE, England	Eder, C (corresponding author), Univ London, Inst Infect & Immun, Cranmer Terrace, London SW17 0RE, England.	ceder@sgul.ac.uk		Charolidi, Nicoletta/0000-0002-5721-5155; Schilling, Tom/0000-0002-0274-5482	EU-FP7 grant "TargetBraIn" [279017]	Funding provided by EU-FP7 grant "TargetBraIn" (#279017).	Bartok A, 2014, TOXICON, V87, P6, DOI 10.1016/j.toxicon.2014.05.002; Benakis C, 2015, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00461; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Chen Y, 2014, CURR MED CHEM, V21, P2146, DOI 10.2174/0929867321666131228203906; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Dissing-Olesen L, 2014, J NEUROSCI, V34, P10511, DOI 10.1523/JNEUROSCI.0405-14.2014; Duque A, 2013, DEV NEUROBIOL, V73, P841, DOI 10.1002/dneu.22105; Eder C, 2005, J NEUROSCI RES, V81, P314, DOI 10.1002/jnr.20476; Eyo UB, 2014, J NEUROSCI, V34, P10528, DOI 10.1523/JNEUROSCI.0416-14.2014; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Huuskonen J, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-25; Jaerve A, 2012, CELL TISSUE RES, V349, P229, DOI 10.1007/s00441-012-1427-3; Kawabori M, 2015, CURR MED CHEM, V22, P1258, DOI 10.2174/0929867322666150209154036; Kigerl KA, 2014, EXP NEUROL, V258, P5, DOI 10.1016/j.expneurol.2014.01.001; Kim B, 2011, J IMMUNOL, V186, P3701, DOI 10.4049/jimmunol.1000212; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lambertsen KL, 2012, J CEREBR BLOOD F MET, V32, P1677, DOI 10.1038/jcbfm.2012.88; Lyons SA, 2000, J CEREBR BLOOD F MET, V20, P1537, DOI 10.1097/00004647-200011000-00003; Melani A, 2005, NEUROCHEM INT, V47, P442, DOI 10.1016/j.neuint.2005.05.014; Menteyne A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006770; Mosher KI, 2014, BIOCHEM PHARMACOL, V88, P594, DOI 10.1016/j.bcp.2014.01.008; Njie EG, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.05.008; Norden DM, 2015, NEUROPHARMACOLOGY, V96, P29, DOI 10.1016/j.neuropharm.2014.10.028; NORENBERG W, 1994, J PHYSIOL-LONDON, V475, P15; Orr AG, 2009, NAT NEUROSCI, V12, P872, DOI 10.1038/nn.2341; Orre M, 2014, NEUROBIOL AGING, V35, P1, DOI 10.1016/j.neurobiolaging.2013.07.008; Peng Y, 2014, NEURO-ONCOLOGY, V16, P528, DOI 10.1093/neuonc/not221; Quick ED, 2014, J VIROL, V88, P13005, DOI 10.1128/JVI.01994-14; Rangaraju S, 2015, J ALZHEIMERS DIS, V44, P797, DOI 10.3233/JAD-141704; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Schilling T, 2007, BRAIN RES, V1186, P21, DOI 10.1016/j.brainres.2007.10.027; Schilling T, 2015, GLIA, V63, P664, DOI 10.1002/glia.22776; Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J; Stock C, 2006, J IMMUNOL, V177, P8560, DOI 10.4049/jimmunol.177.12.8560; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Streit WJ, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0142-6; Streit WJ, 2014, CURR OPIN IMMUNOL, V29, P93, DOI 10.1016/j.coi.2014.05.005; Taylor RA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/746068; Van Wagoner NJ, 1999, J NEUROSCI, V19, P5236; Wang HR, 2011, ACS CHEM BIOL, V6, P845, DOI 10.1021/cb200146a; Wong WT, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00022	43	27	27	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2015	10	5							e0128463	10.1371/journal.pone.0128463			12	Multidisciplinary Sciences	Science & Technology - Other Topics	CJ0QZ	WOS:000355183900237	26011191	DOAJ Gold, Green Published			2021-06-18	
J	Tavender, EJ; Bosch, M; Gruen, RL; Green, SE; Michie, S; Brennan, SE; Francis, JJ; Ponsford, JL; Knott, JC; Meares, S; Smyth, T; O'Connor, DA				Tavender, Emma J.; Bosch, Marije; Gruen, Russell L.; Green, Sally E.; Michie, Susan; Brennan, Sue E.; Francis, Jill J.; Ponsford, Jennie L.; Knott, Jonathan C.; Meares, Sue; Smyth, Tracy; O'Connor, Denise A.			Developing a targeted, theory-informed implementation intervention using two theoretical frameworks to address health professional and organisational factors: a case study to improve the management of mild traumatic brain injury in the emergency department	IMPLEMENTATION SCIENCE			English	Article						Intervention design; Intervention development; Theory use; Theoretical domains framework; Diffusion of innovations in service organisations	BEHAVIOR-CHANGE; KNOWLEDGE TRANSLATION; COLLABORATING-CENTER; HEAD-INJURIES; TASK-FORCE; CARE; TAXONOMY; PROTOCOL; DETERMINANTS; STRATEGIES	Background: Despite the availability of evidence-based guidelines for the management of mild traumatic brain injury in the emergency department (ED), variations in practice exist. Interventions designed to implement recommended behaviours can reduce this variation. Using theory to inform intervention development is advocated; however, there is no consensus on how to select or apply theory. Integrative theoretical frameworks, based on syntheses of theories and theoretical constructs relevant to implementation, have the potential to assist in the intervention development process. This paper describes the process of applying two theoretical frameworks to investigate the factors influencing recommended behaviours and the choice of behaviour change techniques and modes of delivery for an implementation intervention. Methods: A stepped approach was followed: (i) identification of locally applicable and actionable evidence-based recommendations as targets for change, (ii) selection and use of two theoretical frameworks for identifying barriers to and enablers of change (Theoretical Domains Framework and Model of Diffusion of Innovations in Service Organisations) and (iii) identification and operationalisation of intervention components (behaviour change techniques and modes of delivery) to address the barriers and enhance the enablers, informed by theory, evidence and feasibility/acceptability considerations. We illustrate this process in relation to one recommendation, prospective assessment of post-traumatic amnesia (PTA) by ED staff using a validated tool. Results: Four recommendations for managing mild traumatic brain injury were targeted with the intervention. The intervention targeting the PTA recommendation consisted of 14 behaviour change techniques and addressed 6 theoretical domains and 5 organisational domains. The mode of delivery was informed by six Cochrane reviews. It was delivered via five intervention components : (i) local stakeholder meetings, (ii) identification of local opinion leader teams, (iii) a train-the-trainer workshop for appointed local opinion leaders, (iv) local training workshops for delivery by trained local opinion leaders and (v) provision of tools and materials to prompt recommended behaviours. Conclusions: Two theoretical frameworks were used in a complementary manner to inform intervention development in managing mild traumatic brain injury in the ED. The effectiveness and cost-effectiveness of the developed intervention is being evaluated in a cluster randomised trial, part of the Neurotrauma Evidence Translation (NET) program.	[Tavender, Emma J.; Bosch, Marije; Gruen, Russell L.; Ponsford, Jennie L.] Monash Univ, Alfred, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Tavender, Emma J.; Bosch, Marije; Gruen, Russell L.] Monash Univ, Cent Clin Sch, Dept Surg, Melbourne, Vic 3004, Australia; [Gruen, Russell L.] Alfred Hosp, Dept Trauma, Melbourne, Vic, Australia; [Green, Sally E.; Brennan, Sue E.; O'Connor, Denise A.] Monash Univ, Sch Publ Hlth & Preventat Med, Melbourne, Vic 3004, Australia; [Michie, Susan] UCL, Dept Clin Educ & Hlth Psychol, London, England; [Francis, Jill J.] City Univ London, Sch Hlth Sci, London EC1V 0HB, England; [Ponsford, Jennie L.] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie L.] Monash Univ, Sch Psychol Sci, Melbourne, Vic 3004, Australia; [Knott, Jonathan C.] Univ Melbourne, Melbourne Med Sch, Melbourne, Vic, Australia; [Knott, Jonathan C.] Royal Melbourne Hosp, Dept Emergency Med, Melbourne, Vic, Australia; [Meares, Sue] Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia; [Smyth, Tracy] Westmead Hosp, Emergency Dept, Westmead, NSW 2145, Australia	Tavender, EJ (corresponding author), Monash Univ, Alfred, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia.	emma.tavender@monash.edu	O'Connor, Denise/ABC-6655-2020	O'Connor, Denise/0000-0002-6836-122X; Green, Sally Elizabeth/0000-0002-9564-9050; Francis, Jill/0000-0001-5784-8895; Brennan, Sue/0000-0003-1789-8809; Tavender, Emma/0000-0002-7230-712X; Meares, Susanne/0000-0002-3859-9974	Victorian Transport Accident Commission, Australia; Australian Postgraduate Award, Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Australian National Health and Medical Research Council Public Health FellowshipNational Health and Medical Research Council of Australia; Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia	The NET Program is funded by the Victorian Transport Accident Commission, Australia. EJT is supported by an Australian Postgraduate Award, Australian National Health and Medical Research Council. DOC is supported by an Australian National Health and Medical Research Council Public Health Fellowship. RLG is supported by a Practitioner Fellowship from the Australian National Health and Medical Research Council.	Angus D, 2006, IMPLEMENT SCI, V1, DOI 10.1186/1748-5908-1-4; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Bessen T, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3056; Bosch M, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-281; Bosch M, 2013, J EVAL CLIN PRACT, V19, P763, DOI 10.1111/j.1365-2753.2012.01835.x; Brehaut JC, 2007, ACAD EMERG MED, V14, P984, DOI 10.1197/j.aem.2007.06.025; Buetow S, 2010, J HEALTH SERV RES PO, V15, P123, DOI 10.1258/jhsrp.2009.009081; Cane J, 2015, BRIT J HEALTH PSYCH, V20, P130, DOI 10.1111/bjhp.12102; Cane J, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-37; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Colquhoun H, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-51; Craig P, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1655; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Flodgren G, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000125, 10.1002/14651858.CD000125.pub4]; Flottorp SA, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-35; Forsetlund L, 2009, COCHRANE DB SYST REV, V3; Foy R, 2011, BMJ QUAL SAF, V20, P453, DOI 10.1136/bmjqs.2010.047993; Francis JJ, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-35; French SD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065471; French SD, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-38; Giguere A, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004398.pub3; Goh M, 2012, MILD TRAUMATIC BRAIN; Gould NJ, 2014, IMPLEMENT SCI, V9, DOI 10.1186/s13012-014-0092-1; Green SE, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-74; Greenhalgh T, 2004, MILBANK Q, V82, P581, DOI 10.1111/j.0887-378X.2004.00325.x; Grimshaw JM, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-50; Grimshaw JM, 2014, IMPLEMENT SCI, V7, P50; Grol RPTM, 2007, MILBANK Q, V85, P93, DOI 10.1111/j.1468-0009.2007.00478.x; Heskestad B, 2008, J TRAUMA, V65, P1309, DOI 10.1097/TA.0b013e31815e40cd; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1055/s-0041-111066, 10.1136/bmj.g1687]; Hoffmann TC, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f3755; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hrisos S, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-11; Ingebrigtsen T, 1997, ACTA NEUROL SCAND, V95, P51, DOI 10.1111/j.1600-0404.1997.tb00068.x; Ivers N, 2012, COCHRANE DATABASE SY, V6, DOI DOI 10.1002/14651858.CD000259.PUB3; Jabbour M, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-55; Kerr J, 2005, EMERG MED J, V22, P850, DOI 10.1136/emj.2004.022673; Kolehmainen N, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-100; Leeman J, 2007, J ADV NURS, V58, P191, DOI 10.1111/j.1365-2648.2006.04207.x; Lippke S, 2008, APPL PSYCHOL-INT REV, V57, P698, DOI 10.1111/j.1464-0597.2008.00339.x; Lloyd JJ, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-73; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Mazza D, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-32; Michie S, 2005, QUAL SAF HEALTH CARE, V14, P26, DOI 10.1136/qshc.2004.011155; Michie S, 2014, BEHAV CHANGE WHEEL G; Michie S., 2014, ABC BEHAV CHANGE THE; Michie S, 2008, APPL PSYCHOL-INT REV, V57, P660, DOI 10.1111/j.1464-0597.2008.00341.x; Michie S, 2013, ANN BEHAV MED, V46, P81, DOI 10.1007/s12160-013-9486-6; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-42; O'Brien MA, 2007, COCHRANE DB SYST REV, V17; Ovretveit JC, 2011, BMJ QUAL SAF, V20, P604, DOI 10.1136/bmjqs.2010.047035; Peachey T, 2011, EMERG MED J, V28, P707, DOI 10.1136/emj.2010.093872; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Porcheret M, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-42; Powell BJ, 2012, MED CARE RES REV, V69, P123, DOI 10.1177/1077558711430690; Proctor EK, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-139; Scott SD, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-65; Shojania KG, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001096.pub2; Squires JE, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-80; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Tabak RG, 2012, AM J PREV MED, V43, P337, DOI 10.1016/j.amepre.2012.05.024; Tavender EJ, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-8; Tavender EJ, 2011, ACAD EMERG MED, V18, P880, DOI 10.1111/j.1553-2712.2011.01134.x; The Cochrane Library, 2014, BOOK COCHR LIB; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Toma A, 2010, CRIT CARE MED, V38, P504, DOI 10.1097/CCM.0b013e3181cb0a02; Wasserberg J, 2002, BMJ-BRIT MED J, V325, P454, DOI 10.1136/bmj.325.7362.454	69	27	27	0	21	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1748-5908			IMPLEMENT SCI	Implement. Sci.	MAY 25	2015	10								74	10.1186/s13012-015-0264-7			22	Health Care Sciences & Services; Health Policy & Services	Health Care Sciences & Services	CJ0KN	WOS:000355164600001	26003785	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Brizuela, M; Blizzard, CA; Chuckowree, JA; Dawkins, E; Gasperini, RJ; Young, KM; Dickson, TC				Brizuela, Mariana; Blizzard, Catherine A.; Chuckowree, Jyoti A.; Dawkins, Edgar; Gasperini, Robert J.; Young, Kaylene M.; Dickson, Tracey C.			The microtubule-stabilizing drug Epothilone D increases axonal sprouting following transection injury in vitro	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						Epothilone D; Microtubule-stabilizing drug; Axotomy; Microtubules; Traumatic brain injury	CORTICAL-NEURONS; BRAIN-PENETRANT; MOUSE MODEL; REGENERATION; PLASTICITY; DYNAMICS; DIFFERENTIATION; THERAPEUTICS; MECHANISMS; TRANSPORT	Neuronal cytoskeletal alterations, in particular the loss and misalignment of microtubules, are considered a hallmark feature of the degeneration that occurs after traumatic brain injury (TBI). Therefore, microtubule-stabilizing drugs are attractive potential therapeutics for use following TBI. The best-known drug in this category is Paclitaxel, a widely used anti-cancer drug that has produced promising outcomes when employed in the treatment of various animal models of nervous system trauma. However, Paclitaxel is not ideal for the treatment of patients with TBI due to its limited blood-brain barrier (BBB) permeability. Herein we have characterized the effect of the brain penetrant microtubule-stabilizing agent Epothilone D (Epo D) on post-injury axonal sprouting in an in vitro model of CNS trauma. Epo D was found to modulate axonal sprout number in a dose dependent manner, increasing the number of axonal sprouts generated post-injury. Elevated sprouting was observed when analyzing the total population of injured neurons, as well as in selective analysis of Thy1-YFP-labeled excitatory neurons. However, we found no effect of Epo D on axonal sprout length or outgrowth speed. These findings indicate that Epo D specifically affects injury-induced axonal sprout generation, but not net growth. Our investigation demonstrates that primary cultures of cortical neurons are tolerant of Epo D exposure, and that Epo D significantly increases their regenerative response following structural injury. Therefore Epo D may be a potent therapeutic for enhancing regeneration following CNS injury. This article is part of a Special Issue entitled 'Traumatic Brain Injury'. (C) 2015 Elsevier Inc. All rights reserved.	[Brizuela, Mariana; Blizzard, Catherine A.; Chuckowree, Jyoti A.; Dawkins, Edgar; Gasperini, Robert J.; Young, Kaylene M.; Dickson, Tracey C.] Univ Tasmania, Menzies Inst Med Res Tasmania, Hobart, Tas 7000, Australia	Dickson, TC (corresponding author), Univ Tasmania, Menzies Inst Med Res Tasmania, Hobart, Tas 7000, Australia.	Tracey.Dickson@utas.edu.au	Dawkins, Edgar/L-1720-2013	Dawkins, Edgar/0000-0003-1737-9435; Chuckowree, Jyoti/0000-0002-1245-1402; Blizzard, Catherine/0000-0002-8683-2937; Gasperini, Rob/0000-0001-6859-1247; Dickson, Tracey/0000-0002-9196-1661; Young, Kaylene/0000-0002-1686-3463	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [1042556]; Tasmanian Masonic Centenary Medical Research Foundation; Clive and Vera Ramaciotti Foundation; Marian and E.H. Flack Trust	We would like to thank our colleagues at the University of Tasmania for their helpful feedback and comments on this manuscript. Work in the author's laboratories was supported by the National Health and Medical Research Council of Australia (1042556), the Tasmanian Masonic Centenary Medical Research Foundation, the Clive and Vera Ramaciotti Foundation and the Marian and E.H. Flack Trust.	Andrieux A, 2006, BIOL PSYCHIAT, V60, P1224, DOI 10.1016/j.biopsych.2006.03.048; Baas PW, 2013, BRAIN, V136, P2937, DOI 10.1093/brain/awt153; Bahrey HLP, 2003, J NEUROPHYSIOL, V89, P1761, DOI 10.1152/jn.00972.2002; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Barten DM, 2012, J NEUROSCI, V32, P7137, DOI 10.1523/JNEUROSCI.0188-12.2012; Beer TM, 2007, INVEST NEW DRUG, V25, P565, DOI 10.1007/s10637-007-9068-1; Blizzard CA, 2007, EUR J NEUROSCI, V26, P1100, DOI 10.1111/j.1460-9568.2007.05750.x; Blizzard CA, 2013, J NEUROTRAUM, V30, P1908, DOI 10.1089/neu.2013.2850; Blizzard CA, 2011, CEREB CORTEX, V21, P281, DOI 10.1093/cercor/bhq091; Bradke F, 2012, NAT REV NEUROSCI, V13, P183, DOI 10.1038/nrn3176; Brunden KR, 2012, BIOCHEM SOC T, V40, P661, DOI 10.1042/BST20120010; Brunden KR, 2011, PHARMACOL RES, V63, P341, DOI 10.1016/j.phrs.2010.12.002; Brunden KR, 2010, J NEUROSCI, V30, P13861, DOI 10.1523/JNEUROSCI.3059-10.2010; Cafferty WBJ, 2008, TRENDS NEUROSCI, V31, P215, DOI 10.1016/j.tins.2008.02.004; Canty AJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3038; Carmichael ST, 2003, NEUROSCIENTIST, V9, P64, DOI 10.1177/1073858402239592; Cartelli D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01837; Cengiz N, 2012, J NEUROTRAUM, V29, P2465, DOI 10.1089/neu.2009.0947; Chen R, 2002, NEUROSCIENCE, V111, P761, DOI 10.1016/S0306-4522(02)00025-8; Cheng KL, 2008, BIOL-TARGETS THER, V2, P789; Chuckowree JA, 2004, NEUROSCIENTIST, V10, P280, DOI 10.1177/1073858404263511; Chuckowree JA, 2003, J NEUROSCI, V23, P3715; Chung RS, 2002, EXP NEUROL, V178, P1, DOI 10.1006/exnr.2002.8017; Clarke LE, 2012, J NEUROSCI, V32, P8173, DOI 10.1523/JNEUROSCI.0928-12.2012; Conde C, 2009, NAT REV NEUROSCI, V10, P319, DOI 10.1038/nrn2631; Cortes J, 2007, ONCOLOGIST, V12, P271, DOI 10.1634/theoncologist.12-3-271; DeLima AD, 1997, J COMP NEUROL, V382, P230, DOI 10.1002/(SICI)1096-9861(19970602)382:2<230::AID-CNE7>3.0.CO;2-4; DICHTER MA, 1978, BRAIN RES, V149, P279, DOI 10.1016/0006-8993(78)90476-6; Dickey CA, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-6; Dickson TC, 2000, J NEUROTRAUM, V17, P1095, DOI 10.1089/neu.2000.17.1095; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141; Erturk A, 2007, J NEUROSCI, V27, P9169, DOI 10.1523/JNEUROSCI.0612-07.2007; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fournet V, 2012, J NEUROCHEM, V123, P982, DOI 10.1111/jnc.12027; Gomis-Ruth S, 2008, CURR BIOL, V18, P992, DOI 10.1016/j.cub.2008.06.026; Goodin S, 2004, J CLIN ONCOL, V22, P2015, DOI 10.1200/JCO.2004.12.001; Hanell A., 2014, TRAUMATIC BRAIN INJU; Hellal F, 2011, SCIENCE, V331, P928, DOI 10.1126/science.1201148; Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089; Janke C, 2010, TRENDS NEUROSCI, V33, P362, DOI 10.1016/j.tins.2010.05.001; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kar S, 2003, EMBO J, V22, P70, DOI 10.1093/emboj/cdg001; King AE, 2006, J COMP NEUROL, V498, P277, DOI 10.1002/cne.21053; King CE, 2000, CLIN EXP PHARMACOL P, V27, P548, DOI 10.1046/j.1440-1681.2000.03292.x; Kolman Ada, 2005, Curr Opin Investig Drugs, V6, P616; Loov C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055983; Lou K, 2014, J MED CHEM, V57, P6116, DOI 10.1021/jm5005623; Mainen ZF, 1996, NATURE, V382, P363, DOI 10.1038/382363a0; Maxwell W. L., 1995, Journal of Neurotrauma, V12, P363; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; McKinney RA, 1999, P NATL ACAD SCI USA, V96, P11631, DOI 10.1073/pnas.96.20.11631; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Rampersad SN, 2012, SENSORS-BASEL, V12, P12347, DOI 10.3390/s120912347; Rossignol S, 1999, PROG BRAIN RES, V123, P349, DOI 10.1016/S0079-6123(08)62870-8; Sengottuvel Vetrivel, 2011, Commun Integr Biol, V4, P391, DOI 10.4161/cib.4.4.15552; Sengottuvel V, 2011, J NEUROSCI, V31, P2688, DOI 10.1523/JNEUROSCI.4885-10.2011; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; THIEL G, 1993, BRAIN PATHOL, V3, P87, DOI 10.1111/j.1750-3639.1993.tb00729.x; TYTELL M, 1984, P NATL ACAD SCI-BIOL, V81, P1570, DOI 10.1073/pnas.81.5.1570; Wang H, 2005, CANCER CHEMOTH PHARM, V56, P255, DOI 10.1007/s00280-004-0965-0; Wang H., 2005, PRECLINICAL PHARM EP; Weidner N, 2001, P NATL ACAD SCI USA, V98, P3513, DOI 10.1073/pnas.051626798; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011	68	27	28	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	MAY	2015	66		B		SI		129	140		10.1016/j.mcn.2015.02.006			12	Neurosciences	Neurosciences & Neurology	CK7FT	WOS:000356398900009	25684676				2021-06-18	
J	Di Pietro, V; Amorini, AM; Lazzarino, G; Yakoub, KM; D'Urso, S; Lazzarino, G; Belli, A				Di Pietro, Valentina; Amorini, Angela Maria; Lazzarino, Giacomo; Yakoub, Kamal Makram; D'Urso, Serafina; Lazzarino, Giuseppe; Belli, Antonio			S100B and Glial Fibrillary Acidic Protein as Indexes to Monitor Damage Severity in an In Vitro Model of Traumatic Brain Injury	NEUROCHEMICAL RESEARCH			English	Article						Biomarkers; GFAP; Hippocampal stretch injury; S100B; Traumatic brain injury	CEREBROSPINAL-FLUID; MULTIPLE TRAUMA; GENE-EXPRESSION; MESSENGER-RNA; NITRIC-OXIDE; BIOMARKERS; GFAP; RAT; AGE; ISCHEMIA	Traumatic brain injury (TBI) is a leading and rising cause of death and disability worldwide. There is great interest in S100B and Glial Fibrillary Acid Protein (GFAP) as candidate biomarkers of TBI for diagnosis, triage, prognostication and drug development. However, conflicting results especially on S100B hamper their routine application in clinical practice. To try to address this question, we mimicked TBI damage utilizing a well-validated, simplified in vitro model of graded stretch injury induced in rat organotypic hippocampal slice cultures (OHSC). Different severities of trauma, from mild to severe, have been tested by using an equi-biaxial stretch of the OHSCs at a specified Lagrangian strain of 0 (controls), 5, 10, 20 and 50 %. OHSC were analysed at 3, 6, 18, 24, 48 and 96 h post-injury. Cell death, gene expressions and release into the culture medium of S100B and GFAP were determined at each time point. Gene expression and release of S100B slightly increased only in 20 and 50 % stretched OHSC. GFAP over-expression occurred in 10, 20 and 50 % and was inversely correlated with time post-injury. GFAP release significantly increased with time at any level of injury (p < 0.01 with respect to controls). Consequently, the total amount of GFAP released showed a strong linear relationship with the severity of injury (R-2 = 0.7662; p < 0.001). Under these experimental conditions, S100B seems to be useful in diagnosing only moderate to severe TBI-like injuries. Differently, GFAP demonstrates adequate biomarker requisites since its cellular release is affected by all grades of injury severity.	[Di Pietro, Valentina; Yakoub, Kamal Makram; Belli, Antonio] Univ Birmingham, Neurobiol Sect, Sch Clin & Expt Med, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England; [Amorini, Angela Maria; Lazzarino, Giacomo] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, I-00168 Rome, Italy; [D'Urso, Serafina; Lazzarino, Giuseppe] Univ Catania, Dept Biol Geol & Environm Sci, Div Biochem & Mol Biol, Bldg 2,3 Floor,Viale A Doria 6, I-95125 Catania, Italy; [Belli, Antonio] Queen Elizabeth Hosp, Natl Inst Hlth, Res Surg Reconstruct & Microbiol Res Ctr, Birmingham B15 2TH, W Midlands, England	Lazzarino, G (corresponding author), Univ Catania, Dept Biol Geol & Environm Sci, Div Biochem & Mol Biol, Bldg 2,3 Floor,Viale A Doria 6, I-95125 Catania, Italy.	lazzarig@unict.it	Belli, Antonio/I-3799-2015	Belli, Antonio/0000-0002-3211-9933; AMORINI, Angela Maria/0000-0003-3525-9955; Di Pietro, Valentina/0000-0001-9430-4723; Lazzarino, Giacomo/0000-0003-1639-0966	Wessex Medical Research Centre; Smile4rich	We wish to thank the Wessex Medical Research Centre and Smile4rich for funding this study and for their support to our research.	Agosto DV, 2012, FRONT NEUROL SERUM B; Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Astrand Ramona, 2013, Methods Mol Biol, V963, P373, DOI 10.1007/978-1-62703-230-8_23; Bettermann K, 2012, RSC DRUG DISCOV, V24, P1, DOI 10.1039/9781849734745-00001; Bharosay A, 2012, INDIAN J CLIN BIOCHE, V27, P186, DOI 10.1007/s12291-011-0172-9; Bouvier D, 2013, ANN BIOL CLIN-PARIS, V71, P145, DOI 10.1684/abc.2013.0812; Buniatian GH, 2002, ANAT RECORD, V267, P296, DOI 10.1002/ar.10115; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Di Battista AP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00044; Di Pietro V, 2013, MOL CELL BIOCHEM, V375, P185, DOI 10.1007/s11010-012-1541-2; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; FANO G, 1993, NEUROSCIENCE, V53, P919, DOI 10.1016/0306-4522(93)90477-W; Feala JD, 2013, J NEUROTRAUM, V30, P1101, DOI 10.1089/neu.2012.2631; Gonzalez-Garcia S, 2012, CLIN BIOCHEM, V45, P16; GOSS JR, 1991, NEUROBIOL AGING, V12, P165, DOI 10.1016/0197-4580(91)90056-P; Goyal A, 2012, NEUROTRAUMA, V30, P946; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Hu JR, 1997, J NEUROCHEM, V69, P2294; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Johnsson P, 1995, J CARDIOTHOR VASC AN, V9, P694, DOI 10.1016/S1053-0770(05)80231-9; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McAdory BS, 1998, BRAIN RES, V813, P211, DOI 10.1016/S0006-8993(98)01014-2; Middeldorp J, 2011, PROG NEUROBIOL, V93, P421, DOI 10.1016/j.pneurobio.2011.01.005; Morgan TE, 1997, FREE RADICAL BIO MED, V23, P524, DOI 10.1016/S0891-5849(97)00120-2; Morgan TE, 1999, NEUROSCIENCE, V89, P687, DOI 10.1016/S0306-4522(98)00334-0; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Mussack T, 2006, CLIN CHEM LAB MED, V44, P1140, DOI 10.1515/CCLM.2006.190; NICHOLS NR, 1995, NEUROBIOL AGING, V16, P105, DOI 10.1016/0197-4580(95)80013-H; Papa L, 2010, NEUROTHERAPEUTICS, V7, P100; Papa Linda, 2008, Expert Opin Med Diagn, V2, P937, DOI 10.1517/17530059.2.8.937; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Romner B, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00053; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Sen J, 2007, J NEUROSCI RES, V85, P1373, DOI 10.1002/jnr.21211; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Strathmann FG, 2014, CLIN BIOCHEM, V47, P876, DOI 10.1016/j.clinbiochem.2014.01.028; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	48	27	27	0	8	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	MAY	2015	40	5					991	999		10.1007/s11064-015-1554-9			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	CH5SH	WOS:000354095100013	25898931				2021-06-18	
J	Lorente, L; Martin, MM; Almeida, T; Hernandez, M; Ramos, L; Argueso, M; Caceres, JJ; Sole-Violan, J; Jimenez, A				Lorente, Leonardo; Martin, Maria M.; Almeida, Teresa; Hernandez, Mariano; Ramos, Luis; Argueso, Monica; Caceres, Juan J.; Sole-Violan, Jordi; Jimenez, Alejandro			Serum substance P levels are associated with severity and mortality in patients with severe traumatic brain injury	CRITICAL CARE			English	Article							NF-KAPPA-B; HEAD-INJURY; FUNCTIONAL DEFICITS; BLOOD MONOCYTES; NK-1 RECEPTOR; SPINAL-CORD; NEUROPEPTIDE; TACHYKININS; ASTROCYTES; EXPRESSION	Introduction: Substance P (SP) is a member of the tachykinin family of neuropeptides, which are widely distributed throughout the central nervous system (CNS) and actively involved in inflammatory processes. SP is released early following acute injury to the CNS, promoting a neurogenic inflammatory response characterized by an increase in the permeability of the blood-brain barrier and the development of vasogenic edema. High levels of SP could lead to an exacerbated inflammatory response that could be fatal for patients with traumatic brain injury (TBI). Thus, the main goal of the present study was to determine whether serum SP levels are associated with injury severity and mortality in patients with severe TBI. Methods: This multicenter, observational, prospective study was carried out in six Spanish intensive care units and included patients with Glasgow Coma Scale (GCS) scores <= 8. Patients with an Injury Severity Score >= 10 in non-cranial aspects were excluded. Blood samples were collected on day 1 of TBI to measure serum SP levels. The endpoint was 30-day mortality. Results: We found higher serum SP levels (P = 0.002) in non-surviving patients (n = 27) than in surviving patients (n = 73). The area under the curve for serum SP levels with regard to predicting 30-day mortality was 0.70 (95% confidence interval (CI), 0.60 to 0.79; P < 0.001). Survival analysis showed that patients with serum SP levels >299 pg/ml had higher 30-day mortality than patients with lower levels (hazard ratio = 3.7; 95% CI, 1.75 to 7.94; P < 0.001). Multiple binomial logistic regression analysis showed that serum SP levels >299 pg/ml were associated with 30-day mortality when we controlled for APACHE II score and Marshall computed tomography lesion classification (odds ratio (OR) = 5.97; 95% CI, 1.432 to 24.851; P = 0.01) and for GCS score and age (OR = 5.71; 95% CI, 1.461 to 22.280; P = 0.01). We found a negative association between serum SP levels and GCS score (Spearman's rho = -0.22; P = 0.03). Conclusions: We report, for the first time to our knowledge, that serum SP levels were associated with injury severity and mortality in patients with severe TBI. These results open the possibility that SP antagonists may be useful in the treatment of patients with severe TBI.	[Lorente, Leonardo] Hosp Univ Canarias, Intens Care Unit, Tenerife 38320, Spain; [Martin, Maria M.] Hosp Univ Nuestra Senora Candelaria, Intens Care Unit, Santa Cruz de Tenerife 38010, Spain; [Almeida, Teresa; Hernandez, Mariano] Univ La Laguna, Inst Enfermedades Trop & Salud Publ Canarias, Unidad Genet, Tenerife 38071, Spain; [Ramos, Luis] Hosp Gen La Palma, Intens Care Unit, La Palma 38713, Spain; [Argueso, Monica] Hosp Clin Univ Valencia, Intens Care Unit, Valencia 46004, Spain; [Caceres, Juan J.] Hosp Insular, Intens Care Unit, Las Palmas Gran Canaria 35016, Spain; [Sole-Violan, Jordi] Hosp Univ Dr Negrin, Ctr Invest Biomed Red Enfermedades Resp CIBERES, Intens Care Unit, Las Palmas Gran Canaria 35010, Spain; [Jimenez, Alejandro] Hosp Univ Canarias, Res Unit, Santa Cruz De Tenerife 38320, Spain	Lorente, L (corresponding author), Hosp Univ Canarias, Intens Care Unit, S-N La Laguna, Tenerife 38320, Spain.	lorentemartin@msn.com	Hernandez, Mariano/AAK-3143-2020; Hernandez, Mariano/K-6679-2015; Almeida, Teresa/S-1166-2018	Hernandez, Mariano/0000-0003-1219-0246; Hernandez, Mariano/0000-0003-1219-0246; Argueso, Monica/0000-0001-5917-1056; Almeida, Teresa/0000-0002-7644-3436	Fundacion Canaria de Investigacion Sanitaria (FUNCANIS) (La Laguna, Tenerife, Spain)	We thank Andreina Leon Carmenatis and Henoc del Rosario Garcia for their technical assistance. This study was supported by the Fundacion Canaria de Investigacion Sanitaria (FUNCANIS) (La Laguna, Tenerife, Spain). The funders had no role in study design, sample collection, data analysis, decision to publish or preparation of the manuscript.	Almeida TA, 2004, CURR MED CHEM, V11, P2045, DOI 10.2174/0929867043364748; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Ben Borgens R, 2012, Q REV BIOL, V87, P89, DOI 10.1086/665457; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carthew HL, 2012, NEUROSCIENCE, V214, P78, DOI 10.1016/j.neuroscience.2012.04.028; Chavolla-Calderon M, 2003, J CLIN INVEST, V111, P973, DOI 10.1172/JCI200317458; Czeh B, 2006, EXPERT OPIN INV DRUG, V15, P479, DOI 10.1517/13543784.15.5.479; Das S, 2008, J NEUROSCI RES, V86, P1199, DOI 10.1002/jnr.21585; De Swert KO, 2006, EUR J PHARMACOL, V533, P171, DOI 10.1016/j.ejphar.2005.12.066; DEFELIPE C, 1995, SCIENCE, V267, P899, DOI 10.1126/science.7531367; Delgado AV, 2005, EXP BIOL MED, V230, P271; Donkin JJ, 2007, PROG BRAIN RES, V161, P97, DOI 10.1016/S0079-6123(06)61007-8; Donkin JJ, 2011, J NEUROTRAUM, V28, P217, DOI 10.1089/neu.2010.1632; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Duffy Ruth A, 2004, Expert Opin Emerg Drugs, V9, P9; EDVINSSON L, 1988, REGUL PEPTIDES, V20, P181, DOI 10.1016/0167-0115(88)90075-4; Fiebich BL, 2000, J IMMUNOL, V165, P5606, DOI 10.4049/jimmunol.165.10.5606; Bernal EF, 2013, MED INTENSIVA, V37, P327, DOI 10.1016/j.medin.2012.05.015; Gabrielian Levon, 2013, Acta Neurochir Suppl, V118, P201, DOI 10.1007/978-3-7091-1434-6_37; Graham DI, 1996, ACT NEUR S, V66, P96; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; Ho WZ, 1996, J NEUROIMMUNOL, V71, P73, DOI 10.1016/S0165-5728(96)00132-4; Hoehn BD, 2005, STROKE, V36, P2718, DOI 10.1161/01.STR.0000190020.30282.cc; Kleinbaum DG, 1998, APPL REGRESSION ANAL, P281; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LAURENZI MA, 1990, SCAND J IMMUNOL, V31, P529, DOI 10.1111/j.1365-3083.1990.tb02801.x; Li Y, 2003, J NEUROSCI RES, V71, P559, DOI 10.1002/jnr.10504; Lieb K, 1997, J IMMUNOL, V159, P4952; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; Lu J, 2005, ACT NEUR S, V95, P281; Maeda K, 1997, GERONTOLOGY, V43, P11; MANTYH PW, 1989, P NATL ACAD SCI USA, V86, P5193, DOI 10.1073/pnas.86.13.5193; Marmarou A, 2001, J NEUROSURG, V94, P349; MARRIOTT DR, 1991, J NEUROCHEM, V56, P259, DOI 10.1111/j.1471-4159.1991.tb02590.x; Marriott I, 2004, FRONT BIOSCI, V9, P2153, DOI 10.2741/1377; Marriott I, 2000, J NEUROIMMUNOL, V102, P163, DOI 10.1016/S0165-5728(99)00182-4; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARTIN FC, 1993, J NEUROIMMUNOL, V42, P53, DOI 10.1016/0165-5728(93)90212-H; MARTIN FC, 1992, BRAIN RES, V599, P13, DOI 10.1016/0006-8993(92)90846-2; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Munoz M, 2014, AMINO ACIDS, V46, P1727, DOI 10.1007/s00726-014-1736-9; Munoz M, 2011, CURR DRUG TARGETS, V12, P909, DOI 10.2174/138945011795528796; NEWBOLD P, 1995, BRIT J PHARMACOL, V114, P570, DOI 10.1111/j.1476-5381.1995.tb17177.x; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; O'Connor TM, 2004, J CELL PHYSIOL, V201, P167, DOI 10.1002/jcp.20061; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; Palma C, 1997, GLIA, V21, P183, DOI 10.1002/(SICI)1098-1136(199710)21:2<183::AID-GLIA2>3.0.CO;2-8; Park SW, 2007, J NEUROSURG, V107, P593, DOI 10.3171/JNS-07/09/0593; Petroni G, 2010, J TRAUMA, V68, P564, DOI 10.1097/TA.0b013e3181ce1eed; Rasley A, 2002, GLIA, V37, P258, DOI 10.1002/glia.10034; Shi HY, 2014, J NEUROSURG, V3, P1; TEASDALE G, 1974, LANCET, V2, P81; Vink R, 2010, NEUROTHERAPEUTICS, V7, P74, DOI 10.1016/j.nurt.2009.10.018; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Yang S, 2014, CRIT CARE MED, V42, P2092, DOI 10.1097/CCM.0000000000000486; Zacest AC, 2010, ACTA NEUROCHIR SUPPL, V106, P211, DOI 10.1007/978-3-211-98811-4_39; Zhang Y, 2006, CURR DRUG TARGETS, V7, P1011, DOI 10.2174/138945006778019363	58	27	28	1	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	APR 27	2015	19								192	10.1186/s13054-015-0911-z			8	Critical Care Medicine	General & Internal Medicine	CH7VG	WOS:000354244100001	25928056	DOAJ Gold, Green Published			2021-06-18	
J	Moor, HM; Eisenhauer, RC; Killian, KD; Proudfoot, N; Henriques, AA; Congeni, JA; Reneker, JC				Moor, Heather M.; Eisenhauer, Rita C.; Killian, Kathleen D.; Proudfoot, Nick; Henriques, Ashley A.; Congeni, Joseph A.; Reneker, Jennifer C.			THE RELATIONSHIP BETWEEN ADHERENCE BEHAVIORS AND RECOVERY TIME IN ADOLESCENTS AFTER A SPORTS-RELATED CONCUSSION: AN OBSERVATIONAL STUDY	INTERNATIONAL JOURNAL OF SPORTS PHYSICAL THERAPY			English	Article						Adherence; adolescent; concussion; recovery; rest	INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; REHABILITATION; SYMPTOMS; EXERCISE; REST; MANAGEMENT; CHILDREN; ZURICH	Background: Adherence to rehabilitation is widely accepted as vital for recovery and return to play following sports injuries. Medical management of concussion is centered around physical and cognitive rest, a theory largely based on expert opinion, not empirical evidence. Current research on this topic focuses on factors that are predictive of adherence to rehabilitation, but fails to examine if patient adherence leads to a better outcome. The purpose of this study was to determine the adherence tendencies of adolescents to treatment recommendations provided by a sports-medicine physician after a concussion and to determine if adherence to each recommendation was a predictor of treatment duration. Study Design: Observational. Methods: Participants were enrolled in the study at their initial visit to the Sports-Medicine Center for medical care after a sports-related concussion. Individual treatment recommendations provided by a sports-medicine physician for concussion were recorded over the course of each participant's care. Once released from medical care, each participant was contacted to complete an online questionnaire to measure self-reported adherence tendencies to each treatment recommendation. Adherence was measured by two constructs: 1) the reported receptivity to the recommendation and 2) the frequency of following the recommendation. Exploratory univariate Poisson regression analyses were used to describe the relationship between adherence behaviors and the number of days of treatment required before the participant was returned to play. Results: Fifty-six questionnaires were completed, by 30 male and 26 female adolescent athletes. The self-reported adherence tendencies were very high. None of the measures of adherence to the treatment recommendations were significant predictors of the number of days of treatment; however, there was a clear tendency in five of the six rest parameters (physical rest, cognitive rest with restrictions from electronics, and cognitive rest with restrictions from school), where high levels of adherence to rest resulted in an increased average number of days of treatment (slower recovery) and those who reported being less adherent recovered faster. Conclusions: Adolescents were generally adherent to the physician recommendations. Those participants who reported being less adherent to physical and cognitive rest generally recovered faster than those who reported higher levels of adherence to these recommendations. As time progresses after the initial injury, physical and mental rest may be less effective to hasten recovery than more active treatment recommendations.	[Moor, Heather M.; Eisenhauer, Rita C.; Killian, Kathleen D.; Proudfoot, Nick; Henriques, Ashley A.; Reneker, Jennifer C.] Walsh Univ, Dept Phys Therapy, 2020 E Maple St, North Canton, OH 44720 USA; [Reneker, Jennifer C.] Kent State Univ, Coll Publ Hlth, Dept Biostat Epidemiol & Environm Hlth Sci, Kent, OH 44242 USA; [Congeni, Joseph A.] Akron Childrens Hosp, Ctr Orthoped & Sports Med, Akron, OH 44308 USA	Reneker, JC (corresponding author), Walsh Univ, Dept Phys Therapy, 2020 E Maple St, North Canton, OH 44720 USA.		Reneker, Jennifer/N-2038-2016	Reneker, Jennifer/0000-0003-3617-5681			[Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Balasundaram AP, 2013, PHYS THER SPORT, V14, P253, DOI 10.1016/j.ptsp.2013.06.002; Brewer BW, 2013, REHABIL PSYCHOL, V58, P64, DOI 10.1037/a0031297; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Byerly P N, 1994, J Athl Train, V29, P352; Cameron A.C., 2009, MICROECONOMETRICS US; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Craton N, 2014, CURR SPORT MED REP, V13, P201, DOI 10.1249/JSR.0000000000000072; Gaetz MB, 2009, BRIT J SPORT MED, V43, P508, DOI 10.1136/bjsm.2008.051748; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Gagnon I, 2009, J HEAD TRAUMA REHAB, V24, P355, DOI 10.1097/HTR.0b013e3181b97a4e; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Marshall A, 2012, J SPORT REHABIL, V21, P18, DOI 10.1123/jsr.21.1.18; May KH, 2014, INT J SPORTS PHYS TH, V9, P242; McAbee GN, 2015, J CHILD NEUROL, V30, P1378, DOI 10.1177/0883073814551794; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Prince SA, 2008, INT J BEHAV NUTR PHY, V5, DOI 10.1186/1479-5868-5-56; Reneker JC, 2015, BRIT J SPORT MED, V49, P491, DOI 10.1136/bjsports-2014-093634; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	30	27	27	0	3	AMER PHYSICAL THERAPY ASSOC	ALEXANDRIA	1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA	2159-2896			INT J SPORTS PHYS TH	Int. J. Sports Phys. Ther.	APR	2015	10	2					225	233					9	Sport Sciences	Sport Sciences	VA1WM	WOS:000409699200011	25883871				2021-06-18	
J	Shi, H; Wang, HL; Pu, HJ; Shi, YJ; Zhang, J; Zhang, WT; Wang, GH; Hu, XM; Leak, RK; Chen, J; Gao, YQ				Shi, Hong; Wang, Hai-Lian; Pu, Hong-Jian; Shi, Ye-Jie; Zhang, Jia; Zhang, Wen-Ting; Wang, Guo-Hua; Hu, Xiao-Ming; Leak, Rehana K.; Chen, Jun; Gao, Yan-Qin			Ethyl Pyruvate Protects against Blood-Brain Barrier Damage and Improves Long-term Neurological Outcomes in a Rat Model of Traumatic Brain Injury	CNS NEUROSCIENCE & THERAPEUTICS			English	Article						Blood-brain barrier; Ethyl pyruvate; Inflammation; Neuroprotection; Traumatic brain injury	MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; ENDOTHELIAL-CELLS; MATRIX METALLOPROTEINASES; INFLAMMATORY RESPONSE; MICROGLIAL ACTIVATION; CEREBRAL-ISCHEMIA; BREAKDOWN; RESUSCITATION; HEMORRHAGE; MECHANISM	AimsMany traumatic brain injury (TBI) survivors sustain neurological disability and cognitive impairments due to the lack of defined therapies to reduce TBI-induced long-term brain damage. Ethyl pyruvate (EP) has shown neuroprotection in several models of acute brain injury. The present study therefore investigated the potential beneficial effect of EP on long-term outcomes after TBI and the underlying mechanisms. MethodsMale adult rats were subjected to unilateral controlled cortical impact injury. EP was injected intraperitoneally 15min after TBI and again at 12, 24, 36, 48, and 60h after TBI. Neurological deficits, blood-brain barrier (BBB) integrity, and neuroinflammation were assessed. ResultsEthyl pyruvate improved sensorimotor and cognitive functions and ameliorated brain tissue damage up to 28day post-TBI. BBB breach and brain edema were attenuated by EP at 48h after TBI. EP suppressed matrix metalloproteinase (MMP)-9 production from peripheral neutrophils and reduced the number of MMP-9-overproducing neutrophils in the spleen, and therefore mitigated MMP-9-mediated BBB breakdown. Moreover, EP exerted potent antiinflammatory effects in cultured microglia and inhibited the elevation of inflammatory mediators in the brain after TBI. ConclusionEthyl pyruvate confers long-term neuroprotection against TBI, possibly through breaking the vicious cycle among MMP-9-mediated BBB disruption, neuroinflammation, and long-lasting brain damage.	[Shi, Hong; Wang, Hai-Lian; Pu, Hong-Jian; Zhang, Jia; Zhang, Wen-Ting; Wang, Guo-Hua; Hu, Xiao-Ming; Chen, Jun; Gao, Yan-Qin] Fudan Univ, State Key Lab Med Neurobiol, Huashan Hosp, Dept Anesthesiol, Shanghai 200032, Peoples R China; [Shi, Hong; Wang, Hai-Lian; Pu, Hong-Jian; Zhang, Jia; Zhang, Wen-Ting; Wang, Guo-Hua; Hu, Xiao-Ming; Chen, Jun; Gao, Yan-Qin] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China; [Shi, Hong] Tongji Univ, Shanghai Pulm Hosp, Dept Anesthesiol, Shanghai 200092, Peoples R China; [Pu, Hong-Jian; Shi, Ye-Jie; Wang, Guo-Hua; Hu, Xiao-Ming; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA; [Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA	Chen, J (corresponding author), Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, 3500 Terrace St, Pittsburgh, PA 15213 USA.	chenj2@upmc.edu; yqgao@shmu.edu.cn	Leak, Rehana K/I-2607-2019; Shi, Yejie/C-2355-2018; Gao, Yanqin/I-6790-2016	Leak, Rehana K/0000-0003-2817-7417; Shi, Yejie/0000-0001-7502-9201; Gao, Yanqin/0000-0002-4915-9819	Chinese Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81020108021, 81171149, 81371306, 30870794, 81228008, 81301123, 81471332]; Natural Science Foundation of ShanghaiNatural Science Foundation of Shanghai [14ZR1434600]; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS056118, NS045048, NS036736]; Open Research Fund Program of the Institutes of Brain Science at Fudan University; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045048, R01NS036736, R01NS089534, R01NS056118] Funding Source: NIH RePORTER	H.S. and H.W. contributed equally to this manuscript. This work was supported by the Chinese Natural Science Foundation Grants 81020108021, 81171149, 81371306, and 30870794 (to Y.G.), 81228008 (to J.C.), 81301123 (to H.W.), and 81471332 (to W.Z.), Natural Science Foundation of Shanghai 14ZR1434600 (to H.S.), NIH/NINDS Grants NS056118, NS045048, and NS036736 (to J.C.), and the Open Research Fund Program of the Institutes of Brain Science at Fudan University (to Y.G. and H.S.).	AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; An CR, 2014, PROG NEUROBIOL, V115, P6, DOI 10.1016/j.pneurobio.2013.12.002; Cai BL, 2009, CRIT CARE MED, V37, P860, DOI 10.1097/CCM.0b013e31819b8237; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Corl CM, 2010, J DAIRY SCI, V93, P5188, DOI 10.3168/jds.2010-3250; Dong WH, 2010, SHOCK, V34, P205, DOI 10.1097/SHK.0b013e3181cc0c63; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Hamada N, 2008, AM J RESP CELL MOL, V39, P440, DOI 10.1165/rcmb.2007-0330OC; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Johansson AS, 2008, BRIT J PHARMACOL, V154, P1318, DOI 10.1038/bjp.2008.201; Kim JB, 2005, BRAIN RES, V1060, P188, DOI 10.1016/j.brainres.2005.08.029; Kim SW, 2010, NEUROTOX RES, V17, P39, DOI 10.1007/s12640-009-9075-4; Leak RK, 2015, ANTIOXID REDOX SIGN, V22, P135, DOI 10.1089/ars.2013.5511; Leak RK, 2013, CNS NEUROL DISORD-DR, V12, P325, DOI 10.2174/1871527311312030006; Li PY, 2013, ANN NEUROL, V74, P458, DOI 10.1002/ana.23815; Li R, 2004, J NEUROSCI RES, V78, P723, DOI 10.1002/jnr.20315; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; Moro N, 2010, EXP NEUROL, V225, P391, DOI 10.1016/j.expneurol.2010.07.013; Nag S, 2011, NEUROPATH APPL NEURO, V37, P3, DOI 10.1111/j.1365-2990.2010.01138.x; Potts Mathew B, 2006, NeuroRx, V3, P143; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rosell A, 2008, STROKE, V39, P1121, DOI 10.1161/STROKEAHA.107.500868; Saliba E, 2001, BIOL NEONATE, V79, P224; Schwab ME, 1996, PHYSIOL REV, V76, P319; Shen HX, 2010, NEUROBIOL DIS, V37, P711, DOI 10.1016/j.nbd.2009.12.010; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Su XF, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/807142; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yang ZY, 2008, WORLD J GASTROENTERO, V14, P4546, DOI 10.3748/wjg.14.4546; Yu DH, 2010, J VET MED SCI, V72, P1379, DOI 10.1292/jvms.09-0590; Yu Q, 2011, FRONT BIOSCI ELITE E, V3, P978; Yu YM, 2005, STROKE, V36, P2238, DOI 10.1161/01.STR.0000181779.83472.35	41	27	30	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1755-5930	1755-5949		CNS NEUROSCI THER	CNS Neurosci. Ther.	APR	2015	21	4			SI		374	384		10.1111/cns.12366			11	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	CE5JX	WOS:000351870400010	25533312	Green Published, Green Accepted			2021-06-18	
J	Sufrinko, A; Pearce, K; Elbin, RJ; Covassin, T; Johnson, E; Collins, M; Kontos, AP				Sufrinko, Alicia; Pearce, Kelly; Elbin, R. J.; Covassin, Tracey; Johnson, Eric; Collins, Michael; Kontos, Anthony P.			The Effect of Preinjury Sleep Difficulties on Neurocognitive Impairment and Symptoms After Sport-Related Concussion	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; sleep problems; injury	BASE-LINE; POSTTRAUMATIC MIGRAINE; UNITED-STATES; BRAIN-INJURY; CHILDREN; RESTRICTION; PERFORMANCE; RELIABILITY; PREVALENCE; MANAGEMENT	Background: Researchers have reported that sleep duration is positively related to baseline neurocognitive performance. However, researchers have yet to examine the effect of preinjury sleep difficulties on postconcussion impairments. Purpose: To compare neurocognitive impairment and symptoms of athletes with preinjury sleep difficulties to those without after a sport-related concussion (SRC). Study Design: Cohort study; Level of evidence, 3. Methods: The sample included 348 adolescent and adult athletes (age, mean SD, 17.43 2.34 years) with a diagnosed SRC. The sample was divided into 2 groups: (1) 34 (10%) participants with preinjury sleep difficulties (sleeping less as well as having trouble falling asleep; SLEEP SX) and (2) 231 (66%) participants without preinjury sleep difficulties (CONTROL). The remaining 84 (24%) participants with minimal sleep difficulties (1 symptom) were excluded. Participants completed the Immediate Postconcussion Assessment and Cognitive Test (ImPACT) and Postconcussion Symptom Scale (PCSS) at baseline and 3 postinjury intervals (2, 5-7, and 10-14 days after injury). A series of repeated-measures analyses of covariance with Bonferroni correction, controlling for baseline non-sleep-related symptoms, were conducted to compare postinjury neurocognitive performance between groups. Follow-up exploratory t tests examined between-group differences at each time interval. A series of analyses of variance were used to examine total PCSS score, sleep-related, and non-sleep-related symptoms across time intervals between groups. Results: Groups differed significantly in PCSS scores across postinjury intervals for reaction time (P < .001), with the preinjury SLEEP SX group performing worse than controls at 5-7 days (mean +/- SD, 0.70 +/- 0.32 [SLEEP SX], 0.60 +/- 0.14 [CONTROL]) and 10-14 days (0.61 +/- 0.17 [SLEEP SX]; 0.57 +/- 0.10 [CONTROL]) after injury. Groups also differed significantly on verbal memory performance (P = .04), with the SLEEP SX (68.21 +/- 18.64) group performing worse than the CONTROL group (76.76 +/- 14.50) 2 days after injury. The SLEEP SX group reported higher total symptom (P = .02) and sleep-related symptom (P = .02) scores across postinjury time intervals. Conclusion: Preinjury sleep difficulties may exacerbate neurocognitive impairment and symptoms after concussion. The findings may help clinicians identify athletes who are at risk for worse impairments after a concussion due to preinjury sleep difficulties.	Univ Pittsburgh, Pittsburgh, PA 15203 USA; Michigan State Univ, E Lansing, MI 48824 USA	Kontos, AP (corresponding author), Univ Pittsburgh, Med Ctr, Ctr Sports Med, 3200 South Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu	Meijer, Anna/K-5118-2016	Kontos, Anthony/0000-0002-3749-4310			Abu-Arafeh I, 2010, DEV MED CHILD NEUROL, V52, P1088, DOI 10.1111/j.1469-8749.2010.03793.x; Alchanatis M, 2005, J SLEEP RES, V14, P69, DOI 10.1111/j.1365-2869.2004.00436.x; Alfano CA, 2009, DEPRESS ANXIETY, V26, P503, DOI 10.1002/da.20443; Allen BJ, 2011, BRAIN INJURY, V25, P179, DOI 10.3109/02699052.2010.541897; Belenky G, 2003, J SLEEP RES, V12, P1, DOI 10.1046/j.1365-2869.2003.00337.x; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Dewald JF, 2010, SLEEP MED REV, V14, P179, DOI 10.1016/j.smrv.2009.10.004; Dinges DF, 1997, SLEEP, V20, P267; Durmer JS, 2005, SEMIN NEUROL, V25, P117, DOI 10.1055/s-2005-867080; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Jan JE, 2010, EUR J PAEDIATR NEURO, V14, P380, DOI 10.1016/j.ejpn.2010.05.001; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; MADSEN PL, 1991, CEREBROVAS BRAIN MET, V3, P281; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; McClure DJ, 2014, AM J SPORT MED, V42, P472, DOI 10.1177/0363546513510389; McClure DJ, 2013, ORTHOP J SPORTS ME S, V1; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Michael WL Chee,, 2013, Journal of sleep medicine, V10, P1; Mihalik JP, 2013, CLIN J SPORT MED, V23, P343, DOI 10.1097/JSM.0b013e318295a834; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; MILLER JH, 2007, AM J SPORTS MED, P35; MORRISON DN, 1992, J AM ACAD CHILD PSY, V31, P94, DOI 10.1097/00004583-199201000-00014; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moser RS, 2013, APPL NEUROPSYCH-CHIL, DOI [10.1080/21622965.2013.791825, DOI 10.1080/216229.65.2013.791825]; Muzur A, 2002, TRENDS COGN SCI, V6, P475, DOI 10.1016/S1364-6613(02)01992-7; Novati A, 2011, NEUROSCIENCE, V190, P145, DOI 10.1016/j.neuroscience.2011.06.027; O'Brien LM, 2011, SLEEP MED CLIN, V6, P109, DOI 10.1016/j.jsmc.2010.12.007; PASTOR PN, 2008, VITAL HLTH STAT, V10, P1; Polanczyk G, 2007, AM J PSYCHIAT, V164, P942, DOI 10.1176/appi.ajp.164.6.942; Resch JE, 2013, NEUROPSYCHOL REV, V23, P335, DOI 10.1007/s11065-013-9242-5; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stern Y, 2009, NEUROPSYCHOLOGIA, V47, P2015, DOI 10.1016/j.neuropsychologia.2009.03.004; Van Dongen HPA, 2003, SLEEP, V26, P117, DOI 10.1093/sleep/26.2.117; Van Dongen HPA, 2004, SLEEP, V27, P423; Vedaa O, 2012, SCAND J EDUC RES, V56, P55, DOI 10.1080/00313831.2011.567396; Wesensten NJ, 2012, DRUG DISCOV TODAY, V8, P139	46	27	27	0	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	APR	2015	43	4					830	838		10.1177/0363546514566193			9	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	CF4PA	WOS:000352531100010	25649087				2021-06-18	
J	Chong, SL; Liu, N; Barbier, S; Ong, MEH				Chong, Shu-Ling; Liu, Nan; Barbier, Sylvaine; Ong, Marcus Eng Hock			Predictive modeling in pediatric traumatic brain injury using machine learning	BMC MEDICAL RESEARCH METHODOLOGY			English	Article						Brain injuries; Child; Prediction rules; Machine learning	ARTIFICIAL NEURAL-NETWORK; LOGISTIC-REGRESSION; HEAD-INJURY; COMPUTED-TOMOGRAPHY; RISK; SCORE; CHILDHOOD; MORTALITY; CHILDREN; SCANS	Background: Pediatric traumatic brain injury (TBI) constitutes a significant burden and diagnostic challenge in the emergency department (ED). While large North American research networks have derived clinical prediction rules for the head injured child, these may not be generalizable to practices in countries with traditionally low rates of computed tomography (CT). We aim to study predictors for moderate to severe TBI in our ED population aged < 16 years. Methods: This was a retrospective case-control study based on data from a prospective surveillance head injury database. Cases were included if patients presented from 2006 to 2014, with moderate to severe TBI. Controls were age-matched head injured children from the registry, obtained in a 4 control: 1 case ratio. These children remained well on diagnosis and follow up. Demographics, history, and physical examination findings were analyzed and patients followed up for the clinical course and outcome measures of death and neurosurgical intervention. To predict moderate to severe TBI, we built a machine learning (ML) model and a multivariable logistic regression model and compared their performances by means of Receiver Operating Characteristic (ROC) analysis. Results: There were 39 cases and 156 age-matched controls. The following 4 predictors remained statistically significant after multivariable analysis: Involvement in road traffic accident, a history of loss of consciousness, vomiting and signs of base of skull fracture. The logistic regression model was created with these 4 variables while the ML model was built with 3 extra variables, namely the presence of seizure, confusion and clinical signs of skull fracture. At the optimal cutoff scores, the ML method improved upon the logistic regression method with respect to the area under the ROC curve (0.98 vs 0.93), sensitivity (94.9% vs 82.1%), specificity (97.4% vs 92.3%), PPV (90.2% vs 72.7%), and NPV (98.7% vs 95.4%). Conclusions: In this study, we demonstrated the feasibility of using machine learning as a tool to predict moderate to severe TBI. If validated on a large scale, the ML method has the potential not only to guide discretionary use of CT, but also a more careful selection of head injured children who warrant closer monitoring in the hospital.	[Chong, Shu-Ling] KK Womens & Childrens Hosp, Dept Emergency Med, Singapore, Singapore; [Liu, Nan; Ong, Marcus Eng Hock] Singapore Gen Hosp, Dept Emergency Med, Singapore, Singapore; [Liu, Nan; Barbier, Sylvaine] Duke NUS Grad Med Sch, Ctr Quantitat Med, Singapore, Singapore; [Ong, Marcus Eng Hock] Duke NUS Grad Med Sch, Hlth Serv & Syst Res, Singapore, Singapore	Liu, N (corresponding author), Singapore Gen Hosp, Dept Emergency Med, Singapore, Singapore.	liu.nan@sgh.com.sg	Liu, Nan/L-9529-2013	Liu, Nan/0000-0003-3610-4883	SGH Centre Grant from the National Medical Research Council, Singapore [NMRC/CG/016/2013]	The ongoing prospective head injury surveillance is supported by the Paediatrics Academic Clinical Program (Paeds ACP) Young Researcher Pilot Grant, Singapore. This publication was supported in part by the SGH Centre Grant from the National Medical Research Council, Singapore (ref: NMRC/CG/016/2013). We would like to thank Ms Dianna Sri, Ms Lau Yew Ping and Ms Jasmine Feng for their contributions in data collection.	Atabaki SM, 2007, PEDIATR REV, V28, P215, DOI 10.1542/pir.28-6-215; Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; Dayan PS, 2014, ANN EMERG MED, V64, P153, DOI 10.1016/j.annemergmed.2014.02.003; Toledo P, 2009, IEEE T INF TECHNOL B, V13, P794, DOI 10.1109/TITB.2009.2020434; DiRusso SM, 2000, J TRAUMA, V49, P212, DOI 10.1097/00005373-200008000-00006; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Eftekhar Behzad, 2005, BMC Med Inform Decis Mak, V5, P3; Griffin ES, 2014, J EMERG NURS, V40, P98, DOI 10.1016/j.jen.2013.07.001; Haibo He, 2009, IEEE Transactions on Knowledge and Data Engineering, V21, P1263, DOI 10.1109/TKDE.2008.239; Huang GB, 2006, NEUROCOMPUTING, V70, P489, DOI 10.1016/j.neucom.2005.12.126; Jaimes F, 2005, CRIT CARE, V9, pR150, DOI 10.1186/cc3054; Jain AK, 2000, IEEE T PATTERN ANAL, V22, P4, DOI 10.1109/34.824819; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Liu N, 2014, IEEE J BIOMED HEALTH, V18, P1894, DOI 10.1109/JBHI.2014.2303481; Liu N, 2010, IEEE SIGNAL PROC LET, V17, P754, DOI 10.1109/LSP.2010.2053356; Lyttle MD, 2013, EMERG MED J, V30, P790, DOI 10.1136/emermed-2012-201887; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Mathews JD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2360; Mihindu E, 2014, AM SURGEON, V80, P841; Ong MEH, 2012, CRIT CARE, V16, DOI 10.1186/cc11396; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Ottenbacher KJ, 2004, ANN EPIDEMIOL, V14, P551, DOI 10.1016/j.annepidem.2003.10.005; Pal'a A, 2014, J CHILD NEUROL, P1; Pearce CB, 2006, PANCREATOLOGY, V6, P123, DOI 10.1159/000090032; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Peng SY, 2010, EUR J NEUROL, V17, P945, DOI 10.1111/j.1468-1331.2010.02955.x; Rojas R., 1996, NEURAL NETWORKS SYST; Rose S, 2013, AM J EPIDEMIOL, V177, P443, DOI 10.1093/aje/kws241; Rose Sherri, 2008, Int J Biostat, V4, P19, DOI 10.2202/1557-4679.1115; Rughani AI, 2010, J NEUROSURG, V113, P585, DOI 10.3171/2009.11.JNS09857; Strobl C, 2009, PSYCHOL METHODS, V14, P323, DOI 10.1037/a0016973; THOMPSON WD, 1994, EPIDEMIOL REV, V16, P33, DOI 10.1093/oxfordjournals.epirev.a036143; Thurman DJ, 2014, J CHILD NEUROL, V31, P1; Tu JV, 1996, J CLIN EPIDEMIOL, V49, P1225, DOI 10.1016/S0895-4356(96)00002-9	34	27	27	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2288		BMC MED RES METHODOL	BMC Med. Res. Methodol.	MAR 17	2015	15								22	10.1186/s12874-015-0015-0			9	Health Care Sciences & Services	Health Care Sciences & Services	CE3JI	WOS:000351722100001	25886156	DOAJ Gold, Green Published			2021-06-18	
J	Lange, RT; Brickell, TA; French, LM				Lange, Rael T.; Brickell, Tracey A.; French, Louis M.			Examination of the Mild Brain Injury Atypical Symptom Scale and the Validity-10 Scale to detect symptom exaggeration in US military service members	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Military; Symptom exaggeration; Validity-10 Scale; Traumatic brain injury; Mild Brain Injury Atypical Symptoms Scale	MALINGERED NEUROCOGNITIVE DYSFUNCTION; PERSONALITY-ASSESSMENT INVENTORY; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; POSTTRAUMATIC-STRESS-DISORDER; ADULT INTELLIGENCE SCALE; SELF-REPORTED SYMPTOMS; COGNITIVE COMPLAINTS; RESPONSE BIAS; DIGIT SPAN; INDICATORS	Objective: The purpose of this study was to examine the clinical utility of two validity scales designed for use with the Neurobehavioral Symptom Inventory (NSI) and the PTSD Checklist-Civilian Version (PCL-C); the Mild Brain Injury Atypical Symptoms Scale (mBIAS) and Validity-10 scale. Method: Participants were 63 U.S. military service members (age: M = 31.9 years, SD = 12.5; 90.5% male) who sustained a mild traumatic brain injury (MTBI) and were prospectively enrolled from Walter Reed National Military Medical Center. Participants were divided into two groups based on the validity scales of the Minnesota Multiphasic Personality Inventory-2 Restructured Form (MMPI-2-RF): (a) symptom validity test (SVT)-Fail (n = 24) and (b) SVT-Pass (n = 39). Participants were evaluated on average 19.4 months postinjury (SD = 27.6). Results: Participants in the SVT-Fail group had significantly higher scores (p < .05) on the mBIAS (d = 0.85), Validity-10 (d = 1.89), NSI (d = 2.23), and PCL-C (d = 2.47), and the vast majority of the MMPI-2-RF scales (d = 0.69 to d = 2.47). Sensitivity, specificity, and predictive power values were calculated across the range of mBIAS and Validity-10 scores to determine the optimal cutoff to detect symptom exaggeration. For the mBIAS, a cutoff score of >= 8 was considered optimal, which resulted in low sensitivity (.17), high specificity (1.0), high positive predictive power (1.0), and moderate negative predictive power (.69). For the Validity-10 scale, a cutoff score of >= 13 was considered optimal, which resulted in moderate-high sensitivity (.63), high specificity (.97), and high positive (.93) and negative predictive power (.83). Conclusion: These findings provide strong support for the use of the Validity-10 as a tool to screen for symptom exaggeration when administering the NSI and PCL-C. The mBIAS, however, was not a reliable tool for this purpose and failed to identify the vast majority of people who exaggerated symptoms.	[Lange, Rael T.; Brickell, Tracey A.; French, Louis M.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Lange, Rael T.; Brickell, Tracey A.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Bethesda, MD 20814 USA; [Lange, Rael T.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Lange, Rael T.; Brickell, Tracey A.; French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Brickell, Tracey A.; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	Lange, RT (corresponding author), Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bldg 8,Room 2264,8901 Wisconsin Ave, Bethesda, MD 20814 USA.	rael.lange@gmail.com	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Armed Forces Health Surveillance Center, 2011, MED SURVEILLANCE MON, V18, P16; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Ben-Porath Y. S., 2008, MINNESOTA MULTIPHASI; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Calhoun PS, 2000, J PERS ASSESS, V75, P338, DOI 10.1207/S15327752JPA7502_11; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cooper DB, 2011, ARCH CLIN NEUROPSYCH, V26, P718, DOI 10.1093/arclin/acr070; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Defense and Veterans Brain Injury Center D, 2012, DOD NUMB TRAUM BRAIN; French LM, 2014, J REHABIL RES DEV, V51, P933, DOI 10.1682/JRRD.2013.10.0226; Gervais RO, 2010, ARCH CLIN NEUROPSYCH, V25, P274, DOI 10.1093/arclin/acq018; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2009, ASSESSMENT, V16, P237, DOI 10.1177/1073191108326227; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Henry GK, 2009, CLIN NEUROPSYCHOL, V23, P153, DOI 10.1080/13854040801969524; Iverson G., 2006, PSYCHOL INJURIES FOR, P76; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Krishnan M, 2011, ARCH CLIN NEUROPSYCH, V26, P176, DOI 10.1093/arclin/acr010; Lange RT, 2014, ARCH CLIN NEUROPSYCH, V29, P329, DOI 10.1093/arclin/acu013; Lange RT, 2013, J CLIN EXP NEUROPSYC, V35, P192, DOI 10.1080/13803395.2012.761677; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P412, DOI 10.1080/13803390490520319; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P167, DOI 10.1080/13854040801968443; LEESHALEY PR, 2002, J FORENSIC NEUROPSYC, V3, P167, DOI DOI 10.1300/J151V03N01_01; Liljequist L, 1998, J PERS ASSESS, V71, P322, DOI 10.1207/s15327752jpa7103_3; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; ROGERS R, 1993, J PERS ASSESS, V60, P554, DOI 10.1207/s15327752jpa6003_12; Rogers R, 1996, J PERS ASSESS, V67, P629, DOI 10.1207/s15327752jpa6703_15; Schiehser DM, 2011, J CLIN EXP NEUROPSYC, V33, P704, DOI 10.1080/13803395.2011.553587; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Silverton L., 1998, MALIGERING PROBABILI; Smith GP, 1997, J AM ACAD PSYCHIATRY, V25, P183; Strauss E, 2006, COMPENDIUM NEUROPSYC, P3; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003; Tanielian T, 2008, INVISIBLE WOUNDS WAR; The Management of Concussion/mTBI Working Group, 2009, VA DOD CLIN PRACT GU; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Vanderploeg RD, 2014, J HEAD TRAUMA REHAB, V29, P1, DOI 10.1097/HTR.0b013e318281966e; Whitney KA, 2010, APPL NEUROPSYCHOL, V17, P196, DOI 10.1080/09084282.2010.499787; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	53	27	27	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAR 16	2015	37	3					325	337		10.1080/13803395.2015.1013021			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	CI7FV	WOS:000354929200009	25849968				2021-06-18	
J	O'Brien, NF; Maa, T; Yeates, KO				O'Brien, Nicole F.; Maa, Tensing; Yeates, Keith O.			The Epidemiology of Vasospasm in Children With Moderate-to-Severe Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						cerebral blood flow; pediatrics; secondary brain injury; transcranial Doppler ultrasound; traumatic brain injury; vasospasm	CEREBRAL-BLOOD-FLOW; TRANSCRANIAL DOPPLER ULTRASOUND; HEAD-INJURY; SUBARACHNOID HEMORRHAGE; POSTTRAUMATIC VASOSPASM; ANGIOGRAPHIC FINDINGS; COMPUTED-TOMOGRAPHY; GENDER-DIFFERENCES; AGE-DEPENDENCE; VELOCITY	Objective: To gain a description of the prevalence and time course of vasospasm in children suffering moderate-to-severe traumatic brain injury. Design: A prospective, observational study was performed. Children with a diagnosis of traumatic brain injury, a Glasgow Coma Score less than or equal to 12, and abnormal head imaging were enrolled. Transcranial Doppler ultrasound was performed to identify and follow vasospasm. Diagnostic criteria included flow velocity elevation more than or equal to 2 so above age and gender normal values for the middle cerebral and basilar arteries. Additional criteria required for vasospasm diagnosis in the middle cerebral artery was a ratio of flow in the middle cerebral artery to extracranial internal carotid artery more than or equal to 3. Interventions: None. Measurements and Main Results: Sixty-nine children were included. The prevalence of middle cerebral artery vasospasm in children with moderate traumatic brain injury (Glasgow Coma Score, 9-12) was 8.5% and was 33.5% in those with severe traumatic brain injury (Glasgow Coma Score, 5 8). The prevalence of basilar artery vasospasm in children with moderate traumatic brain injury was 3% and with severe traumatic brain injury was 21%. Mean time to onset of vasospasm was 4 days (+/- 2 d) in the middle cerebral arteries and 5 days (+/- 2.5 d) in the basilar artery. Mean duration of vasospasm in the middle cerebral artery was 2 days (+/- 2 d) and 1.5 days (1 d) in the basilar artery. Children in whom vasospasm developed were more likely to have been involved in motor vehicle accidents, had higher Injury Severity Scores, had fever at admission, and had lower Glasgow Coma Score scores. Good neurologic outcome (Glasgow Outcome Score Extended Pediatric version of 4) at 1 month from injury was seen in 76% of those with moderate traumatic brain injury without vasospasm and in 40% of those with vasospasm. In those with severe traumatic brain injury, good neurologic outcome was seen in 29% of those children without vasospasm and in 15% of those with vasospasm. Conclusions: Vasospasm occurs in a sizeable number of children with moderate and severe traumatic brain injury. Children in whom vasospasm developed were more likely to have been involved in a motor vehicle accident, had higher Injury Severity Scores, had fever at admission, and had lower Glasgow Coma scores than in those whom vasospasm did not develop. Based on these findings, we recommend aggressive screening for posttraumatic vasospasm in these patients. Future studies should establish the relationship between vasospasm and long-term functional outcomes and should also evaluate potential preventative or therapeutic options for vasospasm in these children.	[O'Brien, Nicole F.; Maa, Tensing] Ohio State Univ, Nationwide Childrens Hosp, Div Crit Care Med, Columbus, OH 43210 USA; [O'Brien, Nicole F.; Maa, Tensing; Yeates, Keith O.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith O.] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Yeates, Keith O.] Nationwide Childrens Hosp, Sect Pediat Psychol & Neuropsychol, Columbus, OH USA	O'Brien, NF (corresponding author), Ohio State Univ, Nationwide Childrens Hosp, Div Crit Care Med, Columbus, OH 43210 USA.	nicole.obrien@nation-widechildrens.org; tensing.maa@nationwidechildrens.org; kyeates@ucalgary.ca	Yeates, Keith/AAJ-4223-2020; O'brien, Nicole/E-3776-2011; Maa, Tensing/J-9791-2012	Maa, Tensing/0000-0001-6104-8401; Yeates, Keith/0000-0001-7680-2892	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA	Dr. Yeates provided expert testimony for various attorneys, lectured for various scientific and professional organizations, and received royalties from Guilford Press. His institution received grant support from the National Institutes of Health and Centers for Disease Control and Prevention. The remaining authors have disclosed that they do not have any potential conflicts of interest.	AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; ARUTIUNOV AI, 1974, J NEUROSURG, V40, P459, DOI 10.3171/jns.1974.40.4.0459; Beers SR, 2012, J NEUROTRAUM, V29, P1126, DOI 10.1089/neu.2011.2272; BODE H, 1988, ARCH DIS CHILD, V63, P606, DOI 10.1136/adc.63.6.606; BODE H, 1989, J CHILD NEUROL, V4, pS68, DOI 10.1177/0883073889004001S11; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; CHAN KH, 1992, NEUROSURGERY, V30, P697; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Katsnelson M, 2012, NEUROSURGERY, V70, P1095, DOI 10.1227/NEU.0b013e318240c1ed; Lee DJ, 2008, NEUROSURGERY, V63, P1004, DOI 10.1227/01.NEU.0000327685.90800.F7; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; MACDONALD RL, 1991, STROKE, V22, P971, DOI 10.1161/01.STR.22.8.971; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Merkel S I, 1997, Pediatr Nurs, V23, P293; Nakayama K, 2003, BIORHEOLOGY, V40, P307; Newell D W, 1992, Clin Neurosurg, V39, P348; O'Brien NF, 2010, INTENS CARE MED, V36, P680, DOI 10.1007/s00134-009-1747-2; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Philip S, 2009, CRIT CARE MED, V37, P2973, DOI 10.1097/CCM.0b013e3181a963f6; Pluta RM, 2005, PHARMACOL THERAPEUT, V105, P23, DOI 10.1016/j.pharmthera.2004.10.002; SANDER D, 1993, J NEUROL SCI, V119, P1, DOI 10.1016/0022-510X(93)90185-2; Sarkar K, 2014, J NEUROSURG-PEDIATR, V13, P307, DOI 10.3171/2013.12.PEDS13223; SCHONING M, 1993, STROKE, V24, P1305, DOI 10.1161/01.STR.24.9.1305; Shahlaie K, 2011, J NEUROSURG, V115, P602, DOI 10.3171/2011.5.JNS101667; Shahlaie K, 2009, NEUROCRIT CARE, V10, P61, DOI 10.1007/s12028-008-9138-z; Society of Critical Care Medicine, 2012, PEDIAT CRIT CARE S1, V13, pS1; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; Tontisirin N, 2007, PEDIATRICS, V119, pE610, DOI 10.1542/peds.2006-2110; VARDIMAN AB, 1995, AM J NEURORADIOL, V16, P319; Vavilala MS, 2005, PEDIATR RES, V58, P574, DOI 10.1203/01.PDR.0000179405.30737.0F; Voepel-Lewis T, 2010, AM J CRIT CARE, V19, P55, DOI 10.4037/ajcc2010624; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; Wintermark M, 2004, PEDIATRICS, V113, P1642, DOI 10.1542/peds.113.6.1642; Zubkov ZY, 2000, SURG NEUROL, V53, P126	45	27	28	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2015	43	3					674	685		10.1097/CCM.0000000000000745			12	Critical Care Medicine	General & Internal Medicine	CB9PI	WOS:000349963600033	25479116				2021-06-18	
J	Williams, RM; Welch, CE; Parsons, JT; McLeod, TCV				Williams, Richelle M.; Welch, Cailee E.; Parsons, John T.; McLeod, Tamara C. Valovich			Athletic Trainers' Familiarity With and Perceptions of Academic Accommodations in Secondary School Athletes After Sport-Related Concussion	JOURNAL OF ATHLETIC TRAINING			English	Article						adolescent sport-related concussions; concussion management; 504 plans; Individualized Education Programs	INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; HEAD-INJURY; MANAGEMENT; SYMPTOMS; ZURICH	Context: Sport-related concussion can affect athletes' sport participation and academic success. With the recent emphasis on cognitive rest, student-athletes may benefit from academic accommodations (AA) in the classroom; however, athletic trainers' (ATs') perceived familiarity with, and use of, AA is unknown. Objective: To assess secondary school ATs' perceived familiarity with, attitudes and beliefs about, and incorporation of AA for student-athletes after sport-related concussion. A secondary purpose was to determine whether employment status altered familiarity and use of AA. Design: Cross-sectional study. Setting: Online survey. Patients or Other Participants: Of 3286 possible respondents, 851 secondary school ATs accessed the survey (response rate = 25.9%; 308 men [36.2%], 376 women [44.2%], 167 respondents [19.6%] with sex information missing; age = 37.3 +/- 10.1 years). Main Outcome Measure(s): Participants were solicited via e-mail to complete the Beliefs, Attitudes and Knowledge Following Pediatric Athlete Concussion among Athletic Trainers employed in the secondary school setting (BAKPAC-AT) survey. The BAKPAC-AT assessed ATs' perceived familiarity, perceptions, and roles regarding 504 plans, Individualized Education Programs (IEPs), and returning student-athletes to the class-room. Independent variables were employment status (full time versus part time), employment model (direct versus outreach), years certified, and years of experience in the secondary school setting. The dependent variables were participants' responses to the AA questions. Spearman rank-correlation coefficients were used to assess relationships and Mann-Whitney U and chi(2) tests (P < .05) were used to identify differences. Results: Respondents reported that approximately 41% of the student-athletes whose sport-related concussions they managed received AA. Respondents employed directly by the school were more familiar with 504 plans (P < .001) and IEPs (P < .001) and had a greater belief that ATs should have a role in AA. Both the number of years certified and the years of experience at the secondary school were significantly correlated with perceived familiarity regarding 504 plans and IEPs. Conclusions: The ATs employed directly by secondary schools and those with more experience as secondary school ATs were more familiar with AA. Understanding AA is important for all ATs because cognitive rest and "return to learn" are becoming more widely recommended in concussion management.	[Williams, Richelle M.] Univ Michigan, Ann Arbor, MI 48109 USA; [Welch, Cailee E.; McLeod, Tamara C. Valovich] AT Still Univ, Mesa, AZ 85206 USA; [Parsons, John T.] Natl Collegiate Athlet Assoc, Indianapolis, IN USA	McLeod, TCV (corresponding author), AT Still Univ, 5850 E Still Circle, Mesa, AZ 85206 USA.	tmcleod@atsu.edu	McLeod, Tamara/AAU-9435-2020	Williams, Richelle/0000-0003-4728-7443			Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; Bey T, 2009, WEST J EMERG MED, V10, P6; BRUCE DA, 1984, BRIT MED J, V289, P715, DOI 10.1136/bmj.289.6447.715; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Cochrane LJ, 2007, J CONTIN EDUC HEALTH, V27, P94, DOI 10.1002/chp.106; Commission on Accreditation of Athletic Training Education, 2012, STAND ACCR PROF ATHL; Cunningham J, 2011, J EMERG MED, V40, P262, DOI 10.1016/j.jemermed.2008.08.017; Disabilities Rights Center Web site, IND ED PROGR IEP 504; Duggan PS, 2006, PATIENT EDUC COUNS, V62, P271, DOI 10.1016/j.pec.2005.08.001; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Kaloir L., WHATS A 504 PLAN; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mazerolle SM, 2010, J ATHL TRAINING, V45, P170, DOI 10.4085/1062-6050-45.2.170; McCrea M, 2004, SPORTS MED UPDATE, V38, P369, DOI DOI 10.1001/JAMA.290.19.2556.[; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; McLeod TCV, 2013, J ATHL TRAINING, V48, P483, DOI 10.4085/1062-6050-48.4.04; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Mensch J, 2005, J ATHL TRAINING, V40, P333; Moser Rosemarie Scolaro, 2012, Front Neurol, V3, P171, DOI 10.3389/fneur.2012.00171; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; National Athletic Trainers' Association, 2011, ATHL TRAIN ED COMP; National Center for Learning Disabilities, WHAT IS AN IEP; Piebes SK, 2009, J SCH NURS, V25, P270, DOI 10.1177/1059840509339782; Portney LG, 2009, FDN CLIN RES APPL PR; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Sady M, 2001, PHYS MED REH CLIN N, V22, P701	31	27	27	0	9	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	MAR	2015	50	3					262	269		10.4085/1062-6050-49.3.81			8	Sport Sciences	Sport Sciences	CQ8AM	WOS:000360828300005	25562456	Green Published			2021-06-18	
J	Nauman, EA; Breedlove, KM; Breedlove, EL; Talavage, TM; Robinson, ME; Leverenz, LJ				Nauman, Eric A.; Breedlove, Katherine M.; Breedlove, Evan L.; Talavage, Thomas M.; Robinson, Meghan E.; Leverenz, Larry J.			Post-Season Neurophysiological Deficits Assessed by ImPACT and fMRI in Athletes Competing in American Football	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	2nd Annual Meeting of the CIC/Big Ten/Ivy League Traumatic Brain Injury Summit	JUL 16-17, 2014	Philadelphia, PA				HEAD IMPACTS; CONCUSSION; PLAYERS; INJURY; MRI	Neurocognitive assessment, functional magnetic resonance imaging, and head impact monitoring were used to evaluate neurological changes in high school football players throughout competitive seasons. A substantial number of asymptomatic athletes exhibited neurophysiological changes that persisted post-season, with abnormal measures significantly more common in athletes receiving 50 or more hits per week during the season.	[Nauman, Eric A.] Purdue Univ, Sch Mech Engn, Weldon Sch Biomed Engn, Dept Basic Med Sci, W Lafayette, IN 47907 USA; [Breedlove, Katherine M.; Leverenz, Larry J.] Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 USA; [Breedlove, Evan L.] Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA; [Talavage, Thomas M.] Purdue Univ, Sch Elect & Comp Engn, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Robinson, Meghan E.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA	Nauman, EA (corresponding author), Purdue Univ, 585 Purdue Mall, W Lafayette, IN 47907 USA.	enauman@purdue.edu			Indiana State Department of Health Spinal Cord and Brain Injury Research Fund; National Defense Science and Engineering Graduate Fellowship; National Science Foundation Graduate Fellowship ProgramNational Science Foundation (NSF); General Electric HealthcareGE Healthcare	Indiana State Department of Health Spinal Cord and Brain Injury Research Fund; National Defense Science and Engineering Graduate Fellowship; National Science Foundation Graduate Fellowship Program; General Electric Healthcare.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Breedlove KM., 2014, ATHLETIC TRAIN SPORT, V6, P119, DOI [10.3928/19425864-20140507-02, DOI 10.3928/19425864-20140507-02]; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Davis TL, 1998, P NATL ACAD SCI USA, V95, P1834, DOI 10.1073/pnas.95.4.1834; Evans AC, 2006, NEUROIMAGE, V30, P184, DOI 10.1016/j.neuroimage.2005.09.068; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; O'Kane JW, 2014, JAMA PEDIATR, V168, P258, DOI 10.1001/jamapediatrics.2013.4518; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512	16	27	27	0	10	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	FEB 17	2015	40	2			SI		85	91		10.1080/87565641.2015.1016161			7	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	CH6UW	WOS:000354172800007	25961591				2021-06-18	
J	Johnen, VM; Neubert, FX; Buch, ER; Verhagen, LM; O'Reilly, J; Mars, RB; Rushworth, MFS				Johnen, Vanessa M.; Neubert, Franz-Xaver; Buch, Ethan R.; Verhagen, Lennart M.; O'Reilly, Jill; Mars, Rogier B.; Rushworth, Matthew F. S.			Causal manipulation of functional connectivity in a specific neural pathway during behaviour and at rest	ELIFE			English	Article						Resting-state connectivity; functional connectivity; premotor cortex; fMRI; TMS; plasticity	VENTRAL PREMOTOR CORTEX; PRIMARY MOTOR CORTEX; TRANSCRANIAL MAGNETIC STIMULATION; TRACTOGRAPHY-BASED PARCELLATION; PAIRED ASSOCIATIVE STIMULATION; TRAUMATIC BRAIN-INJURY; HUMAN PARIETAL CORTEX; MACAQUE MONKEY; FRONTAL-CORTEX; MR-IMAGES	Correlations in brain activity between two areas (functional connectivity) have been shown to relate to their underlying structural connections. We examine the possibility that functional connectivity also reflects short-term changes in synaptic efficacy. We demonstrate that paired transcranial magnetic stimulation (TMS) near ventral premotor cortex (PMv) and primary motor cortex (M1) with a short 8ms inter-pulse interval evoking synchronous pre- and post-synaptic activity and which strengthens interregional connectivity between the two areas in a pattern consistent with Hebbian plasticity, leads to increased functional connectivity between PMv and M1 as measured with functional magnetic resonance imaging (fMRI). Moreover, we show that strengthening connectivity between these nodes has effects on a wider network of areas, such as decreasing coupling in a parallel motor programming stream. A control experiment revealed that identical TMS pulses at identical frequencies caused no change in fMRI-measured functional connectivity when the inter-pulse-interval was too long for Hebbian-like plasticity.	[Johnen, Vanessa M.; Neubert, Franz-Xaver; Verhagen, Lennart M.; Mars, Rogier B.; Rushworth, Matthew F. S.] Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England; [Buch, Ethan R.] NINDS, Human Cort Physiol & Neurorehabilitat Sect, NIH, Bethesda, MD 20814 USA; [Buch, Ethan R.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Verhagen, Lennart M.; Mars, Rogier B.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Ctr Cognit Neuroimaging, NL-6500 HB Nijmegen, Netherlands; [O'Reilly, Jill; Mars, Rogier B.; Rushworth, Matthew F. S.] Univ Oxford, Funct Magnet Resonance Imaging Brain FMRIB Ctr, John Radcliffe Hosp, Oxford OX3 9DU, England	Johnen, VM (corresponding author), Univ Oxford, Dept Expt Psychol, S Parks Rd, Oxford OX1 3UD, England.	vanessa.johnen@psy.ox.ac.uk	Mars, Rogier B./G-2312-2018; Verhagen, Lennart/D-1070-2013; Buch, Ethan/AAB-4549-2021	Mars, Rogier B./0000-0001-6302-8631; Verhagen, Lennart/0000-0003-3207-7929; Rushworth, Matthew/0000-0002-5578-9884; O'Reilly, Jill/0000-0002-6998-455X	Wellcome TrustWellcome TrustEuropean Commission; Medical Research Council (MRC)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); Christopher Welch Scholarship; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0700399, G0400593] Funding Source: researchfish	Wellcome Trust Matthew FS Rushworth; Medical Research Council (MRC) Matthew FS Rushworth; Christopher Welch Scholarship Franz-Xaver Neubert	Arai N, 2011, J NEUROSCI, V31, P15376, DOI 10.1523/JNEUROSCI.2271-11.2011; Baumer T, 2009, CLIN NEUROPHYSIOL, V120, P1724, DOI 10.1016/j.clinph.2009.07.035; Bassett DS, 2008, J NEUROSCI, V28, P9239, DOI 10.1523/JNEUROSCI.1929-08.2008; Beckmann CF, 2005, NEUROIMAGE, V25, P294, DOI 10.1016/j.neuroimage.2004.10.043; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Brochier T, 2007, CURR OPIN NEUROBIOL, V17, P637, DOI 10.1016/j.conb.2007.12.002; Buch ER, 2011, J NEUROSCI, V31, P17669, DOI 10.1523/JNEUROSCI.1513-11.2011; Buch ER, 2010, J NEUROSCI, V30, P1395, DOI 10.1523/JNEUROSCI.4882-09.2010; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Chawla D, 2000, NEURAL COMPUT, V12, P2805, DOI 10.1162/089976600300014737; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Davare M, 2008, J PHYSIOL-LONDON, V586, P2735, DOI 10.1113/jphysiol.2008.152603; Davare M, 2010, CURR BIOL, V20, P176, DOI 10.1016/j.cub.2009.11.063; Davare M, 2009, CORTEX, V45, P1050, DOI 10.1016/j.cortex.2009.02.011; Dayan E, 2011, NEURON, V72, P443, DOI 10.1016/j.neuron.2011.10.008; Dum RP, 2005, J NEUROSCI, V25, P1375, DOI 10.1523/JNEUROSCI.3902-04.2005; Ernst MO, 2002, NATURE, V415, P429, DOI 10.1038/415429a; Fair DA, 2008, P NATL ACAD SCI USA, V105, P4028, DOI 10.1073/pnas.0800376105; Filippini N, 2009, P NATL ACAD SCI USA, V106, P7209, DOI 10.1073/pnas.0811879106; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Friston KJ, 1995, HUM BRAIN MAPP, V3, P56, DOI 10.1002/hbm.460030106; Friston KJ, 1997, NEUROIMAGE, V6, P218, DOI 10.1006/nimg.1997.0291; Friston KJ, 2003, NEUROIMAGE, V19, P1273, DOI 10.1016/S1053-8119(03)00202-7; Galletti C, 2003, EXP BRAIN RES, V153, P158, DOI 10.1007/s00221-003-1589-z; Gerloff C, 2006, BRAIN, V129, P791, DOI 10.1093/brain/awh713; Geyer S, 2000, ANAT EMBRYOL, V202, P443, DOI 10.1007/s004290000127; GODSCHALK M, 1984, EXP BRAIN RES, V56, P410; Grafton ST, 2010, EXP BRAIN RES, V204, P475, DOI 10.1007/s00221-010-2315-2; Grefkes C, 2010, NEUROIMAGE, V50, P233, DOI 10.1016/j.neuroimage.2009.12.029; Greve DN, 2009, NEUROIMAGE, V48, P63, DOI 10.1016/j.neuroimage.2009.06.060; Grol MJ, 2007, J NEUROSCI, V27, P11877, DOI 10.1523/JNEUROSCI.3923-07.2007; Ham TE, 2012, CURR OPIN NEUROL, V25, P662, DOI 10.1097/WCO.0b013e328359488f; Hampson M, 2002, HUM BRAIN MAPP, V15, P247, DOI 10.1002/hbm.10022; Hartwigsen G, 2012, J NEUROSCI, V32, P16162, DOI 10.1523/JNEUROSCI.1010-12.2012; Jackson A, 2006, NATURE, V444, P56, DOI 10.1038/nature05226; JEANNEROD M, 1995, TRENDS NEUROSCI, V18, P314, DOI 10.1016/0166-2236(95)93921-J; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Johnson PB, 1997, PARIETAL LOBE CONTRI, P222; Koch G, 2013, J NEUROSCI, V33, P9725, DOI 10.1523/JNEUROSCI.4988-12.2013; Lee L, 2003, J NEUROSCI, V23, P5308; Lotze M, 2006, J NEUROSCI, V26, P6096, DOI 10.1523/JNEUROSCI.4564-05.2006; Luppino G, 1999, EXP BRAIN RES, V128, P181, DOI 10.1007/s002210050833; Majdandzic J, 2007, NEUROIMAGE, V37, P589, DOI 10.1016/j.neuroimage.2007.04.071; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Mars RB, 2011, J NEUROSCI, V31, P4087, DOI 10.1523/JNEUROSCI.5102-10.2011; MATELLI M, 1986, J COMP NEUROL, V251, P281, DOI 10.1002/cne.902510302; Matelli M, 1998, J COMP NEUROL, V402, P327; Mayka MA, 2006, NEUROIMAGE, V31, P1453, DOI 10.1016/j.neuroimage.2006.02.004; Munchau A, 2002, J NEUROSCI, V22, P554, DOI 10.1523/JNEUROSCI.22-02-00554.2002; Neubert FX, 2014, NEURON, V81, P700, DOI 10.1016/j.neuron.2013.11.012; Neubert FX, 2010, P NATL ACAD SCI USA, V107, P13240, DOI 10.1073/pnas.1000674107; Neubert FX, 2014, NEURON; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; O'Reilly JX, 2013, P NATL ACAD SCI USA, V110, P13982, DOI 10.1073/pnas.1305062110; O'Reilly JX, 2012, SOC COGN AFFECT NEUR, V7, P604, DOI 10.1093/scan/nss055; O'Reilly JX, 2010, CEREB CORTEX, V20, P953, DOI 10.1093/cercor/bhp157; O'Shea J, 2007, NEURON, V54, P479, DOI 10.1016/j.neuron.2007.04.021; Power JD, 2011, NEURON, V72, P665, DOI 10.1016/j.neuron.2011.09.006; Prabhu G, 2009, J PHYSIOL-LONDON, V587, P1057, DOI 10.1113/jphysiol.2008.165571; Rizzo V, 2009, CEREB CORTEX, V19, P907, DOI 10.1093/cercor/bhn144; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Rushworth MFS, 2006, CEREB CORTEX, V16, P1418, DOI 10.1093/cercor/bhj079; Sallet J, 2013, J NEUROSCI, V33, P12255, DOI 10.1523/JNEUROSCI.5108-12.2013; Seeley WW, 2009, NEURON, V62, P42, DOI 10.1016/j.neuron.2009.03.024; Shimazu H, 2004, J NEUROSCI, V24, P1200, DOI 10.1523/JNEUROSCI.4731-03.2004; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Stefan K, 2000, BRAIN, V123, P572, DOI 10.1093/brain/123.3.572; Sussillo D, 2009, NEURON, V63, P544, DOI 10.1016/j.neuron.2009.07.018; Tanne-Gariepy J, 2002, EXP BRAIN RES, V145, P91, DOI 10.1007/s00221-002-1078-9; Tokuno H, 2000, CEREB CORTEX, V10, P58, DOI 10.1093/cercor/10.1.58; Tomassini V, 2007, J NEUROSCI, V27, P10259, DOI 10.1523/JNEUROSCI.2144-07.2007; Turella L, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00686; VALLSSOLE J, 1992, ELECTROEN CLIN NEURO, V85, P355, DOI 10.1016/0168-5597(92)90048-G; Verhagen L, 2008, J NEUROSCI, V28, P4726, DOI 10.1523/JNEUROSCI.0057-08.2008; Vogels TP, 2011, SCIENCE, V334, P1569, DOI 10.1126/science.1211095; Wang L, 2010, BRAIN, V133, P1224, DOI 10.1093/brain/awq043; Wise SP, 1997, ANNU REV NEUROSCI, V20, P25, DOI 10.1146/annurev.neuro.20.1.25; Wolters A, 2003, J NEUROPHYSIOL, V89, P2339, DOI 10.1152/jn.00900.2002; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	81	27	27	0	14	ELIFE SCIENCES PUBLICATIONS LTD	CAMBRIDGE	SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND	2050-084X			ELIFE	eLife	FEB 9	2015	4								e04585	10.7554/eLife.04585			50	Biology	Life Sciences & Biomedicine - Other Topics	CB2MD	WOS:000349460700002	25664941	DOAJ Gold, Green Published			2021-06-18	
J	Hanell, A; Greer, JE; McGinn, MJ; Povlishock, JT				Hanell, Anders; Greer, John E.; McGinn, Melissa J.; Povlishock, John T.			Traumatic brain injury-induced axonal phenotypes react differently to treatment	ACTA NEUROPATHOLOGICA			English	Article						Traumatic brain injury; Axonal injury; Mitochondrial permeability transition pore; Cyclophilin D; Wallerian degeneration; Mouse	MITOCHONDRIAL PERMEABILITY TRANSITION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CYCLOSPORINE-A; ATP SYNTHASE; WALLERIAN DEGENERATION; C-SUBUNIT; PORE; DISCONNECTION; TRANSPORT; PATHOLOGY	Injured axons with distinct morphologies have been found following mild traumatic brain injury (mTBI), although it is currently unclear whether they reflect varied responses to the injury or represent different stages of progressing pathology. This complicates evaluation of therapeutic interventions targeting axonal injury. To address this issue, we assessed axonal injury over time within a well-defined axonal population, while also evaluating mitochondrial permeability transition as a therapeutic target. We utilized mice expressing yellow fluorescent protein (YFP) in cortical neurons which were crossed with mice which lacked Cyclophilin D (CypD), a positive regulator of mitochondrial permeability transition pore opening. Their offspring were subjected to mTBI and the ensuing axonal injury was assessed using YFP expression and amyloid precursor protein (APP) immunohistochemistry, visualized by confocal and electron microscopy. YFP+ axons initially developed a single, APP(+), focal swelling (proximal bulb) which progressed to axotomy. Disconnected axonal segments developed either a single bulb (distal bulb) or multiple bulbs (varicosities), which were APP(-) and whose ultrastructure was consistent with ongoing Wallerian degeneration. CypD knock-out failed to reduce proximal bulb formation but decreased the number of distal bulbs and varicosities, as well as a population of small, APP(+), callosal bulbs not associated with YFP+ axons. The observation that YFP+ axons contain several pathological morphologies points to the complexity of traumatic axonal injury. The fact that CypD knock-out reduced some, but not all, subtypes highlights the need to appropriately characterize injured axons when evaluating potential neuroprotective strategies.	[Hanell, Anders; Greer, John E.; McGinn, Melissa J.; Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, Med Coll Virginia Campus,POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu	Hanell, Anders/E-4776-2011	Hanell, Anders/0000-0001-9369-3886	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS077675, NS047463]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463, R01NS077675] Funding Source: NIH RePORTER	The authors thank Carol Davis, Susan Walker and Jesse Sims for invaluable technical assistance, Scott Henderson and Frances White for sharing their expertise in confocal microscopy, Audrey Lafrenaye, Vishal Patel and Michal Vascak for scientific discussions and comments on this manuscript as well as Michael Forte and Paolo Bernardi for generating and providing the CypD KO mice. This work was funded by NIH grants NS077675 and NS047463.	Alavian KN, 2014, P NATL ACAD SCI USA, V111, P10580, DOI 10.1073/pnas.1401591111; Avery MA, 2012, CURR BIOL, V22, P596, DOI 10.1016/j.cub.2012.02.043; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Barrientos SA, 2011, J NEUROSCI, V31, P966, DOI 10.1523/JNEUROSCI.4065-10.2011; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Beirowski B, 2010, J NEUROPATH EXP NEUR, V69, P455, DOI 10.1097/NEN.0b013e3181da84db; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bernardi P, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00095; Bonora M, 2013, CELL CYCLE, V12, P674, DOI 10.4161/cc.23599; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Cesarovic N, 2010, LAB ANIM-UK, V44, P329, DOI 10.1258/la.2010.009085; Conforti L, 2014, NAT REV NEUROSCI, V15, P394, DOI 10.1038/nrn3680; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Du H, 2008, NAT MED, V14, P1097, DOI 10.1038/nm.1868; Dziedzic T, 2010, BRAIN PATHOL, V20, P976, DOI 10.1111/j.1750-3639.2010.00401.x; English AW, 2005, EUR J NEUROSCI, V21, P2624, DOI 10.1111/j.1460-9568.2005.04124.x; Ewald AJ, 2011, COLD SPRING HARB PRO; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Forte M, 2007, P NATL ACAD SCI USA, V104, P7558, DOI 10.1073/pnas.0702228104; Giorgio V, 2013, P NATL ACAD SCI USA, V110, P5887, DOI 10.1073/pnas.1217823110; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Hayat MJ, 2014, J NURS EDUC, V53, P208, DOI 10.3928/01484834-20140325-04; Haynes RL, 2008, PEDIATR RES, V63, P656, DOI 10.1203/PDR.0b013e31816c825c; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Lafrenaye AD, 2012, J CEREBR BLOOD F MET, V32, P1919, DOI 10.1038/jcbfm.2012.95; Luvisetto S, 2008, NEUROSCIENCE, V155, P585, DOI 10.1016/j.neuroscience.2008.06.030; Marx M, 2012, NAT PROTOC, V7, P394, DOI 10.1038/nprot.2011.449; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Nikic I, 2011, NAT MED, V17, P495, DOI 10.1038/nm.2324; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Palma E, 2009, HUM MOL GENET, V18, P2024, DOI 10.1093/hmg/ddp126; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Readnower RD, 2011, J NEUROTRAUM, V28, P1845, DOI 10.1089/neu.2011.1755; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844	43	27	27	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	FEB	2015	129	2					317	332		10.1007/s00401-014-1376-x			16	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	AZ7ZS	WOS:000348435100010	25528329				2021-06-18	
J	Li, Y; Korgaonkar, AA; Swietek, B; Wang, JF; Elgammal, FS; Elkabes, S; Santhakumar, V				Li, Ying; Korgaonkar, Akshata A.; Swietek, Bogumila; Wang, Jianfeng; Elgammal, Fatima S.; Elkabes, Stella; Santhakumar, Vijayalakshmi			Toll-like receptor 4 enhancement of non-NMDA synaptic currents increases dentate excitability after brain injury	NEUROBIOLOGY OF DISEASE			English	Article						Traumatic brain injury; Dentate gyrus; Hippocampus; Electrophysiology; Innate immune response; Excitability; Mossy cell; AMPA; NMDA	MOSSY CELLS; SIGNALING PATHWAY; NEURONAL DEATH; MOLECULAR LAYER; GYRUS; RAT; HYPEREXCITABILITY; ACTIVATION; IMPACT; DETERMINANTS	Concussive brain injury results in neuronal degeneration, microglial activation and enhanced excitability in the hippocampal dentate gyrus, increasing the risk for epilepsy and memory dysfunction. Endogenous molecules released during injury can activate innate immune responses including toll-like receptor 4 (TLR4). Recent studies indicate that immune mediators can modulate neuronal excitability. Since non-specific agents that reduce TLR4 signaling can limit post-traumatic neuropathology, we examined whether TLR4 signaling contributes to early changes in dentate excitability after brain injury. Concussive brain injury caused a transient increase in hippocampal TLR4 expression within 4 h, which peaked at 24 h. Post-injury increase in TLR4 expression in the dentate gyrus was primarily neuronal and persisted for one week. Acute, in vitro treatment with TLR4 ligands caused bidirectional modulation of dentate excitability in control and brain-injured rats, with a reversal in the direction of modulation after brain injury. TLR4 antagonists decreased, and agonist increased, afferent-evoked dentate excitability one week after brain injury. NMDA receptor antagonist did not occlude the ability of LPS-RS, a TLR4 antagonist, to decrease post-traumatic dentate excitability. LPS-RS failed to modulate granule cell NMDA EPSCs but decreased perforant path-evoked non-NMDA EPSC peak amplitude and charge transfer in both granule cells and mossy cells. Our findings indicate an active role for TLR4 signaling in early post-traumatic dentate hyperexcitability. The novel TLR4 modulation of non-NMDA glutamatergic currents, identified herein, could represent a general mechanism by which immune activation influences neuronal excitability in neurological disorders that recruit sterile inflammatory responses. (C) 2014 Elsevier Inc. All rights reserved.	[Li, Ying; Korgaonkar, Akshata A.; Swietek, Bogumila; Wang, Jianfeng; Elgammal, Fatima S.; Santhakumar, Vijayalakshmi] Rutgers New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ 07103 USA; [Korgaonkar, Akshata A.; Elkabes, Stella; Santhakumar, Vijayalakshmi] Rutgers New Jersey Med Sch, Grad Sch Biomed Sci, Newark, NJ 07103 USA; [Elkabes, Stella] Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07103 USA; [Santhakumar, Vijayalakshmi] Rutgers New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA	Santhakumar, V (corresponding author), Rutgers New Jersey Med Sch, Dept Neurol & Neurosci, MSB H-512,185 S Orange Ave, Newark, NJ 07103 USA.	santhavi@njms.rutgers.edu	Elkabes, Stella/AAR-8212-2020; Elkabes, Stella/H-7823-2019; Santhakumar, Viji/K-4856-2019	Santhakumar, Viji/0000-0001-6278-4187	CURE Foundation, F.M. Kirby Foundation [NJCBIRCBIR11PJT003, CBIR14IRG024, NIH/NINDSR01 NS069861]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS069861] Funding Source: NIH RePORTER	We thank Drs. Ellen Townes-Anderson, Christine Rohowsky-Kochan and Eldo Kuzhikandathil, Rutgers NJMS for their extensive support with immunostaining and western blotting studies, Dr. Robert F. Heary, Rutgers NJMS for equipment and Ms. Archana Proddutur for her helpful comments and technical assistance. The project was supported by CURE Foundation, F.M. Kirby Foundation, NJCBIRCBIR11PJT003, CBIR14IRG024 and NIH/NINDSR01 NS069861 to V.S.	Aradi I, 2004, J NEUROPHYSIOL, V91, P2849, DOI 10.1152/jn.00916.2003; Balosso S, 2014, ANTIOXID REDOX SIGN, V21, P1726, DOI 10.1089/ars.2013.5349; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Bhaskaran MD, 2010, EXP NEUROL, V223, P529, DOI 10.1016/j.expneurol.2010.01.021; Buckmaster PS, 1996, J COMP NEUROL, V366, P270, DOI 10.1002/(SICI)1096-9861(19960304)366:2<270::AID-CNE7>3.0.CO;2-2; BUCKMASTER PS, 1992, HIPPOCAMPUS, V2, P349, DOI 10.1002/hipo.450020403; Chancey JH, 2014, J NEUROSCI, V34, P2349, DOI 10.1523/JNEUROSCI.3620-13.2014; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; CHENARD BL, 1991, J MED CHEM, V34, P3085, DOI 10.1021/jm00114a018; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Costello DA, 2011, J NEUROSCI, V31, P3871, DOI 10.1523/JNEUROSCI.6676-10.2011; Curtin JF, 2009, PLOS MED, V6, P83, DOI 10.1371/journal.pmed.1000010; DiLeonardi AM, 2012, J NEUROPATH EXP NEUR, V71, P959, DOI 10.1097/NEN.0b013e31826f5876; Diogenes A, 2011, J DENT RES, V90, P759, DOI 10.1177/0022034511400225; Dyhrfjeld-Johnsen J, 2007, J NEUROPHYSIOL, V97, P1566, DOI 10.1152/jn.00950.2006; Fan HG, 2009, MEDIAT INFLAMM, V2009, DOI 10.1155/2009/704706; Ferrario CR, 2013, J NEUROPHYSIOL, V110, P131, DOI 10.1152/jn.01011.2012; Freund TF, 1997, EUR J NEUROSCI, V9, P1815, DOI 10.1111/j.1460-9568.1997.tb00748.x; FROTSCHER M, 1991, J COMP NEUROL, V312, P145, DOI 10.1002/cne.903120111; Fukuda AM, 2012, NEUROSCIENCE, V222, P366, DOI 10.1016/j.neuroscience.2012.06.033; Gao Y, 2009, BIOL PHARM BULL, V32, P1665, DOI 10.1248/bpb.32.1665; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Gupta A, 2012, J NEUROSCI, V32, P2523, DOI 10.1523/JNEUROSCI.4141-11.2012; Howard AL, 2007, J NEUROPHYSIOL, V97, P2394, DOI 10.1152/jn.00509.2006; Hua F, 2007, J NEUROIMMUNOL, V190, P101, DOI 10.1016/j.jneuroim.2007.08.014; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kielian T, 2006, J NEUROSCI RES, V83, P711, DOI 10.1002/jnr.20767; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Mao SS, 2012, J NEUROTRAUM, V29, P1941, DOI 10.1089/neu.2011.2244; Maroso M, 2010, NAT MED, V16, P413, DOI 10.1038/nm.2127; Neese SL, 2007, BRAIN RES, V1128, P157, DOI 10.1016/j.brainres.2006.09.073; Neuberger EJ, 2014, J NEUROSCI RES, V92, P1350, DOI 10.1002/jnr.23401; Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029; Okun E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047522; Okun E, 2011, TRENDS NEUROSCI, V34, P269, DOI 10.1016/j.tins.2011.02.005; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Pang K. C. H., 2014, J NEUROTRAUMA; Pascual O, 2012, P NATL ACAD SCI USA, V109, pE197, DOI 10.1073/pnas.1111098109; Proddutur A, 2013, CHAOS, V23, DOI 10.1063/1.4830138; Ratzliff ADH, 2004, J NEUROSCI, V24, P2259, DOI 10.1523/JNEUROSCI.5191-03.2004; Ratzliff ADH, 2002, TRENDS NEUROSCI, V25, P140, DOI 10.1016/S0166-2236(00)02122-6; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; Redell JB, 2013, J NEUROTRAUM, V30, P752, DOI 10.1089/neu.2012.2437; Rodgers KM, 2009, BRAIN, V132, P2478, DOI 10.1093/brain/awp177; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916; Santhakumar V, 2003, J NEUROSCI, V23, P5865; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; SCHARFMAN HE, 1991, J NEUROSCI, V11, P1660; Stellwagen D, 2011, ADV EXP MED BIOL, V691, P541, DOI 10.1007/978-1-4419-6612-4_57; Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104; Tobon KE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049288; Toth Z, 1997, J NEUROSCI, V17, P8106; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Yu JD, 2013, J NEUROPHYSIOL, V109, P1746, DOI 10.1152/jn.00891.2012; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59	60	27	28	1	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	FEB	2015	74						240	253		10.1016/j.nbd.2014.11.021			14	Neurosciences	Neurosciences & Neurology	CB5GQ	WOS:000349655900023	25497689	Green Accepted			2021-06-18	
J	Naderi, V; Khaksari, M; Abbasi, R; Maghool, F				Naderi, Vida; Khaksari, Mohammad; Abbasi, Reza; Maghool, Fatemeh			Estrogen provides neuroprotection against brain edema and blood brain barrier disruption through both estrogen receptors alpha and beta following traumatic brain injury	IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES			English	Article						Blood-brain-barrier; Brain edema; ER alpha antagonist; ER beta antagonist; ICI182780; Traumatic brain injury	ER-ALPHA; INTRACRANIAL-PRESSURE; NEUROLOGIC OUTCOMES; FOOD-INTAKE; CELL-DEATH; ACTIVATION; ESTRADIOL; 17-BETA-ESTRADIOL; NEURONS; DAMAGE	Objective(s): Estrogen (E-2) has neuroprotective effects on blood-brain-barrier (BBB) after traumatic brain injury (TBI). In order to investigate the roles of estrogen receptors (ERs) in these effects, ER-alpha antagonist (MPP) and, ER-beta antagonist (PHTPP), or non-selective estrogen receptors antagonist (ICI 182780) were administered. Materials and Methods: Ovariectomized rats were divided into 10 groups, as follows: Sham, TBI, E-2, oil, MPP+E-2, PHTPP+E-2, MPP+PHTPP+E-2, ICI+E-2, MPP, and DMSO.E-2 (33.3 mu g/Kg) or oil were administered 30 min after TBI. 1 dose (150 mu g/Kg) of each of MPP, PHTPP, and (4 mg/kg) ICI182780 was injected two times, 24 hr apart, before TBI and estrogen treatment. BBB disruption (Evans blue content) and brain edema (brain water content) evaluated 5 hr and 24 hr after the TBI were evaluated, respectively. Results: The results showed that E-2 reduced brain edema after TBI compared to vehicle (P<0.01). The brain edema in the MPP+E-2 and PHTPP+E-2 groups decreased compared to the vehicle (P<0.001). There was no significant difference in MPP+PHTPP+E-2 and ICI+E-2 compared to TBI. This parameter in MPP was similar to vehicle. Evans blue content in E-2 group was lower than vehicle (P<0.05). The inhibitory effect of E-2 on Evans blue was not reduced by MPP+E-2 and PHTPP+E-2 groups, but decreased by treatment with MPP+PHTPP or ICI. MPP had no effect on Evans blue content. Conclusion: A combined administration of MPP and PHTPP or ICI inhibited the E-2-induced decrease in brain edema and BBB disruption; this may suggest that these effects were mediated via both receptors.	[Naderi, Vida] Kerman Univ Med Sci, Inst Neuropharmacol, Neurosci Res Ctr, Kerman, Iran; [Khaksari, Mohammad; Maghool, Fatemeh] Kerman Univ Med Sci, Physiol Res Ctr, Inst Neuropharmacol, Kerman, Iran; [Abbasi, Reza] Kerman Univ Med Sci, Dept Physiol, Kerman, Iran	Khaksari, M (corresponding author), Kerman Univ Med Sci, Physiol Res Ctr, Kerman, Iran.	khaksar38@yahoo.co.uk	naderi-boldaji, vida/AAZ-4291-2020; Maghool, Fatemeh/ABI-7612-2020; Haddad, Mohammad Khaksari/AAB-9025-2019	naderi-boldaji, vida/0000-0001-9909-207X; Haddad, Mohammad Khaksari/0000-0003-0770-4281	Neuroscience Research Center and Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran	The present study was financially supported by the Neuroscience Research Center and Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran. The results reported in this paper were part of a student thesis.	Aguirre C, 2010, J NEUROCHEM, V115, P1277, DOI 10.1111/j.1471-4159.2010.07038.x; Alkayed NJ, 2001, J NEUROSCI, V21, P7543; Bains M, 2007, EXP NEUROL, V204, P767, DOI 10.1016/j.expneurol.2007.01.020; Baker AE, 2004, ENDOCRINOLOGY, V145, P5021, DOI 10.1210/en.2004-0619; Bliedtner A, 2010, MOL CELL ENDOCRINOL, V314, P41, DOI 10.1016/j.mce.2009.07.032; Brown CM, 2010, ENDOCRINOLOGY, V151, P4916, DOI 10.1210/en.2010-0371; Carswell HV, 2004, J CEREBR BLOOD F MET, V24, P298, DOI 10.1097/01.WCB.0000112322.75217.FD; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Cotroneo MS, 2005, FOOD CHEM TOXICOL, V43, P637, DOI 10.1016/j.fct.2004.12.022; Davis AM, 2006, MOL REPROD DEV, V73, P1034, DOI 10.1002/mrd.20520; Davis LK, 2010, J STEROID BIOCHEM, V122, P272, DOI 10.1016/j.jsbmb.2010.05.009; Dhillon SS, 2011, INT J OBESITY, V35, P198, DOI 10.1038/ijo.2010.124; Eckel LA, 2011, PHYSIOL BEHAV, V104, P517, DOI 10.1016/j.physbeh.2011.04.014; Evans MJ, 2002, ENDOCRINOLOGY, V143, P3785, DOI 10.1210/en.2002-220356; Harrington WR, 2003, MOL CELL ENDOCRINOL, V206, P13, DOI 10.1016/S0303-7207(03)00255-7; Harris HA, 2003, ENDOCRINOLOGY, V144, P4241, DOI 10.1210/en.2003-0550; Kansra S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010060; Keshavarzi Z, 2011, IRAN J BASIC MED SCI, V14, P231; Khaksari M, 2013, IRAN J BASIC MED SCI, V16, P858; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI 10.1139/y10-103; Liu R, 2005, BRAIN RES, V1060, P55, DOI 10.1016/j.brainres.2005.08.048; Mattsson A, 2011, GEN COMP ENDOCR, V172, P251, DOI 10.1016/j.ygcen.2011.03.010; Mazzucco CA, 2006, NEUROSCIENCE, V141, P1793, DOI 10.1016/j.neuroscience.2006.05.032; Miller NR, 2005, ENDOCRINOLOGY, V146, P3070, DOI 10.1210/en.2004-1515; Morissette M, 2008, J STEROID BIOCHEM, V108, P327, DOI 10.1016/j.jsbmb.2007.09.011; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Patisaul HB, 2009, HORM BEHAV, V55, P319, DOI 10.1016/j.yhbeh.2008.11.004; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Santollo J, 2010, HORM BEHAV, V58, P872, DOI 10.1016/j.yhbeh.2010.08.012; Santollo J, 2009, PHYSIOL BEHAV, V97, P193, DOI 10.1016/j.physbeh.2009.02.021; Sarvari M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-82; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shimada K, 2011, HYPERTENSION, V57, P1161, DOI 10.1161/HYPERTENSIONAHA.110.167650; Sierens JE, 2004, J MOL ENDOCRINOL, V32, P703, DOI 10.1677/jme.0.0320703; Somjen D, 2011, J CELL BIOCHEM, V112, P625, DOI 10.1002/jcb.22959; Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001; Sun J, 2002, ENDOCRINOLOGY, V143, P941, DOI 10.1210/en.143.3.941; Suzuki S, 2009, FRONT NEUROENDOCRIN, V30, P201, DOI 10.1016/j.yfrne.2009.04.007; Szymczak S, 2006, HIPPOCAMPUS, V16, P453, DOI 10.1002/hipo.20172; Vegeto E, 2008, FRONT NEUROENDOCRIN, V29, P507, DOI 10.1016/j.yfrne.2008.04.001; Venero JL, 2004, CURR PHARM DESIGN, V10, P2153, DOI 10.2174/1381612043384150; Waters EM, 2009, BRAIN RES, V1290, P1, DOI 10.1016/j.brainres.2009.06.090; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Wong JK, 2003, J NEUROSCI, V23, P4984; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7	45	27	29	0	5	MASHHAD UNIV MED SCIENCES	MASHHAD	VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 - 445, MASHHAD, 00000, IRAN	2008-3866	2008-3874		IRAN J BASIC MED SCI	Iran. J. Basic Med. Sci.	FEB	2015	18	2					138	144					7	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	CF3IO	WOS:000352442100005	25810887	DOAJ Gold			2021-06-18	
J	Rincon, F; Patel, U; Schorr, C; Lee, E; Ross, S; Dellinger, RP; Zanotti-Cavazzoni, S				Rincon, Fred; Patel, Utkal; Schorr, Christa; Lee, Elizabeth; Ross, Steven; Dellinger, R. Phillip; Zanotti-Cavazzoni, Sergio			Brain Injury as a Risk Factor for Fever Upon Admission to the Intensive Care Unit and Association With In-Hospital Case Fatality: A Matched Cohort Study	JOURNAL OF INTENSIVE CARE MEDICINE			English	Article						fever; stroke; intracerebral hemorrhage; traumatic brain injury	SPECIAL WRITING GROUP; SUBARACHNOID HEMORRHAGE; EMERGENCY-DEPARTMENT; BODY-TEMPERATURE; STROKE-COUNCIL; INTRACEREBRAL HEMORRHAGE; DELAYED TRANSFER; CARDIAC-ARREST; HYPERTHERMIA; GUIDELINES	Purpose: To test the hypothesis that fever was more frequent in critically ill patients with brain injury when compared to nonneurological patients and to study its effect on in-hospital case fatality. Methods: Retrospective matched cohort study utilizing a single-center prospectively compiled registry. Critically ill neurological patients 18 years and consecutively admitted to the intensive care unit (ICU) with acute ischemic stroke (AIS), intracerebral hemorrhage (ICH), and traumatic brain injury (TBI) were selected. Patients were matched by sex, age, and Acute Physiology and Chronic Health Evaluation II (APACHE-II) to a cohort of nonneurological patients. Fever was defined as any temperature 37.5 degrees C within the first 24 hours upon admission to the ICU. The primary outcome measure was in-hospital case fatality. Results: Mean age among neurological patients was 65.6 15 years, 46% were men, and median APACHE-II was 15 (interquartile range 11-20). There were 18% AIS, 27% ICH, and 6% TBI. More neurological patients experienced fever than nonneurological patients (59% vs 47%, P = .007). The mean hospital length of stay was higher for nonneurological patients (18 +/- 20 vs 14 +/- 15 days, P = .007), and more neurological patients were dead at hospital discharge (29% vs 20%, P < .0001). After risk factor adjustment, diagnosis (neurological vs nonneurological), and the probability of being exposed to fever (propensity score), the following variables were associated with higher in-hospital case fatality: APACHE-II, neurological diagnosis, mean arterial pressure, cardiovascular and respiratory dysfunction in ICU, and fever (odds ratio 1.9, 95% confidence interval 1.04-3.6, P = .04). Conclusion: These data suggest that fever is a frequent occurrence after brain injury, and that it is independently associated with in-hospital case fatality.	[Rincon, Fred; Patel, Utkal; Schorr, Christa; Lee, Elizabeth; Dellinger, R. Phillip; Zanotti-Cavazzoni, Sergio] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Cooper Univ Hosp, Div Crit Care & Cardiovasc Med,Dept Med, Camden, NJ 08103 USA; [Ross, Steven] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Cooper Univ Hosp, Div Trauma & Crit Care,Dept Surg, Camden, NJ 08103 USA	Rincon, F (corresponding author), Thomas Jefferson Univ, Dept Neurol Surg, Div Crit Care & Neurotrauma, 909 Walnut St,3rd Floor, Philadelphia, PA 19107 USA.	fred.rincon@jefferson.edu		Rincon, Fred/0000-0002-8510-118X; Schorr, Christa/0000-0001-7777-4280	American Heart AssociationAmerican Heart Association [AHA 12CRP12050342]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr Rincon has received salary support from the American Heart Association (AHA 12CRP12050342).	Adams HP, 2007, CIRCULATION, V115, pE478, DOI 10.1161/CIRCULATIONAHA.107.181486; Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Alyagari V, 2007, J NEUROL SCI, V261, P39, DOI 10.1016/j.jns.2007.04.030; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; Badjatia N, 2009, CRIT CARE MED, V37, pS250, DOI 10.1097/CCM.0b013e3181aa5e8d; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; Chalfin DB, 2007, CRIT CARE MED, V35, P1477, DOI 10.1097/01.CCM.0000266585.74905.5A; Childs Charmaine, 2010, Front Neurol, V1, P146, DOI 10.3389/fneur.2010.00146; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cummings P, 2003, EPIDEMIOL REV, V25, P43, DOI 10.1093/epirev/mxg002; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Fernandez A, 2007, NEUROLOGY, V68, P1013, DOI 10.1212/01.wnl.0000258543.45879.f5; Greer DM, 2008, STROKE, V39, P3029, DOI 10.1161/STROKEAHA.108.521583; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Haveman J, 2005, INT J HYPERTHER, V21, P473, DOI 10.1080/02656730500159079; Hemphill JC, 2004, STROKE, V35, P1130, DOI 10.1161/01.STR.0000125858.71051.ca; Hickey RW, 2003, CRIT CARE MED, V31, P531, DOI 10.1097/01.CCM.0000050323.84293.11; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Leira R, 2004, NEUROLOGY, V63, P461, DOI 10.1212/01.WNL.0000133204.81153.AC; O'Grady NP, 2008, CRIT CARE MED, V36, P1330, DOI 10.1097/CCM.0b013e318169eda9; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Rincon F, 2013, NEUROCRIT CARE, V18, P45, DOI 10.1007/s12028-012-9779-9; Rincon F, 2011, J CRIT CARE, V26, P620, DOI 10.1016/j.jcrc.2011.02.009; Rincon F, 2010, NEUROCRIT CARE, V13, P75, DOI 10.1007/s12028-010-9347-0; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Romanovsky AA, 1998, MED HYPOTHESES, V50, P219, DOI 10.1016/S0306-9877(98)90022-6; Rossi S, 2001, J NEUROL NEUROSUR PS, V71, P448, DOI 10.1136/jnnp.71.4.448; Sacho RH, 2010, J NEUROTRAUM, V27, P2157, DOI 10.1089/neu.2010.1384; Saini M, 2009, STROKE, V40, P3051, DOI 10.1161/STROKEAHA.109.556134; Schwarz S, 2000, NEUROLOGY, V54, P354, DOI 10.1212/WNL.54.2.354; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007	42	27	28	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0885-0666	1525-1489		J INTENSIVE CARE MED	J. Intensive Care Med.	FEB	2015	30	2					107	114		10.1177/0885066613508266			8	Critical Care Medicine	General & Internal Medicine	AZ0RY	WOS:000347953400006	24132129				2021-06-18	
J	Shultz, SR; Aziz, NAB; Yang, L; Sun, MJ; MacFabe, DF; O'Brien, TJ				Shultz, Sandy R.; Aziz, Noor A. B.; Yang, Li; Sun, Mujun; MacFabe, Derrick F.; O'Brien, Terence J.			Intracerebroventricular injection of propionic acid, an enteric metabolite implicated in autism, induces social abnormalities that do not differ between seizure-prone (FAST) and seizure-resistant (SLOW) rats	BEHAVIOURAL BRAIN RESEARCH			English	Article						Autism; Animal model; Short chain fatty acid; Astrogliosis; Attention deficit hyperactivity disorder	TRAUMATIC BRAIN-INJURY; KINDLING-PRONE; SPECTRUM DISORDERS; RODENT MODEL; EPILEPSY; NEUROINFLAMMATION; PROFILES; BEHAVIOR; PRODUCT; ACTIVATION	Autism is a complex neurodevelopmental disorder that is characterized by social abnormalities. Genetic, dietary and gut-related factors are implicated in autism, however the causal properties of these factors and how they may interact are unclear. Propionic acid (PPA) is a product of gut microbiota and a food preservative. PPA has been linked to autism, and PPA administration to rats is an animal model of the condition. Seizure-prone (FAST) and seizure-resistant (SLOW) rats were initially developed to investigate differential vulnerability to developing epilepsy. However, FAST rats also display autistic-like features, and have been proposed as a genetic model of autism. Here we examined the effects of PPA on social behavior in FAST and SLOW rats. A single intracerebroventricular injection of PPA, or phosphate-buffered saline (PBS), was administered to young-adult male FAST and SLOW rats. Immediately after treatment, rats were placed in same-treatment and same-strain pairs, and underwent social behavior testing. PPA induced social abnormalities in both FAST and SLOW rat strains. While there was no evidence of social impairment in FAST rats that were not treated with PPA, these rats were hyperactive relative to SLOW rats. Post-mortem immunofluorescence analysis of brain tissue indicated that PPA treatment resulted in increased astrogliosis in the corpus callosum and cortex compared to PBS treatment. FAST rats had increased astrogliosis in the cortex compared to SLOW rats. Together these findings support the use of PPA as a rat model of autism, but indicate there are no interactive effects between the PPA and FAST models. (C) 2014 Elsevier B.V. All rights reserved.	[Shultz, Sandy R.; Aziz, Noor A. B.; Yang, Li; Sun, Mujun; O'Brien, Terence J.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne Brain Ctr, Parkville, Vic, Australia; [Yang, Li] Kunming Med Univ, Dept Histol & Embryol, Kunming, Yunnan, Peoples R China; [MacFabe, Derrick F.] Univ Western Ontario, Kilee Patchell Evans Autism Res Grp, Dept Psychiat & Psychol, London, ON, Canada	Shultz, SR (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne Brain Ctr, Parkville, Vic, Australia.	sshultz@unimelb.edu.au		Sun, Mujun/0000-0002-9923-9913; O'Brien, Terence/0000-0002-7198-8621; Shultz, Sandy/0000-0002-2525-8775	University of MelbourneUniversity of Melbourne; Royal Melbourne Hospital Neuroscience Foundation; Canadian Institute of Health Research fellowshipCanadian Institutes of Health Research (CIHR)	The authors thank Dr. Krista Gilby for providing access to the FAST and SLOW rat strains used in this study. This study was funded by grants from the University of Melbourne to SRS, a Royal Melbourne Hospital Neuroscience Foundation grant to TOB, and a Canadian Institute of Health Research fellowship to SRS.	Al-Lahham SH, 2010, BBA-MOL CELL BIOL L, V1801, P1175, DOI 10.1016/j.bbalip.2010.07.007; Argyropoulos A, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00417; Azarbar A, 2010, BEHAV NEUROSCI, V124, P106, DOI 10.1037/a0018307; Baio Jon, 2012, Morbidity and Mortality Weekly Report, V61, P1; Bonnet U, 2000, EUR NEUROPSYCHOPHARM, V10, P97, DOI 10.1016/S0924-977X(99)00063-2; Cannizzaro C, 2003, NEUROCHEM INT, V43, P9, DOI 10.1016/S0197-0186(02)00211-5; Choi J, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-38; Crunelli V., 2014, NEUROSCIENTIST; Edmonson C, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-3; Foley KA, 2014, BEHAV BRAIN RES; Foley KA, 2014, INT J DEV NEUROSCI, V39, P68, DOI 10.1016/j.ijdevneu.2014.04.001; Foley KA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087072; Frye RE, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2012.143; Gilby KL, 2009, NEUROSCIENCE, V163, P750, DOI 10.1016/j.neuroscience.2009.07.013; Gilby KL, 2008, EPILEPSIA, V49, P108, DOI 10.1111/j.1528-1167.2008.01851.x; Gilby KL, 2013, EPILEPSY BEHAV, V26, P370, DOI 10.1016/j.yebeh.2012.11.002; Hamoda HM, 2009, EXPERT REV NEUROTHER, V9, P1747, DOI 10.1586/ERN.09.128; Herbert MR, 2010, CURR OPIN NEUROL, V23, P103, DOI 10.1097/WCO.0b013e328336a01f; Jeste SS, 2014, NAT REV NEUROL, V10, P74, DOI 10.1038/nrneurol.2013.278; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; KARURI AR, 1993, BRIT J CANCER, V68, P1080, DOI 10.1038/bjc.1993.485; Macfabe Derrick, 2013, Glob Adv Health Med, V2, P52, DOI 10.7453/gahmj.2013.089; MacFabe DF, 2007, BEHAV BRAIN RES, V176, P149, DOI 10.1016/j.bbr.2006.07.025; MacFabe Derrick F., 2012, Microbial Ecology in Health and Disease, V23, P19260, DOI 10.3402/mehd.v23i0.19260; MacFabe DF, 2011, BEHAV BRAIN RES, V217, P47, DOI 10.1016/j.bbr.2010.10.005; McIntyre DC, 2007, EPILEPSIA, V48, P30, DOI 10.1111/j.1528-1167.2007.01398.x; Mitsui R, 2005, NEUROGASTROENT MOTIL, V17, P585, DOI 10.1111/j.1365-2982.2005.00669.x; Pardo CA, 2014, NEUROTHERAPEUTICS, V11, P297, DOI 10.1007/s13311-014-0265-2; Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Racine RJ, 1999, EPILEPSY RES, V35, P183, DOI 10.1016/S0920-1211(99)00013-3; Reiersen Angela M, 2008, Expert Rev Neurother, V8, P657, DOI 10.1586/14737175.8.4.657; Reinhart CJ, 2006, J COMP PSYCHOL, V120, P19, DOI 10.1037/0735-7036.120.1.19; Reinhart CJ, 2004, DEV PSYCHOBIOL, V45, P83, DOI 10.1002/dev.20016; Rossignol DA, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.4; Russell Vivienne A, 2006, Behav Brain Funct, V2, P30, DOI 10.1186/1744-9081-2-30; Severson CA, 2003, NAT NEUROSCI, V6, P1139, DOI 10.1038/nn1130; Shultz SR, 2008, NEUROPHARMACOLOGY, V54, P901, DOI 10.1016/j.neuropharm.2008.01.013; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2009, BEHAV BRAIN RES, V200, P33, DOI 10.1016/j.bbr.2008.12.023; Shultz SR, 2014, COMPREHENSIVE GUIDE, P1755, DOI [10.1007/978-1-4614-4788-7_106, DOI 10.1007/978-1-4614-4788-7_106]; Strickland AD, 2014, MED HYPOTHESES, V82, P522, DOI 10.1016/j.mehy.2014.02.003; Thomas RH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-153; Thomas RH, 2010, J NEUROCHEM, V113, P515, DOI 10.1111/j.1471-4159.2010.06614.x; Vargas DL, 2005, ANN NEUROL, V57, P67, DOI 10.1002/ana.20315; Vitaliti G, 2014, HUM VACC IMMUNOTHER, V10, P868, DOI 10.4161/hv.28400; Wang L, 2014, BIOMARK MED, V8, P331, DOI 10.2217/bmm.14.12; Zeidan-Chulia F, 2014, NEUROSCI BIOBEHAV R, V38, P160, DOI 10.1016/j.neubiorev.2013.11.008	50	27	29	1	21	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	FEB 1	2015	278						542	548		10.1016/j.bbr.2014.10.050			7	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	AY5AQ	WOS:000347586300067	25446754				2021-06-18	
J	Bosco, FM; Angeleri, R; Sacco, K; Bara, BG				Bosco, Francesca M.; Angeleri, Romina; Sacco, Katiuscia; Bara, Bruno G.			Explaining pragmatic performance in traumatic brain injury: a process perspective on communicative errors	INTERNATIONAL JOURNAL OF LANGUAGE & COMMUNICATION DISORDERS			English	Article							CLOSED-HEAD INJURY; COMPREHENSION; DISCOURSE; INFORMATION; IMPAIRMENT; CHILDREN; REQUESTS; ADULTS; EXPRESSION; FAILURES	BackgroundThe purpose of this study is to investigate the pragmatic abilities of individuals with traumatic brain injury (TBI). Several studies in the literature have previously reported communicative deficits in individuals with TBI, however such research has focused principally on communicative deficits in general, without providing an analysis of the errors committed in understanding and expressing communicative acts. Within the theoretical framework of Cognitive Pragmatics theory and Cooperative principle we focused on intermediate communicative errors that occur in both the comprehension and the production of various pragmatic phenomena, expressed through both linguistic and extralinguistic communicative modalities. AimsTo investigate the pragmatic abilities of individuals with TBI. Methods & ProceduresA group of 30 individuals with TBI and a matched control group took part in the experiment. They were presented with a series of videotaped vignettes depicting everyday communicative exchanges, and were tested on the comprehension and production of various kinds of communicative acts (standard communicative act, deceit and irony). The participants' answers were evaluated as correct or incorrect. Incorrect answers were then further evaluated with regard to the presence of different intermediate errors. Outcomes & ResultsIndividuals with TBI performed worse than control participants on all the tasks investigated when considering correct versus incorrect answers. Furthermore, a series of logistic regression analyses showed that group membership (TBI versus controls) significantly predicted the occurrence of intermediate errors. This result holds in both the comprehension and production tasks, and in both linguistic and extralinguistic modalities. Conclusions & ImplicationsParticipants with TBI tend to have difficulty in managing different types of communicative acts, and they make more intermediate errors than the control participants. Intermediate errors concern the comprehension and production of the expression act, the comprehension of the actors' meaning, as well as the respect of the Cooperative principle.	[Bosco, Francesca M.; Angeleri, Romina; Sacco, Katiuscia; Bara, Bruno G.] Univ Turin, Dept Psychol, Ctr Cognit Sci, I-10123 Turin, Italy; [Bosco, Francesca M.; Sacco, Katiuscia; Bara, Bruno G.] Neurosci Inst Turin, Turin, Italy; [Sacco, Katiuscia] Koelliker Hosp, CCS fMRI Neuroradiol, Turin, Italy	Bosco, FM (corresponding author), Univ Turin, Dept Psychol, Via Po 14, I-10123 Turin, Italy.	francesca.bosco@unito.it	bosco, francesca marina/B-6746-2013	bosco, francesca marina/0000-0001-6101-8587	Regione Piemonte under IIINBEMA; Regione Piemonte under IIINBEMA	This research was supported by Regione Piemonte, under project title 'Institutions, Behaviour and Markets in Local and Global Settings' (Project IIINBEMA). The authors would like to thank Lorena Fonte, Viviana Leveratto and Elena Scarsoglio for their contribution to data collection, and Alessandra Ruzzini for assistance with selecting participants. They thank Marco Del Giudice for help with the revision of the manuscript. Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.	AIRENTI G, 1993, J PRAGMATICS, V20, P303, DOI 10.1016/0378-2166(93)90055-T; Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Angeleri R, 2012, BEHAV RES METHODS, V44, P845, DOI 10.3758/s13428-011-0174-9; Bara B. G., 2010, LINGUISTIC PHILOS IN, V9, P182; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Bara BG., 2010, COGNITIVE PRAGMATICS; Body R, 2004, BRAIN INJURY, V18, P707, DOI 10.1080/02699050310001596914; Bogart E, 2012, BRAIN INJURY, V26, P221, DOI 10.3109/02699052.2011.648711; Bosco FM, 2004, J PRAGMATICS, V36, P467, DOI 10.1016/S0378-2166(03)00055-9; Bosco FM, 2008, J PRAGMATICS, V40, P583, DOI 10.1016/j.pragma.2007.05.004; Bosco FM, 2006, J PRAGMATICS, V38, P1398, DOI 10.1016/j.pragma.2005.06.011; Bosco FM, 2013, J CHILD LANG, V40, P741, DOI 10.1017/S0305000913000081; Bosco FM, 2012, J COMMUN DISORD, V45, P290, DOI 10.1016/j.jcomdis.2012.03.002; Bosco FM, 2009, CONSCIOUS COGN, V18, P306, DOI 10.1016/j.concog.2008.06.006; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bucciarelli M, 2003, J PRAGMATICS, V35, P207, DOI 10.1016/S0378-2166(02)00099-1; Carlomagno S, 2011, BRAIN INJURY, V25, P1010, DOI 10.3109/02699052.2011.605097; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Ciccia AH, 2002, ADV SPEECH LANGUAGE, V4, P1, DOI DOI 10.1080/14417040210001669181; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; Colle L, 2013, J COMMUN DISORD, V46, P294, DOI 10.1016/j.jcomdis.2013.01.003; Cummings L., 2014, PRAGMATIC DISORDERS; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Dardier V, 2011, J COMMUN DISORD, V44, P359, DOI 10.1016/j.jcomdis.2011.02.001; Dascal M., 1985, DIALOGUE INTERDISCIP, P441; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; Evans K, 2011, BRAIN INJURY, V25, P767, DOI 10.3109/02699052.2011.576307; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Grice P, 1989, STUDIES WAY WORDS; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Huber W., 1983, AACHENER APHASIE TES; KREUZ RJ, 1993, J PRAGMATICS, V19, P239, DOI 10.1016/0378-2166(93)90030-S; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Luzzatti C., 1996, AACHENER APHASIE TES; Marini A, 2011, NEUROPSYCHOLOGIA, V49, P2904, DOI 10.1016/j.neuropsychologia.2011.06.017; Marquardt TP, 2001, APHASIOLOGY, V15, P1091, DOI 10.1080/02687040143000429; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Mondini S., 2004, ESAME NEUROPSICOLOGI; Pearce S, 1998, BRAIN COGNITION, V38, P150, DOI 10.1006/brcg.1998.1018; REITER R, 1980, ARTIF INTELL, V13, P81, DOI 10.1016/0004-3702(80)90014-4; Sacco K, 2008, J COGN SCI, V9, P111; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Tirassa M, 2006, CONSCIOUS COGN, V15, P197, DOI 10.1016/j.concog.2005.06.005; Tirassa M, 2006, COGN SYST RES, V7, P128, DOI 10.1016/j.cogsys.2006.01.002; Tirassa M, 2008, EMERG COMMUN-STUD NE, V10, P81; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1996, DISABIL REHABIL, V18, P559, DOI 10.3109/09638289609166317; Turkstra L.S., 2006, BRAIN IMPAIR, V7, P234, DOI [DOI 10.1375/BRIM.7.3.234, 10.1375/brim.7.3.234]; Volden J, 2004, INT J LANG COMM DIS, V39, P171, DOI 10.1080/13682820410001663252; Weigand E, 1999, J PRAGMATICS, V31, P763, DOI 10.1016/S0378-2166(98)00068-X; WINNER E, 1977, BRAIN, V100, P717, DOI 10.1093/brain/100.4.717	60	27	27	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1368-2822	1460-6984		INT J LANG COMM DIS	Int. J. Lang. Commun. Disord.	JAN-FEB	2015	50	1					63	83		10.1111/1460-6984.12114			21	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	CA4AJ	WOS:000348846400005	25039503				2021-06-18	
J	Martini, R; Rios, J; Polatajko, H; Wolf, T; McEwen, S				Martini, Rose; Rios, Jorge; Polatajko, Helene; Wolf, Timothy; McEwen, Sara			The performance quality rating scale (PQRS): reliability, convergent validity, and internal responsiveness for two scoring systems	DISABILITY AND REHABILITATION			English	Article						Development coordination disorder; outcome measures; performance quality rating scale; PQRS; psychometric properties; stroke	DEVELOPMENTAL COORDINATION DISORDER; TRAUMATIC BRAIN-INJURY; COGNITIVE ORIENTATION; CHRONIC STROKE; CHILDREN; REPRODUCIBILITY; REHABILITATION; ADULTS; TRIAL	Purpose: The performance quality rating scale (PQRS) is an observational measure of performance quality of client-selected, personally meaningful activities. It has been used inconsistently with different scoring systems, and there have been no formal publications on its psychometric properties. The purpose of this study was to test and compare the psychometric properties of two PQRS scoring systems in two populations. Methods: A secondary analysis of video recorded participant-selected activities from previous studies involving either adults living with stroke or children diagnosed with developmental coordination disorder (DCD) was conducted. Three pairs of raters scored the video recorded performances with PQRS operational definitions (PQRS-OD) and a generic rating system (PQRS-G). Results: For inter-rater reliability, PQRS-OD ICCs were substantial, ranging from 0.83 to 0.93; while the PQRS-G ICCs were moderate, ranging from 0.71 to 0.77. Test-retest reliability was substantial, >0.80 (ICC), for both rating systems across all rater pairs. Internal responsiveness was high for both rating systems. Convergent validity with the Canadian Occupational Performance Measure (COPM) was inconsistent, with scores ranging from low to moderate. Conclusion: Both scoring systems have demonstrated they are reliable and have good internal responsiveness. The PQRS-OD demonstrated greater consistency across raters and is more sensitive to clinically important change than the PQRS-G and should be used when greater accuracy is required. Further exploration of validity with actual rather than perceived performance measures is required.	[Martini, Rose] Univ Ottawa, Sch Rehabil Sci, Ottawa, ON, Canada; [Rios, Jorge; McEwen, Sara] Sunnybrook Res Inst, St Johns Rehab Res Program, Toronto, ON M2M 2G1, Canada; [Polatajko, Helene] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Wolf, Timothy] Washington Univ, Sch Med, Program Occupat Therapy, St Louis, MO USA; [McEwen, Sara] Univ Toronto, Dept Phys Therapy, Toronto, ON, Canada	McEwen, S (corresponding author), Sunnybrook Res Inst, St Johns Rehab Res Program, 285 Cummer Ave, Toronto, ON M2M 2G1, Canada.	sara.mcewen@utoronto.ca	Martini, Rose/AAB-1195-2019	Wolf, Timothy/0000-0003-3607-9454; McEwen, Sara/0000-0002-8529-7717	Canadian Institutes of Health Research (FRN)Canadian Institutes of Health Research (CIHR) [111200]	This study was partially funded by the Canadian Institutes of Health Research (FRN #111200). The authors report no conflict of interest.	Barnett, 2007, MOVEMENT ASSESSMENT; Beckerman H, 2001, QUAL LIFE RES, V10, P571, DOI 10.1023/A:1013138911638; Bragante KC, 2012, REV BRAS FISIOTER, V16, P141, DOI 10.1590/S1413-35552012005000021; Chan CC, 1997, OCCUPATIONAL THERAPY, V4, P231, DOI DOI 10.1002/OTI.58; Cup EHC, 2003, CLIN REHABIL, V17, P402, DOI 10.1191/0269215503cr635oa; Dawson DR, 2009, CAN J OCCUP THER, V76, P115, DOI 10.1177/000841740907600209; Eyssen ICJM, 2005, CLIN REHABIL, V19, P888, DOI 10.1191/0269215505cr883oa; Forbes D A, 1998, J Gerontol Nurs, V24, P34; GOWLAND C, 1995, CHEDOKE MCMASTER STR; Husted JA, 2000, J CLIN EPIDEMIOL, V53, P459, DOI 10.1016/S0895-4356(99)00206-1; Jones G., 2009, J DATA SCI, V7, P179; Kenny D. A., 2006, DYADIC DATA ANALYSIS; Law M, 1990, Can J Occup Ther, V57, P82; Law M, 1998, CANADIAN OCCUPATIONA; Law Mary, 2007, BMC Pediatr, V7, P31, DOI 10.1186/1471-2431-7-31; Lemmens RJM, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-21; Lexell JE, 2005, AM J PHYS MED REHAB, V84, P719, DOI 10.1097/01.phm.0000176452.17771.20; Lu WS, 2008, J REHABIL MED, V40, P615, DOI 10.2340/16501977-0230; Martini R, 1998, OCCUP THER J RES, V18, P157, DOI 10.1177/153944929801800403; Martini R, 2014, BRIT J OCCUP THER, V77, P214, DOI 10.4276/030802214X13968769798917; McEwen SE, 2010, NEUROPSYCHOL REHABIL, V20, P541, DOI 10.1080/09602011003638194; McEwen SE, 2009, BRAIN INJURY, V23, P1041, DOI 10.3109/02699050903421107; Meek GE, 2007, J MOD APPL STAT METH, V6, P91; Middel B, 2002, INT J INTEGR CARE, V2, P2; Miller LT, 2001, HUM MOVEMENT SCI, V20, P183, DOI 10.1016/S0167-9457(01)00034-3; Norman G. R., 2007, BIOSTATISTICS THE BA; Phelan S, 2009, CAN J OCCUP THER, V76, P23, DOI 10.1177/000841740907600107; Phipps S, 2007, AM J OCCUP THER, V61, P328, DOI 10.5014/ajot.61.3.328; Polatajko HJ, 2012, AM J OCCUP THER, V66, P104, DOI 10.5014/ajot.2012.001784; Rodger S., 2008, BRIT J OCCUP THER, V71, P23; Shrout P E, 1998, Stat Methods Med Res, V7, P301, DOI 10.1191/096228098672090967; Uswatte G, 2009, REHABIL PSYCHOL, V54, P398, DOI 10.1037/a0017501; WANG C, 2009, ASIAN J GERONTOL GER, V4, P8	33	27	27	1	13	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2015	37	3					231	238		10.3109/09638288.2014.913702			8	Rehabilitation	Rehabilitation	CA3EP	WOS:000348789500006	24766150				2021-06-18	
J	Mychasiuk, R; Hehar, H; van Waes, L; Esser, MJ				Mychasiuk, Richelle; Hehar, Harleen; van Waes, Linda; Esser, Michael J.			Diet, age, and prior injury status differentially alter behavioral outcomes following concussion in rats	NEUROBIOLOGY OF DISEASE			English	Article						Brain injury; Development; High fat diet; Repetitive TBI; Telomeres	TRAUMATIC BRAIN-INJURY; BODY-MASS INDEX; MOTOR CORTEX LESIONS; MILD HEAD-INJURY; SEX-DIFFERENCES; ALZHEIMERS-DISEASE; CALORIC-INTAKE; MOUSE MODEL; OBESITY; DYSFUNCTION	Mild traumatic brain injury (mTBI) or concussion affects a large portion of the population and although many of these individuals recover completely, a small subset of people experience lingering symptomology and poor outcomes. Little is known about the factors that affect individual susceptibility or resilience to poor outcomes after mTBI and there are currently no biomarkers to delineate mTBI diagnosis or prognosis. Based upon the growing literature associated with caloric intake and altered neurological aging and the ambiguous link between repetitive mTBI and progressive neurodegeneration, the current study was designed to examine the effect of a high fat diet (HFD), developmental age, and repetitive mTBI on behavioral outcomes following a mTBI. In addition, telomere length was examined before and after experimental mTBI. Sprague Dawley rats were maintained on a HFD or standard rat chow throughout life (including the prenatal period) and then experienced an mTBI/concussion at P30, P30 and P60, or only at P60. Behavioral outcomes were examined using a test battery that was administered between P61-P80 and included; beam-walking, open field, elevated plus maze, novel context mismatch, Morris water task, and forced swim task. Animals with a P30 mTBI often demonstrated lingering symptomology that was still present during testing at P80. Injuries at P30 and P60 rarely produced cumulative effects, and in some tests (i.e. beam walking), the first injury may have protected the brain from the second injury. Exposure to the high fat diet exacerbated many of the behavioral deficits associated with concussion. Finally, telomere length was shortened following mTBI and was influenced by the animal's dietary intake. Diet, age at the time of injury, and the number of prior concussion incidents differentially contribute to behavioral deficits and may help explain individual variations in susceptibility and resilience to poor outcomes following an mTBI. (C) 2015 Elsevier Inc. All rights reserved.	[Mychasiuk, Richelle; Hehar, Harleen; Esser, Michael J.] Univ Calgary, Fac Med, Alberta Childrens Hosp Res Inst, Calgary, AB T2N 1N4, Canada; [van Waes, Linda] Univ British Columbia, Fac Med, Vancouver, BC V5Z 1M9, Canada	Mychasiuk, R (corresponding author), Univ Calgary, Fac Med, Alberta Childrens Hosp Res Inst, Heritage Med Res Bldg,Room 274,3330 Hosp Dr NW, Calgary, AB T2N 1N4, Canada.			Mychasiuk, Richelle/0000-0001-5291-5083	Canadian Institute for Military and Veteran Health Research (CIMVHR) program [Rt - 10007008]; Alberta Children's Hospital Foundation (ACHF) [Rt - 10003014]; Alberta Children's Hospital Research Institute (ACHRI) [Rt - 10003877]	The authors would like to thank the Canadian Institute for Military and Veteran Health Research (CIMVHR) (Rt - 10007008) program, the Alberta Children's Hospital Foundation (ACHF) (Rt - 10003014) and the Alberta Children's Hospital Research Institute (ACHRI) (Rt - 10003877) for funding the research conducted in this study. The authors would also like to thank Dr. Yushan Wang and Dr. Thomas Sawyer for their ideological input as well as, Irene Ma, Rose Tobias, and Dr. Jong Rho for their technical and organizational assistance.	Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Blasco MA, 2007, NAT REV GENET, V8, P299, DOI 10.1038/nrg2047; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown CVR, 2006, J TRAUMA, V61, P572, DOI 10.1097/01.ta.0000200842.19740.38; Carroll L., 2004, J REHABIL MED S, V43, P84; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; De Bellis MD, 2001, CEREB CORTEX, V11, P552, DOI 10.1093/cercor/11.6.552; de la Monte SM, 2014, BIOCHEM PHARMACOL, V88, P548, DOI 10.1016/j.bcp.2013.12.012; Demerath EW, 2004, HUM BIOL, V76, P127, DOI 10.1353/hub.2004.0018; Elias MF, 2003, INT J OBESITY, V27, P260, DOI 10.1038/sj.ijo.802225; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Garrido P, 2011, AGING DIS, V2, P80; Gilley D, 2008, MECH AGEING DEV, V129, P27, DOI 10.1016/j.mad.2007.10.010; Gunstad J, 2008, INT J NEUROSCI, V118, P1582, DOI 10.1080/00207450701392282; Gunstad J, 2007, COMPR PSYCHIAT, V48, P57, DOI 10.1016/j.comppsych.2006.05.001; Hood MY, 2000, INT J OBESITY, V24, P1319, DOI 10.1038/sj.ijo.0801396; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Kalichman L, 2007, AM J PHYS MED REHAB, V86, P650, DOI 10.1097/PHM.0b013e318115f41b; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; KIRINO T, 1991, J CEREBR BLOOD F MET, V11, P299, DOI 10.1038/jcbfm.1991.62; Kolb B, 2000, RESTOR NEUROL NEUROS, V17, P61; Kolb B, 2000, BRAIN RES, V882, P62, DOI 10.1016/S0006-8993(00)02828-6; Kolb B., 2008, FUNDAMENTALS HUMAN N; Kolb B, 2007, DEV PSYCHOBIOL, V49, P107, DOI 10.1002/dev.20199; Kolb B, 2012, P NATL ACAD SCI USA, V109, P17186, DOI 10.1073/pnas.1121251109; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lindqvist A, 2006, EUR J NEUROL, V13, P1385, DOI 10.1111/j.1468-1331.2006.01500.x; Liu L, 2004, GENE, V340, P1, DOI 10.1016/j.gene.2004.06.011; LIU Y, 1992, BRAIN RES, V586, P121, DOI 10.1016/0006-8993(92)91380-W; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Luchsinger JA, 2002, ARCH NEUROL-CHICAGO, V59, P1258, DOI 10.1001/archneur.59.8.1258; Mattson MP, 2000, EXP GERONTOL, V35, P489, DOI 10.1016/S0531-5565(00)00115-7; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh TK, 1996, LAB INVEST, V74, P315; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Molteni R, 2001, BRAIN RES REV, V37, P249, DOI 10.1016/S0165-0173(01)00128-X; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Panossian LA, 2003, NEUROBIOL AGING, V24, P77, DOI 10.1016/S0197-4580(02)00043-X; Paul L, 2011, J NUTR BIOCHEM, V22, P895, DOI 10.1016/j.jnutbio.2010.12.001; Pistell PJ, 2010, J NEUROIMMUNOL, V219, P25, DOI 10.1016/j.jneuroim.2009.11.010; Raji CA, 2010, HUM BRAIN MAPP, V31, P353, DOI 10.1002/hbm.20870; Savage JS, 2007, J LAW MED ETHICS, V35, P22, DOI 10.1111/j.1748-720X.2007.00111.x; Schallert T., 2002, PHARM CEREBRAL ISCHE, P201; SENA A, 1985, J NEUROL SCI, V68, P233, DOI 10.1016/0022-510X(85)90104-2; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sowell ER, 2003, NAT NEUROSCI, V6, P309, DOI 10.1038/nn1008; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; Sowell ER, 2001, J INT NEUROPSYCH SOC, V7, P312, DOI 10.1017/S135561770173305X; Spanswick SC, 2010, LEARN MEMORY, V17, P241, DOI 10.1101/lm.1746710; Stranahan AM, 2008, HIPPOCAMPUS, V18, P1085, DOI 10.1002/hipo.20470; Suk SH, 2003, STROKE, V34, P1586, DOI 10.1161/01.STR.0000075294.98582.2F; SUTHERLAND RJ, 1988, J NEUROSCI, V8, P1863; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Walther K, 2010, HUM BRAIN MAPP, V31, P1052, DOI 10.1002/hbm.20916; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; Yadid G, 2001, BRAIN RES, V896, P43, DOI 10.1016/S0006-8993(00)03248-0	67	27	27	0	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JAN	2015	73						1	11		10.1016/j.nbd.2014.09.003			11	Neurosciences	Neurosciences & Neurology	AW5QB	WOS:000346328100001	25270295				2021-06-18	
J	Naro, A; Calabro, RS; Russo, M; Leo, A; Pollicino, P; Quartarone, A; Bramanti, P				Naro, Antonino; Calabro, Rocco Salvatore; Russo, Margherita; Leo, Antonino; Pollicino, Patrizia; Quartarone, Angelo; Bramanti, Placido			Can transcranial direct current stimulation be useful in differentiating unresponsive wakefulness syndrome from minimally conscious state patients?	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Disorders of consciousness; minimally conscious state; unresponsive wakefulness syndrome; transcranial direct current stimulation; transcranial magnetic stimulation; cortical excitability; cortical connectivity	CORTICAL EFFECTIVE CONNECTIVITY; HUMAN MOTOR CORTEX; TRAUMATIC BRAIN-INJURY; COMA RECOVERY SCALE; MAGNETIC STIMULATION; VEGETATIVE STATE; FUNCTIONAL CONNECTIVITY; ELECTRICAL-STIMULATION; OSCILLATORY ACTIVITIES; ORBITOFRONTAL CORTEX	Purpose: Disorders of consciousness (DOC) diagnosis relies on the presence or absence of purposeful motor responsiveness, which characterizes the minimally conscious state (MCS) and the unresponsive wakefulness syndrome (UWS), respectively. Functional neuroimaging studies have raised the question of possible residual conscious awareness also in clinically-defined UWS patients. The aim of our study was to identify electrophysiological parameters, by means of a transcranial magnetic stimulation approach, which might potentially express the presence of residual networks sustaining fragmentary behavioral patterns, even when no conscious behavior can be observed. Methods: We enrolled 25 severe DOC patients, following post-anoxic or traumatic brain injury and 20 healthy individuals (HC) as control group. Baseline electrophysiological evaluation evidenced, in comparison to HC, a partial preservation of cortical effective connectivity and excitability in clinically defined MCS, whereas these components were absent in clinically defined UWS. Then, we applied an anodal transcranial direct current stimulation (a-tDCS) protocol over the orbitofrontal cortex. Result: a-tDCS was able to boost cortical connectivity and excitability in all HC, MCS, and to unmask such excitability/connectivity in some UWS patients. Conclusion: a-tDCS could be useful in identifying residual connectivity markers in clinically-defined UWS, who may lack of purposeful behavior as a result of a motor-output failure.	[Naro, Antonino; Calabro, Rocco Salvatore; Russo, Margherita; Leo, Antonino; Pollicino, Patrizia; Bramanti, Placido] IRCCS Ctr Neurolesi Bonino Pulejo Messina, I-98124 Messina, Italy; [Quartarone, Angelo] Univ Messina, Dept Neurosci, I-98100 Messina, Italy	Calabro, RS (corresponding author), IRCCS Ctr Neurolesi Bonino Pulejo Messina, SS 113, I-98124 Messina, Italy.	salbro77@tiscali.it	Calabro, Rocco S/K-7520-2016; calabro, rocco salvatore/L-9570-2019; Leo, Antonino/K-7529-2016; Leo, Antonino/ABI-7198-2020; Bramanti, Placido/K-5117-2016	calabro, rocco salvatore/0000-0002-8566-3166; Leo, Antonino/0000-0003-4163-5830; Leo, Antonino/0000-0003-4163-5830; QUARTARONE, Angelo/0000-0003-1485-6590			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Alon G, 2011, BRAIN RES, V1403, P37, DOI 10.1016/j.brainres.2011.06.013; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Angelakis E, 2014, ARCH PHYS MED REHAB, V95, P283, DOI 10.1016/j.apmr.2013.09.002; [Anonymous], 2003, Clin Med (Lond), V3, P249; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bagnato S, 2013, NEUROSCI BIOBEHAV R, V37, P2721, DOI 10.1016/j.neubiorev.2013.09.007; Bagnato S, 2012, CLIN NEUROPHYSIOL, V123, P1937, DOI 10.1016/j.clinph.2012.03.014; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Baudewig J, 2001, MAGN RESON MED, V45, P196, DOI 10.1002/1522-2594(200102)45:2<196::AID-MRM1026>3.0.CO;2-1; Bekinschtein P, 2008, P NATL ACAD SCI USA, V105, P2711, DOI 10.1073/pnas.0711863105; Bikson M, 2010, CLIN NEUROPHYSIOL, V121, P1976, DOI 10.1016/j.clinph.2010.05.020; BINDMAN LJ, 1964, J PHYSIOL-LONDON, V172, P369, DOI 10.1113/jphysiol.1964.sp007425; Boly M, 2012, BRAIN CONNECT, V2, P1, DOI 10.1089/brain.2011.0049; Boly M, 2011, CURR OPIN NEUROL, V24, P394, DOI 10.1097/WCO.0b013e328347da94; Boly M, 2011, SCIENCE, V332, P858, DOI 10.1126/science.1202043; Boros K, 2008, EUR J NEUROSCI, V27, P1292, DOI 10.1111/j.1460-9568.2008.06090.x; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Busl KM, 2010, NEUROREHABILITATION, V26, P5, DOI 10.3233/NRE-2010-0531; Cavanna AE, 2007, CNS SPECTRUMS, V12, P545, DOI 10.1017/S1092852900021295; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Civardi C, 2001, NEUROIMAGE, V14, P1444, DOI 10.1006/nimg.2001.0918; CREPEL V, 1993, J NEUROPHYSIOL, V70, P2045; Crick F, 2003, NAT NEUROSCI, V6, P119, DOI 10.1038/nn0203-119; Dehaene S, 2011, NEURON, V70, P200, DOI 10.1016/j.neuron.2011.03.018; Demertzi A, 2013, CURR OPIN NEUROBIOL, V23, P239, DOI 10.1016/j.conb.2012.12.003; Di Filippo M, 2008, NEUROPHARMACOLOGY, V55, P353, DOI 10.1016/j.neuropharm.2008.01.012; Di Lazzaro V, 2011, J NEUROPHYSIOL, V105, P2150, DOI 10.1152/jn.00781.2010; Di Perri C, 2014, EPILEPSY BEHAV, V30, P28, DOI 10.1016/j.yebeh.2013.09.014; Ding MC, 2011, J NEUROSCI, V31, P14085, DOI 10.1523/JNEUROSCI.3572-11.2011; Elliott R, 2000, CEREB CORTEX, V10, P308, DOI 10.1093/cercor/10.3.308; Ferrarelli F, 2010, P NATL ACAD SCI USA, V107, P2681, DOI 10.1073/pnas.0913008107; Ferreri F, 2013, REV NEUROSCIENCE, V24, P431, DOI 10.1515/revneuro-2013-0019; Fuggetta G, 2005, NEUROIMAGE, V27, P896, DOI 10.1016/j.neuroimage.2005.05.013; Fuggetta G, 2008, HUM BRAIN MAPP, V29, P1, DOI 10.1002/hbm.20371; Fuggetta G, 2013, EXP NEUROL, V245, P87, DOI 10.1016/j.expneurol.2012.10.010; Fumagalli M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008865; Gerrard P., 2014, ARCH PHYS MED REHABI; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; GOLDMANRAKIC PS, 1984, TRENDS NEUROSCI, V7, P419, DOI 10.1016/S0166-2236(84)80146-0; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.neuro.11.1.137; Gosseries O, 2014, ANN FR ANESTH, V33, P65, DOI 10.1016/j.annfar.2013.11.002; Gosseries O, 2011, NEUROREHABILITATION, V28, P3, DOI 10.3233/NRE-2011-0625; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; John ER, 2005, PROG BRAIN RES, V150, P143, DOI 10.1016/S0079-6123(05)50011-6; Kalmar K, 2005, NEUROPSYCHOL REHABIL, V15, P454, DOI 10.1080/09602010443000425; Keeser D, 2011, NEUROIMAGE, V55, P644, DOI 10.1016/j.neuroimage.2010.12.004; Kokaia Z, 1998, EXP NEUROL, V154, P289, DOI 10.1006/exnr.1998.6888; Komssi S, 2004, HUM BRAIN MAPP, V21, P154, DOI 10.1002/hbm.10159; Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Lang N, 2005, EUR J NEUROSCI, V22, P495, DOI 10.1111/j.1460-9568.2005.04233.x; Lansbergen MM, 2007, BRAIN RES, V1148, P161, DOI 10.1016/j.brainres.2007.02.034; Lapitskaya N, 2013, BRAIN STIMUL, V6, P590, DOI 10.1016/j.brs.2013.01.002; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2012, NEUROIMAGE, V61, P478, DOI 10.1016/j.neuroimage.2011.12.041; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Leon-Carrion J, 2008, CLIN NEUROPHYSIOL, V119, P1506, DOI 10.1016/j.clinph.2008.03.030; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Luria A. R., 1966, HUMAN BRAIN PSYCHOL; Majerus S, 2005, PROG BRAIN RES, V150, P397, DOI 10.1016/S0079-6123(05)50028-1; Manganotti P, 2013, BRAIN STIMUL, V6, P913, DOI 10.1016/j.brs.2013.06.006; Manuel AL, 2014, NEUROSCIENCE, V265, P21, DOI 10.1016/j.neuroscience.2014.01.052; Massimini M, 2005, SCIENCE, V309, P2228, DOI 10.1126/science.1117256; Massimini M, 2012, ARCH ITAL BIOL, V150, P44, DOI 10.4449/aib.v150i2.1361; Massimini M, 2009, PROG BRAIN RES, V177, P201, DOI 10.1016/S0079-6123(09)17714-2; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; Miranda PC, 2006, CLIN NEUROPHYSIOL, V117, P1623, DOI 10.1016/j.clinph.2006.04.009; Monti MM, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3765; Munchau A, 2002, J NEUROSCI, V22, P554, DOI 10.1523/JNEUROSCI.22-02-00554.2002; Muri RM, 1996, J NEUROPHYSIOL, V76, P2102; NAGEL T, 1974, PHILOS REV, V83, P435, DOI 10.2307/2183914; Nakase-Richardson R, 2009, NEUROLOGY, V73, P1120, DOI 10.1212/WNL.0b013e3181bacf34; Nitsche MA, 2003, CLIN NEUROPHYSIOL, V114, P2220, DOI 10.1016/S1388-2457(03)00235-9; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; Nitsche MA, 2005, J PHYSIOL-LONDON, V568, P291, DOI 10.1113/jphysiol.2005.092429; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Nudo Randolph J, 2013, Handb Clin Neurol, V110, P13, DOI 10.1016/B978-0-444-52901-5.00002-2; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Pape TLB, 2009, BRAIN STIMUL, V2, P22, DOI 10.1016/j.brs.2008.09.004; Piccione F, 2011, NEUROREHAB NEURAL RE, V25, P98, DOI 10.1177/1545968310369802; Polania R, 2011, HUM BRAIN MAPP, V32, P1236, DOI 10.1002/hbm.21104; Pollonini L, 2010, BRAIN TOPOGR, V23, P221, DOI 10.1007/s10548-010-0139-9; PURPURA DP, 1965, J NEUROPHYSIOL, V28, P166; Ragazzoni A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057069; Rosanova M, 2012, BRAIN, V135, P1308, DOI 10.1093/brain/awr340; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Sarasso S, 2014, CLIN EEG NEUROSCI, V45, P40, DOI 10.1177/1550059413513723; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Sehm B, 2012, J NEUROPHYSIOL, V108, P3253, DOI 10.1152/jn.00606.2012; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Soddu A, 2012, HUM BRAIN MAPP, V33, P778, DOI 10.1002/hbm.21249; Song SB, 2011, RESTOR NEUROL NEUROS, V29, P427, DOI 10.3233/RNN-2011-0614; Stagg CJ, 2009, J NEUROSCI, V29, P5202, DOI 10.1523/JNEUROSCI.4432-08.2009; Takano Y, 2011, NEUROSCI LETT, V491, P40, DOI 10.1016/j.neulet.2011.01.004; Thibaut A, 2014, NEUROLOGY, V82, P1112, DOI 10.1212/WNL.0000000000000260; Torres J, 2013, RESTOR NEUROL NEUROS, V31, P501, DOI 10.3233/RNN-130314; TRESCH DD, 1991, ARCH INTERN MED, V151, P930, DOI 10.1001/archinte.151.5.930; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Varotto G, 2014, CLIN NEUROPHYSIOL, V125, P63, DOI 10.1016/j.clinph.2013.06.016; Veniero D, 2011, PSYCHOPHYSIOLOGY, V48, P1381, DOI 10.1111/j.1469-8986.2011.01218.x; VOLKOW ND, 1992, SYNAPSE, V11, P184, DOI 10.1002/syn.890110303; Vucic S, 2009, BRAIN RES, V1273, P39, DOI 10.1016/j.brainres.2009.03.043; Walton ME, 2010, NEURON, V65, P927, DOI 10.1016/j.neuron.2010.02.027; Zaehle T, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-2; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	116	27	31	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2015	33	2					159	176		10.3233/RNN-140448			18	Neurosciences	Neurosciences & Neurology	CB7UX	WOS:000349835000007	25588461				2021-06-18	
J	Ansari, MA; Roberts, KN; Scheff, SW				Ansari, Mubeen A.; Roberts, Kelly N.; Scheff, Stephen W.			A time course of NADPH-oxidase up-regulation and endothelial nitric oxide synthase activation in the hippocampus following neurotrauma	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						NADPH-oxidase; Free radicals; Secondary injury cascades; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; MEDIATED OXIDATIVE DAMAGE; PROTEIN-KINASE-C; SUPEROXIDE-DISMUTASE; CELL-DEATH; RAT-BRAIN; POLY(ADP-RIBOSE) POLYMERASE; SYNAPTIC PROTEINS; INOS EXPRESSION; NEURONAL DEATH	Nicotinamide adenine dinucleotide phosphate oxidase (NADPH-oxidase; NOX) is a complex enzyme responsible for increased levels of reactive oxygen species (ROS), superoxide (O-2(center dot-)). NOX-derived O-2(center dot-) is a key player in oxidative stress and inflammation-mediated multiple secondary injury cascades (SIC) following traumatic brain injury (TBI). The O-2(center dot-) reacts with nitric oxide (NO), produces various reactive nitrogen species (RNS), and contributes to apoptotic cell death. Following a unilateral cortical contusion, young adult rats were killed at various times postinjury (1, 3, 6, 12, 24, 48, 72, and 96 h). Fresh tissue from the hippocampus was analyzed for NOX activity, and level of O-2(center dot-). In addition we evaluated the translocation of cytosolic NOX proteins (p67(Phox), p47(Phox), and p40(Phox)) to the membrane, along with total NO and the activation (phosphorylation) of endothelial nitric oxide synthase (p-eNOS). Results show that both enzymes and levels of O-2(center dot-) and NO have time-dependent injury effects in the hippocampus. Translocation of cytosolic NOX proteins into membrane, NOX activity, and O-2(center dot-) were also increased in a time-dependent fashion. Both NOX activity and Or were increased at 6 h. Levels of p-eNOS increased within 1 h, with significant elevation of NO at 12 h post-TBI. Levels of NO failed to show a significant association with p-eNOS, but did associate with O-2(center dot-). NOX up-regulation strongly associated with both the levels of O-2(center dot-) and the total NO. The initial 12 h post-TBI are very important as a possible window of opportunity to interrupt SIC. It may be important to selectively target the translocation of cytosolic subunits for the modulation of NOX function. (C) 2014 Elsevier Inc. All rights reserved.	[Ansari, Mubeen A.; Roberts, Kelly N.; Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Spinal Cord Brain Injury Res Ctr, Lexington, KY 40536 USA	Ansari, MA (corresponding author), Univ Kentucky, Ctr Aging, 101 Sanders Brown, Lexington, KY 40536 USA.	mubeen.ansari@uky.edu; knorbe2@email.uky.edu; sscheff@email.uky.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R21NS66117]; Kentucky Spinal Cord Head Injury Research Trust [12-16A]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS066117] Funding Source: NIH RePORTER	This research was supported by NIH 5R21NS66117 and the Kentucky Spinal Cord Head Injury Research Trust No. 12-16A.	Abramov AY, 2007, J NEUROSCI, V27, P1129, DOI 10.1523/JNEUROSCI.4468-06.2007; Abramov AY, 2005, J NEUROSCI, V25, P9176, DOI 10.1523/JNEUROSCI.1632-05.2005; Anantharam V, 2007, NEUROTOXICOLOGY, V28, P988, DOI 10.1016/j.neuro.2007.08.008; Ansari MA, 2004, BIOL TRACE ELEM RES, V101, P73, DOI 10.1385/BTER:101:1:73; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Ansari MA, 2013, J NEUROTRAUM, V30, P1542, DOI 10.1089/neu.2013.2910; Ansari MA, 2011, FREE RADICAL BIO MED, V51, P171, DOI 10.1016/j.freeradbiomed.2011.03.025; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P1510, DOI 10.1016/j.freeradbiomed.2008.08.025; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Brennan AM, 2009, NAT NEUROSCI, V12, P857, DOI 10.1038/nn.2334; Brown GC, 2007, BIOCHEM SOC T, V35, P1119, DOI 10.1042/BST0351119; Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9; Campese VM, 2007, BRAIN RES, V1134, P27, DOI 10.1016/j.brainres.2006.11.067; Chang CC, 2011, TOXICOL APPL PHARM, V257, P137, DOI 10.1016/j.taap.2011.08.027; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Chern CM, 2011, PLANTA MED, V77, P1669, DOI 10.1055/s-0030-1271019; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Choi SH, 2005, J NEUROSCI, V25, P4082, DOI 10.1523/JNEUROSCI.4306-04.2005; Cooney SJ, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-155; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Droge W, 2002, PHYSIOL REV, V82, P47; Duchen MR, 2004, DIABETES, V53, pS96, DOI 10.2337/diabetes.53.2007.S96; Egea J, 2012, NEUROPHARMACOLOGY, V62, P1082, DOI 10.1016/j.neuropharm.2011.10.022; Fabian RH, 2008, AM J PHYSIOL-HEART C, V295, pH1809, DOI 10.1152/ajpheart.00301.2007; FUKUI T, 1995, BBA-BIOENERGETICS, V1231, P215, DOI 10.1016/0005-2728(95)00098-4; Gahm C, 2000, NEUROSURGERY, V46, P169; Gao HM, 2012, TRENDS PHARMACOL SCI, V33, P295, DOI 10.1016/j.tips.2012.03.008; Gilmer LK, 2010, J NEUROTRAUM, V27, P939, DOI 10.1089/neu.2009.1181; Gilmer LK, 2010, MECH AGEING DEV, V131, P133, DOI 10.1016/j.mad.2009.12.011; Grzybicki D, 1998, ACTA NEUROPATHOL, V95, P98, DOI 10.1007/s004010050770; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hortobagyi T, 2003, NEUROSCIENCE, V121, P983, DOI 10.1016/S0306-4522(03)00482-2; Hsieh HL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-110; Hsieh HL, 2010, ANTIOXID REDOX SIGN, V13, P1829, DOI 10.1089/ars.2009.2957; Hur J, 2010, BIOCHEM BIOPH RES CO, V391, P1526, DOI 10.1016/j.bbrc.2009.12.114; Hwang JJ, 2002, J NEUROCHEM, V82, P894, DOI 10.1046/j.1471-4159.2002.01040.x; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Jin R, 2011, STROKE, V42, P2033, DOI 10.1161/STROKEAHA.110.601369; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626; Kandasamy R, 2013, INT J NEUROSCI, V123, P385, DOI 10.3109/00207454.2012.761983; Kim JH, 2013, BRAIN RES, V1499, P163, DOI 10.1016/j.brainres.2013.01.007; Kim S, 1998, EXP MOL MED, V30, P221, DOI 10.1038/emm.1998.32; Kim YH, 2002, EXP NEUROL, V177, P407, DOI 10.1006/exnr.2002.7990; Kuhlmann CRW, 2007, J NEUROCHEM, V102, P501, DOI 10.1111/j.1471-4159.2007.04506.x; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Lee ST, 2006, J NEUROCHEM, V96, P1728, DOI 10.1111/j.1471-4159.2006.03697.x; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu X. X., 2012, CHIN J INTEGR MED; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Mathis DM, 2011, JOVE-J VIS EXP, DOI 10.3791/2330; McCann SK, 2008, J NEUROSCI RES, V86, P2524, DOI 10.1002/jnr.21700; MOHAZZABH KM, 1994, AM J PHYSIOL, V266, pH2568; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Oddi S, 2012, J MOL MED, V90, P371, DOI 10.1007/s00109-011-0846-z; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Ozaki M, 2000, FASEB J, V14, P418; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Reeves EP, 1999, BIOCHEM J, V344, P859, DOI 10.1042/0264-6021:3440859; Rooker S, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/90123; Sastry KVH, 2002, ANAL BIOCHEM, V306, P79, DOI 10.1006/abio.2002.5676; Scheff SW, 2013, EXP NEUROL, V239, P183, DOI 10.1016/j.expneurol.2012.09.019; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Shin HK, 2004, CLIN EXP PHARMACOL P, V31, P1, DOI 10.1111/j.1440-1681.2004.03943.x; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SIESJO BK, 1994, ANN NY ACAD SCI, V747, P140; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Stoffel M, 2001, J NEUROTRAUM, V18, P425, DOI 10.1089/089771501750171010; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Tammariello SP, 2000, J NEUROSCI, V20; Tejada-Simon MV, 2005, MOL CELL NEUROSCI, V29, P97, DOI 10.1016/j.mcn.2005.01.007; VALLANCE P, 1989, LANCET, V2, P997; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wu DM, 2012, TOXICOL SCI, V128, P209, DOI 10.1093/toxsci/kfs124; Yoshitomi H, 2011, J STROKE CEREBROVASC, V20, P406, DOI 10.1016/j.jstrokecerebrovasdis.2010.01.014; Zhan XH, 2003, J HISTOCHEM CYTOCHEM, V51, P81, DOI 10.1177/002215540305100110; Zhang Q.-w, 2012, PLOS ONE, V7; Zhou H, 2012, FREE RADICAL BIO MED, V52, P303, DOI 10.1016/j.freeradbiomed.2011.10.488; Zhou YF, 2014, BRAIN RES BULL, V100, P14, DOI 10.1016/j.brainresbull.2013.10.013	94	27	27	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	DEC	2014	77						21	29		10.1016/j.freeradbiomed.2014.08.025			9	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	AW6QA	WOS:000346392500003	25224032	Green Accepted			2021-06-18	
J	Chou, SHY; Robertson, CS				Chou, Sherry H-Y.; Robertson, Claudia S.		Int Multidisciplinary Consensus	Monitoring Biomarkers of Cellular Injury and Death in Acute Brain Injury	NEUROCRITICAL CARE			English	Article						Biomarker; Traumatic brain injury; Subarachnoid hemorrhage; Stroke; Intracerebral hemorrhage; Cardiac arrest; Outcome	ANEURYSMAL SUBARACHNOID HEMORRHAGE; NEURON-SPECIFIC ENOLASE; ACUTE ISCHEMIC-STROKE; SPONTANEOUS INTRACEREBRAL HEMORRHAGE; C-REACTIVE-PROTEIN; BASAL GANGLIA HEMORRHAGE; CEREBRAL-ARTERY OCCLUSION; HOSPITAL CARDIAC-ARREST; SEVERE HEAD-INJURY; EARLY NEUROLOGIC DETERIORATION	Molecular biomarkers have revolutionalized diagnosis and treatment of many diseases, such as troponin use in myocardial infarction. Urgent need for high-fidelity biomarkers in neurocritical care has resulted in numerous studies reporting potential candidate biomarkers. We performed an electronic literature search and systematic review of English language articles on cellular/molecular biomarkers associated with outcome and with disease-specific secondary complications in adult patients with acute ischemic stroke (AIS), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), traumatic brain injury (TBI), and post-cardiac arrest hypoxic ischemic encephalopathic injuries (HIE). A total of 135 articles were included. Though a wide variety of potential biomarkers have been identified, only neuron-specific enolase has been validated in large cohorts and shows 100 % specificity for poor outcome prediction in HIE patients not treated with therapeutic hypothermia. There are many promising candidate blood and CSF biomarkers in SAH, AIS, ICH, and TBI, but none yet meets criteria for routine clinical use. Current studies vary significantly in patient selection, biosample collection/processing, and biomarker measurement protocols, thereby limiting the generalizability of overall results. Future large prospective studies with standardized treatment, biosample collection, and biomarker measurement and validation protocols are necessary to identify high-fidelity biomarkers in neurocritical care.	[Chou, Sherry H-Y.] Harvard Univ, Sch Med, Dept Neurol, Brigham & Womens Hosp, Boston, MA 02115 USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Chou, SHY (corresponding author), Harvard Univ, Sch Med, Dept Neurol, Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	schou1@partners.org; claudiar@bcm.tmc.edu	Oddo, Mauro/R-3370-2016; Diringer, Michael N/C-1165-2008; Chou, Sherry/G-5779-2015	Oddo, Mauro/0000-0002-6155-2525; Diringer, Michael N/0000-0003-2337-5537; Figaji, Anthony/0000-0002-3357-6490; Hutchinson, Peter/0000-0002-2796-1835; Brophy, Gretchen/0000-0002-4749-2693; Schmidt, J. Michael/0000-0001-8141-2944; Citerio, Giuseppe/0000-0002-5374-3161; Provencio, Jose Javier/0000-0003-1298-1806	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23-NS073806, U01-NS062091, R01-DC12584]; American Heart AssociationAmerican Heart Association [10CRP2610341]; NovartisNovartis; Neurocritical Care Society; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277, G0600986, G9439390] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013] Funding Source: researchfish	Sherry H-Y. Chou is funded by NIH Grant # K23-NS073806 and has received research support from the American Heart Association (Grant # 10CRP2610341). She receives stipend for service as a clinical endpoint committee member for a clinical trial funded by Novartis, as the site principal investigator for ATACH-II study funded by the NIH Grant # U01-NS062091, and as DSMB member for a study funded by NIH Grant # R01-DC12584. She has received speaker honorarium from the American Academy of Neurology and travel scholarship from the Neurocritical Care Society.	Abilleira S, 2003, J NEUROSURG, V99, P65, DOI 10.3171/jns.2003.99.1.0065; Agnihotri S, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-160; Alvarez-Sabin J, 2004, STROKE, V35, P1316, DOI 10.1161/01.STR.0000126827.69286.90; Antunes Alessandra Armstrong, 2010, Asian J Neurosurg, V5, P68; Barr TL, 2010, STROKE, V41, pE123, DOI 10.1161/STROKEAHA.109.570515; Beeftink MMA, 2011, NEUROCRIT CARE, V15, P405, DOI 10.1007/s12028-011-9556-1; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Bottiger BW, 2001, CIRCULATION, V103, P2694; Brea D, 2009, CLIN CHEM LAB MED, V47, P1513, DOI 10.1515/CCLM.2009.337; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Cai JY, 2013, CLIN CHIM ACTA, V424, P182, DOI 10.1016/j.cca.2013.06.019; Castellanos M, 2004, STROKE, V35, P1671, DOI 10.1161/01.STR.0000131656.47979.39; Castellanos M, 2003, STROKE, V34, P40, DOI 10.1161/01.STR.0000046764.57344.31; Castellanos M, 2007, STROKE, V38, P1855, DOI 10.1161/STROKEAHA.106.481556; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Chabok SY, 2012, J TRAUMA ACUTE CARE, V72, P1654, DOI 10.1097/TA.0b013e318246887e; Chen YC, 2011, J NEUROSURG, V115, P1184, DOI 10.3171/2011.7.JNS11718; Chiquete E, 2013, CEREBROVASC DIS, V35, P168, DOI 10.1159/000346603; Chiu CC, 2012, J CLIN NEUROSCI, V19, P810, DOI 10.1016/j.jocn.2011.08.032; Chou SHY, 2011, TRANSL STROKE RES, V2, P600, DOI 10.1007/s12975-011-0117-x; Chou SHY, 2012, J INVEST MED, V60, P1054, DOI 10.2310/JIM.0b013e3182686932; Chou SHY, 2011, STROKE, V42, P3624, DOI 10.1161/STROKEAHA.111.631135; Coplin WM, 1999, ARCH NEUROL-CHICAGO, V56, P1348, DOI 10.1001/archneur.56.11.1348; Cronberg T, 2011, NEUROLOGY, V77, P623, DOI 10.1212/WNL.0b013e31822a276d; Cronberg T, 2013, RESUSCITATION, V84, P867, DOI 10.1016/j.resuscitation.2013.01.019; Cuzner ML, 1999, J NEUROIMMUNOL, V94, P1, DOI 10.1016/S0165-5728(98)00241-0; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Daubin C, 2011, BMC CARDIOVASC DISOR, V11, DOI 10.1186/1471-2261-11-48; Delgado P, 2006, STROKE, V37, P2837, DOI 10.1161/01.STR.0000245085.58807.ad; den Hertog HM, 2009, J NEUROL, V256, P2003, DOI 10.1007/s00415-009-5228-x; Dhar R, 2008, NEUROCRIT CARE, V8, P253, DOI 10.1007/s12028-007-9020-4; Di Napoli M, 2011, STROKE, V42, P1230, DOI 10.1161/STROKEAHA.110.604983; Diaz-Arrastia R, 2013, J NEUROTRAUM, V7, P1; Diedler J, 2009, CEREBROVASC DIS, V27, P272, DOI 10.1159/000199465; Dietmann A, 2012, CEREBROVASC DIS, V33, P16, DOI 10.1159/000331925; Dumont AS, 2003, NEUROSURGERY, V53, P123, DOI 10.1227/01.NEU.0000068863.37133.9E; Einav S, 2012, J AM COLL CARDIOL, V60, P304, DOI 10.1016/j.jacc.2012.04.020; Elkind MSV, 2006, ARCH INTERN MED, V166, P2073, DOI 10.1001/archinte.166.19.2073; Fang HY, 2005, SURG NEUROL, V64, P511, DOI 10.1016/j.surneu.2005.03.018; Fang HY, 2005, SURG NEUROL, V64, P7; Fassbender K, 2001, J NEUROL NEUROSUR PS, V70, P534, DOI 10.1136/jnnp.70.4.534; Fernandez-Patron C, 1999, CIRC RES, V85, P906; Fernandez-Patron C, 2001, FASEB J, V15, P2230, DOI 10.1096/fj.01-0178com; Foerch C, 2005, ARCH NEUROL-CHICAGO, V62, P1130, DOI 10.1001/archneur.62.7.1130; Foerch C, 2004, STROKE, V35, P2160, DOI 10.1161/01.STR.0000138730.03264.ac; Foerch C, 2003, J NEUROL NEUROSUR PS, V74, P322, DOI 10.1136/jnnp.74.3.322; Frijns CJM, 2006, J NEUROL NEUROSUR PS, V77, P77, DOI 10.1136/jnnp.2005.064956; FUJIMORI A, 1990, LANCET, V336, P633, DOI 10.1016/0140-6736(90)93432-O; GAETANI P, 1994, J NEUROL NEUROSUR PS, V57, P66, DOI 10.1136/jnnp.57.1.66; Gill R, 2004, J CEREBR BLOOD F MET, V24, P1214, DOI 10.1097/01.WCB.0000136517.61642.99; Graetz D, 2010, NEUROL RES, V32, P728, DOI 10.1179/016164109X12464612122650; Graham CA, 2012, CLIN BIOCHEM, V45, P352, DOI 10.1016/j.clinbiochem.2011.12.006; Gruber A, 2000, J NEUROSURG ANESTH, V12, P297, DOI 10.1097/00008506-200010000-00001; Gu SJ, 2013, CLIN CHIM ACTA, V425, P85, DOI 10.1016/j.cca.2013.07.025; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Guo ZD, 2011, ACTA NEUROCHIR SUPPL, V110, P63, DOI 10.1007/978-3-7091-0353-1_11; Gurkanlar D, 2009, TURK NEUROSURG, V19, P211; Haapaniemi E, 2000, STROKE, V31, P720, DOI 10.1161/01.STR.31.3.720; Hachimi-Idrissi S, 2002, RESUSCITATION, V53, P251, DOI 10.1016/S0300-9572(02)00027-8; HADDAD JG, 1990, P NATL ACAD SCI USA, V87, P1381, DOI 10.1073/pnas.87.4.1381; Hanafy KA, 2010, J NEUROL SCI, V291, P69, DOI 10.1016/j.jns.2009.12.023; Hays A, 2006, NEUROLOGY, V66, P1330, DOI 10.1212/01.wnl.0000210523.22944.9b; Heo JH, 2003, STROKE, V34, pE48, DOI 10.1161/01.STR.0000073788.81170.1C; Hernandez-Guillamon M, 2012, CEREBROVASC DIS, V33, P55, DOI 10.1159/000333370; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Hu HT, 2012, CLIN BIOCHEM, V45, P1320, DOI 10.1016/j.clinbiochem.2012.06.003; Hu YY, 2010, SHOCK, V33, P134, DOI 10.1097/SHK.0b013e3181ad5c88; Huang M, 2009, SURG NEUROL, V72, P481, DOI 10.1016/j.surneu.2008.12.016; Huang Q, 2013, PEPTIDES, V39, P55, DOI 10.1016/j.peptides.2012.11.006; Huang Y, 2012, CNS NEUROSCI THER, V18, P261, DOI 10.1111/j.1755-5949.2012.00296.x; Idicula TT, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-18; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; James ML, 2009, BIOMARKERS, V14, P388, DOI 10.1080/13547500903015784; Jin Y, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2012.01.002; Juvela S, 2009, J NEUROSURG, V110, P989, DOI 10.3171/2008.11.JNS081266; KARKELA J, 1993, J NEUROL SCI, V116, P100, DOI 10.1016/0022-510X(93)90095-G; Kasai A, 2012, CIRC J, V76, P891, DOI 10.1253/circj.CJ-11-0449; Kay A, 2003, STROKE, V34, P637, DOI 10.1161/01.STR.0000057579.25430.16; Kazmierski R, 2012, NEUROLOGY, V79, P1677, DOI 10.1212/WNL.0b013e31826e9a83; Kim J, 2012, ATHEROSCLEROSIS, V222, P464, DOI 10.1016/j.atherosclerosis.2012.02.042; KOBAYASHI H, 1991, NEUROSURGERY, V28, P673, DOI 10.1227/00006123-199105000-00006; Kobayashi H, 1991, NEUROSURGERY, V28, P8; Lampl Y, 1997, STROKE, V28, P1951, DOI 10.1161/01.STR.28.10.1951; Lanterna LA, 2007, NEUROLOGY, V69, P766, DOI 10.1212/01.wnl.0000267640.03300.6b; Lanterna LA, 2005, NEUROLOGY, V64, P1238, DOI 10.1212/01.WNL.0000156523.77347.B4; Le Huong T, 2011, Exp Transl Stroke Med, V3, P13, DOI 10.1186/2040-7378-3-13; Leira R, 2004, NEUROLOGY, V63, P461, DOI 10.1212/01.WNL.0000133204.81153.AC; Leung CHS, 2002, STROKE, V33, P548, DOI 10.1161/hs0202.102326; Li N, 2013, STROKE, V44, P658, DOI 10.1161/STROKEAHA.112.673590; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; LIND SE, 1986, J CLIN INVEST, V78, P736, DOI 10.1172/JCI112634; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Macdonald RL, 2011, LANCET NEUROL, V10, P618, DOI 10.1016/S1474-4422(11)70108-9; Mack WJ, 2002, J NEUROSURG, V96, P71, DOI 10.3171/jns.2002.96.1.0071; Maiuri F, 1987, J Neurosurg Sci, V31, P45; Ramirez-Moreno JM, 2009, STROKE, V40, P1917, DOI 10.1161/STROKEAHA.108.536698; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; MASAOKA H, 1989, LANCET, V2, P1402; Mascia L, 2001, STROKE, V32, P1185, DOI 10.1161/01.STR.32.5.1185; Mathiesen T, 1997, J NEUROSURG, V87, P215, DOI 10.3171/jns.1997.87.2.0215; Matsumoto M, 2013, CEREBROVASC DIS, V35, P64, DOI 10.1159/000345336; McGirt MJ, 2004, NEUROSURGERY, V55, P473, DOI 10.1227/00006123-200408000-00100; McGirt MJ, 2004, NEUROSURGERY, V54, P1369, DOI 10.1227/01.NEU.0000125016.37332.50; McGirt MJ, 2003, J NEUROSURG, V98, P1222, DOI 10.3171/jns.2003.98.6.1222; McGirt MJ, 2002, NEUROSURGERY, V51, P1128, DOI 10.1097/00006123-200211000-00005; McGirt MJ, 2002, NEUROSURGERY, V51, P34; Mees SMD, 2011, NEUROCRIT CARE, V14, P176, DOI 10.1007/s12028-011-9504-0; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Meynaar IA, 2003, INTENS CARE MED, V29, P189, DOI 10.1007/s00134-002-1573-2; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Mlynash M, 2013, NEUROCRIT CARE, V19, P161, DOI 10.1007/s12028-013-9867-5; Moldes O, 2008, STROKE, V39, P2006, DOI 10.1161/STROKEAHA.107.495044; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Montaner J, 2006, STROKE, V37, P1205, DOI 10.1161/01.STR.0000217744.89208.4e; Montaner J, 2003, CIRCULATION, V107, P598, DOI 10.1161/01.CIR.0000046451.38849.90; Montaner J, 2001, STROKE, V32, P2762, DOI 10.1161/hs1201.99512; Mortberg E, 2011, RESUSCITATION, V82, P26, DOI 10.1016/j.resuscitation.2010.10.011; Moussouttas M, 2012, CEREBROVASC DIS, V33, P173, DOI 10.1159/000334660; Nagao K, 2004, CIRC J, V68, P477, DOI 10.1253/circj.68.477; Naidech AM, 2005, CIRCULATION, V112, P2851, DOI 10.1161/CIRCULATIONAHA.105.533620; Nardi K, 2012, J STROKE CEREBROVASC, V21, P819, DOI 10.1016/j.jstrokecerebrovasdis.2011.04.015; Niikawa S, 1997, NEUROL MED CHIR, V37, P4; Niikawa Shuji, 1997, Neurologia Medico-Chirurgica, V37, P881, DOI 10.2176/nmc.37.881; Ning M, 2006, NEUROLOGY, V66, P1550, DOI 10.1212/01.wnl.0000216133.98416.b4; Niskakangas T, 2001, STROKE, V32, P1181, DOI 10.1161/01.STR.32.5.1181; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Oda Y, 2012, RESUSCITATION, V83, P1006, DOI 10.1016/j.resuscitation.2012.01.030; Oertel M, 2006, J CLIN NEUROSCI, V13, P834, DOI 10.1016/j.jocn.2005.11.030; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Olivecrona M, 2009, J NEUROL NEUROSUR PS, V80, P1241, DOI 10.1136/jnnp.2008.158196; Pan JW, 2013, CRIT CARE, V17, DOI 10.1186/cc12828; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Park SM, 2006, PROTEOMICS, V6, P1192, DOI 10.1002/pmic.200500402; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Pfeifer R, 2005, RESUSCITATION, V65, P49, DOI 10.1016/j.resuscitation.2004.10.011; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Provencio JJ, 2005, SEMIN NEUROL, V25, P435, DOI 10.1055/s-2005-923537; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1998, ACTA NEUROCHIR WIEN, V140, P91; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Ramappa P, 2008, NEUROCRIT CARE, V8, P398, DOI 10.1007/s12028-007-9038-7; Rodriguez-Luna D, 2011, STROKE, V42, P2447, DOI 10.1161/STROKEAHA.110.609461; Rodriguez-Rodriguez A, 2012, CLIN CHIM ACTA, V414, P228, DOI 10.1016/j.cca.2012.09.025; ROINE RO, 1989, ARCH NEUROL-CHICAGO, V46, P753, DOI 10.1001/archneur.1989.00520430047015; Rosen H, 2004, J NEUROL SCI, V221, P19, DOI 10.1016/j.jns.2004.03.003; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rossetti AO, 2012, NEUROLOGY, V78, P796, DOI 10.1212/WNL.0b013e318249f6bb; Rossetti AO, 2010, ANN NEUROL, V67, P301, DOI 10.1002/ana.21984; Rovlias A, 2001, SURG NEUROL, V55, P190, DOI 10.1016/S0090-3019(01)00414-1; Rundgren M, 2009, RESUSCITATION, V80, P784, DOI 10.1016/j.resuscitation.2009.03.025; Sadamasa N, 2011, NEUROL MED-CHIR, V51, P745; Soares FMS, 2012, NEUROIMMUNOMODULAT, V19, P377, DOI 10.1159/000342141; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; SEIFERT V, 1995, J NEUROSURG, V82, P55, DOI 10.3171/jns.1995.82.1.0055; Serena J, 2005, STROKE, V36, P1921, DOI 10.1161/01.STR.0000177870.14967.94; Shantikumar S, 2009, STROKE, V40, P977, DOI 10.1161/STROKEAHA.108.525105; Sherman AL, 2000, NEUROLOGY, V54, P889, DOI 10.1212/WNL.54.4.889; Shinozaki K, 2011, RESUSCITATION, V82, P404, DOI 10.1016/j.resuscitation.2010.10.026; Shinozaki K, 2009, RESUSCITATION, V80, P870, DOI 10.1016/j.resuscitation.2009.05.005; Silva Y, 2005, STROKE, V36, P86, DOI 10.1161/01.STR.0000149615.51204.0b; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Sodeck GH, 2007, RESUSCITATION, V74, P439, DOI 10.1016/j.resuscitation.2007.02.001; SPALLONE A, 1987, SURG NEUROL, V27, P253, DOI 10.1016/0090-3019(87)90038-3; Stammet P, 2013, J AM COLL CARDIOL, V62, P851, DOI 10.1016/j.jacc.2013.04.039; Stein DM, 2012, SHOCK, V37, P563, DOI 10.1097/SHK.0b013e3182534f93; Stranjalis G, 2007, ACTA NEUROCHIR, V149, P231, DOI 10.1007/s00701-006-1106-9; Stranjalis G, 2007, ACTA NEUROCHIR WIEN, V149, P7; Sumii T, 2002, STROKE, V33, P831, DOI 10.1161/hs0302.104542; SUZUKI R, 1992, J NEUROSURG, V77, P96, DOI 10.3171/jns.1992.77.1.0096; Tasci A, 2003, NEUROL RES, V25, P871, DOI 10.1179/016164103771953998; Taub PR, 2011, NEUROCRIT CARE, V15, P13, DOI 10.1007/s12028-011-9535-6; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; THOMAS D G T, 1978, Lancet, V1, P113; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Tirschwell DL, 1997, NEUROLOGY, V48, P352, DOI 10.1212/WNL.48.2.352; Topakian R, 2008, J NEUROL, V255, P1190, DOI 10.1007/s00415-008-0866-y; Topolovec-Vranic J, 2011, J TRAUMA, V71, pS478, DOI 10.1097/TA.0b013e318232fa70; Vergouwen MDI, 2009, J CEREBR BLOOD F MET, V29, P1734, DOI 10.1038/jcbfm.2009.88; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wang HC, 2012, EUR J NEUROL, V19, P1532, DOI 10.1111/j.1468-1331.2012.03761.x; Wang HC, 2011, CRIT CARE, V15, DOI 10.1186/cc10568; WEIR B, 1989, NEUROSURGERY, V25, P161, DOI 10.1227/00006123-198908000-00002; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x; Wijman CAC, 2012, NEUROCRIT CARE, V16, P42, DOI 10.1007/s12028-011-9609-5; Winbeck K, 2002, STROKE, V33, P2459, DOI 10.1161/01.STR.0000029828.51413.82; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Xu JF, 2012, J TRAUMA ACUTE CARE, V72, P491, DOI 10.1097/TA.0b013e318226ec39; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Yarlagadda S, 2006, NEUROCRIT CARE, V5, P102, DOI 10.1385/NCC:5:2:102; Yin CG, 2013, PEPTIDES, V42, P101, DOI 10.1016/j.peptides.2013.01.005; Yoshimoto Y, 2001, STROKE, V32, P1989, DOI 10.1161/hs0901.095646; Zandbergen EGJ, 2006, NEUROLOGY, V66, P62, DOI 10.1212/01.wnl.0000191308.22233.88; Zhang X, 2013, PEPTIDES, V43, P133, DOI 10.1016/j.peptides.2013.03.010; Zhang X, 2012, PEPTIDES, V33, P336, DOI 10.1016/j.peptides.2012.01.011; Zhao DQ, 2013, CLIN CHIM ACTA, V415, P202, DOI 10.1016/j.cca.2012.10.048; Zheng HW, 2012, CNS NEUROSCI THER, V18, P1003, DOI 10.1111/cns.12019; ZIV I, 1992, STROKE, V23, P1014, DOI 10.1161/01.STR.23.7.1014	208	27	27	1	16	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2014	21			2			187	214		10.1007/s12028-014-0039-z			28	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	CD7AM	WOS:000351242600014	25208676	Green Accepted			2021-06-18	
J	Shogren, KA; Kennedy, W; Dowsett, C; Little, TD				Shogren, Karrie A.; Kennedy, William; Dowsett, Chantelle; Little, Todd D.			Autonomy, Psychological Empowerment, and Self-Realization: Exploring Data on Self-Determination From NLTS2	EXCEPTIONAL CHILDREN			English	Article							QUALITY-OF-LIFE; STUDENT PARTICIPATION; HIGH-SCHOOL; DETERMINATION INTERVENTIONS; LEARNING-DISABILITIES; ADULT OUTCOMES; DIRECTED-IEP; TRANSITION; PROMOTE; PREDICTORS	The authors used data from the National Longitudinal Transition Study-2 (NLTS2; SRI International, 2000) to examine the aspects of self-determination assessed in NLTS2 and measurement equivalence and latent differences across the 12 disability categories recognized in the Individuals With Disabilities Education Act (IDEA; 2004). NLTS2 included a direct assessment with items representing 3 of the 4 essential characteristics of self-determination-autonomy, self-realization, and psychological empowerment. The authors established measurement equivalence, but significant latent differences occurred across specific disability groups. Students with high-incidence disabilities (learning disabilities, emotional disturbances, speech or language impairments, and other health impairments) showed similar latent means and variances, as did students with sensory disabilities (visual and hearing impairments) and cognitive disabilities (autism, multiple disabilities, and deaf-blindness). Students with intellectual disability, traumatic brain injury, and orthopedic impairments could not be collapsed with any other group. Across the 6 collapsed disability groups, significant differences existed in the latent variances and limited mean level differences.	[Shogren, Karrie A.] Univ Illinois, Urbana, IL USA; [Kennedy, William; Dowsett, Chantelle; Little, Todd D.] Univ Kansas, Ctr Res Methods & Data Anal, Lawrence, KS 66045 USA	Shogren, KA (corresponding author), Univ Illinois, Dept Special Educ, 1310 S 6th St, Champaign, IL 61820 USA.	kshogren@illinois.edu	Stroilova, Nataly/E-6440-2014	Shogren, Karrie/0000-0001-7925-1299			Agran M, 2007, J VISUAL IMPAIR BLIN, V101, P453, DOI 10.1177/0145482X0710100802; Algozzine B, 2001, REV EDUC RES, V71, P219, DOI 10.3102/00346543071002219; Arndt SA, 2006, REM SPEC EDUC, V27, P194, DOI 10.1177/07419325060270040101; Bandalos DL, 2002, STRUCT EQU MODELING, V9, P78, DOI 10.1207/S15328007SEM0901_5; Brown T.A, 2006, CONFIRMATORY FACTOR, V3rd; Bruininks R.H., 1996, SCALES INDEPENDENT B; Calkins C, 2011, EXCEPTIONALITY, V19, P2, DOI 10.1080/09362835.2011.537219; Carter EW, 2010, J EMOT BEHAV DISORD, V18, P67, DOI 10.1177/1063426609332605; CHADSEYRUSCH J, 1991, REM SPEC EDUC, V12, P23; Cheung GW, 2002, STRUCT EQU MODELING, V9, P233, DOI 10.1207/S15328007SEM0902_5; Cobb B, 2009, CAREER DEV TRANSIT E, V32, P108, DOI 10.1177/0885728809336654; HASAZI SB, 1985, EXCEPT CHILDREN, V51, P455, DOI 10.1177/001440298505100601; Hughes C, 1997, EDUC TRAIN MENT RET, V32, P201; Javitz H., 2005, ANAL POTENTIAL BIAS; Konrad M, 2007, LEARN DISABILITY Q, V30, P89, DOI 10.2307/30035545; Lane KL, 2006, J EMOT BEHAV DISORD, V14, P108, DOI 10.1177/10634266060140020101; Lee Y, 2012, REM SPEC EDUC, V33, P150, DOI 10.1177/0741932510392053; Lee Y, 2011, J SPEC EDUC, V45, P104, DOI 10.1177/0022466909358916; Little T. D., PSYCHOL MET IN PRESS; Little T. D., 2013, LONGITUDINAL STRUCTU; Little TD, 1997, MULTIVAR BEHAV RES, V32, P53, DOI 10.1207/s15327906mbr3201_3; Little TD, 2002, STRUCT EQU MODELING, V9, P151, DOI 10.1207/S15328007SEM0902_1; Martin JE, 2006, EXCEPT CHILDREN, V72, P299, DOI 10.1177/001440290607200303; McDougall J, 2010, REM SPEC EDUC, V31, P252, DOI 10.1177/0741932509355989; MITHAUG DE, 1985, EXCEPT CHILDREN, V51, P397; Muthen L.K., 1998, MPLUS USERS GUIDE, V8th; National Research Council, 2001, ED CHILDR AUT; Nota L, 2007, J INTELL DISABIL RES, V51, P850, DOI 10.1111/j.1365-2788.2006.00939.x; Orelove F., 2004, ED CHILDREN MULTIPLE; Palmer SB, 2004, EXCEPT CHILDREN, V70, P427, DOI 10.1177/001440290407000403; Sabornie EJ, 2006, REM SPEC EDUC, V27, P95, DOI 10.1177/07419325060270020701; Sabornie EJ, 2005, EXCEPT CHILDREN, V72, P47, DOI 10.1177/001440290507200103; Shogren KA, 2007, EXCEPT CHILDREN, V73, P488, DOI 10.1177/001440290707300406; Shogren KA, 2012, REM SPEC EDUC, V33, P320, DOI 10.1177/0741932511410072; Shogren KA, 2010, RES PRACT PERS SEV D, V35, P80, DOI 10.2511/rpsd.35.3-4.80; Shogren KA, 2008, ASSES EFF INTERV, V33, P94, DOI 10.1177/1534508407311395; SITLINGTON PL, 1990, LEARN DISABILITY Q, V13, P97, DOI 10.2307/1510654; SRI International, 2000, NAT LONG TRANS STUD; Stancliffe RJ, 2001, MENT RETARD DEV D R, V7, P91, DOI 10.1002/mrdd.1013; Stancliffe RJ, 1997, MENT RETARD, V35, P1, DOI 10.1352/0047-6765(1997)035<0001:CLSSPA>2.0.CO;2; Test DW., 2004, J BEHAV EDUC, V13, P135; Thoma CA, 2002, REM SPEC EDUC, V23, P82, DOI 10.1177/074193250202300204; Van Reusen A.K., 1994, SELF ADVOCACY STRATE; VANREUSEN AK, 1994, EXCEPT CHILDREN, V60, P466, DOI 10.1177/001440299406000510; Wagner M., 2006, ACAD ACHIEVEMENT FUN; Walker HM, 2011, EXCEPTIONALITY, V19, P6, DOI 10.1080/09362835.2011.537220; Wehman P., 2006, LIFE CLASSROOM TRANS; Wehmeyer M, 1997, EXCEPT CHILDREN, V63, P245, DOI 10.1177/001440299706300207; Wehmeyer M., 1995, ARCS SELF DETERMINAT; Wehmeyer M. L., 2011, ADOLESCENT SELF DETE; Wehmeyer M.L., 2004, WHOSE FUTURE IS IT A; Wehmeyer M.L., 2008, ED CHILDREN YOUTH AU, V2nd ed., P433; Wehmeyer ML, 2011, EXCEPTIONALITY, V19, P19, DOI 10.1080/09362835.2011.537225; Wehmeyer ML, 2010, EDUC TRAIN AUTISM DE, V45, P475; Wehmeyer ML, 1996, EDUC TRAIN MENT RET, V31, P282; Wehmeyer ML, 2003, J APPL RES INTELLECT, V16, P255, DOI 10.1046/j.1468-3148.2003.00161.x; Wehmeyer ML, 2003, EDUC TRAIN DEV DISAB, V38, P131; Williams-Diehm K., 2008, J DEV DISABILITIES, V14, P27; Wood WM, 2005, RES PRACT PERS SEV D, V30, P121, DOI 10.2511/rpsd.30.3.121; Ysseldyke J., 2006, TEACHING STUDENTS SE	60	27	28	2	205	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0014-4029	2163-5560		EXCEPT CHILDREN	Except. Child.	WIN	2014	80	2					221	235		10.1177/001440291408000206			15	Education, Special; Rehabilitation	Education & Educational Research; Rehabilitation	287GY	WOS:000329531200007					2021-06-18	
J	Davis, JJ				Davis, Jeremy J.			Further Consideration of Advanced Clinical Solutions Word Choice: Comparison to the Recognition Memory Test-Words and Classification Accuracy in a Clinical Sample	CLINICAL NEUROPSYCHOLOGIST			English	Article						Word Choice; Performance validity; Recognition Memory Test.	TRAUMATIC BRAIN-INJURY; MONOSYLLABIC WORDS; TEST-PERFORMANCE; RESPONSE BIAS; HEAD-INJURY; NEUROPSYCHOLOGY; CONCRETENESS; REPLICATION; IMPAIRMENT; DEFICITS	Word Choice (WC), a test in the Advanced Clinical Solutions package for Wechsler measures, was examined in two studies. The first study compared WC to the Recognition Memory Test-Words (RMT-W) in a clinical sample (N = 46). WC scores were significantly higher than RMT-W scores overall and in sample subsets grouped by separate validity indicators. In item-level analyses, WC items demonstrated lower frequency, greater imageability, and higher concreteness than RMT-W items. The second study explored WC classification accuracy in a different clinical sample grouped by separate validity indicators into Pass (n = 54), Fail-1 (n = 17), and Fail-2 (n = 8) groups. WC scores were significantly higher in the Pass group (M = 49.1, SD = 1.9) than in the Fail-1 (M = 46.0, SD = 5.3) and Fail-2 (M = 44.1, SD = 4.8) groups. WC demonstrated area under the curve of .81 in classifying Pass and Fail-2 participants. Using the test manual cutoff associated with a 10% false positive rate, sensitivity was 38% and specificity was 96% in Pass and Fail-2 groups with 24% of Fail-1 participants scoring below cutoff. WC may be optimally used in combination with other measures given observed sensitivity.	Univ Utah, Sch Med, Div Phys Med & Rehabil, Salt Lake City, UT 84132 USA	Davis, JJ (corresponding author), Univ Utah, Sch Med, Div Phys Med & Rehabil, 30 North 1900 East,1R55, Salt Lake City, UT 84132 USA.	jeremy.davis@hsc.utah.edu					Aggleton JP, 2011, LEARN MEMORY, V18, P384, DOI 10.1101/lm.1884611; Bashem JR, 2014, CLIN NEUROPSYCHOL, V28, P851, DOI 10.1080/13854046.2014.927927; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; CONDER R, 1992, COMPUTERIZED ASSESSM; Cortese MJ, 2010, MEMORY, V18, P595, DOI 10.1080/09658211.2010.493892; Cortese MJ, 2004, BEHAV RES METH INS C, V36, P384, DOI 10.3758/BF03195585; DAVIES M., 1990, CORPUS CONT AM ENGLI; Dean AC, 2008, CLIN NEUROPSYCHOL, V22, P705, DOI 10.1080/13854040701440493; Delis DC, 2000, CALIFORNIA VERBAL LE; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; GILHOOLY KJ, 1980, BEHAV RES METH INSTR, V12, P395, DOI 10.3758/BF03201693; GLANZER M, 1993, PSYCHOL REV, V100, P546, DOI 10.1037/0033-295X.100.3.546; GLANZER M, 1990, J EXP PSYCHOL LEARN, V16, P5, DOI 10.1037/0278-7393.16.1.5; Green P., 2008, MANUAL NONVERBAL MED; Green P., 2003, MANUAL WORD MEMORY T; Green P., 2004, MANUAL MED SYMPTOM V; Green P, 2011, APPL NEUROPSYCHOL, V18, P86, DOI 10.1080/09084282.2010.523389; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Haber AH, 2006, CLIN NEUROPSYCHOL, V20, P524, DOI 10.1080/13854040590967595; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hemmer P, 2013, J EXP PSYCHOL LEARN, V39, P1947, DOI 10.1037/a0033744; Holdnack J., 2009, ADV CLIN SOLUTIONS W; Hosmer D. W., 2000, APPL LOGISTIC REGRES, DOI [10. 1002/0471722146, DOI 10.1002/0471722146, 10.1002/0471722146]; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; Iverson GL, 1998, BRAIN INJURY, V12, P275, DOI 10.1080/026990598122575; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Kaufmann P, 2012, FORENSIC NEUROPSYCHO, P70; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kucera H, 1967, COMPUTATIONAL ANAL P; Larrabee G. J., 2007, ASSESSMENT MALINGERE, P3; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Malmberg KJ, 2008, COGNITIVE PSYCHOL, V57, P335, DOI 10.1016/j.cogpsych.2008.02.004; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; MILLIS SR, 1994, PERCEPT MOTOR SKILL, V79, P384, DOI 10.2466/pms.1994.79.1.384; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; PAIVIO A, 1968, J EXP PSYCHOL, V76, P1, DOI 10.1037/h0025327; Pearson, 2009, WORD CHOIC STIM BOOK; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Ross SR, 2006, J CLIN EXP NEUROPSYC, V28, P111, DOI 10.1080/13803390590929270; Salazar X. F., 2007, ASSESSMENT FEIGNED C, P405; Schock J, 2012, BEHAV RES METHODS, V44, P374, DOI 10.3758/s13428-011-0162-0; Schutte C, 2012, MILD TRAUMATIC BRAIN, P159; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; Strong EK, 1913, PSYCHOL REV, V20, P339, DOI 10.1037/h0072087; Strong EK, 1912, PSYCHOL REV, V19, P447, DOI 10.1037/h0069812; Suhr J. A., 2007, ASSESSMENT MALINGERE; Sweet JJ, 2002, CLIN NEUROPSYCHOL, V16, P481, DOI 10.1076/clin.16.4.481.13914; Tabachnick BG, 2007, USING MULTIVARIATE S; Thorndike EL., 1944, TEACHERS WORD BOOK 3; TOGLIA MP, 1978, HDB SEMANTIC WORD NO; Tombaugh TN, 1996, TEST MEMORY MALINGER; Warrington EK., 1984, RECOGNITION MEMORY T; WILSON M, 1988, BEHAV RES METH INSTR, V20, P6, DOI 10.3758/BF03202594	56	27	27	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	NOV 17	2014	28	8					1278	1294		10.1080/13854046.2014.975844			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	AY0KY	WOS:000347286600006	25372961				2021-06-18	
J	Murray, KN; Girard, S; Holmes, WM; Parkes, LM; Williams, SR; Parry-Jones, AR; Allan, SM				Murray, Katie N.; Girard, Sylvie; Holmes, William M.; Parkes, Laura M.; Williams, Stephen R.; Parry-Jones, Adrian R.; Allan, Stuart M.			Systemic Inflammation Impairs Tissue Reperfusion Through Endothelin-Dependent Mechanisms in Cerebral Ischemia	STROKE			English	Article						brain ischemia; endothelin-1; inflammation; interleukin-1; magnetic resonance imaging; reperfusion	TRAUMATIC BRAIN-INJURY; EXPERIMENTAL STROKE; MAGNETIC-RESONANCE; DIABETIC-RATS; BLOOD-FLOW; THROMBOLYSIS; RECEPTOR; MICE; HYPOPERFUSION; INTERLEUKIN-1	Background and Purpose Systemic inflammation contributes to diverse acute and chronic brain pathologies, and extensive evidence implicates inflammation in stroke susceptibility and poor outcome. Here we investigate whether systemic inflammation alters cerebral blood flow during reperfusion after experimental cerebral ischemia. Methods Serial diffusion and perfusion-weighted MRI was performed after reperfusion in Wistar rats given systemic (intraperitoneal) interleukin-1 or vehicle before 60-minute transient middle cerebral artery occlusion. The expression and location of endothelin-1 was assessed by polymerase chain reaction, ELISA, and immunofluorescence. Results Systemic interleukin-1 caused a severe reduction in cerebral blood flow and increase in infarct volume compared with vehicle. Restriction in cerebral blood flow was observed alongside activation of the cerebral vasculature and upregulation of the vasoconstricting peptide endothelin-1 in the ischemic penumbra. A microthrombotic profile was also observed in the vasculature of rats receiving interleukin-1. Blockade of endothelin-1 receptors reversed this hypoperfusion, reduced tissue damage, and improved functional outcome. Conclusions These data suggest patients with a raised inflammatory profile may have persistent deficits in perfusion after reopening of an occluded vessel. Future therapeutic strategies to interrupt the mechanism identified could lead to enhanced recovery of penumbra in patients with a heightened inflammatory burden and a better outcome after stroke.	[Murray, Katie N.; Allan, Stuart M.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England; [Parkes, Laura M.; Williams, Stephen R.] Univ Manchester, Ctr Imaging Sci, Manchester, Lancs, England; [Girard, Sylvie] Univ Montreal, St Justine Hosp Res Ctr, Montreal, PQ H3C 3J7, Canada; [Holmes, William M.] Univ Glasgow, Glasgow Expt MRI Ctr, Glasgow, Lanark, Scotland; [Parry-Jones, Adrian R.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Salford M6 8DH, Lancs, England	Parry-Jones, AR (corresponding author), Univ Manchester, Manchester Acad Hlth Sci Ctr, Salford Royal NHS Fdn Trust, Stott Lane, Salford M6 8DH, Lancs, England.	adrian.parry-jones@manchester.ac.uk	holmes, william/AAP-3417-2021; Williams, Steve R/C-8945-2011; Allan, Stuart/AAL-1245-2020; Williams, Steve C/D-6979-2011	Williams, Steve R/0000-0001-5940-1675; Williams, Steve C/0000-0003-4299-1941; Parkes, Laura/0000-0001-6488-507X; Allan, Stuart/0000-0001-9646-4456	Neuroscience Research Institute; Biomedical Imaging Institute; Medical Research Council, United KingdomUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/F011350]; Natalie Kate Moss Trust; Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/F011350/1] Funding Source: researchfish; British Heart FoundationBritish Heart Foundation [PG/13/8/29989] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1259754, G0802001] Funding Source: researchfish	This work was supported by the Neuroscience Research Institute, Biomedical Imaging Institute, and Medical Research Council, United Kingdom. This work was made possible by an equipment grant from the Biotechnology and Biological Sciences Research Council (BB/F011350), which funded the imaging console used in this study. K.N. Murray was funded by the Natalie Kate Moss Trust.	ADNER M, 1993, NEUROREPORT, V4, P441, DOI 10.1097/00001756-199304000-00026; Baskerville TA, 2012, J CEREBR BLOOD F MET, V32, P973, DOI 10.1038/jcbfm.2012.19; BEASLEY D, 1989, J CLIN INVEST, V83, P331, DOI 10.1172/JCI113879; Blamire AM, 2000, J NEUROSCI, V20, P8153; Briyal S, 2010, EUR J PHARMACOL, V644, P73, DOI 10.1016/j.ejphar.2010.06.071; D'haeseleer M, 2013, P NATL ACAD SCI USA, V110, P5654, DOI 10.1073/pnas.1222560110; De Silva DA, 2009, STROKE, V40, P2872, DOI 10.1161/STROKEAHA.108.543595; Denes A, 2014, ANN NEUROL, V75, P670, DOI 10.1002/ana.24146; Denes A, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.002006; Denes A, 2010, J NEUROSCI, V30, P10086, DOI 10.1523/JNEUROSCI.1227-10.2010; Dorrance AM, 2007, VASC PHARMACOL, V47, P160, DOI 10.1016/j.vph.2007.05.007; Drake C, 2011, BRAIN BEHAV IMMUN, V25, P1113, DOI 10.1016/j.bbi.2011.02.008; Endeman H, 2011, EUR RESPIR J, V37, P1431, DOI 10.1183/09031936.00074410; Fan X, 2013, STROKE, V44, P745, DOI 10.1161/STROKEAHA.111.000309; FARACI FM, 1990, CIRC RES, V66, P8, DOI 10.1161/01.RES.66.1.8; Gan Y, 2014, P NATL ACAD SCI USA, V111, P2704, DOI 10.1073/pnas.1315943111; Glynn RJ, 2009, NEW ENGL J MED, V360, P1851, DOI 10.1056/NEJMoa0900241; Griebe M, 2013, CEREBROVASC DIS, V35, P554, DOI 10.1159/000351146; Grotta J, 2012, ANN NY ACAD SCI, V1268, P141, DOI 10.1111/j.1749-6632.2012.06690.x; Guo X, 1996, Hypertens Res, V19, P23, DOI 10.1291/hypres.19.23; Herz J, 2014, NEUROBIOL DIS, V62, P456, DOI 10.1016/j.nbd.2013.10.022; Kallakuri S, 2010, NEUROSCIENCE, V168, P820, DOI 10.1016/j.neuroscience.2010.01.018; Kammersgaard L P, 2001, J Stroke Cerebrovasc Dis, V10, P217, DOI 10.1053/jscd.2001.30366; Kaundal RK, 2012, DRUG DISCOV TODAY, V17, P793, DOI 10.1016/j.drudis.2012.02.017; Kreipke CW, 2010, NEUROL RES, V32, P209, DOI 10.1179/174313209X414515; Le Heron CJ, 2014, J CEREBR BLOOD F MET, V34, P964, DOI 10.1038/jcbfm.2014.40; Lenzlinger PM, 2004, RESTOR NEUROL NEUROS, V22, P73; Li WG, 2013, AM J PHYSIOL-REG I, V304, pR1001, DOI 10.1152/ajpregu.00523.2012; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lopez-Castejon G, 2011, CELL MOL LIFE SCI, V68, P3095, DOI 10.1007/s00018-010-0609-y; MACRAE IM, 1993, J CEREBR BLOOD F MET, V13, P276, DOI 10.1038/jcbfm.1993.34; Maher CO, 2003, J NEUROSURG, V99, P907, DOI 10.3171/jns.2003.99.5.0907; McColl BW, 2008, J NEUROSCI, V28, P9451, DOI 10.1523/JNEUROSCI.2674-08.2008; McColl BW, 2007, J NEUROSCI, V27, P4403, DOI 10.1523/JNEUROSCI.5376-06.2007; Meng XJ, 2004, ANN NEUROL, V55, P207, DOI 10.1002/ana.10803; Moffat BA, 2005, J MAGN RESON IMAGING, V21, P290, DOI 10.1002/jmri.20268; Nam J, 2015, INT J STROKE, V10, P13, DOI 10.1111/j.1747-4949.2012.00914.x; Palomares SM, 2012, J CEREBR BLOOD F MET, V32, P1035, DOI 10.1038/jcbfm.2012.14; Pradillo JM, 2012, J CEREBR BLOOD F MET, V32, P1810, DOI 10.1038/jcbfm.2012.101; Rewell SSJ, 2010, J CEREBR BLOOD F MET, V30, P729, DOI 10.1038/jcbfm.2009.273; Rupp J, 2003, EUR RESPIR J, V22, P274, DOI 10.1183/09031936.03.00007303; Selvarajah JR, 2011, INT J STROKE, V6, P187, DOI 10.1111/j.1747-4949.2010.00561.x; Shen Q, 2004, J CEREBR BLOOD F MET, V24, P280, DOI 10.1097/01.WCB.0000110048.43905.E5; Smith CJ, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-2; Soares BP, 2010, STROKE, V41, pE34, DOI 10.1161/STROKEAHA.109.568766; Thornton P, 2010, BLOOD, V115, P3632, DOI 10.1182/blood-2009-11-252643; Tiainen M, 2013, INT J STROKE, V8, P632, DOI 10.1111/ijs.12039; Zhang X, 2013, NEUROBIOL LEARN MEM, V101, P46, DOI 10.1016/j.nlm.2013.01.002	48	27	32	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499	1524-4628		STROKE	Stroke	NOV	2014	45	11					3412	3419		10.1161/STROKEAHA.114.006613			8	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	AS6CD	WOS:000344351500054	25228257	Green Accepted			2021-06-18	
J	Robinson, KE; Fountain-Zaragoza, S; Dennis, M; Taylor, HG; Bigler, ED; Rubin, K; Vannatta, K; Gerhardt, CA; Stancin, T; Yeates, KO				Robinson, Kristen E.; Fountain-Zaragoza, Stephanie; Dennis, Maureen; Taylor, H. Gerry; Bigler, Erin D.; Rubin, Kenneth; Vannatta, Kathryn; Gerhardt, Cynthia A.; Stancin, Terry; Yeates, Keith Owen			Executive Functions and Theory of Mind as Predictors of Social Adjustment in Childhood Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						executive function; pediatric; social adjustment; traumatic brain injury	INHIBITORY CONTROL; HEAD-INJURY; CHILDREN; PATTERNS; OUTCOMES; NEUROSCIENCE	This study examined whether executive function and theory of mind mediate the effects of pediatric traumatic brain injury (TBI) on social adjustment, relative to children with orthopedic injury (OI). Participants included 19 children with severe TBI, 41 children with complicated mild/moderate TBI, and 57 children with OI. They completed measures of executive function, as well as cognitive, affective, and conative theory of mind. Parents provided ratings of children's social adjustment. Children with severe TBI performed more poorly than children with OI on executive function and theory of mind tasks and were rated by parents as having more behavioral symptoms and worse communication and social skills. Executive function and theory of mind were positively correlated with social skills and communication skills, and negatively correlated with behavioral symptoms. In multiple mediator models, theory of mind and executive function were not significant direct predictors of any measure of social adjustment, but mediated the association between injury and adjustment for children with severe TBI. Theory of mind was a significant independent mediator when predicting social skills, but executive function was not. TBI in children, particularly severe injury, is associated with poor social adjustment. The impact of TBI on children's social adjustment is likely mediated by its effects on executive function and theory of mind.	[Robinson, Kristen E.; Vannatta, Kathryn; Gerhardt, Cynthia A.; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43205 USA; [Robinson, Kristen E.; Fountain-Zaragoza, Stephanie; Vannatta, Kathryn; Gerhardt, Cynthia A.; Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA; [Dennis, Maureen] Hosp Sick Children, Dept Psychol, Toronto, ON M5G 1X8, Canada; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Cleveland, OH USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Magnet Resonance Imaging MRI Res Facil, Provo, UT 84602 USA; [Rubin, Kenneth] Univ Maryland, Dept Human Dev & Quantitat Methodol, College Pk, MD 20742 USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Sch Med, Cleveland, OH USA	Robinson, KE (corresponding author), Ohio State Univ, Dept Pediat, Res Inst, Nationwide Childrens Hosp, 700 Childrens Dr, Columbus, OH 43205 USA.	Kristen.robinson@nationwidechildrens.org	Stancin, Terry/L-7993-2019; Hoskinson, Kristen/AAL-9162-2020; Fountain-Zaragoza, Stephanie/AAC-4512-2021; Rubin, Kenneth H/M-5276-2018; Yeates, Keith/AAJ-4223-2020	Hoskinson, Kristen/0000-0003-4044-9753; Fountain-Zaragoza, Stephanie/0000-0002-9365-4884; Rubin, Kenneth H/0000-0002-2608-2484; Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5 R01 HD048946]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048946] Funding Source: NIH RePORTER	The preparation of this article was supported in part by grant 5 R01 HD048946 from the National Institute of Child Health and Human Development to Keith Yeates.	Adolphs R, 2003, NAT REV NEUROSCI, V4, P165, DOI 10.1038/nrn1056; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Brown RL, 2010, CURR OPIN PEDIATR, V22, P321, DOI 10.1097/MOP.0b013e3283395f13; Carlson SM, 2004, J EXP CHILD PSYCHOL, V87, P299, DOI 10.1016/j.jecp.2004.01.002; Crowe LM, 2013, CHILD NEUROPSYCHOL, V19, P113, DOI 10.1080/09297049.2011.651079; De Los Reyes A, 2005, PSYCHOL BULL, V131, P483, DOI 10.1037/0033-2909.131.4.483; DEEGAN J, 1978, EDUC PSYCHOL MEAS, V38, P873, DOI 10.1177/001316447803800404; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M, 2013, DEV COGN NEUROS-NETH, V5, P25, DOI 10.1016/j.dcn.2012.11.006; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P338, DOI 10.1017/S1355617712001440; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P34, DOI 10.1017/S1355617712000884; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Dennis M, 2009, J INT NEUROPSYCH SOC, V15, P331, DOI 10.1017/S1355617709090481; Dennis M, 2009, J CLIN EXP NEUROPSYC, V31, P835, DOI 10.1080/13803390802572419; Dodge KA, 2002, PSYCHOL ASSESSMENT, V14, P60, DOI 10.1037//1040-3590.14.1.60; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; DROTAR D, 1995, J CLIN CHILD PSYCHOL, V24, P184, DOI 10.1207/s15374424jccp2402_6; Gordon ACL, 1998, J EXP CHILD PSYCHOL, V68, P70, DOI 10.1006/jecp.1997.2423; Hanten G, 2011, NEUROPSYCHOLOGIA, V49, P486, DOI 10.1016/j.neuropsychologia.2010.12.007; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Hayes AF, 2009, COMMUN MONOGR, V76, P408, DOI 10.1080/03637750903310360; Heaton SC, 2001, CHILD NEUROPSYCHOL, V7, P251, DOI 10.1076/chin.7.4.251.8736; Howard I, 2005, ETHNIC DIS, V15, pS51; Johnson MH, 2005, DEV PSYCHOPATHOL, V17, P599, DOI 10.1017/S0954579405050297; Kurowski BG, 2013, ARCH PHYS MED REHAB, V94, P543, DOI 10.1016/j.apmr.2012.10.029; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lemerise EA, 2000, CHILD DEV, V71, P107, DOI 10.1111/1467-8624.00124; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Manly T., 1999, TEA CH TEST EVERYDAY; Moses LJ, 2001, CHILD DEV, V72, P688, DOI 10.1111/1467-8624.00306; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879; Reynolds C.R., 2004, BEHAV ASSESSMENT SYS; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2014, CLIN PSYCHOL SCI, V2, P97, DOI 10.1177/2167702613499734; Yeates KO, 2013, J INT NEUROPSYCH SOC, V19, P518, DOI 10.1017/S1355617712001531; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	40	27	27	1	32	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 1	2014	31	22					1835	1842		10.1089/neu.2014.3422			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CB4ZO	WOS:000349637400003	25003478	Green Published			2021-06-18	
J	Shin, SS; Dixon, CE; Okonkwo, DO; Richardson, RM				Shin, Samuel S.; Dixon, C. Edward; Okonkwo, David O.; Richardson, R. Mark			Neurostimulation for traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; neuromodulation; neurostimulation; deep brain stimulation; transcranial magnetic stimulation; direct cortical stimulation	TRANSCRANIAL MAGNETIC STIMULATION; MOTOR CORTEX STIMULATION; ADVANCED PARKINSON-DISEASE; DEEP-BRAIN; ELECTRICAL-STIMULATION; CORTICAL STIMULATION; ANTERIOR THALAMUS; WORKING-MEMORY; MAJOR DEPRESSION; HEAD-INJURY	Traumatic brain injury (TBI) remains a significant public health problem and is a leading cause of death and disability in many countries. Durable treatments for neurological function deficits following TBI have been elusive, as there are currently no FDA-approved therapeutic modalities for mitigating the consequences of TBI. Neurostimulation strategies using various forms of electrical stimulation have recently been applied to treat functional deficits in animal models and clinical stroke trials. The results from these studies suggest that neurostimulation may augment improvements in both motor and cognitive deficits after brain injury. Several studies have taken this approach in animal models of TBI, showing both behavioral enhancement and biological evidence of recovery. There have been only a few studies using deep brain stimulation (DBS) in human TBI patients, and future studies are warranted to validate the feasibility of this technique in the clinical treatment of TBI. In this review, the authors summarize insights from studies employing neurostimulation techniques in the setting of brain injury. Moreover, they relate these findings to the future prospect of using DBS to ameliorate motor and cognitive deficits following TBI.	[Shin, Samuel S.; Dixon, C. Edward; Okonkwo, David O.; Richardson, R. Mark] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA	Shin, SS (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurol Surg, 200 Lothrop St,Ste B400, Pittsburgh, PA 15213 USA.	shinss@upmc.edu	Richardson, Robert/C-6819-2016	Richardson, Robert/0000-0003-2620-7387	MedtronicMedtronic	Dr. Richardson has received research device support from Medtronic. The other authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Adkins-Muir DL, 2003, NEUROL RES, V25, P780, DOI 10.1179/016164103771953853; Aimone JB, 2010, TRENDS COGN SCI, V14, P325, DOI 10.1016/j.tics.2010.04.003; Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; ALEXANDER GE, 1990, PROG BRAIN RES, V85, P119; Ameli M, 2009, ANN NEUROL, V66, P298, DOI 10.1002/ana.21725; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Bashir S, 2010, PM&R, V2, pS253, DOI 10.1016/j.pmrj.2010.10.015; BERKLEY KJ, 1983, J COMP NEUROL, V220, P229, DOI 10.1002/cne.902200210; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Boroojerdi B, 2001, NEUROLOGY, V56, P526, DOI 10.1212/WNL.56.4.526; Boroojerdi B, 1996, J NEUROL SCI, V144, P160, DOI 10.1016/S0022-510X(96)00222-5; BROGGI G, 1993, MOVEMENT DISORD, V8, P206, DOI 10.1002/mds.870080217; Brown JA, 2003, NEUROL RES, V25, P815, DOI 10.1179/016164103771953907; Brown JA, 2006, NEUROSURGERY, V58, P464, DOI 10.1227/01.NEU.0000197100.63931.04; Brown P, 2004, EXP NEUROL, V188, P480, DOI 10.1016/j.expneurol.2004.05.009; Buzsaki G, 2013, NAT NEUROSCI, V16, P130, DOI 10.1038/nn.3304; Canavero S, 2002, J NEUROSURG, V97, P1208, DOI 10.3171/jns.2002.97.5.1208; Carmel JB, 2013, EUR J NEUROSCI, V37, P1090, DOI 10.1111/ejn.12119; Carmel JB, 2010, J NEUROSCI, V30, P10918, DOI 10.1523/JNEUROSCI.1435-10.2010; Carvalho KS, 2014, J CLIN NEUROSCI, V21, P153, DOI 10.1016/j.jocn.2013.02.009; CEBALLOSBAUMAN AO, 1995, ANN NEUROL, V37, P746, DOI 10.1002/ana.410370608; Chang WH, 2010, J REHABIL MED, V42, P758, DOI 10.2340/16501977-0590; Chuang C, 2002, J NEUROL NEUROSUR PS, V72, P59, DOI 10.1136/jnnp.72.1.59; Cilia R, 2008, EUR J NEUROL, V15, P18, DOI 10.1111/j.1468-1331.2007.01993.x; Classen J, 1997, BRAIN, V120, P605, DOI 10.1093/brain/120.4.605; Constantoyannis C, 2009, MOVEMENT DISORD, V24, P306, DOI 10.1002/mds.22350; Datta A, 2010, NEUROIMAGE, V52, P1268, DOI 10.1016/j.neuroimage.2010.04.252; de Hemptinne C, 2013, P NATL ACAD SCI USA, V110, P4780, DOI 10.1073/pnas.1214546110; De Rose M, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/502096; Desmond JE, 2005, ANN NEUROL, V58, P553, DOI 10.1002/ana.20604; Di Lazzaro V, 2008, CLIN NEUROPHYSIOL, V119, P715, DOI 10.1016/j.clinph.2007.11.049; Dougherty DD, 2003, J NEUROSURG, V99, P1010, DOI 10.3171/jns.2003.99.6.1010; Encinas JM, 2011, J COMP NEUROL, V519, P6, DOI 10.1002/cne.22503; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Evers S, 2001, NEUROREPORT, V12, P2915, DOI 10.1097/00001756-200109170-00032; Feydy A, 2002, STROKE, V33, P1610, DOI 10.1161/01.STR.0000017100.68294.52; Fisher R, 2010, EPILEPSIA, V51, P899, DOI 10.1111/j.1528-1167.2010.02536.x; Fitzgerald PB, 2011, J ECT, V27, P38, DOI 10.1097/YCT.0b013e3181eb30c6; Floel A, 2011, STROKE, V42, P2065, DOI 10.1161/STROKEAHA.110.609032; Fontaine D, 2009, J NEUROSURG, V110, P251, DOI 10.3171/2008.6.17602; Foote KD, 2006, NEUROSURGERY, V58, P280, DOI 10.1227/01.NEU.0000192692.95455.FD; Fregni F, 2006, COGN BEHAV NEUROL, V19, P21, DOI 10.1097/00146965-200603000-00003; Fregni F, 2006, STROKE, V37, P2115, DOI 10.1161/01.STR.0000231390.58967.6b; Ghika J, 2002, NEUROLOGY, V58, P311, DOI 10.1212/WNL.58.2.311; Goldapple K, 2004, ARCH GEN PSYCHIAT, V61, P34, DOI 10.1001/archpsyc.61.1.34; Gonzalez MMC, 2013, J NEUROTRAUM, V30, P119, DOI 10.1089/neu.2012.2499; Grafton ST, 2006, NEUROLOGY, V66, P1192, DOI 10.1212/01.wnl.0000214237.58321.c3; Gutman DA, 2009, BIOL PSYCHIAT, V65, P276, DOI 10.1016/j.biopsych.2008.09.021; Hamani C, 2011, EXP NEUROL, V232, P100, DOI 10.1016/j.expneurol.2011.08.023; Hamani C, 2010, EXP NEUROL, V225, P154, DOI 10.1016/j.expneurol.2010.06.007; Hamani C, 2010, BIOL PSYCHIAT, V67, P117, DOI 10.1016/j.biopsych.2009.08.025; Hammond C, 2007, TRENDS NEUROSCI, V30, P357, DOI 10.1016/j.tins.2007.05.004; Huang M, 2008, TOP STROKE REHABIL, V15, P160, DOI 10.1310/tsr1502-160; Ilinsky IA, 2002, MOVEMENT DISORD, V17, pS9, DOI 10.1002/mds.10137; Issar NM, 2013, PARKINSONISM RELAT D, V19, P1100, DOI 10.1016/j.parkreldis.2013.07.022; Jo JM, 2009, AM J PHYS MED REHAB, V88, P404, DOI 10.1097/PHM.0b013e3181a0e4cb; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kang EK, 2012, J REHABIL MED, V44, P346, DOI 10.2340/16501977-0947; Kanno T, 2009, NEUROMODULATION, V12, P33, DOI 10.1111/j.1525-1403.2009.00185.x; Katayama Y, 1997, STEREOT FUNCT NEUROS, V69, P73, DOI 10.1159/000099855; KATAYAMA Y, 1994, STEREOT FUNCT NEUROS, V62, P295, DOI 10.1159/000098635; Katsakiori PF, 2009, ACTA NEUROCHIR, V151, P473, DOI 10.1007/s00701-009-0281-x; Khedr EM, 2005, NEUROLOGY, V65, P466, DOI 10.1212/01.wnl.0000173067.84247.36; Kim JP, 2012, ACTA NEUROCHIR, V154, P823, DOI 10.1007/s00701-012-1306-4; Kim YH, 2006, STROKE, V37, P1471, DOI 10.1161/01.STR.0000221233.55497.51; King RB, 2001, J NEUROSURG, V94, P309, DOI 10.3171/jns.2001.94.2.0309; Kinomura S, 1996, SCIENCE, V271, P512, DOI 10.1126/science.271.5248.512; Kleim JA, 2003, NEUROL RES, V25, P789, DOI 10.1179/016164103771953862; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Koch G, 2008, BRAIN, V131, P3147, DOI 10.1093/brain/awn273; Kohler S, 2004, J COGNITIVE NEUROSCI, V16, P178, DOI 10.1162/089892904322984490; Krauss J K, 1997, Parkinsonism Relat Disord, V3, P117, DOI 10.1016/S1353-8020(96)00043-0; KRAUSS JK, 1992, MOVEMENT DISORD, V7, P263, DOI 10.1002/mds.870070313; Krauss JK, 2002, NEUROSURGERY, V50, P927, DOI 10.1097/00006123-200205000-00003; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Laxton AW, 2010, ANN NEUROL, V68, P521, DOI 10.1002/ana.22089; Lee DJ, 2013, J NEUROTRAUM, V30, P131, DOI 10.1089/neu.2012.2646; Levy R, 2008, J NEUROSURG, V108, P707, DOI 10.3171/JNS/2008/108/4/0707; Lim DA, 2007, STEREOT FUNCT NEUROS, V85, P144, DOI 10.1159/000099072; Lim JY, 2010, J REHABIL MED, V42, P447, DOI 10.2340/16501977-0553; Loher TJ, 2000, J NEUROSURG, V92, P457, DOI 10.3171/jns.2000.92.3.0457; Louis ED, 1996, ARCH NEUROL-CHICAGO, V53, P450, DOI 10.1001/archneur.1996.00550050080027; Lozano AM, 2008, BIOL PSYCHIAT, V64, P461, DOI 10.1016/j.biopsych.2008.05.034; Lozano AM, 2012, J NEUROSURG, V116, P315, DOI 10.3171/2011.10.JNS102122; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Luber B, 2007, BRAIN RES, V1128, P120, DOI 10.1016/j.brainres.2006.10.011; Lujan JL, 2013, BRAIN STIMUL, V6, P737, DOI 10.1016/j.brs.2013.03.008; Malcolm MP, 2007, AM J PHYS MED REHAB, V86, P707, DOI 10.1097/PHM.0b013e31813e0de0; Mansur CG, 2005, NEUROLOGY, V64, P1802, DOI 10.1212/01.WNL.0000161839.38079.92; MARSDEN CD, 1985, BRAIN, V108, P463, DOI 10.1093/brain/108.2.463; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; Mayberg HS, 1999, AM J PSYCHIAT, V156, P675; Mayberg HS, 2000, BIOL PSYCHIAT, V48, P830, DOI 10.1016/S0006-3223(00)01036-2; McIntyre CC, 2010, NEUROBIOL DIS, V38, P329, DOI 10.1016/j.nbd.2009.09.022; McNaughton N, 2006, HIPPOCAMPUS, V16, P1102, DOI 10.1002/hipo.20235; Medina J, 2012, APHASIOLOGY, V26, P1153, DOI 10.1080/02687038.2012.710316; MEYERSON BA, 1993, ACTA NEUROCHIR, P150; MIZUMORI SJY, 1990, BRAIN RES, V528, P12, DOI 10.1016/0006-8993(90)90188-H; Molnar GF, 2006, NEUROLOGY, V66, P566, DOI 10.1212/01.wnl.0000198254.08581.6b; Monfils MH, 2004, CEREB CORTEX, V14, P586, DOI 10.1093/cercor/bhh020; Monti A, 2008, J NEUROL NEUROSUR PS, V79, P451, DOI 10.1136/jnnp.2007.135277; Morimoto T, 2011, CELL TRANSPLANT, V20, P1049, DOI 10.3727/096368910X544915; Morrell MJ, 2011, NEUROLOGY, V77, P1295, DOI 10.1212/WNL.0b013e3182302056; Mull BR, 2001, CLIN NEUROPHYSIOL, V112, P1672, DOI 10.1016/S1388-2457(01)00606-X; Murase N, 2004, ANN NEUROL, V55, P400, DOI 10.1002/ana.10848; Naeser MA, 2005, BRAIN LANG, V93, P95, DOI 10.1016/j.bandl.2004.08.004; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; NGUYEN JP, 1993, ARCH NEUROL-CHICAGO, V50, P498, DOI 10.1001/archneur.1993.00540050050014; Nguyen JP, 1997, ADV STER F, V12, P54; NUDO RJ, 1990, SOMATOSENS MOT RES, V7, P463, DOI 10.3109/08990229009144720; Ohyama M, 1996, STROKE, V27, P897, DOI 10.1161/01.STR.27.5.897; Oliveri M, 2000, BRAIN, V123, P1939, DOI 10.1093/brain/123.9.1939; Osaka N, 2007, NEUROSCI LETT, V418, P232, DOI 10.1016/j.neulet.2007.01.087; Pagni CA, 2005, ACT NEUR S, V93, P113; Palacios EM, 2013, JAMA NEUROL, V70, P845, DOI 10.1001/jamaneurol.2013.38; Pape TLB, 2009, BRAIN STIMUL, V2, P22, DOI 10.1016/j.brs.2008.09.004; Peran P, 2014, J NEUROTRAUM, V31, P642, DOI 10.1089/neu.2013.3103; Plautz EJ, 2003, NEUROL RES, V25, P801, DOI 10.1179/016164103771953880; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Roth Y, 2002, J CLIN NEUROPHYSIOL, V19, P361, DOI 10.1097/00004691-200208000-00008; Sanai N, 2011, NATURE, V478, P382, DOI 10.1038/nature10487; Schiff ND, 2008, NATURE, V452, P120, DOI 10.1038/nature06818; Schiff ND, 2012, ANN NY ACAD SCI, V1265, P56, DOI 10.1111/j.1749-6632.2012.06712.x; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Schuepbach WMM, 2013, NEW ENGL J MED, V368, P610, DOI 10.1056/NEJMoa1205158; SELLAL F, 1993, MOVEMENT DISORD, V8, P515, DOI 10.1002/mds.870080418; Shah PP, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00888; Shahaduzzaman M, 2013, MED HYPOTHESES, V81, P675, DOI 10.1016/j.mehy.2013.07.025; Shin SS, 2012, J NEUROSURG, V116, P1062, DOI 10.3171/2012.1.JNS111282; Shindo K, 2006, J REHABIL MED, V38, P65, DOI 10.1080/16501970500441807; Shirvalkar P, 2006, P NATL ACAD SCI USA, V103, P17007, DOI 10.1073/pnas.0604811103; Silva S, 2008, CLIN NEUROPHYSIOL, V119, P2405, DOI 10.1016/j.clinph.2008.07.248; SILVER JK, 1994, ARCH PHYS MED REHAB, V75, P885, DOI 10.1016/0003-9993(94)90113-9; STERIADE M, 1982, J NEUROPHYSIOL, V48, P352; Stone SSD, 2011, J NEUROSCI, V31, P13469, DOI 10.1523/JNEUROSCI.3100-11.2011; Strafella AP, 2007, MOVEMENT DISORD, V22, P2113, DOI 10.1002/mds.21691; Stypulkowski PH, 2013, STEREOT FUNCT NEUROS, V91, P220, DOI 10.1159/000345493; Suthana N, 2012, NEW ENGL J MED, V366, P502, DOI 10.1056/NEJMoa1107212; Taghva AS, 2013, WORLD NEUROSURG, V80, DOI 10.1016/j.wneu.2012.10.068; Takeuchi N, 2008, J REHABIL MED, V40, P298, DOI 10.2340/16501977-0181; Tani N, 2007, MOVEMENT DISORD, V22, P1645, DOI 10.1002/mds.21593; Tarapore PE, 2013, J NEUROSURG, V118, P1306, DOI 10.3171/2013.3.JNS12398; Teskey GC, 2003, NEUROL RES, V25, P794, DOI 10.1179/016164103771953871; Toda H, 2008, J NEUROSURG, V108, P132, DOI 10.3171/JNS/2008/108/01/0132; TOFTS PS, 1990, PHYS MED BIOL, V35, P1119, DOI 10.1088/0031-9155/35/8/008; Tohyama Takamichi, 2011, Keio Journal of Medicine, V60, P114; Trost M, 2006, NEUROIMAGE, V31, P301, DOI 10.1016/j.neuroimage.2005.12.024; Tsubokawa T, 1990, Brain Inj, V4, P315; TSUBOKAWA T, 1993, J NEUROSURG, V78, P393, DOI 10.3171/jns.1993.78.3.0393; Van der Werf YD, 2002, BRAIN RES REV, V39, P107, DOI 10.1016/S0165-0173(02)00181-9; Vines BW, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-103; Wassermann EM, 2012, PHARMACOL THERAPEUT, V133, P98, DOI 10.1016/j.pharmthera.2011.09.003; Weaver FM, 2009, JAMA-J AM MED ASSOC, V301, P63, DOI 10.1001/jama.2008.929; Williams JM, 2003, HIPPOCAMPUS, V13, P109, DOI 10.1002/hipo.10082; Wong JC, 2013, CRIT REV CL LAB SCI, V50, P103, DOI 10.3109/10408363.2013.844678; Wu CY, 2013, NEUROMODULATION, V16, P10, DOI 10.1111/j.1525-1403.2012.00501.x; Yamamoto T, 2005, ACTA NEUROCHIR SUPPL, V93, P101; Yamamoto T, 2005, NEUROPSYCHOL REHABIL, V15, P406, DOI 10.1080/09602010443000353; Yamamoto T, 2012, NEUROL MED-CHIR, V52, P475, DOI 10.2176/nmc.52.475; Yamamoto T, 2010, EUR J NEUROSCI, V32, P1145, DOI 10.1111/j.1460-9568.2010.07412.x; Yoon YS, 2012, ANN REHABIL MED-ARM, V36, P596, DOI 10.5535/arm.2012.36.5.596; Zheng J, 2013, BRAIN RES, V1504, P25, DOI 10.1016/j.brainres.2013.01.015; Zumsteg D, 2006, CLIN NEUROPHYSIOL, V117, P192, DOI 10.1016/j.clinph.2005.09.015	164	27	28	0	28	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2014	121	5					1219	1231		10.3171/2014.7.JNS131826			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AR4AM	WOS:000343530400030	25170668				2021-06-18	
J	Khailova, LS; Silachev, DN; Rokitskaya, TI; Avetisyan, AV; Lyamsaev, KG; Severina, II; Il'yasova, TM; Gulyaev, MV; Dedukhova, VI; Trendeleva, TA; Plotnikov, EY; Zvyagilskaya, RA; Chernyak, BV; Zorov, DB; Antonenko, YN; Skulachev, VP				Khailova, Ljudmila S.; Silachev, Denis N.; Rokitskaya, Tatyana I.; Avetisyan, Armine V.; Lyamsaev, Konstantin G.; Severina, Irma I.; Il'yasova, Tatyana M.; Gulyaev, Mikhail V.; Dedukhova, Vera I.; Trendeleva, Tatyana A.; Plotnikov, Egor Y.; Zvyagilskaya, Renata A.; Chernyak, Boris V.; Zorov, Dmitry B.; Antonenko, Yuri N.; Skulachev, Vladimir P.			A short-chain alkyl derivative of Rhodamine 19 acts as a mild uncoupler of mitochondria and a neuroprotector	BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS			English	Article						Mitochondria; Mild uncoupler; Protonophore; Rhodamine; Membrane potential	TRAUMATIC BRAIN-INJURY; NEURONAL DEATH; OXIDATIVE-PHOSPHORYLATION; PENETRATING CATIONS; PROTEIN-2 PROTECTS; PROTON TRANSPORT; FATTY-ACIDS; MECHANISM; OXYGEN; ISCHEMIA	Limited uncoupling of oxidative phosphorylation is known to be-beneficial in various laboratory models of diseases. The search for cationic uncouplers is promising as their protonophorous effect is self-limiting because these uncouplers lower membrane potential which is the driving force for their accumulation in mitochondria. In this work, the penetrating cation Rhodamine 19 butyl ester (C(4)R1) was found to decrease membrane potential and to stimulate respiration of mitochondria, appearing to be a stronger uncoupler than its more hydrophobic analog Rhodamine 19 dodecyl ester (C(12)R1). Surprisingly, C(12)R1 increased H+ conductance of artificial bilayer lipid membranes or induced mitochondria swelling in potassium acetate with valinomycin at concentrations lower than C(4)R1. This paradox might be explained by involvement of mitochondrial proteins in the uncoupling action of C(4)R1. In experiments with HeLa cells, C(4)R1 rapidly and selectively accumulated in mitochondria and stimulated oligomycin-sensitive respiration as a mild uncoupler. C(4)R1 was effective in preventing oxidative stress induced by brain ischemia and reperfusion in rats: it suppressed stroke-induced brain swelling and prevented the decline in neurological status more effectively than C(12)R1. Thus, C(4)R1 seems to be a promising example of a mild uncoupler efficient in treatment of brain pathologies related to oxidative stress. (C) 2014 Elsevier B.V. All rights reserved.	[Khailova, Ljudmila S.; Silachev, Denis N.; Rokitskaya, Tatyana I.; Avetisyan, Armine V.; Lyamsaev, Konstantin G.; Severina, Irma I.; Il'yasova, Tatyana M.; Dedukhova, Vera I.; Plotnikov, Egor Y.; Chernyak, Boris V.; Zorov, Dmitry B.; Antonenko, Yuri N.; Skulachev, Vladimir P.] Moscow MV Lomonosov State Univ, Belozersky Inst Phys Chem Biol, Moscow 119991, Russia; [Khailova, Ljudmila S.; Silachev, Denis N.; Rokitskaya, Tatyana I.; Avetisyan, Armine V.; Lyamsaev, Konstantin G.; Severina, Irma I.; Il'yasova, Tatyana M.; Dedukhova, Vera I.; Plotnikov, Egor Y.; Zvyagilskaya, Renata A.; Chernyak, Boris V.; Zorov, Dmitry B.; Antonenko, Yuri N.; Skulachev, Vladimir P.] Moscow MV Lomonosov State Univ, Inst Mitoengn, Moscow 119991, Russia; [Skulachev, Vladimir P.] Moscow MV Lomonosov State Univ, Fac Bioengn & Bioinformat, Moscow 119991, Russia; [Gulyaev, Mikhail V.] Moscow MV Lomonosov State Univ, Fac Fundamental Med, Moscow 117192, Russia; [Trendeleva, Tatyana A.; Zvyagilskaya, Renata A.] Russian Acad Sci, AN Bach Inst Biochem, Moscow 119071, Russia	Antonenko, YN (corresponding author), Moscow MV Lomonosov State Univ, Belozersky Inst Phys Chem Biol, Moscow 119991, Russia.	antonen@genebee.msu.ru; skulach@belozersky.msu.ru	Rokitskaya, Tatyana/J-3541-2013; Silachev, Denis/ABE-8515-2020; Zorov, Dmitry/AAQ-8922-2020; Chernyak, Boris V/D-9917-2012; Gulyaev, Mikhail/A-6163-2014; Lyamzaev, Konstantin/D-3405-2012; Avetisyan, Armine/O-2426-2014; Plotnikov, Egor Y/F-8592-2019; Silachev, Denis N/C-9464-2012; Antonenko, Yuri N/K-1323-2013; Zorov, Dmitry/AAB-1738-2019	Chernyak, Boris V/0000-0003-1523-0864; Gulyaev, Mikhail/0000-0003-4684-2484; Lyamzaev, Konstantin/0000-0001-9921-8031; Plotnikov, Egor Y/0000-0003-2838-3704; Skulachev, Vladimir/0000-0001-5141-7517; Rokitskaya, Tatyana/0000-0002-7719-1875; Silachev, Denis/0000-0003-0581-9755; Avetisyan, Armine/0000-0002-3882-2013	Russian Foundation for Basic ResearchRussian Foundation for Basic Research (RFBR) [12-04-00199, 13-04-01530, 12-04-31970, 14-04-00300, 14-94-00542]; Institute of Mitoengineering, Moscow State University; RSFRussian Science Foundation (RSF) [14-15-00107, 14-15-00147, 14-24-00107]; Grant of the President of Russia [MK-2508.2014.4]	The authors thank Dr. Elena Kotova and Dr. Lev Yaguzhinsky for valuable comments and Dr. Elena Omarova for technical assistance. This work was supported in part by the Russian Foundation for Basic Research grants 12-04-00199,13-04-01530, 12-04-31970, 14-04-00300, and 14-94-00542 and the Institute of Mitoengineering, Moscow State University. RSF grants 14-15-00107, 14-15-00147, 14-24-00107 and Grant of the President of Russia MK-2508.2014.4.	ANDREYEV AY, 1989, EUR J BIOCHEM, V182, P585, DOI 10.1111/j.1432-1033.1989.tb14867.x; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Antonenko YN, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1273, DOI 10.1134/S0006297908120018; Antonenko YN, 2012, J BIOENERG BIOMEMBR, V44, P453, DOI 10.1007/s10863-012-9449-9; Antonenko YN, 2011, J BIOL CHEM, V286, P17831, DOI 10.1074/jbc.M110.212837; Arnold S, 2012, ADV EXP MED BIOL, V748, P305, DOI 10.1007/978-1-4614-3573-0_13; BARONE FC, 1991, BRAIN RES BULL, V26, P285, DOI 10.1016/0361-9230(91)90240-K; Carriedo SG, 1998, J NEUROSCI, V18, P7727; Conti B, 2005, J NEUROCHEM, V93, P493, DOI 10.1111/j.1471-4159.2005.03052.x; Cunha FM, 2011, CURR DRUG TARGETS, V12, P783; Duchen MR, 2012, PFLUG ARCH EUR J PHY, V464, P111, DOI 10.1007/s00424-012-1112-0; DUGAN LL, 1995, J NEUROSCI, V15, P6377; GARLID KD, 1983, J BIOL CHEM, V258, P7974; GEAR ARL, 1974, J BIOL CHEM, V249, P3628; Grundlingh J, 2011, J MED TOXICOL, V7, P205, DOI 10.1007/s13181-011-0162-6; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; Harper J A, 2001, Obes Rev, V2, P255, DOI 10.1046/j.1467-789X.2001.00043.x; Jezek P, 1998, BBA-BIOENERGETICS, V1365, P319, DOI 10.1016/S0005-2728(98)00084-X; Johnson D., 1967, METHODS ENZYMOL, V10, P94, DOI 10.1016/0076-6879(67)10018-9; Jolkkonen J, 2000, EUR J PHARMACOL, V400, P211, DOI 10.1016/S0014-2999(00)00409-X; Kadenbach B, 2010, BBA-GEN SUBJECTS, V1800, P205, DOI 10.1016/j.bbagen.2009.04.019; Kaim G, 1999, EMBO J, V18, P4118, DOI 10.1093/emboj/18.15.4118; Korde AS, 2005, J NEUROTRAUM, V22, P1142, DOI 10.1089/neu.2005.22.1142; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; LARIS PC, 1975, BIOCHIM BIOPHYS ACTA, V376, P415, DOI 10.1016/0005-2728(75)90163-2; Lou PH, 2007, BIOCHEM J, V407, P129, DOI 10.1042/BJ20070606; Maragos WF, 2003, BRAIN RES, V966, P312, DOI 10.1016/S0006-8993(02)04225-7; Martel C, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/213403; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; Perevoshchikova IV, 2008, BBA-BIOMEMBRANES, V1778, P2182, DOI 10.1016/j.bbamem.2008.04.008; Plotnikov EY, 2012, BIOCHEMISTRY-MOSCOW+, V77, P1029, DOI 10.1134/S0006297912090106; Rokitskaya TI, 2013, EUR BIOPHYS J BIOPHY, V42, P477, DOI 10.1007/s00249-013-0898-9; Rokitskaya TI, 2010, BBA-BIOMEMBRANES, V1798, P1698, DOI 10.1016/j.bbamem.2010.05.018; Rupprecht A, 2010, BIOPHYS J, V98, P1503, DOI 10.1016/j.bpj.2009.12.4301; Schonfeld P, 2000, FEBS LETT, V471, P108, DOI 10.1016/S0014-5793(00)01376-4; Severin FF, 2010, P NATL ACAD SCI USA, V107, P663, DOI 10.1073/pnas.0910216107; Silachev DN, 2009, B EXP BIOL MED+, V147, P269, DOI 10.1007/s10517-009-0489-z; Silachev DN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051553; SKULACHEV V. P., 1968, CURR MOD BIOL, V2, P98; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Skulachev VP, 1997, BIOSCIENCE REP, V17, P347, DOI 10.1023/A:1027344914565; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; STARKOV AA, 1994, FEBS LETT, V355, P305, DOI 10.1016/0014-5793(94)01211-3; Strom JO, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-41; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Wu YN, 2011, BRAIN RES, V1395, P86, DOI 10.1016/j.brainres.2011.04.032; YAGUZHINSKY LS, 1973, J BIOENERG, V5, P163, DOI 10.1007/BF01648987	51	27	33	0	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0005-2728	1879-2650		BBA-BIOENERGETICS	Biochim. Biophys. Acta-Bioenerg.	OCT	2014	1837	10					1739	1747		10.1016/j.bbabio.2014.07.006			9	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	AP7RA	WOS:000342273200017	25038514	Bronze			2021-06-18	
J	Rodriguez, CLR; Szu, JI; Eberle, MM; Wang, Y; Hsu, MS; Binder, DK; Park, BH				Rodriguez, Carissa L. R.; Szu, Jenny I.; Eberle, Melissa M.; Wang, Yan; Hsu, Mike S.; Binder, Devin K.; Park, B. Hyle			Decreased light attenuation in cerebral cortex during cerebral edema detected using optical coherence tomography	NEUROPHOTONICS			English	Article						cerebral edema; optical coherence tomography; brain swelling	BLOOD-FLOW; BRAIN EDEMA; REAL-TIME; SPEED	Cerebral edema develops in response to a variety of conditions, including traumatic brain injury and stroke, and contributes to the poor prognosis associated with these injuries. This study examines the use of optical coherence tomography (OCT) for detecting cerebral edema in vivo. Three-dimensional imaging of an in vivo water intoxication model in mice was performed using a spectral-domain OCT system centered at 1300 nm. The change in attenuation coefficient was calculated and cerebral blood flow was analyzed using Doppler OCT techniques. We found that the average attenuation coefficient in the cerebral cortex decreased over time as edema progressed. The initial decrease began within minutes of inducing cerebral edema and a maximum decrease of 8% was observed by the end of the experiment. Additionally, cerebral blood flow slowed during late-stage edema. Analysis of local regions revealed the same trend at various locations in the brain, consistent with the global nature of the cerebral edema model used in this study. These results demonstrate that OCT is capable of detecting in vivo optical changes occurring due to cerebral edema and highlights the potential of OCT for precise spatiotemporal detection of cerebral edema. (C) The Authors.	[Rodriguez, Carissa L. R.; Eberle, Melissa M.; Park, B. Hyle] Univ Calif Riverside, Dept Bioengn, 900 Univ Ave, Riverside, CA 92521 USA; [Szu, Jenny I.; Hsu, Mike S.; Binder, Devin K.] Univ Calif Riverside, Div Biomed Sci, Sch Med, Riverside, CA 92521 USA; [Wang, Yan] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Wang, Yan] Harvard Med Sch, Pulm & Crit Care Unit, Boston, MA 02114 USA; [Hsu, Mike S.; Binder, Devin K.] Umbrella Neurotechnol, Irvine, CA 92620 USA	Park, BH (corresponding author), Univ Calif Riverside, Dept Bioengn, 900 Univ Ave, Riverside, CA 92521 USA.	hylepark@engr.ucr.edu		Wang, Yan/0000-0002-6401-7464	NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R00 EB007241] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R00EB007241] Funding Source: NIH RePORTER		Chen ZP, 1997, OPT LETT, V22, P1119, DOI 10.1364/OL.22.001119; Fujimoto JG, 2003, NAT BIOTECHNOL, V21, P1361, DOI 10.1038/nbt892; Gill AS, 2011, J NEUROSURG, V114, P470, DOI 10.3171/2010.2.JNS091017; Harlow G, 2013, I S BIOMED IMAGING, P910; HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; Marmarou A, 2003, ACT NEUR S, V86, P7; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; OLSON JE, 1990, ANN EMERG MED, V19, P1113, DOI 10.1016/S0196-0644(05)81514-8; Padayachy LC, 2010, CHILD NERV SYST, V26, P441, DOI 10.1007/s00381-009-1034-0; Rabinstein AA, 2006, NEUROLOGIST, V12, P59, DOI 10.1097/01.nrl.0000186810.62736.f0; Szu JI, 2012, JOVE-J VIS EXP, DOI 10.3791/50053; Thiagarajah JR, 2005, J NEUROSCI RES, V80, P293, DOI 10.1002/jnr.20439; Vermeer KA, 2014, BIOMED OPT EXPRESS, V5, P322, DOI 10.1364/BOE.5.000322; Walcott BP, 2012, NEUROTHERAPEUTICS, V9, P65, DOI 10.1007/s13311-011-0087-4; Wang Y, 2012, OPT EXPRESS, V20, P14797, DOI 10.1364/OE.20.014797; Weed L., 1919, AM J PHYSIOL, V73, P194; Westphal V, 2002, OPT LETT, V27, P34, DOI 10.1364/OL.27.000034; White BR, 2003, OPT EXPRESS, V11, P3490, DOI 10.1364/OE.11.003490; Zhao YH, 2000, OPT LETT, V25, P114, DOI 10.1364/OL.25.000114	19	27	29	0	1	SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS	BELLINGHAM	1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA	2329-423X	2329-4248		NEUROPHOTONICS	Neurophotonics	OCT-DEC	2014	1	2							025004	10.1117/1.NPh.1.2.025004			7	Neurosciences; Optics	Neurosciences & Neurology; Optics	V45SP	WOS:000209836600006	25674578	Green Accepted, Other Gold, Green Published			2021-06-18	
J	Zhang, ZY; Zhang, LX; Dong, XQ; Yu, WH; Du, Q; Yang, DB; Shen, YF; Wang, H; Zhu, Q; Che, ZH; Liu, QJ; Jiang, L; Du, YF				Zhang, Zu-Yong; Zhang, Li-Xin; Dong, Xiao-Qiao; Yu, Wen-Hua; Du, Quan; Yang, Ding-Bo; Shen, Yong-Feng; Wang, Hao; Zhu, Qiang; Che, Zhi-Hao; Liu, Qun-Jie; Jiang, Li; Du, Yuan-Feng			Comparison of the performances of copeptin and multiple biomarkers in long-term prognosis of severe traumatic brain injury	PEPTIDES			English	Article						Traumatic brain injury; Prognosis; Copeptin; Biomarkers	S100B PROTEIN; SERUM; OPPORTUNITIES; VASOPRESSIN; MORTALITY; MARKERS; UTILITY; DISEASE; FUTURE; DAMAGE	Enhanced blood levels of copeptin correlate with poor clinical outcomes after acute critical illness. This study aimed to compare the prognostic performances of plasma concentrations of copeptin and other biomarkers like myelin basic protein, glial fibrillary astrocyte protein, S100B, neuron-specific enolase, phosphorylated axonal neurofilament subunit H, Tau and ubiquitin carboxyl-terminal hydrolase L1 in severe traumatic brain injury. We recruited 102 healthy controls and 102 acute patients with severe traumatic brain injury. Plasma concentrations of these biomarkers were determined using enzyme-linked immunosorbent assay. Their prognostic predictive performances of 6-month mortality and unfavorable outcome ( Glasgow Outcome Scale score of 1-3) were compared. Plasma concentrations of these biomarkers were statistically significantly higher in all patients than in healthy controls, in non-survivors than in survivors and in patients with unfavorable outcome than with favorable outcome. Areas under receiver operating characteristic curves of plasma concentrations of these biomarkers were similar to those of Glasgow Coma Scale score for prognostic prediction. Except plasma copeptin concentration, other biomarkers concentrations in plasma did not statistically significantly improve prognostic predictive value of Glasgow Coma Scale score. Copeptin levels may be a useful tool to predict long-term clinical outcomes after severe traumatic brain injury and have a potential to assist clinicians. (C) 2014 Elsevier Inc. All rights reserved.	[Zhang, Zu-Yong; Dong, Xiao-Qiao; Yu, Wen-Hua; Du, Quan; Yang, Ding-Bo; Shen, Yong-Feng; Wang, Hao; Zhu, Qiang; Che, Zhi-Hao; Liu, Qun-Jie; Jiang, Li; Du, Yuan-Feng] Nanjing Med Univ, Affiliated Hangzhou Hosp, Hangzhou Peoples Hosp 1, Dept Neurosurg, Hangzhou 310006, Zhejiang, Peoples R China; [Zhang, Li-Xin] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310009, Zhejiang, Peoples R China	Dong, XQ (corresponding author), Nanjing Med Univ, Affiliated Hangzhou Hosp, Hangzhou Peoples Hosp 1, Dept Neurosurg, 261 Huansha Rd, Hangzhou 310006, Zhejiang, Peoples R China.	dxqhyy@163.com			Zhejiang Province Medical and Health [2012KYB148]	This study was supported by a grant from Zhejiang Province Medical and Health Project (No. 2012KYB148).	Anand T, 2012, J SURG RES, V178, P321, DOI 10.1016/j.jss.2012.02.062; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; De Marchis GM, 2013, NEUROLOGY, V80, P1278, DOI 10.1212/WNL.0b013e3182887944; DeFazio MV, 2014, WORLD NEUROSURG, V81, P151, DOI 10.1016/j.wneu.2013.01.015; Dong XQ, 2011, J TRAUMA, V71, P1194, DOI 10.1097/TA.0b013e31821283f2; Fenske W, 2012, J CLIN ENDOCR METAB, V97, P3426, DOI 10.1210/jc.2012-1981; Forde CT, 2014, BRIT J NEUROSURG, V28, P8, DOI 10.3109/02688697.2013.815317; Freynhofer MK, 2012, WIEN MED WOCHENSCHR, V162, P489, DOI 10.1007/s10354-012-0148-2; Giannopoulos G, 2013, CURR TOP MED CHEM, V13, P231, DOI 10.2174/15680266113139990088; JENNETT B, 1975, LANCET, V1, P480; Kleindienst A, 2010, ACTA NEUROCHIR SUPPL, V106, P221, DOI 10.1007/978-3-211-98811-4_41; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Lin C, 2013, PEPTIDES, V42, P43, DOI 10.1016/j.peptides.2013.01.015; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Papa L, 2013, J NEUROTRAUM, V30, P324, DOI 10.1089/neu.2012.2545; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Rodriguez-Rodriguez A, 2012, CLIN CHIM ACTA, V414, P228, DOI 10.1016/j.cca.2012.09.025; Russell JA, 2009, CRIT CARE MED, V37, P749, DOI 10.1097/CCM.0b013e318194d117; Staub D, 2009, CLIN CHIM ACTA, V399, P69, DOI 10.1016/j.cca.2008.09.016; Stocchetti N, 2014, LANCET NEUROL, V13, P14, DOI 10.1016/S1474-4422(13)70280-1; Wolf H, 2013, J NEUROSURG, V118, P1298, DOI 10.3171/2013.1.JNS121181; Yalta K, 2013, INT J CARDIOL, V167, P1750, DOI 10.1016/j.ijcard.2012.12.039; Yu GF, 2012, PEPTIDES, V33, P164, DOI 10.1016/j.peptides.2011.11.017; Yu WH, 2014, CLIN CHIM ACTA, V433, P174, DOI 10.1016/j.cca.2014.03.014	24	27	31	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0196-9781	1873-5169		PEPTIDES	Peptides	OCT	2014	60						13	17		10.1016/j.peptides.2014.07.016			5	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	AP8YI	WOS:000342364900003	25076464				2021-06-18	
J	Costanzo, ME; Chou, YY; Leaman, S; Pham, DL; Keyser, D; Nathan, DE; Coughlin, M; Rapp, P; Roy, MJ				Costanzo, Michelle E.; Chou, Yi-Yu; Leaman, Suzanne; Pham, Dzung L.; Keyser, David; Nathan, Dominic E.; Coughlin, Mary; Rapp, Paul; Roy, Michael J.			Connecting combat-related mild traumatic brain injury with posttraumatic stress disorder symptoms through brain imaging	NEUROSCIENCE LETTERS			English	Article						Combat-related posttraumatic stress; Mild traumatic brain injury; Diffusion tensor imaging; Functional magnetic resonance imaging; Default mode network	DEFAULT MODE NETWORK; WHITE-MATTER TRACTS; ENDURING FREEDOM; PTSD; SEGMENTATION; VALIDATION; INTEGRITY; VETERANS; SYSTEM; CORTEX	Mild traumatic brain injury (mTBI) and posttraumatic stress disorder (PTSD) may share common symptom and neuropsychological profiles in military service members (SMs) following deployment; while a connection between the two conditions is plausible, the relationship between them has been difficult to discern. The intent of this report is to enhance our understanding of the relationship between findings on structural and functional brain imaging and symptoms of PTSD. Within a cohort of SMs who did not meet criteria for PTSD but were willing to complete a comprehensive assessment within 2 months of their return from combat deployment, we conducted a nested case-control analysis comparing those with combat-related mTBI to age/gender-matched controls with diffusion tensor imaging, resting state functional magnetic resonance imaging and a range of psychological measures. We report degraded white matter integrity in those with a history of combat mTBI, and a positive correlation between the white matter microstructure and default mode network (DMN) connectivity. Higher clinician-administered and self-reported subthreshold PTSD symptoms were reported in those with combat mTBI. Our findings offer a potential mechanism through which mTBI may alter brain function, and in turn, Contribute to PTSD symptoms. Published by Elsevier Ireland Ltd.	[Costanzo, Michelle E.; Leaman, Suzanne; Coughlin, Mary; Roy, Michael J.] Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD 20814 USA; [Costanzo, Michelle E.; Nathan, Dominic E.] Henry M Jackson Fdn, Bethesda, MD USA; [Chou, Yi-Yu; Pham, Dzung L.] Henry M Jackson Fdn, Ctr Neurosci & Regenerat Med, Image Proc Core, Bethesda, MD USA; [Keyser, David; Nathan, Dominic E.; Rapp, Paul] Uniformed Serv Univ Hlth Sci, Dept Mil & Emergency Med, Traumat Injury Res Program, Bethesda, MD 20814 USA	Roy, MJ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	michael.roy@usuhs.edu	Pham, Dzung/AAR-8263-2020		Department of Defense the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [300601 8.01 60855510005]	This work was funded by the Department of Defense the Center for Neuroscience and Regenerative Medicine 300601 8.01 60855510005. Any opinions or assertions expressed are solely those of the authors and do not necessarily represent those of Uniformed Services University, the US Army, US Navy, Department of Defense, or the US Government. Thank you to Mariam Masheeb, Julie McEntee, Rochelle Ndiongue, Carol Roos, Patricia Taylor and Joanna Vivalda for their administrative and facilitative contributions.	Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Bazin PL, 2011, NEUROIMAGE, V58, P458, DOI 10.1016/j.neuroimage.2011.06.020; Bennett CM, 2009, SOC COGN AFFECT NEUR, V4, P417, DOI 10.1093/scan/nsp053; Betthauser LM, 2012, NEUROPSYCHOL REV, V22, P35, DOI 10.1007/s11065-012-9191-4; BOHN MJ, 1995, J STUD ALCOHOL, V56, P423, DOI 10.15288/jsa.1995.56.423; Capehart B, 2012, J REHABIL RES DEV, V49, P789, DOI 10.1682/JRRD.2011.10.0185; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Daniels JK, 2013, DEPRESS ANXIETY, V30, P207, DOI 10.1002/da.22044; Daniels JK, 2010, J PSYCHIATR NEUROSCI, V35, P258, DOI 10.1503/jpn.090010; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; DVBIC, 2007, MIL AC CONC EV; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fransson P, 2008, NEUROIMAGE, V42, P1178, DOI 10.1016/j.neuroimage.2008.05.059; Germain A, 2005, J ANXIETY DISORD, V19, P233, DOI 10.1016/j.janxdis.2004.02.001; Geuze E, 2007, PROG BRAIN RES, V167, P293, DOI 10.1016/S0079-6123(07)67026-5; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Landman BA, 2013, NEUROINFORMATICS, V11, P91, DOI 10.1007/s12021-012-9159-9; Lanius RA, 2010, ACTA PSYCHIAT SCAND, V121, P33, DOI 10.1111/j.1600-0447.2009.01391.x; Lawes INC, 2008, NEUROIMAGE, V39, P62, DOI 10.1016/j.neuroimage.2007.06.041; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Schuff N, 2011, NEUROIMAGE, V54, pS62, DOI 10.1016/j.neuroimage.2010.05.024; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smid GE, 2009, J CLIN PSYCHIAT, V70, P1572, DOI 10.4088/JCP.08r04484; Song XW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025031; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Tang CY, 2012, TRANSL NEUROSCI, V3, P9, DOI 10.2478/s13380-012-0003-3; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Yan CG, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00013; Yan XD, 2013, NEUROSCI LETT, V547, P1, DOI 10.1016/j.neulet.2013.04.032; Zhou Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046833	38	27	27	0	16	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 8	2014	577						11	15		10.1016/j.neulet.2014.05.054			5	Neurosciences	Neurosciences & Neurology	AN0XY	WOS:000340308500003	24907686				2021-06-18	
J	Bonfield, CM; Naran, S; Adetayo, OA; Pollack, IF; Losee, JE				Bonfield, Christopher M.; Naran, Sanjay; Adetayo, Oluwaseun A.; Pollack, Ian F.; Losee, Joseph E.			Pediatric skull fractures: the need for surgical intervention, characteristics, complications, and outcomes	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						pediatric; skull fracture; head injury; trauma; surgical intervention	MANAGEMENT; CHILDREN; INJURIES; INFANTS; TRAUMA	Object. Head trauma is a common cause of morbidity and mortality in the pediatric population and often results in a skull fracture. Pediatric skull fractures are distinct from adult fractures. Pediatric fractures have a greater capacity to remodel, but the pediatric brain and craniofacial skeleton are still developing. Although pediatric head trauma has been extensively studied, there is sparse literature regarding skull fractures. The authors' aim was to investigate the characteristics, injuries, complications, and outcomes of the patients in whom surgical intervention was needed for skull fractures. Methods. The authors performed a retrospective review of patients presenting to the emergency department of a pediatric Level I trauma center between 2000 and 2005 with skull fractures. Patient demographics, mechanism of injury, associated injuries, fracture bone involvement, surgical intervention, complications, and outcomes were analyzed. Groups treated nonoperatively, for skull fracture repair, and for traumatic brain injury were compared. Results. A total of 897 patients with a skull fracture were analyzed. Most patients (n = 772, 86.1%) were treated nonoperatively (Non-Op group). Fifty-eight patients (6.5%) underwent repair of the fracture (Repair group) and 67 (7.5%) required intervention for treatment of traumatic brain injury (TBI group). The Non-Op group was significantly younger, and the TBI group had a lower initial Glasgow Coma Scale (GCS) score. A fall (51.2%) was the most common mechanism of injury in the Non-Op group, whereas a motor vehicle crash (23.9%) and being hit in the head with an object (48.2%) were most prevalent in the TBI and Repair groups, respectively. Associated injuries were seen in all 3 groups, with brain injury (hematoma) being the most common. Frontal bone fracture was seen most in the Repair and TBI groups, and the parietal bone was the most frequent bone fractured in the Non-Op group. Patients in the TBI group were much more likely to have 2 or 3 skull bones fractured. In the Repair group, 36.2% had a complication (38.0% intervention related and 62.0% trauma related), but no patient had a worsening of their neurological status. In the TBI group, 48.7% of the patients suffered a complication, the vast majority (90.6%) of which were related to the trauma. Conclusions. The majority of pediatric skull fractures can be managed conservatively. Of those requiring surgical intervention, fewer than half of the surgeries are performed solely for skull fracture repair only. Patients hit in the head with an object or involved in a motor vehicle crash are more likely to need surgical intervention either to repair the skull fracture or for TBI management, respectively. Frontal bone fractures are more likely to necessitate repair, and those patients treated for TBI have a greater incidence of 2 or 3 bones involved in the fracture. Complications occurred but most were related to underlying trauma, not the surgery. No patients who underwent intervention for repair of their skull fracture only had a worsening of their neurological status.	[Bonfield, Christopher M.; Pollack, Ian F.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Naran, Sanjay; Adetayo, Oluwaseun A.; Losee, Joseph E.] Univ Pittsburgh, Dept Plast Surg, Pittsburgh, PA 15260 USA	Bonfield, CM (corresponding author), 200 Lothrop St,Ste B400, Pittsburgh, PA 15213 USA.	bonfieldcm@upmc.edu					BRAAKMAN R, 1972, J NEUROL NEUROSUR PS, V35, P395, DOI 10.1136/jnnp.35.3.395; Erlichman DB, 2010, PEDIATR RADIOL, V40, P1375, DOI 10.1007/s00247-010-1555-4; Ersahin Y, 1996, CHILD NERV SYST, V12, P323, DOI 10.1007/BF00301021; Haug RH, 2000, ORAL SURG ORAL MED O, V90, P126, DOI 10.1067/moe.2000.107974; Hung KL, 2005, J NEUROSURG, V103, P69, DOI 10.3171/ped.2005.103.1.0069; JENNETT B, 1974, J NEUROSURG, V41, P208, DOI 10.3171/jns.1974.41.2.0208; MANN KS, 1986, CHILD NERV SYST, V2, P258; National Center for Injury Prevention and Control of the Centers for Disease Control and Prevention, 2000, TRAUM BRAIN INJ US A; NELSON EL, 1984, NEUROSURGERY, V15, P318, DOI 10.1227/00006123-198409000-00005; Saadat S, 2011, ULUS TRAVMA ACIL CER, V17, P149, DOI 10.5505/tjtes.2011.26043; Sanford RA, 2010, J NEUROSURG-PEDIATR, V5, P213, DOI 10.3171/2009.9.PEDS09180; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Shane SA, 1997, PEDIATR EMERG CARE, V13, P198, DOI 10.1097/00006565-199706000-00006; Singh DJ, 2004, CLIN PLAST SURG, V31, P499, DOI 10.1016/j.cps.2004.03.012; STEINBOK P, 1987, J NEUROSURG, V66, P506, DOI 10.3171/jns.1987.66.4.0506; VANDENHEEVER CM, 1989, J NEUROSURG, V71, P186, DOI 10.3171/jns.1989.71.2.0186	16	27	29	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	AUG	2014	14	2					205	211		10.3171/2014.5.PEDS13414			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	AL9PJ	WOS:000339472900017	24905840				2021-06-18	
J	Ignatowski, TA; Spengler, RN; Dhandapani, KM; Folkersma, H; Butterworth, RF; Tobinick, E				Ignatowski, Tracey A.; Spengler, Robert N.; Dhandapani, Krishnan M.; Folkersma, Hedy; Butterworth, Roger F.; Tobinick, Edward			Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence	CNS DRUGS			English	Article							TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN-INJURY; TRANSFORAMINAL EPIDURAL ETANERCEPT; VERTEBRAL VENOUS PLEXUS; FACTOR-ALPHA EXPRESSION; PAIN-RELATED BEHAVIOR; OFF-LABEL USE; TNF-ALPHA; ALZHEIMERS-DISEASE; INTRACEREBRAL HEMORRHAGE	There is increasing recognition of the involvement of the immune signaling molecule, tumor necrosis factor (TNF), in the pathophysiology of stroke and chronic brain dysfunction. TNF plays an important role both in modulating synaptic function and in the pathogenesis of neuropathic pain. Etanercept is a recombinant therapeutic that neutralizes pathologic levels of TNF. Brain imaging has demonstrated chronic intracerebral microglial activation and neuroinflammation following stroke and other forms of acute brain injury. Activated microglia release TNF, which mediates neurotoxicity in the stroke penumbra. Recent observational studies have reported rapid and sustained improvement in chronic post-stroke neurological and cognitive dysfunction following perispinal administration of etanercept. The biological plausibility of these results is supported by independent evidence demonstrating reduction in cognitive dysfunction, neuropathic pain, and microglial activation following the use of etanercept, as well as multiple studies reporting improvement in stroke outcome and cognitive impairment following therapeutic strategies designed to inhibit TNF. The causal association between etanercept treatment and reduction in post-stroke disability satisfy all of the Bradford Hill Criteria: strength of the association; consistency; specificity; temporality; biological gradient; biological plausibility; coherence; experimental evidence; and analogy. Recognition that chronic microglial activation and pathologic TNF concentration are targets that may be therapeutically addressed for years following stroke and other forms of acute brain injury provides an exciting new direction for research and treatment.	[Ignatowski, Tracey A.] SUNY Buffalo, Sch Med & Biomed Sci, Dept Pathol & Anat Sci, Buffalo, NY 14260 USA; [Ignatowski, Tracey A.] SUNY Buffalo, Sch Med & Biomed Sci, Program Neurosci, Buffalo, NY 14260 USA; [Spengler, Robert N.] NanoAxis LLC, Clarence, NY USA; [Dhandapani, Krishnan M.] Georgia Regents Univ, Med Coll Georgia, Dept Neurosurg, Augusta, GA USA; [Folkersma, Hedy] Vrije Univ Amsterdam Med Ctr, Neurosurg Ctr Amsterdam, Amsterdam, Netherlands; [Butterworth, Roger F.] Univ Montreal, Hop St Luc CHUM, Neurosci Res Unit, Montreal, PQ, Canada; [Tobinick, Edward] Inst Neurol Recovery, Boca Raton, FL 33431 USA	Tobinick, E (corresponding author), Inst Neurol Recovery, 2300 Glades Rd Suite 305E, Boca Raton, FL 33431 USA.	nrimed@gmail.com	Ignatowski, Tracey/ABG-8740-2020	Dhandapani, Krishnan/0000-0001-7044-1117; Tobinick, Edward/0000-0001-7614-499X; Ignatowski, Tracey/0000-0002-8033-4566			American Psychiatric Association, 2001, PRINC MED ETH ANN ES, P46; ANDERSON R, 1951, J NEUROSURG, V8, P411, DOI 10.3171/jns.1951.8.4.0411; [Anonymous], 2008, LANCET NEUROL, V7, P285, DOI 10.1016/S1474-4422(08)70050-4; Aronowski J, 2005, NEUROL RES, V27, P268, DOI 10.1179/016164105X25225; Aronson JK, 2006, BMJ-BRIT MED J, V333, P1267, DOI 10.1136/bmj.39036.666389.94; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bacher M, 2009, NEUROSCI LETT, V449, P240, DOI 10.1016/j.neulet.2008.08.083; Bains JS, 2007, TRENDS NEUROSCI, V30, P417, DOI 10.1016/j.tins.2007.06.007; BANKS WA, 1995, NEUROIMMUNOMODULAT, V2, P161, DOI 10.1159/000096887; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Bassi E, 2010, AM J CLIN DERMATOL, V11, P44, DOI 10.2165/1153423-S0-000000000-00000; Batson OV, 1940, ANN SURG, V112, P138, DOI 10.1097/00000658-194007000-00016; BATSON OV, 1957, AMER J ROENTGENOL RA, V78, P195; Bauer HH, 2012, DOGMATISM SCI MED DO, Vvii, P293; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Beattie MS, 2010, EUR J NEUROSCI, V32, P290, DOI 10.1111/j.1460-9568.2010.07343.x; Beck JM, 1998, FOOD DRUG LAW J, V53, P71; Belarbi K, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-23; Bemeur C, 2010, NEUROCHEM INT, V56, P213, DOI 10.1016/j.neuint.2009.11.010; Blaylock Russell L, 2013, Surg Neurol Int, V4, P118, DOI 10.4103/2152-7806.118349; Bohac D, 2002, NEUROBIOL AGING S1, V23, pS1; Brambilla L, 2013, PRION, V7, P28, DOI 10.4161/pri.22512; Breschet G, 1819, THESIS F MED PARIS; Breschet G., 1829, RECHERCHES ANATOMIQU, P48; Buchhave P, 2010, NEUROBIOL AGING, V31, P1877, DOI 10.1016/j.neurobiolaging.2008.10.012; Butchart J, 2012, CNS NEUROSCI THER, V18, P64, DOI 10.1111/j.1755-5949.2011.00245.x; Butterworth RF, 2013, NAT REV GASTRO HEPAT, V10, P522, DOI 10.1038/nrgastro.2013.99; Butterworth RF, 2011, NEUROCHEM INT, V59, P830, DOI 10.1016/j.neuint.2011.07.014; Butterworth RF, 2011, HEPATOLOGY, V53, P1372, DOI 10.1002/hep.24228; Camara ML, 2013, PSYCHONEUROENDOCRINO, V38, P3102, DOI 10.1016/j.psyneuen.2013.09.010; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Cavanagh C, 2011, FUTUR NEUROL, V6, P757, DOI 10.2217/FNL.11.50; Chastre A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049670; Chen YM, 2010, JOINT BONE SPINE, V77, P366, DOI 10.1016/j.jbspin.2010.01.017; Cheong CU, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/620837; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Chou RC, AM COLL RHEUM ANN M; Clark IA, 2009, PARASITOLOGY, V136, P1457, DOI 10.1017/S0031182009006088; Clark I A, 1992, Immunol Ser, V56, P365; CLARK IA, 1989, T ROY SOC TROP MED H, V83, P436, DOI 10.1016/0035-9203(89)90240-X; CLARK IA, 1990, IMMUNOL LETT, V25, P195, DOI 10.1016/0165-2478(90)90114-6; CLARK IA, 1991, LANCET, V337, P302, DOI 10.1016/0140-6736(91)90915-C; CLARK IA, 1993, Q J MED, V86, P217; Clark I, 2012, CNS DRUGS, V26, P1071, DOI 10.1007/s40263-012-0014-1; Clark I, 2012, PHARMACOL REV, V64, P1004, DOI 10.1124/pr.112.005850; Clark IA, 2007, CYTOKINE GROWTH F R, V18, P335, DOI 10.1016/j.cytogfr.2007.04.002; Clark IA, 2013, BIOCHEM PHARMACOL, V86, P862, DOI 10.1016/j.bcp.2013.07.030; Clark IA, 2010, PHARMACOL THERAPEUT, V128, P519, DOI 10.1016/j.pharmthera.2010.08.007; Coelho SC, 2014, EUR J PAIN; Cohen SP, 2009, ANESTHESIOLOGY, V110, P1116, DOI 10.1097/ALN.0b013e3181a05aa0; Covey WC, 2002, REGION ANESTH PAIN M, V27, P357, DOI 10.1053/rapm.2002.31930; Covey WC, 2000, BRAIN RES, V859, P113, DOI 10.1016/S0006-8993(00)01965-X; D'Mello C, 2009, J NEUROSCI, V29, P2089, DOI 10.1523/JNEUROSCI.3567-08.2009; Dabus G, 2012, WORLD NEUROSURG, V77, DOI 10.1016/j.wneu.2011.01.031; Dacks PA, 2014, JAMA NEUROL, V71, P137, DOI 10.1001/jamaneurol.2013.5376; De Sanctis JB, 2010, RECENT PATENTS INFLA, V4, P144, DOI 10.2174/187221310791163026; De Wyngaert R, 2009, NEURORADIOLOGY, V51, P385, DOI 10.1007/s00234-009-0505-z; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; DeMonaco HJ, 2006, PHARMACOTHERAPY, V26, P323, DOI 10.1592/phco.26.3.323; Detrait ER, 2014, NEUROCHEM INT, V72, P10, DOI 10.1016/j.neuint.2014.04.001; Di Bona D, 2009, BRAIN RES REV, V61, P60, DOI 10.1016/j.brainresrev.2009.05.001; Dogrul A, 2011, ACTA DIABETOL, V48, P135, DOI 10.1007/s00592-010-0237-x; DUBOIS A, 1988, BRAIN RES, V445, P77, DOI 10.1016/0006-8993(88)91076-1; Dumont TM, 2010, SPINE, V35, pE1238, DOI 10.1097/BRS.0b013e3181f62600; Dziedzic T, 2002, STROKE, V33, P2334, DOI 10.1161/01.STR.0000027211.73567.FA; Elfferich MD, 2010, RESPIRATION, V80, P212, DOI 10.1159/000314225; Esposito E, 2011, TRENDS PHARMACOL SCI, V32, P107, DOI 10.1016/j.tips.2010.11.009; Etz CD, 2008, J THORAC CARDIOV SUR, V135, P324, DOI 10.1016/j.jtcvs.2007.11.002; Faingold C. L., 2014, NEURONAL NETWORKS BR; Fang HY, 2007, J CLIN NEUROSCI, V14, P435, DOI 10.1016/j.jocn.2005.12.022; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Folkersma H, 2011, J NUCL MED, V52, P1235, DOI 10.2967/jnumed.110.084061; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Frattarelli DAC, 2014, PEDIATRICS, V133, P563, DOI 10.1542/peds.2013-4060; Freeman BJC, 2013, SPINE, V38, P1986, DOI 10.1097/01.brs.0000435140.61593.4c; Friedman P J, 1990, Int Disabil Stud, V12, P119; Gabbita SP, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-99; Galluzzi L, 2008, CELL, V135, P1161, DOI 10.1016/j.cell.2008.12.004; Galustian C, 2004, EXPERT OPIN BIOL TH, V4, P1963, DOI 10.1517/14712598.4.12.1963; Gasco J, 2009, SKULL BASE-INTERD AP, V19, P425, DOI 10.1055/s-0029-1224774; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gerhard A, 2005, NEUROIMAGE, V24, P591, DOI 10.1016/j.neuroimage.2004.09.034; Ghaemi S Nassir, 2007, Philos Ethics Humanit Med, V2, P26, DOI 10.1186/1747-5341-2-26; Giuliani F, 2009, BRAIN RES BULL, V80, P302, DOI 10.1016/j.brainresbull.2009.07.009; Glasziou P, 2007, BMJ-BRIT MED J, V334, P349, DOI 10.1136/bmj.39070.527986.68; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Grant GJ, 2005, OBSTET GYNECOL, V106, P384, DOI 10.1097/01.AOG.0000168452.10067.27; Gray H, 1866, ANATOMY DESCRIPTIVE; Griessenauer CJ, 2014, CLIN ANAT; Griessenauer CJ, 2014, VENOUS DRAINAGE SPIN; Griffin WST, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-3; Groen RJM, 1997, ANAT REC, V249, P285, DOI 10.1002/(SICI)1097-0185(199710)249:2<285::AID-AR16>3.0.CO;2-K; Groen RJM, 2004, SPINE, V29, P1465, DOI 10.1097/01.BRS.0000128758.64381.75; Gururaja TL, 2007, CHEM BIOL, V14, P1105, DOI 10.1016/j.chembiol.2007.08.012; Hachinski V, 2010, STROKE, V41, P1084, DOI 10.1161/STROKEAHA.110.586156; HERLIHY W F, 1947, Med J Aust, V1, P661; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Hojlund J, 2012, ANESTHESIOL RES PRAC, V2012, DOI 10.1155/2012/647258; Horrobin DF, 2002, LANCET, V359, P1857, DOI 10.1016/S0140-6736(02)08707-X; Hua Y, 2006, NEUROSURGERY, V58, P542, DOI 10.1227/01.NEU.0000197333.55473.AD; Hughes JL, 2010, NEUROIMAGE, V49, P19, DOI 10.1016/j.neuroimage.2009.08.047; Ignatowski TA, 2013, 4TH INTERNATIONAL CONGRESS ON NEUROPATHIC PAIN, P29; Ignatowski TA, 1999, BRAIN RES, V841, P70, DOI 10.1016/S0006-8993(99)01782-5; Ignatowski TA, 2008, NEUROIMMUNE, V6, P111; Jiang WL, 2009, J CEREBR BLOOD F MET, V29, P944, DOI 10.1038/jcbfm.2009.18; Jiang WL, 2009, J NEUROCHEM, V109, P485, DOI 10.1111/j.1471-4159.2009.05981.x; John CC, 2008, AM J TROP MED HYG, V78, P198, DOI 10.4269/ajtmh.2008.78.198; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P27, DOI 10.1016/S0003-9993(95)80038-7; Kaplan BJ, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-65; Kato K, 2009, NEUROSCIENCE, V160, P492, DOI 10.1016/j.neuroscience.2009.02.038; Kaufman EL, 2013, OPEN SPINE J, V5, P12; Kaushal V, 2008, J NEUROSCI, V28, P2221, DOI 10.1523/JNEUROSCI.5643-07.2008; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kim JS, 1996, STROKE, V27, P1553, DOI 10.1161/01.STR.27.9.1553; King MD, 2014, INT J CELL BIOL; King MD, 2013, NEUROSCI LETT, V542, P92, DOI 10.1016/j.neulet.2013.02.051; Kirschner KL, 2013, PM&R, V5, P882, DOI 10.1016/j.pmrj.2013.08.601; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kooijman E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090584; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kuhn TS, 1962, STRUCTURE SCI REVOLU, Vxv, P172; Kuhn TS, 2000, ROAD STRUCTURE PHILO, Vviii, P335; LaBan MM, 1998, AM J PHYS MED REHAB, V77, P553, DOI 10.1097/00002060-199811000-00021; LaBan MM, 1997, AM J PHYS MED REHAB, V76, P517, DOI 10.1097/00002060-199711000-00016; Laird MD, 2008, FREE RADICAL BIO MED, V45, P1103, DOI 10.1016/j.freeradbiomed.2008.07.003; Laws SM, 2005, HUM MUTAT, V26, P29, DOI 10.1002/humu.20180; Lei BL, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-103; Li SR, 2011, BLOOD, V117, P5157, DOI 10.1182/blood-2010-10-314278; Lindenlaub T, 2000, BRAIN RES, V866, P15, DOI 10.1016/S0006-8993(00)02190-9; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Low PC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4450; Lu AG, 2006, J CEREBR BLOOD F MET, V26, P230, DOI 10.1038/sj.jcbfm.9600183; Marchand F, 2009, EUR J PAIN, V13, P673, DOI 10.1016/j.ejpain.2008.08.001; Martuscello RT, 2012, PAIN, V153, P1871, DOI 10.1016/j.pain.2012.05.028; Maudsley S, 2012, CURR ALZHEIMER RES, V9, P1; Mayhan WG, 2002, BRAIN RES, V927, P144, DOI 10.1016/S0006-8993(01)03348-0; Mayne M, 2001, STROKE, V32, P240, DOI 10.1161/01.STR.32.1.240; McAfoose J, 2009, NEUROSCI BIOBEHAV R, V33, P355, DOI 10.1016/j.neubiorev.2008.10.005; McNaull BBA, 2010, GERONTOLOGY, V56, P3, DOI 10.1159/000237873; Medeiros R, 2007, J NEUROSCI, V27, P5394, DOI 10.1523/JNEUROSCI.5047-06.2007; Mendis S, 2013, INT J STROKE, V8, P3, DOI 10.1111/j.1747-4949.2012.00969.x; Miklossy J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-90; Miller ZA, 2013, J NEUROL NEUROSUR PS, V84, P956, DOI 10.1136/jnnp-2012-304644; MOREIRA AL, 1993, J EXP MED, V177, P1675, DOI 10.1084/jem.177.6.1675; Morimoto Akira, 2009, Legal Medicine, V11, P10, DOI 10.1016/j.legalmed.2008.07.006; MYERS R, 1991, NEUROSCI LETT, V133, P20, DOI 10.1016/0304-3940(91)90047-W; Nathoo N, 2011, NEUROSURGERY, V69, P1007, DOI 10.1227/NEU.0b013e3182274865; Nawashiro H, 1997, BRAIN RES, V778, P265, DOI 10.1016/S0006-8993(97)00981-5; Netter FH, 1958, CIBA COLLECTION MED; Neurex, 2012, M ROL TNF BRAIN DYSF; Nygard M, 2009, NEUROREPORT, V20, P213, DOI 10.1097/WNR.0b013e32831f1ca2; OCEBM Levels of Evidence Working Group, 2011, OXF 2011 LEV EV; Ohtori S, 2012, SPINE, V37, P439, DOI 10.1097/BRS.0b013e318238af83; Oka T, 1996, NEUROIMMUNOMODULAT, V3, P135, DOI 10.1159/000097238; Pan WH, 2007, PROG NEUROBIOL, V83, P363, DOI 10.1016/j.pneurobio.2007.07.008; Pappata S, 2000, NEUROLOGY, V55, P1052, DOI 10.1212/WNL.55.7.1052; Pearce JMS, 2006, EUR NEUROL, V56, P136, DOI 10.1159/000095706; Perry RT, 2001, NEUROBIOL AGING, V22, P873, DOI 10.1016/S0197-4580(01)00291-3; Pettygrove S, 2008, ENCY EPIDEMIOL, V1, P282; Pickering M, 2005, EXP PHYSIOL, V90, P663, DOI 10.1113/expphysiol.2005.030734; Price CJS, 2006, STROKE, V37, P1749, DOI 10.1161/01.STR.0000226980.95389.0b; Puri AS, 2014, J NEUROINTERV SURG, V6, P150, DOI 10.1136/neurintsurg-2012-010589; Quain J, 1867, ELEMENTS ANATOMY; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ramos EM, 2006, ARCH NEUROL-CHICAGO, V63, P1165, DOI 10.1001/archneur.63.8.1165; Reynolds JL, 2005, J NEUROSCI RES, V79, P779, DOI 10.1002/jnr.20407; Riggs JE, 1996, ARCH NEUROL-CHICAGO, V53, P1306, DOI 10.1001/archneur.1996.00550120118026; Roh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040065; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Rossi D, 2011, CNS DRUGS, V25, P641, DOI 10.2165/11593090-000000000-00000; Rubenstein JL, 2003, BLOOD, V101, P466, DOI 10.1182/blood-2002-06-1636; Sainoh T, 2013, INT SOC STUD LUMB SP; Santello M, 2012, TRENDS NEUROSCI, V35, P638, DOI 10.1016/j.tins.2012.06.001; Sarajarvi T, 2010, J ALZHEIMERS DIS, V21, P763, DOI 10.3233/JAD-2010-100597; See Andrew, 2000, DEFENCE COUNSEL J, V67, P478; Shen CH, 2011, ANESTH ANALG, V112, P454, DOI 10.1213/ANE.0b013e3182025b15; Sheridan C, 2009, NAT BIOTECHNOL, V27, P679, DOI 10.1038/nbt0809-679; SHERMAN ML, 1988, J CLIN ONCOL, V6, P344, DOI 10.1200/JCO.1988.6.2.344; Shi JQ, 2011, J AM GERIATR SOC, V59, P1142, DOI 10.1111/j.1532-5415.2011.03445.x; Shi JQ, 2011, BRAIN RES, V1368, P239, DOI 10.1016/j.brainres.2010.10.053; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Siniscalchi Antonio, 2014, Journal of Basic and Clinical Physiology and Pharmacology, V25, P131, DOI 10.1515/jbcpp-2013-0121; Sjogren M, 2004, J NEUROL NEUROSUR PS, V75, P1107, DOI 10.1136/jnnp.2003.019422; Skolarus LE, 2014, STROKE, V45, P224, DOI 10.1161/STROKEAHA.113.002874; Smith GCS, 2003, BRIT MED J, V327, P1459, DOI 10.1136/bmj.327.7429.1459; Sommer C, 2001, BRAIN RES, V913, P86, DOI 10.1016/S0006-8993(01)02743-3; Sommer C, 2001, J PERIPHER NERV SYST, V6, P67, DOI 10.1046/j.1529-8027.2001.01010.x; Sommer C, 1998, EXP NEUROL, V151, P138, DOI 10.1006/exnr.1998.6797; SPRIGGS DR, 1988, J NATL CANCER I, V80, P1039, DOI 10.1093/jnci/80.13.1039; Stellwagen D, 2006, NATURE, V440, P1054, DOI 10.1038/nature04671; Strong C, 2013, J CLIN NEUROSCI, V20, P1546, DOI 10.1016/j.jocn.2013.02.014; Sumbria RK, 2012, J CEREBR BLOOD F MET, V32, P1933, DOI 10.1038/jcbfm.2012.97; Takata F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-106; TANCREDI V, 1992, NEUROSCI LETT, V146, P176, DOI 10.1016/0304-3940(92)90071-E; Tarkowski E, 1999, J CLIN IMMUNOL, V19, P223, DOI 10.1023/A:1020568013953; Tarkowski E, 2003, J NEUROL NEUROSUR PS, V74, P1200, DOI 10.1136/jnnp.74.9.1200; Terrando N, 2010, P NATL ACAD SCI USA, V107, P20518, DOI 10.1073/pnas.1014557107; Tobinick E, 2004, CURR MED RES OPIN, V20, P1075, DOI 10.1185/030079903125004286; Tobinick E, 2007, CURR ALZHEIMER RES, V4, P550, DOI 10.2174/156720507783018217; Tobinick Edward, 2006, MedGenMed, V8, P25; Tobinick Edward, 2006, MedGenMed, V8, P53; Tobinick E, 2014, CLIN DRUG INVEST, V34, P361, DOI 10.1007/s40261-014-0186-1; Tobinick E, 2012, CNS DRUGS, V26, P1051, DOI 10.1007/s40263-012-0013-2; Tobinick E, 2012, CURR ALZHEIMER RES, V9, P99, DOI 10.2174/156720512799015073; Tobinick E, 2011, CNS DRUGS, V25, P145, DOI 10.2165/11588400-000000000-00000; Tobinick E, 2010, EXPERT REV NEUROTHER, V10, P985, DOI 10.1586/ERN.10.52; Tobinick E, 2009, CNS DRUGS, V23, P713, DOI 10.2165/11310810-000000000-00000; Tobinick Edward, 2008, Medscape J Med, V10, P135; Tobinick E, 2009, DRUG DISCOV TODAY, V14, P168, DOI 10.1016/j.drudis.2008.10.005; Tobinick EL, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-27; Tobinick EL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-2; Tobinick Edward L, 2009, BMC Res Notes, V2, P28; Tobinick EL, 2003, CLIN THER, V25, P2279, DOI 10.1016/S0149-2918(03)80219-9; Tobinick EL, 2003, SWISS MED WKLY, V133, P170; Tobinick EL, 2003, CLIN THER, V25, P1211, DOI 10.1016/S0149-2918(03)80077-2; Tracey D, 2008, PHARMACOL THERAPEUT, V117, P244, DOI 10.1016/j.pharmthera.2007.10.001; Trollor JN, 2010, DEMENT GERIATR COGN, V30, P569, DOI 10.1159/000322092; Tubbs RS, 2007, CLIN ANAT, V20, P755, DOI 10.1002/ca.20494; Tweedie D, 2007, CURR ALZHEIMER RES, V4, P378, DOI 10.2174/156720507781788873; WADE DT, 1987, SCAND J REHABIL MED, V19, P25; Wagner KR, 2006, ACTA NEUROCHIR SUPPL, V96, P177; Walsh N., 2010, MEDPAGE TODAY, V9, P2010; Wang QW, 2005, EUR J NEUROSCI, V22, P2827, DOI 10.1111/j.1460-9568.2005.04457.x; Wang Y, 2008, ALZHEIMER DEMENT S, V4, pT749; Wasserman JK, 2007, BRAIN RES, V1180, P140, DOI 10.1016/j.brainres.2007.08.058; Watanabe K, 2011, EUR SPINE J, V20, P1877, DOI 10.1007/s00586-011-1854-y; Wheeler D, 2009, J NEUROCHEM, V109, P1237, DOI 10.1111/j.1471-4159.2009.06038.x; Williams M, 2012, TRANSLATIONAL NEUROSCIENCE: APPLICATIONS IN PSYCHIATRY, NEUROLOGY, AND NEURODEVELOPMENTAL DISORDERS, P129; Winkelstein BA, 2014, INTERVERTEBRAL DISC; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Wolinsky H, 2008, EMBO REP, V9, P416, DOI 10.1038/embor.2008.65; Works MG, 2013, J CEREBR BLOOD F MET, V33, P1376, DOI 10.1038/jcbfm.2013.100; Xi GH, 2001, STROKE, V32, P162, DOI 10.1161/01.STR.32.1.162; Xu XS, 2010, BRAIN RES, V1355, P189, DOI 10.1016/j.brainres.2010.07.080; Yoon JS, 2013, J NEUROSCI RES, V91, P671, DOI 10.1002/jnr.23190; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zanella JM, 2008, SPINE, V33, P227, DOI 10.1097/BRS.0b013e318162340a; Zaremba J, 2000, Folia Morphol (Warsz), V59, P137; Zaremba J, 2001, BIOMED PHARMACOTHER, V55, P258, DOI 10.1016/S0753-3322(01)00058-0; Zaremba J, 2001, ACTA NEUROL SCAND, V104, P288, DOI 10.1034/j.1600-0404.2001.00053.x; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387; Zhu XX, 2003, J MED CHEM, V46, P5222, DOI 10.1021/jm030152f; Zivin JA, 2010, TPA STROKE STORY CON	253	27	29	0	10	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1172-7047	1179-1934		CNS DRUGS	CNS Drugs	AUG	2014	28	8					679	697		10.1007/s40263-014-0174-2			19	Clinical Neurology; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	AT0FX	WOS:000344613600001	24861337	Green Published, Other Gold			2021-06-18	
J	Andelic, N; Ye, JJ; Tornas, S; Roe, C; Lu, J; Bautz-Holter, E; Moger, T; Sigurdardottir, S; Schanke, AK; Aas, E				Andelic, Nada; Ye, Jiajia; Tornas, Sveinung; Roe, Cecilie; Lu, Juan; Bautz-Holter, Erik; Moger, Tron; Sigurdardottir, Solrun; Schanke, Anne-Kristine; Aas, Eline			Cost-Effectiveness Analysis of an Early-Initiated, Continuous Chain of Rehabilitation after Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						head injury; outcome measures; rehabilitation; traumatic brain injury	SEVERE HEAD-INJURY; POPULATION; DIFFERENCE; OUTCOMES; IMPROVE; EUROPE; TRIAL; SCALE; COMA	The aim of this study is to estimate the long-term cost-effectiveness of two different rehabilitation trajectories after severe traumatic brain injury (sTBI). A decision tree model compared hospitalization costs, health effects, and incremental cost-effectiveness ratios (ICER) of a continuous chain versus a broken chain of rehabilitation. The expected costs were estimated by the reimbursement system using diagnosis-related group and based on point estimates of the Disability Rating Scale (DRS); the health effects were measured by means of area under the curve (AUC). The incremental health benefit was estimated as the difference in the AUCs between the chains. Lower values on the DRS scale indicate better health; thus, smaller AUCs were preferred. The modeled population was a cohort of 59 patients with sTBI (30 in continuous chain; 29 in broken chain) with 6-weeks, 1-year, and 5-year post-injury follow-ups. Regarding the DRS estimates, 5-year AUCs were 19.40 (continuous chain) and 23.46 (broken chain). Across 5 years, the continuous chain of rehabilitation had lower costs and better health effects. By replacing the broken chain with the continuous chain, NOK 37.000 could be saved and 4.06 DRS points gained. By means of probabilistic sensitivity analysis, the majority of ICER estimates (67% of the Monte Carlo simulations) indicated that a continuous chain of rehabilitation was less costly and more effective. These findings indicate that the trajectory of continuous rehabilitation represents a dominant strategy in that it reduces costs and improves outcomes after sTBI under reasonable assumptions.	[Andelic, Nada; Sigurdardottir, Solrun] Univ Oslo, Fac Med, Res Ctr Habilitat & Rehabil Models & Serv CHARM, Inst Hlth & Soc, N-0318 Oslo, Norway; [Andelic, Nada; Roe, Cecilie; Bautz-Holter, Erik] Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway; [Ye, Jiajia; Moger, Tron; Aas, Eline] Univ Oslo, Dept Hlth Management & Hlth Econ, Inst Hlth & Soc, N-0318 Oslo, Norway; [Tornas, Sveinung; Sigurdardottir, Solrun; Schanke, Anne-Kristine] Sunnaas Rehabil Hosp Trust, Nesoddtangen, Norway; [Roe, Cecilie] Univ Oslo, Inst Clin Med, N-0318 Oslo, Norway; [Lu, Juan] Virginia Commonwealth Univ, Dept Family Med & Populat Hlth, Div Epidemiol, Richmond, VA USA	Andelic, N (corresponding author), Univ Oslo, Fac Med, Res Ctr Habilitat & Rehabil Models & Serv CHARM, Inst Hlth & Soc, PB 1130 Blindern, N-0318 Oslo, Norway.	nandelic@online.no		Andelic, Nada/0000-0002-3719-4406; Lu, Juan/0000-0002-5389-7603	Institute of Health and Society, CHARM (Research Centre for Habilitation and Rehabilitation Models and Services); Faculty of Medicine, University of Oslo; Department of Physical Medicine and Rehabilitation, Oslo University Hospital, Oslo	This study was funded by the Institute of Health and Society, CHARM (Research Centre for Habilitation and Rehabilitation Models and Services), the Faculty of Medicine, University of Oslo, and the Department of Physical Medicine and Rehabilitation, Oslo University Hospital, Oslo.	Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Drummond MF, 2005, MED DECIS MAKING, V25, P520, DOI 10.1177/0272989X05280561; Drummond MF, 2005, METHODS EC EVALUATIO; Fenwick E, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-52; Frost RB, 2013, NEUROEPIDEMIOLOGY, V40, P154, DOI 10.1159/000343275; Greenwood RJ, 2004, BRIT J NEUROSURG, V18, P462, DOI 10.1080/02688690400012327; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Ho KM, 2011, J TRAUMA, V71, P1637, DOI 10.1097/TA.0b013e31823a08f1; Kompanje EJO, 2007, SCI ENG ETHICS, V13, P371, DOI 10.1007/s11948-007-9027-4; Lu J, 2013, J NEUROTRAUM, V30, P1925, DOI 10.1089/neu.2013.2891; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mishra V, 2001, TRANSPLANT INT, V14, P361, DOI 10.1111/j.1432-2277.2001.tb00074.x; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Polinder S, 2005, J TRAUMA, V59, P1283, DOI 10.1097/01.ta.0000195998.11304.5b; Price MJ, 2011, VALUE HEALTH, V14, P205, DOI 10.1016/j.jval.2010.08.001; Ramsey S, 2005, VALUE HEALTH, V8, P521, DOI 10.1111/j.1524-4733.2005.00045.x; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; Ricker J H, 1998, Appl Neuropsychol, V5, P184, DOI 10.1207/s15324826an0504_3; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sorbo A, 2005, BRAIN INJURY, V19, P493, DOI 10.1080/02699050400013709; TEASDALE G, 1974, LANCET, V2, P81; Turner-Stokes L, 2004, CLIN MED, V4, P61, DOI 10.7861/clinmedicine.4-1-61; TURNERSTOKES L, 2005, COCHRANE DB SYST REV, V3, DOI DOI 10.1016/S0079-6123(09)17707-5; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; Whitmore RG, 2012, J NEUROSURG, V116, P1106, DOI 10.3171/2012.1.JNS11962; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941	31	27	27	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2014	31	14					1313	1320		10.1089/neu.2013.3292			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AN4CA	WOS:000340534000008	24720788				2021-06-18	
J	Lang, GE; Stewart, PS; Vella, D; Waters, SL; Goriely, A				Lang, Georgina E.; Stewart, Peter S.; Vella, Dominic; Waters, Sarah L.; Goriely, Alain			Is the Donnan effect sufficient to explain swelling in brain tissue slices?	JOURNAL OF THE ROYAL SOCIETY INTERFACE			English	Article						Donnan effect; triphasic model; brain mechanics; tissue swelling	MECHANICAL-PROPERTIES; MIXTURE THEORY; MODEL; COMPRESSION; CARTILAGE	Brain tissue swelling is a dangerous consequence of traumatic injury and is associated with raised intracranial pressure and restricted blood flow. We consider the mechanical effects that drive swelling of brain tissue slices in an ionic solution bath, motivated by recent experimental results that showed that the volume change of tissue slices depends on the ionic concentration of the bathing solution. This result was attributed to the presence of large charged molecules that induce ion concentration gradients to ensure electroneutrality (the Donnan effect), leading to osmotic pressures and water accumulation. We use a mathematical triphasic model for soft tissue to characterize the underlying processes that could lead to the volume changes observed experimentally. We suggest that swelling is caused by an osmotic pressure increase driven by both non-permeating solutes released by necrotic cells, in addition to the Donnan effect. Both effects are necessary to explain the dependence of the tissue slice volume on the ionic bath concentration that was observed experimentally.	[Lang, Georgina E.; Stewart, Peter S.; Vella, Dominic; Waters, Sarah L.; Goriely, Alain] Univ Oxford, Inst Math, Oxford OX1 3LB, England; [Stewart, Peter S.] Univ Glasgow, Sch Math & Stat, Glasgow, Lanark, Scotland	Goriely, A (corresponding author), Univ Oxford, Inst Math, 24-29 St Giles, Oxford OX1 3LB, England.	goriely@maths.ox.ac.uk	Vella, Dominic/A-9070-2008; Goriely, Alain/E-3277-2012	Vella, Dominic/0000-0003-1341-8863; Stewart, Peter/0000-0002-0971-8057; Waters, Sarah/0000-0001-5285-0523; Goriely, Alain/0000-0002-6436-8483			Ateshian GA, 2006, J BIOMECH, V39, P464, DOI 10.1016/j.jbiomech.2004.12.013; Atkins P., 2006, PHYS CHEM, VEight; Bilston LE, 2011, BIOL MED PHYS BIOMED, P69, DOI 10.1007/978-1-4419-9997-9_4; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Cho S, 2007, CURR NEUROPHARMACOL, V5, P19, DOI 10.2174/157015907780077105; Cowin SC, 2009, TISSUE MECH; Donnan FG, 1924, CHEM REV, V1, P73, DOI 10.1021/cr60001a003; Drapaca CS., 2012, INT J NUMER ANAL MOD, V3, P82; Elkin BS, 2011, J NEUROTRAUM, V28, P2277, DOI 10.1089/neu.2010.1603; Elkin BS, 2010, PHILOS T R SOC A, V368, P585, DOI 10.1098/rsta.2009.0223; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Frijns AJH, 1997, INT J ENG SCI, V35, P1419, DOI 10.1016/S0020-7225(97)00047-5; FUNG YC, 1984, AM ZOOL, V24, P13, DOI 10.1093/icb/24.1.13; Garcia JJ, 2010, LAT AM APPL RES, V40, P295; Gentili C, 2009, CURR PHARM DESIGN, V15, P1334, DOI 10.2174/138161209787846739; Holzapfel GA, 2000, J ELASTICITY, V61, P1, DOI 10.1023/A:1010835316564; Huyghe JM, 1997, INT J ENG SCI, V35, P793, DOI 10.1016/S0020-7225(96)00119-X; Kawamata Tatsuro, 2007, Neurosurg Focus, V22, pE5, DOI 10.3171/foc.2007.22.5.6; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Kyriacou SK, 2002, BIOMECH MODEL MECHAN, V1, P151, DOI 10.1007/s10237-002-0013-0; LAI WM, 1991, J BIOMECH ENG-T ASME, V113, P245, DOI 10.1115/1.2894880; LEAF A, 1959, ANN NY ACAD SCI, V72, P396, DOI 10.1111/j.1749-6632.1959.tb44168.x; Levine DN, 1999, B MATH BIOL, V61, P875, DOI 10.1006/bulm.1999.0116; Lu XL, 2008, MED SCI SPORT EXER, V40, P193, DOI 10.1249/mss.0b013e31815cb1fc; Marmarou A, 2007, NEUROSURG FOCUS, V22, pE1, DOI DOI 10.3171/F0C.2007.22.5.2; METZ H, 1970, J BIOMECH, V3, P453, DOI 10.1016/0021-9290(70)90017-5; Miller K, 1999, J BIOMECH, V32, P531, DOI 10.1016/S0021-9290(99)00010-X; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; NAGASHIMA T, 1990, Neurologia Medico-Chirurgica, V30, P1, DOI 10.2176/nmc.30.1; NICHOLSON C, 2002, J CEREB BLOOD FLOW M, V22, P80, DOI DOI 10.1097/00004647-200201000-00010; OGDEN RW, 1997, NONLINEAR ELASIC DEF; PAPPIUS HM, 1956, CAN J BIOCHEM PHYS, V34, P1007; Rashid B, 2013, J BIOMECH, V46, P1276, DOI 10.1016/j.jbiomech.2013.02.014; Rashid B, 2012, J MECH BEHAV BIOMED, V10, P23, DOI 10.1016/j.jmbbm.2012.01.022; RASLAN A, 2007, NEUROSURG FOCUS, V220, P1; REULEN HJ, 1977, J NEUROSURG, V46, P24, DOI 10.3171/jns.1977.46.1.0024; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Smillie A, 2005, J FLUID MECH, V539, P417, DOI 10.1017/S0022112005005707; Sun DN, 1999, INT J NUMER METH ENG, V45, P1375, DOI 10.1002/(SICI)1097-0207(19990810)45:10<1375::AID-NME635>3.0.CO;2-7; Taylor Z, 2004, J BIOMECH, V37, P1263, DOI 10.1016/j.jbiomech.2003.11.027; THIEX R, 2007, NEUROSURG FOCUS, V220, P1, DOI DOI 10.3171/FOC.2007.22.5.7); Walberer M, 2008, J NEUROSURG, V109, P287, DOI 10.3171/JNS/2008/109/8/0287; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	44	27	27	0	22	ROYAL SOC	LONDON	6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND	1742-5689	1742-5662		J R SOC INTERFACE	J. R. Soc. Interface	JUL 6	2014	11	96							20140123	10.1098/rsif.2014.0123			8	Multidisciplinary Sciences	Science & Technology - Other Topics	AH5HN	WOS:000336159200009	24759543	Green Accepted, Green Published, Bronze			2021-06-18	
J	Beltran, E; Platt, SR; McConnell, JF; Dennis, R; Keys, DA; De Risio, L				Beltran, E.; Platt, S. R.; McConnell, J. F.; Dennis, R.; Keys, D. A.; De Risio, L.			Prognostic Value of Early Magnetic Resonance Imaging in Dogs after Traumatic Brain Injury: 50 Cases	JOURNAL OF VETERINARY INTERNAL MEDICINE			English	Article						Dogs; MRI; Prognostic; Traumatic brain injury	LATE POSTTRAUMATIC SEIZURES; GLASGOW COMA SCALE; SEVERE HEAD-INJURY; RISK-FACTORS; EPILEPSY; STEM; MRI; LEVETIRACETAM; PREVALENCE; PREDICTION	Background: The prognostic value of early magnetic resonance imaging (MRI) in dogs after traumatic brain injury (TBI) remains unclear. Objectives: Determine whether MRI findings are associated with prognosis after TBI in dogs. Animals: Fifty client-owned dogs. Methods: Retrospective study of dogs with TBI that underwent 1.5T MRI within 14 days after head trauma. MRI evaluators were blinded to the clinical presentation, and all images were scored based on an MRI grading system (Grade I [normal brain parenchyma] to Grade VI [bilateral lesions affecting the brainstem with or without any lesions of lesser grade]). Skull fractures, percentage of intraparenchymal lesions, degree of midline shift, and type of brain herniation were evaluated. MGCS was assessed at presentation. The presence of seizures was recorded. Outcome was assessed at 48 h (alive or dead) and at 3, 6, 12, and 24 months after TBI. Results: Sixty-six percent of the dogs had abnormal MRI findings. MRI grade was negatively correlated (P <.001) with MGCS. A significant negative correlation of MRI grade, degree of midline shift, and percentage of intraparenchymal lesions with follow-up scores was identified. The MGCS was lower in dogs with brain herniation (P =.0191). Follow-up scores were significantly lower in dogs that had brain herniation or skull fractures. The possibility of having seizures was associated with higher percentage of intraparenchymal lesions (P = 0.0054) and 10% developed PTE. Conclusions and Clinical Importance: Significant associations exist between MRI findings and prognosis in dogs with TBI. MRI can help to predict prognosis in dogs with TBI.	[Beltran, E.; Dennis, R.; De Risio, L.] Anim Hlth Trust, Ctr Small Anim Studies, Newmarket CB8 7UU, Suffolk, England; [Platt, S. R.] Univ Georgia, Coll Vet Med, Athens, GA 30602 USA; [McConnell, J. F.] Univ Liverpool, Sch Vet Sci, Liverpool L69 3BX, Merseyside, England	Beltran, E (corresponding author), Anim Hlth Trust, Ctr Small Anim Studies, Lanwades Pk, Newmarket CB8 7UU, Suffolk, England.	elsa.beltran@aht.org.uk	De Risio, Luisa/ABB-3561-2020	De Risio, Luisa/0000-0001-9005-4165; mcconnell, james fraser/0000-0001-7097-786X; Platt, Simon/0000-0002-7818-1011; BELTRAN, ELSA/0000-0002-0807-7817			Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; BYRNE JV, 1989, NEURORADIOLOGY, V31, P129, DOI 10.1007/BF00698839; Chew BG, 2012, J NEUROSURG, V117, P722, DOI 10.3171/2012.6.JNS111736; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Friedenberg SG, 2012, JAVMA-J AM VET MED A, V241, P1479, DOI 10.2460/javma.241.11.1479; Hicks JA, 2013, JAVMA-J AM VET MED A, V243, P1310, DOI 10.2460/javma.243.9.1310; Hilario A, 2012, AM J NEURORADIOL, V33, P1925, DOI 10.3174/ajnr.A3092; Kearsley-Fleet L, 2013, VET REC, V172, DOI 10.1136/vr.101133; Klein P, 2012, ARCH NEUROL-CHICAGO, V69, P1290, DOI 10.1001/archneurol.2012.445; KORNEGAY JN, 1983, J AM VET MED ASSOC, V182, P1111; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; Lannsjo M, 2013, J REHABIL MED, V45, P721, DOI 10.2340/16501977-1169; Lee SY, 2012, J CLIN NEUROL, V8, P224, DOI 10.3988/jcn.2012.8.3.224; LOSCHER W, 1985, ARZNEIMITTEL-FORSCH, V35, P82; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Pearl PL, 2013, EPILEPSIA, V54, pe135, DOI 10.1111/epi.12326; Platt SR, 2001, J VET INTERN MED, V15, P581, DOI 10.1892/0891-6640(2001)015&lt;0581:TPVOTM&gt;2.3.CO;2; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; SCHWARTZ-PORSCHE D., 1986, P ACVIM, P161; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shores A., 1983, CURRENT VET THERAPY, P847; Simpson SA, 2009, J VET EMERG CRIT CAR, V19, P588, DOI 10.1111/j.1476-4431.2009.00468.x; Skandsen T, 2011, J NEUROTRAUM, V28, P691, DOI 10.1089/neu.2010.1590; Steinmetz S, 2013, EPILEPSIA, V54, P580, DOI 10.1111/epi.12071; Tanoue K, 2012, ACTA PAEDIATR, V101, P614, DOI 10.1111/j.1651-2227.2012.02635.x; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Wendt-Hornickle EL, 2011, JAVMA-J AM VET MED A, V239, P194, DOI 10.2460/javma.239.2.194; Widerstrom-Noga EG, 2009, J REHABIL RES DEV, V46, P1, DOI 10.1682/JRRD.2008.03.0038; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zuercher M, 2009, BRAIN INJURY, V23, P371, DOI 10.1080/02699050902926267	39	27	29	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0891-6640	1939-1676		J VET INTERN MED	J. Vet. Intern. Med.	JUL-AUG	2014	28	4					1256	1262		10.1111/jvim.12368			7	Veterinary Sciences	Veterinary Sciences	AN4YT	WOS:000340596600015	24814522	Green Published, Green Accepted, Bronze			2021-06-18	
J	Chan, K; MacDermid, JC; Faber, KJ; King, GJW; Athwal, GS				Chan, Kevin; MacDermid, Joy C.; Faber, Kenneth J.; King, Graham J. W.; Athwal, George S.			Can We Treat Select Terrible Triad Injuries Nonoperatively?	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							CORONOID PROCESS; RADIAL HEAD; ELBOW; FRACTURES; DISLOCATIONS; INSTABILITY; RELIABILITY	While the majority of terrible triad elbow injuries (ulnohumeral dislocation with radial head and coronoid fractures) are managed surgically, nonoperative treatment may be appropriate in selected patients, but results with this approach have been limited by very small studies. We assessed (1) functional outcomes using two validated questionnaires, (2) elbow ROM, strength, and stability, (3) the presence of union and arthritis on radiographs, and (4) complications among a group of patients managed nonoperatively for terrible triad injuries. Between 2006 and 2012, we retrospectively identified 12 patients with terrible triad elbow injuries who were treated nonoperatively and met the following criteria: (1) a concentric joint reduction, (2) a radial head fracture that did not cause a mechanical block to rotation, (3) a smaller coronoid fracture (Regan-Morrey Type 1 or 2), and (4) a stable arc of motion to a minimum of 30A degrees of extension to allow active motion within the first 10 days. Eleven patients were available for followup of at least 12 months after the injury (mean, 36 months; range, 12-90 months). Outcome measures included two patient-reported functional outcome measures (DASH, Mayo Elbow Performance Index [MEPI]), a standardized physical examination to record elbow ROM and stability, isometric strength measurements, and radiographic evidence of bony union and elbow arthrosis. Complications were also recorded. At latest followup, mean +/- A SD DASH score was 8.0 +/- A 11.0 and mean MEPI score was 94 +/- A 9. Mean ROM of the affected elbow was 134A degrees A A +/- A 5A degrees flexion, 6A degrees A A +/- A 8A degrees extension, 87A degrees A A +/- A 4A degrees pronation, and 82A degrees A A +/- A 10A degrees supination. No instability was detected. Strength assessments demonstrated the following mean percentages of the contralateral, unaffected elbow: flexion 100%, extension 89%, pronation 79%, and supination 89%. Four patients had arthritic changes on radiographs that did not call for treatment as of latest followup. Complications included one patient who underwent surgical stabilization for early recurrent instability and another who underwent arthroscopic d,bridement for heterotopic bone. In selected patients, nonoperative treatment of terrible triad injuries is an option that can provide good function and restore stable elbow ROM. However, nonoperative management requires close clinical and radiographic followup to monitor for any delayed elbow subluxation or fracture displacement. Level IV, therapeutic study. See Instructions for Authors for a complete description of levels of evidence.	[Chan, Kevin] McMaster Univ, Div Orthopaed Surg, Hamilton, ON, Canada; [MacDermid, Joy C.] McMaster Univ, Fac Hlth Sci, Inst Appl Hlth Sci, Hamilton, ON, Canada; [MacDermid, Joy C.; Faber, Kenneth J.; King, Graham J. W.; Athwal, George S.] Univ Western Ontario, Hand & Upper Limb Ctr, London, ON N6A 4L6, Canada	Athwal, GS (corresponding author), Univ Western Ontario, Hand & Upper Limb Ctr, 268 Grosvenor St, London, ON N6A 4L6, Canada.	gathwal@uwo.ca	Faber, Kenneth J./H-9137-2017; MacDermid, Joy C/H-7837-2013; King, Graham JW/B-6177-2015; Athwal, George S/H-1762-2015	Faber, Kenneth J./0000-0003-1025-6600; MacDermid, Joy C/0000-0001-9311-7379; 			Armstrong AD, 1998, J SHOULDER ELB SURG, V7, P573, DOI 10.1016/S1058-2746(98)90003-9; BROBERG MA, 1987, CLIN ORTHOP RELAT R, P109; Chemama B, 2010, ORTHOP TRAUMATOL-SUR, V96, P147, DOI [10.1016/j.rcot.2010.02.008, 10.1016/j.otsr.2009.11.009]; Closkey RF, 2000, J BONE JOINT SURG AM, V82A, P1749, DOI 10.2106/00004623-200012000-00009; Doornberg JN, 2006, J HAND SURG-AM, V31A, P794, DOI 10.1016/j.jhsa.2006.01.004; Guitton TG, 2010, J HAND SURG-AM, V35A, P464, DOI 10.1016/j.jhsa.2009.12.015; Lindenhovius A, 2012, J HAND SURG-AM, V37A, P755, DOI 10.1016/j.jhsa.2011.12.043; Longo UG, 2008, BRIT MED BULL, V87, P131, DOI 10.1093/bmb/ldn023; MASON ML, 1954, BRIT J SURG, V42, P123, DOI 10.1002/bjs.18004217203; Mathew PK, 2009, J AM ACAD ORTHOP SUR, V17, P137, DOI 10.5435/00124635-200903000-00003; ODRISCOLL SW, 1991, J BONE JOINT SURG AM, V73A, P440, DOI 10.2106/00004623-199173030-00015; Pipicelli Joey G, 2011, Tech Hand Up Extrem Surg, V15, P198, DOI 10.1097/BTH.0b013e31822911fd; Pugh DMW, 2004, J BONE JOINT SURG AM, V86A, P1122, DOI 10.2106/00004623-200406000-00002; Regan W, 2006, J SHOULDER ELB SURG, V15, P344, DOI 10.1016/j.jse.2005.03.009; REGAN W, 1989, J BONE JOINT SURG AM, V71A, P1348, DOI 10.2106/00004623-198971090-00011; Ring D, 2002, J BONE JOINT SURG AM, V84A, P547, DOI 10.2106/00004623-200204000-00006; Rodriguez-Martin J, 2011, INT ORTHOP, V35, P851, DOI 10.1007/s00264-010-1024-6; Schneeberger AG, 2004, J BONE JOINT SURG AM, V86A, P975, DOI 10.2106/00004623-200405000-00013	18	27	32	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0009-921X	1528-1132		CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	JUL	2014	472	7					2092	2099		10.1007/s11999-014-3518-9			8	Orthopedics; Surgery	Orthopedics; Surgery	AI6XP	WOS:000337021300016	24549776	Green Published			2021-06-18	
J	Karalija, A; Novikova, LN; Kingham, PJ; Wiberg, M; Novikov, LN				Karalija, A.; Novikova, L. N.; Kingham, P. J.; Wiberg, M.; Novikov, L. N.			THE EFFECTS OF N-ACETYL-CYSTEINE AND ACETYL-L-CARNITINE ON NEURAL SURVIVAL, NEUROINFLAMMATION AND REGENERATION FOLLOWING SPINAL CORD INJURY	NEUROSCIENCE			English	Article						adult rats; spinal cord; motoneurons; antioxidants; apoptosis	PERIPHERAL-NERVE INJURY; AXONAL REGENERATION; FUNCTIONAL RECOVERY; OXIDATIVE STRESS; NEURONAL RESCUE; ADULT RATS; ACETYLCYSTEINE; APOPTOSIS; CASPASE-3; BRAIN	Traumatic spinal cord injury induces a long-standing inflammatory response in the spinal cord tissue, leading to a progressive apoptotic death of spinal cord neurons and glial cells. We have recently demonstrated that immediate treatment with the antioxidants N-acetyl-cysteine (NAC) and acetyl-L-carnitine (ALC) attenuates neuroinflammation, induces axonal sprouting, and reduces the death of motoneurons in the vicinity of the trauma zone 4 weeks after initial trauma. The objective of the current study was to investigate the effects of long-term antioxidant treatment on the survival of descending rubrospinal neurons after spinal cord injury in rats. It also examines the short-and long-term effects of treatment on apoptosis, inflammation, and regeneration in the spinal cord trauma zone. Spinal cord hemisection performed at the level C3 induced a significant loss of rubrospinal neurons 8 weeks after injury. At 2 weeks, an increase in the expression of the apoptosis-associated markers BCL-2-associated X protein (BAX) and caspase 3, as well as the microglial cell markers OX42 and ectodermal dysplasia 1 (ED1), was seen in the trauma zone. After 8 weeks, an increase in immunostaining for OX42 and the serotonin marker 5HT was detected in the same area. Antioxidant therapy reduced the loss of rubrospinal neurons by approximately 50%. Treatment also decreased the expression of BAX, caspase 3, OX42 and ED1 after 2 weeks. After 8 weeks, treatment decreased immunoreactivity for OX42, whereas it was increased for 5HT. In conclusion, this study provides further insight in the effects of treatment with NAC and ALC on descending pathways, as well as short-and long-term effects on the spinal cord trauma zone. (C) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.	[Karalija, A.; Novikova, L. N.; Kingham, P. J.; Wiberg, M.; Novikov, L. N.] Umea Univ, Dept Integrat Med Biol, Sect Anat, SE-90187 Umea, Sweden; [Karalija, A.; Wiberg, M.] Umea Univ, Dept Surg & Perioperat Sci, Sect Hand & Plast Surg, SE-90187 Umea, Sweden	Karalija, A (corresponding author), Umea Univ, Dept Integrat Med Biol, SE-90187 Umea, Sweden.	amar.karalija@anatomy.umu.se		Kingham, Paul/0000-0003-2596-5936; Novikov, Lev/0000-0001-5520-3890	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission; European UnionEuropean Commission; Umea University, County of Vasterbotten; Ake Wibergs Stiftelse; Clas Groschinskys Minnesfond; Gunvor and Josef Aner Foundation; Magn. Bergvalls Stiftelse	We would like to thank Mrs G Folkesson and Mrs G Hellstrom for their excellent technical assistance. This study was supported by the Swedish Medical Research Council, European Union, Umea University, County of Vasterbotten, Ake Wibergs Stiftelse, Magn. Bergvalls Stiftelse, Clas Groschinskys Minnesfond and the Gunvor and Josef Aner Foundation.	Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Atkuri KR, 2007, CURR OPIN PHARMACOL, V7, P355, DOI 10.1016/j.coph.2007.04.005; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Benowitz LI, 2011, CURR OPIN NEUROL, V24, P577, DOI 10.1097/WCO.0b013e32834c208d; Bydon M, 2013, WORLD NEUROSURG, V11, P12; Charriaut-Marlangue C, 2004, THERAPIE, V59, P185, DOI 10.2515/therapie:2004035; Circu ML, 2008, FREE RADICAL RES, V42, P689, DOI 10.1080/10715760802317663; Deumens R, 2005, PROG NEUROBIOL, V77, P57, DOI 10.1016/j.pneurobio.2005.10.004; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Fan LZ, 2006, J FUTURES MARKETS, V26, P153, DOI 10.1002/fut.20191; Farr SA, 2003, J NEUROCHEM, V84, P1173, DOI 10.1046/j.1471-4159.2003.01580.x; Hagberg H, 2004, J BIOENERG BIOMEMBR, V36, P369, DOI 10.1023/B:JOBB.0000041770.00567.4f; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hart AM, 2002, EXP BRAIN RES, V145, P182, DOI 10.1007/s00221-002-1100-2; Heard KJ, 2008, NEW ENGL J MED, V359, P285, DOI 10.1056/NEJMct0708278; Hou Q, 2003, APOPTOSIS, V8, P617, DOI 10.1023/A:1026187526113; Jia Z, 2012, SPINAL CORD, V50, P264, DOI 10.1038/sc.2011.111; Karalija A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041086; Karimi-Abdolrezaee S, 2012, MOL NEUROBIOL, V46, P251, DOI 10.1007/s12035-012-8287-4; Kullberg S, 2001, BRAIN RES, V899, P169, DOI 10.1016/S0006-8993(01)02222-3; Kwon BK, 2002, P NATL ACAD SCI USA, V99, P3246, DOI 10.1073/pnas.052308899; Ma JJ, 2001, EXP BRAIN RES, V139, P216, DOI 10.1007/s002210100769; Malaguarnera M, 2012, CURR OPIN GASTROEN, V28, P166, DOI 10.1097/MOG.0b013e3283505a3b; Maragos WF, 2004, J NEUROCHEM, V91, P257, DOI 10.1111/j.1471-4159.2004.02736.x; McEwen ML, 2011, NEUROTHERAPEUTICS, V8, P168, DOI 10.1007/s13311-011-0031-7; Novikov L, 1997, NEUROSCIENCE, V79, P765, DOI 10.1016/S0306-4522(96)00665-3; Novikov LN, 2002, BIOMATERIALS, V23, P3369, DOI 10.1016/S0142-9612(02)00037-6; Novikova LN, 2000, EUR J NEUROSCI, V12, P776, DOI 10.1046/j.1460-9568.2000.00978.x; Palacio JR, 2011, INFLAMM RES, V60, P695, DOI 10.1007/s00011-011-0323-8; PARNETTI L, 1992, EUR J CLIN PHARMACOL, V42, P89, DOI 10.1007/BF00314926; Patel SP, 2012, NEUROSCIENCE, V210, P296, DOI 10.1016/j.neuroscience.2012.03.006; Patel SP, 2010, J NEUROCHEM, V114, P291, DOI 10.1111/j.1471-4159.2010.06764.x; Paxinos G., 1995, RAT NERVOUS SYSTEM; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Priestley John V, 2012, Handb Clin Neurol, V109, P463, DOI 10.1016/B978-0-444-52137-8.00029-2; Rabchevsky AG, 2011, PHARMACOL THERAPEUT, V132, P15, DOI 10.1016/j.pharmthera.2011.05.001; Ribas GS, 2014, GENE, V533, P469, DOI 10.1016/j.gene.2013.10.017; Rudel T, 1999, HERZ, V24, P236, DOI 10.1007/BF03044967; Sadowska AM, 2012, THER ADV RESPIR DIS, V6, P127, DOI 10.1177/1753465812437563; Santos RO, 2011, ACTA MEDICA PORT, V 24, P809; Sayer Faisal T, 2006, Spine J, V6, P335, DOI 10.1016/j.spinee.2005.11.001; Short DJ, 2000, SPINAL CORD, V38, P273, DOI 10.1038/sj.sc.3100986; Silva NA, 2014, PROG NEUROBIOL, V114, P25, DOI 10.1016/j.pneurobio.2013.11.002; Snigdha S, 2012, NEUROSCI BULL, V28, P14, DOI 10.1007/s12264-012-1057-5; Song Y, 2012, NEUROCHEM RES, P610; Springer JE, 2001, CLIN CHEM LAB MED, V39, P299, DOI 10.1515/CCLM.2001.046; Vukojevic K, 2008, J MOL HISTOL, V39, P339, DOI 10.1007/s10735-008-9171-4; Waring WS, 2012, EXPERT REV CLIN PHAR, V5, P311, DOI [10.1586/ecp.12.15, 10.1586/ECP.12.15]; Welin D, 2009, BRAIN RES, V1287, P58, DOI 10.1016/j.brainres.2009.06.038; Wilson ADH, 2007, J PLAST RECONSTR AES, V60, P114, DOI 10.1016/j.bjps.2006.04.017; Yin X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038381; Zhang CG, 2005, BRIT J PLAST SURG, V58, P765, DOI 10.1016/j.bjps.2005.04.012; Zhang N, 2012, INDIAN J MED RES, V135, P287; ZIMENT I, 1988, BIOMED PHARMACOTHER, V42, P513	54	27	29	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUN 6	2014	269						143	151		10.1016/j.neuroscience.2014.03.042			9	Neurosciences	Neurosciences & Neurology	AH1TL	WOS:000335903900014	24680856				2021-06-18	
J	Brooks, BL; Mrazik, M; Barlow, KM; McKay, CD; Meeuwisse, WH; Emery, CA				Brooks, Brian L.; Mrazik, Martin; Barlow, Karen M.; McKay, Carly D.; Meeuwisse, Willem H.; Emery, Carolyn A.			Absence of Differences Between Male and Female Adolescents With Prior Sport Concussion	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						concussion; cumulative; lingering; mild traumatic brain injury; pediatric; gender	TRAUMATIC BRAIN-INJURY; BASE-LINE; SEX-DIFFERENCES; NEUROCOGNITIVE PERFORMANCE; HIGH-SCHOOL; NEUROPSYCHOLOGICAL FUNCTION; SOCCER PLAYERS; SYMPTOMS; OUTCOMES; HISTORY	Objective: Sex differences following concussion are poorly understood. The purpose of this study was to examine whether male and female adolescent athletes with prior concussions differ regarding neurocognitive function and symptom reporting. Setting: Community-based hockey teams. Participants: Participants included 615 elite hockey players 13 to 17 years old (mean = 15.5, 95% confidence interval [CI] = 15.4-15.6). There were 517 males and 98 females. Players with English as a second language, attention or learning problems, a concussion within 6 months of baseline, or suspected invalid test profiles were excluded from these analyses. Design: Cross-sectional. Main Measure: Domain scores and symptom ratings from the ImPACT computerized battery. Results: There were no significant neurocognitive differences between males and females with (F-5,F-227 = 1.40, P = .227) or without (F-5,F-376 = 1.33, P = 0.252) a prior history of concussion. Male and female athletes with a history of concussion reported higher raw symptom scores than those without a prior concussion; however, sex differences disappear when symptom scores are adjusted for known sex differences in controls (total score, F-2,F-230 = 0.77, P = .46; Cohen d = 0.01 or domain scores (F-4,F-227 = 1.52, P = .197; Cohen d = 0.07-0.18). Conclusions: Although those with prior concussions report more symptoms (but do not differ on neurocognition), this study does not support sex differences with cognition or symptoms in adolescent athletes with prior concussions.	[Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Neurosci Program, Calgary, AB T3B 6A8, Canada; [Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Brain Injury Program, Calgary, AB T3B 6A8, Canada; [Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Rehabil Program, Calgary, AB T3B 6A8, Canada; [Brooks, Brian L.] Univ Calgary, Fac Med, Dept Paediat, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Fac Med, Dept Clin Neurosci, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Alberta Childrens Hosp, Res Inst Child & Maternal Hlth, Calgary, AB, Canada; [Mrazik, Martin] Univ Alberta, Dept Educ Psychol, Edmonton, AB T6G 2E1, Canada; [Barlow, Karen M.] Univ Calgary, Alberta Childrens Hosp, Res Inst Child & Maternal Hlth, Fac Med,Neurosci Program, Calgary, AB, Canada; [Barlow, Karen M.] Univ Calgary, Alberta Childrens Hosp, Res Inst Child & Maternal Hlth, Fac Med,Brain Injury Program, Calgary, AB, Canada; [Barlow, Karen M.] Univ Calgary, Alberta Childrens Hosp, Res Inst Child & Maternal Hlth, Fac Med,Rehabil Program, Calgary, AB, Canada; [McKay, Carly D.; Meeuwisse, Willem H.] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Emery, Carolyn A.] Univ Calgary, Alberta Childrens Hosp, Res Inst Child & Maternal Hlth, Sport Injury Prevent Res Ctr,Fac Kinesiol, Calgary, AB, Canada	Brooks, BL (corresponding author), Alberta Childrens Prov Gen Hosp, Neurosci Program, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	brian.brooks@albertahealthservices.ca	Barlow, Karen/I-6492-2019; Meijer, Anna/K-5118-2016; Emery, Carolyn/AAI-2761-2020; Barlow, Karen/C-1323-2014	McKay, Carly/0000-0001-7664-3211; Barlow, Karen/0000-0003-2612-8507	Psychological Assessment Resources, Inc; McCarthy Tetrault award; International Olympic Committee; Alberta Innovates Health Solutions (AIHS); Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Alberta Children's Hospital Research Institute for Child & Maternal Health (ACHRI)	None of the authors have a financial interest in the ImPACT battery. B.L.B. receives funding from a test publisher (Psychological Assessment Resources, Inc), book royalties from Oxford University Press, and in-kind test credits for research from another computerized test publisher (CNS Vital Signs). In-kind support from ImPACT was provided to M. M. for the assessments conducted in Edmonton.; Computerized cognitive testing in this study was funded in Calgary by the McCarthy Tetrault award (administered by the Alberta Children's Hospital Research Institute for Child & Maternal Health on behalf of the Alberta Children's Hospital Foundation) to B.L.B. for a computerized neurocognitive laboratory (computers, test credits) and in Edmonton by funding provided to M. M. and in-kind support by ImPACT to M. M. The Sport Injury Prevention Research Centre is one of the International Research Centres for Prevention of Injury and Protection of Athlete Health supported by the International Olympic Committee. W. H. M. and C. A. E. acknowledge funding from Alberta Innovates Health Solutions (AIHS), Canadian Institutes of Health Research (CIHR), and the Alberta Children's Hospital Research Institute for Child & Maternal Health (ACHRI; Professorship in pediatric rehabilitation for C.A.E.). None of the funding sources were involved in design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.	[Anonymous], 1999, JAMA, V282, P974; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Blake T.A., 2012, CLIN J SPORT MED, V22, P307; Brooks BL, 2013, J NEUROTRAUM, V30, P1469, DOI 10.1089/neu.2012.2720; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dougan BK, J INT NEURO IN PRESS; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Elbin RJ, 2012, BRAIN INJURY, V26, P1217, DOI 10.3109/02699052.2012.672788; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2001, J ATHL TRAINING, V36, P228; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/316575; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kontos AP, 2011, BRAIN INJURY, V25, P1234, DOI 10.3109/02699052.2011.608209; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; McKay C, 2012, CLIN J SPORT MED, V22, P307; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Piland SG, 2010, J ATHL TRAINING, V45, P273, DOI 10.4085/1062-6050-45.3.273; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schneider K.J., 2012, CLIN J SPORT MED, V22, P307; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Thomas DG, 2011, ACAD EMERG MED, V18, P246, DOI 10.1111/j.1553-2712.2011.01015.x; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Tsushima WT, 2009, BRAIN INJURY, V23, P809, DOI 10.1080/02699050903200530; Zuckerman SL, 2012, J NEUROSURG-PEDIATR, V10, P504, DOI 10.3171/2012.8.PEDS12139	43	27	27	0	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2014	29	3					257	264		10.1097/HTR.0000000000000016			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AG9SE	WOS:000335759100014	24413074				2021-06-18	
J	Delaney, JS; Al-Kashmiri, A; Correa, JA				Delaney, J. Scott; Al-Kashmiri, Ammar; Correa, Jose A.			Mechanisms of Injury for Concussions in University Football, Ice Hockey, and Soccer	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussions; mechanisms; ice hockey; soccer; football	HEAD-INJURIES; PLAYERS; IMPACTS; ACCELERATION; STATEMENT; SPORT	Objective:To examine the mechanisms of injury for concussions in university football, ice hockey, and soccer.Design:Prospective cohort deign.Setting:McGill University Sport Medicine Clinic.Participants:Male and female athletes participating in varsity football, ice hockey, and soccer.Main Outcome Measures:Athletes were followed prospectively over a 10-year period to determine the mechanisms of injury for concussions and whether contact with certain areas of the body or individual variables predisposed to longer recovery from concussions. For soccer, data were collected on whether concussions occurred while attempting to head the ball.Results:There were 226 concussions in 170 athletes over the study period. The side/temporal area of the head or helmet was the most common area to be struck resulting in concussion in all 3 sports. Contact from another player's head or helmet was the most probable mechanism in football and soccer. In hockey, concussion impacts were more likely to occur from contact with another body part or object rather than another head/helmet. Differences in mechanisms of injuries were found between males and females in soccer and ice hockey. Athletes with multiple concussions took longer to return to play with each subsequent concussion. Half of the concussions in soccer were related to attempting to head the soccer ball.Conclusions:The side of the head or helmet was the most common area to be struck resulting in concussion in all 3 sports. In ice hockey and soccer, there are differences in the mechanisms of injury for males and females within the same sport.	[Delaney, J. Scott] McGill Sport Med Clin, Montreal, PQ H2W 1S4, Canada; [Delaney, J. Scott] McGill Univ, Dept Emergency Med, Ctr Hlth, Montreal, PQ, Canada; [Al-Kashmiri, Ammar] Khoula Hosp, Emergency Dept, Muscat, Oman; [Correa, Jose A.] McGill Univ, Dept Math & Stat, Montreal, PQ, Canada	Delaney, JS (corresponding author), McGill Sport Med Clin, 475 Pine Ave West, Montreal, PQ H2W 1S4, Canada.	j.delaney@mcgill.ca	Al-Kashmiri, Ammar/AAG-4008-2020				Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney J Scott, 2005, Clin J Sport Med, V15, P216, DOI 10.1097/01.jsm.0000168077.74497.a4; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hodgson VR, 1983, P 27 STAPP CAR CRASH, P225; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; NFL, 2010, NEW NFL RUL DES LIM; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Queen RM, 2003, MED SCI SPORT EXER, V35, P2069, DOI 10.1249/01.MSS.0000099081.20125.A5; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; Withnall C, 2005, BRIT J SPORT MED, V39, pI40, DOI 10.1136/bjsm.2005.019174; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	25	27	27	0	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2014	24	3					233	237		10.1097/JSM.0000000000000017			5	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	AG4KS	WOS:000335389100007	24284949				2021-06-18	
J	Doulames, V; Lee, S; Shea, TB				Doulames, Vanessa; Lee, Sangmook; Shea, Thomas B.			Environmental enrichment and social interaction improve cognitive function and decrease reactive oxidative species in normal adult mice	INTERNATIONAL JOURNAL OF NEUROSCIENCE			English	Article						cognitive performance; social; isolation; environment; enriched environment; dementia; novel object recognition; Y Maze	TRAUMATIC BRAIN-INJURY; INTERVENING TOO LATE; ALZHEIMERS-DISEASE; HIPPOCAMPAL NEUROGENESIS; TRANSGENIC MICE; TG2576 MICE; STRESS; DEMENTIA; RATS; CORTEX	Environmental stimulation and increased social interactions stimulate cognitive performance, while decrease in these parameters can exacerbate cognitive decline as a function of illness, injury, or age. We examined the impact of environmental stimulation and social interactions on cognitive performance in healthy adult C57B1/6J mice. Mice were housed for 1 month individually or in groups of three (to prevent or allow social interaction) in either a standard environment (SE) or an enlarged cage containing nesting material and items classically utilized to stimulate exploration and activity ("enriched environment"; EE). Cognitive performance was tested by Y maze navigation and Novel Object Recognition (NOR; which compares the relative amount of time mice spent investigating a novel vs. a familiar object). Mice maintained for 1 month under isolated conditions in the SE statistically declined in performance versus baseline in the Y maze (p < 0.02; ANOVA). Performance under all other conditions did not change from baseline. Maintenance in groups in the SE statistically improved NOR (p < 0.01), whereas maintenance in isolation in the SE did not alter performance from baseline. Maintenance in the EE statistically improved performance in NOR for mice housed in groups and individually (p < 0.01). Maintenance under isolated conditions slightly increased reactive oxygen/nitrogen species (ROS/RNS) in brain. Environmental enrichment did not influence ROS/RNS. These findings indicate that environmental and social enrichment can positively influence cognitive performance in healthy adult mice, and support the notion that proactive approaches may delay age-related cognitive decline.	[Doulames, Vanessa; Lee, Sangmook; Shea, Thomas B.] Univ Massachusetts, Dept Biol Sci, Ctr Cellular Neurobiol & Neurodegenerat Res, Lowell, MA 01854 USA	Shea, TB (corresponding author), Univ Massachusetts, Dept Biol Sci, Ctr Cellular Neurobiol & Neurodegenerat Res, Lowell, MA 01854 USA.	Thomas_Shea@uml.edu	Doulames, Vanessa/AAG-8828-2021				Anderson-Hanley C, 2012, AM J PREV MED, V42, P109, DOI 10.1016/j.amepre.2011.10.016; Andrew MK, 2010, ALZHEIMERS DEMENT, V6, P319, DOI 10.1016/j.jalz.2009.11.001; Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Barone I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050726; Bonsang E, 2012, J HEALTH ECON, V31, P490, DOI 10.1016/j.jhealeco.2012.03.005; Briones TL, 2004, BRAIN RES, V1018, P130, DOI 10.1016/j.brainres.2004.06.001; Chan A, 2008, J NUTR HEALTH AGING, V12, P252, DOI 10.1007/BF02982630; Chugani HT, 2001, NEUROIMAGE, V14, P1290, DOI 10.1006/nimg.2001.0917; Conroy RM, 2010, PSYCHOL HEALTH MED, V15, P463, DOI 10.1080/13548506.2010.487103; Crooks VC, 2008, AM J PUBLIC HEALTH, V98, P1221, DOI 10.2105/AJPH.2007.115923; Cuadrado-Tejedor M, 2012, J ALZHEIMERS DIS, V28, P567, DOI 10.3233/JAD-2011-110572; Cutuli D, 2011, NEUROBIOL DIS, V42, P9, DOI 10.1016/j.nbd.2010.12.007; Eluvathingal TJ, 2006, PEDIATRICS, V117, P2093, DOI 10.1542/peds.2005-1727; Emery VOB, 2011, J NEURAL TRANSM, V118, P1361, DOI 10.1007/s00702-011-0663-0; Ertel KA, 2008, AM J PUBLIC HEALTH, V98, P1215, DOI 10.2105/AJPH.2007.113654; Fernandez CI, 2004, ANN NY ACAD SCI, V1019, P53, DOI 10.1196/annals.1297.012; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fratiglioni L, 2000, LANCET, V355, P1315, DOI 10.1016/S0140-6736(00)02113-9; GREENOUGH WT, 1973, EXP NEUROL, V40, P491, DOI 10.1016/0014-4886(73)90090-3; Gresack JE, 2004, NEUROSCIENCE, V128, P459, DOI 10.1016/j.neuroscience.2004.06.011; HARLOW HF, 1965, P NATL ACAD SCI USA, V54, P90, DOI 10.1073/pnas.54.1.90; HARLOW HF, 1965, SCIENCE, V148, P666, DOI 10.1126/science.148.3670.666-a; Huang HJ, 2011, BRAIN RES, V1371, P150, DOI 10.1016/j.brainres.2010.11.043; JACOBS B, 1993, J COMP NEUROL, V327, P97, DOI 10.1002/cne.903270108; Jeong YH, 2011, J NEUROCHEM, V119, P1282, DOI 10.1111/j.1471-4159.2011.07514.x; Kalev-Zylinska ML, 2007, J NEUROSCI, V27, P10456, DOI 10.1523/JNEUROSCI.2789-07.2007; Karp A, 2006, DEMENT GERIATR COGN, V21, P65, DOI 10.1159/000089919; KATZMAN R, 1995, J AM GERIATR SOC, V43, P583, DOI 10.1111/j.1532-5415.1995.tb06112.x; KONDO K, 1994, DEMENTIA, V5, P314, DOI 10.1159/000106741; Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015; Lee S, 2012, J ALZHEIMERS DIS, V28, P497, DOI 10.3233/JAD-2011-111562; Lehmann ML, 2011, J NEUROSCI, V31, P6159, DOI 10.1523/JNEUROSCI.0577-11.2011; Mattson MP, 2001, MECH AGEING DEV, V122, P757, DOI 10.1016/S0047-6374(01)00226-3; Miura H, 2002, SYNAPSE, V46, P116, DOI 10.1002/syn.10133; Mulero J, 2011, J NUTR HEALTH AGING, V15, P756, DOI 10.1007/s12603-011-0130-5; Munetsuna E, 2009, BIOCHEM BIOPH RES CO, V379, P480, DOI 10.1016/j.bbrc.2008.12.076; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Rogers E J, 2004, J Nutr Health Aging, V8, P92; SCHAPIRO S, 1970, SCIENCE, V167, P292, DOI 10.1126/science.167.3916.292; Schrijver NCA, 2002, PHARMACOL BIOCHEM BE, V73, P209, DOI 10.1016/S0091-3057(02)00790-6; Shankar A, 2013, PSYCHOSOM MED, V75, P161, DOI 10.1097/PSY.0b013e31827f09cd; Shea TB, 2004, J ALZHEIMERS DIS, V6, P269; Shea TB, 2007, NEUROMOL MED, V9, P264, DOI 10.1007/s12017-007-8005-y; Shea TB, 2012, J NEURAL TRANSM, V119, P1529, DOI 10.1007/s00702-012-0849-0; SIREVAAG AM, 1987, BRAIN RES, V424, P320, DOI 10.1016/0006-8993(87)91477-6; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; van der Borght K, 2006, BEHAV BRAIN RES, V167, P36, DOI 10.1016/j.bbr.2005.08.012; Van der Borght K, 2007, BEHAV NEUROSCI, V121, P324, DOI 10.1037/0735-7044.121.2.324; van der Ploeg ES, 2013, INT PSYCHOGERIATR, V25, P565, DOI 10.1017/S1041610212002128; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Weuve J, 2004, JAMA-J AM MED ASSOC, V292, P1454, DOI 10.1001/jama.292.12.1454	53	27	27	0	31	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0020-7454	1563-5279		INT J NEUROSCI	Int. J. Neurosci.	MAY	2014	124	5					369	376		10.3109/00207454.2013.848441			8	Neurosciences	Neurosciences & Neurology	AF0KS	WOS:000334403300008	24102158				2021-06-18	
J	Kaba, F; Diamond, P; Haque, A; MacDonald, R; Venters, H				Kaba, Fatos; Diamond, Pamela; Haque, Alpha; MacDonald, Ross; Venters, Homer			Traumatic Brain Injury Among Newly Admitted Adolescents in the New York City Jail System	JOURNAL OF ADOLESCENT HEALTH			English	Article						Jail; Traumatic brain injury; Violence	RISK-FACTORS	Purpose: Relatively little is known about the prevalence of traumatic brain injury (TBI) among adolescents who come into contact with the criminal justice system. Methods: We undertook screening for TBI among newly admitted adolescents in the New York City jail system using a validated TBI screening tool. A convenience sample of 300 male and 84 female screenings was examined. Results: Screening revealed that 50% of male and 49% of female adolescents enter jail with a history of TBI. Incidence of TBI was assessed using patient health records, and revealed an incidence of 3,107 TBI per 100,000 person-years. Conclusions: Elevated prevalence and incidence of TBI among incarcerated adolescents may relate to criminal justice involvement as well as friction in jail. Given the large representation of violence as a cause of TBI among our patients, we have begun focus groups with them to elicit meaningful strategies for living with and avoiding TBI. (C) 2014 Society for Adolescent Health and Medicine. All rights reserved.	[Kaba, Fatos; Haque, Alpha; MacDonald, Ross; Venters, Homer] New York City Dept Hlth & Mental Hyg, New York, NY USA; [Diamond, Pamela] Univ Texas Houston, Div Hlth Promot & Behav Sci, Houston, TX USA	Venters, H (corresponding author), NYC DOHMH, 42-09 28th St, Queens, NY 11101 USA.	Hventer1@health.nyc.gov					Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Ferguson PL, 2012, J HEAD TRAUMA REHAB, V27, pE11, DOI 10.1097/HTR.0b013e31824e5f47; Moore E, 2013, J HEAD TRAUMA REHABI; National TBI estimates: Injury prevention & control, NAT TBI EST INJ PREV; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243, DOI 10.1002/cbm.702; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613	9	27	27	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1054-139X	1879-1972		J ADOLESCENT HEALTH	J. Adolesc. Health	MAY	2014	54	5					615	617		10.1016/j.jadohealth.2013.12.013			3	Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics	Psychology; Public, Environmental & Occupational Health; Pediatrics	AF1XG	WOS:000334506600019	24529834				2021-06-18	
J	Osterstock, G; El Yandouzi, T; Romano, N; Carmignac, D; Langlet, F; Coutry, N; Guillou, A; Schaeffer, M; Chauvet, N; Vanacker, C; Galibert, E; Dehouck, B; Robinson, ICAF; Prevot, V; Mollard, P; Plesnila, N; Mery, PF				Osterstock, Guillaume; El Yandouzi, Taoufik; Romano, Nicola; Carmignac, Danielle; Langlet, Fanny; Coutry, Nathalie; Guillou, Anne; Schaeffer, Marie; Chauvet, Norbert; Vanacker, Charlotte; Galibert, Evelyne; Dehouck, Benedicte; Robinson, Iain C. A. F.; Prevot, Vincent; Mollard, Patrice; Plesnila, Nikolaus; Mery, Pierre-Franois			Sustained Alterations of Hypothalamic Tanycytes During Posttraumatic Hypopituitarism in Male Mice	ENDOCRINOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; GROWTH-HORMONE-SECRETION; PROTEIN TRANSGENIC MICE; QUALITY-OF-LIFE; ARCUATE NUCLEUS; GHRH NEURONS; INFLAMMATORY RESPONSE; GENE-EXPRESSION; IN-VIVO	Traumatic brain injury is a leading cause of hypopituitarism, which compromises patients' recovery, quality of life, and life span. To date, there are no means other than standardized animal studies to provide insights into the mechanisms of posttraumatic hypopituitarism. We have found that GH levels were impaired after inducing a controlled cortical impact (CCI) in mice. Furthermore, GHRH stimulation enhanced GH to lower level in injured than in control or sham mice. Because many characteristics were unchanged in the pituitary glands of CCI mice, we looked for changes at the hypothalamic level. Hypertrophied astrocytes were seen both within the arcuate nucleus and the median eminence, two pivotal structures of the GH axis, spatially remote to the injury site. In the arcuate nucleus, GHRH neurons were unaltered. In the median eminence, injured mice exhibited unexpected alterations. First, the distributions of claudin-1 and zonula occludens-1 between tanycytes were disorganized, suggesting tight junction disruptions. Second, endogenous IgG was increased in the vicinity of the third ventricle, suggesting abnormal barrier properties after CCI. Third, intracerebroventricular injection of a fluorescent-dextran derivative highly stained the hypothalamic parenchyma only after CCI, demonstrating an increased permeability of the third ventricle edges. This alteration of the third ventricle might jeopardize the communication between the hypothalamus and the pituitary gland. In conclusion, the phenotype of CCI mice had similarities to the posttraumatic hypopituitarism seen in humans with intact pituitary gland and pituitary stalk. It is the first report of a pathological status in which tanycyte dysfunctions appear as a major acquired syndrome.	[Osterstock, Guillaume; El Yandouzi, Taoufik; Romano, Nicola; Coutry, Nathalie; Guillou, Anne; Schaeffer, Marie; Chauvet, Norbert; Galibert, Evelyne; Mollard, Patrice; Mery, Pierre-Franois] Inst Genom Fonct, INSERM U661, F-34094 Montpellier, France; [Osterstock, Guillaume; El Yandouzi, Taoufik; Romano, Nicola; Coutry, Nathalie; Guillou, Anne; Schaeffer, Marie; Chauvet, Norbert; Galibert, Evelyne; Mollard, Patrice; Mery, Pierre-Franois] Inst Genom Fonct, Ctr Natl Rech Sci, Unite Mixte Rech 5203, F-34094 Montpellier, France; [Osterstock, Guillaume; El Yandouzi, Taoufik; Romano, Nicola; Coutry, Nathalie; Guillou, Anne; Schaeffer, Marie; Chauvet, Norbert; Galibert, Evelyne; Mollard, Patrice; Mery, Pierre-Franois] Univ Montpellier I, F-34967 Montpellier, France; [Carmignac, Danielle; Robinson, Iain C. A. F.] Natl Inst Med Res, Med Res Council, Div Mol Neuroendocrinol, London NW7 1AA, England; [Osterstock, Guillaume; El Yandouzi, Taoufik; Schaeffer, Marie; Plesnila, Nikolaus] Royal Coll Surgeons Ireland, Dublin 2, Ireland; [Langlet, Fanny; Vanacker, Charlotte; Dehouck, Benedicte; Prevot, Vincent] Jean Pierre Aubert Res Ctr, Dept Dev & Plast Postnatal Brain, INSERM U837, F-59045 Lille, France; [Langlet, Fanny; Vanacker, Charlotte; Dehouck, Benedicte; Prevot, Vincent] Univ Lille 2, F-59000 Lille, France	Mery, PF (corresponding author), Inst Genom Fonct, Dept Endocrinol, 141 Rue Cardonille, F-34094 Montpellier, France.	pierre-francois.mery@igf.cnrs.fr	Prevot, Vincent/E-5720-2016; MERY, Pierre-Francois/C-5903-2019; Romano, Nicola/F-3688-2010; Plesnila, Nikolaus/T-7522-2019; Chauvet, Norbert/D-7333-2016; Schaeffer, Marie/C-9815-2019; COUTRY, Nathalie/O-9352-2017	Prevot, Vincent/0000-0001-7185-3615; Romano, Nicola/0000-0002-1316-8940; Chauvet, Norbert/0000-0003-4388-6422; Schaeffer, Marie/0000-0002-2063-5324; COUTRY, Nathalie/0000-0001-5830-4013; Mery, Pierre-Francois/0000-0001-6214-5422	Royal College of Surgeons in Ireland; Institut National de la Sante et de la Recherche MedicaleInstitut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche ScientifiqueCentre National de la Recherche Scientifique (CNRS); Universities of Montpellier; National Biophotonics and Imaging Platform of Ireland; Institut Federatif de Recherches; Region Languedoc RoussillonRegion OccitanieRegion Ile-de-France; Agence Nationale de la RechercheFrench National Research Agency (ANR)European Commission; Ministere Delegue a la Recherche et aux Nouvelles Technologies; Medical Research Council of the United KingdomUK Research & Innovation (UKRI)Medical Research Council UK (MRC)	This work was supported by grants from The Royal College of Surgeons in Ireland, the Institut National de la Sante et de la Recherche Medicale; the Centre National de la Recherche Scientifique; the Universities of Montpellier 1 and 2; the National Biophotonics and Imaging Platform of Ireland; the Institut Federatif de Recherches 3; the Region Languedoc Roussillon; the Agence Nationale de la Recherche (Gliodiabesity project); the Ministere Delegue a la Recherche et aux Nouvelles Technologies; and a core funding from the Medical Research Council of the United Kingdom.	Aberg ND, 2006, THESCIENTIFICWORLDJO, V6, P53, DOI 10.1100/tsw.2006.22; Addison ML, 2012, ENDOCRINOLOGY, V153, P1898, DOI 10.1210/en.2011-1982; Alonso G, 2007, AGING CELL, V6, P197, DOI 10.1111/j.1474-9726.2007.00276.x; Baccam N, 2007, J NEUROSCI, V27, P1631, DOI 10.1523/JNEUROSCI.2693-06.2007; Balthasar N, 2003, ENDOCRINOLOGY, V144, P2728, DOI 10.1210/en.2003-0006; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; Benowitz LI, 2010, NEUROBIOL DIS, V37, P259, DOI 10.1016/j.nbd.2009.11.009; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Briard N, 1998, ENDOCRINOLOGY, V139, P2662, DOI 10.1210/en.139.6.2662; Budry L, 2011, P NATL ACAD SCI USA, V108, P12515, DOI 10.1073/pnas.1105929108; Carraway Coralie A Carothers, 2007, Sci STKE, V2007, pre3, DOI 10.1126/stke.3812007re3; Carretero J, 2007, FOLIA MORPHOL WARSZ, V61, P209; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cetin A, 2006, NAT PROTOC, V1, P3166, DOI 10.1038/nprot.2006.450; Chauvet N, 1998, EXP NEUROL, V151, P1, DOI 10.1006/exnr.1998.6784; Ciofi P, 2011, NEUROSCI LETT, V487, P187, DOI 10.1016/j.neulet.2010.10.019; CLARK RG, 1985, J ENDOCRINOL, V106, P281, DOI 10.1677/joe.0.1060281; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Cordoba-Chacon J, 2011, AM J PHYSIOL-ENDOC M, V300, pE46, DOI 10.1152/ajpendo.00514.2010; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; DANIEL PM, 1959, LANCET, V2, P927; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Faden AI, 2007, ARCH NEUROL-CHICAGO, V64, P794, DOI 10.1001/archneur.64.6.794; Flavell DM, 1996, EMBO J, V15, P3871, DOI 10.1002/j.1460-2075.1996.tb00761.x; Fleiss B, 2012, LANCET NEUROL, V11, P556, DOI 10.1016/S1474-4422(12)70058-3; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Giustina A, 1998, ENDOCR REV, V19, P717, DOI 10.1210/er.19.6.717; Gordon GRJ, 2009, NEURON, V64, P391, DOI 10.1016/j.neuron.2009.10.021; Hanchate NK, 2012, J NEUROSCI, V32, P932, DOI 10.1523/JNEUROSCI.4765-11.2012; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Hurley DL, 1998, NEUROENDOCRINOLOGY, V68, P201, DOI 10.1159/000054367; Husson EC, 2010, J REHABIL MED, V42, P425, DOI 10.2340/16501977-0566; Johanson C, 2011, J NEURAL TRANSM, V118, P115, DOI 10.1007/s00702-010-0498-0; Kasturi BS, 2009, J NEUROTRAUM, V26, P1315, DOI [10.1089/neu.2008.0751, 10.1089/neu.2008-0751]; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Lafont C, 2010, P NATL ACAD SCI USA, V107, P4465, DOI 10.1073/pnas.0902599107; Langlet F, 2013, CELL METAB, V17, P607, DOI 10.1016/j.cmet.2013.03.004; Le Tissier PR, 2005, MOL ENDOCRINOL, V19, P1251, DOI 10.1210/me.2004-0223; LECHAN RM, 1981, ENDOCRINOLOGY, V109, P1950, DOI 10.1210/endo-109-6-1950; Lee DA, 2012, NAT NEUROSCI, V15, P700, DOI 10.1038/nn.3079; Low MJ, 2001, J CLIN INVEST, V107, P1571, DOI 10.1172/JCI11941; Luque RM, 2006, ENDOCRINOLOGY, V147, P2754, DOI 10.1210/en.2005-1549; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maegele M, 2007, EUR SURG RES, V39, P372, DOI 10.1159/000107097; Mantamadiotis T, 2006, MOL ENDOCRINOL, V20, P204, DOI 10.1210/me.2005-0195; McGuinness L, 2003, ENDOCRINOLOGY, V144, P720, DOI 10.1210/en.2002-220847; Mullier A, 2010, J COMP NEUROL, V518, P943, DOI 10.1002/cne.22273; Murray RD, 1999, CLIN ENDOCRINOL, V51, P565, DOI 10.1046/j.1365-2265.1999.00838.x; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Ortinski PI, 2010, NAT NEUROSCI, V13, P584, DOI 10.1038/nn.2535; Pan WH, 2005, ENDOCRINOLOGY, V146, P4898, DOI 10.1210/en.2005-0587; Phelps CJ, 2003, J NEUROENDOCRINOL, V15, P280, DOI 10.1046/j.1365-2826.2003.01009.x; Prevot V, 2010, FRONT NEUROENDOCRIN, V31, P241, DOI 10.1016/j.yfrne.2010.05.003; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rodriguez EM, 2005, INT REV CYTOL, V247, P89, DOI 10.1016/S0074-7696(05)47003-5; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Sanders NM, 2004, DIABETES, V53, P1230, DOI 10.2337/diabetes.53.5.1230; SATO M, 1993, ENDOCRINOLOGY, V133, P793, DOI 10.1210/en.133.2.793; Scheepens A, 2000, J PEDIATR ENDOCR MET, V13, P1483; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schwab JM, 2002, J NEUROSURG, V96, P892, DOI 10.3171/jns.2002.96.5.0892; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Steyn FJ, 2011, ENDOCRINOLOGY, V152, P3165, DOI 10.1210/en.2011-0253; Sumi N, 2010, CELL MOL NEUROBIOL, V30, P247, DOI 10.1007/s10571-009-9446-7; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; Trabold R, 2010, J CEREBR BLOOD F MET, V30, P130, DOI 10.1038/jcbfm.2009.196; Treip C S, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P178; Waite E, 2010, ENDOCRINOLOGY, V151, P234, DOI 10.1210/en.2009-0539; Wettschureck N, 2005, MOL CELL BIOL, V25, P1942, DOI 10.1128/MCB.25.5.1942-1948.2005; Witt CM, 2005, PLOS BIOL, V3, P1062, DOI 10.1371/journal.pbio.0030160; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zheng H, 1997, MOL ENDOCRINOL, V11, P1709, DOI 10.1210/me.11.11.1709; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	76	27	27	0	13	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0013-7227	1945-7170		ENDOCRINOLOGY	Endocrinology	MAY	2014	155	5					1887	1898		10.1210/en.2013-1336			12	Endocrinology & Metabolism	Endocrinology & Metabolism	AP8PY	WOS:000342342200030	24601879	Bronze			2021-06-18	
J	Macolino, CM; Daiutolo, BV; Albertson, BK; Elliott, MB				Macolino, Christine M.; Daiutolo, Brittany V.; Albertson, Brad K.; Elliott, Melanie B.			Mechanical alloydnia induced by traumatic brain injury is independent of restraint stress	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Traumatic brain injury; Headache; Mechanical allodynia; Stress; Corticosterone; Species	CORTICAL IMPACT INJURY; POSTTRAUMATIC HEADACHE; MOUSE STRAINS; NEUROPATHIC PAIN; RATS; ALLODYNIA; MODEL; NEURONS; MIGRAINE; CONCUSSION	Background: This study identifies the relationship between a test for post-traumatic headache and a marker for acute stress in rodent models of traumatic brain injury. New method: C57BL/6 mice and Sprague Dawley rats were divided into Controlled Cortical Impact (CCI) injury, craniotomy (CR), and incision groups. Periorbital and paw allodynia were evaluated using the von Frey test prior to injury and up to four weeks post-operatively. Serum corticosterone was evaluated in groups with and without mild restraint. Results: Periorbital and forepaw thresholds, but not hindpaw thresholds, were reduced in CCI and CR mice compared to incision (p < 0.0001 and p < 0.01). In contrast to mice, reduced periorbital and forepaw periorbital thresholds were found in CCI rats but not CR rats compared to incision (p < 0.0001). Right periorbital thresholds were reduced compared to left thresholds for both rat and mouse at one week (p < 0.01), but there were no side differences for forepaw thresholds. Hindpaw thresholds did not change from baseline values for any groups of mice or rats. In mice serum corticosterone levels were increased at one, two and four weeks post-CCI and CR, while the levels for rats were not different from incision (p < 0.0001). Corticosterone levels were not different in mice subjected to restraint compared to no restraint. Comparison with existing methods: This study presents novel data for allodynia in a rat model of TBI, and differences among mouse and rat species. Conclusions: Mechanical allodynia occurs independent of evoked restraint stress, while hypothalamic pituitary adrenal axis activity is dependent on head trauma and species. (c) 2014 Elsevier B.V. All rights reserved.	[Macolino, Christine M.; Daiutolo, Brittany V.] Thomas Jefferson Univ, Dept Neurol Surg, Philadelphia, PA 19107 USA; [Albertson, Brad K.] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; [Elliott, Melanie B.] Jefferson Hosp Neurosci, Dept Neurosci, Chairs Off, Philadelphia, PA 19107 USA	Elliott, MB (corresponding author), Jefferson Hosp Neurosci, Dept Neurosci, Chairs Off, 900 Walnut St, Philadelphia, PA 19107 USA.	Christine.macolino@jefferson.edu; Brittany.Daiutolo@jefferson.edu; Bradley.alberston@jefferson.edu; Melanie.elliott@jefferson.edu			DoDUnited States Department of Defense [PR110389]; Merck Investigator Initiated Program Award	This research was supported by DoD PR110389 to MBE and Merck Investigator Initiated Program Award to MBE. Thank you to Drs. Michael Oshinsky and Stephen Silberstein, as well as the Thomas Jefferson University Headache Center for their continued feedback on this ongoing research. Thank you to Mason Love and Ashley Tyburski for assistance with behavioral testing.	Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; Atkinson HC, 1997, ENDOCRINOLOGY, V138, P3842, DOI 10.1210/en.138.9.3842; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Babb JA, 2013, NEUROSCIENCE, V234, P40, DOI 10.1016/j.neuroscience.2012.12.051; Bates EA, 2010, CEPHALALGIA, V30, P170, DOI 10.1111/j.1468-2982.2009.01864.x; Bernstein C, 2012, J CLIN NEUROL, V8, P89, DOI 10.3988/jcn.2012.8.2.89; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; Burstein R, 2000, ANN NEUROL, V47, P614, DOI 10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N; Burstein R, 1998, J NEUROPHYSIOL, V79, P964; Burstein R, 2010, ANN NEUROL, V68, P81, DOI 10.1002/ana.21994; Buse DC, 2013, J NEUROL, V260, P1960, DOI 10.1007/s00415-012-6725-x; Cernak I, 1999, BRAIN INJURY, V13, P1005; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; de Kloet ER, 2005, NAT REV NEUROSCI, V6, P463, DOI 10.1038/nrn1683; Defrin R, 2010, EUR J PAIN, V14, P924, DOI 10.1016/j.ejpain.2010.03.004; Edelmayer RM, 2009, ANN NEUROL, V65, P184, DOI 10.1002/ana.21537; Elliott MB, 2010, NEUROSCIENCE, V170, P929, DOI 10.1016/j.neuroscience.2010.07.041; Elliott MB, 2008, J NEUROSCI METH, V168, P320, DOI 10.1016/j.jneumeth.2007.10.019; Elliott MB, 2007, J NEUROTRAUM, V24, P195, DOI 10.1089/neu.2006.0094; Elliott MB, 2012, HEADACHE, V52, P966, DOI 10.1111/j.1526-4610.2012.02160.x; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Elliott MB, 2009, BRAIN RES, V1305, P183, DOI 10.1016/j.brainres.2009.09.104; Elliott MB, 2009, NEUROSCI LETT, V454, P34, DOI 10.1016/j.neulet.2009.01.037; Gibson CA, 2012, J REHABIL RES DEV, V49, P753, DOI 10.1682/JRRD.2011.09.0158; Gwak YS, 2010, J PHYSIOL SCI, V60, P59, DOI 10.1007/s12576-009-0066-2; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Imbe H, 2012, NEUROSCIENCE, V223, P209, DOI 10.1016/j.neuroscience.2012.08.007; Ising Marcus, 2006, Dialogues Clin Neurosci, V8, P433; Kerman IA, 2012, PSYCHONEUROENDOCRINO, V37, P256, DOI 10.1016/j.psyneuen.2011.06.010; Kerr BJ, 2007, EXP NEUROL, V206, P240, DOI 10.1016/j.expneurol.2007.04.014; Lucas S, 2011, PM&R, V3, pS406, DOI 10.1016/j.pmrj.2011.07.016; Martelli MF, 2004, J HEAD TRAUMA REHAB, V19, P10, DOI 10.1097/00001199-200401000-00003; Maxwell CR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015963; McLean SA, 2005, PSYCHOSOM MED, V67, P783, DOI 10.1097/01.psy.0000181276.49204.bb; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Narita M, 2005, J NEUROSCI, V25, P10000, DOI 10.1523/JNEUROSCI.2507-05.2005; Newson MJF, 2013, J ENDOCRINOL, V216, P99, DOI 10.1530/JOE-12-0375; O'Malley D, 2010, STRESS, V13, P114, DOI 10.3109/10253890903067418; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; Oshinsky ML, 2007, HEADACHE, V47, P1026, DOI 10.1111/j.1526-4610.2007.00871.x; Oshinsky ML, 2012, HEADACHE, V52, P1336, DOI 10.1111/j.1526-4610.2012.02247.x; Oshinsky ML, 2006, HEADACHE, V46, pS39, DOI 10.1111/j.1526-4610.2006.00489.x; Ray B, 2011, NEUROSCIENCE, V184, P139, DOI 10.1016/j.neuroscience.2011.03.067; Schwedt TJ, 2011, CEPHALALGIA, V31, P6, DOI 10.1177/0333102410365108; Seifert TD, 2013, HEADACHE, V53, P726, DOI 10.1111/head.12087; Seifert TD, 2010, CURR PAIN HEADACHE R, V14, P292, DOI 10.1007/s11916-010-0117-7; Sotres-Bayon F, 2008, J NEUROSCI, V28, P12147, DOI 10.1523/JNEUROSCI.4373-08.2008; Sullivan RM, 2002, PSYCHONEUROENDOCRINO, V27, P99, DOI 10.1016/S0306-4530(01)00038-5; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; Taylor AN, 2006, J NEUROTRAUM, V23, P1802, DOI 10.1089/neu.2006.23.1802; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; van Gaalen MM, 2000, BEHAV BRAIN RES, V115, P95, DOI 10.1016/S0166-4328(00)00240-0; Vargas BB, 2009, CURR PAIN HEADACHE R, V13, P64, DOI 10.1007/s11916-009-0013-1; Winkelstein BA, 2004, J BIOMECH ENG-T ASME, V126, P258, DOI 10.1115/1.1695571; Winner P, 2013, CEPHALALGIA, V33, P37; Woolf CJ, 2004, LIFE SCI, V74, P2605, DOI 10.1016/j.lfs.2004.01.003; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Zasler ND, 2011, J HEAD TRAUMA REHAB, V26, P397, DOI 10.1097/HTR.0b013e31822721f8	65	27	27	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	APR 15	2014	226						139	146		10.1016/j.jneumeth.2014.01.008			8	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AE4IR	WOS:000333946600014	24486873				2021-06-18	
J	Dhandapani, M; Dhandapani, S; Agarwal, M; Mahapatra, AK				Dhandapani, Manju; Dhandapani, Sivashanmugam; Agarwal, Meena; Mahapatra, Ashok K.			Pressure ulcer in patients with severe traumatic brain injury: significant factors and association with neurological outcome	JOURNAL OF CLINICAL NURSING			English	Article						albumin; haemoglobin; outcome; pressure ulcer; traumatic brain injury	RISK-FACTORS; HOSPITALIZED-PATIENTS; PRACTICAL SCALE; CLINICAL-TRIAL; SORE	Aims and objectives. To assess the factors associated with development of pressure ulcer in patients with severe traumatic brain injury (TBI) and study its prognostic significance with respect to neurological outcome at three months. Background. Patients with severe TBI are prone to develop pressure ulcer due to various factors, which have never been studied in detail. Design. Prospective longitudinal study. Methods. Eighty-nine patients of TBI in age group 20-60 years admitted with Glasgow Coma Scale (GCS) 4-8 without serious systemic disorder were enrolled for the study. Patient characteristics, haemoglobin, serum albumin levels at admission and their weekly changes till 21 days were noted along with daily assessment for presence of pressure ulcer. Mortality was assessed at 21 days and neurological outcome at three months through telephonic interview. Results. Of 89 patients studied, pressure ulcer was observed in 6 (7%) and 14 (16%) at the end of two and three weeks, respectively. Pressure ulcer in univariate analysis was significantly associated with poorer GCS (p = 0.05), delayed enteral feeding (p = 0.005) and fall in haemoglobin at two weeks (p = 0.005). Only the latter two were found significant in multivariate analysis. Age, gender, surgical intervention, tracheostomy, prolonged fever and change in albumin had no significant association with pressure ulcer development. Presence of pressure ulcer was significantly associated with mortality at 21 days (p = 0.006) and unfavourable neurological outcome at three months (p = 0.01). Conclusions. The significant factors influencing pressure ulcer development in patients with TBI were delayed enteral feeding and fall in haemoglobin. Pressure ulcer had significant association with mortality at 21 days and recovery status at three months. Relevance to clinical practice. Early nutritional supplementation and monitoring of haemoglobin should be an important part of nursing care interventions for patients at increased risk of developing pressure ulcer.	[Dhandapani, Manju] PGIMER, Natl Inst Nursing Educ, Chandigarh 160012, India; [Dhandapani, Sivashanmugam] PGIMER, Dept Neurosurg, Chandigarh 160012, India; [Agarwal, Meena] AIIMS, Coll Nursing, New Delhi, India; [Mahapatra, Ashok K.] AIIMS, Dept Neurosurg, New Delhi, India	Dhandapani, S (corresponding author), PGIMER, Dept Neurosurg, Chandigarh 160012, India.	ssdhandapani.neurosurg@gmail.com	Dhandapani, Sivashanmugam/I-2395-2013	Dhandapani, Sivashanmugam/0000-0002-3497-4255; Dhandapani, Manju/0000-0003-3351-3841			ALLMAN RM, 1995, JAMA-J AM MED ASSOC, V273, P865, DOI 10.1001/jama.273.11.865; BERGSTROM N, 1987, NURS CLIN N AM, V22, P417; Chauhan V S, 2005, J Wound Care, V14, P36; de Laat E H E W, 2006, J Wound Care, V15, P269; Dhandapani SS, 2010, INDIAN J NEUROTRAUM, V7, P23, DOI 10.1016/S0973-0508(10)80007-3; DHANDAPANI SS, 2009, PAN ARAB J NEUROSURG, V13, P60; Feuchtinger J, 2005, HEART LUNG, V34, P375, DOI 10.1016/j.hrtlng.2005.04.004; Gengenbacher M, 2002, AGING CLIN EXP RES, V14, P420; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hartgrink HH, 1998, CLIN NUTR, V17, P287, DOI 10.1016/S0261-5614(98)80321-X; Jaul E, 2001, Harefuah, V140, P903; Jay R, 1995, Ostomy Wound Manage, V41, P36; JENNETT B, 1975, LANCET, V1, P480; KANE R, 1989, ESSENTIALS CLIN GERI; Keast David H, 2004, Ostomy Wound Manage, V50, P64; Lindgren M, 2004, SCAND J CARING SCI, V18, P57, DOI 10.1046/j.0283-9318.2003.00250.x; MAKLEBUST J, 1987, NURS CLIN N AM, V22, P359; Mustoe TA, 2006, PLAST RECONSTR SURG, V117, p35S, DOI 10.1097/01.prs.0000225431.63010.1b; Norton D., 1962, INVESTIGATION GERIAT; Pender Lauren R, 2005, Intensive Crit Care Nurs, V21, P29, DOI 10.1016/j.iccn.2004.07.005; Reed RL, 2003, GERONTOLOGY, V49, P255, DOI 10.1159/000070407; REULER JB, 1981, ANN INTERN MED, V94, P661, DOI 10.7326/0003-4819-94-5-661; Reynolds TM, 2006, J CLIN PATHOL, V59, P308, DOI 10.1136/jcp.2005.029405; STOTTS NA, 1988, HEART LUNG, V17, P641; TEASDALE G, 1974, LANCET, V2, P81; United States Department of Health and Human Services, 1992, PUB AG HLTH CAR POL; van Marum RJ, 2001, ANGIOLOGY, V52, P409, DOI 10.1177/000331970105200606	27	27	29	0	11	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0962-1067	1365-2702		J CLIN NURS	J. Clin. Nurs.	APR	2014	23	7-8					1114	1119		10.1111/jocn.12396			6	Nursing	Nursing	AC4BT	WOS:000332466300011	24112115				2021-06-18	
J	Godwin, E; Chappell, B; Kreutzer, J				Godwin, Emilie; Chappell, Brittney; Kreutzer, Jeffrey			Relationships after TBI: A grounded research study	BRAIN INJURY			English	Article						Ambiguous loss; marriage and TBI; qualitative research; relational coring; relational recycling; relationships after TBI; traumatic brain injury	TRAUMATIC BRAIN-INJURY; AMBIGUOUS LOSS; ADJUSTMENT; CAREGIVERS; IDENTITY; QUALITY; MARRIAGE; FAMILIES	Background: While study on the emotional effects of traumatic brain injury (TBI) for individuals and caregivers has increased dramatically over the years, insufficient research has been performed on TBI's impact on the coupled relationship or the healing process successful couples go through following injury. As such, couples are left on their own to adjust to the complex challenges that TBI brings. Methods: This qualitative study aims to develop a framework for conceptualizing and assessing couples after TBI. Additionally, it purposes to establish a foundation built upon the practises of successful couples that have subsisted TBI from which methods of treatment can be drawn. Existing personal narratives written by survivors of TBI and their caregivers were analysed. Data triangulation with clinician-authored literature was performed. Constant comparative analysis of the data was then performed through an involving substantive and theoretical coding. Results: Five primary themes emerged: Ambiguous Losses, Identity Reformations, Tenuous Stability, Non Omnes Moriar and The New Us. From these, two grounded theories were developed: Relational Coring and Relational Recycling. Conclusions: These theories will allow researchers and practitioners to grasp the impact of TBI on the coupled relationship, familiarize themselves with the process by which relational experiences following TBI interact and understand the ways in which couples respond to these interacting experiences to work toward relational healing.	[Godwin, Emilie; Chappell, Brittney; Kreutzer, Jeffrey] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA	Chappell, B (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, POB 980206, Richmond, VA 23298 USA.	bschappell@vcu.edu			National Institute on Disability and Rehabilitation Research (NIDRR), Office of Special Education and Rehabilitative Services (OSERS), Department of Education, Washington, DC [H133A120031]	The authors report no conflicts of interest. This work was supported by Grant # H133A120031 from the National Institute on Disability and Rehabilitation Research (NIDRR), Office of Special Education and Rehabilitative Services (OSERS), Department of Education, Washington, DC.	Assari S, 2009, IRAN J KIDNEY DIS, V3, P242; Blais MC, 2005, BRAIN INJURY, V19, P1223, DOI 10.1080/02699050500309387; Bogdan R, 1998, INTRO QUALITATIVE RE; Bogdan R.C., 2006, QUALITATIVE RES ED I; BOSS P, 1977, J MARRIAGE FAM, V39, P141, DOI 10.2307/351070; Boss P., 2000, AMBIGUOUS LOSS LEARN; Boss P, 2007, FAM RELAT, V56, P105, DOI 10.1111/j.1741-3729.2007.00444.x; *Brown K. G., 1996, THESIS; Carroll E, 2011, NEUROPSYCHOL REHABIL, V21, P289, DOI 10.1080/09602011.2011.555972; CLIPP EC, 1992, CANCER, V69, P1074, DOI 10.1002/1097-0142(19920215)69:4<1074::AID-CNCR2820690440>3.0.CO;2-L; Cloute K, 2008, NEUROPSYCHOL REHABIL, V18, P651, DOI 10.1080/09602010701306989; Corbin J., 2014, BASICS QUALITATIVE R; Coyne JC, 2001, AM J CARDIOL, V88, P526, DOI 10.1016/S0002-9149(01)01731-3; Crabtree B.F., 1999, DOING QUALITATIVE RE; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Department of Health, 2005, NAT SERV FRAM LONG T; Dye J. F., 2000, QUAL REP, V4, P1, DOI DOI 10.HTTPS://NSUW0RKS.N0VA.EDU/TQR/V0L4/ISS1/8; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Glaser B, 1978, THEORETICAL SENSITIV; Glaser B. G., 1967, DISCOVERY GROUNDED T; GLASER BG, 1965, SOC PROBL, V12, P436, DOI 10.1525/sp.1965.12.4.03a00070; Glesne C., 1992, BECOMING QUALITATIVE; Godwin EE, 2011, J HEAD TRAUMA REHAB, V26, P43, DOI 10.1097/HTR.0b013e3182048f54; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kean S, 2010, NURS CRIT CARE, V15, P66, DOI 10.1111/j.1478-5153.2010.00379.x; KIECOLTGLASER JK, 1988, PSYCHOSOM MED, V50, P213, DOI 10.1097/00006842-198805000-00001; Kolb SM., 2012, J EMERGING TRENDS ED, V3, P83; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Landau J., 2008, FAMILIES SYSTEMS HLT, V26, P69, DOI DOI 10.1037/1091-7527.26.1.69; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Marwit SJ, 2006, BRAIN INJURY, V20, P1419, DOI 10.1080/02699050601082214; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; Moore A. D., 1991, J HEAD TRAUMA REHAB, V6, P83; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Panayiotou A, 2010, J CLIN EXP NEUROPSYC, V32, P463, DOI 10.1080/13803390903164371; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Pinsof WH, 2000, J MARITAL FAM THER, V26, P1, DOI 10.1111/j.1752-0606.2000.tb00270.x; Ponsford J, 2003, NEUROPSYCHOL REHABIL, V13, P275, DOI 10.1080/09602010244000363; Rossman G.B., 2003, LEARNING FIELD INTRO, V2nd ed; Roundhill S.J., 2007, QUAL RES PSYCHOL, V4, P241, DOI [10.1080/14780880701473540, DOI 10.1080/14780880701473540]; Ruddle JA., 2005, ILLNESS, V13, P235; Sabat Ayesha, 2006, S Afr J Commun Disord, V53, P17; Segal D, 2010, INT J CHILD YOUTH FA, V1, P293, DOI 10.18357/ijcyfs13/420102093; Sexton T., 2004, BERGIN GARFIELDS HDB, P590; Sexton TL, 2004, J MARITAL FAM THER, V30, P131, DOI 10.1111/j.1752-0606.2004.tb01229.x; Stets JE, 2000, SOC PSYCHOL QUART, V63, P224, DOI 10.2307/2695870; Strauss A., 1990, BASICS QUALITATIVE R; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; Walsh F., 2003, NORMAL FAMILY PROCES; Yin R, 2004, CASE STUDY ANTHOLOGY, V296	54	27	27	0	17	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2014	28	4					398	413		10.3109/02699052.2014.880514			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AF5GL	WOS:000334741900002	24475746				2021-06-18	
J	Rowe, RK; Harrison, JL; O'Hara, BF; Lifshitz, J				Rowe, Rachel K.; Harrison, Jordan L.; O'Hara, Bruce F.; Lifshitz, Jonathan			Recovery of Neurological Function Despite Immediate Sleep Disruption Following Diffuse Brain Injury in the Mouse: Clinical Relevance to Medically Untreated Concussion	SLEEP			English	Article						Behavior; concussion; diffuse; mild; mouse; sleep; sleep disruption; TBI	CONTROLLED CORTICAL IMPACT; TRAUMATIC AXONAL INJURY; COGNITIVE DEFICITS; BEHAVIORAL DEFICITS; HEAD-INJURY; MICE; DEPRIVATION; RATS; NEURONS; MODEL	Study Objective: We investigated the relationship between immediate disruption of posttraumatic sleep and functional outcome in the diffuse brain-injured mouse. Design: Adult male C57BL/6 mice were subjected to moderate midline fluid percussion injury (n = 65; 1.4 atm; 6-10 min righting reflex time) or sham injury (n = 44). Cohorts received either intentional sleep disruption (minimally stressful gentle handling) or no sleep disruption for 6 h following injury. Following disruption, serum corticosterone levels (enzyme-linked immunosorbent assay) and posttraumatic sleep (noninvasive piezoelectric sleep cages) were measured. For 1-7 days postinjury, sensorimotor outcome was assessed by Rotarod and a modified Neurological Severity Score (NSS). Cognitive function was measured using Novel Object Recognition (NOR) and Morris water maze (MWM) in the first week postinjury. Setting: Neurotrauma research laboratory. Measurements and Results: Disrupting posttraumatic sleep for 6 h did not affect serum corticosterone levels or functional outcome. In the hour following the first dark onset, sleep-disrupted mice exhibited a significant increase in sleep; however, this increase was not sustained and there was no rebound of lost sleep. Regardless of sleep disruption, mice showed a time-dependent improvement in Rotarod performance, with braininjured mice having significantly shorter latencies on day 7 compared to sham. Further, brain-injured mice, regardless of sleep disruption, had significantly higher NSS scores postinjury compared with sham. Cognitive behavioral testing showed no group differences among any treatment group measured by MWM and NOR. Conclusion: Short-duration disruption of posttraumatic sleep did not affect functional outcome, measured by motor and cognitive performance. These data raise uncertainty about posttraumatic sleep as a mechanism of recovery from diffuse brain injury.	[Rowe, Rachel K.; Harrison, Jordan L.; Lifshitz, Jonathan] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85016 USA; [Rowe, Rachel K.; Harrison, Jordan L.; Lifshitz, Jonathan] Univ Arizona, Coll Med, Dept Child Hlth, Phoenix, AZ USA; [Lifshitz, Jonathan] Phoenix Vet Affairs Healthcare Syst, Phoenix, AZ USA; [Harrison, Jordan L.; Lifshitz, Jonathan] Arizona State Univ, Interdisciplinary Program Neurosci, Phoenix, AZ USA; [Rowe, Rachel K.; Lifshitz, Jonathan] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY USA; [O'Hara, Bruce F.] Univ Kentucky, Coll Med, Dept Biol, Coll Arts & Sci, Lexington, KY USA; [Rowe, Rachel K.; O'Hara, Bruce F.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY USA	Lifshitz, J (corresponding author), Phoenix Childrens Hosp, Translat Neurotrauma Res Program, Barrow Neurol Inst, Phoenix, AZ 85016 USA.	jlifshitz@email.arizona.edu		Rowe, Rachel/0000-0002-9034-3159	National Institute of Neurological DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Stroke of the National Institutes of Health [R01NS065052, R01NS065052- S, R21NS072611]; KSCHIRT; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052, R21NS072611] Funding Source: NIH RePORTER	This article is dedicated to the memory of Thomas V. Getchell, PhD, Professor of Physiology, University of Kentucky College of Medicine. Dr. Getchell served as a scientific mentor in the art of grant writing, professionalism and leadership. The authors wish to thank Amanda Lisembee for her technical contribution to the corticosterone assays. Thank you to Jennifer Pleasant-Brelsfoard and Dr. Kathryn Saatman for training on behavioral techniques used in these studies. We would also like to thank the members of the laboratory for their help with sleep disruption. Research reported in this publication was supported, in part, by National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award number R01NS065052, R01NS065052- S, R21NS072611, and KSCHIRT 10-5A. These data were recognized by the National Neurotrauma Society as a top abstract at the 31st Annual Symposium, Nashville, TN.	Silva LFA, 2013, J NEUROTRAUM, V30, P1278, DOI 10.1089/neu.2012.2577; ASIKAINEN M, 1995, NEUROSCI LETT, V198, P21, DOI 10.1016/0304-3940(95)11953-T; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Boone DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046204; Cam E, 2013, EXP NEUROL, V247, P673, DOI 10.1016/j.expneurol.2013.03.003; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chokroverty S, 2010, INDIAN J MED RES, V131, P126; COHEN HB, 1965, SCIENCE, V150, P1318, DOI 10.1126/science.150.3701.1318; Cohen S, 2009, ARCH INTERN MED, V169, P62, DOI 10.1001/archinternmed.2008.505; Crane AT, 2012, RESTOR NEUROL NEUROS, V30, P325, DOI 10.3233/RNN-2012-120232; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Donohue KD, 2008, BIOMED ENG ONLINE, V7, DOI 10.1186/1475-925X-7-14; Ennaceur A, 1997, BEHAV BRAIN RES, V88, P181, DOI 10.1016/S0166-4328(97)02297-3; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gao B, 2010, SLEEP, V33, P879, DOI 10.1093/sleep/33.7.879; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Griesbach GS, 2012, J NEUROTRAUM, V29, P1426, DOI 10.1089/neu.2011.2229; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Hagewoud R, 2010, J SLEEP RES, V19, P280, DOI 10.1111/j.1365-2869.2009.00799.x; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Han XD, 2011, J NEUROTRAUM, V28, P995, DOI 10.1089/neu.2010.1563; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Krueger JM, 2007, SLEEP MED CLIN, V2, P161, DOI 10.1016/j.jsmc.2007.03.003; Krueger JM, 2008, CURR PHARM DESIGN, V14, P3408, DOI 10.2174/138161208786549281; KRUEGER JM, 1995, INT ARCH ALLERGY IMM, V106, P97, DOI 10.1159/000236827; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lay CC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011270; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/0897715042664876; Machado RB, 2004, BRAIN RES, V1004, P45, DOI 10.1016/j.brainres.2004.01.019; Martinez-Vargas M, 2012, NEUROSCI LETT, V529, P118, DOI 10.1016/j.neulet.2012.09.037; McEwen BS, 2008, EUR J PHARMACOL, V583, P174, DOI 10.1016/j.ejphar.2007.11.071; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McShane BB, 2010, J NEUROSCI METH, V193, P321, DOI 10.1016/j.jneumeth.2010.08.024; Meerlo P, 2009, SLEEP MED REV, V13, P187, DOI 10.1016/j.smrv.2008.07.004; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; OHARA BF, 1993, SLEEP, V16, P1; Patti CL, 2010, SLEEP, V33, P1669, DOI 10.1093/sleep/33.12.1669; Paul T, 2007, CHRONOBIOL INT, V24, P45, DOI 10.1080/07420520601142569; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prins ML, 2001, J NEUROTRAUM, V18, P31, DOI 10.1089/089771501750055758; Riechers RG, 2013, J REHABIL RES DEV, V50, P455, DOI 10.1682/JRRD.2012.04.0061; Rowe RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082507; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; Schoch KM, 2012, EXP NEUROL, V236, P371, DOI 10.1016/j.expneurol.2012.04.022; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Sheth BR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003190; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Tononi G, 2006, SLEEP MED REV, V10, P49, DOI 10.1016/j.smrv.2005.05.002; Walker MP, 2005, NEUROSCIENCE, V133, P911, DOI 10.1016/j.neuroscience.2005.04.007; Walsh CM, 2011, LEARN MEMORY, V18, P422, DOI 10.1101/lm.2099011; Yang SR, 2012, SLEEP, V35, P849, DOI 10.5665/sleep.1888; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075; Yang XJ, 2012, INT J MOL SCI, V13, P9447, DOI 10.3390/ijms13089447; Zhang F, 2010, MOLECULES, V15, P5246, DOI 10.3390/molecules15085246; Ziebell JM, 2011, BRAIN RES, V1414, P94, DOI 10.1016/j.brainres.2011.07.056; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36; Zunzunegui C, 2011, SLEEP, V34, P1261, DOI 10.5665/SLEEP.1252	74	27	28	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA		1550-9109		SLEEP	Sleep	APR 1	2014	37	4					743	752		10.5665/sleep.3582			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AE0RF	WOS:000333673100014	24899763	Bronze, Green Published			2021-06-18	
J	Hasan, KM; Wilde, EA; Miller, ER; Patel, VK; Staewen, TD; Frisby, ML; Garza, HM; McCarthy, JJ; Hunter, JV; Levin, HS; Robertson, CS; Narayana, PA				Hasan, Khader M.; Wilde, Elisabeth A.; Miller, Emmy R.; Patel, Vipul Kumar; Staewen, Terrell D.; Frisby, Melisa L.; Garza, Hector M.; McCarthy, James J.; Hunter, Jill V.; Levin, Harvey S.; Robertson, Claudia S.; Narayana, Ponnada A.			Serial Atlas-Based Diffusion Tensor Imaging Study of Uncomplicated Mild Traumatic Brain Injury in Adults	JOURNAL OF NEUROTRAUMA			English	Article						atlas-based; corona radiate; corpus callosum; CSF; diffusion tensor imaging; hippocampus; lateral ventricles; mild traumatic brain injury; scanner stability; water phantom	HYPERTONIC SALINE RESUSCITATION; INFLAMMATORY RESPONSE SYNDROME; LENGTH-OF-STAY; NOSOCOMIAL INFECTIONS; HEMORRHAGIC-SHOCK; ACQUIRED INFECTIONS; INHIBITS NEUTROPHIL; HEAD-INJURY; IN-VIVO; COMPLICATIONS	In this report, we applied diffusion tensor imaging (DTI) methods in 36 patients with uncomplicated mild traumatic brain injury (mTBI) and a comparison group of 37 participants with orthopedic injury. Our aim was to characterize regional and global macro- and microstructural attributes of white matter (WM), gray matter (GM), in addition to volume and diffusivity of cerebrospinal fluid (CSF) to identify and differentiate patterns of acute and short-term recovery. Given that previous DTI reports on mTBI in adults using a region-of-interest approach implicated the corona radiata (CR), corpus callosum, and hippocampus, we analyzed and quantified DTI metrics of these regions using atlas-based methods. The normalized volume percentages of global CSF, GM, and WM were not different between the mTBI and orthopedic comparison (OC) groups at either the baseline or follow-up time points or between the baseline and follow-up time points within the OC group (p>0.17; uncorrected for multiple comparisons). The DTI metrics did not differ between groups at either occasion. However, an increase was noted on follow-up in the OC group in the global mean diffusivity of GM (uncorrected p=0.003) and WM (uncorrected p=0.02), indicating a decrease in diffusivity at the 3-month postinjury, as compared to the baseline scan. An analysis of the DTI data collected longitudinally in the CR show insignificant changes in the OC group (p>0.08; N=37). CR radial diffusivity was found to be elevated in the between-group comparison at baseline (mTBI1 vs. OC1), but did not differ in the within-group comparison (mTBI1 vs. mTBI2; N=19), suggesting the possible resolution of edema. Our analysis of the cross-sectional and follow-up data, which is uncorrected for multiple comparisons, demonstrates dissociation between volumetric (macrostructural) and tissue integrity (microstructural) attributes and shows the potential utility of DTI to capture transient edema in the CR.	[Hasan, Khader M.; Patel, Vipul Kumar; Staewen, Terrell D.; Narayana, Ponnada A.] Univ Texas Hlth Sci Ctr Houston, Dept Diagnost & Intervent Imaging, Houston, TX 77030 USA; [McCarthy, James J.] Univ Texas Hlth Sci Ctr Houston, Dept Emergency Med, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Frisby, Melisa L.; Garza, Hector M.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Miller, Emmy R.; Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Hunter, Jill V.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA	Hasan, KM (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Diagnost & Intervent Imaging, 6431 Fannin St,MSB 2-100, Houston, TX 77030 USA.	Khader.M.Hasan@uth.tmc.edu	Hasan, Khader M./ABB-5767-2020		Dunn Research Fund; Congressionally Directed Medical Research Program of the Department of Defense [W81XWH-08-2-0133, W81XWH-08-2-0135, W81XWH-08-2-0138, W81XWH-08-2-0132, W81XWH-08-2-0149, W81XWH-08-2-0142, W81XWH-08-2-0140, W81XWH-08-2-0131]	This study was funded by the Dunn Research Fund (to K. M. H) and awards from the Congressionally Directed Medical Research Program of the Department of Defense (W81XWH-08-2-0133, W81XWH-08-2-0135, W81XWH-08-2-0138, W81XWH-08-2-0132, W81XWH-08-2-0149, W81XWH-08-2-0142, W81XWH-08-2-0140, and W81XWH-08-2-0131).	Alharfi IM, 2013, J NEUROTRAUM, V30, P361, DOI 10.1089/neu.2012.2410; Alharfi IM, 2013, PEDIATR CRIT CARE ME, V14, P203, DOI 10.1097/PCC.0b013e31827127b5; Allison KR, 2011, NATURE, V473, P216, DOI 10.1038/nature10069; Berrouane Y, 1998, J HOSP INFECT, V40, P275, DOI 10.1016/S0195-6701(98)90303-6; Bochicchio GV, 2001, J TRAUMA, V50, P817, DOI 10.1097/00005373-200105000-00007; Boddie DE, 2003, BRIT J NEUROSURG, V17, P405, DOI 10.1080/02688690310001611198; Bone RC, 1996, CRIT CARE MED, V24, P1125, DOI 10.1097/00003246-199607000-00010; Brook I, 1998, J ACCID EMERG MED, V15, P162; Cardo D, 2004, AM J INFECT CONTROL, V32, P470, DOI 10.1016/j.ajic.2004.10.001; Centers for Disease Control and Prevention, 2010, HEALTHC ASS INF HAIS; Ciesla DJ, 2000, SHOCK, V14, P265, DOI 10.1097/00024382-200014030-00004; Ciesla DJ, 2001, SURGERY, V129, P567, DOI 10.1067/msy.2001.113286; CorreaSales C, 1997, INT J IMMUNOPHARMACO, V19, P117, DOI 10.1016/S0192-0561(97)00003-9; Croce MA, 2001, AM SURGEON, V67, P105; Dziedzic T, 2004, CRIT CARE, V8, P266, DOI 10.1186/cc2828; El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831; Fabregas N, 2002, Minerva Anestesiol, V68, P285; Fink Matthew E, 2012, Continuum (Minneap Minn), V18, P640, DOI 10.1212/01.CON.0000415432.84147.1e; Galley HF, 2000, INTENS CARE MED, V26, P267, DOI 10.1007/s001340051149; Glance LG, 2011, ARCH SURG-CHICAGO, V146, P794, DOI 10.1001/archsurg.2011.41; Grohskopf LA, 2002, J PEDIATR-US, V140, P432, DOI 10.1067/mpd.2002.122499; HELLING TS, 1988, J TRAUMA, V28, P1575, DOI 10.1097/00005373-198811000-00009; Hoover L, 2006, J TRAUMA, V61, P310, DOI 10.1097/01.ta.0000229052.75460.c2; Hosmer D, 1989, APPL LOGISTIC REGRES; Hutchison J, 2006, DEV NEUROSCI-BASEL, V28, P291, DOI 10.1159/000094155; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Junger WG, 2012, SHOCK, V38, P341, DOI 10.1097/SHK.0b013e3182635aca; Khan R, 2011, SHOCK, V36, P440, DOI 10.1097/SHK.0b013e3182336bda; Kim JY, 2012, J SURG RES, V178, P401, DOI 10.1016/j.jss.2012.01.055; Kimura F, 2010, SURG TODAY, V40, P793, DOI 10.1007/s00595-010-4323-z; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Nadal P, 1995, Eur J Emerg Med, V2, P14, DOI 10.1097/00063110-199503000-00004; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Ngo QN, 2009, PEDIATR CRIT CARE ME, V10, P346, DOI 10.1097/PCC.0b013e3181a320cd; Pascual JL, 2003, J TRAUMA, V54, P121, DOI 10.1097/00005373-200301000-00015; Pascual JL, 2002, ANN SURG, V236, P634, DOI 10.1097/00000658-200211000-00014; Patel JC, 2000, J PEDIATR SURG, V35, P1174, DOI 10.1053/jpsu.2000.8722; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Ploppa A, 2008, INFECTION, V36, P220, DOI 10.1007/s15010-007-7240-3; Raymond J, 2000, INFECT CONT HOSP EP, V21, P260, DOI 10.1086/501755; Richards MJ, 1999, PEDIATRICS, V103, part. no., DOI 10.1542/peds.103.4.e39; Schneemilch CE, 2005, EUR J ANAESTH, V22, P616, DOI 10.1017/S0265021505001031; Stewart TC, 2013, J TRAUMA ACUTE CARE, V75, P836, DOI 10.1097/TA.0b013e3182a685b0; Suz P, 2006, J NEUROSURG ANESTH, V18, P5, DOI 10.1097/01.ana.0000189079.26212.37; Taira BR, 2009, PEDIATR CRIT CARE ME, V10, P491, DOI 10.1097/PCC.0b013e3181a3108d; Urrea M, 2005, J PEDIATR ORTHOP B, V14, P371, DOI 10.1097/01202412-200509000-00011	47	27	29	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2014	31	5					466	475		10.1089/NEU.2013.3085			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AB4ZV	WOS:000331799600245	24224684				2021-06-18	
J	Mahdy, HM; Mohamed, MR; Emam, MA; Karim, AM; Abdel-Naim, A; Khalifa, AE				Mahdy, Heba M.; Mohamed, Mohamed R.; Emam, Manal A.; Karim, Amr M.; Abdel-Naim, Ashraf; Khalifa, Amani E.			The anti-apoptotic and anti-inflammatory properties of puerarin attenuate 3-nitropropionic-acid induced neurotoxicity in rats	CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY			English	Article						Huntington's disease; puerarin; 3-nitropropionic acid; apoptosis; neuroinflammation; Nissl staining; ATP	FACTOR-KAPPA-B; TRAUMATIC BRAIN-INJURY; COMPLEX-II INHIBITION; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE; STRIATAL DEGENERATION; PC12 CELLS; ACID MODEL; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE MECHANISMS	Puerarin (Pur), an isoflavonoid extracted from the dried roots of Pueraria lobata, has been reported to be useful in the treatment of various diseases. This study was designed to evaluate the anti-apoptotic and anti-inflammatory activities of Pur against 3-nitropropionic acid (3-NP) induced neurotoxicity. For 5 consecutive days, male Wistar rats were given Pur (200 mg/kg body mass) 30 min before treatment with 20 mg/kg body mass of 3-NP. The striata, hippocampi, and cortices of the 3-NP treated group showed apoptotic damage, inflammation, and energy deficit as well as histopathological lesions. The 3-NP-induced alteration in apoptotic biomarkers (caspase-3 activity/level, cytosolic cytochrome c, Bax/Bcl-2 levels) were significantly ameliorated by Pur treatment. Moreover, Pur pretreatment blocked 3-NP-induced inflammatory biomarkers (NF-kappa B, TNF-alpha, and iNOS) and prevented the energy deficit (ATP reduction). Nissl staining further confirmed Pur's neuroprotective effect. These results indicate that Pur may be a useful preventive approach to various neurodegenerative diseases with underlying apoptosis and neuroinflammation.	[Mahdy, Heba M.; Abdel-Naim, Ashraf; Khalifa, Amani E.] Ain Shams Univ, Fac Pharm, Dept Pharmacol & Toxicol, Cairo, Egypt; [Mohamed, Mohamed R.; Emam, Manal A.; Karim, Amr M.] Ain Shams Univ, Dept Biochem, Fac Sci, Cairo, Egypt	Mahdy, HM (corresponding author), Ain Shams Univ, Fac Pharm, Dept Pharmacol & Toxicol, Monazamet Al Wehdah Al Efrikeya St, Cairo, Egypt.	hebamahdy111@yahoo.com	Abdel-Naim, Ashraf B/J-3199-2012; Mohamed, Mohamed Ragaa/V-9143-2019	Abdel-Naim, Ashraf B/0000-0002-0400-9075; Mohamed, Mohamed Ragaa/0000-0002-9269-3128; Khalifa, Amani/0000-0002-1627-7800; Asem, Manal/0000-0002-6463-0656	Faculty of Pharmacy, Ain Shams University, Cairo, EgyptAin Shams University; Faculty of Science, Ain Shams University, Cairo, EgyptAin Shams University	The Faculty of Pharmacy and Faculty of Science, Ain Shams University, Cairo, Egypt, supported this research.	Ahuja M, 2008, TOXICOL MECH METHOD, V18, P335, DOI 10.1080/15376510701563738; Antonawich FJ, 2002, BRAIN RES BULL, V57, P647, DOI 10.1016/S0361-9230(01)00761-4; Bancroft J. D. A., 1996, THEORY PRACTICE HIST; Bantubungi K, 2007, Rev Med Brux, V28, P413; BEAL MF, 1993, J NEUROSCI, V13, P4181; Bhateja DK, 2012, EUR J PHARMACOL, V674, P33, DOI 10.1016/j.ejphar.2011.10.029; Bortolatto CF, 2013, NEUROTOX RES, V23, P214, DOI 10.1007/s12640-012-9336-5; Campbell A, 2004, ANN NY ACAD SCI, V1035, P117, DOI 10.1196/annals.1332.008; Canudas AM, 2003, EXP NEUROL, V180, P123, DOI 10.1016/S0014-4886(02)00029-8; CHAN ASC, 2006, Patent No. 2006042454; Chang Y, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-9; Chen Chiung-Mei, 2011, Chang Gung Med J, V34, P135; Cheng YF, 2009, NEUROSCI RES, V63, P52, DOI 10.1016/j.neures.2008.10.009; Cheng Yuefa, 2011, Zhongguo Zhong Yao Za Zhi, V36, P1222; Cuello AC., 1993, IMMUNOHISTOCHEMISTRY; Duran-Vilaregut J, 2011, NEUROTOXICOLOGY, V32, P734, DOI 10.1016/j.neuro.2011.07.009; Eidelberg D, 2011, J CLIN INVEST, V121, P484, DOI 10.1172/JCI45646; Ferreira IL, 2010, EXP NEUROL, V222, P243, DOI 10.1016/j.expneurol.2010.01.002; Gao L, 2009, NEUROL RES, V31, P402, DOI 10.1179/174313209X444017; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Gil JM, 2008, EUR J NEUROSCI, V27, P2803, DOI 10.1111/j.1460-9568.2008.06310.x; Hickey MA, 2003, PROG NEURO-PSYCHOPH, V27, P255, DOI 10.1016/S0278-5846(03)00021-6; Hu WZ, 2011, PHARMACOL REP, V63, P781, DOI 10.1016/S1734-1140(11)70590-4; Hu WZ, 2010, PHARMACOLOGY, V85, P27, DOI 10.1159/000264938; Jin SE, 2012, ARCH PHARM RES, V35, P823, DOI 10.1007/s12272-012-0508-x; Johri A, 2012, BBA-MOL BASIS DIS, V1822, P664, DOI 10.1016/j.bbadis.2011.11.014; Khan HA, 2003, J BIOSCIENCES, V28, P379, DOI 10.1007/BF02705114; Kumar P, 2011, BRIT J PHARMACOL, V164, P644, DOI 10.1111/j.1476-5381.2011.01418.x; Kumar P, 2010, BEHAV BRAIN RES, V206, P38, DOI 10.1016/j.bbr.2009.08.028; Lacor PN, 2007, J NEUROSCI, V27, P796, DOI 10.1523/JNEUROSCI.3501-06.2007; Lee ST, 2008, BRAIN RES, V1194, P130, DOI 10.1016/j.brainres.2007.11.058; Lee ST, 2008, J NEUROCHEM, V104, P1190, DOI 10.1111/j.1471-4159.2007.05044.x; Li JM, 2010, EUR J PHARMACOL, V649, P195, DOI 10.1016/j.ejphar.2010.09.045; Li Y, 2006, DRUG DEV IND PHARM, V32, P413, DOI 10.1080/03639040600559123; Lim S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024620; Liot G, 2009, CELL DEATH DIFFER, V16, P899, DOI 10.1038/cdd.2009.22; Liu XJ, 2010, PHARMAZIE, V65, P127, DOI 10.1691/ph.2010.9734; LU J, 2004, CHIN J MOD APPL PHAR, V4; Mandavilli BS, 2005, MOL BRAIN RES, V133, P215, DOI 10.1016/j.molbrainres.2004.10.033; Mandy HM, 2011, NEUROCHEM INT, V59, P770, DOI 10.1016/j.neuint.2011.07.012; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Mealer RG, 2013, J NEUROSCI, V33, P4206, DOI 10.1523/JNEUROSCI.3730-12.2013; Menze ET, 2012, NEUROTOXICOLOGY, V33, P1265, DOI 10.1016/j.neuro.2012.07.007; Milakovic T, 2005, J BIOL CHEM, V280, P30773, DOI 10.1074/jbc.M504749200; Mrak RE, 2005, J ALZHEIMERS DIS, V8, P369; Napolitano M, 2008, NEUROSCI LETT, V434, P241, DOI 10.1016/j.neulet.2007.09.056; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Pan HP, 2008, YAKUGAKU ZASSHI, V128, P1689, DOI 10.1248/yakushi.128.1689; Park JE, 2008, NEUROSCI LETT, V448, P143, DOI 10.1016/j.neulet.2008.10.020; Pedraza-Chaverri J, 2009, EXP TOXICOL PATHOL, V61, P491, DOI 10.1016/j.etp.2008.11.002; Prasad K, 2012, J MED SYST, V36, P2621, DOI 10.1007/s10916-011-9737-7; PUNEET K, 2007, J CELL TISSUE RES, V7, P853; Ramos-Vara JA, 2005, VET PATHOL, V42, P405, DOI 10.1354/vp.42-4-405; Rangan GK, 2007, NEPHROLOGY, V12, P553, DOI 10.1111/j.1440-1797.2007.00855.x; Rego AC, 2003, NEUROCHEM RES, V28, P1563, DOI 10.1023/A:1025682611389; Rosenstock TR, 2004, J NEUROCHEM, V88, P1220, DOI 10.1046/j.1471-4159.2003.02250.x; Ross CA, 2009, PARKINSONISM RELAT D, V15, pS135, DOI 10.1016/S1353-8020(09)70800-4; Sugino T, 1999, NEUROSCI LETT, V275, P145, DOI 10.1016/S0304-3940(99)00763-6; Tadros MG, 2005, PHARMACOL BIOCHEM BE, V82, P574, DOI 10.1016/j.pbb.2005.10.018; Tian F, 2013, NEUROSCI LETT, V543, P64, DOI 10.1016/j.neulet.2013.03.039; Tobinick EL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-2; Tunez I, 2009, REV NEUROLOGIA, V48, P430, DOI 10.33588/rn.4808.2008678; Tunez I, 2010, MOLECULES, V15, P878, DOI 10.3390/molecules15020878; Turner C, 2010, J BIOENERG BIOMEMBR, V42, P193, DOI 10.1007/s10863-010-9290-y; VALOR LM, 2013, NEUROPHARMACOLOGY, DOI DOI 10.1016/J.NEUR0PHARM.2013.10.025.PMID:24184315; Vis JC, 2001, NEUROPATH APPL NEURO, V27, P68, DOI 10.1046/j.0305-1846.2001.00305.x; Wang JW, 2014, J SURG RES, V186, P328, DOI 10.1016/j.jss.2013.08.027; Wu HQ, 2012, NEURAL REGEN RES, V7, P421, DOI 10.3969/j.issn.1673-5374.2012.06.003; Xiao Li-zhong, 2004, Zhongguo Zhong Xi Yi Jie He Za Zhi, V24, P790; Xing GH, 2011, BRAIN RES BULL, V85, P212, DOI 10.1016/j.brainresbull.2011.03.024; Xu CS, 2012, BRAIN RES BULL, V87, P37, DOI 10.1016/j.brainresbull.2011.10.007; Yan B, 2006, BIOMED CHROMATOGR, V20, P180, DOI 10.1002/bmc.549; Yang JH, 2013, BIOMETALS, V26, P43, DOI 10.1007/s10534-012-9593-z; Yang XJ, 2010, BASIC CLIN PHARMACOL, V107, P637, DOI 10.1111/j.1742-7843.2010.00548.x; Yu WL, 2004, FOOD CHEM, V86, P525, DOI 10.1016/j.foodchem.2003.09.005; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang HY, 2008, CELL BIOL INT, V32, P1230, DOI 10.1016/j.cellbi.2008.07.006; Zhang HY, 2011, EXP GERONTOL, V46, P30, DOI 10.1016/j.exger.2010.09.013; Zhang Z, 2013, J CLIN PHARMACOL, V53, P787, DOI 10.1002/jcph.96; Zhao LX, 2013, BIOL PHARM BULL, V36, P1263, DOI 10.1248/bpb.b12-00769; Zhou J, 2010, J ETHNOPHARMACOL, V132, P150, DOI 10.1016/j.jep.2010.08.005; Zhu GQ, 2010, PLANTA MED, V76, P1820, DOI 10.1055/s-0030-1249976	82	27	33	0	19	CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS	OTTAWA	65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA	0008-4212	1205-7541		CAN J PHYSIOL PHARM	Can. J. Physiol. Pharmacol.	MAR	2014	92	3					252	258		10.1139/cjpp-2013-0398			7	Pharmacology & Pharmacy; Physiology	Pharmacology & Pharmacy; Physiology	AC6JM	WOS:000332628500010	24593790				2021-06-18	
J	Ferreira, MC; Batista, AM; Ferreira, FD; Ramos-Jorge, ML; Marques, LS				Ferreira, Meire Coelho; Batista, Anne Margareth; Ferreira, Fernanda de Oliveira; Ramos-Jorge, Maria Leticia; Marques, Leandro Silva			Pattern of oral-maxillofacial trauma stemming from interpersonal physical violence and determinant factors	DENTAL TRAUMATOLOGY			English	Article						maxillofacial injuries; soft tissues injuries; tooth injuries; violence; risk factors	INTIMATE PARTNER VIOLENCE; DOMESTIC VIOLENCE; FACIAL INJURIES; RISK-FACTORS; FRACTURES; PREVALENCE; VICTIMS; ASSAULT; MARKERS; WOMEN	Background/Aim: Facial trauma is among the most common types of injury. The aim of the present study was to assess the prevalence and pattern of oral-maxillofacial trauma stemming from interpersonal physical violence (IPV) and determine whether IPV is factor associated with oral-maxillofacial trauma. Materials and methods: A retrospective analysis was conducted of 790 complete patient charts for data on the type of IPV for the gender, area of residence (urban or rural), age and type of trauma. Statistical analysis involved the chi-squared test (P < 0.05), univariate/multivariate Poisson, and logistic regression (P < 0.20). Type of oral-maxillofacial trauma was the dependent variable. Socio-demographic status and type of IPV were the independent variables. Results: One hundred forty (17.7%) individuals had oral-maxillofacial injuries stemming from IPV [80 (10.1%) due to urban violence (UV) and 42 (5.3%) due to domestic violence (DV)]. DV was more prevalent among females (69%), and UV was more prevalent among males (67.5%). The most common types of trauma were facial contusion and laceration, dental concussion, and mandibular fracture. Age and UV were explanatory factors for mandibular fracture. Females from rural areas and who suffered DV were more likely to exhibit facial contusion and dental concussion. Conclusions: Interpersonal physical violence was identified as a factor associated with oral-maxillofacial trauma, specifically mandibular fracture, facial contusion, and dental concussion.	[Ferreira, Meire Coelho; Batista, Anne Margareth; Ramos-Jorge, Maria Leticia; Marques, Leandro Silva] Univ Fed Vales Jequitinhonha & Mucuri, Dept Dent, Sch Biol & Hlth Sci, Diamantina, Brazil; [Ferreira, Fernanda de Oliveira] Fed Univ Jequitinhonha & Mucuri Valleys, Dept Basic Sci, Diamantina, Brazil	Ferreira, MC (corresponding author), R Doze 648, BR-35020690 Governador Valadares, MG, Brazil.	meirecofe@hotmail.com	Marques, Leandro S/J-4053-2014	Marques, Leandro S/0000-0002-7089-8739	Brazilian Coordination of Higher Education (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Ministry of Education; National Council for Scientific and Technological Development (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Ministry of Science and Technology; State of Minas Gerais Research Foundation (FAPEMIG), BrazilFundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)	This study was supported by the Brazilian Coordination of Higher Education (CAPES), Ministry of Education, the National Council for Scientific and Technological Development (CNPq), Ministry of Science and Technology, and the State of Minas Gerais Research Foundation (FAPEMIG), Brazil.	Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21; BERRIOS DC, 1991, WESTERN J MED, V155, P133; Butchart A., 2004, EC DIMENSIONS INTERP; CHEZ RA, 1988, AM J OBSTET GYNECOL, V158, P1; Chrcanovic BR, 2012, ORAL MAXILLOFAC SURG, V16, P3, DOI 10.1007/s10006-011-0280-y; De Sousa A, 2008, BRIT J ORAL MAX SURG, V46, P661, DOI 10.1016/j.bjoms.2008.07.192; Desai J, 2010, S AFR J SURG, V48, P122; Dicker RA, 2009, J TRAUMA, V67, P1169, DOI 10.1097/TA.0b013e3181bdb78a; Eggensperger N, 2007, J CRANIO MAXILL SURG, V35, P161, DOI 10.1016/j.jcms.2007.01.002; Brasileiro BF, 2006, ORAL SURG ORAL MED O, V102, P28, DOI 10.1016/j.tripleo.2005.07.023; Furniss K, 2007, MCN-AM J MATERN-CHIL, V32, P238, DOI 10.1097/01.NMC.0000281964.45905.89; Gandhi S, 2011, DENT TRAUMATOL, V27, P257, DOI 10.1111/j.1600-9657.2011.00996.x; Garcia-Moreno C, 2006, LANCET, V368, P1260, DOI 10.1016/S0140-6736(06)69523-8; Hashemi HM, 2011, DENT TRAUMATOL, V27, P385, DOI 10.1111/j.1600-9657.2011.01016.x; Hegarty K, 2000, MED J AUSTRALIA, V173, P363, DOI 10.5694/j.1326-5377.2000.tb125688.x; Krug E.G., 2002, WORLD REPORT VIOLENC; Landenburger K M, 1998, J Obstet Gynecol Neonatal Nurs, V27, P700, DOI 10.1111/j.1552-6909.1998.tb02641.x; Laverick S, 2008, BRIT J ORAL MAX SURG, V46, P542, DOI 10.1016/j.bjoms.2008.01.021; Le BT, 2001, J ORAL MAXIL SURG, V59, P1277, DOI 10.1053/joms.2001.27490; LE BT, 2001, J ORAL MAXILLOFAC SU, V59, P1283; Leporace Antonio Augusto Ferreirinha, 2009, Rev. Col. Bras. Cir., V36, P472, DOI 10.1590/S0100-69912009000600002; Macedo JLS, 2007, REV SOC BRAS CIR PLA, V22, P209; Maliska Maximiana Cristina de Souza, 2009, Braz. oral res., V23, P268, DOI 10.1590/S1806-83242009000300008; O'Meara C, 2012, BRIT J ORAL MAX SURG, V50, P36, DOI 10.1016/j.bjoms.2010.11.003; Ochs HA, 1996, J AM DENT ASSOC, V127, P757, DOI 10.14219/jada.archive.1996.0311; Othman S, 2008, ASIA PAC FAM MED, V7, P1187; Perciaccante VJ, 1999, J ORAL MAXIL SURG, V57, P760, DOI 10.1016/S0278-2391(99)90808-X; Leles JLR, 2010, J APPL ORAL SCI, V18, P23, DOI 10.1590/S1678-77572010000100006; Saddki N, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-268; SHEPHERD JP, 1990, J ROY SOC MED, V83, P75, DOI 10.1177/014107689008300206; Sheridan DJ, 2007, TRAUMA VIOLENCE ABUS, V8, P281, DOI 10.1177/1524838007303504; Silva Joaquim José de Lima, 2011, Rev. Bras. Cir. Plást., V26, P37, DOI 10.1590/S1983-51752011000100009; World Health Organization, 1997, WHOFRHWHD978; World Health Organization (WHO), 1996, WHOEHASPIPOA2	34	27	30	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-4469	1600-9657		DENT TRAUMATOL	Dent. Traumatol.	FEB	2014	30	1					15	21		10.1111/edt.12047			7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	AH6SE	WOS:000336260200002	23675634				2021-06-18	
J	Vo, NJ; Althoen, M; Hippe, DS; Prabhu, SJ; Valji, K; Padia, SA				Vo, Nghia-Jack; Althoen, Morgan; Hippe, Daniel S.; Prabhu, Somnath J.; Valji, Karim; Padia, Siddharth A.			Pediatric Abdominal and Pelvic Trauma: Safety and Efficacy of Arterial Embolization	JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY			English	Article							ANGIOGRAPHIC EMBOLIZATION; INTERVENTIONAL RADIOLOGY; BLUNT TRAUMA; ORGAN INJURY; CHILDREN; COAGULOPATHY; MANAGEMENT	Purpose: Although transcatheter embolization is a well established technique to treat adults in the trauma setting, evidence is lacking in the pediatric population. This study assesses the safety and efficacy of arterial embolization for blunt abdominal and pelvic trauma in the pediatric population. Materials and Methods: A retrospective review of abdominal and pelvic angiograms in 97 pediatric patients with blunt trauma was conducted over an 11-year period. Abdominal angiography and embolization was performed for ongoing hepatic, I renal, splenic, or nonvisceral retroperitoneal injury. Pelvic angiography was performed in the setting of pelvic fracture with ongoing pelvic hemorrhage. Complications and clinical success rates of these procedures were assessed. Results: Of the 97 pediatric patients who underwent angiography for acute abdominal or pelvic trauma, 54 (56%) required embolization involving 62 separate sites. Injury severity score greater than 15 was present in 94% of patients. Targets of embolization included the pelvis (n = 39), liver (n = 8), kidney (n = 7), spleen (n = 6), and retroperitoneum (n = 2), Effective hemorrhage control was achieved in 47 patients (87%). Overall mortality rate was 22% (12 of 54), with most deaths related to traumatic brain injury. Five complications occurred in four patients (7%), including three major complications (hepatic abscess, bile leak, and Urinary incontinence). Conclusions: Angiography and embolization is relatively safe and potentially effective in the setting of abdominal and pelvic trauma in the pediatric population. Angiography with embolization should be considered in the treatment algorithm for this patient population.	[Vo, Nghia-Jack] Seattle Childrens Hosp, Dept Radiol, Seattle, WA USA; [Vo, Nghia-Jack] Seattle Childrens Hosp, Sect Pediat Intervent Radiol & Vasc & Intervent R, Seattle, WA USA; [Vo, Nghia-Jack] Univ Wisconsin, Madison, WI 53706 USA; [Althoen, Morgan; Prabhu, Somnath J.; Valji, Karim; Padia, Siddharth A.] Univ Wisconsin, Sect Intervent Radiol, Madison, WI 53706 USA	Vo, NJ (corresponding author), Med Coll Wisconsin, Sect Pediat Vasc & Intervent Radiol, Dept Pediat Imaging, 9000 W Wisconsin Ave,MS 721, Milwaukee, WI 53226 USA.	nvo@chw.org		Hippe, Daniel/0000-0003-2427-4404			Agolini SF, 1997, J TRAUMA, V43, P395, DOI 10.1097/00005373-199709000-00001; Bisharat N, 2001, J INFECTION, V43, P182, DOI 10.1053/jinf.2001.0904; Bize PE, 2012, J VASC INTERV RADIOL, V23, P751, DOI 10.1016/j.jvir.2012.02.009; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Christensen R., 2001, SEMIN PEDIATR SURG, P17; Dente CJ, 2009, J TRAUMA, V66, P1616, DOI 10.1097/TA.0b013e3181a59ad5; Glennie D, 2008, PEDIATR RADIOL, V38, P1180, DOI 10.1007/s00247-008-0966-y; Hamner CE, 2008, J PEDIATR SURG, V43, P916, DOI 10.1016/j.jpedsurg.2007.12.039; HANSEN ME, 1990, RADIOLOGE, V30, P331; Hendrickson JE, 2012, J PEDIATR-US, V160, P204, DOI 10.1016/j.jpeds.2011.08.019; Heran MKS, 2010, J VASC INTERV RADIOL, V21, P32, DOI 10.1016/j.jvir.2009.09.006; Johnson GE, 2013, J VASC INTERV RADIOL, V24, P363, DOI 10.1016/j.jvir.2012.12.006; Kiankhooy A, 2010, J TRAUMA, V68, P526, DOI 10.1097/TA.0b013e3181d3e5b7; Letoublon C, 2011, J TRAUMA, V70, P1032, DOI 10.1097/TA.0b013e31820e7ca1; Mayglothling JA, 2011, J EMERG MED, V41, P21, DOI 10.1016/j.jemermed.2008.10.012; Mendelson KG, 2007, SURG CLIN N AM, V87, P207, DOI 10.1016/j.suc.2006.09.016; Ohtsuka Y, 2003, PEDIATR SURG INT, V19, P29, DOI 10.1007/s00383-002-0889-x; Puapong D, 2006, J PEDIATR SURG, V41, P1859, DOI 10.1016/j.jpedsurg.2006.06.013; R Development Core Team, 2011, R LANG ENV STAT COMP; Sacks David, 2003, J Vasc Interv Radiol, V14, pS199; Schnuriger B, 2011, J TRAUMA, V70, P252, DOI 10.1097/TA.0b013e3181f2a92e; Sidhu MK, 2009, J VASC INTERV RADIOL, V20, P1115, DOI 10.1016/j.jvir.2009.07.021; Sidhu MK, 2009, PEDIATR RADIOL, V39, P506, DOI 10.1007/s00247-008-1082-8; Sweed Y., 1997, Harefuah, V132, P252; Tinkoff G, 2008, J AM COLL SURGEONS, V207, P646, DOI 10.1016/j.jamcollsurg.2008.06.342; Vane DW, 2002, J INTENSIVE CARE MED, V17, P230, DOI 10.1177/088506602237107; Velmahos GC, 2002, J TRAUMA, V53, P303, DOI 10.1097/00005373-200208000-00019; Yardeni D, 2004, J TRAUMA, V57, P404, DOI 10.1097/01.TA.0000044633.53328.F0	28	27	28	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1051-0443	1535-7732		J VASC INTERV RADIOL	J. Vasc. Interv. Radiol.	FEB	2014	25	2					215	220		10.1016/j.jvir.2013.09.014			6	Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease	Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology	AA2KU	WOS:000330924300008	24252774				2021-06-18	
J	Desai, A; Kevala, K; Kim, HY				Desai, Abhishek; Kevala, Karl; Kim, Hee-Yong			Depletion of Brain Docosahexaenoic Acid Impairs Recovery from Traumatic Brain Injury	PLOS ONE			English	Article							POLYUNSATURATED FATTY-ACID; OMEGA-3-FATTY-ACIDS; NEUROPROTECTION; PROMOTES; IMPACT; CELLS; MODEL; LEADS; RATS	Omega-3 fatty acids are crucial for proper development and function of the brain where docosahexaenoic acid (DHA), the primary omega-3 fatty acid in the brain, is retained avidly by the neuronal membranes. We investigated the effect of DHA depletion in the brain on the outcome of traumatic brain injury (TBI). Pregnant mice were put on an omega-3 fatty acid adequate or deficient diet from gestation day 14 and the pups were raised on the respective diets. Continuation of this dietary regime for three generations resulted in approximately 70% loss of DHA in the brain. Controlled cortical impact was delivered to both groups of mice to produce severe TBI and the functional recovery was compared. Compared to the omega-3 adequate mice, the DHA depleted mice exhibited significantly slower recovery from motor deficits evaluated by the rotarod and the beam walk tests. Furthermore, the DHA deficient mice showed greater anxiety-like behavior tested in the open field test as well as cognitive deficits evaluated by the novel object recognition test. The level of alpha spectrin II breakdown products, the markers of TBI, was significantly elevated in the deficient mouse cortices, indicating that the injury is greater in the deficient brains. This observation was further supported by the reduction of NeuN positive cells around the site of injury in the deficient mice, indicating exacerbated neuronal death after injury. These results suggest an important influence of the brain DHA status on TBI outcome.	[Desai, Abhishek; Kevala, Karl; Kim, Hee-Yong] NIAAA, Lab Mol Signaling, NIH, Bethesda, MD 20892 USA	Kim, HY (corresponding author), NIAAA, Lab Mol Signaling, NIH, Bethesda, MD 20892 USA.	hykim@nih.gov			Defense Medical Research and Development Program (DMRDP) [W81XWH-11-2-0074]; National Institute of Alcohol Abuse and Alcoholism, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [ZIAAA000501] Funding Source: NIH RePORTER	This work was supported by the Defense Medical Research and Development Program (DMRDP) (W81XWH-11-2-0074) and Intramural Research Program of the National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akbar M, 2005, P NATL ACAD SCI USA, V102, P10858, DOI 10.1073/pnas.0502903102; Arsenault D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017397; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Bazan NG, 2011, MOL NEUROBIOL, V44, P216, DOI 10.1007/s12035-011-8200-6; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Berman DR, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2009.01.020; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bousquet M, 2008, FASEB J, V22, P1213, DOI 10.1096/fj.07-9677com; Bousquet M, 2011, AGEING RES REV, V10, P453, DOI 10.1016/j.arr.2011.03.001; Calder PC, 2009, BIOCHIMIE, V91, P791, DOI 10.1016/j.biochi.2009.01.008; Cao DH, 2009, J NEUROCHEM, V111, P510, DOI 10.1111/j.1471-4159.2009.06335.x; Carrie I, 2000, J LIPID RES, V41, P473; CHIN LS, 1995, P NATL ACAD SCI USA, V92, P9230, DOI 10.1073/pnas.92.20.9230; Danthi SJ, 2005, BIOCHEM BIOPH RES CO, V327, P485, DOI 10.1016/j.bbrc.2004.12.033; DeMar JC, 2006, J LIPID RES, V47, P172, DOI 10.1194/jlr.M500362-JLR200; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; ENNACEUR A, 1992, BEHAV BRAIN RES, V51, P83, DOI 10.1016/S0166-4328(05)80315-8; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gladman SJ, 2012, J NEUROSCI, V32, P563, DOI 10.1523/JNEUROSCI.3371-11.2012; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Kim HY, 2011, BIOCHEM J, V435, P327, DOI 10.1042/BJ20102118; Kim HY, 2012, PROSTAGLANDINS LEUKO, V88, P121; King VR, 2006, J NEUROSCI, V26, P4672, DOI 10.1523/JNEUROSCI.5539-05.2006; Lalancette-Hebert M, 2011, STROKE, V42, P2903, DOI 10.1161/STROKEAHA.111.620856; Lengqvist J, 2004, MOL CELL PROTEOMICS, V3, P692, DOI 10.1074/mcp.M400003-MCP200; Lim SY, 2005, J NEUROCHEM, V95, P848, DOI 10.1111/j.1471-4159.2005.03427.x; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Madathil SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067204; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Moriguchi T, 2000, J NEUROCHEM, V75, P2563, DOI 10.1046/j.1471-4159.2000.0752563.x; Moriguchi T, 2003, J NEUROCHEM, V87, P297, DOI 10.1046/j.1471-4159.2003.01966.x; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; NAKASHIMA Y, 1993, J LIPID RES, V34, P239; Pu HJ, 2013, J CEREBR BLOOD F MET, V33, P1474, DOI 10.1038/jcbfm.2013.108; Rashid MA, 2013, J NEUROCHEM, V125, P869, DOI 10.1111/jnc.12255; REEVES PG, 1993, J NUTR, V123, P1939; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Russell KL, 2013, PROSTAG LEUKOTR ESS, V89, P97, DOI 10.1016/j.plefa.2013.05.004; Sidhu VK, 2011, J PROTEOME RES, V10, P5472, DOI 10.1021/pr2007285; Simopoulos AP, 2011, MOL NEUROBIOL, V44, P203, DOI 10.1007/s12035-010-8162-0; Takeuchi T, 2003, BRAIN RES, V964, P136, DOI 10.1016/S0006-8993(02)04113-6; Wen ZM, 2004, J NEUROCHEM, V89, P1368, DOI 10.1111/j.1471-4159.2004.02433.x; Wu A, 2004, J NEUROTRAUM, V28, P2113; Xiao Y, 2005, BRIT J NUTR, V94, P544, DOI 10.1079/BJN20051539; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhang WT, 2010, STROKE, V41, P2341, DOI 10.1161/STROKEAHA.110.586081	49	27	29	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2014	9	1							e86472	10.1371/journal.pone.0086472			9	Multidisciplinary Sciences	Science & Technology - Other Topics	301BI	WOS:000330507300068	24475126	DOAJ Gold, Green Published			2021-06-18	
J	Hughes, RH; Silva, VA; Ahmed, I; Shreiber, DI; Morrison, B				Hughes, Rebecca H.; Silva, Victoria A.; Ahmed, Ijaz; Shreiber, David I.; Morrison, Barclay, III			Neuroprotection by genipin against reactive oxygen and reactive nitrogen species-mediated injury in organotypic hippocampal slice cultures	BRAIN RESEARCH			English	Article						Genipin; Brain injury; Neuroprotection; Organotypic hippocampal slice culture; Reactive oxygen species	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE; SIGNALING PATHWAY; GRIESS REACTION; ANTIOXIDANT; GENIPOSIDE; METABOLISM; DAMAGE; DYSFUNCTION; PREVENTION	Genipin, the multipotent ingredient in Gardenia jasmenoides fruit extract (GFE), may be an effective candidate for treatment following stroke or traumatic brain injury (TBI). Secondary injury includes damage mediated by reactive oxygen species (ROS) and reactive nitrogen species (RNS), which can alter the biological function of key cellular structures and eventually lead to cell death. In this work, we studied the neuroprotective potential of genipin against damage stemming from ROS and RNS production in organotypic hippocampal slice cultures (OHSC), as well as its potential as a direct free radical scavenger. A 50 mu M dose of genipin provided significant protection against tert-butyl hydroperoxide (tBHP), a damaging organic peroxide. This dosage of genipin significantly reduced cell death at 48 h compared to vehicle control (0.1% DMSO) when administered 0, 1, 6, and 24 h after addition of tBHP. Similarly, genipin significantly reduced cell death at 48 h when administered 0, 1, 2, and 6 h after addition of rotenone, which generates reactive oxygen species via a more physiologically relevant mechanism. Furthermore, genipin significantly reduced both cell death and nitrite levels at 24 h caused by S-nitroso-N-acetylpenicillamine (SNAP), a direct nitric oxide (NO) donor, and successfully quenched 1,1-Diphenyl-2-picryl-hydrazyl (DPPH), a stable free radical, suggesting that genipin may act as a direct free radical scavenger. Our encouraging findings suggest that genipin should be tested in animal models of CNS injury with a significant component of ROS- and RNS-mediated damage, such as TBI and stroke, to assess its in vivo efficacy. (C) 2013 Elsevier B.V. All rights reserved.	[Hughes, Rebecca H.; Silva, Victoria A.; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA; [Ahmed, Ijaz; Shreiber, David I.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA	Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, 351 Engn Terrace,MC 8904,1210 Amsterdam Ave, New York, NY 10027 USA.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Shreiber, David/0000-0001-8248-419X	New Jersey Commission on Brain Injury Research [10-3215-BIR-E-0]	This research was supported by the New Jersey Commission on Brain Injury Research, Award #10-3215-BIR-E-0.	AKAO T, 1994, BIOL PHARM BULL, V17, P1573; Alia M, 2005, J BIOCHEM MOL TOXIC, V19, P119, DOI 10.1002/jbt.20061; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Dorman HJD, 2011, FOOD CHEM, V129, P1612, DOI 10.1016/j.foodchem.2011.06.017; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; Granger DL, 1996, METHOD ENZYMOL, V268, P142; Guangpinx X., 2003, NEUROTOX RES, V5, P529; Guevara I, 1998, CLIN CHIM ACTA, V274, P177, DOI 10.1016/S0009-8981(98)00060-6; Hou YC, 2008, FOOD CHEM TOXICOL, V46, P2764, DOI 10.1016/j.fct.2008.04.033; Jeon WK, 2011, ARCH BIOCHEM BIOPHYS, V512, P119, DOI 10.1016/j.abb.2011.05.016; Jin J, 2004, BIOMACROMOLECULES, V5, P162, DOI 10.1021/bm034286m; Koo HJ, 2006, J ETHNOPHARMACOL, V103, P496, DOI 10.1016/j.jep.2005.08.011; Koo HJ, 2004, EUR J PHARMACOL, V495, P201, DOI 10.1016/j.ejphar.2004.05.031; Lee JH, 2009, FOOD CHEM TOXICOL, V47, P1127, DOI 10.1016/j.fct.2009.01.037; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Morrison B, 2002, BRIT J PHARMACOL, V137, P1255, DOI 10.1038/sj.bjp.0704986; Neuwelt E, 2008, LANCET NEUROL, V7, P84, DOI 10.1016/S1474-4422(07)70326-5; Ohkubo T, 2004, J HEALTH SCI, V50, P193, DOI 10.1248/jhs.50.193; Padayatty SJ, 2003, J AM COLL NUTR, V22, P18, DOI 10.1080/07315724.2003.10719272; Qiu WJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041391; Rigg JL, 2005, J HEAD TRAUMA REHAB, V20, P389, DOI 10.1097/00001199-200507000-00010; Sharma OP, 2009, FOOD CHEM, V113, P1202, DOI 10.1016/j.foodchem.2008.08.008; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Suzuki Y, 2001, PLANTA MED, V67, P807, DOI 10.1055/s-2001-18842; Tseng TY, 2004, ANAL CHIM ACTA, V517, P47, DOI 10.1016/j.aca.2004.04.040; Valgimigli L, 2009, ENVIRON MOL MUTAGEN, V50, P222, DOI 10.1002/em.20468; Wagner KR, 2003, J CEREBR BLOOD F MET, V23, P629, DOI 10.1097/01.WCB.0000073905.87928.6D; Wang GF, 2009, ACTA PHARMACOL SIN, V30, P589, DOI 10.1038/aps.2009.31; Yamazaki M, 2001, BIOL PHARM BULL, V24, P1454, DOI 10.1248/bpb.24.1454; Yamazaki M, 2008, EUR J PHARMACOL, V581, P255, DOI 10.1016/j.ejphar.2007.12.001; Yen GC, 2002, FOOD CHEM, V79, P307, DOI 10.1016/S0308-8146(02)00145-0; Yen GC, 1997, J AGR FOOD CHEM, V45, P30, DOI 10.1021/jf9603994; Yuan Y, 2007, CARBOHYD POLYM, V68, P561, DOI 10.1016/j.carbpol.2006.10.023; Zhang CY, 2006, CELL METAB, V3, P417, DOI 10.1016/j.cmet.2006.04.010	38	27	29	2	21	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 16	2014	1543						308	314		10.1016/j.brainres.2013.11.020			7	Neurosciences	Neurosciences & Neurology	300VE	WOS:000330491300034	24275198				2021-06-18	
J	Morishita, S; Oku, H; Horie, T; Tonari, M; Kida, T; Okubo, A; Sugiyama, T; Takai, S; Hara, H; Ikeda, T				Morishita, Seita; Oku, Hidehiro; Horie, Taeko; Tonari, Masahiro; Kida, Teruyo; Okubo, Akiko; Sugiyama, Tetsuya; Takai, Shinji; Hara, Hideaki; Ikeda, Tsunehiko			Systemic Simvastatin Rescues Retinal Ganglion Cells from Optic Nerve Injury Possibly through Suppression of Astroglial NF-kappa B Activation	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; MONOCYTE CHEMOATTRACTANT PROTEIN-1; TRAUMATIC BRAIN-INJURY; RAT RETINA; REACTIVE ASTROCYTES; MULTIPLE-SCLEROSIS; ADULT-RATS; IN-VIVO; EXPRESSION; NEURONS	Neuroinflammation is involved in the death of retinal ganglion cells (RGCs) after optic nerve injury. The purpose of this study was to determine whether systemic simvastatin can suppress neuroinflammation in the optic nerve and rescue RGCs after the optic nerve is crushed. Simvastatin or its vehicle was given through an osmotic minipump beginning one week prior to the crushing. Immunohistochemistry and real-time PCR were used to determine the degree of neuroinflammation on day 3 after the crushing. The density of RGCs was determined in Tuj-1 stained retinal flat mounts on day 7. The effect of simvastain on the TNF-alpha-induced NF-kappa B activation was determined in cultured optic nerve astrocytes. On day 3, CD68-positive cells, most likely microglia/macrophages, were accumulated at the crushed site. Phosphorylated NF-kB was detected in some astrocytes at the border of the lesion where the immunoreactivity to MCP-1 was intensified. There was an increase in the mRNA levels of the CD68 (11.4-fold), MCP-1 (22.6-fold), ET-1 (2.3-fold), GFAP (1.6-fold), TNF-alpha (7.0-fold), and iNOS (14.8-fold) genes on day 3. Systemic simvastatin significantly reduced these changes. The mean +/- SD number of RGCs was 1816.3 +/- 232.6/mm(2) (n = 6) in the sham controls which was significantly reduced to 831.4 +/- 202.5/mm(2) (n = 9) on day 7 after the optic nerve was crushed. This reduction was significantly suppressed to 1169.2 +/- 201.3/mm(2) (P = 0.01, Scheffe; n = 9) after systemic simvastatin. Simvastatin (1.0 mu M) significantly reduced the TNF-a-induced NF-kB activation in cultured optic nerve astrocytes. We conclude that systemic simvastatin can reduce the death of RGCs induced by crushing the optic nerve possibly by suppressing astroglial NF-kappa B activation.	[Morishita, Seita; Oku, Hidehiro; Horie, Taeko; Tonari, Masahiro; Kida, Teruyo; Okubo, Akiko; Sugiyama, Tetsuya; Ikeda, Tsunehiko] Osaka Med Coll, Dept Ophthalmol, Osaka, Japan; [Takai, Shinji] Osaka Med Coll, Dept Pharmacol, Osaka, Japan; [Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Gifu, Japan	Oku, H (corresponding author), Osaka Med Coll, Dept Ophthalmol, Osaka, Japan.	hidehirooku@aol.com	Oku, Hidehiro/AAD-5029-2019	Oku, Hidehiro/0000-0003-4359-4219	Japanese Ministry of Education Grant [225919739]; Osaka Community Foundation grant; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [25462763] Funding Source: KAKEN	This study was supported by Japanese Ministry of Education Grant 225919739 (HO) and Osaka Community Foundation grant ( HO). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bian ZM, 2001, EXP EYE RES, V73, P111, DOI 10.1006/exer.2001.1019; Brambilla R, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-213; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Chen Y, 2003, J CEREBR BLOOD F MET, V23, P748, DOI 10.1097/01.WCB.0000071885.63724.20; Cui Q, 2003, MOL CELL NEUROSCI, V22, P49, DOI 10.1016/S1044-7431(02)00037-4; Dvoriantchikova G, 2009, EUR J NEUROSCI, V30, P175, DOI 10.1111/j.1460-9568.2009.06814.x; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Ghosh A, 2009, J NEUROSCI, V29, P13543, DOI 10.1523/JNEUROSCI.4144-09.2009; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Indraswari F, 2012, J NEUROTRAUM, V29, P1388, DOI 10.1089/neu.2011.2117; Kawaji T, 2007, CURR EYE RES, V32, P991, DOI 10.1080/02713680701649603; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; Kitaoka Y, 2006, INVEST OPHTH VIS SCI, V47, P1448, DOI 10.1167/iovs.05-0299; Ko ML, 2011, EXP EYE RES, V93, P580, DOI 10.1016/j.exer.2011.07.003; Krempler K, 2011, INVEST OPHTH VIS SCI, V52, P2606, DOI 10.1167/iovs.10-6005; Kretz A, 2006, NEUROBIOL DIS, V21, P421, DOI 10.1016/j.nbd.2005.08.003; Kurimoto T, 2006, NEUROREPORT, V17, P1525, DOI 10.1097/01.wnr.0000234749.80936.54; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1; Nakazawa T, 2007, J NEUROCHEM, V100, P1018, DOI 10.1111/j.1471-4159.2006.04274.x; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Panagis L, 2005, EUR J NEUROSCI, V21, P2305, DOI 10.1111/j.1460-9568.2005.04046.x; Pazman C, 2000, DEVELOPMENT, V127, P1715; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Rattan R, 2003, FREE RADICAL BIO MED, V35, P1037, DOI 10.1016/S0891-5849(03)00459-3; ROSENMAN SJ, 1995, J IMMUNOL, V154, P1888; Saha RN, 2006, ANTIOXID REDOX SIGN, V8, P929, DOI 10.1089/ars.2006.8.929; Schmeer C, 2008, INVEST OPHTH VIS SCI, V49, P4971, DOI 10.1167/iovs.07-1597; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; SNOW RL, 1995, EXP NEUROL, V134, P13, DOI 10.1006/exnr.1995.1032; Tezel G, 2004, BRAIN RES, V996, P202, DOI 10.1016/j.brainres.2003.10.029; Thompson WL, 2009, BRAIN RES, V1287, P47, DOI 10.1016/j.brainres.2009.06.081; Tonari M, 2012, INVEST OPHTH VIS SCI, V53, P3490, DOI 10.1167/iovs.11-9415; Van der Voorn P, 1999, AM J PATHOL, V154, P45, DOI 10.1016/S0002-9440(10)65249-2; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; WINKLER BS, 1972, VISION RES, V12, P1183, DOI 10.1016/0042-6989(72)90106-X; Wu HT, 2010, J NEUROSURG, V113, P591, DOI 10.3171/2009.9.JNS09859	39	27	31	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 2	2014	9	1							e84387	10.1371/journal.pone.0084387			11	Multidisciplinary Sciences	Science & Technology - Other Topics	286ID	WOS:000329460100054	24392131	DOAJ Gold, Green Published			2021-06-18	
J	Kopczak, A; Kilimann, I; von Rosen, F; Krewer, C; Schneider, HJ; Stalla, GK; Schneider, M				Kopczak, Anna; Kilimann, Ingo; von Rosen, Friedrich; Krewer, Carmen; Schneider, Harald Joern; Stalla, Guenter Karl; Schneider, Manfred			Screening for Hypopituitarism in 509 Patients with Traumatic Brain Injury or Subarachnoid Hemorrhage	JOURNAL OF NEUROTRAUMA			English	Article						hypopituitarism; rehabilitation; subarachnoid hemorrhage; traumatic brain injury	ANTERIOR-PITUITARY INSUFFICIENCY; ACUTE-PHASE; PREVALENCE; DYSFUNCTION; HYPOGONADISM; COGNITION	We performed a screening on patients with traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH) to determine the prevalence of post-traumatic hypopituitarism in neurorehabilitation in a cross-sectional, observational single-center study. In addition, the therapeutic consequences of our screening were analyzed retrospectively. From February 2006 to August 2009, patients between 18 and 65 years (n=509) with the diagnosis of TBI (n=340) or SAH (n=169) were screened within two weeks of admittance to neurorehabilitation as clinical routine. Blood was drawn to determine fasting cortisol, free thyroxine (fT4), prolactin, testosterone or estradiol, and insulin-like growth factor I (IGF-I). Patients with abnormalities in the screening or clinical signs of hypopituitarism received further stimulation tests: growth hormone releasing hormone -L-arginine-test and adrenocorticotrophic hormone (ACTH)-test (n=36); ACTH-test alone (n=26); or insulin tolerance test (n=56). In our screening of 509 patients, 28.5% showed lowered values in at least one hormone of the hypothalamus-pituitary axis and 4.5% in two or more axes. The most common disturbance was a decrease of testosterone in 40.7% of all men (in the following 13/131 men were given substitution therapy). Low fT4 was detected in 5.9% (n=3 were given substitution therapy). Low IGF-I was detected in 5.8%, low cortisol in 1.4%, and low prolactin in 0.2%; none were given substitution therapy. Further stimulation tests revealed growth hormone deficiency in 20.7% (n=19/92) and hypocortisolism in 23.7% (n=28/118). Laboratory values possibly indicating hypopituitarism (33%) were common but did not always implicate post-traumatic hypopituitarism. Laboratory values possibly indicating hypopituitarism were common in our screening but most patients were clinically not diagnosed as pituitary insufficient and did not receive hormone replacement therapy. A routine screening of all patients in neurorehabilitation without considering the time since injury, the severity of illness and therapeutic consequences seems not useful.	[Kopczak, Anna; Stalla, Guenter Karl] Max Planck Inst Psychiat, D-80804 Munich, Germany; [Kilimann, Ingo] German Ctr Neurodegenerat Dis, DZNE, Rostock, Germany; [von Rosen, Friedrich] Schon Klin Staffelstein, Dept Neurol, Bad Staffelstein, Germany; [Krewer, Carmen; Schneider, Manfred] Schon Klin, Bad Aibling, Bad Aibling, Germany; [Schneider, Harald Joern] Univ Munich, Med Klin Innenstadt, D-80539 Munich, Germany	Kopczak, A (corresponding author), Max Planck Inst Psychiat, Clin Neuroendocrinol Grp, Kraepelinstr 2-10, D-80804 Munich, Germany.	anna_kopczak@mpipsykl.mpg.de	Krewer, Carmen/H-2845-2019	Krewer, Carmen/0000-0002-4153-0791; Kopczak, Anna/0000-0002-5037-2342	PfizerPfizer; NovartisNovartis; LillyEli Lilly; NovoNordiskNovo Nordisk; Pfizer GmbH, Germany [NRA 6280051]	H.J.S. received research grants from Pfizer, travel grants from Novartis, Pfizer, and Lilly, speaker fees from NovoNordisk, Pfizer, and Lilly, and is a member of the German KIMS (Pfizer International Metabolic Survey) board. M. S. received research grants and travel grants from Pfizer and Novo Nordisk. The other authors report that no competing financial interests exist.; This screening program and the stimulation tests were part of the project "Patients after traumatic brain injury or subarachnoid hemorrhage - screening for hypopituitarism" (project number NRA 6280051) which was supported by an unrestricted grant from Pfizer GmbH, Germany.	Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Berg C, 2010, EXP CLIN ENDOCR DIAB, V118, P139, DOI 10.1055/s-0029-1225611; Bondanelli M, 2002, METABOLISM, V51, P1363, DOI 10.1053/meta.2002.34714; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Brabant G, 2003, HORM RES, V60, P53, DOI 10.1159/000071871; Carlson NE, 2009, BRAIN INJURY, V23, P336, DOI 10.1080/02699050902788535; Cherrier MM, 2009, FRONT HORM RES, V37, P150, DOI 10.1159/000176051; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; Fuck SP, 2009, FRONT HORM RES, V37, P123, DOI 10.1159/000176049; Glynn N, 2013, CLIN ENDOCRINOL, V78, P17, DOI 10.1111/cen.12010; High WM, 2010, J NEUROTRAUM, V27, P1565, DOI 10.1089/neu.2009.1253; Isidori A M, 2005, J Endocrinol Invest, V28, P73; Kaufman JM, 2005, ENDOCR REV, V26, P833, DOI 10.1210/er.2004-0013; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Klose M, 2010, CLIN ENDOCRINOL, V73, P95, DOI 10.1111/j.1365-2265.2010.03791.x; Kokshoorn NE, 2011, EUR J ENDOCRINOL, V165, P225, DOI 10.1530/EJE-11-0365; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Kopczak A, 2011, EUR J ENDOCRINOL, V164, P31, DOI 10.1530/EJE-10-0821; Kreitschmann-Andermahr I, 2011, EXP CLIN ENDOCR DIAB, V119, P15, DOI 10.1055/s-0030-1253414; MAHONEY F I, 1965, Md State Med J, V14, P61; Quinn TJ, 2011, STROKE, V42, P1146, DOI 10.1161/STROKEAHA.110.598540; Schneider HJ, 2011, J NEUROTRAUM, V28, P1693, DOI 10.1089/neu.2011.1887; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2007, LANCET, V369, P1461, DOI 10.1016/S0140-6736(07)60673-4; Schneider HJ, 2009, CLIN ENDOCRINOL, V70, P446, DOI 10.1111/j.1365-2265.2008.03370.x; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; Tanriverdi F, 2011, J ENDOCRINOL INVEST, V34, P541, DOI 10.3275/7805; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Van den Berghe G, 2000, EUR J ENDOCRINOL, V143, P1, DOI 10.1530/eje.0.1430001; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wang C, 2008, EUR J ENDOCRINOL, V159, P507, DOI 10.1530/EJE-08-0601; Zitzmann M, 2009, NAT REV ENDOCRINOL, V5, P673, DOI 10.1038/nrendo.2009.212	34	27	27	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2014	31	1					99	107		10.1089/neu.2013.3002			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	302WJ	WOS:000330635500009	23980725				2021-06-18	
J	Magen, I; Gozes, I				Magen, Iddo; Gozes, Illana			Davunetide: Peptide Therapeutic in Neurological Disorders	CURRENT MEDICINAL CHEMISTRY			English	Article						Activity-dependent neuroprotective protein (ADNP); Alzheimer's disease; Davunetide; NAP; neurodegenerative diseases; neurological disorders	DEPENDENT NEUROPROTECTIVE PROTEIN; FETAL ALCOHOL SYNDROME; FEMTOMOLAR-ACTING PEPTIDES; INDUCED LEARNING-DEFICITS; CLOSED-HEAD INJURY; MOUSE MODEL; NAP DAVUNETIDE; NEUROTROPHIC FACTOR; D-SAL; NEURODEGENERATIVE DISEASES	This review focuses on the therapeutic effects and mechanisms of action of NAP (davunetide), an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP) which was discovered in the laboratory of Prof. Illana Gozes. The effects of NAP and its related peptides in models of neurodegenerative diseases and other neurological disorders will be described here in details. Possible mechanisms of NAP actions include anti-inflammatory effect, antioxidant activity, inhibition of protein aggregation and interaction with microtubules. In line with the fact that all of these features are characteristic to most neurological/neurodegenerative disorders, NAP was found to have beneficial effects on the behavioral manifestations associated with these disorders.	[Gozes, Illana] Tel Aviv Univ, Sackler Fac Med, Adams Super Ctr Brain Studies, IL-69978 Tel Aviv, Israel; [Gozes, Illana] Tel Aviv Univ, Sackler Fac Med, Lily & Avraham Gildor Chair Invest Growth Factors, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Elton Lab Neuroendocrinol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel	Gozes, I (corresponding author), Tel Aviv Univ, Sackler Fac Med, Lily & Avraham Gildor Chair Invest Growth Factors, IL-69978 Tel Aviv, Israel.	igozes@post.tau.ac.il		Magen, Iddo/0000-0002-3011-3175	Post-Doctoral Fellowship from Tel Aviv University; AMN Foundation; CFTAU Montreal Circle of Friends; Adams Super Center for Brain Studies and at Tel Aviv University; Joe and Grace Alter; Barbara and Don Seal; Oberfeld and the Adams families; Diana and Zelman Elton (Elbaum) Laboratory for Molecular Neuroendocrinology	Dr. Iddo Magen was partially supported by a Post-Doctoral Fellowship from Tel Aviv University. Professor Gozes (the Lily and Avraham Gildor Chair for the Investigation of Growth Factors) laboratory is supported by the AMN Foundation, CFTAU Montreal Circle of Friends, Joe and Grace Alter, Barbara and Don Seal, the Oberfeld and the Adams families, Adams Super Center for Brain Studies and at Tel Aviv University and the the Dr. Diana and Zelman Elton (Elbaum) Laboratory for Molecular Neuroendocrinology. Professor Gozes served as a Director Founding Scientist at Allon Therapeutics Inc. that has been developing davunetide (NAP) and related compounds. As this paper was reviewed and processed several new finding accumulated in the field and these are subjects of current and future publications.	Aboonq MS, 2012, J MOL NEUROSCI, V46, P33, DOI 10.1007/s12031-011-9562-y; Ashur-Fabian O, 2003, PEPTIDES, V24, P1413, DOI 10.1016/j.peptides.2003.08.005; Bassan M, 1999, J NEUROCHEM, V72, P1283, DOI 10.1046/j.1471-4159.1999.0721283.x; Belokopytov M, 2011, ACTA OPHTHALMOL, V89, pE126, DOI 10.1111/j.1755-3768.2010.02041.x; Ben-David E, 2013, MOL PSYCHIATR, V18, P1054, DOI 10.1038/mp.2012.148; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Blat D, 2008, J MED CHEM, V51, P126, DOI 10.1021/jm070800l; Borozdin Wiktor, 2007, Hum Mutat, V28, P830, DOI 10.1002/humu.9502; Braitch M, 2010, NEUROIMMUNOMODULAT, V17, P120, DOI 10.1159/000258695; Brenneman DE, 2004, J PHARMACOL EXP THER, V309, P1190, DOI 10.1124/jpet.103.063891; Brenneman DE, 1996, J CLIN INVEST, V97, P2299, DOI 10.1172/JCI118672; Brenneman DE, 1998, J PHARMACOL EXP THER, V285, P619; Busciglio J, 2007, CURR PHARM DESIGN, V13, P1091, DOI 10.2174/138161207780618957; Castorina A, 2012, J MOL NEUROSCI, V48, P674, DOI 10.1007/s12031-012-9755-z; Cattano D, 2008, NEUROSCI LETT, V440, P217, DOI 10.1016/j.neulet.2008.05.086; Chen LM, 2012, J NEUROCHEM, V120, P157, DOI 10.1111/j.1471-4159.2011.07275.x; Chen SZ, 2008, P NATL ACAD SCI USA, V105, P19962, DOI 10.1073/pnas.0807758105; Chen SY, 2005, DEV NEUROSCI-BASEL, V27, P13, DOI 10.1159/000084528; CHO MJ, 1993, SOC PSYCH PSYCH EPID, V28, P156, DOI 10.1007/BF00797317; Cosgrave AS, 2008, NEUROBIOL DIS, V30, P281, DOI 10.1016/j.nbd.2008.02.005; Cosgrave AS, 2009, J MOL NEUROSCI, V39, P9, DOI 10.1007/s12031-008-9169-0; Dangoor D, 2005, PEPTIDES, V26, P2579, DOI 10.1016/j.peptides.2005.06.005; Divinski I, 2004, J BIOL CHEM, V279, P28531, DOI 10.1074/jbc.M403197200; Divinski I, 2006, J NEUROCHEM, V98, P973, DOI 10.1111/j.1471-4159.2006.03936.x; Dresner E, 2012, J BIOL CHEM, V287, P40173, DOI 10.1074/jbc.M112.387027; Dresner E, 2011, EUR NEUROPSYCHOPHARM, V21, P355, DOI 10.1016/j.euroneuro.2010.06.004; Fernagut PO, 2007, SYNAPSE, V61, P991, DOI 10.1002/syn.20456; Fernandez-Montesinos R, 2010, J MOL NEUROSCI, V41, P114, DOI 10.1007/s12031-009-9300-x; Fitzgerald DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024364; Fleming SM, 2011, MOL CELL NEUROSCI, V46, P597, DOI 10.1016/j.mcn.2010.12.011; Fleming SM, 2004, J NEUROSCI, V24, P9434, DOI 10.1523/JNEUROSCI.3080-04.2004; Furman S, 2005, NEUROSCI LETT, V373, P73, DOI 10.1016/j.neulet.2004.09.077; Gennet N, 2008, HISTOL HISTOPATHOL, V23, P309, DOI 10.14670/HH-23.309; Gold M, 2012, NEUROPSYCH DIS TREAT, V8, P85, DOI 10.2147/NDT.S12518; Gozes I, 2000, J PHARMACOL EXP THER, V293, P1091; Gozes I, 2002, J MOL NEUROSCI, V19, P167, DOI 10.1007/s12031-002-0028-0; Gozes I, 2000, ANN NY ACAD SCI, V921, P115; Gozes I, 2001, TRENDS NEUROSCI, V24, P700, DOI 10.1016/S0166-2236(00)01931-7; Gozes I, 2000, J MOL NEUROSCI, V14, P61, DOI 10.1385/JMN:14:1-2:061; Gozes I., 2012, NEUR M PLANN SOC NEU; Gozes I., 2013, HDB BIOL ACTIVE PEPT, p[1611, 1611]; GOZES I, 2007, HDB NEUROCHEMISTRY M, P673; Gozes I, 2007, PHARMACOL THERAPEUT, V114, P146, DOI 10.1016/j.pharmthera.2007.01.004; Gozes Illana, 2005, P251, DOI 10.1017/CBO9780511546310.016; Gozes I, 2005, CNS DRUG REV, V11, P353; Gozes Illana, 2005, Current Alzheimer Research, V2, P149, DOI 10.2174/1567205053585873; Gozes Illana, 2012, Front Endocrinol (Lausanne), V3, P134, DOI 10.3389/fendo.2012.00134; Gozes I, 2011, CURR PHARM DESIGN, V17, P3413, DOI 10.2174/138161211798072553; Gozes I, 2011, CURR PHARM DESIGN, V17, P1040, DOI 10.2174/138161211795589373; Gozes I, 2011, PEPTIDES, V32, P428, DOI 10.1016/j.peptides.2010.10.030; Gozes I, 2010, RSC DRUG DISCOV, V3, P108; Gozes I, 2008, J MOL NEUROSCI, V36, P115, DOI 10.1007/s12031-008-9105-3; Greggio S, 2011, NEUROBIOL DIS, V44, P152, DOI 10.1016/j.nbd.2011.06.018; Greggio S, 2009, NEUROBIOL DIS, V36, P435, DOI 10.1016/j.nbd.2009.08.008; Haro JM, 2011, BRIT J PSYCHIAT, V199, P194, DOI 10.1192/bjp.bp.110.082065; Holtser-Cochav M, 2006, J MOL NEUROSCI, V28, P303, DOI 10.1385/JMN:28:3:303; Idan-Feldman A, 2012, INT J ALZHEIMERS DIS, V2012, DOI DOI 10.1155/2012/493670; Idan-Feldman A, 2011, NEUROBIOL DIS, V44, P327, DOI 10.1016/j.nbd.2011.06.020; Incerti M, 2011, OBSTET GYNECOL, V117, P354, DOI 10.1097/AOG.0b013e3182051ca5; Incerti M, 2010, AM J PERINAT, V27, P743, DOI 10.1055/s-0030-1253558; Incerti M, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.03.050; Incerti M, 2010, OBSTET GYNECOL, V115, P350, DOI 10.1097/AOG.0b013e3181cb59da; Jarskog LF, 2013, NEUROPSYCHOPHARMACOL, V38, P1245, DOI 10.1038/npp.2013.23; Javitt DC, 2012, SCHIZOPHR RES, V136, P25, DOI 10.1016/j.schres.2011.11.001; Jehle T, 2008, GRAEF ARCH CLIN EXP, V246, P1255, DOI 10.1007/s00417-007-0746-7; Johnstone M, 2011, SCHIZOPHRENIA BULL, V37, P14, DOI 10.1093/schbul/sbq135; Jouroukhin Y, 2012, J MOL NEUROSCI, V48, P597, DOI 10.1007/s12031-012-9882-6; Katayama T, 2009, PHARMACOGENOMICS, V10, P1967, DOI [10.2217/pgs.09.147, 10.2217/PGS.09.147]; Kumral A, 2006, BRAIN RES, V1115, P169, DOI 10.1016/j.brainres.2006.07.114; Lagreze WA, 2005, INVEST OPHTH VIS SCI, V46, P933, DOI 10.1167/iovs.04-0766; Leker RR, 2002, STROKE, V33, P1085, DOI 10.1161/01.STR.0000014207.05597.D7; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; Mandel S, 2008, J MOL NEUROSCI, V35, P127, DOI 10.1007/s12031-007-9013-y; Mandel S, 2007, J BIOL CHEM, V282, P34448, DOI 10.1074/jbc.M704756200; Mandel S, 2007, DEV BIOL, V303, P814, DOI 10.1016/j.ydbio.2006.11.039; Merenlender-Wagner A, 2010, PEPTIDES, V31, P1368, DOI 10.1016/j.peptides.2010.04.011; Morimoto BH, 2009, CHIM OGGI, V27, P16; Nakamachi T, 2008, REGUL PEPTIDES, V145, P88, DOI 10.1016/j.regpep.2007.09.025; Nakamachi T, 2006, PEPTIDES, V27, P1859, DOI 10.1016/j.peptides.2006.01.007; O'Roak BJ, 2012, SCIENCE, V338, P1619, DOI 10.1126/science.1227764; O'Roak BJ, 2012, NATURE, V485, P246, DOI 10.1038/nature10989; Offen D, 2000, BRAIN RES, V854, P257, DOI 10.1016/S0006-8993(99)02375-6; Oz S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051458; Parnell SE, 2007, ALCOHOL CLIN EXP RES, V31, P2059, DOI 10.1111/j.1530-0277.2007.00524.x; Pascual M, 2007, J NEUROCHEM, V103, P557, DOI 10.1111/j.1471-4159.2007.04761.x; Pinhasov A, 2003, DEV BRAIN RES, V144, P83, DOI 10.1016/S0165-3806(03)00162-7; Piper M, 2012, PSYCHIAT CLIN N AM, V35, P571, DOI 10.1016/j.psc.2012.06.002; Quintana FJ, 2006, ANN NY ACAD SCI, V1070, P500, DOI 10.1196/annals.1317.069; Quraishe S, 2013, MOL PSYCHIATR, V18, P834, DOI 10.1038/mp.2013.32; Roberson R, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.10.005; Romano J, 2002, J MOL NEUROSCI, V18, P37, DOI 10.1385/JMN:18:1-2:37; Rotstein M, 2006, J PHARMACOL EXP THER, V319, P332, DOI 10.1124/jpet.106.106898; Sari Y, 2009, NEUROSCIENCE, V158, P1426, DOI 10.1016/j.neuroscience.2008.11.021; Sari Y, 2006, BRAIN RES REV, V52, P107, DOI 10.1016/j.brainresrev.2006.01.004; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Shiryaev N, 2011, CURR PHARM DESIGN, V17, P2603, DOI 10.2174/138161211797416093; Smith-Swintosky VL, 2005, J MOL NEUROSCI, V25, P225, DOI 10.1385/JMN:25:3:225; Sokolowska P, 2011, NEUROSCIENCE, V173, P156, DOI 10.1016/j.neuroscience.2010.10.074; Spong CY, 2001, J PHARMACOL EXP THER, V297, P774; Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810; Sudo H, 2011, HUM MOL GENET, V20, P763, DOI 10.1093/hmg/ddq521; Teuchner B, 2011, ACTA OPHTHALMOL, V89, P670, DOI 10.1111/j.1755-3768.2009.01828.x; Thimmasettappa T, 2007, J MOL NEUROSCI, V33, P268; Toso L, 2006, AM J OBSTET GYNECOL, V194, P1153, DOI 10.1016/j.ajog.2005.12.023; Toso L, 2006, AM J OBSTET GYNECOL, V194, P681, DOI 10.1016/j.ajog.2006.01.003; Toso L, 2007, AM J OBSTET GYNECOL, V196, P259, DOI 10.1016/j.ajog.2007.01.015; Vacic V, 2011, NATURE, V471, P499, DOI 10.1038/nature09884; Vink J, 2005, AM J OBSTET GYNECOL, V193, P825, DOI 10.1016/j.ajog.2005.02.101; Vink J, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2009.01.052; Visochek L, 2005, J NEUROSCI, V25, P7420, DOI 10.1523/JNEUROSCI.0333-05.2005; Vulih-Shultzman I, 2007, J PHARMACOL EXP THER, V323, P438, DOI 10.1124/jpet.107.129551; Wilkemeyer MF, 2004, J PHARMACOL EXP THER, V309, P1183, DOI 10.1124/jpet.103.063818; Yang MH, 2012, J PROTEOMICS, V75, P3617, DOI 10.1016/j.jprot.2012.04.017; Zaltzman R, 2005, PEPTIDES, V26, P1520, DOI 10.1016/j.peptides.2005.03.014; Zamostiano R, 2001, J BIOL CHEM, V276, P708, DOI 10.1074/jbc.M007416200; Zemlyak I, 2000, REGUL PEPTIDES, V96, P39, DOI 10.1016/S0167-0115(00)00198-1; Zemlyak I, 2009, J NEUROCHEM, V111, P1252, DOI 10.1111/j.1471-4159.2009.06415.x; Zemlyak I, 2009, EUR J PHARMACOL, V618, P9, DOI 10.1016/j.ejphar.2009.07.013; Zheng H, 2006, J NEURAL TRANSM-SUPP, P163; Zheng YP, 2010, BIOMED PHARMACOTHER, V64, P417, DOI 10.1016/j.biopha.2010.01.016; Zusev M, 2004, REGUL PEPTIDES, V123, P33, DOI 10.1016/j.regpep.2004.05.021	121	27	27	0	10	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	0929-8673	1875-533X		CURR MED CHEM	Curr. Med. Chem.		2014	21	23					2591	2598		10.2174/0929867321666140217124945			8	Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Pharmacology & Pharmacy	AK7TE	WOS:000338629800004	24533805				2021-06-18	
J	Tobin, RP; Mukherjee, S; Kain, JM; Rogers, SK; Henderson, SK; Motal, HL; Rogers, MKN; Shapiro, LA				Tobin, Richard P.; Mukherjee, Sanjib; Kain, Jessica M.; Rogers, Susannah K.; Henderson, Stephanie K.; Motal, Heather L.; Rogers, M. Karen Newell; Shapiro, Lee A.			Traumatic brain injury causes selective, CD74-dependent peripheral lymphocyte activation that exacerbates neurodegeneration	ACTA NEUROPATHOLOGICA COMMUNICATIONS			English	Article						TBI; FPI; Fluid percussion injury; CD74; Neuroinflammation	DELTA-T-CELLS; ANTIGEN; EXPRESSION; RESPONSES; ALPHA; NEUROINFLAMMATION; SUSCEPTIBILITY; INFLAMMATION; TRAFFICKING; RESISTANCE	Introduction: Traumatic brain injury (TBI), a significant cause of death and disability, causes, as in any injury, an acute, innate immune response. A key component in the transition between innate and adaptive immunity is the processing and presentation of antigen by professional antigen presenting cells (APCs). Whether an adaptive immune response to brain injury is beneficial or detrimental is not known. Current efforts to understand the contribution of the immune system after TBI have focused on neuroinflammation and brain-infiltrating immune cells. Here, we characterize and target TBI-induced expansion of peripheral immune cells that may act as potential APCs. Because MHC Class II-associated invariant peptide (CLIP) is important for antigen processing and presentation, we engineered a competitive antagonist (CAP) for CLIP, and tested the hypothesis that peptide competition could reverse or prevent neurodegeneration after TBI. Results: We show that after fluid percussion injury (FPI), peripheral splenic lymphocytes, including CD4+ and CD8+T cells, regulatory T cells (Tregs), and gamma delta T cells, are increased in number within 24 hours after FPI. These increases were reversed by CAP treatment and this antagonism of CLIP also reduced neuroinflammation and neurodegeneration after TBI. Using a mouse deficient for the precursor of CLIP, CD74, we observed decreased peripheral lymphocyte activation, decreased neurodegeneration, and a significantly smaller lesion size following TBI. Conclusion: Taken together, the data support the hypothesis that neurodegeneration following TBI is dependent upon antigen processing and presentation that requires CD74.	[Tobin, Richard P.; Mukherjee, Sanjib; Kain, Jessica M.; Motal, Heather L.; Rogers, M. Karen Newell; Shapiro, Lee A.] Texas A&M Univ, Hlth Sci Ctr, Dept Surg, Temple, TX 76508 USA; [Mukherjee, Sanjib; Kain, Jessica M.; Shapiro, Lee A.] Cent Texas Vet Hlth Care Syst, Temple, TX USA; [Rogers, Susannah K.] Univ Texas Austin, Dept Anthropol, Austin, TX 78712 USA; [Henderson, Stephanie K.; Rogers, M. Karen Newell; Shapiro, Lee A.] Baylor Scott & White Hlth, Dept Surg, Temple, TX USA; [Rogers, M. Karen Newell] Texas ACM Hlth Sci Ctr, Baylor Scott & White Hlth, Temple, TX 76504 USA	Rogers, MKN (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Surg, Temple, TX 76508 USA.	newellrogers@tamhsc.edu		Kain, Jessica/0000-0003-1285-5690	Scott; White Healthcare Foundation (MKNR); Wounded Warrior Fund (MKNR); VG Life Sciences Inc; Texas A&M Health Sciences Center (MKNR, LAS); Texas A&M Health Science center (MKNR); Central Texas Veterans Health Care System, Temple, TX, USA (LAS)	This material is the result of work supported by the following: the Scott and White Healthcare Foundation (MKNR), the Wounded Warrior Fund (MKNR), VG Life Sciences Inc. (MKNR, RPT, LAS), Texas A&M Health Sciences Center (MKNR, LAS) and the use of facilities at the Texas A&M Health Science center (MKNR) and the Central Texas Veterans Health Care System, Temple, TX, USA (LAS). We are grateful to Evan W. Newell for his generous contributions to the design and generation of CAP. We gratefully acknowledge Glen Cryer for his support and his editorial assistance with the manuscript.	ALLEN PM, 1987, IMMUNOL REV, V98, P171, DOI 10.1111/j.1600-065X.1987.tb00524.x; Amini M, 2008, IRAN J PARASITOL, V3, P51; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BARKER CF, 1977, ADV IMMUNOL, V25, P1; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Beschorner R, 2002, J NEUROIMMUNOL, V126, P107, DOI 10.1016/S0165-5728(02)00046-2; Bittner S, 2013, NAT MED, V19, P1161, DOI 10.1038/nm.3303; Blum JS, 2013, ANNU REV IMMUNOL, V31, P443, DOI 10.1146/annurev-immunol-032712-095910; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Butterfield TA, 2006, J ATHL TRAINING, V41, P457; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; Cheng L, 2008, J NEUROIMMUNOL, V203, P3, DOI 10.1016/j.jneuroim.2008.06.007; Cheong CU, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/620837; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Clausen F, 2007, J NEUOTRAUMA; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Collins RA, 1998, J LEUKOCYTE BIOL, V63, P707; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; DAVIDSON WF, 1975, J IMMUNOL METHODS, V7, P291, DOI 10.1016/0022-1759(75)90026-5; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; FREEDMAN MS, 1991, ANN NEUROL, V30, P794, DOI 10.1002/ana.410300608; Haribhai D, 2011, IMMUNITY, V35, P109, DOI [10.1016/.immuni.201103029, DOI 10.1016/.IMMUNI.201103029]; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Huang Z, 2007, NEUROSCI LETT, V417, P160, DOI 10.1016/j.neulet.2007.01.086; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; LANZAVECCHIA A, 1987, IMMUNOL REV, V99, P39, DOI 10.1111/j.1600-065X.1987.tb01171.x; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Li PY, 2013, STROKE, V44, P3509, DOI 10.1161/STROKEAHA.113.002637; Li PY, 2013, ANN NEUROL, V74, P458, DOI 10.1002/ana.23815; Liao H, 2003, J BIOL CHEM, V278, P76, DOI 10.1074/jbc.M208820200; Liesz A, 2013, J NEUROSCI, V33, P17350, DOI 10.1523/JNEUROSCI.4901-12.2013; Ling CY, 2006, J NEUROSCI, V26, P731, DOI 10.1523/JNEUROSCI.3502-05.2006; Liu S, 2013, J MOL NEUROSCI, V51, P1021, DOI 10.1007/s12031-013-0091-8; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; Meyer-Siegler KL, 2006, J IMMUNOL, V177, P8730, DOI 10.4049/jimmunol.177.12.8730; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Molnarfi N, 2013, J EXP MED, V210, P2921, DOI 10.1084/jem.20130699; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Mukherjee S, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00028; Mukherjee S, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00021; Newell MK, 2010, J LEUKOCYTE BIOL, V88, P779, DOI 10.1189/jlb.0410237; Oporto GH, 2014, INT J CLIN EXP MED, V7, P1669; Soares FMS, 2012, NEUROIMMUNOMODULAT, V19, P377, DOI 10.1159/000342141; Schori H, 2002, J IMMUNOL, V169, P2861, DOI 10.4049/jimmunol.169.6.2861; Schori H, 2002, EUR J NEUROSCI, V16, P557, DOI 10.1046/j.1460-9568.2002.02134.x; Schori H, 2007, J IMMUNOL, V178, P163, DOI 10.4049/jimmunol.178.1.163; Segel GB, 2011, J LEUKOCYTE BIOL, V89, P359, DOI 10.1189/jlb.0910538; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Slavin AJ, 2001, J CLIN INVEST, V108, P1133, DOI 10.1172/JCI200113360; Song A, 2000, IMMUNOL REV, V177, P236, DOI 10.1034/j.1600-065X.2000.17610.x; Weiss JM, 2012, J EXP MED, V209, P1723, DOI 10.1084/jem.20120914; Yang MS, 2002, GLIA, V38, P273, DOI 10.1002/glia.10057; Zeine R, 1998, J NEUROIMMUNOL, V87, P49, DOI 10.1016/S0165-5728(98)00047-2; Zhou W, 2012, J APPL MATH, DOI 10.1155/2012/136254	62	27	29	2	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2051-5960			ACTA NEUROPATHOL COM	Acta Neuropathol. Commun.		2014	2								143	10.1186/s40478-014-0143-5			10	Neurosciences	Neurosciences & Neurology	V9K3A	WOS:000422389300109	25329434	DOAJ Gold, Green Published			2021-06-18	
J	Sun, D; McGinn, M; Hankins, JE; Mays, KM; Rolfe, A; Colello, RJ				Sun, Dong; McGinn, Melissa; Hankins, Jeanette E.; Mays, Katherine M.; Rolfe, Andrew; Colello, Raymond J.			Aging-and injury-related differential apoptotic response in the dentate gyrus of the hippocampus in rats following brain trauma	FRONTIERS IN AGING NEUROSCIENCE			English	Article						aging; apoptosis; dentate gyrus; neurogenesis; proteomics; traumatic brain injury	PROGRAMMED CELL-DEATH; NEURONAL DIFFERENTIATION; GRANULE CELLS; HUMAN HSP27; ADULT RATS; HIPPOCALCIN; EXPRESSION; NEUROGENESIS; CALCIUM; PROLIFERATION	The elderly are among the most vulnerable to traumatic brain injury (TBI) with poor functional outcomes and impaired cognitive recovery. Of the pathological changes that occur following TBI, apoptosis is an important contributor to the secondary insults and subsequent morbidity associated with TBI. The current study investigated age-related differences in the apoptotic response to injury, which may represent a mechanistic underpinning of the heightened vulnerability of the aged brain to TBI. This study compared the degree of TBI-induced apoptotic response and changes of several apoptosis-related proteins in the hippocampal dentate gyrus (DG) of juvenile and aged animals following injury. Juvenile (p28) and aged rats (24 months) were subjected to a moderate fluid percussive injury or sham injury and sacrificed at 2 days post-injury. One group of rats in both ages was sacrificed and brain sections were processed for TUNEL and immunofluorescent labeling to assess the level of apoptosis and to identify cell types which undergo apoptosis. Another group of animals was subjected to proteomic analysis, whereby proteins from the ipsilateral DG were extracted and subjected to 2D-gel electrophoresis and mass spectrometry analysis. Histological studies revealed age- and injury-related differences in the number of TUNEL labeled cells in the DG. In sham animals, juveniles displayed a higher number of TUNEL+ apoptotic cells located primarily in the subgranular zone of the DG as compared to the aged brain. These apoptotic cells expressed the early neuronal marker PSA-NCAM, suggestive of newly generated immature neurons. In contrast, aged rats had a significantly higher number of TUNEL+ cells following TBI than injured juveniles, which were NeuN-positive mature neurons located predominantly in the granule cell layer. Fluorescent triple labeling revealed that microglial cells were closely associated to the apoptotic cells. In concert with these cellular changes, proteomic studies revealed both age-associated and injury-induced changes in the expression levels of three apoptotic-related proteins: hippocalcin, leucine-rich acidic nuclear protein and heat shock protein 27. Taken together, this study revealed distinct apoptotic responses following TBI in the juvenile and aged brain which may contribute to the differential cognitive recovery observed.	[Sun, Dong; Rolfe, Andrew] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; [McGinn, Melissa; Hankins, Jeanette E.; Mays, Katherine M.; Colello, Raymond J.] Virginia Commonwealth Univ, Dept Anat, Richmond, VA 23298 USA; [McGinn, Melissa; Hankins, Jeanette E.; Mays, Katherine M.; Colello, Raymond J.] Virginia Commonwealth Univ, Dept Neurobiol, Richmond, VA 23298 USA	Sun, D (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, Med Coll Virginia Campus,POB 980631, Richmond, VA 23298 USA.	dsun@vcu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS055086, NS048377]; NIH-NINDS centerUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463]	This study was funded by the National Institutes of Health Grant No. NS055086 (Sun) and NS048377 (Colello). Microscopy work was performed at the VCU-Department of Anatomy and Neurobiology Microscopy Facility, supported, in part, with funding from NIH-NINDS center core grant 5P30NS047463. We thank Andrew Ottens for his assistance with proteomic data analysis.	Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; Charette SJ, 2000, ANN NY ACAD SCI, V926, P126; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Colello RJ, 2002, ELECTROPHORESIS, V23, P144, DOI 10.1002/1522-2683(200201)23:1<144::AID-ELPS144>3.0.CO;2-P; Conti AC, 1998, J NEUROSCI, V18, P5663; Dayer AG, 2003, J COMP NEUROL, V460, P563, DOI 10.1002/cne.10675; Deng W, 2009, J NEUROSCI, V29, P13532, DOI 10.1523/JNEUROSCI.3362-09.2009; Dickstein DL, 2007, AGING CELL, V6, P275, DOI 10.1111/j.1474-9726.2007.00289.x; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Frank MG, 2006, NEUROBIOL AGING, V27, P717, DOI 10.1016/j.neurobiolaging.2005.03.013; Furuta Y, 1999, NEUROCHEM RES, V24, P651, DOI 10.1023/A:1021000425070; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Guay J, 1997, J CELL SCI, V110, P357; Habrukowich C, 2010, J BIOL CHEM, V285, P26825, DOI 10.1074/jbc.M110.147058; Havasi A, 2008, J BIOL CHEM, V283, P12305, DOI 10.1074/jbc.M801291200; Heine VM, 2004, NEUROBIOL AGING, V25, P361, DOI 10.1016/S0197-4580(03)00090-3; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Kim WR, 2009, EUR J NEUROSCI, V29, P1408, DOI 10.1111/j.1460-9568.2009.06693.x; Kobayashi M, 2005, NEUROSCIENCE, V133, P471, DOI 10.1016/j.neuroscience.2005.02.034; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Korhonen L, 2005, MOL CELL NEUROSCI, V28, P85, DOI 10.1016/j.mcn.2004.08.015; Kuhn HG, 2005, EUR J NEUROSCI, V22, P1907, DOI 10.1111/j.1460-9568.2005.04377.x; Kular RK, 2009, J BIOL CHEM, V284, P7783, DOI 10.1074/jbc.M806150200; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Masuo Y, 2007, NEUROSCIENCE, V145, P495, DOI 10.1016/j.neuroscience.2006.12.011; MATSUOKA K, 1994, P NATL ACAD SCI USA, V91, P9670, DOI 10.1073/pnas.91.21.9670; Mattson MP, 2006, NAT REV NEUROSCI, V7, P278, DOI 10.1038/nrn1886; MEHLEN P, 1995, J IMMUNOL, V154, P363; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Mercer EA, 2000, EMBO J, V19, P3597, DOI 10.1093/emboj/19.14.3597; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Olariu A, 2007, J COMP NEUROL, V501, P659, DOI 10.1002/cne.21268; Palmer CL, 2005, NEURON, V47, P487, DOI 10.1016/j.neuron.2005.06.014; Pan W, 2009, J BIOL CHEM, V284, P6946, DOI 10.1074/jbc.M805801200; Pavlopoulos E, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006373; PAXINOS G, 1986, RRAT BRAIN STEREOTAX; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ramirez-Amaya V, 2006, J NEUROSCI, V26, P12237, DOI 10.1523/JNEUROSCI.2195-06.2006; Rao MS, 2006, AGING CELL, V5, P545, DOI 10.1111/j.1474-9726.2006.00243.x; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; SHAPIRA Y, 1989, Neurological Research, V11, P169; Sierra A, 2010, CELL STEM CELL, V7, P483, DOI 10.1016/j.stem.2010.08.014; Small SA, 2011, NAT REV NEUROSCI, V12, P585, DOI 10.1038/nrn3085; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun W, 2004, J NEUROSCI, V24, P11205, DOI 10.1523/JNEUROSCI.1436-04.2004; Timaru-Kast R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043829; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Vidyasagar A, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-7; Wagstaff MJD, 1999, J BIOL CHEM, V274, P5061, DOI 10.1074/jbc.274.8.5061; Walter J, 2011, NEUROBIOL AGING, V32, P1906, DOI 10.1016/j.neurobiolaging.2009.11.011; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	59	27	29	0	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-4365			FRONT AGING NEUROSCI	Front. Aging Neurosci.	DEC 18	2013	5								95	10.3389/fnagi.2013.00095			13	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	275CQ	WOS:000328653700001	24385964	DOAJ Gold, Green Published			2021-06-18	
J	De Nicola, AF; Coronel, F; Garay, LI; Gargiulo-Monachelli, G; Deniselle, MCG; Gonzalez, SL; Labombarda, F; Meyer, M; Guennoun, R; Schumacher, M				De Nicola, Alejandro F.; Coronel, Florencia; Garay, Laura I.; Gargiulo-Monachelli, Gisella; Gonzalez Deniselle, Maria Claudia; Gonzalez, Susana L.; Labombarda, Florencia; Meyer, Maria; Guennoun, Rachida; Schumacher, Michael			Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Progesterone; neuroprotection; steroid receptors; animal models	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MOTOR-NEURON DISEASE; AMYOTROPHIC-LATERAL-SCLEROSIS; CEREBRAL-ARTERY OCCLUSION; MOUSE MOTONEURON DISEASE; CENTRAL-NERVOUS-SYSTEM; BINDING-PROTEIN 25-DX; MULTIPLE-SCLEROSIS	Substantial evidence supports that progesterone exerts many functions in the central and peripheral nervous system unrelated to its classical role in reproduction. In this review we first discussed progesterone effects following binding to the classical intracellular progesterone receptors A and B and several forms of membrane progesterone receptors, the modulation of intracellular signalling cascades and the interaction of progesterone reduced metabolites with neurotransmitter receptors. We next described our results involving animal models of human neuropathologies to elucidate the protective roles of progesterone. We described: (a) the protective and promyelinating effects of progesterone in experimental spinal cord injury; (b) the progesterone protective effects exerted upon motoneurons in the degenerating spinal cord of Wobbler mouse model of amyotropic lateral sclerosis; (c) the protective and anti-inflammatory effects of progesterone in the murine experimental autoimmune encephalomyelitis model of multiple sclerosis and after lysolecithin demyelination; (d) the progesterone prevention of nociception and neuropathic pain which follow spinal cord injury; and (e) the protective effect of progesterone in experimental ischemic stroke. Whenever available, the molecular mechanisms involved in these progesterone effects were examined. The multiplicity of progesterone beneficial effects has opened new venues of research for neurological disorders. In this way, results obtained in animal models could provide the basis for novel therapeutic strategies and pre-clinical studies.	[De Nicola, Alejandro F.; Garay, Laura I.; Gargiulo-Monachelli, Gisella; Gonzalez Deniselle, Maria Claudia; Labombarda, Florencia; Meyer, Maria] Inst Biol & Med Expt, Lab Neuroendocrine Biochem, RA-1428 Buenos Aires, DF, Argentina; [De Nicola, Alejandro F.; Garay, Laura I.; Gonzalez Deniselle, Maria Claudia; Gonzalez, Susana L.; Labombarda, Florencia] Univ Buenos Aires, Fac Med, Dept Human Biochem, Buenos Aires, DF, Argentina; [Coronel, Florencia; Gonzalez, Susana L.] Inst Biol & Med Expt, Lab Nocicept & Neurophat Pain, RA-1428 Buenos Aires, DF, Argentina; [Guennoun, Rachida; Schumacher, Michael] INSERM, Unite Mixte Rech 788, Le Kremlin Bicetre, France; [Guennoun, Rachida; Schumacher, Michael] Univ Paris 11, Le Kremlin Bicetre, France	De Nicola, AF (corresponding author), Inst Biol & Med Expt, Lab Neuroendocrine Biochem, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	alejandrodenicola@gmail.com	Schumacher, Michael/G-3581-2013; Guennoun, Rachida/F-2420-2011	Schumacher, Michael/0000-0001-6117-5371; Guennoun, Rachida/0000-0002-9219-7300	FONCYTFONCyT [PICT 2007 - 01044]; National Research Council of ArgentinaConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) [CONICET PIP 112-200801-00542]; University of Buenos AiresUniversity of Buenos Aires [20020100100089]; CONICET / INSERM	This work was supported by FONCYT PICT 2007 - 01044, the National Research Council of Argentina (CONICET PIP 112-200801-00542), the University of Buenos Aires (20020100100089) and by an international cooperative program between CONICET / INSERM.	Acs P, 2009, GLIA, V57, P807, DOI 10.1002/glia.20806; Arevalo M. A., 2009, BIOCHIM BIOPHYS ACTA, V1800, P1106; Arnett HA, 2004, SCIENCE, V306, P2111, DOI 10.1126/science.1103709; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Baastrup C, 2008, CNS DRUGS, V22, P455, DOI 10.2165/00023210-200822060-00002; Batchelor PE, 2008, J NEUROTRAUM, V25, P1217, DOI 10.1089/neu.2007.0308; Baulieu EE, 1997, RECENT PROG HORM RES, V52, P1; Baumann N, 2001, PHYSIOL REV, V81, P871; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; Bezzi P, 2001, CURR OPIN NEUROBIOL, V11, P387, DOI 10.1016/S0959-4388(00)00223-3; Boillee S, 2003, MOL NEUROBIOL, V28, P65, DOI 10.1385/MN:28:1:65; Boonyaratanakornkit V, 2008, STEROIDS, V73, P922, DOI 10.1016/j.steroids.2008.01.010; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Carreras Maria C., 2004, Molecular Aspects of Medicine, V25, P125, DOI 10.1016/j.mam.2004.02.014; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; Coronel MF, 2011, J PAIN, V12, P71, DOI 10.1016/j.jpain.2010.04.013; Dai DH, 2003, J STEROID BIOCHEM, V87, P123, DOI 10.1016/j.jsbmb.2003.08.004; Dave KR, 2003, EXP NEUROL, V182, P412, DOI 10.1016/S0014-4886(03)00091-8; de la Puente B, 2009, PAIN, V145, P294, DOI 10.1016/j.pain.2009.05.013; De Nicola AF, 2006, J MOL NEUROSCI, V28, P3, DOI 10.1385/JMN:28:1:3; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Deniselle MCG, 2005, EXP NEUROL, V195, P518, DOI 10.1016/j.expneurol.2005.06.015; Deniselle MCG, 2002, NEUROBIOL DIS, V11, P457, DOI 10.1006/nbdi.2002.0564; Diana V, 2010, EXP NEUROL, V225, P163, DOI 10.1016/j.expneurol.2010.06.008; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dobkin BH, 2008, NAT CLIN PRACT NEURO, V4, P76, DOI 10.1038/ncpneuro0709; Druckmann R, 2005, J STEROID BIOCHEM, V97, P389, DOI 10.1016/j.jsbmb.2005.08.010; El-Etr M, 2005, J NEUROL SCI, V233, P49, DOI 10.1016/j.jns.2005.03.004; Fancy SPJ, 2011, ANNU REV NEUROSCI, V34, P21, DOI 10.1146/annurev-neuro-061010-113629; Coronel MF, 2011, PAIN MED, V12, P1249, DOI 10.1111/j.1526-4637.2011.01178.x; FRYE CA, 1994, BRAIN RES, V643, P194, DOI 10.1016/0006-8993(94)90025-6; Furuzawa-Carballeda J, 2007, AUTOIMMUN REV, V6, P169, DOI 10.1016/j.autrev.2006.10.002; Garay L, 2011, NEUROSCIENCE, V192, P588, DOI 10.1016/j.neuroscience.2011.06.065; Garay L, 2008, NEUROIMMUNOMODULAT, V15, P76, DOI 10.1159/000135627; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Garay L, 2009, BRAIN RES, V1283, P177, DOI 10.1016/j.brainres.2009.04.057; Monachelli GG, 2011, ACTA NEUROL SCAND, V123, P60, DOI 10.1111/j.1600-0404.2010.01385.x; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Giatti S, 2010, NEUROCHEM INT, V56, P118, DOI 10.1016/j.neuint.2009.09.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Gintzler A R, 2001, Prog Brain Res, V133, P83; Deniselle MCG, 2007, EXP NEUROL, V203, P406, DOI 10.1016/j.expneurol.2006.08.019; Deniselle MCG, 2012, J NEUROCHEM, V122, P185, DOI 10.1111/j.1471-4159.2012.07753.x; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Guennoun R, 2008, BRAIN RES REV, V57, P493, DOI 10.1016/j.brainresrev.2007.05.009; Hantaz-Ambroise D, 2001, DIFFERENTIATION, V69, P100, DOI 10.1046/j.1432-0436.2001.690204.x; Henderson JT, 1996, J NEUROSCI, V16, P7574; Hosie AM, 2006, NATURE, V444, P486, DOI 10.1038/nature05324; Hu R, 2010, J NEUROSURG-SPINE, V13, P169, DOI 10.3171/2010.3.SPINE09190; Hubbard P., 2002, J ANAT, V200, P213; Ibanez C, 2004, NEUROPATH APPL NEURO, V30, P80, DOI 10.1046/j.0305-1846.2003.00515.x; Ikeda K, 2000, BRAIN RES, V858, P84, DOI 10.1016/S0006-8993(99)02427-0; KIMBRO KS, 1994, J MOL NEUROSCI, V5, P27, DOI 10.1007/BF02736692; LAAGE S, 1988, DEV NEUROSCI-BASEL, V10, P190, DOI 10.1159/000111969; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2010, NEUROSCIENCE, V166, P94, DOI 10.1016/j.neuroscience.2009.12.012; Labombarda F, 2000, NEUROSCI LETT, V288, P29, DOI 10.1016/S0304-3940(00)01191-5; Labombarda F, 2011, EXP NEUROL, V231, P135, DOI 10.1016/j.expneurol.2011.06.001; Labombarda F, 2008, NEUROSCI LETT, V447, P115, DOI 10.1016/j.neulet.2008.09.062; Leitner H, 2010, MED HYPOTHESES, V75, P229, DOI 10.1016/j.mehy.2010.02.028; Leonelli E, 2007, NEUROSCIENCE, V144, P1293, DOI 10.1016/j.neuroscience.2006.11.014; Li GL, 1999, ACTA NEUROPATHOL, V98, P473, DOI 10.1007/s004010051112; Ligon KL, 2006, GLIA, V54, P1, DOI 10.1002/glia.20273; Lin T, 2006, J NEUROSCI METH, V157, P187, DOI 10.1016/j.jneumeth.2006.04.014; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Losel RM, 2008, STEROIDS, V73, P929, DOI 10.1016/j.steroids.2007.12.017; Lopez A.D., 2012, MEASURING GLOBAL BUR; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Martin WJ, 2001, J NEUROSCI, V21, P5321, DOI 10.1523/JNEUROSCI.21-14-05321.2001; Matute C, 2005, TRENDS NEUROSCI, V28, P173, DOI 10.1016/j.tins.2005.01.006; Maurice T, 2006, PHARMACOL BIOCHEM BE, V84, P581, DOI 10.1016/j.pbb.2006.07.009; McQualter JL, 2007, J NEUROCHEM, V100, P295, DOI 10.1111/j.1471-4159.2006.04232.x; McTigue DM, 2008, J NEUROCHEM, V107, P1, DOI 10.1111/j.1471-4159.2008.05570.x; Mensah-Nyagan AG, 2008, J STEROID BIOCHEM, V109, P286, DOI 10.1016/j.jsbmb.2008.03.002; Mensah-Nyagan A.G., 2009, PSYCHONEUROENDOCRINO, V34, P169; Meyer M, 2012, NEUROSCIENCE, V201, P267, DOI 10.1016/j.neuroscience.2011.11.034; Meyer M, 2010, CELL MOL NEUROBIOL, V30, P123, DOI 10.1007/s10571-009-9437-8; MITSUMOTO H, 1982, BRAIN, V105, P811, DOI 10.1093/brain/105.4.811; Morin-Richaud C, 1998, BRAIN RES, V783, P85, DOI 10.1016/S0006-8993(97)01282-1; National Institute of Neurological Disorders and Stroke, SPIN CORD INJ HOP RE; Nishiyama A, 1999, J NEUROPATH EXP NEUR, V58, P1113, DOI 10.1097/00005072-199911000-00001; Noorbakhsh F, 2011, BRAIN, V134, P2703, DOI 10.1093/brain/awr200; NORDEEN SK, 1989, MOL ENDOCRINOL, V3, P1270, DOI 10.1210/mend-3-8-1270; OMALLEY BW, 1991, RECENT PROG HORM RES, V47, P1; Onuki I, 2001, MICROSC RES TECHNIQ, V52, P731; Park HH, 2009, MOL MED REP, V2, P539, DOI 10.3892/mmr_00000133; PARSONS B, 1982, J NEUROSCI, V2, P1446; Paterson P Y, 1980, Prog Clin Biol Res, V49, P19; Pathirathna S, 2005, PAIN, V114, P429, DOI 10.1016/j.pain.2005.01.009; PAUL SM, 1992, FASEB J, V6, P2311; Peng HY, 2009, PAIN, V143, P12, DOI 10.1016/j.pain.2008.12.023; Penkowa M, 2003, J NEUROSCI RES, V72, P574, DOI 10.1002/jnr.10615; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Qi YC, 2001, DEVELOPMENT, V128, P2723; Quadros PS, 2008, ENDOCRINOLOGY, V149, P3054, DOI 10.1210/en.2007-1133; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Santoro B, 2004, NEUROBIOL DIS, V17, P349, DOI 10.1016/j.nbd.2004.07.003; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schumacher M, 2003, PROG NEUROBIOL, V71, P3, DOI 10.1016/j.pneurobio.2003.09.004; Schumacher M, 2008, CURR OPIN PHARMACOL, V8, P740, DOI 10.1016/j.coph.2008.10.002; Selye H., 1947, TXB ENDOCRINOLOGY; Siegenthaler MM, 2007, J NEUROTRAUM, V24, P1631, DOI 10.1089/neu.2007.0302; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Spence RD, 2012, FRONT NEUROENDOCRIN, V33, P105, DOI 10.1016/j.yfrne.2011.12.001; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Sun DM, 2003, INT IMMUNOL, V15, P261, DOI 10.1093/intimm/dxg023; Trapp BD, 2008, ANNU REV NEUROSCI, V31, P247, DOI 10.1146/annurev.neuro.30.051606.094313; Trivedi A, 2006, CLIN NEUROSCI RES, V6, P283, DOI 10.1016/j.cnr.2006.09.007; Tsuzaka K, 2001, MUSCLE NERVE, V24, P474, DOI 10.1002/mus.1029; van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083; VEDECKIS WV, 1992, P SOC EXP BIOL MED, V199, P1; Wang DD, 2008, PROG NEUROBIOL, V86, P342, DOI 10.1016/j.pneurobio.2008.09.015; Wang JM, 2010, P NATL ACAD SCI USA, V107, P6498, DOI 10.1073/pnas.1001422107; Watanabe M, 2004, GLIA, V46, P311, DOI 10.1002/glia.20006; Waters EM, 2008, J COMP NEUROL, V511, P34, DOI 10.1002/cne.21826; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yates MA, 2010, J NEUROIMMUNOL, V220, P136, DOI 10.1016/j.jneuroim.2010.01.013; Yu HJ, 2010, NEUROSCI LETT, V476, P42, DOI 10.1016/j.neulet.2010.03.079; Zai LJ, 2005, GLIA, V50, P247, DOI 10.1002/glia.20176; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	131	27	27	0	8	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	DEC	2013	12	8					1205	1218					14	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	284FD	WOS:000329300600015	24040821				2021-06-18	
J	Lee, YM; Odom, MJ; Zuckerman, SL; Solomon, GS; Sills, AK				Lee, Young M.; Odom, Mitchell J.; Zuckerman, Scott L.; Solomon, Gary S.; Sills, Allen K.			Does age affect symptom recovery after sports-related concussion? A study of high school and college athletes	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						concussion; sports; age; mild traumatic brain injury; ImPACT; post-concussion symptoms; trauma	TRAUMATIC BRAIN-INJURY; STATES HIGH-SCHOOL; UNITED-STATES; NEUROCOGNITIVE PERFORMANCE; EPIDEMIOLOGY; MILD; DEPRESSION; MANAGEMENT; MODERATE; SCALE	Object. Sport-related concussions (SRCs) in high school and college athletes represent a significant public health concern. Research suggests that younger athletes fare worse symptomatically than older athletes after an SRC. Using reliable change index (RCI) methodology, the authors conducted a study to determine if there are age-related differences in number, severity, and resolution of postconcussion symptoms. Methods. Between 2009 and 2011, baseline measures of neurocognitive functions and symptoms in high school and college athletes were entered into a regional database. Seven hundred forty of these athletes later sustained an SRC. Ninety-two athletes in the 13- to 16-year-old group and 92 athletes in the 18- to 22-year-old group were matched for number of prior concussions, sex, biopsychosocial variables, and days to first postconcussion testing and symptom assessment. A nonparametric Mann-Whitney U-test was used to compare the severity of each of 22 symptoms comprising the Total Symptom Scale (TSS) at baseline and first postconcussion test. To obtain a family-wise p value of 0.05 for each test, the significance level for each symptom comparison was set at an alpha of 0.05/22 = 0.0023. The number of days to return to baseline TSS score was compared using the RCI methodology, set at the 80% confidence interval, equal to a change in raw score of 9.18 points on the TSS. Results. There was no statistically significant difference in symptom presence, symptom severity, and total symptoms between the age groups at baseline or at postconcussion testing. There was no statistically significant difference in return to baseline symptom scores between the age groups. Conclusions. Using RCI methodology, there was no statistically significant difference between younger and older athletes in return to baseline symptoms postconcussion.	[Lee, Young M.; Odom, Mitchell J.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Zuckerman, Scott L.; Solomon, Gary S.; Sills, Allen K.] Vanderbilt Univ, Sch Med, Dept Neurol Surg, Nashville, TN 37212 USA; [Zuckerman, Scott L.; Solomon, Gary S.; Sills, Allen K.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Nashville, TN 37212 USA	Zuckerman, SL (corresponding author), 1500 21st Ave South,Ste 4340, Nashville, TN 37212 USA.	scott.zuckerman@vanderbilt.edu	Solomon, Gary/K-9011-2019				Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Aubry Mark, 2002, Phys Sportsmed, V30, P57, DOI 10.3810/psm.2002.02.176; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BROSHEK DK, 2012, J CHILD NEUROL; Cantu RC, 2011, PM&R, V3, pS440, DOI 10.1016/j.pmrj.2011.07.013; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Dick R, 2007, J ATHL TRAINING, V42, P221; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fourtassi M, 2011, CLIN NEUROL NEUROSUR, V113, P716, DOI 10.1016/j.clineuro.2011.07.010; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Powell JW, 1999, J ATHL TRAINING, V34, P277; RUTHERFORD WH, 1977, LANCET, V1, P1; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Sosin DM, 1996, BRAIN INJURY, V10, P47; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	34	27	27	0	19	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	DEC	2013	12	6					537	544		10.3171/2013.7.PEDS12572			8	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	257EV	WOS:000327367300003	24063601	Bronze			2021-06-18	
J	Pathak, NN; Balaganur, V; Lingaraju, MC; More, AS; Kant, V; Kumar, D; Kumar, D; Tandan, SK				Pathak, Nitya N.; Balaganur, Venkanna; Lingaraju, Madhu C.; More, Amar S.; Kant, Vinay; Kumar, Dhirendra; Kumar, Dinesh; Tandan, Surendra Kumar			Antihyperalgesic and Anti-inflammatory Effects of Atorvastatin in Chronic Constriction Injury-Induced Neuropathic Pain in Rats	INFLAMMATION			English	Article						CCI; neuropathic pain; proinflammatory cytokines; MMP-2; NGF; atorvastatin	NERVE GROWTH-FACTOR; TRAUMATIC BRAIN-INJURY; ROOT GANGLION NEURONS; NECROSIS-FACTOR-ALPHA; SPINAL-CORD-INJURY; KAPPA-B PATHWAY; SCIATIC-NERVE; INDUCED HYPERALGESIA; SIGNALING PATHWAYS; MODEL	Atorvastatin is a 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor used in treatment of hypercholesterolemia and prevention of coronary heart disease. The aim of this study is to investigate the antihyperalgesic and anti-inflammatory effects of atorvastatin (3, 10, and 30 mg/kg by oral gavages for 14 days) in chronic constriction injury (CCI) model of neuropathic pain in rats. CCI caused significant increase in tumor necrosis factor-alpha, interleukin 1 beta, prostaglandin E2, along with matrix metalloproteases (MMP-2) and nerve growth factor (NGF) levels in sciatic nerve and spinal cord concomitant with mechanical and thermal hyperalgesia, which were significantly reduced by oral administration of atorvastatin for 14 days as compared to CCI rats. Our study demonstrated that atorvastatin attenuates neuropathic pain through inhibition of cytokines, MMP-2, and NGF in sciatic nerve and spinal cord suggesting that atorvastatin could be an additional therapeutic strategy in management of neuropathic pain.	[Pathak, Nitya N.; Balaganur, Venkanna; Lingaraju, Madhu C.; More, Amar S.; Kant, Vinay; Kumar, Dhirendra; Kumar, Dinesh; Tandan, Surendra Kumar] Indian Vet Res Inst, Div Pharmacol & Toxicol, Bareilly 243122, Uttar Pradesh, India	Tandan, SK (corresponding author), Indian Vet Res Inst, Div Pharmacol & Toxicol, Bareilly 243122, Uttar Pradesh, India.	sktandan@ivri.res.in	Kant, Vinay/C-2897-2016	Kant, Vinay/0000-0001-9600-4417			Agrawal SM, 2008, SEMIN CELL DEV BIOL, V19, P42, DOI 10.1016/j.semcdb.2007.06.003; Ali S, 2004, CELL BIOCHEM FUNCT, V22, P67, DOI 10.1002/cbf.1082; Amarenco P, 2006, NEW ENGL J MED, V355, P549; Barsante MM, 2005, EUR J PHARMACOL, V516, P282, DOI 10.1016/j.ejphar.2005.05.005; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; Bonnington JK, 2003, J PHYSIOL-LONDON, V551, P433, DOI 10.1113/jphysiol.2003.039990; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; Buss A, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-17; Cain JH, 2007, ANN NEUROSCI, V14, P96, DOI 10.5214/ans.0972.7531.2007.140403; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen YW, 2012, ANESTH ANALG, V114, P1330, DOI 10.1213/ANE.0b013e31824c4ed4; Chu LW, 2012, INT J IMMUNOPATH PH, V25, P219, DOI 10.1177/039463201202500124; Clarke R, 2007, SIGHT SOUND, V17, P52; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dray A, 2008, BRIT J ANAESTH, V101, P48, DOI 10.1093/bja/aen107; Durrenberger PF, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-1; Etminan M, 2010, NEUROLOGY, V75, P1496, DOI 10.1212/WNL.0b013e3181f96253; Folgueras AR, 2009, P NATL ACAD SCI USA, V106, P16451, DOI 10.1073/pnas.0908507106; Fukuoka T, 2001, J NEUROSCI, V21, P4891, DOI 10.1523/JNEUROSCI.21-13-04891.2001; Gandhi R, 2004, J NEUROSCI, V24, P9405, DOI 10.1523/JNEUROSCI.0899-04.2004; Gholami MR, 2008, EUR J PHARMACOL, V590, P111, DOI 10.1016/j.ejphar.2008.05.050; Gwak YS, 2003, NEUROSCI LETT, V336, P117, DOI 10.1016/S0304-3940(02)01251-X; Hao JX, 2000, NEUROSCI LETT, V286, P208, DOI 10.1016/S0304-3940(00)01107-1; Hao SL, 2006, MOL PAIN, V2, DOI 10.1186/1744-8069-2-6; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Herzberg U, 1997, NEUROREPORT, V8, P1613, DOI 10.1097/00001756-199705060-00012; Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313; Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993-06.2006; Ji RR, 2009, TRENDS PHARMACOL SCI, V30, P336, DOI 10.1016/j.tips.2009.04.002; Kawasaki Y, 2008, NAT MED, V14, P331, DOI 10.1038/nm1723; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Lee HL, 2004, NEUROREPORT, V15, P2807; LEWIN GR, 1993, J NEUROSCI, V13, P2136; LEWIN GR, 1994, EUR J NEUROSCI, V6, P1903, DOI 10.1111/j.1460-9568.1994.tb00581.x; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; Massaro M, 2010, CARDIOVASC RES, V86, P311, DOI 10.1093/cvr/cvp375; McMahon SB, 2005, EXP NEUROL, V192, P444, DOI 10.1016/j.expneurol.2004.11.001; Mika J, 2009, EUR J PHARMACOL, V623, P65, DOI 10.1016/j.ejphar.2009.09.030; Moolwaney AS, 2005, MOL BRAIN RES, V137, P202, DOI 10.1016/j.molbrainres.2005.03.010; Muja N, 2004, GLIA, V46, P116, DOI 10.1002/glia.10349; Muthuraman A, 2012, J ETHNOPHARMACOL, V142, P723, DOI 10.1016/j.jep.2012.05.049; Naval NS, 2009, NEUROL RES, V31, P425, DOI 10.1179/174313208X353686; Pan HC, 2010, NEUROSURGERY, V67, P376, DOI 10.1227/01.NEU.0000371729.47895.A0; Paul S, 2009, NAT REV DRUG DISCOV, V8, P14, DOI 10.1038/nrd2800; PETTY BG, 1994, ANN NEUROL, V36, P244, DOI 10.1002/ana.410360221; Planavila A, 2005, BBA-MOL CELL BIOL L, V1687, P76, DOI 10.1016/j.bbalip.2004.11.004; Prasad R, 2005, J NEUROCHEM, V94, P204, DOI 10.1111/j.1471-4159.2005.03182.x; Ramer MS, 1998, NEUROSCI LETT, V251, P53, DOI 10.1016/S0304-3940(98)00493-5; RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409; Ryschich E., 2009, GUT, V23, P243; Sacerdote P, 2013, J NEUROIMMUNE PHARM, V8, P202, DOI 10.1007/s11481-012-9428-2; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Santodomingo-Garzon T, 2006, BRIT J PHARMACOL, V149, P14, DOI 10.1038/sj.bjp.0706836; Schafers Maria, 2007, Expert Rev Neurother, V7, P1613, DOI 10.1586/14737175.7.11.1613; Schonbeck U, 2004, CIRCULATION, V109, P18, DOI 10.1161/01.CIR.0000129505.34151.23; Shamash S, 2002, J NEUROSCI, V22, P3052, DOI 10.1523/JNEUROSCI.22-08-03052.2002; Shi XQ, 2011, PAIN, V152, P1033, DOI 10.1016/j.pain.2011.01.006; Sierra S, 2011, J ALZHEIMERS DIS, V23, P307, DOI 10.3233/JAD-2010-101179; Smaldone Costantino, 2009, Cardiovascular & Hematological Agents in Medicinal Chemistry, V7, P279; Sommer C, 2004, NEUROSCI LETT, V361, P184, DOI 10.1016/j.neulet.2003.12.007; SOMMER C, 1993, J NEUROPATH EXP NEUR, V52, P223, DOI 10.1097/00005072-199305000-00006; Sommer C, 1997, NEUROSCI LETT, V237, P45, DOI 10.1016/S0304-3940(97)00813-6; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; Stepien K, 2005, PHARMACOL REP, V57, P561; Takahashi M, 2004, NEUROSCI LETT, V363, P203, DOI 10.1016/j.neulet.2004.03.040; Tartakover-Matalon S, 2007, HUM REPROD, V22, P1161, DOI 10.1093/humrep/del464; Uceyler N, 2008, NEUROSCI LETT, V437, P194, DOI 10.1016/j.neulet.2008.03.050; van der Most PJ, 2009, PROG NEUROBIOL, V88, P64, DOI 10.1016/j.pneurobio.2009.02.002; Wagner R, 1996, NEUROREPORT, V7, P2897, DOI 10.1097/00001756-199611250-00018; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang Y, 2007, CURR NEUROVASC RES, V4, P176; Watkins LR, 2002, PHYSIOL REV, V82, P981, DOI 10.1152/physrev.00011.2002; Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Wu HT, 2010, J NEUROSURG, V113, P591, DOI 10.3171/2009.9.JNS09859; Wu KK, 2005, PROSTAG LEUKOTR ESS, V72, P89, DOI 10.1016/j.plefa.2004.11.001; Yaksh TL, 2001, J NEUROSCI, V21, P5847; Yamaguchi M, 2007, NEUROSURGERY, V61, P1067, DOI 10.1227/01.neu.0000303203.07866.18; Yang Dongmei, 2012, World J Neurosci, V2, P74; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zelenka M, 2005, PAIN, V116, P257, DOI 10.1016/j.pain.2005.04.018; ZHANG J, 2009, FUNCTIONAL PAIN SYND, P319	83	27	27	2	6	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0360-3997	1573-2576		INFLAMMATION	Inflammation	DEC	2013	36	6					1468	1478		10.1007/s10753-013-9688-x			11	Cell Biology; Immunology	Cell Biology; Immunology	248IM	WOS:000326692200034	23872719				2021-06-18	
J	Ross, DE; Ochs, AL; Seabaugh, JM; Shrader, CR				Ross, David E.; Ochs, Alfred L.; Seabaugh, Jan M.; Shrader, Carole R.		Alzheimer's Dis Neuroimaging	Man Versus Machine: Comparison of Radiologists' Interpretations and NeuroQuant (R) Volumetric Analyses of Brain MRIs in Patients With Traumatic Brain Injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							NEUROIMAGING INITIATIVE ADNI	NeuroQuant (R) is a recently developed, FDA-approved software program for measuring brain MRI volume in clinical settings. The purpose of this study was to compare NeuroQuant with the radiologist's traditional approach, based on visual inspection, in 20 outpatients with mild or moderate traumatic brain injury (TBI). Each MRI was analyzed with NeuroQuant, and the resulting volumetric analyses were compared with the attending radiologist's interpretation. The radiologist's traditional approach found atrophy in 10.0% of patients; NeuroQuant found atrophy in 50.0% of patients. NeuroQuant was more sensitive for detecting brain atrophy than the traditional radiologist's approach. (The Journal of Neuropsychiatry and Clinical Neurosciences 2013; 25:32-39)	[Ross, David E.] Virginia Inst Neuropsychiat, Midlothian, VA USA; Virginia Commonwealth Univ, Richmond, VA USA	Ross, DE (corresponding author), Virginia Inst Neuropsychiat, Midlothian, VA USA.	DRoss@VaNeuropsychiatry.org	Levey, Allan/F-2104-2011; Preda, Adrian/K-8889-2013; Saykin, Andrew/A-1318-2007	Levey, Allan/0000-0002-3153-502X; Preda, Adrian/0000-0003-3373-2438; Saykin, Andrew/0000-0002-1376-8532; Hsiung, Ging-Yuek/0000-0002-8017-0856; Ochs, Alfred/0000-0003-3932-876X	Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 AG024904]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 AG010129, K01 AG030514]; Dana Foundation; Northern California Institute for Research and Education; Virginia Institute of Neuropsychiatry; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010129, K01AG030514, U01AG032438, U01AG024904] Funding Source: NIH RePORTER	Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc., as well as non-profit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the U. S. Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129, K01 AG030514, and the Dana Foundation.; The authors had no conflicts of interest. This project was funded internally by the Virginia Institute of Neuropsychiatry.	Bigler ED, 2011, STRUCTURAL IMAGING, P73; Bigler ED, 2005, STRUCTURAL IMAGING, P79; Brewer JB, 2009, BEHAV NEUROL, V21, P21, DOI [10.3233/BEN-2009-0226, 10.1155/2009/616581]; Brewer JB, 2009, AM J NEURORADIOL, V30, P578, DOI 10.3174/ajnr.A1402; Huppertz HJ, 2010, NEUROIMAGE, V49, P2216, DOI 10.1016/j.neuroimage.2009.10.066; Jack CR, 2008, J MAGN RESON IMAGING, V27, P685, DOI 10.1002/jmri.21049; Kovacevic S, 2009, ALZ DIS ASSOC DIS, V23, P139, DOI 10.1097/WAD.0b013e318192e745; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Miyahira Yoshinao, 2004, Seishin Shinkeigaku Zasshi, V106, P138; Petersen RC, 2010, NEUROLOGY, V74, P201, DOI 10.1212/WNL.0b013e3181cb3e25; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Raz N, 2007, ANN NY ACAD SCI, V1097, P84, DOI 10.1196/annals.1379.018; Raz N, 2010, NEUROIMAGE, V51, P501, DOI 10.1016/j.neuroimage.2010.03.020; Ross DE, 2012, J NEUROPSYCH CLIN N, V24, pE33, DOI 10.1176/appi.neuropsych.11020044; Ross DE, 2011, BRAIN INJURY, V25, P1271, DOI 10.3109/02699052.2011.624568; Talairach J., 1988, COPLANAR STEREOTAXIC; VICTOROFF J, 1994, NEUROLOGY, V44, P2267, DOI 10.1212/WNL.44.12.2267; Weiner MW, 2010, ALZHEIMERS DEMENT, V6, P202, DOI 10.1016/j.jalz.2010.03.007	18	27	27	3	62	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2013	25	1					32	39		10.1176/appi.neuropsych.11120377			8	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	123SK	WOS:000317410800046	23487191	Green Accepted			2021-06-18	
J	Adnan, A; Crawley, A; Mikulis, D; Moscovitch, M; Colella, B; Green, R				Adnan, Areeba; Crawley, Adrian; Mikulis, David; Moscovitch, Morris; Colella, Brenda; Green, Robin			Moderate-severe traumatic brain injury causes delayed loss of white matter integrity: Evidence of fornix deterioration in the chronic stage of injury	BRAIN INJURY			English	Article						Chronic brain injury; diffusion tensor imaging; fornix; fractional anisotropy; neurodegeneration; traumatic brain injury	DIFFUSE AXONAL INJURY; HEAD-INJURY; TENSOR TRACTOGRAPHY; PROGRESSIVE ATROPHY; MEMORY; RATS; TBI; NEUROPATHOLOGY; DEGENERATION; ANISOTROPY	Objectives: To examine structural integrity loss in the fornix from 5-30 months after moderate and severe traumatic brain injury (TBI) using diffusion tensor imaging. Methods: MRIs were prospectively undertaken in 29 adults with moderate and severe TBI at two time points. Fractional anisotropy (FA) was calculated for the fornix (column/body, right crux and left crux) at 5 and 30 months post-injury. Results: Paired t-tests revealed significant FA reductions with large effect sizes across time in the column/body, p<0.001, right crux, p<0.001 and left crux, p<0.001. Conclusions: These data contribute to the growing body of evidence that loss of white matter continues in moderate and severe TBI even after the acute neurological effects of TBI have resolved. As the fornix plays a critical role in memory, this may be a contributing factor to the poor clinical outcomes observed in these patients.	[Adnan, Areeba] Toronto Rehabil Inst, Toronto, ON, Canada; [Crawley, Adrian; Mikulis, David] Univ Toronto, Univ Hlth Network, Div Neuroradiol, Dept Med Imaging, Toronto, ON, Canada; [Moscovitch, Morris] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Moscovitch, Morris] Baycrest Ctr Geriatr Hlth, Rotman Res Inst, Toronto, ON, Canada; [Colella, Brenda; Green, Robin] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada	Green, R (corresponding author), Univ Hlth Network, Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	robin.green@uhn.ca	Mikulis, David J/H-5167-2019	Green, Robin/0000-0001-9451-3963; Mikulis, David/0000-0003-3956-0892	Toronto Rehabilitation InstituteUniversity of Toronto; Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); Physicians Services Incorporated Foundation; Ontario Neurotrauma Foundation; Canada Research Chairs ProgramCanada Research Chairs	The authors acknowledge the support of Toronto Rehabilitation Institute, Canadian Institute of Health Research, Physicians Services Incorporated Foundation, the Ontario Neurotrauma Foundation, and the Canada Research Chairs Program. The authors report no conflicts of interest.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Andersson J. L. R., 2007, TR07JA2 FMRIB CTR; Andersson J.L.R., 2007, TR07JA1 FMRIB; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bach-y-Rita P, 2003, BRAIN INJURY, V17, P643, DOI 10.1080/0269905031000107133; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; Bigler ED, 2013, BRAIN, V136, P9, DOI 10.1093/brain/aws342; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Chang MC, 2010, NEUROREHABILITATION, V26, P347, DOI 10.3233/NRE-2010-0572; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, P1006; Fox RJ, 2011, AM J NEURORADIOL, V32, P85, DOI 10.3174/ajnr.A2238; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Hannay HJ, 2004, NEUROPSYCHOLOGICAL A, P160; Hong JH, 2010, J REHABIL MED, V42, P979, DOI 10.2340/16501977-0603; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jang SH, 2011, INT J NEUROSCI, V121, P94, DOI 10.3109/00207454.2010.531894; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kolb B, 2011, J COMMUN DISORD, V44, P503, DOI 10.1016/j.jcomdis.2011.04.007; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Rorden C, 2007, J COGNITIVE NEUROSCI, V19, P1081, DOI 10.1162/jocn.2007.19.7.1081; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith C, 2012, NEUROPATHOLOGY APPL; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Tsivilis D, 2008, NAT NEUROSCI, V11, P834, DOI 10.1038/nn.2149; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Zhan W, 2010, SET2010 9TH INTERNAT, P1	59	27	28	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2013	27	12					1415	1422		10.3109/02699052.2013.823659			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	235UF	WOS:000325745500012	24102365				2021-06-18	
J	Jiang, JY				Jiang, Ji-yao		Chinese Head Trauma Study Collabor	Head trauma in China	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Head trauma; Data bank; Outcome; China	BRAIN-INJURY; SUBARACHNOID HEMORRHAGE; INTRACRANIAL-PRESSURE; GENDER; COMA; AGE	Objective: The Chinese Head Trauma Data Bank (CHTDB) has been established, which includes 7145 hospitalised cases with acute head trauma patients in 47 hospitals. Methods: We explored factors that might affect the outcome of acute traumatic brain injury. Results: There was no statistical difference in the mortality rate between male (7.5%) and female (7.2%) patients (P > 0.05). The mortality rate in children (< 18 years), adults (18-65 years) and elderly (> 65 years) was 7.3%, 7.2% and 9.0%, respectively (P > 0.05). The mortality rate of patients with mild (2.7%), moderate (5.0%) and severe (21.8%) head trauma was significantly different (P < 0.001). The mortality rate of patients with unilateral tentorial herniation, bilateral tentorial herniation and tonsillar herniation was 24.2%, 60.2% and 78.8% respectively (P < 0.001). The mortality rate of patients with intracranial pressure (ICP) < 20 mmHg, 20-40 mmHg and >40 mmHg was 6.3%, 21.4% and 93.1%, respectively (P < 0.001). The mortality rate of patients with no cerebral contusion, single cerebral contusion and multiple cerebral contusions was 3.9%, 7.8% and 14.8%, respectively (P < 0.001). The mortality rate of patients with and without traumatic subarachnoid haemorrhage (tSAH) was 9.5% and 5.4%, respectively (P < 0.001). The mortality rate of patients with no intracranial haematomas, single intracranial haematoma and multiple intracranial haematomas was 5.8%, 8.4% and 20.6%, respectively (P < 0.001). Conclusion: The CHTDB, the first head trauma data bank in China, has one of the largest numbers of cases of any head trauma data bank in the world. Our major findings on mortality may be helpful to neurosurgeons for predicting the outcome of acute head trauma patients. (c) 2012 Elsevier Ltd. All rights reserved.	[Jiang, Ji-yao; Chinese Head Trauma Study Collabor] Shanghai Jiao Tong Univ, Shanghai Renji Hosp, Sch Med, Dept Neurosurg, Shanghai 200127, Peoples R China	Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Shanghai Renji Hosp, Sch Med, Dept Neurosurg, Shanghai 200127, Peoples R China.	jiyaojiang@126.com			National Health Science Grant [200802093]; National Key Basic Research ProjectNational Basic Research Program of China [2012CB518100]; Science and Technology committee of ShanghaiShanghai Science & Technology Committee [10JC1409800, 08411951900]; Program for Shanghai Outstanding Medical Academic Leader	This work was supported by grants from National Health Science Grant (No. 200802093), National Key Basic Research Project (No. 2012CB518100), Science and Technology committee of Shanghai (Nos. 10JC1409800, 08411951900) and Program for Shanghai Outstanding Medical Academic Leader.	Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Bullock MR, 2006, NEUROSURGERY, V58, pS1; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GHAJAR JBG, 1993, ADV NEUROS, V21, P173; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Lu J, 2005, ACT NEUR S, V95, P281; Maas AI, 2003, LANCET NEUROL, V7, P728; MARMAROU A, 1992, J NEUROTRAUM, V9, pS327; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Nakamura N, 2006, NEUROL MED-CHIR, V46, P567, DOI 10.2176/nmc.46.567; Otani N, 2010, ACTA NEUROCHIR SUPPL, V106, P257, DOI 10.1007/978-3-211-98811-4_48; Ottochian M, 2009, AM J SURG, V197, P155, DOI 10.1016/j.amjsurg.2008.09.008; Pang BC, 2007, J NEUROTRAUM, V24, P136, DOI 10.1089/neu.2006.0113; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; von Wild KRH, 2005, ACTA NEUROCHIR SUPPL, V93, P15	24	27	39	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	NOV	2013	44	11					1453	1457		10.1016/j.injury.2012.08.045			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	227ZT	WOS:000325155000013	23068139				2021-06-18	
J	Kellogg, RG; Fontes, RBV; Lopes, DK				Kellogg, Robert G.; Fontes, Ricardo B. V.; Lopes, Demetrius K.			Massive cerebral involvement in fat embolism syndrome and intracranial pressure management Case report	JOURNAL OF NEUROSURGERY			English	Article						cerebral fat embolism; fat embolism syndrome; decompressive hemicraniectomy; traumatic brain injury	DIFFUSION-WEIGHTED MRI; COMPUTED-TOMOGRAPHY; BRAIN; DIAGNOSIS; INJURY; ARTHROPLASTY; FRACTURE; COMA	Fat embolism syndrome (FES) is a common clinical entity that can occasionally have significant neurological sequelae. The authors report a case of cerebral fat embolism and FES that required surgical management of intracranial pressure (ICP). They also discuss the literature as well as the potential need for neurosurgical management of this disease entity in select patients. A 58-year-old woman presented with a seizure episode and altered mental status after suffering a right femur fracture. Head CT studies demonstrated hypointense areas consistent with fat globules at the gray-white matter junction predominantly in the right hemisphere. This CT finding is unique in the literature, as other reports have not included imaging performed early enough to capture this finding. Brain MR images obtained 3 days later revealed T2-hyperintense areas with restricted diffusion within the same hemisphere, along with midline shift and subfalcine herniation. These findings steered the patient to the operating room for decompressive hemicraniectomy. A review of the literature from 1980 to 2012 disclosed 54 cases in 38 reports concerning cerebral fat embolism and FES. Analysis of all the cases revealed that 98% of the patients presented with mental status changes, whereas only 22% had focal signs and/or seizures. A good outcome was seen in 57.6% of patients with coma and/or abnormal posturing on presentation and in 90.5% of patients presenting with mild mental status changes, focal deficits, or seizure. In the majority of cases ICP was managed conservatively with no surgical intervention. One case featured the use of an ICP monitor, while none featured the use of hemicraniectomy.	[Kellogg, Robert G.; Fontes, Ricardo B. V.; Lopes, Demetrius K.] Rush Univ, Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA	Kellogg, RG (corresponding author), 1725 W Harrison St,Ste 855, Chicago, IL 60612 USA.	Robert_Kellogg@Rush.edu	Lopes, Demetrius/AAD-7334-2020	Lopes, Demetrius/0000-0002-6280-0113			ALLARDYCE DB, 1974, J TRAUMA, V14, P955, DOI 10.1097/00005373-197411000-00008; ANEGAWA S, 1991, Neurologia Medico-Chirurgica, V31, P359, DOI 10.2176/nmc.31.359; Babikian VL, 2000, NEUROLOGY, V54, P797, DOI 10.1212/WNL.54.4.797; Barak M, 2008, ANESTH ANALG, V107, P221, DOI 10.1213/ane.0b013e3181770abb; Beretta Luigi, 2008, J Trauma, V65, pE46, DOI 10.1097/01.ta.0000221368.79241.bd; BROOKS RA, 1977, J COMPUT ASSIST TOMO, V1, P487, DOI 10.1097/00004728-197710000-00016; Bulger EM, 1997, ARCH SURG-CHICAGO, V132, P435; Buskens CJ, 2008, MED SCI MONITOR, V14, pCS125; Butteriss DJA, 2006, AM J NEURORADIOL, V27, P620; Chen JJS, 2008, EMERG RADIOL, V15, P187, DOI 10.1007/s10140-007-0664-3; Chrysikopoulos H, 1996, CLIN RADIOL, V51, P728, DOI 10.1016/S0009-9260(96)80248-0; CITERIO G, 1995, INTENS CARE MED, V21, P679, DOI 10.1007/BF01711549; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cox G, 2011, INJURY, V42, pS6, DOI 10.1016/S0020-1383(11)70005-5; Dive AM, 2002, ANESTHESIOLOGY, V96, P1029, DOI 10.1097/00000542-200204000-00037; Duja CM, 2010, BMC EMERG MED, V10, DOI 10.1186/1471-227X-10-18; Eguia P, 2007, J NEUROIMAGING, V17, P78, DOI 10.1111/j.1552-6569.2006.00068.x; ERDEM E, 1993, NEURORADIOLOGY, V35, P199, DOI 10.1007/BF00588493; FABIAN TC, 1993, NEW ENGL J MED, V329, P961, DOI 10.1056/NEJM199309233291313; FINDLAY JM, 1984, CAN MED ASSOC J, V131, P755; Gombar S, 2005, ACTA ANAESTH SCAND, V49, P723, DOI 10.1111/j.1399-6576.2005.00588.x; GOSSLING HR, 1982, CLIN ORTHOP RELAT R, P68; Gregorakos L, 2000, J ACCID EMERG MED, V17, P144; Guillevin R, 2005, ANN NEUROL, V57, P434, DOI 10.1002/ana.20388; GURD AR, 1974, J BONE JOINT SURG BR, VB 56, P408; JACOBSON DM, 1986, NEUROLOGY, V36, P847, DOI 10.1212/WNL.36.6.847; Kamano M, 2001, CLIN ORTHOP RELAT R, P206; KAMENAR E, 1980, STROKE, V11, P477, DOI 10.1161/01.STR.11.5.477; KAWANO Y, 1991, NEURORADIOLOGY, V33, P72, DOI 10.1007/BF00593341; Kim Kyung-Cheon, 2008, Orthopedics, V31, P170, DOI 10.3928/01477447-20080201-15; Kumar S, 2012, NEUROL INDIA, V60, P100, DOI 10.4103/0028-3886.93597; Lee SC, 2012, J ARTHROPLASTY, V27, P409, DOI 10.1016/j.arth.2011.06.013; LEVY D, 1990, CLIN ORTHOP RELAT R, P281; Marshall GB, 2004, CAN J NEUROL SCI, V31, P417, DOI 10.1017/S0317167100003565; Metting Z, 2009, CLIN NEUROL NEUROSUR, V111, P597, DOI 10.1016/j.clineuro.2009.03.005; Meyer N, 2007, J TRAUMA, V63, P1395, DOI 10.1097/01.ta.0000223953.05151.96; Nastanski F, 2005, J TRAUMA, V58, P372, DOI 10.1097/01.TA.0000108996.10785.0B; Parizel PM, 2001, STROKE, V32, P2942, DOI 10.1161/str.32.12.2942; PELL ACH, 1993, J BONE JOINT SURG BR, V75, P921; Pfeffer G, 2010, CAN J NEUROL SCI, V37, P128, DOI 10.1017/S0317167100009793; Rughani AI, 2011, NEUROCRIT CARE, V15, P190, DOI 10.1007/s12028-010-9388-4; SAITO A, 1990, NEUROSURGERY, V26, P882, DOI 10.1227/00006123-199005000-00027; SAKAMOTO T, 1983, NEURORADIOLOGY, V24, P283, DOI 10.1007/BF00333182; Sasano N, 2004, CAN J ANAESTH, V51, P875, DOI 10.1007/BF03018883; Satoh H, 1997, J TRAUMA, V43, P345, DOI 10.1097/00005373-199708000-00023; SCHNEIDER RC, 1952, J NEUROSURG, V9, P1, DOI 10.3171/jns.1952.9.1.0001; SCOPA M, 1994, J TRAUMA, V36, P906, DOI 10.1097/00005373-199406000-00030; Simon AD, 2003, AM J NEURORADIOL, V24, P97; Stienen MN, 2012, AM J EMERG MED, V30, DOI 10.1016/j.ajem.2011.02.021; Takahashi M, 1999, J TRAUMA, V46, P324, DOI 10.1097/00005373-199902000-00021; Thaunat O, 2004, PLAST RECONSTR SURG, V113, P2235, DOI 10.1097/01.PRS.0000123627.33690.9E; Ammon JT, 2007, J ARTHROPLASTY, V22, P477, DOI 10.1016/j.arth.2006.03.005; Walshe Criona M, 2007, Crit Care Resusc, V9, P184; Yeon HB, 2003, J ARTHROPLASTY, V18, P113, DOI 10.1054/arth.2003.50003; Yoshida A, 1996, J TRAUMA, V40, P437, DOI 10.1097/00005373-199603000-00019; Zenker FA, 1862, BEITRAIGE NORMALEN P	56	27	29	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2013	119	5					1263	1270		10.3171/2013.7.JNS13363			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	238OB	WOS:000325956200033	23952720				2021-06-18	
J	Lam, TI; Bingham, D; Chang, TJ; Lee, CC; Shi, J; Wang, DM; Massa, S; Swanson, RA; Liu, JL				Lam, Tina I.; Bingham, Deborah; Chang, Ting Ju; Lee, Chih Cheng; Shi, Jian; Wang, Dongmin; Massa, Stephen; Swanson, Raymond A.; Liu, Jialing			Beneficial Effects of Minocycline and Botulinum Toxin-Induced Constraint Physical Therapy Following Experimental Traumatic Brain Injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						controlled cortical impact; constraint-induced movement therapy (CIMT); botox; rehabilitation; microglia; glial fibrillary acidic protein (GFAP)	INDUCED MOVEMENT THERAPY; MICROGLIAL ACTIVATION; ANIMAL-MODELS; STROKE; METAANALYSIS; CHILDREN; RECOVERY; TARGETS; ADULT; LIMB	Background. Effective recovery from functional impairments caused by traumatic brain injury (TBI) requires appropriate rehabilitation therapy. Multiple pathways are involved in secondary injury and recovery suggesting a role for multimodal approaches. Objective. Here, we examined the efficacy of the anti-inflammatory agent minocycline and botulinum toxin (botox)-induced limb constraint with structured physical therapy, delivered alone or in combination, after a severe TBI produced by a controlled cortical impact in rats. Methods. Minocycline was administered at 25 mg/kg daily for 2 weeks beginning 1 day after TBI or sham surgery. For constraint/physical therapy, botox-type A was injected into the nonaffected forearm muscle 1 day after injury and 2 weeks of physical therapy commenced at 5 days after injury. Functional evaluations were conducted 8 weeks after injury. Results. Minocycline, either as a monotherapy or as combination treatment with botox/physical therapy significantly reduced impairments of spatial learning and memory in the water maze test, whereas botox/physical therapy reduced forelimb motor asymmetry and improved manual dexterity in the cylinder and vermicelli handling tests, A synergistic effect between the 2 treatments was observed when rats performed tasks requiring dexterity. Inflammation was attenuated in the peri-contusion cortex and hippocampus in all TBI groups receiving mono or combination therapies, though there was no significant difference in lesion size among groups. Conclusion. These data provide a rationale for incorporating anti-inflammatory treatment during rehabilitation therapy.	[Lam, Tina I.; Bingham, Deborah; Chang, Ting Ju; Lee, Chih Cheng; Shi, Jian; Wang, Dongmin; Massa, Stephen; Swanson, Raymond A.; Liu, Jialing] San Francisco VA Med Ctr, San Francisco, CA USA; [Lam, Tina I.; Shi, Jian; Wang, Dongmin; Massa, Stephen; Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Lam, Tina I.] USDA, Foodborne Contaminants Res Unit, Western Reg Res Ctr, Res Serv, Albany, CA USA; [Bingham, Deborah; Chang, Ting Ju; Lee, Chih Cheng; Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA	Liu, JL (corresponding author), Univ Calif San Francisco, Dept Neurol Surg 112C, 4150 Clement St, San Francisco, CA 94121 USA.	jialing.liu@ucsf.edu	Liu, Jialing/A-8627-2012	Liu, Jialing/0000-0003-4420-4382; Swanson, Raymond/0000-0002-3664-5359	Veterans Affairs Research Enhancement Award; Veterans Affairs merit awardsUS Department of Veterans Affairs	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a Veterans Affairs Research Enhancement Award (RAS), and Veterans Affairs merit awards (JL, SM).].	Allred RP, 2008, J NEUROSCI METH, V170, P229, DOI 10.1016/j.jneumeth.2008.01.015; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Blum D, 2004, NEUROBIOL DIS, V17, P359, DOI 10.1016/j.nbd.2004.07.012; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cimolin V, 2012, J HEAD TRAUMA REHAB, V27, P177, DOI 10.1097/HTR.0b013e3182172276; Corbetta D, 2010, EUR J PHYS REHAB MED, V46, P537; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Gauthier LV, 2008, STROKE, V39, P1520, DOI 10.1161/STROKEAHA.107.502229; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Janssen H, 2013, NEUROREHAB NEURAL RE, V27, P3, DOI 10.1177/1545968312449696; Kim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kriz Jasna, 2006, Critical Reviews in Neurobiology, V18, P145; Lampl Y, 2007, NEUROLOGY, V69, P1404, DOI 10.1212/01.wnl.0000277487.04281.db; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Maier IC, 2008, J NEUROSCI, V28, P9386, DOI 10.1523/JNEUROSCI.1697-08.2008; McIntosh TK, 1996, LAB INVEST, V74, P315; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nijland R, 2011, INT J STROKE, V6, P425, DOI 10.1111/j.1747-4949.2011.00646.x; Orsucci D, 2009, CNS NEUROL DISORD-DR, V8, P222; Peurala SH, 2012, CLIN REHABIL, V26, P209, DOI 10.1177/0269215511420306; Ramchand R, 2008, PREVALENCE PTSD DEPR; Reiss AP, 2012, STROKE RES TREAT, V2012, DOI 10.1155/2012/159391; Reitmeir R, 2011, BRAIN, V134, P84, DOI 10.1093/brain/awq344; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Shaw SE, 2005, J REHABIL RES DEV, V42, P769, DOI 10.1682/JRRD.2005.06.0094; Sirtori V, 2010, STROKE, V41, pE57, DOI 10.1161/STROKEAHA.109.569665; Smania N, 2009, EUR J PHYS REHAB MED, V45, P493; Sun SF, 2010, NEUROREHAB NEURAL RE, V24, P34, DOI 10.1177/1545968309341060; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Ulgen Berkin O, 2011, Recent Pat Cardiovasc Drug Discov, V6, P123; Wittenberg GF, 2009, CURR OPIN NEUROL, V22, P582, DOI 10.1097/WCO.0b013e3283320229; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	41	27	27	0	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	NOV	2013	27	9					889	899		10.1177/1545968313491003			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	229IL	WOS:000325256000013	23778701				2021-06-18	
J	Ching, SN; Liberman, MY; Chemali, JJ; Westover, MB; Kenny, JD; Solt, K; Purdon, PL; Brown, EN				Ching, ShiNung; Liberman, Max Y.; Chemali, Jessica J.; Westover, M. Brandon; Kenny, Jonathan D.; Solt, Ken; Purdon, Patrick L.; Brown, Emery N.			Real-time Closed-loop Control in a Rodent Model of Medically Induced Coma Using Burst Suppression	ANESTHESIOLOGY			English	Article							REFRACTORY STATUS EPILEPTICUS; DELIVERY-SYSTEM CLADS(TM); QUANTITATIVE EEG ANALYSIS; BISPECTRAL INDEX; PERFORMANCE ASSESSMENT; PROPOFOL ANESTHESIA; GENERAL-ANESTHESIA; FEEDBACK-CONTROL; REMIFENTANIL; SURGERY	Background: A medically induced coma is an anesthetic state of profound brain inactivation created to treat status epilepticus and to provide cerebral protection after traumatic brain injuries. The authors hypothesized that a closed-loop anesthetic delivery system could automatically and precisely control the electroencephalogram state of burst suppression and efficiently maintain a medically induced coma. Methods: In six rats, the authors implemented a closed-loop anesthetic delivery system for propofol consisting of: a computer-controlled pump infusion, a two-compartment pharmacokinetics model defining propofol's electroencephalogram effects, the burst-suppression probability algorithm to compute in real time from the electroencephalogram the brain's burst-suppression state, an online parameter-estimation procedure and a proportional-integral controller. In the control experiment each rat was randomly assigned to one of the six burst-suppression probability target trajectories constructed by permuting the burst-suppression probability levels of 0.4, 0.65, and 0.9 with linear transitions between levels. Results: In each animal the controller maintained approximately 60 min of tight, real-time control of burst suppression by tracking each burst-suppression probability target level for 15 min and two between-level transitions for 5-10 min. The posterior probability that the closed-loop anesthetic delivery system was reliable across all levels was 0.94 (95% CI, 0.77-1.00; n = 18) and that the system was accurate across all levels was 1.00 (95% CI, 0.84-1.00; n = 18). Conclusion: The findings of this study establish the feasibility of using a closed-loop anesthetic delivery systems to achieve in real time reliable and accurate control of burst suppression in rodents and suggest a paradigm to precisely control medically induced coma in patients.	[Ching, ShiNung; Liberman, Max Y.; Chemali, Jessica J.; Westover, M. Brandon; Kenny, Jonathan D.; Solt, Ken; Purdon, Patrick L.; Brown, Emery N.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA	Brown, EN (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St,Gray Bigelow 444, Boston, MA 02114 USA.	enb@neurostat.mit.edu	Solt, Ken/AAX-8188-2020	Solt, Ken/0000-0001-5328-2062; Kenny, Jonathan/0000-0003-3745-3217	National Institutes of Health, Bethesda, MarylandUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DP1-OD003646, ROI-GM10498, DP2-OD006454, K08-GM094394]; Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts; Burroughs-Wellcome Fund, Durham, North Carolina [1010625]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K08GM094394] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DP2OD006454, DP1OD003646] Funding Source: NIH RePORTER	Support was provided by grants DP1-OD003646 (to Dr. Brown), ROI-GM10498 (to Dr. Brown), DP2-OD006454 (to Dr. Purdon), and K08-GM094394 (to Dr. Solt) from the National Institutes of Health, Bethesda, Maryland, and the Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts. Dr. Ching holds a Career Award at the Scientific Interface (1010625) from the Burroughs-Wellcome Fund, Durham, North Carolina. The first four authors contributed equally to this work.	Absalom AR, 2003, BRIT J ANAESTH, V90, P737, DOI 10.1093/bja/aeg137; Absalom AR, 2002, ANESTHESIOLOGY, V96, P67, DOI 10.1097/00000542-200201000-00017; Agarwal J, 2009, ACTA ANAESTH SCAND, V53, P390, DOI 10.1111/j.1399-6576.2008.01884.x; Mendez JA, 2009, COMPUT METHOD BIOMEC, V12, P727, DOI 10.1080/10255840902911528; Amzica F, 2009, EPILEPSIA, V50, P38, DOI 10.1111/j.1528-1167.2009.02345.x; Bertsekas D, 2005, DYNAMIC PROGRAMMING, V2, P51; BICKFORD RG, 1950, ELECTROEN CLIN NEURO, V2, P93, DOI 10.1016/0013-4694(50)90014-9; Box G, 2008, TIME SERIES ANAL FOR, P59; Brown EN, 2010, NEW ENGL J MED, V363, P2638, DOI 10.1056/NEJMra0808281; Camacho E.F., 2007, ADV TK CONT SIGN PRO, DOI [10.1007/978-0-85729-398-5., 10.1007/978-0-85729-398-5]; Chemali JJ, 2012, ANESTHESIOLOGY, V116, P998, DOI 10.1097/ALN.0b013e3182518bfc; Chemali JJ, 2011, IEEE ENG MED BIO, P1431, DOI 10.1109/IEMBS.2011.6090354; Ching SN, 2012, P NATL ACAD SCI USA, V109, P3095, DOI 10.1073/pnas.1121461109; Cotten JF, 2011, ANESTHESIOLOGY, V115, P764, DOI 10.1097/ALN.0b013e31821950de; De Smet T, 2008, ANESTH ANALG, V107, P1200, DOI 10.1213/ane.0b013e31817bd1a6; De Smet T, 2007, ANESTH ANALG, V105, P1629, DOI 10.1213/01.ane.0000287269.06170.0f; DeGroot M, 2002, PROBABILITY STAT 200, P327; Doyle PW, 1999, CAN J ANAESTH, V57, P725; Eden UT, 2004, NEURAL COMPUT, V16, P971, DOI 10.1162/089976604773135069; Franklin G, 2010, FEEDBACK CONTROL DYN, V166-91, P438; Glass PSA, 2010, CAN J ANESTH, V57, P715, DOI 10.1007/s12630-010-9336-y; Haddad WM, 2007, IEEE T NEURAL NETWOR, V18, P1049, DOI 10.1109/TNN.2007.899164; Hahn JO, 2011, IEEE T BIO-MED ENG, V58, P3, DOI 10.1109/TBME.2010.2076811; Hegde HV, 2009, J CLIN MONIT COMPUT, V23, P189, DOI 10.1007/s10877-009-9181-0; Hemmerling TM, 2010, CAN J ANESTH, V57, P725, DOI 10.1007/s12630-010-9335-z; Kam PCA, 2007, ANAESTHESIA, V62, P690, DOI 10.1111/j.1365-2044.2007.05055.x; Kenny GNC, 1999, BRIT J ANAESTH, V83, P223, DOI 10.1093/bja/83.2.223; Liu HY, 2012, J NEUROSURG ANESTH, V24, P133, DOI 10.1097/ANA.0b013e31823dfb2e; Liu N, 2006, ANESTHESIOLOGY, V104, P686, DOI 10.1097/00000542-200604000-00012; Liu N, 2008, J CARDIOTHOR VASC AN, V22, P611, DOI 10.1053/j.jvca.2008.04.022; Liu N, 2012, ANESTHESIOLOGY, V116, P286, DOI 10.1097/ALN.0b013e318242ad4f; Morley A, 2000, ANAESTHESIA, V55, P953, DOI 10.1046/j.1365-2044.2000.01527.x; Mortier E, 1998, ANAESTHESIA, V53, P749, DOI 10.1046/j.1365-2044.1998.00467.x; Pilge S, 2006, ANESTHESIOLOGY, V104, P488, DOI 10.1097/00000542-200603000-00016; Puri GD, 2007, ANAESTH INTENS CARE, V35, P357, DOI 10.1177/0310057X0703500306; Rausand M, 2003, SYSTEM RELIABILITY T, P539; Rossetti AO, 2005, ARCH NEUROL-CHICAGO, V62, P1698, DOI 10.1001/archneur.62.11.1698; Rossetti AO, 2004, EPILEPSIA, V45, P757, DOI 10.1111/j.0013-9580.2004.01904.x; Scheuer ML, 2004, J CLIN NEUROPHYSIOL, V21, P353; Schnider TW, 1998, ANESTHESIOLOGY, V88, P1170, DOI 10.1097/00000542-199805000-00006; SCHWILDEN H, 1993, BRIT J ANAESTH, V70, P389, DOI 10.1093/bja/70.4.389; SCHWILDEN H, 1987, ANESTHESIOLOGY, V67, P341, DOI 10.1097/00000542-198709000-00011; SCHWILDEN H, 1989, BRIT J ANAESTH, V62, P290, DOI 10.1093/bja/62.3.290; SIGL JC, 1994, J CLIN MONITOR, V10, P392, DOI 10.1007/BF01618421; Smith AC, 2003, NEURAL COMPUT, V15, P965, DOI 10.1162/089976603765202622; Solt K, 2011, ANESTHESIOLOGY, V115, P791, DOI 10.1097/ALN.0b013e31822e92e5; Struys MMRF, 2001, ANESTHESIOLOGY, V95, P6, DOI 10.1097/00000542-200107000-00007; VARVEL JR, 1992, J PHARMACOKINET BIOP, V20, P63, DOI 10.1007/BF01143186; Vijn PCM, 1998, BRIT J ANAESTH, V81, P415, DOI 10.1093/bja/81.3.415	49	27	27	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	OCT	2013	119	4					848	860		10.1097/ALN.0b013e31829d4ab4			13	Anesthesiology	Anesthesiology	219AJ	WOS:000324475400024	23770601	Green Accepted, Bronze			2021-06-18	
J	Inoue, T; Lin, A; Ma, XK; McKenna, SL; Creasey, GH; Manley, GT; Ferguson, AR; Bresnahan, JC; Beattie, MS				Inoue, Tomoo; Lin, Amity; Ma, Xiaokui; McKenna, Stephen L.; Creasey, Graham H.; Manley, Geoffrey T.; Ferguson, Adam R.; Bresnahan, Jacqueline C.; Beattie, Michael S.			Combined SCI and TBI: Recovery of forelimb function after unilateral cervical spinal cord injury (SCI) is retarded by contralateral traumatic brain injury (TBI), and ipsilateral TBI balances the effects of SCI on paw placement	EXPERIMENTAL NEUROLOGY			English	Article						Behavioral analysis; Neuronal plasticity; Spinal cord injury; Traumatic brain injury; 'Dual diagnosis'	CLOSED HEAD-INJURY; LESS-AFFECTED FORELIMB; ADULT MALE RATS; SENSORIMOTOR CORTEX; CORTICAL INFARCTS; CONTUSION INJURY; RISK-FACTORS; FORCED USE; PLASTICITY; STROKE	A significant proportion (estimates range from 16 to 74%) of patients with spinal cord injury (SCI) have concomitant traumatic brain injury (TBI), and the combination often produces difficulties in planning and implementing rehabilitation strategies and drug therapies. For example, many of the drugs used to treat SCI may interfere with cognitive rehabilitation, and conversely drugs that are used to control seizures in TBI patients may undermine locomotor recovery after SCI. The current paper presents an experimental animal model for combined SCI and TBI to help drive mechanistic studies of dual diagnosis. Rats received a unilateral SCI (75 kdyn) at C5 vertebral level, a unilateral TBI (2.0 mm depth, 4.0 m/s velocity impact on the forelimb sensori-motor cortex), or both SCI + TBI. TBI was placed either contralateral or ipsilateral to the SCI. Behavioral recovery was examined using paw placement in a cylinder, grooming, open field locomotion, and the IBB cereal eating test. Over 6 weeks, in the paw placement test, SCI + contralateral TBI produced a profound deficit that failed to recover, but SCI + ipsilateral TBI increased the relative use of the paw on the SCI side. In the grooming test, SCI + contralateral TBI produced worse recovery than either lesion alone even though contralateral TBI alone produced no observable deficit. In the IBB forelimb test, SCI + contralateral TBI revealed a severe deficit that recovered in 3 weeks. For open field locomotion, SCI alone or in combination with TBI resulted in an initial deficit that recovered in 2 weeks. Thus, TBI and SCI affected forelimb function differently depending upon the test, reflecting different neural substrates underlying, for example, exploratory paw placement and stereotyped grooming. Concurrent SCI and TBI had significantly different effects on outcomes and recovery, depending upon laterality of the two lesions. Recovery of function after cervical SCI was retarded by the addition of a moderate TBI in the contralateral hemisphere in all tests, but forepaw placements were relatively increased by an ipsilateral TBI relative to SCI alone, perhaps due to the dual competing injuries influencing the use of both forelimbs. These findings emphasize the complexity of recovery from combined CNS injuries, and the possible role of plasticity and laterality in rehabilitation, and provide a start towards a useful preclinical model for evaluating effective therapies for combine SCI and TBI. (C) 2013 Elsevier Inc. All rights reserved.	[Inoue, Tomoo; Lin, Amity; Ma, Xiaokui; Manley, Geoffrey T.; Ferguson, Adam R.; Bresnahan, Jacqueline C.; Beattie, Michael S.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; [Inoue, Tomoo; Lin, Amity; Ma, Xiaokui; Manley, Geoffrey T.; Ferguson, Adam R.; Bresnahan, Jacqueline C.; Beattie, Michael S.] San Francisco Gen Hosp, San Francisco, CA 94110 USA; [Inoue, Tomoo; Lin, Amity; Ma, Xiaokui; Manley, Geoffrey T.; Ferguson, Adam R.; Bresnahan, Jacqueline C.; Beattie, Michael S.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [McKenna, Stephen L.] Santa Clara Valley Med Ctr, Rehabil Trauma Ctr, San Jose, CA 95128 USA; [Creasey, Graham H.] Palo Alto Hlth Care Syst, Dept Vet Affairs, Spinal Cord Injury & Disorders Serv, Palo Alto, CA USA	Beattie, MS (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr, 1001 Potrero Ave,Bldg 1,Rm 101, San Francisco, CA 94110 USA.	inouet@neurosurg.ucsf.edu; Amity.Lin@ucsf.edu; MaX@neurosurg.ucsf.edu; Stephen.McKenna@hhs.sccgov.org; Graham.Creasey@va.gov; manleyg@neurosurg.ucsf.edu; adam.ferguson@ucsf.edu; jacqueline.bresnahan@ucsf.edu; michael.beattie@ucsf.edu		Ferguson, Adam/0000-0001-7102-1608	DoD/CDMRP SCIRP [W81XWH-10-1-0910]; Uehara Memorial Foundation Research fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038079] Funding Source: NIH RePORTER	This work was supported by DoD/CDMRP SCIRP Translational Partnership Award #W81XWH-10-1-0910. T. Inoue was supported by the Uehara Memorial Foundation Research fellowship. The authors would like to acknowledge Ms. Ellie Stuck and Yvette Nout, DVM, PhD for help with some of the behavioral testing, and Jeffrey Sacramento and Jinghua Yao for help with the histological preparations and analysis.	Allred RP, 2010, BEHAV NEUROSCI, V124, P124, DOI 10.1037/a0018457; Arzaga Deborah, 2003, SCI Nurs, V20, P86; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; BERTELLI JA, 1993, J NEUROSCI METH, V46, P203, DOI 10.1016/0165-0270(93)90068-3; Blanco JE, 2007, EXP NEUROL, V203, P333, DOI 10.1016/j.expneurol.2006.08.017; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS77, DOI 10.1016/j.apmr.2008.07.008; Bury SD, 2004, BEHAV BRAIN RES, V150, P43, DOI 10.1016/S0166-4328(03)00253-5; Cooper D J, 2005, Crit Care Resusc, V7, P181; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF G, 1986, PARAPLEGIA, V24, P97, DOI 10.1038/sc.1986.13; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P41; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P489; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; Dunham KA, 2010, J NEUROTRAUM, V27, P2091, DOI 10.1089/neu.2010.1424; Ferguson AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059712; Gensel JC, 2006, J NEUROTRAUM, V23, P36, DOI 10.1089/neu.2006.23.36; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hagen EM, 2010, ACTA NEUROL SCAND, V122, P51, DOI 10.1111/j.1600-0404.2010.01376.x; Holly LT, 2002, J NEUROSURG, V96, P285, DOI 10.3171/spi.2002.96.3.0285; Hsu JE, 2006, EXP NEUROL, V201, P479, DOI 10.1016/j.expneurol.2006.05.003; Hsu JE, 2005, EUR J NEUROSCI, V22, P2069, DOI 10.1111/j.1460-9568.2005.04370.x; Huie JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039751; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Iida H, 1999, J TRAUMA, V46, P450, DOI 10.1097/00005373-199903000-00018; Irvine K. A., 2010, J VIS EXP, V46; Jones TA, 1996, BRAIN RES, V733, P142, DOI 10.1016/0006-8993(96)00792-5; Jones TA, 2012, J NEUROTRAUM, V29, P1455, DOI 10.1089/neu.2011.2207; Jones TA, 2009, STROKE, V40, pS136, DOI 10.1161/STROKEAHA.108.533653; Keppel G, 2004, DESIGN ANAL RES HDB; Kokotilo KJ, 2009, J NEUROTRAUM, V26, P2113, DOI 10.1089/neu.2008.0688; Lu D.C., 2013, J NEUROTRAU IN PRESS, DOI DOI 10.1089/NEU; Luke LM, 2004, SYNAPSE, V54, P187, DOI 10.1002/syn.20080; Macciocchi SN, 2004, AM J PHYS MED REHAB, V83, P22, DOI 10.1097/01.PHM.0000104661.86307.91; Macciocchi S, 2008, ARCH PHYS MED REHAB, V89, P1350, DOI 10.1016/j.apmr.2007.11.055; Martinez M, 2009, J NEUROTRAUM, V26, P1043, DOI 10.1089/neu.2008.0717; McKenna JE, 2000, J COMP NEUROL, V419, P286, DOI 10.1002/(SICI)1096-9861(20000410)419:3<286::AID-CNE2>3.0.CO;2-3; MICHAEL D B, 1989, Journal of Neurotrauma, V6, P177; Mihai G, 2008, J NEUROTRAUM, V25, P1, DOI 10.1089/neu.2007.0338; Nishimura Y, 2012, EXP NEUROL, V235, P152, DOI 10.1016/j.expneurol.2011.08.013; Nishimura Y, 2009, NEUROSCIENTIST, V15, P436, DOI 10.1177/1073858408331375; Nout YS, 2009, CRIT CARE MED, V37, P2160, DOI 10.1097/CCM.0b013e3181a05d41; OMALLEY KF, 1988, J TRAUMA, V28, P1476, DOI 10.1097/00005373-198810000-00013; POVOLNY MA, 1993, J REHABIL, V59, P23; RICHARDS JS, 1991, ARCH PHYS MED REHAB, V72, P275; Ricker J.H., 1999, TOP SPINAL CORD INJ, V5, P76; Rosenzweig ES, 2010, NAT NEUROSCI, V13, P1505, DOI 10.1038/nn.2691; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schallert T, 2003, J REHABIL RES DEV, V40, P9, DOI 10.1682/JRRD.2003.08.0009; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; SOICHER E, 1991, BRIT J SURG, V78, P1013, DOI 10.1002/bjs.1800780837; Sommer JL, 2004, BRAIN INJURY, V18, P1297, DOI 10.1080/02699050410001672288; SPRAGUE JM, 1966, SCIENCE, V153, P1544, DOI 10.1126/science.153.3743.1544; STAMBROOK M, 1991, J CLIN EXP NEUROPSYC, V13, P521, DOI 10.1080/01688639108401068; Strich S J, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P166; Strong MK, 2009, EXP NEUROL, V217, P96, DOI 10.1016/j.expneurol.2009.01.020; Tian HL, 2009, J TRAUMA, V67, P1305, DOI 10.1097/TA.0b013e31819db57c; Watanabe T, 1999, TOP SPINAL CORD INJ, V5, P83; Wei CW, 2008, ARCH PHYS MED REHAB, V89, pS85, DOI 10.1016/j.apmr.2008.07.005; Willis JK, 2002, PEDIATRICS, V110, P94, DOI 10.1542/peds.110.1.94; WOLF SL, 1989, EXP NEUROL, V104, P125, DOI 10.1016/S0014-4886(89)80005-6	61	27	27	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2013	248						136	147		10.1016/j.expneurol.2013.06.006			12	Neurosciences	Neurosciences & Neurology	261SJ	WOS:000327684600013	23770071	Green Accepted			2021-06-18	
J	Li, Q; Yang, CH; Xu, JG; Li, H; You, C				Li, Q.; Yang, C. H.; Xu, J. G.; Li, H.; You, C.			Surgical treatment for large spontaneous basal ganglia hemorrhage: retrospective analysis of 253 cases	BRITISH JOURNAL OF NEUROSURGERY			English	Article						cerebral hemorrhage; intracranial pressure; decompressive craniectomy (DC); mortality	TRAUMATIC BRAIN-INJURY; SUPRATENTORIAL INTRACEREBRAL HEMORRHAGE; DECOMPRESSIVE CRANIECTOMY; CONSERVATIVE TREATMENT; CEREBRAL EDEMA; MANAGEMENT; EVACUATION; HEMATOMAS; THERAPY; IMPACT	Objectives. Spontaneous intracerebral hemorrhage (ICH) is a challenge to both neurologists and neurosurgeons. We aim to summarize the surgical treatment of ICH based on retrospective analysis of our patients. Methods. Two hundred and fifty-three patients with spontaneous ICH from August 2008 to August 2011 were retrospectively analyzed. Clinical data, including preoperative ICH score, pre- and postoperative GCS score, hematoma volume, postoperative brain infarction, 30-day mortality, and GOS 3 months postictus, were collected. One hundred and fifty patients had their intracranial pressure (ICP) monitored, and data were recorded and analyzed. All patients underwent craniotomy and clot removal under general anesthesia. Outcome analysis was stratified using hematoma volume, ICH score, preoperative GCS score, and decompressive craniectomy (DC). Results. The mean hematoma volume was 70.8 mL, and 68 patients (26.9%) underwent DC. The mean postoperative ICP was 28.8 +/- 6.7 mmHg for patients without DC, and only 17.5 +/- 8.6 mmHg for patients with DC. Twenty-five patients (9.9%) died within 30 days of operation, and 88 patients (34.8%, GOS >= 4) had good outcome 3 months after surgery. ICH volume > 50 mL, preoperative GCS score <= 8, and ICH score >= 3 are risk factors for unfavorable outcomes. Conclusions. DC can be used for patients with low preoperative GCS score, and it effectively reduces ICP and 30-day mortality. Hematoma volume, preoperative GCS score, and ICH score are of predictive value for surgical outcome of large basal ganglia hemorrhage.	[Li, Q.; Yang, C. H.; Xu, J. G.; Li, H.; You, C.] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu 610041, Peoples R China	You, C (corresponding author), Sichuan Univ, West China Hosp, Dept Neurosurg, 37 Guoxue Rd, Chengdu 610041, Peoples R China.	chaoy12345@gmail.com			China National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81172411]	This work is supported by grant No. 81172411 from China National Natural Science Foundation. The authors report no declarations of interest. The authors alone are responsible for the content and writing of the paper.	Albert R, 2004, J CLIN NEUROSCI, V11, P259, DOI 10.1016/S0967-5868(03)00154-1; Andaluz N, 2009, J NEUROSURG, V110, P403, DOI 10.3171/2008.5.17559; Arac A, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0958; Ariesen MJ, 2003, STROKE, V34, P2060, DOI 10.1161/01.STR.0000080678.09344.8D; Barlas O, 2009, MINIM INVAS NEUROSUR, V52, P62, DOI 10.1055/s-0028-1104610; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Castellanos M, 2005, J NEUROL NEUROSUR PS, V76, P691, DOI 10.1136/jnnp.2004.044347; Cho DY, 2008, SURG NEUROL, V70, P628, DOI 10.1016/j.surneu.2007.08.006; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Gazzeri R, 2009, J NEUROSURG, V110, P939, DOI 10.3171/2008.8.JNS17642; Hemphill JC, 2009, NEUROLOGY, V73, P1088, DOI 10.1212/WNL.0b013e3181b8b332; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Hoff JT, 2003, ACT NEUR S, V86, P11; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kim KT, 2009, ACTA NEUROCHIR, V151, P21, DOI 10.1007/s00701-008-0164-6; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Kuo JR, 2006, J CLIN NEUROSCI, V13, P218, DOI 10.1016/j.jocn.2005.01.012; Marion DW, 2006, NEUROSURGERY, V58, P655; Mendelow AD, 2005, LANCET, V365, P387; Murthy JMK, 2005, NEUROCRIT CARE, V2, P258, DOI 10.1385/NCC:2:3:258; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Orakcioglu B, 2008, NEUROCRIT CARE, V8, P448, DOI 10.1007/s12028-007-9047-6; Pantazis G, 2006, SURG NEUROL, V66, P492, DOI 10.1016/j.surneu.2006.05.054; Rincon F, 2008, CRIT CARE, V12, DOI 10.1186/cc7092; Schorl M, 2009, CENT EUR NEUROSURG, V70, P68, DOI 10.1055/s-0028-1093355; Siddique MS, 2000, BRIT MED BULL, V56, P444, DOI 10.1258/0007142001903085; Testai FD, 2008, NEUROL CLIN, V26, P963, DOI 10.1016/j.ncl.2008.06.001; Wang WZ, 2009, INT J STROKE, V4, P11, DOI 10.1111/j.1747-4949.2009.00239.x; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005; Zuccarello M, 1999, STROKE, V30, P1833, DOI 10.1161/01.STR.30.9.1833	32	27	29	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	OCT	2013	27	5					617	621		10.3109/02688697.2013.765938			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	216FG	WOS:000324266800012	23406426				2021-06-18	
J	Yin, T; Lindley, TE; Albert, GW; Ahmed, R; Schmeiser, PB; Grady, MS; Howard, MA; Welsh, MJ				Yin, Terry; Lindley, Timothy E.; Albert, Gregory W.; Ahmed, Raheel; Schmeiser, Peter B.; Grady, M. Sean; Howard, Matthew A.; Welsh, Michael J.			Loss of Acid Sensing Ion Channel-1a and Bicarbonate Administration Attenuate the Severity of Traumatic Brain Injury	PLOS ONE			English	Article							SEVERE HEAD-INJURY; NEURONAL DEGENERATION; HIPPOCAMPAL-NEURONS; MYOCARDIAL-ISCHEMIA; ACTIVATED CURRENTS; FLUID PERCUSSION; OXIDATIVE STRESS; LACTIC-ACIDOSIS; CLINICAL-TRIAL; ASICS	Traumatic brain injury (TBI) is a common cause of morbidity and mortality in people of all ages. Following the acute mechanical insult, TBI evolves over the ensuing minutes and days. Understanding the secondary factors that contribute to TBI might suggest therapeutic strategies to reduce the long-term consequences of brain trauma. To assess secondary factors that contribute to TBI, we studied a lateral fluid percussion injury (FPI) model in mice. Following FPI, the brain cortex became acidic, consistent with data from humans following brain trauma. Administering HCO3- after FPI prevented the acidosis and reduced the extent of neurodegeneration. Because acidosis can activate acid sensing ion channels (ASICs), we also studied ASIC1a(-/-) mice and found reduced neurodegeneration after FPI. Both HCO3- administration and loss of ASIC1a also reduced functional deficits caused by FPI. These results suggest that FPI induces cerebral acidosis that activates ASIC channels and contributes to secondary injury in TBI. They also suggest a therapeutic strategy to attenuate the adverse consequences of TBI.	[Yin, Terry; Schmeiser, Peter B.; Welsh, Michael J.] Univ Iowa, Dept Internal Med, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Lindley, Timothy E.; Albert, Gregory W.; Ahmed, Raheel; Howard, Matthew A.; Welsh, Michael J.] Univ Iowa, Dept Neurosurg, Roy J & Lucille A Carver Coll Med, Iowa City, IA USA; [Welsh, Michael J.] Univ Iowa, Howard Hughes Med Inst, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Grady, M. Sean] Univ Penn, Dept Neurosurg, Perelman Sch Med, Philadelphia, PA 19104 USA	Welsh, MJ (corresponding author), Univ Iowa, Dept Internal Med, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA.	michael-welsh@uiowa.edu		Welsh, Michael/0000-0002-1646-6206; Howard, Matthew/0000-0003-3935-8889	Howard Hughes Medical InstituteHoward Hughes Medical Institute	This work was supported by Howard Hughes Medical Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Askwith CC, 2004, J BIOL CHEM, V279, P18296, DOI 10.1074/jbc.M312145200; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Benson CJ, 2002, P NATL ACAD SCI USA, V99, P2338, DOI 10.1073/pnas.032678399; Benson CJ, 2001, ANN NY ACAD SCI, V940, P96; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bourdeaux C, 2010, NEUROCRIT CARE, V13, P24, DOI 10.1007/s12028-010-9368-8; Bourdeaux CP, 2011, NEUROCRIT CARE, V15, P42, DOI 10.1007/s12028-011-9512-0; Buccafusco JJ, 2009, FRONT NEUROSCI, P1; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Carbonell WS, 1999, ANN NY ACAD SCI, V890, P287, DOI 10.1111/j.1749-6632.1999.tb08005.x; Clausen F, 2012, J NEUROTRAUM, V29, P766, DOI 10.1089/neu.2011.1754; Clausen T, 2005, J NEUROSURG, V103, P597, DOI 10.3171/jns.2005.103.4.0597; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; Deval E, 2010, PHARMACOL THERAPEUT, V128, P549, DOI 10.1016/j.pharmthera.2010.08.006; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Friese MA, 2007, NAT MED, V13, P1483, DOI 10.1038/nm1668; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Grunder Stefan, 2010, Int J Physiol Pathophysiol Pharmacol, V2, P73; Gu L, 2010, NEUROSCI LETT, V479, P63, DOI 10.1016/j.neulet.2010.05.029; Gupta AK, 2004, J NEUROTRAUM, V21, P678, DOI 10.1089/0897715041269722; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Harrison FE, 2006, LEARN MEMORY, V13, P809, DOI 10.1101/lm.334306; Ishrat T, 2012, NEUROSCIENCE, V210, P442, DOI 10.1016/j.neuroscience.2012.03.008; Jasti J, 2007, NATURE, V449, P316, DOI 10.1038/nature06163; Joch M, 2007, MOL BIOL CELL, V18, P3105, DOI 10.1091/mbc.E05-11-1027; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Koseki H, 2009, SYNAPSE, V63, P805, DOI 10.1002/syn.20657; KRAIG RP, 1983, J NEUROPHYSIOL, V49, P831; Krajewska M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024341; Lee DJ, 2013, J NEUROTRAUM, V30, P131, DOI 10.1089/neu.2012.2646; Lehmann H, 2012, NEUROBIOL LEARN MEM; Marion DW, 1998, NEUROL CLIN, V16, P485, DOI 10.1016/S0733-8619(05)70073-6; MARMAROU A, 1992, J NEUROTRAUM, V9, pS551; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NEDERGAARD M, 1991, AM J PHYSIOL, V260, pR581; Picloplichko VI, 2006, P NATL ACAD SCI USA, V103, P11376, DOI 10.1073/pnas.0600768103; RABOW L, 1986, J NEUROSURG, V65, P625, DOI 10.3171/jns.1986.65.5.0625; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Robertson CL, 2001, CRIT CARE MED, V29, P2287, DOI 10.1097/00003246-200112000-00009; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; Sarkar S, 2011, FUNDAMENTAL NEUROPATHOLOGY FOR PATHOLOGISTS AND TOXICOLOGISTS: PRINCIPLES AND TECHNIQUES, P171; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Sherwood TW, 2011, J NEUROSCI, V31, P9723, DOI 10.1523/JNEUROSCI.1665-11.2011; Sherwood TW, 2012, AM J PHYSL CELL PHYS; Stiefel MF, 2005, J NEUROSURG, V103, P707, DOI 10.3171/jns.2005.103.4.0707; Sun X, 2011, BRAIN RES, V1396, P77, DOI 10.1016/j.brainres.2011.04.011; Szydlowska K, 2010, CELL CALCIUM, V47, P122, DOI 10.1016/j.ceca.2010.01.003; Tsai YD, 2013, BRAIN INJURY, V27, P361, DOI 10.3109/02699052.2012.750738; Turner RJ, 2004, J AM COLL NUTR, V23, p534S, DOI 10.1080/07315724.2004.10719397; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014; Weng JY, 2010, J NEUROSCI, V30, P6548, DOI 10.1523/JNEUROSCI.0582-10.2010; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; WOLF AL, 1993, J NEUROSURG, V78, P54, DOI 10.3171/jns.1993.78.1.0054; Wong HK, 2008, HUM MOL GENET, V17, P3223, DOI 10.1093/hmg/ddn218; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Xiong ZG, 2008, CURR OPIN PHARMACOL, V8, P25, DOI 10.1016/j.coph.2007.09.001; Yagi J, 2006, CIRC RES, V99, P501, DOI 10.1161/01.RES.0000238388.79295.4c; Yamada KH, 2012, J BIOL CHEM, V287, P13182, DOI 10.1074/jbc.M111.302612; Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P6752, DOI 10.1073/pnas.0308636100; YOSHIDA K, 1991, J NEUROSURG, V74, P87, DOI 10.3171/jns.1991.74.1.0087; Zhang BL, 2011, BRAIN RES, V1382, P165, DOI 10.1016/j.brainres.2011.01.065; Zhao XR, 2008, J NEUROTRAUM, V25, P1195, DOI 10.1089/neu.2008.0635; Zhuang Z, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-47; Ziemann AE, 2008, NAT NEUROSCI, V11, P816, DOI 10.1038/nn.2132; Ziemann AE, 2009, CELL, V139, P1012, DOI 10.1016/j.cell.2009.10.029	80	27	27	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2013	8	8							e72379	10.1371/journal.pone.0072379			7	Multidisciplinary Sciences	Science & Technology - Other Topics	215RU	WOS:000324228800067	23991103	DOAJ Gold, Green Published			2021-06-18	
J	Deleglise, B; Lassus, B; Soubeyre, V; Alleaume-Butaux, A; Hjorth, JJ; Vignes, M; Schneider, B; Brugg, B; Viovy, JL; Peyrin, JM				Deleglise, Berangere; Lassus, Benjamin; Soubeyre, Vaneyssa; Alleaume-Butaux, Aurelie; Hjorth, Johannes J.; Vignes, Maeva; Schneider, Benoit; Brugg, Bernard; Viovy, Jean-Louis; Peyrin, Jean-Michel			Synapto-Protective Drugs Evaluation in Reconstructed Neuronal Network	PLOS ONE			English	Article							LONG-TERM DEPRESSION; NEUROFIBRILLARY PATHOLOGY; WALLERIAN DEGENERATION; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; RHO; NEURODEGENERATION; DYSFUNCTION; KINASE; MICE	Chronic neurodegenerative syndromes such as Alzheimer's and Parkinson's diseases, or acute syndromes such as ischemic stroke or traumatic brain injuries are characterized by early synaptic collapse which precedes axonal and neuronal cell body degeneration and promotes early cognitive impairment in patients. Until now, neuroprotective strategies have failed to impede the progression of neurodegenerative syndromes. Drugs preventing the loss of cell body do not prevent the cognitive decline, probably because they lack synapto-protective effects. The absence of physiologically realistic neuronal network models which can be easily handled has hindered the development of synapto-protective drugs suitable for therapies. Here we describe a new microfluidic platform which makes it possible to study the consequences of axonal trauma of reconstructed oriented mouse neuronal networks. Each neuronal population and sub-compartment can be chemically addressed individually. The somatic, mid axon, presynaptic and postsynaptic effects of local pathological stresses or putative protective molecules can thus be evaluated with the help of this versatile "brain on chip" platform. We show that presynaptic loss is the earliest event observed following axotomy of cortical fibers, before any sign of axonal fragmentation or post-synaptic spine alteration. This platform can be used to screen and evaluate the synapto-protective potential of several drugs. For instance, NAD(+) and the Rho-kinase inhibitor Y27632 can efficiently prevent synaptic disconnection, whereas the broad-spectrum caspase inhibitor zVAD-fmk and the stilbenoid resveratrol do not prevent presynaptic degeneration. Hence, this platform is a promising tool for fundamental research in the field of developmental and neurodegenerative neurosciences, and also offers the opportunity to set up pharmacological screening of axon-protective and synapto-protective drugs.	[Deleglise, Berangere; Lassus, Benjamin; Soubeyre, Vaneyssa; Brugg, Bernard; Peyrin, Jean-Michel] CNRS, UMR7102, Paris, France; [Deleglise, Berangere; Lassus, Benjamin; Soubeyre, Vaneyssa; Brugg, Bernard; Peyrin, Jean-Michel] Univ Paris 06, Paris, France; [Alleaume-Butaux, Aurelie; Schneider, Benoit] INSERM, UMR S 747, Paris, France; [Alleaume-Butaux, Aurelie; Schneider, Benoit] Univ Paris 05, Sorbonne Paris Cite, UMR S 747, Paris, France; [Vignes, Maeva; Viovy, Jean-Louis] Inst Curie, CNRS, UMR168, F-75231 Paris, France; [Hjorth, Johannes J.] Vrije Univ Amsterdam, CNCR, Amsterdam, Netherlands	Peyrin, JM (corresponding author), CNRS, UMR7102, Paris, France.	jean-michel.peyrin@upmc.fr	Schneider, Benoit/AAF-3850-2019; Maeva, VIGNES L/Q-9495-2016; Hjorth, Johannes/A-2043-2009	Maeva, VIGNES L/0000-0002-4768-9648; Hjorth, Johannes/0000-0002-9302-0750; Peyrin, Jean-Michel/0000-0002-8705-8672; Viovy, Jean-Louis/0000-0002-8223-4040; Peyrin, Jean-Michel/0000-0002-0108-1266	French Research National Agency "Agence Nationale de la Recherche"French National Research Agency (ANR); ANR RPIB "Neuroscreen"French National Research Agency (ANR); ANR "PrionsensiTNF"French National Research Agency (ANR); French 'Ministere de la Recherche'Ministry of Research, France	This work was supported by the French Research National Agency "Agence Nationale de la Recherche," ANR RPIB "Neuroscreen" and ANR "PrionsensiTNF." BD was supported by a PhD grant from the French 'Ministere de la Recherche.' The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alafuzoff I, 2008, BRAIN PATHOL, V18, P484, DOI 10.1111/j.1750-3639.2008.00147.x; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Arendt T, 2009, ACTA NEUROPATHOL, V118, P167, DOI 10.1007/s00401-009-0536-x; Beirowski B, 2009, J NEUROSCI, V29, P653, DOI 10.1523/JNEUROSCI.3814-08.2009; Bishop NA, 2010, NATURE, V464, P529, DOI 10.1038/nature08983; Braak H, 2004, CELL TISSUE RES, V318, P121, DOI 10.1007/s00441-004-0956-9; Braak H, 2006, ACTA NEUROPATHOL, V112, P389, DOI 10.1007/s00401-006-0127-z; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Dasgupta B, 2007, P NATL ACAD SCI USA, V104, P7217, DOI 10.1073/pnas.0610068104; Duyckaerts C, 2009, ACTA NEUROPATHOL, V118, P5, DOI 10.1007/s00401-009-0532-1; Fainzilber M, 2006, NEURON, V50, P819, DOI 10.1016/j.neuron.2006.05.023; Finn JT, 2000, J NEUROSCI, V20, P1333; Garland P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047552; Gillingwater TH, 2003, J ANAT, V203, P265, DOI 10.1046/j.1469-7580.2003.00214.x; Gillingwater TH, 2001, J PHYSIOL-LONDON, V534, P627, DOI 10.1111/j.1469-7793.2001.00627.x; Gillingwater TH, 2006, BRAIN, V129, P1546, DOI 10.1093/brain/awl101; Gonzalez-Forero D, 2012, J NEUROSCI, V32, P68, DOI 10.1523/JNEUROSCI.3215-11.2012; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Jagust W, 2013, NEURON, V77, P219, DOI 10.1016/j.neuron.2013.01.002; Jiao S, 2011, NEURON, V70, P758, DOI 10.1016/j.neuron.2011.04.004; Kilinc D, 2011, NEUROTOX RES, V19, P149, DOI 10.1007/s12640-010-9152-8; Li Z, 2010, CELL, V141, P859, DOI 10.1016/j.cell.2010.03.053; Marcello E, 2012, ADV EXP MED BIOL, V970, P573, DOI 10.1007/978-3-7091-0932-8_25; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Millet Larry J., 2012, Yale Journal of Biology and Medicine, V85, P501; Millet LJ, 2012, TRENDS NEUROSCI; Peyrin JM, 2011, LAB CHIP, V11, P3663, DOI 10.1039/c1lc20014c; Picconi B, 2012, ADV EXP MED BIOL, V970, P553, DOI 10.1007/978-3-7091-0932-8_24; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Raj A, 2012, NEURON, V73, P1204, DOI 10.1016/j.neuron.2011.12.040; Schmandke A, 2007, NEUROSCIENTIST, V13, P454, DOI 10.1177/1073858407303611; Schmitz SK, 2011, J NEUROSCI METH, V195, P185, DOI 10.1016/j.jneumeth.2010.12.011; Seeley WW, 2009, NEURON, V62, P42, DOI 10.1016/j.neuron.2009.03.024; Taylor AM, 2005, NAT METHODS, V2, P599, DOI 10.1038/NMETH777; Taylor AM, 2010, NEURON, V66, P57, DOI 10.1016/j.neuron.2010.03.022; Timofeev I, 2010, NEUROSCIENTIST, V16, P19, DOI 10.1177/1073858409333545; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; To KCW, 2008, NEUROSCIENCE, V153, P645, DOI 10.1016/j.neuroscience.2008.02.043; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; WATSON DF, 1993, J NEUROSCI, V13, P4354; Whitmore AV, 2003, CELL DEATH DIFFER, V10, P260, DOI 10.1038/sj.cdd.4401147; Wishart TM, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002936; Yin DM, 2012, ADV EXP MED BIOL, V970, P493, DOI 10.1007/978-3-7091-0932-8_22; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	44	27	27	0	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2013	8	8							e71103	10.1371/journal.pone.0071103			9	Multidisciplinary Sciences	Science & Technology - Other Topics	207BA	WOS:000323570200027	23976987	DOAJ Gold, Green Published			2021-06-18	
J	Kim, J; Yang, M; Kim, SH; Kim, JC; Wang, HB; Shin, T; Moon, C				Kim, Juhwan; Yang, Miyoung; Kim, Sung-Ho; Kim, Jong-Choon; Wang, Hongbing; Shin, Taekyun; Moon, Changjong			Possible Role of the Glycogen Synthase Kinase-3 Signaling Pathway in Trimethyltin-Induced Hippocampal Neurodegeneration in Mice	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; DENTATE GRANULE CELLS; NEUROTOXICITY IN-VIVO; PROTEIN-KINASE; NEURONAL DEGENERATION; RAT HIPPOCAMPUS; POTENTIAL ROLE; BETA-CATENIN; LITHIUM; ACTIVATION	Trimethyltin (TMT) is an organotin compound with potent neurotoxic effects characterized by neuronal destruction in selective regions, including the hippocampus. Glycogen synthase kinase-3 (GSK-3) regulates many cellular processes, and is implicated in several neurodegenerative disorders. In this study, we evaluated the therapeutic effect of lithium, a selective GSK-3 inhibitor, on the hippocampus of adult C57BL/6 mice with TMT treatment (2.6 mg/kg, intraperitoneal [i.p.]) and on cultured hippocampal neurons (12 days in vitro) with TMT treatment (5 mM). Lithium (50 mg/kg, i.p., 0 and 24 h after TMT injection) significantly attenuated TMT-induced hippocampal cell degeneration, seizure, and memory deficits in mice. In cultured hippocampal neurons, lithium treatment (0-10 mM; 1 h before TMT application) significantly reduced TMT-induced cytotoxicity in a dose-dependent manner. Additionally, the dynamic changes in GSK-3/beta-catenin signaling were observed in the mouse hippocampus and cultured hippocampal neurons after TMT treatment with or without lithium. Therefore, lithium inhibited the detrimental effects of TMT on the hippocampal neurons in vivo and in vitro, suggesting involvement of the GSK-3/beta-catenin signaling pathway in TMT-induced hippocampal cell degeneration and dysfunction.	[Kim, Juhwan; Yang, Miyoung; Kim, Sung-Ho; Kim, Jong-Choon; Moon, Changjong] Chonnam Natl Univ, Coll Vet Med, Dept Vet Anat, Kwangju, South Korea; [Kim, Juhwan; Yang, Miyoung; Kim, Sung-Ho; Kim, Jong-Choon; Moon, Changjong] Chonnam Natl Univ, Coll Vet Med, Dept Vet Toxicol, Kwangju, South Korea; [Kim, Juhwan; Yang, Miyoung; Kim, Sung-Ho; Kim, Jong-Choon; Moon, Changjong] Chonnam Natl Univ, Anim Med Inst, Kwangju, South Korea; [Yang, Miyoung; Wang, Hongbing] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; [Yang, Miyoung; Wang, Hongbing] Michigan State Univ, Neurosci Program, E Lansing, MI 48824 USA; [Shin, Taekyun] Jeju Natl Univ, Coll Vet Med, Dept Vet Anat, Cheju, South Korea	Shin, T (corresponding author), Jeju Natl Univ, Coll Vet Med, Dept Vet Anat, Cheju, South Korea.	shint@jejunu.ac.kr; moonc@chonnam.ac.kr	Moon, Changjong/AAI-2005-2020	Moon, Changjong/0000-0003-2451-0374; SHIN, Taekyun/0000-0002-9851-4354	Basic Science Research Program through the National Research Foundation of Korea (NRF); Ministry of Education, Science and TechnologyMinistry of Education, Science and Technology, Republic of Korea [2012R1A1B4001262]	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012R1A1B4001262). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alvarez G, 1999, FEBS LETT, V453, P260, DOI 10.1016/S0014-5793(99)00685-7; Avila J, 2010, EXPERT REV NEUROTHER, V10, P703, DOI [10.1586/ern.10.40, 10.1586/ERN.10.40]; Bahremand A, 2011, EUR J PHARMACOL, V666, P93, DOI 10.1016/j.ejphar.2011.05.043; BESSER R, 1987, NEUROLOGY, V37, P945, DOI 10.1212/WNL.37.6.945; Bian QM, 2007, BRAIN RES, V1184, P270, DOI 10.1016/j.brainres.2007.09.054; Casalbore P, 2010, J CELL PHYSIOL, V224, P710, DOI 10.1002/jcp.22170; Chang L W, 1990, J Toxicol Sci, V15 Suppl 4, P125; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Chong ZZ, 2004, HISTOL HISTOPATHOL, V19, P495, DOI 10.14670/HH-19.495; Chuang DM, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00015; Crespo-Biel N, 2010, BIPOLAR DISORD, V12, P425, DOI 10.1111/j.1399-5618.2010.00825.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; De Sarno P, 2002, NEUROPHARMACOLOGY, V43, P1158, DOI 10.1016/S0028-3908(02)00215-0; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; EARLEY B, 1992, NEUROCHEM INT, V21, P351, DOI 10.1016/0197-0186(92)90186-U; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; Emamian ES, 2004, NAT GENET, V36, P131, DOI 10.1038/ng1296; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; Eom TY, 2009, BIOL PSYCHIAT, V66, P494, DOI 10.1016/j.biopsych.2009.04.015; Fabrizi C, 2012, J NEURAL TRANSM, V119, P1295, DOI 10.1007/s00702-012-0785-z; FELDMAN RG, 1993, ARCH NEUROL-CHICAGO, V50, P1320, DOI 10.1001/archneur.1993.00540120035010; Fiedorowicz A, 2001, BRAIN RES, V912, P116, DOI 10.1016/S0006-8993(01)02675-0; Fiorentini A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014382; Geloso MC, 2011, NEUROCHEM INT, V58, P729, DOI 10.1016/j.neuint.2011.03.009; Ghasemi M, 2010, EPILEPSY BEHAV, V18, P171, DOI 10.1016/j.yebeh.2010.04.002; Gold AB, 2011, CURR DRUG TARGETS, V12, P243; Goodenough S, 2004, BRAIN RES, V1026, P116, DOI 10.1016/j.brainres.2004.08.021; Harry GJ, 2008, BRAIN RES, V1194, P8, DOI 10.1016/j.brainres.2007.11.076; Harry GJ, 2002, TOXICOL APPL PHARM, V180, P205, DOI 10.1006/taap.2002.9390; Tran HYP, 2012, FREE RADICAL BIO MED, V52, P1159, DOI 10.1016/j.freeradbiomed.2011.12.008; Jope RS, 2006, CURR DRUG TARGETS, V7, P1421, DOI 10.2174/1389450110607011421; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Jope RS, 2003, TRENDS PHARMACOL SCI, V24, P441, DOI 10.1016/S0165-6147(03)00206-2; Jope RS, 2002, MOL PSYCHIATR, V7, pS35, DOI 10.1038/sj.mp.4001017; Kaidanovich-Beilin O, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00040; Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1; Kim JS, 2008, J RADIAT RES, V49, P517, DOI 10.1269/jrr.08020; Kuramoto N, 2011, J NEUROSCI RES, V89, P552, DOI 10.1002/jnr.22588; Lai JS, 2006, EUR J PHARMACOL, V539, P18, DOI 10.1016/j.ejphar.2006.03.076; Leng Y, 2008, J NEUROSCI, V28, P2576, DOI 10.1523/JNEUROSCI.5467-07.2008; Little AR, 2012, NEUROTOXICOL TERATOL, V34, P72, DOI 10.1016/j.ntt.2011.09.012; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Mora A, 2001, J NEUROCHEM, V78, P199, DOI 10.1046/j.1471-4159.2001.00410.x; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Ogita K, 2004, NEUROPHARMACOLOGY, V47, P619, DOI 10.1016/j.neuropharm.2004.06.012; Perez-Costas E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008911; Ponce-Lopez T, 2011, BRAIN RES, V1426, P73, DOI 10.1016/j.brainres.2011.09.056; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Sereno L, 2009, NEUROBIOL DIS, V35, P359, DOI 10.1016/j.nbd.2009.05.025; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Shin EJ, 2005, NEUROSCIENCE, V133, P715, DOI 10.1016/j.neuroscience.2005.02.030; Shirakawa T, 2007, NEUROSCI RES, V59, P117, DOI 10.1016/j.neures.2007.06.1468; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Takashima A, 1996, NEUROSCI LETT, V203, P33, DOI 10.1016/0304-3940(95)12257-5; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Wang Z, 2012, NEUROSCIENCE, V206, P190, DOI 10.1016/j.neuroscience.2011.12.043; Wine RN, 2009, NEUROTOX RES, V16, P280, DOI 10.1007/s12640-009-9060-y; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yan XB, 2007, BEHAV BRAIN RES, V177, P282, DOI 10.1016/j.bbr.2006.11.021; Yang M, 2012, NEUROCHEM INT, V61, P955, DOI 10.1016/j.neuint.2012.09.015; Yang M, 2011, BIOCHEM PHARMACOL, V82, P72, DOI 10.1016/j.bcp.2011.03.020; Yang M, 2010, NEUROBIOL LEARN MEM, V93, P487, DOI 10.1016/j.nlm.2010.01.006; Yao HB, 2002, J CHEM NEUROANAT, V23, P291, DOI 10.1016/S0891-0618(02)00014-5; Yoneyama M, 2008, NEUROCHEM INT, V52, P761, DOI 10.1016/j.neuint.2007.09.003; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zhang M, 2008, J NEUROSCI, V28, P4736, DOI 10.1523/JNEUROSCI.1177-08.2008	73	27	27	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2013	8	8							e70356	10.1371/journal.pone.0070356			11	Multidisciplinary Sciences	Science & Technology - Other Topics	218XC	WOS:000324465000061	23940567	DOAJ Gold, Green Published			2021-06-18	
J	Cross, DJ; Anzai, Y; Petrie, EC; Martin, N; Richards, TL; Maravilla, KR; Peskind, ER; Minoshima, S				Cross, Donna J.; Anzai, Yoshimi; Petrie, Eric C.; Martin, Nathalie; Richards, Todd L.; Maravilla, Kenneth R.; Peskind, Elaine R.; Minoshima, Satoshi			Loss of Olfactory Tract Integrity Affects Cortical Metabolism in the Brain and Olfactory Regions in Aging and Mild Cognitive Impairment	JOURNAL OF NUCLEAR MEDICINE			English	Article						olfactory tract; Alzheimer's disease; fiber tract integrity; glucose metabolism; F-18-FDG PET; DTI	TRAUMATIC AXONAL INJURY; ALZHEIMERS-DISEASE; TAU PATHOLOGY; IN-VIVO; DYSFUNCTION; MRI; EPSILON-4; BULB; PET	Olfactory dysfunction is an early feature of Alzheimer disease. This study used multimodal imaging of PET and F-18-FDG combined with diffusion tensor imaging (DTI) to investigate the association of fiber tract integrity in the olfactory tract with cortical glucose metabolism in subjects with mild cognitive impairment (MCI) and normal controls. We hypothesized that MCI subjects would show loss of olfactory tract integrity and may have altered associations with glucose metabolism. Methods: Subjects diagnosed with amnestic MCI (n = 12) and normal controls (n = 23) received standard brain F-18-FDG PET and DTI with 32 gradient directions on a 3-T MR imaging scanner. Fractional anisotropy (FA) maps were generated. Voxelwise correlation analysis of olfactory tract FA values with F-18-FDG PET images was performed. Results: Integrated analysis over all subjects indicated a positive correlation between white matter integrity in the olfactory tract and metabolic activity in olfactory processing structures, including the rostral prefrontal cortex, dorsomedial thalamus, hypothalamus, orbitofrontal cortex, and uncus, and in the superior temporal gyrus, insula, and anterior cingulate cortex. Subjects with MCI, compared with normal controls, showed differential associations of olfactory tract integrity with medial temporal lobe and posterior cortical structures. Conclusion: These findings indicate that impairment of axonal integrity or neuronal loss may be linked to functional metabolic changes and that disease-specific neurodegeneration may affect this relationship. Multimodal imaging using F-18-FDG PET and DTI may provide better insights into aging and neurodegenerative processes.	[Cross, Donna J.; Anzai, Yoshimi; Petrie, Eric C.; Martin, Nathalie; Richards, Todd L.; Maravilla, Kenneth R.; Minoshima, Satoshi] Univ Washington, Dept Radiol, Seattle, WA 98195 USA; [Petrie, Eric C.; Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Petrie, Eric C.; Peskind, Elaine R.] MIRECC, VA Puget Sound, Seattle, WA USA	Cross, DJ (corresponding author), Univ Washington, Dept Radiol, 1959 NE Pacific St,Box 357115, Seattle, WA 98195 USA.	dcross@uw.edu	Anzai, Yoshimi/AAK-8428-2021	Anzai, Yoshimi/0000-0003-2988-7445; Petrie, Eric/0000-0003-1188-6321; Minoshima, Satoshi/0000-0002-0043-3047; Cross, Donna/0000-0003-1918-2214	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS045254]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005136]; VA Puget Sound Mental Illness Research, Education and Clinical Center (MIRECC); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005136] Funding Source: NIH RePORTER	The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. This study was supported by NIH R01 NS045254, NIA grant P50AG005136, and the VA Puget Sound Mental Illness Research, Education and Clinical Center (MIRECC). No other potential conflict of interest relevant to this article was reported.	Albers MW, 2006, CURR NEUROL NEUROSCI, V6, P379, DOI 10.1007/s11910-996-0018-7; Attems J, 2006, CLIN NEUROPATHOL, V25, P265; Bahar-Fuchs A, 2010, J ALZHEIMERS DIS, V22, P1081, DOI 10.3233/JAD-2010-100696; Bohnen NI, 2012, J NUCL MED, V53, P59, DOI 10.2967/jnumed.111.096578; Chen TF, 2009, PSYCHIAT RES-NEUROIM, V173, P15, DOI 10.1016/j.pscychresns.2008.09.002; Christen-Zaech S, 2003, CAN J NEUROL SCI, V30, P20, DOI 10.1017/S0317167100002389; Cross DJ, 2008, NEUROIMAGE, V39, P915, DOI 10.1016/j.neuroimage.2007.08.036; Duda JE, 2010, J NEUROL SCI, V289, P49, DOI 10.1016/j.jns.2009.08.042; HYMAN BT, 1991, ANN NY ACAD SCI, V640, P14; KANDEL ER, 1991, PRINCIPLES NEURAL SC; Kovacs T, 2004, AGEING RES REV, V3, P215, DOI 10.1016/j.arr.2003.10.003; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Magistretti PJ, 1996, CEREB CORTEX, V6, P50, DOI 10.1093/cercor/6.1.50; Minoshima S, 1999, ANN NY ACAD SCI, V893, P350, DOI 10.1111/j.1749-6632.1999.tb07852.x; MINOSHIMA S, 1994, LANCET, V344, P895, DOI 10.1016/S0140-6736(94)92871-1; Minoshima S, 1998, QUANTITATIVE FUNCTIONAL BRAIN IMAGING WITH POSITRON EMISSION TOMOGRAPHY, P133, DOI 10.1016/B978-012161340-2/50020-2; MINOSHIMA S, 1994, J NUCL MED, V35, P1528; Minoshima S, 2008, EUR J NUCL MED MOL I, V35, pS89, DOI 10.1007/s00259-007-0707-8; Mosconi L, 2007, EXP GERONTOL, V42, P129, DOI 10.1016/j.exger.2006.05.016; Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985; Reiman EM, 1996, NEW ENGL J MED, V334, P752, DOI 10.1056/NEJM199603213341202; Ross GW, 2006, MOVEMENT DISORD, V21, P2062, DOI 10.1002/mds.21076; Scherfler C, 2006, BRAIN, V129, P538, DOI 10.1093/brain/awh674; Talairach J., 1988, COPLANAR STEREOTAXIC; Thomann PA, 2009, J ALZHEIMERS DIS, V17, P213, DOI 10.3233/JAD-2009-1036; Tsuboi Y, 2003, NEUROPATH APPL NEURO, V29, P503, DOI 10.1046/j.1365-2990.2003.00453.x; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Westin CF, 2002, MED IMAGE ANAL, V6, P93, DOI 10.1016/S1361-8415(02)00053-1; Worsley K.J., 1996, QUANTIFICATION BRAIN, P327; Zhang Y, 2007, NEUROLOGY, V68, P13, DOI 10.1212/01.wnl.0000250326.77323.01	31	27	28	1	6	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	AUG	2013	54	8					1278	1284		10.2967/jnumed.112.116558			7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	195HH	WOS:000322692400035	23804325	Bronze, Green Accepted			2021-06-18	
J	Theadom, A; Mahon, S; Barker-Collo, S; McPherson, K; Rush, E; Vandal, AC; Feigin, VL				Theadom, A.; Mahon, S.; Barker-Collo, S.; McPherson, K.; Rush, E.; Vandal, A. C.; Feigin, V. L.			Enzogenol for cognitive functioning in traumatic brain injury: a pilot placebo-controlled RCT	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						brain injury; neurological disorders; randomized clinical trial; rehabilitation; trauma	INTRACEREBRAL INFLAMMATORY RESPONSE; HEAD-INJURY; DIETARY SUPPLEMENTATION; FLAVONOID EXTRACT; OXIDATIVE STRESS; HOSPITAL ANXIETY; BARK EXTRACT; VITAMIN-C; PINE BARK; MILD	Background and purpose: Enzogenol, a flavonoid-rich extract from Pinus radiata bark with antioxidant and anti-inflammatory properties has been shown to improve working memory in healthy adults. In traumatic brain injury (TBI), oxidation and inflammation have been linked to poorer cognitive outcomes. Hence, this phase II, randomized controlled trial investigated safety, compliance and efficacy of Enzogenol for improving cognitive functioning in people following mild TBI. Methods: Sixty adults, who sustained a mild TBI, 3-12 months prior to recruitment, and who were experiencing persistent cognitive difficulties [Cognitive Failures Questionnaire (CFQ) score > 38], were randomized to receive Enzogenol (1000 mg/day) or matching placebo for 6 weeks. Subsequently, all participants received Enzogenol for a further 6 weeks, followed by placebo for 4 weeks. Compliance, side-effects, cognitive failures, working and episodic memory, post-concussive symptoms and mood were assessed at baseline, 6, 12 and 16 weeks. Simultaneous estimation of treatment effect and breakpoint was effected, with confidence intervals (CIs) obtained through a treatment-placebo balance-preserving bootstrap procedure. Results: Enzogenol was found to be safe and well tolerated. Trend and breakpoint analyses showed a significant reduction in cognitive failures after 6 weeks [mean CFQ score, 95% CI, Enzogenol versus placebo -6.9 (-10.8 to -4.1)]. Improvements in the frequency of self-reported cognitive failures were estimated to continue until week 11 before stabilizing. Other outcome measures showed some positive trends but no significant treatment effects. Conclusions: Enzogenol supplementation is safe and well tolerated in people after mild TBI, and may improve cognitive functioning in this patient population. This study provides Class IIB evidence that Enzogenol is well tolerated and may reduce self-perceived cognitive failures in patients 3-12 months post-mild TBI.	[Theadom, A.; Mahon, S.; Feigin, V. L.] AUT Univ, Sch Rehabil & Occupat Studies, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Theadom, A.; McPherson, K.] AUT Univ, Sch Rehabil & Occupat Studies, Person Ctr Res Ctr, Auckland, New Zealand; [Barker-Collo, S.] Univ Auckland, Dept Psychol, Auckland, New Zealand; [Rush, E.] AUT Univ, Ctr Phys Act & Nutr, Auckland, New Zealand; [Vandal, A. C.] AUT Univ, Fac Hlth & Environm Sci, Auckland, New Zealand; [Vandal, A. C.] Ctr Clin Res & Effect Practice, Auckland, New Zealand	Feigin, VL (corresponding author), AUT Univ, Natl Inst Stroke & Appl Neurosci, Fac Hlth & Environm Studies, Sch Rehabil & Occupat Studies,Sch Publ Hlth & Psy, AUT North Shore Campus,AA254,90 Akoranga Dr,North, Auckland 1142, New Zealand.	valery.feigin@aut.ac.nz	Rush, Elaine/AAQ-9992-2021; Feigin, Valery/AAF-2313-2019	Rush, Elaine/0000-0001-7713-6203; Theadom, Alice/0000-0003-0351-6216; McPherson, Kath/0000-0003-0487-8497; McPherson, Kathryn/0000-0003-1240-8882; Feigin, Valery L./0000-0002-6372-1740	ENZO Nutraceuticals; ABI Rehabilitation Management Ltd; University of Auckland; AUT University	The authors would like to acknowledge the financial support of ENZO Nutraceuticals and thank them for their assistance in providing the capsules for the study. The study was partially funded by ENZO Nutraceuticals who manufacture the Enzogenol supplement. The study was designed and conducted independently by the research team, and the funder did not influence the design of the study or analysis of its findings. The authors would also like to thank the participants for their time and interest in taking part in this study, and the service providers (ABI Rehabilitation Management and Integrated Partners in Health) for their support with patient recruitment and discussion around the implications of the study findings. The lead author (A.T.) was co-funded by ABI Rehabilitation Management Ltd, and the co-author (K.M.) is the Laura Fergusson Trust Chair. S.B.-C. was funded by the University of Auckland; E.R., A.C.V. and V.L.F. were funded by the AUT University.	Altman DG, 2005, BRIT MED J, V330, P843, DOI 10.1136/bmj.330.7495.843; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P32, DOI 10.1159/000170090; Bejot Y, 2008, J NEUROL NEUROSUR PS, V79, P1344, DOI 10.1136/jnnp.2008.150318; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P15, DOI 10.1080/16501960410023688; Chayasirisobhon S, 2006, HEADACHE, V46, P788, DOI 10.1111/j.1526-4610.2006.00454.x; Clausen F, 2012, J NEUROTRAUM, V29, P766, DOI 10.1089/neu.2011.1754; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Delis DC, 1987, CALIFORNIA VERBAL LE; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Frevel MAE, 2012, FOOD CHEM TOXICOL, V50, P4316, DOI 10.1016/j.fct.2012.08.051; Gallop R. J., 2011, J DATA SCI, V9, P221; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gilworth G, 2008, J REHABIL MED, V40, P334, DOI 10.2340/16501977-0169; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Hou ZG, 2012, BRAIN RES BULL, V88, P560, DOI 10.1016/j.brainresbull.2012.06.006; Janssen I, 2000, J APPL PHYSIOL, V89, P465; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Pinheiro J, 2011, NLME LINEAR NONLINEA, V3, P1, DOI DOI 10.1371/J0URNAL.P0NE.0018860; Pipingas A, 2008, PHYTOTHER RES, V22, P1168, DOI 10.1002/ptr.2388; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; R Development Core Team, 2011, R LANG ENV STAT COMP; Rigg JL, 2005, J HEAD TRAUMA REHAB, V20, P389, DOI 10.1097/00001199-200507000-00010; Savige G. S., 1997, CURRENT THERAPEUTICS, P57; Senthilmohan ST, 2003, NUTR RES, V23, P1199, DOI 10.1016/S0271-5317(03)00127-1; Shand B, 2003, PHYTOTHER RES, V17, P490, DOI 10.1002/ptr.1181; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Spencer JPE, 2010, P NUTR SOC, V69, P244, DOI 10.1017/S0029665110000054; TEASDALE G, 1974, LANCET, V2, P81; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wallace JC, 2002, J GEN PSYCHOL, V129, P238, DOI 10.1080/00221300209602098; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Wood JE, 2002, FOOD CHEM, V77, P155, DOI 10.1016/S0308-8146(01)00329-6; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Young JM, 2006, FREE RADICAL RES, V40, P85, DOI 10.1080/10715760500329788; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	45	27	27	0	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	AUG	2013	20	8					1135	1144		10.1111/ene.12099			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	176UM	WOS:000321331100010	23384428				2021-06-18	
J	Silva, LFA; Hoffmann, MS; Gerbatin, RD; Fiorin, FD; Dobrachinski, F; Mota, BC; Wouters, ATB; Pavarini, SP; Soares, FAA; Fighera, MR; Royes, LFF				Almeida Silva, Luiz Fernando; Hoffmann, Mauricio Scopel; Gerbatin, Rogerio da Rosa; Fiorin, Fernando da Silva; Dobrachinski, Fernando; Mota, Bibiana Castagna; Barth Wouters, Angelica Terezinha; Pavarini, Saulo Petinatti; Antunes Soares, Felix Alexandre; Fighera, Michele Rechia; Freire Royes, Luiz Fernando			Treadmill Exercise Protects Against Pentylenetetrazol-Induced Seizures and Oxidative Stress after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						EEG; epilepsy; oxidative stress; post-traumatic seizure	VOLUNTARY EXERCISE; NA+,K+-ATPASE ACTIVITY; KINDLING DEVELOPMENT; CORTICAL CONTUSION; ADAPTIVE RESPONSES; LIPID-PEROXIDATION; CEREBRAL-CORTEX; TIME-COURSE; RAT-BRAIN; EPILEPSY	Traumatic brain injury (TBI) is a major cause of acquired epilepsy, and significant resources are required to develop a better understanding of the pathologic mechanism as targets for potential therapies. Thus, we decided to investigate whether physical exercise after fluid percussion injury (FPI) protects from oxidative and neurochemical alterations as well as from behavioral electroencephalographic (EEG) seizures induced by subeffective convulsive doses of pentylenetetrazol (PTZ; 35 mg/kg). Behavioral and EEG recordings revealed that treadmill physical training increased latency to first clonic and tonic-clonic seizures, attenuated the duration of generalized seizures, and protected against the increase of PTZ-induced Racine scale 5 weeks after neuronal injury. EEG recordings also revealed that physical exercise prevented PTZ-induced amplitude increase in TBI animals. Neurochemical analysis showed that exercise training increased glutathione/oxidized glutathione ratio and glutathione levels per se. Exercise training was also effective against alterations in the redox status, herein characterized by lipid peroxidation (thiobarbituric acid reactive substances), protein carbonyl increase, as well as the inhibition of superoxide dismutase and Na+, K+-ATPase activities after FPI. On the other hand, histologic analysis with hematoxylin and eosin revealed that FPI induced moderate neuronal damage in cerebral cortex 4 weeks after injury and that physical exercise did not protect against neuronal injury. These data suggest that the ability of physical exercise to reduce FPI-induced seizures is not related to its protection against neuronal damage; however, the effective protection of selected targets, such as Na+/K+-ATPase elicited by physical exercise, may represent a new line of treatment for post-traumatic seizure susceptibility.	[Almeida Silva, Luiz Fernando; Fiorin, Fernando da Silva; Dobrachinski, Fernando; Antunes Soares, Felix Alexandre; Fighera, Michele Rechia; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Dept Quim, Programa Posgrad Ciencias Biol Bioqim Toxicol, BR-97105900 Santa Maria, RS, Brazil; [Hoffmann, Mauricio Scopel; Fighera, Michele Rechia; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Ctr Ciencias Saude, Programa Posgrad Frmacol, BR-97105900 Santa Maria, RS, Brazil; [Gerbatin, Rogerio da Rosa; Fiorin, Fernando da Silva; Fighera, Michele Rechia; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Lab Bioquim Exerci, Ctr Educ Fis & Desportos, Programa Posgrad Educ Fis, BR-97105900 Santa Maria, RS, Brazil; [Barth Wouters, Angelica Terezinha; Pavarini, Saulo Petinatti] Univ Fed Rio Grande do Sul, Setor Patol Vet, Fac Vet, Porto Alegre, RS, Brazil	Royes, LFF (corresponding author), Univ Fed Santa Maria, Dept Metodos & Cnicas Desport, Ctr Educ Fis & Desportos, Ave Roraima 1000, BR-97105900 Santa Maria, RS, Brazil.	nandoroyes@yahoo.com.br	Hoffmann, Mauricio/AAM-9899-2020; royes, luiz/T-3581-2019; da Silva Fiorin, Fernando/AAQ-9472-2021; Soares, Felix AA/K-7611-2012; Dobrachinski, Fernando/C-4316-2014; Soares, Felix/AAE-6251-2020; Fighera, Michele R/J-9576-2014	Hoffmann, Mauricio/0000-0003-4232-3169; Soares, Felix AA/0000-0002-6453-7902; Dobrachinski, Fernando/0000-0002-3948-1273; Soares, Felix/0000-0002-6453-7902; royes, luiz/0000-0003-4045-4827; da Silva Fiorin, Fernando/0000-0002-6517-7160; Almeida Silva, Luiz Fernando/0000-0002-7621-4836	FAPERGS/CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Amparo a Ciencia e Tecnologia do Estado do Rio Grande do Sul (FAPERGS) [Pronem: 11/2082-4]	The authors thank Dr. Guilherme Bresciani, Dr. Leandro Rodrigo Ribeiro, Iuri Domingues Della-Pace, and Guilherme Busanello for sharing their expertise and knowledge to contribute to this study. This work was supported by FAPERGS/CNPq (grants: Pronem: 11/2082-4).	Silva LFA, 2011, J NEUROL SCI, V308, P35, DOI 10.1016/j.jns.2011.06.030; Ames A, 2000, BRAIN RES REV, V34, P42, DOI 10.1016/S0165-0173(00)00038-2; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Archer T, 2012, NEUROTOX RES, V21, P418, DOI 10.1007/s12640-011-9297-0; Arida RM, 2007, PHYSIOL BEHAV, V90, P629, DOI 10.1016/j.physbeh.2006.11.016; Arida RM, 1999, EPILEPSY RES, V34, P99, DOI 10.1016/S0920-1211(98)00092-8; Arida RM, 1998, EPILEPSY RES, V30, P127, DOI 10.1016/S0920-1211(97)00102-2; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Bao YH, 2011, J NEUROTRAUM, V28, P35, DOI 10.1089/neu.2010.1383; Boveris A, 2008, FREE RADICAL BIO MED, V44, P224, DOI 10.1016/j.freeradbiomed.2007.08.015; Clausen F, 2012, J NEUROTRAUM, V29, P766, DOI 10.1089/neu.2011.1754; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; DeKosky ST, 2004, J NEUROTRAUM, V21, P491, DOI 10.1089/089771504774129838; DISHMAN RK, 1988, PHYSIOL BEHAV, V43, P541, DOI 10.1016/0031-9384(88)90206-5; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Frantseva MV, 2000, NEUROSCIENCE, V97, P431, DOI 10.1016/S0306-4522(00)00041-5; Gluck MR, 2000, EPILEPSY RES, V39, P63, DOI 10.1016/S0920-1211(99)00111-4; GOLDSTEIN LH, 1990, BRIT J CLIN PSYCHOL, V29, P257, DOI 10.1111/j.2044-8260.1990.tb00884.x; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach G.S., 2011, AM ACAD PHYS MED REH, V3, P564; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Gupta A, 2003, BRAIN INJURY, V17, P161, DOI 10.1080/0269905021000010195; Gupta YK, 2003, PHARMACOL BIOCHEM BE, V74, P579, DOI 10.1016/S0091-3057(02)01044-4; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; Jensen FE, 2009, J PEDIATR NEUROL, V7, P5, DOI 10.3233/JPN-2009-0270; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Lima FD, 2008, BEHAV BRAIN RES, V193, P306, DOI 10.1016/j.bbr.2008.05.013; Lima FD, 2009, BRAIN RES, V1279, P147, DOI 10.1016/j.brainres.2009.04.052; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; McColl CD, 2003, NEUROPHARMACOLOGY, V44, P234, DOI 10.1016/S0028-3908(02)00369-6; MISRA HP, 1972, J BIOL CHEM, V247, P6960; Mota BC, 2012, NEUROTOX RES, V21, P175, DOI 10.1007/s12640-011-9257-8; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Oliveira MS, 2004, NEUROSCIENCE, V128, P721, DOI 10.1016/j.neuroscience.2004.07.012; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Packer L, 2007, FREE RADICAL RES, V41, P951, DOI 10.1080/10715760701490975; Patsoukis N, 2004, EPILEPSY RES, V62, P65, DOI 10.1016/j.eplepsyres.2004.08.005; Pitkanen A, 2009, EPILEPSY BEHAV, V14, P16, DOI 10.1016/j.yebeh.2008.09.023; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Rauca C, 1999, BRAIN RES, V847, P347, DOI 10.1016/S0006-8993(99)02084-3; RIOS C, 1991, NEUROCHEM RES, V16, P1139, DOI 10.1007/BF00966592; Sachdev S, 2008, FREE RADICAL BIO MED, V44, P215, DOI 10.1016/j.freeradbiomed.2007.07.019; Seo TB, 2010, NEUROSCI LETT, V481, P178, DOI 10.1016/j.neulet.2010.06.087; Setkowicz Z, 2006, EPILEPSY RES, V71, P142, DOI 10.1016/j.eplepsyres.2006.06.002; Soustiel JF, 2008, NEUROPATH APPL NEURO, V34, P412, DOI 10.1111/j.1365-2990.2007.00906.x; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; WILLMORE LJ, 1984, EXP NEUROL, V83, P62, DOI 10.1016/0014-4886(84)90046-3; WILLMORE LJ, 1980, NEUROSURGERY, V7, P142, DOI 10.1227/00006123-198008000-00005; Wyse ATS, 2000, NEUROREPORT, V11, P2331, DOI 10.1097/00001756-200007140-00052; YAN LJ, 1995, ANAL BIOCHEM, V228, P349, DOI 10.1006/abio.1995.1362	59	27	27	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2013	30	14					1278	1287		10.1089/neu.2012.2577			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	183MV	WOS:000321821100008	23530735	Green Published			2021-06-18	
J	Bali, N; Arimoto, JM; Morgan, TE; Finch, CE				Bali, N.; Arimoto, J. M.; Morgan, T. E.; Finch, C. E.			Progesterone Antagonism of Neurite Outgrowth Depends on Microglial Activation via Pgrmc1/S2R	ENDOCRINOLOGY			English	Article							MEMBRANE COMPONENT 1; BRAIN-INJURY; GENE-EXPRESSION; GRANULOSA-CELLS; ESTROUS-CYCLE; UP-REGULATION; PROTEIN; NEUROPROTECTION; RECEPTORS; ESTRADIOL	Neuronal plasticity is regulated by the ovarian steroids estradiol (E2) and progesterone (P4) in many normal brain functions, as well as in acute response to injury and chronic neurodegenerative disease. In a female rat model of axotomy, the E2-dependent compensatory neuronal sprouting is antagonized by P4. To resolve complex glial-neuronal cell interactions, we used the "wounding in-a-dish" model of neurons cocultured with astrocytes or mixed glia (microglia to astrocytes, 1: 3). Although both astrocytes and mixed glia supported E2-enhanced neurite outgrowth, P4 antagonized E2-induced neurite outgrowth only with mixed glia, but not astrocytes alone. We now show that P4-E2 antagonism of neurite outgrowth is mediated by microglial expression of progesterone receptor (Pgr) membrane component 1 (Pgrmc1)/S2R, a putative nonclassical Pgr mediator with multiple functions. The P4-E2 antagonism of neurite outgrowth was restored by add-back of microglia to astrocyte-neuron cocultures. Because microglia do not express the classical Pgr, we examined the role of Pgrmc1, which is expressed in microglia in vitro and in vivo. Knockdown by siRNA-Pgrmc1 in microglia before add-back to astrocyte-neuron cocultures suppressed the P4-E2 antagonism of neurite outgrowth. Conditioned media from microglia restored the P4-E2 activity, but only if microglia were activated by lipopolysaccharide or by wounding. Moreover, the microglial activation was blocked by Pgmrc1-siRNA knockdown. These findings explain why non-wounded cultures without microglial activation lack P4 antagonism of E2-induced neurite outgrowth. We suggest that microglial activation may influence brain responses to exogenous P4, which is a prospective therapy in traumatic brain injury. (Endocrinology 154: 2468-2480, 2013)	[Bali, N.; Arimoto, J. M.; Finch, C. E.] Univ So Calif, Dornsife Coll Letters Arts & Sci, Program Mol Biol, Los Angeles, CA 90089 USA; [Morgan, T. E.; Finch, C. E.] Univ So Calif, Davis Sch Gerontol, Los Angeles, CA 90089 USA	Finch, CE (corresponding author), Univ So Calif, Davis Sch Gerontol, 3715 McClintock Ave,GER 336A, Los Angeles, CA 90089 USA.	cefinch@usc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2P01 AG026572-06]; Project 2; Animal Core; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG026572] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant 2P01 AG026572-06 (to R.D.B.); Project 2 (to C.E.F and T.E.M); and Animal Core (to T.E.M.).	Aguirre CC, 2009, EUR J NEUROSCI, V29, P447, DOI 10.1111/j.1460-9568.2008.06591.x; Bali N, 2012, ENDOCRINOLOGY, V153, P759, DOI 10.1210/en.2011-1699; Bashour NM, 2012, ENDOCRINOLOGY, V153, P4457, DOI 10.1210/en.2012-1122; Behl C, 1997, MOL PHARMACOL, V51, P535; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Cahill MA, 2007, J STEROID BIOCHEM, V105, P16, DOI 10.1016/j.jsbmb.2007.02.002; Carroll JC, 2007, J NEUROSCI, V27, P13357, DOI 10.1523/JNEUROSCI.2718-07.2007; Chen ZH, 2012, J NEUROSCI, V32, P11706, DOI 10.1523/JNEUROSCI.0730-12.2012; Chiu JJ, 2011, PHYSIOL REV, V91, P327, DOI 10.1152/physrev.00047.2009; Cuevas J, 2011, J PHARMACOL EXP THER, V339, P161, DOI 10.1124/jpet.111.182816; Gatson JW, 2011, ENDOCRINOLOGY, V152, P207, DOI 10.1210/en.2010-0724; Gerdes D, 1998, BIOL CHEM, V379, P907; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Guennoun R, 2008, BRAIN RES REV, V57, P493, DOI 10.1016/j.brainresrev.2007.05.009; Hua F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-42; Intlekofer KA, 2011, NEUROSCIENCE, V176, P86, DOI 10.1016/j.neuroscience.2010.12.033; Jeon H, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-149; Johannessen M, 2011, AM J PHYSIOL-CELL PH, V300, pC328, DOI 10.1152/ajpcell.00383.2010; Labombarda F, 2010, NEUROIMMUNOMODULAT, V17, P146, DOI 10.1159/000258709; Lefrancois T, 1997, J NEUROSCI, V17, P4121; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Liu LF, 2009, ENDOCRINOLOGY, V150, P3186, DOI 10.1210/en.2008-1447; Mir SUR, 2012, INT J CANCER, V131, pE1, DOI 10.1002/ijc.26432; Mir SUR, 2012, J BIOL CHEM, V287, P14494, DOI 10.1074/jbc.M111.324921; Morali G, 2005, NEUROSCI LETT, V382, P286, DOI 10.1016/j.neulet.2005.03.066; Morgan TE, 1999, NEUROSCIENCE, V89, P687, DOI 10.1016/S0306-4522(98)00334-0; Ndiaye K, 2012, J REPROD IMMUNOL, V95, P15, DOI 10.1016/j.jri.2012.04.004; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Noreen M, 2012, INFLAMM RES, V61, P177, DOI 10.1007/s00011-011-0427-1; Oda S, 2011, DRUG METAB DISPOS, V39, P2057, DOI 10.1124/dmd.111.040907; Peluso JJ, 2010, MOL CELL ENDOCRINOL, V320, P153, DOI 10.1016/j.mce.2010.02.005; Peluso JJ, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.103036; Peluso JJ, 2012, ENDOCRINOLOGY, V153, P3929, DOI 10.1210/en.2011-2096; Peluso JJ, 2012, STEROIDS, V77, P1007, DOI 10.1016/j.steroids.2012.01.013; Peluso JJ, 2009, J CLIN ENDOCR METAB, V94, P2644, DOI 10.1210/jc.2009-0147; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Qin LY, 2005, GLIA, V52, P78, DOI 10.1002/glia.20225; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Rohe HJ, 2009, PHARMACOL THERAPEUT, V121, P14, DOI 10.1016/j.pharmthera.2008.09.006; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roy AA, 2006, J BIOL CHEM, V281, P32684, DOI 10.1074/jbc.M604416200; Runko E, 2004, J NEUROSCI, V24, P9015, DOI 10.1523/JNEUROSCI.2385-04.2004; Runko E, 1999, MOL CELL NEUROSCI, V14, P428, DOI 10.1006/mcne.1999.0794; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Shao R, 2003, BIOL REPROD, V68, P914, DOI 10.1095/biolreprod.102.009035; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Sierra A, 2008, GLIA, V56, P659, DOI 10.1002/glia.20644; Singer CA, 1999, J NEUROSCI, V19, P2455; Stone DJ, 2000, EXP NEUROL, V165, P46, DOI 10.1006/exnr.2000.7455; Su C, 2012, ENDOCRINOLOGY, V153, P4389, DOI 10.1210/en.2011-2177; Szczesna-Skorupa E, 2011, MOL PHARMACOL, V79, P340, DOI 10.1124/mol.110.068478; Wendler A, 2012, STEROIDS, V77, P1002, DOI 10.1016/j.steroids.2011.12.023; Wise PM, 2000, BIOL REPROD, V63, P982, DOI 10.1095/biolreprod63.4.982; Wong AM, 2009, ENDOCRINOLOGY, V150, P324, DOI 10.1210/en.2008-0988; WOOLLEY CS, 1992, J NEUROSCI, V12, P2549; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; Xu JB, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1386	58	27	28	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0013-7227	1945-7170		ENDOCRINOLOGY	Endocrinology	JUL	2013	154	7					2468	2480		10.1210/en.2012-2109			13	Endocrinology & Metabolism	Endocrinology & Metabolism	169EL	WOS:000320760700024	23653459	Green Published, Bronze			2021-06-18	
J	Bennett, TD; Niedzwecki, CM; Korgenski, EK; Bratton, SL				Bennett, Tellen D.; Niedzwecki, Christian M.; Korgenski, E. Kent; Bratton, Susan L.			Initiation of Physical, Occupational, and Speech Therapy in Children With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Annual Assembly of the American-Academy-for-Physical-Medicine-and-Rehabilitation	NOV 18, 2011	Orlando, FL	Amer Acad Phys Med & Rehabil		Craniocerebral trauma; Occupational therapy; Pediatrics; Rehabilitation; Speech therapy	CRITICALLY-ILL PATIENTS; OF-CARE INDICATORS; UNITED-STATES; HEALTH-CARE; REHABILITATION; OUTCOMES	Objectives: (1) To determine factors associated with physical therapy (PT) or occupational therapy (OT) evaluation and speech or swallow therapy evaluation in hospitalized children with traumatic brain injury (TBI); (2) to describe when during the hospital stay the initial therapy evaluations typically occur; and (3) to quantify any between-hospital variation in therapy evaluation. Design: Retrospective cohort study. Setting: Children's hospitals participating in the Pediatric Health Information System database (January 2001 June 2011). Participants: Children (age <18y) with TBI (N=21,399) who were admitted to the intensive care unit and survived to hospital discharge. Interventions: Not applicable. Main Outcome Measures: PT or OT evaluation and speech or swallow therapy evaluation. A propensity score was calculated to allow comparison of expected with observed rates of therapy evaluations by the hospital. Results: The median hospital length of stay was 5 days (interquartile range, 3-10d). Overall, 8748 (41%) of 21,399 children received either a PT or OT evaluation, and 5490 (26%) out of 21,399 children received either a speech or swallow evaluation. Older children and those with higher energy injury mechanisms, more severe injuries, extremity fractures, more treatment with neuromuscular blocking agents or pentobarbital, and admission to a hospital with an American College of Surgeons Level I pediatric trauma designation were more likely to receive therapy evaluations. The median time until the first therapy evaluation was 5 (PT or OT) and 7 days (speech or swallow). Expected hospital evaluation rates were 25% to 54% (PT or OT) and 16% to 35% (speech or swallow), while observed hospital evaluation rates were 11% to 74% (PT or OT) and 4% to 55% (speech or swallow). Conclusions: There is wide between-hospital variation in provision of rehabilitation therapies for children with TBI. Evidence-based criteria for initiation of routine therapy evaluations after TBI are needed. (C) 2013 by the American Congress of Rehabilitation Medicine	[Bennett, Tellen D.; Bratton, Susan L.] Univ Utah, Sch Med, Salt Lake City, UT 84158 USA; [Niedzwecki, Christian M.] Baylor Coll Med, Houston, TX 77030 USA; [Korgenski, E. Kent] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84158 USA	Bennett, TD (corresponding author), Univ Utah, Sch Med, POB 581289, Salt Lake City, UT 84158 USA.	tell.bennett@hsc.utah.edu	Guenat, Heather/H-6528-2014	Bennett, Tellen/0000-0003-1483-4236; Bratton, Susan/0000-0002-4605-8078	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [KM1CA156723] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001067] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR001067] Funding Source: Medline; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [KM1 CA156723, 1KM1CA156723] Funding Source: Medline		Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; American College of Surgeons Trauma Programs, 2012, VER TRAUM CTR; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Beaulieu CL, 2002, SURG CLIN N AM, V82, P393, DOI 10.1016/S0039-6109(02)00009-9; Bennett TD, 2012, ARCH PEDIAT ADOL MED, V166, P641, DOI 10.1001/archpediatrics.2012.322; Bennett TD, 2012, CRIT CARE MED, V40, P208, DOI 10.1097/CCM.0b013e31822e9d31; BERWICK DM, 1991, MED CARE, V29, P1212, DOI 10.1097/00005650-199112000-00004; Burtin C, 2009, CRIT CARE MED, V37, P2499, DOI 10.1097/CCM.0b013e3181a38937; Carroll Christopher P, 2010, Ann Adv Automot Med, V54, P233; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; Conway PH, 2009, J PEDIATR-US, V154, P789, DOI 10.1016/j.jpeds.2009.01.010; Dumas HM, 2002, AM J PHYS MED REHAB, V81, P661, DOI 10.1097/00002060-200209000-00005; Fan E, 2012, RESP CARE, V57, P933, DOI 10.4187/respcare.01634; Gerber JS, 2010, PEDIATRICS, V126, P1067, DOI 10.1542/peds.2010-1275; Goldin AB, 2007, PEDIATRICS, V119, P905, DOI 10.1542/peds.2006-2040; Goodman DC, 2009, PEDIATR CLIN N AM, V56, P745, DOI 10.1016/j.pcl.2009.05.007; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; KRAUS JF, 1987, PEDIATRICS, V79, P501; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Medicare Learning Network, 2011, INP REH THER SERV CO; Needham DM, 2010, ARCH PHYS MED REHAB, V91, P536, DOI 10.1016/j.apmr.2010.01.002; Rivara FP, 2012, ARCH PHYS MED REHAB, V93, P381, DOI 10.1016/j.apmr.2011.08.015; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Rivara FP, 2012, ARCH PHYS MED REHAB, V93, P1371, DOI 10.1016/j.apmr.2012.02.031; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Tepas JJ, 2009, J PEDIATR SURG, V44, P368, DOI 10.1016/j.jpedsurg.2008.10.089; Tri-Analytics Inc. and The Johns Hopkins University, 1997, ICDMAP 90 SOFTW US G; US Health Care Financing Administration, 2007, INT CLASS DIS; Weiss PF, 2009, J PEDIAT, V155; Wood JN, 2010, PEDIATRICS, V126, P408, DOI 10.1542/peds.2010-0031	33	27	27	2	41	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2013	94	7					1268	1276		10.1016/j.apmr.2013.02.021			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	182GG	WOS:000321729100007	23473704	Green Accepted			2021-06-18	
J	Szymanski, CR; Chiha, W; Morellini, N; Cummins, N; Bartlett, CA; Doig, RLO; Savigni, DL; Payne, SC; Harvey, AR; Dunlop, SA; Fitzgerald, M				Szymanski, Charis R.; Chiha, Wissam; Morellini, Natalie; Cummins, Nadia; Bartlett, Carole A.; Doig, Ryan L. O'Hare; Savigni, Donna L.; Payne, Sophie C.; Harvey, Alan R.; Dunlop, Sarah A.; Fitzgerald, Melinda			Paranode Abnormalities and Oxidative Stress in Optic Nerve Vulnerable to Secondary Degeneration: Modulation by 670 nm Light Treatment	PLOS ONE			English	Article							SPINAL-CORD-INJURY; RETINAL GANGLION-CELLS; TRAUMATIC BRAIN-INJURY; CYTOCHROME-C-OXIDASE; NEAR-INFRARED LIGHT; REACTIVE OXYGEN; ABSORPTION-MEASUREMENTS; OLIGODENDROCYTES; CALCIUM; DEATH	Secondary degeneration of nerve tissue adjacent to a traumatic injury results in further loss of neurons, glia and function, via mechanisms that may involve oxidative stress. However, changes in indicators of oxidative stress have not yet been demonstrated in oligodendrocytes vulnerable to secondary degeneration in vivo. We show increases in the oxidative stress indicator carboxymethyl lysine at days 1 and 3 after injury in oligodendrocytes vulnerable to secondary degeneration. Dihydroethidium staining for superoxide is reduced, indicating endogenous control of this particular reactive species after injury. Concurrently, node of Ranvier/paranode complexes are altered, with significant lengthening of the paranodal gap and paranode as well as paranode disorganisation. Therapeutic administration of 670 nm light is thought to improve oxidative metabolism via mechanisms that may include increased activity of cytochrome c oxidase. Here, we show that light at 670 nm, delivered for 30 minutes per day, results in in vivo increases in cytochrome c oxidase activity co-localised with oligodendrocytes. Short term (1 day) 670 nm light treatment is associated with reductions in reactive species at the injury site. In optic nerve vulnerable to secondary degeneration superoxide in oligodendrocytes is reduced relative to handling controls, and is associated with reduced paranode abnormalities. Long term (3 month) administration of 670 nm light preserves retinal ganglion cells vulnerable to secondary degeneration and maintains visual function, as assessed by the optokinetic nystagmus visual reflex. Light at a wavelength of 670 nm may serve as a therapeutic intervention for treatment of secondary degeneration following neurotrauma.	[Szymanski, Charis R.; Chiha, Wissam; Morellini, Natalie; Cummins, Nadia; Bartlett, Carole A.; Doig, Ryan L. O'Hare; Savigni, Donna L.; Payne, Sophie C.; Dunlop, Sarah A.; Fitzgerald, Melinda] Univ Western Australia, Sch Anim Biol, Crawley, WA, Australia; [Harvey, Alan R.] Univ Western Australia, Sch Anat Physiol & Human Biol, Crawley, WA, Australia	Fitzgerald, M (corresponding author), Univ Western Australia, Sch Anim Biol, Crawley, WA, Australia.	lindy.fitzgerald@uwa.edu.au	Dunlop, Sarah A/G-9357-2013; Fitzgerald, Melinda/C-4235-2011; Doig, Ryan O'Hare/AAG-7585-2019	Fitzgerald, Melinda/0000-0002-4823-8179; , Alan/0000-0002-2590-831X; Dunlop, Sarah/0000-0002-1306-3962; Cummins, Nadia/0000-0002-4494-2345	Neurotrauma Research Program (Western Australia); National Health and Medical Research Council (NHMRC), AustraliaNational Health and Medical Research Council of Australia [572550]; NHMRC, AustraliaNational Health and Medical Research Council of Australia [APP1002347]	This work was supported by the Neurotrauma Research Program (Western Australia) and National Health and Medical Research Council (NH&MRC), Australia (Grant ID: 572550). Prof. Dunlop is a Principal Research Fellow of the NH&MRC, Australia (Grant ID: APP1002347). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arvanian VL, 2009, EXP NEUROL, V216, P471, DOI 10.1016/j.expneurol.2009.01.004; Back SA, 1998, J NEUROSCI, V18, P6241; Balabanov R, 2005, NAT NEUROSCI, V8, P262, DOI 10.1038/nn0305-262; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Buffo A, 2005, P NATL ACAD SCI USA, V102, P18183, DOI 10.1073/pnas.0506535102; Buttermore ED, 2011, J NEUROSCI, V31, P8013, DOI 10.1523/JNEUROSCI.1015-11.2011; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Chan YC, 2009, J PHARMACOL EXP THER, V329, P450, DOI 10.1124/jpet.108.148353; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; DANNENBERG AM, 1994, J LEUKOCYTE BIOL, V56, P436; Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fitzgerald M, 2010, J NEUROTRAUM, V27, P2107, DOI 10.1089/neu.2010.1426; Fitzgerald M, 2010, J NEUROTRAUM, V27, P439, DOI 10.1089/neu.2009.1112; Fitzgerald M, 2009, INVEST OPHTH VIS SCI, V50, P5456, DOI 10.1167/iovs.09-3717; Fitzgerald M, 2009, EXP NEUROL, V216, P219, DOI 10.1016/j.expneurol.2008.11.026; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; Fu Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006705; Funfschilling U, 2012, NATURE, V485, P517, DOI 10.1038/nature11007; Fuss B, 2000, DEV BIOL, V218, P259, DOI 10.1006/dbio.1999.9574; Giaume C, 2007, CELL DEATH DIFFER, V14, P1324, DOI 10.1038/sj.cdd.4402144; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Griselda CM, 2011, NEUROSCI BIOBEHAV R, V35, P1353, DOI 10.1016/j.neubiorev.2011.02.009; Haynes RL, 2003, J NEUROPATH EXP NEUR, V62, P441, DOI 10.1093/jnen/62.5.441; Howell OW, 2006, BRAIN, V129, P3173, DOI 10.1093/brain/awl290; Jia Z, 2012, SPINAL CORD, V50, P264, DOI 10.1038/sc.2011.111; Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030; Karadottir R, 2005, NATURE, V438, P1162, DOI 10.1038/nature04302; Karu TI, 2005, J PHOTOCH PHOTOBIO B, V81, P98, DOI 10.1016/j.jphotobiol.2005.07.002; Karu TI, 2008, PHOTOMED LASER SURG, V26, P593, DOI 10.1089/pho.2008.2246; Kitada M, 2006, GLIA, V54, P35, DOI 10.1002/glia.20354; Kokkinopoulos I, 2013, NEUROBIOL AGING, V34, P602, DOI 10.1016/j.neurobiolaging.2012.04.014; Komel'kova L V, 2004, Patol Fiziol Eksp Ter, P15; Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004; Lasiene J, 2008, J NEUROSCI, V28, P3887, DOI 10.1523/JNEUROSCI.4756-07.2008; Lee YJ, 2012, NATURE, V487, P443, DOI 10.1038/nature11314; Levkovitch-Verbin H, 2003, INVEST OPHTH VIS SCI, V44, P3388, DOI 10.1167/iovs.02-0646; Li ZS, 2010, FEBS LETT, V584, P2291, DOI 10.1016/j.febslet.2010.03.040; McLellan ME, 2003, J NEUROSCI, V23, P2212; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nave KA, 2010, NAT REV NEUROSCI, V11, P275, DOI 10.1038/nrn2797; Nickells RW, 2004, BRAIN RES BULL, V62, P439, DOI 10.1016/j.brainresbull.2003.07.007; Othman A, 2011, GLIA, V59, P914, DOI 10.1002/glia.21163; Owusu-Ansah E, 2008, PROTOCOL IN VIVO DET; Pacak K, 2001, ENDOCR REV, V22, P502, DOI 10.1210/er.22.4.502; Payne SC, 2012, INVEST OPHTHALMOL VI; Payne SC, 2011, J NEUROTRAUM, V28, P1077, DOI 10.1089/neu.2010.1665; Peng TI, 2010, ANN NY ACAD SCI, V1201, P183, DOI 10.1111/j.1749-6632.2010.05634.x; Reyes RC, 2012, J NEUROSCI, V32, P12973, DOI 10.1523/JNEUROSCI.1597-12.2012; Rinholm JE, 2012, NATURE, V487, P435, DOI 10.1038/487435a; Robinson KM, 2006, P NATL ACAD SCI USA, V103, P15038, DOI 10.1073/pnas.0601945103; Rojas JC, 2008, J NEUROSCI, V28, P13511, DOI 10.1523/JNEUROSCI.3457-08.2008; Rosenbluth J, 2009, J NEUROSCI RES, V87, P3250, DOI 10.1002/jnr.22013; Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-257; Saggu SK, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-97; Salter MG, 2005, NATURE, V438, P1167, DOI 10.1038/nature04301; Schlieve CR, 2006, INVEST OPHTH VIS SCI, V47, P3878, DOI 10.1167/iovs.05-1010; Sharikabad MN, 2001, AM J PHYSIOL-HEART C, V280, pH344; Shen SL, 1999, NEURON, V23, P285, DOI 10.1016/S0896-6273(00)80780-1; Stemer Andrew B, 2010, Curr Cardiol Rep, V12, P29, DOI 10.1007/s11886-009-0071-3; Totoiu MO, 2005, J COMP NEUROL, V486, P373, DOI 10.1002/cne.20517; Tretter L, 2007, J NEUROSCI RES, V85, P3471, DOI 10.1002/jnr.21405; Wells J, 2012, J NEUROSCI RES, V90, P606, DOI 10.1002/jnr.22784; Wong-Riley MTT, 2001, NEUROREPORT, V12, P3033, DOI 10.1097/00001756-200110080-00011; Ziabreva I, 2010, GLIA, V58, P1827, DOI 10.1002/glia.21052	65	27	27	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2013	8	6							e66448	10.1371/journal.pone.0066448			14	Multidisciplinary Sciences	Science & Technology - Other Topics	190ST	WOS:000322361200080	23840470	DOAJ Gold, Green Published			2021-06-18	
J	Leunissen, I; Coxon, JP; Geurts, M; Caeyenberghs, K; Michiels, K; Sunaert, S; Swinnen, SP				Leunissen, Inge; Coxon, James P.; Geurts, Monique; Caeyenberghs, Karen; Michiels, Karla; Sunaert, Stefan; Swinnen, Stephan P.			Disturbed cortico-subcortical interactions during motor task switching in traumatic brain injury	HUMAN BRAIN MAPPING			English	Article						bimanual coordination; cognitive control; fMRI; task switching; traumatic brain injury	RESPONSE-INHIBITION; COGNITIVE CONTROL; BASAL GANGLIA; WORKING-MEMORY; WHITE-MATTER; BIMANUAL COORDINATION; EXECUTIVE DYSFUNCTION; REACTION-TIME; NEURAL BASIS; HEAD-INJURY	The ability to suppress and flexibly adapt motor behavior is a fundamental mechanism of cognitive control, which is impaired in traumatic brain injury (TBI). Here, we used a combination of functional magnetic resonance imaging and diffusion weighted imaging tractography to study changes in brain function and structure associated with motor switching performance in TBI. Twenty-three young adults with moderate-severe TBI and twenty-six healthy controls made spatially and temporally coupled bimanual circular movements. A visual cue signaled the right hand to switch or continue its circling direction. The time to initiate the switch (switch response time) was longer and more variable in the TBI group and TBI patients exhibited a higher incidence of complete contralateral (left hand) movement disruptions. Both groups activated the basal ganglia and a previously described network for task-set implementation, including the supplementary motor complex and bilateral inferior frontal cortex (IFC). Relative to controls, patients had significantly increased activation in the presupplementary motor area (preSMA) and left IFC, and showed underactivation of the subthalamic nucleus (STN) region. This altered functional engagement was related to the white matter microstructural properties of the tracts connecting preSMA, IFC, and STN. Both functional activity in preSMA, IFC, and STN, and the integrity of the connections between them were associated with behavioral performance across patients and controls. We suggest that damage to these key pathways within the motor switching network because of TBI, shifts the patients toward the lower end of the existing structure-function-behavior spectrum. Hum Brain Mapp, 2013. (c) 2012 Wiley Periodicals, Inc.	[Leunissen, Inge; Coxon, James P.; Geurts, Monique; Caeyenberghs, Karen; Swinnen, Stephan P.] Katholieke Univ Leuven, Res Ctr Movement Control & Neuroplast, Dept Biomed Kinesiol, Motor Control Lab,Grp Biomed Sci, B-3001 Heverlee, Belgium; [Michiels, Karla] Univ Hosp, Dept Phys Med & Rehabil, Louvain, Belgium; [Sunaert, Stefan] Katholieke Univ Leuven, Univ Hosp, Dept Radiol, B-3001 Heverlee, Belgium	Swinnen, SP (corresponding author), Katholieke Univ Leuven, Ctr Movement Control & Neuroplast, Dept Biomed Kinesiol, Tervuursevest 101, B-3001 Heverlee, Belgium.	Stephan.Swinnen@faber.kuleuven.be	Coxon, James/S-1286-2019	Coxon, James/0000-0003-2351-8489; Caeyenberghs, Karen/0000-0001-7009-6843; Leunissen, Inge/0000-0002-3977-3620	Research Program of the Research Foundation, Flanders (FWO)FWO [G. 0483.10, G. 0482.10, G. A114.11]; Interuniversity Attraction Poles program of the Belgian federal governmentBelgian Federal Science Policy Office [P6/29]	Contract grant sponsor: The Research Program of the Research Foundation, Flanders (FWO); Contract grant number: G. 0483.10, Levenslijn G. 0482.10, G. A114.11; Contract grant sponsor: The Interuniversity Attraction Poles program of the Belgian federal government; Contract grant number: P6/29.	Alexander MP, 2005, NEUROLOGY, V65, P572, DOI 10.1212/01.wnl.0000172912.07640.92; Amunts K, 1999, J COMP NEUROL, V412, P319, DOI 10.1002/(SICI)1096-9861(19990920)412:2<319::AID-CNE10>3.0.CO;2-7; Aravamuthan BR, 2007, NEUROIMAGE, V37, P694, DOI 10.1016/j.neuroimage.2007.05.050; Aron AR, 2007, NEUROSCIENTIST, V13, P214, DOI 10.1177/1073858407299288; Aron AR, 2007, J NEUROSCI, V27, P3743, DOI 10.1523/JNEUROSCI.0519-07.2007; Aron AR, 2006, J NEUROSCI, V26, P2424, DOI 10.1523/JNEUROSCI.4682-05.2006; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Baunez C, 2001, EUR J NEUROSCI, V13, P1609, DOI 10.1046/j.0953-816x.2001.01521.x; Blinkenberg M, 1996, J CEREBR BLOOD F MET, V16, P794, DOI 10.1097/00004647-199609000-00004; Brett M., 2002, NEUROIMAGE, V16, P2, DOI [10.1016/S1053-8119(02)90010-8, DOI 10.1016/S1053-8119(02)90010-8]; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Byblow WD, 2000, EXP BRAIN RES, V131, P366, DOI 10.1007/s002219900271; Byblow WD, 1999, HUM MOVEMENT SCI, V18, P281, DOI 10.1016/S0167-9457(99)00012-3; Cabeza R, 2002, PSYCHOL AGING, V17, P85, DOI 10.1037//0882-7974.17.1.85; Carson RG, 1997, Q J EXP PSYCHOL-A, V50, P664, DOI 10.1080/027249897392062; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Clark L, 2007, BIOL PSYCHIAT, V61, P1395, DOI 10.1016/j.biopsych.2006.07.020; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Coxon JP, 2010, CEREB CORTEX, V20, P2368, DOI 10.1093/cercor/bhp306; Coxon JP, 2009, J COGNITIVE NEUROSCI, V21, P1193, DOI 10.1162/jocn.2009.21081; Crinion J, 2007, NEUROIMAGE, V37, P866, DOI 10.1016/j.neuroimage.2007.04.065; De Luca C, 2010, J NEUROSCI, V30, P3167, DOI 10.1523/JNEUROSCI.2673-09.2010; Debaere F, 2004, NEUROIMAGE, V21, P1416, DOI 10.1016/j.neuroimage.2003.12.011; Derrfuss J, 2005, HUM BRAIN MAPP, V25, P22, DOI 10.1002/hbm.20127; Dosenbach NUF, 2006, NEURON, V50, P799, DOI 10.1016/j.neuron.2006.04.031; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Forstmann BU, 2008, J NEUROSCI, V28, P9790, DOI 10.1523/JNEUROSCI.1465-08.2008; Frank MJ, 2007, PHILOS T R SOC B, V362, P1641, DOI 10.1098/rstb.2007.2058; Frank MJ, 2006, NEURAL NETWORKS, V19, P1120, DOI 10.1016/j.neunet.2006.03.006; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Hikosaka O, 2010, TRENDS COGN SCI, V14, P154, DOI 10.1016/j.tics.2010.01.006; Inase M, 1999, BRAIN RES, V833, P191, DOI 10.1016/S0006-8993(99)01531-0; Isoda M, 2007, NAT NEUROSCI, V10, P240, DOI 10.1038/nn1830; Johansen-Berg H, 2004, P NATL ACAD SCI USA, V101, P13335, DOI 10.1073/pnas.0403743101; KELSO JAS, 1995, CHAOS, V5, P64, DOI 10.1063/1.166087; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kenner NM, 2010, J NEUROSCI, V30, P8512, DOI 10.1523/JNEUROSCI.1096-10.2010; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; Li CSR, 2008, NEUROIMAGE, V41, P1352, DOI 10.1016/j.neuroimage.2008.04.023; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Mani TM, 2007, NEUROCASE, V13, P229, DOI 10.1080/13554790701594862; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; McAllister TW, 2006, BRAIN COGNITION, V60, P189; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Mecklinger A, 1999, J CLIN EXP NEUROPSYC, V21, P606, DOI 10.1076/jcen.21.5.606.873; Mink JW, 1996, PROG NEUROBIOL, V50, P381, DOI 10.1016/S0301-0082(96)00042-1; Monsell S, 2003, TRENDS COGN SCI, V7, P134, DOI 10.1016/S1364-6613(03)00028-7; Nachev P, 2008, NAT REV NEUROSCI, V9, P856, DOI 10.1038/nrn2478; Nambu A, 2002, NEUROSCI RES, V43, P111, DOI 10.1016/S0168-0102(02)00027-5; Newsome MR, 2008, NEUROPSYCHOLOGY, V22, P419, DOI 10.1037/0894-4105.22.4.419; Nichols T, 2005, NEUROIMAGE, V25, P653, DOI 10.1016/j.neuroimage.2004.12.005; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Picard N, 1996, CEREB CORTEX, V6, P342, DOI 10.1093/cercor/6.3.342; Picton TW, 2007, CEREB CORTEX, V17, P826, DOI 10.1093/cercor/bhk031; Prodoehl J, 2008, NEUROIMAGE, V39, P956, DOI 10.1016/j.neuroimage.2007.09.027; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rasmussen IA, 2008, J NEUROTRAUM, V25, P1057, DOI 10.1089/neu.2008.0520; Rieger M, 2003, NEUROPSYCHOLOGY, V17, P272, DOI 10.1037/0894-4105.17.2.272; Rushworth MFS, 2004, TRENDS COGN SCI, V8, P410, DOI 10.1016/j.tics.2004.07.009; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Seignourel PJ, 2005, NEUROPSYCHOLOGY, V19, P578, DOI 10.1037/0894-4105.19.5.578; Sharp DJ, 2010, P NATL ACAD SCI USA, V107, P6106, DOI 10.1073/pnas.1000175107; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Sosin DM, 1996, BRAIN INJURY, V10, P47; Swinnen SP, 2002, NAT REV NEUROSCI, V3, P350, DOI 10.1038/nrn807; Swinnen SP, 2004, TRENDS COGN SCI, V8, P18, DOI 10.1016/j.tics.2003.10.017; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P181, DOI 10.1017/S1355617710001414; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Turner GR, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00009; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Verhagen L, 2006, NEUROIMAGE; Wager TD, 2003, NEUROIMAGE, V18, P293, DOI 10.1016/S1053-8119(02)00046-0; Ward NS, 2004, CURR OPIN NEUROL, V17, P725, DOI 10.1097/00019052-200412000-00013; Wenderoth N, 2009, J NEUROPHYSIOL, V102, P302, DOI 10.1152/jn.91090.2008	91	27	27	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	JUN	2013	34	6					1254	1271		10.1002/hbm.21508			18	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	129QA	WOS:000317855400002	22287257	Green Published			2021-06-18	
J	Henrich-Noack, P; Voigt, N; Prilloff, S; Fedorov, A; Sabel, BA				Henrich-Noack, Petra; Voigt, Nadine; Prilloff, Sylvia; Fedorov, Anton; Sabel, Bernhard A.			Transcorneal electrical stimulation alters morphology and survival of retinal ganglion cells after optic nerve damage	NEUROSCIENCE LETTERS			English	Article						Neurotrauma; Neuroprotection; Non-invasive alternating current stimulation; In vivo imaging; Retinal ganglion cells; Vision restoration	ALTERNATING-CURRENT STIMULATION; CONFOCAL NEUROIMAGING ICON; IN-VIVO; NEUROPATHY; VISION; PROMOTES; CRUSH; REGENERATION; RESTORATION; DYNAMICS	Traumatic optic nerve injury leads to retrograde death of retinal ganglion cells (RGCs), but transcorneal electrical stimulation (TES) can increase the cell survival rate. To understand the mechanisms and to further define the TES-induced effects we monitored in living animals RGC morphology and survival after optic nerve crush (ONC) in real time by using in vivo confocal neuroimaging (ICON) of the retina. ONC was performed in rats and ICON was performed before crush and on post-lesion days 3, 7 and 15 which allowed us to repeatedly record RGC number and size. TES or sham-stimulation were performed immediately after the crush and on post-injury day 11. Three days after ONC we detected a higher percentage of surviving RGCs in the TES group as compared to sham-treated controls. However, the difference was below significance level on day 7 and disappeared completely by day 15. The death rate was more variable amongst the TES-treated rats than in the control group. Morphological analysis revealed that average cell size changed significantly in the control group but not in stimulated animals and the morphological alterations of surviving neurons were smaller in TES-treated compared to control cells. In conclusion, TES delays post-traumatic cell death significantly. Moreover, we found "responder animals" which also benefited in the long-term from the treatment. Our in vivo cellular imaging results provide evidence that TES reduces ONC-associated neuronal swelling and shrinkage especially in RGCs which survived long-term. Further studies are now needed to determine the differences of responders vs. non-responders. (C) 2013 Elsevier Ireland Ltd. All rights reserved.	[Henrich-Noack, Petra; Voigt, Nadine; Prilloff, Sylvia; Fedorov, Anton; Sabel, Bernhard A.] Otto von Guericke Univ, Inst Med Psychol, D-39120 Magdeburg, Germany; [Henrich-Noack, Petra] ZEBIK, D-39120 Magdeburg, Germany	Henrich-Noack, P (corresponding author), Otto von Guericke Univ, Inst Med Psychol, Leipziger Str 44, D-39120 Magdeburg, Germany.	Petra.Henrich-Noack@med.ovgu.de	Sabel, Bernhard A./E-6579-2013	Henrich-Noack, Petra/0000-0002-3093-6227; Sabel, Bernhard/0000-0002-4472-5543			Al-Majed AA, 2000, J NEUROSCI, V20, P2602; Brushart TM, 2002, J NEUROSCI, V22, P6631; Chrysikou EG, 2011, RESTOR NEUROL NEUROS, V29, P375, DOI 10.3233/RNN-2011-0610; Fedorov A, 2011, BRAIN STIMUL, V4, P189, DOI 10.1016/j.brs.2011.07.007; Fedorov Anton, 2010, Restor Neurol Neurosci, V28, P825, DOI 10.3233/RNN-2010-0580; Fujikado T, 2006, JPN J OPHTHALMOL, V50, P266, DOI 10.1007/s10384-005-0304-y; Gall C, 2011, BRAIN STIMUL, V4, P175, DOI 10.1016/j.brs.2011.07.003; Gall C, 2010, NEUROREHABILITATION, V27, P335, DOI 10.3233/NRE-2010-0617; Goldberg JL, 2002, NEURON, V33, P689, DOI 10.1016/S0896-6273(02)00602-5; Inomata K, 2007, GRAEF ARCH CLIN EXP, V245, P1773, DOI 10.1007/s00417-007-0610-9; Miyake K, 2007, INVEST OPHTH VIS SCI, V48, P2356, DOI 10.1167/iovs.06-1329; Morimoto T, 2005, INVEST OPHTH VIS SCI, V46, P2147, DOI 10.1167/iovs.04-1339; Morimoto T, 2002, NEUROREPORT, V13, P227, DOI 10.1097/00001756-200202110-00011; Morimoto T, 2007, INVEST OPHTH VIS SCI, V48, P4725, DOI 10.1167/iovs.06-1404; Morimoto T, 2010, EXP EYE RES, V90, P285, DOI 10.1016/j.exer.2009.11.002; Ni YQ, 2009, EXP NEUROL, V219, P439, DOI 10.1016/j.expneurol.2009.06.016; Prilloff S, 2007, EUR J NEUROSCI, V25, P3339, DOI 10.1111/j.1460-9568.2007.05550.x; Prilloff S, 2010, EUR J NEUROSCI, V31, P521, DOI 10.1111/j.1460-9568.2010.07078.x; Rousseau V, 1999, NEUROREPORT, V10, P3387, DOI 10.1097/00001756-199911080-00024; Sabel BA, 1997, NAT MED, V3, P244, DOI 10.1038/nm0297-244; Sabel BA, 2011, RESTOR NEUROL NEUROS, V29, P493, DOI 10.3233/RNN-2011-0624; SAUTTER J, 1993, EUR J NEUROSCI, V5, P680, DOI 10.1111/j.1460-9568.1993.tb00533.x; SAUTTER J, 1991, BRAIN RES, V565, P23, DOI 10.1016/0006-8993(91)91732-G; Schatz A, 2011, INVEST OPHTH VIS SCI, V52, P4485, DOI 10.1167/iovs.10-6932	24	27	27	0	14	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	MAY 24	2013	543						1	6		10.1016/j.neulet.2013.03.013			6	Neurosciences	Neurosciences & Neurology	154BH	WOS:000319646000001	23523651				2021-06-18	
J	Hylin, MJ; Orsi, SA; Rozas, NS; Hill, JL; Zhao, J; Redell, JB; Moore, AN; Dash, PK				Hylin, Michael J.; Orsi, Sara A.; Rozas, Natalia S.; Hill, Julia L.; Zhao, Jing; Redell, John B.; Moore, Anthony N.; Dash, Pramod K.			Repeated Mild Closed Head Injury Impairs Short-Term Visuospatial Memory and Complex Learning	JOURNAL OF NEUROTRAUMA			English	Article						active place avoidance; axonal injury; context discrimination; neuroinflammation	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; FLUID PERCUSSION INJURY; ACTIVE PLACE AVOIDANCE; DORSAL HIPPOCAMPUS; COGNITIVE IMPAIRMENT; HISTOLOGICAL-CHANGES; PATTERN SEPARATION; FOOTBALL PLAYERS; MOUSE MODEL	Concussive force can cause neurocognitive and neurobehavioral dysfunction by inducing functional, electrophysiological, and/or ultrastructural changes within the brain. Although concussion-triggered symptoms typically subside within days to weeks in most people, in 15%-20% of the cases, symptomology can continue beyond this time point. Problems with memory, attention, processing speed, and cognitive flexibility (e.g., problem solving, conflict resolution) are some of the prominent post-concussive cognitive symptoms. Repeated concussions (with loss or altered consciousness), which are common to many contact sports, can exacerbate these symptoms. The pathophysiology of repeated concussions is not well understood, nor is an effective treatment available. In order to facilitate drug discovery to treat post-concussive symptoms (PCSs), there is a need to determine if animal models of repeated mild closed head injury (mCHI) can mimic the neurocognitive and histopathological consequences of repeated concussions. To this end, we employed a controlled cortical impact (CCI) device to deliver a mCHI directly to the skull of mice daily for 4 days, and examined the ensuing neurological and neurocognitive functions using beam balance, foot-fault, an abbreviated Morris water maze test, context discrimination, and active place avoidance tasks. Repeated mCHI exacerbated vestibulomotor, motor, short-term memory and conflict learning impairments as compared to a single mCHI. Learning and memory impairments were still observed in repeated mCHI mice when tested 3 months post-injury. Repeated mCHI also reduced cerebral perfusion, prolonged the inflammatory response, and in some animals, caused hippocampal neuronal loss. Our results show that repeated mCHI can reproduce some of the deficits seen after repeated concussions in humans and may be suitable for drug discovery studies and translational research.	[Hylin, Michael J.; Orsi, Sara A.; Rozas, Natalia S.; Hill, Julia L.; Zhao, Jing; Redell, John B.; Moore, Anthony N.; Dash, Pramod K.] Univ Texas Med Sch Houston, Dept Neurobiol & Anat, Houston, TX 77225 USA; [Dash, Pramod K.] Univ Texas Med Sch Houston, Vivian L Smith Dept Neurosurg, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas Med Sch Houston, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu	Hylin, Michael/U-2878-2019	Hill, Julia/0000-0003-4744-0532; Dash, Pramod/0000-0001-6746-1002; Rozas, Natalia/0000-0003-0848-0478	Institute for Rehabilitation and Research/Mission Connect; Vivian L. Smith Foundation; Gilson-Longenbaugh Foundation	This work was supported by The Institute for Rehabilitation and Research/Mission Connect; The Vivian L. Smith Foundation and the Gilson-Longenbaugh Foundation.	Aoyama N, 2008, BRAIN RES, V1230, P310, DOI 10.1016/j.brainres.2008.07.006; Baki SGA, 2009, BRAIN RES, V1280, P98, DOI 10.1016/j.brainres.2009.05.034; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Blum S, 1999, J NEUROSCI, V19, P3535; Burghardt NS, 2012, HIPPOCAMPUS, V22, P1795, DOI 10.1002/hipo.22013; Chen ZY, 2012, J NEUROTRAUM, V29, P268, DOI 10.1089/neu.2011.2057; Cimadevilla JM, 2000, NEUROSCI LETT, V285, P53, DOI 10.1016/S0304-3940(00)01019-3; Cimadevilla JM, 2001, P NATL ACAD SCI USA, V98, P3531, DOI 10.1073/pnas.051628398; Cimadevilla JM, 2001, BRAIN RES BULL, V54, P559, DOI 10.1016/S0361-9230(01)00448-8; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; d'Hemecourt P, 2011, CLIN SPORTS MED, V30, pviii; d'Hemecourt P, 2011, CLIN SPORT MED, V30, P63, DOI 10.1016/j.csm.2010.08.008; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Eakin K, 2012, J NEUROTRAUM, V29, P1180, DOI 10.1089/neu.2011.2192; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frankland PW, 1998, BEHAV NEUROSCI, V112, P863, DOI 10.1037/0735-7044.112.4.863; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Guzowski JF, 1997, P NATL ACAD SCI USA, V94, P2693, DOI 10.1073/pnas.94.6.2693; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Leutgeb JK, 2007, SCIENCE, V315, P961, DOI 10.1126/science.1135801; Levin HS, 2013, J NEUROTRAUM, V30, P610, DOI 10.1089/neu.2012.2394; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Redell JB, 2013, J NEUROTRAUM, V30, P752, DOI 10.1089/neu.2012.2437; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Sosin DM, 1996, BRAIN INJURY, V10, P47; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161; Zhao J, 2012, J NEUROTRAUM, V29, P1209, DOI 10.1089/neu.2011.1858; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511	51	27	27	0	37	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2013	30	9			SI		716	726		10.1089/neu.2012.2717			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	145BJ	WOS:000318987600004	23489238				2021-06-18	
J	Cusimano, MD; Sharma, B; Lawrence, DW; Ilie, G; Silverberg, S; Jones, R				Cusimano, Michael D.; Sharma, Bhanu; Lawrence, David W.; Ilie, Gabriela; Silverberg, Sarah; Jones, Rochelle			Trends in North American Newspaper Reporting of Brain Injury in Ice Hockey	PLOS ONE			English	Article							CONCUSSION; CHILDREN; IMPACT; HEAD; NHL	The frequency and potential long-term effects of sport-related traumatic brain injuries (TBI) make it a major public health concern. The culture within contact sports, such as ice hockey, encourages aggression that puts youth at risk of TBI such as concussion. Newspaper reports play an important role in conveying and shaping the culture around health-related behaviors. We qualitatively studied reports about sport-related TBI in four major North American newspapers over the last quarter-century. We used the grounded-theory approach to identify major themes and then did a content analysis to compare the frequency of key themes between 1998-2000 and 2009-2011. The major themes were: perceptions of brain injury, aggression, equipment, rules and regulations, and youth hockey. Across the full study period, newspaper articles from Canada and America portrayed violence and aggression that leads to TBI both as integral to hockey and as an unavoidable risk associated with playing the game. They also condemned violence in ice hockey, criticized the administrative response to TBI, and recognized the significance of TBI. In Canada, aggression was reported more often recently and there was a distinctive shift in portraying protective equipment as a solution to TBI in earlier years to a potential contributing factor to TBI later in the study period. American newspapers gave a greater attention to 'perception of risks' and the role of protective equipment, and discussed TBI in a broader context in the recent time period. Newspapers from both countries showed similar recent trends in regards to a need for rule changes to curb youth sport-related TBI. This study provides a rich description of the reporting around TBI in contact sport. Understanding this reporting is important for evaluating whether the dangers of sport-related TBI are being appropriately communicated by the media.	[Cusimano, Michael D.; Sharma, Bhanu; Lawrence, David W.; Ilie, Gabriela; Silverberg, Sarah; Jones, Rochelle] Univ Toronto, St Michaels Hosp, Keenan Res Ctr, Div Neurosurg,Dept Surg,Injury Prevent Res Off, Toronto, ON M5B 1W8, Canada	Cusimano, MD (corresponding author), Univ Toronto, St Michaels Hosp, Keenan Res Ctr, Div Neurosurg,Dept Surg,Injury Prevent Res Off, Toronto, ON M5B 1W8, Canada.	injuryprevention@smh.ca	Ilie, Gabriela/AAM-9122-2021; Meijer, Anna/K-5118-2016; Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650	Canadian Institutes of Health Research Strategic Team Grant in Applied Injury ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946]; Ontario Neurotrauma Foundation	This research was supported by the Canadian Institutes of Health Research Strategic Team Grant in Applied Injury Research # TIR-103946, and the Ontario Neurotrauma Foundation. The authors have completed this study on behalf of the Canadian Brain Injury and Violence Research Team. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali SH, 2006, URBAN STUD, V43, P491, DOI 10.1080/00420980500452458; Anderson C. A., 2007, SAGE HDB SOCIAL PSYC, P296; Anderson CA, 2002, ANNU REV PSYCHOL, V53, P27, DOI 10.1146/annurev.psych.53.100901.135231; Audit Bureau of Circulations, 2011, AV CIRC TOP 25 US DA; BANDURA A, 1978, J COMMUN, V28, P12, DOI 10.1111/j.1460-2466.1978.tb01621.x; Bauer M., 2000, QUALITATIVE RES TEXT; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; Bergeron LR, 2002, FAM SOC-J CONTEMP H, V83, P547, DOI 10.1606/1044-3894.48; Bowen Anne Phelan, 2003, J Emerg Nurs, V29, P287, DOI 10.1067/men.2003.90; Boxer P, 2009, J YOUTH ADOLESCENCE, V38, P417, DOI 10.1007/s10964-008-9335-2; Cantor J, 2000, J ADOLESCENT HEALTH, V27, P30, DOI 10.1016/S1054-139X(00)00129-4; Chapman S, 2005, MED J AUSTRALIA, V183, P247, DOI 10.5694/j.1326-5377.2005.tb07029.x; Council on Communications and Media, 2011, Pediatrics, V128, P201, DOI 10.1542/peds.2011-1066; Cusimano MD., 2011, OPEN MED-WARSAW, V5, P57; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gee CJ, 2011, BEHAVIORAL SPORT PSYCHOLOGY: EVIDENCE-BASED APPROACHES TO PERFORMANCE ENHANCEMENT, P199, DOI 10.1007/978-1-4614-0070-7_12; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; HERMAN E., 2002, MANUFACTURING CONSEN; Iyengar Shanto., 1991, IS ANYONE RESPONSIBL; Jordan Amy B, 2008, Adolesc Med State Art Rev, V19, P431; Katz E., 1955, PERSONAL INFLUENCE P; Kepner T, 2012, NY TIMES; Kirsh S. J., 2010, MEDIA YOUTH DEV PERS; LordMaes J, 1996, J LEARN DISABIL, V29, P609, DOI 10.1177/002221949602900605; Lupton D, 1998, SOC SCI MED, V46, P947, DOI 10.1016/S0277-9536(97)10013-2; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McGuire WJ, 2001, PUBLIC COMMUN CAMPAI, V3, P22, DOI [10.4135/9781452233260.n2, DOI 10.4135/9781452233260.N2, DOI 10.4135/9781452233260.n2]; Morse JM, 1998, QUAL HEALTH RES, V8, P147, DOI 10.1177/104973239800800201; National Center for Injury Prevention & Control, 2003, REP C MILD TRAUM BRA; Newspapers Canada, 2011, DAIL NEWSP CIRC PROV; Patton M, 2002, QUALITATIVE RES EVAL, P688; Putnam J. M., 2007, American Journal of Health Studies, V22, P130; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Sheldon JP, 2001, RES Q EXERCISE SPORT, V72, P304, DOI 10.1080/02701367.2001.10608965; Smith AM, 2000, AM SOC TEST MATER, V1341, P199, DOI 10.1520/STP15240S; Stevens ST, 2006, J SCI MED SPORT, V9, P238, DOI 10.1016/j.jsams.2006.03.025; Strauss A., 1998, BASICS QUALITATIVE R; Tesch R, 1991, QUALITATIVE HLTH RES, V1, P309, DOI DOI 10.1177/104973239100100303; Ward-Smith Peggy, 2005, J Neurosci Nurs, V37, P92; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Wennberg RA, 2008, CAN J NEUROL SCI, V35, P647, DOI 10.1017/S031716710000946X; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; WIDMEYER WN, 1984, J PSYCHOL, V117, P77, DOI 10.1080/00223980.1984.9923661; Youl PH, 2009, INT J CANCER, V124, P1963, DOI 10.1002/ijc.24154	47	27	27	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2013	8	4							e61865	10.1371/journal.pone.0061865			6	Multidisciplinary Sciences	Science & Technology - Other Topics	130IK	WOS:000317907200095	23613957	DOAJ Gold, Green Published			2021-06-18	
J	Guyette, FX; Farrell, K; Carlson, JN; Callaway, CW; Phrampus, P				Guyette, Francis X.; Farrell, Kathryn; Carlson, Jestin N.; Callaway, Clifton W.; Phrampus, Paul			COMPARISON OF VIDEO LARYNGOSCOPY AND DIRECT LARYNGOSCOPY IN A CRITICAL CARE TRANSPORT SERVICE	PREHOSPITAL EMERGENCY CARE			English	Article						prehospital; intubation; video laryngocopy; HEMS	HOSPITAL ENDOTRACHEAL INTUBATION; TRAUMATIC BRAIN-INJURY; TRACHEAL INTUBATION; AIRWAY MANAGEMENT; VIDEOLARYNGOSCOPE; GLIDESCOPE(R); METAANALYSIS; PREDICTORS; SUCCESS	Objective. We evaluated video laryngoscopy (VL) (C-MAC, Karl Storz, Tuttlingen, Germany) for use in a critical care transport system. We hypothesized that the total number of airway attempts would decrease when using a video laryngoscope versus use of direct laryngoscopy (DL). Methods. We performed a nonrandomized group-controlled trial where six aircraft were outfitted with VL and the remainder utilized DL responding to a mix of scene runs and interfacility transports. Our primary outcome measure was the number of intubation attempts. We also compared the first-pass success (FPS) rates, laryngoscopic grades, and frequencies of rescue device use (including utilization of surgical airways) between VL and DL. Results. Crews intubated 348 patients with VL and 510 with DL. Successful endotracheal intubation within three attempts occurred 97.6% (confidence interval [CI] 96.5-98.6) of the time. The FPS rate was 85.8% (CI 83.4-88.1). In this cohort of patients, VL did not differ from DL with respect to total number of airway attempts (1.17 [CI 1.11-1.22] vs. 1.16 [CI 1.12-1.20]), FPS rate (85.6% [CI 82-89%] vs. 86.1% [CI 83-89]), or use of rescue airways (2.6% vs. 2.2%). The laryngoscopic view was superior in the VL group relative to the DL group (median Cormack-Lehane grade 1 [interquartile range (IQR) 1, 2] vs. 2 [IQR 1, 2]). Conclusion. VL using the C-MAC video laryngoscope did not reduce the total number of airway attempts or improve intubation compared with DL in a system of highly trained providers.	[Guyette, Francis X.; Farrell, Kathryn; Carlson, Jestin N.; Callaway, Clifton W.] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA 15261 USA; [Guyette, Francis X.] STAT MedEvac, Dept Med, W Mifflin, PA USA; [Phrampus, Paul] Univ Pittsburgh, WISER Ctr, Pittsburgh, PA 15261 USA	Guyette, FX (corresponding author), Univ Pittsburgh, Dept Emergency Med, 3600 Forbes Ave,Iroquois Bldg, Pittsburgh, PA 15261 USA.	fguyette@statmedevac.com		Callaway, Clifton/0000-0002-3309-1573; Guyette, Francis/0000-0002-9151-4896			Aziz MF, 2012, ANESTHESIOLOGY, V116, P629, DOI 10.1097/ALN.0b013e318246ea34; Berg BW, 2009, STUD HEALTH TECHNOL, V142, P34, DOI 10.3233/978-1-58603-964-6-34; Carlson JN, 2012, PREHOSP EMERG CARE, V16, P293, DOI 10.3109/10903127.2011.640764; Cavus E, 2011, EMERG MED J, V28, P650, DOI 10.1136/emj.2010.098707; Cooper RM, 2005, CAN J ANAESTH, V52, P191, DOI 10.1007/BF03027728; Davis DP, 2006, PREHOSP EMERG CARE, V10, P356, DOI 10.1080/10903120600725751; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Griesdale DEG, 2012, CAN J ANESTH, V59, P41, DOI 10.1007/s12630-011-9620-5; Kim YM, 2011, PREHOSP EMERG CARE, V15, P98, DOI 10.3109/10903127.2010.514087; Low D, 2008, ANAESTHESIA, V63, P195, DOI 10.1111/j.1365-2044.2007.05323.x; Nakstad AR, 2009, ACTA ANAESTH SCAND, V53, P1257, DOI 10.1111/j.1399-6576.2009.02094.x; Nouruzi-Sedeh P, 2009, ANESTHESIOLOGY, V110, P32, DOI 10.1097/ALN.0b013e318190b6a7; Su YC, 2011, EUR J ANAESTH, V28, P788, DOI 10.1097/EJA.0b013e32834a34f3; Tremblay MH, 2008, ANESTH ANALG, V106, P1495, DOI 10.1213/ane.0b013e318168b38f; Wang HE, 2006, ACAD EMERG MED, V13, P372, DOI 10.1197/j.aem.2005.11.001; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wang Henry E, 2005, Prehosp Emerg Care, V9, P156; Wang HE, 2006, ANN EMERG MED, V47, P532, DOI 10.1016/j.annemergmed.2006.01.016; Wang HE, 2009, ANN EMERG MED, V54, P645, DOI 10.1016/j.annemergmed.2009.05.024; Wayne MA, 2010, PREHOSP EMERG CARE, V14, P278, DOI 10.3109/10903120903537189	20	27	28	0	4	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1090-3127			PREHOSP EMERG CARE	Prehosp. Emerg. Care	APR-JUN	2013	17	2					149	154		10.3109/10903127.2012.729128			6	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	099PU	WOS:000315634500002	23231426				2021-06-18	
J	Laxe, S; Zasler, N; Selb, M; Tate, R; Tormos, JM; Bernabeu, M				Laxe, Sara; Zasler, Nathan; Selb, Melissa; Tate, Robyn; Tormos, Jose M.; Bernabeu, Montserrat			Development of the International Classification of Functioning, Disability and Health core sets for traumatic brain injury: An International consensus process	BRAIN INJURY			English	Article						Traumatic brain injury; ICF; ICF core sets; functioning and disability; consensus conference	QUALITY-OF-LIFE; CONCEPTUAL DESCRIPTION; UNIFYING MODEL; ICF; TBI	Background: In a patient-oriented healthcare system, the integration of the functional status of the patient from the perspective of different professionals is understandable by the use of the International Classification of Functioning, Disability and Health. Objective: A formal decision-making and consensus process is presented to develop the first version of the International Classification on Functioning, Disability and Health (ICF) Core Sets for Traumatic Brain Injury. Method: A panel with the results from preparatory studies that included a literature review, a qualitative study, empirical data collection and an expert survey, was presented. A consensus conference was held in Barcelona, March 2010 and 23 professionals attended representing nine countries. Results: The preparatory studies identified 183 eligible categories. After the voting process, 139 constituted the Comprehensive Core Sets for TBI and 23 the Brief Core Sets for TBI. Conclusions: The consensus conference led to the integration of evidence and expert opinion based on the ICF. The adoption of the ICF Core Sets for TBI provides a basic international standard for the multidisciplinary assessment of a TBI patient's functioning.	[Laxe, Sara; Bernabeu, Montserrat] Univ Autonoma Barcelona, Brain Injury Unit, Inst Guttmann, Badalona 08916, Spain; [Zasler, Nathan] Concuss Care Ctr Virginia Ltd, Richmond, VA USA; [Zasler, Nathan] Tree Life Serv Inc, Richmond, VA USA; [Selb, Melissa] Guido A Zaech Inst GZI, Swiss Parapleg Res, ICF Res Branch Cooperat World Hlth Org Family Int, DIMDI, Nottwil, Switzerland; [Tate, Robyn] Univ Sydney, Sydney Med Sch, Northern Clin Sch, Rehabil Studies Unit, Ryde, NSW, Australia; [Tormos, Jose M.] Univ Autonoma Barcelona, Res Dept, Inst Guttmann, Badalona 08916, Spain	Laxe, S (corresponding author), Univ Autonoma Barcelona, Brain Injury Unit, Inst Guttmann, Cami Can Ruti Sn, Badalona 08916, Spain.	slaxe@guttmann.com		Tormos Munoz, Jose Maria/0000-0002-8764-2289			Alachini B, 2010, EUR J PHYS REHAB MED, V46, P27; Alguren B, 2012, NEUROREHAB NEURAL RE, V26, P266, DOI 10.1177/1545968311414204; Belmont A, 2009, NEUROREHAB NEURAL RE, V23, P939, DOI 10.1177/1545968309340327; Bernabeu M, 2009, NEUROREHAB NEURAL RE, V23, P464, DOI 10.1177/1545968308328725; Brage S, 2008, DISABIL REHABIL, V30, P1392, DOI 10.1080/09638280701642950; Cerniauskaite M, 2011, DISABIL REHABIL, V33, P281, DOI 10.3109/09638288.2010.529235; Cieza A, 2004, J REHABIL MED, V36, P9, DOI 10.1080/16501960410015353; Cieza A, 2010, SPINAL CORD, V48, P305, DOI 10.1038/sc.2009.183; Dewall Jeremy, 2010, JEMS, V35, P54, DOI 10.1016/S0197-2510(10)70095-4; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Ewert T, 2005, DISABIL REHABIL, V27, P367, DOI 10.1080/09638280400014014; Fleming J, 2011, BRAIN INJURY, V25, P806, DOI 10.3109/02699052.2011.585508; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Geyh S, 2004, J REHABIL MED, V36, P135, DOI 10.1080/16501960410016776; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Koskinen S, 2011, COMPARISON OF SUBJEC; Koskinen S, 2007, J REHABIL MED, V39, P467, DOI 10.2340/16501977-0077; Labi MLC, 2003, BRAIN INJURY, V17, P265, DOI 10.1080/0269905021000038410; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laxe S, 2012, CLIN NEUROLOGY NEURO; Laxe S, 2011, NEUROREHABILITATION, V29, P99, DOI 10.3233/NRE-2011-0683; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Pistarini C, 2011, DISABIL REHABIL, V33, P2333, DOI 10.3109/09638288.2011.570414; Rauch A, 2008, EUR J PHYS REHAB MED, V44, P329; Salter K, 2011, BRAIN INJURY, V25, P1147, DOI 10.3109/02699052.2011.613088; Stucki G, 2008, EUR J PHYS REHAB MED, V44, P315; Stucki G, 2003, DISABIL REHABIL, V25, P628, DOI 10.1080/09638280110070221; Stucki G, 2007, J REHABIL MED, V39, P279, DOI 10.2340/16501977-0041; Stucki G, 2007, J REHABIL MED, V39, P286, DOI 10.2340/16501977-0044; Sveen U, 2012, PROBLEMS IN FUNCTION; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	32	27	29	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2013	27	4					379	387		10.3109/02699052.2012.750757			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	117LG	WOS:000316954300001	23472615				2021-06-18	
J	Iverson, KM; Pogoda, TK; Gradus, JL; Street, AE				Iverson, Katherine M.; Pogoda, Terri K.; Gradus, Jaimie L.; Street, Amy E.			Deployment-Related Traumatic Brain Injury Among Operation Enduring Freedom/Operation Iraqi Freedom Veterans: Associations with Mental and Physical Health by Gender	JOURNAL OF WOMENS HEALTH			English	Article							POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; PSYCHIATRIC DIAGNOSES; RESILIENCE INVENTORY; SERVICE MEMBERS; WAR VETERANS; COMBAT; MILITARY; AFGHANISTAN; CONCUSSION	Background: Traumatic brain injury (TBI) research among Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) veterans has focused primarily on men. We examine associations between probable deployment-related TBI and postdeployment mental and physical health symptoms separately by gender. To identify unique associations of probable TBI with health symptoms, analyses were also conducted separately for veterans with and without probable posttraumatic stress disorder (PTSD). Methods: A mail survey, including self-report measures of probable deployment-related TBI and mental and physical health symptoms, was completed by 2348 OEF/OIF veterans (51% female), sampled randomly within gender from a national roster. We conducted logistic regressions stratified by gender and probable PTSD status to evaluate associations between probable TBI and health symptoms. Results: Of the respondents, 10.7% of women and 19.7% of men screened positive for probable deployment-related TBI. Probable TBI was significantly associated with increased risk of mental and physical health symptoms for both genders, even after adjusting for potential confounders. Odds ratios for the associations of probable TBI with health symptoms ranged between 2.63 and 9.20 for women and between 1.94 and 7.44 for men. Among veterans with probable PTSD, symptomatic anxiety and symptomatic physical health remained associated with probable TBI. Among veterans without probable PTSD, TBI remained strongly associated with all health symptoms for women and symptomatic anxiety and physical health for men, suggesting an association between TBI and some health symptoms independent of PTSD. Conclusions: Strong associations between probable TBI and health symptoms for women and men confirm the importance of screening for TBI and treatment of associated health symptoms for all OEF/OIF veterans.	[Iverson, Katherine M.; Gradus, Jaimie L.; Street, Amy E.] VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA 02130 USA; [Iverson, Katherine M.; Gradus, Jaimie L.; Street, Amy E.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Pogoda, Terri K.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA; [Pogoda, Terri K.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA; [Gradus, Jaimie L.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA	Iverson, KM (corresponding author), VA Boston Healthcare Syst, 150 S Huntington Ave 116B-3, Boston, MA 02130 USA.	katherine.iverson@va.gov	Pogoda, Terri/F-6243-2012	Pogoda, Terri/0000-0003-1397-8780; Street, Amy/0000-0003-4554-9075; Gradus, Jaimie/0000-0003-1459-5327	National Center for PTSD, Mental Health Services, Department of Veterans Affairs; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development (HSRD) ServicesUS Department of Veterans Affairs [CDA 10-029]	This research was supported by the National Center for PTSD, Mental Health Services, Department of Veterans Affairs. The funding agency was not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript. Additionally, the research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development (HSR&D) Services as part of Dr. Katherine Iverson's HSR&D Career Development Award (CDA 10-029). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.	ANDRESEN EM, 1994, AM J PREV MED, V10, P77; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Carlson KF, 2010, J HEAD TRAUMA REHAB, V26, P103; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of Veterans Affairs and Department of Defense, 2009, VA DOD CLIN PRACT GU; Dillman D. A., 2007, MAIL INTERNET SURVEY, V2; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Heltemes KJ, 2011, MIL MED, V176, P147, DOI 10.7205/MILMED-D-10-00191; Hendricks AM, 2013, BRAIN INJURY, V27, P125, DOI 10.3109/02699052.2012.729284; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Iverson KM, 2011, WOMEN HEALTH ISS, V21, pS210, DOI 10.1016/j.whi.2011.04.019; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; King DW, 2003, MANUAL DEPLOYMENT RI; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Kroenke K, 2002, PSYCHOSOM MED, V64, P258, DOI 10.1097/00006842-200203000-00008; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; Lovibond S.H., 1995, MANUAL DEPRESSION AN; Maguen S, 2010, AM J PUBLIC HEALTH, V100, P2450, DOI 10.2105/AJPH.2009.166165; Mattocks KM, 2012, SOC SCI MED, V74, P537, DOI 10.1016/j.socscimed.2011.10.039; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Pogoda TK, 2012, J REHABIL RES DEV, V49, P971, DOI 10.1682/JRRD.2011.06.0099; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2012, PTSD MILD TRAUMATIC, P199; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Smith B, 2007, AM J EPIDEMIOL, V166, P1345, DOI 10.1093/aje/kwm212; Street AE, J GEN INTER IN PRESS; Street AE, 2009, CLIN PSYCHOL REV, V29, P685, DOI 10.1016/j.cpr.2009.08.007; Tanielian T, 2008, INVISIBLE WOUNDS WAR; U.S. General Accounting Office, 2008, GAO08276; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Weathers F. W., 1993, INT SOC TRAUM STRESS; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f	51	27	27	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1540-9996	1931-843X		J WOMENS HEALTH	J. Womens Health	MAR	2013	22	3					267	275		10.1089/jwh.2012.3755			9	Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies	Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies	105IU	WOS:000316061700134	23421581				2021-06-18	
J	Pastotter, B; Weber, J; Bauml, KHT				Pastoetter, Bernhard; Weber, Jasmin; Baeuml, Karl-Heinz T.			Using Testing to Improve Learning After Severe Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; memory; learning; testing; rehabilitation	RETRIEVAL PRACTICE; MEMORY; BUILDUP	Objective: Recent work in cognitive psychology suggests that testing can increase memory for both previously and subsequently studied information. Here we examined whether these beneficial (backward and forward) effects of testing generalize to individuals with severe traumatic brain injury (TBI). Method: Twenty-four persons with severe TBI, 12.7 years postinjury, and 12 healthy controls participated in the study. Participants studied three lists of items in anticipation of a final cumulative recall test. They were tested immediately between the study of lists or not. Results: Immediate testing of Lists 1 and 2 enhanced recall of both the previously studied information (Lists 1 and 2) and the subsequently studied information (List 3). The enhancement for the three lists arose for individuals with severe TBI and healthy controls, and did not differ in size between subject groups. Conclusion: The findings indicate that TBI persons show a very general benefit from testing, including both backward and forward effects of retrieval practice. Testing thus might be a powerful technique to improve learning and memory in persons with severe TBI.	[Pastoetter, Bernhard; Weber, Jasmin; Baeuml, Karl-Heinz T.] Univ Regensburg, Dept Expt Psychol, D-93040 Regensburg, Germany	Pastotter, B (corresponding author), Univ Regensburg, Dept Expt Psychol, Univ Str 31, D-93040 Regensburg, Germany.	bernhard.pastoetter@psychologie.uni-regensburg.de	Pastotter, Bernhard/B-3498-2011; Pastotter, Bernhard/AAF-7997-2019	Pastotter, Bernhard/0000-0001-7364-4702			Bauml KHT, 2013, J MEM LANG, V68, P39, DOI 10.1016/j.jml.2012.07.006; Blanchet S, 2009, BRAIN INJURY, V23, P111, DOI 10.1080/02699050802649688; Carpenter SK, 2009, J EXP PSYCHOL LEARN, V35, P1563, DOI 10.1037/a0017021; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; Harting C., 2000, WECHSLER MEMORY SCAL; Haslam C, 2011, J CLIN EXP NEUROPSYC, V33, P432, DOI 10.1080/13803395.2010.533155; Karpicke JD, 2012, CURR DIR PSYCHOL SCI, V21, P157, DOI 10.1177/0963721412443552; Karpicke JD, 2011, SCIENCE, V331, P772, DOI 10.1126/science.1199327; Kornell N, 2011, J MEM LANG, V65, P85, DOI 10.1016/j.jml.2011.04.002; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; Nunes LD, 2012, MEMORY, V20, P138, DOI 10.1080/09658211.2011.648198; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Pastotter B, 2011, J EXP PSYCHOL LEARN, V37, P287, DOI 10.1037/a0021801; Pyc MA, 2010, SCIENCE, V330, P335, DOI 10.1126/science.1191465; Roediger HL, 2011, TRENDS COGN SCI, V15, P20, DOI 10.1016/j.tics.2010.09.003; Roediger HL, 2006, PSYCHOL SCI, V17, P249, DOI 10.1111/j.1467-9280.2006.01693.x; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Sumowski JF, 2010, J INT NEUROPSYCH SOC, V16, P1147, DOI 10.1017/S1355617710001128; Sumowski JF, 2010, NEUROPSYCHOLOGY, V24, P267, DOI 10.1037/a0017533; Szpunar KK, 2008, J EXP PSYCHOL LEARN, V34, P1392, DOI 10.1037/a0013082; TEASDALE G, 1974, LANCET, V2, P81; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Wegner R., 1980, VERBALER KURZ INTELL; Weinstein Y, 2011, PSYCHON B REV, V18, P518, DOI 10.3758/s13423-011-0085-x; Williamson D. J. G., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [10.1037/10198-001, DOI 10.1037/10198-001]; Wilson Barbara A., 2009, MEMORY REHABILITATIO; Wissman KT, 2011, PSYCHON B REV, V18, P1140, DOI 10.3758/s13423-011-0140-7; Wulfing G., 1971, WORT BILD TEST WBT 1; Zimmermann P., 2002, TESTBATTERIE AUFMERK	30	27	28	0	14	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAR	2013	27	2					280	285		10.1037/a0031797			6	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	111NT	WOS:000316528700015	23527656				2021-06-18	
J	Pomschar, A; Koerte, I; Lee, S; Laubender, RP; Straube, A; Heinen, F; Ertl-Wagner, B; Alperin, N				Pomschar, Andreas; Koerte, Inga; Lee, Sang; Laubender, Ruediger P.; Straube, Andreas; Heinen, Florian; Ertl-Wagner, Birgit; Alperin, Noam			MRI Evidence for Altered Venous Drainage and Intracranial Compliance in Mild Traumatic Brain Injury	PLOS ONE			English	Article							PHASE-CONTRAST MRI; HEAD-INJURY; BLOOD-FLOW; PHYSIOLOGY; OUTFLOW; HUMANS; SYSTEM; ICP	Purpose: To compare venous drainage patterns and associated intracranial hydrodynamics between subjects who experienced mild traumatic brain injury (mTBI) and age-and gender-matched controls. Methods: Thirty adult subjects (15 with mTBI and 15 age- and gender-matched controls) were investigated using a 3T MR scanner. Time since trauma was 0.5 to 29 years (mean 11.4 years). A 2D-time-of-flight MR-venography of the upper neck was performed to visualize the cervical venous vasculature. Cerebral venous drainage through primary and secondary channels, and intracranial compliance index and pressure were derived using cine-phase contrast imaging of the cerebral arterial inflow, venous outflow, and the craniospinal CSF flow. The intracranial compliance index is the defined as the ratio of maximal intracranial volume and pressure changes during the cardiac cycle. MR estimated ICP was then obtained through the inverse relationship between compliance and ICP. Results: Compared to the controls, subjects with mTBI demonstrated a significantly smaller percentage of venous outflow through internal jugular veins (60.9+/-21% vs. controls: 76.8+/-10%; p=0.01) compensated by an increased drainage through secondary veins (12.3+/-10.9% vs. 5.5+/-3.3%; p<0.03). Mean intracranial compliance index was significantly lower in the mTBI cohort (5.8+/-1.4 vs. controls 8.4+/-1.9; p<0.0007). Consequently, MR estimate of intracranial pressure was significantly higher in the mTBI cohort (12.5+/-2.9 mmHg vs. 8.8+/-2.0 mmHg; p<0.0007). Conclusions: mTBI is associated with increased venous drainage through secondary pathways. This reflects higher outflow impedance, which may explain the finding of reduced intracranial compliance. These results suggest that hemodynamic and hydrodynamic changes following mTBI persist even in the absence of clinical symptoms and abnormal findings in conventional MR imaging.	[Pomschar, Andreas; Koerte, Inga; Ertl-Wagner, Birgit] Univ Munich, Inst Clin Radiol, Munich, Germany; [Lee, Sang; Alperin, Noam] Univ Miami, Miller Sch Med, Dept Radiol, Miami, FL 33136 USA; [Laubender, Ruediger P.] Univ Munich, Inst Med Informat Biometry & Epidemiol IBE, Munich, Germany; [Straube, Andreas] Univ Munich, Dept Neurol, D-80539 Munich, Germany; [Heinen, Florian] Univ Munich, Dept Pediat Neurol Dev Med, Dr von Hauners Childrens Hosp, Munich, Germany	Alperin, N (corresponding author), Univ Miami, Miller Sch Med, Dept Radiol, Miami, FL 33136 USA.	nalperin@med.miami.edu	Heinen, Florian/B-6594-2015; Ertl-Wagner, Birgit/AAD-5708-2020	Heinen, Florian/0000-0002-3872-6136; Ertl-Wagner, Birgit/0000-0002-7896-7049	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS05212]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052122] Funding Source: NIH RePORTER	This work was supported in part by National Institutes of Health award R01 NS05212. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alperin N, 2005, ACTA NEUROCHIR SUPPL, V95, P191; Alperin N, 2005, ACT NEUR S, V95, P129; Alperin N, 2005, J MAGN RESON IMAGING, V22, P591, DOI 10.1002/jmri.20427; Alperin N, 2003, MAGNET RESON MED, V49, P934, DOI 10.1002/mrm.10455; Alperin N, 2002, P INT SOC MAG RESON, P2; Alperin NJ, 2000, RADIOLOGY, V217, P877, DOI 10.1148/radiology.217.3.r00dc42877; Bailey DM, 2012, CLIN SCI LOND; BATSON OV, 1957, AMER J ROENTGENOL RA, V78, P195; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; Doepp F, 2004, NEURORADIOLOGY, V46, P565, DOI 10.1007/s00234-004-1213-3; Ertl-Wagner B, 2012, MULT SCLER J, V18, P1000, DOI 10.1177/1352458511432742; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Kivioja J, 2001, J CLIN IMMUNOL, V21, P272, DOI 10.1023/A:1010931309088; Koerte IK, 2011, INVEST RADIOL; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MARMAROU A, 1975, J NEUROSURG, V43, P523, DOI 10.3171/jns.1975.43.5.0523; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P289; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Miyati T, 2007, J MAGN RESON IMAGING, V26, P274, DOI 10.1002/jmri.20999; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Piccio L, 2005, J IMMUNOL, V174, P5805, DOI 10.4049/jimmunol.174.9.5805; Piechnik SK, 2001, NEUROSURGERY, V49, P1214, DOI 10.1097/00006123-200111000-00034; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Schaller B, 2004, BRAIN RES REV, V46, P243, DOI 10.1016/j.brainresrev.2004.04.005; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Stoquart-ElSankari S, 2009, J CEREBR BLOOD F MET, V29, P1208, DOI [10.1038/jcbfm.2009.29, 10.1038/sj.jcbfm.jcbfm200929]; Tain RW, 2009, J MAGN RESON IMAGING, V30, P878, DOI 10.1002/jmri.21925; Tain RW, 2009, IEEE T BIO-MED ENG, V56, P544, DOI 10.1109/TBME.2008.2006010; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Zhang K, 2010, EXP BRAIN RES	37	27	29	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2013	8	2							e55447	10.1371/journal.pone.0055447			9	Multidisciplinary Sciences	Science & Technology - Other Topics	092WJ	WOS:000315153400096	23405151	DOAJ Gold, Green Published			2021-06-18	
J	Sinclair, KL; Ponsford, JL; Rajaratnam, SMW; Anderson, C				Sinclair, Kelly L.; Ponsford, Jennie L.; Rajaratnam, Shantha M. W.; Anderson, Clare			Sustained attention following traumatic brain injury: Use of the Psychomotor Vigilance Task	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Traumatic brain injury; Sustained attention; Psychomotor Vigilance Task; Fatigue; Sleep disturbance; Daytime sleepiness; Information-processing speed	EPWORTH SLEEPINESS SCALE; EXCESSIVE DAYTIME SLEEPINESS; RESPONSE-TIME DISTRIBUTIONS; CLOSED-HEAD INJURY; OBJECTIVE MEASUREMENT; COGNITIVE IMPAIRMENT; SELECTIVE ATTENTION; MENTAL EFFORT; TEST PVT; PERFORMANCE	Objective: Deficits in sustained attention are common following traumatic brain injury (TBI), as a result of primary (i.e., neuropathology) and/or secondary factors (i.e., fatigue, sleep disturbance, depressed mood). The extent to which secondary factors play a role in attention deficits is relatively unexamined. Moreover, the Psychomotor Vigilance Task (PVT) is seldom used in TBI assessment despite its sensitivity to secondary factors observed following injury. The primary aim of the current study was to examine the usefulness of the auditory PVT in identifying attentional difficulties in patients with TBI compared with noninjured controls, and also to explore the impact of fatigue, sleep quality, and daytime sleepiness on sustained attention performances. Method: Participants (n=20 per group) completed the auditory PVT and self-report measures of fatigue, sleep quality, daytime sleepiness, and depression. Results: Compared to controls, patients with TBI had widespread PVT deficits including slower response times, increased response variability and attention lapses, and delayed responding in the slowest 10% of responses. Distribution analyses suggested this was likely due to generalized cognitive slowing. Self-reported secondary factors had varying impacts on aspects of PVT performance, with self-reported fatigue exhibiting a more global impact on attention performance. Conclusions: The auditory PVT is a sensitive measure of sustained attention deficits in patients with TBI, with aspects of performance influenced by fatigue, sleep disturbance, and depression.	[Sinclair, Kelly L.; Ponsford, Jennie L.; Rajaratnam, Shantha M. W.; Anderson, Clare] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia; [Ponsford, Jennie L.] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Richmond, Vic, Australia	Anderson, C (corresponding author), Monash Univ, Fac Med Nursing & Hlth Sci, Sch Psychol & Psychiat, Clayton Campus, Clayton, Vic 3800, Australia.	clare.anderson@monash.edu		Rajaratnam, Shantha/0000-0001-7527-8558; Anderson, Clare/0000-0002-5086-4865	Transport Accident Commission; Jack Brockhoff Foundation; NHMRC (National Health and Medical Research Council) Centre for Integrated Research and Understanding of Sleep (CIRUS), The University of Sydney; RACV (Royal Automobile Club of Victoria) Sir Edmund Herring Memorial Scholarship; Psychology Press; Guilford Press; Vanda Pharmaceuticals; Takeda Pharmaceuticals North AmericaTakeda Pharmaceutical Company Ltd; Philips Lighting; Philips Respironics; Cephalon; ResMed Foundation; Sanofi-AventisSanofi-Aventis; VicRoads; Brown Medical School/Rhode Island Hospital; Ausmed	We thank the Monash Epworth Rehabilitation Research Centre for assistance with participant recruitment. This work was supported by funding from the Transport Accident Commission; Jack Brockhoff Foundation; NHMRC (National Health and Medical Research Council) Centre for Integrated Research and Understanding of Sleep (CIRUS), The University of Sydney; and RACV (Royal Automobile Club of Victoria) Sir Edmund Herring Memorial Scholarship. K. L. S. reports no conflicts of interest. J.L.P. reports that she has received royalties from Psychology Press and Guilford Press for textbooks on traumatic brain injury and received an honorarium, travel, and accommodation support to present a lecture on fatigue and sleep disturbance at the TBI Interagency Conference in Washington, DC, May 2011. S. W. R. reports that he has served as a consultant through his institution to Vanda Pharmaceuticals, Philips Respironics, EdanSafe, The Australian Workers' Union, and National Transport Commission and has through his institution received research grants and/or unrestricted educational grants from Vanda Pharmaceuticals, Takeda Pharmaceuticals North America, Philips Lighting, Philips Respironics, Cephalon, and ResMed Foundation, and reimbursements for conference travel expenses from Vanda Pharmaceuticals. His institution has received equipment donations or other support from Optalert (TM), Compumedics, and Tyco Healthcare. He has also served as an expert witness and/or consultant to shift work organizations. C.A. reports receiving a research award/prize from Sanofi-Aventis, contract research support from VicRoads, and lecturing fees from Brown Medical School/Rhode Island Hospital and Ausmed. In addition, she has served as consultant to the Rail, Bus and Tram Union to produce a report on best practice management of fatigue in the rail industry, through an agreement with Monash University.	Ambulatory Monitoring Inc, 2012, REACT VERS 1 1 05; Anderson C, 2012, SLEEP, V35, P1137, DOI 10.5665/sleep.2004; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Balkin TJ, 2008, CHEST, V134, P653, DOI 10.1378/chest.08-1064; Basner M, 2011, ACTA ASTRONAUT, V69, P949, DOI 10.1016/j.actaastro.2011.07.015; Basner M, 2011, SLEEP, V34, P581, DOI 10.1093/sleep/34.5.581; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Belmont A, 2009, NEUROREHAB NEURAL RE, V23, P939, DOI 10.1177/1545968309340327; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Blatter K, 2006, BEHAV BRAIN RES, V168, P312, DOI 10.1016/j.bbr.2005.11.018; Bloomfield ILM, 2010, J INT NEUROPSYCH SOC, V16, P17, DOI 10.1017/S1355617709990798; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Dinges DF, 1997, SLEEP, V20, P267; DINGES DF, 1985, BEHAV RES METH INSTR, V17, P652, DOI 10.3758/BF03200977; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Doran SM, 2001, ARCH ITAL BIOL, V139, P253; Dorrian J., 2005, SLEEP DEPRIVATION CL, P39; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Edinger JD, 2008, SLEEP, V31, P599, DOI 10.1093/sleep/31.5.599; Epstein JN, 2010, J INT NEUROPSYCH SOC, V16, P138, DOI 10.1017/S1355617709991111; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Ginstfeldt T, 2010, BRAIN INJURY, V24, P1123, DOI 10.3109/02699052.2010.506853; Hervey AS, 2006, CHILD NEUROPSYCHOL, V12, P125, DOI 10.1080/09297040500499081; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; Himanen L, 2009, BRAIN INJURY, V23, P220, DOI 10.1080/02699050902748323; Hultsch DF, 2002, J GERONTOL B-PSYCHOL, V57, pP101, DOI 10.1093/geronb/57.2.P101; Jewett ME, 1999, SLEEP, V22, P171, DOI 10.1093/sleep/22.2.171; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; JOHNS MW, 1994, SLEEP, V17, P703, DOI 10.1093/sleep/17.8.703; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Jung CM, 2011, J SLEEP RES, V20, P348, DOI 10.1111/j.1365-2869.2010.00877.x; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kim H, 2007, SLEEP, V30, P1309, DOI 10.1093/sleep/30.10.1309; KINDLON DJ, 1998, CHILD PSYCHOL PSYCHI, V3, P72, DOI DOI 10.1017/S136064179800149X; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lee IS, 2010, J CLIN SLEEP MED, V6, P163; Leth-Steensen C, 2000, ACTA PSYCHOL, V104, P167, DOI 10.1016/S0001-6918(00)00019-6; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lim JL, 2008, ANN NY ACAD SCI, V1129, P305, DOI 10.1196/annals.1417.002; LUCE RD, 1986, REPONSE TIMES THEIR; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Myerson J, 2007, J EXP ANAL BEHAV, V88, P319, DOI 10.1901/jeab.2007.88-319; Netzer NC, 1999, ANN INTERN MED, V131, P485, DOI 10.7326/0003-4819-131-7-199910050-00002; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; PARSONS LC, 1982, NURS RES, V31, P260; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; Riggio S, 2011, NEUROL CLIN, V29, P35, DOI 10.1016/j.ncl.2010.10.008; Rouder JN, 2005, PSYCHON B REV, V12, P195, DOI 10.3758/BF03257252; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Santhi N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001233; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Short MA, 2012, SLEEP MED, V13, P378, DOI 10.1016/j.sleep.2011.11.005; Slovarp L, 2012, BRAIN INJURY, V26, P48, DOI 10.3109/02699052.2011.635355; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Systat Software Inc, 2008, SIGM VERS 11 0; Teicher MH, 1996, J AM ACAD CHILD PSY, V35, P334, DOI 10.1097/00004583-199603000-00015; Thomas M, 2000, J SLEEP RES, V9, P335, DOI 10.1046/j.1365-2869.2000.00225.x; Van Dongen HPA, 2003, SLEEP, V26, P117, DOI 10.1093/sleep/26.2.117; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Verma A, 2007, J CLIN SLEEP MED, V3, P357; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Wyatt JK, 1999, AM J PHYSIOL-REG I, V277, pR1152; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	89	27	27	0	27	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB 1	2013	35	2					210	224		10.1080/13803395.2012.762340			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	092HM	WOS:000315111000009	23391455				2021-06-18	
J	Berryhill, ME; Wiener, M; Stephens, JA; Lohoff, FW; Coslett, HB				Berryhill, Marian E.; Wiener, Martin; Stephens, Jaclyn A.; Lohoff, Falk W.; Coslett, H. Branch			COMT and ANKK1-Taq-Ia Genetic Polymorphisms Influence Visual Working Memory	PLOS ONE			English	Article							CATECHOL-O-METHYLTRANSFERASE; D2 RECEPTOR GENE; TRAUMATIC BRAIN-INJURY; RIGHT PARIETAL LOBE; VAL(158)MET POLYMORPHISM; PREFRONTAL CORTEX; BASAL GANGLIA; HEALTHY-VOLUNTEERS; EXECUTIVE FUNCTION; MESSENGER-RNA	Complex cognitive tasks such as visual working memory (WM) involve networks of interacting brain regions. Several neurotransmitters, including an appropriate dopamine concentration, are important for WM performance. A number of gene polymorphisms are associated with individual differences in cognitive task performance. COMT, for example, encodes catechol-o-methyl transferase the enzyme primarily responsible for catabolizing dopamine in the prefrontal cortex. Striatal dopamine function, linked with cognitive tasks as well as habit learning, is influenced by the Taq-Ia polymorphism of the DRD2/ANKK1 gene complex; this gene influences the density of dopamine receptors in the striatum. Here, we investigated the effects of these polymorphisms on a WM task requiring the maintenance of 4 or 6 items over delay durations of 1 or 5 seconds. We explored main effects and interactions between the COMT and DRD2/ANKK1-Taq-Ia polymorphisms on WM performance. Participants were genotyped for COMT (Val(158) Met) and DRD2/ANKK1-Taq-Ia (A1+, A1-) polymorphisms. There was a significant main effect of both polymorphisms. Participants' WM reaction times slowed with increased Val loading such that the Val/Val homozygotes made the slowest responses and the Met/Met homozygotes were the fastest. Similarly, WM reaction times were slower and more variable for the DRD2/ANKK1-Taq-Ia A1+ group than the A1- group. The main effect of COMT was only apparent in the DRD2/ANKK1-Taq-Ia A1- group. These findings link WM performance with slower dopaminergic metabolism in the prefrontal cortex as well as a greater density of dopamine receptors in the striatum.	[Berryhill, Marian E.; Stephens, Jaclyn A.] Univ Nevada, Dept Psychol, Memory & Brain Lab, Reno, NV 89557 USA; [Wiener, Martin; Coslett, H. Branch] Univ Penn, Dept Neurol, Perelman Sch Med, Lab Cognit & Neural Stimulat, Philadelphia, PA 19104 USA; [Lohoff, Falk W.] Univ Penn, Dept Psychiat, Perelman Sch Med, Translat Res Lab,Ctr Neurobiol & Behav, Philadelphia, PA 19104 USA	Berryhill, ME (corresponding author), Univ Nevada, Dept Psychol, Memory & Brain Lab, Reno, NV 89557 USA.	mberryhill@unr.edu	Lohoff, Falk W/M-7951-2016	Berryhill, Marian/0000-0002-8218-6587	University of Nevada; COBRE [1P20GM103650-01, R15EY022775]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R15EY022775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103650] Funding Source: NIH RePORTER	This work was supported by faculty start-up funds generously provided by the University of Nevada to MB and by COBRE 1P20GM103650-01 (PI M. Webster, project PI MB) and R15EY022775 to MB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguilera M, 2008, AM J MED GENET B, V147B, P898, DOI 10.1002/ajmg.b.30705; Allen RJ, 2012, Q J EXP PSYCHOL, V65, P2369, DOI 10.1080/17470218.2012.687384; Anderson DE, 2012, J COGNITIVE NEUROSCI, V24, P1069, DOI 10.1162/jocn_a_00207; Arnsten AFT, 1998, TRENDS COGN SCI, V2, P436, DOI 10.1016/S1364-6613(98)01240-6; Backman L, 2011, SCIENCE, V333, P718, DOI 10.1126/science.1204978; Baier B, 2010, J NEUROSCI, V30, P9788, DOI 10.1523/JNEUROSCI.1513-10.2010; Barnett JH, 2007, MOL PSYCHIATR, V12, P502, DOI 10.1038/sj.mp.4001973; Barnett JH, 2008, BIOL PSYCHIAT, V64, P137, DOI 10.1016/j.biopsych.2008.01.005; Berryhill ME, 2008, NEUROPSYCHOLOGIA, V46, P1775, DOI 10.1016/j.neuropsychologia.2008.03.005; Berryhill ME, 2008, NEUROPSYCHOLOGIA, V46, P1767, DOI 10.1016/j.neuropsychologia.2008.01.009; Berryhill ME, 2010, NEUROSCI LETT, V479, P312, DOI 10.1016/j.neulet.2010.05.087; Bilder RM, 2004, NEUROPSYCHOPHARMACOL, V29, P1943, DOI 10.1038/sj.npp.1300542; Bogacz R, 2010, TRENDS NEUROSCI, V33, P10, DOI 10.1016/j.tins.2009.09.002; Boscarino JA, 2012, NEUROPSYCH DIS TREAT, V8, P131, DOI 10.2147/NDT.S29508; Bruder GE, 2005, BIOL PSYCHIAT, V58, P901, DOI 10.1016/j.biopsych.2005.05.010; CAMPS M, 1989, NEUROSCIENCE, V28, P275, DOI 10.1016/0306-4522(89)90179-6; Chen JS, 2004, AM J HUM GENET, V75, P807, DOI 10.1086/425589; Colzato LS, 2010, NEUROPSYCHOLOGIA, V48, P2764, DOI 10.1016/j.neuropsychologia.2010.04.023; Cools R, 2008, J NEUROSCI, V28, P1208, DOI 10.1523/JNEUROSCI.4475-07.2008; Cools R, 2011, CURR OPIN NEUROBIOL, V21, P402, DOI 10.1016/j.conb.2011.04.002; Cools R, 2011, BIOL PSYCHIAT, V69, pE113, DOI 10.1016/j.biopsych.2011.03.028; de Frias CM, 2005, J COGNITIVE NEUROSCI, V17, P1018, DOI 10.1162/0898929054475136; Diamond A, 2007, CEREB CORTEX, V17, pI161, DOI [10.1093/cercor/bhm082, 10.1093/cercor/blini082]; Diaz-Asper CM, 2008, BIOL PSYCHIAT, V63, P72, DOI 10.1016/j.biopsych.2007.03.031; Dickinson D, 2009, NEUROSCIENCE, V164, P72, DOI 10.1016/j.neuroscience.2009.05.014; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Forstmann BU, 2010, P NATL ACAD SCI USA, V107, P15916, DOI 10.1073/pnas.1004932107; Frank MJ, 2011, NEUROPSYCHOPHARMACOL, V36, P133, DOI 10.1038/npp.2010.96; Gogos JA, 1998, P NATL ACAD SCI USA, V95, P9991, DOI 10.1073/pnas.95.17.9991; Goldberg TE, 2003, ARCH GEN PSYCHIAT, V60, P889, DOI 10.1001/archpsyc.60.9.889; Gruber AJ, 2006, J COMPUT NEUROSCI, V20, P153, DOI 10.1007/s10827-005-5705-x; Hazy TE, 2006, NEUROSCIENCE, V139, P105, DOI 10.1016/j.neuroscience.2005.04.067; Hirvonen MM, 2009, PROG NEURO-PSYCHOPH, V33, P630, DOI 10.1016/j.pnpbp.2009.02.021; Ho T, 2012, J NEUROSCI, V32, P7992, DOI 10.1523/JNEUROSCI.0340-12.2012; Jonsson EG, 1999, MOL PSYCHIATR, V4, P290, DOI 10.1038/sj.mp.4000532; Malhotra AK, 2002, AM J PSYCHIAT, V159, P652, DOI 10.1176/appi.ajp.159.4.652; Matsumoto M, 2003, NEUROSCIENCE, V116, P127, DOI 10.1016/S0306-4522(02)00556-0; Mattay VS, 2003, P NATL ACAD SCI USA, V100, P6186, DOI 10.1073/pnas.0931309100; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; Mcnab F, 2008, NAT NEUROSCI, V11, P103, DOI 10.1038/nn2024; Meyer-Lindenberg A, 2005, NAT NEUROSCI, V8, P594, DOI 10.1038/nn1438; Mier D, 2010, MOL PSYCHIATR, V15, P918, DOI 10.1038/mp.2009.36; Nagel IE, 2008, FRONT HUM NEUROSCI, V2, DOI 10.3389/neuro.09.001.2008; Neville MJ, 2004, HUM MUTAT, V23, P540, DOI 10.1002/humu.20039; Noble E P, 2000, Pharmacogenomics, V1, P309, DOI 10.1517/14622416.1.3.309; Nolan KA, 2004, AM J PSYCHIAT, V161, P359, DOI 10.1176/appi.ajp.161.2.359; O'Reilly RC, 2006, NEURAL COMPUT, V18, P283, DOI 10.1162/089976606775093909; Oroszi G, 2004, PHARMACOGENOMICS, V5, P1037, DOI 10.1517/14622416.5.8.1037; Pohjalainen T, 1998, MOL PSYCHIATR, V3, P256, DOI 10.1038/sj.mp.4000350; Savitz J, 2006, GENES BRAIN BEHAV, V5, P311, DOI 10.1111/j.1601-183X.2005.00163.x; Schellekens AF, 2012, ADDICTION BIOL; Slifstein M, 2008, MOL PSYCHIATR, V13, P821, DOI 10.1038/mp.2008.19; Stefanis NC, 2005, AM J PSYCHIAT, V162, P1752, DOI 10.1176/appi.ajp.162.9.1752; Stelzel C, 2009, EUR J NEUROSCI, V29, P1056, DOI 10.1111/j.1460-9568.2009.06647.x; Stormer VS, 2012, DEV PSYCHOL, V48, P875, DOI 10.1037/a0026198; Tammimaki AE, 2010, PHARMACOGENET GENOM, V20, P717, DOI 10.1097/FPC.0b013e328340bdf2; Tunbridge EM, 2006, BIOL PSYCHIAT, V60, P141, DOI 10.1016/j.biopsych.2005.10.024; Tunbridge EM, 2012, CNS NEUROLOGICAL DIS; Wiener M, 2011, J COGNITIVE NEUROSCI, V23, P2811, DOI 10.1162/jocn.2011.21626; Williams GV, 2006, NEUROSCIENCE, V139, P263, DOI 10.1016/j.neuroscience.2005.09.028; Wishart HA, 2011, J INT NEUROPSYCH SOC, V17, P174, DOI 10.1017/S1355617710001402	62	27	27	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2013	8	1							e55862	10.1371/journal.pone.0055862			7	Multidisciplinary Sciences	Science & Technology - Other Topics	085JH	WOS:000314610600166	23383291	DOAJ Gold, Green Published			2021-06-18	
J	Dijkers, M; Brandstater, M; Horn, S; Ryser, D; Barrett, R				Dijkers, Marcel; Brandstater, Murray; Horn, Susan; Ryser, David; Barrett, Ryan			Inpatient rehabilitation for traumatic brain injury: The influence of age on treatments and outcomes	NEUROREHABILITATION			English	Article						Traumatic brain injuries; severity; rehabilitation; aging; hospitalization; mortality; activities of daily living; therapies	OLDER-ADULTS; GALVESTON ORIENTATION; SEVERITY; INTENSITY; ILLNESS; LENGTH	BACKGROUND: Elderly persons with traumatic brain injury (TBI) are increasingly admitted to inpatient rehabilitation, but we have limited knowledge of their characteristics, the treatments they receive, and their short-term and medium-term outcomes. This study explored these issues by means of comparisons between age groups. METHODS: Data on 1419 patients admitted to 9 inpatient rehabilitation facilities for initial rehabilitation after TBI were collected by means of (1) abstraction from medical records; (2) point-of care forms completed by therapists after each treatment session; and (3) interviews at 3 months and 9 months after discharge, conducted with the patient or a proxy. RESULTS: Elderly persons (65 or older) had a lower brain injury severity, and a shorter length of stay (LOS) in acute care. During rehabilitation, they received fewer hours of therapy, due to a shorter LOS and fewer hours of treatment per day, especially from psychology and therapeutic recreation. They regained less functional ability during and after inpatient rehabilitation, and had a very high mortality rate. CONCLUSIONS: Elderly people can be rehabilitated successfully, and discharged back to the community. The treatment therapists deliver, and issues surrounding high mortality need further research.	[Dijkers, Marcel] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; [Brandstater, Murray] Loma Linda Univ, Dept Phys Med & Rehabil, Loma Linda, CA 92350 USA; [Horn, Susan; Barrett, Ryan] Inst Clin Outcomes Res, Salt Lake City, UT USA; [Ryser, David] Intermt Med Ctr, Murray, UT USA	Dijkers, M (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, Box 1240,1 Gustave L Levy Pl, New York, NY 10029 USA.	marcel.dijkers@mssm.edu		Dijkers, Marcel/0000-0002-8362-5596	National Institute on Child Health and Human developmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5R01HD050439-03]; National Institute on Disability and Rehabilitation Research [H133A080023]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD050439] Funding Source: NIH RePORTER	This research was supported by grant 5R01HD050439-03 from the National Institute on Child Health and Human development to the Institute for Clinical Outcomes Research and grant H133A080023 from the National Institute on Disability and Rehabilitation Research to Ohio State University.	AVERILL RF, 1992, HEALTH SERV RES, V27, P587; Baguley IJ, 2012, MED J AUSTRALIA, V196, P40, DOI 10.5694/mja11.10090; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; Clemmer TP, 1999, CRIT CARE MED, V27, P1768, DOI 10.1097/00003246-199909000-00011; Corrigan J. D., 2011, THE JOURNAL OF HEAD, V27, P391; Cuthbert JP, 2011, ARCH PHYS MED REHAB, V92, P721, DOI 10.1016/j.apmr.2010.12.023; Dijkers M, 2008, BRAIN INJURY PROFESS, V5, P14; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Felicetti T, 2008, J HEAD TRAUMA REHAB, V23, P137, DOI 10.1097/01.HTR.0000319929.84590.40; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Goldstein F. C., 2005, REHABILITATION TRAUM, P235; Graham JE, 2010, ARCH PHYS MED REHAB, V91, P43, DOI 10.1016/j.apmr.2009.09.017; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE69, DOI 10.1097/HTR.0b013e3182738010; Hartholt KA, 2011, J NEUROTRAUM, V28, P739, DOI 10.1089/neu.2010.1488; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; Heinemann AW, 1994, TOP STROKE REHABIL, V1, P1; Hirshson C. I., 2012, NEUROREHABILITATION; Horn S. D., 2012, ARCHIVES OF PHYSICAL, V93; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS8, DOI 10.1016/j.apmr.2005.08.116; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS101, DOI 10.1016/j.apmr.2005.09.016; Horn SD, 2002, J PEDIATR-US, V141, P496, DOI 10.1067/mpd.2002.126925; HORN SD, 1991, MED CARE, V29, P305, DOI 10.1097/00005650-199104000-00001; Horn SD, 2007, MED CARE, V45, pS50, DOI 10.1097/MLR.0b013e318070c07b; Horn SD, 2010, MED CARE, V48, pS17, DOI 10.1097/MLR.0b013e3181d57473; Lawes D, 2002, INJURY, V33, P349, DOI 10.1016/S0020-1383(02)00075-X; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Ryser DK, 2005, ARCH PHYS MED REHAB, V86, P1108, DOI 10.1016/j.apmr.2004.11.041; Willson D F, 2000, Pediatr Crit Care Med, V1, P127, DOI 10.1097/00130478-200010000-00007	31	27	27	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2013	32	2					233	252		10.3233/NRE-130841			20	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	115ZT	WOS:000316851900005	23535785				2021-06-18	
J	Sveen, U; Ostensjo, S; Laxe, S; Soberg, HL				Sveen, Unni; Ostensjo, Sigrid; Laxe, Sara; Soberg, Helene L.			Problems in functioning after a mild traumatic brain injury within the ICF framework: the patient perspective using focus groups	DISABILITY AND REHABILITATION			English	Article						Functioning; ICF; patient perspective; traumatic brain injury	QUALITY-OF-LIFE; POST-CONCUSSION SYMPTOMS; INTERNATIONAL CLASSIFICATION; HEALTH ICF; RHEUMATOID-ARTHRITIS; CORE SETS; DISABILITY; SEVERITY; RECOVERY; OUTCOMES	Purpose: To describe problems in body functions, activities, and participation and the influence of environmental factors as experienced after mild traumatic brain injury (TBI), using the ICF framework. To compare our findings with the Brief and Comprehensive ICF Core Sets for TBI. Methods: Six focus-group interviews were performed with 17 participants (nine women, eight men, age ranged from 22 to 55 years) within the context of an outpatient rehabilitation programme for patients with mild TBI. The interviews were transcribed verbatim and analysed using the ICF. Results: One-hundred and eight second-level categories derived from the interview text, showing a large diversity of TBI-related problems in functioning. Problems in cognitive and emotional functions, energy and drive, and in carrying out daily routine and work, were frequently reported. All ICF categories reported with high-to-moderate frequencies were present in the Brief ICF Core Set and 84% in the Comprehensive ICF Core Set. The reported environmental factors mainly concerned aspects of health and social security systems, social network and attitudes towards the injured person. Conclusions: This study confirms the diversity of problems and the environmental factors that have an impact on post-injury functioning of patients with mild TBI.	[Sveen, Unni; Soberg, Helene L.] Oslo Univ Hosp, Dept Phys Med & Rehabil, N-0424 Oslo, Norway; [Sveen, Unni; Ostensjo, Sigrid; Soberg, Helene L.] Oslo & Akershus Univ Coll Appl Sci, Fac Hlth Sci, Oslo, Norway; [Laxe, Sara] Univ Autonoma Barcelona, Guttmann Inst Hosp Neurorehabil, Badalona, Spain	Sveen, U (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, POB 4950 Nydalen, N-0424 Oslo, Norway.	unni.sveen@uus.no			Norwegian Ministry of Health and Care Services	The study is part of a "Return to work" project initiated by the Norwegian Directorate of Health and the Norwegian Ministry of Labour and funded by the Norwegian Ministry of Health and Care Services.	Agan J, 2008, WORK, V31, P259; Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; [Anonymous], 2010, ICF CORE SETS TBI; Bay E, 2011, J HEAD TRAUMA REHAB, V26, P355, DOI 10.1097/HTR.0b013e3181f20146; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Bernabeu M, 2009, NEUROREHAB NEURAL RE, V23, P464, DOI 10.1177/1545968308328725; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Broomhall LGJ, 2009, J NERV MENT DIS, V197, P178, DOI 10.1097/NMD.0b013e318199fe7f; Carlozzi NE, 2011, ARCH PHYS MED REHAB, V92, pS52, DOI 10.1016/j.apmr.2010.12.046; Cieza A, 2005, J REHABIL MED, V37, P212, DOI 10.1080/16501970510040263; Coenen M, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1956; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Koskinen S, 2007, J REHABIL MED, V39, P467, DOI 10.2340/16501977-0077; Koskinen S, 2011, DISABIL REHABIL, V33, P2464, DOI 10.3109/09638288.2011.574776; Kvale S, 1999, KVALITATIVE FORSKNIN; Lane-Brown AT, 2009, NEUROPSYCHOL REHABIL, V19, P481, DOI 10.1080/09602010902949207; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laxe S, 2011, NEUROREHABILITATION, V29, P99, DOI 10.3233/NRE-2011-0683; Levack WMM, 2010, DISABIL REHABIL, V32, P986, DOI 10.3109/09638281003775394; Okochi Jiro, 2005, Health Qual Life Outcomes, V3, P46, DOI 10.1186/1477-7525-3-46; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P132, DOI 10.1080/13803390902858874; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Petchprapai Nutthita, 2007, J Neurosci Nurs, V39, P260; Pistarini C, 2011, DISABIL REHABIL, V33, P2333, DOI 10.3109/09638288.2011.570414; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Ptyushkin P, 2010, BRAIN INJURY, V24, P1519, DOI 10.3109/02699052.2010.523054; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Soberg HL, 2008, DISABIL REHABIL, V30, P98, DOI 10.1080/09638280701216862; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Stucki G, 2008, EUR J PHYS REHAB MED, V44, P315; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Sveen U, 2008, CLIN REHABIL, V22, P45, DOI 10.1177/0269215507080768; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Uhlig T, 2007, ANN RHEUM DIS, V66, P1078, DOI 10.1136/ard.2006.058693; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Weightman MM, 2010, J HEAD TRAUMA REHAB, V25, P206, DOI 10.1097/HTR.0b013e3181dc82d3; World Health Organization, 2001, INT CLASS FUNCT DIS	48	27	28	0	18	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0963-8288			DISABIL REHABIL	Disabil. Rehabil.		2013	35	9					749	757		10.3109/09638288.2012.707741			9	Rehabilitation	Rehabilitation	118XK	WOS:000317060100007	22897238				2021-06-18	
J	Prang, KH; Ruseckaite, R; Collie, A				Prang, Khic-Houy; Ruseckaite, Rasa; Collie, Alex			Healthcare and disability service utilization in the 5-year period following transport-related traumatic brain injury	BRAIN INJURY			English	Article						Compensation; brain injury; health service use; disability	MEDICAL-CARE; OUTCOMES; REHABILITATION; TBI; COSTS	Primary objective: To describe the type, intensity and direct cost of healthcare and disability services used following transport-related traumatic brain injury (TBI). Methods and procedures: Using the transport accident compensation regulator database, claims records were examined of 423 cases of adult (18-65 years of age) transport-related TBI occurring between 1 January 1995 and 31 December 2004. Claimants were stratified by TBI severity using the Glasgow Coma Scale (GCS) score. Service utilization and costs were examined by TBI severity in the 5-year period post-injury. Main outcomes and results: Claimants accessed a total of 409 740 services. Claimants with severe TBI accessed more medical (median 333 per claimant) and paramedical services (median 436 per claimant) than claimants with mild and moderate TBI. Almost 60% of claimants with severe TBI accessed attendant care services compared to 39% and 45% of claimants with moderate and mild TBI, respectively. Average total costs of services were highest among claimants with severe TBI (AUD $324 515 per claimant). Conclusions: Healthcare service utilization and the economic burden of TBI are substantial. Injury compensation data provides a unique opportunity to explore patterns of healthcare usage post-injury, which is important for the planning and management of resources.	[Prang, Khic-Houy; Ruseckaite, Rasa; Collie, Alex] Monash Univ, Inst Safety Compensat & Recovery Res, Melbourne, Vic 3004, Australia; [Prang, Khic-Houy; Ruseckaite, Rasa; Collie, Alex] Monash Univ, Injury Res Inst, Melbourne, Vic 3004, Australia; [Collie, Alex] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia	Collie, A (corresponding author), Monash Univ, Inst Safety Compensat & Recovery Res, Melbourne, Vic 3004, Australia.	alex.collie@monash.edu	Ruseckaite, Rasa/H-4060-2014	Ruseckaite, Rasa/0000-0002-9078-2696; Collie, Alex/0000-0003-2617-9339	Transport Accident Commission (TAC); WorkSafe Victoria	The authors report no conflicts of interest. Funding for this project and authors' involvement in this study was provided by a research grant from the Transport Accident Commission (TAC) and WorkSafe Victoria.	Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; [Anonymous], 2009, EC COST SPINAL CORD, P1; Australian Government. Department of Human Services, 2011, MED; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Brown JH, 2007, HEALTHCARE POLICY, V2, P121; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Clay Fiona J, 2006, Aust Health Rev, V30, P252; Foster M, 2000, BRAIN INJURY, V14, P1035; Gabbe BJ, 2011, INJURY, V42, P985, DOI 10.1016/j.injury.2011.06.003; Harrison J, 2008, INJURY RES STAT SERI, V45; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; Hillier SL, 1997, BRAIN INJURY, V11, P661; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; Hoofien D, 2001, BRAIN INJURY, V15, P189; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Lippert-Gruener M, 2007, BRAIN INJURY, V21, P1001, DOI 10.1080/02699050701468933; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; O'Callaghan AM, 2010, INT J SPEECH-LANG PA, V12, P107, DOI 10.3109/17549500903431774; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ottenbacher KJ, 2007, ARCH PHYS MED REHAB, V88, P1513, DOI 10.1016/j.apmr.2007.06.761; Phillips VL, 2004, J HEAD TRAUMA REHAB, V19, P217, DOI 10.1097/00001199-200405000-00003; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ruseckaite R, 2011, INJURY; Vangel SJ, 2005, AM J PHYS MED REHAB, V84, P153, DOI 10.1097/01.PHM.0000154896.55045.E7; Victorian Injury Surveillance Unit, 2011, TRAUM BRAIN INJ HOSP; Willemse-van Son AHP, 2009, J REHABIL MED, V41, P59, DOI 10.2340/16501977-0294; Wrona RM, 2010, DISABIL REHABIL, V32, P650, DOI 10.3109/09638280903186327	28	27	29	0	14	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2012	26	13-14					1611	1620		10.3109/02699052.2012.698790			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	041RU	WOS:000311419700007	22738249				2021-06-18	
J	Weisbrod, AB; Rodriguez, C; Bell, R; Neal, C; Armonda, R; Dorlac, W; Schreiber, M; Dunne, JR				Weisbrod, Allison B.; Rodriguez, Carlos; Bell, Randy; Neal, Christopher; Armonda, Rocco; Dorlac, Warren; Schreiber, Martin; Dunne, James R.			Long-term outcomes of combat casualties sustaining penetrating traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	42nd Annual Meeting of the Western-Trauma-Association	FEB 26-MAR 03, 2012	Vail, CO	Western Trauma Assoc		Trauma; head injury; traumatic brain injury; military; blast injury	CIVILIAN GUNSHOT WOUNDS; DECOMPRESSIVE CRANIECTOMY; HEAD-INJURY; CRANIOCEREBRAL INJURIES; PREDICTION; MANAGEMENT; MORTALITY; REHABILITATION	BACKGROUND: Previous studies have documented short-term functional outcomes for patients sustaining penetrating brain injuries (PBIs). However, little is known regarding the long-term functional outcome in this patient population. Therefore, we sought to describe the long-term functional outcomes of combat casualties sustaining PBI. METHODS: Prospective data were collected from 2,443 patients. admitted to a single military institution during an 8-year period from 2003 to 2011. PBI was identified in 137 patients and constitute the study cohort. Patients were stratified by age, Injury Severity Score (ISS) and admission Glasgow Coma Scale (aGCS) score. Glasgow Outcome Scale (GOS) scores were calculated at discharge, 6 months, 1 year and 2 years. Patients with a GOS score of 4 or greater were considered to have attained functional independence (FI). RESULTS: The mean (SD) age of the cohort was 25 (7) years, mean (SD) ISS was 28 (9), and mean (SD) aGCS score was 8.8 (4.0). PBI mechanisms included gunshot wounds (31%) and blast injuries (69%). Invasive intracranial monitoring was used in 80% of patients, and 86.9% of the study cohort underwent neurosurgical intervention. Complications included cerebrospinal fluid leak (8.3%), venous thromboembolic events (15.3%), meningitis (24.8%), systemic infection (27.0%), and mortality (5.8%). The cohort was stratified by aGCS score and showed significant improvement in functional status when mean discharge GOS score was compared with mean GOS score at 2 years. For those with aGCS score of 3 to 5 (2.3 [0.9] vs. 2.9 [1.4], p < 0.01), 32% progressed to FI. For those with aGCS score of 6 to 8 (3.1 [0.7] vs. 4.0 [1.2], p < 0.0001), 63% progressed to FI. For those with aGCS score of 9 to 11(3.3 [0.5] vs. 4.3 [0.8], p < 0.0001), 74% progressed to FI. For those with aGCS score of 12 to 15 (3.9 [0.7] vs. 4.8 [0.4], p < 0.00001), 100% progressed to FI. CONCLUSION: Combat casualties with PBI demonstrated significant improvement in functional status up to 2 years from discharge, and a large proportion of patients sustaining severe PBI attained FI. (J Trauma Acute Care Surg. 2012;73: 1525-1530. Copyright (c) 2012 by Lippincott Williams & Wilkins)	[Weisbrod, Allison B.; Rodriguez, Carlos; Dunne, James R.] Walter Reed Natl Mil Med Ctr, Dept Surg, Bethesda, MD 20889 USA; [Bell, Randy; Neal, Christopher; Armonda, Rocco] Walter Reed Natl Mil Med Ctr, Dept Neurosurg, Bethesda, MD 20889 USA; [Dorlac, Warren] Univ Cincinnati, Dept Surg, Div Trauma Crit Care, Cincinnati, OH 45267 USA; [Schreiber, Martin] Oregon Hlth & Sci Univ, Dept Surg, Div Trauma Crit Care & Acute Care Surg, Portland, OR 97201 USA	Dunne, JR (corresponding author), Walter Reed Natl Mil Med Ctr, Dept Gen Surg, 8901 Rockville Pike, Bethesda, MD 20889 USA.	Twobdun@aol.com					AARABI B, 1990, NEUROSURGERY, V27, P692, DOI 10.1227/00006123-199011000-00004; Ahmadi SA, 2010, BRAIN INJURY, V24, P1539, DOI 10.3109/02699052.2010.523049; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Atabey C, 2012, BRIT J NEUROSURG, V26, P208, DOI 10.3109/02688697.2011.626875; BARLOW P, 1986, NEUROSURGERY, V19, P989, DOI 10.1227/00006123-198612000-00014; Bell RS, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1022; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Cripps MW, 2009, AM SURGEON, V75, P44; Dosoglu M, 1999, NEUROCHIRURGIE, V45, P201; DuBose JJ, 2011, J TRAUMA, V70, P11, DOI 10.1097/TA.0b013e318207c563; Dziedzic T, 2004, CRIT CARE, V8, P266, DOI 10.1186/cc2828; Ecker RD, 2011, J NEUROSURG, V115, P124, DOI 10.3171/2011.2.JNS101490; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Ho KM, 2011, CRIT CARE MED, V39, P2495, DOI 10.1097/CCM.0b013e318225764e; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Kazim Syed Faraz, 2011, J Emerg Trauma Shock, V4, P395, DOI 10.4103/0974-2700.83871; LEVI L, 1990, ISRAEL J MED SCI, V26, P548; LEVI L, 1990, ISRAEL J MED SCI, V26, P555; LEVI L, 1991, British Journal of Neurosurgery, V5, P241, DOI 10.3109/02688699109005183; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; Lu J, 2010, J NEUROTRAUM, V27, P843, DOI 10.1089/neu.2010.1293; Ma JP, 2011, CRIT CARE, V15, DOI 10.1186/cc10358; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; POLIN RS, 1995, NEUROSURG CLIN N AM, V6, P689; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Rosenthal G, 2011, CRIT CARE MED, V39, P2575, DOI 10.1097/CCM.0b013e31822e56c7; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; STONE JL, 1995, NEUROSURGERY, V37, P1104, DOI 10.1227/00006123-199512000-00010; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Wertheimer JC, 2008, ARCH PHYS MED REHAB, V89, P1983, DOI 10.1016/j.apmr.2008.04.010; Yatsushige H, 2010, ACTA NEUROCHIR SUPPL, V106, P265, DOI 10.1007/978-3-211-98811-4_50; Zafonte RD, 1997, BRAIN INJURY, V11, P403; Zafonte RD, 2001, ARCH PHYS MED REHAB, V82, P306, DOI 10.1053/apmr.2001.18226	39	27	27	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2012	73	6					1525	1530		10.1097/TA.0b013e318270e179			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	058FV	WOS:000312620400026	23188247				2021-06-18	
J	Edmed, S; Sullivan, K				Edmed, Shannon; Sullivan, Karen			Depression, anxiety, and stress as predictors of postconcussion-like symptoms in a non-clinical sample	PSYCHIATRY RESEARCH			English	Article						Neuropsychology; Mild traumatic brain injury; DASS; Psychopathology; Assessment; Diagnosis	POST-CONCUSSION SYMPTOMS; TRAUMATIC BRAIN-INJURY; SCALES DASS; PERCENTILE NORMS; NORMATIVE DATA; BASE RATES; MILD; MODERATE	This study examined the relationship between postconcussion-like symptoms and depressive symptoms, anxiety and stress respectively. Seventy-one university students with a negative concussion history completed the Depression Anxiety Stress Scales (DASS) and the British Columbia Postconcussion Symptom Inventory (BC-PSI). A multiple regression was conducted using the three DASS subscale scores as predictors of postconcussion-like symptoms. Depressive symptoms, anxiety and stress were significantly positively correlated with postconcussion-like symptoms at the bivariate level. When these three factors were examined together 72.9% of variance in BC-PSI total scores was explained overall. Stress and depressive symptoms emerged as significant multivariate predictors explaining 15% and 3% of unique variance, respectively. Anxiety was not a significant multivariate predictor. These results suggest that stress may be a more important predictor of postconcussion-like symptoms than previously identified. Findings are interpreted in light of Iverson (2012) conceptual model of poor outcomes from mild traumatic brain injury. (C) 2012 Elsevier Ireland Ltd All rights reserved.	[Edmed, Shannon; Sullivan, Karen] Queensland Univ Technol, Clin Neuropsychol Res Grp, Sch Psychol & Counselling, Brisbane, Qld 4001, Australia; [Sullivan, Karen] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia	Sullivan, K (corresponding author), Queensland Univ Technol, O Block,B Wing,Kelvin Grove Campus,Victoria Pk Rd, Kelvin Grove, Qld 4059, Australia.	karen.sullivan@qut.edu.au			School of Psychology and Counselling, Queensland University of Technology	The Human Research Ethics Committee of Queensland University of Technology (QUT-HREC #1000000311) approved this research. This project was granted an occupational workplace health and safety clearance. Funding for this project was provided by the School of Psychology and Counselling, Queensland University of Technology. The authors thank Lauren Cunningham for assistance with manuscript formatting, and Dr Janine Beck for comments about statistical methods.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Brown TA, 1997, BEHAV RES THER, V35, P79, DOI 10.1016/S0005-7967(96)00068-X; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Clara IP, 2001, J PSYCHOPATHOL BEHAV, V23, P61, DOI 10.1023/A:1011095624717; Crawford J, 2011, AUST PSYCHOL, V46, P3, DOI 10.1111/j.1742-9544.2010.00003.x; Crawford JR, 2009, BRIT J CLIN PSYCHOL, V48, P163, DOI 10.1348/014466508X377757; Crawford JR, 2003, BRIT J CLIN PSYCHOL, V42, P111, DOI 10.1348/014466503321903544; Daza P, 2002, J PSYCHOPATHOL BEHAV, V24, P195, DOI 10.1023/A:1016014818163; Edmed S.L., APPL NEUROP IN PRESS; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Hashim HA, 2011, IJCRIMPH, V2011, P29; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Iverson G.L., 2012, PTSD MILD TRAUMATIC, P37; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Lovibond P.F., 1995, MANUAL DESPRESSION A; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Nieuwenhuijsen K, 2003, OCCUP ENVIRON MED, V60, P77; Prigatano GP, 2011, CURR OPIN PSYCHIATR, V24, P243, DOI 10.1097/YCO.0b013e328344698b; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Shea TL, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-21; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Sullivan K, 2011, J HEAD TRAUMA REHAB, V26, P170, DOI 10.1097/HTR.0b013e3181e47f95; Szabo M, 2011, ANXIETY STRESS COPIN, V24, P91, DOI 10.1080/10615801003653430; Taouk M., 2011, PSYCHOMETRIC PROPERT; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; World Health Organization, 1992, ICD 10 INT STAT CLAS	43	27	27	0	18	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	NOV	2012	200	1					41	45		10.1016/j.psychres.2012.05.022			5	Psychiatry	Psychiatry	058IS	WOS:000312627900006	22709538				2021-06-18	
J	Kim, JH; Jang, BG; Choi, BY; Kwon, LM; Sohn, M; Song, HK; Suh, SW				Kim, Jin Hee; Jang, Bong Geom; Choi, Bo Young; Kwon, Lyo Min; Sohn, Min; Song, Hong Ki; Suh, Sang Won			Zinc Chelation Reduces Hippocampal Neurogenesis after Pilocarpine-Induced Seizure	PLOS ONE			English	Article							HYPOGLYCEMIC NEURONAL DEATH; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; ADULT-RAT; DENTATE GYRUS; CELL-PROLIFERATION; CEREBRAL-ISCHEMIA; CHELATABLE ZINC; LIMBIC SEIZURES; GRANULE CELLS	Several studies have shown that epileptic seizures increase hippocampal neurogenesis in the adult. However, the mechanism underlying increased neurogenesis after seizures remains largely unknown. Neurogenesis occurs in the subgranular zone (SGZ) of the hippocampus in the adult brain, although an understanding of why it actively occurs in this region has remained elusive. A high level of vesicular zinc is localized in the presynaptic terminals of the SGZ. Previously, we demonstrated that a possible correlation may exist between synaptic zinc localization and high rates of neurogenesis in this area after hypoglycemia. Using a lithium-pilocarpine model, we tested our hypothesis that zinc plays a key role in modulating hippocampal neurogenesis after seizure. Then, we injected the zinc chelator, clioquinol (CQ, 30 mg/kg), into the intraperitoneal space to reduce brain zinc availability. Neuronal death was detected with Fluoro Jade-B and NeuN staining to determine whether CQ has neuroprotective effects after seizure. The total number of degenerating and live neurons was similar in vehicle and in CQ treated rats at 1 week after seizure. Neurogenesis was evaluated using BrdU, Ki67 and doublecortin (DCX) immunostaining 1 week after seizure. The number of BrdU, Ki67 and DCX positive cell was increased after seizure. However, the number of BrdU, Ki67 and DCX positive cells was significantly decreased by CQ treatment. Intracellular zinc chelator, N,N,N0,N-Tetrakis (2-pyridylmethyl) ethylenediamine (TPEN), also reduced seizure-induced neurogenesis in the hippocampus. The present study shows that zinc chelation does not prevent neurodegeneration but does reduce seizure-induced progenitor cell proliferation and neurogenesis. Therefore, this study suggests that zinc has an essential role for modulating hippocampal neurogenesis after seizure.	[Song, Hong Ki] Hallym Univ, Coll Med, Dept Neurol, Chunchon, South Korea; [Kim, Jin Hee; Jang, Bong Geom; Choi, Bo Young; Kwon, Lyo Min; Suh, Sang Won] Hallym Univ, Coll Med, Dept Physiol, Chunchon, South Korea; [Sohn, Min] Inha Univ, Dept Nursing, Inchon, South Korea	Song, HK (corresponding author), Hallym Univ, Coll Med, Dept Neurol, Chunchon, South Korea.	hksong0@paran.com; swsuh@hallym.ac.kr	Kwon, Lyo Min/ABC-5338-2020	Kwon, Lyo Min/0000-0001-5611-2480; SOHN, MIN/0000-0003-4021-2051; Choi, Bo Young/0000-0002-9579-3503	Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea [A120202]	The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study was supported by the Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A120202).	ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; BAYER SA, 1982, SCIENCE, V216, P890, DOI 10.1126/science.7079742; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Corniola RS, 2008, BRAIN RES, V1237, P52, DOI 10.1016/j.brainres.2008.08.040; DANSCHER G, 1985, J HISTOCHEM CYTOCHEM, V33, P706, DOI 10.1177/33.7.4008918; DVERGSTEN CL, 1983, BRAIN RES, V271, P217, DOI 10.1016/0006-8993(83)90284-6; ECKENHOFF MF, 1988, J NEUROSCI, V8, P2729; Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; GOLUB MS, 1994, AM J CLIN NUTR, V60, P238; GUENEAU G, 1982, DEV NEUROSCI-BASEL, V5, P345, DOI 10.1159/000112694; HALAS ES, 1983, PHYSIOL BEHAV, V30, P371, DOI 10.1016/0031-9384(83)90140-3; HOUSER CR, 1990, J NEUROSCI, V10, P267; Jo SM, 2000, BRAIN RES, V870, P163, DOI 10.1016/S0006-8993(00)02418-5; KAPLAN MS, 1984, J NEUROSCI, V4, P1429; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Kuhn HG, 1996, J NEUROSCI, V16, P2027; MacDonald RS, 2000, J NUTR, V130, p1500S, DOI 10.1093/jn/130.5.1500S; MANFORD M, 1992, NEUROLOGY, V42, P1911; Maret W, 2006, J TRACE ELEM MED BIO, V20, P3, DOI 10.1016/j.jtemb.2006.01.006; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Nacher J, 2001, EUR J NEUROSCI, V14, P629, DOI 10.1046/j.0953-816x.2001.01683.x; Nitzan YB, 2003, J MOL MED-JMM, V81, P637, DOI 10.1007/s00109-003-0462-7; OKANO HJ, 1993, J NEUROSCI, V13, P2930; Parent JM, 1997, J NEUROSCI, V17, P3727; Parent JM, 2002, J NEUROSCI, V22, P3174, DOI 10.1523/JNEUROSCI.22-08-03174.2002; Park MH, 2011, NEUROBIOL DIS; PEREZCLAUSELL J, 1985, BRAIN RES, V337, P91, DOI 10.1016/0006-8993(85)91612-9; PERSINGER MA, 1988, PHYSIOL BEHAV, V44, P27, DOI 10.1016/0031-9384(88)90342-3; PRASAD AS, 1963, AM J CLIN NUTR, V12, P437, DOI 10.1093/ajcn/12.6.437; Sandstead HH, 2000, J NUTR, V130, p496S, DOI 10.1093/jn/130.2.496S; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; SEKI T, 1993, J NEUROSCI, V13, P2351; STEWART GR, 1984, BRAIN RES, V290, P43, DOI 10.1016/0006-8993(84)90734-0; Suh SW, 2007, GLIA, V55, P1280, DOI 10.1002/glia.20440; Suh SW, 2009, J CEREBR BLOOD F MET, V29, P1579, DOI 10.1038/jcbfm.2009.80; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suh SW, 2005, DIABETES, V54, P500, DOI 10.2337/diabetes.54.2.500; Suh SW, 2004, NEUROBIOL DIS, V16, P538, DOI 10.1016/j.nbd.2004.04.017; Suh SW, 2003, J NEUROSCI, V23, P10681; Suh SW, 2001, NEUROREPORT, V12, P1523, DOI 10.1097/00001756-200105250-00044; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; TONDER N, 1990, NEUROSCI LETT, V109, P247, DOI 10.1016/0304-3940(90)90002-Q	50	27	27	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2012	7	10							e48543	10.1371/journal.pone.0048543			10	Multidisciplinary Sciences	Science & Technology - Other Topics	030WJ	WOS:000310600500167	23119054	DOAJ Gold, Green Published			2021-06-18	
J	Macciocchi, S; Seel, RT; Warshowsky, A; Thompson, N; Barlow, K				Macciocchi, Stephen; Seel, Ronald T.; Warshowsky, Adam; Thompson, Nicole; Barlow, Kimether			Co-Occurring Traumatic Brain Injury and Acute Spinal Cord Injury Rehabilitation Outcomes	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Cognition; Prognosis; Rehabilitation; Spinal cord injuries; Traumatic brain injuries	FUNCTIONAL INDEPENDENCE MEASURE; CLOSED HEAD-INJURY; COGNITIVE DYSFUNCTION; VALIDITY	Macciocchi S, Seel RT, Warshowsky A, Thompson N, Barlow K. Co-occurring traumatic brain injury and acute spinal cord injury rehabilitation outcomes. Arch Phys Med Rehabil 2012;93:1788-94. Objective: To determine the impact of co-occurring traumatic brain injury (TBI) on functional motor outcome and cognition during acute spinal cord injury (SCI) rehabilitation. Design: Prospective, longitudinal cohort. Setting: Single-center National Institute of Disability and Rehabilitation Research SCI Model System. Participants: Persons aged 16 to 59 years (N = 189) admitted for acute SCI rehabilitation during the 18-month recruitment window who met inclusion criteria. Interventions: Not applicable. Main Outcome Measures: FIM Motor Scale (Rasch transformed) and acute rehabilitation length of stay (LOS). Results: In the tetraplegia sample, co-occurring TBI was not related to FIM Motor Scale scores or acute rehabilitation LOS despite having negative impacts on memory and problem solving. Persons with paraplegia who sustained co-occurring severe TBI had lower admission and discharge FIM Motor Scale scores and longer acute rehabilitation LOS than did persons with paraplegia and either no TBI or mild TBI. Persons with paraplegia and severe TBI had lower functional comprehension, problem solving, and memory and impairments on tests of processing speed compared with persons with paraplegia and no TBI, mild TBI, and moderate TBI. Persons with paraplegia and co-occurring mild and moderate TBI had equivalent acute rehabilitation motor outcomes and cognitive functioning compared with persons with paraplegia and no TBI. Conclusions: This study provides evidence that persons aged 16 to 59 years with paraplegia and co-occurring severe TBI had worse motor outcomes and longer acute rehabilitation LOS than did persons with paraplegia and no TBI. Impairments in processing speed, comprehension, memory, and problem solving may explain suboptimal motor skill acquisition. Research with larger samples is required to determine whether mild and moderate TBI impact acute rehabilitation motor outcomes and LOS.	[Macciocchi, Stephen; Seel, Ronald T.; Warshowsky, Adam; Thompson, Nicole; Barlow, Kimether] Shepherd Ctr, Atlanta, GA 30309 USA; [Macciocchi, Stephen] Univ Georgia, Dept Kinesiol, Athens, GA 30602 USA	Macciocchi, S (corresponding author), Shepherd Ctr, 2020 Peachtree Rd, Atlanta, GA 30309 USA.	stephen_macciocchi@shepherd.org			National Institute on Disability and Rehabilitation Research, US Department of EducationUS Department of Education [H113G030004]	Supported by the National Institute on Disability and Rehabilitation Research, US Department of Education (grant no. H113G030004).	Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS77, DOI 10.1016/j.apmr.2008.07.008; Brandt J., 2001, HOPKINS VERBAL LEARN; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P489; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; Graves DE, 2006, J SPINAL CORD MED, V29, P39, DOI 10.1080/10790268.2006.11753855; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Heinemann AW, 1994, TOP STROKE REHABIL, V1, P1; Hess DW, 2003, REHABIL PSYCHOL, V48, P151, DOI 10.1037/0090-5550.48.3.151; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Macciocchi SN, 2004, AM J PHYS MED REHAB, V83, P22, DOI 10.1097/01.PHM.0000104661.86307.91; Macciocchi S, 2008, ARCH PHYS MED REHAB, V89, P1350, DOI 10.1016/j.apmr.2007.11.055; Marino RJ, 2002, J SPINAL CORD MED S1, V26, pS50; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; RICHARDS JS, 1991, ARCH PHYS MED REHAB, V72, P275; RICHARDS JS, 1988, AM J PHYS MED REHAB, V67, P211, DOI 10.1097/00002060-198810000-00005; ROTH E, 1989, PARAPLEGIA, V27, P480, DOI 10.1038/sc.1989.75; Smith A, 1995, SYMBOL DIGIT MODALIT; STUTTS M, 1991, NEUROREHABILITATION, V3, P79; Trahan D, 1988, CONTINUOUS VISUAL ME; Wechsler D., 1997, ADM SCORING MANUAL W; Wetzel L., 2000, SHORT CATEGORY TEST; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	25	27	28	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2012	93	10					1788	1794		10.1016/j.apmr.2012.01.022			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	018FP	WOS:000309645800014	22480549				2021-06-18	
J	Esquenazi, A; Mayer, N; Lee, S; Brashear, A; Elovic, E; Francisco, GE; Yablon, S				Esquenazi, Alberto; Mayer, Nathaniel; Lee, Stella; Brashear, Allison; Elovic, Elie; Francisco, Gerard E.; Yablon, Stuart		PROS Study Grp	Patient Registry of Outcomes in Spasticity Care	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						Botulinum Toxin A; Muscle Overactivity; Phenol; Spasticity; Stroke; Traumatic Brain Injury	TOXIN TYPE-A; UPPER-LIMB SPASTICITY; INTERNATIONAL CONSENSUS STATEMENT; PLACEBO-CONTROLLED TRIAL; CHRONIC HEMIPARETIC PATIENTS; RANDOMIZED CONTROLLED-TRIAL; UPPER EXTREMITY SPASTICITY; ELBOW FLEXOR SPASTICITY; BOTULINUM-TOXIN; DOUBLE-BLIND	Esquenazi A, Mayer N, Lee S, Brashear A, Elovic E, Francisco GE, Yablon S, PROS Study Group: Patient registry of outcomes in spasticity care. Am J Phys Med Rehabil 2012; 91: 729-746. Objective: This study aimed to provide clinical injection data and real-world patient-reported and clinical outcomes for the chemodenervation and neurolytic treatment of muscle overactivity including spasticity in patients with traumatic brain injury and stroke. Design: This study used a prospective multicenter observational design. The participants were 487 patients with stroke or traumatic brain injury. The interventions used were onabotulinumtoxin A or phenol. Nine subjects received both onabotulinumtoxin A and phenol. The main outcome measures were satisfaction and goal attainment, pain, and Ashworth Scale scores. Results: The most commonly treated pattern of dysfunction in the upper limb was the flexed wrist, with the flexor carpi radialis as the most frequently treated muscle. The mean total dose for the upper limb muscle was 57.7 +/- 34.1 U, and phenol volume was 3.9 +/- 0.7 ml. The most commonly treated pattern of dysfunction in the lower limb was the equinovarus/equinus foot, with the medial/lateral gastrocnemius as the most frequently treated muscles. The mean total dose for the lower limb muscle was 93.8 +/- 63.5 U, and phenol volume was 4.1 +/- 1.3 ml. There was a significant improvement in Ashworth Scale and pain scores. Generally, the patients reported that they were satisfied with their treatment and made progress toward their goals. No significant treatment-related adverse effects were reported. Conclusions: Based on 487 patients with stroke and traumatic brain injury who were selected by their physician and clinical presentation for treatment using chemodenervation and neurolysis, this report of injection data reflecting actual clinical practice may serve as a further clinical guide in the management of patients with muscle overactivity, including spasticity.	[Esquenazi, Alberto; Mayer, Nathaniel; Lee, Stella] MossRehab, Gait Anal Lab, Elkins Pk, PA 19027 USA; [Esquenazi, Alberto; Mayer, Nathaniel; Lee, Stella] MossRehab, Motor Control Anal Lab, Elkins Pk, PA 19027 USA; [Brashear, Allison] Wake Forest Univ, Dept Neurol, Winston Salem, NC 27109 USA; [Elovic, Elie] Univ Utah, Dept PM&R, Salt Lake City, UT USA; [Francisco, Gerard E.] Univ Texas Hlth Sci Ctr, Dept PM&R, Houston, TX USA; [Francisco, Gerard E.] TIRR Mem Hermann, Houston, TX USA; [Yablon, Stuart] Baylor Univ, Texas Methodist Rehab Ctr, Dallas, TX USA	Esquenazi, A (corresponding author), MossRehab, Gait Anal Lab, 60 Township Line Rd, Elkins Pk, PA 19027 USA.				Allergan Inc.AbbVieAllergan; Ipsen PharmaIpsen; NINDsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)	Alberto Esquenazi, MD, has received research grants from Allergan Inc. and Ipsen Pharma. He also participated as a member of an advisory group supported by Allergan Inc. and has received compensation for research protocol development from Allergan Inc.; Allison Brashear, MD, is a consultant for Allergan Inc., Ipsen Pharma, and Osmotica. She receives salary support from NINDs.	Ashford S, 2009, DISABIL REHABIL, V31, P220, DOI 10.1080/09638280801906388; ASHWORTH B, 1964, PRACTITIONER, V192, P540; Bakheit AMO, 2000, STROKE, V31, P2402, DOI 10.1161/01.STR.31.10.2402; Baricich A, 2008, J REHABIL MED, V40, P870, DOI 10.2340/16501977-0251; Barnes M, 2002, EUR J NEUROL, V9, P53; Borg J, 2011, J REHABIL MED, V43, P15, DOI 10.2340/16501977-0663; Brashear A, 2004, ARCH PHYS MED REHAB, V85, P705, DOI 10.1016/j.apmr.2003.08.077; Brashear A, 2002, NEW ENGL J MED, V347, P395, DOI 10.1056/NEJMoa011892; BRASHEAR A, 2008, SPASTICITY OTHER FOR, P207; Brin MF, 1997, MUSCLE NERVE, pS146; Burbaud P, 1996, J NEUROL NEUROSUR PS, V61, P265, DOI 10.1136/jnnp.61.3.265; Childers MK, 2004, ARCH PHYS MED REHAB, V85, P1063, DOI 10.1016/j.apmr.2003.10.015; Chin T, 2003, DEV MED CHILD NEUROL, V25, P286; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; DUNNE JW, 1995, J NEUROL NEUROSUR PS, V58, P232, DOI 10.1136/jnnp.58.2.232; Esquenazi A, 2004, AM J PHYS MED REHAB, V83, pS19, DOI 10.1097/01.PHM.0000141127.63160.3E; Esquenazi A, 2010, EUR J NEUROL, V17, P1, DOI 10.1111/j.1468-1331.2010.03125.x; Esquenazi A, 2008, AM J PHYS MED REHAB, V87, P305, DOI 10.1097/PHM.0b013e318168d36c; Farrar JT, 2010, ANESTHESIOLOGY, V112, P1464, DOI 10.1097/ALN.0b013e3181de0e6d; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; FDA, LAB INF HIGHL PRESCR; Francisco GE, 2002, AM J PHYS MED REHAB, V81, P355, DOI 10.1097/00002060-200205000-00007; Giovannelli M, 2007, CLIN REHABIL, V21, P331, DOI 10.1177/0269215507072772; Gordon MF, 2004, NEUROLOGY, V63, P1971, DOI 10.1212/01.WNL.0000144349.95487.91; Gracies J, 2009, ARCH PHYS MED REHAB, V90; GRAZKO MA, 1995, NEUROLOGY, V45, P712, DOI 10.1212/WNL.45.4.712; HALPERN DANIEL, 1966, ARCH PHYS MED REHABIL, V47, P659; HECHT JS, 1992, ARCH PHYS MED REHAB, V73, P1036; Heron Melonie, 2009, Natl Vital Stat Rep, V57, P1; HESSE S, 1994, J NEUROL NEUROSUR PS, V57, P1321, DOI 10.1136/jnnp.57.11.1321; Hesse S, 1996, STROKE, V27, P455, DOI 10.1161/01.STR.27.3.455; KATZ JORDAN, 1967, ARCH PHYS MED REHABIL, V48, P97; KEENAN MAE, 1988, CLIN ORTHOP RELAT R, P116; KEENAN MAE, 1990, J HAND SURG-AM, V15A, P340, DOI 10.1016/0363-5023(90)90120-G; KHALILI AA, 1984, CURRENT THERAPY PHYS; KHALILI ALI A., 1964, ARCH PHYS MED REHABIL, V45, P513; Kirazli Y, 1998, AM J PHYS MED REHAB, V77, P510, DOI 10.1097/00002060-199811000-00012; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; Kocabas H, 2010, EUR J PHYS REHAB MED, V46, P5; KOYAMA H, 1992, ARCH PHYS MED REHAB, V73, P1040; Lance J., 1980, SPASTICITY DISORDERE; Love SC, 2010, EUR J NEUROL, V17, P9, DOI 10.1111/j.1468-1331.2010.03126.x; Manca M, 2010, EUR J PHYS REHAB MED, V46, P11; Mancini F, 2005, NEUROL SCI, V26, P26, DOI 10.1007/s10072-005-0378-9; Marco E, 2007, J REHABIL MED, V39, P440, DOI 10.2340/16501977-0066; McCrory P, 2009, J REHABIL MED, V41, P536, DOI 10.2340/16501977-0366; O'Brien C, 1999, EUR J NEUROL, V6, pS77, DOI 10.1111/j.1468-1331.1999.tb00040.x; Olver J, 2010, EUR J NEUROL, V17, P57, DOI 10.1111/j.1468-1331.2010.03128.x; Patel AT, 2011, PHYS THER, V91, P1636, DOI 10.2522/ptj.20100370; Pathak M, 2006, EUR J NEUROL S, V13, P42; ROWE DS, NEUROLYTIC TECHNIQUE; Sampaio C, 1997, CLIN REHABIL, V11, P3, DOI 10.1177/026921559701100102; Sheean G, 2010, EUR J NEUROL, V17, P74, DOI 10.1111/j.1468-1331.2010.03129.x; Shingleton R, 2011, SPASTICITY: DIAGNOSIS AND MANAGEMENT, P155; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; Sung DH, 2001, ARCH PHYS MED REHAB, V82, P671, DOI 10.1053/apmr.2001.21975; Suputtitada A, 2005, DISABIL REHABIL, V27, P176, DOI 10.1080/09638280400009360; Suputtitada A, 2002, AM J PHYS MED REHAB, V81, P770, DOI 10.1097/00002060-200210000-00009; Thompson AJ, 2005, J NEUROL NEUROSUR PS, V76, P459, DOI 10.1136/jnnp.2004.035972; Turner-Stokes L, 2011, J REHABIL MED, V43, P70, DOI 10.2340/16501977-0656; Verplancke D, 2005, CLIN REHABIL, V19, P117, DOI 10.1191/0269215505cr827oa; Wallen M, 2007, ARCH PHYS MED REHAB, V88, P1, DOI 10.1016/j.apmr.2006.10.017; Ward AB, 2002, EUR J NEUROL, V9, P48, DOI 10.1046/j.1468-1331.2002.0090s1048.x; Wissel J, 1999, WIEN KLIN WOCHENSCHR, V111, P837; Yablon SA, 1996, NEUROLOGY, V47, P939, DOI 10.1212/WNL.47.4.939; Yablon SA, 2011, MOVEMENT DISORD, V26, P209, DOI 10.1002/mds.23426; Yelnik AP, 2010, J REHABIL MED, V42, P801, DOI 10.2340/16501977-0613	67	27	27	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	SEP	2012	91	9					729	742		10.1097/PHM.0b013e31824fa9ca			14	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	997AC	WOS:000308135200001	22469872				2021-06-18	
J	Kolbe, S; Bajraszewski, C; Chapman, C; Nguyen, T; Mitchell, P; Paine, M; Butzkueven, H; Johnston, L; Kilpatrick, T; Egan, G				Kolbe, Scott; Bajraszewski, Clare; Chapman, Caron; Tan Nguyen; Mitchell, Peter; Paine, Mark; Butzkueven, Helmut; Johnston, Leigh; Kilpatrick, Trevor; Egan, Gary			Diffusion tensor imaging of the optic radiations after optic neuritis	HUMAN BRAIN MAPPING			English	Article						diffusion tensor imaging; multiple sclerosis; optic radiations	TRAUMATIC AXONAL INJURY; MULTIPLE-SCLEROSIS; WHITE-MATTER; RETROGRADE DEGENERATION; MAGNETIZATION-TRANSFER; CORPUS-CALLOSUM; MRI; ATROPHY; LESIONS; NERVE	Trans-synaptic degeneration could exacerbate neurodegeneration in multiple sclerosis (MS). We aimed to assess whether anterograde trans-synaptic degeneration could be identified in the primary visual pathway in vivo. Diffusion tensor imaging (DTI) was used to assess the optic radiations in 15 patients with previous optic nerve inflammation and 9 healthy volunteers. A probabilistic atlas of the optic radiations was created from healthy diffusion tractography data. Lengthwise profiles for DTI parameters (axial [gimel vertical bar vertical bar|], radial [gimel perpendicular to] and mean diffusivity [MD], fractional anisotropy [FA] and the angle of deviation of the principal eigenvector [alpha]) were analyzed for patients and controls. Patients also underwent multifocal visual evoked potential (mfVEP) assessments to characterize the latency and amplitude of cortical potentials. Correlations were performed between mfVEP latency and amplitude in the left and right visual hemi-fields and DTI parameters in the contra-lateral optic radiations. Patients displayed a significant decrease in lambda vertical bar vertical bar within the body of both optic radiations, which significantly correlated with loss of mfVEP amplitude. Abnormal gimel perpendicular to and FA were detected bilaterally throughout the optic radiations in patients but the abnormality was not associated with amplitude reduction or latency prolongation of the mfVEP. An abnormal a value was observed in the left optic radiations of patients, and the a value in the body of the optic radiations also correlated with mfVEP amplitude loss. The assocation between bilateral DTI abnormalities within the optic radiations and loss of afferent electrical activity could indicate anterograde trans-synaptic degeneration occurs following optic neuritis. Hum Brain Mapp 33:20472061, 2012. (c) 2011 Wiley Periodicals, Inc.	[Kolbe, Scott; Butzkueven, Helmut; Johnston, Leigh; Kilpatrick, Trevor; Egan, Gary] Univ Melbourne, Florey Neurosci Inst, Melbourne, Vic, Australia; [Kolbe, Scott; Bajraszewski, Clare; Chapman, Caron; Butzkueven, Helmut; Kilpatrick, Trevor; Egan, Gary] Univ Melbourne, Ctr Neurosci, Melbourne, Vic, Australia; [Tan Nguyen; Paine, Mark] Royal Victorian Eye & Ear Hosp, Neuroophthalmol Unit, Melbourne, Vic 3002, Australia; [Mitchell, Peter] Royal Melbourne Hosp, Dept Radiol, Melbourne, Vic, Australia; [Butzkueven, Helmut; Kilpatrick, Trevor] Royal Melbourne Hosp, Dept Neurol, Melbourne, Vic, Australia; [Johnston, Leigh] Univ Melbourne, Dept Elect & Elect Engn, Melbourne, Vic, Australia; [Johnston, Leigh] Univ Melbourne, NICTA Victorian Res Lab, Melbourne, Vic, Australia	Kolbe, S (corresponding author), Univ Melbourne, Florey Neurosci Inst, Melbourne, Vic, Australia.	scott.kolbe@florey.edu.au	Johnston, Leigh A/D-7102-2014; Egan, Gary F./A-1381-2013	Johnston, Leigh A/0000-0002-5032-4674; Kolbe, Scott/0000-0003-4685-1380; Butzkueven, Helmut/0000-0003-3940-8727; Kilpatrick, Trevor/0000-0003-3999-085X; Egan, Gary/0000-0002-3186-4026	Australian National Health and Medical Research Council (NHMRC) Principal Research Fellowship, AustraliaNational Health and Medical Research Council of Australia [400317]; Joint MS Research Australia/Trish MS Foundation/NHMRC Betty Cuthbert FellowshipNational Health and Medical Research Council of Australia [400476]; Joint MS Research Australia/Australian Financial Advisors Association Postgraduate Scholarship; Charityworks for MS, Melbourne; Neurosciences Victoria Neuro-Informatics Platform	Contract grant sponsor: Australian National Health and Medical Research Council (NHMRC) Principal Research Fellowship, Australia; Contract grant number: 400317; Contract grant sponsor: Joint MS Research Australia/Trish MS Foundation/NHMRC Betty Cuthbert Fellowship; Contract grant number: 400476; Contract grant sponsors: The Joint MS Research Australia/Australian Financial Advisors Association Postgraduate Scholarship; Charityworks for MS, Melbourne; Neurosciences Victoria Neuro-Informatics Platform.	Alexander DC, 2001, IEEE T MED IMAGING, V20, P1131, DOI 10.1109/42.963816; ALTMAN DG, 1983, J ROY STAT SOC D-STA, V32, P307, DOI 10.2307/2987937; Audoin B, 2006, BRAIN, V129, P1031, DOI 10.1093/brain/awl039; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Brex PA, 2002, NEW ENGL J MED, V346, P158, DOI 10.1056/NEJMoa011341; Chard DT, 2003, J NEUROL NEUROSUR PS, V74, P1551, DOI 10.1136/jnnp.74.11.1551; Ciccarelli O, 2005, HUM BRAIN MAPP, V25, P308, DOI 10.1002/hbm.20101; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; Costello F, 2006, ANN NEUROL, V59, P963, DOI 10.1002/ana.20851; Craner MJ, 2004, P NATL ACAD SCI USA, V101, P8168, DOI 10.1073/pnas.0402765101; Deboy CA, 2007, BRAIN, V130, P2199, DOI 10.1093/brain/awm122; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Evangelou N, 2001, BRAIN, V124, P1813, DOI 10.1093/brain/124.9.1813; Geurts JJG, 2005, RADIOLOGY, V236, P254, DOI 10.1148/radiol.2361040450; GHETTI B, 1972, BRAIN RES, V45, P31, DOI 10.1016/0006-8993(72)90214-4; Ginsberg SD, 2002, J NEUROTRAUM, V19, P99, DOI 10.1089/089771502753460277; GLEES P, 1967, ACTA NEUROPATHOL, V7, P361, DOI 10.1007/BF00688092; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Inglese M, 2001, J NEUROL SCI, V188, P33, DOI 10.1016/S0022-510X(01)00542-1; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Johnson H, 2000, EXP BRAIN RES, V132, P269, DOI 10.1007/s002210000384; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Klistorner A, 2008, ANN NEUROL, V64, P715, DOI 10.1002/ana.21474; Klistorner A, 2007, INVEST OPHTH VIS SCI, V48, P4549, DOI 10.1167/iovs.07-0381; Kolbe S, 2009, NEUROIMAGE, V45, P679, DOI 10.1016/j.neuroimage.2008.12.047; Korsholm K, 2007, BRAIN, V130, P1244, DOI 10.1093/brain/awm045; LeVay S, 1971, CELL TISSUE RES, V113, P396; Lin F, 2007, AM J NEURORADIOL, V28, P278; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Naismith RT, 2009, NEUROLOGY, V72, P589, DOI 10.1212/01.wnl.0000335766.22758.cd; Pagani E, 2005, NEUROIMAGE, V26, P258, DOI 10.1016/j.neuroimage.2005.01.008; Peltier J, 2006, J NEUROSURG, V105, P294, DOI 10.3171/jns.2006.105.2.294; Reich DS, 2010, NEUROIMAGE, V49, P3047, DOI 10.1016/j.neuroimage.2009.11.043; Reich DS, 2009, ARCH NEUROL-CHICAGO, V66, P1; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; Rovaris M, 2005, NEUROLOGY, V65, P1526, DOI 10.1212/01.wnl.0000184471.83948.e0; Rovaris M, 2007, J NEUROIMAGING, V17, p27S, DOI 10.1111/j.1552-6569.2007.00133.x; Shimony JS, 2006, CEREB CORTEX, V16, P1653, DOI 10.1093/cercor/bhj102; Shu N, 2009, HUM BRAIN MAPP, V30, P220, DOI 10.1002/hbm.20507; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Trip SA, 2006, NEUROIMAGE, V31, P286, DOI 10.1016/j.neuroimage.2005.11.051; Trip SA, 2006, NEUROIMAGE, V30, P498, DOI 10.1016/j.neuroimage.2005.09.024; Ueki S, 2006, AM J OPHTHALMOL, V142, P591, DOI 10.1016/j.ajo.2006.05.042; VANBUREN JM, 1963, J NEUROL NEUROSUR PS, V26, P402; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Wu QZ, 2008, J MAGN RESON IMAGING, V27, P446, DOI 10.1002/jmri.21111; Wu QZ, 2007, NEUROIMAGE, V37, P1138, DOI 10.1016/j.neuroimage.2007.06.029; Xie S, 2007, AM J OPHTHALMOL, V143, P642, DOI 10.1016/j.ajo.2006.12.009; Zhang H, 2006, MED IMAGE ANAL, V10, P764, DOI 10.1016/j.media.2006.06.004; Zhang JY, 2009, J NEUROSCI, V29, P3160, DOI 10.1523/JNEUROSCI.3941-08.2009	57	27	30	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	SEP	2012	33	9					2047	2061		10.1002/hbm.21343			15	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	989XB	WOS:000307593400003	21915943	Green Published			2021-06-18	
J	DeCuypere, M; Klimo, P				DeCuypere, Michael; Klimo, Paul, Jr.			Spectrum of Traumatic Brain Injury from Mild to Severe	SURGICAL CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; Neurotrauma; Cerebral edema; Intracranial pressure monitoring; Craniectomy	SEVERE HEAD-INJURY; DECOMPRESSIVE CRANIECTOMY; INTRACRANIAL-PRESSURE; TRANSCRANIAL DOPPLER; UNITED-STATES; OPTIC-NERVE; ELDERLY-PATIENTS; US ARMY; MANAGEMENT; IMPACT	Traumatic brain injury (TBI) involves significant damage of the brain parenchyma, and is the leading cause of morbidity and mortality after trauma. It is thus essential for all physicians involved in acute care medicine and surgery to have a thorough understanding of TBI. Management of the patient with TBI is a rapidly advancing field, characterized by an improved understanding of intracranial pathophysiology and decreasing overall mortality largely because of improved neurocritical and surgical care. This article summarizes the classification system, management approaches, and recent controversies in the care of mild, moderate, and severe TBI.	[Klimo, Paul, Jr.] Semmes Murphey Neurol & Spine Inst, Memphis, TN 38120 USA; [DeCuypere, Michael; Klimo, Paul, Jr.] Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, Memphis, TN 38163 USA; [Klimo, Paul, Jr.] LeBonheur Childrens Hosp, Dept Neurosurg, Memphis, TN 38103 USA	Klimo, P (corresponding author), Semmes Murphey Neurol & Spine Inst, 6325 Humphreys Blvd, Memphis, TN 38120 USA.	pklimo@semmes-murphey.com		DeCuypere, Michael/0000-0002-4598-8644			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Agrawal A, 2008, CLIN NEUROL NEUROSUR, V110, P321, DOI 10.1016/j.clineuro.2008.01.013; Ahmad FU, 2011, WORLD NEUROSURG, V75, P451, DOI 10.1016/j.wneu.2010.12.042; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; American Association for the Surgery of Trauma, 2003, J Trauma, V54, pS235; Anderson RCE, 2004, J NEUROSURG, V101, P53, DOI 10.3171/ped.2004.101.2.0053; Arienta C, 1997, SURG NEUROL, V48, P213, DOI 10.1016/S0090-3019(97)00019-0; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Barmparas G, 2011, WORLD J SURG, V35, P1809, DOI 10.1007/s00268-011-1149-9; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock M Ross, 2006, Neurosurgery, V58, pS7; Bullock MR, 2006, NEUROSURGERY S, V58, pSi; Carey ME, 1996, J TRAUMA, V40, pS165, DOI 10.1097/00005373-199603001-00036; CHESNUT RM, 1993, J TRAUMA, V35, P492, DOI 10.1097/00005373-199309000-00036; COLOHAN ART, 1992, J NEUROTRAUM, V9, pS259; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cruz J, 1996, CRIT CARE MED, V24, P953, DOI 10.1097/00003246-199606000-00013; Czosnyka M, 1998, J NEUROSURG, V88, P802, DOI 10.3171/jns.1998.88.5.0802; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Eastridge BJ, 2006, J TRAUMA, V61, P1366, DOI 10.1097/01.ta.0000245894.78941.90; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Figaji AA, 2009, CHILD NERV SYST, V25, P1325, DOI 10.1007/s00381-009-0822-x; Fodale V, 2007, ACTA ANAESTH SCAND, V51, P839, DOI 10.1111/j.1399-6576.2007.01355.x; Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009; Geeraerts T, 2008, CRIT CARE, V12, DOI 10.1186/cc6893; Geeraerts T, 2008, CRIT CARE, V12, DOI 10.1186/cc7006; Gittleman AM, 2005, AM J NEURORADIOL, V26, P603; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Holcomb JB, 2007, ANN SURG, V245, P986, DOI 10.1097/01.sla.0000259433.03754.98; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Hutchinson PJ, 2011, BRIT J NEUROSURG, V25, P441, DOI 10.3109/02688697.2011.583366; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jia XF, 2008, RESUSCITATION, V76, P431, DOI 10.1016/j.resuscitation.2007.08.014; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; KLINGELHOFER J, 1988, J NEUROL, V235, P159, DOI 10.1007/BF00314307; Koenig MA, 2008, NEUROLOGY, V70, P1023, DOI 10.1212/01.wnl.0000304042.05557.60; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lazaridis C, 2011, J CRIT CARE; Ling GSF, 2008, NEUROL CLIN, V26, P409, DOI 10.1016/j.ncl.2008.02.001; LIU D, 1993, AM J OPHTHALMOL, V116, P548, DOI 10.1016/S0002-9394(14)73195-2; Lu J, 2005, ACT NEUR S, V95, P281; Marion DW, 2011, LANCET NEUROL, V10, P497, DOI 10.1016/S1474-4422(11)70098-9; Marion DW, 2006, NEUROSURGERY, V58, P655; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marion DW, 1998, NEUROL CLIN, V16, P485, DOI 10.1016/S0733-8619(05)70073-6; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, pS6, DOI 10.1017/S0084255900003685; Munch E, 2000, NEUROSURGERY, V47, P315; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Patel TH, 2004, J TRAUMA, V57, P201, DOI 10.1097/01.TA.0000133638.30269.38; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Qureshi AI, 1999, J TRAUMA, V47, P659, DOI 10.1097/00005373-199910000-00009; Rasulo EA, 2008, EUR J ANAESTH, V25, P167, DOI 10.1017/S0265021507003341; Reynolds FD, 2003, J TRAUMA, V54, P492, DOI 10.1097/01.TA.0000051601.60556.FC; ROCKSWOLD GL, 1993, ANN EMERG MED, V22, P1004, DOI 10.1016/S0196-0644(05)82742-8; Rosenfeld JV, 2007, J NEUROSURG, V106, P195, DOI 10.3171/jns.2007.106.1.195; Rustemeyer J, 2007, BRIT J ORAL MAX SURG, V45, P556, DOI 10.1016/j.bjoms.2007.01.003; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sariego Jack, 2006, Disaster Manag Response, V4, P114, DOI 10.1016/j.dmr.2006.09.001; Schlifka B, 2007, J TRAUMA, V62, pS103, DOI 10.1097/TA.0b013e318065b4e5; Schreckinger M, 2009, NEUROCRIT CARE, V11, P427, DOI 10.1007/s12028-009-9256-2; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Selassie AW, 2004, AM J EMERG MED, V22, P465, DOI 10.1016/j.ajem.2004.07.024; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; Soldatos T, 2009, EMERG MED J, V26, P630, DOI 10.1136/emj.2008.058453; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WISNER DH, 1993, J TRAUMA, V35, P271, DOI 10.1097/00005373-199308000-00017; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Ziai WC, 2007, J NEUROL SCI, V261, P157, DOI 10.1016/j.jns.2007.04.048; Zwahlen RA, 2007, J CRANIO MAXILL SURG, V35, P142, DOI 10.1016/j.jcms.2007.01.006	97	27	29	1	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0039-6109	1558-3171		SURG CLIN N AM	Surg. Clin.-North Am.	AUG	2012	92	4					939	+		10.1016/j.suc.2012.04.005			20	Surgery	Surgery	000IE	WOS:000308379100011	22850156				2021-06-18	
J	Kaneko, T; Kibayashi, K				Kaneko, Tomomi; Kibayashi, Kazuhiko			Mild hypothermia facilitates the expression of cold-inducible RNA-binding protein and heat shock protein 70.1 in mouse brain	BRAIN RESEARCH			English	Article						Mild hypothermia; Cold ambience; CIRP; hsp70.1; Cytokine; Cell survival	MAMMALIAN HIBERNATION; CEREBRAL-ISCHEMIA; CIRP EXPRESSION; GENE-EXPRESSION; MICE; TEMPERATURE; RESUSCITATION; ACCLIMATION; ACTIVATION; MECHANISM	An appropriate thermal control system is essential for maintaining brain homeostasis. Hypothermia is a decrease in core body temperature that occurs when the thermoregulatory responses of homeotherrnic animals are impaired by environmental and situational influences, such as cold ambience and anesthesia. In recent years, hypothermia has been used for medical treatment, i.e., therapeutic hypothermia, for patients with stroke, traumatic brain injury, and heart surgery. However, the target molecules acting during hypothermia have not been identified. To understand the molecular mechanisms, we generated a mouse model of mild hypothermia (1 degrees C-2 degrees C below normal), and analyzed the expression of several genes. After mice were exposed to cold for 24 and 48 h, their rectal temperature reached 33 degrees C-35 degrees C. Then, using real-time quantitative PCR, we analyzed the mRNA expression levels of c-fos, cold-inducible RNAbinding protein (CIRP), heat shock protein (hsp) 70.1, oxytocin, and representative inflammatory cytokines, i.e., tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 in target organs. Importantly, we found that the expression levels of CIRP and hsp70.1 were elevated in the olfactory bulb within 48 h. In the hypothalamus, CIRP expression levels increased and were followed by an increase in hsp70.1 expression. Meanwhile, TNF-alpha and IL-6 expression decreased gradually over 24 and 48 h in the olfactory bulb and hypothalamus. These specific expression profiles, i.e., enhanced CIRP and hsp70.1 expression and depressed cytokine expression, suggest that they could regulate apoptosis related to the cytokine signaling. (c) 2012 Elsevier B.V. All rights reserved.	[Kaneko, Tomomi; Kibayashi, Kazuhiko] Tokyo Womens Med Univ, Sch Med, Dept Legal Med, Shinjuku Ku, Tokyo 1628666, Japan	Kaneko, T (corresponding author), Tokyo Womens Med Univ, Sch Med, Dept Legal Med, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	kaneko@research.twmu.ac.jp	Kazuhiko, Kibayashi/F-5173-2013	Kazuhiko, Kibayashi/0000-0001-6510-5215	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [23790730, 21659177]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23790730] Funding Source: KAKEN	This research was supported by a Grant-in-Aid for Young Scientists (B) (No. 23790730) to Dr. T. Kaneko and a Grant-inAid for Challenging Exploratory Research (No. 21659177) to Dr. K. Kibayashi from the Japan Society for the Promotion of Science.	Al-Fageeh MB, 2009, RNA, V15, P1164, DOI 10.1261/rna.1179109; Belsham DD, 2004, ENDOCRINOLOGY, V145, P393, DOI 10.1210/en.2003-0946; Bischoff F, 1942, CANCER RES, V2, P370; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Carey HV, 2003, PHYSIOL REV, V83, P1153, DOI 10.1152/physrev.00008.2003; Carlson NG, 1999, J IMMUNOL, V163, P3963; CARTER N, 1995, INT J LEGAL MED, V108, P116, DOI 10.1007/BF01369918; Furuse M, 2007, NEUROL RES, V29, P53, DOI 10.1179/174313206X152537; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Hagioka S, 2003, CRIT CARE MED, V31, P2502, DOI 10.1097/01.CCM.0000084845.76762.F4; Ji Y, 2002, COMPUT BIOL MED, V32, P495, DOI 10.1016/S0010-4825(02)00030-6; Kasahara Y, 2007, BIOSCI BIOTECH BIOCH, V71, P3122, DOI 10.1271/bbb.70498; Kibayashi K, 2009, INT J LEGAL MED, V123, P371, DOI 10.1007/s00414-008-0278-7; Lapiz-Bluhm MDS, 2009, PSYCHOPHARMACOLOGY, V202, P329, DOI 10.1007/s00213-008-1224-6; Lapo IB, 2003, PHYSIOL BEHAV, V78, P345, DOI 10.1016/S0031-9384(02)01004-1; Lee SH, 2001, STROKE, V32, P2905, DOI 10.1161/hs1201.099604; LIU AYC, 1994, J BIOL CHEM, V269, P14768; Matsui T, 2006, J NEUROSURG ANESTH, V18, P189, DOI 10.1097/01.ana.0000188639.39844.f6; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; McPherson CA, 2011, BRAIN BEHAV IMMUN, V25, P850, DOI 10.1016/j.bbi.2010.09.003; Meng XZ, 2002, SHOCK, V17, P345, DOI 10.1097/00024382-200205000-00001; Morin P, 2009, INT J DEV BIOL, V53, P433, DOI 10.1387/ijdb.082643pm; Nishimura M, 1999, PHARMACOLOGY, V59, P149, DOI 10.1159/000028315; Nishiyama H, 1998, BIOCHEM BIOPH RES CO, V245, P534, DOI 10.1006/bbrc.1998.8482; Nishiyama H, 1997, J CELL BIOL, V137, P899, DOI 10.1083/jcb.137.4.899; Nishiyama H, 1998, AM J PATHOL, V152, P289; Peirson SN, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng073; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Sakurai T, 2006, BBA-MOL CELL RES, V1763, P290, DOI 10.1016/j.bbamcr.2006.02.007; SATO K, 1994, CLIN SCI, V86, P133, DOI 10.1042/cs0860133; Shintani Y, 2011, STROKE RES TREAT, V2011, DOI 10.4061/2011/809874; Takata T, 1997, NEUROSCI LETT, V227, P41, DOI 10.1016/S0304-3940(97)00296-6; Tatar CL, 2010, ASN NEURO, V2, DOI 10.1042/AN20100016; Terao Y, 2009, NEUROREPORT, V20, P745, DOI 10.1097/WNR.0b013e32832a2f32; Wirth D, 2002, CELL STRESS CHAPERON, V7, P387, DOI 10.1379/1466-1268(2002)007<0387:DHSGHR>2.0.CO;2; Wolfson MR, 2008, NEUROCRIT CARE, V8, P437, DOI 10.1007/s12028-008-9064-0; Zeiner A, 2000, STROKE, V31, P86, DOI 10.1161/01.STR.31.1.86	37	27	33	1	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUL 23	2012	1466						128	136		10.1016/j.brainres.2012.05.001			9	Neurosciences	Neurosciences & Neurology	989ZH	WOS:000307600300013	22609236				2021-06-18	
J	Jacobowitz, DM; Cole, JT; McDaniel, DP; Pollard, HB; Watson, WD				Jacobowitz, David M.; Cole, Jeffrey T.; McDaniel, Dennis P.; Pollard, Harvey B.; Watson, William D.			Microglia activation along the corticospinal tract following traumatic brain injury in the rat: A neuroanatomical study	BRAIN RESEARCH			English	Article						Microglia; Traumatic brain injury; Corticospinal neuron; Electron microscopy; Light microscopy; Rat	CLOSED-HEAD INJURY; NERVOUS-SYSTEM; MICE; INTERLEUKIN-1-BETA; RECEPTORS; RECOVERY; PROTEIN	Traumatic injury to the brain often manifests itself symptomatically and structurally long after the traumatic event. The cellular basis of this complex response is not completely understood. However, we hypothesized that microglia might contribute to the brain-wide process. To test this hypothesis, we employed optical and electron microscopy to study the microglia in rat brains up to 2 months after digitally controlled cortical impact (CCI) to produce traumatic brain injury (TBI). We also used antibodies against ED-1 and Iba-1, respectively, as markers for activated and resting microglia. ED-1 positive microglial cells are observed accompanying the entire corticospinal tract (CST) on the injured side, but not the control, contralateral side of the brain at 2 months. In this case, ED-1 and Iba-1 were observed to co-localize uniquely on the injured side of the brain. At earlier times following CCI, ultrastructural studies reveal that microglial cells have very irregular shapes and have many processes that intermingle with degenerating nerve axons of the CST in the hindbrain pyramids. These cells appear to be engulfing degenerating myelinated axons. The debris within the cells is converted to lipofuscin, the antigen for the ED-1 antibody, and remains in the cell cytoplasm throughout the life of the cell. We conclude, as hypothesized, that microglia are critical cellular components. Based on observed close association with myelin degeneration, interdigitating activated microglia may be contributing to damage control. Finally, based on the close neuroanatomical relationship between the lesioned corticospinal tract and the wide distribution of activated microglia, primary signals from CST neurons per se, may be directing microglial responses along the entire damaged rat neuroaxis. The role of persistent activation of microglia has not been determined. Published by Elsevier B.V.	[Jacobowitz, David M.; Pollard, Harvey B.] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Cole, Jeffrey T.; Watson, William D.] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Neurol, Bethesda, MD 20814 USA; [McDaniel, Dennis P.] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Biomed Instrumentat Ctr, Bethesda, MD 20814 USA	Jacobowitz, DM (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA.	djacobowitz@usuhs.mil			Comprehensive National Neuroscience Program (CNNP) [W81XWH-07-0679]	This work was supported in part by the Comprehensive National Neuroscience Program (CNNP, award number W81XWH-07-0679). Additionally, the authors would like to thank Mr. William Kean for the preparation of the animals, Ms. Xiuying Zhang for her expert help in preparing this manuscript and the excellent technical assistance of Ms. Tinghua Chen.	Basiri M, 2010, BRAIN RES BULL, V81, P43, DOI 10.1016/j.brainresbull.2009.11.002; Benveniste E.N., 1994, IMMUNOLOGY NERVOUS S; Del Rio-Hortega R., 1965, CYTOLOGY CELLULAR PA, P483; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1988, J NEUROSCI, V8, P4707; Gomes-Leal W, 2005, BRAIN RES, V1066, P57, DOI 10.1016/j.brainres.2005.10.069; Harting MT, 2010, J SURG RES, V159, P557, DOI 10.1016/j.jss.2008.10.014; Harting MT, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E17; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Helmy A, 2009, J NEUROTRAUM, V26, P549, DOI 10.1089/neu.2008.0719; Hoge CW, 2011, JAMA-J AM MED ASSOC, V306, P549, DOI 10.1001/jama.2011.1096; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Inoue K, 2002, GLIA, V40, P156, DOI 10.1002/glia.10150; JACOBOWITZ DM, 1974, BRAIN RES, V80, P111, DOI 10.1016/0006-8993(74)90726-4; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LEENEN LPH, 1985, BRAIN RES, V359, P65, DOI 10.1016/0006-8993(85)91413-1; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; RAIVICH G, 1991, J NEUROSCI RES, V30, P682, DOI 10.1002/jnr.490300412; RAIVICH G, 1994, GLIA, V11, P129, DOI 10.1002/glia.440110208; SAMORAJSKI T, 1965, J CELL BIOL, V26, P779, DOI 10.1083/jcb.26.3.779; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Thiel A, 2011, STROKE, V42, P507, DOI 10.1161/STROKEAHA.110.598821; Thiel A, 2010, J NUCL MED, V51, P1404, DOI 10.2967/jnumed.110.076612; Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527; VAUGHN JE, 1970, J COMP NEUROL, V140, P175, DOI 10.1002/cne.901400204; Yamamoto S, 2010, J NEUROCHEM, V115, P1057, DOI 10.1111/j.1471-4159.2010.06996.x; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008	33	27	27	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 17	2012	1465						80	89		10.1016/j.brainres.2012.05.008			10	Neurosciences	Neurosciences & Neurology	974PI	WOS:000306448300009	22617376				2021-06-18	
J	Faruqui, S; Stern, PJ; Kiefhaber, TR				Faruqui, Safi; Stern, Peter J.; Kiefhaber, Thomas R.			Percutaneous Pinning of Fractures in the Proximal Third of the Proximal Phalanx: Complications and Outcomes	JOURNAL OF HAND SURGERY-AMERICAN VOLUME			English	Article						Complication; percutaneous; phalanx; proximal; outcome	CLOSED REDUCTION; FIXATION	Purpose Two common techniques for fixation of extra-articular fractures at the proximal phalanx base are transarticular (across the metacarpophalangeal joint) and extra-articular cross-pinning. The aim of this study was to assess the complications and outcomes of these 2 techniques. Our hypothesis was that transarticular and extra-articular closed reduction and percutaneous pinning of base of proximal phalanx fractures have similar complication rates and outcomes. Methods A retrospective chart review identified 338 patients with base of proximal phalanx fractures. We treated 50 isolated fractures with closed reduction and percutaneous pinning using 1 of 2 techniques: transarticular (25 fractures through the metacarpal head) or extra-articular (25 fractures cross-pinned through the base of the proximal phalanx). Outcome measures included total active motion and complications. Results We found a substantial overall complication rate in both groups. The mean total active motion for the transarticular group and cross-pinning group was 201 degrees and 198 degrees, respectively. Proximal interphalangeal joint motion was notably affected; nearly half of the patients in each group had flexion loss greater than 20 degrees (average, 27 degrees) at the proximal interphalangeal joint. Nearly a third of patients in both groups had fixed flexion contracture greater than 15 degrees at the proximal interphalangeal joint. There were more secondary procedures in the transarticular group (6) than in the cross-pinning group (2). There was no statistical significance between groups in any of the outcome parameters used. Conclusions Closed pinning minimizes additional soft tissue injury and allows for early motion, but neither fixation method was superior in terms of the measured parameters. In addition, overall results were not as good as what has been reported in the literature. (J Hand Surg 2012;37A:1342-1348. Copyright (c) 2012 by the American Society for Surgery of the Hand All rights reserved)	[Faruqui, Safi] Naval Med Ctr Portsmouth, Dept Orthoped Surg, Div Hand Surg, Portsmouth, VA 23700 USA; Univ Cincinnati, Coll Med, Dept Orthoped Surg & Hand Surg, Cincinnati, OH USA; Hand Surg Spedalists Inc, Cincinnati, OH USA	Faruqui, S (corresponding author), Naval Med Ctr Portsmouth, Dept Orthoped Surg, Div Hand Surg, 620 John Paul Jones Circle, Portsmouth, VA 23700 USA.	safi.faruqui@med.navy.mil					AGEE J, 1992, ORTHOP CLIN N AM, V23, P35; BELSKY MR, 1984, J HAND SURG-AM, V9A, P725, DOI 10.1016/S0363-5023(84)80023-4; Chung KC, 2001, J HAND SURG-AM, V26A, P908, DOI 10.1053/jhsu.2001.26322; COONRAD RW, 1969, J BONE JOINT SURG AM, VA 51, P1291, DOI 10.2106/00004623-196951070-00006; Day CS, 2011, OPERATIVE HAND SURG, V1, P695; Elmaraghy MW, 1998, ANN PLAS SURG, V41, P125; GREEN DP, 1986, HAND CLIN, V2, P307; GREEN DP, 1973, J BONE JOINT SURG AM, VA 55, P1651, DOI 10.2106/00004623-197355080-00009; Hornbach EE, 2001, J HAND SURG-BRIT EUR, V26, P45, DOI 10.1054/jhsb.2000.0524; Joshi BB, 1976, HAND, V8, P85; Vahey JW, 1998, J HAND SURG-AM, V23A, P673, DOI 10.1016/S0363-5023(98)80054-3	11	27	28	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0363-5023			J HAND SURG-AM	J. Hand Surg.-Am. Vol.	JUL	2012	37A	7					1342	1348		10.1016/j.jhsa.2012.04.019			7	Orthopedics; Surgery	Orthopedics; Surgery	031VN	WOS:000310670700007	22721457				2021-06-18	
J	Bivona, U; D'Ippolito, M; Giustini, M; Vignally, P; Longo, E; Taggi, F; Formisano, R				Bivona, Umberto; D'Ippolito, Mariagrazia; Giustini, Marco; Vignally, Pascal; Longo, Eloise; Taggi, Franco; Formisano, Rita			Return to Driving After Severe Traumatic Brain Injury: Increased Risk of Traffic Accidents and Personal Responsibility	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						rehabilitation; return to driving; risk factors; severe traumatic brain injury; traffic safety	PRACTICAL SCALE; DAMAGE	Objective: To determine the frequency of road traffic accidents among individuals who start or resume driving after severe traumatic brain injury (TBI) and to investigate their responsibility for these accidents. Design: Observational/retrospective study. Participants: Sixty adults with severe TBI and their caregivers. Measures: Return to Driving Questionnaire and Glasgow Outcome Scale. Results: Thirty of the 60 participants started to drive or resumed driving after TBI. Nineteen (63%) of them were involved in traffic accidents, with personal responsibility in 26 of 36 after return to driving. Participants caused a significantly higher number of accidents after TBI than before. Conclusions: The ability to drive is frequently compromised after severe TBI. Specific rehabilitation of this complex activity should be a main goal of social reintegration programs in this population.	[Bivona, Umberto; D'Ippolito, Mariagrazia; Formisano, Rita] IRCCS Fdn Santa Lucia, Rome, Italy; [Giustini, Marco; Vignally, Pascal; Longo, Eloise; Taggi, Franco] Ist Super Sanita, Environm & Trauma Unit, I-00161 Rome, Italy	Bivona, U (corresponding author), IRCCS Fdn Santa Lucia, Rome, Italy.	u.bivona@hsantalucia.it	D'Ippolito, Mariagrazia/K-4010-2016; Giustini, Marco/Q-3166-2017	D'Ippolito, Mariagrazia/0000-0001-7818-7352; Giustini, Marco/0000-0003-2691-1956			AVOLIO BJ, 1985, HUM FACTORS, V27, P577; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; Ciurli P, 2010, J INT NEUROPSYCH SOC, V29, P1; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; Formisano R, 2005, BRAIN INJURY, V19, P159, DOI 10.1080/02699050400017163; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JENNETT B, 1975, LANCET, V1, P480; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Novack TA, 2010, BRAIN INJURY, V24, P464, DOI 10.3109/02699051003601713; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rao V, 2007, PSYCHOSOMATICS, V48, P217, DOI 10.1176/appi.psy.48.3.217; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; STELMACH GE, 1992, HUM FACTORS, V34, P53, DOI 10.1177/001872089203400107; Stuss D, 2002, FRONTAL LOBES; TEASDALE G, 1974, LANCET, V2, P81	19	27	28	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2012	27	3					210	215		10.1097/HTR.0b013e31822178a9			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	941CV	WOS:000303941500009	21829135				2021-06-18	
J	Boggild, M; Tator, CH				Boggild, Miranda; Tator, Charles H.			Concussion Knowledge among Medical Students and Neurology/Neurosurgery Residents	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							BRAIN-INJURY; SPORT; MANAGEMENT; TBI	Background and Objectives: Concussion is a prevalent brain injury in the community. While primary prevention strategies need to be enhanced, it is also important to diagnose and treat concussions expertly and expeditiously to prevent serious complications that may be life-threatening or long lasting. Therefore, physicians should be knowledgeable about the diagnosis and management of concussions. The present study assesses Ontario medical students' and residents' knowledge of concussion management. Methods: A survey to assess the knowledge and awareness of the diagnosis and treatment of concussions was developed and administered to graduating medical students (n = 222) and neurology and neurosurgery residents (n = 80) at the University of Toronto. Results: Residents answered correctly significantly more of the questions regarding the diagnosis and management of concussions than the medical students (mean = 5.8 vs 4.1, t = 4.48, p<0.01). Gender, participation in sports, and personal concussion history were not predictive of the number of questions answered correctly. Several knowledge ups were identified in the sample population as a whole. Approximately half of the medical students and residents did not recognize chronic traumatic encephalopathy (n = 36) or the second impact syndrome (n = 44) as possible consequences of repetitive concussions. Twenty-four percent of the medical students (n = 18) did not think that "every concussed individual should see a physician" as part of management. Conclusions: A significant number of medical students and residents have incomplete knowledge about concussion diagnosis and management. This should be addressed by targeting this population during undergraduate medical education.	[Tator, Charles H.] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada; [Tator, Charles H.] Div Neurosurg, Toronto, ON, Canada; [Boggild, Miranda] Univ Toronto, Toronto, ON, Canada	Tator, CH (corresponding author), Toronto Western Hosp, 399 Bathurst St,Ste 4W-433, Toronto, ON M5T 2S8, Canada.	charles.tator@uhn.ca					Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Centers for Disease Control and Prevention, 2003, NAT CTR INJ PREV CON; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Delaney J, THINKFIRST CONCUSSIO; Demorest RA, 2005, PEDIATRICS, V115, P28, DOI 10.1542/peds.2004-0266; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Government of Canada, 2000, CAN COMM HLTH SURV Q; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Kelly JP, 1997, NEUROLOGY, V48, P581; King NS, 2001, BRAIN INJURY, V25, P462; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Tator CH, 2010, CAN J NEUROL SCI, V37, P714, DOI 10.1017/S0317167100051337; Tator CH, 2009, CAN J NEUROL SCI, V36, P405, DOI 10.1017/S031716710000771X; Tator CH, 2009, CAN J NEUROL SCI, V36, P269, DOI 10.1017/S0317167100006922; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; Willer B, 2004, INJURY PREV, V10, P144, DOI 10.1136/ip.2003.005017; Zafonte R, 2011, JAMA-J AM MED ASSOC, V306, P79, DOI 10.1001/jama.2011.819	25	27	27	0	9	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0317-1671	2057-0155		CAN J NEUROL SCI	Can. J. Neurol. Sci.	MAY	2012	39	3					361	368		10.1017/S0317167100013524			8	Clinical Neurology	Neurosciences & Neurology	946VR	WOS:000304386100018	22547519	Bronze			2021-06-18	
J	Coats, B; Eucker, SA; Sullivan, S; Margulies, SS				Coats, Brittany; Eucker, Stephanie A.; Sullivan, Sarah; Margulies, Susan S.			Finite element model predictions of intracranial hemorrhage from non-impact, rapid head rotations in the piglet	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Subdural hemorrhage; Traumatic brain injury; Falls; Brain-skull displacement; Pediatric; Finite element	BRAIN-TISSUE; CHILDREN FALL; INJURIES; BIOMECHANICS; BEHAVIOR; IMPACT	Clinicians are charged with the significant task of distinguishing between accidental and inflicted head trauma. Oftentimes this distinction is straightforward, but many times probabilities of injuries from accidental scenarios are unknown making the differential diagnosis difficult. For example, it is unknown whether intracranial hemorrhage (IH) can occur at a location other than a focal contact site following a low height fall. To create a foundation for predicting regional IH in infants, we sought to identify the biomechanical response and injury threshold best able to predict IH in 3-5 day old piglets. First, finite element (FE) model simulations of in situ animal studies were performed to ascertain the optimal representation of the pia-arachnoid complex, cerebrospinal fluid and cortical vasculature (PCC) for predicting brain strain and brain/skull displacement. Second, rapid head rotations resulting in various degrees of IH were simulated (n = 24) to determine the biomechanical predictor and injury threshold most closely correlated with IH. FE models representing the PCC with either spring connectors or solid elements between the brain and skull resulted in peak brain strain and brain/skull displacement similar to measured values in situ. However, when predicting IH, the spring connector representation of the PCC had the best predictive capability for IH with a sensitivity of 80% and a specificity of 85% when >= 1% of all spring connectors had at least a peak strain of 0.31 mm/mm. These findings and reported methodology will be used in the development of a human infant FE model to simulate real-world falls and identify injury thresholds for predicting IH in infants. (C) 2012 ISDN. Published by Elsevier Ltd. All rights reserved.	[Coats, Brittany] Univ Utah, Dept Mech Engn, Salt Lake City, UT 84112 USA; [Eucker, Stephanie A.] Univ Virginia, Dept Emergency Med, Charlottesville, VA 22908 USA; [Sullivan, Sarah; Margulies, Susan S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Coats, B (corresponding author), Univ Utah, Dept Mech Engn, 50 S Cent Campus Dr, Salt Lake City, UT 84112 USA.	brittany.coats@utah.edu	Eucker, Stephanie/AAL-1828-2021	Eucker, Stephanie/0000-0001-9986-5773	CDC-NCIPCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01-CE001445]; NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS39679, T32-NS043126-07]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01CE001445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679, T32NS043126] Funding Source: NIH RePORTER	The authors would like to thank Erica Hummel and Jill Ralston for their technical assistance with the IHP scoring. This study was made possible by the generous support of the CDC-NCIPC R01-CE001445, NIH-NINDS R01-NS39679, and NIH-NINDS T32-NS043126-07.	Arbogast K., 1997, P 41 STAPP CAR CRASH; Bertocci GE, 2004, INJURY, V35, P417, DOI 10.1016/S0020-1383(03)00062-7; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; Bloomfield IG, 1998, PEDIATR NEUROSURG, V28, P246, DOI 10.1159/000028659; Brands D., 1999, P 43 STAPP CAR CRASH; BYLSKI DI, 1986, J BIOMECH, V19, P19, DOI 10.1016/0021-9290(86)90105-3; Chafi MS, 2009, P I MECH ENG H, V223, P1003, DOI 10.1243/09544119JEIM631; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Coats B., 2008, PEDIATRICS, V2, P1; Couper Z, 2008, BIOMECH MODEL MECHAN, V7, P105, DOI 10.1007/s10237-007-0079-9; Delye Hans, 2006, Stapp Car Crash J, V50, P625; Depreitere B, 2006, J NEUROSURG, V104, P950, DOI 10.3171/jns.2006.104.6.950; Eucker S., 2009, EFFECT HEAD ROTATION; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Haney SB, 2010, PEDIATR EMERG CARE, V26, P914, DOI 10.1097/PEC.0b013e3181fe9139; Hennrikus WL, 2003, CLIN ORTHOP RELAT R, P148, DOI 10.1097/01.blo.0000043059.62337.97; Ibrahim NG, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000956; KUIJPERS AHWM, 1995, J NEUROTRAUM, V12, P715, DOI 10.1089/neu.1995.12.715; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Macgregor D M, 2000, Inj Prev, V6, P291, DOI 10.1136/ip.6.4.291; Meaney D.F., 1991, BIOMECHANICS ACUTE S; Meyers MA., 1994, DYNAMIC BEHAV MAT; MILLER RT, 1999, 43 STAPP CAR CRASH C; Monson KL, 2005, J BIOMECH, V38, P737, DOI 10.1016/j.jbiomech.2004.05.004; MUSEMECHE CA, 1991, J TRAUMA, V31, P1347, DOI 10.1097/00005373-199110000-00004; Nicolle S, 2005, BIORHEOLOGY, V42, P209; NIMITYONGSKUL P, 1987, J PEDIATR ORTHOPED, V7, P184, DOI 10.1097/01241398-198703000-00014; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; REIBER GD, 1993, AM J FOREN MED PATH, V14, P201, DOI 10.1097/00000433-199309000-00005; ROOT I, 1992, AM J FOREN MED PATH, V13, P85, DOI 10.1097/00000433-199203000-00017; Roth S, 2008, COMPUT METH PROG BIO, V90, P262, DOI 10.1016/j.cmpb.2008.01.007; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Sawyer JR, 2000, J PEDIATR ORTHOPED, V20, P197, DOI 10.1097/00004694-200003000-00013; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; SMITH MD, 1975, J TRAUMA, V15, P987, DOI 10.1097/00005373-197511000-00008; Stemper BD, 2007, ANN BIOMED ENG, V35, P285, DOI 10.1007/s10439-006-9229-y; Takhounts EG, 2008, STAPP CAR C, V52, P1; Tarantino CA, 1999, PEDIATR EMERG CARE, V15, P5, DOI 10.1097/00006565-199902000-00002; Wang MY, 2001, J PEDIATR SURG, V36, P1528, DOI 10.1053/jpsu.2001.27037; Yamada H, 1970, STRENGTH BIOL MAT; YAMASHIMA T, 1984, J NEUROL NEUROSUR PS, V47, P121, DOI 10.1136/jnnp.47.2.121; Yan W., 2011, COMPUTER METHODS BIO	44	27	28	1	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	MAY	2012	30	3			SI		191	200		10.1016/j.ijdevneu.2011.12.009			10	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	936XH	WOS:000303622800004	22239917	Green Accepted, Green Published			2021-06-18	
J	Fulton, JB; Yeates, KO; Taylor, HG; Walz, NC; Wade, SL				Fulton, John B.; Yeates, Keith Owen; Taylor, H. Gerry; Walz, Nicolay C.; Wade, Shari L.			Cognitive Predictors of Academic Achievement in Young Children 1 Year After Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; preschool children; academic achievement; memory; executive function	CLOSED-HEAD-INJURY; EARLY-CHILDHOOD; PRESCHOOL-CHILDREN; SHAPE SCHOOL; SHORT-TERM; FUNCTIONAL RECOVERY; EXECUTIVE CONTROL; BEHAVIOR PROBLEMS; AGE; SKILLS	Objective: To examine cognitive predictors of academic achievement in young children with traumatic brain injury (TBI) and orthopedic injury (OI) shortly after injury and I year postinjury. Methods: Participants included 3- to 6-year-old children, 63 with TBI (46 with moderate TBI and 17 with severe TBI) and a comparison group of 80 children with OI. Academic achievement was assessed approximately 1 and 12 months postinjury using three subtests from the Woodcock-Johnson Tests of Achievement-Third Edition and the School Readiness Composite from the Bracken Basic Concepts Scale-Revised. General intellectual functioning, memory, and executive functions were measured at the initial assessment using standardized tests. Results: Hierarchical linear regression was used to predict academic achievement at the initial and 1-year follow-up assessments. Memory and executive functions were significant predictors of academic achievement at both assessments after controlling for group membership and demographic variables. Executive function remained a significant predictor of some outcomes after taking general intellectual functioning into account. Predictive relationships did not vary across the TBI and 01 groups. Similar results were obtained when regression analyses were completed with only TBI participants using the Glasgow Coma Scale score as a predictor, although memory and executive functioning were somewhat less robust in predicting academic achievement than before. Conclusion: Memory and executive function predict academic achievement after TBI in preschool children, although some of the associations may be accounted for by general intellectual functioning.	[Fulton, John B.] Phoenix Childrens Hosp, Dept Psychol, Barrow Neurol Inst, Phoenix, AZ 85016 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Walz, Nicolay C.; Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Walz, Nicolay C.; Wade, Shari L.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45221 USA	Fulton, JB (corresponding author), Phoenix Childrens Hosp, Dept Psychol, Barrow Neurol Inst, 1919 E Thomas Rd, Phoenix, AZ 85016 USA.	jfulton@phoenixchildrens.com	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	National Institutes of Health (NIH)/National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [1UL1RR026314]; National Institute of Child Health and Human Development (NICHD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD42729]; State of Ohio Emergency Medical Services; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02 HD44099]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD044099] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR026314] Funding Source: NIH RePORTER	This publication was supported by an Institutional Clinical and Translational Science Award, National Institutes of Health (NIH)/National Center for Research Resources grant number 1UL1RR026314. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NIH. Additional support provided to Dr. Wade included grant R01 HD42729 from the National Institute of Child Health and Human Development (NICHD) and Trauma Research grants from the State of Ohio Emergency Medical Services. Dr. Yeates received support from career development grant K02 HD44099 from NICHD during the conduct of the research. The authors wish to acknowledge the contributions of Christine Abraham, Andrea Beebe, Lori Bernard, Anne Birnbaum, Beth Bishop, Tammy Matecun, Karen Oberjohn, Elizabeth Roth, and Elizabeth Shaver in data collection and coding. The authors also thank Nori Minich for her assistance in data analysis. The Cincinnati Children's Medical Center Trauma Registry, Rainbow Pediatric Trauma Center, Rainbow Babies & Children's Hospital, Nationwide Children's Hospital Trauma Program, and the Metro Health Center Department of Pediatrics and Trauma Registry provided assistance with recruitment.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Beres K.A., 2000, HDB PSYCHOL ASSESSME, P65, DOI DOI 10.1016/B978-008043645-6/50082-3; Bracken B. A., 2006, BRACKEN BASIC CONCEP; Bruce D. A., 1995, TRAUMATIC HEAD INJUR, P40; Bull R, 2008, DEV NEUROPSYCHOL, V33, P205, DOI 10.1080/87565640801982312; Catroppa C, 1999, Pediatr Rehabil, V3, P167; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Catroppa C, 2007, CHILD NEUROPSYCHOL, V13, P240, DOI 10.1080/09297040600837362; Catroppa C, 2009, NEUROPSYCHOL REHABIL, V19, P716, DOI 10.1080/09602010902732868; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Clark CAC, 2010, DEV PSYCHOL, V46, P1176, DOI 10.1037/a0019672; Elliott C.D., 1990, DIFFERENTIAL ABILITY; Espy KA, 1997, DEV NEUROPSYCHOL, V13, P495, DOI 10.1080/87565649709540690; Espy KA, 2004, DEV NEUROPSYCHOL, V26, P465, DOI 10.1207/s15326942dn2601_6; Espy KA, 1999, BRAIN COGNITION, V41, P178, DOI 10.1006/brcg.1999.1117; Espy KA, 2006, PSYCHOL ASSESSMENT, V18, P373, DOI 10.1037/1040-3590.18.4.373; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Freeman SS, 2008, ANESTHESIOLOGY, V108, P588, DOI 10.1097/ALN.0b013e31816725d7; Goldstein G., 2000, HDB PSYCHOL ASSESSME; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; McClelland MM, 2007, DEV PSYCHOL, V43, P947, DOI 10.1037/0012-1649.43.4.947; MCGREW KS, 2001, TECHNICAL MANUAL W J; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; Pritchard VE, 2011, PSYCHOL ASSESSMENT, V23, P31, DOI 10.1037/a0021095; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Stancin T, 2008, J DEV BEHAV PEDIATR, V29, P253, DOI 10.1097/DBP.0b013e31816b6b0f; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Verger K, 2000, BRAIN INJURY, V14, P495; Wade SL, 2008, REHABIL PSYCHOL, V53, P180, DOI 10.1037/0090-5550.53.2.180; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	46	27	28	0	16	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2012	26	3					314	322		10.1037/a0027973			9	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	937AG	WOS:000303630800005	22563873	Green Accepted			2021-06-18	
J	Tagliaferri, F; Zani, G; Iaccarino, C; Ferro, S; Ridolfi, L; Basaglia, N; Hutchinson, P; Servadei, F				Tagliaferri, Fernanda; Zani, Giulia; Iaccarino, Corrado; Ferro, Salvatore; Ridolfi, Lorenza; Basaglia, Nino; Hutchinson, Peter; Servadei, Franco			Decompressive craniectomies, facts and fiction: a retrospective analysis of 526 cases	ACTA NEUROCHIRURGICA			English	Article						Age; Bone flap size; Decompressive craniectomy; Outcome	TRAUMATIC BRAIN-INJURY; REFRACTORY INTRACRANIAL HYPERTENSION; SEVERE HEAD-INJURY; MANAGEMENT; PRESSURE; MULTICENTER; HEMORRHAGE	The aim of this article was to review the clinical practice of "bone flap decompression" in Regional Neurosurgical Units with no particular protocol in use. From January 2005 to December 2008, a retrospective and multicentre study was conducted on patients who were treated with decompressive craniectomy (DC) in seven departments of neurosurgery in Italy. This study included patients with traumatic brain injury, stroke, aneurysmal subarachnoid haemorrhage and cerebral arteriovenous malformations. Data were retrieved from individual medical records. We identified 526 patients with DC. Age was the most significant predictor factor of survival, together with pupil reactivity, time of decompression and size of the bone flap. The effect of age in predicting survival was so important that in patients over 65 years old we did not find any other significant factor related to survival. In younger patients, the survival rate was much better with a large bone flap (p = 0.01). Unfortunately, 57% of patients were decompressed with a bone flap of less than 12 cm in diameter. This was probably due to the association in 80% of cases between haematoma evacuation and decompression. The current practice in many centres is different from published papers. Decompression is common over the age of 65 years, is associated with haematoma evacuation and often the bone flaps are inadequate in terms of size.	[Tagliaferri, Fernanda] Azienda Osped Univ Parma, Dept Anesthesiol Intens Care & Pain Therapy 2, Parma, Italy; [Zani, Giulia; Basaglia, Nino] Azienda Osped Univ Ferrara, Rehabil Unit, Ferrara, Italy; [Iaccarino, Corrado; Servadei, Franco] Azienda Osped Univ Parma, Neurtraumatol Neurosurg Unit, Parma, Italy; [Iaccarino, Corrado; Servadei, Franco] Azienda Santa Maria Nuova, Parma, Italy; [Iaccarino, Corrado; Servadei, Franco] Azienda Osped Univ Parma, Neurtraumatol Neurosurg Unit, Reggio Emilia, Italy; [Iaccarino, Corrado; Servadei, Franco] Azienda Santa Maria Nuova, Reggio Emilia, Italy; [Ferro, Salvatore; Ridolfi, Lorenza] Emilia Romagna Reg Hlth Care Dept, Bologna, Italy; [Hutchinson, Peter] Univ Cambridge, Dept Neurosurg, Cambridge, England	Tagliaferri, F (corresponding author), Azienda Osped Univ Parma, Dept Anesthesiol Intens Care & Pain Therapy 2, Via A Gramsci 14, Parma, Italy.	fernanda.tagliaferri@gmail.com	Iaccarino, Corrado/L-3190-2013; Iaccarino, Corrado/ABE-2361-2020	Iaccarino, Corrado/0000-0002-5133-6327; Iaccarino, Corrado/0000-0002-5133-6327; Servadei, Franco/0000-0002-3595-3464			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Aarabi B, 2009, NEUROSURGERY, V64, P927, DOI 10.1227/01.NEU.0000341907.30831.D2; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Bentley JN, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.8.FOCUS09166; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P493; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cooper P R, 1976, Surg Neurol, V5, P25; De Bonis P, 2011, J NEUROTRAUM, V28, P2043, DOI 10.1089/neu.2011.1889; De Bonis P, 2010, J NEUROSURG, V112, P1150, DOI 10.3171/2009.7.JNS09505; Di Rienzo A, 2008, ACTA NEUROCHIR, V150, P1057, DOI 10.1007/s00701-008-0019-1; Augusto DE, 2008, MED INTENSIVA, V32, P282; Guresir E, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0954; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kocher T, 1901, HIRNERSCHUTTERUNG HI, P262; Li LM, 2010, ANESTH ANALG, V111, P736, DOI 10.1213/ANE.0b013e3181e75cd1; Marion DW, 2006, NEUROSURGERY, V58, P655; Mitchell P, 2007, J NEUROL SCI, V261, P89, DOI 10.1016/j.jns.2007.04.040; Munch E, 2000, NEUROSURGERY, V47, P315; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; RANSOHOFF J, 1971, J NEUROL NEUROSUR PS, V34, P106, DOI 10.1136/jnnp.34.1.106-a; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Servadei F, 2011, NEW ENGL J MED, V364, P1558, DOI 10.1056/NEJMe1102998; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Wendell LC, 2010, NEUROCRIT CARE, V13, P113, DOI 10.1007/s12028-010-9361-2; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4; Wirtz C R, 1997, Neurosurg Focus, V2, pE3	31	27	30	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAY	2012	154	5					919	926		10.1007/s00701-012-1318-0			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	934PG	WOS:000303455800022	22402877				2021-06-18	
J	Corrigan, F; Vink, R; Blumbergs, PC; Masters, CL; Cappai, R; van den Heuvel, C				Corrigan, Frances; Vink, Robert; Blumbergs, Peter C.; Masters, Colin L.; Cappai, Roberto; van den Heuvel, Corinna			Characterisation of the effect of knockout of the amyloid precursor protein on outcome following mild traumatic brain injury	BRAIN RESEARCH			English	Article						Amyloid precursor protein; Caspase-3; GAP-43; sAPP alpha; Synaptophysin; Traumatic brain injury	CLOSED-HEAD INJURY; LONG-TERM ACCUMULATION; SECRETED FORMS; BETA-PROTEIN; HIPPOCAMPAL-NEURONS; CEREBROSPINAL-FLUID; NEURITE OUTGROWTH; AXONAL DAMAGE; UP-REGULATION; MICE LACKING	The amyloid precursor protein (APP) increases following traumatic brain injury (TBI), although the functional significance of this remains unclear largely because the functions of the subsequent APP metabolites are so different: A beta is neurotoxic whilst sAPP alpha is neuroprotective. To investigate this further, APP wildtype and knockout mice were subjected to mild diffuse TBI and their outcomes compared. APP knockout mice displayed significantly worse cognitive and motor deficits, as demonstrated by the Barnes Maze and rotarod respectively, than APP wildtype mice. This was associated with a significant increase in hippocampal and cortical cell loss, as well as axonal injury, in APP knockout mice and an impaired neuroreparative response as indicated by diminished GAP-43 immunoreactivity when compared to APP wildtype mice. This study is the first to demonstrate that endogenous APP is beneficial following mild TBI, suggesting that the upregulation of APP observed following injury is an acute protective response. (C) 2012 Elsevier B.V. All rights reserved.	[Corrigan, Frances; Vink, Robert; Blumbergs, Peter C.; van den Heuvel, Corinna] Univ Adelaide, Sch Med Sci, Discipline Anat & Pathol, Adelaide, SA 5005, Australia; [Corrigan, Frances; Vink, Robert; Blumbergs, Peter C.; van den Heuvel, Corinna] Hanson Inst, Ctr Neurol Dis, Adelaide, SA, Australia; [Masters, Colin L.] Mental Hlth Res Inst, Parkville, Vic 3052, Australia; [Cappai, Roberto] Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia; [Cappai, Roberto] Univ Melbourne, Mol Sci & BioTechnol Inst Bio21, Melbourne, Vic 3010, Australia	van den Heuvel, C (corresponding author), Univ Adelaide, Sch Med Sci, Discipline Anat & Pathol, Adelaide, SA 5005, Australia.	corinna.vandenheuvel@adelaide.edu.au	AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012; Cappai, Roberto/B-3347-2010	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; , Corinna/0000-0003-0664-8935; Cappai, Roberto/0000-0002-9505-8496; Corrigan, Frances/0000-0001-6150-8893	Brain Foundation; Neurological Research Foundation	We thank Prof. Hui Zheng for providing the APP knockout mice and Dr Stephen Helps, Dr Emma Thornton, Dr Jenna Zeibell and Jim Manavis for expert technical assistance. We also thank the staff within the IMVS animal care facility. This work was funded in part by grants from the Brain Foundation and the Neurological Research Foundation. RC is a National Health and Medical Research Council Senior Research Fellow.	ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bell KFS, 2008, NEUROBIOL AGING, V29, P554, DOI 10.1016/j.neurobiolaging.2006.11.004; Bendotti C, 1997, EUR J NEUROSCI, V9, P93, DOI 10.1111/j.1460-9568.1997.tb01357.x; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BHASIN R, 1991, P NATL ACAD SCI USA, V88, P10307, DOI 10.1073/pnas.88.22.10307; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Boyd-Kimball D, 2004, J ALZHEIMERS DIS, V6, P515; Caille I, 2004, DEVELOPMENT, V131, P2173, DOI 10.1242/dev.01103; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Dawson GR, 1999, NEUROSCIENCE, V90, P1, DOI 10.1016/S0306-4522(98)00410-2; Emery DL, 2000, J COMP NEUROL, V424, P521; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; FRASER PE, 1992, J NEUROCHEM, V59, P1531, DOI 10.1111/j.1471-4159.1992.tb08470.x; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; Gordon-Krajcer W, 2001, FOLIA NEUROPATHOL, V39, P163; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Herms J, 2004, EMBO J, V23, P4106, DOI 10.1038/sj.emboj.7600390; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Johnson V. E., 2010, NAT REV NEUROSCI; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Kim HS, 2004, J NEUROSCI RES, V75, P117, DOI 10.1002/jnr.10845; Koo EH, 1996, J CELL SCI, V109, P991; Koopmans G, 2003, PHYSIOL BEHAV, V79, P683, DOI 10.1016/S0031-9384(03)00171-9; Leyssen M, 2005, EMBO J, V24, P2944, DOI 10.1038/sj.emboj.7600757; LIN LH, 1992, MOL BRAIN RES, V14, P147, DOI 10.1016/0169-328X(92)90024-6; Loane DJ, 2011, J NEUROTRAUM, V28, P225, DOI 10.1089/neu.2010.1595; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Mattson MP, 1997, PHYSIOL REV, V77, P1081; McKinney RA, 1999, P NATL ACAD SCI USA, V96, P11631, DOI 10.1073/pnas.96.20.11631; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Nihashi T, 2001, ACTA NEUROCHIR, V143, P287, DOI 10.1007/s007010170109; Ohsawa I, 1997, BIOCHEM BIOPH RES CO, V236, P59, DOI 10.1006/bbrc.1997.6903; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Opazo C, 2000, BIOL RES, V33, P125; Phinney AL, 1999, NEUROSCIENCE, V90, P1207, DOI 10.1016/S0306-4522(98)00645-9; Popa-Wagner A, 1998, STROKE, V29, P2196, DOI 10.1161/01.STR.29.10.2196; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; QIU WQ, 1995, J NEUROSCI, V15, P2157; Raby CA, 1998, J NEUROCHEM, V71, P2505; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Ring S, 2007, J NEUROSCI, V27, P7817, DOI 10.1523/JNEUROSCI.1026-07.2007; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; Shukla D, 2010, J NEUROSCI RURAL PRA, V1, P82, DOI 10.4103/0976-3147.71723; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; TEASDALE G, 1974, LANCET, V2, P81; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Wallace WC, 1997, MOL BRAIN RES, V52, P201, DOI 10.1016/S0169-328X(97)00258-1; Wang YC, 2004, MOL CELL, V15, P343, DOI 10.1016/j.molcel.2004.06.037; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	74	27	31	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 27	2012	1451						87	99		10.1016/j.brainres.2012.02.045			13	Neurosciences	Neurosciences & Neurology	943MQ	WOS:000304128100010	22424792				2021-06-18	
J	Cervellin, G; Benatti, M; Carbucicchio, A; Mattei, L; Cerasti, D; Aloe, R; Lippi, G				Cervellin, Gianfranco; Benatti, Mario; Carbucicchio, Andrea; Mattei, Loris; Cerasti, Davide; Aloe, Rosalia; Lippi, Giuseppe			Serum levels of protein S100B predict intracranial lesions in mild head injury	CLINICAL BIOCHEMISTRY			English	Article						S100B; Computed tomography; Brain injury; Head trauma	TRAUMATIC BRAIN-INJURY; COMPUTED-TOMOGRAPHY; GUIDELINES; RULE; DIAGNOSIS; MARKER; ADULTS; SCAN	Objectives: This study was aimed to assess whether serum S100B levels at emergency department admission can be used to omit unnecessary computed tomography (CT) in patients with minor head injury (MHI). Design and methods: Sixty consecutive patients with recent MHI were included in this study. Serum S100B measurement and CT scanning were performed in all patients within 3 h from head injury. Results: A positive CT scan was present in 20 out of 60 subjects. Significantly higher values of protein S100B were found in CT positive than in CT negative patients (1.35 versus 0.48 mu g/L; p<0.001). The area under the ROC curve for protein S100B was highly significant (AUC 0.80; p<0.001) and a S100B cut-off value of 0.38 mu g/L displayed 100% sensitivity and 58% specificity. Conclusions: Serum S100-B levels might allow to omit unnecessary CT in patients with pure MHI, thus reducing radiation exposure and saving healthcare resources. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.	[Aloe, Rosalia; Lippi, Giuseppe] Univ Parma, Azienda Osped, Dipartimento Patol, UO Diagnost Ematochim, I-43126 Parma, Italy; [Aloe, Rosalia; Lippi, Giuseppe] Univ Parma, Azienda Osped, Med Lab, UO Diagnost Ematochim, I-43126 Parma, Italy; [Cerasti, Davide] Univ Parma, Azienda Osped, Dipartimento Neurosci, UO Neuroradiol, I-43126 Parma, Italy; [Cervellin, Gianfranco; Benatti, Mario; Carbucicchio, Andrea; Mattei, Loris] Univ Parma, Azienda Osped, Dipartimento Emergenza Urgenza, UO Pronto Soccorso Med Urgenza, I-43126 Parma, Italy	Lippi, G (corresponding author), Univ Parma, Azienda Osped, Dipartimento Patol, UO Diagnost Ematochim, Via Gramsci 14, I-43126 Parma, Italy.	glippi@ao.pr.it	Lippi, Giuseppe/X-7198-2018	Lippi, Giuseppe/0000-0001-9523-9054			af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Dummer R, 2010, ANN ONCOL, V21, pv194, DOI 10.1093/annonc/mdq188; Goncalves CA, 2008, CLIN BIOCHEM, V41, P755, DOI 10.1016/j.clinbiochem.2008.04.003; Gonzalez-Quevedo A, 2011, CLIN BIOCHEM, V44, P154, DOI 10.1016/j.clinbiochem.2010.11.006; Hall EJ, 2008, BRIT J RADIOL, V81, P362, DOI 10.1259/bjr/01948454; Hatpio R, 2004, CLIN BIOCHEM, V37, P512, DOI 10.1016/j.clinbiochem.2004.05.012; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Lippi G, 2011, CLIN BIOCHEM, V44, P567, DOI 10.1016/j.clinbiochem.2011.03.133; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; Pham N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012691; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; SNOEY ER, 1994, ANN EMERG MED, V23, P1127, DOI 10.1016/S0196-0644(94)70115-6; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tsoporis JN, 2011, AMINO ACIDS, V41, P843, DOI 10.1007/s00726-010-0527-1; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Yates DW, 2003, EMERG MED J, V20, P117, DOI 10.1136/emj.20.2.117; Zongo D, 2011, ANN EMERG MED   0922	30	27	32	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0009-9120	1873-2933		CLIN BIOCHEM	Clin. Biochem.	APR	2012	45	6					408	411		10.1016/j.clinbiochem.2012.01.006			4	Medical Laboratory Technology	Medical Laboratory Technology	916OA	WOS:000302111900007	22285378				2021-06-18	
J	Kansu, E				Kansu, Emin			Thrombosis in stem cell transplantation	HEMATOLOGY			English	Article						Thrombosis; Stem cell transplantation; Sinusoidal obstructive syndrome; Transplant-associated thrombotic microangiopathy	HEPATIC VENOOCCLUSIVE DISEASE; BONE-MARROW-TRANSPLANTATION; COMPLICATIONS; MICROANGIOPATHY; CHILDREN	Hemostatic changes and thrombotic events are frequent in patients undergoing stem cell transplantation. Arterial and venous thromboses are major causes of morbidity and mortality. Thrombotic complications can be classified into four groups including: catheter-related thrombosis, venous thromboembolic (VTE) events, sinusoidal obstructive syndrome (SOS)/veno-occlusive disease, and transplant-associated thrombotic microangiopathy (TAM). The incidence of catheter-related thrombosis is 8-20% in patients undergoing autologous hematopoietic stem cell transplantation (HSCT), and the incidence is low in syngeneic and allogeneic transplant patients. Venous duplex Doppler ultrasound, venogram, and computed tomography scan are required to visualize the venous thrombus. The treatment should be aimed at the prevention of pulmonary embolism, the avoidance of thrombus extension, and the preservation of catheter patency. Patients undergoing HSCT may have risk factors for VTE including underlying malignancy, traumatic brain injury, prolonged hospitalization, administration of conditioning regimens, and central venous catheters. Important risk factors are presence of history of VTE and graft-versus-host disease. One-year incidence of symptomatic VTE is 3.7%. SOS, also known as veno-occlusive disease, is a serious liver disease, seen in approximately 50-60% of HSCT patients. The mortality rate from the severe form of SOS is 84.3% and majority of the patients have multi-organ failure. The frequency is quite low after autologous transplantation. Risk factors for SOS include pre-existing hepatic damage, previous high-dose chemotherapy and abdominal irradiation, female gender and donor-recipient human leukocyte antigen disparity. Cyclophosphamide and busulphan are the most common agents with the highest incidence and fatal SOS. Histopathologic features of SOS include dilatation of sinusoids, necrosis of perivenular hepatocytes, and obstruction of small intrahepatic central venules by microthrombi and fibrin deposition. Signs of SOS usually occur within first 30 days after HSCT including hyperbilirubinemia, hepatomegaly, ascites, and weight gain. Symptoms of liver failure, including encephalopathy, coagulopathy, and renal failure will appear in severe form. A hepatic venous pressure gradient above 10 mmHg is highly specific for SOS. Early use of defibrotide has been shown to be effective in the treatment of high-risk SOS. TAM is a distinct, infrequent, and significant life-threatening complication of HSCT. TAM is seen in the range of 0.5-76% and was reported to be 10-25% in patients undergoing allogeneic HSCT with a mortality rate around 50%. It can also be seen after autologous HSCT and mainly affects the glomerular capillaries. There has been no standard therapy for TAM. Few case series reported good response to rituximab and high-dose corticosteroids were used with limited success. Trials with complement inhibitors such as eculizumab are currently underway.	Hacettepe Univ, Inst Oncol, Hematopoiet Stem Cell Transplantat Unit, Ankara, Turkey	Kansu, E (corresponding author), Hacettepe Univ, Inst Oncol, Hematopoiet Stem Cell Transplantat Unit, Ankara, Turkey.	eminkansu47@gmail.com					Batts ED, 2007, BONE MARROW TRANSPL, V40, P709, DOI 10.1038/sj.bmt.1705758; Cho BS, 2010, TRANSPLANTATION, V90, P918, DOI 10.1097/TP.0b013e3181f24e8d; Coppell JA, 2010, BIOL BLOOD MARROW TR, V16, P157, DOI 10.1016/j.bbmt.2009.08.024; Gonsalves A, 2008, J THROMB HAEMOST, V6, P1468, DOI 10.1111/j.1538-7836.2008.03077.x; Graf L, 2012, HAMOSTASEOLOGIE, V32, P1; Hasegawa S, 1998, BONE MARROW TRANSPL, V22, P1191, DOI 10.1038/sj.bmt.1701506; Ho VT, 2008, BONE MARROW TRANSPL, V41, P229, DOI 10.1038/sj.bmt.1705899; Laskin BL, 2011, BLOOD, V118, P1452, DOI 10.1182/blood-2011-02-321315; Miano M, 2008, BONE MARROW TRANSPL, V41, pS39, DOI 10.1038/bmt.2008.53; Nadir Y, 2007, THROMB RES, V120, pS92, DOI 10.1016/S0049-3848(07)70136-6; Paz IB, 2008, THOMASS HEMATOPOIETI, P1244; Pihusch M, 2004, SEMIN HEMATOL, V41, P93, DOI 10.1053/j.seminhematol.2003.11.018; Pihusch R, 2002, TRANSPLANTATION, V74, P1303, DOI 10.1097/00007890-200211150-00018; Pihusch V, 2005, THROMB RES, V116, P233, DOI 10.1016/j.thromres.2004.12.010; Richardson PG, 2010, BIOL BLOOD MARROW TR, V16, P1005, DOI 10.1016/j.bbmt.2010.02.009; Strasser SI, 2008, THOMASS HEMATOPOIETI, P1434; Sullivan K M, 1998, Biol Blood Marrow Transplant, V4, P20; Vassal G, 1996, CANCER CHEMOTH PHARM, V37, P247	18	27	28	0	4	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	1024-5332			HEMATOLOGY	Hematology	APR	2012	17			1			S159	S162		10.1179/102453312X13336169156735			4	Hematology	Hematology	927OA	WOS:000302916200045	22507809				2021-06-18	
J	Medaglia, JD; Chiou, KS; Slocomb, J; Fitzpatrick, NM; Wardecker, BM; Ramanathan, D; Vesek, J; Good, DC; Hillary, FG				Medaglia, John D.; Chiou, Kathy S.; Slocomb, Julia; Fitzpatrick, Neal M.; Wardecker, Britney M.; Ramanathan, Deepa; Vesek, Jeffrey; Good, David C.; Hillary, Frank G.			The Less BOLD, the Wiser: Support for the latent resource hypothesis after traumatic brain injury	HUMAN BRAIN MAPPING			English	Article						reorganization; traumatic brain injury; working memory; functional MRI; cognitive control	DIFFUSE AXONAL INJURY; ADULT AGE-DIFFERENCES; WORKING-MEMORY TASK; MULTIPLE-SCLEROSIS; PREFRONTAL CORTEX; PROCESSING-SPEED; FUNCTIONAL MRI; NEUROPSYCHOLOGICAL DEFICITS; ANTERIOR CINGULATE; COGNITIVE-CONTROL	Previous studies of the BOLD response in the injured brain have revealed neural recruitment relative to controls during working memory tasks in several brain regions, most consistently the right prefrontal cortex and anterior cingulate cortices. We previously proposed that the recruitment observed in this literature represents auxiliary support resources, and that recruitment of PFC is not abnormal or injury specific and should reduce as novelty and challenge decrease. The current study directly tests this hypothesis in the context of practice of a working memory task. It was hypothesized that individuals with brain injury would demonstrate recruitment of previously indicated regions, behavioral improvement following task practice, and a reduction in the BOLD signal in recruited regions after practice. Individuals with traumatic brain injury and healthy controls performed the n-back during fMRI acquisition, practiced each task out of the scanner, and returned to the scanner for additional fMRI n-back acquisition. Statistical parametric maps demonstrated a number of regions of recruitment in the 1-back in individuals with brain injury and a number of corresponding regions of reduced activation in individuals with brain injury following practice in both the 1-back and 2-back. Regions of interest demonstrated reduced activation following practice, including the anterior cingulate and right prefrontal cortices. Individuals with brain injury demonstrated modest behavioral improvements following practice. These findings suggest that neural recruitment in brain injury does not represent reorganization but a natural extension of latent mechanisms that engage transiently and are contingent upon cerebral challenge. Hum Brain Mapp, 2012. (c) 2011 Wiley Periodicals, Inc.	[Medaglia, John D.; Chiou, Kathy S.; Wardecker, Britney M.; Ramanathan, Deepa; Hillary, Frank G.] Penn State Univ, Dept Psychol, State Coll, PA USA; [Slocomb, Julia; Fitzpatrick, Neal M.; Good, David C.; Hillary, Frank G.] Hershey Med Ctr, Dept Neurol, Hershey, PA USA; [Vesek, Jeffrey] Hershey Med Ctr, Dept Radiol, Hershey, PA USA	Hillary, FG (corresponding author), Penn State Univ, Dept Psychol, 223 Moore Bldg, University Pk, PA 16802 USA.	fhillary@psu.edu	Hillary, Frank/AAN-8622-2021	Ramanathan-Elion, Deepa/0000-0001-7723-7346; Wardecker, Britney/0000-0003-2168-538X	Pennsylvania Tobacco Funds [4100031293]; New Jersey Commission on Brain Injury Research [0120090178]; Social Sciences Research Institute, PSU	Contract grant sponsor: Pennsylvania Tobacco Funds; Contract grant number: 4100031293; Contract grant sponsor: New Jersey Commission on Brain Injury Research; Contract grant number: 0120090178; Contract grant sponsor: Social Sciences Research Institute, PSU.	ALEXANDER JE, 1995, PSYCHOPHYSIOLOGY, V32, P467, DOI 10.1111/j.1469-8986.1995.tb02098.x; Army Individual Test Battery, 1990, MAN DIR SCOR; Ashburner J, 1997, NEUROIMAGE, V6, P344, DOI 10.1006/nimg.1997.0299; BADDELEY A, 1992, J COGNITIVE NEUROSCI, V4, P281, DOI 10.1162/jocn.1992.4.3.281; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; BRADLEY VA, 1989, J NEUROL NEUROSUR PS, V52, P1228, DOI 10.1136/jnnp.52.11.1228; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Chang L, 2001, NEUROLOGY, V57, P1001, DOI 10.1212/WNL.57.6.1001; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Collette F, 1999, NEUROPSYCHOLOGIA, V37, P905, DOI 10.1016/S0028-3932(98)00148-1; Courtney Susan M., 2004, Cognitive Affective & Behavioral Neuroscience, V4, P501, DOI 10.3758/CABN.4.4.501; Daffner KR, 2000, BRAIN, V123, P927, DOI 10.1093/brain/123.5.927; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; Demaree HA, 1999, J NEUROL NEUROSUR PS, V67, P661, DOI 10.1136/jnnp.67.5.661; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; Garavan H, 2000, MICROSC RES TECHNIQ, V51, P54, DOI 10.1002/1097-0029(20001001)51:1<54::AID-JEMT6>3.3.CO;2-A; Gazzaniga MS, 2000, BRAIN, V123, P1293, DOI 10.1093/brain/123.7.1293; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; Hillary FG, 2007, CLIN NEUROPSYCHOL, V21, P58, DOI 10.1080/13854040601064542; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hillary FG, 2006, HUM BRAIN MAPP, V27, P837, DOI 10.1002/hbm.20226; Hillary FG, 2010, BRAIN IMAGING BEHAV, V4, P141, DOI 10.1007/s11682-010-9094-z; Jaeggi SM, 2003, NEUROIMAGE, V19, P210, DOI 10.1016/S1053-8119(03)00098-3; Jansma JM, 2001, J COGNITIVE NEUROSCI, V13, P730, DOI 10.1162/08989290152541403; Kelly AMC, 2005, CEREB CORTEX, V15, P1089, DOI 10.1093/cercor/bhi005; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; KIRCHNER WK, 1958, J EXP PSYCHOL, V55, P352, DOI 10.1037/h0043688; Knight RT, 1998, J CLIN NEUROPHYSIOL, V15, P3, DOI 10.1097/00004691-199801000-00003; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; Landau SM, 2004, NEUROIMAGE, V22, P211, DOI 10.1016/j.neuroimage.2004.01.003; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Milham MP, 2003, NEUROIMAGE, V18, P483, DOI 10.1016/S1053-8119(02)00050-2; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; MORRIS RG, 1988, J CLIN EXP NEUROPSYC, V10, P279, DOI 10.1080/01688638808408242; Mostofsky SH, 2003, COGNITIVE BRAIN RES, V17, P419, DOI 10.1016/S0926-6410(03)00144-7; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Price CJ, 2006, J MAGN RESON IMAGING, V23, P816, DOI 10.1002/jmri.20580; Ramsey NF, 2004, BRAIN, V127, P517, DOI 10.1093/brain/awh060; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P471, DOI 10.1080/01688638908400907; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P699, DOI 10.1080/01688638908400926; Reitan RM., 1985, HALSTEAD REITAN NEUR; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; Rypma B, 1999, P NATL ACAD SCI USA, V96, P6558, DOI 10.1073/pnas.96.11.6558; Rypma B, 2006, NEUROIMAGE, V33, P969, DOI 10.1016/j.neuroimage.2006.05.065; Salthouse T. A., 1993, J GERONTOL B-PSYCHOL, V48, P245; SALTHOUSE TA, 1992, MEM COGNITION, V20, P413, DOI 10.3758/BF03210925; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; SAYKIN AJ, 1994, ARCH GEN PSYCHIAT, V51, P124; SAYKIN AJ, 1991, ARCH GEN PSYCHIAT, V48, P618; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Speck O, 2000, NEUROREPORT, V11, P2581, DOI 10.1097/00001756-200008030-00046; Strangman GE, 2009, NEUROREHAB NEURAL RE, V23, P226, DOI 10.1177/1545968308324225; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Sweet LH, 2006, HUM BRAIN MAPP, V27, P28, DOI 10.1002/hbm.20163; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Vul E, 2009, PERSPECT PSYCHOL SCI, V4, P274, DOI 10.1111/j.1745-6924.2009.01125.x; Wechsler D., 1997, WECHSLER ADULT INTEL; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	72	27	27	0	13	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1065-9471			HUM BRAIN MAPP	Hum. Brain Mapp.	APR	2012	33	4					979	993		10.1002/hbm.21264			15	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	906JI	WOS:000301341000018	21591026	Green Published			2021-06-18	
J	Chen, AY; Zagorski, B; Parsons, D; Vander Laan, R; Chan, V; Colantonio, A				Chen, Amy Y.; Zagorski, Brandon; Parsons, Daria; Vander Laan, Rika; Chan, Vincy; Colantonio, Angela			Factors associated with discharge destination from acute care after acquired brain injury in Ontario, Canada	BMC NEUROLOGY			English	Article							RACIAL DISPARITIES; MEDICAL-CARE; REHABILITATION; OUTCOMES; EPIDEMIOLOGY; MODERATE; ADULTS	Background: The aim of this paper is to examine factors associated with discharge destination after acquired brain injury in a publicly insured population using the Anderson Behavioral Model as a framework. Methods: We utilized a retrospective cohort design. Inpatient data from provincial acute care records from fiscal years 2003/4 to 2006/7 with a diagnostic code of traumatic brain injury (TBI) and non-traumatic brain injury (nTBI) in Ontario, Canada were obtained for the study. Using multinomial logistic regression models, we examined predisposing, need and enabling factors from inpatient records in relation to major discharge outcomes such as discharge to home, inpatient rehabilitation and other institutionalized care. Results: Multinomial logistic regression revealed that need factors were strongly correlated with discharge destinations overall. Higher scores on the Charlson Comorbidity Index were associated with discharge to other institutionalized care in the nTBI population. Length of stay and special care days were identified as markers for severity and were both strongly positively correlated with discharge to other institutionalized care and inpatient rehabilitation, compared to discharge home, in both nTBI and TBI populations. Injury by motor vehicle collisions was found to be positively correlated with discharge to inpatient rehabilitation and other institutionalized care for patients with TBI. Controlling for need factors, rural location was associated with discharge to home versus inpatient rehabilitation. Conclusions: These findings show that need factors (Charlson Comorbidity Index, length of stay, and number of special care days) are most significant in terms of discharge destination. However, there is evidence that other factors such as rural location and access to supplemental insurance (e. g., through motor vehicle insurance) may influence discharge destination outcomes as well. These findings should be considered in creating more equitable access to healthcare services across the continuum of care.	[Chen, Amy Y.; Zagorski, Brandon; Parsons, Daria; Vander Laan, Rika; Chan, Vincy; Colantonio, Angela] Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; [Colantonio, Angela] Univ Toronto, Fac Med, Dept Occupat Sci & Occupat Therapy, Toronto, ON M5G 1V7, Canada; [Zagorski, Brandon] Univ Toronto, Fac Med, Dept Hlth Policy Management & Evaluat, Toronto, ON M5T 3M6, Canada; [Chen, Amy Y.] Queens Univ, Sch Med, Kingston, ON K7L 3N6, Canada; [Chan, Vincy] Univ Toronto, Fac Med, Dalla Lana Sch Publ Hlth, Toronto, ON M5T 3M6, Canada	Colantonio, A (corresponding author), Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	angela.colantonio@utoronto.ca	Chan, Vincy/AAA-7813-2020	Colantonio, Angela/0000-0003-2094-4765; Chan, Vincy/0000-0002-6884-044X	Ontario Neurotrauma Foundation; Toronto Rehabilitation Institute Foundation; Ministry of Health and Long Term Care to Toronto Rehabilitation Institute	Funding for this study was obtained from the Ontario Neurotrauma Foundation, The Toronto Rehabilitation Institute Foundation, and a grant from the Ministry of Health and Long Term Care to Toronto Rehabilitation Institute. We would like to thank the Ministry of Health and Long Term Care for providing us with data and Lori Moskal and her team at the Canadian Institute for Health Information for advice on data quality and coding. We thank Sandra Sokoloff and Jennifer Fergenbaum, and Debbie Sutton for their assistance with the study.	ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; Arundine A, 2012, J HEAD TRAUMA REHAB, V27, P104, DOI 10.1097/HTR.0b013e3182125591; Bergquist T, 2009, BRAIN INJURY, V23, P790, DOI 10.1080/02699050903196688; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Chen AY, 2011, EMERG THEMES EPIDEMI, V8, DOI 10.1186/1742-7622-8-4; Colantonio A, 2010, HEALTHCARE POLICY, V5, P120; Colantonio A, 2010, J REHABIL MED, V42, P773, DOI 10.2340/16501977-0582; Cuthbert JP, 2011, ARCH PHYS MED REHAB, V92, P721, DOI 10.1016/j.apmr.2010.12.023; Graham JE, 2010, ARCH PHYS MED REHAB, V91, P43, DOI 10.1016/j.apmr.2009.09.017; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Malec JF, 2009, BRAIN INJURY, V23, P22, DOI 10.1080/02699050802590320; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Shore AD, 2005, BRAIN INJURY, V19, P613, DOI 10.1080/02699050400013568; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; World Health Organization, 2006, TRAUM BRAIN INJ NEUR, P164	19	27	28	0	8	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	MAR 24	2012	12								16	10.1186/1471-2377-12-16			9	Clinical Neurology	Neurosciences & Neurology	975MF	WOS:000306514700001	22443681	DOAJ Gold, Green Published			2021-06-18	
J	Frugier, T; Conquest, A; McLean, C; Currie, P; Moses, D; Goldshmit, Y				Frugier, Tony; Conquest, Alison; McLean, Catriona; Currie, Peter; Moses, David; Goldshmit, Yona			Expression and Activation of EphA4 in the Human Brain After Traumatic Injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Astrocytes; EphA4; Ephrin; Human brain; MAPK; Rho; Traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; RECEPTOR TYROSINE KINASES; UP-REGULATION; AXONAL REGENERATION; EPHA4-DEFICIENT MICE; ASTROCYTIC GLIOSIS; WHITE-MATTER; RHO KINASE; INHIBITION	Glial scars that consist predominantly of reactive astrocytes create a major barrier to neuronal regeneration after traumatic brain injury (TBI). In experimental TBI, Eph receptors and their ephrin ligands are upregulated on reactive astrocytes at injury sites and inhibit axonal regeneration, but very little is known about Eph receptors in the human brain after TBI. A better understanding of the functions of glial cells and their interactions with inflammatory cells and injured axons will allow the development of treatment strategies that may promote regeneration. We analyzed EphA4 expression and activation in postmortem brain tissue from 19 patients who died after acute closed head injury and had evidence of diffuse axonal injury and 8 controls. We also examined downstream pathways that are mediated by EphA4 in human astrocyte cell cultures. Our results indicate that, after TBI in humans, EphA4 expression is upregulated and is associated with reactive astrocytes. The expression was increased shortly after the injury and remained activated for several days. EphA4 activation induced under inflammatory conditions in vitro was inhibited using unclustered EphA4 ligand. These results suggest that blocking EphA4 activation may represent a therapeutic approach for TBI and other types of brain injuries in humans.	[Currie, Peter; Goldshmit, Yona] Monash Univ, Australian Regenerat Med Inst, Melbourne, Vic 3800, Australia; [Moses, David] St Vincents Hosp, Ctr Neurosci & Neurol Res, Melbourne, Vic, Australia; [Frugier, Tony; Conquest, Alison] Monash Univ, Natl Trauma Res Inst, Alfred Hosp, Melbourne, Vic 3800, Australia; [McLean, Catriona] Monash Univ, Alfred Hosp, Dept Anat Pathol, Melbourne, Vic 3800, Australia; [Frugier, Tony; Conquest, Alison] Monash Univ, Dept Med, Melbourne, Vic 3800, Australia	Goldshmit, Y (corresponding author), Monash Univ, Australian Regenerat Med Inst, Melbourne, Vic 3800, Australia.	yona.goldshmit@monash.edu.au		Frugier, Tony/0000-0002-1275-5158; Currie, Peter/0000-0001-8874-8862	Victorian Neurotrauma Initiative; National Trauma Research Institute; University of MelbourneUniversity of Melbourne; Mental Health Research Institute of Victoria; Victorian Institute of Forensic Medicine; Victorian Neurotrauma Initiative, Neurosciences Australia; National Health & Medical Research Council of AustraliaNational Health and Medical Research Council of Australia	This work was supported by the Victorian Neurotrauma Initiative. Tissues were received from the Victorian Brain Bank Network, supported by The National Trauma Research Institute, The University of Melbourne, The Mental Health Research Institute of Victoria, and The Victorian Institute of Forensic Medicine and were funded by the Victorian Neurotrauma Initiative, Neurosciences Australia, and the National Health & Medical Research Council of Australia.	Carpentier PA, 2005, GLIA, V49, P360, DOI 10.1002/glia.20117; Carter N, 2002, NAT CELL BIOL, V4, P565, DOI 10.1038/ncb823; Davies SJA, 1997, NATURE, V390, P680; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Ellezam B, 2002, PROG BRAIN RES, V137, P371; Fabes J, 2006, EUR J NEUROSCI, V23, P1721, DOI 10.1111/j.1460-9568.2006.04704.x; Fabes J, 2007, EUR J NEUROSCI, V26, P2496, DOI 10.1111/j.1460-9568.2007.05859.x; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Figueroa JD, 2006, J NEUROSCI RES, V84, P1438, DOI 10.1002/jnr.21048; Fournier AE, 2003, J NEUROSCI, V23, P1416; Frugier T, 2011, CELL MOL NEUROBIOL, V31, P569, DOI 10.1007/s10571-011-9650-0; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Fu Q, 2007, J NEUROSCI, V27, P4154, DOI 10.1523/JNEUROSCI.4353-06.2007; Goldshmit Y, 2004, J NEUROSCI, V24, P10064, DOI 10.1523/JNEUROSCI.2981-04.2004; Goldshmit Y, 2006, BRAIN RES REV, V52, P327, DOI 10.1016/j.brainresrev.2006.04.006; Goldshmit Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024636; Goldshmit Y, 2010, J NEUROTRAUM, V27, P1321, DOI 10.1089/neu.2010.1294; Irizarry-Ramirez M, 2005, J NEUROTRAUM, V22, P929, DOI 10.1089/neu.2005.22.929; Lawrenson ID, 2002, J CELL SCI, V115, P1059; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Liebl DJ, 2003, J NEUROSCI RES, V71, P7, DOI 10.1002/jnr.10457; LIUZZI FJ, 1987, SCIENCE, V237, P642, DOI 10.1126/science.3603044; Martone ME, 1997, BRAIN RES, V771, P238, DOI 10.1016/S0006-8993(97)00792-0; Mor E, 2011, NUCLEIC ACIDS RES, V39, P3710, DOI 10.1093/nar/gkq1325; Moreno-Flores MT, 1999, NEUROSCIENCE, V91, P193, DOI 10.1016/S0306-4522(98)00568-5; Munoz JJ, 2006, J IMMUNOL, V177, P804, DOI 10.4049/jimmunol.177.2.804; Nakanishi M, 2007, EUR J NEUROSCI, V25, P649, DOI 10.1111/j.1460-9568.2007.05309.x; Ohta K, 1997, MECH DEVELOP, V64, P127, DOI 10.1016/S0925-4773(97)00056-7; Olivieri G, 1999, J HISTOCHEM CYTOCHEM, V47, P855, DOI 10.1177/002215549904700702; Parmentier-Batteur S, 2011, J NEUROCHEM, V118, P1016, DOI 10.1111/j.1471-4159.2011.07375.x; Pawate S, 2004, J NEUROSCI RES, V77, P540, DOI 10.1002/jnr.20180; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sobel RA, 2005, BRAIN PATHOL, V15, P35; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Wang XX, 2009, J NEUROTRAUM, V26, P81, DOI 10.1089/neu.2007.0464; Willson CA, 2002, CELL TRANSPLANT, V11, P229	38	27	28	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	2012	71	3					242	250		10.1097/NEN.0b013e3182496149			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	897EM	WOS:000300627500006	22318127	Bronze			2021-06-18	
J	Marshall, S; Bayley, M; McCullagh, S; Velikonja, D; Berrigan, L				Marshall, Shawn; Bayley, Mark; McCullagh, Scott; Velikonja, Diana; Berrigan, Lindsay			Clinical practice guide for traumatic light cerebral lesions and persistent symptoms	CANADIAN FAMILY PHYSICIAN			French	Article							WESTMEAD PTA SCALE; BRAIN-INJURY; TASK-FORCE; INTERNATIONAL-CONFERENCE; EARLY IDENTIFICATION; HEAD-INJURY; CONCUSSION; STATEMENT; VALIDITY; FATIGUE		[Marshall, Shawn] Ctr Readaptat Hop Ottawa, Programme Les Cerebrales Acquises, Ottawa, ON K1H 8M2, Canada; [Marshall, Shawn] Univ Ottawa, Fac Med, Ottawa, ON K1N 6N5, Canada; [Bayley, Mark] Toronto Rehabil Inst, Programme Neuroreadaptat, Toronto, ON, Canada; [Bayley, Mark] Univ Toronto, Fac Med, Toronto, ON M5S 1A1, Canada; [McCullagh, Scott] Sunnybrook Hlth Sci Ctr, Programme Neuropsychiat, Toronto, ON M4N 3M5, Canada; [McCullagh, Scott] Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A1, Canada; [Velikonja, Diana] Hamilton Hlth Sci Ctr, Programme Les Cerebrales Acquises, Hamilton, Vic, Australia; [Velikonja, Diana] McMaster Univ, Dept Psychiat & Neurosci Comportementales, Hamilton, ON, Canada; [Berrigan, Lindsay] Dalhousie Univ, Dept Psychiat, Halifax, NS, Canada	Marshall, S (corresponding author), Ctr Readaptat Hop Ottawa, Programme Les Cerebrales Acquises, 505 Chemin Smyth, Ottawa, ON K1H 8M2, Canada.	smarshall@lho.on.ca					American Academy of Sleep Medicine, 2006, PRACT PAR PSYCH BEH; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; [Anonymous], 2006, OPT PRACT GUID AD IN; Askham, 1998, HEALTH TECHNOL ASSES, V2, DOI [10.3310/hta2030, DOI 10.3310/hta2030]; Berrigan L, 2011, BRAIN INJURY, V25, P742, DOI 10.3109/02699052.2011.580317; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Cappa SF, 2005, EUR J NEUROL, V12, P665; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Centers for Disease Control and Prevention, 2007, HEADS TOOL KIT; Centers for Disease Control and Prevention, 2007, HEADS FACTS PHYS MIL; Commission de la securite professionnelle et de l'assurance contre les accidents de travail de l'Ontario, 2006, PROGR CAR MILD TRAUM; Cook KF, 2011, ARCH PHYS MED REHAB, V92, P818, DOI 10.1016/j.apmr.2010.12.008; Defense and Veterans Brain Injury Center, 2008, UPD MTBI CLIN GUID; Department of Labor and Employment, 2005, TRAUM BRAIN INJ MED; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Graham Ian D, 2005, Evid Based Nurs, V8, P68, DOI 10.1136/ebn.8.3.68; Guidelines and Protocols Advisory Committee, 2004, PRIM CAR MAN SLEEP C; Hillier SL, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005397.pub2; HILTON M, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003162.PUB2; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Keane T., 1994, PTSD CHECKLIST CIVIL; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Lemonick MD., 2008, TIME            0131; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; MTBI Guidelines Development Team, 2010, GUID MILD TRAUM BRAI; Multiple Sclerosis Council for Clinical Practice Guidelines, 1998, FAT MULT SCLER EV BA; National Institute for Health and Clinical Excellence, 2007, HEAD INJ TRIAG ASS I, V56; New South Wales Motor Accident Authority, 2008, GUID MILD TRAUM BRAI; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Organisation mondiale de la Sante, 1992, INT STAT CLASS DIS R; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Shores EA, 2008, J NEUROL NEUROSUR PS, V79, P1100, DOI 10.1136/jnnp.2007.132571; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; The Management of Concussion/mTBI Working Group, 2009, VA DOD CLIN PRACT GU; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	44	27	27	0	3	COLL FAMILY PHYSICIANS CANADA	MISSISSAUGA	2630 SKYMARK AVE, MISSISSAUGA, ONTARIO L4W 5A4, CANADA	0008-350X	1715-5258		CAN FAM PHYSICIAN	Can. Fam. Phys.	MAR	2012	58	3					E128	E140					13	Primary Health Care; Medicine, General & Internal	General & Internal Medicine	909DO	WOS:000301542700002					2021-06-18	
J	Mbye, LH; Keles, E; Tao, LY; Zhang, J; Chung, J; Larvie, M; Koppula, R; Lo, EH; Whalen, MJ				Mbye, Lamin H.; Keles, Eyup; Tao, Luyang; Zhang, Jimmy; Chung, Joonyong; Larvie, Mykol; Koppula, Rajani; Lo, Eng H.; Whalen, Michael J.			Kollidon VA64, a membrane-resealing agent, reduces histopathology and improves functional outcome after controlled cortical impact in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						blood-brain barrier; edema; Kollidon VA64; mice; plasmalemma; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SURFACTANT POLOXAMER-188; MECHANICAL TRAUMA; PRENATAL EXPOSURE; CELL-DEATH; PERMEABILITY; NEURONS; DAMAGE; EPILEPTOGENESIS; RECOVERY	Loss of plasma membrane integrity is a feature of acute cellular injury/death in vitro and in vivo. Plasmalemma-resealing agents are protective in acute central nervous system injury models, but their ability to reseal cell membranes in vivo has not been reported. Using a mouse controlled cortical impact (CCI) model, we found that propidium iodide-positive (PI+) cells pulse labeled at 6, 24, or 48 hours maintained a degenerative phenotype and disappeared from the injured brain by 7 days, suggesting that plasmalemma permeability is a biomarker of fatal cellular injury after CCI. Intravenous or intracerebroventricular administration of Kollidon VA64, poloxamer P188, or polyethylene glycol 8000 resealed injured cell membranes in vivo (P < 0.05 versus vehicle or poloxamer P407). Kollidon VA64 (1 mmol/L, 500 mu L) administered intravenously to mice 1 hour after CCI significantly reduced acute cellular degeneration, chronic brain tissue damage, brain edema, blood-brain barrier damage, and postinjury motor deficits (all P < 0.05 versus vehicle). However, VA64 did not rescue pulse-labeled PI+ cells from eventual demise. We conclude that PI permeability within 48 hours of CCI is a biomarker of eventual cell death/loss. Kollidon VA64 reduces secondary damage after CCI by mechanisms other than or in addition to resealing permeable cells. Journal of Cerebral Blood Flow & Metabolism (2012) 32, 515-524; doi: 10.1038/jcbfm.2011.158; published online 16 November 2011	[Mbye, Lamin H.; Keles, Eyup; Zhang, Jimmy; Chung, Joonyong; Koppula, Rajani; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA; [Mbye, Lamin H.; Keles, Eyup; Zhang, Jimmy; Chung, Joonyong; Koppula, Rajani; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA 02129 USA; [Tao, Luyang] Soochow Univ, Inst Forens Sci, Suzhou, Peoples R China; [Larvie, Mykol; Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA; [Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA	Whalen, MJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Charlestown, MA 02129 USA.	mwhalen@partners.org		Chung, Joon Yong/0000-0002-3980-2065	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5RO1NS061255]; Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061255, R01NS064545] Funding Source: NIH RePORTER	This study was supported by NINDS 5RO1NS061255 (MJW) and the Nature Science Foundation of China (LT).	Bassanini S, 2007, NEUROBIOL DIS, V26, P481, DOI 10.1016/j.nbd.2007.02.008; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Borgens RB, 2004, J NEUROSCI RES, V76, P141, DOI 10.1002/jnr.20053; Cacheaux LP, 2009, J NEUROSCI, V29, P8927, DOI 10.1523/JNEUROSCI.0430-09.2009; Cadichon SB, 2007, J NEUROSURG, V106, P36, DOI 10.3171/ped.2007.106.1.36; Cevik IU, 2003, CELL DEATH DIFFER, V10, P928, DOI 10.1038/sj.cdd.4401250; Curry DJ, 2004, NEUROSURGERY, V55, P943, DOI 10.1227/01.NEU.0000137890.29862.2C; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Frim DM, 2004, NEUROREPORT, V15, P171, DOI 10.1097/00001756-200401190-00033; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Grindel JM, 2002, J PHARM SCI-US, V91, P1936, DOI 10.1002/jps.10190; Hallene KL, 2006, NEUROSCIENCE, V142, P267, DOI 10.1016/j.neuroscience.2006.06.017; Janigro D, 2010, EPILEPSY CURR, V10, P67, DOI 10.1111/j.1535-7511.2010.01359.x; Kilinc D, 2007, P ANN INT IEEE EMBS, P5395, DOI 10.1109/IEMBS.2007.4353562; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Marchi N, 2011, CARDIOVASC PSYCHIAT, P1; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pisetsky DS, 2011, ANTIOXID REDOX SIGN, V15, P2209, DOI 10.1089/ars.2010.3865; Prado GR, 2005, J NEURAL ENG, V2, P148, DOI 10.1088/1741-2560/2/4/011; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Riess P, 2007, J NEUROTRAUM, V24, P216, DOI 10.1089/neu.2006.0141; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Serbest G, 2005, J NEUROTRAUM, V22, P119, DOI 10.1089/neu.2005.22.119; Serbest G, 2006, FASEB J, V20, P308, DOI 10.1096/fj.05-4024fje; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44	36	27	28	1	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2012	32	3					515	524		10.1038/jcbfm.2011.158			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	901FN	WOS:000300948200013	22086196	Green Published, Bronze			2021-06-18	
J	Hu, XB; Feng, Z; Fan, YC; Xiong, ZY; Huang, QW				Hu, Xue-Bin; Feng, Zhe; Fan, Yu-Cong; Xiong, Zhi-Yong; Huang, Qi-Wei			Health-related quality-of-life after traumatic brain injury: A 2-year follow-up study in Wuhan, China	BRAIN INJURY			English	Article						Health-related quality-of-life; traumatic brain injury; SF-36; follow-up	FUNCTIONAL OUTCOMES; HEAD-INJURY; 1ST YEAR; SATISFACTION; ADULTS	Objective: To assess health-related quality-of-life (HRQoL) 2 years after traumatic brain injury (TBI) among a group of Chinese. Methods: A total of 358 adult patients with moderate-to-severe TBI based on Glasgow Coma Scale score were recruited in a large trauma centre in Wuhan, China during May 2005 to April 2008. They were followed up for 2 years and the Medical Outcome Short Form 36 was used to measure HRQoL. Results: After a 2-year follow-up, there were 312 (87.2%) survivors. All domains of HRQoL had the lowest scores at discharge, greatly improved over the first 6 months and showed continued improvement. Patients with TBI still had significantly lower scores in every domain than the reference group 2 years after discharge. Female patients had lower MCS scores than the males (OR = 1.8, 95% CI: 1.1-2.9). Patients older than 30 had lower scores in PCS (OR = 1.7, 95% CI: 1.1-2.6). Patients with severe TBI had lower scores in both PCS (OR = 1.9, 95% CI: 1.2-3.1) and MCS (OR = 1.6, 95% CI: 1.0-2.6) compared with those with moderate TBI. Conclusions: HRQoL of a group of Chinese patients with TBI improved during 2 years after discharge. Age, sex and severity of TBI were significantly associated with physical or mental HRQoL after discharge.	[Hu, Xue-Bin; Fan, Yu-Cong; Xiong, Zhi-Yong; Huang, Qi-Wei] Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan Union Hosp, Dept Neurosurg, Wuhan 430032, Hubei, Peoples R China; [Feng, Zhe] Huazhong Univ Sci & Technol, Sch Life Sci & Technol, Wuhan 430032, Hubei, Peoples R China	Hu, XB (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan Union Hosp, Dept Neurosurg, Wuhan 430032, Hubei, Peoples R China.	huxb7276@163.com					Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Bercaw EL, 2011, CLIN NEUROPSYCHOL, V25, P72, DOI 10.1080/13854046.2010.532813; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Centers for Disease Control and Prevention, 2000, MEAS HLTH DAYS POP A; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Guilfoyle MR, 2010, J NEUROTRAUM, V27, P2173, DOI 10.1089/neu.2010.1353; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; Johansson U, 2003, BRAIN INJURY, V17, P991, DOI 10.1080/0269905031000110508; Li L, 2003, J EPIDEMIOL COMMUN H, V57, P259, DOI 10.1136/jech.57.4.259; Lin MR, 2010, ARCH PHYS MED REHAB, V91, P474, DOI 10.1016/j.apmr.2009.10.031; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; Novack TA, 2010, BRAIN INJURY, V24, P464, DOI 10.3109/02699051003601713; Ulvik A, 2008, ACTA ANAESTH SCAND, V52, P195, DOI 10.1111/j.1399-6576.2007.01533.x; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803	27	27	28	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2012	26	2					183	187		10.3109/02699052.2011.648707			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	897NP	WOS:000300658200007	22360524				2021-06-18	
J	Livingston, SC; Goodkin, HP; Hertel, JN; Saliba, EN; Barth, JT; Ingersoll, CD				Livingston, Scott C.; Goodkin, Howard P.; Hertel, Jay N.; Saliba, Ethan N.; Barth, Jeffrey T.; Ingersoll, Christopher D.			Differential Rates of Recovery After Acute Sport-Related Concussion: Electrophysiologic, Symptomatic, and Neurocognitive Indices	JOURNAL OF CLINICAL NEUROPHYSIOLOGY			English	Article						Mild traumatic brain injury; Cerebral concussion; Transcranial magnetic stimulation; Motor evoked potentials; Postconcussion signs/symptoms; Neuropsychological test performance	TRANSCRANIAL MAGNETIC STIMULATION; INDUCED AXONAL INJURY; BRAIN-INJURY; POSTCONCUSSION SYMPTOMS; FOOTBALL PLAYERS; MILD; RETURN; PATHOPHYSIOLOGY; PATHOBIOLOGY; ASSOCIATION	Purpose: To determine if motor evoked potentials (MEPs), postconcussion signs and symptoms, and neurocognitive functions follow a similar recovery pattern after concussion. Methods: Nine collegiate athletes with acute concussion (>24 hours after injury) participated in this retrospective time series design. Transcranial magnetic stimulation was applied over the motor cortex, and MEPs were recorded from the contralateral upper extremity. Self-reported symptoms were evaluated using the Head Injury Scale, and the Concussion Resolution Index was used to assess neurocognitive function. All measures were repeated on days 3, 5, and 10 after injury. Results: Composite scores on the Head Injury Scale were significantly higher on day 1 after injury (F-3,F-51 = 15.3; P = 0.0001). Processing speed on the Concussion Resolution Index was slower on days 1, 3, and 5 compared with that on day 10 (F-3,F-24 = 6.75; P = 0.0002). Median MEP latencies were significantly longer on day 10 compared with day 1 after concussion (t(8) = -2.69; P = 0.03). Ulnar MEP amplitudes were significantly smaller on day 3 after concussion compared with day 5 (t(8) = -3.48; P = 0.008). Conclusions: Acutely concussed collegiate athletes demonstrate changes in MEPs, which persist for up to 10 days after injury and do not follow the same recovery pattern as symptoms and neuropsychological test performance. The apparent differential rates of recovery most likely indicate different pathophysiological processes occurring in the immediate postconcussion period.	[Livingston, Scott C.] Univ Kentucky, Div Phys Therapy, Concuss Assessment Res Lab, Lexington, KY 40536 USA; [Goodkin, Howard P.] Univ Virginia, Curry Sch Educ, Dept Neurol, Charlottesville, VA 22903 USA; [Hertel, Jay N.; Saliba, Ethan N.] Univ Virginia, Curry Sch Educ, Div Kinesiol, Dept Human Serv, Charlottesville, VA 22903 USA; [Barth, Jeffrey T.] Univ Virginia, Dept Neuropsychol, Charlottesville, VA USA; [Ingersoll, Christopher D.] Cent Michigan Univ, Coll Hlth Profess, Mt Pleasant, MI 48859 USA	Livingston, SC (corresponding author), Univ Kentucky, Div Phys Therapy, Concuss Assessment Res Lab, 900 S Limestone, Lexington, KY 40536 USA.	scott.livingston@uky.edu	Ingersoll, Christopher/H-6474-2015	Ingersoll, Christopher/0000-0001-9157-6846; Goodkin, Howard/0000-0003-0528-4949	National Operating Committee on the Standards of Athletic Equipment [13-06]; National Athletic Trainers' Association Research and Education Foundation [305DGP002]	Supported by the National Operating Committee on the Standards of Athletic Equipment (grant 13-06) and the National Athletic Trainers' Association Research and Education Foundation (grant 305DGP002).	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Chistyakov AV, 1999, CLIN NEUROPHYSIOL, V110, P1080, DOI 10.1016/S1388-2457(99)00029-2; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Conforto AB, 2004, CLIN NEUROPHYSIOL, V115, P812, DOI 10.1016/j.clinph.2003.11.010; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GHEZZI A, 1991, ACTA NEUROL SCAND, V84, P503, DOI 10.1111/j.1600-0404.1991.tb05003.x; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2000, NEUROLOGIC ATHLETIC, P80; Grindel Scott H, 2003, Curr Sports Med Rep, V2, P18, DOI 10.1249/00149619-200302000-00005; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; HeadMinder, 2002, HEADMINDER CONC RES; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Hugon M., 1973, NEW DEVELOPMENTS ELE, P277; Hurley RA, 2004, J NEUROPSYCH CLIN N, V16, P1, DOI 10.1176/appi.neuropsych.16.1.1; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Kimura J., 1989, ELECTRODIAGNOSIS DIS, V2nd ed.; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lefebvre R, 2004, J MANIP PHYSIOL THER, V27, P97, DOI 10.1016/j.jmpt.2003.12.004; Livingston S, 2007, RELATIONSHIP TRANSCR; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Mills KR, 1997, MUSCLE NERVE, V20, P570, DOI 10.1002/(SICI)1097-4598(199705)20:5<570::AID-MUS5>3.3.CO;2-F; Mills KR, 1999, MAGNETIC STIMULATION; Misulis K, 2001, BASIC SCI EVOKED POT, P26; MURRAY NMF, 1999, ELECTRODIAGNOSIS CLI, P549; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Piland SG, 2003, J ATHL TRAINING, V38, P104; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Pridmore S, 1998, J ECT, V14, P25; Rossini PM, 2007, NEUROLOGY, V68, P484, DOI 10.1212/01.wnl.0000250268.13789.b2; Sosin DM, 1996, BRAIN INJURY, V10, P47; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8	58	27	27	1	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0736-0258	1537-1603		J CLIN NEUROPHYSIOL	J. Clin. Neurophysiol.	FEB	2012	29	1					23	32		10.1097/WNP.0b013e318246ae46			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	897GF	WOS:000300634700003	22353982				2021-06-18	
J	Tian, ZR; Sharma, A; Nozari, A; Subramaniam, R; Lundstedt, T; Sharma, HS				Tian, Z. Ryan; Sharma, Aruna; Nozari, Ala; Subramaniam, Raman; Lundstedt, Torbjorn; Sharma, Hari Shanker			Nanowired Drug Delivery to Enhance Neuroprotection in Spinal Cord Injury	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Nanowired drug delivery; spinal cord injury; blood-spinal cord barrier; spinal cord edema; TiO2 nanowires; silica nanowires; neuronal injury; stem cells; functional recovery; astrocytes; myelin; ultrastructure; nanoparticles	CENTRAL-NERVOUS-SYSTEM; TITANIUM-DIOXIDE NANOPARTICLES; SEROTONIN SYNTHESIS INHIBITOR; IN-VIVO; ELECTRON-MICROSCOPY; PARTICULATE MATTER; OXIDATIVE STRESS; TRAUMATIC INJURY; EDEMA FORMATION; BRAIN DELIVERY	Spinal cord injury (SCI) is a serious clinical situation for which no suitable drug therapy exists. SCI often results in paraplegia or quadriplegia and, apart from the personal trauma leads to huge costs to society for rehabilitation or day-to-day life support. Sensory motor dysfunction following SCI is mainly a consequence of the slowly progressing cord pathology after primary injury that worsens over tine. Thus, almost all sensory and motor nerve control and pathways passing through spinal cord and reflexes are compromised in SCI patients. As a result their peripheral nervous system, autonomic nervous function and central nervous system regulations are adversely affected. Experiments carried out in our laboratory show that various therapeutic agents, if given within 10 to 30 minutes after primary SCI could correct morphological changes to a certain extent. In these rat models of SCI reduction in cord pathology, e.g., blood-spinal cord barrier (BSCB) breakdown, edema formation and cell injury by the neuroprotective agents that also limited sensory motor dysfunction and improved functional behavior. However, these drugs if given beyond 30 minutes after SCI showed a markedly reduced neuroprotective efficacy. Thus, new strategies are needed to enhance neuroprotection in SCI to prevent structural and functional changes over longer periods of time. To that end our laboratory has initiated a series of investigations in which nanowired delivery of various neurotherapeutic agents are applied after different time periods of SCI, that resulted in a much better outcome than with the parent compounds under identical conditions. The superior neuroprotective activity of nanowired compound delivery could be due to a reduced metabolism of active compounds in the central nervous system (CNS) or by sustained release of the drug for longer times. In addition, nanowired drugs may penetrate the CNS faster and could reach widespread areas once entering the spinal cord. Thus, nanowired drug delivery to treat SCI may have potential therapeutic value. These aspects of nanowired drug delivery to enhance neuroprotection in SCI are discussed in this review based on our own investigations.	[Sharma, Aruna; Sharma, Hari Shanker] Uppsala Univ, Univ Hosp, Dept Surg Sci Anesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden; [Tian, Z. Ryan; Subramaniam, Raman] Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA; [Nozari, Ala] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA; [Lundstedt, Torbjorn] AcurePharma AB, Uppsala, Sweden; [Lundstedt, Torbjorn] Uppsala Univ, Div Organ Chem, Dept Med Chem, SE-75185 Uppsala, Sweden	Sharma, HS (corresponding author), Uppsala Univ, Univ Hosp, Dept Surg Sci Anesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden.	Sharma@surgsci.uu.se	Nozari, Ala/AAH-6070-2021; Tian, Z. Ryan/R-6671-2016	Tian, Z. Ryan/0000-0002-5644-8483	Air Force Office of Scientific Research (London), Air Force Material Command, USAFUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA8655-05-1-3065]; Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission [2710]; Astra-Zeneca, Molndal, SwedenAstraZeneca; Alexander von Humboldt Foundation, GermanyAlexander von Humboldt Foundation; IPSEN Medical, FranceIpsen; University Grants Commission, New Delhi, IndiaUniversity Grants Commission, India; Indian Council of Medical Research, New Delhi, IndiaIndian Council of Medical Research (ICMR)	This investigation was partially supported by the Air Force Office of Scientific Research (London), Air Force Material Command, USAF, under grant number FA8655-05-1-3065. The U.S. Government is authorized to reproduce and distribute reprints for Government purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the Air Force Office of Scientific Research or the U.S. Government. We express sincere gratitude to several laboratories where a part of the work was done or some data recorded and evaluated. Financial support Swedish Medical Research Council (Grant Nr. 2710, HSS); Astra-Zeneca, Molndal, Sweden (HSS), Alexander von Humboldt Foundation, Germany (HSS); IPSEN Medical, France (HSS); and University Grants Commission, New Delhi, India (HSS); Indian Council of Medical Research, New Delhi, India (HSS) is gratefully acknowledged. The authors have no conflict of interest with any financial agencies mentioned above.	Assie MB, 2007, N-S ARCH PHARMACOL, V375, P241, DOI 10.1007/s00210-007-0162-x; Bechara S, 2011, ACTA BIOMATER, V7, P2892, DOI 10.1016/j.actbio.2011.04.009; Beck-Broichsitter M., 2011, J CONTROL RELEASE; Betbeder D., 2002, PHARM RES, V17, P743; Boffetta P, 2004, CANCER CAUSE CONTROL, V15, P697, DOI 10.1023/B:CACO.0000036188.23970.22; Brewer M, 2007, MED CLIN N AM, V91, P963, DOI 10.1016/j.mcna.2007.05.006; Brigger I, 2002, J PHARMACOL EXP THER, V303, P928, DOI 10.1124/jpet.102.039669; Brokx RD, 2002, J CONTROL RELEASE, V78, P115, DOI 10.1016/S0168-3659(01)00491-6; Campbell A, 2005, NEUROTOXICOLOGY, V26, P133, DOI 10.1016/j.neuro.2004.08.003; Carty CL, 2003, J ENVIRON MONITOR, V5, P953, DOI 10.1039/b308488d; CHEN JL, 1988, J OCCUP ENVIRON MED, V30, P937, DOI 10.1097/00043764-198812000-00011; Chi B, 2007, J NANOSCI NANOTECHNO, V7, P668, DOI 10.1166/jnn.2007.147; Cho Y, 2012, EXP NEUROL, V233, P126, DOI 10.1016/j.expneurol.2011.09.028; Chvatal SA, 2008, BIOMATERIALS, V29, P1967, DOI 10.1016/j.biomaterials.2008.01.002; COSTIGAN S, 2006, TOXICOLOGY NANOPARTI; De Jong WH, 2008, INT J NANOMED, V3, P133, DOI 10.2147/ijn.s596; Dong W, 2006, NANOMED-NANOTECHNOL, V2, P248, DOI 10.1016/j.nano.2006.10.005; Duncan R, 2005, ADV DRUG DELIVER REV, V57, P2215, DOI 10.1016/j.addr.2005.09.019; Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088; Dyer AM, 2002, PHARM RES-DORDR, V19, P998, DOI 10.1023/A:1016418523014; ECETOC, 2006, WORKSH TEST STRAT ES; Elder A, 2006, ENVIRON HEALTH PERSP, V114, P1172, DOI 10.1289/ehp.9030; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122; *EUR SCI FDN, 2005, POL BRIEF ESF ESF SC; Fabian E, 2008, ARCH TOXICOL, V82, P151, DOI 10.1007/s00204-007-0253-y; Fang C, 2006, EUR J PHARM SCI, V27, P27, DOI 10.1016/j.ejps.2005.08.002; Fernandes C, 2010, PHARMACOL RES, V62, P166, DOI 10.1016/j.phrs.2010.02.004; Gao XL, 2006, BIOMATERIALS, V27, P3482, DOI 10.1016/j.biomaterials.2006.01.038; Gibaud S, 1996, J PHARM SCI, V85, P944, DOI 10.1021/js960032d; Gomes AJ, 2006, PHOTOMED LASER SURG, V24, P514, DOI 10.1089/pho.2006.24.514; Gommersall L, 2007, EUR UROL, V52, P368, DOI 10.1016/j.eururo.2007.04.065; Grassian VH, 2007, ENVIRON HEALTH PERSP, V115, P397, DOI 10.1289/ehp.9469; Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012; Kane RS, 2007, BIOTECHNOL PROGR, V23, P316, DOI 10.1021/bp060388n; Kipp JE, 2004, INT J PHARMACEUT, V284, P109, DOI 10.1016/j.ijpharm.2004.07.019; Kreuter J, 2004, J NANOSCI NANOTECHNO, V4, P484, DOI 10.1166/jnn.2003.077; Kreuter J, 2003, PHARM RES-DORDR, V20, P409, DOI 10.1023/A:1022604120952; Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8; Lockman PR, 2004, J DRUG TARGET, V12, P635, DOI 10.1080/10611860400015936; Lockman PR, 2003, PHARM RES-DORDR, V20, P705, DOI 10.1023/A:1023492015851; Michaelis K, 2006, J PHARMACOL EXP THER, V317, P1246, DOI 10.1124/jpet.105.097139; Modi G, 2009, PROG NEUROBIOL, V88, P272, DOI 10.1016/j.pneurobio.2009.05.002; Moghimi SM, 2001, PHARMACOL REV, V53, P283; Mouritsen OG, 2011, EUR J LIPID SCI TECH, V113, P1174, DOI 10.1002/ejlt.201100050; Muller J, 2005, TOXICOL APPL PHARM, V207, P221, DOI 10.1016/j.taap.2005.01.008; Na K, 2006, EUR J PHARM SCI, V27, P115, DOI 10.1016/j.ejps.2005.08.012; Nair BG, 2011, MED CHEM, V7, P488; Niidome T, 2006, J CONTROL RELEASE, V114, P343, DOI 10.1016/j.jconrel.2006.06.017; Oberdorster E, 2004, ENVIRON HEALTH PERSP, V112, P1058, DOI 10.1289/ehp.7021; Olivier JC, 1999, PHARMACEUT RES, V16, P1836, DOI 10.1023/A:1018947208597; Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013; Peracchia MT, 1999, J CONTROL RELEASE, V60, P121, DOI 10.1016/S0168-3659(99)00063-2; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; Ricci-Junior E, 2006, J MICROENCAPSUL, V23, P523, DOI 10.1080/02652040600775525; Ross R., 2007, TOWN CTRY MAG    APR, P68; Saez A, 2000, EUR J PHARM BIOPHARM, V50, P379, DOI 10.1016/S0939-6411(00)00125-9; SCENIHR. EU Scientific Committee on Emerging and Newly Identified Health Risks, 2006, EU SCI COMM EM NEWL; Schins RPF, 2004, TOXICOL APPL PHARM, V195, P1, DOI 10.1016/j.taap.2003.10.002; Schins RPF, 2002, CHEM RES TOXICOL, V15, P1166, DOI 10.1021/tx025558u; Seki J, 2004, INT J PHARM, V273, P75, DOI 10.1016/j.ijpharm.2003.12.022; SENIOR J, 1991, BIOCHIM BIOPHYS ACTA, V1062, P77, DOI 10.1016/0005-2736(91)90337-8; SENIOR J, 1982, FEBS LETT, V145, P109, DOI 10.1016/0014-5793(82)81216-7; Sharma, 2004, BLOOD SPINAL CORD BR, P437; Sharma A, 2012, EXPERT OPIN DRUG MET, V8, P47, DOI 10.1517/17425255.2012.637916; Sharma HS, 2007, CURR PHARM DESIGN, V13, P1929; Sharma H.S., 2012, NEUROTROPHIC FACTOR, V846, P1; Sharma HS, 2011, J NEURAL TRANSM, V118, P3, DOI 10.1007/s00702-010-0542-0; Sharma HS, 2009, J NANOSCI NANOTECHNO, V9, P5014, DOI 10.1166/jnn.2009.GR04; Sharma HS, 2009, J NANOSCI NANOTECHNO, V9, P5055, DOI 10.1166/jnn.2009.GR09; Sharma HS, 2008, EXPERT OPIN PHARMACO, V9, P2773, DOI [10.1517/14656566.9.16.2773, 10.1517/14656566.9.16.2773 ]; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P197, DOI 10.1196/annals.1403.014; Sharma HS, 2007, NANOMEDICINE-UK, V2, P753, DOI 10.2217/17435889.2.6.753; Sharma HS, 2007, PROG BRAIN RES, V162, P245, DOI 10.1016/S0079-6123(06)62013-X; Sharma HS, 2007, CURR PHARM DESIGN, V13, P1841; Sharma HS, 2012, WIRES NANOMED NANOBI, V4, P184, DOI 10.1002/wnan.172; Sharma HS, 2011, J NANOSCI NANOTECHNO, V11, P7549, DOI 10.1166/jnn.2011.5114; Sharma Hari Shanker, 2011, Expert Rev Neurother, V11, P1121, DOI 10.1586/ern.11.100; Sharma HS, 2011, J NEURAL TRANSM, V118, P87, DOI 10.1007/s00702-010-0486-4; Sharma HS, 2009, PROG BRAIN RES, V180, P155, DOI 10.1016/S0079-6123(08)80009-X; Sharma HS, 2009, J NANOSCI NANOTECHNO, V9, P5073, DOI 10.1166/jnn.2009.GR10; Sharma Hari Shanker, 2008, Central Nervous System Agents in Medicinal Chemistry, V8, P143; SHARMA HS, 1995, NEUROSCI RES, V21, P241, DOI 10.1016/0168-0102(94)00855-A; Sharma HS, 2005, ANN NY ACAD SCI, V1053, P407, DOI 10.1196/annals.1344.036; Sharma HS, 2006, J NEURAL TRANSM, V113, P497, DOI 10.1007/s00702-005-0406-1; Sharma HS, 2006, J NEURAL TRANSM, V113, P521, DOI 10.1007/s00702-005-0405-2; Sharma HS, 2005, CURR PHARM DESIGN, V11, P1353, DOI 10.2174/1381612053507837; Sharma HS, 1995, PROG BRAIN RES, V104, P401; Sharma HS, 2000, ACTA NEUROCHIR SUPPL, V76, P297; SHARMA HS, 1995, RESTOR NEUROL NEUROS, V7, P207, DOI 10.3233/RNN-1994-7403; Sharma HS, 1996, NEUROSCI RES, V24, P373, DOI 10.1016/0168-0102(95)01015-7; SHARMA HS, 1991, J NEUROL SCI, V102, P150, DOI 10.1016/0022-510X(91)90063-D; SHARMA HS, 1993, ACTA NEUROPATHOL, V85, P145; SHARMA HS, 1990, ACTA NEUROPATHOL, V79, P604, DOI 10.1007/BF00294237; Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783; Stratmeyer M.E., 2007, SOC TOX 46 ANN M TOX; Tomazic-Jezic VJ, 2001, J BIOMED MATER RES, V55, P523, DOI 10.1002/1097-4636(20010615)55:4<523::AID-JBM1045>3.0.CO;2-G; Wang JX, 2007, TOXICOL LETT, V168, P176, DOI 10.1016/j.toxlet.2006.12.001; Warheit DB, 2007, TOXICOLOGY, V230, P90, DOI 10.1016/j.tox.2006.11.002; Winkler T, 1998, SPINAL CORD MONITORING, P283; Xia T, 2006, NANO LETT, V6, P1794, DOI 10.1021/nl061025k; Yao CP, 2006, EPILEPSIA, V47, P1822, DOI 10.1111/j.1528-1167.2006.00814.x; Zhao DB, 2006, SMALL, V2, P879, DOI 10.1002/smll.200500317; Zhao LZ, 2010, BIOMATERIALS, V31, P8341, DOI 10.1016/j.biomaterials.2010.07.036	103	27	29	0	15	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	FEB	2012	11	1					86	95					10	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	934MW	WOS:000303449400010	22385571				2021-06-18	
J	Bennett, TD; Statler, KD; Korgenski, EK; Bratton, SL				Bennett, Tellen D.; Statler, Kimberly D.; Korgenski, E. Kent; Bratton, Susan L.			Osmolar therapy in pediatric traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						brain edema; craniocerebral trauma; hypertonic saline solution; intracranial hypertension; mannitol; pediatrics	INTRACRANIAL-PRESSURE; HYPERTONIC SALINE; HEAD-INJURY; FOLLOW-UP; CHILDREN; MANNITOL; HOSPITALIZATIONS; EPIDEMIOLOGY; DISCHARGE; OUTCOMES	Objectives: To describe patterns of use for mannitol and hypertonic saline in children with traumatic brain injury, to evaluate any potential associations between hypertonic saline and mannitol use and patient demographic, injury, and treatment hospital characteristics, and to determine whether the 2003 guidelines for severe pediatric traumatic brain injury impacted clinical practice regarding osmolar therapy. Design: Retrospective cohort study. Setting: Pediatric Health Information System database, January, 2001 to December, 2008. Patients: Children (age <18 yrs) with traumatic brain injury and head/neck Abbreviated Injury Scale score >= 3 who received mechanical ventilation and intensive care. Interventions: None. Measurements and Main Results: The primary outcome was hospital billing for parenteral hypertonic saline and mannitol use, by day of service. Overall, 33% (2,069 of 6,238) of the patients received hypertonic saline, and 40% (2,500 of 6,238) received mannitol. Of the 1,854 patients who received hypertonic saline or mannitol for >= 2 days in the first week of therapy, 29% did not have intracranial pressure monitoring. After adjustment for hospital-level variation, primary insurance payer, and overall injury severity, use of both drugs was independently associated with older patient age, intracranial hemorrhage (other than epidural), skull fracture, and higher head/neck injury severity. Hypertonic saline use increased and mannitol use decreased with publication of the 2003 guidelines, and these trends continued through 2008. Conclusions: Hypertonic saline and mannitol are used less in infants than in older children. The patient-level and hospital-level variation in osmolar therapy use and the substantial amount of sustained osmolar therapy without intracranial pressure monitoring suggest opportunities to improve the quality of pediatric traumatic brain injury care. With limited high-quality evidence available, published expert guidelines appear to significantly impact clinical practice in this area. (Crit Care Med 2012; 40: 208-215)	[Bennett, Tellen D.; Korgenski, E. Kent] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84112 USA	Bennett, TD (corresponding author), Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84112 USA.	tell.bennett@hsc.utah.edu		Bratton, Susan/0000-0002-4605-8078; Bennett, Tellen/0000-0003-1483-4236	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH/NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [1KM1CA156723]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [KM1CA156723] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001067] Funding Source: NIH RePORTER	Supported, in part, by the National Institutes of Health. Dr. Bennett is partially supported by the Mentored Scholars Program for Translational Comparative Effectiveness Research, NIH/NCI Grant Number 1KM1CA156723.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS40; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; *CHILD HLTH CORP A, CTC 2010 COD STRUCT; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; Conway PH, 2009, J PEDIATR-US, V154, P789, DOI 10.1016/j.jpeds.2009.01.010; Cruz J, 2004, J NEUROSURG, V100, P376, DOI 10.3171/jns.2004.100.3.0376; Cruz J, 2002, NEUROSURGERY, V51, P628, DOI 10.1097/00006123-200209000-00006; Cruz J, 2001, NEUROSURGERY, V49, P864; Dawson L, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000111; Di Gennaro JL, 2010, DEV NEUROSCI-BASEL, V32, P420, DOI 10.1159/000322083; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Durbin D R, 2001, Inj Prev, V7, P96, DOI 10.1136/ip.7.2.96; *EXP GROUP INJ SEV, DISC DOC INJ SEV MEA; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Goldin AB, 2007, PEDIATRICS, V119, P905, DOI 10.1542/peds.2006-2040; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; JAMES HE, 1980, ACTA NEUROCHIR, V51, P161, DOI 10.1007/BF01406742; Johnson DL, 1998, PEDIATR NEUROSURG, V28, P167, DOI 10.1159/000028643; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kochanek PM, 2006, PEDIAT CRITICAL CARE, P1596; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Madden JM, 2002, NEW ENGL J MED, V347, P2031, DOI 10.1056/NEJMsa020408; Meara E, 2004, PEDIATRICS, V113, P1619, DOI 10.1542/peds.113.6.1619; Miller J D, 1993, Acta Neurochir Suppl (Wien), V57, P152; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Shardell M, 2007, CLIN INFECT DIS, V45, P901, DOI 10.1086/521255; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P831, DOI 10.1001/jama.263.6.831; Tasker RC, 2011, BRIT J NEUROSURG, V25, P68, DOI 10.3109/02688697.2010.538770; Tilford JM, 2005, CRIT CARE MED, V33, P2074, DOI 10.1097/01.CCM.0000171839.65687.F5; *TRIAN, 1997, ICDMAP 90 SOFTW US G; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; Wakai A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub4; Weiss PF, 2009, J PEDIATR-US, V155, P812, DOI 10.1016/j.jpeds.2009.05.030; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Wood JN, 2010, PEDIATRICS, V126, P408, DOI 10.1542/peds.2010-0031; Zebrack M, 2009, PEDIATRICS, V124, P56, DOI 10.1542/peds.2008-1006	44	27	29	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2012	40	1					208	215		10.1097/CCM.0b013e31822e9d31			8	Critical Care Medicine	General & Internal Medicine	866KO	WOS:000298379800030	21926592	Green Accepted			2021-06-18	
J	Ho, L; Zhao, W; Dams-O'Connor, K; Tang, CY; Gordon, W; Peskind, ER; Yemul, S; Haroutunian, V; Pasinetti, GM				Ho, Lap; Zhao, Wei; Dams-O'Connor, Kristen; Tang, Cheuk Y.; Gordon, Wayne; Peskind, Elaine R.; Yemul, Shrishailam; Haroutunian, Vahram; Pasinetti, Giulio Maria			Elevated Plasma MCP-1 Concentration Following Traumatic Brain Injury as a Potential "Predisposition" Factor Associated with an Increased Risk for Subsequent Development of Alzheimer's Disease	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Alzheimer's disease; biomarker; long-term clinical TBI phenotypes; mild cognitive impairment; monocyte chemotactic protein-1; plasma; traumatic brain injury	DIFFUSE AXONAL INJURY; MULTIPLE-SCLEROSIS; EXPRESSION; CHEMOKINES; PROTEIN; MECHANISMS; RAT; IDENTIFICATION; LOCALIZATION; INFLAMMATION	We explored whether changes in the expression profile of peripheral blood plasma proteins may provide a clinical, readily accessible "window" into the brain, reflecting molecular alterations following traumatic brain injury (TBI) that might contribute to TBI complications. We recruited fourteen TBI and ten control civilian participants for the study, and also analyzed banked plasma specimens from 20 veterans with TBI and 20 control cases. Using antibody arrays and ELISA assays, we explored differentially-regulated protein species in the plasma of TBI compared to healthy controls from the two independent cohorts. We found three protein biomarker species, monocyte chemotactic protein-1 (MCP-1), insulin-like growth factor-binding protein-3, and epidermal growth factor receptor, that are differentially regulated in plasma specimens of the TBI cases. A three-biomarker panel using all three proteins provides the best potential criterion for separating TBI and control cases. Plasma MCP-1 contents are correlated with the severity of TBI and the index of compromised axonal fiber integrity in the frontal cortex. Based on these findings, we evaluated postmortem brain specimens from 7 mild cognitive impairment (MCI) and 7 neurologically normal cases. We found elevated MCP-1 expression in the frontal cortex of MCI cases that are at high risk for developing Alzheimer's disease. Our findings suggest that additional application of the three-biomarker panel to current diagnostic criteria may lead to improved TBI detection and more sensitive outcome measures for clinical trials. Induction of MCP-1 in response to TBI might be a potential predisposing factor that may increase the risk for development of Alzheimer's disease.	[Ho, Lap; Zhao, Wei; Yemul, Shrishailam; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; [Dams-O'Connor, Kristen; Gordon, Wayne] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; [Tang, Cheuk Y.; Haroutunian, Vahram] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; [Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, GRECC, Bronx, NY USA; [Peskind, Elaine R.] Univ Washington, Sch Med, VA NW Network Mental Illness Res Educ & Clin Ctr, Seattle, WA USA; [Peskind, Elaine R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	Pasinetti, GM (corresponding author), Mt Sinai Sch Med, Dept Neurol, 1468 Madison Ave,Annenberg Bldg,Room 20-02, New York, NY 10029 USA.	Giulio.Pasinetti@mssm.edu	Zhao, Wei/A-2206-2010	Pasinetti, Giulio/0000-0002-1524-5196	UW Alzheimer's Disease Research Center [P50AG05136]; Pacific Northwest Udall Center [P50NS062684]; ADRC [AG05138, PPG AG02219]; Department of Veterans Affairs Rehabilitation Research and DevelopmentUS Department of Veterans Affairs; National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1RR029887]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR029887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS062684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG002219, P50AG005136, P50AG005138] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000521, I01RX001612] Funding Source: NIH RePORTER	This study was supported by UW Alzheimer's Disease Research Center (P50AG05136), Pacific Northwest Udall Center (P50NS062684), the ADRC (AG05138 and PPG AG02219), the Department of Veterans Affairs Rehabilitation Research and Development, and the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) (UL1RR029887).	Alberini CM, 2009, PHYSIOL REV, V89, P121, DOI 10.1152/physrev.00017.2008; [Anonymous], 2008, GULF WAR HLTH, V7; Archer T, 2012, ACTA NEUROL SCAND, V125, P293, DOI 10.1111/j.1600-0404.2011.01638.x; Banisor I, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-7; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Cantor JB, 2004, ARCH PHYS MED REHAB, V85, pS54, DOI 10.1016/j.apmr.2003.08.113; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Chandler S, 1995, NEUROSCI LETT, V201, P223, DOI 10.1016/0304-3940(95)12173-0; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Conductier G, 2010, J NEUROIMMUNOL, V224, P93, DOI 10.1016/j.jneuroim.2010.05.010; Correa JD, 2011, ARQ NEURO-PSIQUIAT, V69, P455, DOI 10.1590/S0004-282X2011000400009; Cross AK, 1999, GLIA, V28, P183, DOI 10.1002/(SICI)1098-1136(199912)28:3<183::AID-GLIA2>3.3.CO;2-V; Dams-O'Connor K, 2010, PSYCHIAT CLIN N AM, V33, P893, DOI 10.1016/j.psc.2010.08.002; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gardiner E, 2012, MOL PSYCHIATR, V17, P827, DOI 10.1038/mp.2011.78; Gobbel GT, 2007, CHILD NERV SYST, V23, P1171, DOI 10.1007/s00381-007-0345-2; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Grammas P, 2001, NEUROBIOL AGING, V22, P837, DOI 10.1016/S0197-4580(01)00276-7; Hannay HJ, 2004, NEUROPSYCHOLOGICAL A, P160; Haroutunian V, 1998, ARCH NEUROL-CHICAGO, V55, P1185, DOI 10.1001/archneur.55.9.1185; Hickman SE, 2010, CNS NEUROL DISORD-DR, V9, P168, DOI 10.2174/187152710791011982; Huang Ruo-Pan, 2004, Methods Mol Biol, V264, P215; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Ishizuka K, 1997, PSYCHIAT CLIN NEUROS, V51, P135, DOI 10.1111/j.1440-1819.1997.tb02375.x; Iverson GL, 2007, BRAIN INJURY MED PRI, P333; Janelsins MC, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-23; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kim JS, 1996, J NEUROL SCI, V137, P69, DOI 10.1016/0022-510X(95)00338-3; Kim SM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-51; Kooij G, 2011, BRAIN, V134, P555, DOI 10.1093/brain/awq330; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Lee ST, 2009, NEUROLOGY, V72, P1858, DOI 10.1212/WNL.0b013e3181a711f4; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mahad DJ, 2003, SEMIN IMMUNOL, V15, P23, DOI 10.1016/S1044-5323(02)00125-2; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Mayeux R, 2011, ALZHEIMERS DEMENT, V7, P15, DOI 10.1016/j.jalz.2010.11.005; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Minami M, 2003, LIFE SCI, V74, P321, DOI 10.1016/j.lfs.2003.09.019; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Patanella AK, 2010, J NEUROSCI RES, V88, P1106, DOI 10.1002/jnr.22276; Qu CS, 2010, J NEUROTRAUM, V27, P1625, DOI 10.1089/neu.2010.1359; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ray S, 2007, NAT MED, V13, P1359, DOI 10.1038/nm1653; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Ruan LF, 2009, CURR ALZHEIMER RES, V6, P531, DOI 10.2174/156720509790147070; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Stefini R, 2008, J NEUROSURG, V108, P958, DOI 10.3171/JNS/2008/108/5/0958; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Szczygielski J, 2005, J NEURAL TRANSM, V112, P1547, DOI 10.1007/s00702-005-0326-0; Tang CY, 2012, TRANSL NEUROSCI, V3, P9, DOI 10.2478/s13380-012-0003-3; Tanriverdi F, 2010, J NEUROTRAUM, V27, P301, DOI 10.1089/neu.2009.1102; Tanuma N, 2006, ACTA NEUROPATHOL, V112, P195, DOI 10.1007/s00401-006-0083-7; Tasker RC, 2010, DEV NEUROSCI-BASEL, V32, P374, DOI 10.1159/000316806; van Heerden Johan H, 2009, BMC Res Notes, V2, P195, DOI 10.1186/1756-0500-2-195; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Xia MQ, 1999, J NEUROVIROL, V5, P32, DOI 10.3109/13550289909029743; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	72	27	30	0	14	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877			J ALZHEIMERS DIS	J. Alzheimers Dis.		2012	31	2					301	313		10.3233/JAD-2012-120598			13	Neurosciences	Neurosciences & Neurology	986WS	WOS:000307377300007	22543850	Green Accepted			2021-06-18	
J	Jovanovski, D; Zakzanis, K; Ruttan, L; Campbell, Z; Erb, S; Nussbaum, D				Jovanovski, Diana; Zakzanis, Konstantine; Ruttan, Lesley; Campbell, Zachariah; Erb, Suzanne; Nussbaum, David			Ecologically Valid Assessment of Executive Dysfunction Using a Novel Virtual Reality Task in Patients with Acquired Brain Injury	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						acquired brain injury; executive function; neuropsychology; stroke; traumatic brain injury; virtual reality	STRATEGY APPLICATION; SIMPLIFIED VERSION; DEFICITS; DAMAGE	The current investigation sought to further establish the psychometric properties and ecological validity of the Multitasking in the City Test (MCT) in a clinical population. Ecological validity was addressed via correlational analyses between performance on this test and a subjective measure of everyday executive functioning (Frontal Systems Behavior Scale; FrSBe). The sample was composed of 13 individuals (11 males) who suffered a stroke or traumatic brain injury. A neuropsychological test battery consisting of the MCT and common executive and nonexecutive measures was administered. The only executive function tests that were significantly related to the FrSBe were the MCT and a semantic fluency test. Compared with a sample of normal participants, the patient group produced better plans but completed fewer tasks on the MCT. Patients made similar types of errors as normals, although some of these errors occurred more frequently in the patient sample. This study demonstrated the ecological validity of the MCT and suggested that patients can be differentiated from healthy individuals by quantitative (i.e., number of errors) rather than qualitative (i.e., type of errors) aspects of performance. Further interpretation of MCT performance and comparison with existing executive function tests is discussed.	[Jovanovski, Diana; Zakzanis, Konstantine] Univ Toronto Scarborough, Dept Psychol, Toronto, ON M1C 1A4, Canada; [Ruttan, Lesley] Toronto Rehabil Inst, Neurorehab Program, Toronto, ON, Canada; [Campbell, Zachariah; Erb, Suzanne; Nussbaum, David] Univ Toronto Scarborough, Dept Psychol, Toronto, ON M1C 1A4, Canada	Zakzanis, K (corresponding author), Univ Toronto Scarborough, Dept Psychol, 1265 Mil Trail, Toronto, ON M1C 1A4, Canada.	diana.jovanovski@utoronto.ca			Sibley & Associates Inc.	The authors wish to acknowledge Sibley & Associates Inc. for their support in the completion of this study and manuscript.	Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; American Heart Association, 2010, HEART DIS STROK STAT; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Beck A.T., 1993; BENTON A, 1975, NEUROLOGY, V25, P907, DOI 10.1212/WNL.25.10.907; Benton A, 1989, MULTILINGUAL APHASIA; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; Dawson DR, 2009, ARCH PHYS MED REHAB, V90, pS41, DOI 10.1016/j.apmr.2009.07.012; Delis DC, 2000, CALIFORNIA VERBAL LE; Finkelstein EA., 2006, INCIDENCE EC BURDEN; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Heaton R., 1993, WISCONSIN CARD SORTI; Hoerold D, 2008, EXP BRAIN RES, V186, P509, DOI 10.1007/s00221-008-1341-9; Jovanovski D, 2012, APPL NEUROPSYCH-ADUL, V19, P171, DOI 10.1080/09084282.2011.643955; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; Lazar RM, 2007, COGN BEHAV NEUROL, V20, P157, DOI 10.1097/WNN.0b013e31804c703f; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Marcotte TD., 2010, NEUROPSYCHOLOGY PRED, P5; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McGeorge P, 2001, PRESENCE-TELEOP VIRT, V10, P375, DOI 10.1162/1054746011470235; Meyers J., 1995, REY COMPLEX FIGURE T; National Center for Injury Prevention and Control, 2010, TRAUM BRAIN INJ US E; Pohjasvaara T, 2002, EUR J NEUROL, V9, P269, DOI 10.1046/j.1468-1331.2002.00396.x; Psychological Corporation, 1997, WAIS 3 WMS 3 TECHN M; Psychological Corporation, 2001, WECHSLER TEST ADULT; Rand D, 2009, NEUROPSYCHOL REHABIL, V19, P583, DOI 10.1080/09602010802469074; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SAZBON L, 1991, Brain Injury, V5, P3, DOI 10.3109/02699059108998505; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Teuber H. L., 1964, FRONTAL GRANULAR COR, P410; Tombaugh TN, 1996, TEST MEMORY MALINGER; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7; Zinn S, 2007, ARCH PHYS MED REHAB, V88, P173, DOI 10.1016/j.apmr.2006.11.015	43	27	28	1	14	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult		2012	19	3					207	220		10.1080/09084282.2011.643956			14	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	994RU	WOS:000307949900007	23373607				2021-06-18	
J	Williamson, DJ; Holsman, M; Chaytor, N; Miller, JW; Drane, DL				Williamson, David J.; Holsman, Maria; Chaytor, Naomi; Miller, John W.; Drane, Daniel L.			Abuse, Not Financial Incentive, Predicts Non-Credible Cognitive Performance in Patients With Psychogenic Non-Epileptic Seizures	CLINICAL NEUROPSYCHOLOGIST			English	Article						Psychogenic seizures; Non-epileptic seizures; Symptom validity testing; Word Memory Test; WMT	DISSOCIATIVE SYMPTOMS; RESPONSE BIAS; IMPAIRMENT; EPILEPSY; MMPI-2	Participants with psychogenic non-epileptic seizures (PNES) who fail symptom validity testing (SVT) perform worse on neuropsychological testing than those who do not, consistent with results found in participants with different clinical presentations (e. g., mild traumatic brain injury). However, little is known about how variables typically associated with SVT failure in other populations (e. g., the presence of financial incentives, exaggerated report of psychopathology) correlate with SVT failure in participants with PNES. Likewise the relationship between SVT failure and reported abuse, one of the most frequently described demographic characteristics of the PNES population, has not been examined. We found that failure on the Word Memory Test (WMT) in 91 participants with PNES was strongly associated with reported abuse but, contrary to expectations, was not associated with the presence of financial incentives or severity of reported psychopathology. These results indicate that the factors driving WMT failure may differ significantly in participants with PNES in ways that are potentially clinically relevant.	[Williamson, David J.] Janssen Sci Affairs LLC, Mobile, AL USA; [Williamson, David J.] Univ S Alabama, Dept Neurol, Mobile, AL 36688 USA; [Holsman, Maria] Puget Sound Vet Affairs, Dept Rehabil Psychol, Seattle, WA USA; [Chaytor, Naomi; Miller, John W.; Drane, Daniel L.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA; [Chaytor, Naomi; Miller, John W.] Harbor Med Ctr, UW Reg Epilepsy Ctr, Seattle, WA USA; [Drane, Daniel L.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA	Williamson, DJ (corresponding author), 100 Mem Hosp Dr,Suite 2A, Mobile, AL 36608 USA.	dj.williamson@alumni.duke.edu	Chaytor, Naomi/L-4315-2019	Chaytor, Naomi/0000-0001-8821-289X			ALPER K, 1993, NEUROLOGY, V43, P1950, DOI 10.1212/WNL.43.10.1950; Betts T, 1992, Seizure, V1, P27, DOI 10.1016/1059-1311(92)90051-2; Binder LM, 1998, ARCH CLIN NEUROPSYCH, V13, P513, DOI 10.1016/S0887-6177(97)00042-5; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Bortz JJ, 2003, MAYO CLIN PROC, V78, P781, DOI 10.4065/78.6.781; Bowman ES, 1999, NEUROLOGY, V53, pS84; Chafetz MD, 2011, ARCH CLIN NEUROPSYCH, V26, P306, DOI 10.1093/arclin/acr030; CHU JA, 1990, AM J PSYCHIAT, V147, P887; Cragar DE, 2002, NEUROPSYCHOL REV, V12, DOI 10.1023/A:1015491123070; Cragar DE, 2006, CLIN NEUROPSYCHOL, V20, P552, DOI 10.1080/13854040590947380; DePrince AP, 1999, PSYCHOL SCI, V10, P449, DOI 10.1111/1467-9280.00185; DODRILL CB, 2000, NONEPILEPTIC SEIZURE; Drake M E Jr, 1992, Seizure, V1, P11; Drane DL, 2006, EPILEPSIA, V47, P1879, DOI 10.1111/j.1528-1167.2006.00611.x; Drane DL, 2011, LITTLE BLACK BOOK NE; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 2007, ASSESSMENT FEIGNED C, P50; Green P., 1996, WORD MEMORY TEST USE; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hill SK, 2003, J FORENSIC NEUROPSYC, V3, P1; HOREN SA, 1995, CAN J PSYCHIAT, V40, P185; Hoskins LL, 2010, ARCH CLIN NEUROPSYCH, V25, P591, DOI 10.1093/arclin/acq060; Iverson G. L., 1999, J COGNITIVE REHABILI, V17, P4; Kaemmer B, 2001, MMPI-2: Manual for Administration and Scoring; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P841, DOI 10.1080/13854040902796735; Locke DEC, 2006, J CLIN EXP NEUROPSYC, V28, P325, DOI 10.1080/13803390490918183; Merckelbach H., 1999, PERSONALITY INDIVIDU, V194, P289; Rossini ED, 1996, J NERV MENT DIS, V184, P289, DOI 10.1097/00005053-199605000-00004; Selkirk M, 2008, EPILEPSIA, V49, P1446, DOI 10.1111/j.1528-1167.2008.01611.x; SPSS Inc, 2006, SPSS BAS 15 0 WIND U; Sweet JJ, 1999, STUD NEUROPSYCHOL DE, P255; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	35	27	27	0	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2012	26	4					588	598		10.1080/13854046.2012.670266			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	945XW	WOS:000304311100003	22439651				2021-06-18	
J	Jin, W; Kong, J; Lu, TY; Wang, HD; Ni, HB; Wu, J; Dai, YX; Jiang, JA; Liang, WB				Jin, Wei; Kong, Jie; Lu, Tianyu; Wang, Handong; Ni, Hongbin; Wu, Jun; Dai, Yuxiang; Jiang, Jian; Liang, Weibang			Erythropoietin Prevents Secondary Brain Injury Induced by Cortical Lesion in Mice: Possible Involvement of Nrf2 Signaling Pathway	ANNALS OF CLINICAL AND LABORATORY SCIENCE			English	Article							HEME OXYGENASE-1 EXPRESSION; CEREBRAL-ISCHEMIA; NEURONAL APOPTOSIS; NEUROPROTECTION; MODEL; PATHOPHYSIOLOGY; INFLAMMATION; ACTIVATION; RECOVERY	Erythropoietin (EPO) has demonstrated neuroprotective effects against traumatic brain injury (TBI), but the underlying mechanisms remain unclear. The signaling pathway of an antioxidant transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2), has been shown in our previous studies to play an important role in protecting mice from TBI-induced secondary brain injury. The present study explored the effect of recombinant human erythropoietin (rhEPO) on cerebral activation of the Nrf2 signaling pathway and secondary brain injury in mice after TBI. Adult male ICR mice were randomly divided into three groups: (1) Sham group; (2) TBI group; and (3) TBI+rhEPO group (n = 12 per group). Closed head injury was performed using Hall's weight-dropping method. rhEPO was administered at a dose of 5,000 IU/kg at 30 min after TBI. Brain samples were extracted at 24 hr after the trauma. The treatment with rhEPO markedly up-regulated the mRNA expression and activities of Nrf2 and its downstream cytoprotective enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO1). Administration of rhEPO also significantly ameliorated the secondary brain injury, as shown by decreased severity of neurological deficit, brain edema, and cortical apoptosis. In summary, post-TBI rhEPO administration induces Nrf2-mediated cytoprotective responses in the injured brain, and this may be a mechanism whereby rhEPO improves the outcome following TBI.	[Jin, Wei; Kong, Jie; Lu, Tianyu; Ni, Hongbin; Wu, Jun; Dai, Yuxiang; Jiang, Jian; Liang, Weibang] Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu Prov, Peoples R China; [Wang, Handong] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu Prov, Peoples R China	Liang, WB (corresponding author), Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Neurosurg, 321 Zhongshan Rd, Nanjing 210008, Jiangsu Prov, Peoples R China.	njneurosurgery@yahoo.com.cn			Drum Tower Hospital of China	This work was supported by grants from the Drum Tower Hospital of China. The authors thank Dr. Lizhi Xu and Dr. Gengbao Feng for their technical assistance.	Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Byts Nadiya, 2009, Exp Transl Stroke Med, V1, P4, DOI 10.1186/2040-7378-1-4; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Chen XL, 2004, CURR PHARM DESIGN, V10, P879, DOI 10.2174/1381612043452901; Chesnut Randall M., 1997, Emergency Medicine Clinics of North America, V15, P581, DOI 10.1016/S0733-8627(05)70319-9; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Genc K, 2010, CELL BIOCHEM FUNCT, V28, P197, DOI 10.1002/cbf.1639; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; Katavetin P, 2007, BIOCHEM BIOPH RES CO, V359, P928, DOI 10.1016/j.bbrc.2007.05.207; Kilic E, 2005, FASEB J, V19, P2026, DOI 10.1096/fj.05-3941fje; Kumral A, 2005, BIOL NEONATE, V87, P15, DOI 10.1159/000080490; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; McKee JA, 2005, NEUROCRIT CARE, V2, P342, DOI 10.1385/NCC:2:3:342; Osburn WO, 2006, ARCH BIOCHEM BIOPHYS, V454, P7, DOI 10.1016/j.abb.2006.08.005; Owuor ED, 2002, BIOCHEM PHARMACOL, V64, P765, DOI 10.1016/S0006-2952(02)01137-1; Ozturk E, 2005, PROG NEURO-PSYCHOPH, V29, P920, DOI 10.1016/j.pnpbp.2005.04.028; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiong Y, 2010, J NEUROTRAUM, V27, P205, DOI 10.1089/neu.2009.1001; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhu L, 2009, BRAIN RES, V1289, P96, DOI 10.1016/j.brainres.2009.07.015	31	27	35	0	4	ASSOC CLINICAL SCIENTISTS	MIDDLEBURY	PO BOX 1287, MIDDLEBURY, VT 05753 USA	0091-7370	1550-8080		ANN CLIN LAB SCI	Ann. Clin. Lab. Sci.	WIN	2011	41	1					25	32					8	Medical Laboratory Technology	Medical Laboratory Technology	727BC	WOS:000287771300005	21325251				2021-06-18	
J	Ishigami, Y; Klein, RM				Ishigami, Yoko; Klein, Raymond M.			Repeated measurement of the components of attention of older adults using the two versions of the Attention Network Test: stability, isolability, robustness, and reliability	FRONTIERS IN AGING NEUROSCIENCE			English	Article						attention; alerting; orienting; executive control; older adults; attention network test; aging	ANTERIOR CINGULATE CORTEX; TRAUMATIC BRAIN-INJURY; AGE-RELATED-CHANGES; ALZHEIMERS-DISEASE; VISUAL-ATTENTION; LIFE-SPAN; SUSTAINED ATTENTION; YOUNGER ADULTS; ALERTNESS; REHABILITATION	Ishigami and Klein (2010) showed that scores of the three attention networks (alerting, orienting, and executive control) measured with the two versions of the Attention Network Test (ANT; Fan et al., 2002; Callejas et al., 2005) were robust over 10 sessions of repeated testing even though practice effects were consistently observed especially in the executive network when young adults were tested. The current study replicated their method to examine robustness, stability, reliability, and isolability of the networks scores when older adults were tested with these ANTs. Ten test sessions, each containing two versions of the ANT, were administered to 10 older adults. Participants were asked to indicate the direction of a target arrow, flanked by distractors, presented either above or below the fixation following auditory signals or/and visual cue. Network scores were calculated using orthogonal subtractions of performance in selected conditions. All network scores remained highly significant even after nine previous sessions despite some practice effects in the executive and the alerting networks. Some lack of independence among the networks was found. The relatively poor reliability of network scores with one session of data rises to respectable levels as more data is added.	[Ishigami, Yoko] Dalhousie Univ, Dept Psychol, Life Sci Ctr, Halifax, NS B3H 4R2, Canada	Ishigami, Y (corresponding author), Dalhousie Univ, Dept Psychol, Life Sci Ctr, 1355 Oxford St, Halifax, NS B3H 4R2, Canada.	ishigami@dal.ca			Natural Sciences and Engineering Research Council Discovery grantNatural Sciences and Engineering Research Council of Canada (NSERC); Killam Trust and Multiple Sclerosis Society of Canada	This research was made possible by a Natural Sciences and Engineering Research Council Discovery grant to Raymond M. Klein and scholarship support to Yoko Ishigami from the Killam Trust and Multiple Sclerosis Society of Canada. The research reported here is drawn from a thesis by Yoko Ishigami in partialful fillment of requirements for a PhD degree at the Dalhousie University.	Bherer L, 2008, EXP AGING RES, V34, P188, DOI 10.1080/03610730802070068; Brodeur DA, 1997, CAN J EXP PSYCHOL, V51, P20, DOI 10.1037/1196-1961.51.1.20; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Callejas A, 2005, EXP BRAIN RES, V167, P27, DOI 10.1007/s00221-005-2365-z; Casey BJ, 2000, P NATL ACAD SCI USA, V97, P8728, DOI 10.1073/pnas.97.15.8728; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Coull JT, 1996, NEUROPSYCHOLOGIA, V34, P1085, DOI 10.1016/0028-3932(96)00029-2; D'Aloisio A, 1990, DEV ATTENTION RES TH, P447, DOI DOI 10.1016/S0166-4115(08)60470-7; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Fernandez-Duque D, 2006, NEUROPSYCHOLOGY, V20, P133, DOI 10.1037/0894-4105.20.2.133; Festa-Martino E, 2004, NEUROPSYCHOLOGY, V18, P258, DOI 10.1037/0894-4105.18.2.258; FOLK CL, 1992, PSYCHOL AGING, V7, P453, DOI 10.1037/0882-7974.7.3.453; Funes MJ, 2007, J EXP PSYCHOL HUMAN, V33, P348, DOI 10.1037/0096-1523.33.2.348; GREENWOOD PM, 1993, NEUROPSYCHOLOGIA, V31, P471, DOI 10.1016/0028-3932(93)90061-4; Groth KE, 2000, FRONT BIOSCI-LANDMRK, V5, pD284, DOI 10.2741/Groth; HARTLEY AA, 1990, J EXP PSYCHOL HUMAN, V16, P523, DOI 10.1037/0096-1523.16.3.523; Ishigami Y, 2010, J NEUROSCI METH, V190, P117, DOI 10.1016/j.jneumeth.2010.04.019; Ishigami Y, 2009, J INDIVID DIF, V30, P220, DOI 10.1027/1614-0001.30.4.220; Jennings JM, 2007, AGING NEUROPSYCHOL C, V14, P353, DOI 10.1080/13825580600788837; Jha AP, 2007, COGN AFFECT BEHAV NE, V7, P109, DOI 10.3758/CABN.7.2.109; Klein R, 2009, CAN J EXP PSYCHOL, V63, P240, DOI 10.1037/a0015807; Kok A, 2000, BIOL PSYCHOL, V54, P107, DOI 10.1016/S0301-0511(00)00054-5; Kok A, 1999, ACTA PSYCHOL, V101, P129, DOI 10.1016/S0001-6918(99)00003-7; KRAMER AF, 1994, PSYCHOL AGING, V9, P491, DOI 10.1037/0882-7974.9.4.491; Lincourt AE, 1997, AGING NEUROPSYCHOL C, V4, P290, DOI 10.1080/13825589708256654; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Madden DJ, 1997, AGING NEUROPSYCHOL C, V4, P185, DOI 10.1080/13825589708256647; Marrocco RT, 1998, ATTENTIVE BRAIN, P35; NEBES RD, 1993, CORTEX, V29, P77, DOI 10.1016/S0010-9452(13)80213-4; NISSEN MJ, 1985, J GERONTOL, V40, P185, DOI 10.1093/geronj/40.2.185; NORMAN DA, 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Pero S, 2006, BRAIN INJURY, V20, P1207, DOI 10.1080/02699050600983271; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; POSNER MI, 1994, P NATL ACAD SCI USA, V91, P7398, DOI 10.1073/pnas.91.16.7398; Posner MI., 1978, CHRONOMETRIC EXPLORA; RABBITT P, 1984, ATTENTION PERFORM, V10, P515; ROBERTSON IH, 1995, J CLIN EXP NEUROPSYC, V17, P416, DOI 10.1080/01688639508405133; ROGERS WA, 2000, COGNITIVE AGING PRIM, P57; Serino A, 2007, BRAIN INJURY, V21, P11, DOI 10.1080/02699050601151811; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Spearman C, 1904, AM J PSYCHOL, V15, P72, DOI 10.2307/1412159; Sturm W, 2006, RESTOR NEUROL NEUROS, V24, P371; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; Tales A, 2002, NEUROREPORT, V13, P2557, DOI 10.1097/00001756-200212200-00035; Tales A, 2002, NEUROPSYCHOLOGIA, V40, P2000, DOI 10.1016/S0028-3932(02)00057-X; Tang YY, 2007, P NATL ACAD SCI USA, V104, P17152, DOI 10.1073/pnas.0707678104; Thimm M, 2006, NEUROPSYCHOLOGIA, V44, P1230, DOI 10.1016/j.neuropsychologia.2005.09.008; Waszak F, 2010, DEV PSYCHOL, V46, P337, DOI 10.1037/a0018541; WRIGHT LL, 1979, J GERONTOL, V34, P704, DOI 10.1093/geronj/34.5.704; Zeef EJ, 1996, PSYCHOPHYSIOLOGY, V33, P555, DOI 10.1111/j.1469-8986.1996.tb02432.x	52	27	28	0	15	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1663-4365			FRONT AGING NEUROSCI	Front. Aging Neurosci.	NOV 15	2011	3								17	10.3389/fnagi.2011.00017			13	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	054KA	WOS:000312341200001	22110440	DOAJ Gold, Green Published			2021-06-18	
J	Haddad, S; Aldawood, AS; Alferayan, A; Russell, NA; Tamim, HM; Arabi, YM				Haddad, S.; Aldawood, A. S.; Alferayan, A.; Russell, N. A.; Tamim, H. M.; Arabi, Y. M.			Relationship between intracranial pressure monitoring and outcomes in severe traumatic brain injury patients	ANAESTHESIA AND INTENSIVE CARE			English	Article						trauma; brain injury; intracranial pressure monitoring; outcomes	SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; CEREBRAL PERFUSION-PRESSURE; INTENSIVE-CARE-UNIT; DECOMPRESSIVE CRANIECTOMY; HEMORRHAGIC COMPLICATIONS; RISK-FACTORS; MANAGEMENT; EPIDEMIOLOGY; HYPERTENSION	Intracranial pressure (ICP) monitoring is recommended in patients with a severe traumatic brain injury (TBI) and an abnormal computed tomography (CT) scan. However, there is contradicting evidence about whether ICP monitoring improves outcome. The purpose of this study was to examine the relationship between ICP monitoring and outcomes in patients with severe TBI. From February 2001 to December 2008, a total of 477 consecutive adult (>= 18 years) patients with severe TBI were included retrospectively in the study. Patients who underwent ICP monitoring (n=52) were compared with those who did not (n=425). The primary outcome was hospital mortality. Secondary outcomes were ICU mortality, mechanical ventilation duration, the need for tracheostomy, and ICU and hospital length of stay (LOS). After adjustment for multiple potential confounding factors, ICP monitoring was not associated with significant difference in hospital or ICU mortality (odds ratio [OR]=1.71, 95% confidence interval [CI]=0.79 to 3.70, P=0.17; OR=1.01, 95% CI=0.41 to 2.45, P=0.99, respectively). ICP monitoring was associated with a significant increase in mechanical ventilation duration (coefficient=5.66, 95% CI=3.45 to 7.88, P <0.0001), need for tracheostomy (OR=2.02, 95% CI=1.02 to 4.03, P=0.04), and ICU LOS (coefficient=5.62, 95% CI=3.27 to 7.98, P <0.0001), with no significant difference in hospital LOS (coefficient=8.32, 95% CI=-82.6 to 99.25, P=0.86). Stratified by the Glasgow Coma Scale score, ICP monitoring was associated with a significant increase in hospital mortality in the group of patients with Glasgow Coma Scale 7 to 8 (adjusted OR=12.89, 95% CI=3.14 to 52.95, P=0.0004). In patients with severe TBI, ICP monitoring was not associated with reduced hospital mortality, however, with a significant increase in mechanical ventilation duration, need for tracheostomy, and ICU LOS.	[Haddad, S.] King Fahad Natl Guard Hosp, Dept Intens Care, Surg Intens Care Unit, Riyadh 11426, Saudi Arabia; [Alferayan, A.; Russell, N. A.] King Fahad Natl Guard Hosp, Dept Neurosurg, Riyadh 11426, Saudi Arabia	Haddad, S (corresponding author), King Fahad Natl Guard Hosp, Dept Intens Care, Surg Intens Care Unit, MC 1425,POB 22490, Riyadh 11426, Saudi Arabia.			Arabi, Yaseen/0000-0001-5735-6241			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Arabi Y, 2006, CRIT CARE MED, V34, P605, DOI 10.1097/01.CCM.0000203947.60552.DD; Arabi Y, 2005, AM J INFECT CONTROL, V33, P137, DOI 10.1016/j.ajic.2004.11.008; Arabi YM, 2010, J CRIT CARE, V25, P190, DOI 10.1016/j.jcrc.2009.05.004; AUCOIN PJ, 1986, AM J MED, V80, P369, DOI 10.1016/0002-9343(86)90708-4; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BarrientosVega R, 1997, CRIT CARE MED, V25, P33, DOI 10.1097/00003246-199701000-00009; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bekar A, 1998, NEUROSURG REV, V21, P254, DOI 10.1007/BF01105781; Blaha M, 2005, J NEUROL NEUROSUR PS, V76, P147, DOI 10.1136/jnnp.2003.030817; Blaha M, 2003, PEDIATR NEUROSURG, V39, P27, DOI 10.1159/000070877; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, GUID MAN SEV TRAUM B; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Cremer OL, 2008, EUR J ANAESTH, V25, P87, DOI 10.1017/S0265021507003237; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Cremer OL, 2004, ANESTH ANALG, V99, P1211, DOI 10.1213/01.ANE.0000133917.67728.2A; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Demetriades D, 1998, J AM COLL SURGEONS, V187, P373, DOI 10.1016/S1072-7515(98)00209-9; Dings J, 1996, ZBL NEUROCHIR, V57, P177; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Forsyth RJ, 2010, COCHRANE DB SYST REV, V3; GELPKE GJ, 1983, J NEUROSURG, V59, P745, DOI 10.3171/jns.1983.59.5.0745; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lane PL, 2000, CAN J SURG, V43, P442; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; Maitinez-Manas RM, 2000, J NEUROL NEUROSUR PS, V69, P82, DOI 10.1136/jnnp.69.1.82; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; Meyer AA, 1998, J TRAUMA, V44, P1, DOI 10.1097/00005373-199801000-00001; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Mortifee PRS, 1996, ARCH PHYS MED REHAB, V77, P436, DOI 10.1016/S0003-9993(96)90030-1; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SAUL TG, 1982, AM SURGEON, V48, P477; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Shafer A, 1998, CRIT CARE MED, V26, P947, DOI 10.1097/00003246-199805000-00034; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; 2000, J NEUROTRAUMA, V17, P457	62	27	30	0	4	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA	0310-057X	1448-0271		ANAESTH INTENS CARE	Anaesth. Intensive Care	NOV	2011	39	6					1043	1050		10.1177/0310057X1103900610			8	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	853LV	WOS:000297428700009	22165356	Bronze			2021-06-18	
J	Jiang, C; Cui, KF; Wang, JP; He, YH				Jiang, Chao; Cui, Kefei; Wang, Jianping; He, Yuanhong			Microglia and cyclooxygenase-2: Possible therapeutic targets of progesterone for stroke	INTERNATIONAL IMMUNOPHARMACOLOGY			English	Article						Progesterone; Microglia; Inflammatory reaction; Cyclooxygenase-2; Cerebral infarction; Mechanism	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; MARROW CHIMERIC MICE; INFLAMMATORY RESPONSE; ARTERY OCCLUSION; IN-VITRO; RATS; MACROPHAGES; ACTIVATION; PROTECTS	Previous studies have demonstrated that progesterone (PROG) may be a pleiotropic neuroprotective agent. Although there have been reports about the neurotoxicity of activated microglia and cyclooxygenase-2 (COX-2) in animal models of ischemic stroke, the influence of PROG on the activation of microglia and the expression of COX-2 after stroke has not been examined in detail. In this investigation, we carried out research about the influence of PROG on cultured microglia by detection of the expression of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta) in their supernatant fluid before and after induced with lipopolysaccharide (LPS) or influenced by PROG with Enzyme-Linked Immunosorbent Assay technique in vitro. Moreover, the expression of COX-2 and ionized calcium-binding adapter molecule 1 (Iba1) was also detected in the cortex of rats that underwent permanent middle cerebral artery occlusion and received PROG or vehicle treatment by immunohistochemistry and western blot technique. The results revealed that PROG significantly reduced the expression of INF-alpha and IL-1 beta in cultured microglia after activated with LPS in vitro. In addition, PROG also valuably inhibited the expression of Ibal and COX-2 after stroke in vivo. These observations raised the possibility that PROG can exert its neuroprotective effects by inhibiting the activation of microglia and the over expression of COX-2 after stroke. (C) 2011 Elsevier B.V. All rights reserved.	[Jiang, Chao; Wang, Jianping; He, Yuanhong] Zhengzhou Univ, Dept Neurol, Affiliated Hosp 5, Zhengzhou 450052, Henan, Peoples R China; [Cui, Kefei] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou 450052, Henan, Peoples R China; [Cui, Kefei] Zhengzhou Univ, Affiliated Hosp 1, Dept Ultrasound, Zhengzhou 450052, Henan, Peoples R China	Wang, JP (corresponding author), Zhengzhou Univ, Dept Neurol, Affiliated Hosp 5, Zhengzhou 450052, Henan, Peoples R China.	wjpwfy666@126.com			Medical Science and Technology Research Programs of Henan Province [WKJ2010-2-016]	This work was supported by grants from Medical Science and Technology Research Programs of Henan Province (WKJ2010-2-016).	Ahmad M, 2009, BRAIN RES, V1279, P168, DOI 10.1016/j.brainres.2009.05.020; Araki E, 2001, STROKE, V32, P2370, DOI 10.1161/hs1001.096057; Benedetto N, 2003, INT IMMUNOPHARMACOL, V3, P825, DOI 10.1016/S1567-5769(03)00047-X; Bianchi R, 2010, NEUROBIOL AGING, V31, P665, DOI 10.1016/j.neurobiolaging.2008.05.017; Candelario-Jalil E, 2008, CURR PHARM DESIGN, V14, P1401, DOI 10.2174/138161208784480216; Cherubini A, 2005, FREE RADICAL BIO MED, V39, P841, DOI 10.1016/j.freeradbiomed.2005.06.025; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dubal DB, 1999, J NEUROSCI, V19, P6385; Ekdahl CT, 2009, NEUROSCIENCE, V158, P1021, DOI 10.1016/j.neuroscience.2008.06.052; Fillpovic R, 2008, EXP NEUROL, V211, P41, DOI 10.1016/j.expneurol.2007.12.024; Frank MG, 2007, BRAIN BEHAV IMMUN, V21, P47, DOI 10.1016/j.bbi.2006.03.005; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Gonzalez-Rey E, 2008, BRAIN BEHAV IMMUN, V22, P35, DOI 10.1016/j.bbi.2007.07.004; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hu ZY, 2009, CURR MED CHEM, V16, P1418, DOI 10.2174/092986709787846523; Jiang C, 2009, INFLAMM RES, V58, P619, DOI 10.1007/s00011-009-0032-8; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Kim HS, 2008, FREE RADICAL BIO MED, V45, P950, DOI 10.1016/j.freeradbiomed.2008.06.009; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; LEVI G, 1993, P NATL ACAD SCI USA, V90, P1541, DOI 10.1073/pnas.90.4.1541; Li SQ, 2009, NEUROCHEM RES, V34, P1451, DOI 10.1007/s11064-009-9932-9; Liang X, 2007, J MOL NEUROSCI, V33, P94, DOI 10.1007/s12031-007-0058-8; Munhoz CD, 2008, BRAZ J MED BIOL RES, V41, P1037, DOI 10.1590/S0100-879X2008001200001; Nicholas RS, 2002, J NEUROIMMUNOL, V124, P36, DOI 10.1016/S0165-5728(02)00011-5; Pang Y, 2010, NEUROSCIENCE, V166, P464, DOI 10.1016/j.neuroscience.2009.12.040; Pola R, 2009, THROMB HAEMOSTASIS, V101, P800, DOI 10.1160/TH09-03-0206; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schilling M, 2005, EXP NEUROL, V196, P290, DOI 10.1016/j.expneurol.2005.08.004; Schilling M, 2003, EXP NEUROL, V183, P25, DOI 10.1016/S0014-4886(03)00082-7; Schilling M, 2009, BRAIN RES, V1289, P79, DOI 10.1016/j.brainres.2009.06.054; Schumacher M, 2002, HORMONES BRAIN BEHAV, P683; Shen J, 2007, EUR J PHARMACOL, V558, P88, DOI 10.1016/j.ejphar.2006.11.059; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Vagnerova K, 2008, ANESTH ANALG, V107, P201, DOI 10.1213/ane.0b013e31817326a5; Wu D, 2005, ACTA MED OKAYAMA, V59, P121; Yin W, 2002, BRAIN RES, V926, P165, DOI 10.1016/S0006-8993(01)03304-2	42	27	29	0	16	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1567-5769	1878-1705		INT IMMUNOPHARMACOL	Int. Immunopharmacol.	NOV	2011	11	11					1925	1931		10.1016/j.intimp.2011.08.001			7	Immunology; Pharmacology & Pharmacy	Immunology; Pharmacology & Pharmacy	853MV	WOS:000297431300039	21843661				2021-06-18	
J	Haar, CV; Anderson, GD; Hoane, MR				Haar, Cole Vonder; Anderson, Gail D.; Hoane, Michael R.			Continuous nicotinamide administration improves behavioral recovery and reduces lesion size following bilateral frontal controlled cortical impact injury	BEHAVIOURAL BRAIN RESEARCH			English	Article						Traumatic brain injury; Vitamin B(3); Treatment; Recovery of function; Rat	TRAUMATIC BRAIN-INJURY; FLUID PERCUSSION INJURY; FUNCTIONAL RECOVERY; CELL-DEATH; CONTUSION INJURY; CLINICAL-TRIALS; NADP(+)/NADPH; MECHANISMS; PRECURSOR; NAD(+)	Previous research has demonstrated considerable preclinical efficacy of nicotinamide (NAM; vitamin B(3)) in animal models of TBI with systemic dosing at 50 and 500 mg/kg yielding improvements on sensory, motor, cognitive and histological measures. The current study aimed to utilize a more specific dosing paradigm in a clinically relevant delivery mechanism: continuously secreting subcutaneous pumps. A bilateral frontal controlled cortical impact (CCI) or sham surgery was performed and rats were treated with NAM (150 mg/kg day) or saline (1 ml/kg) pumps 30 min after CCI, continuing until seven days post-CCI. Rats were given a loading dose of NAM (50 mg/kg) or saline (1 ml/kg) following pump implant. Rats received behavioral testing (bilateral tactile adhesive removal, locomotor placing task and Morris water maze) starting on day two post-CC and were sacrificed at 31 days post-CCI and brains were stained to examine lesion size. NAM-treated rats had reductions in sensory, motor and cognitive behavioral deficits compared to vehicle-treated rats. Specifically, NAM-treated rats significantly improved on the bilateral tactile adhesive removal task, locomotor placing task and the reference memory paradigm of the Morris water maze. Lesion size was also significantly reduced in the NAM-treated group. The results from this study indicate that at the current dose, NAM produces beneficial effects on recovery from a bilateral frontal brain injury and that it may be a relevant compound to be explored in human studies. (C) 2011 Elsevier BM. All rights reserved.	[Haar, Cole Vonder; Hoane, Michael R.] So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Carbondale, IL 62901 USA; [Anderson, Gail D.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA	Hoane, MR (corresponding author), So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Vonder Haar, Cole/0000-0001-7949-2068; Hoane, Michael/0000-0001-7779-2657	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045647-04]; NIH/NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD061944-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061944] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER	The authors would like to thank Andrew Vaz for his help with behavioral data collection and scoring and Michael Emery and Kris Martens for assisting in surgical procedures. Funding for this project was provided by ARRA funds from NINDS grant NS045647-04 and NIH/NICHD grant HD061944-01.	Centers for Disease Control, 2010, INJ PREV CONTR TRAUM; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Goffus AM, 2010, OXID MED CELL LONGEV, V3, P145, DOI 10.4161/oxim.3.2.11315; Hoane MR, 2008, NEUROSCIENCE, V154, P861, DOI 10.1016/j.neuroscience.2008.04.044; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2008, OXID MED CELL LONGEV, V1, P46, DOI 10.4161/oxim.1.1.6694; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; Klaidman L, 2003, PHARMACOLOGY, V69, P150, DOI 10.1159/000072668; Komotar RJ, 2007, NAT PROTOC, V2, P2345, DOI 10.1038/nprot.2007.359; Li FQ, 2006, CURR MED CHEM, V13, P883, DOI 10.2174/092986706776361058; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NEAFSEY EJ, 1990, CEREBRAL CORTEX RAT, P197; Quigley A, 2009, BRAIN RES, V1304, P138, DOI 10.1016/j.brainres.2009.09.062; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Xia WL, 2009, CURR PHARM DESIGN, V15, P12, DOI 10.2174/138161209787185832; Yang J, 2002, MINI-REV MED CHEM, V2, P125, DOI 10.2174/1389557024605483; Ying WH, 2008, ANTIOXID REDOX SIGN, V10, P179, DOI 10.1089/ars.2007.1672	25	27	27	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328			BEHAV BRAIN RES	Behav. Brain Res.	OCT 31	2011	224	2					311	317		10.1016/j.bbr.2011.06.009			7	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	818ZQ	WOS:000294795600012	21704653	Green Accepted			2021-06-18	
J	Turgeon, C; Champoux, F; Lepore, F; Leclerc, S; Ellemberg, D				Turgeon, Christine; Champoux, Francois; Lepore, Franco; Leclerc, Suzanne; Ellemberg, Dave			Auditory Processing After Sport-Related Concussions	EAR AND HEARING			English	Article								Objective: The aim of the study is to investigate whether sport-related concussions disrupt auditory processes. Design: Sixteen university athletes participated in the study: eight had one or more sport-related concussions, and eight never experienced a concussion. The Frequency Pattern Sequence test, the Duration Pattern Sequence test, the Synthetic Sentence Identification test, and the Staggered Spondaic Word test were used to assess auditory processing. Results: All nonconcussed athletes have normal auditory processing. In contrast, more than half of the concussed athletes had deficits for one or more of the auditory processing tests. Conclusions: The pattern of results suggests that sport-related concussions can disrupt the neurological mechanisms implicated in several auditory processes, including monaural low-redundancy speech recognition, tone pattern recognition, and dichotic listening.	[Leclerc, Suzanne; Ellemberg, Dave] Univ Montreal, Dept Kinesiol, Montreal, PQ H3T 1C5, Canada; [Turgeon, Christine; Champoux, Francois; Lepore, Franco; Ellemberg, Dave] Univ Montreal, Ctr Rech Neuropsychol & Cognit, Montreal, PQ H3T 1C5, Canada; [Champoux, Francois] Inst Raymond Dewar, Ctr Rech Interdisciplinaire Readaptat Montreal Me, Montreal, PQ, Canada	Ellemberg, D (corresponding author), Univ Montreal, Dept Kinesiol, 2100 Edouard Montpetit, Montreal, PQ H3T 1C5, Canada.	dave.ellemberg@umontreal.ca			Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR	This work was supported by grants from the Canadian Institutes for Health Research and the Natural Sciences and Engineering Research Council of Canada (to D. E.).	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bellis T.J., 2003, ASSESSMENT MANAGEMEN, V2nd; Bergemalm PO, 2005, INT J AUDIOL, V44, P39, DOI 10.1080/14992020400022546; Champoux F, 2007, EUR J NEUROSCI, V25, P291, DOI 10.1111/j.1460-9568.2006.05260.x; Cockrell J. L., 1992, BRAIN INJURY, V6, P216; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; JERGER J, 1974, ARCH OTOLARYNGOL, V99, P342; KATZ J, 1968, J SPEECH HEAR DISORD, V33, P132, DOI 10.1044/jshd.3302.132; Kelly JP, 1997, NEUROLOGY, V48, P581; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Musiek Frank E, 2004, J Am Acad Audiol, V15, P117, DOI 10.3766/jaaa.15.2.3; Pinheiro M. L., 1995, ASSESSMENT CENTRAL A; PINHEIRO ML, 1971, J ACOUST SOC AM, V49, P1778, DOI 10.1121/1.1912581	15	27	31	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0196-0202	1538-4667		EAR HEARING	Ear Hear.	SEP-OCT	2011	32	5					667	670		10.1097/AUD.0b013e31821209d6			4	Audiology & Speech-Language Pathology; Otorhinolaryngology	Audiology & Speech-Language Pathology; Otorhinolaryngology	812HI	WOS:000294281400016	21399499				2021-06-18	
J	Wang, L; Tang, XG; Zhang, HX; Yuan, JS; Ding, H; Wei, YZ				Wang, Lei; Tang, Xingguo; Zhang, Hongxi; Yuan, Jishan; Ding, Hua; Wei, Yongzhong			Elevated leptin expression in rat model of traumatic spinal cord injury and femoral fracture	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Leptin; Fracture; Osteogenesis; Spinal cord injuries; Bone; Callus	SYMPATHETIC NERVOUS-SYSTEM; HETEROTOPIC OSSIFICATION; SERUM LEPTIN; BRAIN-INJURY; BONE; LOCALIZATION; OSTEOBLASTS; RECEPTORS; INCREASES; HUMANS	Background: Few studies have reported a relationship between leptin induced by spinal cord injury (SCI) and healing bone tissue. Objective: To observe serum and callus leptin expression within the setting of fracture and traumatic SCI. Methods: Seventy-two male Sprague Dawley rats were randomized equally into four groups: control, SCI group, fracture group, and fracture/SCI group. Rats were sacrificed at 7, 14, 21, and 28 days post-fracture/SCI. Serum leptin was detected using radioimmunoassay at 1, 7, 14, 21, and 28 days, and callus formation was measured radiologically at 14, 21, and 28 days. Callus leptin was analyzed by means of immunohistochemistry. Results: Serum leptin in the fracture group, SCI group, and combined fracture/SCI group were all significantly increased compared to control group at the 1, 7, 14, and 2-day time points (P < 0.05). Serum leptin in the combined fracture/SCI group was significantly higher than in the fracture group at 7, 14, and 21 days (P < 0.05), and higher than in SCI groups at 14 and 21days after operation (P < 0.05). The percentage of leptin-positive cells in the fracture/SCI callus, and callus volume was significantly higher than in the fracture-only group (P < 0.001). Conclusions: Overall, elevated leptin expression was demonstrated within healing bone especially in the 21 days of a rat model combining fracture and SCI. A close association exists between leptin levels and the degree of callus formation in fractures.	[Wang, Lei; Tang, Xingguo; Zhang, Hongxi; Yuan, Jishan; Ding, Hua] Jiangsu Univ, Affiliated Peoples Hosp, Dept Orthoped, Zhenjiang, Jiangsu Provinc, Peoples R China; [Wei, Yongzhong] Nanjing Univ, Affiliated Hosp 1, Dept Orthoped, Nanjing, Jiangsu Provinc, Peoples R China	Zhang, HX (corresponding author), Dianli Rd 8, Zhenjiang 212001, Jiangsu Provinc, Peoples R China.	zhanghx-ortho@hotmail.com			Medical Science and Technology Development of Jiangsu Health Bureau, China [H200512]	Supported by funds from the Medical Science and Technology Development of Jiangsu Health Bureau (H200512), China.	Barr VA, 1999, J BIOL CHEM, V274, P21416, DOI 10.1074/jbc.274.30.21416; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bonnet N, 2007, BONE, V40, P1209, DOI 10.1016/j.bone.2007.01.006; Cipriano CA, 2009, J AM ACAD ORTHOP SUR, V17, P689, DOI 10.5435/00124635-200911000-00003; COUSIN B, 1993, ENDOCRINOLOGY, V133, P2255, DOI 10.1210/en.133.5.2255; Desborough JP, 1993, ANAESTHESIA REV, V10, P131; Ealey KN, 2006, REGUL PEPTIDES, V136, P9, DOI 10.1016/j.regpep.2006.04.013; Faggioni R, 2000, AM J PATHOL, V156, P1781, DOI 10.1016/S0002-9440(10)65049-3; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Freehafer A A, 1966, Med Serv J Can, V22, P471; Gordeladze JO, 2002, J CELL BIOCHEM, V85, P825, DOI 10.1002/jcb.10156; Janik JE, 1997, J CLIN ENDOCR METAB, V82, P3084, DOI 10.1210/jc.82.9.3084; Kim JS, 1996, STROKE, V27, P1553, DOI 10.1161/01.STR.27.9.1553; Kolaczynski JW, 1996, DIABETES, V45, P699, DOI 10.2337/diabetes.45.5.699; KURER MHJ, 1992, PARAPLEGIA, V30, P165, DOI 10.1038/sc.1992.48; Lee YJ, 2002, FEBS LETT, V528, P43, DOI 10.1016/S0014-5793(02)02889-2; Li JL, 2000, J BONE MINER RES, V15, P2042, DOI 10.1359/jbmr.2000.15.10.2042; Li S, 2001, Hua Xi Yi Ke Da Xue Xue Bao, V32, P240; Lin Ji, 2006, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V18, P19; Lolmede K, 2003, INT J OBESITY, V27, P1187, DOI 10.1038/sj.ijo.0802407; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mantzoros CS, 1997, J CLIN ENDOCR METAB, V82, P3408, DOI 10.1210/jc.82.10.3408; Mantzoros CS, 1996, DIABETES, V45, P909, DOI 10.2337/diabetes.45.7.909; Miell JP, 1996, HORM METAB RES, V28, P704, DOI 10.1055/s-2007-979882; PASINETTI GM, 1993, NEUROSCIENCE, V54, P893, DOI 10.1016/0306-4522(93)90583-2; Patel L, 2002, J PEDIATR ENDOCR MET, V15, P963; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P5214; Rayner DV, 2001, J MOL MED-JMM, V79, P8, DOI 10.1007/s001090100198; Reseland JE, 2001, J BONE MINER RES, V16, P1426, DOI 10.1359/jbmr.2001.16.8.1426; Schell H, 2006, BONE, V38, P547, DOI 10.1016/j.bone.2005.09.018; Shahbazian LM, 1999, METABOLISM, V48, P1397, DOI 10.1016/S0026-0495(99)90149-X; SMITH JA, 1994, J LEUKOCYTE BIOL, V56, P672; Stamatovic SM, 2006, ACTA NEUROCHIR SUPPL, V96, P444; Steppan CM, 2000, REGUL PEPTIDES, V92, P73, DOI 10.1016/S0167-0115(00)00152-X; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630; Thomas T, 2004, CURR OPIN PHARMACOL, V4, P295, DOI 10.1016/j.coph.2004.01.009; Thomas T, 2002, J BONE MINER RES, V17, P1563, DOI 10.1359/jbmr.2002.17.9.1563; Utriainen T, 1996, DIABETES, V45, P1364, DOI 10.2337/diabetes.45.10.1364; Wang YH, 2005, ARCH PHYS MED REHAB, V86, P1964, DOI 10.1016/j.apmr.2005.04.017; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009	43	27	28	0	13	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	1079-0268			J SPINAL CORD MED	J. Spinal Cord. Med.	SEP	2011	34	5					501	509		10.1179/2045772311Y.0000000034			9	Clinical Neurology	Neurosciences & Neurology	835OS	WOS:000296046300009	22118258	Green Published			2021-06-18	
J	Shin, SS; Dixon, CE				Shin, Samuel S.; Dixon, C. Edward			Oral fish oil restores striatal dopamine release after traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Fish oil; Omega-3 fatty acid; Docosahexaenoic acid; Eicosapentaenoic acid; Traumatic brain injury; Dopamine	POLYUNSATURATED FATTY-ACID; RAT FRONTAL-CORTEX; SPINAL-CORD-INJURY; DOCOSAHEXAENOIC ACID; EVOKED RELEASE; AXONAL INJURY; DOUBLE-BLIND; MODEL; DEFICIENCY; HIPPOCAMPUS	Omega-3 fatty acid administration can affect the release of neurotransmitters and reduce inflammation and oxidative stress, but its use in traumatic brain injury (TBI) has not been described extensively. We investigated the effect of 7 day oral fish oil treatment in the recovery of potassium evoked dopamine release after TBI. Sham rats and TBI rats were given either olive oil or fish oil by oral gavage and were subject to cerebral microdialysis. Olive oil treated TBI rats showed significant dopamine release deficit compared to sham rats, and this deficit was restored with oral fish oil treatment. There was no effect of fish oil treatment on extracellular levels of dopamine metabolites such as 3,4-dihydroxyphenylacetic acid and homovanillic acid. These results suggest the therapeutic potential of omega-3 fatty acids in restoring dopamine neurotransmission deficits after TBI. Published by Elsevier Ireland Ltd.	[Shin, Samuel S.; Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; [Shin, Samuel S.; Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA	Dixon, CE (corresponding author), Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.	dixonec@upmc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1F30NS067731-01, 5R01NS060672-02]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F30NS067731, R01NS060672] Funding Source: NIH RePORTER	Supported by NIH grants: 1F30NS067731-01, 5R01NS060672-02.	Agut J, 2000, ANN NY ACAD SCI, V920, P332; Aid S, 2005, J NUTR, V135, P1008; Aid S, 2003, J LIPID RES, V44, P1545, DOI 10.1194/jlr.M300079-JLR200; BAILES J, 2011, NEUROSURGERY    0105; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Bazan NG, 2009, J LIPID RES, V50, pS400, DOI 10.1194/jlr.R800068-JLR200; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Bousquet M, 2008, FASEB J, V22, P1213, DOI 10.1096/fj.07-9677com; Bousquet M, 2009, PROG NEURO-PSYCHOPH, V33, P1401, DOI 10.1016/j.pnpbp.2009.07.018; Cansev M, 2008, ALZHEIMERS DEMENT, V4, pS153, DOI 10.1016/j.jalz.2007.10.005; Corrigan FM, 1998, INT J BIOCHEM CELL B, V30, P197, DOI 10.1016/S1357-2725(97)00125-8; Dangour AD, 2010, AM J CLIN NUTR, V91, P1725, DOI 10.3945/ajcn.2009.29121; Delattre AM, 2010, NEUROSCI RES, V66, P256, DOI 10.1016/j.neures.2009.11.006; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Favreliere S, 2003, NEUROBIOL AGING, V24, P233, DOI 10.1016/S0197-4580(02)00064-7; GREEN D, 1985, STROKE, V16, P706, DOI 10.1161/01.STR.16.4.706; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; KIMURA M, 1995, NEUROSCI RES, V22, P353, DOI 10.1016/0168-0102(95)00914-F; King VR, 2006, J NEUROSCI, V26, P4672, DOI 10.1523/JNEUROSCI.5539-05.2006; Kodas E, 2002, J LIPID RES, V43, P1209, DOI 10.1194/jlr.M200132-JLR200; Korchounov AM, 2008, B EXP BIOL MED+, V146, P14, DOI 10.1007/s10517-008-0197-0; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Mura A, 2003, MOVEMENT DISORD, V18, P860, DOI 10.1002/mds.10472; Pan HC, 2009, J NUTR BIOCHEM, V20, P715, DOI 10.1016/j.jnutbio.2008.06.014; Peet M, 2003, PROSTAG LEUKOTR ESS, V69, P477, DOI 10.1016/j.plefa.2003.08.020; Sarsilmaz M, 2003, PROSTAG LEUKOTR ESS, V69, P253, DOI 10.1016/S0952-3278(03)00107-8; SHIN SS, 2010, BRAIN RES; Smi CK, 2004, DEV BRAIN RES, V152, P11, DOI [10.1016/j.debrainres.2004.05.004, 10.1016/j.devbrainres.2004.05.004]; Tanriover G, 2010, FOLIA HISTOCHEM CYTO, V48, P434, DOI 10.2478/v10042-010-0047-6; WAINWRIGHT PE, 1992, NEUROSCI BIOBEHAV R, V16, P193, DOI 10.1016/S0149-7634(05)80180-0; Wang L, 2005, J MOL NEUROSCI, V27, P137, DOI 10.1385/JMN:27:1:137; Wang X, 2003, NEUROREPORT, V14, P2457, DOI 10.1097/00001756-200312190-00033; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wurtman RJ, 2009, ANNU REV NUTR, V29, P59, DOI 10.1146/annurev-nutr-080508-141059; Zimmer L, 2000, NEUROSCI LETT, V284, P25, DOI 10.1016/S0304-3940(00)00950-2; Zimmer L, 1998, NEUROSCI LETT, V240, P177, DOI 10.1016/S0304-3940(97)00938-5; Zimmer L, 2002, AM J CLIN NUTR, V75, P662	39	27	29	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUN 8	2011	496	3					168	171		10.1016/j.neulet.2011.04.009			4	Neurosciences	Neurosciences & Neurology	774TF	WOS:000291408800005	21514362	Green Accepted			2021-06-18	
J	Rossi, JL; Ranaivo, HR; Patel, F; Chrzaszcz, M; Venkatesan, C; Wainwright, MS				Rossi, Janet L.; Ranaivo, Hantamalala Ralay; Patel, Fatima; Chrzaszcz, MaryAnn; Venkatesan, Charu; Wainwright, Mark S.			Albumin Causes Increased Myosin Light Chain Kinase Expression in Astrocytes Via p38 Mitogen-Activated Protein Kinase	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						myosin light chain kinase; blood-brain barrier; astrocyte; traumatic brain injury; transforming growth factor	EPITHELIAL BARRIER DYSFUNCTION; LUNG INJURY; RHO-KINASE; INHIBITION; PHOSPHORYLATION; SUSCEPTIBILITY; INVOLVEMENT; KNOCKOUT; ISOFORM; MODEL	Myosin light chain kinase (MLCK) plays an important role in the reorganization of the cytoskeleton, leading to disruption of vascular barrier integrity in multiple organs, including the blood-brain barrier (BBB), after traumatic brain injury (TBI). MLCK has been linked to transforming growth factor (TGF) and rho kinase signaling pathways, but the mechanisms regulating MLCK expression following TBI are not well understood. Albumin leaks into the brain parenchyma following TBI, activates glia, and has been linked to TGF-beta receptor signaling. We investigated the role of albumin in the increase of MLCK in astrocytes and the signaling pathways involved in this increase. After midline closed-skull TBI in mice, there was a significant increase in MLCK-immunoreactive (IR) cells and albumin extravasation, which was prevented by treatment with the MLCK inhibitor ML-7. Using immunohistochemical methods, we identified the MLCK-IR cells as astrocytes. In primary astrocytes, exposure to albumin increased both isoforms of MLCK, 130 and 210. Inhibition of the TGF-b receptor partially prevented the albumin-induced increase in both isoforms, which was not prevented by inhibition of smad3. Inhibition of p38 MAPK, but not ERK, JNK, or rho kinase, also prevented this increase. These results are further evidence of a role of MLCK in the mechanisms of BBB compromise following TBI and identify astrocytes as a cell type, in addition to endothelium in the BBB, that expresses MLCK. These findings implicate albumin, acting through p38 MAPK, in a novel mechanism by which activation of MLCK following TBI may lead to compromise of the BBB. (C) 2011 Wiley-Liss, Inc.	[Rossi, Janet L.; Wainwright, Mark S.] Northwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Div Crit Care,Dept Pediat, Chicago, IL 60614 USA; [Ranaivo, Hantamalala Ralay; Patel, Fatima; Chrzaszcz, MaryAnn; Venkatesan, Charu; Wainwright, Mark S.] Northwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Div Neurol,Dept Pediat, Chicago, IL 60614 USA; [Rossi, Janet L.; Ranaivo, Hantamalala Ralay; Patel, Fatima; Chrzaszcz, MaryAnn; Venkatesan, Charu; Wainwright, Mark S.] Northwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Ctr Interdisciplinary Res Pediat Crit Illness & I, Chicago, IL 60614 USA	Wainwright, MS (corresponding author), Childrens Mem Hosp, Div Neurol 51, 2300 Childrens Plaza, Chicago, IL 60614 USA.	m-wainwright@northwestern.edu	Venkatesan, Charu/D-5944-2016		Department of Pediatrics Faculty Research Development Award; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12 HD052902]; Medical Research Junior Board Foundation; Lyndsey Whittingham Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD052902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS044998] Funding Source: NIH RePORTER	Contract grant sponsor: Department of Pediatrics Faculty Research Development Award (to J.L.R.); Contract grant sponsor: NIH; Contract grant number: K12 HD052902 (to C. V.); Contract grant sponsor: Medical Research Junior Board Foundation (to M. S. W.); Contract grant sponsor: Lyndsey Whittingham Foundation (to M.S.W.).	Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Afonso PV, 2007, J IMMUNOL, V179, P2576, DOI 10.4049/jimmunol.179.4.2576; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BAORTO DM, 1992, J CELL BIOL, V117, P357, DOI 10.1083/jcb.117.2.357; Bazzoni G, 1999, CURR OPIN CELL BIOL, V11, P573, DOI 10.1016/S0955-0674(99)00023-X; Cacheaux LP, 2009, J NEUROSCI, V29, P8927, DOI 10.1523/JNEUROSCI.0430-09.2009; Chrzaszcz M, 2010, J NEUROTRAUM, V27, P1283, DOI 10.1089/neu.2009.1227; Clements RT, 2005, AM J PHYSIOL-LUNG C, V288, pL294, DOI 10.1152/ajplung.00213.2004; Drexler H, 1999, J MOL CELL CARDIOL, V31, P51, DOI 10.1006/jmcc.1998.0843; EDELMAN AM, 1992, MOL BRAIN RES, V14, P27, DOI 10.1016/0169-328X(92)90006-W; Eiznhamer DA, 2004, PULM PHARMACOL THER, V17, P105, DOI 10.1016/j.pupt.2003.11.003; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Haorah J, 2005, ALCOHOL CLIN EXP RES, V29, P999, DOI 10.1097/01.ALC.0000166944.79914.0A; Hooper C, 2009, J NEUROCHEM, V109, P694, DOI 10.1111/j.1471-4159.2009.05953.x; Ivens S, 2007, BRAIN, V130, P535, DOI 10.1093/brain/awl317; Kudryashov DS, 2004, EXP CELL RES, V298, P407, DOI 10.1016/j.yexcr.2004.04.025; Kuhlmann CRW, 2007, J NEUROCHEM, V102, P501, DOI 10.1111/j.1471-4159.2007.04506.x; Kuhlmann CRW, 2006, NEUROPHARMACOLOGY, V51, P907, DOI 10.1016/j.neuropharm.2006.06.004; Kuhlmann CRW, 2009, STROKE, V40, P1458, DOI 10.1161/STROKEAHA.108.535930; Luh C, 2010, J NEUROCHEM, V112, P1015, DOI 10.1111/j.1471-4159.2009.06514.x; Mihaescu A, 2010, BRIT J SURG, V97, P226, DOI 10.1002/bjs.6811; Mirzapoiazova T, 2011, AM J RESP CELL MOL, V44, P40, DOI 10.1165/rcmb.2009-0197OC; Padmanabhan J, 1998, NEUROCHEM RES, V23, P377, DOI 10.1023/A:1022413718447; Park SY, 2010, KOREAN J PHYSIOL PHA, V14, P29, DOI 10.4196/kjpp.2010.14.1.29; Parker JC, 2000, J APPL PHYSIOL, V89, P2241; Ranaivo HR, 2010, EXP NEUROL, V226, P310, DOI 10.1016/j.expneurol.2010.09.005; Ranaivo HR, 2010, BRAIN RES, V1313, P222, DOI 10.1016/j.brainres.2009.11.063; Reynoso R, 2007, SHOCK, V28, P589, DOI 10.1097/SHK.0b013c31804d415f; Rossi JL, 2007, AM J PHYSIOL-LUNG C, V292, pL1327, DOI 10.1152/ajplung.00380.2006; Schmidt OI., 2004, EUR J TRAUMA, V30, P135, DOI [10.1007/s00068-004-1394-9, DOI 10.1007/S00068-004-1394-9]; Shen QA, 2010, CARDIOVASC RES, V87, P272, DOI 10.1093/cvr/cvq144; Sinpitaksakul SN, 2008, BIOCHEM BIOPH RES CO, V371, P713, DOI 10.1016/j.bbrc.2008.04.128; Somera-Molina KC, 2007, EPILEPSIA, V48, P1785, DOI 10.1111/j.1528-1167.2007.01135.x; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; Wainwright MS, 2003, P NATL ACAD SCI USA, V100, P6233, DOI 10.1073/pnas.1031595100; Wang FJ, 2005, AM J PATHOL, V166, P409, DOI 10.1016/S0002-9440(10)62264-X; Yu CG, 2010, J NEUROCHEM, V113, P131, DOI 10.1111/j.1471-4159.2010.06579.x; YURCHENCO PD, 1990, FASEB J, V4, P1577	38	27	29	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JUN	2011	89	6					852	861		10.1002/jnr.22600			10	Neurosciences	Neurosciences & Neurology	749OI	WOS:000289477500008	21360574	Green Accepted			2021-06-18	
J	Oda, Y; Gao, GY; Wei, EP; Povlishock, JT				Oda, Yasutaka; Gao, Guoyi; Wei, Enoch P.; Povlishock, John T.			Combinational therapy using hypothermia and the immunophilin ligand FK506 to target altered pial arteriolar reactivity, axonal damage, and blood-brain barrier dysfunction after traumatic brain injury in rat	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						amyloid precursor protein; blood-brain barrier; brain arteriolar reactivity; diffuse axonal injury; hypothermia; immunosuppressant	POSTTRAUMATIC HYPOTHERMIA; HEAD-INJURY; ISCHEMIA; MODEL; CONSEQUENCES; ENDOTHELIUM; TACROLIMUS; CHILDREN; PROTECTS; SYSTEM	This study evaluated the utility of combinational therapy, coupling delayed posttraumatic hypothermia with delayed FK506 administration, on altered cerebral vascular reactivity, axonal injury, and blood-brain barrier (BBB) disruption seen following traumatic brain injury (TBI). Animals were injured, subjected to various combinations of hypothermic/FK506 intervention, and equipped with cranial windows to assess pial vascular reactivity to acetylcholine. Animals were then processed with antibodies to the amyloid precursor protein and immunoglobulin G to assess axonal injury and BBB disruption, respectively. Animals were assigned to five groups: (1) sham injury plus delayed FK506, (2) TBI, (3) TBI plus delayed hypothermia, (4) TBI plus delayed FK506, and (5) TBI plus delayed hypothermia with FK506. Sham injury plus FK506 had no impact on vascular reactivity, axonal injury, or BBB disruption. Traumatic brain injury induced dramatic axonal injury and altered pial vascular reactivity, while triggering local BBB disruption. Delayed hypothermia or FK506 after TBI provided limited protection. However, TBI with combinational therapy achieved significantly enhanced vascular and axonal protection, with no BBB protection. This study shows the benefits of combinational therapy, using posttraumatic hypothermia with FK506 to attenuate important features of TBI. This suggests that hypothermia not only protects but also extends the therapeutic window for improved FK506 efficacy. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 1143-1154; doi: 10.1038/jcbfm.2010.208; published online 15 December 2010	[Oda, Yasutaka; Gao, Guoyi; Wei, Enoch P.; Povlishock, John T.] Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, Richmond, VA 23298 USA; [Oda, Yasutaka] Yamaguchi Univ, Adv Med Emergency & Crit Care Ctr, Yamaguchi, Japan; [Gao, Guoyi] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Neurosurg, Shanghai 200030, Peoples R China	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD 055813, NS 057175]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS057175] Funding Source: NIH RePORTER	This study is supported by NIH grants HD 055813 and NS 057175.	Bacher A, 1998, ANESTHESIOLOGY, V88, P403, DOI 10.1097/00000542-199802000-00019; Baranova AI, 2008, J NEUROSURG, V109, P502, DOI 10.3171/JNS/2008/109/9/0502; Bayir H, 2009, CRIT CARE MED, V37, P689, DOI 10.1097/CCM.0b013e318194abf2; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Dietrich WD, 2009, J NEUROTRAUM, V26, P301, DOI 10.1089/neu.2008.0806; ELLISON MD, 1990, J NEUROIMMUNOL, V28, P249, DOI 10.1016/0165-5728(90)90018-I; Furuichi Y, 2003, J CEREBR BLOOD F MET, V23, P1183, DOI 10.1097/01.WCB.0000088761.02615.EB; Gao GY, 2010, J CEREBR BLOOD F MET, V30, P628, DOI 10.1038/jcbfm.2009.235; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HUTCHISON JS, N ENGL J MED, V358, P2447; Jiang JY, 2009, J NEUROTRAUM, V26, P399, DOI 10.1089/neu.2008.0525; Kawai N, 2000, J NEUROTRAUM, V17, P193, DOI 10.1089/neu.2000.17.193; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KONTOS HA, 1988, AM J PHYSIOL, V255, pH1259; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Namgaladze D, 2005, BIOCHEM BIOPH RES CO, V334, P1061, DOI 10.1016/j.bbrc.2005.07.003; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nito C, 2004, BRAIN RES, V1008, P179, DOI 10.1016/j.brainres.2004.02.031; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Povlishock JT, 2009, J NEUROTRAUM, V26, P333, DOI 10.1089/neu.2008.0604; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Sasakawa T, 2005, CYTOKINE, V29, P67, DOI 10.1016/j.cyto.2004.04.006; Sasaki T, 2004, BRAIN RES, V1009, P34, DOI 10.1016/j.brainres.2004.01.088; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Thomale UW, 2007, IMMUNOBIOLOGY, V212, P567, DOI 10.1016/j.imbio.2007.01.007; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; Ueda Y, 2003, J NEUROSURG, V99, P899, DOI 10.3171/jns.2003.99.5.0899; Wei EP, 2009, J NEUROTRAUM, V26, P527, DOI 10.1089/neu.2008.0797; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95	37	27	30	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2011	31	4					1143	1154		10.1038/jcbfm.2010.208			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	744AQ	WOS:000289064500017	21157473	Green Published, Bronze			2021-06-18	
J	Tazarourte, K; Atchabahian, A; Tourtier, JP; David, JS; Ract, C; Savary, D; Monchi, M; Vigue, B				Tazarourte, K.; Atchabahian, A.; Tourtier, J. -P.; David, J. -S.; Ract, C.; Savary, D.; Monchi, M.; Vigue, B.			Pre-hospital transcranial Doppler in severe traumatic brain injury: a pilot study	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							SEVERE HEAD-INJURY; BLOOD-FLOW; HYPOTENSION; ULTRASOUND; MODERATE; MANAGEMENT; ADMISSION; DIAGNOSIS	Background Investigation of the feasibility and usefulness of pre-hospital transcranial Doppler (TCD) to guide early goal-directed therapy following severe traumatic brain injury (TBI). Methods Prospective, observational study of 18 severe TBI patients during pre-hospital medical care. TCD was performed to estimate cerebral perfusion in the field and upon arrival at the Level 1 trauma centre. Specific therapy (mannitol, noradrenaline) aimed at improving cerebral perfusion was initiated if the initial TCD was abnormal (defined by a pulsatility index > 1.4 and low diastolic velocity). Results Nine patients had a normal initial TCD and nine an abnormal one, without a significant difference between groups in terms of the Glasgow Coma Scale or the mean arterial pressure. Among patients with an abnormal TCD, four presented with an initial areactive bilateral mydriasis. Therapy normalized TCD in five patients, with reversal of the initial mydriasis in two cases. Among these five patients for whom TCD was corrected, only two died within the first 48 h. All four patients for whom the TCD could not be corrected during transport died within 48 h. Only patients with an initial abnormal TCD required emergent neurosurgery (3/9). Mortality at 48 h was significantly higher for patients with an initial abnormal TCD. Conclusions Our preliminary study suggests that TCD could be used in pre-hospital care to detect patients whose cerebral perfusion may be impaired.	[Tazarourte, K.; Tourtier, J. -P.; David, J. -S.; Savary, D.; Monchi, M.] Hop Marc Jacquet, Serv Aide Med Urgente SAMU 77, F-77000 Melun, France; [Tazarourte, K.; Ract, C.; Vigue, B.] Univ Paris 11, Hop Bicetre, AP HP, Dept Anesthesie Reanimat, Le Kremlin Bicetre, France; [Atchabahian, A.] NYU, Med Ctr, Dept Anesthesiol, New York, NY 10016 USA	Tazarourte, K (corresponding author), Hop Marc Jacquet, Serv Aide Med Urgente SAMU 77, F-77000 Melun, France.	karim.tazarourte@ch-melun.fr	David, Jean Stephane/H-9399-2019	David, Jean Stephane/0000-0001-6274-7044; Hertling, Arthur/0000-0002-1634-6538; tazarourte, karim/0000-0002-3376-1258			Bouhours G, 2008, ANN FR ANESTH, V27, P397, DOI 10.1016/j.annfar.2008.02.015; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BRATTON SL, 2007, J NEUROTRAUM, V27, pS1; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; CZOSNYKA M, 1994, NEUROSURGERY, V35, P287, DOI 10.1227/00006123-199408000-00015; DeWitt D S, 1995, New Horiz, V3, P376; Ducrocq X, 1998, J NEUROL SCI, V159, P145, DOI 10.1016/S0022-510X(98)00158-0; Geeraerts T, 2008, INTENS CARE MED, V34, P551, DOI 10.1007/s00134-007-0863-0; Holscher T, 2008, CEREBROVASC DIS, V26, P659, DOI 10.1159/000166844; Hukkelhoven CWPM, 2005, INTENS CARE MED, V31, P799, DOI 10.1007/s00134-005-2628-y; Jaffres P, 2005, INTENS CARE MED, V31, P785, DOI 10.1007/s00134-005-2630-4; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kirkpatrick PJ, 2007, HEAD INJURY, P243; Klemen P, 2006, ACTA ANAESTH SCAND, V50, P1250, DOI 10.1111/J.1399-6576.2006.01039.X; Lapostolle F, 2006, AM J EMERG MED, V24, P237, DOI 10.1016/j.ajem.2005.07.010; McQuire JC, 1998, J NEUROSURG, V89, P526, DOI 10.3171/jns.1998.89.4.0526; Ract C, 2007, INTENS CARE MED, V33, P645, DOI 10.1007/s00134-007-0558-6; Rouxel JPM, 2004, ANN FR ANESTH, V23, P6, DOI 10.1016/j.annfar.2003.09.021; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Svenson J, 2008, AM J EMERG MED, V26, P465, DOI 10.1016/j.ajem.2007.05.013; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; Vigue B, 1999, INTENS CARE MED, V25, P445, DOI 10.1007/s001340050878	24	27	27	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2011	55	4					422	428		10.1111/j.1399-6576.2010.02372.x			7	Anesthesiology	Anesthesiology	733FS	WOS:000288249200008	21288224				2021-06-18	
J	Berthet, C; Lei, HX; Gruetter, R; Hirt, L				Berthet, Carole; Lei, Hongxia; Gruetter, Rolf; Hirt, Lorenz			Early Predictive Biomarkers for Lesion After Transient Cerebral Ischemia	STROKE			English	Article						biological markers; magnetic resonance spectroscopy; middle cerebral artery occlusion; transient ischemic attack; stroke	MAGNETIC-RESONANCE-SPECTROSCOPY; TRAUMATIC BRAIN-INJURY; N-ACETYL ASPARTATE; MR SPECTROSCOPY; ARTERY OCCLUSION; MOUSE-BRAIN; BLOOD-FLOW; ECHO-TIME; STROKE; TAURINE	Background and Purpose-Despite the improving imaging techniques, it remains challenging to predict the outcome early after transient cerebral ischemia. The aim of this study was thus to identify early metabolic biomarkers for outcome prediction. Methods-We modeled transient ischemic attacks and strokes in mice. Using high-field MR spectroscopy, we correlated early changes in the neurochemical profile of the ischemic striatum with histopathologic alterations at a later time point. Results-A significant increase in glutamine was measured between 3 hours and 8 hours after all ischemic events followed by reperfusion independently of the outcome and can thus be considered as an indicator of recent transient ischemia. On the other hand, a reduction of the score obtained by summing the concentrations of N-acetyl aspartate, glutamate, and taurine was a good predictor of an irreversible lesion as early as 3 hours after ischemia. Conclusions-We identified biomarkers of reversible and irreversible ischemic damage, which can be used in an early predictive evaluation of stroke outcome. (Stroke. 2011;42:799-805.)	[Lei, Hongxia; Gruetter, Rolf] Ecole Polytech Fed Lausanne, Lab Funct & Metab Imaging, CH-1015 Lausanne, Switzerland; [Berthet, Carole; Hirt, Lorenz] CHU Vaudois, Dept Clin Neurosci, CH-1011 Lausanne, Switzerland; [Lei, Hongxia; Gruetter, Rolf] Univ Lausanne, Dept Radiol, Lausanne, Switzerland; [Gruetter, Rolf] Univ Geneva, Dept Radiol, Geneva, Switzerland	Lei, HX (corresponding author), Ecole Polytech Fed Lausanne, Lab Funct & Metab Imaging, CH-1015 Lausanne, Switzerland.	hongxia.lei@epfl.ch	Gruetter, Rolf/H-6260-2011; Hirt, Lorenz/G-3553-2010	Gruetter, Rolf/0000-0003-1870-4025; Hirt, Lorenz/0000-0002-2921-5000; Lei, Hongxia/0000-0002-4065-9331	Centre d'Imagerie BioMedicale of the University of Lausanne (UNIL); University of Geneva (UNIGE); Hopital universitaire de Geneve (HUG); Centre Hospitalier Universtaire Vaudois (CHUV); Ecole Polytechnique Federale de Lausanne (EPFL); Leenaards, Jeantet and Gianni Biaggi de Blasys Foundations	This work was supported by the Centre d'Imagerie BioMedicale of the University of Lausanne (UNIL), University of Geneva (UNIGE), Hopital universitaire de Geneve (HUG), Centre Hospitalier Universtaire Vaudois (CHUV), and Ecole Polytechnique Federale de Lausanne (EPFL); and the Leenaards, Jeantet and Gianni Biaggi de Blasys Foundations.	Bisschops RHC, 2002, STROKE, V33, P110, DOI 10.1161/hs0102.100879; Brouns R, 2008, CLIN CHIM ACTA, V397, P27, DOI 10.1016/j.cca.2008.07.016; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; Cvoro V, 2009, STROKE, V40, P767, DOI 10.1161/STROKEAHA.108.525626; DECAVEL C, 1995, J COMP NEUROL, V354, P13, DOI 10.1002/cne.903540103; Easton JD, 2009, STROKE, V40, P2276, DOI 10.1161/STROKEAHA.108.192218; Federico F, 1998, ARCH NEUROL-CHICAGO, V55, P489, DOI 10.1001/archneur.55.4.489; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Frykholm P, 2005, J NEUROSURG, V102, P1076, DOI 10.3171/jns.2005.102.6.1076; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Giroud M, 1999, NEUROL RES, V21, P563, DOI 10.1080/01616412.1999.11740976; Gruetter R, 2000, MAGNET RESON MED, V43, P319, DOI 10.1002/(SICI)1522-2594(200002)43:2<319::AID-MRM22>3.0.CO;2-1; HENNIG J, 1988, J MAGN RESON, V78, P397, DOI 10.1016/0022-2364(88)90128-X; Hertz L, 2008, NEUROPHARMACOLOGY, V55, P289, DOI 10.1016/j.neuropharm.2008.05.023; Higuchi T, 1996, NEUROSURGERY, V38, P121, DOI 10.1097/00006123-199601000-00030; Hirt L, 2004, STROKE, V35, P1738, DOI 10.1161/01.STR.0000131480.03994.b1; Kidwell CS, 2000, ANN NEUROL, V47, P462, DOI 10.1002/1531-8249(200004)47:4<462::AID-ANA9>3.3.CO;2-P; KUNZ N, 2009, P INT SOC MAG RESON, P1378; Lei HX, 2009, J CEREBR BLOOD F MET, V29, P811, DOI 10.1038/jcbfm.2009.8; Liebeskind DS, 2009, ANN NEUROL, V66, P574, DOI 10.1002/ana.21787; Mekle R, 2009, MAGN RESON MED, V61, P1279, DOI 10.1002/mrm.21961; Mlynarik V, 2006, MAGN RESON MED, V56, P965, DOI 10.1002/mrm.21043; Mlynash M, 2009, NEUROLOGY, V72, P1127, DOI 10.1212/01.wnl.0000340983.00152.69; NAGELHUS EA, 1993, NEUROSCIENCE, V54, P615, DOI 10.1016/0306-4522(93)90233-6; Neumann-Haefelin T, 2000, STROKE, V31, P1965, DOI 10.1161/01.STR.31.8.1965; Pereira AC, 1999, STROKE, V30, P1577, DOI 10.1161/01.STR.30.8.1577; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Saenger AK, 2010, CLIN CHEM, V56, P21, DOI 10.1373/clinchem.2009.133801; Sager TN, 2000, J CEREBR BLOOD F MET, V20, P780, DOI 10.1097/00004647-200005000-00004; Sanak D, 2009, BIOMED PAP, V153, P181, DOI 10.5507/bp.2009.030; Saransaari P, 2010, AMINO ACIDS, V38, P739, DOI 10.1007/s00726-009-0278-z; Sicard KM, 2006, J CEREBR BLOOD F MET, V26, P1451, DOI 10.1038/sj.jcbfm.9600299; Tkac I, 1999, MAGNET RESON MED, V41, P649, DOI 10.1002/(SICI)1522-2594(199904)41:4<649::AID-MRM2>3.0.CO;2-G; van der Zwaag W, 2009, J MAGN RESON IMAGING, V30, P1171, DOI 10.1002/jmri.21951; Weber R, 2006, J CEREBR BLOOD F MET, V26, P591, DOI 10.1038/sj.jcbfm.9600241; Wintermark M, 2002, ANN NEUROL, V51, P417, DOI 10.1002/ana.10136	36	27	27	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	MAR	2011	42	3					799	805		10.1161/STROKEAHA.110.603647			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	723AW	WOS:000287479402019	21293024	Bronze, Green Published			2021-06-18	
J	Lee, S; Ueno, M; Yamashita, T				Lee, S.; Ueno, M.; Yamashita, T.			Axonal remodeling for motor recovery after traumatic brain injury requires downregulation of gamma-aminobutyric acid signaling	CELL DEATH & DISEASE			English	Article						axonal sprouting; compensatory recovery; corticospinal tract; GABA type A receptor; plasticity; traumatic brain injury	TEMPORAL-LOBE EPILEPSY; GABA(A) RECEPTOR; SPINAL-CORD; IN-VIVO; CORTICAL CIRCUITS; STROKE RECOVERY; MOUSE MODEL; PLASTICITY; INHIBITION; EXPRESSION	Remodeling of the remnant neuronal network after brain injury possibly mediates spontaneous functional recovery; however, the mechanisms inducing axonal remodeling during spontaneous recovery remain unclear. Here, we show that altered gamma-aminobutyric acid (GABA) signaling is crucial for axonal remodeling of the contralesional cortex after traumatic brain injury. After injury to the sensorimotor cortex in mice, we found a significant decrease in the expression of GABA(A)R-alpha 1 subunits in the intact sensorimotor cortex for 2 weeks. Motor functions, assessed by grid walk and cylinder tests, spontaneously improved in 4 weeks after the injury to the sensorimotor cortex. With motor recovery, corticospinal tract (CST) axons from the contralesional cortex sprouted into the denervated side of the cervical spinal cord at 2 and 4 weeks after the injury. To determine the functional implications of the changes in the expression of GAB(A)AR-alpha 1 subunits, we infused muscimol, a GABA R agonist, into the contralesional cortex for a week after the injury. Compared with the vehicle-treated mice, we noted significantly inhibited recovery in the muscimol-treated mice. Further, muscimol infusion greatly suppressed the axonal sprouting into the denervated side of the cervical spinal cord. In conclusion, recovery of motor function and axonal remodeling of the CST following cortical injury requires suppressed GABA(A)R subunit expression and decreased GABAergic signaling. Cell Death and Disease (2011) 2, e133; doi: 10.1038/cddis.2011.16; published online 17 March 2011	[Lee, S.; Ueno, M.; Yamashita, T.] Osaka Univ, Grad Sch Med, Dept Mol Neurosci, Suita, Osaka 5650871, Japan; [Lee, S.; Ueno, M.; Yamashita, T.] Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; [Ueno, M.; Yamashita, T.] CREST, JST, Chiyoda Ku, Tokyo 1020075, Japan	Yamashita, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yamashita@molneu.med.osaka-u.ac.jp	Ueno, Masaki/J-1216-2019	Yamashita, Toshihide/0000-0003-4559-7018	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [21700381] Funding Source: KAKEN	This work was supported by a Grant-in-Aid for Young Scientists (S) from the Japan Society for the Promotion of Science.	Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Benowitz LI, 2010, NEUROBIOL DIS, V37, P259, DOI 10.1016/j.nbd.2009.11.009; Biernaskie J, 2004, J NEUROSCI, V24, P1245, DOI 10.1523/JNEUROSCI.3834-03.2004; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Brown CE, 2007, J NEUROSCI, V27, P4101, DOI 10.1523/JNEUROSCI.4295-06.2007; Brown CE, 2009, J NEUROSCI, V29, P1719, DOI 10.1523/JNEUROSCI.4249-08.2009; Cramer SC, 2006, EXP BRAIN RES, V168, P25, DOI 10.1007/s00221-005-0082-2; Devaud LL, 1997, J NEUROCHEM, V69, P126; Farrant M, 2005, NAT REV NEUROSCI, V6, P215, DOI 10.1038/nrn1625; Hata K, 2006, J CELL BIOL, V173, P47, DOI 10.1083/jcb.200508143; Hensch TK, 2005, NAT REV NEUROSCI, V6, P877, DOI 10.1038/nrn1787; Hu YH, 2008, J BIOL CHEM, V283, P9328, DOI 10.1074/jbc.M705110200; Hua JY, 2005, NATURE, V434, P1022, DOI 10.1038/nature03409; Hurley LM, 2008, J NEUROPHYSIOL, V100, P1656, DOI 10.1152/jn.90536.2008; Jacob TC, 2008, NAT REV NEUROSCI, V9, P331, DOI 10.1038/nrn2370; Katagiri H, 2007, NEURON, V53, P805, DOI 10.1016/j.neuron.2007.02.026; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Klausberger T, 2002, J NEUROSCI, V22, P2513, DOI 10.1523/JNEUROSCI.22-07-02513.2002; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Lenzlinger PM, 2005, NEUROSCIENCE, V134, P1047, DOI 10.1016/j.neuroscience.2005.04.048; Lund IV, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1162396; Maier IC, 2008, J NEUROSCI, V28, P9386, DOI 10.1523/JNEUROSCI.1697-08.2008; Martin JH, 1999, EXP BRAIN RES, V125, P184, DOI 10.1007/s002210050673; MONTPIED P, 1993, MOL BRAIN RES, V18, P267, DOI 10.1016/0169-328X(93)90199-Y; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Omoto S, 2010, J NEUROSCI, V30, P13045, DOI 10.1523/JNEUROSCI.3228-10.2010; Ono T, 2003, J NEUROSCI, V23, P5887; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Peng ZC, 2004, J NEUROSCI, V24, P8629, DOI 10.1523/JNEUROSCI.2877-04.2004; Pronichev I V, 1998, Neurosci Behav Physiol, V28, P80, DOI 10.1007/BF02461916; Redecker C, 2000, J NEUROSCI, V20, P5045; Redecker C, 2002, J CEREBR BLOOD F MET, V22, P1463, DOI 10.1097/01.WCB.0000034149.72481.BD; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; Ruthazer ES, 2003, SCIENCE, V301, P66, DOI 10.1126/science.1082545; Schiene K, 1996, J CEREBR BLOOD F MET, V16, P906, DOI 10.1097/00004647-199609000-00014; Shen H, 2010, SCIENCE, V327, P1515, DOI 10.1126/science.1184245; Uesaka N, 2005, J NEUROSCI, V25, P1, DOI 10.1523/JNEUROSCI.3855-04.2005; Whiting PJ, 2003, DRUG DISCOV TODAY, V8, P445, DOI 10.1016/S1359-6446(03)02703-X; Witte OW, 1998, CURR OPIN NEUROL, V11, P655, DOI 10.1097/00019052-199812000-00008	40	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	MAR	2011	2								e133	10.1038/cddis.2011.16			8	Cell Biology	Cell Biology	742UE	WOS:000288969700010	21412279	DOAJ Gold, Green Published			2021-06-18	
J	Perez-Barcena, J; Ibanez, J; Brell, M; Crespi, C; Frontera, G; Llompart-Pou, JA; Homar, J; Abadal, JM				Perez-Barcena, Jon; Ibanez, Javier; Brell, Marta; Crespi, Catalina; Frontera, Guiem; Antonio Llompart-Pou, Juan; Homar, Javier; Maria Abadal, Josep			Lack of correlation among intracerebral cytokines, intracranial pressure, and brain tissue oxygenation in patients with traumatic brain injury and diffuse lesions	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; head trauma; microdialysis; cytokines; inflammation	TUMOR-NECROSIS-FACTOR; ACUTE-PHASE RESPONSE; CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; CEREBRAL MICRODIALYSIS; INTERLEUKIN-6 LEVELS; NERVOUS-SYSTEM; MESSENGER-RNA; INFLAMMATION; CATHETERS	Objectives: To determine the evolution of cytokine patterns using microdialysis in patients with traumatic brain injury with diffuse lesions and to study the relationship between cytokines and intracranial pressure, brain tissue oxygenation and lesion type on the computed cranial tomography scan (patients with and without brain swelling). Design: Prospective and observational study. Setting: Third-level university hospital. Patients: Patients between 15 and 65 yrs with severe traumatic brain injury and a diffuse lesion requiring intracranial pressure and brain tissue oxygenation monitoring were eligible. Interventions: Microdialysis catheters with a high-cutoff membrane of 100 kDa were inserted. Results: Sixteen patients were included in the analysis. There was a substantial interindividual variability between cytokine values. The highest concentrations for the interleukin-1 beta, interleukin-6, and interleukin-8 were measured during the first 24 hrs followed by a gradual decline. The average concentration for interleukin-10 did not vary over time. This pattern is the most frequent in patients with traumatic brain injury with diffuse lesions. The intracranial pressure-cytokines correlation coefficients for the 16 patients varied substantially: interleukin-1 beta-intracranial pressure (-0.76 to 0.63); interleukin-6 -intracranial pressure (-0.83 to 0.78); interleukin-8 -intracranial pressure (-0.86 to 0.84); and interleukin-10 -intracranial pressure (-0.36 to 0.65). The brain tissue oxygenation-cytokine correlation coefficients, like with intracranial pressure, also varied between patients: interleukin-1 beta-brain tissue oxygenation (-0.49 to 0.68), interleukin-6-brain tissue oxygenation (-0.99 to 0.84); interleukin-8-brain tissue oxygenation (-0.65 to 0.74); and interleukin-10-brain tissue oxygenation (-0.34 to 0.52). Similarly, we found no difference in the cytokine values inpatient microdialysis with and without swelling in the computed tomographic scan. Conclusions: No clear relationship was found between the temporal pattern of cytokines and the behavior of the intracranial pressure, brain tissue oxygenation, and the presence or absence of swelling in the computed tomography scan. This study demonstrates the feasibility of microdialysis in recovering cytokines for a prolonged time, although there may be some nonresolved methodologic problems with this technique when we try to study the inflammation during traumatic brain injury that could affect the results and make interpretation of microdialysis data prone to difficulties. (Crit Care Med 2011; 39: 533-540)	[Perez-Barcena, Jon; Antonio Llompart-Pou, Juan; Homar, Javier; Maria Abadal, Josep] Son Dureta Univ Hosp, Intens Care Unit Dept, Palma De Mallorca, Spain; [Ibanez, Javier; Brell, Marta] Son Dureta Univ Hosp, Dept Neurosurg, Palma De Mallorca, Spain; [Crespi, Catalina; Frontera, Guiem] Son Dureta Univ Hosp, Invest Unit, Palma De Mallorca, Spain	Perez-Barcena, J (corresponding author), Son Dureta Univ Hosp, Intens Care Unit Dept, Palma De Mallorca, Spain.	juan.perez@ssib.es	Crespi, Catalina/A-5543-2013	Crespi, Catalina/0000-0003-0781-9708; Ibanez, Javier/0000-0003-3735-8332	Spanish government's Fondo de Investigacion SanitariaInstituto de Salud Carlos III [FIS PI070307]	This research was supported by a public grant from the Spanish government's Fondo de Investigacion Sanitaria (FIS PI070307) awarded to J.P.B. This public institution will not gain or lose financially from the publication of this manuscript in any way.	Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Brain Trauma Foundation; American Association of Neurological Surgeons, 2007, J NEUROTRAUM, V24, pS71, DOI [10.1089/neu.2007.9985, DOI 10.1089/NEU.2007.9985]; Cohen D, 1991, J LAB CLIN MED, V118, P225; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; ENG LF, 1988, BIOCH PATHOLOGY ASTR, P79; FAN L, 1995, MOL BRAIN RES, V30, P125; Folkersma H, 2008, ACTA NEUROCHIR, V150, P1277, DOI 10.1007/s00701-008-0151-y; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Hans VHJ, 1999, NEUROREPORT, V10, P409; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; Mellergard P, 2008, NEUROSURGERY, V62, P151, DOI 10.1227/01.NEU.0000311072.33615.3A; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nelson DW, 2004, CRIT CARE MED, V32, P2428, DOI 10.1097/01.CCM.0000147688.08813.9C; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; O'CALLAGHAN J P, 1991, Biomedical and Environmental Sciences, V4, P197; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PERRY VH, 1991, INT REV CYTOL, V125, P203, DOI 10.1016/S0074-7696(08)61220-6; Poca MA, 2006, J NEUROTRAUM, V23, P1510, DOI 10.1089/neu.2006.23.1510; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Unterberg AW, 1997, ACT NEUR S, V70, P106; Waelgaard L, 2006, SCAND J IMMUNOL, V64, P345, DOI 10.1111/j.1365-3083.2006.01826.x; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Winter CD, 2002, J NEUROSCI, V119, P315; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	43	27	28	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2011	39	3					533	540		10.1097/CCM.0b013e318205c7a4			8	Critical Care Medicine	General & Internal Medicine	723BB	WOS:000287480000016	21169825				2021-06-18	
J	Rughani, AI; Lin, CT; Ares, WJ; Cushing, DA; Horgan, MA; Tranmer, BI; Jewell, RP; Florman, JE				Rughani, Anand I.; Lin, Chih-Ta; Ares, William J.; Cushing, Deborah A.; Horgan, Michael A.; Tranmer, Bruce I.; Jewell, Ryan P.; Florman, Jeffrey E.			Helmet use and reduction in skull fractures in skiers and snowboarders admitted to the hospital Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						helmet use; skiing; skull fracture; snowboarding; traumatic brain injury	HEAD-INJURIES; SKIING INJURIES; SAFETY HELMETS; RISK; CHILDREN; SLOPES; WEAR	Object. Helmet use has been associated with fewer hospital visits among injured skiers and snowboarders, but there remains no evidence that helmets alter the intracranial injury patterns. The authors hypothesized that helmet use among skiers and snowboarders reduces the incidence of head injury as defined by findings on head CT scans. Methods. The authors performed a retrospective review of head-injured skiers and snowboarders at 2 Level I trauma centers in New England over a 6-year period. The primary outcome of interest was intracranial injury evident on CT scans. Secondary outcomes included the following: need for a neurosurgical procedure, presence of spine injury, need for ICU admission, length of stay, discharge location, and death. Results. Of the 57 children identified who sustained a head injury while skiing or snowboarding, 33.3% were wearing a helmet at the time of injury. Of the helmeted patients, 5.3% sustained a calvarial fracture compared with 36.8% of the unhelmeted patients (p = 0.009). Although there was a favorable trend, there was no significant difference in the incidence of epidural hematoma, subdural hematoma, intraparenchymal hemorrhage, subarachnoid hemorrhage, or contusion in helmeted and unhelmeted patients. With regard to secondary outcomes, there were no significant differences between the 2 groups in percentage of patients requiring neurosurgical intervention, percentage requiring admission to an ICU, total length of stay, or percentage discharged home. There was no difference in the incidence of cervical spine injury. There was 1 death in an unhelmeted patient, and there were no deaths among helmeted patients. Conclusions. Among hospitalized children who sustained a head injury while skiing or snowboarding, a significantly lower number of patients suffered a skull fracture if they were wearing helmets at the time of the injury. (DOI: 10.3171/2010.12.PEDS10415)	[Rughani, Anand I.; Lin, Chih-Ta; Horgan, Michael A.; Tranmer, Bruce I.; Jewell, Ryan P.] Univ Vermont, Div Neurosurg, Burlington, VT 05401 USA; [Ares, William J.] Univ Vermont, Coll Med, Burlington, VT 05401 USA; [Cushing, Deborah A.; Florman, Jeffrey E.] Maine Med Ctr, Inst Neurosci, Portland, ME 04102 USA	Rughani, AI (corresponding author), Univ Vermont, Div Neurosurg, 111 Colchester Ave,Fletcher 507, Burlington, VT 05401 USA.	anand.rughani@mail.mcgill.ca					Buller DB, 2003, J TRAUMA, V55, P939, DOI 10.1097/01.TA.0000078694.53320.CA; Cusimano MD, 2010, BRIT J SPORT MED, V44, P781, DOI 10.1136/bjsm.2009.070573; Cusimano MD, 2010, JAMA-J AM MED ASSOC, V303, P661, DOI 10.1001/jama.2010.147; Fukuda O, 2001, AM J SPORT MED, V29, P437, DOI 10.1177/03635465010290040901; FURRER M, 1995, J TRAUMA, V39, P737, DOI 10.1097/00005373-199510000-00024; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Lawrence L, 2008, PEDIATR EMERG CARE, V24, P219, DOI 10.1097/PEC.0b013e31816a9f0a; Levy AS, 2002, J TRAUMA, V53, P695, DOI 10.1097/00005373-200210000-00013; Machold W, 2000, J TRAUMA, V48, P1109, DOI 10.1097/00005373-200006000-00018; Macnab AJ, 2002, INJURY PREV, V8, P324, DOI 10.1136/ip.8.4.324; McBeth PB, 2009, AM J SURG, V197, P560, DOI [10.1016/j.amjsurg.2008.12.016, 10.1016/j.amjsurg.2008.08.010]; MORROW PL, 1988, J TRAUMA, V28, P95, DOI 10.1097/00005373-198801000-00014; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Nakaguchi H, 2002, J NEUROSURG, V97, P542, DOI 10.3171/jns.2002.97.3.0542; Ruedl G, 2010, BRIT J SPORT MED, V44, P204, DOI 10.1136/bjsm.2009.066779; Russell K, 2010, CAN MED ASSOC J, V182, P333, DOI 10.1503/cmaj.091080; Scott MD, 2007, INJURY PREV, V13, P173, DOI 10.1136/ip.2006.014142; Shorter NA, 1996, J TRAUMA, V40, P997, DOI 10.1097/00005373-199606000-00024; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; Wasden CC, 2009, J TRAUMA, V67, P1022, DOI 10.1097/TA.0b013e3181b0d559	20	27	27	0	12	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707			J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	MAR	2011	7	3					268	271		10.3171/2010.12.PEDS10415			4	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	725WE	WOS:000287676800011	21361765				2021-06-18	
J	Steel, JL; Dunlavy, AC; Stillman, J; Pape, HC				Steel, Jennifer L.; Dunlavy, Andrea C.; Stillman, Jessica; Pape, Hans Christoph			Measuring depression and PTSD after trauma: Common scales and checklists	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Traumatic injury; Depression; PTSD; Measurement	POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; BRAIN-INJURY; MAJOR DEPRESSION; PSYCHOMETRIC PROPERTIES; MENTAL-HEALTH; SELF-REPORT; CULTURAL-DIFFERENCES; OUTCOMES MEASUREMENT; CIVILIAN VERSION	Traumatic injury is an important public health problem secondary to high levels of morbidity and mortality. Injured survivors face several physical, emotional, and financial repercussions that can significantly impact their lives as well as their family. Depression and posttraumatic stress disorder ( PTSD) are the most common psychiatric sequelae associated with traumatic injury. Factors affecting the prevalence of these psychiatric symptoms include: concomitant TBI, the timing of assessment of depression and PTSD, the type of injury, premorbid, sociodemographic, and cultural factors, and comorbid medical conditions and medication side effects. The appropriate assessment of depression and PTSD is critical to an understanding of the potential consequences of these disorders as well as the development of appropriate behavioural and pharmacological treatments. The reliability and validity of screening instruments and structured clinical interviews used to assess depression and PTSD must be considered. Common self-report instruments and structured clinical interviews used to assess depression and PTSD and their reliability and validity are described. Future changes in diagnostic criteria for depression and PTSD and recent initiatives by the National Institute of Health regarding patient-reported outcomes may result in new methods of assessing these psychiatric sequelae of traumatic injury. (C) 2010 Elsevier Ltd. All rights reserved.	[Steel, Jennifer L.] Univ Pittsburgh, Sch Med, Starzl E Transplantat Inst, Dept Surg & Psychiat,Liver Canc Ctr, Pittsburgh, PA 15213 USA; [Dunlavy, Andrea C.; Stillman, Jessica] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA	Steel, JL (corresponding author), Univ Pittsburgh, Sch Med, Starzl E Transplantat Inst, Dept Surg & Psychiat,Liver Canc Ctr, 3459 5th Ave,Montefiore 7S, Pittsburgh, PA 15213 USA.	steeljl@upmc.edu		Pape, Hans-Christoph/0000-0002-2059-4980	 [NCI-5K07CA118576];  [NCI-R21CA127046-01A1];  [3K07CA118576-04S1]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R21CA127046, K07CA118576] Funding Source: NIH RePORTER	The following is the corresponding author's support and financial disclosure declaration: NCI-5K07CA118576; NCI-R21CA127046-01A1; 3K07CA118576-04S1.	Aben I, 2002, PSYCHOSOMATICS, V43, P386, DOI 10.1176/appi.psy.43.5.386; Akdemir A, 2001, COMPR PSYCHIAT, V42, P161, DOI 10.1053/comp.2001.19756; Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; *AM PSYCH ASS, 2000, HDB PSYCH MEAS; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Antony M.M., 2001, PRACTITIONERS GUIDE; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Bagby RM, 2004, AM J PSYCHIAT, V161, P2163, DOI 10.1176/appi.ajp.161.12.2163; Basco MR, 2000, AM J PSYCHIAT, V157, P1599, DOI 10.1176/appi.ajp.157.10.1599; Bay E, 2002, J NURS SCHOLARSHIP, V34, P221, DOI 10.1111/j.1547-5069.2002.00221.x; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Beck AT., 1996, BECK DEPRESSION INVE, V2; Beck JG, 2008, J ANXIETY DISORD, V22, P187, DOI 10.1016/j.janxdis.2007.02.007; Beck JG, 2009, J ANXIETY DISORD, V23, P443, DOI 10.1016/j.janxdis.2008.09.001; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; BLANCHARD EB, 1995, J NERVOUS MENTAL DIS; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; BREWIN CR, 2009, J TRAUMATIC STRESS; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2003, J TRAUMA STRESS, V16, P439, DOI 10.1023/A:1025750209553; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Caspi Y, 2005, J LOSS TRAUMA, V10, P319, DOI 10.1080/15325020590956756; Cella D, 2007, QUAL LIFE RES, V16, P133, DOI 10.1007/s11136-007-9204-6; Cella D, 2007, MED CARE, V45, pS3, DOI 10.1097/01.mlr.0000258615.42478.55; Centers for Disease Control, 2006, CDC INJ FACT BOOK; COMPTON WM, 2004, DIAGNOSTIC INTERVIEW; Coughlan AK, 1988, CLIN REHABIL, V2, P207, DOI DOI 10.1177/026921558800200305; Darnall BD, 2005, ARCH PHYS MED REHAB, V86, P650, DOI 10.1016/j.apmr.2004.10.028; DAVIDSON J, 1989, J NERV MENT DIS, V177, P336, DOI 10.1097/00005053-198906000-00003; Davidson J R, 1997, Depress Anxiety, V5, P127, DOI 10.1002/(SICI)1520-6394(1997)5:3<127::AID-DA3>3.0.CO;2-B; Davidson JRT, 1990, BIOL ASSESSMENT TREA, P205; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Ehring T, 2008, PSYCHIAT RES, V161, P67, DOI 10.1016/j.psychres.2007.08.014; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Foa EB, 1997, PSYCHOL ASSESSMENT; Fullerton CS, 2001, AM J PSYCHIAT, V158, P1486, DOI 10.1176/appi.ajp.158.9.1486; GABRYS JB, 1985, PSYCHOL REP, V57, P1091, DOI 10.2466/pr0.1985.57.3f.1091; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Goldberg DP, 1997, PSYCHOL MED, V27, P191, DOI 10.1017/S0033291796004242; Gray LB, 2009, CURR PSYCHIAT REP, V11, P106, DOI 10.1007/s11920-009-0017-x; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; HAMMARBERG M, 1992, PSYCHOL ASSESSMENT, V4, P67, DOI [10.1037/1040-3590.4.1.67, DOI 10.1037/1040-3590.4.1.67]; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Holbrook TL, 2001, J TRAUMA, V50, P270, DOI 10.1097/00005373-200102000-00012; Jackson C, 2007, OCCUP MED-OXFORD, V57, P79, DOI 10.1093/occmed/kql169; Jobson L, 2008, BRIT J CLIN PSYCHOL, V47, P95, DOI 10.1348/014466507X235953; Jones C, 2001, CRIT CARE MED, V29, P573, DOI 10.1097/00003246-200103000-00019; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Karasz A, 2005, SOC SCI MED, V60, P1625, DOI 10.1016/j.socscimed.2004.08.011; KEANE TM, 1988, J CONSULT CLIN PSYCH, V56, P85, DOI 10.1037/0022-006X.56.1.85; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Klein E, 2003, CAN J PSYCHIAT, V48, P28; Kulka RA, 1988, CONTRACTUAL REPORT F; Lauterbach D, 1997, J TRAUMA STRESS, V10, P499, DOI 10.1002/jts.2490100313; LAUTERBACH D, 1996, ASSESSMENT, V3, P17, DOI DOI 10.1177/107319119600300102; Lee PW, 2007, J AFFECT DISORDERS, V99, P139, DOI 10.1016/j.jad.2006.09.002; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Liossi C, 2009, J NEUROPSYCH CLIN N, V21, P43, DOI 10.1176/appi.neuropsych.21.1.43; Lowe B, 2005, J PSYCHOSOM RES, V58, P163, DOI 10.1016/j.jpsychores.2004.09.006; McCauley SR, 2006, BRAIN INJURY, V20, P519, DOI 10.1080/02699050600676651; McMillan TM, 2003, NEUROPSYCHOL REHABIL, V13, P149, DOI 10.1080/09602010244000453; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; Mellman TA, 2001, DEPRESS ANXIETY, V14, P226, DOI 10.1002/da.1071; Mendlowicz MV, 2000, AM J PSYCHIAT, V157, P669, DOI 10.1176/appi.ajp.157.5.669; MOLLICA RF, 1992, J NERV MENT DIS, V180, P111, DOI 10.1097/00005053-199202000-00008; Mollica RF, 2002, BRIT J PSYCHIAT, V181, P339, DOI 10.1192/bjp.181.4.339; Morris DW, 2007, J CLIN PSYCHIAT, V68, P1339, DOI 10.4088/JCP.v68n0903; *NORTH CENTR REG T, 2006, NAT TRAUM STAT; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P1390, DOI 10.1176/appi.ajp.161.8.1390; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Olatunji BO, 2007, CLIN PSYCHOL REV, V27, P572, DOI 10.1016/j.cpr.2007.01.015; Ouellet MC, 2009, J REHABIL MED, V41, P179, DOI 10.2340/16501977-0306; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; Pies RW, 2009, J AFFECT DISORDERS, V116, P1, DOI 10.1016/j.jad.2008.11.009; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Richter JC, 2006, PSYCHOSOMATICS, V47, P223, DOI 10.1176/appi.psy.47.3.223; Romans SE, 2008, J NERV MENT DIS, V196, P237, DOI 10.1097/NMD.0b013e318166350f; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; RYDER AG, 2005, CROSS CULTURAL DIFFE; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; Schotte CKW, 1996, PSYCHOL MED, V26, P1161, DOI 10.1017/S0033291700035881; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Shalev AY, 1997, BRIT J PSYCHIAT, V170, P558, DOI 10.1192/bjp.170.6.558; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; Snyder JJ, 2009, PSYCHIAT RES, V170, P256, DOI 10.1016/j.psychres.2008.11.008; Spitzer, 2004, STRUCTURED CLIN INTE; Spitzer RL, 2007, J ANXIETY DISORD, V21, P233, DOI 10.1016/j.janxdis.2006.09.006; Stahl S.M., 2000, ESSENTIAL PSYCHOPHAR; Strik JJMH, 2001, PSYCHOSOMATICS, V42, P423, DOI 10.1176/appi.psy.42.5.423; Turner-Stokes L, 2005, J NEUROL NEUROSUR PS, V76, P1273, DOI 10.1136/jnnp.2004.050096; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; VREVEN DL, 1995, J TRAUMA STRESS, V8, P91, DOI 10.1007/BF02105409; WATSON CG, 1994, J TRAUMA STRESS, V7, P75, DOI 10.1007/BF02111913; WATSON CG, 1991, J CLIN PSYCHOL, V47, P179, DOI 10.1002/1097-4679(199103)47:2<179::AID-JCLP2270470202>3.0.CO;2-P; Weathers F., 1994, PTSD RES Q, V5, P2, DOI DOI 10.1037/E572192010-003; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; WHO, 2010, DEPR; *WHO, 2010, INJ; WILSON JP, 2007, LENS CULTURE THEORET; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943	120	27	28	0	25	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	MAR	2011	42	3					288	300		10.1016/j.injury.2010.11.045			13	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	717CJ	WOS:000287019700012	21216400	Green Accepted			2021-06-18	
J	Tate, DF; Khedraki, R; Neeley, ES; Ryser, DK; Bigler, ED				Tate, David F.; Khedraki, Rola; Neeley, E. Shannon; Ryser, David K.; Bigler, Erin D.			Cerebral Volume Loss, Cognitive Deficit, and Neuropsychological Performance: Comparative Measures of Brain Atrophy: II. Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						MRI; TBI; Cognition; Atrophy; Brain/behavior relationships; CNS	ALZHEIMERS-DISEASE; HIPPOCAMPAL VOLUME; MRI; MEMORY; SCHIZOPHRENIA; IMPAIRMENT; DEMENTIA; MODERATE; CORTEX; AD	Traumatic brain injury (TB!) results in a variable degree of cerebral atrophy that is not always related to cognitive measures across studies. However, the use of different methods for examining atrophy may be a reason why differences exist. The purpose of this manuscript was to examine the predictive utility of seven magnetic resonance imaging (MRI) - derived brain volume or indices of atrophy for a large cohort of TBI patients (n = 65). The seven quantitative MRI (qMRI) measures included uncorrected whole brain volume, brain volume corrected by total intracranial volume, brain volume corrected by the ratio of the individual TICV by group TICV, a ventricle to brain ratio, total ventricular volume, ventricular volume corrected by TICV, and a direct measure of parenchymal volume loss. Results demonstrated that the various qMRI measures were highly interrelated and that corrected measures proved to be the most robust measures related to neuropsychological performance. Similar to an earlier study that examined cerebral atrophy in aging and dementia, these results suggest that a single corrected brain volume measure is all that is necessary in studies examining global MRI indicators of cerebral atrophy in relationship to cognitive function making additional measures of global atrophy redundant and unnecessary. (JINS, 2011, 17, 308-316)	[Tate, David F.] Boston Univ, Med Ctr, Alzheimers Dis Ctr, Boston, MA USA; [Tate, David F.; Neeley, E. Shannon] Brigham Young Univ, Dept Stat, Provo, UT 84602 USA; [Ryser, David K.] Intermt Med Ctr, Dept Phys Med & Rehabil, Murray, UT USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol & Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Tate, David F.; Khedraki, Rola] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Imaging, Boston, MA 02115 USA	Tate, DF (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Imaging, 1249 Boylston St,Room 345, Boston, MA 02115 USA.	dftatephd@mac.com	Tate, David F/I-3963-2013; Tate, David/G-5166-2011	Tate, David F/0000-0003-0213-1920; Tate, David/0000-0003-0213-1920; Khedraki, Rola/0000-0002-6334-923X	Deseret Foundation at LDS Hospital; Ira Fulton Foundation; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH073416] Funding Source: NIH RePORTER	Support for this study was provided by grants from the Deseret Foundation at LDS Hospital and the Ira Fulton Foundation. There are no financial and/or relationship conflicts of interest to disclose.	ARNDT S, 1991, PSYCHIAT RES-NEUROIM, V40, P79; Balthazar MLF, 2010, J INT NEUROPSYCH SOC, V16, P205, DOI 10.1017/S1355617709990956; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bergeson AG, 2004, CLIN NEUROPSYCHOL, V18, P509, DOI 10.1080/1385404049052414; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P442, DOI 10.1017/S1355617704103111; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, INVEST RADIOL, V36, P539, DOI 10.1097/00004424-200109000-00006; Bigler ED, 2000, AM J NEURORADIOL, V21, P1857; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Blinkov S. M., 1968, HUMAN BRAIN FIGURES; BRADLEY WG, 2000, NEUROIMAGING, P704; Brewer JB, 2009, BEHAV NEUROL, V21, P21, DOI [10.3233/BEN-2009-0226, 10.1155/2009/616581]; Cahn DA, 1998, J INT NEUROPSYCH SOC, V4, P106, DOI 10.1017/S1355617798001064; Carne RP, 2006, J CLIN NEUROSCI, V13, P60, DOI 10.1016/j.jocn.2005.02.013; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Courchesne E, 2000, RADIOLOGY, V216, P672, DOI 10.1148/radiology.216.3.r00au37672; DEKABAN AS, 1978, ANN NEUROL, V4, P345, DOI 10.1002/ana.410040410; Fama R, 2000, NEUROPSYCHOLOGY, V14, P29, DOI 10.1037/0894-4105.14.1.29; Fjell AM, 2009, J NEUROSCI, V29, P15223, DOI 10.1523/JNEUROSCI.3252-09.2009; Forstl H, 1996, BRIT J PSYCHIAT, V168, P280, DOI 10.1192/bjp.168.3.280; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Gur RE, 2000, ARCH GEN PSYCHIAT, V57, P769, DOI 10.1001/archpsyc.57.8.769; HAUG JO, 1962, ACTA PSYCHIAT SCAND, V165, P1; He J, 2009, ARCH NEUROL-CHICAGO, V66, P1393, DOI 10.1001/archneurol.2009.252; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Jack CR, 1998, NEUROLOGY, V51, P993, DOI 10.1212/WNL.51.4.993; Jack CR, 1999, NEUROLOGY, V52, P1397, DOI 10.1212/WNL.52.7.1397; JACK CR, 1995, MAGN RESON IMAGING, V13, P1057, DOI 10.1016/0730-725X(95)02013-J; Killiany RJ, 2000, ANN NEUROL, V47, P430, DOI 10.1002/1531-8249(200004)47:4<430::AID-ANA5>3.3.CO;2-9; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Loewenstein DA, 2009, AM J GERIAT PSYCHIAT, V17, P1050, DOI 10.1097/JGP.0b013e3181b7ef42; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; NELLHAUS G, 1968, PEDIATRICS, V41, P106; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Penna S, 2010, J HEAD TRAUMA REHAB, V25, P52, DOI 10.1097/HTR.0b013e3181c29952; Perry ME, 2009, NEUROPSYCHOLOGIA, V47, P2835, DOI 10.1016/j.neuropsychologia.2009.06.008; Peterson BS, 2000, JAMA-J AM MED ASSOC, V284, P1939, DOI 10.1001/jama.284.15.1939; RAZ N, 1988, PSYCHIAT RES, V26, P245, DOI 10.1016/0165-1781(88)90079-0; RAZ S, 1988, PSYCHIAT RES, V24, P71, DOI 10.1016/0165-1781(88)90142-4; Reiss AL, 1996, BRAIN, V119, P1763, DOI 10.1093/brain/119.5.1763; ROBB R, 1995, ANALYZE 3 DIMENSIONA; Robb RA, 2001, IEEE T MED IMAGING, V20, P854, DOI 10.1109/42.952724; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; SHEAR PK, 1995, ARCH NEUROL-CHICAGO, V52, P392, DOI 10.1001/archneur.1995.00540280078021; Smith CD, 2000, NEUROLOGY, V54, P838, DOI 10.1212/WNL.54.4.838; Tanabe JL, 1997, AM J NEURORADIOL, V18, P115; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Wilson RS, 1996, NEUROPSYCHOLOGY, V10, P459; Xu Y, 2000, NEUROLOGY, V54, P1760, DOI 10.1212/WNL.54.9.1760; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Zar J.H., 1996, BIOSTATISTICAL ANAL	52	27	27	0	3	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2011	17	2					308	316		10.1017/S1355617710001670			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	738DY	WOS:000288620900011	21352625				2021-06-18	
J	Murphy-Human, T; Welch, E; Zipfel, G; Diringer, MN; Dhar, R				Murphy-Human, Theresa; Welch, Emily; Zipfel, Gregory; Diringer, Michael N.; Dhar, Rajat			Comparison of Short-Duration Levetiracetam with Extended-Course Phenytoin for Seizure Prophylaxis After Subarachnoid Hemorrhage	WORLD NEUROSURGERY			English	Article						Levetiracetam; Phenytoin; Seizures; Subarachnoid hemorrhage	TRAUMATIC BRAIN-INJURY; CRITICALLY-ILL PATIENTS; INTRAVENOUS LEVETIRACETAM; ANTIEPILEPTIC DRUGS; EPILEPSY; TRIAL; TOLERABILITY; ANEURYSMS; EFFICACY; ONSET	BACKGROUND: The optimal regimen for seizure prophylaxis after subarachnoid hemorrhage (SAH) remains uncertain. Based on data suggesting that a short course may be adequate, coupled with an association between phenytoin exposure and poor cognitive outcome, our institution modified their seizure prophylaxis protocol for patients with SAH from an extended course of phenytoin to 3 days of levetiracetam. This study sought to compare the incidence of seizures before and after this change to evaluate whether a short course of levetiracetam would be as effective in preventing in-hospital seizures. METHODS: This study analyzed 442 consecutive patients admitted with SAH between January 2003 and January 2008, including 297 patients treated before the protocol change (PHT group) and 145 treated afterward (LEV group). Occurrence of all seizures was extracted from a prospectively collected intensive care unit database and further review of medical records. In-hospital seizures were divided into early (occurring on or before day 3, all patients on prophylaxis) and those occurring late (after day 3, LEV group off prophylaxis). RESULTS: In-hospital seizures occurred in 3.4% of the PHT group and 8.3% of the LEV group (P = 0.03). Although the rate of early seizures was not different (1.4% PHT vs. 2.8% LEV, P = 0.45), there was a higher rate of late seizures (2% PHT vs. 5.5% LEV, P = 0.05). CONCLUSIONS: The use of short-duration levetiracetam for seizure prophylaxis after SAH was associated with a higher rate of in-hospital seizures than an extended course of phenytoin, mainly related to an increase in late seizures, when the levetiracetam had been discontinued. This suggests that a longer duration of prophylaxis may be required to minimize seizures in patients with SAH, although confirmatory studies are required.	[Murphy-Human, Theresa; Welch, Emily] Barnes Jewish Hosp, Dept Pharm, St Louis, MO 63110 USA; [Zipfel, Gregory; Diringer, Michael N.; Dhar, Rajat] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Zipfel, Gregory; Diringer, Michael N.] Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO USA	Murphy-Human, T (corresponding author), Barnes Jewish Hosp, Dept Pharm, St Louis, MO 63110 USA.	txm5120@bjc.org	Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537; Dhar, Rajat/0000-0002-5167-5097			Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Buczacki SJ, 2004, J NEUROL NEUROSUR PS, V75, P1620, DOI 10.1136/jnnp.2003.026856; Butzkueven H, 2000, NEUROLOGY, V55, P1315, DOI 10.1212/WNL.55.9.1315; Cereghino JJ, 2000, NEUROLOGY, V55, P236, DOI 10.1212/WNL.55.2.236; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Chumnanvej S, 2007, NEUROSURGERY, V60, P99, DOI 10.1227/01.NEU.0000249207.66225.D9; Claassen J, 2005, J CLIN NEUROPHYSIOL, V22, P92, DOI 10.1097/01.WNP.0000145006.02048.3A; Claassen J, 2003, NEUROLOGY, V60, P208, DOI 10.1212/01.WNL.0000038906.71394.DE; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; HART RG, 1981, NEUROSURGERY, V8, P417, DOI 10.1227/00006123-198104000-00002; HASAN D, 1993, ANN NEUROL, V33, P286; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Knake S, 2008, J NEUROL NEUROSUR PS, V79, P588, DOI 10.1136/jnnp.2007.130260; LaRoche SM, 2004, JAMA-J AM MED ASSOC, V291, P615, DOI 10.1001/jama.291.5.615; LaRoche SM, 2004, JAMA-J AM MED ASSOC, V291, P605, DOI 10.1001/jama.291.5.605; Lim DA, 2009, J NEURO-ONCOL, V93, P349, DOI 10.1007/s11060-008-9781-4; Lin CL, 2003, J NEUROSURG, V99, P978, DOI 10.3171/jns.2003.99.6.0978; Lin YJ, 2008, EUR J NEUROL, V15, P451, DOI 10.1111/j.1468-1331.2008.02096.x; Liu KC, 2007, NEUROCRIT CARE, V7, P175, DOI 10.1007/s12028-007-0061-5; Milligan TA, 2008, NEUROLOGY, V71, P665, DOI 10.1212/01.wnl.0000324624.52935.46; Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5; Naidech AM, 2005, STROKE, V36, P583, DOI 10.1161/01.STR.0000141936.36596.1e; Newton HB, 2006, J NEURO-ONCOL, V78, P99, DOI 10.1007/s11060-005-9070-4; Pinto AN, 1996, J NEUROL, V243, P161, DOI 10.1007/BF02444009; Rhoney DH, 2000, NEUROLOGY, V55, P258, DOI 10.1212/WNL.55.2.258; ROSE FC, 1965, BRIT MED J, V1, P18, DOI 10.1136/bmj.1.5426.18; Rosengart AJ, 2007, J NEUROSURG, V107, P253, DOI 10.3171/JNS-07/08/0253; Ruegg S, 2008, EPILEPSY BEHAV, V12, P477, DOI 10.1016/j.yebeh.2008.01.004; Szaflarski JP, 2007, NEUROCRIT CARE, V7, P140, DOI 10.1007/s12028-007-0042-8; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; THOMSON T, 2007, COCHRANE DB SYST REV, V1; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; Zubkov Alexander Y, 2008, Rev Neurol Dis, V5, P178	35	27	30	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	FEB	2011	75	2					269	274		10.1016/j.wneu.2010.09.002			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	793JG	WOS:000292816700048	21492729				2021-06-18	
J	Tasker, RC; Fleming, TJ; Young, AE; Morris, KP; Parslow, RC				Tasker, Robert C.; Fleming, Thomas J.; Young, Amber Er; Morris, Kevin P.; Parslow, Roger C.			Severe head injury in children: intensive care unit activity and mortality in England and Wales	BRITISH JOURNAL OF NEUROSURGERY			English	Article							TRAUMATIC-BRAIN-INJURY; PEDIATRIC INDEX; FUNNEL PLOTS; MODEL; EPIDEMIOLOGY; PERFORMANCE; REGRESSION; HYPOXIA; KINGDOM; TESTS	Methods: aEuro integral Analysis of HI cases ((age aEuroS < 16 years)) from the Paediatric Intensive Care Audit Network national cohort of sequential PICU admissions in 27 units in England and Wales, in the 5 years 2004--2008. Risk-adjusted mortality using the Paediatric Index of Mortality ((PIM)) model was compared between PICUs aggregated into quartile groups, first to fourth based on descending number of HI admissions//year: highest volume, medium--higher volume, medium--lower volume, and lowest volume. The effect of category of PICU interventions -- observation only, mechanical ventilation ((MV)) only, and intracranial pressure ((ICP)) monitoring -- on outcome was also examined. Observations were reported in relation to specialist paediatric neurosurgical PICU practice. Results: aEuro integral There were 2575 admissions following acute HI ((4.4%% of non-cardiac surgery PICU admissions in England and Wales)). PICU mortality was 9.3%%. Units in the fourth-quartile ((lowest volume)) group did not have significant specialist paediatric neurosurgical activity on the PICU; the other groups did. Overall, there was no effect of HI admissions by individual PICU on risk-adjusted mortality. However, there were significant effects for both intensive care intervention category ((p < 0.001)) and HI admissions by grouping ((p < 0.005)). Funnel plots and control charts using the PIM model showed a hierarchy in increasing performance from lowest volume ((group IV)), to medium--higher volume ((group II)), to highest volume ((group I)), to medium--lower volume ((group III)) sectors of the health care system. Conclusions: aEuro integral The health care system in England and Wales for critically ill HI children requiring PICU admission performs as expected in relation to the PIM model. However, the lowest-volume sector, comprising 14 PICUs with little or no paediatric neurosurgical activity on the unit, exhibits worse than expected outcome, particularly in those undergoing ICP monitoring. The best outcomes are seen in units in the mid-volume sector. These data do not support the hypothesis that there is a simple relationship between PICU volume and performance.	[Tasker, Robert C.] Univ Cambridge, Sch Clin, Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2QQ, England; [Fleming, Thomas J.] Univ Leeds, Ctr Epidemiol & Biostat, Data Management Grp, Leeds, W Yorkshire, England; [Young, Amber Er] Frenchay Hosp, Dept Anaesthesia, Bristol BS16 1LE, Avon, England; [Young, Amber Er] Birmingham Childrens Hosp, Paediat Intens Care Unit, Birmingham, W Midlands, England; [Parslow, Roger C.] Univ Leeds, Ctr Epidemiol & Biostat, Paediat Epidemiol Grp, Leeds, W Yorkshire, England	Tasker, RC (corresponding author), Univ Cambridge, Sch Clin, Addenbrookes Hosp, Dept Paediat, Box 116,Hills Rd, Cambridge CB2 2QQ, England.	rct31@cam.ac.uk	Parslow, Roger/AAV-1477-2020; Tasker, Robert C/R-5837-2019; Young, Amber/H-2988-2018	Tasker, Robert/0000-0003-3647-8113; Parslow, Roger/0000-0002-3945-5294; Young, Amber/0000-0001-7205-492X	National Clinical Audit and Patient Outcomes Programme via Healthcare Quality Improvement Partnership (HQIP); Health Commission Wales Specialised Services; NHS Lothian/National Service Division NHS Scotland; Royal Belfast Hospital for Sick Children; Evelyn Trust; Pan Thames PICU Commissioning Consortium	We would like to thank all the staff in participating hospitals that have collected data for PICANet. PICANet is funded by the National Clinical Audit and Patient Outcomes Programme via Healthcare Quality Improvement Partnership (HQIP), Health Commission Wales Specialised Services, NHS Lothian/National Service Division NHS Scotland, the Royal Belfast Hospital for Sick Children and the Pan Thames PICU Commissioning Consortium. RCT is supported by the Evelyn Trust.	Baghurst PA, 2008, INTENS CARE MED, V34, P1281, DOI 10.1007/s00134-008-1081-0; Brady AR, 2006, PEDIATRICS, V117, pE733, DOI 10.1542/peds.2005-1853; Brier GW, 1950, MONTHLY WEATHER REV, V75, P1, DOI DOI 10.1175/1520-0493(1950)078<0001:V0FEIT>2.0.C0;2; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Cooke MW, 2007, ARCH DIS CHILD, V92, P6, DOI 10.1136/adc.2006.094920; COX DR, 1958, BIOMETRIKA, V45, P562, DOI 10.1093/biomet/45.3-4.562; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hannan EL, 1997, JAMA-J AM MED ASSOC, V277, P892, DOI 10.1001/jama.277.11.892; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; Hyam JA, 2006, CRIT CARE, V10, DOI 10.1186/cc5066; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kochanek PM, 2009, PEDIATR CRIT CARE ME, V10, P517, DOI 10.1097/PCC.0b013e3181ab88cd; Kunadian B, 2008, BRIT MED J, V336, P931, DOI 10.1136/bmj.39512.529120.BE; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; MurphyFilkins RL, 1996, CRIT CARE MED, V24, P1968, DOI 10.1097/00003246-199612000-00007; *PAED INT CAR AUD, DAT DEF VERS 3 NOV 2; *PAED INT CAR AUD, ANN REP PAED INT CAR; Parslow RC, 2009, ARCH DIS CHILD, V94, P210, DOI 10.1136/adc.2007.134403; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; *ROYAL COLL SURG E, 1999, WORK PART MAN PAT HE; Royal College of Surgeons of England and the British Orthopaedic Society, 2000, BETT CAR SEV INJ; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Shann F, 1997, INTENS CARE MED, V23, P201, DOI 10.1007/s001340050317; Slater A, 2003, INTENS CARE MED, V29, P278, DOI 10.1007/s00134-002-1601-2; *SOC BRIT NEUR SUR, 1999, SAF NEUR 2000; Spiegelhalter D, 2003, INT J QUAL HEALTH C, V15, P7, DOI 10.1093/intqhc/15.1.7; Spiegelhalter DJ, 2005, STAT MED, V24, P1185, DOI 10.1002/sim.1970; Tasker RC, 2006, EMERG MED J, V23, P519, DOI 10.1136/emj.2005.028779; Tasker RC, 2004, EMERG MED J, V21, P433, DOI 10.1136/emj.2002.004069; Tasker RC, 2009, CURR OPIN PEDIATR, V21, P724, DOI 10.1097/MOP.0b013e328331e813; *UK NAT HLTH SERV, 2008, COMM SAF SUST SPEC P	34	27	28	0	1	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	FEB	2011	25	1					68	77		10.3109/02688697.2010.538770			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	722BO	WOS:000287405000010	21083365	Green Published			2021-06-18	
J	Zohar, O; Lavy, R; Zi, XM; Nelson, TJ; Hongpaisan, J; Pick, CG; Alkon, DL				Zohar, Ofer; Lavy, Rotem; Zi, Xiaomei; Nelson, Thomas J.; Hongpaisan, Jarin; Pick, Chaim G.; Alkon, D. L.			PKC activator therapeutic for mild traumatic brain injury in mice	NEUROBIOLOGY OF DISEASE			English	Article						Mild traumatic brain injury; Therapeutic; Dose dependent; Time frame; Cognitive deficits; Synaptic structures; ADAM10; BACE1	PROTEIN-KINASE-C; AMYLOID PRECURSOR PROTEIN; NECROSIS-FACTOR-ALPHA; CLOSED-HEAD INJURY; LONG-TERM-MEMORY; COGNITIVE DEFICITS; BRYOSTATIN 1; ANTICANCER DRUGS; HIPPOCAMPAL PKC; TRANSGENIC MICE	Traumatic brain injury (TBI) is a frequent consequence of vehicle, sport and war related injuries. More than 90% of TBI patients suffer mild injury (mTBI). However, the pathologies underlying the disease are poorly understood and treatment modalities are limited. We report here that in mice, the potent PKC activator bryostatin1 protects against mTBI induced learning and memory deficits and reduction in pre-synaptic synaptophysin and post-synaptic spinophylin immunostaining. An effective treatment has to start within the first 8 h after injury, and includes 5x i.p. injections over a period of 14 days. The treatment is dose dependent. Exploring the effects of the repeated bryostatin1 treatment on the processing of the amyloid precursor protein, we found that the treatment induced an increase in the putative alpha-secretase ADAM10 and a reduction in beta-secretase activities. Both these effects could contribute towards a reduction in beta-amyloid production. These results suggest that bryostatin1 protects against mTBI cognitive and synaptic sequela by rescuing synapses, which is possibly mediated by an increase in ADAM10 and a decrease in BACE1 activity. Since bryostatin1 has already been extensively used in clinical trials as an anti-cancer drug, its potential as a remedy for the short- and long-term TBI sequelae is quite promising. (C) 2010 Elsevier Inc. All rights reserved.	[Zohar, Ofer; Lavy, Rotem; Zi, Xiaomei; Nelson, Thomas J.; Hongpaisan, Jarin; Alkon, D. L.] W Virginia Univ, Blanchette Rockefeller Neurosci Inst, Rockville, MD 20850 USA; [Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel	Zohar, O (corresponding author), W Virginia Univ, Blanchette Rockefeller Neurosci Inst, 9601 Med Ctr Dr, Rockville, MD 20850 USA.	zohar@brni-jhu.org					Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; ALKON DL, 1988, SCIENCE, V239, P998, DOI 10.1126/science.2830669; Alkon DL, 2005, P NATL ACAD SCI USA, V102, P16432, DOI 10.1073/pnas.0508001102; Amador ML, 2003, ANN ONCOL, V14, P1607, DOI 10.1093/annonc/mdg443; Asai M, 2003, BIOCHEM BIOPH RES CO, V301, P231, DOI 10.1016/S0006-291X(02)02999-6; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; BANK B, 1988, P NATL ACAD SCI USA, V85, P1988, DOI 10.1073/pnas.85.6.1988; BASU A, 1993, PHARMACOL THERAPEUT, V59, P257, DOI 10.1016/0163-7258(93)90070-T; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Bird CM, 2008, NAT REV NEUROSCI, V9, P182, DOI 10.1038/nrn2335; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Bonini JS, 2007, NEUROSCIENCE, V147, P37, DOI 10.1016/j.neuroscience.2007.04.013; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Craske ML, 2005, J CELL BIOL, V170, P1147, DOI 10.1083/jcb.200503118; Deuss M, 2008, CURR ALZHEIMER RES, V5, P187, DOI 10.2174/156720508783954686; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Etcheberrigaray R, 2004, P NATL ACAD SCI USA, V101, P11141, DOI 10.1073/pnas.0403921101; Farrow B, 2002, J GASTROINTEST CANC, V32, P63, DOI 10.1385/IJGC:32:2-3:63; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; Gescher A, 1998, GEN PHARMACOL, V31, P721, DOI 10.1016/S0306-3623(98)00069-X; Goekjian PG, 2001, EXPERT OPIN INV DRUG, V10, P2117; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hongpaisan J, 2007, P NATL ACAD SCI USA, V104, P19571, DOI 10.1073/pnas.0709311104; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Jin GX, 2002, ANAL BIOCHEM, V302, P269, DOI 10.1006/abio.2001.5549; Johnston Andrew J, 2002, Curr Opin Crit Care, V8, P121, DOI 10.1097/00075198-200204000-00006; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Karkkainen I, 2000, MOL CELL NEUROSCI, V15, P547, DOI 10.1006/mcne.2000.0848; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Kojro E, 2005, SUB CELL BIOCHEM, V38, P105; Kortmansky J, 2003, CANCER INVEST, V21, P924, DOI 10.1081/CNV-120025095; Kuzirian AM, 2006, BIOL BULL-US, V210, P201, DOI 10.2307/4134558; Lan JY, 2001, NAT NEUROSCI, V4, P382, DOI 10.1038/86028; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; LEWIN NE, 1991, CANCER COMMUN, V3, P67; Lorenzo PS, 1997, J BIOL CHEM, V272, P33338, DOI 10.1074/jbc.272.52.33338; Lorenzo PS, 1999, CANCER RES, V59, P6137; Majewski H, 1997, CLIN EXP PHARMACOL P, V24, P619, DOI 10.1111/j.1440-1681.1997.tb02102.x; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Mutter R, 2000, BIOORGAN MED CHEM, V8, P1841, DOI 10.1016/S0968-0896(00)00150-4; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nogues X, 1997, PROG NEURO-PSYCHOPH, V21, P507, DOI 10.1016/S0278-5846(97)00015-8; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; OLDS JL, 1989, SCIENCE, V245, P866, DOI 10.1126/science.2772638; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; Paterson I, 2005, SCIENCE, V310, P451, DOI 10.1126/science.1116364; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Postina R, 2008, CURR ALZHEIMER RES, V5, P179, DOI 10.2174/156720508783954668; Reilly PL, 2001, J CLIN NEUROSCI, V8, P398, DOI 10.1054/jocn.2001.0916; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Sun MK, 2006, CNS DRUG REV, V12, P1, DOI 10.1111/j.1527-3458.2006.00001.x; Sun MK, 2009, P NATL ACAD SCI USA, V106, P14676, DOI 10.1073/pnas.0907842106; Sun MK, 2005, EUR J PHARMACOL, V512, P43, DOI 10.1016/j.ejphar.2005.02.028; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; VanderZee EA, 1997, PROG NEURO-PSYCHOPH, V21, P531, DOI 10.1016/S0278-5846(97)00017-1; Wang DH, 2008, BEHAV PHARMACOL, V19, P245, DOI 10.1097/FBP.0b013e3282feb0d2; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Zhang XS, 1996, CANCER RES, V56, P802; Zohar O, 2006, NEUROSCI LETT, V394, P239, DOI 10.1016/j.neulet.2005.10.099; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	78	27	28	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	FEB	2011	41	2					329	337		10.1016/j.nbd.2010.10.001			9	Neurosciences	Neurosciences & Neurology	705QZ	WOS:000286154300011	20951803				2021-06-18	
J	Matthews, S; Simmons, A; Strigo, I				Matthews, Scott; Simmons, Alan; Strigo, Irina			The effects of loss versus alteration of consciousness on inhibition-related brain activity among individuals with a history of blast-related concussion	PSYCHIATRY RESEARCH-NEUROIMAGING			English	Article						Functional magnetic resonance imaging; Self awareness; Somatic symptoms	COGNITIVE CONTROL; VALIDITY	In this investigation, 27 individuals who experienced blast-related concussion, i.e., brief loss (LOC) or alteration (AOC) of consciousness, performed a stop task during functional magnetic resonance imaging. LOC versus AOC subjects displayed altered ventromedial prefrontal cortex activity, which correlated with somatic symptom severity-findings which may suggest a neural correlate of impaired self awareness after LOC. Published by Elsevier Ireland Ltd.	[Matthews, Scott; Simmons, Alan; Strigo, Irina] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Matthews, Scott; Simmons, Alan] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA	Matthews, S (corresponding author), VASDHS 3350 Jolla Village Dr,Mail Code 116-A, La Jolla, CA 92093 USA.	scmatthews@ucsd.edu	Simmons, Alan N/A-9815-2008	Simmons, Alan N/0000-0003-3963-2112	Veterans AdministrationUS Department of Veterans Affairs; Veterans Affairs San Diego Healthcare SystemUS Department of Veterans Affairs; Center of Excellence for Stress and Mental Health; Veterans Affairs Mental illness Education and Clinical Center (MIRECC)	The authors thank Ryan M. O'Connell, Lindsay E. Reinhardt, Suzanne A. Moseley, Martin P. Paulus, Dean C. Delis and Larry Frank, Ph.D., for their contributions to this research, which was funded by grants from the Veterans Administration and Congressionally Directed Medical Research Program, and supported by the Veterans Affairs San Diego Healthcare System, Center of Excellence for Stress and Mental Health and Veterans Affairs Mental illness Education and Clinical Center (MIRECC).	Aron AR, 2007, NEUROSCIENTIST, V13, P214, DOI 10.1177/1073858407299288; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; *CDC, 2006, FACTS TRAUM BRAIN IN; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; First MB., 1997, STRUCTURED CLIN INTE; Floden D, 2006, J COGNITIVE NEUROSCI, V18, P1843, DOI 10.1162/jocn.2006.18.11.1843; Gallagher HL, 2002, NEUROIMAGE, V16, P814, DOI 10.1006/nimg.2002.1117; Kroenke K, 2002, PSYCHOSOM MED, V64, P258, DOI 10.1097/00006842-200203000-00008; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; Matthews SC, 2005, NEUROREPORT, V16, P755, DOI 10.1097/00001756-200505120-00020; Ochsner KN, 2005, TRENDS COGN SCI, V9, P242, DOI 10.1016/j.tics.2005.03.010; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Schwab KA, 2006, NEUROLOGY, V66, pA235; Spikman JM, 2010, J NEUROTRAUM, V27, P1195, DOI 10.1089/neu.2010.1277; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Zysset S, 2002, NEUROIMAGE, V15, P983, DOI 10.1006/nimg.2001.1008	21	27	27	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0925-4927	1872-7506		PSYCHIAT RES-NEUROIM	Psychiatry Res. Neuroimaging	JAN 30	2011	191	1					76	79		10.1016/j.pscychresns.2010.09.013			4	Clinical Neurology; Neuroimaging; Psychiatry	Neurosciences & Neurology; Psychiatry	737TM	WOS:000288591100011	21144713				2021-06-18	
J	Kobori, N; Hu, B; Dash, PK				Kobori, N.; Hu, B.; Dash, P. K.			ALTERED ADRENERGIC RECEPTOR SIGNALING FOLLOWING TRAUMATIC BRAIN INJURY CONTRIBUTES TO WORKING MEMORY DYSFUNCTION	NEUROSCIENCE			English	Article						catecholamines; neurotransmitter signaling; protein kinase A; CREB-mediated gene expression; chromatin immunoprecipitation	CONTROLLED CORTICAL IMPACT; HUMAN ALPHA(1A)-ADRENERGIC RECEPTOR; SUBTYPE MESSENGER-RNAS; PREFRONTAL CORTEX; CARDIAC MYOCYTES; PROTEIN-KINASE; RAT; DEFICITS; GENE; PROMOTER	The prefrontal cortex is highly vulnerable to traumatic brain injury (TBI) and its structural and/or functional alterations as a result of TBI can give rise to persistent working memory (WM) dysfunction. Using a rodent model of TBI, we have described profound WM deficits following TBI that are associated with increases in prefrontal catecholamine (both dopamine and norepinephrine) content. In this study, we examined if enhanced norepinephrine signaling contributes to TBI-associated WM dysfunction. We demonstrate that administration of alpha 1 adrenoceptor antagonists, but not alpha 2A agonist, at 14 days post-injury significantly improved WM performance. mRNA analysis revealed increased levels of alpha 1A, but not alpha 1B or alpha 1D, adrenoceptor in the medial prefrontal cortex (mPFC) of brain-injured rats. As alpha 1A and 1B adrenoceptor promoters contain putative cAMP response element (CRE) sequences, we therefore examined if CRE-binding protein (CREB) actively engages these sequences in order to increase receptor gene transcription following TBI. Our results show that the phosphorylation of CREB is enhanced in the mPFC at time points during which increased alpha 1A mRNA expression was observed. Chromatin immuno-precipitation (ChIP) assays using mPFC tissue from injured animals indicated increased phospho-CREB binding to the CRE sites of alpha 1A, but not alpha 1B, promoter compared to that observed in uninjured controls. To address the translatability of our findings, we tested the efficacy of the FDA-approved alpha 1 antagonist Prazosin and observed that this drug improves WM in injured animals. Taken together, these studies suggest that enhanced CREB-mediated expression of alpha 1 adrenoceptor contributes to TBI-associated WM dysfunction, and therapies aimed at reducing alpha 1 signaling may be useful in the treatment of TBI-associated WM deficits in humans. (C) 2011 IBRO. Published by Elsevier Ltd. All rights reserved.	[Kobori, N.; Hu, B.; Dash, P. K.] Univ Texas Med Sch Houston, Vivian L Smith Dept Neurosurg, Dept Neurobiol & Anat, Houston, TX 77225 USA	Kobori, N (corresponding author), Univ Texas Med Sch Houston, Vivian L Smith Dept Neurosurg, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	Nobuhide.Kobori@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS052313, NS49160, MH072933]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH072933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052313, R01NS049160] Funding Source: NIH RePORTER	The authors would like to thank Anthony Moore and John Redell for critical review of the manuscript. This work was supported by grants [NS052313, NS49160, MH072933] from National Institutes of Health.	Arnsten AFT, 2000, NEURAL PLAST, V7, P133, DOI 10.1155/NP.2000.133; Arnsten AFT, 2005, BIOL PSYCHIAT, V57, P1377, DOI 10.1016/j.biopsych.2004.08.019; ARNSTEN AFT, 1985, SCIENCE, V230, P1273, DOI 10.1126/science.2999977; Autelitano DJ, 1998, J MOL CELL CARDIOL, V30, P1515, DOI 10.1006/jmcc.1998.0717; Bergles DE, 1996, J NEUROSCI, V16, P572; Birnbaum S, 1999, BIOL PSYCHIAT, V46, P1266, DOI 10.1016/S0006-3223(99)00138-9; Birnbaum SG, 2000, PHARMACOL BIOCHEM BE, V67, P397, DOI 10.1016/S0091-3057(00)00306-3; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Franowicz JS, 1999, NEUROPSYCHOPHARMACOL, V21, P611, DOI 10.1016/S0893-133X(99)00060-3; Gao B, 1997, MOL PHARMACOL, V52, P1019; GAO B, 1993, GENE, V131, P243, DOI 10.1016/0378-1119(93)90300-R; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; Hein L, 2006, CELL TISSUE RES, V326, P541, DOI 10.1007/s00441-006-0285-2; Jensen BC, 2009, N-S ARCH PHARMACOL, V379, P409, DOI 10.1007/s00210-008-0368-6; Kawaguchi Y, 1998, J NEUROSCI, V18, P6963; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kobayashi M, 2009, SYNAPSE, V63, P269, DOI 10.1002/syn.20604; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Kobori N, 2004, J BIOL CHEM, V279, P2182, DOI 10.1074/jbc.M310734200; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; Lee K, 1998, DNA SEQUENCE, V8, P271, DOI 10.3109/10425179809008464; LI BM, 1994, BEHAV NEURAL BIOL, V62, P134, DOI 10.1016/S0163-1047(05)80034-2; Liang M, 1998, MOL PHARMACOL, V54, P44; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Marti D, 2005, AM J PHYSIOL-HEART C, V289, pH1923, DOI 10.1152/ajpheart.00288.2005; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; Michelotti GA, 2003, J BIOL CHEM, V278, P8693, DOI 10.1074/jbc.M211986200; Missale C, 1998, PHYSIOL REV, V78, P189; Moghaddam B, 2008, NEUROPSYCHOPHARMACOL, V33, P42, DOI 10.1038/sj.npp.1301554; MOHELL N, 1983, EUR J PHARMACOL, V92, P15, DOI 10.1016/0014-2999(83)90103-6; O'Connell TD, 2001, MOL PHARMACOL, V59, P1225; Rama P, 1996, PHARMACOL BIOCHEM BE, V55, P415, DOI 10.1016/S0091-3057(96)00111-6; Raskind MA, 2003, AM J PSYCHIAT, V160, P371, DOI 10.1176/appi.ajp.160.2.371; Razik MA, 1997, J BIOL CHEM, V272, P28237, DOI 10.1074/jbc.272.45.28237; Rokosh DG, 1996, J BIOL CHEM, V271, P5839, DOI 10.1074/jbc.271.10.5839; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Southwick SM, 1999, BIOL PSYCHIAT, V46, P1192, DOI 10.1016/S0006-3223(99)00219-X; Steele RJ, 1999, HIPPOCAMPUS, V9, P118, DOI 10.1002/(SICI)1098-1063(1999)9:2<118::AID-HIPO4>3.0.CO;2-8; Stibick DL, 2001, J NEUROTRAUM, V18, P303, DOI 10.1089/08977150151070955; Wang XJ, 2004, P NATL ACAD SCI USA, V101, P1368, DOI 10.1073/pnas.0305337101; Whittington MA, 2003, TRENDS NEUROSCI, V26, P676, DOI 10.1016/j.tins.2003.09.016; Yuan WX, 2009, NEUROSCIENCE, V158, P1616, DOI 10.1016/j.neuroscience.2008.11.022	44	27	27	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	JAN 13	2011	172						293	302		10.1016/j.neuroscience.2010.10.048			10	Neurosciences	Neurosciences & Neurology	705RC	WOS:000286154600029	20974230	Green Accepted			2021-06-18	
J	Barnes, PD				Barnes, Patrick D.			Imaging of Nonaccidental Injury and the Mimics: Issues and Controversies in the Era of Evidence-Based Medicine	RADIOLOGIC CLINICS OF NORTH AMERICA			English	Article						Evidence-based medicine; Nonaccidental injury; Nonaccidental trauma; Nonaccidental head injury; Child abuse	SHAKEN BABY SYNDROME; CHRONIC SUBDURAL-HEMATOMA; TRAUMATIC BRAIN-INJURY; INFLICTED HEAD-INJURY; CEREBRAL SINOVENOUS THROMBOSIS; BENIGN EXTERNAL HYDROCEPHALUS; PERIMACULAR RETINAL FOLDS; YOUNG-CHILDREN; INTRACRANIAL HEMORRHAGE; CLINICAL ANALYSIS	Because of the controversy involving the determination of child abuse, or nonaccidental injury (NAI), radiologists must be familiar with the issues, literature, and principles of evidence-based medicine to understand the role of imaging. Children with suspected NAI must receive protective evaluation along with a timely and complete clinical and imaging work-up. Imaging findings cannot stand alone and must be correlated with clinical findings, laboratory testing, and pathologic and forensic examinations. Only the child protection investigation may provide the basis for inflicted injury in the context of supportive clinical, imaging, biomechanical, or pathology findings.	Stanford Univ, Med Ctr, Dept Radiol, Lucile Packard Childrens Hosp, Palo Alto, CA 94304 USA	Barnes, PD (corresponding author), Stanford Univ, Med Ctr, Dept Radiol, Lucile Packard Childrens Hosp, 725 Welch Rd, Palo Alto, CA 94304 USA.	pbarnes@stanford.edu					Alexander JM, 2006, OBSTET GYNECOL, V108, P885, DOI 10.1097/01.AOG.0000237116.72011.f3; AOKI N, 1990, J NEUROSURG, V73, P201, DOI 10.3171/jns.1990.73.2.0201; AOKI N, 1984, J NEUROSURG, V61, P273, DOI 10.3171/jns.1984.61.2.0273; Arbogast KB, 2005, PEDIATRICS, V116, P180, DOI 10.1542/peds.2004-2671; Aryan HE, 2005, J CLIN NEUROSCI, V12, P624, DOI 10.1016/j.jocn.2005.05.005; AZAIS M, 1992, ANN PEDIATR-PARIS, V39, P550; Bandak FA, 2005, FORENSIC SCI INT, V151, P71, DOI 10.1016/j.forsciint.2005.02.033; BARKOVICH AJ, 2005, PEDIAT NEUROIMAGING, P190; Barlow KM, 1999, ACTA PAEDIATR, V88, P734; Barnes C, 2006, THROMB RES, V118, P67, DOI 10.1016/j.thromres.2005.05.021; BARNES P, 2009, PEDIAT RADIOLOGY REQ, P221; BARNES P, 2008, SCI SESS SCOTTSD AZ; Barnes Patrick D, 2007, Top Magn Reson Imaging, V18, P53, DOI 10.1097/RMR.0b013e3180d0a455; Barnes PD, 2008, SEMIN PEDIATR NEUROL, V15, P178, DOI 10.1016/j.spen.2008.10.009; Barnes PD, 2000, PEDIATR RADIOL, V30, P74, DOI 10.1007/s002470050018; BIRD CR, 1987, RADIOLOGY, V163, P373, DOI 10.1148/radiology.163.2.3562816; Bishop N, 2007, ARCH DIS CHILD, V92, P251, DOI 10.1136/adc.2006.106120; Blackmore C Craig, 2006, J Am Coll Radiol, V3, P505, DOI 10.1016/j.jacr.2006.03.003; Bonkowsky JL, 2008, PEDIATRICS, V122, P125, DOI 10.1542/peds.2007-3376; Brousseau TJ, 2005, J EMERG MED, V29, P283, DOI 10.1016/j.jemermed.2005.02.009; BROWN S, 2007, J AAPOS, V11, P85; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1984, BRIT MED J, V289, P715, DOI 10.1136/bmj.289.6447.715; Byard RW, 2007, PEDIATR DEVEL PATHOL, V10, P348, DOI 10.2350/06-08-0154.1; Carvalho KS, 2001, J CHILD NEUROL, V16, P574, DOI 10.2310/7010.2001.16834; *CDC NAT IMM PROGR, 2000, GEN PERT INF, P2; Chabrol B, 1999, CHILD ABUSE NEGLECT, V23, P217, DOI 10.1016/S0145-2134(98)00128-8; Chadwick DL, 2008, PEDIATRICS, V121, P1213, DOI 10.1542/peds.2007-2281; CHADWICK DL, 1991, J TRAUMA, V31, P1353, DOI 10.1097/00005373-199110000-00006; Chamnanvanakij S, 2002, PEDIATR NEUROL, V26, P301, DOI 10.1016/S0887-8994(01)00420-9; Christian CW, 1999, J PEDIATR-US, V135, P125, DOI 10.1016/S0022-3476(99)70343-4; Clemetson C. A. B., 2004, J AM PHYS SURG, V9, P78; CLEMETSON CAB, 2006, J AM PHYS SURG, V11, P20; Cohen MC, 2009, PEDIATR DEVEL PATHOL, V12, P169, DOI 10.2350/08-08-0509.1; COHEN RA, 1985, AM J NEURORADIOL, V6, P883; Collins Jannette, 2007, J Am Coll Radiol, V4, P551, DOI 10.1016/j.jacr.2006.12.007; Croft PR, 2009, AM J FOREN MED PATH, V30, P10, DOI 10.1097/PAF.0b013e31818737be; Croskerry P, 2003, ACAD MED, V78, P775, DOI 10.1097/00001888-200308000-00003; Datta S, 2005, ARCH DIS CHILD, V90, P947, DOI 10.1136/adc.2002.021154; David TJ, 2008, PEDIATR RADIOL, V38, pS370, DOI 10.1007/s00247-008-0829-6; Denton S, 2003, AM J FOREN MED PATH, V24, P371, DOI 10.1097/01.paf.0000097851.18478.16; deVeber G, 2001, NEW ENGL J MED, V345, P417, DOI 10.1056/NEJM200108093450604; DeWolfe CC, 2005, PEDIATR CLIN N AM, V52, P1127, DOI 10.1016/j.pcl.2005.05.004; Di Pietro MA, 2009, PEDIATRICS, V123, P1430, DOI 10.1542/peds.2009-0558; Donohoe M, 2003, AM J FOREN MED PATH, V24, P239, DOI 10.1097/01.paf.0000083635.85457.97; Doumouchtsis SK, 2008, CLIN PERINATOL, V35, P69, DOI 10.1016/j.clp.2007.11.006; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V25, P116, DOI 10.1159/000121108; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Durham SR, 2007, J NEUROTRAUM, V24, P5, DOI 10.1089/neu.2006.0054; Dyer O, 2003, BRIT MED J, V326, P616; Emerson MV, 2007, OPHTHALMOLOGY, V114, P1384, DOI 10.1016/j.ophtha.2007.04.015; Emerson MV, 2001, OPHTHALMOLOGY, V108, P36, DOI 10.1016/S0161-6420(00)00474-7; Ernst LM, 2006, J PEDIATR-US, V148, P779, DOI 10.1016/j.jpeds.2006.01.040; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Feldman KW, 2001, PEDIATRICS, V108, P636, DOI 10.1542/peds.108.3.636; Fitzgerald KC, 2006, ARCH NEUROL-CHICAGO, V63, P405, DOI 10.1001/archneur.63.3.405; Forbes BJ, 2008, J AAPOS, V12, P177, DOI 10.1016/j.jaapos.2007.07.009; Forbes BJ, 2007, J AAPOS, V11, P179, DOI 10.1016/j.jaapos.2006.08.006; Frasier L, 2006, ABUSIVE HEAD TRAUMA; Fullerton HJ, 2001, NEUROLOGY, V57, P1155, DOI 10.1212/WNL.57.7.1155; Fung ELW, 2002, PEDIATR INT, V44, P37, DOI 10.1046/j.1442-200X.2002.01500.x; GALAZNIK J, 2007, PEDIATRICS, V19, P1232; Galaznik JG, 2008, DEV MED CHILD NEUROL, V50, P317; Ganesh A, 2004, OPHTHALMOLOGY, V111, P1428, DOI 10.1016/j.ophtha.2003.10.028; Gardner H, 2003, AM J OPHTHALMOL, V135, P745, DOI 10.1016/S0002-9394(02)02284-5; Gardner HB, 2007, ARCH OPHTHALMOL-CHIC, V125, P1142, DOI 10.1001/archopht.125.8.1142-c; Geddes JF, 2006, NEUROPATH APPL NEURO, V32, P625, DOI 10.1111/j.1365-2990.2006.00771.x; Geddes JF, 2003, NEUROPATH APPL NEURO, V29, P14, DOI 10.1046/j.1365-2990.2003.00434.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENA M, 2007, WISC LAW REV, V701, P1; Gilles EE, 2003, J PEDIATR-US, V143, P494, DOI 10.1067/S0022-3476(03)00416-5; Gilliland MGF, 2003, HISTOPATHOLOGY, V43, P592, DOI 10.1111/j.1365-2559.2003.01762.x; Goldsmith W, 2004, AM J FOREN MED PATH, V25, P89, DOI 10.1097/01.paf.0000127407.28071.63; Greenes DS, 1998, ANN EMERG MED, V32, P680, DOI 10.1016/S0196-0644(98)70067-8; Groninger A, 2005, PEDIATR NEUROL, V32, P140, DOI 10.1016/j.pediatrneurol.2004.07.011; GROOPMAN J, WALL ST J; GUYATT HRB, 2000, JAMA-J AM MED ASSOC, V284, P1290; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; HALL JR, 1989, J TRAUMA, V29, P1273, DOI 10.1097/00005373-198909000-00015; Hangique S, 2002, IND J RADIOL IMAG, V12, P197; HAYASHI T, 1987, CHILD NERV SYST, V3, P23, DOI 10.1007/BF00707189; HELFER RE, 1977, PEDIATRICS, V60, P533; Hellbusch LC, 2007, J NEUROSURG, V107, P119, DOI 10.3171/PED-07/08/119; Hobbs C, 2005, ARCH DIS CHILD, V90, P952, DOI 10.1136/adc.2003.037739; Holden KR, 1999, J CHILD NEUROL, V14, P708, DOI 10.1177/088307389901401104; HON STG, 2008, REPORT INQUIRY PEDIA; HOWARD MA, 1993, BRIT J NEUROSURG, V7, P355, DOI 10.3109/02688699309103489; Hwang SK, 2000, CHILD NERV SYST, V16, P590, DOI 10.1007/s003810000312; Hymel Kent P, 2002, Child Maltreat, V7, P329, DOI 10.1177/107755902237263; Hymel KP, 1997, PEDIATR RADIOL, V27, P743, DOI 10.1007/s002470050215; Ichord RN, 2007, J NEUROTRAUM, V24, P106, DOI 10.1089/neu.2006.0087; IKEDA A, 1987, CHILD NERV SYST, V3, P19, DOI 10.1007/BF00707188; Innis MD, 2006, J AM PHYS SURG, V11, P17; Jaspan T, 2008, PEDIATR RADIOL, V38, pS378, DOI 10.1007/s00247-008-0896-8; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Jayawant S, 2007, ARCH DIS CHILD, V92, P343, DOI 10.1136/adc.2005.084988; Jenny C, 2007, PEDIATRICS, V119, P1232, DOI 10.1542/peds.2007-0883; Jenny C, 2006, PEDIATRICS, V118, P1299, DOI 10.1542/peds.2006-1795; KAWAKAMI Y, 1989, NEUROSURGERY, V25, P25, DOI 10.1227/00006123-198907000-00005; Keierleber JA, 2005, J FORENSIC SCI, V50, P1154; Keller KA, 2008, PEDIATR RADIOL, V38, P1210, DOI 10.1007/s00247-008-1001-z; Keller KA, 2009, PEDIATR RADIOL, V39, P1130, DOI 10.1007/s00247-009-1381-8; Kemp AM, 2002, ARCH DIS CHILD, V86, P98, DOI 10.1136/adc.86.2.98; Kim KA, 2000, NEUROSURG FOCUS, V8, P1; KIRSCHNER RH, 1985, AM J DIS CHILD, V139, P873, DOI 10.1001/archpedi.1985.02140110027022; Kleinman PK, 2008, PEDIATR RADIOL, V38, pS388, DOI 10.1007/s00247-008-0845-6; Kleinman PK., 1998, DIAGNOSTIC IMAGING C, V2; KRASNOKUTSKY M, 2007, SCI PAP SESS MIAM FL; Lantz PE, 2004, BRIT MED J, V328, P754, DOI 10.1136/bmj.328.7442.754; LANTZ PE, 2006, AAFS ANN M SEATTL WA; LEESTMA J, 2009, FORENSIC NEUROPATHOL, P603; Leestma JE, 2005, AM J FOREN MED PATH, V26, P199, DOI 10.1097/01.paf.0000164228.79784.5a; Liesner R, 2004, BLOOD COAGUL FIBRIN, V15, pS41, DOI 10.1097/00001721-200405001-00009; Looney CB, 2007, RADIOLOGY, V242, P535, DOI 10.1148/radiol.2422060133; Lueder GT, 2006, ARCH OPHTHALMOL-CHIC, V124, P1782, DOI 10.1001/archopht.124.12.1782; LYONS G, 2003, UTAH LAW REV, V1109, P1; LYONS TJ, 1993, PEDIATRICS, V92, P125; Mack J, 2009, PEDIATR RADIOL, V39, P200, DOI 10.1007/s00247-008-1084-6; Mackey M, 2006, ARCH DIS CHILD, V91, P873, DOI 10.1136/adc.2006.100719; Marinetti L, 2005, J ANAL TOXICOL, V29, P738, DOI 10.1093/jat/29.7.738; Maxeiner H, 2001, J FORENSIC SCI, V46, P85; McNeely PD, 2006, AM J NEURORADIOL, V27, P1725; Menge T, 2005, ARCH NEUROL-CHICAGO, V62, P1673, DOI 10.1001/archneur.62.11.1673; Minns RA, 2005, ARCH DIS CHILD, V90, P883, DOI 10.1136/adc.2004.060657; Mohan Parvathi, 2002, Pediatr Rev, V23, P330, DOI 10.1542/pir.23-9-330; Morad Y, 2002, AM J OPHTHALMOL, V134, P354, DOI 10.1016/S0002-9394(02)01628-8; MORI K, 1993, CHILD NERV SYST, V9, P282, DOI 10.1007/BF00306274; Mori K, 2002, J NEUROTRAUM, V19, P1017, DOI 10.1089/089771502760341938; Moritani T, 2005, AM J NEURORADIOL, V26, P216; Murakami H, 2002, J NEUROSURG, V96, P877, DOI 10.3171/jns.2002.96.5.0877; Murray JA, 2000, AM SURGEON, V66, P863; Nassogne MC, 2002, CHILD NERV SYST, V18, P729, DOI 10.1007/s00381-002-0630-z; NEWMAN DH, 2009, NY TIMES        0204; NEWMAN DH, 2009, AMA NEWS        0304; Ney JP, 2005, NEUROLOGY, V65, P517, DOI 10.1212/01.wnl.0000178166.06001.b0; OBI E, 2007, J AAPOS, V11, P99, DOI DOI 10.1016/J.JAAPOS.2007.01.031; Oehmichen M, 2005, NEUROPEDIATRICS, V36, P240, DOI 10.1055/s-2005-872812; Ommaya A.K., 1968, JAMA-J AM MED ASSOC, V204, P75; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Page M, 2000, EARLY HUM DEV, V59, P127, DOI 10.1016/S0378-3782(00)00093-1; Papasian NC, 2000, PEDIATR NEUROSURG, V33, P188, DOI 10.1159/000055951; PARENT AD, 1992, PEDIATR NEUROSURG, V18, P266, DOI 10.1159/000120674; PIATT J, 1999, NEUROSURG FOCUS, V7, P1; Pierce MC, 2008, ANNU REV BIOMED ENG, V10, P85, DOI 10.1146/annurev.bioeng.9.060906.151907; Pittman T, 2003, PEDIATR NEUROSURG, V39, P57, DOI 10.1159/000071315; Plunkett J, 2001, AM J FOREN MED PATH, V22, P1, DOI 10.1097/00000433-200103000-00001; Pollina J, 2001, PEDIATR NEUROSURG, V35, P113, DOI 10.1159/000050403; Powers CJ, 2007, PEDIATR NEUROSURG, V43, P25, DOI 10.1159/000097521; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Ravid S, 2003, PEDIATR NEUROL, V28, P139, DOI 10.1016/S0887-8994(02)00500-3; REIBER GD, 1993, AM J FOREN MED PATH, V14, P201, DOI 10.1097/00000433-199309000-00005; Roach ES, 2008, STROKE, V39, P2644, DOI 10.1161/STROKEAHA.108.189696; Rooks VJ, 2008, AM J NEURORADIOL, V29, P1082, DOI 10.3174/ajnr.A1004; Rooks VJ, 1998, PEDIATR RADIOL, V28, P193, DOI 10.1007/s002470050330; Rooms L, 2003, PEDIATRICS, V111, pE636, DOI 10.1542/peds.111.5.e636; Ross M G, 2000, J Matern Fetal Med, V9, P321; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Sebire G, 2005, BRAIN, V128, P477, DOI 10.1093/brain/awh412; SIROTNAK AP, 2006, ABUSIVE HEAD TRAUMA, P191; SLOVIS TL, 2005, EXPERT PANEL PEDIATR; Squier W, 2008, DEV MED CHILD NEUROL, V50, P10, DOI 10.1111/j.1469-8749.2007.02004.x; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Steinbok P, 2007, NEUROSURGERY, V60, P689, DOI 10.1227/01.NEU.0000255398.00410.6B; Stoodley N, 2005, CLIN RADIOL, V60, P22, DOI 10.1016/j.crad.2004.06.023; Strauss KA, 2003, AM J MED GENET C, V121C, P38, DOI 10.1002/ajmg.c.20007; Suh DY, 2001, NEUROSURGERY, V49, P309, DOI 10.1097/00006123-200108000-00011; Surridge J, 2007, ARCH DIS CHILD, V92, P970, DOI 10.1136/adc.2006.114082; Talbert DG, 2006, MED HYPOTHESES, V66, P691, DOI 10.1016/j.mehy.2005.10.025; TONGUE AC, 1991, OPHTHALMOLOGY, V98, P1009; Towner D, 1999, NEW ENGL J MED, V341, P1709, DOI 10.1056/NEJM199912023412301; Trenchs V, 2007, PEDIATR NEUROSURG, V43, P352, DOI 10.1159/000106382; Tuerkheimer D, 2009, WASHINGTON U LAW REV, V87, P1; Tung GA, 2006, PEDIATRICS, V118, P626, DOI 10.1542/peds.2006-0130; UDASHEN G, 2006, TEXAS V HURTADO DAUB; Uscinski R, 2002, BRIT J NEUROSURG, V16, P217, DOI 10.1080/02688690220148978; Vezina G, 2009, PEDIATR RADIOL, V39, P586, DOI 10.1007/s00247-009-1212-y; Vinchon M, 2004, J NEUROSURG, V101, P44, DOI 10.3171/ped.2004.101.2.0044; Vinchon M, 2002, PEDIATR NEUROSURG, V37, P245, DOI 10.1159/000066216; VOLPE JJ, 2000, NEUROLOGY NEWBORN; Wells RG, 2003, ARCH PEDIAT ADOL MED, V157, P1005, DOI 10.1001/archpedi.157.10.1005; Wells RG, 2002, ARCH PEDIAT ADOL MED, V156, P252, DOI 10.1001/archpedi.156.3.252; Whitby EH, 2004, LANCET, V363, P846, DOI 10.1016/S0140-6736(04)15730-9; WILLIAMS RA, 1991, J TRAUMA, V31, P1350, DOI 10.1097/00005373-199110000-00005; Wygnanski-Jaffe T, 2006, AM J OPHTHALMOL, V142, P233, DOI 10.1016/j.ajo.2006.03.038; YAZBAK F, MULTIPLE VACCINATION; ZIMMERMAN RA, 1978, NEURORADIOLOGY, V16, P39, DOI 10.1007/BF00395197; Zouros A, 2004, J NEUROSURG, V100, P512, DOI 10.3171/ped.2004.100.5.0512; ZUERRER M, 1991, NEURORADIOLOGY, V33, P223, DOI 10.1007/BF00588222; 2003, PERTUSSIS, P472	192	27	27	1	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0033-8389	1557-8275		RADIOL CLIN N AM	Radiol. Clin. N. Am.	JAN	2011	49	1					205	+		10.1016/j.rcl.2010.08.001			26	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	701VE	WOS:000285850900011	21111136				2021-06-18	
J	Donders, J; Strong, CAH				Donders, Jacobus; Strong, Carrie-Ann H.			Embedded Effort Indicators on the California Verbal Learning Test - Second Edition (CVLT-II): An Attempted Cross-Validation	CLINICAL NEUROPSYCHOLOGIST			English	Article						Effort; assessment; validity; California Verbal Learning Test - Second edition; CVLT-II	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; VALIDITY; ISSUES; RATES; BIAS	This study determined whether the logistic regression method that was recently developed by Wolfe and colleagues (2010) for the detection of invalid effort on the California Verbal Learning Test - Second Edition (CVLT-II) could be cross-validated in an independent sample of 100 consecutively referred patients with traumatic brain injury. Although the CVLT-II logistic regression formula demonstrated a statistically significant level of agreement with results from the Word Memory Test, it was associated with an unacceptably high proportion of false positives. The component variables of the logistic regression were sensitive to length of coma but did not covary with psychosocial complicating factors (e. g., unresolved prior psychiatric history) that were associated with a higher relative risk of failure of WMT validity criteria. It is concluded that the Wolfe et al. logistic regression should be used only with great caution in the context of clinical neuropsychological evaluations.	[Donders, Jacobus; Strong, Carrie-Ann H.] Mary Free Bed Rehabil Hosp, Psychol Serv, Grand Rapids, MI 49503 USA	Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com					Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Boone, 2007, ASSESSMENT FEIGNED C; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Delis DC, 2000, CALIFORNIA VERBAL LE; Donders J, 2007, BRAIN INJURY, V21, P319, DOI 10.1080/02699050701253129; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P534, DOI 10.1080/13854040802232690; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Horwitz JE, 2006, APPL NEUROPSYCHOL, V13, P175, DOI 10.1207/s15324826an1303_5; Iverson GL, 2003, HANDBOOK OF FORENSIC NEUROPSYCHOLOGY, P137; Jacobs ML, 2007, ARCH CLIN NEUROPSYCH, V22, P143, DOI 10.1016/j.acn.2006.12.002; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; LARRABEE GJ, 2005, FORENSIC NEUROPSYCHO, P115; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Rosenfeld B, 2000, ARCH CLIN NEUROPSYCH, V15, P349, DOI 10.1016/S0887-6177(99)00025-6; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	22	27	27	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	1					173	184		10.1080/13854046.2010.536781			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	722FM	WOS:000287417100012	21181604				2021-06-18	
J	Gordon, SN; Fitzpatrick, PJ; Hilsabeck, RC				Gordon, Shalanda N.; Fitzpatrick, Pamela J.; Hilsabeck, Robin C.			No Effect of PTSD and Other Psychiatric Disorders on Cognitive Functioning in Veterans With Mild TBI	CLINICAL NEUROPSYCHOLOGIST			English	Article						Mild traumatic brain injury; mTBI; Post-traumatic stress disorder; PTSD; Cognitive functioning	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; VIETNAM VETERANS; PROCESSING SPEED; TEST-PERFORMANCE; IRAQ-WAR; ATTENTION; SEQUELAE	There has been speculation that post-traumatic stress disorder (PTSD) superimposed on mild traumatic brain injury (mTBI) may have synergistic, negative effects on cognitive functioning. The purpose of this study was to investigate differences in processing speed, executive functioning, and memory of 82 veterans with mTBI and PTSD, mTBI, and another psychiatric condition, or mTBI alone. It was hypothesized that there would be no group differences in cognitive performances. Participants completed the Trail Making Test, Stroop, Rey Complex Figure, and California Verbal Learning Test-2. There were no significant group differences on any cognitive measure. Findings suggest that PTSD and other psychiatric disorders do not necessarily have a negative exacerbating effect on processing speed, executive functioning, or memory in veterans with mTBI.	[Hilsabeck, Robin C.] S Texas Vet Hlth Care Syst, Psychol Serv 116B, San Antonio, TX 78229 USA; [Hilsabeck, Robin C.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Hilsabeck, Robin C.] Univ Calif San Diego, San Diego, CA 92103 USA; [Gordon, Shalanda N.] Cent Texas Vet Hlth Care Syst, Temple, TX USA	Hilsabeck, RC (corresponding author), S Texas Vet Hlth Care Syst, Psychol Serv 116B, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.	Hilsabeck@uthscsa.edu	Hilsabeck, Robin/ABC-5093-2020				American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Baker DG, 2009, MIL MED, V174, P773; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Brandes D, 2002, PSYCHIAT RES, V110, P231, DOI 10.1016/S0165-1781(02)00125-7; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Buckley TC, 2000, CLIN PSYCHOL REV, V20, P1041, DOI 10.1016/S0272-7358(99)00030-6; Campbell TA, 2009, PSYCHIAT ANN, V39, P796, DOI 10.3928/00485713-20090728-01; Delis DC, 2000, CALIFORNIA VERBAL LE; Gabbe BJ, 2003, BRIT J SPORT MED, V37, P545, DOI 10.1136/bjsm.37.6.545; Gilbertson MW, 2006, J ABNORM PSYCHOL, V115, P484, DOI 10.1037/0021-843X.115.3.484; Golden CJ, 2002, STROOP COLOR WORD TE; Golier J, 1997, INTEGR PHYS BEH SCI, V32, P52, DOI 10.1007/BF02688613; Green P., 1996, WORD MEMORY TEST USE; GURVITS TV, 1993, J NEUROPSYCH CLIN N, V5, P183; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Leskin LP, 2007, NEUROPSYCHOLOGY, V21, P275, DOI 10.1037/0894-4105.21.3.275; Levin HS, 1989, MILD HEAD INJURY; LEVINE MJ, 1988, COGNITIVE REHABILITA, V6, P14; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lux WE, 2007, J REHABIL RES DEV, V44, P951, DOI 10.1682/JRRD.2007.01.0009; Macklin ML, 1998, J CONSULT CLIN PSYCH, V66, P323, DOI 10.1037/0022-006X.66.2.323; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McGrath J, 1997, NEUROPSYCHOL REHABIL, V7, P231, DOI 10.1080/713755532; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; Ommaya AK, 1996, J TRAUMA, V41, P972, DOI 10.1097/00005373-199612000-00005; Parslow RA, 2007, AM J PSYCHIAT, V164, P509, DOI 10.1176/appi.ajp.164.3.509; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Ruff RM, 1999, BRAIN INJURY, V13, P943; Sachinvala N, 2000, J NERV MENT DIS, V188, P818, DOI 10.1097/00005053-200012000-00005; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; Sattler J.M., 2001, ASSESSMENT CHILDREN, V4th edn; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Spiro A, 2006, J AMBUL CARE MANAG, V29, P71; Stulemeijer M, 2007, BRAIN INJURY, V21, P309, DOI 10.1080/02699050701209980; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Tombaugh TN, 1996, TEST MEMORY MALINGER; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Wolfson D., 1993, HALSTEAD REITAN NEUR; Zeitzer MB, 2008, AAOHN J, V56, P347, DOI 10.3928/08910162-20080801-03	52	27	27	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	3					337	347	PII 934025482	10.1080/13854046.2010.550634			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	751RU	WOS:000289636100001	21360415				2021-06-18	
J	Resnik, L; Gray, M; Borgia, M				Resnik, Linda; Gray, Melissa; Borgia, Matthew			Measurement of community reintegration in sample of severely wounded servicemembers	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						community reintegration; disability; measurement; military healthcare; outcomes assessment; participation; psychometric testing; reliability; traumatic brain injury; veterans	TRAUMATIC-BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; VIETNAM VETERANS; DISABILITY; COMBAT; AFGHANISTAN; INTEGRATION; DEPLOYMENT; HANDICAP	The Community Reintegration of Servicemembers (CRIS) is a new measure of community reintegration. The purpose of this study was to test the CRIS with seriously injured combat veterans. Subjects were 68 patients at the Center for the Intrepid. Each patient completed three CRIS subscales, the 3-6Item Short Form Health Survey for Veterans (SF-36V), the Quality of Life Scale (QOLS), and two Craig Handicap Assessment and Reporting Technique subscales at visit 1 and the 3-month follow-up. Of the patients, 11 also completed the measures within 2 weeks of visit 1. We abstracted diagnoses and activities of daily living from the medical record. We evaluated test-retest reliability using intraclass correlation coefficients (ICCs). We evaluated concurrent validity with Pearson product moment correlations. We used multivariate analyses of variance to compare scores for subjects with and without posttraumatic stress disorder (PTSD), traumatic brain injury (TBI), and depression. Responsiveness analyses evaluated floor and ceiling effects, percent achieving minimal detectable change (MDC), effect size (ES), and the standardized response mean (SRM). CRIS subscale ICCs were 0.90 to 0.91. All subscales were moderately or strongly correlated with QOLS and SF-36V subscales. CRIS subscale scores were lower in PTSD and TBI groups (p < 0.05). CRIS Extent of Participation and Satisfaction with Participation subscales were lower for subjects with depression (p < 0.05). Of the sample, 17.4% to 23.2% had change greater than MDC. The ES ranged from 0.227 to 0.273 (SRM = 0.277-0.370), showing a small effect between visit 1 and the 3-month follow-up. Results suggest that the CRIS is a psychometrically sound choice for community reintegration measurement in severely wounded servicemembers.	[Resnik, Linda] Providence Dept Vet Affairs Med Ctr, Providence, RI USA; [Resnik, Linda; Borgia, Matthew] Brown Univ, Dept Community Hlth, Providence, RI 02912 USA; [Gray, Melissa] Brooke Army Med Ctr, San Antonio, TX USA	Resnik, L (corresponding author), Providence VA Med Ctr, 830 Chalkstone Ave, Providence, RI 02908 USA.	Linda_Resnik@brown.edu			VA, Veterans Health Administration, Office of Research and Development, Health Services Research and Development [SDR-07-327]	This material was based on work supported by the VA, Veterans Health Administration, Office of Research and Development, Health Services Research and Development (grant SDR-07-327).	Bellack AS, 2007, SCHIZOPHRENIA BULL, V33, P805, DOI 10.1093/schbul/sbl035; *BROOK, 2010, IR IND; BRUSTEIN J, 2006, GOTHAM GAZETTE   MAR, P4; BULLMAN TA, 1994, J NERV MENT DIS, V182, P604, DOI 10.1097/00005053-199411000-00002; Burckhardt Carol S, 2003, Health Qual Life Outcomes, V1, P60, DOI 10.1186/1477-7525-1-60; Cohen J., 1977, STAT POWER ANAL BEHA, P1; Committee on the Initial Assessment of Readjustment Needs of Military Personnel Veterans and Their Families, 2010, RET HOM IR AFGH PREL; Dekel R, 2004, ISRAEL J PSYCHIAT, V41, P237; Doyle ME, 2005, PSYCHIAT QUART, V76, P361, DOI 10.1007/s11126-005-4972-z; Fischer Hannah, 2009, US MILITARY CASUALTY; Freeman TW, 2001, J NERV MENT DIS, V189, P317, DOI 10.1097/00005053-200105000-00008; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hooper TI, 2006, ACCIDENT ANAL PREV, V38, P518, DOI 10.1016/j.aap.2005.11.009; Jette DU, 1996, PHYS THER, V76, P930, DOI 10.1093/ptj/76.9.930; Johnson DR, 2004, J NERV MENT DIS, V192, P35, DOI 10.1097/01.nmd.0000105998.90425.6a; Kazis LE, 1999, AM J MED QUAL, V14, P28, DOI 10.1177/106286069901400105; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Linden MA, 2005, DISABIL REHABIL, V27, P1353, DOI 10.1080/09638280500164180; Litz B., 2004, IRAQ WAR CLIN GUIDE; Luty SE, 2002, J AFFECT DISORDERS, V70, P143, DOI 10.1016/S0165-0327(01)00331-7; MCHORNEY CA, 1995, QUAL LIFE RES, V4, P293, DOI 10.1007/BF01593882; Neal LA, 2004, BRIT J PSYCHIAT, V184, P247, DOI 10.1192/bjp.184.3.247; Resnik L, 2009, J REHABIL RES DEV, V46, P469, DOI 10.1682/JRRD.2008.07.0082; Resnik LJ, 2007, J REHABIL RES DEV, V44, P991, DOI 10.1682/JRRD.2007.05.0071; ROSENHECK R, 1994, AM J PUBLIC HEALTH, V84, P466, DOI 10.2105/AJPH.84.3.466; ROSENHECK R, 1994, AM J PSYCHIAT, V151, P421; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Smith Mark W, 2005, Ment Health Serv Res, V7, P89, DOI 10.1007/s11020-005-3780-2; Stratford PW, 1996, PHYS THER, V76, P1109, DOI 10.1093/ptj/76.10.1109; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Ware JE., 1993, SF 36 HLTH SURVEY MA; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Yancosek K, 2008, J HAND THER, V21, P189, DOI 10.1197/j.jht.2007.12.002	35	27	29	0	12	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2011	48	2					89	101		10.1682/JRRD.2010.04.0070			13	Rehabilitation	Rehabilitation	733BQ	WOS:000288235800002	21480084	Bronze			2021-06-18	
J	Ahmed, AI; Eynon, CA; Kinton, L; Nicoll, JAR; Belli, A				Ahmed, A. I.; Eynon, C. A.; Kinton, L.; Nicoll, J. A. R.; Belli, A.			Decompressive Craniectomy for Acute Disseminated Encephalomyelitis	NEUROCRITICAL CARE			English	Article						Decompressive craniectomy; Acute disseminated encephalomyelitis	TRAUMATIC BRAIN-INJURY; HEMICRANIECTOMY; MULTICENTER	Acute disseminated encephalomyelitis (ADEM) is a rare, acute demyelinating condition. Although it usually presents in an acute or subacute manner over days, its clinical course may be rapid with symptoms and signs of severe intracerebral mass effect secondary to cerebral oedema. Case report and literature review. We report a case of a patient presenting with a hyperacute course manifested by rapid loss of consciousness and focal neurological signs. Management with emergency hemicraniectomy and steroids resulted in rapid neurological improvement and minimal long-term deficit. We believe that only surgical decompression is likely to be life saving in similar cases of hyperacute cerebral oedema due to ADEM. The wide decompression performed was concordant with that indicated for traumatic brain swelling. Such aggressive management is vindicated by the rapid recovery shown by our patient within days of surgery and the finding of minimal neurological sequelae at 3 months.	[Ahmed, A. I.; Nicoll, J. A. R.; Belli, A.] Univ Southampton, Div Clin Neurosci, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England; [Ahmed, A. I.; Eynon, C. A.; Kinton, L.; Nicoll, J. A. R.; Belli, A.] Southampton Univ Hosp NHS Trust, Wessex Neurol Ctr, Southampton SO16 6YD, Hants, England	Ahmed, AI (corresponding author), Univ Southampton, Div Clin Neurosci, Southampton Gen Hosp, LD83,Level D,S Acad Block,Tremona Rd, Southampton SO16 6YD, Hants, England.	a.ahmed@soton.ac.uk	Belli, Antonio/I-3799-2015; Nicoll, James/I-9253-2017	Belli, Antonio/0000-0002-3211-9933; Ahmed, Aminul/0000-0001-6670-0438; Nicoll, James/0000-0002-9444-7246			Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kakar V, 2009, BRIT J NEUROSURG, V23, P147, DOI 10.1080/02688690902756702; Marchioni E, 2008, NEUROL SCI, V29, pS286, DOI 10.1007/s10072-008-0966-6; Menge T, 2007, CURR OPIN NEUROL, V20, P247, DOI 10.1097/WCO.0b013e3280f31b45; Nilsson P, 2009, EUR J NEUROL, V16, P639, DOI 10.1111/j.1468-1331.2009.02547.x; Ragel BT, 2006, SURG NEUROL, V65, P582, DOI 10.1016/j.surneu.2005.08.015; Refai D, 2005, NEUROSURGERY, V56, P872, DOI 10.1227/01.NEU.0000156201.46473.A8; Schirmer CM, 2008, NEUROCRIT CARE, V8, P456, DOI 10.1007/s12028-008-9082-y; Sonneville R, 2009, J INFECTION, V58, P321, DOI 10.1016/j.jinf.2009.02.011; Takata T, 1999, J NEUROL SCI, V165, P94, DOI 10.1016/S0022-510X(99)00089-1; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; von Stuckrad-Barre S, 2003, NEUROLOGY, V61, P420, DOI 10.1212/01.WNL.0000073540.35919.AE	13	27	27	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	DEC	2010	13	3					393	395		10.1007/s12028-010-9420-8			3	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	685UO	WOS:000284653800017	20711687				2021-06-18	
J	Ball, CG; Navsaria, P; Kirkpatrick, AW; Vercler, C; Dixon, E; Zink, J; Laupland, KB; Lowe, M; Salomone, JP; Dente, CJ; Wyrzykowski, AD; Hameed, SM; Widder, S; Inaba, K; Ball, JE; Rozycki, GS; Montgomery, SP; Hayward, T; Feliciano, DV				Ball, Chad G.; Navsaria, Pradeep; Kirkpatrick, Andrew W.; Vercler, Christian; Dixon, Elijah; Zink, John; Laupland, Kevin B.; Lowe, Michael; Salomone, Jeffrey P.; Dente, Christopher J.; Wyrzykowski, Amy D.; Hameed, S. Morad; Widder, Sandy; Inaba, Kenji; Ball, Jill E.; Rozycki, Grace S.; Montgomery, Sean P.; Hayward, Thomas; Feliciano, David V.			The Impact of Country and Culture on End-of-Life Care for Injured Patients: Results From an International Survey	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Annual Scientific Meeting of the Trauma-Association-of-Canada	MAY 06-07, 2010	Halifax, CANADA	Trauma Assoc Canada		Trauma; End-of-life; Withdrawal of treatment	INTENSIVE-CARE; SUSTAINING TREATMENTS; CRITICALLY-ILL; CARDIAC DEATH; UNITED-STATES; DECISION-MAKING; TRAUMA PATIENTS; FAMILY-MEMBERS; ORGAN DONATION; PHYSICIANS	Background: Up to 20% of all trauma patients admitted to an intensive care unit die from their injuries. End-of-life decision making is a variable process that involves prognosis, predicted functional outcomes, personal beliefs, institutional resources, societal norms, and clinician experience. The goal of this study was to better understand end-of-life processes after major injury by comparing clinician viewpoints from various countries and cultures. Methods: A clinician-based, 38-question international survey was used to characterize the impacts of medical, religious, social, and system factors on end-of-life care after trauma. Results: A total of 419 clinicians from the United States (49%), Canada (19%), South Africa (11%), Europe (9%), Asia (8%), and Australasia (4%) completed the survey. In America, the admitting surgeon guided most end-of-life decisions (51%), when compared with all other countries (0-27%). The practice structure of American respondents also varied from other regions. Formal medical futility laws are rarely available (14-38%). Ethical consultation services are often accessible (29-98%), but rarely used (0-29%), and typically unhelpful (<30%). End-of-life decision making for patients with traumatic brain injuries varied extensively across regions with regard to the impact of patient age, Glasgow Coma Scale score, and clinician philosophy. Similar differences were observed for spinal cord injuries (age and functional level). The avail-ability and use of "donation after cardiac death" also varied substantially between countries. Conclusions: In this unique study, geographic differences in religion, practice composition, decision-maker viewpoint, and institutional resources resulted in significant variation in end-of-life care after injury. These disparities reflect competing concepts (patient autonomy, distributive justice, and religion).	[Ball, Chad G.; Vercler, Christian; Zink, John; Lowe, Michael; Salomone, Jeffrey P.; Dente, Christopher J.; Wyrzykowski, Amy D.; Ball, Jill E.; Rozycki, Grace S.; Feliciano, David V.] Emory Univ, Grady Mem Hosp, Dept Surg, Atlanta, GA 30322 USA; [Navsaria, Pradeep] Univ Cape Town, Dept Surg, Groote Schuur Hosp, ZA-7925 Cape Town, South Africa; [Kirkpatrick, Andrew W.; Dixon, Elijah; Laupland, Kevin B.] Univ Calgary, Dept Surg, Calgary, AB, Canada; [Hameed, S. Morad] Univ British Columbia, Dept Surg, Vancouver, BC V6T 1W5, Canada; [Widder, Sandy] Univ Alberta, Dept Surg, Edmonton, AB, Canada; [Inaba, Kenji] Univ So Calif, Dept Surg, Los Angeles, CA USA; [Montgomery, Sean P.] Walter Reed Army Med Ctr, Dept Surg, Washington, DC 20307 USA; [Hayward, Thomas] Wishard Mem Hosp, Dept Surg, Indianapolis, IN USA	Ball, CG (corresponding author), Emory Univ, Grady Mem Hosp, Dept Surg, Grady Mem Hosp Campus,Glenn Mem Bldg,Room 302,69, Atlanta, GA 30322 USA.	ball.chad@gmail.com	Navsaria, Pradeep/AAS-1807-2020; INABA, KENJI/AAC-8532-2020; Laupland, kevin/AAJ-6339-2020; Laupland, Kevin/AAG-3656-2020	Navsaria, Pradeep/0000-0002-5152-3317; Laupland, kevin/0000-0002-1205-5354; 			ALEMAYEHU E, 1991, CAN MED ASSOC J, V144, P1133; Angus DC, 2004, CRIT CARE MED, V32, P638, DOI 10.1097/01.CCM.0000114816.62331.08; [Anonymous], 1995, JAMA, V274, P1591; ASCH DA, 1995, AM J RESP CRIT CARE, V151, P288, DOI 10.1164/ajrccm.151.2.7842181; Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987, DOI 10.1164/rccm.200409-1295OC; BEDELL SE, 1984, NEW ENGL J MED, V310, P1089, DOI 10.1056/NEJM198404263101706; Bernat JL, 2006, AM J TRANSPLANT, V6, P281, DOI 10.1111/j.1600-6143.2005.01194.x; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; Carlet J, 2004, INTENS CARE MED, V30, P770, DOI 10.1007/s00134-004-2241-5; Cohen S, 2005, INTENS CARE MED, V31, P1215, DOI 10.1007/s00134-005-2742-x; COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; Cooper Z, 2009, J TRAUMA, V66, P1327, DOI 10.1097/TA.0b013e31819ea047; Curtis JR, 2004, CRIT CARE CLIN, V20, P363, DOI 10.1016/j.ccc.2004.03.001; DANIS M, 1988, CRIT CARE MED, V16, P594, DOI 10.1097/00003246-198806000-00006; Deliens L, 2000, LANCET, V356, P1806, DOI 10.1016/S0140-6736(00)03233-5; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; Ethics Section of the European Society of Intensive Care Medicine, 2009, WELPICUS PROJ CONS G; FaberLangendoen K, 1996, ARCH INTERN MED, V156, P2130, DOI 10.1001/archinte.156.18.2130; Ferrand E, 2001, LANCET, V357, P9, DOI 10.1016/S0140-6736(00)03564-9; Field MJ, 1997, APPROACHING DEATH IM; Giannini A, 2003, INTENS CARE MED, V29, P1902, DOI 10.1007/s00134-003-1919-4; Grossman E, 2009, WORLD J SURG, V33, P1338, DOI 10.1007/s00268-009-9997-2; Heyland DK, 2003, INTENS CARE MED, V29, P75, DOI 10.1007/s00134-002-1569-y; HIGH DM, 1988, GERONTOLOGIST, V28, P46, DOI 10.1093/geront/28.Suppl.46; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jones JW, 2002, J VASC SURG, V35, P1305, DOI 10.1067/mva.2002.124492; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; Lynn J, 2000, J AM GERIATR SOC, V48, pS214, DOI 10.1111/j.1532-5415.2000.tb03135.x; Mandell MS, 2006, CRIT CARE MED, V34, P2952, DOI 10.1097/01.CCM.0000247718.27324.65; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; Mosenthal AC, 2008, J TRAUMA, V64, P1587, DOI 10.1097/TA.0b013e318174f112; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Norris P, 2004, SACRED SECULAR RELIG; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2101, DOI 10.1001/jama.267.15.2101; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; Pochard F, 2001, CRIT CARE MED, V29, P1887, DOI 10.1097/00003246-200110000-00006; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; President ' Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DEC FOR LIF SUST TRE, P73; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; Sjokvist P, 1998, CLIN INTENSIVE CARE, V9, P81; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; Sprung CL, 2007, INTENS CARE MED, V33, P104, DOI 10.1007/s00134-006-0405-1; Sprung CL, 2007, INTENS CARE MED, V33, P1732, DOI 10.1007/s00134-007-0693-0; SPRUNG CL, 1992, CRIT CARE MED, V20, P320; Sprung CL, 1996, INTENS CARE MED, V22, P1003; Sprung CL, 1996, MAYO CLIN PROC, V71, P512, DOI 10.4065/71.5.512; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; Steinberg A, 2006, INTENS CARE MED, V32, P1234, DOI 10.1007/s00134-006-0186-6; Steinbrook R, 2007, NEW ENGL J MED, V357, P209, DOI 10.1056/NEJMp078066; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; Truog RD, 2001, CRIT CARE MED, V29, P2332, DOI 10.1097/00003246-200112000-00017; WEBSTER GC, 1991, CAN J ANAESTH, V38, P553, DOI 10.1007/BF03008184; WEIR RF, 1990, JAMA-J AM MED ASSOC, V264, P1846, DOI 10.1001/jama.264.14.1846	56	27	27	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2010	69	6					1323	1333		10.1097/TA.0b013e3181f66878			11	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	695RT	WOS:000285391000012	21045742				2021-06-18	
J	Metting, Z; Rodiger, LA; de Jong, BM; Stewart, RE; Kremer, BP; van der Naalt, J				Metting, Zwany; Rodiger, Lars A.; de Jong, Bauke M.; Stewart, Roy E.; Kremer, Berry P.; van der Naalt, Joukje			Acute Cerebral Perfusion CT Abnormalities Associated with Posttraumatic Amnesia in Mild Head Injury	JOURNAL OF NEUROTRAUMA			English	Article						mild head injury; perfusion computed tomography; posttraumatic amnesia	TRANSIENT GLOBAL AMNESIA; TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; PREFRONTAL CORTEX; DISSOCIATION; DYSFUNCTION; IMPAIRMENT; METABOLISM; ANATOMY; RETURN	Posttraumatic amnesia (PTA) is a common symptom following traumatic brain injury. Although this transient memory deficit implies specific impairment of higher brain function, the actual pathophysiology of PTA is not well understood. The aim of this study was to assess regional cerebral hemodynamics with perfusion computed tomography (CT) in patients during PTA following mild head injury compared to patients with resolved PTA. A total of 74 patients with mild head injury without structural abnormalities on a non-contrast CT scan were included and compared to 25 healthy controls. Two patient groups were defined: (1) a PTA group that was scanned during the episode of PTA (n = 34), and (2) a post-PTA group scanned after resolution of PTA (n = 40). The PTA group had significantly reduced cerebral blood flow (CBF) in the frontal grey matter (41.78 [SD 7.4] versus 44.44 [SD 6.2] mL . 100 g(-1) . min(-1), p = 0.023), and caudate nucleus (44.59 [SD 6.2] versus 47.85 [SD 7.7] mL . 100 g(-1) . min(-1), p = 0.021), compared to the post-PTA group. Thus in patients with mild head injury, PTA is associated with cerebral perfusion abnormalities in specific cortical and subcortical regions.	[Metting, Zwany; de Jong, Bauke M.; Kremer, Berry P.; van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9700 RB Groningen, Netherlands; [Rodiger, Lars A.] Univ Groningen, Univ Med Ctr Groningen, Dept Radiol, NL-9700 RB Groningen, Netherlands; [Stewart, Roy E.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, NL-9700 RB Groningen, Netherlands	Metting, Z (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1,POB 30-001, NL-9700 RB Groningen, Netherlands.	z.metting@neuro.umcg.nl			ZonMw, Den Haag, The NetherlandsNetherlands Organization for Health Research and DevelopmentNetherlands Government [39200002]	This study was funded by a grant (number 39200002) from ZonMw, Den Haag, The Netherlands. The authors thank W.G.J. Tukker and M.M. Sprenger for their assistance.	Ahmed S, 2000, BRAIN INJURY, V14, P765; BARON JC, 1994, BRAIN, V117, P545, DOI 10.1093/brain/117.3.545; Bartsch T, 2010, LANCET NEUROL, V9, P205, DOI 10.1016/S1474-4422(09)70344-8; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Blumenfeld RS, 2007, NEUROSCIENTIST, V13, P280, DOI 10.1177/1073858407299290; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; Eastwood JD, 2002, RADIOLOGY, V222, P227, DOI 10.1148/radiol.2221010471; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Eustache F, 1997, J NEUROL NEUROSUR PS, V63, P357, DOI 10.1136/jnnp.63.3.357; FAZIO F, 1992, J CEREBR BLOOD F MET, V12, P353, DOI 10.1038/jcbfm.1992.52; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Fletcher PC, 2001, BRAIN, V124, P849, DOI 10.1093/brain/124.5.849; Funahashi S, 2006, NEUROSCIENCE, V139, P251, DOI 10.1016/j.neuroscience.2005.07.003; GOLDBERG E, 1982, Journal of Clinical Neuropsychology, V4, P219, DOI 10.1080/01688638208401131; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Metting Z, 2009, ANN NEUROL, V66, P809, DOI 10.1002/ana.21785; Nariai T, 2001, J NEUROTRAUM, V18, P1323, DOI 10.1089/08977150152725623; NISSEN MJ, 1987, NEUROLOGY, V37, P789, DOI 10.1212/WNL.37.5.789; Pantoni L, 2000, ACTA NEUROL SCAND, V102, P275, DOI 10.1034/j.1600-0404.2000.102005275.x; Raichle ME, 1998, P NATL ACAD SCI USA, V95, P765, DOI 10.1073/pnas.95.3.765; RIESE W, 1958, Int Rec Med Gen Pract Clin, V171, P73; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Schlosser RGM, 2006, NEUROSCIENCE, V139, P91, DOI 10.1016/j.neuroscience.2005.06.037; Schmidtke K, 1998, J NUCL MED, V39, P155; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; Soustiel JF, 2008, NEURORADIOLOGY, V50, P189, DOI 10.1007/s00234-007-0337-7; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Warren JD, 2000, J CLIN NEUROSCI, V7, P57, DOI 10.1054/jocn.1998.0129; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Yamane Y, 2008, J COMPUT ASSIST TOMO, V32, P415, DOI 10.1097/RCT.0b013e3180de5b9b; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	37	27	28	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2183	2189		10.1089/neu.2010.1395			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400008	20939700				2021-06-18	
J	Bondanelli, M; Ambrosio, MR; Carli, A; Bergonzoni, A; Bertocchi, A; Zatelli, MC; Ceruti, S; Valle, D; Basaglia, N; degli Uberti, E				Bondanelli, Marta; Ambrosio, Maria Rosaria; Carli, Anna; Bergonzoni, Antonella; Bertocchi, Amedeo; Zatelli, Maria Chiara; Ceruti, Stefano; Valle, Domenico; Basaglia, Nino; degli Uberti, Ettore			Predictors of Pituitary Dysfunction in Patients Surviving Ischemic Stroke	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article							TRAUMATIC BRAIN-INJURY; ENDOCRINE-SOCIETY; ASSOCIATION; HYPOPITUITARISM; ABNORMALITIES; HYPERGLYCEMIA; RELIABILITY; GUIDELINES; STATEMENT; DIAGNOSIS	Backround: Stroke is a leading cause of death in industrialized countries, representing the main cause of long-term disability. Recent studies indicate that hypopituitarism may be observed after an acute stroke. Objective: The aim was to prospectively investigate incidence and pattern of pituitary dysfunction in patients suffering ischemic stroke and to assess the predictive value of different clinical and radiological parameters for hypopituitarism. Patients and Methods: We assessed endocrine, clinical, radiological, and functional parameters in 56 patients (34 males; mean age, 64.8 +/- 1.3 yr; mean body mass index, 25.8 +/- 0.45 kg/m(2)) at 1-3 months (visit 1) and 12-15 months (visit 2) after an ischemic stroke. Results: At visit 1, hypopituitarism was detected in 20 (35.7%) of 56 stroke patients, with multiple deficits in three and isolated deficits in 17. At visit 2, hypopituitarism was detected in 18 (37.5%) of 48 stroke patients, with multiple deficits in two. Four patients with previously diagnosed isolated GH or LH/FSH deficit exhibited normal pituitary function, whereas GH deficiency was newly diagnosed in three cases. Hypopituitarism was associated with worse outcome. We identified both clinical (preexisting diabetes mellitus, medical complications during hospitalization) and radiological (Alberta Stroke Programme Early CT Score <= 7) parameters as major risk factors for developing hypopituitarism after ischemic stroke. Conclusions: Hypopituitarism may associate with ischemic stroke in one third of cases and persist in a long-term period, aggravating the functional outcome. We identified specific risk factors for hypopituitarism after stroke, which may help to select patients needing an accurate endocrine evaluation to improve stroke outcome. (J Clin Endocrinol Metab 95: 4660-4668, 2010)	[Bondanelli, Marta; Ambrosio, Maria Rosaria; Carli, Anna; Zatelli, Maria Chiara; degli Uberti, Ettore] Univ Ferrara, Endocrinol Sect, Dept Biomed Sci & Adv Therapies, I-44100 Ferrara, Italy; [Bergonzoni, Antonella; Bertocchi, Amedeo; Basaglia, Nino] Univ Ferrara, Azienda Osped, Dept Rehabil Med, I-44121 Ferrara, Italy; [Ceruti, Stefano] Univ Ferrara, Azienda Osped, Neuroradiol Unit, I-44121 Ferrara, Italy; [Valle, Domenico] Eli Lilly & Co, I-50019 Florence, Italy	degli Uberti, E (corresponding author), Univ Ferrara, Endocrinol Sect, Dept Biomed Sci & Adv Therapies, Via Savonarola 9, I-44100 Ferrara, Italy.	ti8@unife.it	Zatelli, Maria Chiara/Y-1160-2019; Zatelli, Maria Chiara/U-2649-2018	ambrosio, maria rosaria/0000-0002-7911-9770; Bondanelli, Marta/0000-0001-8071-6559; degli Uberti, Ettore/0000-0002-9441-7223; Zatelli, Maria Chiara/0000-0001-8408-7796	Fondazione Cassa di Risparmio di FerraraFondazione Carife; Associazione Ferrarese dell'Ipertensione Arteriosa; Italian Ministry of University and Scientific and Technological ResearchMinistry of Education, Universities and Research (MIUR)	This work was supported by grants from the Italian Ministry of University and Scientific and Technological Research to the University of Ferrara and FAR 2009, Fondazione Cassa di Risparmio di Ferrara, and Associazione Ferrarese dell'Ipertensione Arteriosa.	Adams HP, 2004, CEREBROVASC DIS, V18, P124, DOI 10.1159/000079260; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aviv RI, 2007, AM J NEURORADIOL, V28, P1975, DOI 10.3174/ajnr.A0689; Baliga Bantwal Suresh, 2006, Curr Cardiol Rep, V8, P23, DOI 10.1007/s11886-006-0006-1; Barber PA, 2000, LANCET, V355, P1670, DOI 10.1016/S0140-6736(00)02237-6; BERGER L, 1986, STROKE, V17, P865, DOI 10.1161/01.STR.17.5.865; Bhasin S, 2006, J CLIN ENDOCR METAB, V91, P1995, DOI 10.1210/jc.2005-2847; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bondanelli M, 2008, J Endocrinol Invest, V31, P16; Bondanelli M, 2008, PITUITARY, V11, P187, DOI 10.1007/s11102-008-0112-8; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Bondanelli M, 2006, J CLIN ENDOCR METAB, V91, P3928, DOI 10.1210/jc.2006-1040; Denti L, 2004, AM J MED, V117, P312, DOI 10.1016/j.amjmed.2004.02.049; Dimopoulou I, 2005, INTENS CARE MED, V31, P1020, DOI 10.1007/s00134-005-2689-y; Dimopoulou I, 2004, STROKE, V35, P2884, DOI 10.1161/01.STR.0000147716.45571.45; Dimopoulou I, 2004, INTENS CARE MED, V30, P1216, DOI 10.1007/s00134-004-2297-2; GANDOLFO C, 2007, SPREAD STROKE PREVEN, P45; Goldstein LB, 1997, STROKE, V28, P307, DOI 10.1161/01.STR.28.2.307; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Johansson A, 2000, J INTERN MED, V247, P179, DOI 10.1046/j.1365-2796.2000.00600.x; Kelly-Hayes M, 1998, STROKE, V29, P1274, DOI 10.1161/01.STR.29.6.1274; Kissela B, 2009, STROKE, V40, P530, DOI 10.1161/STROKEAHA.108.521906; Klose M, 2010, CLIN ENDOCRINOL, V73, P95, DOI 10.1111/j.1365-2265.2010.03791.x; Nordborg C, 1996, ACTA NEUROPATHOL, V91, P61; OLSSON T, 1992, STROKE, V23, P1573, DOI 10.1161/01.STR.23.11.1573; Puetz V, 2008, STROKE, V39, P2485, DOI 10.1161/STROKEAHA.107.511162; Qiao M, 2009, INT J DEV NEUROSCI, V27, P691, DOI 10.1016/j.ijdevneu.2009.07.004; Sacco RL, 2006, STROKE, V37, P577, DOI 10.1161/01.STR.0000199147.30016.74; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Szczudlik A, 2001, J NEUROL SCI, V189, P105, DOI 10.1016/S0022-510X(01)00566-4; Ustrell-Roig X, 2007, REV ESP CARDIOL, V60, P753, DOI 10.1157/13108281; van Rijn MJE, 2006, J NEUROL NEUROSUR PS, V77, P24, DOI 10.1136/jnnp.2005.067447; Walker A, 1981, STROKE S1, V12, P113; Weant KA, 2008, NEUROSURGERY, V63, P645, DOI 10.1227/01.NEU.0000325728.50939.15	35	27	27	1	2	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0021-972X	1945-7197		J CLIN ENDOCR METAB	J. Clin. Endocrinol. Metab.	OCT	2010	95	10					4660	4668		10.1210/jc.2010-0611			9	Endocrinology & Metabolism	Endocrinology & Metabolism	659NK	WOS:000282573300024	20660027	Bronze			2021-06-18	
J	Ottens, AK; Bustamante, L; Golden, EC; Yao, CP; Hayes, RL; Wang, KKW; Tortella, FC; Dave, JR				Ottens, Andrew K.; Bustamante, Liliana; Golden, Erin C.; Yao, Changping; Hayes, Ronald L.; Wang, Kevin K. W.; Tortella, Frank C.; Dave, Jitendra R.			Neuroproteomics: A Biochemical Means To Discriminate the Extent and Modality of Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; middle cerebral artery occlusion; ischemia; proteomics; traumatic brain injury	NEURON-SPECIFIC ENOLASE; CYTOSKELETON-ASSOCIATED PROTEIN; SERUM BIOMARKER CONCENTRATIONS; CONTROLLED CORTICAL IMPACT; CEREBROSPINAL-FLUID; PROTEOMIC ANALYSIS; CEREBRAL-ISCHEMIA; DIAGNOSTIC-TEST; FOCAL ISCHEMIA; CARDIAC-ARREST	Diagnosis and treatment of stroke and traumatic brain injury remain significant health care challenges to society. Patient care stands to benefit from an improved understanding of the interactive biochemistry underlying neurotrauma pathobiology. In this study, we assessed the power of neuroproteomics to contrast biochemical responses following ischemic and traumatic brain injuries in the rat. A middle cerebral artery occlusion (MCAO) model was employed in groups of 30-min and 2-h focal neocortical ischemia with reperfusion. Neuroproteomes were assessed via tandem cation-anion exchange chromatography-gel electrophoresis, followed by reversed-phase liquid chromatography-tandem mass spectrometry. MCAO results were compared with those from a previous study of focal contusional brain injury employing the same methodology to characterize homologous neocortical tissues at 2 days post-injury. The 30-min MCAO neuroproteome depicted abridged energy production involving pentose phosphate, modulated synaptic function and plasticity, and increased chaperone activity and cell survival factors. The 2-h MCAO data indicated near complete loss of ATP production, synaptic dysfunction with degraded cytoarchitecture, more conservative chaperone activity, and additional cell survival factors than those seen in the 30-min MCAO model. The TBI group exhibited disrupted metabolism, but with retained malate shuttle functionality. Synaptic dysfunction and cytoarchitectural degradation resembled the 2-h MCAO group; however, chaperone and cell survival factors were more depressed following TBI. These results underscore the utility of neuroproteomics for characterizing interactive biochemistry for profiling and contrasting the molecular aspects underlying the pathobiological differences between types of brain injuries.	[Ottens, Andrew K.] Virginia Commonwealth Univ, Dept Anat, Med Coll Virginia, Richmond, VA 23298 USA; [Ottens, Andrew K.] Virginia Commonwealth Univ, Dept Neurobiol, Med Coll Virginia, Richmond, VA 23298 USA; [Ottens, Andrew K.] Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia, Richmond, VA 23298 USA; [Bustamante, Liliana; Golden, Erin C.; Wang, Kevin K. W.] Univ Florida, Dept Psychiat, McKnight Brain Inst, Gainesville, FL 32611 USA; [Yao, Changping; Tortella, Frank C.; Dave, Jitendra R.] Walter Reed Army Inst Res, Dept Appl Neurobiol, Div Psychiat & Neurosci, Silver Spring, MD USA; [Hayes, Ronald L.; Wang, Kevin K. W.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL USA	Ottens, AK (corresponding author), Virginia Commonwealth Univ, Dept Anat, Med Coll Virginia, POB 980709, Richmond, VA 23298 USA.	akottens@vcu.edu	Ottens, Andrew/K-3352-2012; Dave, Jitendra R/A-8940-2011	Wang, Kevin/0000-0002-9343-6473; Ottens, Andrew/0000-0002-2118-3796	Department of DefenseUnited States Department of Defense [DAMD1703-1-0066]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS055012]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K25NS055012] Funding Source: NIH RePORTER	Our thanks go to Drs. Povlishock and McGinn Greer for their thoughtful feedback. This work was supported by Department of Defense grant DAMD1703-1-0066, and the National Institute of Neurological Disorders and Stroke grant NS055012. This article was reviewed by the Walter Reed Army Institute of Research, and there was no objection to its presentation and publication. The opinions and assertions contained herein are the private views of the authors, and are not to be construed as official, or as reflecting the views of the Department of the Army or the Department of Defense.	Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724; Angeletti PC, 2002, CELL STRESS CHAPERON, V7, P258, DOI 10.1379/1466-1268(2002)007<0258:SGRPVP>2.0.CO;2; Baird Alison E, 2006, Curr Atheroscler Rep, V8, P267, DOI 10.1007/s11883-006-0003-2; Baron JC, 2001, CEREBROVASC DIS, V11, P2, DOI 10.1159/000049119; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Britton P, 1997, LIFE SCI, V60, P1729, DOI 10.1016/S0024-3205(97)00132-X; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Chan PH, 2004, NEUROCHEM RES, V29, P1943, DOI 10.1007/s11064-004-6869-x; Chen A, 2007, NEUROCHEM INT, V50, P1078, DOI 10.1016/j.neuint.2006.11.008; Chen DM, 2006, J PHARMACOL EXP THER, V319, P165, DOI 10.1124/jpet.106.104380; Chen MZ, 1998, J NEUROTRAUM, V15, P171, DOI 10.1089/neu.1998.15.171; Cid C, 2007, PROTEOMICS, V7, P3207, DOI 10.1002/pmic.200700214; Cunningham RT, 1996, EUR J CLIN INVEST, V26, P298, DOI 10.1046/j.1365-2362.1996.129282.x; CUNNINGHAM RT, 1991, EUR J CLIN INVEST, V21, P497, DOI 10.1111/j.1365-2362.1991.tb01401.x; Daniel S, 2008, BBA-MOL CELL RES, V1783, P1003, DOI 10.1016/j.bbamcr.2008.01.014; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; DAUBERSCHMIDT R, 1991, MOL CHEM NEUROPATHOL, V14, P237, DOI 10.1007/BF03159939; Depaz IM, 2006, BRAIN RES, V1081, P59, DOI 10.1016/j.brainres.2006.01.126; Dhodda VK, 2004, J NEUROCHEM, V89, P73, DOI 10.1111/j.1471-4159.2004.02316.x; Dubaquie Y, 1997, P NATL ACAD SCI USA, V94, P9011, DOI 10.1073/pnas.94.17.9011; Ekegren T, 2008, J MASS SPECTROM, V43, P559, DOI 10.1002/jms.1409; Focking M, 2006, ACTA NEUROBIOL EXP, V66, P273; Gao WM, 2007, J NEUROTRAUM, V24, P43, DOI 10.1089/neu.2006.0061; Giffard RG, 2004, J EXP BIOL, V207, P3213, DOI 10.1242/jeb.01034; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Haqqani AS, 2007, J NEUROTRAUM, V24, P54, DOI 10.1089/neu.2006.0079; Hergenroeder G, 2008, J NEUROTRAUM, V25, P79, DOI 10.1089/neu.2007.0386; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Ito M, 2005, NEUROSCI LETT, V378, P125, DOI 10.1016/j.neulet.2004.12.079; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Junker H, 2007, GLIA, V55, P1630, DOI 10.1002/glia.20581; Kang CB, 2008, NEUROSIGNALS, V16, P318, DOI 10.1159/000123041; Kent DM, 2003, STROKE, V34, P464, DOI 10.1161/01.STR.0000051506.43212.8B; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kleindienst A, 2005, J NEUROSURG, V102, P1115, DOI 10.3171/jns.2005.102.6.1115; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Kochanek AR, 2006, DEV NEUROSCI-BASEL, V28, P410, DOI 10.1159/000094167; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Koh PO, 2010, J VET MED SCI, V72, P181, DOI 10.1292/jvms.09-0364; Kukacka J, 2006, NEUROENDOCRINOL LETT, V27, P116; Laskowitz DT, 2009, STROKE, V40, P77, DOI 10.1161/STROKEAHA.108.516377; Lee JE, 2001, EXP NEUROL, V170, P129, DOI 10.1006/exnr.2000.7614; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Lynch JR, 2004, STROKE, V35, P57, DOI 10.1161/01.STR.0000105927.62344.4C; Macleod MR, 2005, J CEREBR BLOOD F MET, V25, P713, DOI 10.1038/sj.jcbfm.9600064; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Minger SL, 1998, BRAIN RES, V810, P181, DOI 10.1016/S0006-8993(98)00921-4; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Montaner J, 2006, DRUG NEWS PERSPECT, V19, P523, DOI 10.1358/dnp.2006.19.9.1050422; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Ottens AK, 2005, ANAL CHEM, V77, P4836, DOI 10.1021/ac050478r; Ottens AK, 2007, PROG BRAIN RES, V161, P401, DOI 10.1016/S0079-6123(06)61029-7; Pak JH, 2000, P NATL ACAD SCI USA, V97, P11232, DOI 10.1073/pnas.210184697; Pettigrew LC, 1996, J CEREBR BLOOD F MET, V16, P1189, DOI 10.1097/00004647-199611000-00013; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Prieto DA, 2008, EXPERT REV PROTEOMIC, V5, P283, DOI 10.1586/14789450.5.2.283; Rajdev S, 2000, TOXICOL PATHOL, V28, P105, DOI 10.1177/019262330002800113; Reynolds MA, 2003, CLIN CHEM, V49, P1733, DOI 10.1373/49.10.1733; ROINE RO, 1989, ARCH NEUROL-CHICAGO, V46, P753, DOI 10.1001/archneur.1989.00520430047015; Schellinger PD, 2003, STROKE, V34, P575, DOI 10.1161/01.STR.0000051504.10095.9C; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sung JH, 2009, J PINEAL RES, V46, P300, DOI 10.1111/j.1600-079X.2008.00661.x; Terada K, 2001, CEREBROVASC DIS, V11, P9, DOI 10.1159/000047606; Tsuchiya D, 2003, NEUROSURGERY, V53, P1179, DOI 10.1227/01.NEU.0000090341.38659.CF; Tzoulaki I, 2007, CIRCULATION, V115, P2119, DOI 10.1161/CIRCULATIONAHA.106.635029; Tzoulaki I, 2007, EUR HEART J, V28, P354, DOI 10.1093/eurheartj/ehl441; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Williams AJ, 2000, J PHARMACOL EXP THER, V294, P378; Wunderlich MT, 2006, CLIN NEUROL NEUROSUR, V108, P558, DOI 10.1016/j.clineuro.2005.12.006; Yao C, 2003, NEUROTOX RES, V5, P245, DOI 10.1007/BF03033382; Yao CP, 2008, BRAIN INJURY, V22, P723, DOI 10.1080/02699050802304706; Yao CP, 2009, J NEUROTRAUM, V26, P1295, DOI [10.1089/neu.2008.0811, 10.1089/neu.2008-0811]; Yao H, 2009, NEUROCHEM RES, V34, P1999, DOI 10.1007/s11064-009-9988-6; Zetterberg H, 2008, ACTA NEUROL SCAND, V118, P1, DOI 10.1111/j.1600-0404.2007.00985.x; Zhang J, 2008, J NEUROPATH EXP NEUR, V67, P923, DOI 10.1097/NEN.0b013e318187a832; Zhang ZJ, 2009, NEUROCHEM INT, V54, P488, DOI 10.1016/j.neuint.2009.02.005	89	27	27	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2010	27	10					1837	1852		10.1089/neu.2010.1374			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	665OZ	WOS:000283046600008	20698760	Green Published			2021-06-18	
J	Egeland, J; Johansen, SN; Ueland, T				Egeland, Jens; Johansen, Susanne Nordby; Ueland, Torill			Do Low-Effort Learning Strategies Mediate Impaired Memory in ADHD?	JOURNAL OF LEARNING DISABILITIES			English	Article						ADHD; memory; effort; elaborative encoding; semantic organization; proactive and retroactive interference; serial position effect	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; CHILDREN; MODEL; PERFORMANCE; DEFICITS; BOYS; SCHIZOPHRENIA; HYPERACTIVITY	As a group, participants with attention-deficit/hyperactivity disorder (ADHD) are impaired in academic performance and learning. This may be due to a mild intellectual impairment, impaired attention, or inability to allocate sufficient effort. If the latter is the case, this should be evident in the learning strategies applied. Four indices of learning strategy, considered to measure degree of effort, were analyzed from 67 participants with ADHD and 67 age-matched normal controls between 9 and 16 years of age. The participants with ADHD were impaired with regard to semantic clustering, retroactive interference, and percentage items reported from the middle section of the list even when controlling for IQ and comorbid conduct or oppositional defiant disorders symptoms. In addition, participants with combined ADHD (ADHD-C) did not display the normal proactive interference effect. The four effort indices explained 39% and 35% of the variance in free recall among participants with inattentive ADHD (ADHD-I) and ADHD-C, respectively. IQ was still significant when the effect of strategy measures were accounted for, whereas diagnosis was no longer significant when entered into the regression analysis after the effort indices. The study shows that participants with ADHD employ less effortful learning strategies than healthy controls and that low effort to a large degree can account for diagnosis related variance in memory performance.	[Egeland, Jens] Vestfold Mental Hlth Care Trust, Dept Res, N-3103 Tonsberg, Norway	Egeland, J (corresponding author), Vestfold Mental Hlth Care Trust, Dept Res, Box 2267, N-3103 Tonsberg, Norway.	jens.egeland@piv.no	Ueland, Torill/AAO-1277-2021	Ueland, Torill/0000-0002-8638-1152			Achenbach T. M., 1991, MANUAL CHILD BEHAV C; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Barkley R. A., 1997, ADHD NATURE SELF CON; BENEZRA E, 1988, J ABNORM CHILD PSYCH, V16, P511, DOI 10.1007/BF00914263; Blanchet S, 2001, NEUROPSYCHOLOGIA, V39, P502, DOI 10.1016/S0028-3932(00)00119-6; Carlson CL, 2002, J LEARN DISABIL-US, V35, P104, DOI 10.1177/002221940203500202; Cornoldi C, 1999, DEV NEUROPSYCHOL, V15, P53; Cutting LE, 2003, J LEARN DISABIL-US, V36, P259, DOI 10.1177/002221940303600305; Delis D, 1994, CALIFORNIA VERBAL LE; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; Delis DC, 2000, CALIFORNIA VERBAL LE; Donders J, 2004, J INT NEUROPSYCH SOC, V10, P482, DOI 10.1017/S1355617704104025; Egeland, 2005, TIDSSKRIFT NORSK PSY, V42, P99; Egeland J, 2007, ARCH CLIN NEUROPSYCH, V22, P763, DOI 10.1016/j.acn.2007.06.004; Egeland J, 2006, NORD PSYCHOL, V58, P136, DOI 10.1027/1901-2276.58.2.136; ELLIS HC, 1984, J EXP PSYCHOL LEARN, V10, P470, DOI 10.1037/0278-7393.10.3.470; Elwood RW, 1995, NEUROPSYCHOL REV, V5, P173, DOI 10.1007/BF02214761; Friedman NP, 2004, J EXP PSYCHOL GEN, V133, P101, DOI 10.1037/0096-3445.133.1.101; GUALTIERI CT, 1982, J AM ACAD CHILD PSY, V21, P19, DOI 10.1097/00004583-198201000-00005; Hallowell E. D., 2005, DELIVERED DISTRACTIO; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; Hazell PL, 1999, J CHILD PSYCHOL PSYC, V40, P275, DOI 10.1111/1469-7610.00441; HILDEBRAND DK, 2001, HDB PSYCHOEDUCATIONA, P13; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P77, DOI 10.1016/j.acn.2005.07.007; Jensen PS, 2001, J DEV BEHAV PEDIATR, V22, P60, DOI 10.1097/00004703-200102000-00008; Kaplan BJ, 1998, J CLIN EXP NEUROPSYC, V20, P518, DOI 10.1076/jcen.20.4.518.1477; Kareken D A, 1996, J Int Neuropsychol Soc, V2, P486; KATARIA S, 1992, J CLIN PSYCHOL, V48, P371, DOI 10.1002/1097-4679(199205)48:3<371::AID-JCLP2270480316>3.0.CO;2-F; Levin HS, 2000, J CLIN EXP NEUROPSYC, V22, P1, DOI 10.1076/1380-3395(200002)22:1;1-8;FT001; Lockwood KA, 2001, J CLIN EXP NEUROPSYC, V23, P317, DOI 10.1076/jcen.23.3.317.1179; LOGE DV, 1990, J AM ACAD CHILD PSY, V29, P540, DOI 10.1097/00004583-199007000-00006; LORSBACH TC, 1985, J LEARN DISABIL-US, V18, P222, DOI 10.1177/002221948501800408; Martinussen R, 2005, J AM ACAD CHILD PSY, V44, P377, DOI 10.1097/01.chi.0000153228.72591.73; Muir-Broaddus JE, 2002, ARCH CLIN NEUROPSYCH, V17, P671, DOI 10.1016/S0887-6177(01)00170-6; Novik TS, 2000, EUR CHILD ADOLES PSY, V9, P54, DOI 10.1007/s007870050116; O'Donnell L., 2005, DISS ABSTR INT B, V65, P4843; Perry W, 2001, SCHIZOPHRENIA BULL, V27, P157, DOI 10.1093/oxfordjournals.schbul.a006854; *PSYCH CORP, 1999, WECHLS ABBR SCAL INT; Reid R., 1998, ADHD RATING SCALE 4; Sahakyan L, 2003, J MEM LANG, V48, P195, DOI 10.1016/S0749-596X(02)00524-7; Seidman LJ, 2001, NEUROPSYCHOLOGY, V15, P544, DOI 10.1037/0894-4105.15.4.544; Sergeant J. A., 1999, HDB DISRUPTIVE BEHAV, P75, DOI [DOI 10.1007/978-1-4615-4881-2_4, 10.1007/978-1-4615-4881-2_4]; Sergeant JA, 2005, BIOL PSYCHIAT, V57, P1248, DOI 10.1016/j.biopsych.2004.09.010; Sonuga-Barke EJS, 2002, BEHAV BRAIN RES, V130, P29, DOI 10.1016/S0166-4328(01)00432-6; SONUGABARKE EJS, 1992, J CHILD PSYCHOL PSYC, V33, P387, DOI 10.1111/j.1469-7610.1992.tb00874.x; Talley, 1993, CHILDRENS AUDITORY V; Van Der Meere J, 2002, HYPERACTIVITY ATTENT, P162; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Wechsler D., 1997, WECHSLER INTELLIGENC; WEISS LG, 1999, CANADIAN J SCH PSYCH, V14, P1, DOI DOI 10.1177/082957359901400202; White Holly A, 2007, J Atten Disord, V11, P141, DOI 10.1177/1087054706295604	51	27	28	0	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0022-2194			J LEARN DISABIL-US	J. Learn. Disabil.	SEP-OCT	2010	43	5					430	440		10.1177/0022219409355473			11	Education, Special; Rehabilitation	Education & Educational Research; Rehabilitation	646QQ	WOS:000281557500004	20445203				2021-06-18	
J	Hoffmann, U; Dilekoz, E; Kudo, C; Ayata, C				Hoffmann, Ulrike; Dilekoz, Ergin; Kudo, Chiho; Ayata, Cenk			Gabapentin suppresses cortical spreading depression susceptibility	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cortex; electrophysiology; gabapentin; rat; spreading depression	CALCIUM-CHANNEL; BRAIN-INJURY; DEPOLARIZATIONS; DRUG; RATS; NEURONTIN; BLOCKADE; PLASMA	Cortical spreading depression (CSD) is an intense depolarization wave implicated in the pathophysiology of brain injury states and migraine aura. As Ca(v)2.1 channels modulate CSD susceptibility, we tested gabapentin, which inhibits Ca(v)2.1 through high-affinity binding to its alpha(2)delta subunit, on CSD susceptibility in anesthetized rats. Gabapentin, 100 or 200 mg/kg, elevated the electrical threshold for CSD and diminished recurrent CSDs evoked by topical KCl, when administered 1 hour before testing. With its favorable safety and tolerability profile, gabapentin may have a role in suppression of injury depolarizations in stroke, intracranial hemorrhage, and traumatic brain injury. Journal of Cerebral Blood Flow & Metabolism (2010) 30, 1588-1592; doi:10.1038/jcbfm.2010.92; published online 30 June 2010	[Hoffmann, Ulrike; Dilekoz, Ergin; Kudo, Chiho; Ayata, Cenk] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Neurovasc Res Lab, Charlestown, MA 02129 USA; [Ayata, Cenk] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Stroke Serv & Neurosci Intens Care Unit,Dept Neur, Charlestown, MA 02129 USA	Ayata, C (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Neurovasc Res Lab, 149 13th St,Room 6408, Charlestown, MA 02129 USA.	cayata@partners.org			National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS061505, NS055104]; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [HO 4211/1-1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061505, P01NS055104] Funding Source: NIH RePORTER	This work was supported by the National Institute of Health (NS061505 and NS055104, Ayata) and Deutsche Forschungsgemeinschaft (HO 4211/1-1, Hoffmann).	Ayata C, 2006, ANN NEUROL, V59, P652, DOI 10.1002/ana.20778; Dooley DJ, 2007, TRENDS PHARMACOL SCI, V28, P75, DOI 10.1016/j.tips.2006.12.006; Gee NS, 1996, J BIOL CHEM, V271, P5768, DOI 10.1074/jbc.271.10.5768; Hashemi P, 2009, J CEREBR BLOOD F MET, V29, P166, DOI 10.1038/jcbfm.2008.108; Hendrich J, 2008, P NATL ACAD SCI USA, V105, P3628, DOI 10.1073/pnas.0708930105; Hunter JC, 1997, EUR J PHARMACOL, V324, P153, DOI 10.1016/S0014-2999(97)00070-8; Kunkler PE, 2004, HIPPOCAMPUS, V14, P356, DOI 10.1002/hipo.10181; RADULOVIC LL, 1995, DRUG METAB DISPOS, V23, P441; Richter F, 2002, NEUROSCI LETT, V334, P123, DOI 10.1016/S0304-3940(02)01120-5; Sakowitz OW, 2009, STROKE, V40, pE519, DOI 10.1161/STROKEAHA.109.549303; Shin HK, 2006, J CEREBR BLOOD F MET, V26, P1018, DOI 10.1038/sj.jcbfm.9600252; STEWART BH, 1993, PHARMACEUT RES, V10, P276, DOI 10.1023/A:1018951214146; Strong AJ, 2007, BRAIN, V130, P995, DOI 10.1093/brain/awl392; van Hooft JA, 2002, EUR J PHARMACOL, V449, P221, DOI 10.1016/S0014-2999(02)02044-7; WELTY DF, 1993, EPILEPSY RES, V16, P175, DOI 10.1016/0920-1211(93)90078-L; Williams AJ, 2006, J PHARMACOL EXP THER, V318, P947, DOI 10.1124/jpet.106.105999	16	27	28	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2010	30	9					1588	1592		10.1038/jcbfm.2010.92			5	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	646SF	WOS:000281562300005	20588320	Green Published, Bronze			2021-06-18	
J	Kanjwal, K; Karabin, B; Kanjwal, Y; Grubb, BP				Kanjwal, Khalil; Karabin, Beverly; Kanjwal, Yousuf; Grubb, Blair P.			Autonomic dysfunction presenting as postural tachycardia syndrome following traumatic brain injury	CARDIOLOGY JOURNAL			English	Article						postural tachycardia syndrome; trauma; brain injury	SEVERE HEAD-INJURY; MANAGEMENT; DIAGNOSIS; DYSAUTONOMIA	Background Autonomic dysregulation (also called diencephalic epilepsy) has been reported following traumatic brain injuries (TBI) However, until now, postural tachycardia syndrome (POTS) has not been reported as a long-term complication in patients who have suffered a TBI We report on a series of patients who developed POTS after suffering TBI Methods Eight patients who were referred to our center had suffered TBI and developed features of orthostatic intolerance following head trauma The patients' neurological, neurosurgical and autonomic data (charts and/or physician letters) were then carefully reviewed for demographic characteristics, comorbid conditions, symptoms of orthostatic intolerance, medications and response to medication These patients were diagnosed as having POTS, primarily based on their clinical features and findings from the head-up tilt test (HUTT) The data presented is observational and descriptive (percentages or means) Results Eight patients (seven of them women) aged 21-41 years had suffered from TBI and had developed features of POTS All had been normal with no symptoms prior to their TBI All patients experienced orthostatic dizziness, fatigue, palpitations and near syncope Six patients suffered from frank syncope Six patients developed significant cognitive dysfunction, and three developed a chronic pain syndrome following trauma All of the patients reported severe limitations to their daily activities and had been unable to keep their jobs, and two were housebound Six patients demonstrated a good response to therapy with various combinations of medication The symptoms of orthostatic intolerance and syncope improved with the initiation of medical therapy, as well as their reported quality of life Two patients failed to show any improvement with various combinations of medications and tilt training, and continued to experience orthostatic difficulties Conclusions Postural tachycardia syndrome may, in some cases, be a late complication of traumatic brain injury (Cardiol J 2010, 17, 5 482-487)	[Grubb, Blair P.] Univ Toledo, Med Ctr, Electrophysiol Serv, Div Cardiol,Dept Med,Sect Electrophysiol, Toledo, OH 43614 USA	Grubb, BP (corresponding author), Univ Toledo, Med Ctr, Electrophysiol Serv, Div Cardiol,Dept Med,Sect Electrophysiol, Hlth Sci Campus,Mail Stop 1118,3000 Arlington ave, Toledo, OH 43614 USA.		Kanjwal, Khalil/AAO-5841-2021				Baguley IJ, 2007, J NEUROL NEUROSUR PS, V78, P539, DOI 10.1136/jnnp.2006.096388; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; CARMEL PW, 1985, ACTA NEUROCHIR, V75, P113, DOI 10.1007/BF01406331; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Grubb BP, 2008, CIRCULATION, V117, P2814, DOI 10.1161/CIRCULATIONAHA.107.761643; Grubb BP, 2001, MED CLIN N AM, V85, P457, DOI 10.1016/S0025-7125(05)70322-9; Grubb BP, 2006, J CARDIOVASC ELECTR, V17, P108, DOI 10.1111/j.1540-8167.2005.00318.x; Grubb BP, 2001, J INTERV CARD ELECTR, V5, P9, DOI 10.1023/A:1009845521949; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Kanjwal Y, 2003, PACE, V26, P1747, DOI 10.1046/j.1460-9592.2003.t01-1-00262.x; KISHNER S, POSTHEAD INJURY AUTO; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Metz SA, 1978, ANNS INT MED, V88, P89; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; Sandroni P, 1999, MAYO CLIN PROC, V74, P1106, DOI 10.4065/74.11.1106; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009	19	27	28	0	5	VIA MEDICA	GDANSK	UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND	1897-5593	1898-018X		CARDIOL J	Cardiol. J.	SEP	2010	17	5					482	487					6	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	681TI	WOS:000284341800009	20865679	DOAJ Gold			2021-06-18	
J	Wei, CW; Montanera, W; Selchen, D; Lian, J; Stevens, C; de Tilly, LN				Wei, Corie W.; Montanera, Walter; Selchen, Daniel; Lian, Jackie; Stevens, Christopher; de Tilly, Lyne Noel			Blunt Cerebrovascular Injuries: Diagnosis and Management Outcomes	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CAROTID-ARTERY; ARTERIOVENOUS-FISTULAS; ENDOVASCULAR STENTS; VASCULAR INJURIES; NECK INJURIES; TRAUMA; ACCURACY; THERAPY; ANTICOAGULATION	Background: Blunt cerebrovascular injury (BCVI) to the carotid and vertebral arteries is a potentially devastating injury in trauma patients. The optimal management for BCVI has not been standardized. At our institution, 64-slice multi-detector computed tomographic angiography (CTA) has been used as the initial screening exam for BCVI in patients who met predefined screening criteria. The purpose of this study is to review the incidence of CTA-diagnosed BCVI in at-risk patients and to evaluate the treatment and clinical outcome of patients with BCVI. Methods: This study included trauma patients with a positive diagnosis of BCVI on CTA during a 41-month study period. The medical records and relevant radiographic findings were retrospectively reviewed. Results: Twenty seven of 222 blunt trauma patients evaluated with CTA had a positive diagnosis of BCVI, with an occurrence rate of 12.2%. Traumatic brain injury (72.2%) and basal skull fractures (55.6%) were the most frequent associated injuries with carotid trauma while 100% of blunt vertebral injuries occurred in the setting of cervical fractures. Fourteen (51.8%) patients received medical therapy; Eleven (40.7%) patients received conservative treatment. Endovascular treatment was attempted in a single case of vertebral arteriovenous fistula. BCVI-related stroke was found in four patients (14.8%), one of whom developed an infarct while on medical treatment. Conclusions: BCVI is found in a significant portion of blunt trauma patients with identifiable risk factors, and screening CTA has high diagnostic yield in detecting these lesions. Medical therapy is the mainstay of treatment at our institution; however, BCVI-related stroke may occur despite treatment.	[Wei, Corie W.; Montanera, Walter; de Tilly, Lyne Noel] Univ Toronto, St Michaels Hosp, Dept Med Imaging, Toronto, ON M5B 1W8, Canada; [Selchen, Daniel] Univ Toronto, St Michaels Hosp, Dept Neurol, Toronto, ON M5B 1W8, Canada; [Lian, Jackie] McGill Univ, Dept Med Imaging, Montreal, PQ, Canada; [Stevens, Christopher] Univ British Columbia, Dept Med Imaging, Vancouver, BC V5Z 1M9, Canada	de Tilly, LN (corresponding author), Univ Toronto, St Michaels Hosp, Dept Med Imaging, 30 Bond St, Toronto, ON M5B 1W8, Canada.						Anaya C, 2009, SEMIN ULTRASOUND CT, V30, P205, DOI 10.1053/j.sult.2009.02.003; Berne JD, 2006, J TRAUMA, V60, P1204, DOI 10.1097/01.ta.0000220435.55791.ce; Berne JD, 2010, J VASC SURG, V51, P57, DOI 10.1016/j.jvs.2009.08.071; Biffl Walter L, 2003, Curr Opin Crit Care, V9, P530, DOI 10.1097/00075198-200312000-00011; Biffl WL, 2006, J TRAUMA, V60, P745, DOI 10.1097/01.ta.0000204034.94034.c4; Biffl WL, 2002, ANN SURG, V235, P699, DOI 10.1097/00000658-200205000-00012; Biffl WL, 1998, ANN SURG, V228, P462, DOI 10.1097/00000658-199810000-00003; Biffl WL, 2001, J TRAUMA, V50, P969, DOI 10.1097/00005373-200105000-00039; Biffl WL, 2000, ANN SURG, V231, P672, DOI 10.1097/00000658-200005000-00007; Biffl WL, 1999, AM J SURG, V178, P517, DOI 10.1016/S0002-9610(99)00245-7; BROMBERG WJ, 2007, BLUNT CEREBROVASCULA; Bush RL, 2001, J ENDOVASC THER, V8, P53, DOI 10.1583/1545-1550(2001)008<0053:ESPACE>2.0.CO;2; Cothren CC, 2009, ARCH SURG-CHICAGO, V144, P685, DOI 10.1001/archsurg.2009.111; Cothren CC, 2005, ARCH SURG-CHICAGO, V140, P480, DOI 10.1001/archsurg.140.5.480; Cothren CC, 2004, ARCH SURG-CHICAGO, V139, P540, DOI 10.1001/archsurg.139.5.540; Cothren CC, 2003, J TRAUMA, V55, P811, DOI 10.1097/01.TA.0000092700.92587.32; COTHREN CC, 2004, ARCH SURG-CHICAGO, V139, P455; Duke BJ, 1997, J NEUROSURG, V87, P825, DOI 10.3171/jns.1997.87.6.0825; Eachempati SR, 1998, J TRAUMA, V45, P997, DOI 10.1097/00005373-199812000-00004; Edwards NM, 2007, J AM COLL SURGEONS, V204, P1007, DOI 10.1016/j.jamcollsurg.2006.12.041; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; Feiz-Erfan I, 2007, J NEUROSURG, V107, P364, DOI 10.3171/JNS-07/08/0364; Goodwin RB, 2009, J TRAUMA, V67, P1046, DOI 10.1097/TA.0b013e3181b83b63; Herrera DA, 2008, AM J NEURORADIOL, V29, P1585, DOI 10.3174/ajnr.A1123; HIGASHIDA RT, 1989, AM J ROENTGENOL, V153, P577, DOI 10.2214/ajr.153.3.577; Kerwin AJ, 2001, J TRAUMA, V51, P308, DOI 10.1097/00005373-200108000-00013; Krings T, 2008, EUR RADIOL, V18, P1531, DOI 10.1007/s00330-008-0915-z; Mayberry JC, 2004, ARCH SURG-CHICAGO, V139, P609, DOI 10.1001/archsurg.139.6.609; McGuinness BJ, 2008, INJURY, V39, P1242, DOI 10.1016/j.injury.2008.01.054; Melton S, 2007, J AM COLL SURGEONS, V204, P1014; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; Miller PR, 2001, J TRAUMA, V51, P279, DOI 10.1097/00005373-200108000-00009; Miller PR, 2001, J TRAUMA, V51, P285; Mutze S, 2005, RADIOLOGY, V237, P884, DOI 10.1148/radiol.2373042189; Redekop G, 2001, J NEUROSURG, V95, P412, DOI 10.3171/jns.2001.95.3.0412; Risgaard O, 2007, ANZ J SURG, V77, P686, DOI 10.1111/j.1445-2197.2007.04187.x; Schneidereit NP, 2006, J TRAUMA, V60, P209, DOI 10.1097/01.ta.0000195651.60080.2c; Sliker CW, 2008, AM J ROENTGENOL, V190, P790, DOI 10.2214/AJR.07.2378; Spain DA, 2006, J TRAUMA, V60, P751; Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146; Utter GH, 2006, J AM COLL SURGEONS, V203, P838, DOI 10.1016/j.jamcollsurg.2006.08.003; Vinchon M, 1994, Cardiovasc Surg, V2, P359; Wahl WL, 2002, J TRAUMA, V52, P896, DOI 10.1097/00005373-200205000-00012; Waitzman AA, 1996, J OTOLARYNGOL, V25, P322	44	27	31	0	4	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0317-1671	2057-0155		CAN J NEUROL SCI	Can. J. Neurol. Sci.	SEP	2010	37	5					574	579		10.1017/S0317167100010726			6	Clinical Neurology	Neurosciences & Neurology	650BH	WOS:000281821800008	21059501	Bronze			2021-06-18	
J	Lesko, MM; Woodford, M; White, L; O'Brien, SJ; Childs, C; Lecky, FE				Lesko, Mehdi M.; Woodford, Maralyn; White, Laura; O'Brien, Sarah J.; Childs, Charmaine; Lecky, Fiona E.			Using Abbreviated Injury Scale (AIS) codes to classify Computed Tomography (CT) features in the Marshall System	BMC MEDICAL RESEARCH METHODOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; CLASSIFICATION; PREDICTION	Background: The purpose of Abbreviated Injury Scale (AIS) is to code various types of Traumatic Brain Injuries (TBI) based on their anatomical location and severity. The Marshall CT Classification is used to identify those subgroups of brain injured patients at higher risk of deterioration or mortality. The purpose of this study is to determine whether and how AIS coding can be translated to the Marshall Classification Methods: Initially, a Marshall Class was allocated to each AIS code through cross-tabulation. This was agreed upon through several discussion meetings with experts from both fields (clinicians and AIS coders). Furthermore, in order to make this translation possible, some necessary assumptions with regards to coding and classification of mass lesions and brain swelling were essential which were all approved and made explicit. Results: The proposed method involves two stages: firstly to determine all possible Marshall Classes which a given patient can attract based on allocated AIS codes; via cross-tabulation and secondly to assign one Marshall Class to each patient through an algorithm. Conclusion: This method can be easily programmed in computer softwares and it would enable future important TBI research programs using trauma registry data.	[Lesko, Mehdi M.; Woodford, Maralyn; White, Laura; Lecky, Fiona E.] Univ Manchester, Manchester Acad Hlth Sci Ctr, TARN, Salford Royal NHS Fdn Trust, Salford, Lancs, England; [O'Brien, Sarah J.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Occupat & Environm Hlth Res Grp, Salford Royal NHS Fdn Trust, Salford, Lancs, England; [Childs, Charmaine] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore; [Childs, Charmaine] Univ Manchester, Brain Injury Res Grp, Salford Royal NHS Fdn Trust, Salford, Lancs, England	Lesko, MM (corresponding author), Univ Manchester, Manchester Acad Hlth Sci Ctr, TARN, Salford Royal NHS Fdn Trust, Salford, Lancs, England.	Mehdi_m_lesko@yahoo.com	Childs, Charmaine/G-9928-2012	O'Brien, Sarah Jane/0000-0003-2896-8999	Trauma Audit and Research Network (TARN); Overseas Research Students (ORS) Award Scheme, University of Manchester	We would like to acknowledge the help of Prof. Andrew Mass from the IMPACT collaboration in discussion of the methods used to arrive at our final algorithm. This work is supported by the funding from the Trauma Audit and Research Network (TARN) and Overseas Research Students (ORS) Award Scheme, University of Manchester.	*ASS ADV AUT MED, 2001, ABBR INJ SCAL 1990 R; Association for the Advancement of Automotive Medicine, 2008, ABBR INJ SCAL 2005; Bouamra O, 2006, J TRAUMA, V61, P701, DOI 10.1097/01.ta.0000197175.91116.10; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Gennarelli TA, 2006, INJURY, V37, P1083, DOI 10.1016/j.injury.2006.07.009; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Servadei F, 2000, NEUROSURGERY, V46, P70; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170; INT MISSION PROGNOSI; TRAUMA AUDIT RES NET	15	27	27	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2288		BMC MED RES METHODOL	BMC Med. Res. Methodol.	AUG 6	2010	10								72	10.1186/1471-2288-10-72			10	Health Care Sciences & Services	Health Care Sciences & Services	649UY	WOS:000281801500001	20691038	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Taylor, AN; Rahman, SU; Tio, DL; Gardner, SM; Kim, CJ; Sutton, RL				Taylor, Anna N.; Rahman, Shayan U.; Tio, Delia L.; Gardner, Stephen M.; Kim, Christine J.; Sutton, Richard L.			Injury Severity Differentially Alters Sensitivity to Dexamethasone after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						adrenocorticotropic hormone; corticosterone; corticotropin-releasing hormone; dexamethasone; glucocorticoid negative feedback; rat; stress	CORTICOTROPIN-RELEASING HORMONE; PREFRONTAL CORTEX; HYPOPITUITARISM; NEUROENDOCRINE; STRESS; RECEPTOR; RESPONSES; AXIS; RAT; HIPPOCAMPUS	We have reported differential short-and long-term dysregulation of the neuroendocrine stress response after traumatic brain injury (TBI) produced by controlled cortical impact (CCI). We have now investigated three possible mechanisms for this TBI-induced dysregulation: (1) effects on the sensitivity of negative-feedback systems to glucocorticoids; (2) effects on the sensitivity of pituitary corticotrophs to corticotropin-releasing hormone (CRH); and (3) effects on neuronal loss in the hilar region of the dentate gyrus and in the CA3b layer of the dorsal hippocampus. TBI was induced to the left parietal cortex in adult male rats with a pneumatic piston, at two different impact velocities and compression depths, to produce either moderate or mild CCI. At 7 and 35 days after surgery, the rats were injected SC with the synthetic glucocorticoid analog dexamethasone (DEX; 0.01, 0.10, or 1.00mg/kg) or saline, and 2 h later were subjected to 30min of restraint stress and tail vein blood collection. Whereas all doses of DEX suppressed corticosterone (CORT) and adrenocorticotropic hormone (ACTH) responses to stress on both days, CORT and ACTH were significantly more suppressed after 0.01mg/kg DEX in the moderate TBI group than in the mild TBI or sham groups. At both 7 and 35 days post-TBI, CRH (1.0 and 10.0 mu g/kg IP) stimulated CORT and ACTH in all rats, regardless of injury condition. Hippocampal cell loss was greatest at 48 days after moderate TBI. Enhanced sensitivity to glucocorticoid negative feedback and greater hippocampal cell loss, but not altered pituitary responses to CRH, contribute to the short-and long-term attenuation of the neuroendocrine stress response following moderate TBI. The role of TBI-induced alterations in glucocorticoid receptors in limbic system sites in enhanced glucocorticoid feedback sensitivity requires further investigation.	[Taylor, Anna N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Brain Res Inst, Los Angeles, CA 90095 USA; [Sutton, Richard L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Taylor, Anna N.] VAGLAHS, W Los Angeles Healthcare Ctr, Los Angeles, CA USA	Taylor, AN (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Brain Res Inst, 10833 Le Conte Ave,Box 951763, Los Angeles, CA 90095 USA.	ataylor@mednet.ucla.edu			Department of Veterans Affairs Medical Research ServiceUS Department of Veterans Affairs; UCLA Brain Injury Research Center	We thank Sima Ghavim for her expert assistance with the histological preparations. This research was supported by the Department of Veterans Affairs Medical Research Service, and the UCLA Brain Injury Research Center.	Agha A, 2007, BRIT J NEUROSURG, V21, P210, DOI 10.1080/02688690701253331; Akana SF, 2001, J NEUROENDOCRINOL, V13, P625, DOI 10.1046/j.1365-2826.2001.00676.x; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Cernak I, 1999, BRAIN INJURY, V13, P1005; CHILDERS MK, 1998, BRAIN INJURY, V12, P547; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cullinan WE, 2008, BRAIN STRUCT FUNCT, V213, P63, DOI 10.1007/s00429-008-0192-2; de Kloet CS, 2007, PSYCHONEUROENDOCRINO, V32, P215, DOI 10.1016/j.psyneuen.2006.12.009; de Kloet ER, 2000, EUR J PHARMACOL, V405, P187, DOI 10.1016/S0014-2999(00)00552-5; Di S, 2009, J NEUROSCI, V29, P393, DOI 10.1523/JNEUROSCI.4546-08.2009; DIORIO D, 1993, J NEUROSCI, V13, P3839; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fukushima M, 2009, J NEUROTRAUM, V26, P1095, DOI 10.1089/neu.2008.0771; Furay AR, 2008, ENDOCRINOLOGY, V149, P5482, DOI 10.1210/en.2008-0642; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Grundy PL, 2001, J NEUROTRAUM, V18, P1373, DOI 10.1089/08977150152725669; Haller J, 2008, FRONT NEUROENDOCRIN, V29, P273, DOI 10.1016/j.yfrne.2007.10.004; HERMAN JP, 1993, CELL MOL NEUROBIOL, V13, P349, DOI 10.1007/BF00711577; HERMAN JP, 1995, J NEUROENDOCRINOL, V7, P475, DOI 10.1111/j.1365-2826.1995.tb00784.x; Herman JP, 2003, FRONT NEUROENDOCRIN, V24, P151, DOI 10.1016/j.yfrne.2003.07.001; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Kasturi BS, 2009, J NEUROTRAUM, V26, P1315, DOI [10.1089/neu.2008.0751, 10.1089/neu.2008-0751]; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MATHESON GK, 1971, BRAIN RES, V32, P151, DOI 10.1016/0006-8993(71)90160-0; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; McCullers DL, 2002, BRAIN RES, V947, P41, DOI 10.1016/S0006-8993(02)02904-9; Miklos IH, 2002, NEUROSCIENCE, V113, P581, DOI 10.1016/S0306-4522(02)00147-1; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Roe SY, 1998, EUR J NEUROSCI, V10, P553, DOI 10.1046/j.1460-9568.1998.00064.x; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; Sullivan RM, 1999, J NEUROSCI, V19, P2834; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tasker JG, 2006, ENDOCRINOLOGY, V147, P5549, DOI 10.1210/en.2006-0981; Taylor AN, 2009, J NEUROTRAUM, V26, pA47; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; TAYLOR AN, 2004, 7 INT NEUR S AD AUST; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; Taylor AN, 2006, J NEUROTRAUM, V23, P1802, DOI 10.1089/neu.2006.23.1802; Urban RJ, 2006, GROWTH HORM IGF RES, V16, pS25, DOI 10.1016/j.ghir.2006.03.017; Walilko T, 2009, J TRAUMA, V67, P1311, DOI 10.1097/TA.0b013e31819adc36; Yehuda R, 2009, ANN NY ACAD SCI, V1179, P56, DOI 10.1111/j.1749-6632.2009.04979.x; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; Zhong C, 2006, J NEUROCHEM, V97, P1015, DOI 10.1111/j.1471-4159.2006.03786.x	48	27	27	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2010	27	6					1081	1089		10.1089/neu.2009.1252			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	612VO	WOS:000278933300011	20560754				2021-06-18	
J	Forsyth, RJ; Salorio, CF; Christensen, JR				Forsyth, Rob J.; Salorio, Cynthia F.; Christensen, James R.			Modelling early recovery patterns after paediatric traumatic brain injury	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							HEAD-INJURY; CHILDREN; REHABILITATION; ADOLESCENTS; SEVERITY; INSTRUMENT; OUTCOMES; LESIONS; WEEFIM; MEMORY	Objective To describe the range of early recovery patterns seen in children admitted for inpatient rehabilitation after traumatic brain injury and to build simple predictive models of expected recovery. Patients 103 consecutive paediatric admissions to a neurological rehabilitation facility after closed head injury. Methods Children's recoveries were defined by repeated scores on the WeeFIM (a validated paediatric measure of functional independence) assembled into recovery trajectories. Non-linear mixed effects modelling was used to define 'typical' recoveries and to identify useful simple predictor variables. Results WeeFIM recovery curves showed a characteristic sigmoidal form with an initial slow phase followed by a mid-phase of fastest improvement and a late plateau. Final WeeFIM scores ranged from 18 to 125 (median 105, IQR 87-117). The time taken to reach 50% final WeeFIM score ranged from 5 to 145 days (median 27, IQR 17-46). Both final WeeFIM and time to reach 50% final WeeFIM correlated with time to follow commands (TFC), defined as the post-injury day on which a child was first observed to follow two simple commands in a 24 h period. Conclusions Simple models predicting outcome trajectory can be built incorporating early rate-of-recovery indices (such as TFC) as proxies of injury severity. Such models allow informed discussion with families of likely rates of progress and the CI on these estimates. Models of this nature also potentially allow identification of children making better-or worse-than-expected recoveries.	[Forsyth, Rob J.] Univ Newcastle, Royal Victoria Infirm, Sir James Spence Inst, Inst Neurosci, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Salorio, Cynthia F.; Christensen, James R.] Johns Hopkins Sch Med, Kennedy Krieger Inst, Baltimore, MD USA	Forsyth, RJ (corresponding author), Univ Newcastle, Royal Victoria Infirm, Sir James Spence Inst, Inst Neurosci, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	r.j.forsyth@newcastle.ac.uk	Forsyth, Rob/H-9193-2019	Forsyth, Rob/0000-0002-5657-4180			Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Blackman JA, 2003, J HEAD TRAUMA REHAB, V18, P493, DOI 10.1097/00001199-200311000-00003; Chen CC, 2005, AM J PHYS MED REHAB, V84, P671, DOI 10.1097/01.phm.0000176439.32318.36; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Forsyth R, 2009, NEUROPSYCHOL REHABIL, V19, P891, DOI 10.1080/09602010903091066; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Golomb MR, 2004, PEDIATR NEUROL, V31, P311, DOI 10.1016/j.pediatrneurol.2004.05.011; GOTSCHALL CS, 1995, J NEUROTRAUM, V12, P611, DOI 10.1089/neu.1995.12.611; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Kelly T P, 1999, Pediatr Rehabil, V3, P187; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Kunik CL, 2006, ARCH PHYS MED REHAB, V87, P1590, DOI 10.1016/j.apmr.2006.09.001; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; *MED RES COUNC, 2000, FRAM DEV EV RCTS COM; *MRC CRASH TRIAL C, 2008, BMJ-BRIT MED J, V36, P425; MSALL ME, 1994, CLIN PEDIATR, V33, P421, DOI 10.1177/000992289403300708; Pinheiro J., NLME LINEAR NONLINEA; Pinheiro JC., 2004, MIXED EFFECTS MODELS; Poggi G, 2003, BRAIN INJURY, V17, P835, DOI 10.1080/0269905031000088612; R Core Development Team, 2008, R LANG ENV STAT COMP; Rice SA, 2005, ARCH PHYS MED REHAB, V86, P834, DOI 10.1016/j.apmr.2004.11.006; Segui-Gomez M, 2003, EPIDEMIOL REV, V25, P3, DOI 10.1093/epirev/mxg007; Warschausky S, 2001, ARCH PHYS MED REHAB, V82, P329, DOI 10.1053/apmr.2001.21510; Wong PP, 2001, BRAIN INJURY, V15, P519, DOI 10.1080/02699050010005995; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	31	27	27	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888	1468-2044		ARCH DIS CHILD	Arch. Dis. Child.	APR	2010	95	4					266	270		10.1136/adc.2008.147926			5	Pediatrics	Pediatrics	573QG	WOS:000275928900007	19948516				2021-06-18	
J	Kreutzer, JS; Marwitz, JH; Godwin, EE; Arango-Lasprilla, JC				Kreutzer, Jeffrey S.; Marwitz, Jennifer H.; Godwin, Emilie E.; Arango-Lasprilla, Juan C.			Practical Approaches to Effective Family Intervention After Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; caregivers; family therapy; intervention	THERAPEUTIC ALLIANCE; REHABILITATION; CAREGIVERS; PREDICTORS; PROGRAM; BURDEN; IMPACT; DAMAGE; TBI	Rehabilitation professionals have become increasingly aware that traumatic brain injury has a long-term adverse impact on family members as well as on survivors. Family members often have a critical supporting role in the recovery process, and researchers have identified a relationship between caregiver well-being and survivor outcome. Drawing from the fields of family therapy, cognitive-behavioral therapy, and individual psychotherapy, this article provides information to help clinicians effectively serve families. First, historically important and widely cited publications are reviewed and their implications for practice are discussed. Recommendations for developing successful therapeutic alliances are provided along with a rationale for their importance. Descriptions of common challenges and issues faced by families are presented along with corresponding therapeutic goals. Intervention principles and strategies, selectively chosen to help family members achieve therapeutic goals, are discussed. The article concludes with a presentation of ideas to help practitioners and systems of care more effectively help family members adjust and live fulfilling lives.	[Kreutzer, Jeffrey S.; Marwitz, Jennifer H.; Godwin, Emilie E.; Arango-Lasprilla, Juan C.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Neurosurg & Psychiat, Richmond, VA 23298 USA	Kreutzer, JS (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, POB 980542, Richmond, VA 23298 USA.	jskreutz@vcu.edu			National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of EducationUS Department of Education [H133A070036]	Supported in part by the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of Education (grant H133A070036).	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Anderson MI, 2009, BRAIN INJURY, V23, P931, DOI 10.3109/02699050903302336; ANGUS LE, 2003, HDB NARRATIVE PSYCHO; Aragno A, 2008, J AM PSYCHOANAL ASS, V56, P713, DOI 10.1177/0003065108322097; Beck J.S., 1995, COGNITIVE THERAPY BA; Boschen K, 2007, NEUROREHABILITATION, V22, P19; BROTHERTON FA, 1988, ARCH PHYS MED REHAB, V69, P827; Corey G., 2008, THEORY PRACTICE COUN; Ducharme JM, 2000, CLIN PSYCHOL REV, V20, P405, DOI 10.1016/S0272-7358(98)00102-0; Duncan B. L., 2004, HEROIC CLIENT REVOLU; Duncan B. L., 1996, HDB SOLUTION FOCUSED; Dunst CJ, 2002, FAM RELAT, V51, P221, DOI 10.1111/j.1741-3729.2002.00221.x; Hogarty GE., 1986, SCHIZOPHRENIA FAMILY, V1. Edition; Hubble M., 2006, HEART SOUL CHANGE WH; Jackson D, 2009, BRAIN INJURY, V23, P433, DOI 10.1080/02699050902788451; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; Kreutzer JS, 2002, J HEAD TRAUMA REHAB, V17, P349, DOI 10.1097/00001199-200208000-00008; Levack WMM, 2009, BRAIN INJURY, V23, P192, DOI 10.1080/02699050802695582; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; Martin DJ, 2000, J CONSULT CLIN PSYCH, V68, P438, DOI 10.1037//0022-006X.68.3.438; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; Messer SB, 2002, CLIN PSYCHOL-SCI PR, V9, P21, DOI 10.1093/clipsy/9.1.21; Miller W. R., 2002, MOTIVATIONAL INTERVI; Minuchin S., 1981, FAMILY THERAPY TECHN; Minuchin S., 1993, FAMILY HEALING STRAT; MUIR C, 1990, REHABILITATION ADULT, P433; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Nichols M. P., 2007, FAMILY THERAPY CONCE; Nicki Andrea, 2001, HYPATIA, V16, P80; Panting A., 1972, REHABILITATION, V38, P33; Piercy F., 1996, FAMILY THERAPY SOURC; ROBINSON KM, 1988, ADV NURS SCI, V10, P59, DOI 10.1097/00012272-198801000-00010; Rogers C.R., 1961, BECOMING PERSON; ROGERS CR, 1957, J CONSULT PSYCHOL, V21, P95, DOI 10.1037/0022-006X.60.6.827; Rosenthal M, 1988, J HEAD TRAUMA REHAB, V3, P42; ROSENTHAL M, 1983, REHABILITATION HEAD, P407; Rotondi AJ, 2005, J HEAD TRAUMA REHAB, V20, P173, DOI 10.1097/00001199-200503000-00005; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; SANDER A, 1999, REHABILITATION ADULT, P199; Schonberger M, 2006, BRAIN INJURY, V20, P1271, DOI 10.1080/02699050601049395; Sherer M, 2007, BRAIN INJURY, V21, P663, DOI 10.1080/02699050701481589; Weakland J. H., 1992, 1 SESSION BRIEF THER, P306; White M., 2007, MAPS NARRATIVE PRACT; White M., 1990, NARRATIVE MEANS THER	47	27	27	1	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2010	25	2					113	120		10.1097/HTR.0b013e3181cf0712			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	578EJ	WOS:000276276000006	20134331				2021-06-18	
J	Qian, JC; Herrera, JJ; Narayana, PA				Qian, Junchao; Herrera, Juan J.; Narayana, Ponnada A.			Neuronal and Axonal Degeneration in Experimental Spinal Cord Injury: In Vivo Proton Magnetic Resonance Spectroscopy and Histology	JOURNAL OF NEUROTRAUMA			English	Article						choline; histology; N-acetyl aspartate; proton magnetic resonance spectroscopy; rat; spinal cord injury	TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; N-ACETYLASPARTATE; MR SPECTROSCOPY; HISTOPATHOLOGIC CORRELATION; CEREBRAL-ISCHEMIA; METABOLIC-CHANGES; DAMAGE; DYSFUNCTION; ASPARTATE	Longitudinal in vivo proton magnetic resonance spectroscopy (H-1-MRS) and immunohistochemistry were performed to investigate the tissue degeneration in traumatically injured rat spinal cord rostral and caudal to the lesion epicenter. On H-1-MRS significant decreases in N-acetyl aspartate (NAA) and total creatine (Cr) levels in the rostral, epicenter, and caudal segments were observed by 14 days, and levels remained depressed up to 56 days post-injury (PI). In contrast, the total choline (Cho) levels increased significantly in all three segments by 14 days PI, but recovered in the epicenter and caudal, but not the rostral region, at 56 days PI. Immunohistochemistry demonstrated neuronal cell death in the gray matter, and reactive astrocytes and axonal degeneration in the dorsal, lateral, and ventral white-matter columns. These results suggest delayed tissue degeneration in regions both rostrally and caudally from the epicenter in the injured spinal cord tissue. A rostral-caudal asymmetry in tissue recovery was seen both on MRI-observed hyperintense lesion volume and the Cho, but not NAA and Cr, levels at 56 days PI. These studies suggest that dynamic metabolic changes take place in regions away from the epicenter in injured spinal cord.	[Qian, Junchao; Herrera, Juan J.; Narayana, Ponnada A.] Univ Texas Med Sch Houston, Dept Diagnost & Intervent Imaging, Houston, TX 77030 USA	Narayana, PA (corresponding author), Univ Texas Med Sch Houston, Dept Diagnost & Intervent Imaging, 6431 Fannin St, Houston, TX 77030 USA.	Ponnada.a.Narayana@uth.tmc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS045624]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR014804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS030821, R01NS045624] Funding Source: NIH RePORTER	This work is supported by NIH grant NS045624 awarded to P.A.N. We thank Tessy Chacko, B.S., for assistance with animal care, and Chirag Patel, M.S.E., for assistance with histology.	Aimone JB, 2004, EXP NEUROL, V189, P204, DOI 10.1016/j.expneurol.2004.05.042; ARNOLD DL, 1990, MAGNET RESON MED, V14, P154, DOI 10.1002/mrm.1910140115; ARNOLD DL, 1992, ANN NEUROL, V31, P235, DOI 10.1002/ana.410310302; Balla DZ, 2007, MAGN RESON MATER PHY, V20, P183, DOI 10.1007/s10334-007-0081-3; Baptiste DC, 2006, J NEUROTRAUM, V23, P318, DOI 10.1089/neu.2006.23.318; Bilgen M, 2001, MAGN RESON MED, V46, P1250, DOI 10.1002/mrm.1325; Bitsch A, 1999, AM J NEURORADIOL, V20, P1619; Blamire AM, 2007, MAGN RESON MED, V58, P880, DOI 10.1002/mrm.21382; Carpentier A, 2006, J NEUROTRAUM, V23, P674, DOI 10.1089/neu.2006.23.674; Cooke FJ, 2004, MAGN RESON MED, V51, P1122, DOI 10.1002/mrm.20084; Demougeot C, 2004, J NEUROCHEM, V90, P776, DOI 10.1111/j.1471-4159.2004.02583.x; Demougeot C, 2001, J NEUROCHEM, V77, P408, DOI 10.1046/j.1471-4159.2001.00285.x; Deng X, 2007, MAGN RESON MED, V57, P620, DOI 10.1002/mrm.21163; Deo AA, 2006, J NEUROSCI RES, V83, P801, DOI 10.1002/jnr.20783; Edden RAE, 2007, J MAGN RESON IMAGING, V26, P1101, DOI 10.1002/jmri.21008; Falconer JC, 1996, J NEUROCHEM, V66, P717; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Ge Y, 2006, AM J NEURORADIOL, V27, P1165; Gomez-Anson B, 2000, NEURORADIOLOGY, V42, P515, DOI 10.1007/s002340000323; Henning A, 2008, MAGN RESON MED, V59, P1250, DOI 10.1002/mrm.21578; Higuchi T, 1996, NEUROSURGERY, V38, P121, DOI 10.1097/00006123-199601000-00030; Holly LT, 2009, J NEUROSURG-SPINE, V10, P194, DOI 10.3171/2008.12.SPINE08367; Kendi ATK, 2004, NEURORADIOLOGY, V46, P764, DOI 10.1007/s00234-004-1231-1; Kim YG, 2004, J SPINAL DISORD TECH, V17, P405, DOI 10.1097/01.bsd.0000124762.36865.9f; Konaka K, 2003, J CEREBR BLOOD F MET, V23, P700, DOI 10.1097/01.WCB.0000071888.63724.56; LARSSON HBW, 1991, MAGN RESON MED, V22, P23, DOI 10.1002/mrm.1910220104; Mader I, 2000, AM J NEURORADIOL, V21, P1220; Malisza KL, 1998, BIOCHEM CELL BIOL, V76, P487, DOI 10.1139/bcb-76-2-3-487; Marliani AF, 2007, MAGN RESON MED, V57, P160, DOI 10.1002/mrm.21113; McBride DQ, 1995, SURG NEUROL, V44, P137, DOI 10.1016/0090-3019(95)00139-5; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Moore Gregory J, 2002, Psychopharmacol Bull, V36, P5; Narayana PA, 2005, J NEUROIMAGING, V15, p46S, DOI 10.1177/1051228405284200; Narayana PA, 2004, J NEUROSCI RES, V78, P749, DOI 10.1002/jnr.20275; Narayana PA, 1998, ANN NEUROL, V43, P56, DOI 10.1002/ana.410430112; Pilatus U, 2009, PSYCHIAT RES-NEUROIM, V173, P1, DOI 10.1016/j.pscychresns.2008.07.015; Sager TN, 2000, J CEREBR BLOOD F MET, V20, P780, DOI 10.1097/00004647-200005000-00004; Sajja BR, 2009, NEUROIMAG CLIN N AM, V19, P45, DOI 10.1016/j.nic.2008.08.002; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2008, J NEUROSURG, V108, P42, DOI 10.3171/JNS/2008/108/01/0042; Silver X, 2001, MAGN RESON MED, V46, P1216, DOI 10.1002/mrm.1319; Simoes RV, 2008, MAGN RESON MATER PHY, V21, P237, DOI 10.1007/s10334-008-0114-6; Tartaglia MC, 2002, J NEUROL, V249, P1382, DOI 10.1007/s00415-002-0846-6; URENJAK J, 1993, J NEUROSCI, V13, P981, DOI 10.1523/jneurosci.13-03-00981.1993; van Walderveen MAA, 1999, ANN NEUROL, V46, P79, DOI 10.1002/1531-8249(199907)46:1<79::AID-ANA12>3.3.CO;2-0; VINK R, 1989, ANN NEUROL, V25, P26, DOI 10.1002/ana.410250105; Vroemen M, 2006, AM J NEURORADIOL, V27, P598; WEIRICH SD, 1990, SPINE, V15, P630, DOI 10.1097/00007632-199007000-00004; Zelaya FO, 1996, MAGNET RESON MED, V35, P443, DOI 10.1002/mrm.1910350401	51	27	28	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2010	27	3					599	610		10.1089/neu.2009.1145			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	575PJ	WOS:000276079100012	20001674	Green Published			2021-06-18	
J	Gao, C; Wang, CL; Wu, P; Liu, Z; Liu, XZ				Gao Cheng; Wang Chunlei; Wu Pei; Liu Zhen; Liu Xiangzhen			Simvastatin activates Akt/glycogen synthase kinase-3 beta signal and inhibits caspase-3 activation after experimental subarachnoid hemorrhage	VASCULAR PHARMACOLOGY			English	Article						Subarachnoid hemorrhage; Acute brain injury; Akt/GSK3 beta; Simvastatin; Apoptosis	NITRIC-OXIDE SYNTHASE; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; PROTEIN-KINASE-B; CELL-DEATH; STATIN USE; AKT PHOSPHORYLATION; NEURONAL APOPTOSIS; DNA FRAGMENTATION; CYTOCHROME-C	This study was designed to explore the role of simvastatin and its effects on the Akt/GSK3 beta survival signal and apoptosis pathway after experimental subarachnoid hemorrhage (SAH). SAH was induced by blood injection into the cisterna magna in New Zealand white rabbits. Increased expression of phospho-Akt and phospho-GSK3 beta was observed in brain tissue after SAH. Apoptosis and related proteins, including P53, apoptosis-inducing factor (AIF). cytochrome C, and cleaved caspase-3, were also activated. Simvastatin, at both low dose (10 mg/kg) and high dose (40 mg/kg), further increased expression of phospho-Akt and phospho-GSK3 beta decreased activation of caspase-3, and inhibited apoptosis. Preserved blood-brain barrier and attenuated brain edema were observed following simvastatin treatment. In addition, the neuroprotective effects of simvastatin were blocked by wortmannin (2.5 mu g/kg/min), an irreversible PIK3 inhibitor. P53, AIF, and cytochrome C were not affected by simvastatin treatment. Findings from the present study suggest that simvastatin ameliorates acute brain injury after SAH. The potential mechanisms of action include activation of the Akt/GSK3 beta survival signal and inhibition of caspase-dependent apoptosis pathway. (C) 2009 Elsevier Inc. All rights reserved.	[Gao Cheng; Wang Chunlei; Wu Pei; Liu Zhen; Liu Xiangzhen] Harbin Med Univ, Dept Neurosurg, Affiliated Hosp 1, Harbin, Peoples R China	Gao, C (corresponding author), Harbin Med Univ, Dept Neurosurg, Affiliated Hosp 1, 23 Youzheng St, Harbin, Peoples R China.	doctorgaocheng@yahoo.com.cn; wangchunlei@163.com; wupei001@163.com; liuzhen8028@163.com; liuxzhen001@yahoo.com.cn	Gao, C/B-6388-2009	Gao, Cheng/0000-0002-8867-1591	Youth Special Foundation of Heilongjiang Province [QC07C100]; Special Found of The First Affiliated Hospital of Harbin Medical University [2007035]	This research was supported by the Youth Special Foundation of Heilongjiang Province to Gao C (No.QC07C100) and The Special Found of The First Affiliated Hospital of Harbin Medical University (No.2007035).	Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bederson JB, 1998, NEUROSURGERY, V42, P352, DOI 10.1097/00006123-199802000-00091; Cahill J, 2007, NEUROSURGERY, V60, P531, DOI 10.1227/01.NEU.0000249287.99878.9B; Cahill WJ, 2006, J CEREBR BLOOD F MET, V26, P1341, DOI 10.1038/sj.jcbfm.9600283; Cheng Y, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-156; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Endo H, 2006, J CEREBR BLOOD F MET, V26, P1479, DOI 10.1038/sj.jcbfm.9600303; Endo H, 2006, STROKE, V37, P2140, DOI 10.1161/01.STR.0000229888.55078.72; ENDO S, 1988, STROKE, V19, P1420, DOI 10.1161/01.STR.19.11.1420; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Gabikian P, 2002, STROKE, V33, P2681, DOI 10.1161/01.STR.0000033931.62992.B1; Gao C, 2008, AUTON NEUROSCI-BASIC, V141, P22, DOI 10.1016/j.autneu.2008.04.007; Hetman M, 2000, J NEUROSCI, V20, P2567; Hutter BO, 2001, J NEUROSURG, V94, P241, DOI 10.3171/jns.2001.94.2.0241; Kramer AH, 2008, NEUROSURGERY, V62, P422, DOI 10.1227/01.neu.0000316009.19012.e3; Kusaka G, 2003, J NEUROSURG, V99, P383, DOI 10.3171/jns.2003.99.2.0383; Madonna R, 2005, J BIOL CHEM, V280, P13503, DOI 10.1074/jbc.M411859200; Matz PG, 2001, STROKE, V32, P506, DOI 10.1161/01.STR.32.2.506; Matz PG, 2000, STROKE, V31, P2450, DOI 10.1161/01.STR.31.10.2450; Matz PG, 2000, BRAIN RES, V858, P312, DOI 10.1016/S0006-8993(99)02454-3; McGirt MJ, 2009, J NEUROSURG, V110, P968, DOI 10.3171/2008.10.JNS08901; McGirt MJ, 2006, NEUROSURGERY, V58, P945, DOI 10.1227/01.NEU.0000210262.67628.7E; McGirt MJ, 2002, STROKE, V33, P2950, DOI 10.1161/01.STR.0000038986.68044.39; Miida T, 2007, PHARMACOL THERAPEUT, V113, P378, DOI 10.1016/j.pharmthera.2006.09.003; Nau R, 2002, BRAIN PATHOL, V12, P329; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Ogungbo B, 2001, BRIT J NEUROSURG, V15, P388, DOI 10.1080/02688690120082387; Ostrowski RP, 2005, J CEREBR BLOOD F MET, V25, P554, DOI 10.1038/sj.jcbfm.9600048; Park S, 2004, STROKE, V35, P2412, DOI 10.1161/01.STR.0000141162.29864.e9; Parra A, 2005, NEUROSURGERY, V56, P476, DOI 10.1227/01.NEU.0000153925.96889.8A; Prunell GF, 2005, J NEUROSURG, V102, P1046, DOI 10.3171/jns.2005.102.6.1046; Sanada S, 2004, CIRCULATION, V110, P2143, DOI 10.1161/01.CIR.0000143830.59419.73; Schievink WI, 1997, NEW ENGL J MED, V336, P28, DOI 10.1056/NEJM199701023360106; Sillberg VAH, 2008, STROKE, V39, P2622, DOI 10.1161/STROKEAHA.107.508341; Sugawara T, 2008, J NEUROSCI RES, V86, P3635, DOI 10.1002/jnr.21807; Tseng Ming-Yuan, 2006, Neurosurg Focus, V21, pE10; Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Yu FS, 2005, NEUROBIOL DIS, V20, P491, DOI 10.1016/j.nbd.2005.04.004; Zhou ML, 2007, J NEUROSCI METH, V159, P318, DOI 10.1016/j.jneumeth.2006.07.026	42	27	28	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	JAN-FEB	2010	52	1-2					77	83		10.1016/j.vph.2009.12.001			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	563TR	WOS:000275157900010	20004738				2021-06-18	
J	Greve, KW; Bianchini, KJ; Etherton, JL; Meyers, JE; Curtis, KL; Ord, JS				Greve, Kevin W.; Bianchini, Kevin J.; Etherton, Joseph L.; Meyers, John E.; Curtis, Kelly L.; Ord, Jonathan S.			The Reliable Digit Span Test in Chronic Pain: Classification Accuracy in Detecting Malingered Pain-Related Disability	CLINICAL NEUROPSYCHOLOGIST			English	Article						Reliable digit span; Chronic pain; Cognition; Malingered pain-related disability; Criterion groups design; Symptom validity test; Response bias	TRAUMATIC BRAIN-INJURY; MMPI-2 VALIDITY SCALES; NEUROCOGNITIVE DYSFUNCTION; WAIS-III; INDICATORS; SPECIFICITY; SENSITIVITY; DEPRESSION	This study used criterion groups validation (known-groups design) to examine the classification accuracy of the Reliable Digit Span test (RDS) in a large group of chronic pain patients referred for psychological evaluation. The sample consisted of 612 patients classified into one of six groups based on evidence of malingered pain-related disability (MPRD): No-Incentive, Not MPRD; Incentive-Only, Not MPRD; Indeterminate; Possible MPRD; Probable MPRD; Definite MPRD. A total of 30 college student simulators were also included. Lower average RDS scores and higher rates of RDS failure were seen in patients classified as MPRD and in simulators. Consistent with previous literature in a variety of populations, RDS = 6 provided the most accurate differentiation between MPRD and non-MPRD pain patients. Clinical implications are discussed.	[Greve, Kevin W.; Bianchini, Kevin J.; Curtis, Kelly L.; Ord, Jonathan S.] Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; [Greve, Kevin W.; Bianchini, Kevin J.; Etherton, Joseph L.; Curtis, Kelly L.] Jefferson Neurobehav Grp, Metairie, LA USA; [Etherton, Joseph L.] SW Texas State Univ, Dept Psychol, San Marcos, TX 78666 USA; [Meyers, John E.] Ctr Neurosci Orthoped & Spine, Dakota Dunes, SD USA	Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					Bianchini K. J., 2004, J FORENSIC NEUROPSYC, V4, P65; Bianchini KJ, 2008, ASSESSMENT, V15, P435, DOI 10.1177/1073191108317341; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, PORTLAN DIGIT RECOGN; Boone, 2007, ASSESSMENT FEIGNED C; Butcher J. N., 1989, MMPI 2 MANUAL ADM SC; Butters N, 1980, ALCOHOLIC KORSAKOFFS; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; Ericsson M, 2002, DISABIL REHABIL, V24, P334, DOI 10.1080/09638280110096241; Etherton J, 2005, ASSESSMENT, V12, P130, DOI 10.1177/1073191105274859; Etherton JL, 2005, ASSESSMENT, V12, P101, DOI 10.1177/1073191104270789; Green P., 2005, GREENS WORD MEMORY T; Green P., 1996, WORD MEMORY TEST USE; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2007, ASSESSMENT, V14, P12, DOI 10.1177/1073191106295095; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P1250, DOI 10.1080/13854040902828272; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P850, DOI 10.1080/13854040802585055; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH PHYS MED REHAB, V84, P1233, DOI 10.1016/S0003-9993(03)00145-X; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Grote C.L., 2007, ASSESSMENT MALINGERE, P44; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; Iverson G.L., 2001, J FORENSIC NEUROPSYC, V2, P19, DOI [https://doi.org/10.1300/J151v02n01_02, DOI 10.1300/J151v02n01_02]; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P1, DOI 10.1016/S0887-6177(01)00176-7; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Meyers J E, 2000, Appl Neuropsychol, V7, P133, DOI 10.1207/S15324826AN0703_3; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; SCHNURR RF, 1995, CLIN J PAIN, V11, P103, DOI 10.1097/00002508-199506000-00004; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr J. A., 2007, ASSESSMENT MALINGERE; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilson KG, 2002, CLIN J PAIN, V18, P77, DOI 10.1097/00002508-200203000-00002	42	27	27	1	5	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2010	24	1					137	152	PII 915733575	10.1080/13854040902927546			16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	535MK	WOS:000272972300011	19816837				2021-06-18	
J	Helmick, K				Helmick, Katherine		Consensus Conf	Cognitive rehabilitation for military personnel with mild traumatic brain injury and chronic post-concussional disorder: Results of April 2009 consensus conference	NEUROREHABILITATION			English	Article							POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; NEUROPSYCHOLOGIC REHABILITATION; MEMORY REMEDIATION; SELF-AWARENESS; PROGRAM; MANAGEMENT; INTERVENTION; ATTENTION; DEFICITS	A consensus conference on cognitive rehabilitation for mild traumatic brain injury was conducted by the Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury and the Defense and Veterans Brain Injury Center. Fifty military and civilian subject matter experts from a broad range of clinical and scientific disciplines developed clinical guidance for the care of Service Members with persistent post-concussion cognitive symptoms three or more months post injury. "Cognitive rehabilitation" was identified to be a broad group of diverse services. Specific services within this rubric were identified as effective or not, and were evaluated both as single-services and as combined integrated cognitive rehabilitation programs. Co-morbidities were acknowledged and addressed, but the conference and ensuing guidance focused primarily upon treatment of cognitive impairment. Guidance regarding effective services addressed the areas of assessment, intervention, outcome measurement, and treatment program implementation.	[Helmick, Katherine; Consensus Conf] Def Ctr Excellence Psychol Hlth & Traumat Brain I, Silver Spring, MD 20910 USA	Helmick, K (corresponding author), Def Ctr Excellence Psychol Hlth & Traumat Brain I, 1335 East West Highway,9th Floor,Suite 400, Silver Spring, MD 20910 USA.	Katherine.Helmick@tma.osd.mil					Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Berg I. J., 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI [DOI 10.1080/09602019108401384, 10.1080/09602019108401384]; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cheng SKW, 2006, BRAIN INJURY, V20, P621, DOI 10.1080/02699050600677196; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; DePompei R, 2008, NEUROREHABILITATION, V23, P487; Ehlhardt LA, 2005, BRAIN INJURY, V19, P569, DOI 10.1080/002699050400013550; Evans JJ, 1998, J INT NEUROPSYCH SOC, V4, P399, DOI 10.1017/S1355617798003993; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; Glisky EL, 2002, NEUROPSYCHOLOGICAL INTERVENTIONS, P137; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Gordon WA, 2006, J HEAD TRAUMA REHAB, V21, P156, DOI 10.1097/00001199-200603000-00008; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Goverover Y, 2007, BRAIN INJURY, V21, P913, DOI 10.1080/02699050701553205; Griesbach GS, 2009, J NEUROSCI RES, V87, P795, DOI 10.1002/jnr.21893; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; IVERSON GL, 2006, POSTCONCUSSIVE DISOR, P373; Kaschel R, 2002, NEUROPSYCHOL REHABIL, V12, P127, DOI 10.1080/09602010143000211; KIM Y, 2009, NEUROREHABILITATION, V23, P1; Kime SK, 1996, BRAIN INJURY, V10, P17; Levin H. S., 1997, SEMINARS CLIN NEUROP, V2, P207; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Lew HL, 2009, AM J PHYS MED REHAB, V88, P1, DOI 10.1097/PHM.0b013e3181911102; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Malec JF, 1999, NEUROPSYCHOL REHABIL, V9, P253, DOI 10.1080/096020199389365; McCrea M, 2008, MILD TRAUMATIC BRAIN; McKerracher G, 2005, NEUROPSYCHOL REHABIL, V15, P115, DOI 10.1080/09602010443000056; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; *NIH CONS DEV PAN, 1999, JAMA-J AM MED ASSOC, V282, P947; Novack TA, 1996, J HEAD TRAUMA REHAB, V11, P52, DOI 10.1097/00001199-199606000-00008; Ownsworth T, 2006, J INT NEUROPSYCH SOC, V12, P54, DOI 10.1017/S135561770606005X; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; RATTOK J, 1992, NEUROPSYCHOLOGIA, V6, P395, DOI DOI 10.1037/0894-4105.6.4.395; Rees L, 2007, BRAIN INJURY, V21, P161, DOI 10.1080/02699050701201813; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Sarajuuri JM, 2005, ARCH PHYS MED REHAB, V86, P2296, DOI 10.1016/j.apmr.2005.06.018; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Schutz LE, 2007, BRAIN INJURY, V21, P545, DOI 10.1080/02699050701426923; Serino A, 2007, BRAIN INJURY, V21, P11, DOI 10.1080/02699050601151811; SINOTTE M, 2003, J MED SPEECH PATHOLO, V11, P19; SOHLBERG M, 2007, J MED SPEECH PATHOLO, V15; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sohlberg M. M., 2003, J MED SPEECH LANGUAG, V11; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; SOHLBERG MM, 2002, J CLIN EXPT NEUROPSY, V22, P656; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Strangman GE, 2009, NEUROREHAB NEURAL RE, V23, P226, DOI 10.1177/1545968308324225; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thickpenny-Davis KL, 2007, J HEAD TRAUMA REHAB, V22, P303, DOI 10.1097/01.HTR.0000290975.09496.93; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Tsaousides T, 2009, MT SINAI J MED, V76, P173, DOI 10.1002/msj.20099; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015; Vaynman S, 2005, NEUROREHAB NEURAL RE, V19, P283, DOI 10.1177/1545968305280753; Weathers F.W., 1993, PTSD CHECKLIST PCL R; WEBB PM, 1994, REHABIL PSYCHOL, V39, P179, DOI 10.1037/h0080321; Westerberg H, 2007, BRAIN INJURY, V21, P21, DOI 10.1080/02699050601148726	72	27	28	0	6	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2010	26	3					239	255		10.3233/NRE-2010-0560			17	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	603OQ	WOS:000278218300008	20448314				2021-06-18	
J	Langley, J; Johnson, S; Slatyer, M; Skilbeck, CE; Thomas, M				Langley, J.; Johnson, S.; Slatyer, M.; Skilbeck, C. E.; Thomas, M.			Issues of loss to follow-up in a population study of traumatic brain injury (TBI) followed to 3 years post-trauma	BRAIN INJURY			English	Article						Traumatic brain injury; loss to follow up; mild traumatic brain injury	HEAD-INJURY; COMMUNITY INTEGRATION; LIFE SATISFACTION; SILENT EPIDEMIC; SYSTEMATIC BIAS; RETURN; WORK; PREDICTORS; COMPLAINTS; SYMPTOMS	Primary objective: To examine loss to follow-up (LTFU) using a population with traumatic brain injury (TBI) to include a range of severity and to follow participants to 3 years post-injury. Also investigated were cause of TBI and employment status. Research design: The research included 947 adults from a TBI population study. Data were obtained on severity, cause of TBI and employment status and participants were followed up at 1, 3, 6, 12, 24 and 36 months after injury. Chi-squared analyses were used to examine rates of loss to follow-up. Main outcome and results: Overall LTFU increased from 22% at 1 month post-injury to 81% at 3-year follow-up. Most participants (52%) were employed at the time of their TBI, with 39% of TBIs being motor vehicle related. Lower LTFU at 2 and 3 years post-TBI was significantly associated with severe TBI. Within the mTBI sub-group significantly higher LTFU at 1 and 6 months after injury and at 2 and 3 years post-injury was associated with TBI from assault. Those sustaining mTBI from a fall or sport-related injury showed significantly lower LTFU at the 6-month, 12-month and 2-year follow-up points. The highest LTFU was noted for unemployed participants, with retired participants showing the lowest rate.	[Langley, J.] Community Rehabil Royal Hobart Hosp, Hobart, Tas, Australia; [Langley, J.; Johnson, S.; Slatyer, M.; Skilbeck, C. E.; Thomas, M.] Royal Hobart Hosp, Sch Med, Hobart, Tas, Australia; [Slatyer, M.] Royal Hobart Hosp, Sch Med, Hobart, Tas, Australia; [Skilbeck, C. E.] Univ Tasmania, Sch Psychol, Hobart, Tas 7001, Australia; [Thomas, M.] Charles Sturt Univ, Bathurst, NSW 2795, Australia	Langley, J (corresponding author), Community Rehabil Unit, 90 Davey St, Hobart, Tas 7001, Australia.	jenny.langley@dhhs.tas.gov.au			Motor Accident Insurance Board of Tasmania	The Tasmanian Neurotrauma Register was funded by the Motor Accident Insurance Board of Tasmania.	Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Feinstein A, 2000, CAN J PUBLIC HEALTH, V91, P325, DOI 10.1007/BF03404799; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FORTUNE N, 1999, DIS15 AIHW; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hillier SL, 1997, BRAIN INJURY, V11, P649; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Labi MLC, 2003, BRAIN INJURY, V17, P265, DOI 10.1080/0269905021000038410; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pickelsimer EE, 2006, J HEAD TRAUMA REHAB, V21, P491, DOI 10.1097/00001199-200611000-00004; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; RIBISL JM, MINIMIZING PARTICIPA; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SILVER JM, 2005, TXB TRAUMATIC BRAIN, P279; SLATYER M, 2004, BRAIN INJ ASS TASM C; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stuart M, 2004, J HEAD TRAUMA REHAB, V19, P329, DOI 10.1097/00001199-200407000-00007; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; TABCHNICK BG, 1995, USING MULTIVARIANTE; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Thomas MD, 2009, BRAIN INJURY, V23, P516, DOI 10.1080/02699050902926333; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207	36	27	27	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	7-8					939	947		10.3109/02699052.2010.491494			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	620MW	WOS:000279505000003	20545449				2021-06-18	
J	Lew, HL; Weihing, J; Myers, PJ; Pogoda, TK; Goodrich, GL				Lew, Henry L.; Weihing, Jeffrey; Myers, Paula J.; Pogoda, Terri K.; Goodrich, Gregory L.			Dual sensory impairment (DSI) in traumatic brain injury (TBI) - An emerging interdisciplinary challenge	NEUROREHABILITATION			English	Article						Dual sensory impairment; DSI; auditory; hearing; visual; military; blast	CLOSED-HEAD-INJURY; INFORMATION-PROCESSING DEFICITS; LOW-VISION REHABILITATION; INTRACEREBRAL POTENTIALS; VISUAL-STIMULI; RARE TARGET; AUDITORY DYSFUNCTION; HEARING IMPAIRMENT; NOISE EXPOSURE; CONCUSSION	The present review characterizes dual sensory impairment (DSI) as co-existing auditory and visual deficits in TBI that can be peripherally or centrally based. Current research investigating DSI in the military population, along with applicable research which focuses on unimodal deficits, is considered. Due to the heterogenous nature of TBI lesions, an important challenge that the clinician faces is ruling out the influence of multiple sensory deficits and/or the influence of cognitive processes on diagnosis and rehabilitation of the patient. Treatment options for DSI involve remediation of the sensory deficits via existing sensory aids or training exercises.	[Lew, Henry L.] Virginia Commonwealth Univ, Sch Med, DVBIC, Richmond, VA 23219 USA; [Lew, Henry L.] Virginia Commonwealth Univ, Sch Med, Dept PM&R, Richmond, VA 23219 USA; [Lew, Henry L.] Harvard Univ, Sch Med, Dept PM&R, Boston, MA USA; [Weihing, Jeffrey; Pogoda, Terri K.] VA Boston Healthcare Syst, TBI Res Ctr, Boston, MA USA; [Myers, Paula J.] James A Haley Vet Hosp, Audiol Serv, Tampa, FL 33612 USA; [Pogoda, Terri K.] Boston Healthcare Syst, VA, Ctr Org Leadership & Management Res, Boston, MA USA; [Pogoda, Terri K.] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Goodrich, Gregory L.] VA Palo Alto Hlth Care Syst, Psychol Serv, Palo Alto, CA USA; [Goodrich, Gregory L.] VA Palo Alto Hlth Care Syst, Western Blind Rehabil Ctr, Palo Alto, CA USA	Lew, HL (corresponding author), Virginia Commonwealth Univ, Sch Med, DVBIC, 730 E Broad St, Richmond, VA 23219 USA.	hlew@dvbic.org	Goodrich, Gregory L./AAF-7184-2019; Pogoda, Terri/F-6243-2012	Pogoda, Terri/0000-0003-1397-8780			*AM SPEECH LANG HE, AUD PROC DIS; American Speech-Language-Hearing Association, PREF PRACT PATT PROF; Attias J., 2005, Journal of Basic and Clinical Physiology and Pharmacology, V16, P117; Bamiou DE, 2007, BRAIN RES REV, V56, P170, DOI 10.1016/j.brainresrev.2007.07.003; BAUDENA P, 1995, ELECTROEN CLIN NEURO, V94, P251, DOI 10.1016/0013-4694(95)98476-O; Bellis TJ, 2008, BRAIN COGNITION, V66, P280, DOI 10.1016/j.bandc.2007.09.006; Bergemalm PO, 2001, ACTA OTO-LARYNGOL, V121, P724, DOI 10.1080/00016480152583674; BERGMAN M, 1987, EAR HEARING, V8, P87, DOI 10.1097/00003446-198704000-00005; Bertone A, 2007, J CLIN EXP NEUROPSYC, V29, P467, DOI 10.1080/13803390600770793; Bouwmeester L, 2007, J NEUROL NEUROSUR PS, V78, P555, DOI 10.1136/jnnp.2006.103853; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Cacace Anthony T, 2005, Am J Audiol, V14, P112, DOI 10.1044/1059-0889(2005/012); Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; CHANDLER D, 2006, ASHA LEADER, V11, P9; Chermak GD, 2007, HDB CENTRAL AUDITORY, V2; Chisolm Theresa Hnath, 2007, Trends Amplif, V11, P73, DOI 10.1177/1084713807300879; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; COCKERHAM G, 2009, J REHABILIT IN PRESS; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Drake M E Jr, 1996, Electromyogr Clin Neurophysiol, V36, P457; Duncan CC, 2005, INT J PSYCHOPHYSIOL, V58, P133, DOI 10.1016/j.ijpsycho.2005.05.011; Duncan CC, 2003, PSYCHOPHYSIOLOGY, V40, P45, DOI 10.1111/1469-8986.00006; Dutton GN, 2003, EYE, V17, P289, DOI 10.1038/sj.eye.6700344; Duvdevany A, 2007, INT J AUDIOL, V46, P119, DOI 10.1080/14992020600937402; Fligor BJ, 2002, ARCH PHYS MED REHAB, V83, P141, DOI 10.1053/apmr.2002.26813; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; Gaetz M, 2000, BRAIN INJURY, V14, P815; Giorgi RG, 2009, OPTOMETRY VISION SCI, V86, P492, DOI 10.1097/OPX.0b013e31819f9e4d; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; GRANICK S, 1976, J GERONTOL, V31, P434, DOI 10.1093/geronj/31.4.434; HALGREN E, 1995, ELECTROEN CLIN NEURO, V94, P191, DOI 10.1016/0013-4694(94)00259-N; HALGREN E, 1995, ELECTROEN CLIN NEURO, V94, P229, DOI 10.1016/0013-4694(95)98475-N; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Isaki E, 2000, BRAIN INJURY, V14, P441; Jordan Nikki N., 2009, Seminars in Hearing, V30, P28, DOI 10.1055/s-0028-1111104; KOONS P, EYE BRAIN IN PRESS; LEVIN HS, 1989, J NEUROL NEUROSUR PS, V52, P1162, DOI 10.1136/jnnp.52.10.1162; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2007, J CLIN NEUROPHYSIOL, V24, P398, DOI 10.1097/WNP.0b013e318150694b; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Markowitz SN, 2006, CAN J OPHTHALMOL, V41, P289, DOI 10.1139/I06-027; Marshall RS, 2009, NEUROLOGIST, V15, P185, DOI 10.1097/NRL.0b013e3181942894; McBride D, 2001, SCAND AUDIOL, V30, P106, DOI 10.1080/010503901300112211; McFarland DJ, 1997, AUDIOLOGY, V36, P249; MCFARLAND DJ, 1995, PSYCHOL RES-PSYCH FO, V57, P80; McFarland DJ, 1998, J SPEECH LANG HEAR R, V41, P300, DOI 10.1044/jslhr.4102.300; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P79, DOI 10.1016/S0887-6177(00)00105-0; MUSIEK FE, 2007, HDB CENTRAL AUDITORY, V1; Musiek Frank E, 2004, J Am Acad Audiol, V15, P117, DOI 10.3766/jaaa.15.2.3; Myers Paula J., 2009, Seminars in Hearing, V30, P5, DOI 10.1055/s-0028-1111103; Nolle C, 2004, J NEUROTRAUM, V21, P251, DOI 10.1089/089771504322972040; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; ONOFRJ M, 1991, ACTA NEUROL SCAND, V83, P273, DOI 10.1111/j.1600-0404.1991.tb04700.x; Owsley C, 2009, ARCH OPHTHALMOL-CHIC, V127, P681, DOI 10.1001/archophthalmol.2009.55; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; Putter-Katz Hanna, 2008, Journal of Basic and Clinical Physiology and Pharmacology, V19, P301; Rappaport M, 1990, J Neuropsychiatry Clin Neurosci, V2, P399; Reinvang I, 2000, NEUROPSYCHOLOGIA, V38, P995, DOI 10.1016/S0028-3932(99)00153-0; Riggs RV, 2007, AM J PHYS MED REHAB, V86, P853, DOI 10.1097/PHM.0b013e318151f907; Schuett S, 2008, NEUROPSYCHOLOGIA, V46, P2445, DOI 10.1016/j.neuropsychologia.2008.04.016; Schuett S, 2009, NEUROPSYCHOLOGIA, V47, P733, DOI 10.1016/j.neuropsychologia.2008.12.004; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Smith SL, 2008, J REHABIL RES DEV, V45, P597, DOI 10.1682/JRRD.2007.02.0023; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; SOUSTIEL JF, 1995, BRAIN INJURY, V9, P805, DOI 10.3109/02699059509008236; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tay T, 2006, GERONTOLOGY, V52, P386, DOI 10.1159/000095129; TEUFERTAUTREY S, 2004, HEARING HLTH, V20, P20; Thach AB, 2008, OPHTHALMOLOGY, V115, P377, DOI 10.1016/j.ophtha.2007.04.032; THOMAS PD, 1983, J GERONTOL, V38, P321, DOI 10.1093/geronj/38.3.321; *US GOV ACC OFF, 2008, GAO08276; Valentijn SAM, 2005, J AM GERIATR SOC, V53, P374, DOI 10.1111/j.1532-5415.2005.53152.x; van Boxtel MPJ, 2000, J CLIN EXP NEUROPSYC, V22, P147, DOI 10.1076/1380-3395(200002)22:1;1-8;FT147; Voyer D, 2003, BRAIN COGNITION, V53, P393, DOI 10.1016/S0278-2626(03)00152-0; Weichel EA, 2009, J HEAD TRAUMA REHAB, V24, P41, DOI 10.1097/HTR.0b013e3181956ffd; Weihing J., 2007, AUDITORY PROCESSING; WEIHING J, J AM ACAD AUDI UNPUB; WEXLER B, 1980, NEUROPSYCHOLOGIA, V28, P71; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; YOUNG S, 2008, HOME HEALTHCARE NURS, V26, P472	87	27	27	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2010	26	3					213	222		10.3233/NRE-2010-0557			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	603OQ	WOS:000278218300005	20448311				2021-06-18	
J	Tasker, RC; Westland, AG; White, DK; Williams, GB				Tasker, Robert C.; Westland, Amber Gunn; White, Deborah K.; Williams, Guy B.			Corpus Callosum and Inferior Forebrain White Matter Microstructure Are Related to Functional Outcome from Raised Intracranial Pressure in Child Traumatic Brain Injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						Diffusion tensor imaging; Fractional anisotropy; Social interaction; Corpus callosum; Intracranial pressure	PEDIATRIC INTENSIVE-CARE; DIFFUSION-TENSOR MRI; CLOSED-HEAD INJURY; WALLERIAN DEGENERATION; WATER DIFFUSION; NEUROPSYCHOLOGICAL SEQUELAE; NEUROPSYCHOMETRIC TESTS; SEX-DIFFERENCES; ADOLESCENTS; ANISOTROPY	In severe paediatric traumatic brain injury (TBI), a common focus of treatment is raised intracranial pressure (ICP). We have previously reported frontal cerebral vulnerability with executive deficits from raised ICP in paediatric TBI. Now, using diffusion tensor imaging (DTI) in a different population, we have examined fractional anisotropy (FA), and mean, axial and radial diffusivity (MD, AD, RD) in 4 regions of the corpus callosum (CC) and in both inferior frontal regions. Our aim was to examine during the chronic phase of TBI whether the CC cross-sectional area correlated with regional DTI metrics of white matter microstructure, with global outcome ratings of function (Functional Independence Measure and Multiattribute Health Status Classification) and with performance in the Rey-Osterrieth Complex Figure (ROCF) test. We examined 33 paediatric TBI cases who were followed, on average, 4.9 years after severe injury. All cases had received mechanical ventilation during their acute treatment and, a priori, they were assigned to a non-ICP or a raised ICP group. Twenty-two participants had mainly right-sided injury at the time of acute ictus. The findings confirm that severe TBI in childhood, complicated by intracranial hypertension, results in CC vulnerability. In the chronic phase of recovery, it is reduced in the cross-sectional area, it is more compact and thinned, and the anterior region is disproportionately small. Late after raised ICP, we have also found that individuals exhibit regional microstructural abnormality with combined reduced FA and increased MD, AD and RD. Smaller size and such microstructural changes in the anterior CC were associated with similar right-sided (rather than left-sided) frontal microstructural changes in the ICP group. Taken together, this evidence points to an interaction between raised ICP-related brain tissue perturbation and focal frontal extracallosal injury, leading to anterior CC regional vulnerability, most likely wallerian degeneration. At long-term follow-up, this lack of white matter integrity in the anterior CC is correlated with functional outcome, particularly in aspects of social interaction and the copy component of the ROCF test, which suggests that the CC-to-forebrain function warrants further study in chronic TBI. Copyright (C) 2010 S. Karger AG, Basel	[Tasker, Robert C.] Univ Cambridge, Sch Clin, Addenbrookes Hosp, Dept Paediat,Paediat Intens Care Unit, Cambridge CB2 2QQ, England; [Tasker, Robert C.; Westland, Amber Gunn] Univ Cambridge, Sch Clin Med, Dept Paediat, Cambridge CB2 2QQ, England; [Williams, Guy B.] Univ Cambridge, Sch Clin Med, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England	Tasker, RC (corresponding author), Univ Cambridge, Sch Clin, Addenbrookes Hosp, Dept Paediat,Paediat Intens Care Unit, Box 116,Hills Rd, Cambridge CB2 2QQ, England.	rct31@cam.ac.uk	Tasker, Robert C/R-5837-2019	Tasker, Robert/0000-0003-3647-8113	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390]; Evelyn Trust; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	We wish to thank the patients and families who participated in this study, and the staff in the Department of Paediatrics and radiographers at the Wolfson Brain Imaging Centre. The Medical Research Council (G9439390) and the Evelyn Trust supported this study.	ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; ALLEN LS, 1991, J NEUROSCI, V11, P933; Barkovich AJ, 2000, AM J NEURORADIOL, V21, P1099; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Beauchamp MH, 2009, J NEUROTRAUM, V26, P1645, DOI [10.1089/neu.2009.0916, 10.1089/neu.2009-0916]; BEAULIEU C, 1994, MAGNET RESON MED, V31, P394, DOI 10.1002/mrm.1910310408; Beebe DW, 2004, APPL NEUROPSYCHOL, V11, P91, DOI 10.1207/s15324826an1102_4; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; Bonekamp D, 2007, NEUROIMAGE, V34, P733, DOI 10.1016/j.neuroimage.2006.09.020; Braga LW, 2007, J CHILD NEUROL, V22, P1084, DOI 10.1177/0883073807306246; Butt AM, 2000, J NEUROSCI RES, V59, P477, DOI 10.1002/(SICI)1097-4547(20000215)59:4<477::AID-JNR2>3.0.CO;2-J; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; *CTR FUNCT ASS RES, 1991, GUID US FUNCT IND ME; *CTR FUNCT ASS RES, 1990, GUID US UN SET MED R; DELACOSTE MC, 1985, J NEUROPATH EXP NEUR, V44, P578, DOI 10.1097/00005072-198511000-00004; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Gale SD, 2010, J HEAD TRAUMA REHAB, V25, P15, DOI 10.1097/HTR.0b013e3181c39960; GEMKE RJBJ, 1995, ARCH DIS CHILD, V73, P196, DOI 10.1136/adc.73.3.196; Gemke RJBJ, 1996, J CLIN EPIDEMIOL, V49, P327, DOI 10.1016/0895-4356(95)00528-5; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; Giedd JN, 1996, DEV BRAIN RES, V91, P274; Giorgio A, 2008, NEUROIMAGE, V39, P52, DOI 10.1016/j.neuroimage.2007.07.043; Glenn OA, 2003, J MAGN RESON IMAGING, V18, P641, DOI 10.1002/jmri.10420; Green HAL, 2002, STROKE, V33, P1517, DOI 10.1161/01.STR.0000016973.80180.7B; Gupta RK, 2006, J MAGN RESON IMAGING, V24, P549, DOI 10.1002/jmri.20677; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hasan KM, 2009, BRAIN RES, V1249, P91, DOI 10.1016/j.brainres.2008.10.026; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kinoshita Y, 1999, ENVIRON RES, V80, P348, DOI 10.1006/enrs.1998.3935; KOLB B, 1990, FUNDAMENTALS HUMAN N, P838; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Morriss MC, 1999, NEURORADIOLOGY, V41, P929, DOI 10.1007/s002340050869; Mukherjee P, 2002, AM J NEURORADIOL, V23, P1445; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Pandya D. N., 1986, 2 HEMISPHERES ONE BR, P47; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Pizzini FB, 2010, BRAIN RES, V1312, P10, DOI 10.1016/j.brainres.2009.11.030; PUJOL J, 1993, ANN NEUROL, V34, P71, DOI 10.1002/ana.410340113; Qiu DQ, 2008, NEUROIMAGE, V41, P223, DOI 10.1016/j.neuroimage.2008.02.023; Rajapakse JC, 1996, BRAIN DEV-JPN, V18, P379, DOI 10.1016/0387-7604(96)00034-4; RAUCH RA, 1994, BEHAV BRAIN RES, V64, P65, DOI 10.1016/0166-4328(94)90119-8; Robertson Charlene M. T., 2001, Pediatr Crit Care Med, V2, P145, DOI 10.1097/00130478-200104000-00009; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; SCHAEFER GB, 1990, J CHILD NEUROL, V5, P127, DOI 10.1177/088307389000500211; Schmithorst VJ, 2002, RADIOLOGY, V222, P212, DOI 10.1148/radiol.2221010626; Shimony JS, 1999, RADIOLOGY, V212, P770, DOI 10.1148/radiology.212.3.r99au51770; Shiramizu H, 2008, NEUROL MED-CHIR, V48, P1, DOI 10.2176/nmc.48.1; Slawik H, 2009, J NEUROTRAUM, V26, P1891, DOI 10.1089/neu.2009.0942; Somerville J, 2000, J CLIN EXP NEUROPSYC, V22, P613, DOI 10.1076/1380-3395(200010)22:5;1-9;FT613; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Sperle PA, 1997, AM J OCCUP THER, V51, P35, DOI 10.5014/ajot.51.1.35; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Thomalla G, 2005, J NEUROL NEUROSUR PS, V76, P266, DOI 10.1136/jnnp.2004.046375; Thomas B, 2005, BRAIN, V128, P2562, DOI 10.1093/brain/awh600; Ulug AM, 2002, DEVELOPMENTAL SCI, V5, P286, DOI 10.1111/1467-7687.t01-1-00005; Verger K, 2001, BRAIN INJURY, V15, P211; Virta A, 1999, MAGN RESON IMAGING, V17, P1121, DOI 10.1016/S0730-725X(99)00048-X; Waller A, 1850, PHILOS T R SOC LOND, V140, P423, DOI [10.1098/rspl.1843.0224, DOI 10.1098/RSTL.1850.0021, 10.1098/rstl.1850.0021]; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; WIMBERGER DM, 1995, J COMPUT ASSIST TOMO, V19, P28, DOI 10.1097/00004728-199501000-00005; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799	71	27	27	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					374	384		10.1159/000316806			11	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900005	20829579				2021-06-18	
J	Wright, MJ; Schmitter-Edgecombe, M; Woo, E				Wright, Matthew J.; Schmitter-Edgecombe, Maureen; Woo, Ellen			Verbal memory impairment in severe closed head injury: The role of encoding and consolidation	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Traumatic brain injury; Memory; Neuropsychology; Encoding; Consolidation	TRAUMATIC BRAIN-INJURY; LEARNING TEST; RETRIEVAL DEFICITS; FOCAL LESIONS; AXONAL INJURY; FREE-RECALL; ACQUISITION; RATIONALE; PATTERNS; RECOVERY	We applied the item-specific deficit approach (ISDA) to California Verbal Learning Test data obtained from 56 severe, acceleration-deceleration closed head injury (CHI) participants and 62 controls. The CHI group demonstrated deficits on all ISDA indices in comparison to controls. Regression analyses indicated that encoding deficits, followed by consolidation deficits, accounted for most of the variance in delayed recall. Additionally, level of acquisition played a partial role in CHI-associated consolidation difficulties. Finally, CHI encoding deficits were largely driven by low semantic clustering during list learning. These results suggest that encoding (primary) and consolidation (secondary) deficits account for CHI-associated verbal memory impairment.	[Wright, Matthew J.] Harbor UCLA Med Ctr, Dept Psychiat, Torrance, CA 90502 USA; [Schmitter-Edgecombe, Maureen] Washington State Univ, Pullman, WA 99164 USA; [Woo, Ellen] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Mary S Easton Ctr Alzheimers Dis Res, Los Angeles, CA 90095 USA	Wright, MJ (corresponding author), Harbor UCLA Med Ctr, Dept Psychiat, 1124 W Carson St,B-4 South, Torrance, CA 90502 USA.	mwright@labiomed.org			Washington State University; American Psychological Association; Van Vleet Memorial Doctoral Fellowship; The University of Memphis; National Institute of Child Health and Human Development (NICHD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD35838]; National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS47690]; National Institute of Mental Health (NIMH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH19535]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD035838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019535] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047690] Funding Source: NIH RePORTER	Special thanks to Anna Curren for her assistance in data collection and coding. This research was supported in part by a Marchionne Memorial Doctoral Fellowship awarded by Washington State University, an American Psychological Association Dissertation Research Award, a Van Vleet Memorial Doctoral Fellowship, a Vidulich Research Fellowship awarded by The University of Memphis, National Institute of Child Health and Human Development (NICHD) Grant HD35838, National Institute of Neurological Disorders and Stroke (NINDS) Grant NS47690, and National Institute of Mental Health (NIMH) Grant MH19535.	AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Aggleton JP, 2006, TRENDS COGN SCI, V10, P455, DOI 10.1016/j.tics.2006.08.003; Arnett PA, 1997, NEUROPSYCHOLOGY, V11, P535, DOI 10.1037/0894-4105.11.4.535; AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Basden BH, 1996, MEMORY, V4, P633, DOI 10.1080/741941000; BASDEN BH, 1993, J EXP PSYCHOL LEARN, V19, P603, DOI 10.1037/0278-7393.19.3.603; Basden BH, 2003, CONSCIOUS COGN, V12, P354, DOI 10.1016/S1053-8100(03)00004-7; Bernard F, 2001, NEUROREPORT, V12, P1737, DOI 10.1097/00001756-200106130-00044; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; BLACHSTEIN H, 1993, NEUROPSYCHOLOGY, V7, P530, DOI DOI 10.1037/0894-4105.7.4.530; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; Delis DC, 1987, CALIFORNIA VERBAL LE; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; Duchnick JJ, 2002, J CLIN EXP NEUROPSYC, V24, P840, DOI 10.1076/jcen.24.6.840.8405; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; FORRESTER WE, 1971, J EXP PSYCHOL, V88, P16, DOI 10.1037/h0030653; Gongvatana A, 2007, J NEUROPSYCH CLIN N, V19, P36, DOI 10.1176/appi.neuropsych.19.1.36; Greicius MD, 2003, HIPPOCAMPUS, V13, P164, DOI 10.1002/hipo.10064; KEPPEL G, 2004, DESIGN ANAL RES HDB, P153; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Miller RR, 2006, LEARN MEMORY, V13, P491, DOI 10.1101/lm.241006; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Nader K, 2006, LEARN MEMORY, V13, P489, DOI 10.1101/lm.405106; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; NIELSENBOHLMAN L, 1994, NEUROREPORT, V5, P1517, DOI 10.1097/00001756-199407000-00027; Nyberg L, 2002, COGNITIVE BRAIN RES, V13, P281, DOI 10.1016/S0926-6410(02)00052-6; Nyberg L, 1996, PSYCHON B REV, V3, P135, DOI 10.3758/BF03212412; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rao SM, 1996, BRAIN COGNITION, V31, P250, DOI 10.1006/brcg.1996.0044; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P104, DOI 10.1037/0894-4105.18.1.104; Scott JC, 2006, NEUROPSYCHOLOGIA, V44, P1336, DOI 10.1016/j.neuropsychologia.2006.01.008; Squire LR, 2006, LEARN MEMORY, V13, P522, DOI 10.1101/lm.310306; STALLINGS G, 1995, J CLIN EXP NEUROPSYC, V17, P706, DOI 10.1080/01688639508405160; Stricker JL, 2002, J INT NEUROPSYCH SOC, V8, P425, DOI 10.1017/S1355617702813224; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Timmerman ME, 1999, NEUROPSYCHOLOGIA, V37, P467, DOI 10.1016/S0028-3932(98)00085-2; Tulving E, 1998, HIPPOCAMPUS, V8, P198, DOI 10.1002/(SICI)1098-1063(1998)8:3<198::AID-HIPO2>3.0.CO;2-G; TULVING E, 1973, PSYCHOL REV, V80, P352, DOI 10.1037/h0020071; TULVING E, 1968, J EXP PSYCHOL, V77, P593, DOI 10.1037/h0026069; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Wilde MC, 1995, J CLIN EXP NEUROPSYC, V17, P849, DOI 10.1080/01688639508402434; Williamson D. J. G., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [10.1037/10198-001, DOI 10.1037/10198-001]; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; Wright MJ, 2009, J CLIN EXP NEUROPSYC, V31, P790, DOI 10.1080/13803390802508918	61	27	27	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2010	32	7					728	736	PII 919390416	10.1080/13803390903512652			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	631WB	WOS:000280380200006	20175012	Green Accepted			2021-06-18	
J	Zhang, J; Mitsis, EM; Chu, K; Newmark, RE; Hazlett, EA; Buchsbaum, MS				Zhang, Jing; Mitsis, Effie M.; Chu, Kingwai; Newmark, Randall E.; Hazlett, Erin A.; Buchsbaum, Monte S.			Statistical Parametric Mapping and Cluster Counting Analysis of [F-18] FDG-PET Imaging in Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral metabolism; head injury; spatial pattern; voxel statistics	POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL GLUCOSE-METABOLISM; HEAD-INJURY; IMAGES; CONSCIOUSNESS; ACTIVATION; IMPAIRMENT; MEMORY; SPECT; SCALE	In this study we investigated regional cerebral glucose metabolism abnormalities of [F-18] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in traumatic brain injury (TBI). PET images of 81 TBI patients and 68 normal controls were acquired and a word list learning task was administered during the uptake period. The TBI group included 35 patients with positive structural imaging (CT or MRI) findings soon after injury, 40 patients with negative findings, and 6 cases without structural imaging. Statistical parametric mapping (SPM) analysis was applied with several levels of spatial smoothing. Cluster counting analysis was performed for each subject to identify abnormal clusters with contiguous voxel values that deviated by two standard deviations or more from the mean of the normal controls, and to count the number of clusters in 10 size categories. SPM maps demonstrated that the 81 patients had significantly lower FDG uptake than normal controls, widely across the cortex (including bilateral frontal and temporal regions), and in the thalamus. Cluster counting results indicated that TBI patients had a higher proportion of larger clusters than controls. These large low-FDG-uptake clusters of the TBI patients were closer to the brain edge than those of controls. These results suggest that deficits of cerebral metabolism in TBI are spread over multiple brain areas, that they are closer to the cortical surface than clusters in controls, and that group spatial patterns of abnormal cerebral metabolism may be similar in TBI patients with cognitive deficits with and without obvious acute abnormalities identified on structural imaging.	[Buchsbaum, Monte S.] Univ Calif San Diego, Ctr Mol Imaging, Mt Sinai Sch Med, San Diego, CA 92121 USA	Buchsbaum, MS (corresponding author), Univ Calif San Diego, Ctr Mol Imaging, Mt Sinai Sch Med, 11388 Sorrento Valley Rd, San Diego, CA 92121 USA.	mbuchsbaum@ucsd.edu					Allman JM, 2001, ANN NY ACAD SCI, V935, P107, DOI 10.1111/j.1749-6632.2001.tb03476.x; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P615; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Buchsbaum MS, 2007, SCHIZOPHR RES, V94, P293, DOI 10.1016/j.schres.2007.04.027; Choo IH, 2007, ALZ DIS ASSOC DIS, V21, P77, DOI 10.1097/WAD.0b013e3180687418; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Coles JP, 2007, BRIT J ANAESTH, V99, P49, DOI 10.1093/bja/aem141; FEDIO P, 1970, EXP NEUROL, V29, P84, DOI 10.1016/0014-4886(70)90039-7; FRISTON KJ, 1991, J COMPUT ASSIST TOMO, V15, P634, DOI 10.1097/00004728-199107000-00020; Hattori N, 2003, J NUCL MED, V44, P1709; Hattori N, 2009, J NUCL MED, V50, P1054, DOI 10.2967/jnumed.108.060368; Hazlett EA, 1999, AM J PSYCHIAT, V156, P1190; Hazlett EA, 1998, NEUROBIOL AGING, V19, P437, DOI 10.1016/S0197-4580(98)00075-X; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jeong Y, 2005, J NUCL MED, V46, P233; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Lovell MK FM, 1994, NEUROPSYCHIATRY TRAU, P152; MARKLUND N, 2009, J NEUROTRAUMA   0408; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Newberg AB, 2003, SEMIN NUCL MED, V33, P136, DOI 10.1053/snuc.2003.127299; POLINE JB, 1993, J CEREBR BLOOD F MET, V13, P425, DOI 10.1038/jcbfm.1993.57; Rapoport M, 2008, J NEUROPSYCH CLIN N, V20, P68, DOI 10.1176/jnp.2008.20.1.68; Reimold M, 2006, J CEREBR BLOOD F MET, V26, P751, DOI 10.1038/sj.jcbfm.9600231; Roland P. E., 1993, Human Brain Mapping, V1, P3, DOI 10.1002/hbm.460010103; Ruff R. M., 1989, NEUROPSY NEUROPSY BE, V2, P103; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Shin YB, 2006, BRAIN INJURY, V20, P661, DOI 10.1080/02699050600677071; SINGH M, 2009, MAGN RESON IMAG 0714; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Stamatakis EA, 2002, J NUCL MED, V43, P476; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; TEASDALE G, 1974, LANCET, V2, P81; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Van Heertum RL, 2004, SEMIN NUCL MED, V34, P300, DOI 10.1053/j.semnuclmed.2004.03.003; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P74, DOI 10.1002/(SICI)1097-0193(1996)4:1<74::AID-HBM5>3.0.CO;2-M; Ziolko SK, 2006, NEUROIMAGE, V33, P94, DOI 10.1016/j.neuroimage.2006.05.063	47	27	28	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					35	49		10.1089/neu.2009.1049			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200003	19715400				2021-06-18	
J	DeJong, J; Donders, J				DeJong, Joy; Donders, Jacobus			A Confirmatory Factor Analysis of the California Verbal Learning Test-Second Edition (CVLT-II) in a Traumatic Brain Injury Sample	ASSESSMENT			English	Article						learning; memory; construct validity; factor analysis; traumatic brain injury	STANDARDIZATION SAMPLE; WAIS-III; WMS-III; RECALL DISCRIMINABILITY; CONSTRUCT-VALIDITY; CRITERION VALIDITY; 2ND EDITION; MEMORY; PERFORMANCE; INDEXES	The latent structure of the California Verbal Learning Test-Second Edition (CVLT-II) was examined in a clinical sample of 223 persons with traumatic brain injury that had been screened to remove individuals with complicating premorbid (e. g., psychiatric) or comorbid (e. g., financial compensation seeking) histories. Analyses incorporated the z scores from 12 CVLT-II variables. Maximum-likelihood confirmatory analyses were performed to test the fit and parsimony of four hypothetical models. A four-factor model, consisting of Attention Span, Learning Efficiency, Delayed Memory, and Inaccurate Memory, met all the a priori specified criteria for model fit and parsimony. This model was consistent with that identified previously in a confirmatory factor analysis of the CVLT-II standardization sample. The results support the construct validity of the CVLT-II in individuals with traumatic brain injury and indicate that a multifactorial interpretation is appropriate for clinical practice.	[Donders, Jacobus] Mary Free Bed Rehabil Hosp, Psychol Serv, Grand Rapids, MI 49503 USA	Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com					Baldo JV, 2002, J INT NEUROPSYCH SOC, V8, P539, DOI 10.1017/S135561770281428X; Bell BD, 2004, CLIN NEUROPSYCHOL, V18, P303, DOI 10.1080/13854040490501646; Burton DB, 2003, ARCH CLIN NEUROPSYCH, V18, P629, DOI 10.1093/arclin/18.6.629; Caruso JC, 1999, PSYCHOL ASSESSMENT, V11, P198, DOI 10.1037/1040-3590.11.2.198; Cliff N, 1998, PSYCHOL METHODS, V3, P291, DOI 10.1037/1082-989X.3.3.291; Coronado V. G., 2006, Morbidity and Mortality Weekly Report, V55, P201; Crawford JR, 2008, J INT NEUROPSYCH SOC, V14, P1069, DOI 10.1017/S1355617708081228; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; Delis DC, 2003, J INT NEUROPSYCH SOC, V9, P936, DOI 10.1017/S1355617703960139; Delis DC, 2005, J INT NEUROPSYCH SOC, V11, P708, DOI 10.1017/S1355617705050812; Delis DC, 2000, CALIFORNIA VERBAL LE; Dodson CS, 2007, PSYCHOL AGING, V22, P122, DOI 10.1037/0882-7974.22.1.122; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Donders J, 2008, J CLIN EXP NEUROPSYC, V30, P741, DOI 10.1080/13803390701689595; Donders J, 2008, ASSESSMENT, V15, P123, DOI 10.1177/1073191107310926; Donders J, 2007, J INT NEUROPSYCH SOC, V13, P354, DOI 10.1017/S1355617707070439; Donders J, 2006, PSYCHOL ASSESSMENT, V18, P458, DOI 10.1037/1040-3590.18.4.458; FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312; Hanks RA, 2004, DIFFERENTIAL DIAGNOSIS IN ADULT NEUROPSYCHOLOGICAL ASSESSMENT, P218; Hatcher L., 1994, STEP BY STEP APPROAC; Jacobs ML, 2007, ARCH CLIN NEUROPSYCH, V22, P143, DOI 10.1016/j.acn.2006.12.002; Kaufman AS, 1999, ESSENTIALS WAIS 3 AS; Lange RT, 2006, PSYCHOL ASSESSMENT, V18, P174, DOI 10.1037/1040-3590.18.2.174; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; McCabe DP, 2007, MEM COGNITION, V35, P231, DOI 10.3758/BF03193444; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Mottram L, 2005, PSYCHOL ASSESSMENT, V17, P212, DOI 10.1037/1040-3590.17.2.212; *NAT COUNC MEAS ED, 1999, STAND ED PSYCH TESTS; Roebuck-Spencer T., 2008, TXB CLIN NEUROPSYCHO, P411; *SAS I, 1990, SAS STAT US GUID VER, V1; SHESLOW D, 1999, WIDE RANGE ASSESSMEN; Stricker JL, 2002, J INT NEUROPSYCH SOC, V8, P425, DOI 10.1017/S1355617702813224; Thompson B., 2004, EXPLORATORY CONFIRMA; Tulsky DS, 2004, J CLIN EXP NEUROPSYC, V26, P563, DOI 10.1080/13803390490490782; van der Heijden P, 2003, J CLIN EXP NEUROPSYC, V25, P59, DOI 10.1076/jcen.25.1.59.13627; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Zasler N. D., 2007, BRAIN INJURY MED PRI, P779	38	27	27	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	DEC	2009	16	4					328	336		10.1177/1073191109336989			9	Psychology, Clinical	Psychology	519QC	WOS:000271781100002	19546480				2021-06-18	
J	Esposito, DP; Walker, JB				Esposito, Domenic P.; Walker, James B.			Contemporary Management of Penetrating Brain Injury	NEUROSURGERY QUARTERLY			English	Article						debridement; penetrating brain injury; surgical management	CIVILIAN GUNSHOT WOUNDS; CEREBRAL-BLOOD-FLOW; CRANIOCEREBRAL INJURIES; INTRACRANIAL-PRESSURE; MISSILE WOUNDS; TRAUMATIC ANEURYSMS; HEAD-INJURY; EXPERIENCE; INFECTIONS; BALLISTICS	Penetrating brain injury includes all traumatic brain injury that is not the result of a blunt mechanism. Concerning these injuries, gunshot wounds are by far the most prevalent. Despite law enforcement efforts, these injuries unfortunately continue to be commonplace in large trauma centers as well as in metropolitan and large community emergency departments. Great efforts have been undertaken to standardize the medical and Surgical management of these patients. The authors review the Guidelines of Penetrating Brain Injury published in 2001 and performed ail updated literature search concerning this topic. There is evidence to suggest based upon current data that aggressive antibiotic prophylaxis and avoidance of aggressive debridement of deep-seated bone and bullet fragments has improved morbidity and mortality over the last 35 years.	[Esposito, Domenic P.; Walker, James B.] Univ Mississippi, Med Ctr, Dept Neurosurg, Jackson, MS 39216 USA	Walker, JB (corresponding author), Univ Mississippi, Med Ctr, Dept Neurosurg, 2500 N State St, Jackson, MS 39216 USA.	jbwalker@neurosurgery.umsmed.edu					Aarabi B, 1998, NEUROSURGERY, V42, P500, DOI 10.1097/00006123-199803000-00014; AARABI B, 1987, NEUROSURGERY, V20, P610, DOI 10.1227/00006123-198704000-00018; AARABI B, 1995, NEUROSURG CLIN N AM, V6, P775; Aarabi Bizhan, 2001, Journal of Trauma Injury Infection and Critical Care, V51, pS1; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; AMEEN AA, 1984, INJURY, V16, P88, DOI 10.1016/S0020-1383(84)80004-2; Amirjamshidi A, 1996, J NEUROSURG, V84, P769, DOI 10.3171/jns.1996.84.5.0769; ARENDALL REH, 1983, NEUROSURGERY, V13, P377, DOI 10.1227/00006123-198310000-00005; BARACH E, 1986, J TRAUMA, V26, P225, DOI 10.1097/00005373-198603000-00003; BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CAREY ME, 1971, J NEUROSURG, V34, P145, DOI 10.3171/jns.1971.34.2part1.0145; CAREY ME, 1995, NEUROSURG CLIN N AM, V6, P629; CHAUDHRI KA, 1994, ACTA NEUROCHIR, V126, P120, DOI 10.1007/BF01476420; CROCKARD HA, 1975, J TRAUMA, V15, P339, DOI 10.1097/00005373-197504000-00011; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; Gonul E, 1997, NEUROSURG REV, V20, P177, DOI 10.1007/BF01105561; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; HELLING TS, 1992, J TRAUMA, V32, P398, DOI 10.1097/00005373-199203000-00019; HUBSCHMANN O, 1979, J TRAUMA, V19, P6, DOI 10.1097/00005373-197901000-00002; KAUFMAN HH, 1991, SURG NEUROL, V36, P370, DOI 10.1016/0090-3019(91)90026-6; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; Kordestani RK, 1997, NEUROSURGERY, V41, P351, DOI 10.1097/00006123-199708000-00003; LEVI L, 1990, ISRAEL J MED SCI, V26, P548; LEVY ML, 1999, TRAUMATIC BRAIN INJU, P201; LILLARD PL, 1978, SURG NEUROL, V9, P79; MEIROWSKY AM, 1981, J NEUROSURG, V54, P44, DOI 10.3171/jns.1981.54.1.0044; MINER ME, 1990, NEUROSURGERY, V26, P20, DOI 10.1227/00006123-199001000-00002; Mokri B, 2001, NEUROLOGY, V56, P1746, DOI 10.1212/WNL.56.12.1746; Muench E, 2007, CRIT CARE MED, V35, P1844, DOI 10.1097/01.CCM.0000275392.08410.DD; MUNSLOW RA, 1946, ANN SURG, V123, P180, DOI 10.1097/00000658-194602000-00002; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; Oliver C, 1997, CLIN RADIOL, V52, P299, DOI 10.1016/S0009-9260(97)80058-X; ORDOG GJ, 1984, ANN EMERG MED, V13, P1113, DOI 10.1016/S0196-0644(84)80336-4; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; RISH BL, 1981, NEUROSURGERY, V9, P535, DOI 10.1227/00006123-198111000-00008; RISH BL, 1973, J NEUROSURG, V38, P155, DOI 10.3171/jns.1973.38.2.0155; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SARNAIK AP, 1989, J TRAUMA, V29, P1434, DOI 10.1097/00005373-198910000-00023; SHIMURA T, 1997, SHINKEI GEKA, V25, P607; TAHA JM, 1991, NEUROSURGERY, V29, P864, DOI 10.1227/00006123-199112000-00010; TEITELBAUM GP, 1990, RADIOLOGY, V175, P855, DOI 10.1148/radiology.175.3.2343136; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; VRANKOVIC D, 1992, NEUROCHIRURGIA, V35, P150; Whitaker R, 1916, BRIT J SURG, V3, P708; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236	48	27	27	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-6438	1534-4916		NEUROSURG QUART	Neurosurg. Q.	DEC	2009	19	4					249	254		10.1097/WNQ.0b013e3181bd1d53			6	Neurosciences; Surgery	Neurosciences & Neurology; Surgery	524AK	WOS:000272116000006					2021-06-18	
J	Beauchamp, MH; Anderson, VA; Catroppa, C; Maller, JJ; Godfrey, C; Rosenfeld, JV; Kean, M				Beauchamp, Miriam H.; Anderson, Vicki A.; Catroppa, Cathy; Maller, Jerome J.; Godfrey, Celia; Rosenfeld, Jeffery V.; Kean, Michael			Implications of Reduced Callosal Area for Social Skills after Severe Traumatic Brain Injury in Children	JOURNAL OF NEUROTRAUMA			English	Article						behavior; magnetic resonance imaging; pediatric brain injury; recovery; traumatic brain injury	CLOSED-HEAD-INJURY; HUMAN CORPUS-CALLOSUM; INTERHEMISPHERIC COOPERATION; PROCESSING DEFICITS; EARLY-CHILDHOOD; SEX-DIFFERENCES; AUTISM; MRI; AGENESIS; RECOVERY	The corpus callosum has been shown to be particularly vulnerable to the effects of traumatic brain injury (TBI) in childhood, and severe injury frequently results in a smaller corpus callosum post-injury. However, the long-term effects of TBI on the integrity of the callosum, as well as the potential functional significance of callosal injury are poorly understood. Some studies suggest the corpus callosum may be involved in social skills, which are often reduced following TBI. In this study, callosal size was investigated in 37 individuals 10 years post-childhood TBI, and its relationship with social competence was examined. The results indicate that individuals who sustain severe TBI in childhood display reduced callosal size 10 years post-injury. In addition, callosal size correlated significantly with social skills, suggesting that callosal atrophy may be related to poorer social skills after TBI. These findings highlight the persistence of callosal abnormalities, which may be a result of interrupted neural development after childhood TBI. The results further underscore the potential importance of the corpus callosum for social competence after TBI.	[Beauchamp, Miriam H.; Anderson, Vicki A.; Catroppa, Cathy; Godfrey, Celia; Kean, Michael] Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic, Australia; [Beauchamp, Miriam H.; Anderson, Vicki A.; Catroppa, Cathy] Univ Melbourne, Sch Behav Sci, Melbourne, Vic, Australia; [Beauchamp, Miriam H.; Anderson, Vicki A.; Catroppa, Cathy; Godfrey, Celia; Kean, Michael] Royal Childrens Hosp, Melbourne, Vic, Australia; [Maller, Jerome J.] Monash Univ, Alfred Psychiat Res Ctr, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffery V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Rosenfeld, Jeffery V.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia	Beauchamp, MH (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	miriam.beauchamp@mcri.edu.au	Maller, Jerome J/H-4963-2014; Rosenfeld, Jeffrey V/B-7249-2011	Maller, Jerome J/0000-0003-4685-1508; 	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [284518]	This work was supported by the National Health and Medical Research Council ( project grant no. 284518).	ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; Alexander AL, 2007, NEUROIMAGE, V34, P61, DOI 10.1016/j.neuroimage.2006.08.032; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2000, BRAIN INJURY, V14, P679; Anderson V, 2007, BRAIN INJURY, V21, P1399, DOI 10.1080/02699050701785070; Badaruddin DH, 2007, CHILD PSYCHIAT HUM D, V38, P287, DOI 10.1007/s10578-007-0065-6; Bayley N., 2006, BAYLEY SCALES INFANT; Bedell JR, 1997, HDB COMMUNICATION PR; Belmonte MK, 2004, J NEUROSCI, V24, P9228, DOI 10.1523/JNEUROSCI.3340-04.2004; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Boger-Megiddo I, 2006, J AUTISM DEV DISORD, V36, P733, DOI 10.1007/s10803-006-0121-2; Brambilla P, 2003, BRAIN RES BULL, V61, P557, DOI 10.1016/j.brainresbull.2003.06.001; Brown WS, 2005, NEUROPSYCHOLOGIA, V43, P906, DOI 10.1016/j.neuropsychologia.2004.09.008; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Daniel A. E., 1983, POWER PRIVILEGE PRES; Doron KW, 2008, CORTEX, V44, P1023, DOI 10.1016/j.cortex.2008.03.007; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Geschwind DH, 2007, CURR OPIN NEUROBIOL, V17, P103, DOI 10.1016/j.conb.2007.01.009; Giedd JN, 1996, DEV BRAIN RES, V91, P274; Gresham F. M., 1990, SOCIAL SKILLS RATING; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Hill EL, 2003, PHILOS T R SOC B, V358, P281, DOI 10.1098/rstb.2002.1209; Hrdlicka M, 2008, NEUROENDOCRINOL LETT, V29, P281; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Johnson SC, 1996, NEUROPSYCHOLOGY, V10, P408, DOI 10.1037/0894-4105.10.3.408; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Paul LK, 2004, ARCH CLIN NEUROPSYCH, V19, P215, DOI 10.1016/S0887-6177(03)00024-6; Paul LK, 2007, NAT REV NEUROSCI, V8, P287, DOI 10.1038/nrn2107; Paul LK, 2006, INT J PSYCHOPHYSIOL, V61, P47, DOI 10.1016/j.ijpsycho.2005.10.017; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; PUJOL J, 1993, ANN NEUROL, V34, P71, DOI 10.1002/ana.410340113; Raine A, 2003, ARCH GEN PSYCHIAT, V60, P1134, DOI 10.1001/archpsyc.60.11.1134; Reynolds C.R., 1992, BEHAV ASSESSMENT SYS; Schmitz C, 2008, NEUROPATH APPL NEURO, V34, P4, DOI 10.1111/j.1365-2990.2007.00872.x; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Talairach J., 1993, REFERENTIALLY ORIENT; Tamietto M, 2007, NEUROPSYCHOLOGIA, V45, P836, DOI 10.1016/j.neuropsychologia.2006.08.012; Tamietto M, 2006, EXP BRAIN RES, V171, P389, DOI 10.1007/s00221-005-0279-4; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; TEASDALE G, 1974, LANCET, V2, P81; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Verger K, 2001, BRAIN INJURY, V15, P211; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D., 1989, WECHSLER PRESCHOOL P; Wechsler D., 1991, WECHSLER INTELLIGENC; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wildgruber D, 2005, NEUROIMAGE, V24, P1233, DOI 10.1016/j.neuroimage.2004.10.034; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Xu Y, 2000, NEUROLOGY, V54, P1760, DOI 10.1212/WNL.54.9.1760; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	73	27	27	0	10	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2009	26	10					1645	1654		10.1089/neu.2009.0916			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	507CT	WOS:000270829200003	19413462				2021-06-18	
J	Ruan, S; Noyes, K; Bazarian, JJ				Ruan, Shuolun; Noyes, Katia; Bazarian, Jeffrey J.			The Economic Impact of S-100B as a Pre-Head CT Screening Test on Emergency Department Management of Adult Patients with Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						computed tomography; cost minimization; S-100B; mild traumatic brain injury	COMPUTED-TOMOGRAPHY SCAN; NEW-ORLEANS CRITERIA; PULMONARY-EMBOLISM; PROTEIN MEASUREMENTS; DECISION-MAKING; CLINICAL POLICY; S100B LEVELS; RULE; ADMISSION; MULTICENTER	Recent research suggests that serum S-100B may serve as a good pre-head computed tomography (CT) screening test because of its high sensitivity for abnormal head CT scans. The potential economic impact of using S-100B in the emergency department setting for management of adult patients with isolated mild traumatic brain injury (mTBI) has not been evaluated despite its clinical implementation in Europe. Using evidence from the literature, we constructed a decision tree to compare the average cost per patient of using S-100B as a pre-head CT screening test to the current practice of ordering CT scans based on patients' presenting symptoms without the aid of S-100B. When compared to scanning 45-77% of isolated mTBI patients based upon their presenting symptoms, using S-100B as a pre-head CT screen does not lower hospital costs ($281 versus $160), primarily due to its low specificity for abnormal head CT scans. Sensitivity analyses showed, however, that S-100B becomes cost-lowering when the proportion of mTBI patients being scanned exceeds 78%, or when final CT scan results require 96 min or more than the wait for blood test results. Generally speaking, if blood test results require less time than imaging, and if head CT scan rates for patients with isolated mTBI are relatively high, using S-100B will lower costs. Recommendations for using S-100B as a screening tool should account for setting-specific characteristics and their consequent economic impacts. Despite its high sensitivity and excellent negative predictive value, serum S-100B has low specificity and low positive predictive value, limiting its ability to reduce numbers of CT scans and hospital costs.	[Ruan, Shuolun; Noyes, Katia] Univ Rochester, Sch Med & Dent, Dept Community & Prevent Med, Rochester, NY 14642 USA; [Bazarian, Jeffrey J.] Univ Rochester, Sch Med & Dent, Dept Emergency Med, Rochester, NY 14642 USA	Ruan, S (corresponding author), Univ Rochester, Sch Med & Dent, Dept Community & Prevent Med, 601 Elmwood Ave,Box 189, Rochester, NY 14642 USA.	shuolun.ruan@aya.yale.edu			National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [1 UL1 RR024160-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD051865] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024160] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K01AG020980] Funding Source: NIH RePORTER	This research was partially supported by grant 1 UL1 RR024160-01 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on the NCRR is available at http://www.ncrr.nih.gov/.	af Geijerstam JL, 2005, EMERG MED J, V22, P103, DOI 10.1136/emj.2004.015396; af Geijerstam JL, 2004, EMERG MED J, V21, P54, DOI 10.1136/emj.2003.003178; Atabaki SM, 2008, ARCH PEDIAT ADOL MED, V162, P439, DOI 10.1001/archpedi.162.5.439; Bayley MD, 2005, ANN EMERG MED, V45, P110, DOI 10.1016/j.annemergmed.2004.09.010; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2004, UNFALLCHIRURG, V107, P197, DOI 10.1007/s00113-004-0730-1; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Duriseti RS, 2006, ACAD EMERG MED, V13, P755, DOI 10.1197/j.aem.2006.02.011; Fabbri A, 2005, J NEUROTRAUM, V22, P1419, DOI 10.1089/neu.2005.22.1419; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Falvo T, 2007, ACAD EMERG MED, V14, P332, DOI 10.1197/j.aem.2006.11.011; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hemphill RR, 1999, ACAD EMERG MED, V6, P957, DOI 10.1111/j.1553-2712.1999.tb01248.x; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Konstantinides S, 2008, NEW ENGL J MED, V359, P2804, DOI 10.1056/NEJMcp0804570; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; National Centre for Injury Prevention and Control, 2007, MOM NOT SURG CAP TER; Poli-de-Figueiredo Luiz F, 2006, Clinics, V61, P41, DOI 10.1590/S1807-59322006000100008; Righini M, 2007, J THROMB HAEMOST, V5, P1869, DOI 10.1111/j.1538-7836.2007.02667.x; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; Thiessen ML, 2006, PEDIATR CLIN N AM, V53, P1, DOI 10.1016/j.pcl.2005.09.004; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; VOSS M, 1995, BRIT MED J, V311, P1395, DOI 10.1136/bmj.311.7017.1395	40	27	28	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2009	26	10					1655	1664		10.1089/neu.2009.0928			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	507CT	WOS:000270829200004	19413465	Green Published			2021-06-18	
J	Arun, P; Moffett, JR; Namboodiri, AMA				Arun, Peethambaran; Moffett, John R.; Namboodiri, Aryan M. A.			Evidence for mitochondrial and cytoplasmic N-acetylaspartate synthesis in SH-SY5Y neuroblastoma cells	NEUROCHEMISTRY INTERNATIONAL			English	Article						NAA; Aspartate-N-acetyltransferase; Aspartate aminotransferase; Aminooxyacetic acid; Mitochondria; Cytoplasm; Microsomes	L-ASPARTIC ACID; MAGNETIC-RESONANCE SPECTROSCOPY; TRAUMATIC BRAIN-INJURY; RAT-BRAIN; ACETYL-ASPARTATE; IN-VIVO; DIFFERENTIAL DISTRIBUTION; ENZYMATIC SYNTHESIS; ACETYLASPARTYLGLUTAMATE; OLIGODENDROCYTES	N-acetylaspartate (NAA) is synthesized predominantly in neurons, and brain homogenate subfractionation studies suggest that biosynthesis occurs at both microsomal (cytoplasmic) and mitochondrial sites. We investigated NAA synthesis in SH-SY5Y human neuroblastoma cells using distinct metabolic precursors that are preferentially metabolized in mitochondria and cytoplasm. Incorporation of C-14-aspartate and C-14-malate into NAA was examined in the presence and absence of an inhibitor (aminooxyacetic acid, AOAA) of aspartate aminotransferase (AAT), a central enzyme involved in the biosynthesis of aspartate in mitochondria, and degradation of aspartate in the cytoplasm. AOAA increased the incorporation of C-14-aspartate into NAA, reflecting direct aspartate -> NAA synthesis in an extramitochondrial location. As expected, AOAA decreased incorporation of C-14-malate into NAA, reflecting NAA synthesis in mitochondria via the malate -> oxaloacetate -> aspartate -> NAA pathway. When C-14-malate was used as substrate, the C-14-NAA/C-14-aspartate ratio was over 20-fold higher than the ratio obtained with C-14-aspartate. Because NAA can only be synthesized from aspartate, the higher C-14-NAA/C-14-aspartate (product/substrate) ratio obtained with C-14-malate suggests greater NAA biosynthetic activity. We conclude that NAA biosynthesis occurs in both the cytoplasm and mitochondria of SH-SY5Y cells, and that the contribution from the mitochondrial compartment is quantitatively larger than that in the extramitochondrial compartment. Published by Elsevier Ltd.	[Arun, Peethambaran; Moffett, John R.; Namboodiri, Aryan M. A.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	Moffett, JR (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	jmoffett@usuhs.mil			USUHS [C070PB, R070WG]	The work was supported by USUHS internal grants C070PB and R070WG to M.A.A.N.	Ariyannur PS, 2008, BRAIN RES, V1227, P34, DOI 10.1016/j.brainres.2008.06.040; Arun P, 2008, J NEUROCHEM, V106, P1669, DOI 10.1111/j.1471-4159.2008.05524.x; Arun P, 2006, J NEUROCHEM, V98, P2034, DOI 10.1111/j.1471-4159.2006.04068.x; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; BENUCK M, 1968, BIOCHIM BIOPHYS ACTA, V152, P611, DOI 10.1016/0005-2760(68)90101-X; Bhakoo KK, 2000, J NEUROCHEM, V74, P254, DOI 10.1046/j.1471-4159.2000.0740254.x; Blum S, 1999, J MAGN RESON, V136, P219, DOI 10.1006/jmre.1998.1618; CHEESEMAN AJ, 1988, J NEUROCHEM, V50, P1559, DOI 10.1111/j.1471-4159.1988.tb03044.x; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; del Arco A, 1998, J BIOL CHEM, V273, P23327, DOI 10.1074/jbc.273.36.23327; GOLDSTEIN FB, 1959, BIOCHIM BIOPHYS ACTA, V33, P583, DOI 10.1016/0006-3002(59)90161-1; GOLDSTEIN FB, 1969, J BIOL CHEM, V244, P4257; Jalil MA, 2005, J BIOL CHEM, V280, P31333, DOI 10.1074/jbc.M505286200; KNIZLEY H, 1967, J BIOL CHEM, V242, P4619; Lu ZH, 2004, MOL BRAIN RES, V122, P71, DOI 10.1016/j.molbrainres.2003.12.002; Madhavarao CN, 2003, J NEUROCHEM, V86, P824, DOI 10.1046/j.1471-4159.2003.01905.x; Madhavarao CN, 2002, ANAL BIOCHEM, V308, P314, DOI 10.1016/S0003-2697(02)00225-7; MATALON R, 1995, J PEDIATR-US, V127, P511, DOI 10.1016/S0022-3476(95)70105-2; McKenna MC, 2006, BIOCHEM PHARMACOL, V71, P399, DOI 10.1016/j.bcp.2005.10.011; McKenna MC, 2000, NEUROCHEM INT, V36, P451, DOI 10.1016/S0197-0186(99)00148-5; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; MOFFETT JR, 1995, J NEUROCYTOL, V24, P409, DOI 10.1007/BF01181604; MOFFETT JR, 1991, NEUROREPORT, V2, P131, DOI 10.1097/00001756-199103000-00005; PATEL TB, 1979, BIOCHEM J, V184, P539, DOI 10.1042/bj1840539; Sherry AD, 1998, AM J PHYSIOL-HEART C, V274, pH591; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2008, J NEUROSURG, V108, P42, DOI 10.3171/JNS/2008/108/01/0042; SIMMONS ML, 1991, NEUROSCIENCE, V45, P37, DOI 10.1016/0306-4522(91)90101-S; TRUCKENMILLER ME, 1985, J NEUROCHEM, V45, P1658, DOI 10.1111/j.1471-4159.1985.tb07240.x	29	27	28	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	SEP	2009	55	4					219	225		10.1016/j.neuint.2009.03.003			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	468SC	WOS:000267839600007	19524112				2021-06-18	
J	King, DA; Hume, PA; Milburn, P; Gianotti, S				King, D. A.; Hume, P. A.; Milburn, P.; Gianotti, S.			Rugby league injuries in New Zealand: a review of 8 years of Accident Compensation Corporation injury entitlement claims and costs	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORTS INJURIES; SEASONAL-CHANGE; FOOTBALL; PREVENTION; RATES	Aim: This paper provides an overview of the epidemiology of rugby league injuries and associated costs in New Zealand requiring medical treatment. Method: New Zealand national Accident Compensation Corporation injury data for the period 1999 to 2007 were searched for rugby league injury cases. Data were analysed by demographics, body region, nature/severity of injury, and medical procedure and costs. Results: A total of 5941 injury entitlement claims were recorded over the study period with a significant decrease observed in the injury rate between the 1999-2000 and 2002-2003 reporting years. The total cost of the injuries for the study period was $42 822 048 (equivalent to L15 916 072). The mean (SD) number of injury entitlement claims per year was 743 (271) and yearly cost was $5 352 760 (L1 989 880) ($2 485 535 (L923 994)). The knee was the most commonly reported injury site (225 per 1000 entitlement claims; $8 750 147 (L3 252 020)) and soft tissue injuries were the most common injury types (474 per 1000 entitlement claims; $17 324 214 (L6 438 599)). Accounting for only 1.8% of total injury entitlement claims, concussion/brain injuries accounted for 6.3% of injury entitlement costs and had the highest mean cost per claim ($25 347 (L9420)). The upper and lower arm recorded the highest mean injury site claim cost of $43 096 (L16 016) per claim. The 25-29 age group recorded 27.7% of total injury entitlement claims and 29.6% of total injury entitlement costs, which was slightly more than the 20-24 age group (27.3% claims; 24.7% costs). Nearly 15% of total moderate to serious injury entitlement claims and 20% of total costs were recorded from participants 35 years or older. Discussion: This study identified that the knee was the most common injury site and soft tissue injuries were the most common injury type requiring medical treatment, which is consistent with other international studies on rugby league epidemiology. This study also highlights that the rate of injury and the average age of injured rugby league players increased over time. The high cost of concussion/brain injuries is a cause for concern as it reflects the severity of the injuries. Conclusion: Injury prevention programmes for rugby league should focus on reducing the risk of concussion/brain injury and knee and soft tissue injury, and should target participants in the 20-30 years old age range. More longitudinal epidemiological studies with specific details on injury mechanisms and participation data are warranted to further identify the injury circumstances surrounding participation in rugby league activities.	[King, D. A.] Hutt Valley Dist Hlth Board, Emergency Dept, Lower Hutt, New Zealand; [King, D. A.; Hume, P. A.; Gianotti, S.] Auckland Univ Technol, Inst Sports & Recreat Res New Zealand, Sch Sport & Recreat, Fac Hlth & Environm Sci, Auckland, New Zealand; [Milburn, P.] Griffith Univ, Sch Physiotherapy & Exercise Sci, Gold Coast, Australia; [Gianotti, S.] Accid Compensat Corp, Wellington, New Zealand	King, DA (corresponding author), Hutt Valley Dist Hlth Board, Emergency Dept, Private Bag 31-907, Lower Hutt, New Zealand.	Douglas.King@huttvalleydhb.org.nz	Hume, Patria/AAN-5514-2021	Hume, Patria/0000-0003-1847-8128			Carter AF, 2008, J SCI MED SPORT, V11, P167, DOI 10.1016/j.jsams.2007.01.004; Estell J, 1995, Aust J Sci Med Sport, V27, P95; Gabbett TJ, 2008, J SCI MED SPORT, V11, P323, DOI 10.1016/j.jsams.2007.06.003; Gabbett TJ, 2004, SPORTS MED, V34, P849, DOI 10.2165/00007256-200434120-00004; Gabbett TJ, 2000, BRIT J SPORT MED, V34, P98, DOI 10.1136/bjsm.34.2.98; Gabbett TJ, 2003, BRIT J SPORT MED, V37, P36, DOI 10.1136/bjsm.37.1.36; Gabbett TJ, 2001, J SPORT SCI, V19, P341, DOI 10.1080/02640410152006117; Gianotti S, 2007, J SCI MED SPORT, V10, P436, DOI 10.1016/j.jsams.2006.10.006; GIBBS N, 1994, SPORTS MED, V18, P438, DOI 10.2165/00007256-199418060-00007; GIBBS N, 1993, AM J SPORT MED, V21, P696, DOI 10.1177/036354659302100510; Gissane C, 2003, AM J SPORT MED, V31, P954, DOI 10.1177/03635465030310063501; Hinton-Bayre AD, 2004, J SCI MED SPORT, V7, P400, DOI 10.1016/S1440-2440(04)80035-5; Hodgson L, 2006, CLIN J SPORT MED, V16, P305, DOI 10.1097/00042752-200607000-00004; King D, 2006, NZ J SPORTS MED, V34, P21; King D, 2007, NZ J SPORTS MED, V34, P18; King DA, 2006, J SCI MED SPORT, V9, P110, DOI 10.1016/j.jsams.2005.09.001; King DA, 2008, J SCI MED SPORT, V11, P562, DOI 10.1016/j.jsams.2007.04.011; KING DA, 2009, SPORTS MED IN PRESS; KING DA, 2007, INJURIES NZ BARTERCA; KING DA, 2009, NZ J SPORTS IN PRESS; KING DA, 2009, CLIN J SPOR IN PRESS; Lythe M, 1992, NZ J SPORTS MED, V20, P6; Mac Auley DC, 2001, INT J SPORTS MED, V22, P379; Meir R, 1993, STRENGTH COND, V1, P11; MEIR R, 1993, STRENGTH COND, V1, P24; Meir RA, 1997, BRIT J SPORT MED, V31, P132, DOI 10.1136/bjsm.31.2.132; NORTON R, 1995, NZ J SPORTS MED, V22, P37; ORCHARD J, 2003, SPORTSLINK       SEP, P12; Orchard J., 2004, SPORT HLTH, V22, P11; Phillips LH, 1998, BRIT J SPORT MED, V32, P144, DOI 10.1136/bjsm.32.2.144; Phillips LH, 2000, BRIT J SPORT MED, V34, P133, DOI 10.1136/bjsm.34.2.133; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Raftery M., 1999, INCIDENCE INJURY JUN; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; *STAT NZ, 2006, STAT; Stevens Sean T, 2008, Res Sports Med, V16, P68, DOI 10.1080/15438620701879020; Twellaar M, 1996, AM J SPORT MED, V24, P528, DOI 10.1177/036354659602400419; WALKER RD, 1985, PRACTITIONER, V229, P205	38	27	27	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2009	43	8					595	602		10.1136/bjsm.2009.061481			8	Sport Sciences	Sport Sciences	480WN	WOS:000268767800010	19553223				2021-06-18	
J	Ramati, A; Rubin, LH; Wicklund, A; Pliskin, NH; Ammar, AN; Fink, JW; Bodnar, EN; Lee, RC; Cooper, MA; Kelley, KM				Ramati, Alona; Rubin, Leah H.; Wicklund, Alissa; Pliskin, Neil H.; Ammar, Alia N.; Fink, Joseph W.; Bodnar, Elena N.; Lee, Raphael C.; Cooper, Mary Ann; Kelley, Kathleen M.			Psychiatric morbidity following electrical injury and its effects on cognitive functioning	GENERAL HOSPITAL PSYCHIATRY			English	Article						Electrical injury; Psychopathology; Cognitive	TRAUMATIC BRAIN-INJURY; DISORDERS; THERAPY; ECT	Objective: This study examines the prevalence of psychiatric morbidity in a large sample of electrical injury (EI) patients in three phases of recovery and its effects on cognitive functioning. Methods: Eight-six self-referred El patients received psychiatric and neuropsychological evaluations. Descriptive statistics were conducted to examine the prevalence of psychiatric morbidity. Polytomous logistic regression was used to identify predictors of psychiatric diagnosis. Between-subjects analysis of variances (ANOVA) was conducted to examine the effects of psychiatric morbidity on cognitive functioning. Results: Seventy-eight percent of subjects warranted a psychiatric diagnosis. Long-term patients compared to acute patients were more likely to be diagnosed with two diagnoses than not having any diagnosis (OR= 14.30, 95% CI 1.40-38.71). Patients with two diagnoses performed worse than both patients with a single or no diagnosis on all cognitive outcome measures (P<05). Voltage level, chronic pain and litigation status did not predict psychiatric morbidity. Conclusions: Psychiatric difficulties commonly emerge and persist following EI. EI patients with psychiatric conditions exhibited poorer cognitive performance as compared to EI patients with no post-injury psychiatric difficulties. Health care professionals need to devote careful attention to psychiatric and cognitive status when treating survivors of EI. (C) 2009 Elsevier Inc. All rights reserved.	[Ramati, Alona; Rubin, Leah H.; Wicklund, Alissa; Pliskin, Neil H.; Ammar, Alia N.; Kelley, Kathleen M.] Univ Illinois, Dept Psychiat, Coll Med, Chicago, IL 60612 USA; [Cooper, Mary Ann] Univ Illinois, Dept Emergency Med, Coll Med, Chicago, IL 60612 USA; [Ramati, Alona; Pliskin, Neil H.; Fink, Joseph W.; Bodnar, Elena N.; Lee, Raphael C.; Cooper, Mary Ann; Kelley, Kathleen M.] Chicago Elect Trauma Res Program, Chicago, IL USA; [Fink, Joseph W.] Univ Illinois, Dept Psychiat, Pritzker Sch Med, Chicago, IL 60612 USA; [Bodnar, Elena N.; Lee, Raphael C.] Univ Illinois, Dept Surg, Pritzker Sch Med, Chicago, IL 60612 USA	Pliskin, NH (corresponding author), Univ Illinois, Dept Psychiat, Coll Med, Chicago, IL 60612 USA.	npliskin@uic.edu	Cooper, Mary Ann/AAF-2524-2020				American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Ammar A, 2006, ACTA NEUROPSYCHOL, V4, P119; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Barrash J, 1996, Appl Neuropsychol, V3, P75, DOI 10.1207/s15324826an0302_5; Castaneda AE, 2008, J AFFECT DISORDERS, V106, P1, DOI 10.1016/j.jad.2007.06.006; Cawley JC, 2003, J SAFETY RES, V34, P241, DOI 10.1016/S0022-4375(03)00028-8; Chanpattana W, 2000, BIOL PSYCHIAT, V48, P222, DOI 10.1016/S0006-3223(00)00830-1; Delis DC, 2000, CALIFORNIA VERBAL LE; Fink M, 2001, J AFFECT DISORDERS, V63, P1, DOI 10.1016/S0165-0327(00)00367-0; GOLDEN CJ, 2002, STROUP COLOR WORD TE; Grossman A. Richard, 1993, Journal of Burn Care and Rehabilitation, V14, P169, DOI 10.1097/00004630-199303000-00008; HOOSHMAND H, 1989, CLIN ELECTROENCEPHAL, V20, P111, DOI 10.1177/155005948902000208; Ishihara K, 1999, JPN J PHARMACOL, V80, P185, DOI 10.1254/jjp.80.185; JARVIS PE, 1984, HALSTED REITAN TEST; JOHANSSON B, 1987, MED HYPOTHESES, V24, P313, DOI 10.1016/0306-9877(87)90208-8; KELLEY KM, 1994, ANN NY ACAD SCI, V720, P213, DOI 10.1111/j.1749-6632.1994.tb30449.x; Kelley KM, 1999, ANN NY ACAD SCI, V888, P356, DOI 10.1111/j.1749-6632.1999.tb07970.x; Kleinbaum DG, 2002, LOGISTIC REGRESSION, P267; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Madianos MG, 2001, PSYCHOTHER PSYCHOSOM, V70, P30, DOI 10.1159/000056222; Mancusi-Ungaro H R Jr, 1986, J Burn Care Rehabil, V7, P521, DOI 10.1097/00004630-198611000-00015; PATTERSON DR, 1993, PSYCHOL BULL, V113, P362, DOI 10.1037/0033-2909.113.2.362; Pliskin NH, 2006, J INT NEUROPSYCH SOC, V12, P17, DOI 10.1017/S1355617706060061; Pliskin NH, 1998, J TRAUMA, V44, P709, DOI 10.1097/00005373-199804000-00027; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; *SAS I INC, 2001, SAS VERS 8 2 WIND; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624	27	27	27	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0163-8343	1873-7714		GEN HOSP PSYCHIAT	Gen. Hosp. Psych.	JUL-AUG	2009	31	4					360	366		10.1016/j.genhosppsych.2009.03.010			7	Psychiatry	Psychiatry	468DN	WOS:000267794500010	19555797				2021-06-18	
J	Rishiraj, N; Lloyd-Smith, R; Lorenz, T; Niven, B; Michel, M				Rishiraj, N.; Lloyd-Smith, R.; Lorenz, T.; Niven, B.; Michel, M.			University men's ice hockey: rates and risk of injuries over 6-years	JOURNAL OF SPORTS MEDICINE AND PHYSICAL FITNESS			English	Article						Hockey; Athletic injuries; Epidemiology; Sports	PLAYERS; MULTIVARIATE; CHECKING; FINLAND; CANADA	Aim. The aim of this study was to determine the injury rates of a Men's Varsity Ice Hockey team over six-years. Data on ice hockey injury rates and profile continue to increase in the hope of assisting with injury prevention. Methods. The University of British Columbia Men's Varsity team has been followed prospectively over a six-year period. All student-athletes completed a preseason medical examinations and physiological assessments. The team physician evaluated each injury and the team therapist completed the injury report forms and the attendance records for each player. Results. A total of 46 215 player exposures were recorded. The combined injury rate was 3.70 injuries/1 000 player game and practice exposures. A statistically significantly higher risk of injury was observed during games and the greatest risk of injury was observed during the second period. Forwards sustained greater percentage of injuries compared to defensemen and goalies. Sprains and strains accounted for 40% of all injuries, followed by concussions (13%). Non-contact injuries were most common, while the anatomy sustaining the most injuries was the head/neck/face region. A high percent-age of the recorded injuries required less than seven days to return to full activity. Conclusion. The risk of injury for university ice hockey players is greater during games and is dependant on playing position. Players are prone to sprains and strains, which may not involve any contact. Concussion and knee joint injury rates continue to cause concern.	[Rishiraj, N.] ACTIN Hlth & Rehabil Inc, Vancouver, BC V6M 2V7, Canada; [Rishiraj, N.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Rishiraj, N.] Univ Otago, Otago, New Zealand; [Lloyd-Smith, R.; Michel, M.] Univ British Columbia Athlet, Vancouver, BC, Canada; [Lloyd-Smith, R.] Allan McGavin Sports Med Ctr, Vancouver, BC, Canada; [Lorenz, T.] SportsMed British Columbia, Vancouver, BC, Canada; [Lorenz, T.] Univ British Columbia Athlet Therapy Serv, Vancouver, BC, Canada; [Niven, B.] Univ Otago, Dept Math & Stat, Ctr Applicat Stat & Math, Dunedin, New Zealand	Rishiraj, N (corresponding author), ACTIN Hlth & Rehabil Inc, 5767 Oak St, Vancouver, BC V6M 2V7, Canada.	nrishiraj@actinhealth.com					Agel J, 2007, J ATHL TRAINING, V42, P241; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; BIASCA N, 1995, UNFALLCHIRURG, V98, P283; BJORKENHEIM JM, 1993, ACTA ORTHOP SCAND, V64, P459; DALY PJ, 1990, SPORTS MED, V10, P122, DOI 10.2165/00007256-199010020-00005; Ferrara MS, 1999, CLIN J SPORT MED, V9, P30; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Groger A, 2001, SPORTVERLETZ SPORTSC, V15, P82, DOI 10.1055/s-2001-19047; Hayes D., 1975, PHYSICIAN SPORTSMED, V3, P61, DOI 10.1080/00913847.1975.11948128; Hipp E, 1993, Fortschr Med, V111, P173; Hostetler SG, 2004, PEDIATRICS, V114, pE661, DOI 10.1542/peds.2004-1565; Jorgensen U, 1986, Br J Sports Med, V20, P7; LORENTZON R, 1988, AM J SPORT MED, V16, P392, DOI 10.1177/036354658801600415; Macpherson A, 2006, PEDIATRICS, V117, pE143, DOI 10.1542/peds.2005-1163; MEEUWISSE WH, 1988, CLIN J SPORT MED, V8, P164; Molsa J, 2000, AM J SPORT MED, V28, P322; Molsa J, 2003, AM J SPORT MED, V31, P751; Molsa J, 1997, AM J SPORT MED, V25, P495, DOI 10.1177/036354659702500412; *NCAA, 2003, INJ SURV SYST MENS I; PATTERSSON M, 1993, BRIT J SPORT MED, V27, P251, DOI 10.1136/bjsm.27.4.251; PELLETIER RL, 1993, AM J SPORT MED, V21, P78, DOI 10.1177/036354659302100114; Pforringer W, 1987, J SPORT SCI, V5, P327, DOI 10.1080/02640418708729786; RIELLY MF, 1982, ATHLETIC TRAINING, V17, P88; Schick DM, 2003, AM J SPORT MED, V31, P47, DOI 10.1177/03635465030310011901; SIM FH, 1987, AM J SPORT MED, V15, P30, DOI 10.1177/036354658701500105; Smith AM, 1997, AM J SPORT MED, V25, P500, DOI 10.1177/036354659702500413; STUART MJ, 1995, AM J SPORT MED, V23, P458, DOI 10.1177/036354659502300415; Tator CH, 2000, CAN MED ASSOC J, V162, P787; Watson RC, 1996, CLIN J SPORT MED, V6, P108, DOI 10.1097/00042752-199604000-00008	29	27	27	0	14	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0022-4707	1827-1928		J SPORT MED PHYS FIT	J. Sports Med. Phys. Fit.	JUN	2009	49	2					159	166					8	Sport Sciences	Sport Sciences	510SK	WOS:000271111800005	19528893				2021-06-18	
J	Wilson, C; Huston, T; Koval, J; Gordon, SA; Schwebel, A; Gassaway, J				Wilson, Catherine; Huston, Toby; Koval, Jill; Gordon, Samuel A.; Schwebel, Andrea; Gassaway, Julie			SCIRehab Project Series: The Psychology Taxonomy	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Spinal cord injuries; Rehabilitation, physical; Psychology; Classification; Taxonomy; Practice-based evidence; Health services research	SPINAL-CORD-INJURY; THERAPEUTIC WORKING ALLIANCE; TRAUMATIC BRAIN-INJURY; STROKE REHABILITATION; DEPRESSION; OUTCOMES; TEAM; CARE; SATISFACTION; AWARENESS	Context: The integration of psychologists as members of the rehabilitation team has occurred in conjunction with the evolution and adoption of interdisciplinary teams as the standard of care in spinal cord injury (SCI) rehabilitation. Although the value of psychological services during rehabilitation is endorsed widely, specific interventions and their association with patient outcomes have not been examined adequately. Objective: To address this shortcoming, psychologists from 6 SCI centers collaborated to develop a psychology intervention taxonomy and documentation framework. Methods: Utilizing an interactive process, the lead psychologists from 6 centers compiled an inclusive list of patient characteristics assessed and interventions delivered in routine psychological practice at the participating rehabilitation facilities. These were systematically grouped, defined, and compared. Results: The resulting taxonomy became the basis of a documentation framework utilized by psychologists for the study. The psychology taxonomy includes 4 major clinical categories (assessment, psychotherapeutic interventions, psychoeducational interventions, and consultation) with 5 to 10 specific activities in each category. Conclusions: Examination of psychological interventions and their potential association with positive outcomes for persons who sustain SCI requires the development of a taxonomy. Results of these efforts illustrate similarities and differences in psychological practice among SCI centers and offer the opportunity to blend research and clinical practice in an innovative approach to evidence-based practice improvement. The established taxonomy provides a basic framework for future studies on the effect of psychological interventions.	[Gassaway, Julie] Inst Clin Outcomes Res, Salt Lake City, UT 84102 USA; [Wilson, Catherine] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Huston, Toby] Craig Hosp, Englewood, CO USA; [Koval, Jill] Shepherd Ctr, Atlanta, GA USA; [Gordon, Samuel A.] Natl Rehabil Hosp, Washington, DC USA; [Schwebel, Andrea] Carolinas Rehabil, Charlotte, NC USA	Gassaway, J (corresponding author), Inst Clin Outcomes Res, 699 E S Temple, Salt Lake City, UT 84102 USA.	jgassaway@isisicor.com			Department of EducationUS Department of Education; NIDRR [H133A060103, H133N060005, H133N060028, H133A21943-16, H133N060009, H133N060027, H133N060014]	The contents of this article were developed under grants from the Department of Education, NIDRR grant numbers H133A060103 and H133N060005 to Craig Hospital, H133N060028 to National Rehabilitation Hospital, H133A21943-16 to Carolinas Rehabilitation, H133N060009 to Shepherd Center, H133N060027 to Mount Sinai School of Medicine, and H133N060014 to Rehabilitation Institute of Chicago. However, these contents do not necessarily represent the policy of the Department of Education, and you should not assume endorsement by the federal government.	AGICH G, 1982, HIST VIEW HLTH CARE; Bombardier CH, 2004, ARCH PHYS MED REHAB, V85, P1749, DOI 10.1016/j.apmr.2004.07.348; CRAIG AR, 1994, BRIT J CLIN PSYCHOL, V33, P221, DOI 10.1111/j.2044-8260.1994.tb01116.x; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; DeJong G, 2005, ARCH PHYS MED REHAB, V86, pS1, DOI 10.1016/j.apmr.2005.09.003; Derogatis LR, 2000, BSI 18 ADM SCORING P; Elliott TR, 1996, ARCH PHYS MED REHAB, V77, P816, DOI 10.1016/S0003-9993(96)90263-4; Fenton L R, 2001, J Psychother Pract Res, V10, P262; FRANK RG, 1985, AM J PSYCHIAT, V142, P252; GANS JS, 1983, ARCH PHYS MED REHAB, V64, P176; Gassaway J, 2005, ARCH PHYS MED REHAB, V86, pS16, DOI 10.1016/j.apmr.2005.08.114; Gassaway J, 2009, J SPINAL CORD MED, V32, P260, DOI 10.1080/10790268.2009.11760780; GASTON L, 1988, WORKING ALLIANCE THE, P85; Hammell KW, 2007, SPINAL CORD, V45, P260, DOI 10.1038/sj.sc.3102034; Hartman D., 2004, J HEART CTR THERAPIE, V7, P3; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; Kazdin AE, 2008, AM PSYCHOL, V63, P146, DOI 10.1037/0003-066X.63.3.146; Keith MS, 1998, BRAIN INJURY, V12, P1037, DOI 10.1080/026990598121945; KEITH RA, 1991, ARCH PHYS MED REHAB, V72, P269; Kennedy P, 2000, ARCH PHYS MED REHAB, V81, P932, DOI 10.1053/apmr.2000.5580; Lenze EJ, 2004, ARCH PHYS MED REHAB, V85, P380, DOI 10.1016/j.apmr.2003.06.001; *NAT SPIN CORD INJ, 2006, ANN STAT REP; Pegg PO, 2005, REHABIL PSYCHOL, V50, P366, DOI 10.1037/0090-5550.50.4.366; Richards JS, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P11, DOI 10.1037/10361-001; RICHARDS JS, 1988, AM J PHYS MED REHAB, V67, P211, DOI 10.1097/00002060-198810000-00005; ROHE D, 1998, REHABILITATION MED P; Schonberger M, 2006, NEUROPSYCHOL REHABIL, V16, P298, DOI 10.1080/09602010500176476; Schonberger M, 2006, BRAIN INJURY, V20, P445, DOI 10.1080/02699050600664772; Schonberger M, 2006, BRAIN INJURY, V20, P1271, DOI 10.1080/02699050601049395; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Strasser DC, 2008, ARCH PHYS MED REHAB, V89, P10, DOI 10.1016/j.apmr.2007.08.127; Strasser DC, 1997, TOP STROKE REHABIL, V4, P34; Verhoef J, 2008, CLIN REHABIL, V22, P23, DOI 10.1177/0269215507079845; Whitford DL, 2009, DIABETES CARE, V32, P251, DOI 10.2337/dc08-1200	34	27	27	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	JUN	2009	32	3					319	328		10.1080/10790268.2009.11760785			10	Clinical Neurology	Neurosciences & Neurology	474NF	WOS:000268290100012	19810633	Green Published			2021-06-18	
J	Xing, GQ; Ren, M; Watson, WA; O'Neil, JT; Verma, A				Xing, Guoqiang; Ren, Ming; Watson, William A.; O'Neil, J. Timothy; Verma, Ajay			Traumatic brain injury-induced expression and phosphorylation of pyruvate dehydrogenase: A mechanism of dysregulated glucose metabolism	NEUROSCIENCE LETTERS			English	Article						Brain injury; Pyruvate dehydrogenase; Pyruvate metabolism	SEVERE HEAD-INJURY; POSITRON-EMISSION-TOMOGRAPHY; PENTOSE-PHOSPHATE PATHWAY; CEREBRAL MICRODIALYSIS; LACTIC-ACIDOSIS; RAT; CRISIS; FLUX; FAILURE; COMPLEX	Dysregulated brain glucose metabolism and lactate accumulation are seen following traumatic brain injury (TBI). The underlying molecular mechanism is poorly understood. Pyruvate dehydrogenase (PDH), the rate-limiting enzyme coupling cytosolic glycolysis to mitochondrial citric acid cycle, plays a critical role in maintaining homeostasis of brain glucose metabolism. PDH activity is maintained by the expression of its E1 alpha 1 subunit 1 (PDHE1 alpha 1) and is inhibited by the phosphorylation of PDHE1 alpha 1 (p-PDHE1 alpha 1). We hypothesized that PDHE1 alpha 1 expression and phosphorylation was altered in rat brain following controlled cortical impact (CCI)-induced TBI. Compared to naive controls (=100%), PDHE1 alpha 1 protein decreased significantly ipsilateral to CCI (62%, P< 0.05; 75%, P< 0.05; 57%. P < 0.05; and 39%, P< 0.01) and contralateral to CCI (77%, 78%. 78% and 36% P< 0.01) at 4 h, 24 h, 3- and 7-day post-CCI, respectively. PDHE1 alpha 1 protein phosphorylation level also decreased significantly ipsilateral to CCI (31 %, P< 0.01; 102%, P> 0.05; 64%, P< 0.05; and 14%, P < 0.01) and to contralateral CCl (35%, 74%, P< 0.05; 60%, P< 0.05; 20%, P < 0.01) at 4 h, 24 h, 3- and 7-day post-CCI, respectively. Similar reduction in PDHE1 alpha 1 and p-PDHE1 alpha 1 protein was found in the craniotomy (sham CCI) group. TBI-induced change in PDHE1 alpha 1 expression and phosphorylation could alter brain PDH activity and glucose metabolism. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Xing, Guoqiang] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA; [Ren, Ming; Watson, William A.; Verma, Ajay] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [O'Neil, J. Timothy] Uniformed Serv Univ Hlth Sci, Dept Pediat, Bethesda, MD 20814 USA	Xing, GQ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Psychiat, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	gxing@usuhs.mil	Xing, Guoqiang/ABA-8450-2020		GEMI Fund research [074/05]	This work was supported, in part, by a GEMI Fund research grant (074/05) and a Henry M. Jackson Foundation TRP grant.	Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/neu.2004.21.1539; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Bartnik BL, 2007, J NEUROTRAUM, V24, P181, DOI 10.1089/neu.2006.0038; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Berry EV, 2006, NEUROTOXICOLOGY, V27, P1043, DOI 10.1016/j.neuro.2006.05.011; Chesler M, 2005, GLIA, V50, P398, DOI 10.1002/glia.20141; Clausen T, 2005, J NEUROSURG, V103, P597, DOI 10.3171/jns.2005.103.4.0597; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Hattori N, 2003, ACTA NEUROCHIR SUPPL, V86, P49; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hillered L, 2008, CRIT CARE MED, V36, P2952, DOI 10.1097/CCM.0b013e3181872178; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; MA M, 2008, EXP NEUROL; MALLOCH GDA, 1986, BIOCHEM J, V238, P729, DOI 10.1042/bj2380729; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Marklund N, 2006, NEUROCHEM RES, V31, P1085, DOI 10.1007/s11064-006-9120-0; Matthews CC, 2003, BRAIN RES, V978, P59, DOI 10.1016/S0006-8993(03)02765-3; Nakamichi N, 2005, J NEUROCHEM, V93, P84, DOI 10.1111/j.1471-4159.2005.02999.x; Paquin J, 2005, ARZNEIMITTELFORSCH, V55, P359; Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217; PAXTON R, 1986, BIOCHEM J, V234, P295, DOI 10.1042/bj2340295; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; RABOW L, 1986, J NEUROSURG, V65, P625, DOI 10.3171/jns.1986.65.5.0625; ROBERTSON CS, 1988, J TRAUMA, V28, P1523, DOI 10.1097/00005373-198811000-00002; SCHINDLER U, 1976, B EUR PHYSIOPATH RES, V12, P277; Siesjo B K, 1982, Ciba Found Symp, V87, P77, DOI 10.1002/9780470720691.ch5; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Yamaki T, 1996, J NUCL MED, V37, P1166; Zeng JY, 2007, J CEREBR BLOOD F MET, V27, P304, DOI 10.1038/sj.jcbfm.9600335	33	27	27	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	APR 17	2009	454	1					38	42		10.1016/j.neulet.2009.01.047			5	Neurosciences	Neurosciences & Neurology	434LD	WOS:000265275300008	19429050				2021-06-18	
J	Stalnacke, BM				Stalnacke, Britt-Marie			RELATIONSHIP BETWEEN SYMPTOMS AND PSYCHOLOGICAL FACTORS FIVE YEARS AFTER WHIPLASH INJURY	JOURNAL OF REHABILITATION MEDICINE			English	Article						whiplash injuries; depression; stress disorders; post-traumatic	POSTTRAUMATIC-STRESS-DISORDER; NECK PAIN INTENSITY; SOFT-TISSUE INJURY; PSYCHOSOCIAL FACTORS; PROGNOSTIC-FACTORS; RECOVERY; DISABILITY; DEPRESSION; ACCIDENTS; FINLAND	Objective: The aims of this study were: to describe the frequency of whiplash-related symptoms and psychological factors in persons 5 years after a whiplash injury; to study the relationship between symptoms and psychological factors; to examine gender differences; and to investigate the cause of sick leave. Methods: Questionnaires addressing neck pain, pain intensity, whiplash-related symptoms, post-traumatic stress, depression, social support and life satisfaction were used. Results: Neck pain was reported by, 59% of subjects, whiplash-related symptoms (Rivermead Post-Concussion Symptoms Questionnaire, RPQ) by 76%, depression (Beck's Depression Inventory, BDI) by 22%, and post-traumatic stress (Impact of Event Scale, IES), by 38%, The scores of pain intensity, and RPQ were correlated to BDI, IES and LiSat-11 scores. Men reported a lower level of quality of social support than women. Men reporting many symptoms also reported reduced availability of social interaction, whereas women with many symptoms reported reduced availability of attachment (i.e. lack of intimate partner, close family and friends). A multivariate logistic regression showed an association between sick leave and depression. Conclusion: These findings indicate the importance of assessing possible relationships between symptoms, depression and post-traumatic stress in persons with long-term problems after whiplash injury, and of treating existing symptoms, especially depression. Because social support may play a role in recovery, social relationships should also be examined.	[Stalnacke, Britt-Marie] Umea Univ, Dept Community Med & Rehabil, SE-90185 Umea, Sweden	Stalnacke, BM (corresponding author), Umea Univ, Umea Univ Hosp, Dept Community Med & Rehabil Rehabil Med, Bldg 9A, SE-90185 Umea, Sweden.	brittmarie.stalnacke@rehabmed.umu.se	Kasch, Helge/H-1325-2012	Kasch, Helge/0000-0002-9302-4946	Swedish Association of Survivors of Traffic Accidents; Polio Cancer and Traffic Injury Fund	The study was supported by the Swedish Association of Survivors of Traffic Accidents and the Polio Cancer and Traffic Injury Fund.	Andersson AL, 1997, INJURY, V28, P539, DOI 10.1016/S0020-1383(97)00083-1; Beck A.T., 2005, BECK DEPRESSION INVE; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Berglund A, 2006, PAIN, V125, P244, DOI 10.1016/j.pain.2006.05.026; Berry H, 2000, ARCH NEUROL-CHICAGO, V57, P592, DOI 10.1001/archneur.57.4.592; BJORNSTIG U, 1990, SCAND J SOC MED, V18, P263, DOI 10.1177/140349489001800405; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; Buitenhuis J, 2003, SPINE, V28, P896, DOI 10.1097/00007632-200305010-00011; Bunketorp L, 2002, EUR SPINE J, V11, P227, DOI 10.1007/s00586-002-0393-y; Bylund PO, 1998, SPINE, V23, P1023, DOI 10.1097/00007632-199805010-00012; Fugl-Meyer AR, 2002, J REHABIL MED, V34, P239, DOI 10.1080/165019702760279242; Guez M, 2002, ACTA ORTHOP SCAND, V73, P455, DOI 10.1080/00016470216329; Hagan KS, 2007, ANN ROY COLL SURG, V89, P624, DOI 10.1308/003588407X202029; Haldorsen T, 2003, APPL NEUROPSYCHOL, V10, P170, DOI 10.1207/S15324826AN1003_06; Herrstrom P, 2000, SCAND J PRIM HEALTH, V18, P154; HILDINGSSON C, 1990, ACTA ORTHOP SCAND, V61, P357, DOI 10.3109/17453679008993536; Holm LW, 2006, SPINE, V31, pE98, DOI 10.1097/01.brs.0000199901.52053.87; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Jansen GB, 2008, EUR SPINE J, V17; KARLSSON J, 1995, J CLIN EPIDEMIOL, V48, P817, DOI 10.1016/0895-4356(94)00196-W; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KISCHKA U, 1991, EUR NEUROL, V31, P136, DOI 10.1159/000116663; Kongsted A, 2008, EUR J PAIN, V12, P455, DOI 10.1016/j.ejpain.2007.07.008; Kyhlback M, 2002, INT J REHABIL RES, V25, P181, DOI 10.1097/00004356-200209000-00003; Mayou R, 1997, PSYCHOSOM MED, V59, P578, DOI 10.1097/00006842-199711000-00004; Mayou R, 1996, INJURY, V27, P617, DOI 10.1016/S0020-1383(96)00114-3; Miettinen T, 2004, EUR SPINE J, V13, P415, DOI 10.1007/s00586-004-0677-5; Miettinen T, 2004, DISABIL REHABIL, V26, P1367, DOI 10.1080/09638280400000203; Peolsson M, 2007, J REHABIL MED, V39, P260, DOI 10.2340/16501977-0052; PRICE DD, 1994, PAIN, V56, P217, DOI 10.1016/0304-3959(94)90097-3; RADANOV BP, 1991, LANCET, V338, P712, DOI 10.1016/0140-6736(91)91441-V; Radanov BP, 1999, J NEUROL NEUROSUR PS, V66, P485, DOI 10.1136/jnnp.66.4.485; RADANOV BP, 1995, MEDICINE, V74, P281, DOI 10.1097/00005792-199509000-00005; SPITZER WO, 1995, SPINE, V20, pS1; Sterling M, 2005, PAIN, V114, P141, DOI 10.1016/j.pain.2004.12.005; Sterner Y, 2003, J SPINAL DISORD TECH, V16, P195, DOI 10.1097/00024720-200304000-00013; Sullivan Michael J L, 2002, Pain Res Manag, V7, P68; Twamley EW, 2004, PSYCHIAT RES, V126, P265, DOI 10.1016/j.psychres.2004.01.008; Williamson E, 2008, PAIN, V135, P20, DOI 10.1016/j.pain.2007.04.035	39	27	30	0	5	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	APR	2009	41	5					353	359		10.2340/16501977-0349			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	446CH	WOS:000266097400010	19363569	DOAJ Gold			2021-06-18	
J	MacLellan, CL; Langdon, KD; Churchill, KP; Granter-Button, S; Corbett, D				MacLellan, Crystal L.; Langdon, Kristopher D.; Churchill, Kayla P.; Granter-Button, Shirley; Corbett, Dale			Assessing cognitive function after intracerebral hemorrhage in rats	BEHAVIOURAL BRAIN RESEARCH			English	Article						Hemorrhagic stroke; Cognition; Behavioural testing; Recovery; Spatial memory; Learning; Maze	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; SHORT-TERM-MEMORY; BILATERAL STRIATAL LESIONS; WHITE-MATTER CHANGES; BASAL GANGLIA; ARTERY OCCLUSION; SPATIAL MEMORY; PREFRONTAL CORTEX; OPERANT TEST	Preclinical studies must rigorously assess whether putative therapies improve motor and cognitive function following brain injury. Intracerebral hemorrhage (ICH) causes significant sensory-motor and cognitive deficits in humans. However, no study has evaluated cognition in rodent ICH models. Thus, we used a battery of tests to comprehensively examine whether a striatal ICH causes cognitive impairments in rats. Bacterial collagenase (or sterile saline for SHAM surgery) was injected into the striatum to create an]CH. Two days later, functional deficits were assessed using a neurological deficit scale (NDS), which is most sensitive to ICH injury. Sensory and/or motor deflcits may confound cognitive testing; thus, we waited until these had resolved before testing learning and memory. Testing was conducted 1-7 months after ICH and included spontaneous alternation, elevated plus maze, open-field, Morris water maze, T-maze (win-shift and win-stay paradigms), and the radial arm maze (eight and four arms baited protocols). Significant motor deficits at 2 days completely resolved by 1 month, at which time cognitive testing began. In contrast to persistent cognitive deficits that occur after ICH in humans, we did not detect significant learning or memory deficits after ICH in rats. Our results suggest that these tests will not likely be useful for assessing outcome in experimental ICH studies. In conclusion, animal models that better mimic clinical ICH (both motor and cognitive deficits) must be developed. This may include increasing ICH severity or injuring other functional subdivisions within the striatum that may lead to more profound cognitive deficits. (C) 2008 Elsevier B.V. All rights reserved.	[MacLellan, Crystal L.; Langdon, Kristopher D.; Churchill, Kayla P.; Granter-Button, Shirley; Corbett, Dale] Mem Univ Newfoundland, Fac Med, Div Biomed Sci, St John, NL A1B 3V6, Canada	MacLellan, CL (corresponding author), Mem Univ Newfoundland, Fac Med, Div Biomed Sci, St John, NL A1B 3V6, Canada.	cmaclell@mun.ca	Corbett, Dale/D-6625-2011; Langdon, Kristopher D/K-4036-2012	Corbett, Dale/0000-0003-0217-4576; Langdon, Kristopher D/0000-0002-3717-4712	Canadian Institutes for Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; Astra-ZenicaAstraZeneca	This research was supported by a grant (to D.C.) from the Canadian Institutes for Health Research (CIHR). D. Corbett holds a Canada Research Chair in Stroke and Neuroplasticity. C. MacLellan is supported by a CIHR post-doctoral fellowship. K. Langdon received a Focus on Stroke Doctoral award from the Heart and Stroke Foundation of Canada, CIHR, and Astra-Zenica. The authors are grateful to Michael Keough for excellent technical assistance, and to Jared Clarke and Garry Chernenko for helpful comments on earlier drafts of the manuscript.	Andersen MB, 1998, BEHAV BRAIN RES, V91, P15, DOI 10.1016/S0166-4328(97)00103-4; Belayev L, 2007, BRAIN RES, V1157, P146, DOI 10.1016/j.brainres.2007.04.077; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; Birrell JM, 2000, J NEUROSCI, V20, P4320; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Clarke J, 2007, BRAIN RES, V1145, P204, DOI 10.1016/j.brainres.2007.01.135; Colbourne F, 1998, BRAIN RES, V803, P69, DOI 10.1016/S0006-8993(98)00612-X; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; DelBigio MR, 1996, STROKE, V27, P2312, DOI 10.1161/01.STR.27.12.2312; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DOBROSSY MD, 1995, NEUROREPORT, V6, P2049; Dobrossy MD, 1996, BRAIN RES BULL, V41, P159; DUNNETT SB, 1981, BEHAV BRAIN RES, V2, P189, DOI 10.1016/0166-4328(81)90055-3; Dunnett SB, 2005, NEUROSCIENCE, V135, P1055, DOI 10.1016/j.neuroscience.2005.07.033; DUNNETT SB, 1990, CAN J PSYCHOL, V44, P210, DOI 10.1037/h0084240; Dunnett SB, 1999, BEHAV BRAIN RES, V106, P13, DOI 10.1016/S0166-4328(99)00076-5; El Massioui N, 2007, NEUROSCIENCE, V147, P906, DOI 10.1016/j.neuroscience.2007.05.015; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Felberg RA, 2002, ANN NEUROL, V51, P517, DOI 10.1002/ana.10160; Hardman CD, 2002, J COMP NEUROL, V445, P238, DOI 10.1002/cne.10165; Hartman RE, 2005, BRAIN RES, V1043, P48, DOI 10.1016/j.brainres.2005.02.030; HIRAKAWA M, 1994, STROKE, V25, P2471, DOI 10.1161/01.STR.25.12.2471; Hochstenbach J, 1998, CLIN REHABIL, V12, P514, DOI 10.1191/026921598666870672; Hua Y, 2002, STROKE, V33, P2478, DOI 10.1161/01.STR.0000032302.91894.0F; Kiprianova I, 1999, EXP NEUROL, V159, P511, DOI 10.1006/exnr.1999.7109; Leys D, 1999, EUR NEUROL, V42, P67, DOI 10.1159/000069414; MacLellan CL, 2006, STROKE, V37, P1266, DOI 10.1161/01.STR.0000217268.81963.78; MacLellan CL, 2005, J CEREBR BLOOD F MET, V25, P1020, DOI 10.1038/sj.jcbfm.9600099; MacLellan CL, 2004, J CEREBR BLOOD F MET, V24, P432, DOI 10.1097/00004647-200404000-00008; MacLellan CL, 2008, J CEREBR BLOOD F MET, V28, P516, DOI 10.1038/sj.jcbfm.9600548; MacLellan CL, 2006, BEHAV BRAIN RES, V175, P82, DOI 10.1016/j.bbr.2006.08.001; MacLellan CL, 2006, J CEREBR BLOOD F MET, V26, P1031, DOI 10.1038/sj.jcbfm.9600255; Morgenstern LB, 2005, STROKE, V36, pE23, DOI 10.1161/01.STR.0000155685.77775.4c; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Nys GMS, 2007, CEREBROVASC DIS, V23, P408, DOI 10.1159/000101464; OKADA M, 1995, J CEREBR BLOOD F MET, V15, P1012, DOI 10.1038/jcbfm.1995.127; OKADA M, 1995, J CEREBR BLOOD F MET, V15, P505, DOI 10.1038/jcbfm.1995.62; OLTON DS, 1976, J EXP PSYCHOL-ANIM B, V2, P97, DOI 10.1037/0097-7403.2.2.97; PACKARD MG, 1990, BEHAV NEURAL BIOL, V53, P39, DOI 10.1016/0163-1047(90)90780-A; Pantoni L, 1997, ANN NY ACAD SCI, V826, P92, DOI 10.1111/j.1749-6632.1997.tb48463.x; Ray KM, 2006, RADIOLOGY, V241, P197, DOI 10.1148/radiol.2411051051; Reid WM, 2008, J NEUROTRAUM, V25, P248, DOI 10.1089/neu.2007.0389; RICHMAN C L, 1986, Current Psychological Research and Reviews, V5, P358, DOI 10.1007/BF02686603; ROSENBERG GA, 1990, STROKE, V21, P801, DOI 10.1161/01.STR.21.5.801; Sakai N, 1996, BEHAV BRAIN RES, V77, P181, DOI 10.1016/0166-4328(95)00232-4; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; Shah AA, 2004, BRAIN RES, V1028, P112, DOI 10.1016/j.brainres.2004.08.061; Su CY, 2007, ARCH CLIN NEUROPSYCH, V22, P465, DOI 10.1016/j.acn.2007.01.025; Thompson HJ, 2006, RESTOR NEUROL NEUROS, V24, P109; von Euler M, 2006, BEHAV BRAIN RES, V166, P204, DOI 10.1016/j.bbr.2005.07.016; Wasserman JK, 2007, BRAIN RES, V1136, P208, DOI 10.1016/j.brainres.2006.12.035; Wen HM, 2004, STROKE, V35, P1826, DOI 10.1161/01.STR.0000133686.29320.58; Werring DJ, 2004, BRAIN, V127, P2265, DOI 10.1093/brain/awh253; White NM, 2002, NEUROBIOL LEARN MEM, V77, P125, DOI 10.1006/nlme.2001.4008; Whitehead SN, 2007, STROKE, V38, P3245, DOI 10.1161/STROKEAHA.107.492660; YAMAMOTO M, 1988, BRAIN RES, V452, P323, DOI 10.1016/0006-8993(88)90036-4; Yonemori F, 1999, J CEREBR BLOOD F MET, V19, P483, DOI 10.1097/00004647-199905000-00002; Yonemori F, 1996, J CEREBR BLOOD F MET, V16, P973, DOI 10.1097/00004647-199609000-00022	59	27	28	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	MAR 17	2009	198	2					321	328		10.1016/j.bbr.2008.11.004			8	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	420SP	WOS:000264309800008	19041895				2021-06-18	
J	Hassett, LM; Moseley, AM; Tate, RL; Harmer, AR; Fairbairn, TJ; Leung, J				Hassett, Leanne M.; Moseley, Anne M.; Tate, Robyn L.; Harmer, Alison R.; Fairbairn, Timothy J.; Leung, Joan			EFFICACY OF A FITNESS CENTRE-BASED EXERCISE PROGRAMME COMPARED WITH A HOME-BASED EXERCISE PROGRAMME IN TRAUMATIC BRAIN INJURY: A RANDOMIZED CONTROLLED TRIAL	JOURNAL OF REHABILITATION MEDICINE			English	Article						brain injuries; exercise; physical therapy (specialty); rehabilitation; physical fitness	PHYSICAL-ACTIVITY; AEROBIC CAPACITY; REHABILITATION; DEPRESSION; DISABILITIES; INDIVIDUALS; RELIABILITY; PREVENTION; RECOVERY; PEOPLE	Objective: To compare the effects of a supervised fitness centre-based exercise programme with an unsupervised home-based exercise programme on cardiorespiratory fitness and psychosocial functioning in people with traumatic brain injury. Design: Multi-centre, assessor-blinded, parallel group, randomized controlled trial. Participants: Sixty-two participants with severe traumatic brain injuries, who could walk at a speed exceeding 1 m/sec, discharged from 3 brain injury units. Interventions: The fitness centre group completed a combined fitness and strength training exercise programme supervised by a personal trainer in a local fitness centre 3 times per week for 12 weeks. The home group completed a similar exercise programme unsupervised at home. Main outcome measure: Cardiorespiratory fitness measured using the modified 20-m shuttle test. Results: Both groups improved in fitness: the maximal velocity achieved on the modified 20-m shuttle test increased with intervention and was maintained at follow-up. However, the difference between groups was not significant ( mean between-group difference (95% confidence interval) 0 m/sec (-0.6 to 0.6) at the end of intervention). There were also no between-group differences in psychosocial functioning at the end of intervention or at follow-up. Conclusion: Both interventions were equally effective at improving cardiorespiratory fitness in adults with traumatic brain injuries.	[Hassett, Leanne M.; Harmer, Alison R.] Univ Sydney, Discipline Physiotherapy, Sydney, NSW 2006, Australia; [Hassett, Leanne M.] Univ Sydney, Liverpool Hlth Serv, Brain Injury Rehabil, Sydney, NSW 2006, Australia; [Moseley, Anne M.] Univ Sydney, George Inst Int Hlth, Sydney, NSW 2006, Australia; [Tate, Robyn L.] Univ Sydney, No Clin Sch Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia; [Fairbairn, Timothy J.] Westmead Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Leung, Joan] Royal Rehabil Ctr Sydney, Brain Injury Rehabil Unit, Sydney, NSW, Australia	Hassett, LM (corresponding author), Liverpool Hlth Serv, Brain Injury Rehabil Unit, Locked Bag 7103, Liverpool Bc, NSW 1871, Australia.	leanne.hassett@sswahs.nsw.gov.au	Harmer, Alison/I-2593-2013; Leung, Joan/AAC-8623-2019	Harmer, Alison/0000-0003-4877-5801; Leung, Joan/0000-0003-0888-558X; Hassett, Leanne/0000-0002-3546-1822			ACSM, 2000, GUID EX TEST PRESCR; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; *AM COLL SPORTS ME, 2005, HLTH REL PHYS FITN A; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; Booth FW, 2000, J APPL PHYSIOL, V88, P774; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; BULL SJ, 1999, ADHERENCE ISSUES SPO; Chervinsky AB, 1998, ARCH CLIN NEUROPSYCH, V13, P433, DOI 10.1016/S0887-6177(97)00016-4; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Driver S, 2004, BRAIN INJURY, V18, P847, DOI 10.1080/02699050410001671856; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Hassett LM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006123.pub2; Hassett LM, 2007, BRAIN INJURY, V21, P1069, DOI 10.1080/02699050701630375; LANDIS JR, 1977, BIOMETRICS, V33, P174; LASKIN JJ, 2001, THESIS U ALBERTA ALB; Lawlor DA, 2001, BMJ-BRIT MED J, V322, P763, DOI 10.1136/bmj.322.7289.763; LOVIBOND SH, 1996, MANUAL DEPRESSION AN; MCARDLE WD, 1978, MED SCI SPORT EXER, V10, P16; MCNAIR DM, 1992, MANUAL POMS PROFILE; MORAN AJ, 1976, MED J AUSTRALIA, V1, P396, DOI 10.5694/j.1326-5377.1976.tb140699.x; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; Palmer-McLean K, 2003, ACSMS EXERCISE MANAG, P238; Paluska SA, 2000, SPORTS MED, V29, P167, DOI 10.2165/00007256-200029030-00003; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Ready AE, 2005, J SPORT MED PHYS FIT, V45, P199; Rimmer JH, 2004, AM J PREV MED, V26, P419, DOI 10.1016/j.amepre.2004.02.002; Rimmer JH, 1999, PHYS THER, V79, P495, DOI 10.1093/ptj/79.5.495; Rusconi S, 2003, DISABIL REHABIL, V25, P1281, DOI 10.1080/09638280310001608582; SALTIN B, 1968, CIRCULATION        S, V7, P1; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; SULLIVAN S J, 1990, Brain Injury, V4, P407, DOI 10.3109/02699059009026194; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; van den Broek MD, 2005, J HEAD TRAUMA REHAB, V20, P464, DOI 10.1097/00001199-200509000-00007; Vickers Andrew J, 2005, BMC Med Res Methodol, V5, P35, DOI 10.1186/1471-2288-5-35; Vitale AE, 1997, BRAIN INJURY, V11, P67, DOI 10.1080/026990597123827; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	37	27	28	0	22	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977			J REHABIL MED	J. Rehabil. Med.	MAR	2009	41	4					247	255		10.2340/16501977-0316			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	416PE	WOS:000264017200007	19247544	DOAJ Gold			2021-06-18	
J	Hemmen, TM; Lyden, PD				Hemmen, Thomas M.; Lyden, Patrick D.			Hypothermia after Acute Ischemic Stroke	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	2nd International Brain Hypothermia Symposium	OCT, 2007	Miami Beach, FL			cerebral vascular disease; hypothermia; regeneration; stem cells; stroke; traumatic brain injury; traumatic spinal cord injury	CEREBRAL-ARTERY OCCLUSION; DELAYED POSTISCHEMIC HYPOTHERMIA; DAMAGE COOL AID; MILD HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; MODERATE HYPOTHERMIA; SHIVERING THRESHOLD; FOCAL ISCHEMIA; CARDIAC-ARREST; INFARCT SIZE	Induced hypothermia after ischemic stroke is a promising neuroprotective therapy and is the most potent in preclinical models. Technological limitations and homeostatic mechanisms that maintain core body temperature, however, have limited the clinical application of hypothermia. Advances in intravascular cooling and successful trials of hypothermia after global cerebral ischemia, such as in cardiac arrest and neonatal asphyxia, have renewed interest in hypothermia for stroke.	[Hemmen, Thomas M.; Lyden, Patrick D.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA; [Lyden, Patrick D.] Dept Vet Affairs, San Diego, CA USA	Hemmen, TM (corresponding author), Univ Calif San Diego, Dept Neurosci, 200 W Arbor Dr,MC 8466 OPC 3rd Floor,Suite 3, San Diego, CA 92103 USA.	themmen@ucsd.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS044148-02S2, P50 NS044148, P50 NS044148-06] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS044148] Funding Source: NIH RePORTER		Adams H, 2005, STROKE, V36, P916, DOI 10.1161/01.STR.0000163257.66207.2d; Alfonsi P, 1998, ANESTHESIOLOGY, V89, P43, DOI 10.1097/00000542-199807000-00009; BAKER CJ, 1991, SURG NEUROL, V36, P175, DOI 10.1016/0090-3019(91)90109-M; Baumgardner JE, 1999, ANESTH ANALG, V89, P163, DOI 10.1097/00000539-199907000-00029; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BURKS LC, 1980, ARCH INTERN MED, V140, P483, DOI 10.1001/archinte.140.4.483; CHEN H, 1991, NEUROLOGY, V41, P1133, DOI 10.1212/WNL.41.7.1133; CHENG C, 1995, ANESTHESIOLOGY, V82, P1160, DOI 10.1097/00000542-199505000-00011; Cheng Yu Dennis, 2004, NeuroRx, V1, P36, DOI 10.1602/neurorx.1.1.36; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; CORREIA M, 2001, COOLING THERAPY ACUT; De Georgia MA, 2004, NEUROLOGY, V63, P312, DOI 10.1212/01.WNL.0000129840.66938.75; DELAUNAY L, 1993, ANESTHESIOLOGY, V79, P470, DOI 10.1097/00000542-199309000-00009; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Doufas AG, 2003, STROKE, V34, P1218, DOI 10.1161/01.STR.0000068787.76670.A4; Eberspacher E, 2005, ACTA ANAESTH SCAND, V49, P477, DOI 10.1111/j.1399-6576.2005.00649.x; Ehrlich MP, 2002, ANN THORAC SURG, V73, P191, DOI 10.1016/S0003-4975(01)03273-8; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Guluma KZ, 2006, ACAD EMERG MED, V13, P820, DOI 10.1197/j.aem.2006.03.559; HAGERDAL M, 1975, J NEUROCHEM, V24, P311, DOI 10.1111/j.1471-4159.1975.tb11881.x; Hemmen TM, 2007, STROKE, V38, P794, DOI 10.1161/01.STR.0000247920.15708.fa; Hemmen TM, 2006, STROKE, V37, P706; Holzer M, 2002, NEW ENGL J MED, V346, P549; HU BR, 1995, NEUROSCIENCE, V68, P1003, DOI 10.1016/0306-4522(95)00213-3; IKONOMIDOU C, 1989, BRAIN RES, V487, P184, DOI 10.1016/0006-8993(89)90956-6; Inamasu J, 2001, NEUROL RES, V23, P105, DOI 10.1179/016164101101198217; JESSEN K, 1980, ACTA ANAESTH SCAND, V24, P138, DOI 10.1111/j.1399-6576.1980.tb01522.x; Kammersgaard LP, 2000, STROKE, V31, P2251, DOI 10.1161/01.STR.31.9.2251; Kasner SE, 2002, STROKE, V33, P130, DOI 10.1161/hs0102.101477; Krieger DW, 2004, STROKE, V35, P1482, DOI 10.1161/01.STR.0000126118.44249.5c; Krieger DW, 2001, STROKE, V32, P1847, DOI 10.1161/01.STR.32.8.1847; KURZ M, 1993, ANESTHESIOLOGY, V79, P1193, DOI 10.1097/00000542-199312000-00009; Lyden Patrick D, 2005, J Stroke Cerebrovasc Dis, V14, P107, DOI 10.1016/j.jstrokecerebrovasdis.2005.01.001; Lyden PD, 2006, INT J STROKE, V1, P9, DOI 10.1111/j.1747-4949.2005.00011.x; Mack WJ, 2003, STROKE, V34, P1994, DOI 10.1161/01.STR.0000079813.31539.6D; Mahmood MA, 2007, J NEUROL SCI, V261, P47, DOI 10.1016/j.jns.2007.04.038; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Martin-Schild S, 2008, STROKE, V39, P532; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; Mokhtarani M, 2001, ANESTH ANALG, V93, P1233, DOI 10.1097/00000539-200111000-00038; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; Nolan JP, 2003, CIRCULATION, V108, P118, DOI 10.1161/01.CIR.0000079019.02601.90; O'Collins VE, 2006, ANN NEUROL, V59, P467, DOI 10.1002/ana.20741; Popovic R, 2000, ANESTHESIOLOGY, V92, P1343, DOI 10.1097/00000542-200005000-00024; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; Roelfsema V, 2004, J CEREBR BLOOD F MET, V24, P877, DOI 10.1097/01.WCB.0000123904.17746.92; Rogalewski A, 2006, STROKE, V37, P1129, DOI 10.1161/01.STR.0000209330.73175.34; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Sumii T, 2002, STROKE, V33, P831, DOI 10.1161/hs0302.104542; Takata T, 1997, NEUROSCI LETT, V227, P41, DOI 10.1016/S0304-3940(97)00296-6; TREKOVA NA, 2004, ANESTEZIOL REANIMAT, V5, P86; van Breda Eric J, 2005, BMC Cardiovasc Disord, V5, P24, DOI 10.1186/1471-2261-5-24; Wang GJ, 2002, NEUROSCIENCE, V114, P1081, DOI 10.1016/S0306-4522(02)00350-0; Wang LM, 2005, CELL RES, V15, P387, DOI 10.1038/sj.cr.7290306; Watts DD, 1998, J TRAUMA, V44, P846, DOI 10.1097/00005373-199805000-00017; Wolberg AS, 2004, J TRAUMA, V56, P1221, DOI 10.1097/01.TA.0000064328.97941.FC; Yanamoto H, 1999, STROKE, V30, P2720, DOI 10.1161/01.STR.30.12.2720; Yenari MA, 2002, J CEREBR BLOOD F MET, V22, P29, DOI 10.1097/00004647-200201000-00004; YENARI MA, 1995, THROMB RES, V77, P475, DOI 10.1016/0049-3848(95)93883-2; YOUNG RSK, 1980, JAMA-J AM MED ASSOC, V244, P1233, DOI 10.1001/jama.244.11.1233; Zausinger S, 2000, BRAIN RES, V863, P94, DOI 10.1016/S0006-8993(00)02100-4; Zausinger S, 2003, STROKE, V34, P2246, DOI 10.1161/01.STR.0000083622.65684.21; ZHANG RL, 1993, STROKE, V24, P1235, DOI 10.1161/01.STR.24.8.1235; Zweifler Richard M, 2003, J Stroke Cerebrovasc Dis, V12, P237, DOI 10.1016/j.jstrokecerebrovasdis.2003.09.006	68	27	28	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2009	26	3					387	391		10.1089/neu.2008.0574			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	420ZO	WOS:000264327900012	19231919	Green Published, Green Accepted			2021-06-18	
J	Jiang, JY				Jiang, Ji-Yao			Clinical Study of Mild Hypothermia Treatment for Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	2nd International Brain Hypothermia Symposium	OCT, 2007	Miami Beach, FL			adult brain injury; animal studies; biomarkers; blood-brain barrier dysfunction; clinical management of CNS injury; hypothermia; regeneration; stem cells; traumatic brain injury; traumatic spinal cord injury	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; HOSPITAL CARDIAC-ARREST; COLD INTRAVENOUS FLUID; MODERATE HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; INTRACRANIAL-PRESSURE; COMATOSE SURVIVORS; LONG; HYPERTENSION	Clinical randomized controlled trials (RCTs) suggest that mild hypothermia may improve the outcome of severe traumatic brain injured patients with intracranial hypertension when cooling is maintained for longer than 48 h. However, the results are not yet conclusive, and more RCTs are required. Mild hypothermia significantly decreases intracranial pressure (ICP) values when refractory intracranial hypertension cannot be controlled by conventional measures in patients with severe traumatic brain injury (TBI). Prolonged mild-to-moderate hypothermia may be associated with high incidence of pneumonia and hypokalemia, which should be prevented.	Shanghai Jiao Tong Univ, Shanghai Renji Hosp, Dept Neurosurg, Sch Med, Shanghai 200127, Peoples R China	Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Shanghai Renji Hosp, Dept Neurosurg, Sch Med, Shanghai 200127, Peoples R China.	Jiangjyb@online.sh.cn					Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Bernard S, 2003, RESUSCITATION, V56, P9, DOI 10.1016/S0300-9572(02)00276-9; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BOHN DJ, 1986, CRIT CARE MED, V14, P529, DOI 10.1097/00003246-198606000-00002; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS21; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Clifton Guy L, 2004, Curr Opin Crit Care, V10, P116, DOI 10.1097/00075198-200404000-00007; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Gal R, 2002, CLIN NEUROL NEUROSUR, V104, P318, DOI 10.1016/S0303-8467(02)00023-9; Hashiguchi N, 2003, J TRAUMA, V55, P1054, DOI 10.1097/01.TA.0000033252.43742.8B; Hayashi N, 1999, Nihon Geka Gakkai Zasshi, V100, P443; Hayashi N, 1998, Nihon Rinsho, V56, P1627; Hayashi S, 2005, ACT NEUR S, V95, P269; HENDRICK EB, 1959, ARCH SURG-CHICAGO, V79, P362; Holzer M, 2002, NEW ENGL J MED, V346, P549; Iida K, 2003, J NEUROSURG, V98, P793, DOI 10.3171/jns.2003.98.4.0793; Ishikawa K, 2000, J TRAUMA, V49, P912, DOI 10.1097/00005373-200011000-00020; Jiang JY, 2007, CURR OPIN CRIT CARE, V13, P153, DOI 10.1097/MCC.0b013e32807f2a80; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jiang JY, 1998, CHINESE MED J-PEKING, V111, P180; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Masaoka Hiroyuki, 2000, Keio Journal of Medicine, V49, pA159; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Mrlian A, 2006, Bratisl Lek Listy, V107, P113; Murakami M, 2007, NEUROL MED-CHIR, V47, P116, DOI 10.2176/nmc.47.116; Nara I, 1998, ACT NEUR S, V71, P22; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Polderman KH, 2005, CRIT CARE MED, V33, P2744, DOI 10.1097/01.CCM.0000190427.88735.19; ROSOMOFF HL, 1960, SURG GYNECOL OBSTET, V110, P27; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; Shann F, 2003, LANCET, V362, P1950, DOI 10.1016/S0140-6736(03)15083-0; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; Shiozaki T, 2003, J NEUROSURG, V99, P47, DOI 10.3171/jns.2003.99.1.0047; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Smrcka M, 2005, ACT NEUR S, V95, P273; Soukup J, 2002, NEUROL RES, V24, P161, DOI 10.1179/016164102101199710; Soukup J, 2002, J NEUROTRAUM, V19, P559, DOI 10.1089/089771502753754046; Sund-Levander M, 2000, J CLIN NURS, V9, P55, DOI 10.1046/j.1365-2702.2000.00352.x; Tateishi A, 1998, NEUROSURGERY, V42, P1065, DOI 10.1097/00006123-199805000-00066; Zhang Sai, 2002, Chin J Traumatol, V5, P43; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	46	27	32	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2009	26	3					399	406		10.1089/neu.2008.0525			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	420ZO	WOS:000264327900014	19260782				2021-06-18	
J	Weaver, FM; Burns, SP; Evans, CT; Rapacki, LM; Goldstein, B; Hammond, MC				Weaver, Frances M.; Burns, Stephen P.; Evans, Charlesnika T.; Rapacki, Lauren M.; Goldstein, Barry; Hammond, Margaret C.			Provider Perspectives on Soldiers With New Spinal Cord Injuries Returning From Iraq and Afghanistan	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Health personnel; Rehabilitation; Spinal cord injuries; Veterans	TRAUMATIC BRAIN-INJURY; COMBAT; WAR; REHABILITATION; CASUALTIES; RISK	Objective: The military conflicts in Iraq and Afghanistan have resulted in many soldiers returning with serious combat injuries, including spinal cord injuries (SCIs). The purpose of this study was to query providers regarding any unique problems or needs in a cohort of these soldiers treated in Veterans Health Administration (VHA) SCI Centers. Design: Semi structured questionnaire. Setting: Seventeen VHA SCI Centers. Participants: Thirty-eight providers, including physicians, nurses, therapists, social workers, and psychologists who volunteered to return completed questionnaires. Interventions: Not applicable. Main Outcome Measures: Identification of medical and psychosocial issues, rehabilitation delays, therapy and vocational needs, social support, and discharge planning. Results: Providers identified several injuries and conditions beyond SCI that were experienced by these soldiers including fractures, pressure ulcers, traumatic brain injuries, posttraumatic stress disorder, and resistant infections. Rehabilitation was often delayed because these problems needed to be addressed first. Soldiers' family and friends provide considerable support. Vocational needs include use of technology, especially computers; education; and participation in sports. Although most return to the community after discharge, many soldiers are still active duty, and some return to military base housing. Conclusions: Combat soldiers returning with SCI often have additional medical and psychosocial problems that require appropriate and timely intervention. They have strong support from family and friends and are motivated to integrate back into the community after discharge.	[Weaver, Frances M.; Evans, Charlesnika T.; Rapacki, Lauren M.] Edward Hines Jr VA Hosp, Ctr Complex Chron Care, Hines, IL 60141 USA; [Weaver, Frances M.; Evans, Charlesnika T.; Rapacki, Lauren M.] Edward Hines Jr VA Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL 60141 USA; [Weaver, Frances M.; Evans, Charlesnika T.] Northwestern Univ, Inst Healthcare Studies, Chicago, IL 60611 USA; [Weaver, Frances M.] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA; [Burns, Stephen P.; Goldstein, Barry; Hammond, Margaret C.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA; [Burns, Stephen P.; Goldstein, Barry; Hammond, Margaret C.] Univ Washington, Dept Rehabil, Seattle, WA 98195 USA; [Burns, Stephen P.; Goldstein, Barry; Hammond, Margaret C.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Goldstein, Barry; Hammond, Margaret C.] Dept Vet Affairs, Spinal Cord Injury & Disorders Serv, Seattle, WA USA	Weaver, FM (corresponding author), VA Hosp, 5000 S 5th Ave 151H, Hines, IL 60141 USA.	Frances.Weaver@va.gov	Weaver, Frances/S-1540-2019		Spinal Cord Injury Quality Enhancement Research Initiative (QUERI) in the Department of Veterans Affairs [SC198-001]	Supported by the Spinal Cord Injury Quality Enhancement Research Initiative (QUERI) in the Department of Veterans Affairs (grant no. SC198-001).	Cirillo VJ, 2008, PERSPECT BIOL MED, V51, P121, DOI 10.1353/pbm.2008.0005; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DILLINGHAM TR, 1993, AM J PHYS MED REHAB, V72, P214, DOI 10.1097/00002060-199308000-00008; Friedemann-Sanchez G, 2008, ARCH PHYS MED REHAB, V89, P171, DOI 10.1016/j.apmr.2007.10.017; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Mahmoud A, 1999, TOP SPINAL CORD INJ, V5, P42; Martz E, 2005, ARCH PHYS MED REHAB, V86, P1182, DOI 10.1016/j.apmr.2004.11.036; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; POLLACK P, 2007, ACAD ORTHOPED SU MAR; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Tolonen A, 2007, J REHABIL MED, V39, P622, DOI 10.2340/16501977-0101; Westgren N, 1998, ARCH PHYS MED REHAB, V79, P1433, DOI 10.1016/S0003-9993(98)90240-4	14	27	28	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2009	90	3					517	521		10.1016/j.apmr.2008.09.560			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	421YW	WOS:000264395200023	19254621				2021-06-18	
J	Sharma, D; Jelacic, J; Chennuri, R; Chaiwat, O; Chandler, W; Vavilala, MS				Sharma, Deepak; Jelacic, Jill; Chennuri, Rohini; Chaiwat, Onuma; Chandler, Wayne; Vavilala, Monica S.			Incidence and Risk Factors for Perioperative Hyperglycemia in Children with Traumatic Brain Injury	ANESTHESIA AND ANALGESIA			English	Article							INTENSIVE INSULIN THERAPY; BLOOD-GLUCOSE; ADMISSION; ACIDOSIS	BACKGROUND: Hyperglycemia after traumatic brain injury (TBI) is associated with poor outcome. In this study, we examined the incidence and risk factors for perioperative hyperglycemia in children with TBI. METHODS: A retrospective cohort study of children <= 13 yr who underwent urgent or emergent craniotomy for TBI at Harborview Medical Center (level I Adult and Pediatric Trauma Center) between 1994 and 2004 was performed. Preoperative (emergency department to general anesthesia start), intraoperative (during general anesthesia), and immediate postoperative (first 24 h after surgery) glucose Values for each patient were retrieved. The incidence of hyperglycemia (glucose >= 200 mg/dL) and hyperglycemia (glucose <60 mg/dL) was determined Persistent. hyperglycemia was defined as hyperglycemia during any 2/3 (preoperative, intraoperative immediate postoperative) study periods, whereas transient hyperglycemia was hyperglycemia during any one study period. Multivariate logistic regression analysis was used to determine the independent predictors of perioperative hyperglycemia. Data are resented as adjusted odds ratio (AOR) (95% CI) and P < 0.05 reflects significance. RESULTS: At least one serum glucose value was recorded during each study period: preoperative (86 [82%]), intraoperative (94 [89%), and postoperative (101 [97%]). Sixty-four percent of children had less than one glucose recorded per anesthetic hour. Forty-seven (45%) children had hyperglycemia during at least one study period. Transient hyperglycemia occurred in 29 (28%) and persistent hyperglcemia Occurred in 18 (17%) children. Independent predictors of perioperative hyperglycemia were a e <4 yr (AOR 95% CI]; 3.5 [1.2-10.6]), Glasgow Coma Scale <= 8 (AOR 95%) CI; 7.2 [2.4-2.5]) and the presence of multi le lesions subdural hematoma (AOR 95%, CI; 34.7 [2.3-525.5]). Six children were treated with insulin, and two children had hypoglycemia, unrelated to insulin treatment. CONCLUSIONS: Perioperative hyperglycemia was common and intraoperative hypo glycemia was not rare, but More frequent intraoperative glucose sampling may be needed to better determine the incidence of hypo and hyperglycemia during the perioperative period. Age <4 yr, severe TBI a and the presence of multiple lesions, including subdural hematoma, were risk factors for perioperative hyperglycemia.	[Vavilala, Monica S.] Univ Washington, Harborview Med Ctr, Dept Anesthesiol, Seattle, WA 98104 USA; [Vavilala, Monica S.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Chandler, Wayne] Univ Washington, Dept Lab Med, Seattle, WA 98104 USA; [Vavilala, Monica S.] Univ Washington, Dept Pediat & Neurol Surg, Seattle, WA 98104 USA; [Chaiwat, Onuma; Vavilala, Monica S.] Univ Washington, Harborview Anesthesia Res Ctr, Seattle, WA 98104 USA	Vavilala, MS (corresponding author), Univ Washington, Harborview Med Ctr, Dept Anesthesiol, 325 9th Ave,Box 359724, Seattle, WA 98104 USA.	vavilala@u.washington.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23HDO44632-05]; HARC; Departmental Resources; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD044632] Funding Source: NIH RePORTER	Supported by NIH K23HDO44632-05 (to M.S.V.), HARC (to O.C.), Departmental Resources (to D.S., J.J., R.C.).	Allen HF, 2008, PEDIATR CRIT CARE ME, V9, P153, DOI 10.1097/PCC.0b013e3181668b33; American Association for the Surgery of Trauma, 2003, J Trauma, V54, pS235; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Chiaretti A, 1998, CHILD NERV SYST, V14, P455, DOI 10.1007/s003810050259; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Freeman SS, 2008, ANESTHESIOLOGY, V108, P588, DOI 10.1097/ALN.0b013e31816725d7; Gandhi GY, 2007, ANN INTERN MED, V146, P233, DOI 10.7326/0003-4819-146-4-200702200-00002; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LONGSTRETH WT, 1984, ANN NEUROL, V15, P59, DOI 10.1002/ana.410150111; Marton E, 2007, CHILD NERV SYST, V23, P873, DOI 10.1007/s00381-007-0314-9; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; PARISH RA, 1988, J TRAUMA, V28, P517, DOI 10.1097/00005373-198804000-00017; PENTELENYI T, 1979, INJURY, V10, P201, DOI 10.1016/0020-1383(79)90009-3; REHNCRONA S, 1980, ACTA PHYSIOL SCAND, V110, P435, DOI 10.1111/j.1748-1716.1980.tb06692.x; ROLIH CA, 1995, MED CLIN N AM, V79, P211, DOI 10.1016/S0025-7125(16)30093-1; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SOOD SC, 1980, ACTA NEUROCHIR, V53, P47, DOI 10.1007/BF02074520; Treggiari MM, 2008, CRIT CARE, V12, DOI 10.1186/cc6807; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Wintergerst KA, 2006, PEDIATRICS, V118, P173, DOI 10.1542/peds.2005-1819; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; Zygun DA, 2004, NEUROSURGERY, V55, P877, DOI 10.1227/01.NEU.0000137658.14906.E4	31	27	30	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2009	108	1					81	89		10.1213/ane.0b013e31818a6f32			9	Anesthesiology	Anesthesiology	387PB	WOS:000261963000015	19095835	Green Accepted			2021-06-18	
J	Siegert, RJ; Walkey, FH; Turner-Stokes, L				Siegert, Richard J.; Walkey, Frank H.; Turner-Stokes, Lynne			An examination of the factor structure of the Beck Depression Inventory-II in a neurorehabilitation inpatient sample	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Beck Depression Inventory; BDI-II; Depression; Rehabilitation; Factor analysis; Statistical; Brain injuries	TRAUMATIC BRAIN-INJURY; INTEGRATED CARE PATHWAY; PAIN	The Beck Depression Inventory-II (BDI-II) is widely used for assessing depression in neurorehabilitation. Given the concern that the somatic items might be misleading, we examined its factor structure in 353 inpatients. Exploratory factor analysis was undertaken to compare two- to five-factor solutions. Confirmatory factor analysis was then used to test the best exploratory solutions for goodness of fit on a subsample. Both provided strong support for a general depression factor and two specific factors, one somatic and one cognitive/affective. The BDI-II provides a meaningful score of overall depression, and it can also yield two subscores-one measuring somatic symptoms and the other measuring psychological symptoms of depression. To avoid confusing the common symptoms of neurological disability with depression in neurorehabilitation, clinicians need to consider all three scores carefully. (JINS, 2009, 15, 142-147.)	[Siegert, Richard J.; Turner-Stokes, Lynne] Kings Coll London, Dept Palliat Care Policy & Rehabil, London WC2R 2LS, England; [Walkey, Frank H.] Victoria Univ Wellington, Sch Psychol, Wellington, New Zealand; [Turner-Stokes, Lynne] Northwick Pk Hosp & Clin Res Ctr, Reg Rehabil Unit, London, England	Siegert, RJ (corresponding author), Guys Kings Coll, Dept Palliat Care Policy & Rehabil, Sch Med, 3rd Floor,Cutcombe Rd,Denmark Hill, London SE5 9RJ, England.	richard.siegert@kcl.ac.uk	Turner-Stokes, Lynne/F-4418-2012; Siegert, Richard/C-3241-2009; Siegert, Richard J./K-2030-2019	Turner-Stokes, Lynne/0000-0002-3302-9462; Siegert, Richard/0000-0002-3074-0929	Dunhill Medical TrustDunhill Medical Trust; Luff Foundation	We are grateful to all the patients on the Regional Rehabilitation Unit, Northwick Park Hospital, who allowed their data to be used and staff who performed the assessments. We are especially grateful to Dr. Frances Clegg for initiating the data set and to Margot Kalmus, Jo Clark, and Heather Williams for assistance with collation and validation of the data set. Financial support for the preparation of this manuscript was provided by the Dunhill Medical Trust and the Luff Foundation. Three anonymous reviewers made suggestions that assisted the authors to substantially improve the original manuscript.	Arnau RC, 2001, HEALTH PSYCHOL, V20, P112, DOI 10.1037//0278-6133.20.2.112; BARRETT PT, 1981, PERS INDIV DIFFER, V2, P311, DOI 10.1016/0191-8869(81)90086-6; Beck A. T., 1966, BECK DEPRESSION INVE; CATTELL RB, 1974, AUST J PSYCHOL, V26, P103, DOI 10.1080/00049537408255223; CHRISTENSEN BK, 1995, J INT NEUROPSYCH SOC, V1, P122; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Hassan N, 2002, CLIN REHABIL, V16, P534, DOI 10.1191/0269215502cr523oa; Hau KT, 2004, BRIT J MATH STAT PSY, V57, P327, DOI 10.1111/j.2044-8317.2004.tb00142.x; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Morley S, 2002, PAIN, V99, P289, DOI 10.1016/S0304-3959(02)00137-9; Munoz DJ, 2007, OBES SURG, V17, P1097, DOI 10.1007/s11695-007-9185-0; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; *ROYAL COLL PHYS, 2005, US ANT MED AD UND RE; Schumacker, 2001, NEW DEV TECHNIQUES S, P269, DOI DOI 10.4324/9781410601858; Thombs BD, 2007, BURNS, V33, P547, DOI 10.1016/j.burns.2006.10.398; Thompson B., 2004, EXPLORATORY CONFIRMA; Turner-Stokes L, 2002, CLIN REHABIL, V16, P231, DOI 10.1191/0269215502cr487oa; Ullman J. B., 2001, USING MULTIVARIATE S, V4th, P653; Wesley AL, 1999, CLIN J PAIN, V15, P117, DOI 10.1097/00002508-199906000-00008	22	27	27	0	4	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2009	15	1					142	147		10.1017/S1355617708090048			6	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	398NR	WOS:000262739300016	19128538				2021-06-18	
J	Temple, RO; Zgaljardic, DJ; Abreu, BC; Seale, GS; Ostir, GV; Ottenbacher, KJ				Temple, Richard O.; Zgaljardic, Dennis J.; Abreu, Beatriz C.; Seale, Gary S.; Ostir, Glenn V.; Ottenbacher, Kenneth J.			Ecological validity of the neuropsychological assessment battery screening module in post-acute brain injury rehabilitation	BRAIN INJURY			English	Article						Traumatic brain injury; neuropsychological assessment; outcomes assessment; rehabilitation	FUNCTIONAL INDEPENDENCE; STROKE; NAB; PERFORMANCE; IMPAIRMENT; VALIDATION; SAMPLE; SCORES; SCALE	Primary objective: To assess the ecological validity of the Screening Module of the Neuropsychological Assessment Battery (NAB-SM) using the Functional Independence Measure (FIM). Method: Seventy individuals with moderate-to-severe traumatic brain injury at a residential post-acute rehabilitation facility were administered the FIM instrument and the NAB-SM upon admission. Hierarchical regression analysis was used to examine the relationship between the variables from these two assessment measures. Results: Hierarchical models revealed that (1) the NAB-SM Total score was significantly associated with the FIM instrument Total score as well as the Motor and Cognition sub-scale scores, above and beyond the contribution of demographic variables, (2) the NAB-SM Language, Memory and Spatial domain scores were significantly associated with of the FIM instrument Cognition sub-scale score and (3) the NAB-SM Spatial domain score was significantly associated with of the FIM instrument Total and Motor sub-scale scores. Conclusions: The current findings support previous research and provide strong evidence for the ecological validity of the NAB-SM with regard to functional abilities as assessed by the FIM instrument.	[Zgaljardic, Dennis J.] Transit Learning Ctr, Dept Neuropsychol, Galveston, TX 77550 USA; [Temple, Richard O.] CORE Hlth Care, Dripping Springs, TX USA; [Zgaljardic, Dennis J.; Abreu, Beatriz C.; Seale, Gary S.; Ostir, Glenn V.; Ottenbacher, Kenneth J.] Univ Texas Med Branch, Galveston, TX USA	Zgaljardic, DJ (corresponding author), Transit Learning Ctr, Dept Neuropsychol, 1528 PO St, Galveston, TX 77550 USA.	dzgaljardic@tlc-galveston.org		Ottenbacher, Kenneth/0000-0001-5990-3982	National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K02-AG019736]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01-HD046682]; Moody Foundation [2005-24]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD046682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K02AG019736, R01AG031178, R01AG024806] Funding Source: NIH RePORTER	This work was supported in part by the National Institute on Aging, Grant K02-AG019736; and by the National Institute of Child Health and Human Development, Grant K01-HD046682 and by the Moody Foundation, Grant #2005-24. We also gratefully acknowledge Jason Levinson, MA, for his assistance with data collection and Renee Pearcy for her research assistance.	Brooks BL, 2007, J INT NEUROPSYCH SOC, V13, P490, DOI 10.1017/D1355617707070531; Brown LB, 2005, ARCH CLIN NEUROPSYCH, V20, P209, DOI 10.1016/j.acn.2004.06.003; Chan CHC, 1999, ARCH CLIN NEUROPSYCH, V14, P71, DOI 10.1093/arclin/14.1.71; Chang PFJ, 2008, ARCH PHYS MED REHAB, V89, P231, DOI 10.1016/j.apmr.2007.08.143; COTE R, 1986, STROKE, V17, P731, DOI 10.1161/01.STR.17.4.731; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; Fong KNK, 2001, BRAIN INJURY, V15, P443, DOI 10.1080/02699050010005940; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Golding E., 1989, MIDDLESEX ELDERLY AS; GOLDSTEIN LB, 1989, ARCH NEUROL-CHICAGO, V46, P660, DOI 10.1001/archneur.1989.00520420080026; GOWLAND C, 1993, STROKE, V24, P58, DOI 10.1161/01.STR.24.1.58; Hajek VE, 1997, ARCH PHYS MED REHAB, V78, P1331, DOI 10.1016/S0003-9993(97)90306-3; HAJEK VE, 1989, ARCH PHYS MED REHAB, V70, P114; Iverson GL, 2007, APPL NEUROPSYCHOL, V14, P178, DOI 10.1080/09084280701508952; Kaplan E, 1978, BOSTON NAMING TEST; Kutlay S, 2007, DISABIL REHABIL, V29, P315, DOI 10.1080/09638280600756612; Lynch WJ, 2004, J HEAD TRAUMA REHAB, V19, P180, DOI 10.1097/00001199-200403000-00009; MAHONEY F I, 1965, Md State Med J, V14, P61; NELSON A, 1986, J NERV MENT DIS, V174, P73, DOI 10.1097/00005053-198602000-00002; RAVEN JA, 1947, COLORED PROGRESSIVE; Reitan RM., 1985, HALSTEAD REITAN NEUR; SEABY L, 1989, Physiotherapy Canada, V41, P264; SEGAL ME, 1993, PARAPLEGIA, V31, P622, DOI 10.1038/sc.1993.101; SmithKnapp K, 1996, BRAIN INJURY, V10, P651, DOI 10.1080/026990596124070; *STAT U NEW YORK B, 1997, GUID UN DAT SET MED; TEMPLE RO, 2006, ANN M NAT AC NEUR SA; Wechsler D., 1987, MANUAL WECHSLER ADUL; White T., 2003, NEUROPSYCHOLOGICAL A; ZGALJARDIC DJ, 2008, ANN M INT NEUR SOC W	29	27	29	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	1					45	50	PII 906993240	10.1080/02699050802590361			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	399FY	WOS:000262787000009	19096970	Green Accepted			2021-06-18	
J	Wehman, P; Gentry, T; West, M; Arango-Lasprilla, JC				Wehman, Paul; Gentry, Tony; West, Michael; Arango-Lasprilla, Juan Carlos			Community integration: Current issues in cognitive and vocational rehabilitation for individuals with ABI	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						acquired brain injury; alternative work arrangements; cognitive rehabilitation; community integration; employer supports; posttraumatic stress disorder; race/ethnicity; return-to-work; veterans; vocational rehabilitation	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; SPINAL-CORD-INJURY; FUNCTIONAL OUTCOMES; MINORITY STATUS; WORK; RETURN; ENVIRONMENT; PREVALENCE; EMPLOYMENT	In this article, we examine cognitive and vocational rehabilitation and the issues related to minority veterans with acquired brain injury (ABI). As more servicemembers are returning from conflict, ways to help them repair their lives, not only physically but also socially and economically, are increasingly needed. The challenges of ABI are multifactorial; that is, the problems are not just cognitive or emotional but spill over into community living and vocational issues. Individuals from racial/ethnic minority backgrounds often face even more difficulties. Therefore, we review the nature of cognitive and vocational rehabilitation and suggest areas for additional research.	[West, Michael] Virginia Commonwealth Univ, Rehabil Res & Training Ctr, Dept Phys Med & Rehabil, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Dept Occupat Therapy, Richmond, VA 23284 USA	West, M (corresponding author), Virginia Commonwealth Univ, Rehabil Res & Training Ctr, Dept Phys Med & Rehabil, POB 842011, Richmond, VA 23284 USA.	mdwest@vcu.edu			Virginia Commonwealth University Rehabilitation Research and Training Center [H133B040011]	This material was based on work partially supported by the Virginia Commonwealth University Rehabilitation Research and Training Center (grant H133B040011).	Arango-Lasprilla JC, 2008, ARCH PHYS MED REHAB, V89, P988, DOI 10.1016/j.apmr.2008.02.012; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Arango-Lasprilla JC, 2009, PM&R, V1, P41, DOI 10.1016/j.pmrj.2008.07.001; BERGMAN M, 2004, US CENSUS BUREA 0318; Buffington ALH, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199710000-00002; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CICERONE KD, 2007, BRAIN INJURY MED PRI, P765; *GENT HLTH CAR, REH WALLS; GIANUTSOS R, 1980, J REHABIL, V46, P36; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; HOOFT IH, 2005, THESIS KAROLINSKA U; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Johansson BB, 1996, EXP NEUROL, V139, P322, DOI 10.1006/exnr.1996.0106; Johansson BB, 1996, STROKE, V27, P324, DOI 10.1161/01.STR.27.2.324; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; Kowalske K, 2000, J HEAD TRAUMA REHAB, V15, P989, DOI 10.1097/00001199-200008000-00003; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Kulka R. A., 1990, TRAUMA VIETNAM WAR G; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Liepert J, 1998, NEUROSCI LETT, V250, P5, DOI 10.1016/S0304-3940(98)00386-3; Luria A. R., 1963, RESTORATION FUNCTION; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Olesen PJ, 2004, NAT NEUROSCI, V7, P75, DOI 10.1038/nn1165; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Ortega AN, 2000, AM J PSYCHIAT, V157, P615, DOI 10.1176/appi.ajp.157.4.615; Ponsford J, 2006, NEUROPSYCHOL REHABIL, V16, P315, DOI 10.1080/09602010500176534; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Rosenthal M, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P49, DOI 10.1037/10361-003; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; SBORDONNE RJ, 1998, ECOLOGICAL VALIDITY; SCHLENGER WE, 1992, J TRAUMA STRESS, V5, P333, DOI 10.1002/jts.2490050303; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Targett P, 2004, NEUROREHABILITATION, V19, P131; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; *US DEP DEF, 2005, 2005 DEM REP; *US DEP LAB, 2007, 071678 USDL DEP LAB; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; Wehman P, 1989, Brain Inj, V3, P397, DOI 10.3109/02699058909004563; Wehman P, 1994, Int J Rehabil Res, V17, P268, DOI 10.1097/00004356-199409000-00008; WEHMAN P, 1989, J HEAD TRAUMA REHAB, V4, P66; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011; Ylvisaker M., 1998, COLLABORATIVE BRAIN; 2007, NY TIMES        1025; 1998, NIH CONSENS STATEMEN, V16, P1	53	27	27	0	24	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	6					909	918		10.1682/JRRD.2008.08.0105			10	Rehabilitation	Rehabilitation	531BQ	WOS:000272638100019	20104411	Bronze			2021-06-18	
J	Wood, RLL; Williams, C; Kalyani, T				Wood, Rodger L. L.; Williams, Claire; Kalyani, Tania			The impact of alexithymia on somatization after traumatic brain injury	BRAIN INJURY			English	Article						TBI; TAS-20; somatization; affective disorder	ORGANIC ALEXITHYMIA; GENERAL-POPULATION; HEAD-INJURY; SCALE; DEPRESSION; SYMPTOMS; ASSOCIATION; DISORDERS; VALIDITY	Introduction: High rates of alexithymia have been reported following traumatic brain injury (TBI). Difficulty modulating emotional states has been shown to increase the risk of affective distress and the tendency to express this distress in the form of physical symptoms. The current study therefore examined relationships between alexithymia, affective distress and somatization in a TBI sample. Method: Eighty-three patients with TBI completed the Toronto Alexithymia Scale (TAS-20) and the Symptom Checklist (SCL-90-R). Results: Alexithymic individuals reported higher ratings of anxiety, low mood and somatic symptoms. Alexithymia accounted for a significant amount of variance in anxiety, depression and somatization ratings. Scores on sub-scale 1 of the TAS-20 (difficulty identifying feelings) made a significant unique contribution to explaining somatization ratings after controlling for the influence of anxiety and depression ratings. Conclusion: Alexithymia after TBI increases the risk of affective disturbance and somatization. It needs to be identified at an early stage to direct rehabilitation interventions and improve prospects for psychosocial outcome.	[Wood, Rodger L. L.; Williams, Claire; Kalyani, Tania] Swansea Univ, Dept Psychol, Sch Human Sci, Brain Injury Res Grp, Swansea SA2 8PP, W Glam, Wales	Wood, RLL (corresponding author), Swansea Univ, Dept Psychol, Sch Human Sci, Brain Injury Res Grp, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	r.l.wood@swansea.ac.uk		Williams, Claire/0000-0002-0791-744X			Bach M, 1996, PSYCHOSOMATICS, V37, P451, DOI 10.1016/S0033-3182(96)71533-5; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P33, DOI 10.1016/0022-3999(94)90006-X; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; Becerra R, 2002, BRAIN INJURY, V16, P633, DOI 10.1080/02699050110119817; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COX BJ, 1995, COMPR PSYCHIAT, V36, P195, DOI 10.1016/0010-440X(95)90081-6; De Gucht V, 2003, J PSYCHOSOM RES, V54, P425, DOI 10.1016/S0022-3999(02)00467-1; De Gucht V, 2004, PERS INDIV DIFFER, V36, P1655, DOI 10.1016/j.paid.2003.06.012; Derogatis LR, 1977, SCL90R J HOPK U SCH; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P62, DOI 10.1016/j.neuropsychologia.2005.04.011; Honkalampi K, 2000, J PSYCHOSOM RES, V48, P99, DOI 10.1016/S0022-3999(99)00083-5; Hoofien D, 2005, APPL NEUROPSYCHOL, V12, P30, DOI 10.1207/s15324826an1201_6; Jones MP, 2004, PSYCHOSOMATICS, V45, P508, DOI 10.1176/appi.psy.45.6.508; Koh KB, 2005, J CLIN PSYCHIAT, V66, P485, DOI 10.4088/JCP.v66n0411; Kooiman CG, 2002, J PSYCHOSOM RES, V53, P1083, DOI 10.1016/S0022-3999(02)00348-3; Koponen S, 2005, PSYCHOSOM MED, V67, P807, DOI 10.1097/01.psy.0000181278.92249.e5; Loas G, 2001, J PSYCHOSOM RES, V50, P255, DOI 10.1016/S0022-3999(01)00197-0; Luminet O, 2001, PSYCHOTHER PSYCHOSOM, V70, P254, DOI 10.1159/000056263; Mattila AK, 2008, PSYCHOSOM MED, V70, P716, DOI 10.1097/PSY.0b013e31816ffc39; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Nelson HE, 1982, NATL ADULT READING T; PARKER JDA, 1993, EUR J PERSONALITY, V7, P221, DOI 10.1002/per.2410070403; Parker JDA, 2001, PERS INDIV DIFFER, V30, P107, DOI 10.1016/S0191-8869(00)00014-3; PASINI A, 1992, COMPR PSYCHIAT, V33, P42, DOI 10.1016/0010-440X(92)90078-5; PENNEBAKER JW, 1995, CANADIAN PSYCHOL, V26, P82; Rasquin S, 2005, CEREBROVASC DIS, V19, P309, DOI 10.1159/000084499; Salminen JK, 1999, J PSYCHOSOM RES, V46, P75, DOI 10.1016/S0022-3999(98)00053-1; Taylor G. J., 1997, DISORDERS AFFECT REG; TAYLOR GJ, 1992, J PSYCHOSOM RES, V36, P417, DOI 10.1016/0022-3999(92)90002-J; TEASDALE G, 1974, LANCET, V2, P81; WILLIAMS C, J CLIN EXPT IN PRESS; Williams KR, 2001, BRAIN INJURY, V15, P349, DOI 10.1080/026990501750111319; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P471, DOI 10.1017/S1355617707070518	34	27	27	1	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	7-8					649	654	PII 912684062	10.1080/02699050902970786			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	462QL	WOS:000267370600009	19557568				2021-06-18	
J	Suchyta, MR; Beck, CJ; Key, CW; Jephson, A; Hopkins, RO				Suchyta, Mary R.; Beck, Callie J.; Key, Colin W.; Jephson, Al; Hopkins, Ramona O.			Substance dependence and psychiatric disorders are related to outcomes in a mixed ICU population	INTENSIVE CARE MEDICINE			English	Article						ICU; Critical care; Alcohol dependence; Drug dependence; Substance dependence; Psychiatric disorders	INTENSIVE-CARE-UNIT; TRAUMATIC BRAIN INJURY; ALCOHOL-USE DISORDERS; SEPTIC SHOCK; ADMISSIONS; ABUSE; PREVALENCE; SEVERITY; SEPSIS	Objective: Substance dependence disorders are common in hospitalized patients and are associated with poor recovery. We compared mortality and discharge disposition in critically ill patients with and without substance dependence and patients with and without psychiatric disorders. We also compared the prevalence of substance dependence and psychiatric disorders to population data. Methods: All medical records of shock trauma intensive care unit (ICU) patients (mixed medical and surgical) at LDS Hospital were reviewed for pre-critical illness alcohol dependence, drug dependence, and psychiatric disorders. Results: There were 742 critically ill patients of whom 54% were male, acute respiratory distress syndrome developed in 5.5% and hospital mortality was 21%. The mean acute physiology and chronic health evaluation II scores were 16.5 +/- 7.9, sequential organ failure assessment scores were 6.7 +/- 4.2, duration of mechanical ventilation was 5 +/- 6.2 days, ICU length of stay (LOS) was 7.3 +/- 10.1 days, hospital LOS was 12.3 +/- 12.9 days. Multivariable regression analyses found psychiatric disorders predicted higher hospital mortality (Odds ratio = 1.50), but was not statistically significant (p = 0.08); substance dependence predicted shorter hospital LOS (R-2 = 0.08, p = 0.01) after controlling for covariates. There was a higher prevalence of substance dependence compared to Utah (p < 0.001) and US population data (p < 0.001). The prevalence of psychiatric disorders was significantly lower in our patients compared to US population data (19 vs. 26%, p < 0.001). Our data suggest that substance dependence increases hospital LOS and that patients with drug or alcohol dependence are at higher risk for ICU admission compared to the general population.	[Suchyta, Mary R.; Jephson, Al; Hopkins, Ramona O.] Intermt Med Ctr, Dept Pulm & Crit Care Med, Murray, UT 84107 USA; [Suchyta, Mary R.; Jephson, Al; Hopkins, Ramona O.] LDS Hosp, Pulm & Crit Care Div, Dept Med, Salt Lake City, UT USA; [Beck, Callie J.; Key, Colin W.; Hopkins, Ramona O.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Hopkins, Ramona O.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA	Hopkins, RO (corresponding author), Intermt Med Ctr, Dept Pulm & Crit Care Med, 5121 S Cotttonwood St, Murray, UT 84107 USA.	mary.suchyta@imail.org; mona_hopkins@byu.edu					American Psychiatric Association, 1994, DIAGN STAT MENT DIS; BALDWIN WA, 1993, CHEST, V103, P21, DOI 10.1378/chest.103.1.21; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Chen CH, 2004, GEN HOSP PSYCHIAT, V26, P219, DOI 10.1016/j.genhosppsych.2004.01.001; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Marik P, 1996, ALCOHOL ALCOHOLISM, V31, P393; Moss M, 2003, CRIT CARE MED, V31, P869, DOI 10.1097/01.CCM.0000055389.64497.11; Mostafa SM, 2002, EUR J ANAESTH, V19, P193, DOI 10.1017/S0265021502000340; O'Brien JM, 2007, CRIT CARE MED, V35, P345, DOI 10.1097/01.CCM.0000254340.91644.B2; Roche AM, 2006, DRUG ALCOHOL DEPEN, V83, P1, DOI 10.1016/j.drugalcdep.2005.10.011; Smothers BA, 2004, ARCH INTERN MED, V164, P749, DOI 10.1001/archinte.164.7.749; SUCHYTA MR, 2006, P AM THORAC SOC, V3, pA737; Uusaro A, 2005, ACTA ANAESTH SCAND, V49, P1236, DOI 10.1111/j.1399-6576.2005.00839.x; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; WRIGHT D, 2005, NCDUH SERIES, V26; WRIGHT D, 2005, DHHS PUBLICATION; Yeatman Richard, 2005, Australas Psychiatry, V13, P124, DOI 10.1111/j.1440-1665.2005.02174.x	19	27	28	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	DEC	2008	34	12					2264	2267		10.1007/s00134-008-1263-9			4	Critical Care Medicine	General & Internal Medicine	374SA	WOS:000261062800020	18802686				2021-06-18	
J	Kuppermann, N				Kuppermann, Nathan			Pediatric head trauma: the evidence regarding indications for emergent neuroimaging	PEDIATRIC RADIOLOGY			English	Article; Proceedings Paper	4th ALARA Conference on Imaging Safety and Quality for Children in the Emergency Setting	FEB 23-24, 2008	Orlando, FL			Traumatic brain injury; Blunt head trauma; Pediatric trauma; Radiation exposure	COMPUTED-TOMOGRAPHY; INTRACRANIAL INJURY; YOUNG-CHILDREN; DECISION RULE; CANCER RISKS; PREDICT; CONSCIOUSNESS; MANAGEMENT; INFANTS; HISTORY	Traumatic brain injury (TBI) is a leading cause of childhood death and disability worldwide. In the United States, childhood head trauma results in approximately 3,000 deaths, 50,000 hospitalizations, and 650,000 emergency department (ED) visits annually. Children presenting to the ED with seemingly minor head trauma account for approximately one-half of children with documented TBIs. Despite the frequency and importance of childhood minor head trauma, there exists no highly accurate., reliable and validated clinical scoring system or prediction rule for assessing risk of TBI among those with minor head trauma. At the same time, use of CT scanning in these children in recent years has increased substantially. The major benefit of CT scanning is early identification (and treatment) of TBIs that might otherwise be missed and result in increased risk of morbidity and mortality. Unnecessary CT imaging, however, exposes the child needlessly to the risk of radiation-induced malignancies. What constitutes appropriate criteria for obtaining CT scans in children after minor blunt head trauma remains controversial. Current evidence to guide clinicians in this regard is limited; however, large studies performed in multi-center research networks have recently been conducted. These studies should provide the foundation of	[Kuppermann, Nathan] UC Davis Med Ctr, Dept Emergency Med, Sacramento, CA 95817 USA; [Kuppermann, Nathan] Univ Calif Davis, Davis Sch Med, Dept Emergency Med & Pediat, Davis, CA 95616 USA	Kuppermann, N (corresponding author), UC Davis Med Ctr, Dept Emergency Med, 2315 Stockton Blvd,PSSB Suite 2100, Sacramento, CA 95817 USA.	nkuppermann@ucdavis.edu					Aitken ME, 1998, ARCH PEDIAT ADOL MED, V152, P1176; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; *CDCP NAT CTR HLTH, 2000, NAT HOSP AMB MED 13; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; Dayan PS, 2007, ACAD EMERG MED, V14, P978, DOI 10.1197/j.aem.2007.06.033; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Gerein RB, 2006, ACAD EMERG MED, V13, P653, DOI 10.1197/j.aem.2005.12.025; Greenes DS, 1997, ANN EMERG MED, V30, P253, DOI 10.1016/S0196-0644(97)70158-6; Greenes DS, 2001, PEDIATR EMERG CARE, V17, P88, DOI 10.1097/00006565-200104000-00002; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Hall EJ, 2002, PEDIATR RADIOL, V32, P700, DOI 10.1007/S00247-002-0774-8; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Hettler J, 2003, PEDIATRICS, V111, P602, DOI 10.1542/peds.111.3.602; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; National Center for Injury Prevention and Control, 2002, TRAUM BRAIN INJ US A; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Palchak MJ, 2004, PEDIATRICS, V113, pE507, DOI 10.1542/peds.113.6.e507; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983	29	27	27	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0301-0449	1432-1998		PEDIATR RADIOL	Pediatr. Radiol.	NOV	2008	38			4			S670	S674		10.1007/s00247-008-0996-5			5	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	403FK	WOS:000263068300010	18810402				2021-06-18	
J	Bonatti, E; Zamarian, L; Wagner, M; Benke, T; Hollosi, P; Strubreither, W; Delazer, M				Bonatti, Elisabeth; Zamarian, Laura; Wagner, Michaela; Benke, Thomas; Hollosi, Pia; Strubreither, Wilhelm; Delazer, Margarete			Making decisions and advising decisions in traumatic brain injury	COGNITIVE AND BEHAVIORAL NEUROLOGY			English	Article						decision-making; risk; ambiguity; executive functions; TBI	ORBITAL PREFRONTAL CORTEX; SOMATIC MARKER HYPOTHESIS; IOWA GAMBLING TASK; HEAD-INJURY; ADVANTAGEOUS DECISIONS; ORBITOFRONTAL CORTEX; COGNITIVE ESTIMATION; MAKING PROCESSES; PERFORMANCE; RISK	Objective and Background: Decision under ambiguity and decision under risk are fundamental in every-day life. Methods: We investigated these 2 types of decision in traumatic brain injury (TBI) patients through the Iowa Gambling Task (IGT), the Probability-Associated Gambling (PAG) task, and a Counsel version of the PAG task. Although in the IGT rules for gain and losses are implicit and probability information is missing, in the PAG task and the counsel task rules are explicit and probabilities are well-defined. Results: In the IGT, TBI patients selected more disadvantageously than healthy controls and failed to develop,in advantageous strategy over time. Patients also made less advantageous choices than controls in the PAG task and the counsel task. Compared with controls, TBI patients gambled more frequently with low probabilities and less frequently With high probabilities. Overall, participants decided more advantageously in the counsel task, which does not provide feedback. than in the PAG task. Importantly, our results indicate that TBI patients' performance oil all decision tasks correlated with executive functions. Conclusions: Our study shows that TBI patients have difficulties in decision under risk and decision Under ambiguity. Difficulties may be attributed to deficient learning from feedback and to reduced risk estimation. but not to impulsive risk taking behavior.	[Bonatti, Elisabeth; Zamarian, Laura; Benke, Thomas; Delazer, Margarete] Innsbruck Med Univ, Dept Clin Neurol, A-6020 Innsbruck, Austria; [Wagner, Michaela] Innsbruck Med Univ, Dept Radiol, A-6020 Innsbruck, Austria; [Hollosi, Pia; Strubreither, Wilhelm] Austrian Workers Compensat Board, Rehabil Ctr Haring, Bad Haring, Austria	Bonatti, E (corresponding author), Innsbruck Med Univ, Dept Clin Neurol, Anichstr 35, A-6020 Innsbruck, Austria.	Elisabeth.Bonatti@i-med.ac.at	Zamarian, Laura/J-9575-2018	Zamarian, Laura/0000-0002-1640-4179; Delazer, Margarete/0000-0001-6482-4445			ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; [Anonymous], 2002, TESTBATTERIE AUFMERK; Aschenbrenner S, 2000, REGENSBURGER WORTFLU; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Bechara A, 2005, TRENDS COGN SCI, V9, P159, DOI 10.1016/j.tics.2005.02.002; Bechara A, 1998, J NEUROSCI, V18, P428; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; Bolla KI, 2004, CEREB CORTEX, V14, P1226, DOI 10.1093/cercor/bhh083; BRAND M, 2008, J NEUROPSYC IN PRESS; Brand M., 2002, TEST ZUM KOGNITIVEN; Brand M, 2007, J CLIN EXP NEUROPSYC, V29, P86, DOI 10.1080/13803390500507196; Brand M, 2006, NEURAL NETWORKS, V19, P1266, DOI 10.1016/j.neunet.2006.03.001; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; Damasio H., 1995, HUMAN BRAIN ANATOMY; Denburg NL, 2007, ANN NY ACAD SCI, V1121, P480, DOI 10.1196/annals.1401.031; Denburg NL, 2005, NEUROPSYCHOLOGIA, V43, P1099, DOI 10.1016/j.neuropsychologia.2004.09.012; Denburg NL, 2001, BRAIN COGNITION, V47, P156; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; Dunn BD, 2006, NEUROSCI BIOBEHAV R, V30, P239, DOI 10.1016/j.neubiorev.2005.07.001; *ENJOIMESOFT, 2002, PLAN COMP PROGR; Fein G, 2007, J INT NEUROPSYCH SOC, V13, P480, DOI 10.1017/S135561770707052X; FLOWERS KA, 1985, J NEUROL NEUROSUR PS, V48, P517, DOI 10.1136/jnnp.48.6.517; Fox AM, 2000, CLIN NEUROPHYSIOL, V111, P1045, DOI 10.1016/S1388-2457(00)00257-1; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Fukui H, 2005, NEUROIMAGE, V24, P253, DOI 10.1016/j.neuroimage.2004.08.028; Garcia-Molina A, 2007, NEUROLOGIA, V22, P206; Harting C., 2000, WMS R WECHSLER GEDAC; Helmstaedter C., 2001, VERBALER LERNUND MER; Hsu M, 2005, SCIENCE, V310, P1680, DOI 10.1126/science.1115327; JACKSON M, 1986, CORTEX, V22, P611, DOI 10.1016/S0010-9452(86)80020-X; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P615, DOI 10.1017/S1355617707070762; LEHRL S, 1991, MANUAL ZUM MWT B; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; LEZAK MD, 1998, NEUROPSYCHOLOGICAL A; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Overman WH, 2004, BRAIN COGNITION, V55, P134, DOI 10.1016/s0278-2626(03)00279-3; Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; Salmond CH, 2005, J NEUROTRAUM, V22, P613, DOI 10.1089/neu.2005.22.613; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; SHALLICE T, 1978, CORTEX, V14, P294, DOI 10.1016/S0010-9452(78)80055-0; Shiv B, 2005, COGNITIVE BRAIN RES, V23, P85, DOI 10.1016/j.cogbrainres.2005.01.006; Silverberg ND, 2007, J INT NEUROPSYCH SOC, V13, P898, DOI 10.1017/S1355617707071135; Sinz H, 2008, NEUROPSYCHOLOGIA, V46, P2043, DOI 10.1016/j.neuropsychologia.2008.02.002; Smith G. J., 2002, MEASURING GAMBLING P; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Trepel C, 2005, COGNITIVE BRAIN RES, V23, P34, DOI 10.1016/j.cogbrainres.2005.01.016; Wade DT, 1992, MEASUREMENT NEUROLOG; Wiederkehr S, 2005, REV NEUROL-FRANCE, V161, P201, DOI 10.1016/S0035-3787(05)85023-4; Yacubian J, 2007, NEUROIMAGE, V38, P557, DOI 10.1016/j.neuroimage.2007.08.007; Yody BB, 2000, J HEAD TRAUMA REHAB, V15, P1041, DOI 10.1097/00001199-200008000-00006; ZAMARIAN L, 2008, NEUROPSYCHO IN PRESS	59	27	28	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1543-3633			COGN BEHAV NEUROL	Cogn. Behav. Neurol.	SEP	2008	21	3					164	175		10.1097/WNN.0b013e318184e688			12	Behavioral Sciences; Clinical Neurology	Behavioral Sciences; Neurosciences & Neurology	354UL	WOS:000259664400007	18797259				2021-06-18	
J	Constantinidou, F; Thomas, RD; Robinson, L				Constantinidou, Fofi; Thomas, Robin D.; Robinson, Lacy			Benefits of categorization training in patients with traumatic brain injury during post-acute rehabilitation: Additional evidence from a randomized controlled trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; categorization; cognitive rehabilitation; effectiveness; efficacy	COGNITIVE REHABILITATION; POSTACUTE REHABILITATION; PARKINSONS-DISEASE; CATEGORY; SYSTEMS; SIMILARITY; DEFICITS	Background: Preliminary research with the Categorization Program (CP) indicated that this therapeutic modality is beneficial in improving cognitive abilities in survivors of moderate-to-severe traumatic brain injury (TBI). This study provides additional evidence for the use of the CP in postacute TBI cognitive rehabilitation. Methods: Twenty-one participants in the experimental group received the CP training, and 14 participants in the control group received the conventional treatment used at their rehabilitation center. Following neuropsychological testing, participants began their therapy program. Results: There was no significant difference in the baseline performance of the 2 TBI groups on any of the measures. CP-dependent measures correlated significantly with several neuropsychological tests. Both groups improved in their neuropsychological test performance and on functional outcomes tests. However, subjects in the experimental group improved on more tests than participants in the control group. Posttest performance of subjects in the TBI control group was significantly lower on the CP Test I and CP Test 2 as compared with the experimental group. Furthermore, the performance of participants in the CP group unproved across the 3 probe tasks demonstrating generalizability to new tasks; the performance of participants in the control group did not improve. Conclusions: The CP is an effective therapy method to reduce categorization impairment and improve cognitive performance of survivors of TBI who ire enrolled in postacute rehabilitation. This study contributes to the growing body of evidence supporting cognitive rehabilitation efforts after TBI.	[Constantinidou, Fofi] Univ Cyprus, Dept Psychol, CY-16789 Nicosia, Cyprus; [Constantinidou, Fofi] Miami Univ, Dept Speech Pathol & Audiol, Oxford, OH 45056 USA; [Thomas, Robin D.] Miami Univ, Dept Psychol, Oxford, OH 45056 USA; [Robinson, Lacy] Genesis Healthcare Syst, Zanesville, OH USA	Constantinidou, F (corresponding author), Univ Cyprus, Dept Psychol, 75 Kallipolcos,POB 20537, CY-16789 Nicosia, Cyprus.	fofic@ucy.ac.cy		Constantinidou, Fofi/0000-0002-7928-8363	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R15HD044554A01A1] Funding Source: Medline		Adamovich B. B., 1992, SCALES COGNITIVE ABI; ADAMOVICH BB, 1985, COGNITIVE REHABILITA; Allison P, 2002, SAGE U PAPERS SERIES; American Psychiatric Association, 1994, DSM 4 DIAGN STAT MAN; Ashby F Gregory, 2004, Behav Cogn Neurosci Rev, V3, P101, DOI 10.1177/1534582304270782; Ashby FG, 1998, PSYCHOL REV, V105, P442, DOI 10.1037/0033-295X.105.3.442; Ashby FG, 1999, PSYCHON B REV, V6, P363, DOI 10.3758/BF03210826; Ashby FG, 2003, NEUROPSYCHOLOGY, V17, P115, DOI 10.1037/0894-4105.17.1.115; Ashby FG, 2002, MEM COGNITION, V30, P666, DOI 10.3758/BF03196423; Beck A. T., 1996, BECK DEPRESSION INVE; Benton AL, 1978, MULTILINGUAL APHASIA; Bracy O. L., 1986, COGN REHABIL, V4, P11; Cahn DA, 1998, ARCH CLIN NEUROPSYCH, V13, P575, DOI 10.1016/S0887-6177(98)00024-9; Caramazza A, 1998, J COGNITIVE NEUROSCI, V10, P1, DOI 10.1162/089892998563752; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Coelho CA, 1996, J SPEECH HEAR RES, V39, pS5, DOI 10.1044/jshr.3905.s5; Cohen J., 2003, APPL MULTIPLE CORREL; Constantinidou F, 2005, J HEAD TRAUMA REHAB, V20, P143, DOI 10.1097/00001199-200503000-00003; CONSTANTINIDOU F, 2001, CATEGORIZATION PROGR; Constantinidou F., 2004, TRAUMATIC BRAIN INJU, P337; Cree GS, 2003, J EXP PSYCHOL GEN, V132, P163, DOI 10.1037/0096-3445.132.2.163; De Filippis N. A., 1998, BOOKLET CATEGORY TES; DeCaro MS, 2008, COGNITION, V107, P284, DOI 10.1016/j.cognition.2007.07.001; Delis DC, 2000, CALIFORNIA VERBAL LE; Erickson MA, 1998, J EXP PSYCHOL GEN, V127, P107, DOI 10.1037/0096-3445.127.2.107; FARAH MJ, 1991, J EXP PSYCHOL GEN, V120, P339, DOI 10.1037/0096-3445.120.4.339; GENTILINI M, 1989, MILD HEAD INJURY, P163; Goodglass H., 2000, BOSTON DIAGNOSTIC AP; Grant DA., 1981, WISCONSIN CARD SORTI; Hagen C., 1972, REHABILITATION HEAD; Humphreys GW, 1999, PSYCHOL RES-PSYCH FO, V62, P118, DOI 10.1007/s004260050046; Humphreys GW, 2001, BEHAV BRAIN SCI, V24, P453, DOI 10.1017/S0140525X01004150; *INT C HARM, 1998, ICH TRIP GUID STAT P; Joseph JE, 2001, COGN AFFECT BEHAV NE, V1, P119, DOI 10.3758/CABN.1.2.119; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Levin H. S., 1979, GALVESTON ORIENTATIO; LEVIN HS, 1992, SCAND J REHABIL MED, P14; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Little RJA, 1987, STAT ANAL MISSING DA; Luria A. R., 1963, RESTORATION FUNCTION; Maddox WT, 2003, J EXP PSYCHOL LEARN, V29, P650, DOI 10.1037/0278-7393.29.4.650; Maddox WT, 2004, BEHAV PROCESS, V66, P309, DOI 10.1016/j.beproc.2004.03.011; Maddox WT, 2001, J INT NEUROPSYCH SOC, V7, P710, DOI 10.1017/S1355617701766076; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Myers JM., 1995, REY COMPLEX FIGURE T; NOSOFSKY RM, 1986, J EXP PSYCHOL GEN, V115, P39, DOI 10.1037/0096-3445.115.1.39; Smith A., 1973, SYMBOL DIGIT MODALIT; Task Force on Promotion and Dissemination of Psychological Procedures, 1995, CLIN PSYCHOL, V48, P13; WECHLER D, 1999, WECHSLER MEMORY SCAL; Wechsler D., 2011, WECHLSER ABBREVIATED; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; WOODCOCK RW, 2001, W JOHNSON TESTS COGN; Zeno S. M, 1995, ED WORD FREQUENCY GU; ISHIHARA TEST COLOR	60	27	29	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2008	23	5					312	328		10.1097/01.HTR.0000336844.99079.2c			17	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	357GN	WOS:000259834400006	18815508				2021-06-18	
J	Awad, H; Suntres, Z; Heijmans, J; Smeak, D; Bergdall-Costell, V; Christofi, FL; Magro, C; Oglesbee, M				Awad, Hamdy; Suntres, Zacharias; Heijmans, John; Smeak, Daniel; Bergdall-Costell, Valerie; Christofi, Fievos L.; Magro, Cynthia; Oglesbee, Michael			Intracellular and extracellular expression of the major inducible 70kDa heat shock protein in experimental ischemia-reperfusion injury of the spinal cord	EXPERIMENTAL NEUROLOGY			English	Article						spinal cord; ischemia-reperfusion injury; heat shock protein 70	WHOLE-BODY HYPERTHERMIA; TRAUMATIC BRAIN-INJURY; STRESS-RESPONSE; OXIDATIVE STRESS; IN-VITRO; DIABETIC-KETOACIDOSIS; HSP72 INDUCTION; MESSENGER-RNA; BLOOD-VOLUME; GLIAL-CELLS	Inflammatory responses exacerbate ischemia-reperfusion (IR) injury of spinal Cord, although understanding of mediators is incomplete. The major inducible 70kDa heat shock protein (hsp70) is induced by ischemia and extracellular hsp70 (e-hsp70) can modulate inflammatory responses, but there is no published information regarding e-hsp70 levels in the cerebrospinal fluid (CSF) or serum as part of any neurological disease state save trauma. The present work addresses this deficiency by examining e-hsp70 in serum and CSF of dogs in an experimental model of spinal cord IR injury. IR injury of spinal cord caused hind limb paraplegia within 2-3 h that was correlated to lumbosacral poliomalacia with T cell infiltrates at 3 d post-ischemia. In this context, we showed a 5.2-fold elevation of e-hsp70 in CSF that was induced by ischemia and was sustained for the following 3 d observation interval. Plasma e-hsp70 levels were unaffected by IR injury, indicating e-hsp70 release from within the central nervous system. A putative Source of this e-hsp70 was ependymal cells in the ischemic penumbra, based upon elevated i-hsp70 levels detected within these cells. Results warrant further investigation of e-hsp70's potential to modulate spinal cord IR injury. (C) 2008 Elsevier Inc. All rights reserved.	[Oglesbee, Michael] Ohio State Univ, Dept Vet Biosci, Coll Vet Med, Columbus, OH 43212 USA; [Awad, Hamdy; Christofi, Fievos L.] Ohio State Univ, Dept Anesthesiol, Coll Med & Publ Hlth, Columbus, OH 43212 USA; [Magro, Cynthia] Ohio State Univ, Dept Pathol, Coll Med & Publ Hlth, Columbus, OH 43212 USA; [Suntres, Zacharias] Lakehead Univ, No Ontario Sch Med, Thunder Bay, ON P7B 5E1, Canada; [Heijmans, John] Maastricht Univ, Univ Hosp Maastricht, Maastricht, Netherlands; [Smeak, Daniel] Ohio State Univ, Dept Vet Clin Sci, Coll Vet Med, Columbus, OH 43212 USA; [Bergdall-Costell, Valerie] Ohio State Univ, Univ Lab Anim Resources, Columbus, OH 43212 USA	Oglesbee, M (corresponding author), Ohio State Univ, Dept Vet Biosci, Coll Vet Med, 1925 Coffey Rd, Columbus, OH 43212 USA.						ARTRU AA, 1987, J CEREBR BLOOD F MET, V7, P471, DOI 10.1038/jcbfm.1987.90; Asea A, 2005, EXERC IMMUNOL REV, V11, P34; Asea A, 2000, NAT MED, V6, P435; *AVMA PAN EUTH AM, 2001, 2000 REP AVMA PAN EU; Batulan Z, 2003, J NEUROSCI, V23, P5789; BERGUER R, 1992, J VASC SURG, V15, P62, DOI 10.1016/0741-5214(92)70014-C; Boros P, 2006, AM J TRANSPLANT, V6, P652, DOI 10.1111/j.1600-6143.2005.01228.x; Calabrese V, 2001, INT J TISSUE REACT, V23, P127; Cizkova D, 2004, EXP NEUROL, V185, P97, DOI 10.1016/j.expneurol.2003.09.020; Da Rocha AB, 2005, J NEUROTRAUM, V22, P966, DOI 10.1089/neu.2005.22.966; DICESARE S, 1992, IMMUNOLOGY, V76, P341; Diehl KA, 2000, AM J HEMATOL, V64, P262, DOI 10.1002/1096-8652(200008)64:4<262::AID-AJH5>3.0.CO;2-D; Febbraio MA, 2002, J PHYSIOL-LONDON, V544, P957, DOI 10.1113/jphysiol.2002.025148; FINSTERER U, 1973, PFLUG ARCH EUR J PHY, V341, P63, DOI 10.1007/BF00587330; Foster JA, 1997, MOL BRAIN RES, V45, P207, DOI 10.1016/S0169-328X(96)00138-6; Gifondorwa DJ, 2007, J NEUROSCI, V27, P13173, DOI 10.1523/JNEUROSCI.4057-07.2007; Guzhova I, 2001, BRAIN RES, V914, P66, DOI 10.1016/S0006-8993(01)02774-3; Hoffman WH, 2007, EXP MOL PATHOL, V83, P65, DOI 10.1016/j.yexmp.2007.01.006; Ishikawa M, 2004, J CEREBR BLOOD F MET, V24, P907, DOI 10.1097/01.WCB.0000132690.96836.7F; Johnson JD, 2006, J LEUKOCYTE BIOL, V79, P425, DOI 10.1189/jlb.0905523; Kearns RJ, 1999, CLIN EXP IMMUNOL, V116, P188; Kelly S, 2001, J CEREBR BLOOD F MET, V21, P972, DOI 10.1097/00004647-200108000-00010; Kim BS, 2005, TRANSPLANTATION, V79, P1370, DOI 10.1097/01.TP.0000158355.83327.62; Lai YC, 2004, J NEUROTRAUM, V21, P229, DOI 10.1089/089771504322972022; LI Y, 1992, ACTA NEUROPATHOL, V84, P94, DOI 10.1007/BF00427221; Manzerra P, 1996, EXP CELL RES, V229, P35, DOI 10.1006/excr.1996.0341; Marcuccilli CJ, 1996, J NEUROSCI, V16, P478; MARINI AM, 1990, J NEUROCHEM, V54, P1509, DOI 10.1111/j.1471-4159.1990.tb01198.x; Marini M, 1996, INT J RADIAT BIOL, V70, P337, DOI 10.1080/095530096145076; Matsuyama K, 1997, ANN THORAC SURG, V63, P1315, DOI 10.1016/S0003-4975(97)00104-5; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; MULTHOFF G, 1995, INT J CANCER, V61, P272, DOI 10.1002/ijc.2910610222; Offner H, 2006, J CEREBR BLOOD F MET, V26, P654, DOI 10.1038/sj.jcbfm.9600217; Oglesbee MJ, 1999, VET IMMUNOL IMMUNOP, V69, P185, DOI 10.1016/S0165-2427(99)00053-7; Oglesbee MJ, 2005, CLIN BIOCHEM, V38, P900, DOI 10.1016/j.clinbiochem.2005.05.011; Oglesbee MJ, 2002, NEUROSCIENCE, V113, P55, DOI 10.1016/S0306-4522(02)00159-8; Orendacova J, 2004, CELL MOL NEUROBIOL, V24, P477, DOI 10.1023/B:CEMN.0000022775.67975.ed; Peppelenbosch N, 2005, J VASC SURG, V42, P608, DOI 10.1016/j.jvs.2005.06.023; Pockley AG, 2003, HYPERTENSION, V42, P235, DOI 10.1161/01.HYP.0000086522.13672.23; POTTS DG, 1969, AMER J ROENTGENOL RA, V105, P756, DOI 10.2214/ajr.105.4.756; Rajdev S, 2000, ANN NEUROL, V47, P782, DOI 10.1002/1531-8249(200006)47:6<782::AID-ANA11>3.0.CO;2-3; Robinson MB, 2008, DEV NEUROBIOL, V68, P1, DOI 10.1002/dneu.20550; Sakurai M, 1996, NEUROSCI LETT, V217, P113, DOI 10.1016/S0304-3940(96)13079-2; Sakurai M, 1998, J VASC SURG, V27, P720, DOI 10.1016/S0741-5214(98)70238-1; SATOH J, 1994, BRAIN RES, V653, P243, DOI 10.1016/0006-8993(94)90396-4; Steensberg A, 2006, BRAIN BEHAV IMMUN, V20, P585, DOI 10.1016/j.bbi.2006.03.002; Su FH, 2005, SHOCK, V23, P516, DOI 10.1097/01.shk.000161390.46688.da; SUNTRES ZE, 1991, J PHARMACOL EXP THER, V258, P797; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; van Eden W, 2005, NAT REV IMMUNOL, V5, P318, DOI 10.1038/nri1593; Walsh RC, 2001, CELL STRESS CHAPERON, V6, P386, DOI 10.1379/1466-1268(2001)006<0386:EISHIH>2.0.CO;2; Watanabe N, 1998, INT J HYPERTHER, V14, P309, DOI 10.3109/02656739809018235; Weinstein PR, 2004, STROKE, V35, P2666, DOI 10.1161/01.STR.0000144052.10644.ed; Yenari MA, 1998, ANN NEUROL, V44, P584, DOI 10.1002/ana.410440403; Yilmaz G, 2006, CIRCULATION, V113, P2105, DOI 10.1161/CIRCULATIONAHA.105.593046	55	27	28	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	AUG	2008	212	2					275	284		10.1016/j.expneurol.2008.03.024			10	Neurosciences	Neurosciences & Neurology	334WL	WOS:000258252000009	18511046				2021-06-18	
J	Hoane, MR; Pierce, JL; Kaufman, NA; Beare, JE				Hoane, Michael R.; Pierce, Jeremy L.; Kaufman, Nicholas A.; Beare, Jason E.			Variation in chronic nicotinamide treatment after traumatic brain injury can alter components of functional recovery independent of histological damage	OXIDATIVE MEDICINE AND CELLULAR LONGEVITY			English	Article						traumatic brain injury; therapy; window of opportunity; vitamin; recovery of function	FOCAL CEREBRAL-ISCHEMIA; HEAD-INJURY; DYSFUNCTION; TRIALS	Previously, we have shown that the window of opportunity for nicotinamide (NAM) therapy (50 mg/kg) following cortical contusion injuries (CCI) extended to 4-8 hrs post-CCI when administered over a six day post-CCI interval. The purpose of the present study was to determine if a more chronic NAM treatment protocol administered following CCI would extend the current window of opportunity for effective treatment onset. Groups of rats received either unilateral CCI's or sham procedures. Initiation of NAM therapy (50 mg/kg, ip) began at either 15-min, 4-hrs, 8-hrs or 24-hrs post-injury. All groups received daily systemic treatments for 12 days post-CCI at 24 hr intervals. Behavioral assessments were conducted for 28 days post injury and included: vibrissae forelimb placing, bilateral tactile adhesive removal, forelimb asymmetry task and locomotor placing testing. Behavioral analysis on both the tactile removal and locomotor placing tests showed that all NAM-treated groups facilitated recovery of function compared to saline treatment. However, on the vibrissae-forelimb placing and forelimb asymmetry tests only the 4-hr and 8-hr NAM-treated groups were significantly different from the saline-treated group. The lesion analysis showed that treatment with NAM out to 8 hrs post-CCI significantly reduced the size of the injury cavity. The window of opportunity for NAM treatment is task-dependent and in some situations can extend to 24 hrs post-CCI. These results suggest that a long term treatment regimen of 50 mg/kg of NAM starting at the clinically relevant time points may prove efficacious in human TBI.	[Hoane, Michael R.; Pierce, Jeremy L.; Kaufman, Nicholas A.; Beare, Jason E.] So Illinois Univ, Restorat Neurosci Lab, Dept Psychol, Ctr Integrat Res Cognit & Neural Sci, Carbondale, IL 62901 USA	Hoane, MR (corresponding author), So Illinois Univ, Restorat Neurosci Lab, Dept Psychol, Ctr Integrat Res Cognit & Neural Sci, Life Sci 2,MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu	Beare, Jason E/D-2870-2016	Beare, Jason E/0000-0003-3988-1223; Hoane, Michael/0000-0001-7779-2657	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER	The authors would like to thank Jordan Yearwood for his assistance on this project. Research supported by NINDS (NS045647-03) to M.R.H.	Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; CHOI DW, 1987, J NEUROSCI, V7, P369; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; HOANE MR, 2008, NEUROSCIENC IN PRESS; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; HORSMAN MR, 1993, RADIOTHER ONCOL, V27, P131, DOI 10.1016/0167-8140(93)90133-S; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Maiese K, 2003, TRENDS PHARMACOL SCI, V24, P228, DOI 10.1016/S0165-6147(03)00078-6; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; PAXINOS G, 2005, RAT BRAIN STEREMAXIC; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; Sadanaga-Akiyoshi F, 2003, NEUROCHEM RES, V28, P1227, DOI 10.1023/A:1024236614015; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sakakibara Y, 2000, NEUROSCI LETT, V281, P111, DOI 10.1016/S0304-3940(00)00854-5; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Tam D, 2005, ANN NY ACAD SCI, V1053, P258, DOI 10.1196/annals.1344.023; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Woodlee M.T., 2005, BEHAV LAB RAT HDB TE, P129; Yang J, 2002, MINI-REV MED CHEM, V2, P125, DOI 10.2174/1389557024605483; Yang J, 2002, NEUROSCI LETT, V333, P91, DOI 10.1016/S0304-3940(02)01005-4	34	27	27	0	8	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1942-0900	1942-0994		OXID MED CELL LONGEV	Oxidative Med. Cell. Longev.	JUL-AUG	2008	1	1					46	53		10.4161/oxim.1.1.6694			8	Cell Biology	Cell Biology	520QO	WOS:000271861500006	19794908	Green Published, Other Gold			2021-06-18	
J	Bansal, V; Fortlage, D; Lee, J; Kuncir, E; Potenza, B; Coimbra, R				Bansal, Vishal; Fortlage, Dale; Lee, Jeanne; Kuncir, Eric; Potenza, Bruce; Coimbra, Raul			A 21-year history of all-terrain vehicle injuries: has anything changed?	AMERICAN JOURNAL OF SURGERY			English	Article						all-terrain vehicles (ATVs); trauma; helmet use; injury prevention	MOTORCYCLE HELMETS; TRAUMA CENTERS; REGULATIONS; PATTERNS; IMPACT	BACKGROUND: All-terrain vehicle (ATV)-related injuries have increased. The purpose of this study was to determine if the increase in injuries correlates with the expiration of government mandates. METHODS: ATV-injured patients admitted to a level I trauma center were reviewed over the years 1985-1999 and 2000-2005. Several demographic variables and injuries sustained were analyzed. RESULTS: There were a total of 433 injuries, which increased from 164 between 1985 and 1999, to 269 between 2000 and 2005. By comparing the time periods we observed a decrease in closed-head injury (53.6% vs 27.5%; P <.001), spinal cord injury (11.6% vs 5.2%; P <.05), and soft-tissue injury (62.8% vs 45.3%; P <.01), but an increase in long-bone fractures (18.9% vs 33.0%; P <.05). No differences were observed in other injuries. CONCLUSIONS: The number of patients sustaining ATV-related injuries has increased and correlates with the expiration of government mandates. Even though ATVs remain dangerous, injury prevention strategies such as helmet laws may be having a positive impact. (C) 2008 Elsevier Inc. All rights reserved.	[Bansal, Vishal; Fortlage, Dale; Lee, Jeanne; Kuncir, Eric; Potenza, Bruce; Coimbra, Raul] Univ Calif San Diego, Dept Surg, Div Trauma Burns & Crit Care, San Diego, CA 92103 USA	Coimbra, R (corresponding author), Univ Calif San Diego, Dept Surg, Div Trauma Burns & Crit Care, San Diego, CA 92103 USA.	rcoimbra@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851			BACHULIS BL, 1988, AM J SURG, V155, P708, DOI 10.1016/S0002-9610(88)80151-X; Eastridge BJ, 2006, J TRAUMA, V60, P978, DOI 10.1097/01.ta.0000215582.86115.01; Fonseca AH, 2005, AM SURGEON, V71, P937; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; Moore MJ, 1997, INT REV LAW ECON, V17, P379, DOI 10.1016/S0144-8188(97)00022-7; Mullins RJ, 2007, J AM COLL SURGEONS, V204, P216, DOI 10.1016/j.jamcollsurg.2006.10.025; ORSAY EM, 1994, ANN EMERG MED, V23, P802, DOI 10.1016/S0196-0644(94)70317-5; Rodgers GB, 1999, ACCIDENT ANAL PREV, V31, P409, DOI 10.1016/S0001-4575(98)00080-3; Rodgers GB, 2001, AM J EPIDEMIOL, V153, P1112, DOI 10.1093/aje/153.11.1112; RODGERS GB, 1993, ACCIDENT ANAL PREV, V25, P335, DOI 10.1016/0001-4575(93)90027-T; Scutchfield SB, 2003, CLIN ORTHOP RELAT R, P61, DOI 10.1097/01.blo.0000060441.40507.3e; Smith LM, 2005, J TRAUMA, V58, P783, DOI 10.1097/01.TA.0000158252.11002.6E; Upperman JS, 2003, J PEDIATR SURG, V38, P1284, DOI 10.1016/S0022-3468(03)00383-X; US Consumer Product Safety Commission, 1998, FED REGISTER, V63, P48199; 2005, FED REG, V67	15	27	27	0	0	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610			AM J SURG	Am. J. Surg.	JUN	2008	195	6					789	792		10.1016/j.amjsurg.2007.05.049			4	Surgery	Surgery	311FI	WOS:000256585700011	18367134				2021-06-18	
J	Desilva, TM; Billiards, SS; Borenstein, NS; Trachtenberg, FL; Volpe, JJ; Kinney, HC; Rosenberg, PA				Desilva, Tara M.; Billiards, Saraid S.; Borenstein, Natalia S.; Trachtenberg, Felicia L.; Volpe, Joseph J.; Kinney, Hannah C.; Rosenberg, Paul A.			Glutamate transporter EAAT2 expression is up-regulated in reactive astrocytes in human periventricular leukomalacia	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						cerebral palsy; reactive astrocytes; inflammation; microglia; oligodendrocytes; prematurity	TRAUMATIC BRAIN-INJURY; CEREBRAL WHITE-MATTER; EXCITATORY AMINO-ACIDS; RAT-BRAIN; NITRIC-OXIDE; VESICULAR RELEASE; NMDA RECEPTORS; MICE LACKING; SPINAL-CORD; IN-VITRO	The major neuropathological correlate of cerebral palsy in premature infants is periventricular leukomalacia (PVL), a disorder of the immature cerebral white matter. Cerebral ischemia leading to excitotoxicity is thought to be important in the pathogenesis of this disorder, implying a critical role for glutamate transporters, the major determinants of extracellular glutamate concentration. Previously, we found that EAAT2 expression is limited primarily to premyelinating oligodendrocytes early in development and is rarely observed in astrocytes until >40 weeks. In this study, we analyzed the expression of EAAT2 in cerebral white matter from PVL and control cases. Western blot analysis suggested an up-regulation of EAAT2 in PVL compared, with control cases. Single- and double-label immunocytochemistry showed a significantly higher percentage of EAAT2-immunopositive astrocytes in PVL (51.8% +/- 5.6%) compared with control white matter (21.4% +/- 5.6%; P = 0.004). Macrophages in the necrotic foci in PVL also expressed EAAT2. Premyelinating oligodendrocytes in both PVL and control cases expressed EAAT2, without qualitative difference in expression. The previously unrecognized up-regulation of EAAT2 in reactive astrocytes and its presence in macrophages in PVL reported here may reflect a response to either hypoxic-ischemic injury or inflammation.	[Desilva, Tara M.; Volpe, Joseph J.; Rosenberg, Paul A.] Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; [Desilva, Tara M.; Billiards, Saraid S.; Borenstein, Natalia S.; Volpe, Joseph J.; Kinney, Hannah C.; Rosenberg, Paul A.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Billiards, Saraid S.; Borenstein, Natalia S.; Kinney, Hannah C.] Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; [Trachtenberg, Felicia L.] New England Res Inst, Watertown, MA 02472 USA	Rosenberg, PA (corresponding author), Childrens Hosp, Dept Neurol, Enders Res Bldg,Enders 349,300 Longwood Ave, Boston, MA 02115 USA.	paul.rosenberg@childrens.harvard.edu		Rosenberg, Paul/0000-0002-5185-1118	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD18655, P30 HD018655] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS07473, NS40753, R01 NS040753, NS41883, T32NS07473, P01 NS038475-10, P01 NS038475, T32 NS007473, P01 NS038475-09, R01 NS041883, NS38475] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041883, R01NS040753, T32NS007473, P01NS038475] Funding Source: NIH RePORTER		ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Back SA, 2007, J CEREBR BLOOD F MET, V27, P334, DOI 10.1038/sj.jcbfm.9600344; BANKER BQ, 1962, ARCH NEUROL-CHICAGO, V7, P386, DOI 10.1001/archneur.1962.04210050022004; Beschorner R, 2007, HISTOL HISTOPATHOL, V22, P515, DOI 10.14670/HH-22.515; Billiards SS, 2006, J COMP NEUROL, V497, P199, DOI 10.1002/cne.20991; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Chen WZ, 2004, J NEUROSCI, V24, P1136, DOI 10.1523/JNEUROSCI.1586-03.2004; Chen WZ, 2002, J NEUROSCI, V22, P2142, DOI 10.1523/JNEUROSCI.22-06-02142.2002; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Choi JW, 2004, J NEUROSCI RES, V75, P722, DOI 10.1002/jnr.20009; Chretien F, 2004, J NEUROPATH EXP NEUR, V63, P1058, DOI 10.1093/jnen/63.10.1058; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Deng WB, 2003, P NATL ACAD SCI USA, V100, P6801, DOI 10.1073/pnas.1136624100; Desilva TM, 2007, J COMP NEUROL, V501, P879, DOI 10.1002/cne.21289; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fern R, 2000, J NEUROSCI, V20, P34, DOI 10.1523/JNEUROSCI.20-01-00034.2000; Folkerth RD, 2004, BRAIN PATHOL, V14, P265; Follett PL, 2000, J NEUROSCI, V20, P9235; Fukamachi S, 2001, DEV BRAIN RES, V132, P131, DOI 10.1016/S0165-3806(01)00303-0; Furuta A, 1997, J NEUROSCI, V17, P8363; Furuta A, 2005, DEV BRAIN RES, V155, P155, DOI 10.1016/j.devbrainres.2005.01.005; Gibson CL, 2005, GLIA, V50, P417, DOI 10.1002/glia.20143; Halliwell B, 1998, FREE RADICAL BIO MED, P246; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Haynes RL, 2003, J NEUROPATH EXP NEUR, V62, P441, DOI 10.1093/jnen/62.5.441; Itoh T, 2002, J NEUROCHEM, V81, P390, DOI 10.1046/j.1471-4159.2002.00866.x; Karadottir R, 2005, NATURE, V438, P1162, DOI 10.1038/nature04302; Lehre KP, 1998, J NEUROSCI, V18, P8751, DOI 10.1523/jneurosci.18-21-08751.1998; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Maragakis NJ, 2004, GLIA, V45, P133, DOI 10.1002/glia.10310; Martin LJ, 1997, ANN NEUROL, V42, P335, DOI 10.1002/ana.410420310; Matute C, 1997, P NATL ACAD SCI USA, V94, P8830, DOI 10.1073/pnas.94.16.8830; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Micu I, 2006, NATURE, V439, P988, DOI 10.1038/nature04474; Mitani A, 2003, J NEUROSCI, V23, P7176, DOI 10.1523/JNEUROSCI.23-18-07176.2003; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nakajima K, 2001, NEUROSCI LETT, V307, P171, DOI 10.1016/S0304-3940(01)01943-7; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Noh KM, 2000, J NEUROSCI, V20; Northington FJ, 1999, J NEUROBIOL, V39, P515; O'Shea RD, 2006, NEUROCHEM INT, V48, P604, DOI 10.1016/j.neuint.2005.12.028; Persson M, 2005, GLIA, V51, P111, DOI 10.1002/glia.20191; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Porcheray F, 2006, AM J PHYSIOL-CELL PH, V291, pC618, DOI 10.1152/ajpcell.00021.2006; Pow DV, 2004, DEV BRAIN RES, V153, P1, DOI 10.1016/j.devbrainres.2004.06.019; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, NEUROCHEM RES, V26, P497; Rimaniol AC, 2000, J IMMUNOL, V164, P5430, DOI 10.4049/jimmunol.164.10.5430; ROSENBERG PA, 1992, J NEUROSCI, V12, P56; Rosenberg PA, 2003, J NEUROSCI RES, V71, P237, DOI 10.1002/jnr.10472; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; ROTHSTEIN JD, 1994, BIOCHEM PHARMACOL, V34, P73; Salter MG, 2005, NATURE, V438, P1167, DOI 10.1038/nature04301; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Tolias CM, 1999, NEUROSCI LETT, V273, P57, DOI 10.1016/S0304-3940(99)00630-8; Tolias CM, 1999, FREE RADICAL BIO MED, V26, P99, DOI 10.1016/S0891-5849(98)00146-4; TORP R, 1995, EXP BRAIN RES, V103, P51; Van Landeghem FKH, 2006, J NEUROTRAUM, V23, P1518, DOI 10.1089/neu.2006.23.1518; Volpe J, 2001, NEUROLOGY NEWBORN, P296; Yamada K, 1998, J NEUROSCI, V18, P5706; Yi JH, 2005, GLIA, V49, P121, DOI 10.1002/glia.20099; Yoshioka A, 1996, J NEUROSCI RES, V46, P164; Zaheer A, 2004, NEUROCHEM RES, V29, P1473, DOI 10.1023/B:NERE.0000029558.82943.00; Ziskin JL, 2007, NAT NEUROSCI, V10, P321, DOI 10.1038/nn1854	71	27	30	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	MAY 10	2008	508	2					238	248		10.1002/cne.21667			11	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	288CK	WOS:000254963600003	18314905	Green Accepted			2021-06-18	
J	Moseley, AM; Hassett, LM; Leung, J; Clare, JS; Herbert, RD; Harvey, LA				Moseley, Anne M.; Hassett, Leanne M.; Leung, Joan; Clare, Jennifer S.; Herbert, Robert D.; Harvey, Lisa A.			Serial casting versus positioning for the treatment of elbow contractures in adults with traumatic brain injury: a randomized controlled trial	CLINICAL REHABILITATION			English	Article							SPINAL-CORD INJURIES; PASSIVE ANKLE DORSIFLEXION; SOLEUS MUSCLE; STRESS-RELAXATION; CONNECTIVE-TISSUE; PROLONGED STRETCH; LOW-LOAD; IMMOBILIZATION; MOBILITY; RABBIT	Objective: To compare the effects of serial casting with positioning for 1 hour per day for the treatment of elbow flexion contracture in adults with traumatic brain injury. Design: Pragmatic randomized controlled trial with concealed allocation and assessor blinding. Setting: Four brain injury rehabilitation units. Subjects: Twenty-six adults with elbow flexion contracture after traumatic brain injury participating in multidisciplinary inpatient rehabilitation. Interventions: Subjects were randomized to receive either serial casting or positioning for two weeks. In the subsequent four weeks subjects could be positioned for up to 1 hour/day. Main measures: Torque-controlled passive elbow extension was measured at baseline, post-intervention (two weeks), post-intervention plus one day, and at follow-up (four weeks post-intervention). Results: All 26 subjects completed the study. Post-intervention, serial casting reduced contracture by an average of 22 degrees (95% confidence interval (0) 13 to 31; P < 0.001) compared with the positioning group. One day later this effect had decreased to 11 degrees (95% CI 0 to 21 degrees; P = 0.052). The effect had almost completely disappeared at the four-week follow-up (mean 2 degrees, 95% CI - 13 to 17; P = 0.782). Conclusions: Serial casting induces transient increases in range of motion. These effects are not maintained.	[Moseley, Anne M.] Univ Sydney, Ctr Evidence Based Physiotherapy, Lidcombe, NSW 1825, Australia; [Hassett, Leanne M.] Liverpool Hlth Serv, Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Leung, Joan] Royal Rehabil Ctr, Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Clare, Jennifer S.] Westmead Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Herbert, Robert D.] Univ Sydney, Ctr Evidence Based Physiotherapy, Sydney, NSW 2006, Australia; [Harvey, Lisa A.] Univ Sydney, Fac Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia	Moseley, AM (corresponding author), Univ Sydney, Ctr Evidence Based Physiotherapy, POB 170, Lidcombe, NSW 1825, Australia.	a.moseley@usyd.edu.au	Leung, Joan/AAC-8623-2019; Herbert, Rob/E-9442-2012	Leung, Joan/0000-0003-0888-558X; Herbert, Rob/0000-0003-4188-9195; Hassett, Leanne/0000-0002-3546-1822; Harvey, Lisa A/0000-0002-4365-0236			AKESON WH, 1974, CONNECT TISSUE RES, V2, P315, DOI 10.3109/03008207409152261; Ben M, 2005, AUST J PHYSIOTHER, V51, P251, DOI 10.1016/S0004-9514(05)70006-4; Beurskens AJHM, 1996, PAIN, V65, P71, DOI 10.1016/0304-3959(95)00149-2; BOHANNON RW, 1985, PHYS THER, V65, P1676, DOI 10.1093/ptj/65.11.1676; Boyd RN, 2001, UPPER MOTOR NEURONE SYNDROME AND SPASTICITY, P96; CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X; Dean CM, 1997, STROKE, V28, P722, DOI 10.1161/01.STR.28.4.722; Desrosiers J, 1993, CAN J OCCUP THER, V60, P9, DOI DOI 10.1177/000841749306000104; Duong B, 2001, CLIN BIOMECH, V16, P601, DOI 10.1016/S0268-0033(01)00043-2; Folpp H, 2006, AUST J PHYSIOTHER, V52, P45, DOI 10.1016/S0004-9514(06)70061-7; Glanz M, 1996, ARCH PHYS MED REHAB, V77, P549, DOI 10.1016/S0003-9993(96)90293-2; Glasgow Celeste, 2003, J Hand Ther, V16, P207, DOI 10.1016/S0894-1130(03)00036-X; Harvey LA, 2000, ARCH PHYS MED REHAB, V81, P1340, DOI 10.1053/apmr.2000.9168; Harvey LA, 2003, AUST J PHYSIOTHER, V49, P176, DOI 10.1016/S0004-9514(14)60237-3; Harvey Lisa, 2002, Physiother Res Int, V7, P1, DOI 10.1002/pri.236; HERBERT RD, 1993, J ORTHOPAED RES, V11, P358, DOI 10.1002/jor.1100110307; Herbert RD, 1997, EUR J APPL PHYSIOL, V76, P472, DOI 10.1007/s004210050277; HERBERT RD, 2005, SCI BASED REHABILITA, P107; HILL J, 1994, AM J OCCUP THER, V48, P219, DOI 10.5014/ajot.48.3.219; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; HOWELL DC, RESAMPLING PROCEDURE; Hyde SA, 2000, NEUROMUSCULAR DISORD, V10, P257, DOI 10.1016/S0960-8966(99)00135-2; LIGHT KE, 1984, PHYS THER, V64, P330, DOI 10.1093/ptj/64.3.330; Magnusson SP, 1996, SCAND J MED SCI SPOR, V6, P323; Mortenson PA, 2003, PHYS THER, V83, P648, DOI 10.1093/ptj/83.7.648; Moseley A, 1991, Aust J Physiother, V37, P175, DOI 10.1016/S0004-9514(14)60540-7; Moseley AM, 1997, PHYS THER, V77, P240, DOI 10.1093/ptj/77.3.240; Moseley AM, 2005, ARCH PHYS MED REHAB, V86, P1118, DOI 10.1016/j.apmr.2004.11.017; Moseley AM, 2003, J HEAD TRAUMA REHAB, V18, P526, DOI 10.1097/00001199-200311000-00006; STEFFEN TM, 1995, PHYS THER, V75, P886, DOI 10.1093/ptj/75.10.886; TABARY JC, 1972, J PHYSIOL-LONDON, V224, P231, DOI 10.1113/jphysiol.1972.sp009891; WILLIAMS PE, 1984, J ANAT, V138, P343; YARKONY GM, 1987, CLIN ORTHOP RELAT R, P93	33	27	27	0	5	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	MAY	2008	22	5					406	417		10.1177/0269215507083795			12	Rehabilitation	Rehabilitation	304TN	WOS:000256132100003	18441037				2021-06-18	
J	Hahnel, S; Stippich, C; Weber, I; Darm, H; Schill, T; Jost, J; Friedmann, B; Heiland, S; Blatow, M; Meyding-Lamade, U				Hahnel, S.; Stippich, C.; Weber, I.; Darm, H.; Schill, T.; Jost, J.; Friedmann, B.; Heiland, S.; Blatow, M.; Meyding-Lamade, U.			Prevalence of cerebral microhemorrhages in amateur boxers as detected by 3T MR imaging	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; PROFESSIONAL BOXERS; DIFFUSION; DAMAGE	BACKGROUND AND PURPOSE: The evidence for traumatic brain injury in amateur boxers is controversial. Hypothetically, sudden acceleration of the head due to the impact of the blow during the boxing fight might result in diffuse axonal injury or contusion. We wanted to determine whether cerebral microhemorrhages occur more often in amateur boxers than in nonboxers. MATERIALS AND METHODS: In 42 male, classical amateur boxers and in 37 healthy, nonboxing male volunteers we performed cranial MR imaging at 3T. The study protocol included a transverse dual spin-echo MR imaging sequence, a 3D sagittal magnetization-prepared rapid acquisition of gradient echo sequence, a coronal T2*-weighted sequence, and an axial time-of-flight MR angiography sequence. MR imaging data were made anonymous before 2 neuroradiologists independently evaluated the images. In addition, the following risk factors were assessed: total numbers of fights and knockouts, weight division, and duration of boxing. We compared the group proportions of microhemorrhages with Fisher test of exact probability. RESULTS: There was a statistically higher prevalence of cerebral microhemorrhages in the group of boxers (3 of 42; 7.1 %) than in nonboxing persons (0 of 37; 0%). This difference was not statistically significant, however (P = .2479; Fisher exact test). CONCLUSION: Although we detected more microhemorrhages in amateur boxers than in nonboxing persons, this difference did not prove to be significant.	[Hahnel, S.; Stippich, C.; Weber, I.; Schill, T.; Heiland, S.; Blatow, M.] Univ Heidelberg, Med Ctr, Dept Neurol, Div Neuroradiol, D-69120 Heidelberg, Germany; [Friedmann, B.] Univ Heidelberg, Med Ctr, Med Clin & Policlin, Dept Sports Med, Heidelberg, Germany; [Darm, H.; Meyding-Lamade, U.] Univ Heidelberg, Med Ctr, Dept Neurol, Div Neurol, Heidelberg, Germany; [Jost, J.] Natl Training Ctr Boxing, Heidelberg, Germany	Hahnel, S (corresponding author), Univ Heidelberg, Med Ctr, Dept Neurol, Div Neuroradiol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	Stefan-Haehnel@med.uni-heidelberg.de		Blatow, Maria/0000-0003-3371-5697			Blennow K., 2005, LAKARTIDINGEN, V102, P2472; Blennow Kaj, 2005, Lakartidningen, V102, P2468; HOLZGRAEFE M, 1992, INT J SPORTS MED, V13, P616, DOI 10.1055/s-2007-1024576; Livingston EH, 2005, J SURG RES, V126, P149, DOI 10.1016/j.jss.2004.12.013; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497; Moseley IF, 2000, NEURORADIOLOGY, V42, P1, DOI 10.1007/s002340050001; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Tokuda T, 1993, No To Shinkei, V45, P1109; Unterharnscheidt F, 1995, Rev Neurol, V23, P661; Unterharnscheidt F, 1995, Rev Neurol, V23, P1027; Zhang L, 2006, AM J NEURORADIOL, V27, P2000; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	12	27	28	0	3	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	FEB	2008	29	2					388	391		10.3174/ajnr.A0799			4	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	265FT	WOS:000253345200041	17974608	Green Published, Other Gold			2021-06-18	
J	Mailer, BJ; McLeod, TCV; Bay, RC				Mailer, Brandy J.; McLeod, Tamara C. Valovich; Bay, R. Curtis			Healthy youth are reliable in reporting symptoms on a graded symptom scale	JOURNAL OF SPORT REHABILITATION			English	Article						concussion; patient-oriented evidence; POEM; outcomes	CONCUSSION ASSESSMENT; VALIDITY; MANAGEMENT; OUTCOMES; TOOLS	Context: Clinicians often rely on the self-report symptoms of patients in making clinical decisions; hence it is important that these scales be reliable. Objective: To determine the test-retest reliability of healthy youth in completing a graded symptom scale (GSS), modified from the Head Injury Scale Self-Report Concussion Symptoms Scale (HIS). Design: Repeated-measures. Setting: Middle school classroom. Patients or Other Participants: 126 middle school students. Intervention: A survey consisting of a demographic and life events questionnaire and a GSS asking about symptom severity and duration. Main Outcomes Measures: Score for each symptom on the severity and duration scale and a total symptom score (TSS) and the total number of symptoms endorsed (TSE) from the severity scale. Responses on a life events questionnaire were also recorded. Results: We found excellent reliability for TSS (ICC = .93) and TSE (ICC = .88) for the severity scale. We found moderate to excellent reliability on the individual symptoms of both the severity (ICC = .65-.89) and duration (ICC = .56-.96) scales. Conclusions: Healthy youth can reliably self-report symptoms using a GSS. This patient-oriented outcome measure should be incorporated into more investigations in this age group.	[Mailer, Brandy J.] Linfield Coll, McMinnville, OR USA; [McLeod, Tamara C. Valovich] AT Still Univ, Arizona Sch Hlth Sci, Athlet Training Program, Mesa, AZ USA; [Bay, R. Curtis] AT Still Univ, Dept Interdisciplinary Hlth Sci, Mesa, AZ USA	Mailer, BJ (corresponding author), Linfield Coll, McMinnville, OR USA.		McLeod, Tamara/AAU-9435-2020	Bay, Ralph/0000-0003-3525-9269			Barr WB, 2001, J ATHL TRAINING, V36, P297; Binkley JM, 1999, PHYS THER, V79, P371; Clancy CM, 1998, SCIENCE, V282, P245, DOI 10.1126/science.282.5387.245; Ebell MH, 2004, J AM BOARD FAM PRACT, V17, P59, DOI 10.3122/jabfm.17.1.59; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; FLANDRY F, 1991, AM J SPORT MED, V19, P112, DOI 10.1177/036354659101900204; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hudak PL, 1996, AM J IND MED, V29, P602, DOI 10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L; Hurwitz SR, 2000, J BONE JOINT SURG AM, V82A, P888, DOI 10.2106/00004623-200006000-00020; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Piland SG, 2003, J ATHL TRAINING, V38, P104; Portney L., 2015, FDN CLIN RES APPL PR, V3rd ed.; Randolph C, 2005, J ATHL TRAINING, V40, P139; Rhee H., 2005, PEDIAT NURS, V31, P350; Rhee Hyekyun, 2005, Pediatr Nurs, V31, P314; Sackett DL, 1995, J ROY SOC MED, V88, P620; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; SNYDER AR, IN PRESS J ATHL TRAI; Snyder AR, 2007, ATHL TRAIN ED J, V2, P1; Swiontkowski MF, 1999, J BONE JOINT SURG AM, V81A, P1245, DOI 10.2106/00004623-199909000-00006; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wilson JK, 2000, J SPORT REHABIL, V9, P304, DOI 10.1123/jsr.9.4.304	27	27	27	0	3	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1056-6716	1543-3072		J SPORT REHABIL	J. Sport Rehabil.	FEB	2008	17	1					11	20		10.1123/jsr.17.1.11			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	261SG	WOS:000253099700002	18270383				2021-06-18	
J	Sachse, KT; Jackson, EK; Wisniewski, SR; Gillespie, DG; Puccio, AM; Clark, RSB; Dixon, CE; Kochanek, PM				Sachse, Kathleen T.; Jackson, Edwin K.; Wisniewski, Stephen R.; Gillespie, Delbert G.; Puccio, Ava M.; Clark, Robert S. B.; Dixon, C. Edward; Kochanek, Patrick M.			Increases in cerebrospinal fluid caffeine concentration are associated with favorable outcome after severe traumatic brain injury in humans	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						adenosine; alcohol; coffee; head injury; head trauma; theobromine	ADENOSINE RECEPTOR AGONISTS; CEREBRAL-BLOOD-FLOW; PARKINSONS-DISEASE; HEAD-INJURY; RISK; MICE; CONSUMPTION; ANTAGONISTS; ETHANOL; PLASMA	Caffeine, the most widely consumed psychoactive drug and a weak adenosine receptor antagonist, can be neuroprotective or neurotoxic depending on the experimental model or neurologic disorder. However, its contribution to pathophysiology and outcome in traumatic brain injury (TBI) in humans is undefined. We assessed serial cerebrospinal fluid (CSF) concentrations of caffeine and its metabolites (theobromine, paraxanthine, and theophylline) by high-pressure liquid chromatography/ultraviolet in 97 ventricular CSF samples from an established bank, from 30 adults with severe TBI. We prospectively selected a threshold caffeine level of >= 1 mu mol/L (194 ng/mL) as clinically significant. Demographics, Glasgow Coma Scale (GCS) score, admission blood alcohol level, and 6-month dichotomized Glasgow Outcome Scale (GOS) score were assessed. Mean time from injury to initial CSF sampling was 10.77 +/- 3.13 h. On initial sampling, caffeine was detected in 24 of 30 patients, and the threshold was achieved in 9 patients. Favorable GOS was seen more often in patients with CSF caffeine concentration >= versus < the threshold (55.6 versus 11.8%, P = 0.028). Gender, age, admission CGS score, admission blood alcohol level, and admission systolic arterial blood pressure did not differ between patients with CSF caffeine concentration >= versus < the threshold. Increases in CSF concentrations of the caffeine metabolites theobromine and paraxanthine were also associated with favorable outcome (P = 0.018 and 0.056, respectively). Caffeine and its metabolites are commonly detected in CSF in patients with severe TBI and in an exploratory assessment are associated with favorable outcome. We speculate that caffeine may be neuroprotective by long-term upregulation of adenosine A1 receptors or acute inhibition of A2a receptors.	[Sachse, Kathleen T.; Clark, Robert S. B.; Dixon, C. Edward; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Sachse, Kathleen T.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15260 USA; [Jackson, Edwin K.; Gillespie, Delbert G.] Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15260 USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Sch Med, Dept Epidemiol & Publ Hlth, Pittsburgh, PA 15260 USA; [Puccio, Ava M.; Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Puccio, Ava M.; Clark, Robert S. B.; Dixon, C. Edward; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Jackson, Edwin/0000-0002-8101-6009; Wisniewski, Stephen/0000-0002-3877-9860	NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01 DK068575, DK68575] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38087, R01 NS038087, P50 NS030318, P01 NS030318, NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK068575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318, R01NS038087, P01NS030318] Funding Source: NIH RePORTER		Al Moutaery K, 2003, NEUROSURGERY, V53, P704, DOI 10.1227/01.NEU.0000079487.66013.6F; Arendash GW, 2006, NEUROSCIENCE, V142, P941, DOI 10.1016/j.neuroscience.2006.07.021; Ascherio A, 2001, ANN NEUROL, V50, P56, DOI 10.1002/ana.1052; Azam Sonish, 2003, Med Sci Monit, V9, pBR325; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; BOULENGER JP, 1983, LIFE SCI, V32, P1135, DOI 10.1016/0024-3205(83)90119-4; Cassada DC, 2002, J TRAUMA, V53, P225, DOI 10.1097/00005373-200208000-00005; Cheng P, 1999, J POROUS MEDIA, V2, P19, DOI 10.1615/JPorMedia.v2.i1.20; Clark RSB, 1997, NEUROSURGERY, V41, P1284, DOI 10.1097/00006123-199712000-00010; Conde SV, 2006, J NEUROCHEM, V98, P616, DOI 10.1111/j.1471-4159.2006.03912.x; *CTR SCI PUBL INT, 2007, NUTR ACT NEWSL; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/neu.2004.21.1573; Dassesse D, 1999, EUR J NEUROSCI, V11, P3101, DOI 10.1046/j.1460-9568.1999.00725.x; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Evans SM, 1999, J PHARMACOL EXP THER, V289, P285; FREDHOLM BB, 1982, ACTA PHYSIOL SCAND, V115, P283, DOI 10.1111/j.1748-1716.1982.tb07078.x; Frye RF, 1998, J LIQ CHROMATOGR R T, V21, P1161, DOI 10.1080/10826079808006591; George FR, 1993, EXP CLIN PSYCHOPHARM, V1, P7, DOI 10.1037/1064-1297.1.1-4.7; Huang ZL, 2005, NAT NEUROSCI, V8, P858, DOI 10.1038/nn1491; Jacobson KA, 1996, TRENDS PHARMACOL SCI, V17, P108, DOI 10.1016/0165-6147(96)10002-X; JOHANSSON B, 1993, N-S ARCH PHARMACOL, V347, P407, DOI 10.1007/BF00165391; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kochanek PM, 2005, J CEREBR BLOOD F MET, V25, P1596, DOI 10.1038/sj.jcbfm.9600154; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Phillis JW, 2001, NEUROL RES, V23, P183, DOI 10.1179/016164101101198316; Pignataro G, 2007, J CEREBR BLOOD F MET, V27, P1, DOI 10.1038/sj.jcbfm.9600334; Pugliese AM, 2006, BRIT J PHARMACOL, V147, P524, DOI 10.1038/sj.bjp.0706646; RAMKUMAR V, 1988, J CLIN INVEST, V82, P242, DOI 10.1172/JCI113577; Reece TB, 2004, J SURG RES, V121, P130, DOI 10.1016/j.jss.2004.04.006; Ribeiro JA, 2005, CNS NEUROL DISORD-DR, V4, P325, DOI 10.2174/1568007054546090; Robertson CL, 2001, CRIT CARE MED, V29, P2287, DOI 10.1097/00003246-200112000-00009; Ross GW, 2000, JAMA-J AM MED ASSOC, V283, P2674, DOI 10.1001/jama.283.20.2674; Schapira AHV, 2006, NAT REV DRUG DISCOV, V5, P845, DOI 10.1038/nrd2087; Shi D, 1999, CELL MOL NEUROBIOL, V19, P719, DOI 10.1023/A:1006901005925; SOTO J, 1994, THER DRUG MONIT, V16, P108, DOI 10.1097/00007691-199402000-00017; Strong R, 2000, NEUROPHARMACOLOGY, V39, P515, DOI 10.1016/S0028-3908(99)00156-2; SUTHERLAND GR, 1991, NEUROSCIENCE, V42, P171, DOI 10.1016/0306-4522(91)90157-J; Tan EK, 2003, J NEUROL SCI, V216, P163, DOI 10.1016/j.jns.2003.07.006; Tsutsui S, 2004, J NEUROSCI, V24, P1521, DOI 10.1523/JNEUROSCI.4271-03.2004; Varma MR, 2002, BRAIN RES, V951, P191, DOI 10.1016/S0006-8993(02)03161-X; Yu LQ, 2004, NAT MED, V10, P1081, DOI 10.1038/nm1103; 1996, J NEUROTRAUMA, V11, P643	43	27	28	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2008	28	2					395	401		10.1038/sj.jcbfm.9600539			7	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	255MS	WOS:000252662700017	17684518	Bronze, Green Accepted			2021-06-18	
J	Zhao, X; Rizzo, A; Malek, B; Fakhry, S; Watson, J				Zhao, Xueren; Rizzo, Anne; Malek, Bobby; Fakhry, Samir; Watson, Joseph			Basilar skull fracture: A risk factor for transverse/sigmoid venous sinus obstruction	JOURNAL OF NEUROTRAUMA			English	Article						basilar skull fracture; cerebral venous infarction; cerebral venous sinus thrombosis; CT angiogram; intracranial pressure; traumatic brain injury	SIGMOID SINUS; THROMBOSIS; DIAGNOSIS; ANGIOGRAPHY; INJURY	In trauma practice, basilar skull fracture is an extremely common finding while transverse/sigmoid venous sinus thrombosis is generally considered quite a rare complication. During evaluation of cervical computed tomography (CT) angiography after trauma, we identified five patients in just three months with unexpected transverse/sigmoid venous sinus obstruction ipsilateral to a basilar skull fracture. This number represented a surprisingly high percentage of our neurosurgical trauma consults for the study period (31%). Three of the five patients were found to have sinus thrombosis: two with right transverse/sigmoid sinus thrombosis experienced significant neurological deficits and prolonged hospital courses even with anti-coagulation therapy; one patient with a left transverse/sigmoid sinus thrombosis had a good outcome with anti-coagulation therapy. The other two of the five patients had outflow obstruction, likely from focal epidural bleeding and extrinsic compression: one patient with partial obstruction in the right transverse-siginoid junction, due to epidural bleeding, experienced a difficult recovery; one patient with a right sigmoid sinus obstruction presented and remained asymptomatic and experienced a benign hospital course. Two of the five patients had a posterior temporal hemorrhagic area ipsilateral to the affected sinus, suggesting that this finding may have represented hemorrhagic venous infarction rather than traumatic contusion. We propose that a basilar skull fracture in the region of temporal or occipital bone should be considered as a significant risk factor for the development of transverse/sigmoid venous sinus obstruction and may be an under-recognized and treatable cause of increased intracranial pressure. Failure to detect this complication may explain, in part, unexpected clinical outcomes.	[Zhao, Xueren; Malek, Bobby; Watson, Joseph] Inova Fairfax Hosp, Dept Neurosci, Reg Neurosurg Serv, Falls Church, VA USA; [Rizzo, Anne; Fakhry, Samir] Inova Fairfax Hosp, Dept Gen Surg, Trauma Serv, Falls Church, VA USA	Watson, J (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, Reg Neurosurg Serv, Inova Fairfax Campus,3300 Gallows Rd,IHVI 3rd Flo, Falls Church, VA 22042 USA.	joseph.watson@inova.com	Watson, Joe/AAP-2155-2020				Berne JD, 2004, J TRAUMA, V57, P11, DOI 10.1097/01.TA.0000135499.70048.C7; Biffl WL, 2000, ANN SURG, V231, P672, DOI 10.1097/00000658-200005000-00007; BJORNEBRINK J, 1976, ANGIOLOGY, V27, P688, DOI 10.1177/000331977602701203; Cothren CC, 2003, J TRAUMA, V55, P811, DOI 10.1097/01.TA.0000092700.92587.32; Eastman AL, 2006, J TRAUMA, V60, P925, DOI 10.1097/01.ta.0000197479.28714.62; Fink JN, 2002, STROKE, V33, P290, DOI 10.1161/hs0102.101016; Frey JL, 1999, STROKE, V30, P489, DOI 10.1161/01.STR.30.3.489; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; HADEISHI H, 1995, NEUROSURGERY, V36, P1220, DOI 10.1227/00006123-199506000-00028; HASSO AN, 1979, RADIOLOGY, V132, P375, DOI 10.1148/132.2.375; HERMAN JM, 1995, J NEUROSURG, V83, P539, DOI 10.3171/jns.1995.83.3.0539; Kim SY, 1997, AM J NEURORADIOL, V18, P639; Kuether TA, 1998, NEUROSURGERY, V42, P1163, DOI 10.1097/00006123-199805000-00129; MARQUARDT G, 2003, ACTA NEUROL SCAND, V10, P1046; MATSUDA M, 1982, SURG NEUROL, V18, P206, DOI 10.1016/0090-3019(82)90394-9; Quinones-Hinojosa A, 2004, J TRAUMA, V56, P201, DOI 10.1097/01.TA.0000032310.26731.C2; Stiefel D, 2000, EUR J PEDIATR SURG, V10, P41, DOI 10.1055/s-2008-1072321; TAHA JM, 1993, NEUROSURGERY, V32, P541, DOI 10.1227/00006123-199304000-00008; Takamura Yukio, 1996, Neurologia Medico-Chirurgica, V36, P650, DOI 10.2176/nmc.36.650; VOGL TJ, 1994, AM J ROENTGENOL, V162, P1191, DOI 10.2214/ajr.162.5.8166009; Yuen HW, 2005, ANN ACAD MED SINGAP, V34, P639	21	27	29	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2008	25	2					104	111		10.1089/neu.2007.0351			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	266RZ	WOS:000253456000003	18260793				2021-06-18	
J	Chen, G; Shi, J; Qi, M; Yin, H; Hang, C				Chen, G.; Shi, J.; Qi, M.; Yin, H.; Hang, C.			Glutamine decreases intestinal nuclear factor kappa B activity and pro-inflammatory cytokine expression after traumatic brain injury in rats	INFLAMMATION RESEARCH			English	Article						traumatic brain injury; intestine; nuclear factor kappa B; inflammation; glutamine	COLONIC EPITHELIAL-CELLS; NITRIC-OXIDE SYNTHASE; BACTERIAL TRANSLOCATION; INDUCED APOPTOSIS; MULTIPLE TRAUMA; GENE-EXPRESSION; TNF-ALPHA; HUMAN GUT; ACTIVATION; PERMEABILITY	Objective: To investigate whether glutamine supplementation modulates intestinal nuclear factor kappa B (NF-kappa B) activity and pro-inflammatory cytokine expression after traumatic brain injury (TBI) in rats. Materials and methods: Right parietal cortical contusion in male rats was made by the weight-dropping method. After trauma, the rats were randomly given chow alone or glutamine mixed chow for 5 d. Gut samples were extracted at 5 d postinjury. We measured NF-kappa B binding activity by electrophoretic mobility shift assay; NF-kappa B subunits p50 and p65 expression by immunohistochemistry; the concentrations of interleukin-1 beta, tumor necrosis factor-alpha and interleukin-6 by enzyme-linked immunosorbent assay; intestinal mucosal morphological changes by histopathological study and electron microscopy; and apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining. Results: Administration of glutamine following TBI could decrease NF-kappa B binding activity, NF-kappa B p65 protein expression and concentrations of pro-inflammatory cytokines in the gut. TBI-induced damage of gut structure was ameliorated after glutamine supplementation. Conclusion: The results of the present study suggest that the therapeutic benefit of post-TBI glutamine supplementation might be due to its inhibitory effects on intestinal NF-kappa B activation and pro-inflammatory cytokine expression.	[Chen, G.; Shi, J.; Qi, M.; Yin, H.; Hang, C.] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Peoples R China	Hang, C (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Peoples R China.	nju_neurosurgery@163.com	QI, Meng/F-2802-2012	Chen, Gang/0000-0002-0758-1907			Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bastian L, 2002, BRIT J NUTR, V87, pS133, DOI 10.1079/BJN2001466; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Coeffier M, 2003, CLIN NUTR, V22, P407, DOI 10.1016/S0261-5614(03)00040-2; Coeffier M, 2001, CYTOKINE, V13, P148, DOI 10.1006/cyto.2000.0813; deBlaauw I, 1997, GASTROENTEROLOGY, V112, P118, DOI 10.1016/S0016-5085(97)70226-9; Ellis RD, 1998, INFLAMM RES, V47, P440, DOI 10.1007/s000110050358; Erbil Y, 1999, HEPATO-GASTROENTEROL, V46, P2791; Evans ME, 2005, AM J PHYSIOL-GASTR L, V289, pG388, DOI 10.1152/ajpgi.00072.2005; Evans ME, 2003, J NUTR, V133, P3065; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FILLMANN H, IN PRESS TOXICOLOGY; Fiocchi C, 1997, AM J PHYSIOL-GASTR L, V273, pG769; Garcia-de-Lorenzo A, 2003, NUTRITION, V19, P805, DOI 10.1016/S0899-9007(03)00103-5; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Ha WY, 2006, INFLAMM RES, V55, P293, DOI 10.1007/s00011-006-0086-9; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hang CH, 2007, J SURG RES, V137, P53, DOI 10.1016/j.jss.2006.06.026; Hang CH, 2005, WORLD J GASTROENTERO, V11, P1149, DOI 10.3748/wjg.v11.i8.1149; Houdijk APJ, 1998, LANCET, V352, P772, DOI 10.1016/S0140-6736(98)02007-8; Huang Y, 2003, CYTOKINE, V22, P77, DOI 10.1016/S1043-4666(03)00115-7; Li N, 2004, AM J PHYSIOL-GASTR L, V286, pG914, DOI 10.1152/ajpgi.00493.2003; Margaritis VG, 2005, WORLD J SURG, V29, P1329, DOI 10.1007/s00268-005-7721-4; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Novak F, 2002, CRIT CARE MED, V30, P2022, DOI 10.1097/00003246-200209000-00011; Papaconstantinou HT, 2000, J GASTROINTEST SURG, V4, P416, DOI 10.1016/S1091-255X(00)80022-0; Paquette JC, 2005, J CELL PHYSIOL, V202, P912, DOI 10.1002/jcp.20194; Parikh AA, 1997, J SURG RES, V69, P139, DOI 10.1006/jsre.1997.5061; PARK PO, 1990, SURGERY, V107, P574; Paterson RL, 2000, CRIT CARE MED, V28, P1047, DOI 10.1097/00003246-200004000-00022; Pieper GM, 2004, INFLAMM RES, V53, P22, DOI 10.1007/s00011-003-1223-3; SCHRODER J, 1995, JPEN-PARENTER ENTER, V19, P502, DOI 10.1177/0148607195019006502; Suh GJ, 2003, NUTR RES, V23, P131, DOI 10.1016/S0271-5317(02)00479-7; Swank GM, 1996, WORLD J SURG, V20, P411, DOI 10.1007/s002689900065; VENTE JP, 1989, ANN SURG, V209, P57, DOI 10.1097/00000658-198901000-00009; Wischmeyer PE, 2003, NUTRITION, V19, P1, DOI 10.1016/S0899-9007(02)00839-0	40	27	33	0	1	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1023-3830	1420-908X		INFLAMM RES	Inflamm. Res.	JAN	2008	57	2					57	64		10.1007/s00011-007-7101-7			8	Cell Biology; Immunology	Cell Biology; Immunology	267NV	WOS:000253516600003	18288455				2021-06-18	
J	Coetzer, R				Coetzer, Rudi			Holistic neuro-rehabilitation in the community: Is identity a key issue?	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Identity; Brain injury; Psychotherapy; Holistic neuro-rehabilitation	TRAUMATIC BRAIN-INJURY; SELF-AWARENESS; COGNITIVE REHABILITATION; SUBJECTIVE EXPERIENCE; CLOSE RELATIVES; MODEL	Many people experience identity change after brain injury. Impaired self-awareness after acquired brain injury is also common and can, along with other factors, affect the identity change a person may experience. Holistic rehabilitation programmes attempt to address both cognitive and emotional difficulties and specifically problems of self-awareness after brain injury. Does identity change require longer-term rehabilitation interventions? This paper describes a community-based neuro-rehabilitation service that has incorporated some principles from more traditional holistic programmes with a view to providing long-term, low-intensity brain injury rehabilitation. Specific reference is made to problems of identity and how these may be addressed during long-term psychotherapeutic follow-up. The potential relevance of the total duration of rehabilitation input rather than simply the number of sessions when working with adjustment and identity change after brain injury in community settings is discussed. The service model is compared to more traditional holistic rehabilitation programmes. A case study and early outcome data are presented to illustrate some of these points and to provide more information about the nature of the programme.	[Coetzer, Rudi] Colwyn Bay Hosp, N Wales Brain Injury Serv, Conwy & Denbighshire NHS Trust, Colwyn Bay LL29 8AY, Wales; [Coetzer, Rudi] Bangor Univ, Bangor, Gwynedd, Wales	Coetzer, R (corresponding author), Colwyn Bay Hosp, N Wales Brain Injury Serv, Conwy & Denbighshire NHS Trust, Hesketh Rd, Colwyn Bay LL29 8AY, Wales.	Rudi.Coetzer@cd-tr.wales.nhs.uk		Coetzer, Rudi/0000-0003-4505-7230			Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; BATEMAN A, 2006, OL ZANGW CTR 10 ANN; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; *BRIT PSYCH SOC DI, 2005, CLIN NEUR REH SERV A; CAETANO C, 2000, INT HDB NEUROPSYCHOL, P259; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Coetzer B. R., 2003, J COGNITIVE REHABILI, V21, P4; Coetzer R, 2005, INT J REHABIL RES, V28, P361, DOI 10.1097/00004356-200512000-00010; Coetzer R, 2007, J HEAD TRAUMA REHAB, V22, P39, DOI 10.1097/00001199-200701000-00005; Department of Health, 2005, NAT SERV FRAM LONG T; Diller L, 2005, ARCH PHYS MED REHAB, V86, P1075, DOI 10.1016/j.apmr.2004.11.009; Erikson EH., 1963, CHILDHOOD SOC, V2nd Edn.; Farmer JE, 2003, J HEAD TRAUMA REHAB, V18, P116, DOI 10.1097/00001199-200303000-00003; Fleming JM, 2006, NEUROPSYCHOL REHABIL, V16, P474, DOI 10.1080/09602010500505518; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; Gracey F, 2007, NEUROPSYCHOL REHABIL, V17, P106, DOI 10.1080/09602010500505260; Hayes S, 2004, ACCEPTANCE COMMITMEN; Judd D. P., 1999, COUNS PSYCHOL, V14, P4; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Miller L., 1993, PSYCHOTHERAPY BRAIN; MORRIS SD, 2004, J COGN REHABIL, V22, P15; Myles SM, 2004, INT J PSYCHOL PSYCHO, V4, P487; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Ownsworth T, 2006, REHABIL PSYCHOL, V51, P50, DOI 10.1037/0090-5550.51.1.50; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; Pollack IW, 2005, TXB TRAUMATIC BRAIN, P641; Ponsford J, 2006, NEUROPSYCHOL REHABIL, V16, P315, DOI 10.1080/09602010500176534; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Prigatano G. P., 1997, NEUROPSYCHOL REHABIL, P301; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Sarajuuri JM, 2006, INT J PSYCHOL, V41, P362, DOI 10.1080/01650250500346103; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Svendsen HA, 2004, NEUROPSYCHOL REHABIL, V14, P495, DOI 10.1080/09602010343000318; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Trexler L, 2000, INT HDB NEUROPSYCHOL, P215; TREXLER LE, 2000, INT HDB NEUROPSYCHOL, P137; Williams WH, 1999, NEUROPSYCHOL REHABIL, V9, P421, DOI 10.1080/096020199389482; Wilson BA, 2005, J INT NEUROPSYCH SOC, V11, P488, DOI 10.1017/S1355617705050599; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020; Wilson BA, 2000, INT HDB NEUROPSYCHOL, P231; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876; Yeates G, 2007, NEUROPSYCHOL REHABIL, V17, P151, DOI 10.1080/09602010600696423	44	27	27	0	6	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2008	18	5-6					766	783		10.1080/09602010701860266			18	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	360PQ	WOS:000260070200003	18654932				2021-06-18	
J	Pfister, D; Strebel, SP; Steiner, LA				Pfister, D.; Strebel, S. P.; Steiner, L. A.			Effects of catecholamines on cerebral blood vessels in patients with traumatic brain injury	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article; Proceedings Paper	Brain Annual Meeting	MAY 09-12, 2007	Brescia, ITALY			brain injury; trauma; regional blood flow; brain; catecholamines	CORTICAL IMPACT INJURY; PERFUSION-PRESSURE AUGMENTATION; SEVERE HEAD-INJURY; OVINE MODEL; INDUCED HYPERTENSION; PROPOFOL INFUSION; EDEMA FORMATION; DOPAMINE; NOREPINEPHRINE; FLOW	Data on the cerebrovascular effects of catecholamines after head injury are difficult both to interpret and to compare. Diverse parameters with regard to brain trauma animal models, methods of determining the effects on the cerebral blood flow and metabolism and choice of end-points have been used. Many studies investigate the cerebrovascular effects of catecholamines over a range of cerebral perfusion pressures above the range recommended by current guidelines. The relationship between patient outcome and the use of a specific substance to improve cerebral perfusion has not been investigated. Dopamine, norepinephrine and phenylephrine all seem to increase cerebral blood flow in various animal models and in patients. The data suggest that norepinephrine may be the most predictable. It is associated with an improved restoration of global and regional oxygenation when compared to dopamine. Dopamine has been associated with an increase in brain oedema. There is further evidence that dopamine has many disadvantages in critically ill patients due to its ability to suppress circulating concentrations of most anterior pituitary-dependent hormones. Both aspects would further discourage its use. Data on phenylephrine are scarce. It has been associated with increased intracranial pressure and a failure to improve cerebral oxygenation despite markedly improved cerebral perfusion pressure. For all other catecholamines and related substances there are insufficient data on the cerebrovascular effects after head injury. This suggests that norepinephrine may be the catecholamine that is the most suitable substance to maintain or restore adequate cerebral perfusion. The data, however, are insufficient to formulate a guideline.	[Pfister, D.; Strebel, S. P.; Steiner, L. A.] Univ Basel Hosp, Dept Anesthesia, CH-4031 Basel, Switzerland	Steiner, LA (corresponding author), Univ Basel Hosp, Dept Anesthesia, Spitalstr 21, CH-4031 Basel, Switzerland.	lsteiner@uhbs.ch	Steiner, Luzius/J-1987-2019; Steiner, Luzius/C-9836-2011				Alspaugh DM, 2000, J TRAUMA, V48, P851, DOI 10.1097/00005373-200005000-00008; [Anonymous], 2003, GUIDELINES MANAGEMEN; Beaumont A, 2001, J NEUROTRAUM, V18, P1359, DOI 10.1089/08977150152725650; Beaumont A, 2000, ACT NEUR S, V76, P147; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Chieregato A, 2003, ACTA NEUROCHIR SUPPL, V86, P361; CHILLON JM, 2002, CEREBRAL BLOOD FLOW, P395; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Corbett SM, 2006, CRIT CARE MED, V34, P2479, DOI 10.1097/01.CCM.0000230238.72846.B3; Edvinsson L, 2002, CEREBRAL BLOOD FLOW, P384; Edvinsson L, 2002, CEREBRAL BLOOD FLOW, P191; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Kroppenstedt SN, 2003, CRIT CARE MED, V31, P2211, DOI 10.1097/01.CCM.0000080482.06856.62; Kroppenstedt SN, 2002, ACT NEUR S, V81, P225; Kroppenstedt SN, 2002, J NEUROTRAUM, V19, P1421, DOI 10.1089/089771502320914651; Kroppenstedt SN, 2000, CRIT CARE MED, V28, P3792, DOI 10.1097/00003246-200012000-00004; Malhotra AK, 2003, J NEUROTRAUM, V20, P827, DOI 10.1089/089771503322385764; Mascia L, 2000, INTENS CARE MED, V26, P202, DOI 10.1007/s001340050046; Moppett IK, 2004, BRIT J ANAESTH, V92, P39, DOI 10.1093/bja/aeh014; Myburgh JA, 1998, ACT NEUR S, V71, P19; Myburgh JA, 2003, ANAESTH INTENS CARE, V31, P259, DOI 10.1177/0310057X0303100303; Myburgh JA, 2003, INTENS CARE MED, V29, P817, DOI 10.1007/s00134-003-1684-4; Myburgh JA, 2001, INTENS CARE MED, V27, P276, DOI 10.1007/s001340000793; Ract C, 2001, INTENS CARE MED, V27, P101, DOI 10.1007/s001340000754; Ract C, 2001, J NEUROTRAUM, V18, P1247, DOI 10.1089/089771501317095287; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Sahuquillo J, 2000, ACT NEUR S, V76, P457; SOKRAB TEO, 1989, ACTA PHYSIOL SCAND, V137, P101, DOI 10.1111/j.1748-1716.1989.tb08725.x; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; Steiner LA, 2003, ANESTH ANALG, V97, P572, DOI 10.1213/01.ANE.0000070234.17226.B0; Stover JF, 2002, INTENS CARE MED, V28, P1491, DOI 10.1007/s00134-002-1431-2; Strebel SP, 1998, ANESTHESIOLOGY, V89, P67, DOI 10.1097/00000542-199807000-00012; Stubbe HD, 2006, CRIT CARE MED, V34, P2651, DOI 10.1097/01.CCM.0000239196.17999.B7; VandenBerghe G, 1996, CRIT CARE MED, V24, P1580, DOI 10.1097/00003246-199609000-00024	38	27	27	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.		2008	25			42			98	103		10.1017/S0265021507003407			6	Anesthesiology	Anesthesiology	283AY	WOS:000254610100017	18289425				2021-06-18	
J	Jiang, Y; Sun, XC; Gui, L; Xia, YX; Tang, WY; Cao, YQ; Gu, YJ				Jiang, Yong; Sun, Xiaochuan; Gui, Li; Xia, Yuxian; Tang, Wenyuan; Cao, Yueqing; Gu, Yingjiang			Correlation between APOE-491AA promoter in epsilon 4 carriers and clinical deterioration in early stage of traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						APOE; early response; polymorphism; promoter; traumatic brain injury	APOLIPOPROTEIN-E EPSILON-4; HEAD-INJURY; ALZHEIMERS-DISEASE; REGULATORY REGION; E POLYMORPHISM; APOE GENOTYPE; E4; ASSOCIATION; ALLELE; DEPOSITION	The objective of this work was to investigate the relationship between apolipoprotein E (APOE) promoters (G-219T, C-427T, A-491T) polymorphisms and the clinical deterioration in early stage of traumatic brain injury (TBI) in a cohort of Chinese patients. In this study, we used the cohort of patients which has been reported previously. A total of 110 subjects with TBI (80 males and 30 females, with mean age of 43.87 years) were admitted from December 2003 to May 2004, and demographic and clinical data were collected. The clinical deterioration of patient's condition in acute stage (< 7 days after TBI) was judged by either of the following criteria: decrease of Glasgow Coma Scale (GCS) score (compared with initial admission GCS), increase in hematoma volume or delayed hematoma both detected by repeated computed tomography (CT) scanning compared to that on admission. Venous blood was collected from patients with TBI on admission to determine the APOE promoter polymorphisms. The APOE genotyping was performed by means of polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). chi(2) test and logistic regression analyses were done by SPSS. In 110 Chinese patients, the distributions of APOE genotypes and alleles matched Hardy-Weinberg Law, and 19 subjects presented with deteriorated clinical condition in acute stage after hospitalization. chi(2) test showed insignificant differences in association of APOE promoter polymorphisms with clinical deterioration (p > 0.05). But logistic regression analyses, after adjusting patients' age, injury severity and injury mechanism etc, showed that -491AA (OR = 11.681, p = 0.009, 95%, CI 1.824-74.790) and APOE epsilon 4 were all risk factors, with injury severity and alcohol-drinking as other risk factors. In Chinese population, as a significant but not independent risk factor, only APOE -491AA promoter in epsilon 4 carriers is apt to the clinical deterioration and may contribute to the poor outcome after TBI.	[Jiang, Yong; Sun, Xiaochuan; Tang, Wenyuan] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China; [Jiang, Yong; Gui, Li; Gu, Yingjiang] Luzhou Med Coll, Affiliated Hosp 1, Dept Neurosurg, Luzhou, Peoples R China; [Xia, Yuxian; Cao, Yueqing] Chongqing Univ, Bioengn Coll, Ctr Gene Res, Chongqing 630044, Peoples R China	Sun, XC (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China.	sunxch1445@gmail.com					Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3; Bullido MJ, 1998, NAT GENET, V18, P69, DOI 10.1038/ng0198-69; Buttini M, 2000, NEUROSCIENCE, V97, P207, DOI 10.1016/S0306-4522(00)00069-5; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Corbo RM, 2001, CLIN CHEM LAB MED, V39, P2, DOI 10.1515/CCLM.2001.002; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Ezra Y, 2003, NEUROSCIENCE, V121, P315, DOI 10.1016/S0306-4522(03)00436-6; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Guo L, 2004, J MOL NEUROSCI, V23, P205, DOI 10.1385/JMN:23:3:205; Houlden H, 2006, J NEUROL NEUROSUR PS, V77, P1106, DOI 10.1136/jnnp.2006.095513; Jiang Y, 2006, NEUROSCI LETT, V408, P155, DOI 10.1016/j.neulet.2006.08.082; Johansson K, 1997, LANCET, V349, P1143, DOI 10.1016/S0140-6736(97)24016-X; Katzman R, 1996, NEUROLOGY, V46, P889; Lambert JC, 2000, HUM MOL GENET, V9, P57, DOI 10.1093/hmg/9.1.57; Lambert JC, 2001, LANCET, V357, P608, DOI 10.1016/S0140-6736(00)04063-0; Laws SM, 2002, MOL PSYCHIATR, V7, P886, DOI 10.1038/sj.mp.4001097; Lendon CL, 2003, NEUROLOGY, V61, P683, DOI 10.1212/01.WNL.0000078033.81925.80; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Michikawa M, 1999, MECH AGEING DEV, V107, P233, DOI 10.1016/S0047-6374(98)00134-1; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Pahnke J, 2003, ACTA NEUROPATHOL, V105, P25, DOI 10.1007/s00401-002-0602-0; Qiu Z, 2003, NEUROSCIENCE, V122, P291, DOI 10.1016/j.neuroscience.2003.08.017; SHEARER MJ, 1995, LANCET, V345, P229, DOI 10.1016/S0140-6736(95)90227-9; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; White F, 2001, EXP NEUROL, V169, P307, DOI 10.1006/exnr.2001.7655; Yang JD, 2003, NEUROSCI LETT, V350, P25, DOI 10.1016/S0304-3940(03)00815-2	38	27	39	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2007	24	12					1802	1810		10.1089/neu.2007.0299			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	245BR	WOS:000251910000002	18159991				2021-06-18	
J	Shein, NA; Tsenter, J; Alexandrovich, AG; Horowitz, M; Shohami, E				Shein, Na'ama A.; Tsenter, Jeanna; Alexandrovich, Alexander G.; Horowitz, Michal; Shohami, Esther			Akt phosphorylation is required for heat acclimation-induced neuroprotection	JOURNAL OF NEUROCHEMISTRY			English	Article						protein kinase B; apoptosis; erythropoietin; traumatic brain injury	TRICYCLIC NUCLEOSIDE PHOSPHATE; FOCAL CEREBRAL-ISCHEMIA; NEURONAL SURVIVAL; CROSS-TOLERANCE; INJURY; ERYTHROPOIETIN; MICE; PATHWAY; INHIBITION; ACTIVATION	Long-term heat exposure, known as heat acclimation (HA; 30 days at 34 +/- 1 degrees C) is neuroprotective against traumatic brain injury. Acclimated mice were previously found to display improved functional recovery as well as an increase in the levels of the specific erythropoietin receptor. As the activation of this receptor is known to facilitate functional recovery on one hand and the phosphorylation and activation of Akt, an intracellular kinase which regulates anti-apoptotic pathways on the other, in this study we investigated whether HA affects Akt phosphorylation prior to and following injury and whether this step is required for development of HA-induced neuroprotection. Akt phosphorylation was blocked using Triciribine (TCN), a compound shown to block the phosphorylation process without affecting upstream effectors of this kinase, and several post-injury functional end-point measures were subsequently evaluated. Acclimation led to a post-injury increase in the levels of phosphorylated Akt, resulting in higher levels when compared with normothermic controls at 4 h post-injury (63.6 +/- 5.2% and 42.7 +/- 3.7%, respectively, p <= 0.05). This increase was diminished following TCN administration. Post-injury TCN treatment abolished the HA-induced functional benefits, including effects on motor and cognitive functions as well as the attenuation of edema formation. We therefore suggest that Akt phosphorylation is essential for HA-induced neuroprotection after traumatic brain injury.	Hebrew Univ Jerusalem, Fac Med Dent, Environm Physiol Lab, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Pharmacol, Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Physiol, Jerusalem, Israel; Hadassah Med Ctr, Rehabil Ctr, Jerusalem, Israel	Horowitz, M (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	horowitz@cc.huji.ac.il					Arieli Y, 2003, BRAIN RES, V962, P15, DOI 10.1016/S0006-8993(02)03681-8; ASSAYAG M, 2007, ANN M ISR GROUP HEAR; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Cao L, 2007, ACTA PHARMACOL SIN, V28, P173, DOI 10.1111/j.1745-7254.2007.00504.x; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chong ZZ, 2002, J CEREBR BLOOD F MET, V22, P503, DOI 10.1097/00004647-200205000-00001; Delgado-Esteban M, 2007, J NEUROCHEM, V102, P194, DOI 10.1111/j.1471-4159.2007.04450.x; Ennaceur A, 2005, BEHAV BRAIN RES, V159, P247, DOI 10.1016/j.bbr.2004.11.006; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; FEUN LG, 1993, AM J CLIN ONCOL-CANC, V16, P506, DOI 10.1097/00000421-199312000-00010; FEUN LG, 1984, CANCER RES, V44, P3608; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Horowitz M, 2004, J APPL PHYSIOL, V97, P1496, DOI 10.1152/japplphysiol.00306.2004; Horowitz M, 2002, COMP BIOCHEM PHYS A, V131, P475, DOI 10.1016/S1095-6433(01)00500-1; Isele NB, 2007, NEUROCHEM INT, V50, P243, DOI 10.1016/j.neuint.2006.08.007; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Liu RQ, 2006, J NEUROCHEM, V96, P1101, DOI 10.1111/j.1471-4159.2005.03597.x; Malhotra S, 2006, J NEUROSCI RES, V83, P19, DOI 10.1002/jnr.20705; Maloyan A, 2005, PHYSIOL GENOMICS, V23, P79, DOI 10.1152/physiolgenomics.00279.2004; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474; Shein NA, 2005, J CEREBR BLOOD F MET, V25, P1456, DOI 10.1038/sj.jcbfm.9600142; SHOHAMI E, 1994, ACTA NEUROCHIR, P443; Treinin M, 2003, PHYSIOL GENOMICS, V14, P17, DOI 10.1152/physiolgenomics.00179.2002; WOTRING LL, 1990, CANCER RES, V50, P4891; Yang L, 2004, CANCER RES, V64, P4394, DOI 10.1158/0008-5472.CAN-04-0343; YANNAI EB, 1997, J CEREB BLOOD FLOW M, V17, P273; Yin W, 2007, STROKE, V38, P1017, DOI 10.1161/01.STR.0000258102.18836.ca	29	27	29	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	NOV	2007	103	4					1523	1529		10.1111/j.1471-4159.2007.04862.x			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	223WH	WOS:000250403500023	17725578	Bronze			2021-06-18	
J	Beis, K; Pieter, W; Abatzides, G				Beis, Konstantinos; Pieter, Willy; Abatzides, George			Taekwondo techniques and competition characteristics involved in time-loss injuries	JOURNAL OF SPORTS SCIENCE AND MEDICINE			English	Article						martial arts; taekwondo; time-loss; Greek; injuries	CHAMPIONSHIPS; KARATE; BLOWS; HEAD	The purpose of this study was to assess time-loss injuries in young and adult taekwondo athletes. Participants were 2739 children (11-13 years), Junior (14-17 years) and adult males and females (18 years and older) competing in the national Greek championships. Injury data were collected by project staff with all diagnoses made by the tournament physician. Odds ratios were computed as well as 95% confidence intervals around the injury rates. The female Juniors had a higher time-loss injury rate ( Fisher's Exact Test p = 0.033) than their adult counterparts. However, they were not at a higher risk of incurring a time- loss injury: OR = 0.143, 95% CI: 0.018-1.124. Collapsed over age, the females as a group recorded more time- loss injuries [11.36/1,000 A-E (95% CI: 6.25-16.47) versus 7.40/1,000 A-E (95% CI: 4.44-10.36)], but this was not significant (OR = 0.703, 95% CI: 0.383-1.293). In the Juniors, the boys only incurred time- loss injuries to the head and neck. There was no difference in the Junior girls in the distribution of time- loss injuries across body region, although they were at higher risk of sustaining an injury to the head and neck (OR = 1.510, 95% CI: 0.422-5.402) but this was not statistically significant. Although there were no statistical differences among age groups within gender, the Junior boys and girls (11-13 years) sustained more cerebral concussions. The Junior boys were at a higher risk of incurring a cerebral concussion than the boys (OR = 7.871, 95% CI: 0.917-67.583, Fisher's Exact Test p = 0.036). In the males, there was no difference between the men and Junior boys in injury rate for swing kicks compared to other techniques (OR = 2.000, 95% CI = 0.397-28.416). There also was no difference between the men and boys (OR = 4.800, 95% CI: 0.141-58.013). To help reduce the incidence of time- loss injuries in taekwondo, especially cerebral concussions, it is suggested for coaches to emphasize blocking skills. Educating referees, coaches and athletes plays an important role in helping to reduce taekwondo time- loss injuries.	Univ Sci Malaysia, Sch Hlth Sci, Sports Sci Program, Kubang Kerian 16150, Kelantan, Malaysia; Aristotle Univ Thessaloniki, Dept Phys Educ & Sport Sci, GR-54006 Thessaloniki, Greece	Pieter, W (corresponding author), Univ Sci Malaysia, Sch Hlth Sci, Sports Sci Program, Kubang Kerian 16150, Kelantan, Malaysia.	kostbeis@phed.auth.gr; yshin516@yahoo.com; abi@phed.auth.gr					Arriaza R, 2005, KNEE SURG SPORT TR A, V13, P603, DOI 10.1007/s00167-004-0593-6; Beis K, 2001, EUR J SPORT TRAUMA R, V23, P130; Dah C, 1989, CINESIOLOGIE, V28, P153; GUMMERSON T, 2005, COACHING CHAMPIONS D; Kazemi M, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471-2474-5-22; Koh JO, 2004, CLIN J SPORT MED, V14, P72, DOI 10.1097/00042752-200403000-00004; Koh JO, 2002, J SPORT MED PHYS FIT, V42, P348; Koh JO, 2001, INT J APPL SPORTS SC, V13, P33; MATSUBAYASHI K, 1993, 1993 ADV BIOENG, P259; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; OLER M, 1991, J TRAUMA, V31, P251, DOI 10.1097/00005373-199131020-00017; Pieter F., 1995, BIOL SPORT, V12, P257; Pieter W, 1997, SPORTS EXERC INJURY, V3, P37; Pieter W, 1997, J TRAUMA, V43, P89, DOI 10.1097/00005373-199707000-00020; Pieter W., 1994, Journal of Sports Traumatology and Related Research, V16, P49; PIETER W, 1998, BRIT J SPORT MED, V32, P88; PIETER W, 1998, KINESIOLOGY, V30, P22, DOI DOI 10.1589/JPTS.28.231; Pieter W, 1995, J HUM MOVEMENT STUD, V28, P1; Pieter W, 1997, COACH SPORT SCI J, V2, P7; Pieter W., 1999, 5 IOC WORLD C SPORT; Pieter W, 1997, ICHPERSD 40 WORLD C, P355; PIETER W, 1990, GENEESK SPORT, V23, P222; PIETER W, 1996, EPIDEMIOLOGY SPORTS, P268; PIETER W, 2004, 1 REG C HUM PERF KUD; Siana J E, 1986, Br J Sports Med, V20, P165; Tuominen Risto, 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P44; WHITING WC, 1988, AM J SPORT MED, V16, P130, DOI 10.1177/036354658801600207; WIRTZ PD, 1988, J AM PODIAT MED ASSN, V78, P474, DOI 10.7547/87507315-78-9-474; ZANDBERGEN A, THESIS TWENTSE AKAD, P1; Zemper E D, 1989, Br J Sports Med, V23, P161; Zemper E. D., 1991, INT C EXP SPORTS MED	31	27	27	0	14	JOURNAL SPORTS SCIENCE & MEDICINE	BURSA	MEDICAL FACULTY ULUDAG UNIV, DEPT SPORTS MEDICINE, BURSA, 16059, TURKEY	1303-2968			J SPORT SCI MED	J. Sport. Sci. Med.	OCT	2007	6				2		45	51					7	Sport Sciences	Sport Sciences	215DS	WOS:000249789100009	24198703	DOAJ Gold			2021-06-18	
J	Ling, X; Liu, DX				Ling, Xiang; Liu, Danxia			Temporal and spatial profiles of cell loss after spinal cord injury: Reduction by a metalloporphyrin	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						secondary cell death; apoptosis; antioxidant therapy; scavenger of reactive species; Mn(III) tetrakis (4-benzoic acid) porphyrin	4-BENZOIC ACID PORPHYRIN; TRAUMATIC BRAIN-INJURY; LIPID-PEROXIDATION; NEURON DEATH; SUPEROXIDE-PRODUCTION; COMPRESSION TRAUMA; HYDROGEN-PEROXIDE; HYDROXYL RADICALS; CONTROLLED TRIAL; POTENTIAL ROLE	This study presents quantitative temporal and spatial profiles of neuronal loss and apoptosis following a contusion spinal cord injury (50 g center dot cm). The profiles were evaluated by counting the cresol violet-stained surviving cells and the total number of TUNEL-positive cells and of TUNEL-positive neurons in sections 0- 4 mm from the epicenter and 1, 6, 12, 24, 48, and 72 hr and 1 week postinjury. We demonstrated that neurons continue to disappear over 1 week postinjury and that neuronal loss shifts to areas longer distances from the epicenter over time. TUNEL-positive cells in both gray and white matter appeared after 6 hr, gradually increased to a peak level after 48 hr, and declined by 72 hr postinjury. TUNEL-positive neurons peaked earlier and were present for 1 week, although the total number of neurons was reduced significantly by the end of the week. The neuronal loss and apoptosis were partially prevented by a metalloporphyrin [Mn(III) tetrakis (4-benzoic acid) porphyrin (MnTBAP)]. We demonstrated that MnTBAP (10 and 50 mg/kg, given intraperitoneally) significantly reduced neuronal death in the sections 1-2.5 mm rostral and 1 mm caudal from the epicenter compared with that in the vehicle-treated group, suggesting MnTBAP is more effective in the sections rostral than in those caudal to the epicenter. MnTBAP (10 mg/kg) significantly reduced the number of TUNEL-positive neurons in the sections 1 mm caudal from the epicenter. Our profiles provide a database for pharmacological intervention, and our results on MnTBAP treatment support an important role for antioxidant therapy in spinal cord injury. (c) 2007 Wiley-Liss, Inc.	Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA	Liu, DX (corresponding author), Univ Texas, Med Branch, Dept Neurol, 301 Univ Blvd,Rte 0881, Galveston, TX 77555 USA.	dliu@utmb.edu		liu, danxia/0000-0001-8172-2344			Abe Y, 1999, J NEUROTRAUM, V16, P945, DOI 10.1089/neu.1999.16.945; Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Balentine JD, 1985, CENTRAL NERVOUS SYST, P455; Bao F, 2003, J NEUROSCI RES, V71, P220, DOI 10.1002/jnr.10481; Bao F, 2004, NEUROSCIENCE, V126, P285, DOI 10.1016/j.neuroscience.2004.03.054; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Bao F, 2002, NEUROSCIENCE, V115, P839, DOI 10.1016/S0306-4522(02)00506-7; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Bresnahan JC, 1991, J NEUROTRAUM, V8, P91, DOI 10.1089/neu.1991.8.91; BRESNAHAN JC, 1987, EXP NEUROL, V95, P548, DOI 10.1016/0014-4886(87)90299-8; Crow JP, 2000, FREE RADICAL BIO MED, V28, P1487, DOI 10.1016/S0891-5849(00)00249-5; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Day BJ, 1999, FREE RADICAL BIO MED, V26, P730, DOI 10.1016/S0891-5849(98)00261-5; Day BJ, 1997, ARCH BIOCHEM BIOPHYS, V347, P256, DOI 10.1006/abbi.1997.0341; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; DUCKER TB, 1971, J NEUROSURG, V35, P700, DOI 10.3171/jns.1971.35.6.0700; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; GOODKIN R, 1969, Surgical Forum (Chicago), V20, P430; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Hachmeister JE, 2006, J NEUROTRAUM, V23, P1766, DOI 10.1089/neu.2006.23.1766; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Katoh K, 1996, NEUROSCI LETT, V216, P9; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Leski ML, 2001, FREE RADICAL BIO MED, V30, P613, DOI 10.1016/S0891-5849(00)00500-1; Li GL, 1999, ACTA NEUROPATHOL, V98, P473, DOI 10.1007/s004010051112; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Liang LP, 2000, NEUROSCIENCE, V101, P563, DOI 10.1016/S0306-4522(00)00397-3; Liu DX, 1999, FREE RADICAL BIO MED, V27, P478, DOI 10.1016/S0891-5849(99)00073-8; Liu DX, 2004, J NEUROTRAUM, V21, P805, DOI 10.1089/0897715041269650; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; Liu DX, 2003, FREE RADICAL BIO MED, V34, P64, DOI 10.1016/S0891-5849(02)01184-X; Liu DX, 2005, J NEUROTRAUM, V22, P1123, DOI 10.1089/neu.2005.22.1123; Liu DX, 2001, J NEUROCHEM, V77, P1036, DOI 10.1046/j.1471-4159.2001.00306.x; Liu DX, 1998, FREE RADICAL BIO MED, V25, P298, DOI 10.1016/S0891-5849(98)00055-0; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lou J, 1998, SPINAL CORD, V36, P683, DOI 10.1038/sj.sc.3100632; Lucas JH, 2002, J NEUROTRAUM, V19, P763, DOI 10.1089/08977150260139138; Luo J, 2004, NEUROSCI LETT, V359, P167, DOI 10.1016/j.neulet.2004.02.027; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; Patel M, 1999, TRENDS PHARMACOL SCI, V20, P359, DOI 10.1016/S0165-6147(99)01336-X; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Qian H, 1997, NEUROCHEM RES, V22, P1231, DOI 10.1023/A:1021980929422; Sheng HX, 2004, NEUROSCI LETT, V366, P220, DOI 10.1016/j.neulet.2004.05.050; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Springer JE, 1997, J NEUROCHEM, V68, P2469; Tatton WG, 1997, J NEURAL TRANSM-SUPP, P245; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Vaziri ND, 2004, BRAIN RES, V995, P76, DOI 10.1016/j.brainres.2003.09.056; WHITE RJ, 1975, CLIN ORTHOP RELAT R, V112, P16; WU L, 2004, 34 ANN M SOC NEUR SA; Xu W, 2005, SPINAL CORD, V43, P204, DOI 10.1038/sj.sc.3101674; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Young W, 1987, Cent Nerv Syst Trauma, V4, P27; Zingarelli B, 1997, BRIT J PHARMACOL, V120, P259, DOI 10.1038/sj.bjp.0700872	61	27	32	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	AUG 1	2007	85	10					2175	2185		10.1002/jnr.21362			11	Neurosciences	Neurosciences & Neurology	196XO	WOS:000248516700012	17551979				2021-06-18	
J	Marton, E; Mazzucco, M; Nascimben, E; Martinuzzi, A; Longatti, P				Marton, Elisabetta; Mazzucco, Marina; Nascimben, Ennio; Martinuzzi, Andrea; Longatti, Pierluigi			Severe head injury in early infancy: analysis of causes and possible predictive factors for outcome	CHILDS NERVOUS SYSTEM			English	Article						paediatric head injury; childhood trauma; functional outcome; paediatric coma scales; prognostic factors	TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; POSTTRAUMATIC SEIZURES; COMPUTERIZED-TOMOGRAPHY; PROGNOSTIC FACTORS; COMA SCALE; IMPACT; AGE; MECHANISMS; EXPERIENCE	Object The aim of this study was to analyse the causes and prognostic factors for outcome in severe traumatic brain injuries (TBI) in early infancy. Materials and methods We present a retrospective study on 16 infants aged less than 12 months observed over the last 20 years in our department for severe brain injury. Infants were evaluated by the Children Coma Scale (CCS). We assessed Glasgow Outcome Scale (GOS) at discharge and at 12 months after discharge. Conclusions The main causes of trauma were domestic accidents followed by car accidents. The highest positive correlation was found between the GOS score at I year and the presence of hypoxia and hypotension at admission, the presence of hyperglycaemia at 24 It and the occurrence of major clotting disorders. A significant but weaker correlation was found with the CCS at admission, the occurrence of early post-traumatic seizures and the length of stay in the intensive care unit.	Univ Padua, Dept Neurosurg, Ca Foncello Hosp, I-31100 Treviso, Italy; Ca Foncello Hosp, Neurosurg Intens Care Unit, Treviso, Italy; Conegliano Res Ctr, E Medea Sci Inst, Conegliano, Italy	Marton, E (corresponding author), Univ Padua, Dept Neurosurg, Ca Foncello Hosp, I-31100 Treviso, Italy.	emarton@libero.it	Martinuzzi, Andrea/K-3887-2016	Martinuzzi, Andrea/0000-0002-0319-3579; MARTON, ELISABETTA/0000-0001-9430-6518			Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Chiaretti A, 2002, CHILD NERV SYST, V18, P54, DOI 10.1007/s00381-001-0533-4; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; Dashti SR, 1999, PEDIATR NEUROSURG, V31, P302, DOI 10.1159/000028880; Dias MS, 1999, PEDIATR NEUROSURG, V30, P232, DOI 10.1159/000028803; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; EWINGCOBBS L, 1995, J HEAD TRAUMA REHAB, V10, P13, DOI 10.1097/00001199-199510000-00004; HAHN YS, 1983, CHILD BRAIN, V10, P229; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; HAHN YS, 1988, CHILD NERV SYST, V4, P34; Johnson DL, 1998, PEDIATR NEUROSURG, V28, P167, DOI 10.1159/000028643; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; Morris MW, 2000, PEDIATRICS, V105, P549, DOI 10.1542/peds.105.3.549; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; Potoka DA, 2000, J TRAUMA, V49, P237, DOI 10.1097/00005373-200008000-00009; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; Ratan SK, 1999, PEDIATR NEUROSURG, V30, P127, DOI 10.1159/000028779; Rubin DM, 2003, PEDIATRICS, V111, P1382, DOI 10.1542/peds.111.6.1382; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Vinchon M, 2003, PEDIATR NEUROSURG, V39, P122, DOI 10.1159/000071648	33	27	27	0	3	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	AUG	2007	23	8					873	880		10.1007/s00381-007-0314-9			8	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	191SD	WOS:000248151400012	17384952				2021-06-18	
J	Benvenisti-Zarom, L; Regan, RF				Benvenisti-Zarom, Luna; Regan, Raymond F.			Astrocyte-specific heme oxygenase-1 hyperexpression attenuates heme-mediated oxidative injury	NEUROBIOLOGY OF DISEASE			English	Article						cell culture; free radical; gene therapy; iron; hemoglobin toxicity; intracerebral hemorrhage; oxidative stress; stroke	EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; TRAUMATIC BRAIN-INJURY; SMOOTH-MUSCLE CELLS; GENE-TRANSFER; TRANSGENE EXPRESSION; PROTECTS ASTROCYTES; HEMOGLOBIN TOXICITY; CORTICAL ASTROCYTES; CARBON-MONOXIDE; GFAP PROMOTER	In prior studies, we have observed that HO activity protects astrocytes from heme-mediated injury, but paradoxically increases neuronal injury. In this study, we tested the hypothesis that an adenovirus encoding the human HO-1 gene driven by an enhanced glial fibrillary acidic protein promoter (Ad-GFAP-HO-1) would increase HO-1 expression selectively in astrocytes, and provide cytoprotection. Treatment with 100 MOI Ad-GFAP-HO-1 for 24 h resulted in HO-1 expression that was 6.4-fold higher in cultured primary astrocytes than in neurons. Astrocyte HO activity was increased by approximately fourfold over baseline, which was sufficient to reduce cell death after 24-h hemin exposure by 60%, as assessed by both MTT and LDH release assays. A similar reduction in cell protein oxidation, quantified by carbonyl assay, was also observed. These results suggest that HO-1 transgene expression regulated by an enhanced GFAP promoter selectively increases HO-1 expression in astrocytes, and is cytoprotective. Further investigation of this strategy in vivo is warranted. (c) 2007 Elsevier Inc. All rights reserved.	Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA	Regan, RF (corresponding author), Thomas Jefferson Univ, Dept Emergency Med, 1020 Sansom St,Thompson Bldg Rm 239, Philadelphia, PA 19107 USA.	Raymond.Regan@jefferson.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050662] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS050662-01A1, R01 NS050662-02, NS50662, R01 NS050662] Funding Source: Medline		Abraham NG, 2002, AM J PHYSIOL-LUNG C, V283, pL1117, DOI 10.1152/ajplung.00365.2001; BALLA G, 1992, J BIOL CHEM, V267, P18148; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; Benvenisti-Zarom L, 2006, NEUROSCI LETT, V398, P230, DOI 10.1016/j.neulet.2006.01.003; Botros FT, 2005, KIDNEY INT, V68, P2745, DOI 10.1111/j.1523-1755.2005.00745.x; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; BRENNER M, 1994, J NEUROSCI, V14, P1030; BUNN HF, 1968, J BIOL CHEM, V243, P465; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Chang EF, 2003, J NEUROSCI, V23, P3689; Chen J, 2005, CURR NEUROVASC RES, V2, P189, DOI 10.2174/1567202054368344; Chen J, 2004, BIOCHEM BIOPH RES CO, V318, P88, DOI 10.1016/j.bbrc.2004.03.187; Chen-Roetling J, 2006, BIOCHEM BIOPH RES CO, V350, P233, DOI 10.1016/j.bbrc.2006.09.036; de Leeuw B, 2006, J NEUROSCI RES, V83, P744, DOI 10.1002/jnr.20776; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Gennuso F, 2004, P NATL ACAD SCI USA, V101, P2470, DOI 10.1073/pnas.0308452100; Goldstein L, 2003, J NEUROSCI RES, V73, P113, DOI 10.1002/jnr.10633; Gong Y, 2006, ACTA NEUROCHIR SUPPL, V96, P232; Hansen TWR, 1997, BIOCHEM MOL MED, V60, P155, DOI 10.1006/bmme.1996.2565; HEBBEL RP, 1989, SEMIN HEMATOL, V26, P136; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Jing CR, 2005, J NEUROSCI RES, V82, P802, DOI 10.1002/jnr.20681; Juan SH, 2001, CIRCULATION, V104, P1519, DOI 10.1161/hc3801.095663; Koeppen AH, 2004, J NEUROPATH EXP NEUR, V63, P587, DOI 10.1093/jnen/63.6.587; KOH JY, 1988, J NEUROSCI, V8, P2153, DOI 10.1523/jneurosci.08-06-02153.1988; LETARTE PB, 1993, J NEUROSURG, V79, P252, DOI 10.3171/jns.1993.79.2.0252; Liu XM, 2002, CIRCULATION, V105, P79, DOI 10.1161/hc0102.101369; Masada T, 2001, J NEUROSURG, V95, P680, DOI 10.3171/jns.2001.95.4.0680; Matz PG, 1997, NEUROSURGERY, V40, P152, DOI 10.1097/00006123-199701000-00034; McKie EA, 1998, GENE THER, V5, P440, DOI 10.1038/sj.gt.3300621; Morelli AE, 1999, J GEN VIROL, V80, P571, DOI 10.1099/0022-1317-80-3-571; Morimoto S, 2002, J BIOL CHEM, V277, P33235, DOI 10.1074/jbc.M204309200; MUCKE L, 1991, NEW BIOL, V3, P465; Nakamura T, 2004, J NEUROSURG, V100, P672, DOI 10.3171/jns.2004.100.4.0672; Ono S, 2002, J NEUROSURG, V96, P1094, DOI 10.3171/jns.2002.96.6.1094; Quan S, 2004, KIDNEY INT, V65, P1628, DOI 10.1111/j.1523-1755.2004.00562.x; Quan S, 2002, J CELL BIOCHEM, V85, P410, DOI 10.1002/jcb.10147; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; Regan RF, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-34; Regan RF, 2000, NEUROSCI LETT, V282, P1, DOI 10.1016/S0304-3940(00)00817-X; Regan RF, 2002, NEUROSCIENCE, V113, P985, DOI 10.1016/S0306-4522(02)00243-9; Rogers B, 2003, FREE RADICAL BIO MED, V35, P872, DOI 10.1016/S0891-5849(03)00431-3; Ryter SW, 2004, BIOESSAYS, V26, P270, DOI 10.1002/bies.20005; Salim M, 2001, J BIOL CHEM, V276, P10929, DOI 10.1074/jbc.M010753200; SHAFITZAGARDO B, 1988, GLIA, V1, P346, DOI 10.1002/glia.440010507; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Su M, 2004, NEUROCHEM RES, V29, P2075, DOI 10.1007/s11064-004-6881-1; Swanson RA, 2004, CURR MOL MED, V4, P193, DOI 10.2174/1566524043479185; Taketani S, 2005, TOHOKU J EXP MED, V205, P297, DOI 10.1620/tjem.205.297; Teng ZP, 2004, NEUROBIOL DIS, V17, P179, DOI 10.1016/j.nbd.2004.07.009; TENG ZP, 2003, ACAD EMERG MED, V10, P480; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004; VREMAN HJ, 1988, ANAL BIOCHEM, V168, P31, DOI 10.1016/0003-2697(88)90006-1; Weng YH, 2003, J BIOL CHEM, V278, P50999, DOI 10.1074/jbc.M307644200; Wu JM, 2003, STROKE, V34, P2964, DOI 10.1161/01.STR.0000103140.52838.45; Xi GH, 1998, J NEUROSURG, V89, P991, DOI 10.3171/jns.1998.89.6.0991; Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163	58	27	27	1	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JUN	2007	26	3					688	695		10.1016/j.nbd.2007.03.006			8	Neurosciences	Neurosciences & Neurology	177II	WOS:000247146400019	17467999	Green Accepted			2021-06-18	
J	Nakajima, H; Uchida, K; Kobayashi, S; Inukai, T; Horiuchi, Y; Yayama, T; Sato, R; Baba, H				Nakajima, Hideaki; Uchida, Kenzo; Kobayashi, Shigeru; Inukai, Tomoo; Horiuchi, Yukiko; Yayama, Takafumi; Sato, Ryuichiro; Baba, Hisatoshi			Rescue of rat anterior horn neurons after spinal cord injury by retrograde transfection of adenovirus vector carrying brain-derived neurotrophic factor gene	JOURNAL OF NEUROTRAUMA			English	Article						axonal transport; growth factor; regeneration; spinal cord injury; therapeutic approaches for the treatment of CNS injury; traumatic spinal cord injury	FUNCTIONAL RECOVERY; AXONAL REGENERATION; VIRAL VECTORS; MOTOR-NEURONS; MOUSE TWY/TWY; EXPRESSION; COMPRESSION; SURVIVAL; DELIVERY; BDNF	We investigated the efficacy of retrograde gene delivery via the sternomastoid muscle of recombinant adenovirus vector (AdV) carrying brain-derived neurotrophic factor (BDNF) gene for the rescue of injured rat spinal cord. One hundred-thirty five adult Sprague-Dawley rats were used in the study with a standard weight-compression technique to produce spinal cord injury. AdV-BDNF gene or AdV-beta-galactosidase (AdV-LacZ) gene was injected into the sternomastoid muscle immediately after traumatic C4 segment spinal cord injury. AdV-BDNF was successfully appeared in the injured cervical spinal cord following injection into the sternomastoid muscle. BDNF expression in the anterior horn neurons of the cervical spinal cord reached peak levels at 1-2 weeks; and the expression persisted at significant levels for approximately 4 weeks after injury. AdV-BDNF transfection was associated with increased numbers of intact neurons as confirmed by Nissl, cholineacetyltransferase (ChAT), and acetylcholine esterase (AChE) staining especially from 2 weeks after injury, compared with the AdV-LacZ injected rats. Our results suggest that in vivo targeted retrograde AdV-BDNF-gene delivery may enhance neuronal survival following traumatic injury of the spinal cord.	Univ Fukui, Fac Med Sci, Dept Surg, Div Orthopaed & Rehabil Med, Fukui 9101193, Japan	Nakajima, H (corresponding author), Univ Fukui, Fac Med Sci, Dept Surg, Div Orthopaed & Rehabil Med, 23-3 Matsuokashimoaizuki, Fukui 9101193, Japan.	nhideaki@fmsrsa.fukui-med.ac.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17591558, 19791023, 18390411] Funding Source: KAKEN		Baba H, 1996, J NEUROL, V243, P109, DOI 10.1007/BF02443999; Baba H, 1997, J NEUROL, V244, P222, DOI 10.1007/s004150050076; BLACK P, 1986, NEUROSURGERY, V19, P752, DOI 10.1227/00006123-198611000-00006; Blesch A, 2002, BRAIN RES BULL, V57, P833, DOI 10.1016/S0361-9230(01)00774-2; Blitts B, 2003, NEUROSCIENCE, V118, P271, DOI 10.1016/S0306-4522(02)00970-3; Boulis NM, 2003, NEUROSURGERY, V52, P381, DOI 10.1227/01.NEU.0000044459.24519.3E; Boulis NM, 2002, J NEUROSURG, V96, P212, DOI 10.3171/spi.2002.96.2.0212; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Collazos-Castro JE, 2005, J NEUROTRAUM, V22, P544, DOI 10.1089/neu.2005.22.544; Dougherty KD, 2000, NEUROBIOL DIS, V7, P574, DOI 10.1006/nbdi.2000.0318; Emborg ME, 2000, PROG BRAIN RES, V128, P323; Giehl KM, 2001, J NEUROSCI, V21, P3492, DOI 10.1523/JNEUROSCI.21-10-03492.2001; Haase G, 1998, J NEUROL SCI, V160, pS97, DOI 10.1016/S0022-510X(98)00207-X; HEDREEN JC, 1985, J HISTOCHEM CYTOCHEM, V33, P134, DOI 10.1177/33.2.2578498; Hendriks WTJ, 2004, PROG BRAIN RES, V146, P451; Hermens WTJMC, 1998, PROG NEUROBIOL, V55, P399, DOI 10.1016/S0301-0082(98)00007-0; Kaspar BK, 2002, MOL THER, V5, P50, DOI 10.1006/mthe.2001.0520; KEIR SD, 1995, J NEUROVIROL, V1, P259, DOI 10.3109/13550289509114022; Kishino A, 2003, BRAIN RES, V964, P56, DOI 10.1016/S0006-8993(02)04066-0; Kishino A, 1997, EXP NEUROL, V144, P273, DOI 10.1006/exnr.1996.6367; KITAMURA S, 1982, ANAT REC, V202, P527, DOI 10.1002/ar.1092020412; Koda M, 2004, J NEUROTRAUM, V21, P329, DOI 10.1089/089771504322972112; Kuo H, 1995, BRAIN RES, V705, P31, DOI 10.1016/0006-8993(95)01065-3; LIUDMILA N, 2002, J COMP NEUROL, V452, P255; Mannes AJ, 1998, BRAIN RES, V793, P1, DOI 10.1016/S0006-8993(97)01422-4; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Nakahara S, 1999, J NEUROPATH EXP NEUR, V58, P442, DOI 10.1097/00005072-199905000-00003; Nakajima H, 2005, NEUROSCI LETT, V385, P30, DOI 10.1016/j.neulet.2005.05.012; Nakamura M, 2001, EXP NEUROL, V169, P407, DOI 10.1006/exnr.2001.7670; Nakamura M, 1996, NEUROSCIENCE, V75, P481, DOI 10.1016/0306-4522(96)00220-5; Namiki J, 2000, J NEUROTRAUM, V17, P1219, DOI 10.1089/neu.2000.17.1219; Novikova L, 1996, NEUROSCI LETT, V220, P203, DOI 10.1016/S0304-3940(96)13267-5; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Ruitenberg MJ, 2002, METHODS, V28, P182, DOI 10.1016/S1046-2023(02)00222-0; Thomas CE, 2001, MOL THER, V3, P36, DOI 10.1006/mthe.2000.0224; Uchida K, 2002, SPINE, V27, P480, DOI 10.1097/00007632-200203010-00008; Uchida K, 1998, J NEUROL, V245, P781, DOI 10.1007/s004150050287; Uchida K, 2003, ACTA NEUROPATHOL, V106, P29, DOI 10.1007/s00401-003-0691-4; Xu K, 2006, SPINE, V31, P1867, DOI 10.1097/01.brs.0000228772.53598.cc; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407	42	27	34	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2007	24	4					703	712		10.1089/neu.2006.0004			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	159NE	WOS:000245872000011	17439352				2021-06-18	
J	Nursal, TZ; Erdogan, B; Noyan, T; Cekinmez, M; Atalay, B; Bilgin, N				Nursal, Tarik Zafer; Erdogan, Bulent; Noyan, Turgut; Cekinmez, Melih; Atalay, Betul; Bilgin, Nevzat			The effect of metoclopramide on gastric emptying in traumatic brain injury	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						traumatic brain injury; enteral nutrition; gastric emptying; metoclopramide; gastric residue; paracetamol method	CRITICALLY-ILL PATIENTS; SEVERE HEAD-INJURIES; ENTERAL NUTRITION; GASTROPARESIS; CISAPRIDE	Objective: Gastric paresis in traumatic brain injury (TBI) hinders the effectiveness of enteral support in this patient group. In this study we have investigated the effect of metoclopramide on gastric emptying in TBI patients. Method: In this prospective, randomized, controlled, double-blind study, 19 TBI patients with Glasgow Coma Scale scores of 3-11 were included. In all patients, enteral nutrition was commenced with a nasogastric feeding tube within 48 hours of trauma. Patients were randomized into two groups. In the metoclopramide (M) group, 10 mg metoclopramide was delivered intravenously three times daily for 5 days. In the control (Q group, an equal volume of saline was administered. Besides demographics, gastric emptying according to a paracetamol absorption test at days 0 and 5, time to reach target nutritional requirements, gastric residues, intolerance to feeding, nutritional complications, and clinical outcomes were recorded for each patient. Results: The gastric residue rates were 2.7 +/- 7.4 mL and 8.1 +/- 17.7 mL per 100 patient days for groups C and M respectively (p = 0.408). Similarly, feeding intolerance and complication rates did not significantly differ between groups C and M, (respectively p = 0.543 and 0.930). Gastric emptying parameters also were similar between the study groups. Conclusion: We were unable to document any advantage to using metoclopramide in TBI patients. Simple intragastric enteral feeding with close monitoring of the possible complications seems to be sufficient with acceptable morbidity rates. (c) 2005 Elsevier Ltd. All rights reserved.	Baskent Univ, Adana Teaching & Med Res Ctr, Dept Gen Surg, TR-01250 Adana, Turkey; Baskent Univ, Adana Teaching & Med Res Ctr, Dept Neurosurg, TR-01250 Adana, Turkey; Baskent Univ, Adana Teaching & Med Res Ctr, Dept Nutr, TR-01250 Adana, Turkey	Nursal, TZ (corresponding author), Baskent Univ, Adana Teaching & Med Res Ctr, Dept Gen Surg, Dadaloglu Mah 39 Sok 6, TR-01250 Adana, Turkey.	tznursal@baskent-adri.edu.tr	Atalay, Betul Gulsen/ABF-8847-2020; Atalay, Betul/S-5609-2019; NOYAN, MUSTAFA TURGUT/AAK-2011-2021	Atalay, Betul Gulsen/0000-0003-0879-5189; NOYAN, MUSTAFA TURGUT/0000-0003-0268-8999; cekinmez, melih/0000-0001-9658-9005			Altmayer T, 1996, ARCH PHYS MED REHAB, V77, P1093, DOI 10.1016/S0003-9993(96)90075-1; Cohen J, 2000, CLIN NUTR, V19, P233, DOI 10.1054/clnu.2000.0097; HADLEY MN, 1986, NEUROSURGERY, V19, P367, DOI 10.1097/00006123-198609000-00006; Harbrecht BG, 1998, AM J SURG, V176, P311, DOI 10.1016/S0002-9610(98)00206-2; JACKSON MD, 1989, ARCH PHYS MED REHAB, V70, P553; Jooste CA, 1999, INTENS CARE MED, V25, P464, DOI 10.1007/s001340050881; MacLaren R, 2000, CRIT CARE MED, V28, P438, DOI 10.1097/00003246-200002000-00025; Marino LV, 2003, BRIT J NEUROSURG, V17, P24, DOI 10.1080/026889031000093708; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Minard G, 2000, JPEN-PARENTER ENTER, V24, P145, DOI 10.1177/0148607100024003145; MOORE R, 1989, J TRAUMA, V29, P1633, DOI 10.1097/00005373-198912000-00007; Sanaka M, 1998, J GASTROENTEROL, V33, P785, DOI 10.1007/s005350050177; Spain DA, 1995, J TRAUMA, V39, P1100, DOI 10.1097/00005373-199512000-00015; Suchner U, 1996, NUTRITION, V12, P13, DOI 10.1016/0899-9007(95)00016-X; Thor Piotr J, 2003, Med Sci Monit, V9, pCR392	15	27	32	0	9	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0967-5868			J CLIN NEUROSCI	J. Clin. Neurosci.	APR	2007	14	4					344	348		10.1016/j.jocn.2005.11.011			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	158BP	WOS:000245766200008	17336229				2021-06-18	
J	Hardy, P; Johnston, KM; De Beaumont, L; Montgomery, DL; Lecomte, JM; Soucy, JP; Bourbonnais, D; Lassonde, M				Hardy, Paule; Johnston, Karen M.; De Beaumont, Louis; Montgomery, David L.; Lecomte, Jacqueline M.; Soucy, Jean-Paul; Bourbonnais, Daniel; Lassonde, Maryse			Pilot case study of the therapeutic potential of hyperbaric oxygen therapy on chronic brain injury	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						hyperbaric oxygen; brain injuries; neuropsychology; ERPs; P300; SPECT; MRI; case report	STROKE; P300; STRENGTH; ISCHEMIA; MILD; EEG	Background: Recently, the effect of hyperbaric oxygen (HBO2) therapy was explored in the treatment of chronic TBI. It has been speculated that idling neurons in the penumbra zone remain viable several years after injury and might be reactivated by enhanced oxygenation. We studied the therapeutic potential of HBO2 therapy in a 54-year-old man who had sustained traumatic brain injuries one year before testing that resulted in permanent neurological symptoms. Methods: Two treatment series separated by a one-year inter-session interval were administered. Treatment series consisted of 20 and 60 daily one-hour exposures to 100% oxygen at 2 ATA. Electrophysiological (event-related potentials), metabolic and behavioral (sensorimotor and neuropsychological) measurements were obtained to evaluate the effects of hyperbaric oxygen therapy on neurocognitive functioning. Results: Following the initial treatment, the patient showed improvements in sensorimotor functions, as well as enhanced P300 amplitude in the damaged hemisphere. Although most of these gains were no longer observed one year after treatment, these were reinstated with an additional series of 60 exposures. Neuropsychological improvements were also observed after the completion of the second series of treatments. Conclusion: The present single-case study provides preliminary evidence of neuropsychological and electrophysiological improvements after series of 20 and 60 treatments, although the first dosage appeared to be insufficient to produce permanent benefits. Longitudinal studies using different treatment parameters should be conducted if we are to systematically investigate long-term improvements resulting from HBO2 therapy. (c) 2006 Elsevier B.V. All rights reserved.	Univ Montreal, Canada Res Chair Dev Neuropsychol, Dept Psychol, Ctr Rech Neuropsychol & Cognit, Montreal, PQ H3C 3J7, Canada; McGill Univ, Ctr Hlth, Trauma Unit, Montreal, PQ, Canada; McGill Univ, Seagram Sports Med, Montreal, PQ, Canada; McGill Univ, Seagram Sports Sci Ctr, Cleghorn Hyperbar Oxygen Lab, Montreal, PQ, Canada; Univ Montreal, CHU Montreal, Fac Med Radiol Oncol & Med Nucl, Montreal, PQ, Canada; Univ Montreal, Ecole Readaptat, Montreal, PQ, Canada	Lassonde, M (corresponding author), Univ Montreal, Canada Res Chair Dev Neuropsychol, Dept Psychol, Ctr Rech Neuropsychol & Cognit, POB 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	maryse.lassonde@umontreal.ca					*AM EL SOC AM EL S, 1992, J CLIN NEUROPHYSIOL, V8, P200; ANDERSON DC, 1991, STROKE, V22, P1137, DOI 10.1161/01.STR.22.9.1137; Badr AE, 2001, AM J PHYSIOL-REG I, V280, pR766; Barrett KF, 1998, NEUROLOGY, V50, pA178; BERG K, 1989, Physiotherapy Canada, V41, P304; CARTER LP, 1983, NEUROSURGERY, V12, P620; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Clifton G L, 1995, New Horiz, V3, P474; Collet JP, 2001, LANCET, V357, P582, DOI 10.1016/S0140-6736(00)04054-X; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; Duncan P, 1998, STROKE, V29, P2055, DOI 10.1161/01.STR.29.10.2055; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; ENGARDT M, 1995, ARCH PHYS MED REHAB, V76, P419, DOI 10.1016/S0003-9993(95)80570-2; GRATTON G, 1988, J EXP PSYCHOL HUMAN, V14, P331, DOI 10.1037/0096-1523.14.3.331; Greenberg L., 1996, TEST VARIABLES ATTEN; HAKIM AM, 1987, CAN J NEUROL SCI, V14, P557; HAMPSON NB, 1999, HYBERBARIC OXYGEN TH; Hardy P, 2002, DEV MED CHILD NEUROL, V44, P436; HOLBACH KH, 1978, J NEUROL, V219, P227, DOI 10.1007/BF00312976; Jain K K, 1996, TXB HYPERBARIC MED; Kondo A, 1996, NEUROPATH APPL NEURO, V22, P350, DOI 10.1111/j.1365-2990.1996.tb01114.x; Lanier WL, 1999, CAN J ANAESTH, V46, pR46, DOI 10.1007/BF03013181; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Leach RM, 1998, BRIT MED J, V317, P1140; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MARCOUX FW, 1982, STROKE, V13, P339, DOI 10.1161/01.STR.13.3.339; McDonagh M, 2004, ARCH PHYS MED REHAB, V85, P1198, DOI 10.1016/j.apmr.2003.12.026; NEUBAUER RA, 1985, LANCET, V1, P810; NEUBAUER RA, 1980, STROKE, V11, P297, DOI 10.1161/01.STR.11.3.297; Neubauer RA, 1998, NEUROL RES, V20, pS33; NEUBAUER RA, 1990, LANCET, V335, P542, DOI 10.1016/0140-6736(90)90777-3; Nighoghossian N, 1997, J NEUROL SCI, V150, P27, DOI 10.1016/S0022-510X(97)05398-7; Polich J, 1997, EVOKED POTENTIAL, V104, P244, DOI 10.1016/S0168-5597(97)96139-6; Polich J, 2000, INT J PSYCHOPHYSIOL, V38, P3, DOI 10.1016/S0167-8760(00)00127-6; ROTHI LJG, 1988, APHASIOLOGY, V2, P381, DOI 10.1080/02687038808248942; Santamaria J P, 1995, Adv Pediatr, V42, P335; Sarno JE, 1972, STROKE, V3, P10, DOI 10.1161/01.STR.3.1.10; SARNO MT, 1972, J SPEECH HEAR RES, V15, P42, DOI 10.1044/jshr.1501.42; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Sharp SA, 1997, ARCH PHYS MED REHAB, V78, P1231, DOI 10.1016/S0003-9993(97)90337-3; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Teixeira-Salmela LF, 1999, ARCH PHYS MED REHAB, V80, P1211, DOI 10.1016/S0003-9993(99)90018-7; Tibbles PM, 1996, NEW ENGL J MED, V334, P1642, DOI 10.1056/NEJM199606203342506; WEINSTEIN PR, 1987, NEUROSURGERY, V20, P518, DOI 10.1227/00006123-198704000-00002; Weiss A, 2000, AM J PHYS MED REHAB, V79, P369, DOI 10.1097/00002060-200007000-00009; Whyte J, 2004, ARCH PHYS MED REHAB, V85, P1732, DOI 10.1016/j.apmr.2004.07.349; ZIVIN J, 1991, POUR SCI, V167, P20	48	27	41	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	FEB 15	2007	253	1-2					94	105		10.1016/j.jns.2006.12.005			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	141ZY	WOS:000244619200017	17234213				2021-06-18	
J	Clark, RSB; Nathaniel, PD; Zhang, XP; Dixon, CE; Alber, SM; Watkins, SC; Melick, JA; Kochanek, PM; Graham, SH				Clark, Robert S. B.; Nathaniel, Paula D.; Zhang, Xiaopeng; Dixon, C. Edward; Alber, Sean M.; Watkins, Simon C.; Melick, John A.; Kochanek, Patrick M.; Graham, Steven H.			boc-Aspartyl(OMe)-fluoromethylketone attenuates mitochondrial release of cytochrome c and delays brain tissue loss after traumatic brain injury in rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						apoptosis; caspase; cysteine protease; head injury; nerve growth factor; programmed cell death	CONTROLLED CORTICAL IMPACT; NEURONAL APOPTOSIS; CELL-DEATH; COGNITIVE DEFICITS; CASPASE ACTIVATION; DNA FRAGMENTATION; SPATIAL PROFILE; IN-VITRO; INHIBITION; RECEPTOR	The pathobiology of traumatic brain injury (TBI) includes activation of multiple caspases followed by cell death with a spectrum of apoptotic phenotypes. There are initiator (e. g. caspase-2, -8, and -9) and effector (e. g. caspase-3 and -7) caspases. Recently, caspase-2 and -8 have been shown to regulate cell death via provoking cytochrome c release from the mitochondria upstream of caspase-9. Here, we show that an intracerebral injection of the pan-caspase inhibitor boc-Aspartyl(OMe)fluoromethylketone (BAF; 1 mu mol) 1 min after TBI in rats reduces caspase-3-like activity, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) and tissue damage, and cytochrome c release in ipsilateral cortex at 24 h versus vehicle. To investigate whether either caspase-2 and/or caspase-8 activation may contribute to cytochrome release, the effect of BAF treatment on caspase-2 and caspase-8 proteolysis was also examined. boc-aspartyl(OMe) fluoromethylketone treatment inhibited proteolysis of caspase-2 but not caspase-8 24 h after TBI in rats versus vehicle. However, BAF with or without nerve growth factor (12.5 ng/h x 14 days intracerebrally via osmotic pump) did not result in differences in motor function, Morris water maze performance, hippocampal neuron survival, nor contusion volume at 14 days. These data suggest that BAF treatment reduces acute cell death after TBI by inhibiting mitochondrial release of cytochrome c, possibly via a mechanism involving initiator caspases; however, BAF appears to delay cell death, rather than result in permanent protection.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; VA Pittsburgh Hlth Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA	Clark, RSB (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; watkins, simon/0000-0003-4092-1552	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38620, P50 NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R01NS038620] Funding Source: NIH RePORTER		Allen JW, 1999, FASEB J, V13, P1875; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bizat N, 2005, NEUROPHARMACOLOGY, V49, P695, DOI 10.1016/j.neuropharm.2005.04.030; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Dash PK, 2000, NEUROREPORT, V11, P2811, DOI 10.1097/00001756-200008210-00040; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Enoksson M, 2004, J BIOL CHEM, V279, P49575, DOI 10.1074/jbc.C400374200; Franz G, 2002, J CEREBR BLOOD F MET, V22, P951, DOI 10.1097/00004647-200208000-00006; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Henshall DC, 2001, NEUROBIOL DIS, V8, P568, DOI 10.1006/nbdi.2001.0415; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lemaire C, 1998, FEBS LETT, V425, P266, DOI 10.1016/S0014-5793(98)00252-X; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; Morita-Fujimura Y, 1999, NEUROSCI LETT, V267, P201, DOI 10.1016/S0304-3940(99)00327-4; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Omori N, 2002, BRAIN RES, V954, P317, DOI 10.1016/S0006-8993(02)03366-8; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Qiu JH, 2002, J NEUROSCI, V22, P3504; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Snyder SH, 1998, NEURON, V21, P283, DOI 10.1016/S0896-6273(00)80538-3; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Troy CM, 2002, J BIOL CHEM, V277, P34295, DOI 10.1074/jbc.M205167200; Werth JL, 2000, EXP NEUROL, V161, P203, DOI 10.1006/exnr.1999.7241; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhang H, 2003, RESPIROLOGY, V8, P17, DOI 10.1046/j.1440-1843.2003.00433.x; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	46	27	27	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2007	27	2					316	326		10.1038/sj.jcbfm.9600338			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	128UY	WOS:000243685700008	16736044	Bronze			2021-06-18	
J	Newsome, MR; Scheibel, RS; Hunter, JV; Wang, ZYJ; Chu, ZL; Li, XQ; Levin, HS				Newsome, Mary R.; Scheibel, Randall S.; Hunter, Jill V.; Wang, Zhiyue J.; Chu, Zili; Li, Xiaoqi; Levin, Harvey S.			Brain activation during working memory after traumatic brain injury in children	NEUROCASE			English	Article						fMRI; traumatic brain injury; children; working memory	CLOSED-HEAD INJURY; PREFRONTAL CORTEX; CHILDHOOD; FMRI; ADOLESCENCE; IMPAIRMENT; ATTENTION; MODERATE; SKILLS; TASK	Eight children with moderate to severe traumatic brain injury (TBI) and eight matched, uninjured control children underwent fMRI during an N-back task to test effects of TBI on working memory performance and brain activation. Two patterns in the TBI group were observed. Patients whose criterion performance was reached at lower memory loads than control children demonstrated less extensive frontal and extrafrontal brain activation than controls. Patients who performed the same, highest (3-back) memory load as controls demonstrated more frontal and extrafrontal activation than controls. Our findings of performance and brain activation changes in children after TBI await longitudinal investigation.	Baylor Coll Med, Cognit Neurosci Lab, Houston, TX 77030 USA; Texas Childrens Hosp, Diagnost Imaging Lab, Houston, TX 77030 USA; Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA	Newsome, MR (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	mnewsome@bcm.tmc.edu	Wang, Zhiyue J/L-3851-2014	Wang, Zhiyue J/0000-0002-5649-2900	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; Bookheimer SY, 2000, MENT RETARD DEV D R, V6, P161, DOI 10.1002/1098-2779(2000)6:3<161::AID-MRDD2>3.3.CO;2-N; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; CASEY BJ, 1995, NEUROIMAGE, V2, P221, DOI 10.1006/nimg.1995.1029; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Casey BJ, 1998, NEUROIMAGE, V8, P249, DOI 10.1006/nimg.1998.0360; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Davidson MC, 2003, MENT RETARD DEV D R, V9, P161, DOI 10.1002/mrdd.10076; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Downing P, 2001, NEUROPSYCHOLOGIA, V39, P1329, DOI 10.1016/S0028-3932(01)00121-X; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Jones JA, 2003, NEUROREPORT, V14, P1129, DOI 10.1097/00001756-200306110-00006; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; Liston C, 2006, CEREB CORTEX, V16, P553, DOI 10.1093/cercor/bhj003; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Munson S, 2006, PEDIATRICS, V117, P1372, DOI 10.1542/peds.2005-0826; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Poldrack Russell A, 2002, Top Magn Reson Imaging, V13, P61, DOI 10.1097/00002142-200202000-00005; Price CJ, 1999, HUM BRAIN MAPP, V8, P102, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<102::AID-HBM6>3.0.CO;2-J; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Schlaggar BL, 2002, SCIENCE, V296, P1476, DOI 10.1126/science.1069464; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Sowell ER, 2001, J INT NEUROPSYCH SOC, V7, P312, DOI 10.1017/S135561770173305X; Swanson HL, 2001, J EXP CHILD PSYCHOL, V79, P294, DOI 10.1006/jecp.2000.2587; Swanson HL, 1999, DEV PSYCHOL, V35, P986, DOI 10.1037/0012-1649.35.4.986; TEASDALE G, 1974, LANCET, V2, P81; Thomas KM, 1999, NEUROIMAGE, V10, P327, DOI 10.1006/nimg.1999.0466; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Wechsler D., 2011, WECHLSER ABBREVIATED; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Woodcock R. W., 2001, WOODCOCKJOHNSON TEST; Yakovlev P.I., 1967, RETIONAL DEV BRAIN E, P3	56	27	27	0	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1355-4794	1465-3656		NEUROCASE	Neurocase	FEB	2007	13	1					16	24		10.1080/13554790601186629			9	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	161KO	WOS:000246014000003	17454685				2021-06-18	
J	Girard, P				Girard, Philip			Military and VA telemedicine systems for patients with traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						brain injury; care coordination; concussion assessment; distance learning; home healthcare; rehabilitation; tele-consultation; telehealth; telemedicine; telerehabilitation	TELEREHABILITATION; RECOVERY	Telemedicine plays a critical role within the Department of Veterans Affairs (VA) Veterans Health Administration by allowing the surveillance and care of patients who are isolated by geography, poverty, and disability. In military settings, telemedicine is being widely used to identify injury and illness and aid in the treatment, rehabilitation, and recovery of combat-wounded soldiers in theater. Rapid advances in both domains are transforming the way clinicians provide care, education, and support to patients with traumatic brain injury (TBI) and their families. This article discusses the military and VA telemedicine capabilities that are supporting the care of service members and veterans with TBI. These capabilities include new technologies that enhance the identification of TBI, management of symptoms in theater, and application of proven technologies (interactive video, Internet, and World Wide Web) to improve overall care coordination throughout military and VA systems. The impact of distance learning, tele-consultation, telerehabilitation, and home telehealth programs is also described within this context.	[Girard, Philip] Manchester Dept Vet Affairs Med Ctr, Off Telemed, Def & Vet Brain Injury Ctr, Manchester, NH 03103 USA; [Girard, Philip] Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA	Girard, P (corresponding author), Manchester Dept Vet Affairs Med Ctr, Off Telemed, Def & Vet Brain Injury Ctr, 718 Smyth Rd, Manchester, NH 03103 USA.	philip.girard@va.gov					ACKERMAN RK, 2005, SIGNAL AFCEA     MAR, P58; ACKERMAN RK, 2005, TELEMEDICINE REACHES, P55; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; BERGQUIST T, 2006, 2 FED INT C TBI NAT; COLLINS M, 2006, 2 FED INT C TBI U PI; CORNISPOP M, 2006, CAPABILITIES, V14, P8; Darkins A, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.03.0029; Forducey PG, 2003, NEUROREHABILITATION, V18, P103; KENYON HS, 2005, SIGNAL           MAR, P73; LILIE C, 2005, MOVING IMAGES NOT PA, P63; Martin EM, 2006, REHABIL NURS, V31, P54, DOI 10.1002/j.2048-7940.2006.tb00125.x; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; SAMSON K, 2006, NEUROLOGY TODAY 0103, P21; WHITE J, 1993, REHABILITATION PRINC; 2002, US MED           JUL; 2006, DAILY ILLINI    0915	18	27	28	0	11	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2007	44	7					1017	1026		10.1682/JRRD.2006.12.0174			10	Rehabilitation	Rehabilitation	253NL	WOS:000252524800014	18075958	Bronze			2021-06-18	
J	Van Baalen, B; Ribbers, GM; Medema-Meulepas, D; Pas, MS; Odding, E; Stam, HJ				Van Baalen, B.; Ribbers, G. M.; Medema-Meulepas, D.; Pas, M. S.; Odding, E.; Stam, H. J.			Being restricted in participation after a traumatic brain injury is negatively associated by passive coping style of the caregiver	BRAIN INJURY			English	Article						traumatic brain injury; outcome; caregiver; coping	FRENCHAY ACTIVITIES INDEX; SICKNESS IMPACT PROFILE; FUNCTIONAL STATUS; STROKE PATIENTS; SOCIAL SUPPORT; PREDICTORS; SEVERITY; REHABILITATION; CLASSIFICATION; POPULATION	Purpose: To examine whether the caregivers' coping style is associated with the functional outcome of the traumatic brain injury ( TBI) patient 1 year post- injury. Method: A cross-sectional study among patients with a TBI, including their primary caregivers. The study included 51 patients aged 17-64 years with a moderate-to-severe TBI and 51 caregivers ( 23 parents and 28 partners) aged 23-67 years. The coping preferences of the caregivers were assessed at minimum 6 and maximum 12 months post- injury, by filling out the Utrecht Coping List ( UCL) and were related to limitations in activity, as measured with the Frenchay Activities Index and with restrictions in participation as measured with the Sickness Impact Profile-68 of TBI patients 1 year post-injury. The patients were interviewed at their homes; the caregivers received and returned the UCL by mail. Results: The patients' age and the caregivers' coping style are independently associated with restrictions in participation 1 year post- injury. Conclusions: A passive coping style of the primary caregiver is negatively associated with the patient's functional outcome in terms of participation in society.	Erasmus MC, Dept Rehabil Med, Rotterdam, Netherlands; Rijndam Rehabil Ctr, Rotterdam, Netherlands	Van Baalen, B (corresponding author), Erasmus MC, Dept Rehabil Med, POB 3000 CA, Rotterdam, Netherlands.	j.t.m.vanbaalen@erasmusmc.nl	Ribbers, Gerard M/C-1454-2014; Ribbers, Gerard/N-3623-2019	Ribbers, Gerard M/0000-0002-6114-349X; 			DEBRUIN AF, 1994, J CLIN EPIDEMIOL, V47, P407, DOI 10.1016/0895-4356(94)90162-7; DeJong G., 1990, J HEAD TRAUMA REHAB, V5, P9, DOI [https://doi.org/10.1097/00001199-199003000-00004, DOI 10.1097/00001199-199003000-00004]; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; GILSON BS, 1975, AM J PUBLIC HEALTH, V65, P1304, DOI 10.2105/AJPH.65.12.1304; Hachisuka K, 1999, J CLIN EPIDEMIOL, V52, P1089, DOI 10.1016/S0895-4356(99)00085-2; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; Kosciulek JF, 1997, BRAIN INJURY, V11, P821, DOI 10.1080/026990597123034; KWASNICA CM, 1994, ARCH PHYS MED REHAB, V75, P384, DOI 10.1016/0003-9993(94)90159-7; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Poon WS, 2005, ACT NEUR S, V93, P207; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Sander AM, 2003, ARCH PHYS MED REHAB, V84, P197, DOI 10.1053/apmr.2003.50105; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sanderman R, 1992, GEDRAG GEZONDHEID, V20, P32; Schreurs PJG, 1988, HANDLEIDING UTRECHTS; SCHULING J, 1993, STROKE, V24, P1173, DOI 10.1161/01.STR.24.8.1173; Stalenhoef PA, 2000, FAM PRACT, V17, P490, DOI 10.1093/fampra/17.6.490; Toschlog EA, 2003, AM SURGEON, V69, P491; Turnbull JC, 2000, ARCH PHYS MED REHAB, V81, P1034, DOI 10.1053/apmr.2000.7162; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406	29	27	27	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	9					925	931		10.1080/02699050701553197			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	202ZA	WOS:000248942600004	17729045				2021-06-18	
J	Laatsch, L; Kirsky, C				Laatsch, Linda; Kirsky, Christine			Changes in fMRI activation following rehabilitation of reading and visual processing deficits in subjects with traumatic brain injury	BRAIN INJURY			English	Article						cognitive rehabilitation; fMRI; reading; visual perception; traumatic brain injury	WORDS	In this case series fMRI was used to examine activation patterns during presentation of a reading comprehension (RC) task in three adult subjects with a history of severe traumatic brain injury (TBI). These subjects received cognitive rehabilitation therapy (CRT) for visual processing and acquired reading deficits. fMRI and neuropsychological testing occurred pre- and post-rehabilitation. The study's objective was to evaluate the neurobiological changes using fMRI occurring with CRT and to compare these results to repeat fMRI in matched control subjects. While improvements in neuropsychological testing occurred post-CRT, diffuse and variable activation patterns in the subjects with TBI were still demonstrated when compared to the control subjects repeat imaging. Multiple networks exist to accomplish the complex task of sentence reading and rehabilitation of the cognitive components of reading, such as visual processing; in subjects with TBI, can alter the activation pattern demonstrated during reading comprehension in subjects many years post-injury. This is the first demonstration of changes in network activation patterns post-CRT in patients with severe, chronic TBI on an fMRI task shown to have imaging stability in a normal control sample.	Univ Illinois, Coll Med, Dept Rehabil & Neurol, Chicago, IL 60612 USA; Oregon Hlth & Sci Univ, Dept Endocrinol, Portland, OR 97201 USA	Laatsch, L (corresponding author), Univ Illinois, Coll Med, Dept Rehabil & Neurol, MC 888 912 S Wood, Chicago, IL 60612 USA.	llaatsch@uic.edu					BRACY O, 1985, SOFT TOOLS COGNITIVE; Brunswick N, 1999, BRAIN, V122, P1901, DOI 10.1093/brain/122.10.1901; CHAPMAN SB, 1989, BRAIN LANG, V36, P651, DOI 10.1016/0093-934X(89)90092-8; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cohen L, 2000, BRAIN, V123, P291, DOI 10.1093/brain/123.2.291; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Eddy WF, 1996, P COMP STAT, P39; GIANUTSOS R, 1984, COGNITIVE REHAB TASK; GLADSOJO J, 1999, NORMS LETT CATEGORY; Gold BT, 2000, BRAIN LANG, V73, P456, DOI 10.1006/brln.2000.2317; Grossman M, 2002, BRAIN LANG, V80, P296, DOI 10.1006/brln.2001.2581; Heaton R.K., 1991, COMPREHENSIVE NORMS; Jastak S, 1984, WIDE RANGE ACHIEVEME; Joseph J, 2001, J LEARN DISABIL-US, V34, P566, DOI 10.1177/002221940103400609; Laatsch L, 2000, NEUROREHABILITATION, V15, P189; Lewis R. F, 1995, PSYCHOL ASSESSMENT R; MANZEL K, 1995, M MIDW PSYCH ASS CHI; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McGonigle DJ, 2000, NEUROIMAGE, V11, P708, DOI 10.1006/nimg.2000.0562; Poggi G, 2000, BRAIN INJURY, V14, P833, DOI 10.1080/026990500421930; Price CJ, 2003, NEUROIMAGE, V20, pS30, DOI 10.1016/j.neuroimage.2003.09.012; Price CJ, 1998, TRENDS COGN SCI, V2, P281, DOI 10.1016/S1364-6613(98)01201-7; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Pugh K.R., 2001, LEARN DISABIL RES PR, V16, P240, DOI [10.1111/0938-8982.00024, DOI 10.1111/0938-8982.00024]; Reitan RM., 1985, HALSTEAD REITAN NEUR; Shaywitz SE, 2003, BIOL PSYCHIAT, V54, P25, DOI 10.1016/S0006-3223(02)01836-X; Small SL, 1998, BRAIN LANG, V62, P298, DOI 10.1006/brln.1998.1951; Talairach J., 1988, COPLANAR STEREOTAXIC; THULBORN K, 1999, MED RADIOLOGY DIAGNO, P337; Thulborn KR, 1999, STROKE, V30, P749, DOI 10.1161/01.STR.30.4.749; Wechsler D, 1997, WAIS 3 ADM SCORING M	33	27	27	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2006	20	13-14					1367	1375		10.1080/02699050600983743			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	130GF	WOS:000243787100006	17378228				2021-06-18	
J	D'Innocenzo, J; Tjaden, K; Greenman, G				D'Innocenzo, Juliana; Tjaden, Kris; Greenman, Geoff			Intelligibility in dysarthria: Effects of listener familiarity and speaking condition	CLINICAL LINGUISTICS & PHONETICS			English	Article						dysarthria; treatment techniques; intelligibility	VOICE-TREATMENT-PROGRAM; ATAXIC DYSARTHRIA; SPEECH; MANIPULATIONS; PERCEPTION; SEQUENCES; SCLEROSIS; LOUDNESS; DISEASE	This study examined the effects of familiarization and speaking condition on sentence intelligibility for a speaker with dysarthria secondary to a traumatic brain injury (TBI). Familiarization procedures included hearing the speaker read a paragraph or a word list comprised of a random ordering of the words in the paragraph. Such an approach allowed for statements concerning the benefit of prior exposure to a sentence-level prosody and word level articulatory-acoustic patterns versus only word-level articulatory-acoustic patterns. Following word list, paragraph, or no familiarization, listeners orthographically transcribed sentences in either a habitual, slow, fast, or loud condition. Listeners receiving either word list or paragraph familiarization accurately transcribed a higher percentage of words in sentences than listeners receiving no familiarization. Intelligibility scores did not differ for word list or paragraph familiarization, however. Listeners also were more accurate transcribing sentences produced in the loud condition compared to habitual and fast conditions. Clinical implications are discussed.	SUNY Buffalo, Dept Communicat Disorders & Sci, Buffalo, NY 14214 USA; SL Hunter & Associates, Burlington, ON, Canada	Tjaden, K (corresponding author), SUNY Buffalo, Dept Communicat Disorders & Sci, 122 Cary Hall,3435 Main St, Buffalo, NY 14214 USA.	tjaden@acsu.buffalo.edu			NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC004689] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01 DC04689] Funding Source: Medline		DARLEY FL, 1969, J SPEECH HEAR RES, V12, P462, DOI 10.1044/jshr.1203.462; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P246, DOI 10.1044/jshr.1202.246; DEPAUL R, 2002, AM J SPEECH-LANG PAT, V9, P230; DINNOCENZO J, 2004, CONV AM SPEECH LANG; Duffy J. R., 2020, MOTOR SPEECH DISORDE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Hustad KC, 2003, AM J SPEECH-LANG PAT, V12, P198, DOI 10.1044/1058-0360(2003/066); Kent R. D., 1992, ACOUSTIC ANAL SPEECH; Liss JM, 2002, J ACOUST SOC AM, V112, P3022, DOI 10.1121/1.1515793; McHenry M., 1997, AM J SPEECH-LANG PAT, V6, P55; McHenry MA, 2003, J SPEECH LANG HEAR R, V46, P702, DOI 10.1044/1092-4388(2003/055); MILENKOVIC P, 2002, TF32 COMPUTER SOFTWA; MILENKOVIC P, 1997, CSPEECH COMPUTER SOF; Ramig L., 1994, J MED SPEECH LANG PA, V2, P191; Sebastian-Galles N, 2000, PERCEPT PSYCHOPHYS, V62, P834, DOI 10.3758/BF03206926; Solomon NP, 2001, AM J SPEECH-LANG PAT, V10, P51, DOI 10.1044/1058-0360(2001/008); Spitzer SM, 2000, J MED SPEECH-LANG PA, V8, P285; *SYNTR CORP, 1999, COOL ED PRO COMP SOF; Theodoros DG, 1999, J MED SPEECH-LANG PA, V7, P157; Tjaden K, 2004, J SPEECH LANG HEAR R, V47, P766, DOI 10.1044/1092-4388(2004/058); Tjaden K, 2003, J SPEECH LANG HEAR R, V46, P990, DOI 10.1044/1092-4388(2003/077); TJADEN K, IN PRESS J SPEECH LA; Tjaden K. K., 1995, AM J SPEECH-LANG PAT, V4, P39; TJADEN KK, 1995, CLIN LINGUIST PHONET, V9, P139, DOI 10.3109/02699209508985329; TURNER GS, 1993, J SPEECH HEAR RES, V36, P1134, DOI 10.1044/jshr.3606.1134; Ward EC, 2000, J MED SPEECH-LANG PA, V8, P331; Weismer G, 2000, FOLIA PHONIATR LOGO, V52, P201, DOI 10.1159/000021536; Wohlert AB, 2000, J SPEECH LANG HEAR R, V43, P1229, DOI 10.1044/jslhr.4305.1229; Yorkston K.M., 1981, ASSESSMENT INTELLIGI; Yorkston K. M., 1983, CLIN DYSARTHRIA, P155; YORKSTON KM, 1981, J SPEECH HEAR DISORD, V46, P398, DOI 10.1044/jshd.4604.398; YORKSTON KM, 1990, J SPEECH HEAR DISORD, V55, P550, DOI 10.1044/jshd.5503.550; YORKSTON KM, 1995, MANAGEMENT SPEECH SW	33	27	28	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9206	1464-5076		CLIN LINGUIST PHONET	Clin. Linguist. Phon.	NOV	2006	20	9					659	675		10.1080/02699200500224272			17	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	127KU	WOS:000243585600002	17342875				2021-06-18	
J	de Guise, E; LeBlanc, J; Feyz, M; Lamoureux, J				de Guise, Elaine; LeBlanc, Joanne; Feyz, Mitra; Lamoureux, Julie			Prediction of outcome at discharge from acute care following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						acute care; Glasgow Outcome Scale (GOS); traumatic brain injury	GLASGOW COMA SCALE; SEVERE HEAD-INJURY; POSTTRAUMATIC AMNESIA; COGNITIVE RESERVE; MORTALITY; PROGNOSIS; AGE; HEMORRHAGE; RECOVERY; MODERATE	Objective: To compute outcome probabilities for persons with traumatic brain injury at discharge from acute care. Participants: Three hundred thirty-nine patients with traumatic brain injury (239 mild, 48 moderate, 52 severe). Setting: Level I trauma center. Main Measures: Predictor variables considered were age, education, Glasgow Coma Scale score, duration of posttraumatic amnesia, cerebral imaging results, and need for neurosurgical intervention. Outcome measures were Extended Glasgow Outcome Scale and discharge destination. Results: Logistic regressions showed that a shorter posttraumatic amnesia decreased the probability of moderate to severe disability. Moreover, discharge home was less probable for patients with positive cerebral imaging. Conclusion: This model can help predict rehabilitation needs upon discharge from an acute care hospital.	McGill Univ, Ctr Hlth, Montreal Gen Hosp, Montreal, PQ, Canada; Univ Montreal, Dept Prevent & Social Med, Montreal, PQ, Canada	de Guise, E (corresponding author), Montreal Gen Hosp, Local D13-124,1650 Av Cedar, Montreal, PQ H3G 1A4, Canada.	elaine.deguise@muhc.mcgill.ca					Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; de Guise E, 2005, CAN J NEUROL SCI, V32, P186, DOI 10.1017/S0317167100003954; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Harris OA, 2000, J TRAUMA, V49, P1076, DOI 10.1097/00005373-200012000-00017; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1981, MANAGEMENT HEAD INJU, P295; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Khan S, 2002, BRAIN INJURY, V16, P537, DOI 10.1080/02699050110119862; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; Lane PL, 2000, CAN J SURG, V43, P442; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Orient-Lopez F, 2004, REV NEUROLOGIA, V39, P901, DOI 10.33588/rn.3910.2004302; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ritchie PD, 2000, J CLIN NEUROSCI, V7, P301, DOI 10.1054/jocn.1999.0198; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Tooth L, 2001, BRAIN INJURY, V15, P613, DOI 10.1080/02699050010013923; Vath A, 2001, NEUROL RES, V23, P315, DOI 10.1179/016164101101198677; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; WHITLOCK J A JR, 1992, Brain Injury, V6, P447, DOI 10.3109/02699059209008140; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	49	27	27	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2006	21	6					527	536		10.1097/00001199-200611000-00007			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	109UC	WOS:000242333400007	17122683				2021-06-18	
J	Boto, GR; Gomez, PA; De la Cruz, J; Lobato, RD				Boto, G. R.; Gomez, P. A.; De la Cruz, J.; Lobato, R. D.			Severe head injury and the risk of early death	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; RANDOMIZED CONTROLLED-TRIALS; SHOW CONVINCING EFFICACY; NEUROPROTECTIVE AGENTS; CLINICAL-TRIALS; THEORETICAL CONSIDERATIONS; COMPUTERIZED-TOMOGRAPHY; PREDICTING SURVIVAL; PRAGMATIC ANALYSIS; PRACTICAL SCALE	Background: Severe head injury (SHI) is one of the most important health, social and economic problems in industrialised countries. Unfortunately, none of the neuroprotection trials for traumatic brain injury have shown efficacy. One of the reasons for this failure could be the inclusion of patients with high probability of early death. A population-based, retrospective study was conducted to develop a prognostic model for identification of these patients. Methods: Between January 1987 and August 1999, a total of 895 patients (>= 15 years of age) with non-missile SHI were studied, in whom a computed tomography scan was carried out within the first 6 h of injury. The association between early death ( first 48 h after injury) and independent prognostic factors was determined by logistic regression analysis. A scoring system was also constructed. Results: The early-death rate was 20%. Independent predictors of early mortality after SHI were non-evacuated mass ( odds ratio ( OR) 65, 95% confidence interval (CI) 11 to 379), diffuse injury IV ( OR 25, 95% CI 5 to 112), diffuse injury III ( OR 8, 95% CI 3 to 22), flaccidity ( OR 7, 95% CI 3 to 15), non-reactive bilaterally mydriasis ( OR 6, 95% CI 3 to 12), evacuated mass ( OR 4, 95% CI 1 to 11), age >= 65 years ( OR 4, 95% CI 1 to 9), decerebration ( OR 3, 95% CI 2 to 7) and shock ( OR 3, 95% CI 2 to 6). The prognostic model correctly identified 93% of the patients. Conclusions: This prognostic model is based on simple clinical and radiological data readily available during the first 6 h after injury and is useful for identification of early death after SHI.		Boto, GR (corresponding author), Avda Doctor Garcia Tapia,159 Portal D Atico B, Madrid 28030, Spain.	grboto@yahoo.es	Gomez, Pedro/N-5051-2019	Gomez, Pedro/0000-0002-4185-5238			Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; CHOI SC, 1996, NEUROTRAUMA, P779; CLIFTON GL, 1981, NEUROSURGERY, V8, P309, DOI 10.1227/00006123-198103000-00002; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/s001340050269; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; Contant CF, 1996, NEUROLOGICAL SURG, P1792; Dickerson J, 2002, J NEUROSURG, V97, P811, DOI 10.3171/jns.2002.97.4.0811; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; FELDMAN Z, 1991, LANCET, V337, P1451, DOI 10.1016/0140-6736(91)93137-X; FELDMAN Z, 1996, NEUROTRAUMA, P805; GIANNOTTA SL, 1987, HEAD INJURY, P464; GIBSON RM, 1989, LANCET, V2, P369; Hukkelhoven CWPM, 2000, BRIT MED J, V321, P704, DOI 10.1136/bmj.321.7262.704; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Imberti R, 2003, NEUROSURGERY, V53, P241, DOI 10.1227/01.NEU.0000072302.16102.A8; Jennett B, 1975, Ciba Found Symp, P309; JENNETT B, 1975, LANCET, V1, P480; KAUFMANN MA, 1992, RESUSCITATION, V23, P199, DOI 10.1016/0300-9572(92)90003-U; Lang EW, 1997, NEUROL RES, V19, P274, DOI 10.1080/01616412.1997.11740813; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; Marshall L F, 1988, Clin Neurosurg, V34, P549; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; MURRAY GD, 1986, STAT MED, V5, P403, DOI 10.1002/sim.4780050504; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Sekulovic N, 1979, Acta Neurochir Suppl (Wien), V28, P203; Servadei F, 2000, NEUROSURGERY, V46, P70; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; TEASDALE G, 1974, LANCET, V2, P81; VOLLMER DG, 1993, HEAD INJURY, P553; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; YAMAKI T, 1992, ACTA NEUROCHIR, V119, P153, DOI 10.1007/BF01541800	40	27	36	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	SEP	2006	77	9					1054	1059		10.1136/jnnp.2005.087056			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	074MS	WOS:000239817100015	16740580	Green Published, Bronze			2021-06-18	
J	Gill, M; Steele, R; Windemuth, R; Green, SM				Gill, Michelle; Steele, Robert; Windemuth, Ryan; Green, Steven M.			A comparison of five simplified scales to the out-of-hospital Glasgow Coma Scale for the prediction of traumatic brain injury outcomes	ACADEMIC EMERGENCY MEDICINE			English	Article						Glasgow Coma Score; traumatic brain injury; prehospital care; out-of-hospital care	PLACEBO-CONTROLLED TRIAL; MINOR HEAD-INJURY; INTERRATER RELIABILITY; EMERGENCY-DEPARTMENT; MOTOR SCORE; MRC CRASH; HYPOTHERMIA; PREVENTION; ADULTS	Background: The 15-point Glasgow Coma Scale (GCS) frequently is used in the initial evaluation of traumatic brain injury (TBI) in out-of-hospital settings. We hypothesized that the GCS might be unnecessarily complex for out-of-hospital use. Objectives: To assess whether a simpler scoring system might demonstrate similar accuracy in the prediction of TBI outcomes. Methods: We performed a retrospective analysis of a trauma registry consisting of patients evaluated at our Level I trauma center from 1990 to 2002. The ability of out-of-hospital GCS scores to predict four clinically relevant TBI outcomes (emergency intubation, neurosurgical intervention, brain injury, and mortality) by using areas under receiver operating characteristic curves (AUROCs) was calculated. The same analyses for five simplified scales were performed, and compared with the predictive accuracies of the total GCS score. Results: In this evaluation of 7,233 trauma patients over a 12-year period of time, the AUROCs for the total GCS score were 0.83 (95% confidence interval [CI] = 0.81 to 0.84) for emergency intubation, 0.86 (95% Cl = 0.85 to 0.88) for neurosurgical intervention, 0.83 (95% Cl = 0.82 to 0.84) for brain injury, and 0.89 (95% CI = 0.88 to 0.90) for mortality. The five simplified scales approached the performance of the total GCS score for all clinical outcomes. Conclusions: In the evaluation of injured patients, five simplified neurological scales approached the performance of the total GCS score for the prediction of four clinically relevant TBI outcomes.	Loma Linda Univ, Med Ctr, Sch Med, Dept Emergency Med, Loma Linda, CA 92354 USA	Gill, M (corresponding author), Loma Linda Univ, Med Ctr, Sch Med, Dept Emergency Med, 11234 Anderson St,POB 2000,Room A-108, Loma Linda, CA 92354 USA.	mgill@ahs.llumc.edu					Al-Salamah MA, 2004, ACAD EMERG MED, V11, P834, DOI 10.1197/j.aem.2004.03.008; [Anonymous], 1999, RES OPT CAR INJ PAT; BAXT WG, 1989, ANN EMERG MED, V18, P1, DOI 10.1016/S0196-0644(89)80302-6; *BRAIN TRAUM FDN, GUID PREH MAN TRAUM; Bull MJ, 2002, PEDIATRICS, V109, P542; Bull MJ, 2001, PEDIATRICS, V108, P1030; Centers for Disease Control and Prevention, TRAUM BRAIN INJ US R; Chesnut RM, 1998, CRIT CARE MED, V26, P10, DOI 10.1097/00003246-199801000-00008; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Edwards P, 2005, LANCET, V365, P1957; Gabbe BJ, 2004, ACAD EMERG MED, V11, P181, DOI 10.1197/j.aem.2003.08.019; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; GILL M, IN PRESS ANN EMERG M; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Grmec S, 2001, CRIT CARE, V5, P19; HACKNEY RG, 1994, BRIT MED J, V308, P1356, DOI 10.1136/bmj.308.6940.1356; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Hollander JE, 2003, ACAD EMERG MED, V10, P830, DOI 10.1111/j.1553-2712.2003.tb00624.x; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; Mace SE, 2001, ANN EMERG MED, V38, P405, DOI 10.1067/mem.2001.115882; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; Mulholland SA, 2005, INJURY, V36, P1298, DOI 10.1016/j.injury.2005.07.010; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Narayan RK, 2001, NEW ENGL J MED, V344, P602, DOI 10.1056/NEJM200102223440810; Pilkington P, 2005, BMJ-BRIT MED J, V330, P331, DOI 10.1136/bmj.38324.646574.AE; PLANT JR, 1995, ANN EMERG MED, V26, P133, DOI 10.1016/S0196-0644(95)70142-7; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE G, 1974, LANCET, V2, P81; Watts Dorraine D, 2004, Prehosp Emerg Care, V8, P254; World Health Organization, 1977, INT CLASS DIS 9 REV	33	27	29	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	SEP	2006	13	9					968	973		10.1197/j.aem.2006.05.019			6	Emergency Medicine	Emergency Medicine	082DK	WOS:000240366700009	16894005				2021-06-18	
J	Nacajauskaite, O; Endziniene, M; Jureniene, K; Schrader, H				Nacajauskaite, Olga; Endziniene, Milda; Jureniene, Kristina; Schrader, Harald			The validity of post-concussion syndrome in children: A controlled historical cohort study	BRAIN & DEVELOPMENT			English	Article						mild brain injury; post-concussion syndrome; post-traumatic stress syndrome	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; POSTCONCUSSION SYNDROME; SYMPTOM EXPECTATION; BEHAVIOR PROBLEMS; ADOLESCENTS; OUTCOMES; FAMILY; TERM; ETIOLOGY	The aim of this controlled historical cohort study was to assess the validity of post-concussion syndrome in children. We identified 301 children aged 4-15 years who had sustained an isolated brain concussion, and another group of 301 children who sustained any other mild body injury excluding the head. Parents from both groups filled in standardized questionnaires containing questions about the health condition of the children: headache, neck pain, dizziness, malaise, fatigability, exercise or noise intolerance, irritability, weepiness, sadness, anxiety, nocturnal enuresis, tics, sleep disorders, memory or learning difficulties, hyperactivity, seizures, attention disorder, buzzing in the ears, subjective parental concerns about the child's health condition, and parental concerns about their child having a brain disorder. The severity of the complaints was rated on the Visual Analogue Scale. After the final exclusion, 102 pairs strictly matched by sex, age, and the date of trauma were analyzed. The differences of parental complaints about the health condition of their children between case and control groups were statistically insignificant for all symptoms, except parental concerns about their child having brain damage which were significantly higher in the case group. The likelihood of parental concerns about the possibility of their child having brain damage was 2.7 times higher in the case group. Headache, learning difficulties, and sleep disorders were significant variables predicting the concerns. These results question the validity of the post-concussion syndrome in children. (c) 2006 Elsevier B.V. All rights reserved.	Kaunas Univ Med, Dept Neurol, Kaunas, Lithuania; Vilnius State Univ, Childrens Hosp, Ctr Pediat Surg, Vilnius, Lithuania; Kaunas Univ Med, Dept Phys Math & Biol, Kaunas, Lithuania; Univ Trondheim Hosp, Dept Neurol & Clin Neurophysiol, Trondheim, Norway	Endziniene, M (corresponding author), Kaunas Univ Med, Dept Neurol, Mickeviciaus 9, Kaunas, Lithuania.	olgutene@takas.lt; endziniene@centras.lt; harald.schrader@medisin.ntnu.no		Schrader, Harald/0000-0001-9975-1960			Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; BIJUR PE, 1990, PEDIATRICS, V86, P337; Callaghan M, 2001, DEV MED CHILD NEUROL, V43, P819, DOI 10.1017/S0012162201001487; CASEY R, 1986, PEDIATRICS, V78, P497; DAILIDIENE N, 2001, VISUOMENES SVEIKATA, V14, P13; EMANUELSON I, 1999, THESIS U HELSINKI; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P254, DOI 10.1016/S0303-8467(01)00161-5; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P184, DOI 10.1016/S0303-8467(01)00143-3; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Leathem JM, 2000, J HEAD TRAUMA REHAB, V15, P1246, DOI 10.1097/00001199-200012000-00005; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Overweg-Plandsoen WCG, 1999, EUR J PEDIATR, V158, P249, DOI 10.1007/s004310051061; PELCO L, 1992, Brain Injury, V6, P29, DOI 10.3109/02699059209008119; POLISSAR NL, 1994, BRAIN INJURY, V8, P249, DOI 10.3109/02699059409150977; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M; World Health Organization, 1992, ICD 10 INT STAT CLAS; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	45	27	27	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0387-7604	1872-7131		BRAIN DEV-JPN	Brain Dev.	SEP	2006	28	8					507	514		10.1016/j.braindev.2006.02.010			8	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	074UO	WOS:000239837500006	16682158				2021-06-18	
J	Knox, CL; Comstock, RD; McGeehan, J; Smith, GA				Knox, Christy L.; Comstock, R. Dawn; McGeehan, Jennifer; Smith, Gary A.			Differences in the risk associated with head injury for pediatric ice skaters, roller skaters, and in-line skaters	PEDIATRICS			English	Article						skating; recreation; pediatric; head injury; helmet	SKATING INJURIES; WRIST SPLINTS; CHILDREN	OBJECTIVE. The goals were to describe the epidemiologic features of pediatric skating-related injuries sustained from 1993 to 2003 and to compare ice skating - related injuries with roller skating - and in-line skating - related injuries. METHODS. An analysis of pediatric skating-related injury data from the National Electronic Injury Surveillance System of the US Consumer Product Safety Commission was performed. RESULTS. An estimated 1 235 467 pediatric skating participants presented to hospital emergency departments with injuries between 1993 and 2003. These children had a mean age of 10.9 years (SD: 3.2 years; range: 1 - 18 years), and 50.0% were male. The most common mechanism of injury was a fall (83.1%). Ice skaters sustained a greater proportion of head injuries (13.3%), compared with roller skaters (4.4%) and in-line skaters (5.0%). Ice skaters also experienced a greater proportion of concussions (4.3%), compared with roller skaters (0.6%) and in-line skaters (0.8%). The proportion of facial injuries among ice skaters was greater than the proportions among roller skaters and in-line skaters. The majority of roller skating - and in-line skating - related injuries were upper-extremity fractures (53.9% and 59.7%, respectively). Children <= 6 years of age experienced a greater proportion of head and facial injuries than did older children in each skating activity. CONCLUSIONS. The epidemiologic features of pediatric ice skating - related injuries differ from those of roller skating - and in-line skating - related injuries. Children should wear helmets during all recreational skating activities, especially ice skating, because of the risk of serious head injuries. Wrist guards should be worn to protect against the common upper-extremity fractures sustained during skating.	Childrens Hosp, Columbus Childrens Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Pediat, Columbus, OH 43210 USA	Knox, CL (corresponding author), Childrens Hosp, Columbus Childrens Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	knoxc@pediatrics.ohio-state.edu					Boyce SH, 2001, SCOT MED J, V46, P102, DOI 10.1177/003693300104600403; Cheng SL, 1995, J TRAUMA, V39, P1194, DOI 10.1097/00005373-199512000-00036; de Nooijer J, 2004, EUR J PUBLIC HEALTH, V14, P178, DOI 10.1093/eurpub/14.2.178; FREELAND P, 1998, BRIT MED J, V296, P96; Hassan I, 1999, J ACCID EMERG MED, V16, P348; Katcher ML, 1998, PEDIATRICS, V101, P720; Knox CL, 2006, BRIT J SPORT MED, V40, P268, DOI 10.1136/bjsm.2005.022855; Lam C. K., 1997, Hong Kong Medical Journal, V3, P131; McGeehan J, 2004, PEDIATRICS, V114, P124, DOI 10.1542/peds.114.1.124; McGrath D, 1996, J ACCID EMERG MED, V13, P354; *NAT SAF KIDS CAMP, 2004, RECR INJ FACT SHEET; Nguyen D, 2001, J PEDIATR ORTHOPED, V21, P613, DOI 10.1097/00004694-200109000-00012; O'Farrell DA, 1997, INJURY, V28, P377, DOI 10.1016/S0020-1383(97)00030-2; Osberg JS, 1998, ARCH PEDIAT ADOL MED, V152, P985; Powell EC, 1996, PEDIATR EMERG CARE, V12, P259, DOI 10.1097/00006565-199608000-00006; Pudpud AA, 1997, PEDIATR EMERG CARE, V13, P376, DOI 10.1097/00006565-199712000-00004; Schieber RA, 1996, NEW ENGL J MED, V335, P1630, DOI 10.1056/NEJM199611283352202; SCHIEBER RA, 1995, SPORTS MED, V19, P427, DOI 10.2165/00007256-199519060-00006; *US CONS PROD SAF, NEISS SAMPL DES IMPL	19	27	29	0	11	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	AUG	2006	118	2					549	554		10.1542/peds.2005-2913			6	Pediatrics	Pediatrics	069IW	WOS:000239440600014	16882806				2021-06-18	
J	Davis, DP; Fisher, R; Buono, C; Brainard, C; Smith, S; Ochs, G; Poste, JC; Dunford, JV				Davis, Daniel P.; Fisher, Roger; Buono, Colleen; Brainard, Criss; Smith, Susan; Ochs, Ginger; Poste, Jennifer C.; Dunford, James V.			Predictors of intubation success and therapeutic value of paramedic airway management in a large, urban EMS system	PREHOSPITAL EMERGENCY CARE			English	Article; Proceedings Paper	Field Triage 2005 - A Meeting of Experts	MAY 17-18, 2005	Atlanta, GA	Natl Ctr Injury Preven & Control, Ctrs Disease Control & Preven, Div Injury Response		endotracheal intubation; emergency medical services; end-tidal carbon dioxide	RAPID-SEQUENCE INTUBATION; TRAUMATIC BRAIN-INJURY; MEDICAL-SERVICES SYSTEM; PULSE OXIMETER ACCURACY; TIDAL CARBON-DIOXIDE; SEVERE HEAD-INJURY; BAG-VALVE-MASK; ENDOTRACHEAL INTUBATION; CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION	Background. Endotracheal intubation (ETI) is commonly used by paramedics for definitive airway management. The predictors of success and therapeutic value with regard to oxygenation are not well studied. Objectives. 1) To explore the relationship between intubation success and perfusion status, Glasgow Coma Scale (GCS) score, and end-tidal carbon dioxide (EtCO2); 2) to describe the incidence of unrecognized esophageal intubations with use of continuous capnometry; and 3) to document the incremental benefit of invasive versus noninvasive airway management techniques in correcting hypoxemia. Methods. This was a prospective, observational study conducted in a large urban emergency medical services system. Paramedics completed a telephone debriefing interview with quality assurance personnel following delivery of all patients in whom invasive airway management had been attempted. Continuous capnometry was used for confirmation of tube position in all patients. Descriptive statistics were used to document airway management performance, including first-attempt ETI success, overall ETI success, and Combitube insertion (CTI) success. In addition, the incidence of unrecognized esophageal intubation was recorded. The relationship between intubation success and perfusion status, GCS score, and initial EtCO2 value was explored using logistic regression. Finally, recorded SpO(2) values and the incidence of hypoxemia (SpO(2) < 90%) at baseline, following noninvasive airway maneuvers, and after invasive airway management were compared for perfusing patients. Results. A total of 703 patients were enrolled over 12 months. First-attempt ETI success was 61%, and overall ETI success was 81%; invasive airway management ( ETI or CTI) was unsuccessful in 11% of patients. A single unrecognized esophageal intubation was observed (0.1%). A clear relationship between airway management success and perfusion status, GCS score, and initial EtCO2 value was observed. Only EtCO2 demonstrated an independent association with ETI success after adjusting for the other variables. Significant improvements in mean SpO(2) and the incidence of hypoxemia over baseline were observed with both noninvasive and invasive airway management techniques in 168 perfusing patients. Conclusions. A relationship between intubation success and perfusion status, GCS score, and initial EtCO2 value was observed. Capnometry was effective in eliminating unrecognized esophageal intubations. Both noninvasive and invasive airway management strategies were effective in increasing SpO(2) values and decreasing the incidence of hypoxemia, with additional benefit observed with invasive airway maneuvers in some patients.	Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; San Diego Med Serv Enterprise, San Diego, CA USA	Davis, DP (corresponding author), UCSD Emergency Med, 200 W Arbor Dr,8676, San Diego, CA 92103 USA.	davismd@cox.net					APRAHAMIAN C, 1985, ANN EMERG MED, V14, P583, DOI 10.1016/S0196-0644(85)80785-X; Aslanyan S, 2004, EUR J NEUROL, V11, P49, DOI 10.1046/j.1468-1331.2003.00749.x; ATHERTON GL, 1993, ANN EMERG MED, V22, P1263, DOI 10.1016/S0196-0644(05)80104-0; Aufderheide Tom P, 2004, Crit Care Med, V32, pS345, DOI 10.1097/01.CCM.0000134335.46859.09; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; BARKER SJ, 1993, ANESTHESIOLOGY, V79, P248, DOI 10.1097/00000542-199308000-00009; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; CHAWLA R, 1992, ANESTH ANALG, V74, P196, DOI 10.1213/00000539-199202000-00004; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; DAVIS DP, 2004, J TRAUMA; DAVIS DP, 2005, J TRAUMA; Doerges V, 1999, RESUSCITATION, V41, P63, DOI 10.1016/S0300-9572(99)00036-2; Dorges V, 2003, CRIT CARE MED, V31, P800, DOI 10.1097/01.CCM.0000054869.21603.9A; Dorges V, 2000, RESUSCITATION, V44, P37, DOI 10.1016/S0300-9572(99)00161-6; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Falcone R E, 1996, Air Med J, V15, P163, DOI 10.1016/S1067-991X(96)90024-3; Garza AG, 2003, J EMERG MED, V25, P251, DOI 10.1016/S0736-4679(03)00198-7; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Harrison TH, 2004, PEDIATR EMERG CARE, V20, P101, DOI 10.1097/01.pec.0000113879.10140.7f; Hatley T, 1998, J Emerg Med, V16, P731, DOI 10.1016/S0736-4679(98)00087-0; HEDGES JR, 1988, ANN EMERG MED, V17, P469, DOI 10.1016/S0196-0644(88)80238-5; JAY GD, 1994, ANN EMERG MED, P24; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; LANGBAUM M, 1994, J PEDIATR-US, V125, P591, DOI 10.1016/S0022-3476(94)70016-8; LAWSON D, 1987, ANESTHESIOLOGY, V67, P599, DOI 10.1097/00000542-198710000-00032; Levine RL, 1997, NEW ENGL J MED, V337, P301, DOI 10.1056/NEJM199707313370503; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MATEER JR, 1993, ANN EMERG MED, V22, P675, DOI 10.1016/S0196-0644(05)81846-3; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Ochs M, 2000, Prehosp Emerg Care, V4, P333, DOI 10.1080/10903120090941065; Pace SA, 2000, ANN EMERG MED, V35, P568, DOI 10.1016/S0196-0644(00)70029-1; Pepe PE, 2003, J TRAUMA, V54, P1048, DOI 10.1097/01.TA.0000064280.05372.7C; Sagarin MJ, 2002, PEDIATR EMERG CARE, V18, P417, DOI 10.1097/00006565-200212000-00004; Sehra R, 2003, PACE, V26, P515, DOI 10.1046/j.1460-9592.2003.00085.x; SEVERINGHAUS JW, 1990, J CLIN MONITOR, V6, P85, DOI 10.1007/BF02828282; Silvestri S, 2005, ANN EMERG MED, V45, P497, DOI 10.1016/j.annemergmed.2004.09.014; Sing RF, 1998, AM J EMERG MED, V16, P598, DOI 10.1016/S0735-6757(98)90227-3; Sivilotti MLA, 2003, ACAD EMERG MED, V10, P612, DOI 10.1197/aemj.10.6.612; SMITH JP, 1985, JAMA-J AM MED ASSOC, V253, P544, DOI 10.1001/jama.253.4.544; SYVERUD SA, 1988, ANN EMERG MED, V17, P236, DOI 10.1016/S0196-0644(88)80114-8; VADEBONCOEUR TF, 2004, J EMERG MED; Vilke Gary M., 1994, Journal of Emergency Medicine, V12, P217, DOI 10.1016/0736-4679(94)90702-1; Vilke GM, 2002, J EMERG MED, V22, P71, DOI 10.1016/S0736-4679(01)00439-5; Wang H E, 2001, Prehosp Emerg Care, V5, P10, DOI 10.1080/10903120190940254; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916; Wenzel V, 2001, RESUSCITATION, V49, P123, DOI 10.1016/S0300-9572(00)00349-X; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592; 2005, RESUSCITATION, V46, P1	54	27	27	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1090-3127			PREHOSP EMERG CARE	Prehosp. Emerg. Care	JUL-SEP	2006	10	3					356	362		10.1080/10903120600725751			7	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	110RQ	WOS:000242396800019	16801280				2021-06-18	
J	Salem, KH; Lindemann, I; Keppler, P				Salem, KH; Lindemann, I; Keppler, P			Flexible intramedullary nailing in pediatric lower limb fractures	JOURNAL OF PEDIATRIC ORTHOPAEDICS			English	Article						eSIN nails; pediatric femoral fractures; torsion; malalignment; limb length discrepancy	FEMORAL-SHAFT FRACTURES; FEMUR FRACTURES; LONG BONES; CHILDREN; COMPLICATIONS; FIXATION; ADOLESCENT; HEAD; PLATE	Seventy-three children (48 boys and 25 girls; mean age, 5.7 years) with unilateral femoral or tibial shaft fractures were treated using elastic intramedullary nails at the authors' institution. There were 61 simple type A fractures (84%) and 12 wedge type B fractures (16%). All but 3 children had closed fractures. Associated injuries were seen in one third of the cases. All fractures were reduced by closed manipulation. Union was achieved in all cases without additional intervention. Technical problems Occurred in few patients. Improper nail length was seen in 4 cases. None of the study patients developed deep infection. No angulation greater than 15 degrees was found after femoral fractures. Nine patients had length discrepancy greater than 10 turn. Spiral fractures showed a tendency for shortening whereas transverse fractures were more associated with post-traumatic lengthening. No significant axial malalignment or shortening was seen in tibial fractures. Torsional differences of greater than 15 degrees were detected by computed tomography or navigated ultrasound examination in nearly half of the patients: however, only 4 children had clinically apparent gait changes. The study confirms the satisfactory results of treating pediatric lower limb fractures using elastic nails. Proper surgical technique and intraoperative control of limb alignment can help avoid postoperative deformities.	Univ Ulm, Dept Trauma Hand & Reconstruct Surg, D-89075 Ulm, Germany; Cairo Univ, Fac Med, Dept Orthopaed Surg, Cairo, Egypt	Salem, KH (corresponding author), Univ Ulm, Dept Trauma Hand & Reconstruct Surg, Steinhoevelstr 9, D-89075 Ulm, Germany.	khaled_hamedsalem@hotmail.com					BEATY JH, 1994, J PEDIATR ORTHOPED, V14, P178, DOI 10.1097/01241398-199403000-00009; Buechsenschuetz KE, 2002, J TRAUMA, V53, P914, DOI 10.1097/00005373-200211000-00017; Carey TP, 1996, CLIN ORTHOP RELAT R, P110; Christian C. A., 1998, CAMPBELLS OPERATIVE, P1993; DIETZ HG, 1997, INTRAMEDULLARE OSTEO; Dietz HG, 1993, LANGENBECKS ARCH C S, P946; Ender J, 1970, ACTA CHIR AUSTRIACA, V2, P40; Firica A, 1978, Ital J Orthop Traumatol, V4, P23; Flynn JM, 2001, J PEDIATR ORTHOPED, V21, P4, DOI 10.1097/01241398-200101000-00003; GLENN JN, 1973, J TRAUMA, V13, P958, DOI 10.1097/00005373-197311000-00004; GUSTILO RB, 1976, J BONE JOINT SURG AM, V58, P453, DOI 10.2106/00004623-197658040-00004; HANSEN TB, 1992, ACTA ORTHOP SCAND, V63, P50, DOI 10.3109/17453679209154849; Heinrich S D, 1992, J Orthop Trauma, V6, P452, DOI 10.1097/00005131-199212000-00011; HUGHES BF, 1995, J PEDIATR ORTHOPED, V15, P457, DOI 10.1097/01241398-199507000-00009; Kasser James R., 1996, P1195; Knorr P, 1996, UNFALLCHIRURG, V99, P410; KREGOR PJ, 1993, J BONE JOINT SURG AM, V75A, P1774, DOI 10.2106/00004623-199312000-00006; LASCOMBES P, 1988, REV CHIR ORTHOP, V74, P293; Lascombes P, 1993, HEFTE UNFALLCHIRURG, V230, P955; LIGIER JN, 1985, Z KINDERCHIR, V40, P209; LIGIER JN, 1988, J BONE JOINT SURG BR, V70, P74; Linhart WE, 1999, J TRAUMA, V47, P372, DOI 10.1097/00005373-199908000-00028; Maier M, 2003, UNFALLCHIRURG, V106, P48, DOI 10.1007/s00113-002-0481-9; Metaizeau JP, 2004, J BONE JOINT SURG BR, V86B, P954, DOI 10.1302/0301-620X.86B7.15620; Narayanan UG, 2004, J PEDIATR ORTHOPED, V24, P363, DOI 10.1097/01241398-200407000-00004; Oh CW, 2002, INT ORTHOP, V26, P52, DOI 10.1007/s00264-001-0304-6; OMALLEY DE, 1995, J PEDIATR ORTHOPED, V15, P21, DOI 10.1097/01241398-199501000-00005; Prevot J, 1993, Chirurgie, V119, P473; PREVOT J, 1995, HEFTE UNFALLCHIR, V249, P77; RANEY EM, 1993, J PEDIATR ORTHOPED, V13, P516, DOI 10.1097/01241398-199307000-00018; Scharli A F, 1989, Z Unfallchir Versicherungsmed Berufskr, V82, P216; SCHMITTENBECHER PP, 1995, OPERAT ORTHOP TRAUMA, V7, P215; SHANNAK AO, 1988, J PEDIATR ORTHOPED, V8, P306, DOI 10.1097/01241398-198805000-00010; THOMETZ JG, 1995, J BONE JOINT SURG AM, V77, P1423, DOI 10.2106/00004623-199509000-00019; Tscherne H, 1984, FRACTURES SOFT TISSU; Vinz H, 1972, Zentralbl Chir, V97, P90; WARD WT, 1992, J PEDIATR ORTHOPED, V12, P626	37	27	31	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-6798			J PEDIATR ORTHOPED	J. Pediatr. Orthop.	JUL-AUG	2006	26	4					505	509		10.1097/01.bpo.0000217733.31664.a1			5	Orthopedics; Pediatrics	Orthopedics; Pediatrics	059NR	WOS:000238740000015	16791070				2021-06-18	
J	Shiga, T; Ikoma, K; Katoh, C; Isoyama, H; Matsuyama, T; Kuge, Y; Kageyama, H; Kohno, T; Terae, S; Tamaki, N				Shiga, T; Ikoma, K; Katoh, C; Isoyama, H; Matsuyama, T; Kuge, Y; Kageyama, H; Kohno, T; Terae, S; Tamaki, N			Loss of neuronal integrity: a cause of hypometabolism in patients with traumatic brain injury without MRI abnormality in the chronic stage	EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING			English	Article						brain imaging; PET; MRI; flumazenil; traumatic brain injury	POSITRON-EMISSION-TOMOGRAPHY; I-123 IOMAZENIL SPECT; CEREBRAL-ISCHEMIA; CORTICAL DAMAGE; FLUMAZENIL-PET; HEAD-INJURY; BLOOD-FLOW; INFARCTION; EPILEPSY; STROKE	Purpose: Traumatic brain injury (TBI) causes brain dysfunction in many patients. However, some patients have severe brain dysfunction but display no abnormalities on magnetic resonance imaging (MRI). There have been some reports of hypometabolism even in such patients. The purpose of this study was to investigate the relationship between metabolic abnormality and loss of neuronal integrity in TBI patients with some symptoms but without MRI abnormalities. Methods: The study population comprised ten patients with TBI and ten normal volunteers. All of the patients were examined at least 1 year after the injury. O-15-labelled gas PET and [C-11]flumazenil (FMZ) positron emission tomography (PET) were carried out. The cerebral metabolic rate of oxygen (CMRO2) and binding potential (BP) images of FMZ were calculated. Axial T2WI, T2*WI and FLAIR images were obtained. Coronal images were added in some cases. Results: All of the patients had normal MRI findings, and all showed areas with abnormally low CMRO2. Low uptake on BP images was observed in six patients (60%). No lesions that showed low uptake on BP images were without low CMRO2. On the other hand, there were 14 lesions with low CMRO2 but without BP abnormalities. Conclusion: These results indicate that there are metabolic abnormalities in TBI patients with some symptoms after brain injury but without abnormalities on MRI. Some of the hypometabolic lesions showed low BP, indicating a loss of neuronal integrity. Thus, FMZ PET may have potential to distinguish hypometabolism caused by neuronal loss from that caused by other factors.	Hokkaido Univ, Sch Med, Dept Nucl Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Dept Rehabil, Sapporo, Hokkaido, Japan; Hokkaido Univ, Dept Tracer Kinet, Sapporo, Hokkaido, Japan; Hokkaido Univ, Dept Radiol, Sapporo, Hokkaido, Japan	Shiga, T (corresponding author), Hokkaido Univ, Sch Med, Dept Nucl Med, Kita Ku, North 15th,West 7th, Sapporo, Hokkaido 0608638, Japan.	tshiga@med.hokudai.ac.jp	Shiga, Tohru/D-9072-2012; Kuge, Yuji/E-1290-2012; Yasuda, Kazunori/D-4156-2012; Terae, Satoshi/D-7587-2012; Ikoma, Katsunori/D-8158-2012				ADAMS JH, 1991, NEUROIMAG CLIN N AM, P397; ADRIAAN AL, 1996, NEUROIMAGE, V4, P153; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Goshen E, 1996, NUCL MED COMMUN, V17, P418, DOI 10.1097/00006231-199605000-00011; HAGLUND MM, 1992, J NEUROSURG, V77, P209, DOI 10.3171/jns.1992.77.2.0209; Heiss WD, 2000, STROKE, V31, P366, DOI 10.1161/01.STR.31.2.366; Heiss WD, 1998, STROKE, V29, P454, DOI 10.1161/01.STR.29.2.454; Heiss WD, 2001, CEREBROVASC DIS, V11, P73, DOI 10.1159/000047616; Heiss WD, 2001, BRAIN, V124, P20, DOI 10.1093/brain/124.1.20; Juhasz C, 1999, EPILEPSIA, V40, P566, DOI 10.1111/j.1528-1157.1999.tb05558.x; Kaji T, 2004, EUR J NUCL MED MOL I, V31, P64, DOI 10.1007/s00259-003-1319-6; Kuroda S, 2004, J NUCL MED, V45, P943; Mattioli F, 1996, CORTEX, V32, P121, DOI 10.1016/S0010-9452(96)80021-9; MAZIERE M, 1983, CR ACAD SCI III-VIE, V296, P871; Moriwaki Hiroshi, 1996, Kaku Igaku, V33, P587; Muller V, 2002, NUCL MED COMMUN, V23, P1191, DOI 10.1097/01.mnm.0000046211.83338.0c; Nakagawara J, 1997, STROKE, V28, P124, DOI 10.1161/01.STR.28.1.124; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; Ohyama M, 1999, ANN NUCL MED, V13, P309, DOI 10.1007/BF03164869; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Rudolf J, 2000, LANCET, V355, P115, DOI 10.1016/S0140-6736(99)04280-4; Ryvlin P, 1999, NEUROLOGY, V53, P1882, DOI 10.1212/WNL.53.8.1882; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Shiga T, 2001, CLIN NUCL MED, V26, P334, DOI 10.1097/00003072-200104000-00011; Shiozaki T, 2001, J NEUROTRAUM, V18, P665, DOI 10.1089/089771501750357618; Son BC, 2000, ACT NEUR S, V76, P13; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tsuchida T, 1999, ANN NUCL MED, V13, P265, DOI 10.1007/BF03164903; Wechsler D., 1981, WAIS R MANUAL WECHSL; Wolf HK, 1996, ACTA NEUROPATHOL, V91, P376, DOI 10.1007/s004010050439	31	27	27	0	1	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	1619-7070			EUR J NUCL MED MOL I	Eur. J. Nucl. Med. Mol. Imaging	JUL	2006	33	7					817	822		10.1007/s00259-005-0033-y			6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	058MK	WOS:000238668900009	16565846				2021-06-18	
J	Rodriguez, SR; Mallonee, S; Archer, A; Gofton, J				Rodriguez, SR; Mallonee, S; Archer, A; Gofton, J			Evaluation of death certificate-based surveillance for traumatic brain injury - Oklahoma 2002	PUBLIC HEALTH REPORTS			English	Article							MEDICAL EXAMINER; NEW-MEXICO; ACCURACY; COMPLETION	Objectives. Death certificate data are used to estimate state and national incidence of traumatic brain injury (TBI)-related deaths. This study evaluated the accuracy of this estimate in Oklahoma and examined the case characteristics of those persons who experienced a TBI-related death but whose death certificate did not reflect a TBI. Methods. Data from Oklahoma's vital statistics multiple-cause-of-death database and from the Oklahoma Injury Surveillance System database were analyzed for TBI deaths that occurred during 2002. Cases were defined using the Centers for Disease Control and Prevention (CDC) ICD-10 code case definition. In multivariate analysis using a logistic regression model, we examined the association of case characteristics and the absence of a death certificate for persons who experienced a TBI-related death. Results. Overall, sensitivity of death certificate-based surveillance was 78%. The majority (62%) of missed cases were due to listing "multiple trauma" as the cause of death. Death certificate surveillance was more likely to miss TBI-related deaths among traffic crashes, falls, and persons aged <= 65 years. After adding missed cases to cases captured by death certificate surveillance, traffic crashes surpassed firearm fatalities as the leading external cause of TBI-related death. Conclusions. Death certificate surveillance underestimated TBI-related death in Oklahoma and might lead to national underreporting. More accurate and detailed completion of death certificates would result in better estimates of the burden of TBI-related death. Educational efforts to improve death certificate completion could substantially increase the accuracy of mortality statistics.	Oklahoma Dept Hlth, Off Sci Affairs, Oklahoma City, OK 73117 USA; Oklahoma Dept Hlth, Injury Prevent Program, Oklahoma City, OK 73117 USA; Oklahoma Chief Med Examiner, Oklahoma City, OK USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA	Rodriguez, SR (corresponding author), Oklahoma Dept Hlth, Communicable Dis Div, 1000 NE 10th St, Oklahoma City, OK 73117 USA.	sara@health.ok.gov			ODCDC CDC HHS [U17/CCU611902] Funding Source: Medline		Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Archer P, 1996, MMWR-MORBID MORTAL W, V45, P209; Archer PJ, 1998, AM J PREV MED, V15, P83, DOI 10.1016/S0749-3797(98)00054-3; BONNIE RJ, 1999, REDUCING BURDEN INJU, P78; *CDCP, 2005, INSTR CLASS MULT CAU; *CENS BUR, 2003, METR STAT AR COMP; Centers for Disease Control and Prevention, 2003, NAT VIOL DEATH REP S; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P303; Chugh SS, 2004, J AM COLL CARDIOL, V44, P1268, DOI 10.1016/j.jacc.2004.06.029; Comstock RD, 2005, INJURY PREV, V11, P58, DOI 10.1136/ip.2004.007567; Coultas DB, 1996, THORAX, V51, P717, DOI 10.1136/thx.51.7.717; CROSS J, 2003, MMWR-MORBID MORTAL W, V52, P276; *DEP LAB, 1995 1999 CHARTB; DIJKHUIS H, 1994, AM J EPIDEMIOL, V139, P637, DOI 10.1093/oxfordjournals.aje.a117053; Gabella B, 1997, ANN EPIDEMIOL, V7, P207, DOI 10.1016/S1047-2797(96)00150-0; Horan JM, 2003, EPIDEMIOL REV, V25, P24, DOI 10.1093/epirev/mxg010; HOYERT DL, 2005, NATL VITAL STAT REP, V523, P1; *INF INC, 2004, LINKPR V301; JORDAN JM, 1993, CLIN INVEST MED, V16, P249; KRAUS JF, 1995, AM J EPIDEMIOL, V141, P973, DOI 10.1093/oxfordjournals.aje.a117364; Lakkireddy DR, 2004, AM J MED, V117, P492, DOI 10.1016/j.amjmed.2004.04.018; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; LAPIDUS G, 1994, ACCIDENT ANAL PREV, V26, P535, DOI 10.1016/0001-4575(94)90044-2; Lloyd-Jones DM, 1998, ANN INTERN MED, V129, P1020, DOI 10.7326/0003-4819-129-12-199812150-00005; Lyman JM, 2004, DEATH STUD, V28, P659, DOI 10.1080/07481180490476515; Marr AL., 2004, CENTRAL NERVOUS SYST; MAUDSLEY G, 1993, J PUBLIC HEALTH MED, V15, P192; Messite J, 1996, JAMA-J AM MED ASSOC, V275, P794, DOI 10.1001/jama.275.10.794; MOOLENAAR RL, 1995, WESTERN J MED, V163, P431; Myers KA, 1998, CAN MED ASSOC J, V158, P1317; Nelson David E., 1993, Morbidity and Mortality Weekly Report, V42, P29; Bridges C B, 2001, MMWR Recomm Rep, V50, P1; Pezzotti P, 2003, INT J EPIDEMIOL, V32, P778, DOI 10.1093/ije/dyg202; SAS Institute, 2004, SAS 9 1; Schootman M, 2000, J TRAUMA, V48, P70, DOI 10.1097/00005373-200001000-00012; THURMAN DJ, 2001, HEAD TRAUMA BASIC PR; Washko RM, 1996, PUBLIC HEALTH REP, V111, P251; Will JC, 2001, J CLIN EPIDEMIOL, V54, P239, DOI 10.1016/S0895-4356(00)00303-6; World Health Organization, 1992, ICD 10 INT STAT CLAS	41	27	27	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0033-3549	1468-2877		PUBLIC HEALTH REP	Public Health Rep.	MAY-JUN	2006	121	3					282	289		10.1177/003335490612100310			8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	034HF	WOS:000236919200010	16640151	Green Published			2021-06-18	
J	Giles, GM; Manchester, D				Giles, GM; Manchester, D			Two approaches to behavior disorder after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	Galveston Brain Injury Conference (GBIC)	APR, 2005	Galveston, TX	Moody Fdn		behavior disorder; extinction; motivational interviewing; non-aversive treatment; rehabilitation; therapeutic relationship	NONCONTINGENT REINFORCEMENT; THERAPEUTIC ALLIANCE; AGGRESSIVE-BEHAVIOR; WORKING ALLIANCE; SOCIAL EXCLUSION; OVERT AGGRESSION; REHABILITATION; MANAGEMENT; REDUCTION; ATTENTION	A 3-stage model of intervention is used to contrast the philosophy and treatment practices of 2 behavioral approaches to behavior disorder following traumatic brain injury. The first referred to here as the Operant Neurobehavioral Approach developed from neuropsychology and learning theory. The second referred to as the Relational Neurobehavioral Approach builds on the nonaversive behavioral techniques of the Operant Neurobehavioral Approach. It also incorporates principles of motivational interviewing, places more overt emphasis on the therapeutic relationship, and targets staff attributions for aggression in staff training. The strengths and weaknesses of both approaches are discussed. It is suggested that the Relational Neurobehavioral Approach is more likely to engage and/or reengage clients with traumatic brain injury who are resistant to behavior change. Research implications are discussed including the need to measure the fidelity of all intervention variables.	Samuel Merritt Coll, OTRL, FAOTA, Oakland, CA 94609 USA; Crestwood Treatment Ctr, Fremont, CA USA; Anson Med Ctr, Manchester, Lancs, England	Giles, GM (corresponding author), Samuel Merritt Coll, OTRL, FAOTA, 450 30th Str, Oakland, CA 94609 USA.	ggiles@samuelmerritt.edu					ALDERMAN N, 1994, NEUROPSYCHOL REHABIL, V4, P31, DOI 10.1080/09602019408401454; Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Alderman N, 1999, BRAIN INJURY, V13, P669; ALDERMAN N, 1991, NEUROPSYCHOL REHABIL, V1, P65, DOI DOI 10.1080/09602019108401380; Barrowclough C, 2003, CLIN PSYCHOL REV, V23, P849, DOI 10.1016/S0272-7358(03)00075-8; Baumeister RF, 2005, J PERS SOC PSYCHOL, V88, P589, DOI 10.1037/0022-3514.88.4.589; BLACKERBY EF, 1988, J HEAD TRAUMA REHAB, V3, P33; BREHM SS, 1981, THEORY FREEDOM CONTR; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BURKE WH, 1986, INT J REHABIL RES, V9, P335, DOI 10.1097/00004356-198612000-00003; BURKE WH, 1988, INT J REHABIL RES, V11, P235, DOI 10.1097/00004356-198809000-00003; BURNS DD, 1996, THERAPEUTIC EMPATHY; Castonguay LG, 1996, J CONSULT CLIN PSYCH, V64, P497, DOI 10.1037/0022-006X.64.3.497; EAMES P, 1992, J NEUROL NEUROSUR PS, V55, P1046, DOI 10.1136/jnnp.55.11.1046; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; Eames P, 1985, Int Rehabil Med, V7, P130; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; FESTINGER L, 1959, J ABNORM SOC PSYCH, V58, P203, DOI 10.1037/h0041593; Fluharty G, 2001, BRAIN INJURY, V15, P995, DOI 10.1080/02699050010025795; Follette WC, 1996, BEHAV THER, V27, P623, DOI 10.1016/S0005-7894(96)80047-5; FOWLES GP, 1995, CLIN NEUROPSYCHOL, V9, P251, DOI 10.1080/13854049508400490; Giles G. M., 1999, REHABILITATION SEVER, P81; GILES GM, 1989, J CLIN EXP NEUROPSYC, V11, P311, DOI 10.1080/01688638908400891; Giles GM, 2005, BRAIN INJURY, V19, P753, DOI 10.1080/02699050500110108; Giles GM, 2005, COGNITION OCCUPATION, P139; GILES GM, 1993, BRAIN INJURY REHAB N; HAGOPIAN LP, 1994, J APPL BEHAV ANAL, V27, P317, DOI 10.1901/jaba.1994.27-317; Heflin L. J., 2001, FOCUS AUTISM OTHER D, V16, P93, DOI DOI 10.1177/108835760101600205; HORVATH AO, 1991, J COUNS PSYCHOL, V38, P139, DOI 10.1037/0022-0167.38.2.139; HORVATH AO, 1989, J COUNS PSYCHOL, V36, P223, DOI 10.1037/0022-0167.36.2.223; JOHNSON T, 1986, J PERS SOC PSYCHOL, V3, P1; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Koestner R, 2002, J PERS SOC PSYCHOL, V83, P231, DOI 10.1037//0022-3514.83.1.231; KULIK JA, 1979, J EXP SOC PSYCHOL, V15, P183, DOI 10.1016/0022-1031(79)90029-5; LUBORSKY L, 1985, ARCH GEN PSYCHIAT, V42, P602; MACE FC, 1991, J APPL BEHAV ANAL, V24, P553, DOI 10.1901/jaba.1991.24-553; Man DWK, 2001, BRAIN INJURY, V15, P961, DOI 10.1080/02699050110065664; Manchester D, 1997, BRAIN INJURY, V11, P271; Manchester D, 2001, BRAIN DAM B, P157; MANCHESTER D, 2002, THESIS SURREY U; MANCHESTER D, IN PRESS NEUROPSYCHO; Martin DJ, 2000, J CONSULT CLIN PSYCH, V68, P438, DOI 10.1037//0022-006X.68.3.438; Miller W. R., 2002, MOTIVATIONAL INTERVI; Miller WR, 2001, BEHAV COGN PSYCHOTH, V29, P457, DOI 10.1017/S1352465801004064; MILLER WR, 1993, J CONSULT CLIN PSYCH, V61, P455, DOI 10.1037/0022-006X.61.3.455; NOVACO RW, 1989, CLIN APPROACHES VIOL, P39; ORLINSKY DE, 1994, HDB PSYCHOTHERAPY BE, V4, P270; PETERS M D, 1992, Brain Injury, V6, P299, DOI 10.3109/02699059209034944; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037//0022-006X.51.3.390; ROOLNICK S, 1999, HLTH BEHAV CHANG PRA; ROSENHAN DL, 1973, SCIENCE, V179, P250, DOI 10.1126/science.179.4070.250; Rothwell NA, 1999, BRAIN INJURY, V13, P521; SHELDON KM, 2001, LIFE GOALS WELL BEIN, P18; Skinner BF, 1938, BEHAV ORGANISMS; Smith RG, 1997, J APPL BEHAV ANAL, V30, P343, DOI 10.1901/jaba.1997.30-343; Swan L, 2004, BRAIN INJURY, V18, P143, DOI 10.1080/02699050310001596923; TERRACE HS, 1963, J EXP ANAL BEHAV, V6, P1, DOI 10.1901/jeab.1963.6-1; Triandis H. C., 1977, INTERPERSONAL BEHAV; Turner J. M., 1990, BEHAV RESIDENTIAL TR, V5, P15, DOI [10.1002/bin.2360050103, DOI 10.1002/BIN.2360050103]; Twenge JM, 2001, J PERS SOC PSYCHOL, V81, P1058, DOI 10.1037/0022-3514.81.6.1058; VOLLMER TR, 1993, J APPL BEHAV ANAL, V26, P9, DOI 10.1901/jaba.1993.26-9; Watson C, 2001, BRAIN INJURY, V15, P1003, DOI 10.1080/02699050010022662; WESOLOWSKI MD, 1992, BEHAV RESIDENTIAL TR, V7, P205; Whittington R, 1996, BRIT J CLIN PSYCHOL, V35, P11, DOI 10.1111/j.2044-8260.1996.tb01158.x; Willis TJ, 2003, J HEAD TRAUMA REHAB, V18, P75, DOI 10.1097/00001199-200301000-00008; Wilson S, 1998, Int J Nurs Pract, V4, P51, DOI 10.1111/j.1440-172X.1998.00068.x; WOOD RL, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P153; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746; Woody SR, 2002, BEHAV THER, V33, P5, DOI 10.1016/S0005-7894(02)80003-X; Yuen HK, 1996, BRAIN INJURY, V10, P229, DOI 10.1080/026990596124548; Zencius A H, 1989, Brain Inj, V3, P199, DOI 10.3109/02699058909004553; Zimbardo P.G., 1991, PSYCHOL ATTITUDE CHA	73	27	28	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2006	21	2					168	178		10.1097/00001199-200603000-00009			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	031PK	WOS:000236716300008	16569990				2021-06-18	
J	Hillman, J; Milos, P; Yu, ZQ; Sjogren, F; Anderson, C; Mellergard, P				Hillman, J; Milos, P; Yu, ZQ; Sjogren, F; Anderson, C; Mellergard, P			Intracerebral microdialysis in neurosurgical intensive care patients utilising catheters with different molecular cut-off (20 and 100 kD)	ACTA NEUROCHIRURGICA			English	Article						cerebral microdialysis; head trauma; intensive care; monitoring; protein; subarachnoidal haemorrhage	HUMAN BRAIN; SUBARACHNOID HEMORRHAGE; CEREBRAL MICRODIALYSIS; BEDSIDE MICRODIALYSIS; METABOLISM	Objective. To compare the properties of a new intracerebral micro-dialysis catheter with a high cut-off membrane (molecular cut-off 100kDalton) with a standard catheter (CMA70, molecular cut-off 20kDalton). Methods. Paired intracerebral microdialysis catheters were inserted in fifteen comatose patients treated in a neurosurgical intensive care unit following subarachnoid haemorrhage or traumatic brain injury. The high-cut-off catheter (D-100) differed from the CMA 70 catheter by the length (20mm) and cut-off properties of the catheter membranes (100kDalton) and the perfusion fluids used (Ringer-Dextran 60). Samples were collected every 4-6 hours, analyzed bedside (for glucose, glutamate, glycerol, lactate, pyruvate and urea) and later in the laboratory (for total protein). Results. Fluid recovery was similar for the two types of catheters, but significantly more protein was recovered by the D-100 catheter. The recovery of glycerol and pyruvate did not differ, while minor differences in recovery of glutamate and glucose were observed. The recovery of lactate was considerably lower in the D-100 catheter (p < 0.01), influencing the lactate/pyruvate-ratio. The patterns of concentration changes over time were consistent for all metabolites, and independent of type of catheter. Conclusion. Microdialysis catheters with high cut-off membranes can be used in routine clinical practice in the NSICU, adding the possibility of macro-molecule sampling from the extracellular space during monitoring.	Linkoping Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden; Linkoping Univ Hosp, Dept Dermatol, S-58185 Linkoping, Sweden	Hillman, J (corresponding author), Linkoping Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden.	Jan.Hillman@lio.se					BENEVISTE H, 1990, PROG NEUROBIOL, V35, P195; Hamani C, 1997, NEUROL RES, V19, P281, DOI 10.1080/01616412.1997.11740814; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; KEHR J, 1993, J NEUROSCI METH, V48, P251, DOI 10.1016/0165-0270(93)90096-A; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X	15	27	27	1	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAR	2006	148	3					319	324		10.1007/s00701-005-0670-8			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	018BL	WOS:000235737700019	16411015				2021-06-18	
J	Wilson, DJ; Powell, M; Gorham, JL; Childers, MK				Wilson, DJ; Powell, M; Gorham, JL; Childers, MK			Ambulation training with and without partial weighthearing after traumatic brain injury - Results of a randomized, controlled trial	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						gait; partial weight bearing; traumatic brain injury	BODY-WEIGHT SUPPORT; SPINAL-CORD-INJURY; TREADMILL; GAIT; STROKE; WALKING; LOCOMOTION; OUTCOMES	Objective: To test the hypothesis that 8 wks of partial weight-bearing gait retraining improves functional ambulation to a greater extent than traditional physical therapy in individuals after traumatic brain injury. Desiqn: A randomized, open-label, controlled, cohort study was conducted at two inpatient university-based rehabilitation hospitals. A total of 38 adults with a primary diagnosis of traumatic brain injury and significant gait abnormalities received either 8 wks of standard physical therapy or physical therapy supplemented with partial weight-bearing gait training twice weekly. Results: Significant (P < 0.05) improvements were detected in both groups on Functional Ambulation Category, Standing Balance Scale, Rivermead Mobility Index, and FIM (R). However, no differences were found between the treatment groups. Conclusions: Results did not support the hypothesis that 8 wks of partial weight-bearing gait retraining improves functional ambulation to a greater extent than traditional physical therapy in individuals after traumatic brain injury based on common clinical measures.	Missouri State Univ, Exercise & Rehabil Biomech Lab, Dept Hlth Phys Educ & Recreat, Springfield, MO 65897 USA; Missouri Rehabil Ctr, Mt Vernon, MO USA; Univ Missouri, Sch Med, Dept Phys Med & Rehabil, Columbia, MO USA; Univ Missouri, Dept Biomed Sci, Coll Vet Med, Columbia, MO USA	Wilson, DJ (corresponding author), Missouri State Univ, Exercise & Rehabil Biomech Lab, Dept Hlth Phys Educ & Recreat, 121C McDonald Arena,901 S Natl Ave, Springfield, MO 65897 USA.		sahely, ahmad/R-6293-2017	Childers, Martin/0000-0003-4754-0883	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A980008] Funding Source: Medline		Barbeau H, 2003, ARCH PHYS MED REHAB, V84, P1458, DOI 10.1016/S0003-9993(03)00361-7; BOHANNON R W, 1989, Physiotherapy Canada, V41, P198; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Collen F M, 1991, Int Disabil Stud, V13, P50; da Cunha IT, 2002, ARCH PHYS MED REHAB, V83, P1258, DOI 10.1053/apmr.2002.34267; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DITUNNO JF, 1982, J NEUROTRAUMA S1, V9, pS301; Eich HJ, 2004, CLIN REHABIL, V18, P640, DOI 10.1191/0269215504cr779oa; Field-Fote EC, 2001, ARCH PHYS MED REHAB, V82, P818, DOI 10.1053/apmr.2001.23752; Frattali C M, 1993, Disabil Rehabil, V15, P1; Gardner MB, 1998, PHYS THER, V78, P361, DOI 10.1093/ptj/78.4.361; GURALNIK JM, 1989, J GERONTOL, V44, pM141, DOI 10.1093/geronj/44.5.M141; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; HESSE S, 1995, STROKE, V26, P976, DOI 10.1161/01.STR.26.6.976; HESSE S, 1994, ARCH PHYS MED REHAB, V75, P1087, DOI 10.1016/0003-9993(94)90083-3; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; HUNTER D, 1995, J ORTHOP SPORT PHYS, V21, P268, DOI 10.2519/jospt.1995.21.5.268; McNevin NH, 2000, ARCH PHYS MED REHAB, V81, P525, DOI 10.1053/mr.2000.4429; McPherson KM, 1996, DISABIL REHABIL, V18, P341, DOI 10.3109/09638289609165892; Miller EW, 2001, NEUROREHABILITATION, V16, P155; Miyai I, 2002, ARCH PHYS MED REHAB, V83, P1370, DOI 10.1053/apmr.2002.34603; Nilsson L, 2001, CLIN REHABIL, V15, P515, DOI 10.1191/026921501680425234; Protas EJ, 2001, ARCH PHYS MED REHAB, V82, P825, DOI 10.1053/apmr.2001.23198; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Schindl MR, 2000, ARCH PHYS MED REHAB, V81, P301, DOI 10.1053/apmr.2000.0810301; Seif-Naraghi AH, 1999, J HEAD TRAUMA REHAB, V14, P146, DOI 10.1097/00001199-199904000-00005; SUDARSKY L, 1990, NEW ENGL J MED, V322, P1441; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; VISINTIN M, 1989, CAN J NEUROL SCI, V16, P315, DOI 10.1017/S0317167100029152; WERNIG A, 1992, PARAPLEGIA, V30, P229, DOI 10.1038/sc.1992.61; Wilson DJ, 2002, BRAIN INJURY, V16, P259, DOI 10.1080/02699050110103922	32	27	28	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JAN	2006	85	1					68	74		10.1097/01.phm.0000193507.28759.37			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	996QW	WOS:000234190400010	16357551				2021-06-18	
J	Wrona, RM				Wrona, RM			The use of state workers' compensation administrative data to identify injury scenarios and quantify costs of work-related traumatic brain injuries	JOURNAL OF SAFETY RESEARCH			English	Article						WC data and TBI; cost of work related TBI; industry specific injury scenarios for TBI; occupations and industries with high frequencies of TBI; ANSI Z16.2 Injury Typology	LADDER FALL ACCIDENTS; WASHINGTON-STATE	Problem: Traumatic brain injury (TBI) is a public health problem but little is known about the nature of that problem in the working population. Method: The author used a national definition to identify cases in Washington State from workers' compensation (WC) hospital billing data, quantified the cost of WC insurance benefits using actuarial cost estimates, and identified high risk industries using ANSI Z16.2 typology. Results: There were 928 cases of TBI with a lifetime claim cost of $159 million from the Washington State Fund (1994-2001). Sixty percent of injuries resulted in death or disability. The highest risks of TBI are concentrated in 16 industrial insurance risk classes and the highest costs in 19 North American Industry Classification codes. Injury scenarios were identified for nine industrial insurance risk classes. Conclusions: TBI is a disabling and costly workplace injury in the state of Washington, affecting even teenagers and seniors who are not generally considered to be part of the workforce. Injury typology codes provide useful information for improving workplace safety. Impact on industry: This research provides industry with quantitative information regarding the cost of work-related traumatic brain injury and the usefulness of using workers' compensation claims data to reduce the burden of workplace injury. (c) 2006 National Safety Council and Elsevier Ltd. All rights reserved.	Washington State Dept Labor & Ind, Olympia, WA 98504 USA	Wrona, RM (corresponding author), 3608 Stevens Dr NE, Lacey, WA 98516 USA.	ronwrona@comcast.net	Wrona, Ronald/W-9319-2019		NIOSH CDC HHS [5U01OH07292-01] Funding Source: Medline; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [U01OH007292] Funding Source: NIH RePORTER		Alexander BH, 1999, AM J IND MED, V36, P317, DOI 10.1002/(SICI)1097-0274(199908)36:2<317::AID-AJIM11>3.3.CO;2-I; *ANSI, 1995, ANSI Z 16 2 COD MAN; Bell JL, 2003, AM J IND MED, V44, P502, DOI 10.1002/ajim.10307; *CDCP, 2001, MORBIDITY MORTALITY, V46, P1; COHEN HH, 1991, J SAFETY RES, V22, P21, DOI 10.1016/0022-4375(91)90010-S; COHEN HH, 1991, J SAFETY RES, V22, P31, DOI 10.1016/0022-4375(91)90011-J; COHEN M, 1999, 571 SHARP DEP LAB IN; HEYER NJ, 1994, AM J PUBLIC HEALTH, V84, P1106, DOI 10.2105/AJPH.84.7.1106; Johantgen M, 2004, J SAFETY RES, V35, P309, DOI 10.1016/j.jsr.2004.01.003; Jones Derek, 2003, Work, V20, P179; Newcombe RG, 1998, STAT MED, V17, P857, DOI 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E; OREILLY JT, 2001, ACCIDENT PREVENTION; Partridge RA, 1998, ACAD EMERG MED, V5, P31, DOI 10.1111/j.1553-2712.1998.tb02571.x; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ., 1995, GUIDELINES SURVEILLA; *US DEP HHS, 1995, PREV INJ DEATHS LOGG; *US OFF MAN BUDG, 2002, N AM IND CLASS SYST; *US OFF MAN BUDG, 2000, STAND OCC CLASS MAN; *US OFF MAN BUDG, 1980, SOURC SOC DAT GEN AP; *WASH DEP LAB IND, 2000, STAT WASH WORK COMP	20	27	28	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-4375			J SAFETY RES	J. Saf. Res.		2006	37	1					75	81		10.1016/j.jsr.2005.08.008			7	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	027QT	WOS:000236431000008	16519901				2021-06-18	
J	Hughes, S; Colantonio, A; Santaguida, PL; Paton, T				Hughes, S; Colantonio, A; Santaguida, PL; Paton, T			Amantadine to enhance readiness for rehabilitation following severe traumatic brain injury	BRAIN INJURY			English	Article						amantadine; brain injury; recovery; coma	SOMATOSENSORY-EVOKED-POTENTIALS; SEVERE HEAD-INJURY; FRONTAL-LOBE DYSFUNCTION; VEGETATIVE STATE; PREDICTION; RECOVERY; SURVIVAL; COMA; MANAGEMENT; PROGNOSIS	Primary objective: To evaluate the association between amantadine and recovery of consciousness from prolonged traumatic coma. Research design: A retrospective cohort study. Methods: Subjects included 123 adults with severe traumatic brain injury (TBI) admitted over a 10-year period who remained in coma despite becoming medically stable. Experimental interventions: Cases received 100-200 mg of amantadine twice daily. Main outcomes and results: 46.4% (13/28) of cases emerged from coma compared to 37.9% (36/95) of controls (p = 0.42). Somatosensory evoked potential (SSEP) was the only significant predictor of emergence from coma (p = 0.02), while SSEP, age and Glasgow Coma Score (GCS) significantly predicted time to emerge from coma (p < 0.05). Conclusions: Although the study and its design do not support the view that amantadine has an effect on recovery of consciousness; it remains safe, inexpensive and has few side effects. The lack of treatment alternatives and anecdotal support for its use may warrant further study. Prospective controlled trials would yield more definitive results.	Sunnybrook & Womens Coll Hlth Sci Ctr, Physiotherapy Serv, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Occupat Therapy, Toronto Rehabil Inst, Toronto, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada	Hughes, S (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Physiotherapy Serv, CG13,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	shari.hughes@sw.ca		Colantonio, Angela/0000-0003-2094-4765			Andrews K, 1996, BRAIN INJURY, V10, P797, DOI 10.1080/026990596123918; Ansell B. J., 1993, J HEAD TRAUMA REHAB, V8, P88, DOI DOI 10.1097/00001199-199309000-00011; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; AOKI FY, 1988, CLIN PHARMACOKINET, V14, P35, DOI 10.2165/00003088-198814010-00003; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bassetti C, 1996, J NEUROL NEUROSUR PS, V61, P610, DOI 10.1136/jnnp.61.6.610; BECA J, 1995, J PEDIATR-US, V126, P44, DOI 10.1016/S0022-3476(95)70498-1; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; Carter BG, 1999, INTENS CARE MED, V25, P722, DOI 10.1007/s001340050936; Chandler M C, 1988, Brain Inj, V2, P309; CHEN HSV, 1992, J NEUROSCI, V12, P4427; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/s001340050269; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; COWELL LC, 1995, J HEAD TRAUMA REHAB, V10, P91, DOI 10.1097/00001199-199512000-00018; DAVIS CW, 1985, CLIN MANAGEMENT PHYS, V5, P23; DAVIS CW, 1985, CLIN MANAGEMENT PHYS, V5, P16; DAVIS CW, 1985, CLIN MANAGEMENT PHYS, V5, P20; EDBY K, 1983, CHILD NERV SYST, V11, P607; EDWARDS SM, 1987, CLIN MANAGEMENT PHYS, V7, P6; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; Gladstone DJ, 2000, CAN J NEUROL SCI, V27, P97; Goldberg G, 1998, J HEAD TRAUMA REHAB, V13, P51, DOI 10.1097/00001199-199802000-00008; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; HAGEN C, 1979, REAHBILITATION HEAD; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; Hall M, 1992, J Neurosci Nurs, V24, P199; HANS P, 1987, BRIT J HOSP MED, V37, P535; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; LYLE DM, 1986, J NEUROSURG, V65, P15, DOI 10.3171/jns.1986.65.1.0015; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Metman LV, 1998, NEUROLOGY, V50, P1323, DOI 10.1212/WNL.50.5.1323; Meythaler JM, 2003, J HEAD TRAUMA REHAB, V18, P5, DOI 10.1097/00001199-200301000-00004; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Patrick PD, 2003, BRAIN INJURY, V17, P497, DOI 10.1080/0269905031000070279; Patrick PD, 2000, BEHAV INTERVENT, V15, P225, DOI 10.1002/1099-078X(200007/09)15:3<225::AID-BIN58>3.3.CO;2-#; Phillips JP, 2003, J HEAD TRAUMA REHAB, V18, P342, DOI 10.1097/00001199-200307000-00005; PohlmannEden B, 1997, INTENS CARE MED, V23, P301, DOI 10.1007/s001340050332; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; Raffaele R, 2002, ARCH GERONTOL GERIAT, P309; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P384; Rudnik A, 1992, Acta Neurochir Suppl (Wien), V55, P33; Schneider WN, 1999, BRAIN INJURY, V13, P863; SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168; Shiller AD, 1999, BRAIN INJURY, V13, P715; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; WHYTE J, 1992, ARCH PHYS MED REHAB, V73, P940; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Yamamoto T, 1999, ACT NEUR S, V75, P17; Zafonte RD, 1998, BRAIN INJURY, V12, P617	69	27	29	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2005	19	14					1197	1206		10.1080/02699050500309296			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	983ZF	WOS:000233270200003	16286335				2021-06-18	
J	Dallmeijer, AJ; Dekker, J; Roorda, LD; Knol, DL; van Baalen, B; de Groot, V; Schepers, VPM; Lankhorst, GJ				Dallmeijer, AJ; Dekker, J; Roorda, LD; Knol, DL; van Baalen, B; de Groot, V; Schepers, VPM; Lankhorst, GJ		FuPro Study Grp	Differential item functioning of the functional independence measure in higher performing neurological patients	JOURNAL OF REHABILITATION MEDICINE			English	Article						disability evaluation; neurological disorders; Rasch analysis; rehabilitation	APPLYING PSYCHOMETRIC CRITERIA; RASCH ANALYSIS; MEDICAL REHABILITATION; IMPAIRMENT; CATEGORIES; SCALES; MODEL	Objective: When comparing outcomes of the Functional Independence Measure (FIM(TM)) between patient groups, item characteristics of the FIM(TM) should be consistent across groups. The purpose of this study was to compare item difficulty of the FIM(TM) in 3 patient groups with neurological disorders. Subjects: Patients with stroke (n = 295), multiple sclerosis ( n = 150), and traumatic brain injury ( n = 88). Methods: FIM(TM) scores were administered in each group. The FIM(TM) consists of a motor domain ( 13 items) and a cognitive domain ( 5 items). Rasch rating scale analysis was performed to investigate differences in item difficulty ( differential item functioning) between groups. Results: Answering categories of the FIM(TM) items were reduced to 3 ( from the original 7) because of disordered thresholds and low answering frequencies. Two items of the motor domain ("bladder" and "bowel") did not fit the Rasch model. For 7 out of the 11 fitting motor items, item difficulties were different between groups (i.e. showed differential item functioning). All cognitive items fitted the Rasch model, and 4 out of 5 cognitive items showed differential item functioning. Conclusion: Differential item functioning is present in several items of both the motor and cognitive domain of the FIM(TM). Adjustments for differential item functioning may be required when FIM(TM) data will be compared between groups or will be used in a pooled data analysis.	VU Univ Med Ctr Amsterdam, Dept Rehabil Med, NL-1007 MB Amsterdam, Netherlands; VU Univ Med Ctr Amsterdam, Inst Res Extramural Med, EMGO Inst, NL-1007 MB Amsterdam, Netherlands; VU Univ Med Ctr Amsterdam, Dept Clin Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands; Erasmus Med Ctr, Dept Rehabil Med, Rotterdam, Netherlands; Univ Med Ctr, Dept Rehabil Med, Utrecht, Netherlands	Dallmeijer, AJ (corresponding author), VU Univ Med Ctr Amsterdam, Dept Rehabil Med, POB 7057, NL-1007 MB Amsterdam, Netherlands.	a.dallmeijer@vumc.nl	De Groot, Vincent/S-3482-2019; de Groot, Vincent/J-8977-2013; IJzerman, Maarten J/Q-8963-2016	de Groot, Vincent/0000-0002-6073-6250; IJzerman, Maarten J/0000-0001-5788-5805; Dekker, Joost/0000-0003-2027-0027; Beckerman, Heleen/0000-0002-8421-3630			ANDRICH D, 1978, PSYCHOMETRIKA, V43, P561, DOI 10.1007/BF02293814; Brock KA, 2002, ARCH PHYS MED REHAB, V83, P92, DOI 10.1053/apmr.2002.27348; CHANG WC, 1995, ARCH PHYS MED REHAB, V76, P934, DOI 10.1016/S0003-9993(95)80070-0; Dickson HG, 1996, SCAND J REHABIL MED, V28, P159; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; HAMILTON BB, 2003, UNIFORM NATL DATA SY, P137; Hawley CA, 1999, J NEUROL NEUROSUR PS, V67, P749, DOI 10.1136/jnnp.67.6.749; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Keith R A, 1987, Adv Clin Rehabil, V1, P6; KIM JO, 1996, INTRO FACTOR ANAL WH; Kucukdeveci AA, 2001, CLIN REHABIL, V15, P311, DOI 10.1191/026921501676877265; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; LINACRE JM, 1998, USERS GUIDE BIGSTEPS; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; Sharrack B, 1999, BRAIN, V122, P141, DOI 10.1093/brain/122.1.141; SILVERSTEIN B, 1992, ARCH PHYS MED REHAB, V73, P507; SILVERSTEIN B, 1991, ARCH PHYS MED REHAB, V72, P631; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; Streiner D., 1995, HLTH MEASUREMENT SCA, V2; TEASDALE G, 1974, LANCET, V2, P81; Tennant A, 2004, MED CARE, V42, P37, DOI 10.1097/01.mlr.0000103529.63132.77; Tesio L, 2003, J REHABIL MED, V35, P105, DOI 10.1080/16501970310010448; Tsuji T, 1995, AM J PHYS MED REHAB, V74, P432, DOI 10.1097/00002060-199511000-00007; Wade DT, 1992, MEASUREMENT NEUROLOG; Wright BD, 1997, SCAND J REHABIL MED, V29, P267; Wright BD., 1994, RASCH MEASUREMENT T, V8, P370, DOI DOI 10.1177/01461672012710004	26	27	27	0	2	TAYLOR & FRANCIS AS	OSLO	PO BOX 12 POSTHUSET, NO-0051 OSLO, NORWAY	1650-1977			J REHABIL MED	J. Rehabil. Med.	NOV	2005	37	6					346	352		10.1080/16501970510038284			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	984VW	WOS:000233334700003	16287665	DOAJ Gold			2021-06-18	
J	Yeates, KO; Enrile, BG				Yeates, KO; Enrile, BG			Implicit and explicit memory in children with congenital and acquired brain disorder	NEUROPSYCHOLOGY			English	Article; Proceedings Paper	31st Annual Meeting of the International-Neuropsychological-Society	FEB 05-08, 2003	HONOLULU, HI	Int Neuropsychol Soc		myelomeningocele; traumatic brain injury; implicit memory; explicit memory	ALZHEIMERS-DISEASE; COGNITIVE-DEVELOPMENT; PARKINSONS-DISEASE; DECLARATIVE MEMORY; VISUAL COMPLEXITY; NAME AGREEMENT; HEAD-INJURY; AMNESIA; DISSOCIATION; HYDROCEPHALUS	Implicit and explicit memory were examined in 8- to 15-year-old children with myelomeningocele and shunted hydrocephalus, severe traumatic brain injuries, or orthopedic injuries. Each group included between 22 and 29 children. Children completed a fragmented picture identification task to assess perceptual priming and a semantic decision-making task to assess conceptual priming. Each task also assessed procedural learning as well as explicit recall and recognition. All 3 groups showed significant perceptual and semantic priming of similar magnitude. In contrast, both brain-disordered groups displayed poorer explicit memory than did the comparison group. No group showed significant procedural learning on either task. Age and IQ were stronger predictors of explicit recall than of implicit memory. The findings indicate that implicit memory is relatively intact in many children with congenital and acquired brain disorders, despite deficits in explicit memory, and support the existence of separate memory systems in children.	Childrens Hosp, Dept Psychol, Columbus, OH 43205 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Columbus Childrens Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; Childrens Hosp, Sect Behav & Dev Pediat, Columbus, OH 43205 USA	Yeates, KO (corresponding author), Childrens Hosp, Dept Psychol, 700 Childrens Dr, Columbus, OH 43205 USA.	yeatesk@chi.osu.edu	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03-HD36680] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD036680] Funding Source: NIH RePORTER		BERMAN S, 1989, BEHAV RES METH INSTR, V21, P371, DOI 10.3758/BF03202800; Blaxton T A, 1995, J Int Neuropsychol Soc, V1, P112; BLYSMA FW, 1991, NEUROPSYCHOLOGIA, V12, P1213; BONDI MW, 1993, BRAIN COGNITION, V22, P213, DOI 10.1006/brcg.1993.1035; BONDI MW, 1991, J CLIN EXP NEUROPSYC, V13, P339, DOI 10.1080/01688639108401048; BUTTERS N, 1990, B PSYCHONOMIC SOC, V28, P359; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Colvin AN, 2003, J INT NEUROPSYCH SOC, V9, P642, DOI 10.1017/S1355617703940045; Cycowicz YM, 2000, MEMORY, V8, P19, DOI 10.1080/096582100387687; DELBIGIO MR, 1993, ACTA NEUROPATHOL, V85, P573, DOI 10.1007/BF00334666; Dennis M, 1998, MED PEDIATR ONCOL, P25; Dennis M, 2004, BRAIN, V127, P1292, DOI 10.1093/brain/awh154; DIGIULIO DV, 1994, BRAIN COGNITION, V25, P79, DOI 10.1006/brcg.1994.1024; Donders J, 1997, PSYCHOL ASSESSMENT, V9, P15; Doyon J, 2003, NEUROPSYCHOLOGIA, V41, P252, DOI 10.1016/S0028-3932(02)00158-6; Edelstein K, 2004, J INT NEUROPSYCH SOC, V10, P877, DOI 10.1017/S1355617704106085; FLEISCHMAN DA, 1995, NEUROPSYCHOLOGY, V9, P187; Fletcher JM, 1996, ARCH NEUROL-CHICAGO, V53, P549, DOI 10.1001/archneur.1996.00550060093022; FLETCHER JM, IN PRESS INT REV RES; Gabrieli J D, 1995, J Int Neuropsychol Soc, V1, P115; GILBERT JN, 1986, NEUROSURGERY, V18, P559, DOI 10.1227/00006123-198605000-00008; GLISKY EL, 1989, HDB NEUROPSYCHOLOGY, P233; GRAF P, 1990, B PSYCHONOMIC SOC, V28, P353; HEINDEL WC, 1989, J NEUROSCI, V9, P582; KEANE MM, 1991, BEHAV NEUROSCI, V105, P326, DOI 10.1037/0735-7044.105.2.326; KEANE MM, 1995, BRAIN, V118, P1129, DOI 10.1093/brain/118.5.1129; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; Levy DA, 2004, PSYCHOL SCI, V15, P680, DOI 10.1111/j.0956-7976.2004.00740.x; LORSBACH TC, 1989, CONTEMP EDUC PSYCHOL, V14, P67, DOI 10.1016/0361-476X(89)90006-4; Mattson SN, 1999, J INT NEUROPSYCH SOC, V5, P462, DOI 10.1017/S1355617799555082; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Mitchell David B., 1993, P171; NAITO M, 1990, J EXP CHILD PSYCHOL, V50, P462, DOI 10.1016/0022-0965(90)90081-I; Naito Mika, 1993, P231; NELSON CA, 1995, DEV PSYCHOL, V31, P723, DOI 10.1037/0012-1649.31.5.723; Parkin Alan J., 1993, P191; PASCUALLEONE A, 1993, ANN NEUROL, V34, P594, DOI 10.1002/ana.410340414; Poldrack RA, 1999, NEUROPSYCHOLOGY, V13, P564, DOI 10.1037/0894-4105.13.4.564; Renner P, 2000, J AUTISM DEV DISORD, V30, P3, DOI 10.1023/A:1005487009889; Rich JB, 1996, J CLIN EXP NEUROPSYC, V18, P148, DOI 10.1080/01688639608408270; Roediger HL., 1989, VARIETIES MEMORY CON, P3; RoveeCollier C, 1997, PSYCHOL REV, V104, P467, DOI 10.1037/0033-295X.104.3.467; SAINTCYR JA, 1992, NEUROPSYCHOLOGY MEMO, P188; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; Schacter DL, 2001, CURR DIR PSYCHOL SCI, V10, P1, DOI 10.1111/1467-8721.00101; SHIMAMURA AP, 1986, Q J EXP PSYCHOL-A, V38, P619, DOI 10.1080/14640748608401617; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P149, DOI 10.1076/jcen.21.2.149.929; SNODGRASS JG, 1987, BEHAV RES METH INSTR, V19, P270, DOI 10.3758/BF03203798; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; SNODGRASS JG, 1988, J EXP PSYCHOL GEN, V117, P34, DOI 10.1037/0096-3445.117.1.34; SNODGRASS JG, 1989, IMPLICIT MEMORY, P259; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; VAIDYA CJ, 1995, NEUROPSYCHOLOGY, V9, P580, DOI 10.1037/0894-4105.9.4.580; Vakil E, 1997, J Int Neuropsychol Soc, V3, P327; Verfaellie M, 1996, NEUROPSYCHOLOGY, V10, P517, DOI 10.1037/0894-4105.10.4.517; Vicari S, 2001, Downs Syndr Res Pract, V7, P35; Vicari S, 2001, NEUROPSYCHOLOGIA, V39, P665, DOI 10.1016/S0028-3932(01)00012-4; Ward H, 2002, J CLIN EXP NEUROPSYC, V24, P458, DOI 10.1076/jcen.24.4.458.1032; Wechsler D., 1991, MANUAL WECHSLER INTE; Willingham DB, 1999, PSYCHOL SCI, V10, P531, DOI 10.1111/1467-9280.00201; Wyatt BS, 1998, AM J MENT RETARD, V102, P511; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; YEATES KO, 1995, J PEDIATR PSYCHOL, V20, P801, DOI 10.1093/jpepsy/20.6.801; Yonelinas AP, 2002, J MEM LANG, V46, P441, DOI 10.1006/jmla.2002.2864; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555	65	27	31	0	8	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	SEP	2005	19	5					618	628		10.1037/0894-4105.19.5.618			11	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	970HU	WOS:000232296700007	16187880				2021-06-18	
J	Kim, DY; Park, CI; Chon, JS; Ohn, SH; Park, TH; Bang, IK				Kim, DY; Park, CI; Chon, JS; Ohn, SH; Park, TH; Bang, IK			Biomechanical assessment with electromyography of post-stroke ankle plantar flexor spasticity	YONSEI MEDICAL JOURNAL			English	Article						spasticity; electromyographic activity; peak torque; threshold angle; stretch reflex	MODIFIED ASHWORTH SCALE; TRAUMATIC BRAIN INJURY; SPINAL-CORD-INJURY; CEREBRAL-PALSY; MUSCLE SPASTICITY; PENDULUM TEST; HYPERTONIA; RELIABILITY; CHILDREN; STROKE	Spasticity has been defined as a motor disorder characterized by a velocity-dependent increase in tonic stretch reflex (muscle tone). Muscle tone consists of mechanical-elastic characteristics, reflex muscle contraction and other elements. The aims of this study were to determine whether to assess,pasticity quantitatively, and to characterize biomechanical and electromyographic spasticity assessment parameters. These assessment parameters were described by investigating the correlation between clinical measures and;he response to passive sinusoidal movement with consecutive velocity increments. Twenty post-stroke hemiplegic patients and twenty normal healthy volunteers were included in the study. Five consecutive sinusoidal passive movements of the ankle were performed at specific velocities (60, 120, 180, and 240 degrees/sec). We recorded the peak torque, work, and threshold angle using a computerized isokinetic dynamometer, and simultaneously measured the rectified integrated electromyographic activity. We compared these parameters both between groups and between different velocities. The peak torque, threshold angle, work, and rectified integrated electromyographic activity were significantly higher in the post-stroke spastic group at all angular velocities than in the normal control group. The threshold angle and integrated electromyographic activity increased significantly and linearly as angular velocity increased, but the peak torque and work were not increased in the post-stroke spastic group. Peak torque, work, and threshold angle were significantly correlated to the Modified Ashworth scale, but the integrated electromyographic activity was not. The biomechanical and electromyographic approach may be useful to quantitatively assess spasticity. However, it may also be very important to consider the different characteristics of each biomechanical parameter.	Inje Univ, Coll Med, Dept Rehabil Med, Pusan, South Korea; Yonsei Univ, Coll Med, Dept Rehabil Med, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Res Inst Rehabil Med, Seoul 120749, South Korea; Hansarang Asan Gen Hosp, Dept Rehabil Med, Asan, South Korea	Bang, IK (corresponding author), Inje Univ, Coll Med, Dept Rehabil Med, Pusan, South Korea.	bangik@sanggyepaik.ac.kr		kim, deog young/0000-0001-7622-6311			Akman MN, 1999, SPINAL CORD, V37, P638, DOI 10.1038/sj.sc.3100892; Allison SC, 1996, INT J REHABIL RES, V19, P67, DOI 10.1097/00004356-199603000-00007; ALLISON SC, 1995, J NEUROL, V242, P699, DOI 10.1007/BF00866923; BAJD T, 1984, J BIOMED ENG, V6, P9, DOI 10.1016/0141-5425(84)90003-7; Benecke R, 1983, Adv Neurol, V39, P1035; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BOITEAU M, 1995, PHYS THER, V75, P796, DOI 10.1093/ptj/75.9.796; Booth CM, 2001, DEV MED CHILD NEUROL, V43, P314, DOI 10.1017/S0012162201000597; BROWN RA, 1988, J NEUROL NEUROSUR PS, V51, P1171, DOI 10.1136/jnnp.51.9.1171; CORCOS DM, 1986, BRAIN, V109, P1043, DOI 10.1093/brain/109.5.1043; Damiano DL, 2002, DEV MED CHILD NEUROL, V44, P112, DOI 10.1017/S0012162201001761; Engsberg JR, 1996, ARCH PHYS MED REHAB, V77, P594, DOI 10.1016/S0003-9993(96)90301-9; FIROOZBAKHSH KK, 1993, AM J PHYS MED REHAB, V72, P379; GIVEN JD, 1995, J NEUROL NEUROSUR PS, V59, P271, DOI 10.1136/jnnp.59.3.271; GOTTLIEB GL, 1978, J NEUROL NEUROSUR PS, V41, P32, DOI 10.1136/jnnp.41.1.32; Johnson GR, 2002, EUR J NEUROL, V9, P10, DOI 10.1046/j.1468-1331.2002.0090s1010.x; KATZ RT, 1989, ARCH PHYS MED REHAB, V70, P144; KATZ RT, 1992, ARCH PHYS MED REHAB, V73, P339, DOI 10.1016/0003-9993(92)90007-J; KATZ RT, 1994, MECH SPASTIC HYPERTO, P441; Lance J. W., 1980, SPASTICITY DISORDERE, P485; LEHMANN JF, 1989, ARCH PHYS MED REHAB, V70, P6; LIN JP, 1994, DEV MED CHILD NEUROL, V36, P290; Nuyens GE, 2002, ARCH PHYS MED REHAB, V83, P930, DOI 10.1053/apmr.2002.33233; ODwyer NJ, 1996, BRAIN, V119, P1737, DOI 10.1093/brain/119.5.1737; Pandyan AD, 2003, CLIN REHABIL, V17, P290, DOI 10.1191/0269215503cr610oa; PINELLI P, 1985, CLIN NEUROPHYSIOL, P141; Singer BJ, 2003, CLIN BIOMECH, V18, P157, DOI 10.1016/S0268-0033(02)00173-0; Skold C, 2002, J REHABIL MED, V34, P86, DOI 10.1080/165019702753557881; Skold C, 2000, ARCH PHYS MED REHAB, V81, P144, DOI 10.1016/S0003-9993(00)90132-1; Skold C, 1998, ARCH PHYS MED REHAB, V79, P959, DOI 10.1016/S0003-9993(98)90095-8; Sloan R L, 1992, Int J Rehabil Res, V15, P158, DOI 10.1097/00004356-199206000-00009; STILLMAN B, 1995, ARCH PHYS MED REHAB, V76, P166, DOI 10.1016/S0003-9993(95)80026-3; Wyke B, 1976, Physiotherapy, V62, P316	33	27	34	0	3	YONSEI UNIV COLL MEDICINE	SEOUL	50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA	0513-5796	1976-2437		YONSEI MED J	Yonsei Med. J.	AUG 31	2005	46	4					546	554		10.3349/ymj.2005.46.4.546			9	Medicine, General & Internal	General & Internal Medicine	961CR	WOS:000231640000015	16127781	DOAJ Gold, Green Published			2021-06-18	
J	Liao, CC; Lui, TN; Chen, LR; Chuang, CC; Huang, YC				Liao, CC; Lui, TN; Chen, LR; Chuang, CC; Huang, YC			Spinal cord injury without radiological abnormality in preschool-aged children: correlation of magnetic resonance imaging findings with neurological outcomes	JOURNAL OF NEUROSURGERY			English	Article						spinal cord injury; spine; SCIWORA; magnetic resonance imaging; pediatric neurosurgery	RADIOGRAPHIC ABNORMALITY; CERVICAL-SPINE; TRAUMA; SCIWORA	Object. Spinal cord injury without radiological abnormality (SCIWORA) was defined in the era when magnetic resonance (MR) images were not popularly used as diagnostic tools. Although it is generally accepted that MR imaging can effectively illustrate the level and severity of spinal cord injury in the acute phase of trauma, only a few reports of MR imaging studies of SCIWORA have been published. The authors retrospectively reviewed nine preschool-aged patients with SCIWORA to study the correlation between MR imaging findings and the outcomes of neurological deficits, with an elimination of the bias for age. Methods. Clinical manifestations, radiological images, surgical records, and MR imaging studies were reviewed. The pre- and postoperative neurological statuses of the patients were reappraised using American Spinal Injury Association scores and Nurick grades. Nonparametric tests were used to analyze the correlations among the variables of patient characteristics, MR imaging appearances of the injured spinal cord, and neurological outcome. Conclusions. Among the patients with SCIWORA younger than 8 years old, the different patterns of the injured spinal cords could be identified using MR imaging as transection, contusive hemorrhage, traumatic edema, and concussion. The MR imaging patterns of SCIWORA had significant prognostic correlations with the neurological outcomes of these patients; that is, a normal spinal cord appearance was prognostic of a complete recovery of neurological deficits, and intramedullary lesions correlated with permanent deficits with functional disability.	Chang Gung Mem Hosp, Dept Neurosurg, Taoyuan 333, Taiwan; Chang Gung Univ, Dept Neurosurg, Taoyuan, Taiwan; Taoyuan Gen Hosp, Dept Phys Med & Rehabil, Taoyuan, Taiwan	Liao, CC (corresponding author), Chang Gung Mem Hosp, Dept Neurosurg, 5 Fu Shing St, Taoyuan 333, Taiwan.	liao2901@adm.cgmh.org.tw					ARMSTRONG DC, 1999, MAGNETIC RESONANCE I, V3, P1917; BAILEY DK, 1952, RADIOLOGY, V59, P712, DOI 10.1148/59.5.712; BEERS GJ, 1988, J COMPUT ASSIST TOMO, V12, P755, DOI 10.1097/00004728-198809010-00007; Bosch PP, 2002, SPINE, V27, P2788, DOI 10.1097/00007632-200212150-00009; Dare AO, 2002, J NEUROSURG, V97, P33, DOI 10.3171/spi.2002.97.1.0033; DICKMAN CA, 1991, J SPINAL DISORD, V4, P296, DOI 10.1097/00002517-199109000-00006; FLANDERS AE, 1990, RADIOLOGY, V177, P25, DOI 10.1148/radiology.177.1.2399326; GRABB PA, 1994, NEUROSURGERY, V35, P406, DOI 10.1227/00006123-199409000-00007; HADLEY MN, 1988, J NEUROSURG, V68, P18, DOI 10.3171/jns.1988.68.1.0018; HAMILTON MG, 1992, J NEUROSURG, V77, P700, DOI 10.3171/jns.1992.77.5.0700; LAKHANPAL SK, 1999, MAGNETIC RESONANCE I, V3, P1379; LEVENTHAL HR, 1960, J PEDIATR-US, V56, P447, DOI 10.1016/S0022-3476(60)80356-3; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; MATSUMURA A, 1990, SURG NEUROL, V33, P281, DOI 10.1016/0090-3019(90)90049-U; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; MONTEIRO L, 1992, ACTA NEUROL SCAND, V86, P563, DOI 10.1111/j.1600-0404.1992.tb05487.x; NURICK S, 1972, BRAIN, V95, P87; OSENBACH RK, 1992, NEUROSURGERY, V30, P385, DOI 10.1227/00006123-199203000-00012; PANG D, 1989, J TRAUMA, V29, P654, DOI 10.1097/00005373-198905000-00021; PANG D, 1982, J NEUROSURG, V57, P114, DOI 10.3171/jns.1982.57.1.0114; PENNECOT GF, 1984, J PEDIATR ORTHOPED, V4, P346, DOI 10.1097/01241398-198405000-00011; POLLACK IF, 1988, J NEUROSURG, V69, P177, DOI 10.3171/jns.1988.69.2.0177; Proctor MR, 2002, CRIT CARE MED, V30, pS489, DOI 10.1097/00003246-200211001-00014; Selden NR, 1999, NEUROSURGERY, V44, P785, DOI 10.1097/00006123-199904000-00057; WITTENBERG RH, 1990, CLIN ORTHOP RELAT R, P176; ZWIMPFER TJ, 1990, J NEUROSURG, V72, P894, DOI 10.3171/jns.1990.72.6.0894	26	27	30	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	2005	103	1		S			17	23		10.3171/ped.2005.103.1.0017			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	955GY	WOS:000231215100005	16122000				2021-06-18	
J	Hu, H; Chen, G; Zhang, JM; Zhang, WP; Zhang, L; Ge, QF; Yao, HT; Ding, W; Chen, Z; Wei, EQ				Hu, H; Chen, G; Zhang, JM; Zhang, WP; Zhang, L; Ge, QF; Yao, HT; Ding, W; Chen, Z; Wei, EQ			Distribution of cysteinyl leukotriene receptor 2 in human traumatic brain injury and brain tumors	ACTA PHARMACOLOGICA SINICA			English	Article						cysteinyl leukotriene receptor 2; brain injuries; brain neoplasms; vascular smooth muscle cell	FOCAL CEREBRAL-ISCHEMIA; CYSLT(2) RECEPTOR; ENDOTHELIAL-CELLS; INFLAMMATION; EXPRESSION; FIBROSIS; INCREASE; RHINITIS; PATHWAY; CLONING	Aim: To determine the distribution of cysteinyl leukotriene receptor 2 (CysLT(2)), one of the cysteinyl leukotriene receptors, in human brains with traumatic injury and tumors. Methods: Brain specimens were obtained from patients who underwent brain surgery. CysLT(2) in brain tissues was examined using immunohistochemical analysis. Results: CysLT(2) was expressed in the smooth muscle cells (not in the endothelial cells) of arteries and veins. CysLT(2) was also expressed in the granulocytes in both vessels and in the brain parenchyma. In addition, CysLT(2) was detected in neuron- and glial-appearing cells in either the late stages of traumatic injury or in the area surrounding the tumors. Microvessels regenerated 8 d after trauma and CysLT(2) expression was recorded in their endothelial cells. Conclusion: CysLT(2) is distributed in vascular smooth muscle cells and granulocytes, and brain trauma and tumor can induce its expression in vascular endothelial cells and in a number of other cells.	Zhejiang Univ, Sch Med, Hosp 2, Dept Neurosurg, Hangzhou 310009, Peoples R China; Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310031, Peoples R China; Zhejiang Univ, Sch Med, Dept Pathol, Hosp 1, Hangzhou 310003, Peoples R China	Wei, EQ (corresponding author), Zhejiang Univ, Sch Med, Hosp 2, Dept Neurosurg, Hangzhou 310009, Peoples R China.	weieq2001@yahoo.com	Zhang, Lei/F-2603-2011				Beller TC, 2004, J BIOL CHEM, V279, P46129, DOI 10.1074/jbc.M407057200; Beller TC, 2004, P NATL ACAD SCI USA, V101, P3047, DOI 10.1073/pnas.0400235101; Borish L, 2002, ANN ALLERG ASTHMA IM, V88, P16, DOI 10.1016/S1081-1206(10)62024-8; Ciccarelli R, 2004, EUR J NEUROSCI, V20, P1514, DOI 10.1111/j.1460-9568.2004.03613.x; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; Di Gennaro A, 2004, FASEB J, V18, P842, DOI 10.1096/fj.03-0599fje; Evans JF, 2002, PROSTAG OTH LIPID M, V68-9, P587, DOI 10.1016/S0090-6980(02)00057-6; Fujita M, 1999, EUR J PHARMACOL, V369, P349, DOI 10.1016/S0014-2999(99)00037-0; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hui YQ, 2001, J BIOL CHEM, V276, P47489, DOI 10.1074/jbc.M107556200; Inamura Takanori, 1992, Neurological Research, V14, P405; Kamohara M, 2001, BIOCHEM BIOPH RES CO, V287, P1088, DOI 10.1006/bbrc.2001.5695; Lotzer K, 2003, ARTERIOSCL THROM VAS, V23, pE32, DOI 10.1161/01.ATV.0000082690.23131.CB; Lynch KR, 1999, NATURE, V399, P789; Paruchuri S, 2002, J CELL SCI, V115, P1883; Sarau HM, 1999, MOL PHARMACOL, V56, P657; Schuhmann MU, 2003, NEUROL RES, V25, P481, DOI 10.1179/016164103101201896; Shinonaga M, 1990, Adv Neurol, V52, P475; Sjostrom M, 2003, ARTERIOSCL THROM VAS, V23, pE37, DOI 10.1161/01.ATV.0000082689.46538.DF; Storms WW, 2003, ANN ALLERG ASTHMA IM, V91, P131, DOI 10.1016/S1081-1206(10)62167-9; Takasaki J, 2000, BIOCHEM BIOPH RES CO, V274, P316, DOI 10.1006/bbrc.2000.3140; Zhang WP, 2004, NEUROSCI LETT, V363, P247, DOI 10.1016/j.neulet.2004.03.088; Zhang WP, 2002, ACTA PHARMACOL SIN, V23, P871	23	27	33	0	4	ACTA PHARMACOLOGICA SINICA	SHANGHAI	294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA	1671-4083	1745-7254		ACTA PHARMACOL SIN	Acta Pharmacol. Sin.	JUN	2005	26	6					685	690		10.1111/j.1745-7254.2005.00092.x			6	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	937IL	WOS:000229917700007	15916734	Bronze			2021-06-18	
J	Ayr, LK; Yeates, KO; Enrile, BG				Ayr, LK; Yeates, KO; Enrile, BG			Arithmetic skills and their cognitive correlates in children with acquired and congenital brain disorder	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						arithmetic; children; brain disorder	SHORT-TERM; WISC-III; MATHEMATICS; DISABILITIES; PERFORMANCE; LONDON; TOWER; ABILITY; INJURY; MEMORY	Arithmetic skills and their cognitive correlates were studied in 24 children with myelomeningocele and shunted hydrocephalus (MM), 27 children with severe traumatic brain injuries (TBI), and 26 children with orthopedic injuries (OI). Their average age was 11.56 years (SD = 2.36). They completed the WRAT-3 Arithmetic subtest and a subtraction task consisting of 20 problems of varying difficulty, as well as measures of working memory, declarative memory. processing speed, planning skills. and visuospatial abilities. The MM group performed more poorly on the WRAT-3 Arithmetic subtest and the Subtraction task than the other two groups, which did not differ from each other on either measure. The groups did not differ in the number of math fact errors or visual-spatial errors on the subtraction task, but the MM group made more procedural errors than the OI group. The five cognitive abilities explained substantial variance in performance on both arithmetic tests;, processing speed, working memory, declarative memory. and planning accounted for unique variance. Exploratory analyses showed that the cognitive correlates of arithmetic skills varied across Groups and ages. Congenital and acquired brain disorders are associated with distinct patterns of arithmetic skills. which are related to specific cognitive abilities.	Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Columbus Childrens Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; Childrens Hosp, Sect Behav & Dev Pediat, Columbus, OH USA	Yeates, KO (corresponding author), Childrens Hosp, Dept Psychol, 700 Childrens Dr, Columbus, OH 43205 USA.	yeatesk@chi.osu.edu	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03-HD36680] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD036680] Funding Source: NIH RePORTER		Aiken L.S., 1991, MULTIPLE REGRESSION; ASHCRAFT MH, 1992, BRAIN COGNITION, V19, P208, DOI 10.1016/0278-2626(92)90046-O; Baddeley A. D., 1994, Neuropsychology, V8, P485, DOI [10.1037/0894-4105.8.4.485., 10.1037/0894-4105.8.4.485]; Badian NA, 1983, PROGR LEARNING DISAB, P235; Barnes MA, 2002, J INT NEUROPSYCH SOC, V8, P72, DOI 10.1017/S1355617702811079; BROOKSHIRE BL, 1995, J PEDIATR PSYCHOL, V20, P785, DOI 10.1093/jpepsy/20.6.785; Bull R, 1999, DEV NEUROPSYCHOL, V15, P421, DOI 10.1080/87565649909540759; Bull R, 2001, DEV NEUROPSYCHOL, V19, P273, DOI 10.1207/S15326942DN1903_3; Bull R, 1997, J EXP CHILD PSYCHOL, V65, P1, DOI 10.1006/jecp.1996.2358; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Cirino PT, 2002, DEV NEUROPSYCHOL, V21, P201, DOI 10.1207/S15326942DN2102_6; Cohen M.J., 1997, CHILDRENS MEMORY SCA; Dennis M, 2002, DEV NEUROPSYCHOL, V21, P141, DOI 10.1207/S15326942DN2102_2; Donders J, 1997, PSYCHOL ASSESSMENT, V9, P15; Espy KA, 2004, DEV NEUROPSYCHOL, V26, P465, DOI 10.1207/s15326942dn2601_6; EWINGCOBBS L, 1998, TRAUMATIC BRAIN INJU, P11; GARNETT K, 1987, PEDIATR ANN, V16, P159, DOI 10.3928/0090-4481-19870201-09; Geary D. C., 1994, CHILDRENS MATH DEV R; GEARY DC, 1993, PSYCHOL BULL, V114, P345, DOI 10.1037/0033-2909.114.2.345; GEARY DC, 1991, DEV PSYCHOL, V27, P787, DOI 10.1037/0012-1649.27.5.787; GEARY DC, 1991, DEV PSYCHOL, V27, P398, DOI 10.1037/0012-1649.27.3.398; Geary DC, 2004, J LEARN DISABIL-US, V37, P4, DOI 10.1177/00222194040370010201; GEARY DC, 1990, J EXP CHILD PSYCHOL, V49, P363, DOI 10.1016/0022-0965(90)90065-G; GEARY DC, 1992, J EXP CHILD PSYCHOL, V54, P372, DOI 10.1016/0022-0965(92)90026-3; Ginsburg HP, 1997, J LEARN DISABIL, V30, P20, DOI 10.1177/002221949703000102; Graham S., 1996, ATTENTION MEMORY EXE, P349; Hartje W., 1987, MATH DISABILITIES CO, P121; HECAEN H., 1961, REV NEUROL [PARIS], V105, P85; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Jordan NC, 1997, J LEARN DISABIL-US, V30, P624, DOI 10.1177/002221949703000606; Kaemingk KL, 2004, CHILD NEUROPSYCHOL, V10, P14, DOI 10.1076/chin.10.1.14.26240; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KOSC L, 1974, J LEARN DISABIL, V7, P164, DOI 10.1177/002221947400700309; KRIKORIAN R, 1994, J CLIN EXP NEUROPSYC, V16, P840, DOI 10.1080/01688639408402697; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; MCCLOSKEY M, 1991, BRAIN COGNITION, V17, P154, DOI 10.1016/0278-2626(91)90074-I; MCCLOSKEY M, 1985, BRAIN COGNITION, V4, P171, DOI 10.1016/0278-2626(85)90069-7; McLean JF, 1999, J EXP CHILD PSYCHOL, V74, P240, DOI 10.1006/jecp.1999.2516; Passolunghi MC, 2001, J EXP CHILD PSYCHOL, V80, P44, DOI 10.1006/jecp.2000.2626; Pennington B.F., 1996, ATTENTION MEMORY EXE, P327; PENNINGTON BF, 1997, DEV PREFRONTAL CORTE, P2665; Reynolds CR, 1997, ARCH CLIN NEUROPSYCH, V12, P29, DOI 10.1016/S0887-6177(96)00015-7; Riccio CA, 1997, J PSYCHOEDUC ASSESS, V15, P27, DOI 10.1177/073428299701500103; Rourke BP, 1997, J LEARN DISABIL, V30, P34, DOI 10.1177/002221949703000103; ROURKE BP, 1978, J ABNORM CHILD PSYCH, V6, P121, DOI 10.1007/BF00915788; ROVET J, 1994, J CLIN EXP NEUROPSYC, V16, P820, DOI 10.1080/01688639408402696; Sikora DA, 2002, DEV NEUROPSYCHOL, V21, P243, DOI 10.1207/S15326942DN2103_2; SNOW JH, 1992, J LEARN DISABIL, V25, P265, DOI 10.1177/002221949202500408; Spiers P. A, 1987, MATH DISABILITIES CO, P1; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEMPLE CM, 1989, COGN NEUROPSYCHOL, V6, P93, DOI 10.1080/02643298908253287; Temple CM, 1998, DEV NEUROPSYCHOL, V14, P47, DOI 10.1080/87565649809540700; TEMPLE CM, 1991, COGNITIVE NEUROPSYCH, V8, P155, DOI 10.1080/02643299108253370; Temple CM, 1997, DEV COGNITIVE NEUROP; VanLehn K., 1982, J MATH BEHAV, V3, P3; Wechsler D., 1991, WECHSLER INTELLIGENC; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; WOODCOCK RW, 1989, WOODCOCKJOHNSON PSYC; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92	60	27	27	0	11	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2005	11	3					249	262		10.1017/S1355617705050307			14	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	924UL	WOS:000229005900004	15892901				2021-06-18	
J	McKerracher, G; Powell, T; Oyebode, J				McKerracher, G; Powell, T; Oyebode, J			A single case experimental design comparing two memory notebook formats for a man with memory problems caused by traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							HEAD-INJURY; REHABILITATION; AID; REMEDIATION; DEFICITS; AMNESIA; PATIENT; PEOPLE; IMPAIRMENT; FRAMEWORK	There is extensive literature demonstrating that restoration of memory is not a realistic goal for rehabilitation and that efforts are more effective if focused on developing compensatory strategies. This paper compares two formats of memory notebook using an ABAB single-case experimental design with a 46-year-old man with a history of head injury. Results revealed significantly better performance on a series of prospective memory tasks for the "modified" notebook. The study highlights the importance of tailoring the diary to the patient's needs and giving careful consideration to the way in which the diary is introduced.	Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England; Birmingham Childrens Hosp NHS Trust, Birmingham, W Midlands, England	Powell, T (corresponding author), Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England.	t.powell@bham.ac.uk		Oyebode, Jan/0000-0002-0263-8740; Powell, Theresa/0000-0002-3351-9453			ALDERMAN N, 1995, NEUROPSYCHOL REHABIL, V5, P193, DOI 10.1080/09602019508401467; BACKMAN L, 1992, PSYCHOL BULL, V112, P259, DOI 10.1037/0033-2909.112.2.259; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Bajo A, 2002, BRAIN INJURY, V16, P385, DOI 10.1080/02699050110119826; Beck A.T., 1987, BECK DEPRESSION INVE; Berg I. J., 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI [DOI 10.1080/09602019108401384, 10.1080/09602019108401384]; BOAKE C, 1987, J CLIN EXP NEUROPSYC, V9, P53; BURKE JM, 1994, BRAIN INJURY, V8, P71, DOI 10.3109/02699059409150960; CERMAK LS, 1975, NEW DIRECTIONS MEMOR; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Donaghy S, 1998, BRAIN INJURY, V12, P1061, DOI 10.1080/026990598121963; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; Fluharty George, 1993, Brain Injury, V7, P85, DOI 10.3109/02699059309008160; GILES GM, 1993, BRAIN INJURY REHABIL; GLISKY EL, 1995, NEUROPSYCHOL REHABIL, V5, P299, DOI 10.1080/09602019508401474; GLISKY EL, 1986, J HEAD TRAUMA REHAB, V1, P54, DOI DOI 10.1097/00001199-198609000-00009; GOBBLE EM, 1987, COMMUNITY REENTRY HE; GOLDSTEIN G, 1985, BEHAV MODIF, V9, P357, DOI 10.1177/01454455850093005; KAPUR N, 1995, HDB MEMORY DISORDERS, P533; Kime SK, 1996, BRAIN INJURY, V10, P17; MALEC J, 1992, NEUROREHABILITATION, V2, P1; MORLEY S, 1989, BEHAV MENTAL HLTH RE; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; PARENTE R, 1991, COGNITIVE REHABILITA; Prigatano G. P., 1991, AWARENESS DEFICIT BR; RANSEEN JD, 1987, J CLIN EXP NEUROPSYC, V9, P56; RICHARDSON JTE, 1995, NEUROPSYCHOLOGIA, V33, P1345, DOI 10.1016/0028-3932(95)00068-E; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Squires EJ, 1996, NEUROPSYCHOL REHABIL, V6, P55, DOI 10.1080/713755494; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI DOI 10.1177/030802269505800204; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; WILSON B, 1981, BEHAV PSYCHOTHER, V9, P338, DOI 10.1017/S0141347300008089; WILSON B, 1995, HDB MEMORY DISORDERS; Wilson B. A, 1984, CLIN MANAGEMENT MEMO, P89; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Wilson B.A., 1991, NEUROPSYCHOL REHABIL, V1, P117, DOI [https://doi.org/10.1080/09602019108401386, DOI 10.1080/09602019108401386]; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wilson BA, 1996, MEMORY, V4, P465, DOI 10.1080/741940776; WILSON BA, 1995, COMPENSATING PSYCHOL, P171; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239; ZENICUS A, 1991, BRAIN INJURY, V5, P321; ZENICUS A, 1990, BRAIN INJURY, V4, P33	48	27	27	0	6	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAY	2005	15	2					115	128		10.1080/09602010443000056			14	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	927IE	WOS:000229186800003	16353505				2021-06-18	
J	Agrawal, D; Gowda, NK; Bal, CS; Pant, M; Mahapatra, AK				Agrawal, D; Gowda, NK; Bal, CS; Pant, M; Mahapatra, AK			Is medial temporal injury responsible for pediatric postconcussion syndrome? A prospective controlled study with single-photon emission computerized tomography	JOURNAL OF NEUROSURGERY			English	Article						persistent postconcussion syndrome; minor head injury; mild traumatic brain injury; medial temporal ischemia; medial temporal hypoperfusion	TRAUMATIC BRAIN-INJURY; ENDURING MEMORY IMPAIRMENT; MILD HEAD-INJURY; HIPPOCAMPUS; CONCUSSION; SPECT; LONG; CT	Object. The authors sought to correlate the finding of medial temporal hypoperfusion (MTH) demonstrated on single photon emission computerized tomography (SPECT) with pediatric persistent postconcussion syndrome (PPCS) and to ascertain its usefulness in routine clinical practice. Methods. Thirty consecutive children with minor head injury and features of PPCS underwent SPECT scanning within 72 hours of injury. Those children having MTH on SPECT were included in the test group (14 patients), and the remaining 16 children comprised the control group. At the end of a 3-month period SPECT scanning was repeated and the incidence of PPCS was assessed clinically in both groups. Repeated SPECT scanning at 3 months revealed persisting MTH in 13 children (93%) in the test group; no child developed MTH in the control group. Twelve children were found to have PPCS in the MTH group compared with only two in the control group, and this was highly statistically significant (relative risk 6.86 [95% confidence interval 1.84-25.51], p = 0.0003). Conclusions. There exists significant MTH in pediatric patients with PPCS, which would imply that medial temporal lobe damage (involving the hippocampus and related structures) may occur after minor head injury and could be responsible for the symptoms of PPCS observed in this group of patients. Brain SPECT scans may thus help in the early identification of children prone to develop PPCS, and serial SPECT scanning may serve as a platform for testing the efficacy of various neurobehavioral and pharmacological interventions in these patients.	All India Inst Med Sci, Dept Neurosurg, New Delhi 110029, India; All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, India; Univ Coll Med Sci, Dept Community Med, Delhi 110095, India	Mahapatra, AK (corresponding author), All India Inst Med Sci, Dept Neurosurg, New Delhi 110029, India.	akmahapatra_22000@yahoo.com		Agrawal, Deepak/0000-0002-5499-0746			AGRAWAL D, 2003, NEUROSCIENCES TODAY, V7, P33; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ARVIGO F, 1985, SURG NEUROL, V24, P211, DOI 10.1016/0090-3019(85)90187-9; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; JACOBS A, 1994, J NUCL MED, V35, P942; Jenkins LW, 1999, BRAIN RES, V817, P132, DOI 10.1016/S0006-8993(98)01237-2; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Masdeu J C, 1994, J Neuroimaging, V4, P177; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; RempelClower NL, 1996, J NEUROSCI, V16, P5233; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; TIKOFSKY RS, 1994, J NUCL MED, V35, P947; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; World Health Organization, 1992, ICD 10 INT STAT CLAS; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	26	27	27	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2005	102	2		S			167	171		10.3171/jns.2005.102.2.0167			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	912GR	WOS:000228066100006	16156226				2021-06-18	
J	Adachi, K; Yimin, Y; Satake, K; Matsuyama, Y; Ishiguro, N; Sawada, M; Hirata, Y; Kiuchi, K				Adachi, K; Yimin, Y; Satake, K; Matsuyama, Y; Ishiguro, N; Sawada, M; Hirata, Y; Kiuchi, K			Localization of cyclooxygenase-2 induced following traumatic spinal cord injury	NEUROSCIENCE RESEARCH			English	Article						cyclooxygenase-2; endothelial cells; pia matters; blood vessels; rat; spinal cord injury; weight-drop technique	NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; MESSENGER-RNA; INDUCIBLE CYCLOOXYGENASE; GENE-EXPRESSION; BRAIN; CELLS; INFLAMMATION; INDUCTION; NEURONS	Objective: Up-regulation of cyclooxygenase-2 (COX-2), a key enzyme in the synthesis of prostaglandins (PGs), is postulated to be involved in pathological processes of acute spinal cord injury (SCI). In the present study, we sought to clarify temporal and spatial expression patterns of the COX-2 gene induced in the spinal cord after traumatic insults using a weight-drop technique. Results: Reverse transcriptase-polymerase chain reaction (RT-PCR) revealed that COX-2 transcription in the spinal cord began to increase within 30 min, peaked at 3 h after injury. Western blotting analysis indicated that the deglycosylated COX-2 protein significantly increased 6 h after injury. Double-immunofluorescent staining analysis showed that COX-2 immunoreactivity was present only in endothelial cells of blood vessels, but not in neurons, astrocytes, monocytes, macrophages, or microglia 6 h after injury. Conclusions: The results suggested that COX-2 gene induction seems not to require any new protein synthesis and that its expression in endothelial cells may be a component of an inflammatory process after traumatic SCI. (C) 2004 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.	Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 5011193, Japan; Fujita Hlth Univ, Inst Comprehens Med Sci, Joint Res Div Therapies Against Inctractable Dis, Toyoake, Aichi 4701192, Japan; Nagoya Univ, Sch Med, Dept Orthopaed Surg, Nagoya, Aichi 4668550, Japan	Kiuchi, K (corresponding author), Gifu Univ, Fac Engn, Dept Biomol Sci, 1-1 Yanagido, Gifu 5011193, Japan.	kiuchi@biomol.gifu-u.ac.jp	Hirata, Yoko/L-3142-2019; Hirata, Yoko/AAG-6798-2020	Hirata, Yoko/0000-0002-7081-4937; 	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15650072, 17591562] Funding Source: KAKEN		Allen AR, 1914, J NERV MENT DIS, V41, P141, DOI 10.1097/00005053-191403000-00002; Breder CD, 1996, BRAIN RES, V713, P64, DOI 10.1016/0006-8993(95)01474-8; Chao CC, 1997, NEUROREPORT, V8, P3163, DOI 10.1097/00001756-199709290-00031; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FAN ZH, 1995, AM J CHINESE MED, V23, P279, DOI 10.1142/S0192415X9500033X; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; Garavito RM, 2002, PROSTAG OTH LIPID M, V68-9, P129; Guhring H, 2000, J NEUROSCI, V20, P6714, DOI 10.1523/JNEUROSCI.20-17-06714.2000; IALENTI A, 1992, EUR J PHARMACOL, V211, P177, DOI 10.1016/0014-2999(92)90526-A; Ichitani Y, 1997, NEUROREPORT, V8, P2949, DOI 10.1097/00001756-199709080-00028; Inoue A, 1999, J NEUROCHEM, V73, P2206; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; Jobin C, 1998, IMMUNOLOGY, V95, P537; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; Madrigal JLM, 2001, J NEUROCHEM, V76, P532, DOI 10.1046/j.1471-4159.2001.00108.x; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Nishiya T, 2000, BIOCHEM BIOPH RES CO, V275, P268, DOI 10.1006/bbrc.2000.3293; Nogawa S, 1998, P NATL ACAD SCI USA, V95, P10966, DOI 10.1073/pnas.95.18.10966; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OTTO JC, 1993, J BIOL CHEM, V268, P18234; Poligone B, 2001, J BIOL CHEM, V276, P38658, DOI 10.1074/jbc.M106599200; Resnick DK, 1998, J NEUROTRAUM, V15, P1005, DOI 10.1089/neu.1998.15.1005; Satake K, 2000, NEUROREPORT, V11, P3877, DOI 10.1097/00001756-200011270-00054; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Serou MJ, 1999, J NEUROSCI RES, V58, P593, DOI 10.1002/(SICI)1097-4547(19991115)58:4<593::AID-JNR12>3.3.CO;2-W; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Tanaka M, 2000, BBA-GENE STRUCT EXPR, V1494, P63, DOI 10.1016/S0167-4781(00)00218-9; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tonai T, 1999, J NEUROCHEM, V72, P302, DOI 10.1046/j.1471-4159.1999.0720302.x; Wong ML, 1996, NAT MED, V2, P581, DOI 10.1038/nm0596-581; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	37	27	29	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-0102	1872-8111		NEUROSCI RES	Neurosci. Res.	JAN	2005	51	1					73	80		10.1016/j.neures.2004.10.007			8	Neurosciences	Neurosciences & Neurology	889HK	WOS:000226433900010	15596243				2021-06-18	
J	Reistetter, TA; Spencer, JC; Trujillo, L; Abreu, BC				Reistetter, TA; Spencer, JC; Trujillo, L; Abreu, BC			Examining the Community Integration Measure (CIM): A replication study with life satisfaction	NEUROREHABILITATION			English	Article						community integration; life satisfaction; measurement; brain injury	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; POSTTRAUMATIC-STRESS-DISORDER; PSYCHOMETRIC PROPERTIES; QUESTIONNAIRE CIQ; REHABILITATION; OUTCOMES; DISABILITY; HANDICAP; RECOVERY	Objective: To examine instrument reliability, validity, factor structure, and conceptual underpinnings of the Community Integration Measure (CIM) with the Community Integration Questionnaire Revised (CIQ-R) and the Satisfaction with Life Scale (SWLS). Design: A replication study. Setting: Community living. Participants: Ninety-one participants: 51 individuals with a brain injury, and 40 without brain injury. Main Outcomes: Internal consistency, criterion validity, construct validity, discriminant validity factor structure. Results: CIM items produced standardized alphas ranging from 0.72 to 0.83. Significant positive correlations were found among the CIM and both the CIQ-R and SWLS, with the CIM performing better with the SWLS than did the CIQ-R. The CIM discriminated between subject samples as well as by living arrangement. The factor loading solution revealed a three-factor model that explained 63.72 percent of the variance. Conclusion: The CIM shows good promise for capturing an individual's perception of community integration. The factor structure supports the original Model of Community Integration. Further research is needed to examine the influence of objective items on the CIM and Model of Community Integration.	Brain Injury & Stroke Program, Inst Rehabil & Res, Houston, TX 77030 USA; Texas Womans Univ, Sch Occupat Therapy, Houston, TX USA; Univ Texas, Med Branch, Sch Occupat Therapy, Div Rehabil Sci, Galveston, TX 77550 USA; Transit Learning Ctr, Galveston, TX USA; E Carolina Univ, Sch Allied Hlth Sci, Dept Occupat Therapy, Greenville, NC USA	Reistetter, TA (corresponding author), Brain Injury & Stroke Program, Inst Rehabil & Res, 1333 Moursand, Houston, TX 77030 USA.	reistt@tirr.tmc.edu					Bell K R, 2001, Phys Med Rehabil Clin N Am, V12, P169; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Cusick CP, 2001, ARCH PHYS MED REHAB, V82, P1018, DOI 10.1053/apmr.2001.25098; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; DeVellis R.F, 1991, SCALE DEV THEORY APP; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Gurka JA, 1999, J HEAD TRAUMA REHAB, V14, P247, DOI 10.1097/00001199-199906000-00005; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Huebner RA, 2003, AM J OCCUP THER, V57, P177, DOI 10.5014/ajot.57.2.177; Kaplan CP, 2001, BRAIN INJURY, V15, P725, DOI 10.1080/02699050010005913; Karlovits T, 1999, BRAIN INJURY, V13, P845; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; McColl MA, 1999, BRAIN INJURY, V13, P311, DOI 10.1080/026990599121511; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Millis S R, 1994, Int J Neurosci, V79, P165; Minnes P, 2003, BRAIN INJURY, V17, P149, DOI 10.1080/02699050301828; Novack TA, 2000, BRAIN INJURY, V14, P987; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Ocampo S, 1997, OCCUP THER INT, V4, P161; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Rintala DH, 2002, REHABIL PSYCHOL, V47, P144, DOI 10.1037//0090-5550.47.2.144; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Seale GS, 2002, BRAIN INJURY, V16, P955, DOI 10.1080/02699050210155258; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 2001, INT CLASS FUNCT DIS; ZHANG ZT, 2002, ABSTR APPL ANAL, V7, P509	48	27	27	0	10	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2005	20	2					139	148					10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	966EG	WOS:000232001800010	15920306				2021-06-18	
J	Shimamura, M; Garcia, JM; Prough, DS; Dewitt, DS; Uchida, T; Shah, SA; Avila, MAA; Hellmich, HL				Shimamura, M; Garcia, JM; Prough, DS; Dewitt, DS; Uchida, T; Shah, SA; Avila, MAA; Hellmich, HL			Analysis of long-term gene expression in neurons of the hippocampal subfields following traumatic brain injury in rats	NEUROSCIENCE			English	Article						antioxidant gene expression; apoptotic gene expression; laser capture microdissection; linear mRNA amplification; neurodegeneration; neuroprotective gene expression	CORTICAL IMPACT INJURY; NERVE GROWTH-FACTOR; MESSENGER-RNA; UP-REGULATION; HEAD-INJURY; TRANSCRIPTION FACTORS; REACTIVE ASTROCYTES; NEUROTROPHIC FACTOR; COGNITIVE DEFICITS; NEURITE OUTGROWTH	After experimental traumatic brain injury (TBI), widespread neuronal loss is progressive and continues in selectively vulnerable brain regions, such as the hippocampus, for months to years after the initial insult. To clarify the molecular mechanisms underlying secondary or delayed cell death in hippocampal neurons after TBI, we compared longterm changes in gene expression in the CA1, CA3 and dentate gyrus (DG) subfields of the rat hippocampus at 24 h and 3, 6, and 12 months after TBI with changes in gene expression in sham-operated rats. We used laser capture microdissection to collect several hundred hippocampal neurons from the CA1, CA3, and DG subfields and linearly amplified the nanogram samples of neuronal RNA with T7 RNA polymerase. Subsequent quantitative analysis of gene expression using ribonuclease protection assay revealed that mRNA expression of the anti-apoptotic gene, Bcl-2, and the chaperone heat shock protein 70 was significantly downregulated at 3, 6 (Bcl-2 only), and 12 months after TBI. Interestingly, the expression of the pro-apoptotic genes caspase-3 and caspase-9 was also significantly decreased at 3, 6 (caspase-9 only), and 12 months after TBI, suggesting that long-term neuronal loss after TBI is not mediated by increased expression of pro-apoptotic genes. The expression of two aging-related genes, p21 and integrin beta3 (ITbeta3), transiently increased 24 h after TBI, returned to baseline levels at 3 months and significantly decreased below sham levels at 12 months (ITbeta3 only). Expression of the gene for the antioxidant glutathione peroxidase-1 also significantly increased 6 months after TBI. These results suggest that decreased levels of neuroprotective genes may contribute to long-term neurodegeneration in animals and human patients after TBI. Conversely, long-term increases in antioxidant gene expression after TBI may be an endogenous neuroprotective response that compensates for the decrease in expression of other neuroprotective genes. (C) 2005 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; Yokohama City Univ, Sch Med, Dept Neurol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Univ Texas, Med Branch, Off Biostat, Galveston, TX 77555 USA	Hellmich, HL (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, 301 Univ Blvd, Galveston, TX 77555 USA.	hhelimic@utmb.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X			Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Asai S, 1996, NEUROREPORT, V7, P1092, DOI 10.1097/00001756-199604100-00028; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; CORKIN S, 1989, J NEUROSCI, V9, P3876; Currie RW, 2000, BRAIN RES, V863, P169, DOI 10.1016/S0006-8993(00)02133-8; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; DASH PK, 1995, J NEUROSCI, V15, P2030; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dutcher SA, 2001, NEUROL RES, V23, P203, DOI 10.1179/016164101101198343; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Furling D, 2000, P NATL ACAD SCI USA, V97, P4351, DOI 10.1073/pnas.060574597; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; Geisert EE, 2002, J COMP NEUROL, V453, P22, DOI 10.1002/cne.10364; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; Gillardon F, 1999, NEUROSCIENCE, V93, P1219, DOI 10.1016/S0306-4522(99)00292-4; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; GRONWALL D, 1974, LANCET, V2, P605; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; HARPER JW, 1995, MOL BIOL CELL, V6, P387; Harry GJ, 2003, NEUROTOXICOLOGY, V24, P343, DOI 10.1016/S0161-813X(03)00039-1; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hellmich HL, 2004, NEUROSCI LETT, V355, P221, DOI 10.1016/j.neulet.2003.10.074; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hughes PE, 1999, PROG NEUROBIOL, V57, P421, DOI 10.1016/S0301-0082(98)00057-4; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Kamme F, 2003, J NEUROSCI, V23, P3607; Katano H, 2000, NEUROREPORT, V11, P2073, DOI 10.1097/00001756-200007140-00003; Katano H, 1998, BRAIN RES, V800, P69, DOI 10.1016/S0006-8993(98)00493-4; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kelley MS, 1997, REV NEUROSCIENCE, V8, P147; Kramer DL, 2001, CANCER RES, V61, P7754; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1976, CORTEX, V12, P175, DOI 10.1016/S0010-9452(76)80021-4; Lotocki G, 2003, J CEREBR BLOOD F MET, V23, P1129, DOI 10.1097/01.WCB.0000086938.68719.E0; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; PLANAS AM, 1994, MOL BRAIN RES, V27, P127, DOI 10.1016/0169-328X(94)90193-7; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RAPS SP, 1989, BRAIN RES, V493, P398, DOI 10.1016/0006-8993(89)91178-5; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; *SAS I INC, 1999, SAS I I SAS STAT US; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; STUSS DT, 1989, CAN J NEUROL SCI, V16, P161, DOI 10.1017/S0317167100028833; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Xu DG, 1999, J NEUROSCI, V19, P5026; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; ZENG YC, 1995, MECH AGEING DEV, V79, P169, DOI 10.1016/0047-6374(94)01559-5; Zhao XY, 2001, J COMP NEUROL, V441, P187, DOI 10.1002/cne.1406	85	27	29	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2005	131	1					87	97		10.1016/j.neuroscience.2004.10.041			11	Neurosciences	Neurosciences & Neurology	896RM	WOS:000226951200008	15680694				2021-06-18	
J	Green, LB; Hornyak, JE; Hurvitz, EA				Green, LB; Hornyak, JE; Hurvitz, EA			Amantadine in pediatric patients with traumatic brain injury - A retrospective, case-controlled study	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						rehabilitation; traumatic brain injury; amantadine; pediatric	FRONTAL-LOBE DYSFUNCTION; CEREBRAL-CORTEX; NMDA RECEPTOR; HYDROCHLORIDE; ANTAGONIST; THERAPY; STATE	Objective: To determine if amantadine use in pediatric patients with traumatic brain injury is well tolerated and to attempt to assess its effectiveness. Design: This was a retrospective, case-controlled study. Results: Of the 54 patients, aged 3-18 yrs, who were administered amantadine, five (9%) had side effects that might have been related to the drug. These included hallucinations, delusions, increased aggression, and nausea/vomiting. The side effects were reversed when the medication was stopped or the dosage decreased. Patients in the amantadine group had a greater increase in Ranchos Los Amigos level during their admission than those in the control group (median, 3 vs. 2; P < 0.01). This difference may be, at least in part, explained by the fact that the amantadine group started at a lower Ranchos Los Amigos level (median, 3 vs. 4; P < 0.01). There were subjective improvements noted in 29 of the 46 patients (63%) in the amantadine group whose full charts were available for review. Conclusion: Amantadine is a well tolerated medication when it is used in pediatric patients with traumatic brain injury. Subjective improvements were noted in the majority of the patients administered amantadine, and the amantadine group showed a greater improvement in Ranchos Los Amigos level during admission, suggesting that it may be effective.	Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48103 USA	Green, LB (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, 325 E Eisenhower, Ann Arbor, MI 48103 USA.						ALLEN RM, 1983, CLIN NEUROPHARMACOL, V6, pS64; AOKI FY, 1988, CLIN PHARMACOKINET, V14, P35, DOI 10.2165/00003088-198814010-00003; BROWN RM, 1979, BRAIN RES, V168, P133, DOI 10.1016/0006-8993(79)90132-X; CHANDLER M, 1988, BRAIN INJURY, V4, P309; EDBY K, 1995, CHILD NERV SYST, V11, P607, DOI 10.1007/BF00301001; GIANUTSOS G, 1985, EUR J PHARMACOL, V110, P357, DOI 10.1016/0014-2999(85)90564-3; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; HERRMANN EC, 1960, P SOC EXP BIOL MED, V103, P625; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; KRACH LE, 1999, PEDIAT REHABILITATIO, P245; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; NICKELS JL, 1998, BRAIN INJURY, V8, P708; Patrick PD, 2003, BRAIN INJURY, V17, P497, DOI 10.1080/0269905031000070279; PEARLSON GD, 1981, BRAIN RES, V218, P233, DOI 10.1016/0006-8993(81)91303-2; Rao VLR, 2001, BRAIN RES, V911, P96; Schneider WN, 1999, BRAIN INJURY, V13, P863; SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; VECHT CJ, 1975, ARCH NEUROL-CHICAGO, V32, P792, DOI 10.1001/archneur.1975.00490540036004; WELLER M, 1992, MED HYPOTHESES, V38, P329, DOI 10.1016/0306-9877(92)90027-A; Zafonte RD, 1998, BRAIN INJURY, V12, P617; Zafonte RD, 2001, J HEAD TRAUMA REHAB, V16, P112, DOI 10.1097/00001199-200102000-00014	23	27	28	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	DEC	2004	83	12					893	897		10.1097/01.PHM.0000143400.15346.C8			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	874HB	WOS:000225340400003	15624567				2021-06-18	
J	Kovac, AD; Kwidzinski, E; Heimrich, B; Bittigau, P; Deller, T; Nitsch, R; Bechmann, I				Kovac, AD; Kwidzinski, E; Heimrich, B; Bittigau, P; Deller, T; Nitsch, R; Bechmann, I			Entorhinal cortex lesion in the mouse induces transsynaptic death of perforant path target neurons	BRAIN PATHOLOGY			English	Article							METHYL-D-ASPARTATE; TRAUMATIC BRAIN-INJURY; APOPTOTIC CELL-DEATH; DEVELOPING RAT-BRAIN; RECEPTOR ANTAGONIST MK-801; CYTOCHROME-C RELEASE; FASCIA-DENTATA; ADULT-RAT; ASTROGLIAL REACTIONS; GLOBAL-ISCHEMIA	Entorhinal cortex lesion (ECL) is a well described model of anterograde axonal degeneration, subsequent sprouting and reactive synaptogenesis in the hippocampus. Here, we show that such lesions induce transsynaptic degeneration of the target cells of the lesions pathway in the dentate gyrus. Peaking between 24 and 36 hours post-lesion, dying neurons were labeled with DeOlmos silver-staining and antisera against activated caspase 3 (CCP32), a downstream inductor of programmed cell death. Within caspase 3-positive neurons, fragmented nuclei were co-localized using Hoechst 33342 staining. Chromatin condensation and nuclear fragmentation were also evident in semithin sections and at the ultrastructural level, where virtually all caspase 3-positive neurons showed these hallmarks of apoptosis. There is a well-described upregulation of the apoptosis-inducing CD95/L system within the CNS after trauma, yet a comparison of caspase 3-staining patterns between CD95 (lpr)- and CD95L (gld)-deficient with non-deficient mice (C57/bl6) provided no evidence for CD95L-mediated neuronal cell death in this setting. However, inhibition of NMDA receptors with MK-801 completely suppressed caspase 3 activation, pointing to glutamate neurotoxicity as the upstream inducer of the observed cell death. Thus, these data show that axonal injury in the CNS does not only damage the axotomized neurons themselves, but can also lethally affect their target cells, apparently by activating glutamate-mediated intracellular pathways of programmed cell death.	Univ Med Berlin, Charite, Inst Anat, Dept Cell & Neurobiol, D-10098 Berlin, Germany; Univ Med Berlin, Charite, Dept Pediat Neurol, D-10098 Berlin, Germany; Goethe Univ Frankfurt, D-6000 Frankfurt, Germany	Bechmann, I (corresponding author), Univ Med Berlin, Charite, Inst Anat, Dept Cell & Neurobiol, D-10098 Berlin, Germany.	ingo.bechmann@charite.de	Nitsch, Robert/AAI-9129-2021				Arvidsson A, 2001, EUR J NEUROSCI, V14, P10, DOI 10.1046/j.0953-816x.2001.01611.x; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Bechmann I, 2000, GLIA, V32, P25, DOI 10.1002/1098-1136(200010)32:1<25::AID-GLIA30>3.0.CO;2-Y; Bechmann I, 1997, GLIA, V20, P145, DOI 10.1002/(SICI)1098-1136(199706)20:2<145::AID-GLIA6>3.0.CO;2-8; Bechmann I, 2002, BIOCHEM PHARMACOL, V64, P363, DOI 10.1016/S0006-2952(02)01166-8; Bechmann I, 2001, RESTOR NEUROL NEUROS, V19, P189; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Braun JS, 1999, NAT MED, V5, P298, DOI 10.1038/6514; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; BUCHAN A, 1990, J NEUROSCI, V10, P311; Buki A, 2000, J NEUROSCI, V20, P2825; CAMERON HA, 1995, J NEUROSCI, V15, P4687; CHAPMAN AG, 1991, EPILEPSIA, V32, P578, DOI 10.1111/j.1528-1157.1991.tb04695.x; Cid C, 2003, J NEUROL SCI, V206, P91, DOI 10.1016/S0022-510X(02)00339-8; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; COHEN PL, 1992, IMMUNOL TODAY, V13, P427, DOI 10.1016/0167-5699(92)90066-G; Colbourne F, 1999, J NEUROSCI, V19, P4200; Conti AC, 1998, J NEUROSCI, V18, P5663; DALCANTO MC, 1994, AM J PATHOL, V145, P1271; Del Turco D, 2003, HIPPOCAMPUS, V13, P685, DOI 10.1002/hipo.10118; Deller T, 2001, RESTOR NEUROL NEUROS, V19, P159; DEOLMOS JS, 1971, BRAIN RES, V33, P523, DOI 10.1016/0006-8993(71)90130-2; DIETRICH WD, 1992, ACTA NEUROPATHOL, V84, P630, DOI 10.1007/BF00227740; Dodd PR, 2002, BIOGERONTOLOGY, V3, P51, DOI 10.1023/A:1015255312948; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; FIX AS, 1993, EXP NEUROL, V123, P204, DOI 10.1006/exnr.1993.1153; FROIDEVAUX S, 1991, AUTOIMMUNITY, V10, P233, DOI 10.3109/08916939109001894; Frotscher M, 1997, TRENDS NEUROSCI, V20, P218, DOI 10.1016/S0166-2236(96)01018-1; GALL C, 1979, BRAIN RES, V175, P37, DOI 10.1016/0006-8993(79)90512-2; Ginsberg SD, 2002, J NEUROTRAUM, V19, P99, DOI 10.1089/089771502753460277; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ikonomidou C, 2000, SCIENCE, V287, P1056, DOI 10.1126/science.287.5455.1056; Ishimaru MJ, 1999, J COMP NEUROL, V408, P461; Jensen MB, 1997, EXP NEUROL, V143, P103, DOI 10.1006/exnr.1996.6337; JENSEN MB, 1994, EXP BRAIN RES, V98, P245; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kerr JFR, 2002, TOXICOLOGY, V181, P471, DOI 10.1016/S0300-483X(02)00457-2; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; LEWIS SJ, 1989, HYPERTENSION, V13, P759, DOI 10.1161/01.HYP.13.6.759; Lok J, 2002, J NEUROTRAUM, V19, P815, DOI 10.1089/08977150260190410; Luetjens CM, 2000, J NEUROSCI, V20, P5715; LYNCH G, 1972, BRAIN RES, V42, P311, DOI 10.1016/0006-8993(72)90533-1; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Meyer R, 2001, J NEUROSCI, V21, P6214; MONTECINORODRIGUEZ EM, 1991, IMMUNOLOGY, V74, P127; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; NITSCH R, 1992, P NATL ACAD SCI USA, V89, P5197, DOI 10.1073/pnas.89.11.5197; NITSCH R, 1993, HIPPOCAMPUS, V3, P481, DOI 10.1002/hipo.450030409; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Olney JW, 2002, BRAIN PATHOL, V12, P488, DOI 10.1111/j.1750-3639.2002.tb00467.x; OLNEY JW, 1994, NEUROBIOL AGING, V15, P259, DOI 10.1016/0197-4580(94)90127-9; PODURI A, 1995, NEUROSCI LETT, V197, P1, DOI 10.1016/0304-3940(95)11879-2; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Puig B, 2002, NEUROSCI LETT, V321, P182, DOI 10.1016/S0304-3940(01)02518-6; Qiu JH, 2002, J NEUROSCI, V22, P3504; Racke MM, 2002, J NEUROCHEM, V80, P1039, DOI 10.1046/j.0022-3042.2002.00787.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Ribotta MG, 2002, PROG BRAIN RES, V137, P191; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; Sloviter RS, 1996, J COMP NEUROL, V366, P516, DOI 10.1002/(SICI)1096-9861(19960311)366:3<516::AID-CNE10>3.0.CO;2-N; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Stuart LM, 2002, J IMMUNOL, V168, P1627, DOI 10.4049/jimmunol.168.4.1627; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Tenneti L, 1998, J NEUROCHEM, V71, P946; Ullrich O, 2001, FASEB J, V15, P1460, DOI 10.1096/fj.00-0540fje; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Viswanath V, 2000, P NATL ACAD SCI USA, V97, P2270, DOI 10.1073/pnas.030365297; Waldmeier PC, 2003, PROG NEURO-PSYCHOPH, V27, P303, DOI 10.1016/S0278-5846(03)00025-3; Wang XD, 2001, GENE DEV, V15, P2922; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Zhang CY, 2002, NEUROSCI LETT, V328, P265, DOI 10.1016/S0304-3940(02)00543-8	81	27	28	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	JUL	2004	14	3					249	257					9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	846ZW	WOS:000223359400003	15446579				2021-06-18	
J	Fujii, D; Ahmed, I; Hishinuma, E				Fujii, D; Ahmed, I; Hishinuma, E			A neuropsychological comparison of psychotic disorder following traumatic brain injury, traumatic brain injury without psychotic disorder, and schizophrenia	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							DORSOLATERAL PREFRONTAL CORTEX; PHYSIOLOGICAL DYSFUNCTION; ALZHEIMERS-DISEASE; EPILEPSY; SECONDARY	Neuropsychological functioning in individuals with psychotic disorder following traumatic brain injury (PDFTBI), traumatic brain injury without psychosis (TBIWP), and schizophrenia were compared against each other and to the means of normal subjects. It was predicted that the PDFTBI group would be similar to the schizophrenic group in patterns of deficits, but milder in severity. Compared to scores from a normal sample, the PDFTBI group scored significantly lower in intelligence, vocabulary, verbal memory, and executive functioning, while the schizophrenic group scored significantly lower in intelligence, working memory, verbal memory, visual spatial abilities, and executive functioning. No differences were found between normal subjects and the TBIWP group. Implications of our findings for the conceptualization of psychotic disorders are discussed.	Hawaii State Hosp, Dept Neuropsychol, Kaneohe, HI 96744 USA; Univ Hawaii, Dept Psychiat, John A Burns Sch Med, Manoa, HI USA	Fujii, D (corresponding author), Hawaii State Hosp, Dept Neuropsychol, 45-710 Keaahala Rd, Kaneohe, HI 96744 USA.	defujii@hsh.health.state.hi.us					ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; Ahmed II, 1998, SEMIN CLIN NEUROPSYC, V3, P23; *AM PSYCH ASS, 1994, DIAGN STAT MANAUL ME; Andreasen NC, 1998, SCHIZOPHRENIA BULL, V24, P203, DOI 10.1093/oxfordjournals.schbul.a033321; Benton A., 1994, MULTILINGUAL APHASIA; Bilder RM, 2000, AM J PSYCHIAT, V157, P549, DOI 10.1176/appi.ajp.157.4.549; Cantillon M., 1998, SEMIN CLIN NEUROPSYC, V3, P34; CAUTHEN N, 1977, J CLIN PSYCHOL, V34, P456; CUMMINGS JL, 1988, PSYCHOSOMATICS, V29, P16, DOI 10.1016/S0033-3182(88)72418-4; Davison K, 1969, BRIT J PSYCHIATRY SP, V4, P113; Edelstyn NMJ, 1999, INT J GERIATR PSYCH, V14, P48, DOI 10.1002/(SICI)1099-1166(199901)14:1<48::AID-GPS891>3.3.CO;2-S; FLORHENRY P, 1969, EPILEPSIA, V10, P363, DOI 10.1111/j.1528-1157.1969.tb03853.x; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; Fujii Daryl, 2002, Cogn Neuropsychiatry, V7, P41, DOI 10.1080/135468000143000131; Fujii DE, 2001, J NEUROPSYCH CLIN N, V13, P61, DOI 10.1176/appi.neuropsych.13.1.61; Fujii DE, 2001, J NEUROPSYCH CLIN N, V13, P534, DOI 10.1176/appi.neuropsych.13.4.534; Fujii DEM, 1996, NEUROPSY NEUROPSY BE, V9, P133; Fujii DEM, 1999, NEUROPSY NEUROPSY BE, V12, P110; Heinrichs RW, 1998, NEUROPSYCHOLOGY, V12, P426, DOI 10.1037/0894-4105.12.3.426; JESTE DV, 1996, AM J PSYCHIAT, V53, P90; KOTRLA KJ, 1995, AM J PSYCHIAT, V152, P1470; KOVELMAN JA, 1984, BIOL PSYCHIAT, V19, P1601; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Lisanby S. H., 1998, SEMIN CLIN NEUROPSYC, V3, P12; McCarley RW, 1999, BIOL PSYCHIAT, V45, P1099, DOI 10.1016/S0006-3223(99)00018-9; Mellers JDC, 2000, PSYCHOL MED, V30, P325, DOI 10.1017/S0033291799001786; Reitan RM., 1985, HALSTEAD REITAN NEUR; Sachdev P, 1998, AM J PSYCHIAT, V155, P325, DOI 10.1176/ajp.155.3.325; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Schatzberg AF, 2000, AM J PSYCHIAT, V157, P1095, DOI 10.1176/appi.ajp.157.7.1095; Selemon LD, 1999, BIOL PSYCHIAT, V45, P17, DOI 10.1016/S0006-3223(98)00281-9; STARKSTEIN SE, 1992, NEUROPSY NEUROPSY BE, V5, P114; SULTZER DL, 1995, J NEUROPSYCH CLIN N, V7, P476; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; VIOLON A, 1987, ACTA NEUROCHIR, V85, P96, DOI 10.1007/BF01456104; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D, 1997, WAIS 3 ADM SCORING M; Weickert TW, 2000, COGNITION SCHIZOPHRE, P3; WEINBERGER DR, 1995, LANCET, V346, P552, DOI 10.1016/S0140-6736(95)91386-6; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WEINBERGER DR, 1988, ARCH GEN PSYCHIAT, V45, P609; Wright IC, 2000, AM J PSYCHIAT, V157, P16, DOI 10.1176/ajp.157.1.16; YOUNG AW, 1992, PSYCHOL MED, V22, P799, DOI 10.1017/S003329170003823X	44	27	28	0	7	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	2004	16	3					306	314		10.1176/appi.neuropsych.16.3.306			9	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	855PN	WOS:000223986300007	15377737				2021-06-18	
J	Hohlrieder, M; Hinterhoelzl, J; Ulmer, H; Hackl, W; Schmutzhard, E; Gassner, R				Hohlrieder, M; Hinterhoelzl, J; Ulmer, H; Hackl, W; Schmutzhard, E; Gassner, R			Maxillofacial fractures masking traumatic intracranial hemorrhages	INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article						craniofacial trauma; maxillofacial; fractures; intracranial hemorrhage; skull base fractures; risk factors; injury mechanisms	CLOSED-HEAD INJURIES; FACIAL FRACTURES; COMA SCORE; HEMATOMA; SEVERITY; ADULTS; IMPACT; RISKS	Maxillofacial trauma may mask intracranial injuries prompting intensive care treatment. The purpose of this study was to identify whether craniofacial fracture patterns predispose patients with maxillofacial fractures to different types of intracranial hemorrhages. Within 7 years, 6649 patients with craniomaxillofacial injuries were admitted for treatment. The charts of the patients were analyzed according to age, sex, cause and mechanism of injury, type and location of facial injury, and intracranial trauma; 2195 sustained maxillofacial fractures. Statistical analyses were followed by logistic regression analyses for the four main types of intracranial hemorrhage to determine the impact of the different maxillofacial fractures. Intracranial hemorrhages in 212 patients (9.7%) occurred as epidural (2.5%), subdural (4.3%), subarachnoid (5.3%), and intracerebral hemorrhages (6.3%). Le Fort, orbit, nose, zygoma, and maxillary fractures increased the risk for accompanying intracranial hemorrhage by two- to fourfold (P < 0.05). Basal skull fractures caused a multiplication of the risk up to 17-fold, while fractures of the cranial vault were associated with a risk up to 14-fold. Nearly 10% of patients with craniomaxillofacial fractures sustain intracranial hemorrhages requiring frequently immediate neurosurgical intervention. Those patients, suffering from central midface fractures and skull base fractures, are prone to highly significant elevated risks of intracranial hemorrhage.	Univ Innsbruck, Dept Oral & Maxillofacial Surg, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Anesthesiol & Crit Care Med, A-6020 Innsbruck, Austria; Univ Innsbruck, Intens Care Unit, Dept Neurol, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Biostat, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Traumatol, A-6020 Innsbruck, Austria	Hohlrieder, M (corresponding author), Univ Innsbruck, Dept Oral & Maxillofacial Surg, Maximilianstr 10, A-6020 Innsbruck, Austria.	robert.gassner@uibk.ac.at	Ulmer, Hanno/S-6615-2019	Ulmer, Hanno/0000-0001-5911-1002			Alvarez M, 1998, CRIT CARE MED, V26, P142, DOI 10.1097/00003246-199801000-00030; DAVIDOFF G, 1988, ANN EMERG MED, V17, P6, DOI 10.1016/S0196-0644(88)80492-X; DERDYN C, 1990, PLAST RECONSTR SURG, V86, P238, DOI 10.1097/00006534-199008000-00005; Egol A, 1999, CRIT CARE MED, V27, P633; Gopalakrishna G, 1998, ANN EMERG MED, V32, P425, DOI 10.1016/S0196-0644(98)70170-2; Hachl O, 2002, INT J ORAL MAX SURG, V31, P90, DOI 10.1054/ijom.2001.0166; Hackl W, 2001, J TRAUMA, V50, P41, DOI 10.1097/00005373-200101000-00007; Hanley DF, 1999, CRIT CARE MED, V27, P477, DOI 10.1097/00003246-199903000-00019; HAUG HZ, 1992, J ORAL MAXIL SURG, V50, P218, DOI 10.1016/0278-2391(92)90315-Q; HAUG RH, 1994, J ORAL MAXIL SURG, V52, P729, DOI 10.1016/0278-2391(94)90488-X; HAUG RH, 1990, J ORAL MAXIL SURG, V48, P926, DOI 10.1016/0278-2391(90)90004-L; Heard C, 2002, CRIT CARE MED, V30, P1403, DOI 10.1097/00003246-200206000-00059; Kennan HT, 1999, ARCH SURG-CHICAGO, V134, P14, DOI 10.1001/archsurg.134.1.14; LEE KF, 1987, J NEUROSURG, V66, P542, DOI 10.3171/jns.1987.66.4.0542; LIM LH, 1993, BRIT J PLAST SURG, V46, P635, DOI 10.1016/0007-1226(93)90191-D; LUCE EA, 1979, PLAST RECONSTR SURG, V63, P26, DOI 10.1097/00006534-197901000-00005; Maladiere E, 2001, INT J ORAL MAX SURG, V30, P291, DOI 10.1054/ijom.2001.0059; MENDELOW AD, 1983, BRIT MED J, V287, P1173, DOI 10.1136/bmj.287.6400.1173; Plaisier BR, 2000, J ORAL MAXIL SURG, V58, P708, DOI 10.1053/joms.2000.7250; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; Teasdale GM, 2000, INTENS CARE MED, V26, P153, DOI 10.1007/s001340050037; Woisetschlager C, 2000, INTENS CARE MED, V26, P1561, DOI 10.1007/s001340000663; Yang WG, 2003, PLAST RECONSTR SURG, V111, P789, DOI 10.1097/01.PRS.0000041541.72469.53	26	27	27	0	1	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0901-5027	1399-0020		INT J ORAL MAX SURG	Int. J. Oral Maxillofac. Surg.	JUN	2004	33	4					389	395		10.1016/j.ijom.2003.10.011			7	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	828BJ	WOS:000221947300012	15145043				2021-06-18	
J	Otori, T; Friedland, JC; Sinson, G; McIntosh, TK; Raghupathi, R; Welsh, FA				Otori, T; Friedland, JC; Sinson, G; McIntosh, TK; Raghupathi, R; Welsh, FA			Traumatic brain injury elevates glycogen and induces tolerance to ischemia in rat brain	JOURNAL OF NEUROTRAUMA			English	Article						glucose; glycogen; head injury; ischemic tolerance; secondary injury	CEREBRAL BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; FLUID-PERCUSSION INJURY; HEAD-INJURY; GLUCOSE-UTILIZATION; NEURONAL INJURY; HIPPOCAMPAL CA1; FOCAL ISCHEMIA; MOUSE-BRAIN; HYPOXIA	Previous studies have demonstrated that traumatic brain injury (TBI) increases the vulnerability of the brain to an acute episode of hypoxia-ischemia. The objective of the present study was to determine whether TBI alters the vulnerability of the brain to a delayed episode of ischemia and, if so, to identify contributing mechanisms. Sprague-Dawley rats were subjected to lateral fluid-percussion (FP) brain injury (n = 14) of moderate severity (2.3-2.5 atm), or sham-injury (n = 12). After recovery for 24 h, all animals underwent an 8-min episode of forebrain ischemia, followed by survival for 6 days. Ischemic damage in the hippocampus and cerebral cortex of the FP-injured hemisphere was compared to that in the contralateral hemisphere and to that in sham-injured animals. Remarkably, the number of surviving CA, neurons in the middle and lateral segments of the hippocampus in the FP-injured hemisphere was signficantly greater than that in the contralateral hemisphere and sham-injured animals (p < 0.05). Likewise, in the cerebral cortex the number of damaged neurons tended to be lower in the FP-injured hemisphere than in the contralateral hemisphere. These results suggest that TBI decreased the vulnerability of the brain to a delayed episode of ischemia. To determine whether TBI triggers protective metabolic alterations, glycogen levels were measured in cerebral cortex and hippocampus in additional animals 24 h after FP-injury (n 13) or sham-injury (n = 7). Cortical glycogen levels in the ipsilateral hemisphere increased to 12.9 +/- 6.4 mmol/kg (mean SD), compared to 6.4 +/- 1.8 mmol/kg in the opposite hemisphere and 5.7 +/- 1.3 mmol/kg in sham-injured animals (p < 0.001). Similarly, in the hippocampus glycogen levels in the FP-injured hemisphere increased to 13.4 +/- 4.9 mmol/kg, compared to 8.1 +/- 2.4 mmol/kg in the contralateral hemisphere (p < 0.004) and 6.2 +/- 1.5 mmol/kg in sham-injured animals (P < 0.001). These results demonstrate that TBI triggers a marked accumulation of glycogen that may protect the brain during ischemia by serving as an endogenous source of metabolic energy.	Univ Penn, Dept Neurosurg, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Sch Med, Philadelphia, PA 19104 USA	Welsh, FA (corresponding author), Univ Penn, Dept Neurosurg, Sch Med, 371 Stemmler Hall,Box 44,36th & Hamilton Walk, Philadelphia, PA 19104 USA.	fwelsh@mail.med.upenn.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-08803] Funding Source: Medline		BENVENISTE H, 1989, J CEREBR BLOOD F MET, V9, P629, DOI 10.1038/jcbfm.1989.90; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; CARDELL M, 1991, J CEREBR BLOOD F MET, V11, P122, DOI 10.1038/jcbfm.1991.14; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; Folbergrova J, 1996, J NEUROL SCI, V137, P7, DOI 10.1016/0022-510X(96)82226-X; FRIEDLAND JC, 2002, J NEUROTRAUM, V19, P1357; GATFIELD PD, 1966, J NEUROCHEM, V13, P185, DOI 10.1111/j.1471-4159.1966.tb07512.x; GLAZIER SS, 1994, J CEREBR BLOOD F MET, V14, P545, DOI 10.1038/jcbfm.1994.68; GUTH L, 1968, EXP NEUROL, V22, P590, DOI 10.1016/0014-4886(68)90151-9; HAYMAKER W, 1970, BIBL PSYCHIAT, P71; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Kapinya KJ, 2002, STROKE, V33, P1889, DOI 10.1161/01.STR.0000020092.41820.58; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIRINO T, 1991, J CEREBR BLOOD F MET, V11, P299, DOI 10.1038/jcbfm.1991.62; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; KLATZO I, 1961, J NEUROPATH EXP NEUR, V20, P459, DOI 10.1097/00005072-196120040-00001; KOBAYASHI S, 1995, J CEREBR BLOOD F MET, V15, P721, DOI 10.1038/jcbfm.1995.92; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MURAMATSU H, 2003, J CEREB BLOOD FLOW M, V23, P509; OTORI T, 2001, J NEUROTRAUM, V18, P1131; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; PASSONNEAU JV, 1974, ANAL BIOCHEM, V60, P405, DOI 10.1016/0003-2697(74)90248-6; PHELPS CH, 1975, J NEUROCYTOL, V4, P479, DOI 10.1007/BF01261377; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; Rogatsky G, 1996, J Basic Clin Physiol Pharmacol, V7, P23; SANDERS JE, 1996, IEEE T REHABIL ENG, V4, P285; SHIMIZU N, 1958, NATURE, V181, P781, DOI 10.1038/181781a0; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.iy.02.040184.001535; Sunami K, 1989, Neurol Med Chir (Tokyo), V29, P975, DOI 10.2176/nmc.29.975; SWANSON RA, 1990, STROKE, V21, P322, DOI 10.1161/01.STR.21.2.322; TAKAHATA Y, 1986, BRAIN RES, V381, P368, DOI 10.1016/0006-8993(86)90091-0; Tasaki K, 1997, BRAIN RES, V748, P267, DOI 10.1016/S0006-8993(96)01383-2; WATANABE H, 1974, BRAIN RES, V66, P147, DOI 10.1016/0006-8993(74)90084-5; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WELSH FA, 1983, J CEREBR BLOOD F MET, V3, P486, DOI 10.1038/jcbfm.1983.75; WELSH FA, 1991, J CEREBR BLOOD F MET, V11, P459, DOI 10.1038/jcbfm.1991.88; WELSH FA, 1980, STROKE, V11, P355, DOI 10.1161/01.STR.11.4.355; Wiegand F, 1999, J CEREBR BLOOD F MET, V19, P1229, DOI 10.1097/00004647-199911000-00007; WOLFE LS, 1962, J NEUROCHEM, V9, P213, DOI 10.1111/j.1471-4159.1962.tb11862.x; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	53	27	28	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2004	21	6					707	718		10.1089/0897715041269623			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	836EG	WOS:000222537600007	15253799				2021-06-18	
J	Bellander, BM; Bendel, O; Von Euler, G; Ohlsson, M; Svensson, M				Bellander, BM; Bendel, O; Von Euler, G; Ohlsson, M; Svensson, M			Activation of microglial cells and complement following traumatic injury in rat entorhinal-hippocampal slice cultures	JOURNAL OF NEUROTRAUMA			English	Article						complement; slice cultures; traumatic brain injury	SULFATED GLYCOPROTEIN-2; BRAIN MACROPHAGES; NERVOUS-SYSTEM; MYELIN; ATTACK; PROTEIN; DEGENERATION; RECRUITMENT; INCREASE; NUCLEUS	The complement cascade has been suggested to be involved in development of secondary brain damage following traumatic brain injury (TBI). Previous studies have shown that reactive microglia are involved in activation of the complement cascade following various injuries to the nervous system. Macrophages seem to have a significant role in this process, but it is still unclear whether these cells, as well as the complement components, are derived from reactive microglia or if these biological events only can occur as a result from the influx of plasma and monocytes via a disrupted blood-brain barrier (BBB). The aim of this study was to investigate the response of microglial cells and the complement system in the absence of plasma/blood components following a standardized crush injury in an entorhinal-hippocampal slice culture. There was a clear increase in complement component C1q and C5b-9-IR (Membrane Attack Complex, MAC) in the area near the crush injury. MAC-IR appeared as numerous dots in clusters which co-localized with anti-NeuN labelled neurons in the injury border zone. Complement C1q-IR co-localized with reactive microglia, co-labelled with OX42 antisera. These findings show activation of the complement cascade near the injury zone and in particular, formation of MAC at the surface of neurons in this area. There was a distinct activation of microglial cells (OX42-IR) near the site of injury, as well as an increase in ED-1 expressing macrophages. In the absence of blood and plasma components it is likely that ED-1-labelled cells represent reactive microglia transformed into macrophages. In addition, Neurons (Neun-IR) near the injury were found to co-localize with clusterin-IR indicating upregulation of a defense system to the endogenous complement attack. The present study provides evidence that microglia and complement is activated in the injury border zone of the tissue slice in a similar fashion as in vivo following TBI, despite the absence of plasma/blood products and cells. These findings support the hypothesis that reactive microglia have a key role in complement activation following TBI by local synthesis of complement with a potential impact on development of secondary neuronal insults.	Karolinska Hosp, Dept Clin Neurosci, Neurosurg Sect, S-17176 Stockholm, Sweden	Bellander, BM (corresponding author), Karolinska Hosp, Dept Clin Neurosci, Neurosurg Sect, R3-02 Karolinska Vagen, S-17176 Stockholm, Sweden.	bob@ks.se	Ohlsson, Marcus R/H-1395-2011; Svensson, Mikael/F-8662-2012	Svensson, Mikael/0000-0003-1179-7003			AGOSTONI A, 1992, INT J IMMUNOPATH PH, V5, P123, DOI 10.1177/039463209200500207; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; BHAKDI S, 1991, IMMUNOL TODAY, V12, P318, DOI 10.1016/0167-5699(91)90007-G; Blumbergs P. C., 1997, HEAD INJURY PATHOPHY, P39; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; BROWN EJ, 1991, CURR OPIN IMMUNOL, V3, P76, DOI 10.1016/0952-7915(91)90081-B; BRUCK W, 1991, J NEUROL SCI, V103, P182, DOI 10.1016/0022-510X(91)90162-Z; CAMPBELL AK, 1981, BIOCHEM J, V194, P551, DOI 10.1042/bj1940551; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; ESSER AF, 1991, IMMUNOL TODAY, V12, P316, DOI 10.1016/0167-5699(91)90006-F; FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I; GIULIAN D, 1993, J NEUROSCI, V13, P29; Graham D.I., 1993, HEAD INJURY, P91; GRAHAM DI, 1971, LANCET, V1, P265; HANSCH GM, 1992, IMMUNOPHARMACOLOGY, V24, P107, DOI 10.1016/0162-3109(92)90017-7; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; LACHMANN PJ, 1991, IMMUNOL TODAY, V12, P312, DOI 10.1016/0167-5699(91)90005-E; MAY PC, 1992, TRENDS NEUROSCI, V15, P391, DOI 10.1016/0166-2236(92)90190-J; MCGEER PL, 1989, CAN J NEUROL SCI, V16, P516, DOI 10.1017/S0317167100029863; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MICHEL D, 1992, SYNAPSE, V11, P105, DOI 10.1002/syn.890110203; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173; MORGAN BP, 1994, SPRINGER SEMIN IMMUN, V15, P369, DOI 10.1007/BF01837366; MORGAN BP, 1992, CURR TOP MICROBIOL, V178, P115; MULLEREBERHARD HJ, 1986, ANNU REV IMMUNOL, V4, P503, DOI 10.1146/annurev.iy.04.040186.002443; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; OKUSAWA S, 1987, J IMMUNOL, V139, P2635; OKUSAWA S, 1988, J EXP MED, V168, P443, DOI 10.1084/jem.168.1.443; OLSSON T, 1992, AUTOIMMUNITY, V13, P117, DOI 10.3109/08916939209001912; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; Raivich G, 1998, J NEUROSCI, V18, P5804; ROSEN H, 1990, J LEUKOCYTE BIOL, V48, P465; SCHILLING MT, 1990, IEEE T POWER SYST, V5, P1, DOI 10.1109/59.49079; Soares HD, 1995, J NEUROSCI, V15, P8223; STOLL G, 1991, ANN NEUROL, V30, P147, DOI 10.1002/ana.410300205; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; SVENSSON M, 1992, J NEUROIMMUNOL, V40, P99, DOI 10.1016/0165-5728(92)90217-9; Takayama A, 1996, PHYS PLASMAS, V3, P3, DOI 10.1063/1.871832; THERY C, 1991, EUR J NEUROSCI, V3, P1155, DOI 10.1111/j.1460-9568.1991.tb00050.x; TODD NV, 1990, ACT NEUR S, V51, P296; VACA K, 1992, EXP NEUROL, V118, P62, DOI 10.1016/0014-4886(92)90023-J; VANGURI P, 1988, J BIOL CHEM, V263, P7228; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X; YAO J, 1990, J NEUROSCI RES, V27, P36, DOI 10.1002/jnr.490270106	51	27	29	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2004	21	5					605	615		10.1089/089771504774129937			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821LK	WOS:000221461900011	15165368				2021-06-18	
J	MacKay, RJ				MacKay, RJ			Brain injury after head trauma: pathophysiology, diagnosis, and treatment	VETERINARY CLINICS OF NORTH AMERICA-EQUINE PRACTICE			English	Article							BASILAR SKULL FRACTURES; TEMPOROHYOID OSTEOARTHROPATHY; 3 HORSES; RADIOGRAPHIC DIAGNOSIS; OTITIS-MEDIA; MANAGEMENT; DISEASES; TRIAL; CARE	Brain injury after impact to the head is due to both immediate mechanical effects and delayed responses of neural tissues. In horses, traumatic brain injury occurs in three main settings: (1) poll impact in horses that flip over backwards; (2) frontal/parietal impact in horses that run into a fixed object, and (3) injury to the vestibular apparatus secondary to temporohyoid osteoarthropathy. Distinct forebrain, vestibular, midbrain, hindbrain, or multifocal syndromes may be encountered in horses with traumatic brain injury. The most important components of treatment are those consistent with principles of "evidence-based medicine". Accordingly, secondary brain injury can most effectively be prevented by establishing normal blood pressure, temperature, blood glucose concentration, and tissue oxygenation. Pain must be controlled and brain swelling may be treated with infusions of hypertonic saline or mannitol. Surgical procedures, including unilateral hyoid bone transaction or elevation of skull fracture fragments, are indicated in selected cases. Optional additional treatments include use of antioxidants, conventional doses of corticosteroids, magnesium sulfate and drainage of CSF. There is no indication for the use of massive doses of methyl prednisolone sodium succinate.	Univ Florida, Dept Large Anim Clin Sci, Gainesville, FL 32610 USA	MacKay, RJ (corresponding author), Univ Florida, Dept Large Anim Clin Sci, POB 100136,2015 SW 16th Ave,Room VH-136, Gainesville, FL 32610 USA.	mackayr@mail.vetmed.ufl.edu					Alexander K, 2002, J AM VET MED ASSOC, V220, P297, DOI 10.2460/javma.2002.220.297; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; BLOGG JR, 1990, EQUINE VET J S, V10, P5; BLYTHE LL, 1984, J AM VET MED ASSOC, V185, P775; Blythe LL, 1997, VET CLIN N AM-EQUINE, V13, P21, DOI 10.1016/S0749-0739(17)30253-5; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Braet V, 2002, EMERG MED J, V19, P510; DARIEN BJ, 1991, J AM VET MED ASSOC, V198, P1799; Donaldson J, 2000, Crit Care Nurs Clin North Am, V12, P465; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Foreman JH, 1998, VET CLIN N AM-EQUINE, V14, P205, DOI 10.1016/S0749-0739(17)30220-1; Ginsberg MD, 2003, STROKE, V34, P214, DOI 10.1161/01.STR.0000048846.09677.62; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Johnson PJ, 1996, J AM VET MED ASSOC, V209, P901; Kohn CW, 1999, AM J VET RES, V60, P299; Komaromy AM, 2003, VET OPHTHALMOL, V6, P27, DOI 10.1046/j.1463-5224.2003.00261.x; Kramer GC, 2003, J TRAUMA, V54, pS89, DOI 10.1097/01.TA.0000065609.82142.F1; Lacombe VA, 2001, J VET INTERN MED, V15, P385, DOI 10.1892/0891-6640(2001)015&lt;0385:DVOEIE&gt;2.3.CO;2; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MARTIN L, 1986, EQUINE VET J, V18, P133, DOI 10.1111/j.2042-3306.1986.tb03569.x; MAYHEW IG, 1990, BRIT VET J, V146, P509, DOI 10.1016/0007-1935(90)90054-7; MCKELVEY WAC, 1979, J AM VET MED ASSOC, V175, P295; MCLLWRAITH CWR, 1998, TURNERS EQUINE SURG, P276; Newton SA, 1999, VET REC, V145, P142, DOI 10.1136/vr.145.5.142; RAGLE CA, 1993, VET CLIN N AM-EQUINE, V9, P171, DOI 10.1016/S0749-0739(17)30422-4; Ramirez O, 1998, VET RADIOL ULTRASOUN, V39, P391, DOI 10.1111/j.1740-8261.1998.tb01624.x; Rhoney DH, 2001, NEUROL RES, V23, P237, DOI 10.1179/016164101101198398; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; SINHA AK, 1991, VET REC, V128, P518, DOI 10.1136/vr.128.22.518; STICK JA, 1980, J AM VET MED ASSOC, V176, P228; SWEENEY CR, 1993, J AM VET MED ASSOC, V202, P1129; Tietje S, 1996, EQUINE VET J, V28, P98, DOI 10.1111/j.2042-3306.1996.tb01599.x; TYLER CM, 1993, AUST VET J, V70, P445, DOI 10.1111/j.1751-0813.1993.tb00846.x; Walker AM, 2002, J VET INTERN MED, V16, P697, DOI 10.1892/0891-6640(2002)016<0697:TOIH>2.3.CO;2; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003; 2000, J NEUROTRAUMA, V17, P457	38	27	27	1	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-0739	1558-4224		VET CLIN N AM-EQUINE	Vet. Clin. N. Am.-Equine Pract.	APR	2004	20	1					199	+		10.1016/j.cveq.2003.11.006			19	Veterinary Sciences	Veterinary Sciences	808QN	WOS:000220583700011	15062465				2021-06-18	
